The	O
Tax	B-protein
protein	I-protein
of	O
HTLV-I	O
,	O
a	O
positive	B-protein
transcriptional	I-protein
activator	I-protein
of	O
HTLV-I	O
gene	O
expression	O
,	O
is	O
a	O
viral	O
oncogene	O
that	O
also	O
increases	O
transcription	O
of	O
cellular	B-DNA
genes	I-DNA
including	O
GM-CSF	B-protein
,	O
IL-2R	B-protein
alpha	I-protein
and	O
IL-2	B-protein
.	O

While	O
the	O
sera	O
of	O
EBV-negative	O
individuals	O
(	O
0/3	O
)	O
or	O
healthy	O
carriers	O
(	O
0/33	O
)	O
did	O
not	O
contain	O
detectable	O
levels	O
of	O
antibodies	O
,	O
patients	O
with	O
mononucleosis	O
(	O
5/18	O
)	O
,	O
chronic	O
EBV	O
infection	O
(	O
2/7	O
)	O
,	O
EBV	O
reactivation	O
(	O
7/20	O
)	O
and	O
human	O
immunodeficiency	O
virus	O
infection	O
(	O
5/24	O
)	O
showed	O
elevated	O
antibody	O
titres	O
against	O
the	O
enzyme	O
.	O

Degenerate	O
primers	O
corresponding	O
to	O
the	O
TFIIIA	B-DNA
zinc-finger	I-DNA
consensus	I-DNA
amino	I-DNA
acid	I-DNA
sequences	I-DNA
and	O
to	O
the	O
POU-homeodomain	B-protein
and	O
POU-specific	B-protein
domain	I-protein
were	O
used	O
to	O
amplify	O
genes	O
on	O
the	O
basis	O
that	O
they	O
contained	O
similarities	O
in	O
structural	O
motifs	O
shared	O
within	O
these	O
families	O
of	O
transcription	B-protein
factors	I-protein
.	O

Nuclear	O
accumulation	O
of	O
NFAT4	B-protein
opposed	O
by	O
the	O
JNK	B-protein
signal	O
transduction	O
pathway	O
.	O

Additionally	O
,	O
herbimycin	O
A	O
,	O
a	O
tyrosine	B-protein
kinase	I-protein
inhibitor	O
,	O
blocked	O
the	O
R24	B-protein
-stimulated	O
increase	O
in	O
proliferation	O
but	O
not	O
cytotoxicity	O
at	O
concentrations	O
consistent	O
with	O
specificity	O
for	O
tyrosine	B-protein
kinases	I-protein
.	O

However	O
,	O
when	O
used	O
simultaneously	O
,	O
DHEA	O
and	O
LPS	O
0.2	O
ng/ml	O
displayed	O
a	O
synergistic	O
effect	O
on	O
monocyte	O
cytotoxicity	O
against	O
cancerous	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
IL-1	B-protein
secretion	O
,	O
reactive	O
nitrogen	O
intermediate	O
release	O
,	O
complement	B-protein
receptor-1	I-protein
cell-surface	I-protein
protein	I-protein
,	O
and	O
TNF-alpha	B-protein
protein	I-protein
to	O
levels	O
comparable	O
with	O
levels	O
obtained	O
using	O
LPS	O
1.0	O
microgram/ml	O
.	O

The	O
physiological	O
relevance	O
of	O
this	O
phenomenon	O
is	O
emphasized	O
by	O
similar	O
CD30	B-protein
-mediated	O
effects	O
in	O
naive	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Monocytic	O
cell	O
type-specific	O
transcriptional	O
induction	O
of	O
collagenase	B-protein
.	O

Significantly	O
increased	O
oestrogen	B-protein
receptor	I-protein
expression	O
,	O
bcl-2	B-protein
expression	O
and	O
numbers	O
of	O
CD8+	O
leukocytes	B-cell_type
were	O
found	O
in	O
ectopic	O
compared	O
with	O
eutopic	O
endometrium	O
in	O
endometriosis	O
,	O
and	O
CD56+	O
endometrial	O
granulated	O
lymphocytes	O
(	O
eGLs	O
)	O
were	O
significantly	O
reduced	O
in	O
ectopic	O
endometrium	O
.	O

Intravenous	O
PCr	O
injection	O
led	O
to	O
smaller	O
changes	O
in	O
ACTH	B-protein
and	O
cortisol	O
concentrations	O
as	O
well	O
as	O
to	O
a	O
lower	O
activation	O
of	O
glucocorticoid	O
binding	O
in	O
lymphocytes	B-cell_type
.	O

Addition	O
of	O
ASA	O
to	O
an	O
in	O
vitro	O
T	O
helper	O
cell	O
differentiation	O
system	O
,	O
at	O
concentrations	O
compatible	O
with	O
plasma	O
levels	O
reached	O
during	O
anti-inflammatory	O
therapy	O
,	O
resulted	O
in	O
reduced	O
development	O
of	O
Th1	B-cell_type
cells	I-cell_type
.	O

NFAT-1	B-protein
activity	O
had	O
previously	O
been	O
thought	O
to	O
be	O
confined	O
to	O
activated	B-cell_type
T-lymphocytes	I-cell_type
upon	O
release	O
of	O
intracellular	B-cell_type
calcium	I-cell_type
.	O

The	O
signaling	O
events	O
that	O
link	O
FGF	B-protein
receptor-1	I-protein
engagement	O
and	O
NF-kappaB	B-protein
activation	O
in	O
Jurkat	B-cell_line
are	O
probably	O
distinct	O
from	O
the	O
CD28	B-protein
costimulation	O
pathway	O
,	O
since	O
FGF-1	B-protein
-induced	O
Rel/kappaB	B-protein
binding	I-protein
proteins	I-protein
do	O
not	O
contain	O
significant	O
levels	O
of	O
c-Rel	B-protein
and	O
are	O
not	O
identical	O
with	O
the	O
CD28	B-protein
response	I-protein
complex	I-protein
.	O

EMSA	O
showed	O
that	O
both	O
constitutive	O
and	O
inducible	O
complexes	O
bound	O
to	O
CLE0	B-DNA
,	O
P	B-DNA
,	O
P2	B-DNA
and	O
P4	B-DNA
,	O
whereas	O
only	O
a	O
constitutive	O
complex	O
bound	O
to	O
P3	B-DNA
.	O

AML1a	B-protein
but	O
not	O
AML1b	B-protein
inhibits	O
erythroid	O
differentiation	O
induced	O
by	O
sodium	O
butyrate	O
and	O
enhances	O
the	O
megakaryocytic	O
differentiation	O
of	O
K562	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

Both	O
inhibitors	O
inhibited	O
monocyte	O
chemotactic	O
activity	O
in	O
the	O
culture	O
supernatant	O
of	O
P-LPS-treated	O
cells	O
.	O

All	O
TCC	B-cell_line
expressed	O
equal	O
levels	O
of	O
the	O
low-affinity	B-protein
IL-12R	I-protein
beta1	I-protein
subunit	I-protein
.	O

The	O
transcription	B-protein
factors	I-protein
PU.1	B-protein
and	O
C/EBPalpha	B-protein
are	O
responsible	O
for	O
normal	O
myeloid	O
differentiation	O
from	O
stem	B-cell_type
cells	I-cell_type
to	O
monocytes	B-cell_type
or	O
granulocytes	O
.	O

In	O
addition	O
,	O
a	O
dominant-negative	B-DNA
mutant	I-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
receptor	I-DNA
I	I-DNA
(	I-DNA
TNFRI	I-DNA
)	I-DNA
expression	I-DNA
vector	I-DNA
was	O
co-transfected	O
in	O
inhibition	O
studies	O
.	O

Antisense	O
phosphorothioate	O
oligonucleotides	O
to	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
were	O
used	O
to	O
define	O
the	O
physiologic	O
role	O
of	O
this	O
transcription	B-protein
factor	I-protein
in	O
resting	B-cell_line
and	I-cell_line
stimulated	I-cell_line
granulocytes	I-cell_line
.	O

Identification	O
of	O
a	O
physical	O
interaction	O
between	O
calcineurin	B-protein
and	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFATp	B-protein
)	O
.	O

However	O
,	O
DCoH	B-protein
did	O
not	O
confer	O
transcriptional	O
activation	O
to	O
the	O
GAL4	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
.	O

Interleukin-4	B-protein
inhibits	O
the	O
lipopolysaccharide-induced	O
expression	O
of	O
c-jun	B-RNA
and	I-RNA
c-fos	I-RNA
messenger	I-RNA
RNA	I-RNA
and	O
activator	B-protein
protein-1	I-protein
binding	O
activity	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Additionally	O
,	O
CoCl2	O
caused	O
a	O
two-	O
to	O
threefold	O
increase	O
in	O
the	O
rate	O
of	O
transendothelial	O
migration	O
of	O
monocyte-like	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
and	O
a	O
twentyfold	O
increase	O
in	O
phosphorylation	O
of	O
platelet	B-protein
endothelial	I-protein
cell	I-protein
adhesion	I-protein
molecules	I-protein
(	O
PECAM-1	B-protein
)	O
.	O

Both	O
TNF-alpha	B-protein
and	O
NF-kappa	B-protein
B	I-protein
are	O
also	O
involved	O
in	O
the	O
stimulation	O
of	O
the	O
pathway	O
that	O
leads	O
to	O
the	O
expression	O
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
class	I-protein
I	I-protein
molecules	I-protein
and	O
,	O
hence	O
,	O
antigen	O
presentation	O
to	O
the	O
T	B-cell_type
cells	I-cell_type
.	O

No	O
instance	O
of	O
microsatellite	O
instability	O
was	O
observed	O
in	O
a	O
total	O
of	O
880	O
comparisons	O
of	O
granulocyte	B-DNA
and	I-DNA
T-cell	I-DNA
DNA	I-DNA
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

G28-5	B-protein
IgG	I-protein
partially	O
blocked	O
,	O
whereas	O
G28-5	B-protein
sFv	I-protein
augmented	O
CD40	B-protein
responses	O
during	O
stimulation	O
with	O
natural	B-protein
ligand	I-protein
(	O
gp39-CD8	B-protein
fusion	I-protein
protein	I-protein
)	O
.	O

In	O
B	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
,	O
deltaspi-B	B-RNA
and	I-RNA
spi-B	I-RNA
mRNAs	I-RNA
were	O
present	O
simultaneously	O
in	O
a	O
ratio	O
of	O
around	O
10	O
%	O
.	O

A	O
gel	O
retardation	O
experiment	O
with	O
synthetic	O
double-stranded	O
oligonucleotides	O
showed	O
that	O
activated	O
NF-kappa	B-protein
B	I-protein
consisting	O
of	O
p50/p65	B-protein
heterodimer	I-protein
bound	O
to	O
all	O
four	O
putative	O
NF-kappa	B-DNA
B	I-DNA
DNA	I-DNA
probes	I-DNA
,	O
suggesting	O
that	O
all	O
four	O
putative	O
NF-kappa	B-DNA
B	I-DNA
recognition	I-DNA
sites	I-DNA
play	O
an	O
important	O
role	O
in	O
inducible	O
TNF-alpha	B-protein
expression	O
.	O

IL-10	B-protein
effected	O
dose-dependent	O
inhibition	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
release	O
in	O
PBMC	B-cell_type
stimulated	O
by	O
LPS	O
and	O
C.	O
neoformans	O
,	O
with	O
significant	O
inhibition	O
seen	O
with	O
0.1	O
U/ml	O
and	O
greater	O
than	O
90	O
%	O
inhibition	O
noted	O
with	O
10	O
U/ml	O
.	O

Using	O
mitogen	O
stimulated	O
and	O
quiescent	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
and	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
we	O
compared	O
differences	O
in	O
basal	O
transcription	O
and	O
amounts	O
and	O
binding	O
of	O
transcription	B-protein
factors	I-protein
with	O
TRE-1	B-DNA
.	O

Cell-to-cell	O
contact	O
activates	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
of	O
human	O
immunodeficiency	O
virus	O
1	O
through	O
its	O
kappaB	B-DNA
motif	I-DNA
.	O

Thus	O
these	O
data	O
suggest	O
that	O
the	O
phorbol	O
myristate-induced	O
signal	O
(	O
prolonged	O
protein	B-protein
kinase	I-protein
C	I-protein
activation	O
?	O
)	O
can	O
not	O
be	O
inhibited	O
by	O
prior	O
incubation	O
with	O
dexamethasone	O
and	O
it	O
also	O
protects	O
the	O
induced	B-RNA
mRNA	I-RNA
for	O
the	O
degradative	O
action	O
of	O
dexamethasone	O
.	O

Receptor	O
binding	O
studies	O
with	O
dexamethasone	O
were	O
performed	O
with	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

CAT	O
expression	O
directed	O
by	O
the	O
IL2	B-DNA
regulatory	I-DNA
region	I-DNA
or	O
by	O
a	O
multimer	O
of	O
the	O
NF-AT-binding	B-DNA
site	I-DNA
was	O
markedly	O
lower	O
in	O
the	O
patient	O
relative	O
to	O
controls	O
.	O

Both	O
proteins	O
display	O
a	O
high	O
turnover	O
in	O
B	B-cell_type
cells	I-cell_type
although	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
is	O
considerably	O
more	O
stable	O
than	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

However	O
,	O
we	O
show	O
that	O
mutant	O
forms	O
of	O
E1A	B-protein
that	O
no	O
longer	O
bind	O
p300/CBP	B-protein
can	O
still	O
interact	O
directly	O
with	O
Stat1	B-protein
(	O
via	O
E1A	B-protein
N-terminal	I-protein
and	I-protein
Stat1	I-protein
C-terminal	I-protein
residues	I-protein
)	O
and	O
block	O
IFNgamma-driven	O
,	O
Stat1	B-protein
-dependent	O
gene	O
activation	O
and	O
consequent	O
function	O
during	O
early-phase	O
infection	O
in	O
the	O
natural	B-cell_type
host	I-cell_type
cell	I-cell_type
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
expression	O
of	O
two	O
T-cell-specific	B-protein
transcription	I-protein
factors	I-protein
(	O
TCF-1	B-protein
and	O
GATA-3	B-protein
)	O
and	O
one	O
B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
(	O
BSAP	B-protein
)	O
in	O
cultured	B-cell_line
H-RS	I-cell_line
cells	I-cell_line
by	O
using	O
a	O
gel	O
mobility	O
shift	O
assay	O
.	O

From	O
these	O
observations	O
we	O
conclude	O
that	O
free	O
thiols	O
in	O
the	O
IL-1RI	B-protein
complex	I-protein
are	O
essential	O
for	O
the	O
activation	O
of	O
the	O
IL-1RI-associated	B-protein
protein	I-protein
kinase	I-protein
and	O
that	O
this	O
process	O
is	O
mandatory	O
for	O
IL-1	B-protein
signaling	O
leading	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Additional	O
work	O
,	O
employing	O
sequential	O
and	O
internal	O
deletions	O
of	O
ZEBRA	B-protein
's	O
N-terminal	B-protein
activation	I-protein
domain	I-protein
,	O
indicates	O
that	O
its	O
separate	O
activities	O
are	O
not	O
attributable	O
to	O
specific	O
subdomains	B-protein
but	O
are	O
spread	O
throughout	O
its	O
N	B-protein
terminus	I-protein
and	O
therefore	O
can	O
not	O
be	O
inactivated	O
by	O
deleting	O
localized	O
regions	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
PGG-Glucan	O
induced	O
the	O
activation	O
of	O
an	O
NF-kappaB-like	B-protein
nuclear	I-protein
transcription	I-protein
factor	I-protein
in	O
purified	B-cell_type
human	I-cell_type
neutrophils	I-cell_type
.	O

HTLV-1-transformed	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
expressed	O
higher	O
amounts	O
of	O
STAT1	B-RNA
,	I-RNA
STAT3	I-RNA
and	I-RNA
STAT5	I-RNA
RNA	I-RNA
and	O
proteins	O
than	O
virus-negative	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Despite	O
constitutive	O
association	O
with	O
TRADD	B-protein
or	O
RIP	B-protein
,	O
LMP1	B-protein
does	O
not	O
induce	O
apoptosis	O
in	O
EBV-negative	B-cell_line
Burkitt	I-cell_line
lymphoma	I-cell_line
or	I-cell_line
human	I-cell_line
embryonic	I-cell_line
kidney	I-cell_line
293	I-cell_line
cells	I-cell_line
.	O

Megakaryocytic	B-cell_line
and	I-cell_line
erythrocytic	I-cell_line
lineages	I-cell_line
share	O
specific	O
transcription	B-protein
factors	I-protein
.	O

EBNA-5	B-protein
is	O
one	O
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
-encoded	I-protein
nuclear	I-protein
proteins	I-protein
required	O
for	O
immortalization	O
of	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

The	O
effect	O
of	O
heat	O
shock	O
on	O
the	O
expression	O
of	O
the	O
nuclear	B-DNA
protooncogenes	I-DNA
c-fos	B-DNA
,	O
c-jun	B-DNA
,	O
and	O
c-myc	B-DNA
was	O
studied	O
in	O
human	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

This	O
core	O
contains	O
a	O
GATA	B-DNA
site	I-DNA
separated	O
by	O
10	O
base	O
pairs	O
from	O
an	O
E-box	B-DNA
motif	I-DNA
.	O

4	O
+/-	O
1	O
U/mL	O
in	O
the	O
AIDS-C	O
group	O
and	O
2	O
+/-	O
0.5	O
U/mL	O
in	O
the	O
C	O
group	O
;	O
P	O
<	O
0.01	O
)	O
.	O

Both	O
CD2	B-protein
and	O
CD3	B-protein
cross-linking	O
increased	O
binding	O
of	O
nuclear	B-protein
proteins	I-protein
to	O
a	O
radiolabelled	O
CRE	O
oligonucleotide	O
probe	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggesting	O
that	O
lymphocyte	O
activation	O
enhances	O
binding	O
independently	O
of	O
phosphorylation	O
of	O
CREB	B-protein
at	O
serine	O
133	O
.	O

An	O
androgen	O
receptor	O
binding	O
assay	O
of	O
cultured	B-cell_line
genital	I-cell_line
skin	I-cell_line
fibroblasts	I-cell_line
was	O
negative	O
.	O

Activation	O
of	O
T	O
cells	O
results	O
in	O
the	O
rapid	O
calcineurin	B-protein
-dependent	O
translocation	O
of	O
NFAT	B-protein
transcription	B-protein
factors	I-protein
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
.	O

By	O
using	O
a	O
nucleosome	B-protein
-assembly	O
system	O
derived	O
from	O
Drosophila	O
embryos	O
,	O
we	O
find	O
that	O
the	O
packaging	O
of	O
DNA	O
into	O
chromatin	B-DNA
in	O
vitro	O
strongly	O
represses	O
HIV-1	O
transcription	O
and	O
that	O
repression	O
can	O
be	O
counteracted	O
efficiently	O
by	O
preincubation	O
of	O
the	O
DNA	O
with	O
LEF-1	B-protein
(	O
or	O
LEF-1	B-protein
and	O
Ets-1	B-protein
)	O
supplemented	O
with	O
fractions	O
containing	O
the	O
promoter-binding	B-protein
protein	I-protein
,	O
Sp1	B-protein
.	O

Recent	O
reports	O
have	O
suggested	O
a	O
previously	O
unexpected	O
variability	O
in	O
the	O
expression	O
of	O
the	O
dominant	B-cell_line
neoplastic	I-cell_line
clone	I-cell_line
in	O
myeloproliferative	O
disorders	O
(	O
MPD	O
)	O
.	O

To	O
date	O
,	O
little	O
is	O
known	O
about	O
the	O
intracellular	O
pathway	O
of	O
M-CSF	B-protein
signal	O
transduction	O
.	O

Thus	O
,	O
substitutions	O
within	O
the	O
ligand-binding	B-protein
domain	I-protein
of	O
the	O
squirrel	O
monkey	O
glucocorticoid	B-protein
receptor	I-protein
can	O
not	O
account	O
for	O
the	O
decreased	O
binding	O
affinity	O
of	O
these	O
receptors	O
in	O
squirrel	B-cell_type
monkey	I-cell_type
cells	I-cell_type
.	O

However	O
,	O
BRL49653	O
,	O
a	O
PPARgamma	B-protein
ligand	O
,	O
failed	O
to	O
induce	O
MCP-1	B-protein
secretion	O
either	O
alone	O
or	O
to	O
modify	O
the	O
expression	O
level	O
induced	O
by	O
RA	O
.	O

Mechanical	O
ventilation	O
induced	O
low	O
levels	O
of	O
IL-8	B-protein
secretion	O
by	O
alveolar	B-cell_type
type	I-cell_type
II-like	I-cell_type
cells	I-cell_type
.	O

Reversions	O
or	O
additional	O
mutations	O
were	O
not	O
detected	O
in	O
the	O
U3	B-DNA
and	I-DNA
R	I-DNA
regions	I-DNA
of	O
proviral	B-DNA
DNA	I-DNA
from	O
CEMxl74	B-cell_line
cells	I-cell_line
infected	O
with	O
the	O
SIVmac239	O
mutants	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
(	O
1	O
)	O
determine	O
the	O
time	O
course	O
of	O
neutrophil	O
adhesion	O
to	O
monolayers	O
of	O
human	B-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
HUVECs	B-cell_line
)	O
that	O
were	O
exposed	O
to	O
60	O
minutes	O
of	O
anoxia	O
followed	O
by	O
30	O
to	O
600	O
minutes	O
of	O
reoxygenation	O
and	O
(	O
2	O
)	O
define	O
the	O
mechanisms	O
responsible	O
for	O
both	O
the	O
early	O
(	O
minutes	O
)	O
and	O
late	O
(	O
hours	O
)	O
hyperadhesivity	O
of	O
postanoxic	B-cell_line
HUVECs	I-cell_line
to	O
human	B-cell_type
neutrophils	I-cell_type
.	O

The	O
Zfh	B-protein
family	I-protein
of	O
zinc	B-protein
finger/homeodomain	I-protein
proteins	I-protein
was	O
first	O
identified	O
in	O
Drosophila	O
where	O
it	O
is	O
required	O
for	O
differentiation	O
of	O
tissues	O
such	O
as	O
the	O
central	O
nervous	O
system	O
and	O
muscle	O
.	O

mRNA	O
for	O
c-fes	O
has	O
been	O
detected	O
exclusively	O
in	O
myeloid	B-cell_type
cells	I-cell_type
and	O
vascular	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
in	O
adult	O
mammals	O
.	O

Towards	O
a	O
molecular	O
understanding	O
of	O
T-cell	O
differentiation	O
.	O

We	O
have	O
shown	O
previously	O
that	O
EBNA2	B-protein
transactivates	O
the	O
promoters	O
of	O
the	O
latent	B-protein
membrane	I-protein
antigens	I-protein
LMP	B-protein
,	O
TP1	B-protein
and	O
TP2	B-protein
.	O

AFR	O
behaves	O
like	O
ascorbate	O
,	O
while	O
DHA	O
and	O
ascorbate	O
phosphate	O
do	O
not	O
affect	O
TNF-alpha	B-protein
-mediated	O
NF-kappaB	B-protein
activation	O
.	O

Oxidants	O
such	O
as	O
hydrogen	O
peroxide	O
are	O
known	O
to	O
activate	O
certain	O
transcription	B-protein
factors	I-protein
such	O
as	O
nuclear	B-protein
transcription	I-protein
factor	I-protein
kappa	I-protein
beta	I-protein
.	O

Cell	O
sorting	O
of	O
normal	O
bone	O
marrow	O
showed	O
MNDA	B-protein
expression	O
in	O
CD20	B-protein
+/CD10-/CD5-	O
B	B-cell_type
cells	I-cell_type
.	O

Expression	O
of	O
the	O
gene	O
encoding	O
human	B-protein
inosine-	I-protein
5'-monophosphate	I-protein
dehydrogenase	I-protein
(	I-protein
IMPDH	I-protein
)	I-protein
type	I-protein
II	I-protein
,	O
an	O
enzyme	B-protein
catalyzing	O
the	O
rate-limiting	O
step	O
in	O
the	O
generation	O
of	O
guanine	O
nucleotides	O
,	O
is	O
increased	O
more	O
than	O
10-fold	O
in	O
activated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
is	O
required	O
for	O
T	O
cell	O
activation	O
.	O

CTLA-4	B-protein
engagement	O
by	O
mAbs	B-protein
inhibits	O
,	O
while	O
CD28	B-protein
enhances	O
,	O
IL-2	B-protein
production	O
and	O
proliferation	O
upon	O
T	O
cell	O
activation	O
.	O

Estrogen	O
binding	O
sites	O
in	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
effects	O
of	O
danazol	O
on	O
their	O
sites	O
in	O
vitro	O
.	O

Mutations	O
in	O
the	O
TSC2	B-DNA
gene	I-DNA
on	O
chromosome	B-DNA
16p13.3	I-DNA
are	O
responsible	O
for	O
approximately	O
50	O
%	O
of	O
familial	O
tuberous	O
sclerosis	O
(	O
TSC	O
)	O
.	O

During	O
15	O
days	O
of	O
treatment	O
of	O
K562	B-cell_line
cells	I-cell_line
with	O
sodium	O
phenylacetate	O
,	O
we	O
observed	O
an	O
increase	O
in	O
the	O
cellular	O
hemoglobin	B-protein
concentration	O
with	O
a	O
similar	O
increase	O
in	O
the	O
expression	O
of	O
gamma-globin	B-RNA
mRNA	I-RNA
.	O

Here	O
,	O
we	O
show	O
that	O
OCA-B	B-protein
alters	O
the	O
activity	O
of	O
Oct-1	B-protein
in	O
two	O
ways	O
.	O

Nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
by	O
macrophages	B-cell_type
and	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
requires	O
the	O
presence	O
of	O
the	O
bacterial	O
flagellum	O
.	O

Furthermore	O
,	O
an	O
important	O
role	O
for	O
egr-1	B-DNA
in	O
determining	O
the	O
differentiation	O
pathway	O
of	O
myeloid	B-cell_type
cell	I-cell_type
precursors	I-cell_type
has	O
been	O
recently	O
elaborated	O
.	O

Inhibition	O
of	O
T	O
cell	O
activation	O
by	O
the	O
extracellular	B-protein
matrix	I-protein
protein	I-protein
tenascin	B-protein
.	O

RESULTS	O
:	O
Six	O
mAECA	B-protein
were	O
selected	O
,	O
the	O
mixture	O
of	O
which	O
produced	O
100	O
%	O
inhibition	O
of	O
binding	O
of	O
the	O
original	O
IgG	B-protein
(	O
from	O
the	O
patient	O
with	O
Takayasu	O
arteritis	O
)	O
to	O
HUVEC	B-cell_line
.	O

They	O
are	O
composed	O
of	O
different	O
structural	B-protein
domains	I-protein
,	O
including	O
distinct	O
domains	O
for	O
DNA	O
and	O
ligand	O
binding	O
.	O

A	O
reduction	O
of	O
serum	O
androgens	O
was	O
found	O
,	O
whereas	O
no	O
change	O
was	O
observed	O
in	O
either	O
basal	O
or	O
GnRH-stimulated	O
gonadotropins	O
or	O
in	O
the	O
cortisol	O
and	O
17	O
alpha-hydroxyprogesterone	O
response	O
to	O
ACTH	O
.	O

It	O
predicts	O
for	O
two	O
open	B-DNA
reading	I-DNA
frames	I-DNA
(	O
ORFs	B-DNA
)	O
.	O

Transcription	B-protein
factor	I-protein
activation	O
and	O
gene	O
transcription	O
were	O
studied	O
by	O
gel-shift	O
assays	O
and	O
Northern	O
blot	O
analysis	O
,	O
respectively	O
.	O

Furthermore	O
,	O
as	O
compared	O
to	O
regulation	O
by	O
phorbol	O
ester	O
,	O
collagenase	B-protein
induction	O
in	O
monocytic	B-cell_type
cells	I-cell_type
by	O
cell	O
wall	O
derivatives	O
of	O
bacteria	O
or	O
yeast	O
is	O
largely	O
independent	O
of	O
upstream	B-DNA
promoter	I-DNA
sequences	I-DNA
.	O

CCAAT/enhancer	B-protein
binding	I-protein
protein	I-protein
(	I-protein
C/EBP	I-protein
)	I-protein
epsilon	I-protein
is	O
a	O
recently	O
cloned	O
member	O
of	O
the	O
C/EBP	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
and	O
is	O
expressed	O
exclusively	O
in	O
cells	O
of	O
hematopoietic	O
origin	O
.	O

First	O
,	O
we	O
show	O
that	O
mutations	O
in	O
the	O
LEF-1-binding	B-DNA
site	I-DNA
inhibit	O
the	O
activity	O
of	O
multimerized	B-DNA
copies	I-DNA
of	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
and	O
that	O
LEF-1/GAL4	B-protein
can	O
activate	O
a	O
GAL4-substituted	B-DNA
HIV-1	I-DNA
enhancer	I-DNA
80-	O
to	O
100-fold	O
in	O
vivo	O
.	O

Identification	O
of	O
nucleotide	B-DNA
sequences	I-DNA
that	O
regulate	O
transcription	O
of	O
the	O
MCF13	O
murine	O
leukemia	O
virus	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
in	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O

These	O
mechanisms	O
include	O
the	O
assembly	O
of	O
higher	B-protein
order	I-protein
nucleoprotein	I-protein
complexes	I-protein
and	O
other	O
protein-protein	O
interactions	O
that	O
enhance	O
the	O
functional	O
specificity	O
of	O
transcriptional	B-protein
regulators	I-protein
in	O
lymphocytes	O
.	O

Both	O
molecules	O
enhanced	O
LPS-induced	O
NF-kappaB	B-protein
and	O
activating	B-protein
protein-1	I-protein
binding	O
activity	O
.	O

The	O
intracellular	O
events	O
that	O
lead	O
to	O
the	O
inactivation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
i.e.	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
are	O
complex	O
.	O

Parental	O
as	O
well	O
as	O
transfected	O
SKW6.4	B-cell_line
cells	I-cell_line
were	O
transiently	O
transfected	O
with	O
an	O
IgH-enhancer-luciferase	B-DNA
construct	I-DNA
.	O

Pretreatment	O
with	O
B.pertussis	O
,	O
V.cholera.	O
or	O
C.botulinum	O
toxin	O
did	O
not	O
influence	O
histamine-induced	O
[	O
Ca2+	O
]	O
i	O
rise	O
.	O

This	O
suggests	O
that	O
higher	O
intracellular	O
levels	O
of	O
STAT1	B-protein
,	O
STAT2	B-protein
,	O
and	O
p48	B-protein
protein	I-protein
may	O
result	O
in	O
enhanced	O
signal	O
transduction	O
for	O
cytokines	B-protein
utilizing	O
these	O
transcription	B-protein
factors	I-protein
.	O

Deletion	O
analysis	O
of	O
the	O
carboxyl-terminal	B-protein
region	I-protein
of	O
Stat6	B-protein
and	O
recombination	O
of	O
this	O
region	O
with	O
a	O
heterologous	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
allowed	O
the	O
delimitation	O
and	O
characterization	O
of	O
the	O
transactivation	O
domain	O
of	O
Stat6	B-protein
.	O

Recent	O
studies	O
have	O
defined	O
genetic	O
alterations	O
commonly	O
associated	O
with	O
transformed	B-cell_line
lymphocytes	I-cell_line
.	O

The	O
virulence	O
defect	O
conferred	O
by	O
mutations	O
in	O
the	O
phoP	B-DNA
-phoQ	B-DNA
two-component	O
regulatory	O
system	O
is	O
not	O
completely	O
explained	O
by	O
alterations	O
in	O
resistance	O
to	O
cationic	B-protein
proteins	I-protein
and	O
involves	O
the	O
control	O
of	O
other	O
proteins	O
necessary	O
for	O
S.	O
typhimurium	O
survival	O
within	O
macrophages	B-cell_type
.	O

Thus	O
,	O
we	O
focused	O
our	O
study	O
on	O
isolated	O
FDC	B-cell_type
clusters	O
from	O
normal	O
tonsils	O
.	O

Gender	O
and	O
vascular	O
reactivity	O
.	O

These	O
results	O
indicate	O
that	O
LMP1	B-protein
appropriates	O
TRADD	B-protein
to	O
enable	O
efficient	O
long-term	O
lymphoblastoid	O
cell	O
outgrowth	O
.	O

These	O
results	O
suggest	O
that	O
p47phox	O
is	O
involved	O
in	O
the	O
signal	O
transduction	O
of	O
IL-4	B-protein
in	O
B	B-cell_type
cells	I-cell_type
.	O

The	O
critical	O
region	O
of	O
THR	B-protein
beta	O
was	O
mapped	O
to	O
3	O
amino	O
acids	O
in	O
the	O
distal	B-protein
box	I-protein
of	O
the	O
DNA	B-protein
binding	I-protein
domain	I-protein
.	O

Activation	O
of	O
the	O
LTR	B-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
was	O
strongly	O
enhanced	O
by	O
vanadate	O
and	O
inhibited	O
by	O
catalase	B-protein
,	O
implicating	O
H2O2	O
.	O

The	O
serum	O
also	O
detected	O
a	O
170-kD	B-protein
protein	I-protein
that	O
seems	O
to	O
be	O
a	O
mouse	O
homologue	O
of	O
human	B-protein
BAF170	I-protein
.	O

Since	O
this	O
is	O
the	O
first	O
report	O
on	O
IL-10	B-protein
induced	O
signal	O
transduction	O
,	O
these	O
data	O
may	O
help	O
to	O
identify	O
the	O
intracellular	O
mechanisms	O
by	O
which	O
IL-10	B-protein
stimulates	O
human	B-cell_type
B-cells	I-cell_type
.	O

We	O
constructed	O
a	O
yeast	O
reporter	O
strain	O
containing	O
the	O
lacZ	B-DNA
gene	I-DNA
under	O
the	O
control	O
of	O
the	O
CYC1	B-DNA
promoter	I-DNA
associated	O
with	O
three	O
copies	O
of	O
TRE-1	B-DNA
.	O

To	O
determine	O
and	O
compare	O
protein/DNA	O
interactions	O
at	O
the	O
native	O
IFN-gamma	B-protein
locus	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
we	O
analyzed	O
the	O
human	B-DNA
IFN-gamma	I-DNA
promoter	I-DNA
by	O
ligation-mediated	O
polymerase	O
chain	O
reaction	O
(	O
LM-PCR	O
)	O
techniques	O
.	O

In	O
this	O
study	O
,	O
we	O
isolated	O
a	O
cDNA	B-DNA
coding	O
for	O
FK506-binding	O
protein	O
(	O
FKBP	B-protein
)	O
from	O
human	O
peripheral	O
blood	O
T	B-cell_type
cells	I-cell_type
by	O
using	O
mixed	O
20-mer	O
oligonucleotide	O
probes	O
synthesized	O
on	O
the	O
basis	O
of	O
the	O
sequence	O
,	O
Glu-Asp-Gly-Lys-Lys-Phe-Asp	O
,	O
reported	O
for	O
bovine	B-protein
FKBP	I-protein
.	O

The	O
molecular	O
mechanisms	O
regulating	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
persistence	O
in	O
a	O
major	O
cell	O
reservoir	O
such	O
as	O
the	O
macrophage	B-cell_type
remain	O
unknown	O
.	O

A	O
complementary	B-DNA
DNA	I-DNA
encoding	O
a	O
DNA-binding	B-protein
protein	I-protein
(	O
human	B-protein
X	I-protein
box	I-protein
binding	I-protein
protein	I-protein
,	O
hXBP-1	B-protein
)	O
whose	O
target	O
is	O
the	O
human	B-DNA
DR	I-DNA
alpha	I-DNA
X	I-DNA
box	I-DNA
and	O
the	O
3	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
has	O
now	O
been	O
cloned	O
.	O

In	O
the	O
first	O
approach	O
,	O
stable	O
clones	O
of	O
two	O
B-cell	B-cell_line
lines	I-cell_line
carrying	O
an	O
LMP1	B-protein
gene	O
under	O
the	O
control	O
of	O
an	O
inducible	O
metallothionein	B-DNA
promoter	I-DNA
were	O
induced	O
to	O
express	O
LMP1	B-protein
in	O
all	O
cells	O
.	O

Apoptosis	O
,	O
or	O
programmed	O
cell	O
death	O
,	O
was	O
demonstrated	O
as	O
the	O
mode	O
of	O
cell	O
death	O
by	O
using	O
the	O
TUNEL	O
assay	O
,	O
which	O
detects	O
single	O
strand	O
nicks	O
in	O
DNA	O
,	O
or	O
by	O
the	O
Nicoletti	O
technique	O
demonstrating	O
a	O
subdiploid	O
population	O
by	O
DNA	O
staining	O
.	O

This	O
study	O
was	O
initiated	O
to	O
investigate	O
whether	O
a	O
cytokine	B-protein
imbalance	O
oriented	O
toward	O
Th2	O
type	O
response	O
plays	O
a	O
role	O
in	O
chronic	O
hepatitis	O
B	O
.	O

Cyclosporin	O
A	O
interferes	O
with	O
the	O
inducible	O
degradation	O
of	O
NF-kappa	B-protein
B	I-protein
inhibitors	O
,	O
but	O
not	O
with	O
the	O
processing	O
of	O
p105/	O
NF-kappa	B-protein
B1	I-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

Inhibition	O
of	O
proliferation	O
and	O
apoptosis	O
of	O
human	B-cell_type
and	I-cell_type
rat	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
by	O
curcumin	O
,	O
a	O
curry	O
pigment	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
further	O
analyze	O
changes	O
in	O
cytokine	B-protein
production	O
and	O
intracellular	O
signaling	O
during	O
anergy	O
induction	O
using	O
high	O
concentrations	O
of	O
native	O
peptide	O
ligand	O
of	O
tetanus	B-cell_line
toxoid	I-cell_line
(	I-cell_line
TT	I-cell_line
)	I-cell_line
-	I-cell_line
and	I-cell_line
myelin	I-cell_line
basic	I-cell_line
protein	I-cell_line
(	I-cell_line
MBP	I-cell_line
)	I-cell_line
-specific	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Binding	O
of	O
AP-2	B-protein
prevented	O
the	O
subsequent	O
binding	O
of	O
members	O
of	O
the	O
CREB/ATF	B-protein
family	I-protein
to	O
an	O
adjacent	B-DNA
regulatory	I-DNA
motif	I-DNA
in	O
the	O
21	B-DNA
bp	I-DNA
repeat	I-DNA
.	O

We	O
next	O
studied	O
p65	O
and	O
c-Rel	O
protein	O
expression	O
in	O
FDC	B-cell_type
clusters	O
.	O

The	O
PB1	B-DNA
sequence	O
motif	O
is	O
highly	O
conserved	O
in	O
both	O
human	B-DNA
and	I-DNA
murine	I-DNA
GM-CSF	I-DNA
genes	I-DNA
.	O

In	O
mutant	O
leukemic	B-cell_type
cells	I-cell_type
resistant	O
to	O
the	O
lytic	O
effects	O
of	O
dexamethasone	O
,	O
CVZ	O
both	O
lyses	O
the	O
cells	O
and	O
recognizes	O
a	O
single	O
class	O
of	O
sites	O
similar	O
to	O
the	O
high	O
affinity	O
site	O
in	O
CEM	B-cell_line
C7	I-cell_line
cells	I-cell_line
.	O

In	O
attempting	O
to	O
investigate	O
its	O
effect	O
on	O
activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
we	O
found	O
triptolide	O
induces	O
apoptotic	O
death	O
of	O
T	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
and	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
but	O
not	O
that	O
of	O
thymocytes	B-cell_type
.	O

We	O
found	O
that	O
removal	O
of	O
the	O
TNF-alpha	B-protein
containing	O
medium	O
causes	O
a	O
rapid	O
decrease	O
in	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
.	O

Dr.	O
Dezube	O
of	O
Beth	O
Israel	O
Hospital	O
(	O
Boston	O
)	O
concisely	O
reviews	O
the	O
state	O
of	O
our	O
knowledge	O
regarding	O
the	O
effects	O
of	O
pentoxifylline	O
on	O
expression	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
a	O
cytokine	B-protein
known	O
to	O
influence	O
HIV-1	O
replication	O
and	O
to	O
play	O
a	O
possible	O
role	O
in	O
the	O
clinical	O
manifestations	O
of	O
advanced	O
infection	O
with	O
this	O
virus	O
.	O

[	O
Differential	O
diagnostic	O
value	O
of	O
receptors	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
calcitriol	O
)	O
determination	O
in	O
lymphocytes	B-cell_type
of	O
children	O
with	O
rickets	O
and	O
rickets-like	O
diseases	O
]	O

The	O
disruption	O
of	O
HIV-TF1-binding	B-DNA
site	I-DNA
induced	O
a	O
60	O
%	O
decrease	O
in	O
the	O
level	O
of	O
transcription	O
from	O
the	O
HIV	B-DNA
promoter	I-DNA
in	O
vivo	O
.	O

Fos	B-protein
kinase	I-protein
was	O
shown	O
to	O
be	O
distinct	O
from	O
other	O
identified	O
serine/threonine	B-protein
kinases	I-protein
,	O
including	O
protein	B-protein
kinase	I-protein
A	I-protein
,	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
casein	B-protein
kinase	I-protein
II	I-protein
,	O
MAP	B-protein
kinases	I-protein
,	O
p70S6K	B-protein
and	O
p90RSK	B-protein
.	O

STAT5A-STAT5A	B-protein
homodimers	I-protein
and	O
STAT5A-STAT5B	B-protein
heterodimers	I-protein
formed	O
in	O
response	O
to	O
GM-CSF	B-protein
.	O

Moreover	O
,	O
we	O
found	O
that	O
ectopic	O
expression	O
of	O
a	O
B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
(	O
Oct-2	B-protein
)	O
dramatically	O
altered	O
both	O
the	O
phenotype	O
and	O
chromosome	O
constitution	O
of	O
hybrids	O
arising	O
in	O
these	O
cell	O
fusions	O
.	O

Signals	O
transduced	O
through	O
the	O
CD4	B-protein
molecule	I-protein
on	O
T	B-cell_type
lymphocytes	I-cell_type
activate	O
NF-kappa	B-protein
B	I-protein
.	O

We	O
also	O
report	O
three	O
additional	O
isoforms	O
of	O
NFATx	B-protein
,	O
designated	O
NFATx2	B-protein
,	O
NFATx3	B-protein
,	O
and	O
NFATx4	B-protein
.	O

Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
were	O
stably	O
transfected	O
with	O
a	O
single	O
vector	O
encoding	O
the	O
tetracycline	B-protein
trans-activator	I-protein
protein	I-protein
,	O
controlled	O
by	O
a	O
constitutive	B-DNA
promoter	I-DNA
,	O
and	O
the	O
chimeric	B-protein
TCR	I-protein
,	O
under	O
the	O
control	O
of	O
a	O
trans-activator	B-DNA
protein-responsive	I-DNA
promoter	I-DNA
.	O

Constitutive	O
expression	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
was	O
detected	O
in	O
various	O
kinds	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
including	O
macrophages	O
and	O
activated	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
as	O
well	O
as	O
in	O
cell	O
lines	O
KG-1	B-cell_line
(	O
myeloblasts	B-cell_line
)	O
,	O
HL-60	B-cell_line
(	O
promyelocytes	B-cell_line
)	O
,	O
ML-3	B-cell_line
(	O
myelomonoblasts	B-cell_line
)	O
,	O
U937	B-cell_line
,	O
THP-1	B-cell_line
(	O
monoblasts	B-cell_line
)	O
,	O
K562	B-cell_line
(	O
erythroblasts	B-cell_line
)	O
,	O
and	O
S-LB1	B-cell_line
(	O
HTLV-1-transfected	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
)	O
.	O

ZRE-B	B-DNA
can	O
be	O
deleted	O
without	O
affecting	O
the	O
R-dependent	O
enhancer	O
activity	O
.	O

The	O
underlying	O
mechanisms	O
by	O
which	O
the	O
corresponding	O
genes	O
are	O
transcriptionally	O
initiated	O
after	O
virus	O
infection	O
are	O
still	O
poorly	O
understood	O
.	O

Furthermore	O
,	O
these	O
core	O
regions	O
of	O
the	O
enhancer	O
and	O
promoter	O
each	O
encompass	O
closely	B-DNA
linked	I-DNA
binding	I-DNA
sites	I-DNA
for	O
CBF	B-protein
,	O
AP-1	B-protein
,	O
and	O
NFATp	B-protein
.	O

We	O
demonstrate	O
that	O
0.1-0.5	O
microM	O
DMDTC	O
inhibits	O
TNF-alpha	B-protein
-induced	O
activation	O
of	O
NF-kappaB	B-protein
in	O
primary	B-cell_type
human	I-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
upstream	O
regions	O
UAS3	B-DNA
(	O
-1168	B-DNA
to	I-DNA
-440	I-DNA
)	O
and	O
UAS2	B-DNA
(	O
-352	B-DNA
to	I-DNA
-264	I-DNA
)	O
both	O
functioned	O
in	O
a	O
cell	O
lineage-independent	O
manner	O
and	O
were	O
together	O
responsible	O
for	O
the	O
bulk	O
of	O
Wp	O
activity	O
in	O
non-B	B-cell_type
cells	I-cell_type
;	O
mutational	O
analysis	O
indicated	O
the	O
importance	O
of	O
a	O
YY1	B-DNA
binding	I-DNA
site	I-DNA
in	O
UAS2	B-DNA
in	O
that	O
context	O
.	O

Cutting	O
edge	O
:	O
TCR	B-protein
stimulation	O
by	O
antibody	O
and	O
bacterial	O
superantigen	O
induces	O
Stat3	B-protein
activation	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Recently	O
,	O
the	O
development	O
of	O
monoclonal	O
antibodies	O
directed	O
against	O
ER	B-protein
has	O
been	O
applied	O
to	O
the	O
study	O
of	O
breast	O
carcinomas	O
and	O
results	O
obtained	O
show	O
good	O
correlation	O
with	O
the	O
quantitative	O
SBA	O
.	O

V3-BH10	B-protein
,	O
which	O
consists	O
of	O
42	B-protein
amino	I-protein
acids	I-protein
and	O
has	O
a	O
loop	B-protein
structure	I-protein
,	O
suppressed	O
IL-2	B-protein
-driven	O
proliferation	O
of	O
all	O
IL-2-dependent	B-cell_line
cells	I-cell_line
[	O
Kit225	B-cell_line
,	O
ED-40515	B-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
,	O
KT-3	B-cell_line
,	O
7-day	B-cell_line
PHA-blasts	I-cell_line
,	O
and	O
fresh	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
]	O
tested	O
,	O
whereas	O
it	O
did	O
not	O
suppress	O
the	O
cell	O
growth	O
of	O
IL-2-independent	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
Hut102	B-cell_line
,	O
Molt-4	B-cell_line
,	O
and	O
Jurkat	B-cell_line
)	O
.	O

We	O
propose	O
that	O
KBF1	B-protein
is	O
a	O
competitive	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
discuss	O
how	O
these	O
factors	O
may	O
be	O
involved	O
in	O
the	O
transient	O
expression	O
of	O
IL-2	B-protein
and	O
IL-2	B-protein
alpha	I-protein
genes	O
during	O
the	O
immune	O
response	O
.	O

However	O
,	O
Rta	B-protein
has	O
recently	O
been	O
reported	O
to	O
disrupt	O
latency	O
in	O
an	O
epithelial	O
specific	O
manner	O
(	O
S.	O
Zalani	O
,	O
E.	O
Holley-Guthrie	O
,	O
and	O
S.	O
Kenney	O
,	O
Proc.	O
Natl.	O
Acad.	O
Sci.	O
USA	O
93	O
:	O
9194-9199	O
,	O
1996	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

9-cis	O
retinoic	O
acid	O
induces	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
secretion	O
in	O
human	B-cell_type
monocytic	I-cell_type
THP-1	I-cell_type
cells	I-cell_type
.	O

Eight	O
patients	O
in	O
long-term	O
(	O
LT	O
;	O
3	O
to	O
15	O
years	O
)	O
and	O
15	O
patients	O
in	O
short-term	O
(	O
ST	O
;	O
up	O
to	O
3	O
years	O
)	O
remission	O
were	O
studied	O
.	O

This	O
was	O
also	O
accompanied	O
by	O
a	O
decrease	O
in	O
both	O
PKC	B-protein
activity	O
and	O
nuclear	O
transcription	O
factor-	O
kappaB	B-protein
activation	O
,	O
also	O
without	O
loss	O
of	O
cell	O
viability	O
.	O

One	O
of	O
the	O
essential	O
proteins	O
which	O
bound	O
to	O
the	O
enhancer	O
was	O
similar	O
or	O
identical	O
to	O
members	O
of	O
the	O
C/EBP	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
required	O
for	O
both	O
IL-1	B-protein
-and	O
LPS-specific	O
induction	O
of	O
the	O
IL-6	B-DNA
gene	I-DNA
(	O
i.e.	O
,	O
the	O
NF-IL6	B-DNA
proteins	I-DNA
)	O
.	O

We	O
used	O
cytokine	O
production	O
as	O
a	O
readout	O
for	O
monocyte	O
activation	O
and	O
found	O
that	O
CD15	O
cross-linking	O
induced	O
TNF-alpha	B-protein
release	O
from	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
cells	O
from	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
MM6	I-cell_line
.	O

Human	O
lysosomal	B-protein
acid	I-protein
lipase	I-protein
(	O
LAL	B-protein
)	O
is	O
a	O
hydrolase	B-protein
required	O
for	O
the	O
cleavage	O
of	O
cholesteryl	O
esters	O
and	O
triglycerides	O
derived	O
from	O
plasma	O
lipoproteins	O
.	O

Beta-catenin	O
is	O
the	O
vertebrate	O
homolog	O
of	O
the	O
Drosophila	B-DNA
segment	I-DNA
polarity	I-DNA
gene	I-DNA
Armadillo	B-DNA
and	O
plays	O
roles	O
in	O
both	O
cell-cell	O
adhesion	O
and	O
transduction	O
of	O
the	O
Wnt	O
signaling	O
cascade	O
.	O

High-level	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
in	O
thymocytes	B-cell_type
requires	O
NF-kappaB	B-protein
activation	O
through	O
interaction	O
with	O
thymic	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O

To	O
further	O
explore	O
the	O
link	O
between	O
the	O
HPA	O
and	O
the	O
immune	O
system	O
in	O
relation	O
to	O
glucocorticoid	B-protein
receptor	I-protein
function	O
,	O
dose-response	O
curves	O
were	O
obtained	O
for	O
Con	O
A	O
-and	O
PHA	B-protein
-induced	O
T-cell	O
mitogenesis	O
,	O
PWM	B-protein
-generated	O
B-cell	O
mitogenesis	O
and	O
spontaneous	O
lymphocyte	O
proliferation	O
in	O
13	O
healthy	O
controls	O
.	O

A	O
more	O
than	O
additive	O
increase	O
in	O
IRF-1	B-DNA
gene	I-DNA
expression	O
was	O
seen	O
with	O
ATRA	O
and	O
IFN-gamma	B-protein
in	O
NB4	B-cell_line
cells	I-cell_line
.	O

The	O
role	O
of	O
PtdIns	B-protein
3-kinase	I-protein
in	O
Ras	B-protein
signaling	O
in	O
T	B-cell_type
cells	I-cell_type
has	O
not	O
been	O
explored	O
.	O

Thus	O
,	O
the	O
block	O
of	O
apoptosis	O
imposed	O
by	O
E2A-HLF	B-protein
in	O
pro-B	B-cell_type
lymphocytes	I-cell_type
depends	O
critically	O
on	O
the	O
transactivating	B-protein
regions	I-protein
of	O
E2A	B-protein
.	O

The	O
AML1a-transfected	B-cell_line
K562	I-cell_line
cells	I-cell_line
had	O
a	O
reduced	O
capacity	O
to	O
differentiate	O
in	O
the	O
presence	O
of	O
sodium	O
n-butyrate	O
but	O
not	O
in	O
the	O
presence	O
of	O
other	O
inducers	O
,	O
such	O
as	O
hemin	O
,	O
1-beta-D-arabinofuranosylcytosine	O
,	O
and	O
herbimycin	O
A	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
regulation	O
of	O
NF-Y	B-protein
expression	O
during	O
human	O
monocyte	O
to	O
macrophage	O
maturation	O
.	O

Ligation	O
of	O
Ag	B-protein
receptors	I-protein
in	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
initiates	O
signal	O
transduction	O
cascades	O
which	O
alter	O
the	O
expression	O
of	O
genes	O
that	O
regulate	O
cellular	O
proliferation	O
and	O
differentiation	O
.	O

In	O
addition	O
,	O
they	O
respond	O
to	O
LPS	O
and	O
cytokines	O
with	O
activation	O
and	O
expression	O
of	O
inflammatory	B-protein
effector	I-protein
gene	I-protein
products	I-protein
similar	O
to	O
those	O
elicited	O
by	O
the	O
antigen	O
driven	O
response	O
.	O

However	O
,	O
when	O
HL60R	B-cell_line
cells	I-cell_line
were	O
transduced	O
with	O
a	O
functional	O
copy	O
of	O
the	O
RAR	B-DNA
alpha	I-DNA
gene	I-DNA
,	O
RA	O
induced	O
a	O
10-fold	O
increase	O
in	O
E3	B-protein
mRNA	O
levels	O
.	O

Constitutive	O
expression	O
of	O
HIV-1	B-protein
tat	I-protein
protein	I-protein
in	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
using	O
a	O
BK	O
virus	O
vector	O
.	O

ATRA	O
also	O
induced	O
expression	O
of	O
C/EBP	B-protein
epsilon	I-protein
protein	I-protein
in	O
NB4	B-cell_line
cells	I-cell_line
,	O
as	O
shown	O
by	O
Western	O
blotting	O
.	O

Similar	O
constructs	O
controlled	O
by	O
NF-kappa	B-protein
B	I-protein
or	O
the	O
entire	O
interleukin-2	B-DNA
enhancer	I-DNA
show	O
bimodal	O
expression	O
patterns	O
during	O
induction	O
,	O
suggesting	O
that	O
thresholds	O
set	O
by	O
the	O
concentration	O
of	O
transcription	B-protein
factors	I-protein
may	O
be	O
a	O
common	O
property	O
of	O
inducible	B-DNA
genes	I-DNA
.	O

Both	O
Tax	B-protein
-mediated	O
apoptosis	O
and	O
oxidative	O
stress	O
can	O
be	O
potently	O
suppressed	O
by	O
antioxidants	O
,	O
as	O
is	O
seen	O
with	O
the	O
administration	O
of	O
recombinant	B-protein
thioredoxin	I-protein
(	O
adult	B-protein
T	I-protein
cell	I-protein
leukemia-derived	I-protein
factor	I-protein
)	O
or	O
pyrrolidine	O
dithiocarbamate	O
.	O

Encephalomyocarditis	O
virus	O
internal	O
ribosomal	O
entry	O
site	O
RNA-protein	O
interactions	O
.	O

Our	O
results	O
demonstrated	O
that	O
:	O
(	O
i	O
)	O
PGN	O
induced	O
phosphorylation	O
of	O
the	O
transcription	B-protein
factors	I-protein
ATF-1	B-protein
and	O
CREB	B-protein
;	O
(	O
ii	O
)	O
ATF-1	B-protein
and	O
CREB	B-protein
bound	O
DNA	O
as	O
a	O
dimer	O
and	O
induced	O
transcriptional	O
activation	O
of	O
a	O
CRE	B-DNA
reporter	I-DNA
plasmid	I-DNA
,	O
which	O
was	O
inhibited	O
by	O
dominant	O
negative	O
CREB	B-protein
and	O
ATF-1	B-protein
;	O
(	O
iii	O
)	O
PGN	O
induced	O
phosphorylation	O
of	O
c-Jun	B-protein
,	O
protein	O
synthesis	O
of	O
JunB	B-protein
and	O
c-Fos	B-protein
,	O
and	O
transcriptional	O
activation	O
of	O
the	O
AP-1	B-DNA
reporter	I-DNA
plasmid	I-DNA
,	O
which	O
was	O
inhibited	O
by	O
dominant	O
negative	O
c-Fos	B-protein
;	O
and	O
(	O
iv	O
)	O
PGN-induced	O
activation	O
of	O
CREB/ATF	B-protein
and	O
AP-1	B-protein
was	O
mediated	O
through	O
CD14	B-protein
.	O

These	O
results	O
raise	O
the	O
possibility	O
that	O
NF-kappaB/Rel	B-protein
may	O
participate	O
in	O
the	O
growth	O
control	O
of	O
HTLV-I-transformed	B-cell_line
T	I-cell_line
cells	I-cell_line
by	O
regulating	O
genes	O
driven	O
by	O
both	O
kappaB	B-DNA
and	O
certain	O
STAT	B-DNA
enhancers	I-DNA
.	O

Exogenously	O
transfected	O
TAL1	B-protein
and	O
LMO	B-protein
,	O
but	O
not	O
either	O
alone	O
,	O
induced	O
RALDH2	B-protein
expression	O
in	O
a	O
T-ALL	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
HPB-ALL	B-cell_line
,	O
not	O
expressing	O
endogeneous	O
TAL1	B-protein
or	O
LMO	B-protein
.	O

Retinoidal	O
antagonists	O
and	O
potential	O
agonists	O
.	O

Consistent	O
with	O
these	O
data	O
,	O
CD40	B-protein
signals	O
up-regulate	O
c-jun	B-RNA
but	I-RNA
not	I-RNA
c-fos	I-RNA
mRNA	I-RNA
and	O
alter	O
the	O
transcription	B-protein
factor	I-protein
ATF2	B-protein
but	O
not	O
the	O
Raf-1	B-protein
protein	I-protein
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
cytokines	B-protein
on	O
IL-2	B-protein
deprivation-induced	O
apoptosis	O
of	O
human	B-cell_line
antigen-specific	I-cell_line
T	I-cell_line
helper	I-cell_line
clones	I-cell_line
with	O
different	O
cytokine	B-protein
production	O
profiles	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
DM	O
on	O
IL-2R	B-protein
alpha	I-protein
transcription	O
was	O
examined	O
by	O
determining	O
the	O
mRNA	O
levels	O
of	O
the	O
p50	O
subunit	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
that	O
stimulates	O
IL-2R	B-protein
alpha	I-protein
gene	O
expression	O
.	O

The	O
mechanism	O
by	O
which	O
progesterone	O
causes	O
localized	O
suppression	O
of	O
the	O
immune	O
response	O
during	O
pregnancy	O
has	O
remained	O
elusive	O
.	O

Expression	O
of	O
Retinoid	B-protein
X	I-protein
Receptor	I-protein
alpha	I-protein
is	O
increased	O
upon	O
monocytic	O
cell	O
differentiation	O
.	O

Evidence	O
for	O
a	O
trans-acting	B-protein
activator	I-protein
function	O
regulating	O
the	O
expression	O
of	O
the	O
human	B-protein
CD5	I-protein
antigen	I-protein
.	O

Ad5	B-DNA
E1A	I-DNA
DNA	I-DNA
was	O
detected	O
by	O
polymerase	O
chain	O
reaction	O
in	O
five	O
of	O
six	O
animals	O
20	O
days	O
after	O
infection	O
and	O
in	O
five	O
of	O
five	O
animals	O
47	O
days	O
after	O
infection	O
.	O

In	O
addition	O
to	O
NB4	O
cells	O
,	O
ATRA	O
also	O
activated	O
IRF-1	B-DNA
gene	I-DNA
expression	O
in	O
HL-60	B-cell_line
,	O
U937	B-cell_line
,	O
and	O
THP-1	B-cell_line
cells	I-cell_line
,	O
which	O
all	O
respond	O
to	O
ATRA	O
by	O
growth	O
inhibition	O
.	O

Using	O
reporter	B-DNA
gene	I-DNA
constructs	I-DNA
driven	O
by	O
the	O
CD4	B-DNA
promoter	I-DNA
,	O
we	O
report	O
that	O
HHV-6	O
can	O
efficiently	O
transactivate	O
such	O
genetic	B-DNA
elements	I-DNA
.	O

METHODS	O
:	O
Cultured	O
bovine	O
corneal	O
endothelium	O
was	O
stimulated	O
for	O
6	O
hours	O
by	O
40	O
micron/ml	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNFalpha	B-protein
)	O
.	O

These	O
results	O
establish	O
TCL1	B-protein
as	O
the	O
most	O
prevalent	O
of	O
all	O
of	O
the	O
surveyed	O
oncogenes	B-DNA
associated	O
with	O
AIDS	O
IBLP	O
.	O

In	O
addition	O
,	O
the	O
combined	O
inhibitory	O
effects	O
on	O
NFAT	B-protein
and	O
NF-KB	B-protein
support	O
a	O
potential	O
use	O
of	O
DTCs	O
as	O
immunosuppressants	O
.	O

Following	O
glucocorticoid	O
treatment	O
of	O
6TG1.1	B-cell_line
cells	I-cell_line
,	O
chromatin	B-DNA
fragmentation	O
was	O
observed	O
after	O
a	O
delay	O
of	O
24	O
h	O
.	O

It	O
was	O
recently	O
demonstrated	O
that	O
EKLF	B-protein
is	O
also	O
required	O
for	O
the	O
activity	O
of	O
the	O
beta-globin	B-DNA
locus	I-DNA
control	I-DNA
region	I-DNA
(	O
LCR	B-DNA
)	O
5'HS3	B-DNA
.	O

A	O
survey	O
of	O
promoters	O
has	O
revealed	O
that	O
the	O
wild-type	B-protein
,	I-protein
unfused	I-protein
EBNA3C	I-protein
can	O
specifically	O
repress	O
expression	O
from	O
reporter	B-DNA
plasmids	I-DNA
containing	O
the	O
Epstein-Barr	O
virus	O
Cp	B-DNA
latency-associated	I-DNA
promoter	I-DNA
.	O

The	O
percentages	O
of	O
the	O
T/NK-cell	B-cell_type
subsets	I-cell_type
in	O
the	O
PB	O
were	O
not	O
significantly	O
different	O
among	O
these	O
groups	O
.	O

Consequently	O
,	O
these	O
results	O
suggest	O
that	O
physiologically	O
relevant	O
concentrations	O
of	O
ethanol	O
may	O
affect	O
production	O
of	O
inflammatory	B-protein
cytokines	I-protein
,	O
such	O
as	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
interleukin-1	B-protein
beta	I-protein
,	O
and	O
interleukin-6	B-protein
by	O
disrupting	O
NF-kappa	B-protein
B	I-protein
signaling	O
in	O
monocytes	B-cell_type
.	O

The	O
expression	O
of	O
distinct	O
sets	O
of	O
genes	O
at	O
different	O
stages	O
of	O
B-lymphocyte	O
and	O
T-lymphocyte	O
differentiation	O
is	O
controlled	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Fusion	O
of	O
subdomains	O
of	O
BOB.1/OBF.1	B-protein
with	O
the	O
GAL4	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
reveals	O
that	O
both	O
NH2-	B-protein
and	I-protein
COOH-terminal	I-protein
domains	I-protein
of	O
BOB.1/OBF.1	B-protein
contribute	O
to	O
full	O
transactivation	O
function	O
,	O
the	O
COOH-terminal	B-protein
domain	I-protein
is	O
more	O
efficient	O
in	O
this	O
transactivation	O
assay	O
.	O

These	O
observations	O
suggest	O
that	O
adherence	O
results	O
in	O
increases	O
of	O
c-fos	B-RNA
,	I-RNA
c-jun	I-RNA
,	I-RNA
EGR2	I-RNA
,	I-RNA
and	I-RNA
PDGF	I-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
.	O

Since	O
GH	B-protein
stimulates	O
the	O
development	O
and	O
function	O
of	O
granulocytes	B-cell_type
,	O
we	O
investigated	O
the	O
expression	O
of	O
GH	B-protein
in	O
granulocyte	B-cell_type
subsets	I-cell_type
.	O

We	O
have	O
used	O
this	O
DNA	O
fragment	O
to	O
isolate	O
and	O
purify	O
a	O
60-kDa	B-protein
protein	I-protein
binding	O
to	O
this	O
fragment	O
and	O
obtained	O
its	O
amino-terminal	B-protein
sequence	I-protein
,	O
which	O
was	O
used	O
to	O
design	O
degenerate	B-DNA
probes	I-DNA
to	O
screen	O
a	O
cDNA	O
library	O
from	O
THP-1	B-cell_line
cells	I-cell_line
.	O

Both	O
cytokines	B-protein
activated	O
factors	O
that	O
bound	O
to	O
the	O
sis-inducible	B-DNA
element	I-DNA
and	O
included	O
STAT1	B-protein
and	O
STAT3	B-protein
.	O

These	O
factors	O
control	O
the	O
activity	O
of	O
the	O
regulatory	B-DNA
immediate-early	I-DNA
genes	I-DNA
and	O
,	O
in	O
addition	O
,	O
lytic	O
and	O
latent	O
cycle	O
regulatory	O
genes	O
negatively	O
interfere	O
with	O
each	O
other	O
and	O
thus	O
link	O
cellular	O
and	O
viral	B-DNA
gene	I-DNA
regulatory	O
mechanisms	O
.	O

Stat3gamma	B-protein
is	O
derived	O
from	O
Stat3alpha	B-protein
by	O
limited	O
proteolysis	O
and	O
lacks	O
the	O
carboxyl-terminal	B-protein
portion	I-protein
of	O
Stat3alpha	B-protein
.	O

In	O
the	O
studies	O
described	O
in	O
this	O
report	O
,	O
we	O
have	O
identified	O
two	O
potential	O
Ets	B-DNA
binding	I-DNA
sites	I-DNA
,	O
EBS1	O
and	O
EBS2	B-DNA
,	O
which	O
are	O
conserved	O
in	O
both	O
the	O
human	B-DNA
and	I-DNA
murine	I-DNA
interleukin-2	I-DNA
enhancers	I-DNA
.	O

OBJECTIVE	O
:	O
The	O
authors	O
'	O
objective	O
was	O
to	O
investigate	O
the	O
possibility	O
that	O
glucocorticoid	B-protein
receptor	I-protein
changes	O
may	O
be	O
involved	O
in	O
the	O
dysregulation	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
axis	O
in	O
posttraumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
.	O

These	O
results	O
indicate	O
that	O
,	O
as	O
already	O
reported	O
for	O
the	O
IL2Rbeta	B-DNA
promoter	I-DNA
,	O
GA-binding	B-protein
protein	I-protein
is	O
an	O
essential	O
component	O
of	O
gammac	O
basal	O
promoter	O
activity	O
.	O

The	O
cells	O
of	O
hyperlipidemic	O
patients	O
had	O
lowered	O
levels	O
of	O
glucocorticoid	B-protein
receptors	I-protein
concomitantly	O
with	O
a	O
partial	O
loss	O
of	O
their	O
sensitivity	O
to	O
glucocorticoids	O
.	O

A	O
novel	O
function	O
of	O
Stat1	B-protein
and	O
Stat3	B-protein
proteins	O
in	O
erythropoietin	B-protein
-induced	O
erythroid	O
differentiation	O
of	O
a	O
human	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

The	O
DNA	O
isolated	O
contained	O
an	O
open	O
reading	O
frame	O
encoding	O
108	O
amino	O
acid	O
residues	O
.	O

Tyrosine	O
phosphorylation	O
of	O
p38	B-protein
and	O
p63	B-protein
is	O
also	O
observed	O
in	O
platelets	B-cell_type
stimulated	O
by	O
the	O
tyrosine	B-protein
kinase	I-protein
-linked	O
receptor	O
agonist	O
collagen	B-protein
and	O
by	O
the	O
G	B-protein
protein	I-protein
-coupled	O
receptor	O
agonist	O
thrombin	B-protein
,	O
although	O
phosphorylation	O
of	O
SLP-76	B-protein
is	O
only	O
observed	O
in	O
collagen	B-protein
-stimulated	O
platelets	B-cell_type
.	O

Nuclear	B-protein
transcription	I-protein
factor	I-protein
kB	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
and	O
pleiotropic	B-protein
regulator	I-protein
of	O
numerous	O
genes	O
involved	O
in	O
the	O
immune	O
and	O
inflammatory	O
responses	O
.	O

NF-kappa	B-protein
B	I-protein
activation	O
involves	O
signaled	O
phosphorylation	O
,	O
ubiquitination	O
,	O
and	O
proteolysis	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
.	O

The	O
Epstein-Barr	B-DNA
virus	I-DNA
DR	I-DNA
promoter	I-DNA
is	O
located	O
upstream	O
of	O
the	O
PstI	B-DNA
repeats	I-DNA
,	O
and	O
in	O
addition	O
to	O
the	O
TATA	B-DNA
box	I-DNA
,	O
it	O
contains	O
an	O
upstream	B-DNA
region	I-DNA
(	O
positions	O
-69	O
to	O
-220	O
)	O
responsive	O
to	O
EB1	B-protein
(	I-protein
Z	I-protein
)	I-protein
(	O
the	O
BZLF1-encoded	B-protein
transcription	I-protein
factor	I-protein
)	O
and	O
an	O
enhancer	B-DNA
with	O
two	O
functionally	O
distinct	O
domains	O
,	O
A	O
and	O
B	B-DNA
.	O

Notably	O
,	O
we	O
do	O
not	O
see	O
particularly	O
strong	O
transcription	O
when	O
the	O
immunoglobulin	B-DNA
kappa	I-DNA
enhancer	I-DNA
(	O
or	O
the	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
)	O
is	O
used	O
to	O
activate	O
a	O
kappa	O
gene	O
promoter	B-DNA
.	O

These	O
involve	O
activation	O
of	O
the	O
sodium/proton	B-protein
exchanger	I-protein
of	O
the	O
cell	O
membrane	O
at	O
very	O
low	O
,	O
physiological	O
concentrations	O
of	O
aldosterone	O
with	O
an	O
acute	O
onset	O
within	O
1-2	O
min	O
.	O

Costimulation	O
of	O
phytohemagglutinin/anti-CD28	B-cell_line
activated	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
with	O
IL-7	B-protein
induces	O
a	O
fivefold	O
enhanced	O
IL-2	B-protein
-mRNA	O
accumulation	O
and	O
a	O
2.5-fold	O
enhanced	O
protein	O
secretion	O
.	O

This	O
function	O
has	O
been	O
attributed	O
to	O
the	O
coordinated	O
binding	O
of	O
subunits	O
of	O
NF-kappa	B-protein
B	I-protein
to	O
distinct	O
regions	O
of	O
the	O
promoter	B-DNA
elements	I-DNA
of	O
numerous	O
genes	O
,	O
including	O
cytokines	B-protein
,	O
growth	B-protein
factor	I-protein
receptors	I-protein
,	O
and	O
adhesion	B-protein
molecules	I-protein
.	O

The	O
MR-count	O
was	O
significantly	O
decreased	O
in	O
the	O
PIH-group	O
.	O

In	O
order	O
to	O
investigate	O
this	O
possibility	O
,	O
we	O
measured	O
the	O
concentration	O
of	O
VDR	B-protein
in	O
PHA-activated	B-cell_line
peripheral	I-cell_line
mononuclear	I-cell_line
cells	I-cell_line
from	O
10	O
XLH	O
patients	O
.	O

In	O
apparent	O
contradiction	O
,	O
expression	O
of	O
a	O
dominant	O
negative	O
form	O
of	O
Ras	B-protein
,	O
RasN17	B-protein
,	O
also	O
inhibited	O
IL-2	B-protein
-induced	O
activation	O
of	O
the	O
promoter	O
containing	O
the	O
minimal	O
beta-casein	B-DNA
STAT5	I-DNA
element	I-DNA
as	O
well	O
as	O
the	O
promoters	O
of	O
CIS	B-protein
and	O
OSM	B-protein
.	O

The	O
other	O
is	O
a	O
region	O
interposed	O
between	O
the	O
21-bp	B-DNA
elements	I-DNA
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
DNA-binding	B-protein
factor	I-protein
specific	O
to	O
adult	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
(	O
polypryrimidine-binding	B-protein
factor	I-protein
,	O
PYBF	B-protein
)	O
binds	O
to	O
a	O
pyrimidine-rich	B-DNA
region	I-DNA
1	B-DNA
kb	I-DNA
upstream	I-DNA
from	O
the	O
human	B-DNA
delta-globin-encoding	I-DNA
gene	I-DNA
(	O
HBD	B-DNA
)	O
.	O

Also	O
in	O
the	O
current	O
study	O
,	O
binding	O
activity	O
to	O
the	O
CD28RE/AP-1	B-DNA
sequence	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
is	O
evaluated	O
.	O

G0S2	B-DNA
may	O
be	O
of	O
value	O
as	O
a	O
reporter	O
gene	O
for	O
analyzing	O
the	O
mechanism	O
of	O
action	O
of	O
CsA	O
and	O
its	O
influence	O
on	O
the	O
positive	O
and	O
negative	O
selection	O
of	O
lymphocytes	B-cell_type
in	O
response	O
to	O
self	O
and	O
not-self	O
antigens	O
.	O

Finally	O
,	O
gel	O
shift	O
analysis	O
showed	O
synergistic	O
complex	O
formation	O
between	O
proteins	O
that	O
bind	O
to	O
the	O
putative	O
X	B-DNA
boxes	I-DNA
of	O
the	O
DM	O
genes	O
,	O
as	O
is	O
found	O
for	O
the	O
DRA	B-DNA
gene	I-DNA
.	O

Nevertheless	O
,	O
the	O
simian	B-protein
EBV	I-protein
LMP1s	I-protein
retain	O
most	O
functions	O
in	O
common	O
with	O
EBV	O
LMP1	B-protein
,	O
including	O
the	O
ability	O
to	O
induce	O
NF-	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
activity	O
in	O
human	B-cell_type
cells	I-cell_type
,	O
to	O
bind	O
the	O
tumor	B-protein
necrosis	I-protein
factor-associated	I-protein
factor	I-protein
3	I-protein
(	O
TRAF3	B-protein
)	O
in	O
vitro	O
,	O
and	O
to	O
induce	O
expression	O
of	O
tumor	B-DNA
necrosis	I-DNA
factor-responsive	I-DNA
genes	I-DNA
,	O
such	O
as	O
ICAM1	B-DNA
,	O
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

These	O
protoenhancers	B-DNA
alone	O
are	O
weakly	O
or	O
not	O
responsive	O
to	O
R	B-protein
.	O

Activation	O
is	O
delayed	O
a	O
further	O
1-2	O
hr	O
when	O
mononuclear	B-cell_line
cell	I-cell_line
cultures	I-cell_line
are	O
stimulated	O
by	O
an	O
antigen	O
which	O
requires	O
processing	O
.	O

Signalling	O
into	O
the	O
T-cell	O
nucleus	O
:	O
NFAT	B-protein
regulation	O
.	O

Within	O
1	O
min	O
of	O
activation	O
,	O
JAK2	B-protein
was	O
phosphorylated	O
,	O
and	O
peaked	O
in	O
10	O
min	O
.	O

Inhibition	O
of	O
protein	B-protein
phosphatase	I-protein
2A	I-protein
induces	O
serine/threonine	O
phosphorylation	O
,	O
subcellular	O
redistribution	O
,	O
and	O
functional	O
inhibition	O
of	O
STAT3	B-protein
.	O

These	O
effects	O
were	O
specific	O
in	O
that	O
the	O
potentiated	O
phagocytosis	O
of	O
apoptotic	B-cell_type
neutrophils	I-cell_type
was	O
completely	O
blocked	O
by	O
the	O
glucocorticoid	B-protein
receptor	I-protein
antagonist	O
RU38486	O
,	O
and	O
glucocorticoids	O
did	O
not	O
promote	O
5-day	O
M	O
phi	O
ingestion	O
of	O
opsonized	B-cell_type
erythrocytes	I-cell_type
.	O

Using	O
the	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
(	O
RT	O
)	O
assay	O
,	O
the	O
limit	O
of	O
detection	O
was	O
10	O
(	O
-5	O
)	O
to	O
10	O
(	O
-6	O
)	O
for	O
PML/RAR	B-RNA
alpha	I-RNA
transcript	I-RNA
and	O
10	O
(	O
-4	O
)	O
to	O
10	O
(	O
-5	O
)	O
for	O
the	O
AML1/ETO	B-RNA
transcript	I-RNA
.	O

The	O
finding	O
that	O
patients	O
with	O
PTSD	O
had	O
a	O
substantially	O
greater	O
number	O
of	O
lymphocyte	B-protein
glucocorticoid	I-protein
receptors	I-protein
than	O
normal	O
comparison	O
subjects	O
is	O
consistent	O
with	O
the	O
authors	O
'	O
previous	O
observations	O
of	O
low	O
24-hour	O
urinary	O
cortisol	O
excretion	O
in	O
subjects	O
with	O
PTSD	O
.	O

In	O
elderly	O
healthy	O
subjects	O
,	O
Type	B-protein
II	I-protein
receptors	I-protein
were	O
also	O
significantly	O
decreased	O
(	O
from	O
1796	O
+/-	O
671	O
to	O
720	O
+/-	O
345	O
)	O
.	O

Fragments	O
of	O
a	O
3.6	O
kb	O
sequence	O
of	O
the	O
human	B-DNA
CRH	I-DNA
gene	I-DNA
promoter	I-DNA
were	O
amplified	O
by	O
PCR	O
and	O
ligated	O
upstream	O
of	O
a	O
CAT	B-DNA
reporter	I-DNA
.	O

At	O
physiological	O
concentrations	O
,	O
DG	O
and	O
GG	O
were	O
weakly	O
estrogenic	O
,	O
and	O
they	O
activated	O
human	B-cell_type
NK	I-cell_type
cells	I-cell_type
in	O
nutritionally	O
relevant	O
concentrations	O
in	O
vitro	O
,	O
probably	O
at	O
a	O
site	O
different	O
from	O
IL-2	B-protein
action	O
.	O

Phosphorylated	O
Bcl-2	B-protein
can	O
not	O
bind	O
calcineurin	B-protein
,	O
and	O
NFAT	B-protein
activation	O
,	O
FasL	B-protein
expression	O
,	O
and	O
apoptosis	O
can	O
occur	O
after	O
Bcl-2	B-protein
phosphorylation	O
.	O

The	O
Id	B-protein
(	O
inhibitor	O
of	O
DNA	O
binding	O
and	O
differentiation	O
)	O
HLH	B-protein
proteins	I-protein
,	O
in	O
a	O
dominantly	O
negative	O
fashion	O
,	O
regulate	O
transcriptional	O
activities	O
of	O
basic	B-protein
HLH	I-protein
proteins	I-protein
.	O

During	O
this	O
process	O
,	O
IL-6	B-protein
downregulated	O
expression	O
of	O
BCL2	B-protein
in	O
1A9-M	B-cell_line
cells	I-cell_line
and	O
stimulated	O
BCL-XL	O
expression	O
,	O
but	O
had	O
no	O
effect	O
on	O
p53	O
,	O
Bax	O
,	O
or	O
Bak	O
gene	O
expression	O
.	O

Based	O
on	O
the	O
presence	O
of	O
T	B-DNA
cell	I-DNA
receptor-beta	I-DNA
(	I-DNA
TcR-beta	I-DNA
)	I-DNA
gene	I-DNA
rearrangements	I-DNA
in	O
L428	B-cell_line
and	I-cell_line
HDLM-1	I-cell_line
cells	I-cell_line
,	O
the	O
expression	O
of	O
CD2	B-protein
in	O
HDLM-1	B-cell_line
cells	I-cell_line
,	O
and	O
the	O
presence	O
of	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
gene	I-DNA
rearrangement	I-DNA
in	O
KM-H2	B-cell_line
cells	I-cell_line
,	O
some	O
researchers	O
have	O
concluded	O
that	O
these	O
long-term	B-cell_line
cell	I-cell_line
lines	I-cell_line
derived	O
from	O
patients	O
with	O
Hodgkin	O
's	O
disease	O
are	O
lymphoid	O
in	O
nature	O
.	O

To	O
assess	O
whether	O
this	O
inhibition	O
was	O
mediated	O
via	O
modulation	O
of	O
the	O
cellular	B-protein
transcription	I-protein
factor	I-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
we	O
carried	O
out	O
gel	O
shift	O
analysis	O
on	O
nuclear	O
extracts	O
prepared	O
under	O
different	O
conditions	O
of	O
cell	O
stimulation	O
in	O
the	O
presence	O
or	O
absence	O
of	O
ascorbate	O
,	O
N-acetylcysteine	O
(	O
NAC	O
)	O
,	O
or	O
zidovudine	O
(	O
AZT	O
)	O
.	O

Core-specific	B-protein
mAb	I-protein
inhibited	O
mCD14	B-protein
-mediated	O
uptake	O
of	O
homologous	O
and	O
heterologous	O
LPS	O
,	O
while	O
producing	O
less	O
concurrent	O
enhancement	O
of	O
non-	O
mCD14	B-protein
-mediated	O
LPS	O
uptake	O
.	O

Stimulation	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
with	O
interleukin-1beta	B-protein
(	O
IL-1beta	B-protein
)	O
led	O
to	O
ROI	O
production	O
and	O
NF-kappaB	B-protein
activation	O
,	O
which	O
could	O
both	O
be	O
blocked	O
by	O
antioxidants	O
or	O
FLAP	B-protein
inhibitors	O
,	O
confirming	O
that	O
5-LOX	B-protein
was	O
the	O
source	O
of	O
ROIs	O
and	O
was	O
required	O
for	O
NF-kappaB	B-protein
activation	O
in	O
these	O
cells	O
.	O

Remarkably	O
,	O
we	O
observed	O
that	O
these	O
samples	O
displayed	O
a	O
persistent	O
expression	O
of	O
the	O
c-fos	B-DNA
protooncogene	I-DNA
,	O
associated	O
to	O
an	O
increased	O
AP-1	B-protein
DNA-binding	O
activity	O
,	O
whereas	O
no	O
variations	O
of	O
CREB	B-protein
or	O
NF-kB	B-protein
were	O
detected	O
.	O

For	O
that	O
purpose	O
,	O
we	O
established	O
several	O
lines	O
of	O
transgenic	O
mice	O
displaying	O
erythroid-specific	O
expression	O
of	O
a	O
thermosensitive	B-protein
SV40	I-protein
T	I-protein
antigen	I-protein
.	O

To	O
analyze	O
the	O
effects	O
of	O
ectopic	O
expression	O
of	O
spi-1	B-protein
on	O
the	O
proliferation/differentiation	O
of	O
human	B-cell_type
myeloid	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
,	O
K562	B-cell_line
cells	I-cell_line
were	O
stably	O
transfected	O
with	O
a	O
spi-1	B-DNA
expression	I-DNA
vector	I-DNA
.	O

BACKGROUND	O
:	O
We	O
reported	O
on	O
the	O
constitutive	O
interferon-gamma	B-protein
receptor	I-protein
(	O
IFN-gammaR	B-protein
)	O
expression	O
on	O
eosinophils	B-cell_type
.	O

Expression	O
of	O
c-fos	B-DNA
,	O
c-jun	B-DNA
and	O
jun	B-DNA
B	I-DNA
in	O
peripheral	O
blood	O
lymphocytes	O
from	O
young	O
and	O
elderly	O
adults	O
.	O

Are	O
there	O
effects	O
of	O
CyA	O
and	O
FK	O
506	O
all	O
attributable	O
to	O
CN	O
inhibition	O
,	O
and	O
how	O
much	O
of	O
them	O
are	O
mediated	O
through	O
the	O
NFATC	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
?	O

The	O
NF-kappaB	B-protein
family	O
of	O
transcription	O
factors	O
regulates	O
the	O
inducible	O
expression	O
of	O
a	O
variety	O
of	O
genes	O
.	O

Given	O
the	O
role	O
of	O
this	O
transcription	O
factor	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
in	O
the	O
inflammatory	O
response	O
,	O
NF-kappaB	B-protein
inhibitors	O
have	O
been	O
suggested	O
as	O
potential	O
therapeutic	O
drugs	O
for	O
inflammatory	O
diseases	O
.	O

oriP	B-DNA
is	O
essential	O
for	O
EBNA	B-DNA
gene	I-DNA
promoter	O
activity	O
in	O
Epstein-Barr	B-cell_line
virus-immortalized	I-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

However	O
,	O
all	O
these	O
cell	O
types	O
still	O
gave	O
strong	O
Ca2+	O
and	O
tyrosine	O
phosphorylation	O
responses	O
to	O
H2O2	O
.	O

The	O
resolution	O
of	O
immune	O
responses	O
is	O
characterized	O
by	O
extensive	O
apoptosis	O
of	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O

Results	O
in	O
all	O
cell	O
lines	O
indicated	O
that	O
mutations	O
of	O
the	O
SP1	B-DNA
,	O
TATA	B-DNA
and	O
the	O
TAR	O
loop	O
and	O
stem	O
secondary	O
structure	O
resulted	O
in	O
marked	O
decreases	O
in	O
gene	O
expression	O
while	O
mutations	O
of	O
the	O
enhancer	B-DNA
motif	I-DNA
or	O
TAR	B-DNA
primary	I-DNA
sequence	I-DNA
resulted	O
in	O
only	O
slight	O
decreases	O
.	O

An	O
increase	O
in	O
the	O
ratio	O
of	O
memory	B-cell_type
to	I-cell_type
naive	I-cell_type
T	I-cell_type
cells	I-cell_type
has	O
been	O
postulated	O
to	O
underlie	O
immune	O
hyporesponsiveness	O
accompanying	O
aging	O
.	O

Interleukin	O
(	O
IL	O
)	O
6	O
levels	O
were	O
determined	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O

We	O
conclude	O
that	O
fetal	B-cell_type
nucleated	I-cell_type
blood	I-cell_type
cells	I-cell_type
constitutively	O
express	O
important	O
genes	O
for	O
cytokine	B-protein
regulation	O
and	O
are	O
able	O
to	O
increase	O
intracellular	O
accumulation	O
of	O
the	O
mRNAs	B-RNA
for	O
these	O
factors	O
in	O
response	O
to	O
anti-CD3	B-protein
stimulation	O
.	O

These	O
data	O
suggest	O
that	O
cortisol	O
binding	O
to	O
glucocorticoid	B-protein
receptor	I-protein
is	O
slightly	O
impaired	O
in	O
patients	O
with	O
essential	O
hypertension	O
.	O

The	O
probable	O
regulatory	O
point	O
was	O
the	O
cytoplasmic	O
IkappaB	B-protein
inhibitor	O
:	O
in	O
CD45RA+	O
cells	O
,	O
H2O2	O
caused	O
a	O
more	O
profound	O
depression	O
in	O
the	O
levels	O
of	O
IkappaB	B-protein
alpha	I-protein
.	O

Mechanisms	O
that	O
contribute	O
to	O
the	O
development	O
of	O
lymphoid	O
malignancies	O
:	O
roles	O
for	O
genetic	O
alterations	O
and	O
cytokine	B-protein
production	O
.	O

Like	O
IkappaBalpha	B-protein
,	O
Tax	B-protein
-mediated	O
breakdown	O
of	O
IkappaBbeta	B-protein
in	O
transfected	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
is	O
blocked	O
either	O
by	O
cell-permeable	O
proteasome	O
inhibitors	O
or	O
by	O
mutation	O
Of	O
IkappaBbeta	B-protein
at	O
two	O
serine	O
residues	O
present	O
within	O
its	O
N-terminal	B-protein
region	I-protein
.	O

Since	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
contains	O
two	O
functional	O
nuclear	B-DNA
factor	I-DNA
kB	I-DNA
(	I-DNA
NF-kB	I-DNA
)	I-DNA
regulatory	I-DNA
elements	I-DNA
,	O
we	O
studied	O
the	O
ability	O
of	O
PMA	O
to	O
induce	O
NF-kB	B-protein
binding	O
activity	O
by	O
different	O
assays	O
.	O

A	O
human	O
homologue	O
of	O
the	O
Drosophila	B-protein
Toll	I-protein
protein	I-protein
signals	O
activation	O
of	O
adaptive	O
immunity	O
[	O
see	O
comments	O
]	O

It	O
is	O
unknown	O
which	O
Stat3	B-protein
isoform	I-protein
(	O
s	O
)	O
is	O
activated	O
in	O
response	O
to	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
and	O
IL-15	B-protein
.	O

These	O
results	O
demonstrate	O
a	O
complex	O
role	O
for	O
VitD3	O
in	O
modifying	O
the	O
retinoid	O
differentiation	O
pathway	O
and	O
may	O
have	O
implications	O
for	O
differentiation-inducing	O
therapy	O
of	O
hematopoietic	O
tumors	O
.	O

One	O
patient	O
with	O
incomplete	O
androgen	O
insensitivity	O
was	O
a	O
mosaic	O
for	O
the	O
mutation	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
AECA	B-protein
may	O
directly	O
stimulate	O
EC	B-cell_type
in	O
Takayasu	O
arteritis	O
through	O
elevation	O
of	O
adhesion	B-protein
molecule	I-protein
expression	O
associated	O
with	O
NF-kappaB	B-protein
activation	O
and	O
adhesion	O
of	O
monocytes	B-cell_type
,	O
and	O
may	O
therefore	O
play	O
a	O
pathogenic	O
role	O
in	O
the	O
development	O
of	O
the	O
vasculopathy	O
in	O
Takayasu	O
arteritis	O
.	O

The	O
frequency	O
of	O
FGF-1	B-protein
-responsive	O
T	B-cell_type
cells	I-cell_type
is	O
increased	O
in	O
the	O
peripheral	O
blood	O
of	O
these	O
disorders	O
,	O
and	O
a	O
high	O
percentage	O
of	O
infiltrating	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
rheumatoid	O
arthritis	O
synovium	O
express	O
receptors	O
for	O
FGF-1	B-protein
.	O

A	O
3	O
'	O
--	O
>	O
5	O
'	O
XPB	B-protein
helicase	I-protein
defect	O
in	O
repair/transcription	B-protein
factor	I-protein
TFIIH	B-protein
of	O
xeroderma	O
pigmentosum	O
group	O
B	O
affects	O
both	O
DNA	O
repair	O
and	O
transcription	O
.	O

The	O
proliferative	O
deficiency	O
of	O
the	O
transgenic	B-cell_type
T	I-cell_type
cells	I-cell_type
was	O
associated	O
with	O
an	O
increased	O
apoptosis	O
.	O

This	O
result	O
suggests	O
that	O
two	O
catalytically	O
similar	O
proteins	O
,	O
cyclophilin	B-protein
and	O
FKBP	B-protein
,	O
evolved	O
independently	O
.	O

The	O
results	O
indicate	O
that	O
a	O
small	O
molecule	O
can	O
activate	O
a	O
receptor	O
that	O
normally	O
binds	O
a	O
relatively	O
large	O
protein	O
ligand	O
.	O

We	O
used	O
our	O
monoclonal	O
model	O
of	O
germinal	O
center	O
maturation	O
,	O
CL-01	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
to	O
investigate	O
the	O
role	O
of	O
CD30	B-protein
in	O
human	O
B	O
cell	O
differentiation	O
.	O

Th1	O
cells	O
produce	O
IL-2	B-protein
and	O
IFN-gamma	B-protein
,	O
whereas	O
Th2	B-cell_line
cells	I-cell_line
produce	O
IL-4	B-protein
,	O
IL-5	B-protein
,	O
IL-6	B-protein
,	O
IL-10	B-protein
,	O
and	O
IL-13	B-protein
.	O

METHODS	O
:	O
Allergen-specific	B-cell_line
T-cell	I-cell_line
clones	I-cell_line
and	O
T-cell	B-cell_line
hybridomas	I-cell_line
were	O
established	O
from	O
the	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
of	O
patients	O
with	O
asthma	O
,	O
and	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IL-5	B-DNA
gene	I-DNA
was	O
investigated	O
with	O
transient	O
transfection	O
and	O
electrophoretic	O
mobility	O
shift	O
analysis	O
.	O

They	O
also	O
suggest	O
that	O
the	O
function	O
of	O
Spi-1/PU.1	B-protein
in	O
the	O
late	O
phase	O
of	O
Friend	O
leukemia	O
requires	O
specific	O
signaling	O
from	O
the	O
gp55-modified	B-protein
EpoR	I-protein
generated	O
during	O
the	O
early	O
phase	O
of	O
the	O
disease	O
.	O

Since	O
the	O
adenovirus	B-DNA
E2	I-DNA
promoter	I-DNA
has	O
been	O
well	O
characterized	O
and	O
is	O
known	O
to	O
be	O
regulated	O
by	O
transactivators	B-protein
encoded	O
by	O
many	O
viruses	O
,	O
the	O
activity	O
of	O
this	O
promoter	O
in	O
specific	O
cell	O
types	O
is	O
discussed	O
in	O
reference	O
to	O
both	O
the	O
biology	O
of	O
the	O
cell	O
and	O
the	O
possible	O
presence	O
of	O
as	O
yet	O
undetected	O
viral	B-protein
gene	I-protein
products	I-protein
.	O

In	O
particular	O
,	O
our	O
findings	O
suggest	O
that	O
local	O
metabolism	O
of	O
steroids	O
by	O
normal	O
as	O
well	O
as	O
leukemic	B-cell_type
myeloid	I-cell_type
cells	I-cell_type
influences	O
their	O
responsiveness	O
to	O
D3	O
and	O
retinoids	O
.	O

Like	O
Drosophila	O
Toll	B-protein
,	O
human	B-protein
Toll	I-protein
is	O
a	O
type	O
I	O
transmembrane	O
protein	O
with	O
an	O
extracellular	O
domain	O
consisting	O
of	O
a	O
leucine-rich	B-protein
repeat	I-protein
(	I-protein
LRR	I-protein
)	I-protein
domain	I-protein
,	O
and	O
a	O
cytoplasmic	O
domain	O
homologous	O
to	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
the	O
human	B-protein
interleukin	I-protein
(	I-protein
IL	I-protein
)	I-protein
-1	I-protein
receptor	I-protein
.	O

As	O
a	O
consequence	O
,	O
the	O
immune	O
response	O
developed	O
in	O
senescent	O
organisms	O
is	O
usually	O
inappropriate	O
,	O
often	O
inefficient	O
,	O
sometimes	O
aberrant	O
,	O
and	O
potentially	O
detrimental	O
.	O

Few	O
host	O
factors	O
that	O
directly	O
limit	O
HIV-1	O
transcription	O
and	O
could	O
support	O
this	O
state	O
of	O
nonproductive	O
HIV-1	O
infection	O
have	O
been	O
described	O
.	O

During	O
T	O
cell	O
differentiation	O
,	O
expression	O
peaked	O
in	O
the	O
actively	B-cell_type
dividing	I-cell_type
immature	I-cell_type
single	I-cell_type
positive	I-cell_type
cells	I-cell_type
.	O

However	O
,	O
the	O
reduced	O
expression	O
of	O
these	O
proteins	O
was	O
not	O
the	O
result	O
of	O
a	O
global	O
TCR/CD3	B-protein
-signaling	O
defect	O
because	O
CD3	B-protein
cross-linking	O
induced	O
an	O
equivalent	O
increase	O
in	O
intracellular-free	O
calcium	O
ions	O
,	O
as	O
well	O
as	O
NFATp	B-protein
dephosphorylation	O
,	O
translocation	O
to	O
the	O
nucleus	O
,	O
and	O
DNA	O
binding	O
in	O
both	O
normal	B-cell_type
and	O
anergic	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

A	O
few	O
47.10	B-cell_line
cells	I-cell_line
(	O
3-5	O
%	O
)	O
do	O
not	O
express	O
lineage	O
specific	O
markers	O
;	O
they	O
differentiate	O
spontaneously	O
to	O
lineage-positive	B-cell_line
cells	I-cell_line
after	O
replating	O
on	O
2M-1	B-cell_line
cells	I-cell_line
.	O

Anti-CD28-stimulated	B-cell_line
T	I-cell_line
cells	I-cell_line
produced	O
significant	O
amounts	O
of	O
IL-8	B-protein
;	O
additionally	O
,	O
costimulation	O
with	O
anti-CD3	B-protein
and	O
anti-CD28	B-protein
Abs	I-protein
resulted	O
in	O
a	O
synergistic	O
induction	O
of	O
IL-8	B-protein
secretion	O
.	O

However	O
NF-ATs	B-protein
appear	O
in	O
the	O
nuclei	O
of	O
IL-4-	B-cell_line
,	I-cell_line
IL-5-	I-cell_line
,	I-cell_line
or	I-cell_line
ionomycin-stimulated	I-cell_line
eosinophils	I-cell_line
.	O

Biochemical	O
analysis	O
by	O
Western	O
blotting	O
of	O
fetal	B-cell_type
and	I-cell_type
adult	I-cell_type
hematopoietic	I-cell_type
populations	I-cell_type
shows	O
several	O
runt	B-protein
isoforms	I-protein
.	O

The	O
action	O
of	O
physiological	O
and	O
pharmacological	O
concentration	O
of	O
GC	O
may	O
be	O
mediated	O
by	O
low	B-protein
affinity	I-protein
specific	I-protein
binding	I-protein
sites	I-protein
of	O
glucocorticoid	B-protein
receptors	I-protein
.	O

Our	O
results	O
show	O
that	O
deletion	O
of	O
the	O
C	B-protein
terminus	I-protein
of	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
molecule	O
up	O
to	O
amino	B-protein
acid	I-protein
279	I-protein
abolishes	O
constitutive	O
but	O
not	O
ligand-inducible	O
phosphorylation	O
and	O
inhibits	O
ligand-inducible	O
degradation	O
.	O

Homodimerization	O
of	O
the	O
human	B-protein
interleukin	I-protein
4	I-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
induces	O
Cepsilon	B-RNA
germline	I-RNA
transcripts	I-RNA
in	O
B	B-cell_type
cells	I-cell_type
in	O
the	O
absence	O
of	O
the	O
interleukin	B-protein
2	I-protein
receptor	I-protein
gamma	I-protein
chain	I-protein
.	O

The	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
is	O
maintained	O
in	O
an	O
inactive	O
cytoplasmic	O
state	O
by	O
I	B-protein
kappa	I-protein
B	I-protein
inhibitors	I-protein
.	O

Exposure	O
of	O
activated	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
or	O
of	O
a	O
natural	B-cell_line
killer	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
NKL	B-cell_line
)	O
to	O
IL-2	B-protein
leads	O
to	O
the	O
phosphorylation	O
of	O
Stat1	B-protein
alpha	I-protein
,	O
Stat1	O
beta	O
,	O
and	O
Stat3	B-protein
,	O
as	O
well	O
as	O
of	O
two	O
Stat-related	B-protein
proteins	I-protein
,	O
p94	B-protein
and	O
p95	B-protein
.	O

Globin	B-DNA
genes	I-DNA
are	O
subject	O
to	O
tissue-specific	O
and	O
developmental	O
stage-specific	O
regulation	O
.	O

Furthermore	O
,	O
activation	O
of	O
PKC	B-protein
was	O
pertussis-toxin-sensitive	O
and	O
was	O
associated	O
with	O
the	O
detection	O
of	O
an	O
NF	B-protein
kappa	I-protein
B	I-protein
protein	I-protein
in	O
nuclear	O
extracts	O
of	O
M-CSF-induced	B-cell_line
blood	I-cell_line
monocytes	I-cell_line
but	O
not	O
in	O
monocytes	B-cell_type
exposed	O
to	O
medium	O
treatment	O
only	O
.	O

In	O
contrast	O
,	O
Zap	B-protein
and	O
other	O
protein-tyrosine	B-protein
kinases	I-protein
were	O
unable	O
to	O
reconstitute	O
these	O
signaling	O
pathways	O
when	O
expressed	O
at	O
the	O
same	O
levels	O
.	O

The	O
thrombin	B-protein
-generating	O
potential	O
of	O
the	O
apoptotic	B-cell_line
VSMC-myc	I-cell_line
cells	I-cell_line
was	O
greater	O
than	O
that	O
of	O
unactivated	B-cell_type
platelets	I-cell_type
(	O
P	O
=	O
.003	O
for	O
AUC	O
;	O
P	O
=	O
.0002	O
for	O
PT	O
)	O
and	O
similar	O
to	O
calcium-ionophore	O
activated	B-cell_type
platelets	I-cell_type
(	O
AUC	O
of	O
332	O
+/-	O
15	O
nmol	O
x	O
min/L	O
,	O
P	O
=	O
.3	O
;	O
PT	O
of	O
172	O
+/-	O
8	O
nmol/L	O
,	O
P	O
=	O
.2	O
)	O
.	O

The	O
patients	O
are	O
insensitive	O
to	O
mineralocorticoids	O
;	O
however	O
,	O
sodium	O
supplementation	O
is	O
able	O
to	O
correct	O
electrolyte	O
abnormalities	O
.	O

Cleavage	O
could	O
be	O
completely	O
inhibited	O
by	O
zDEVD-fmk	O
,	O
an	O
inhibitor	O
specific	O
for	O
caspase	B-protein
3-like	I-protein
proteases	I-protein
.	O

A	O
new	O
mouse	B-DNA
gene	I-DNA
,	O
SRG3	B-DNA
,	O
related	O
to	O
the	O
SWI3	B-DNA
of	O
Saccharomyces	O
cerevisiae	O
,	O
is	O
required	O
for	O
apoptosis	O
induced	O
by	O
glucocorticoids	O
in	O
a	O
thymoma	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

The	O
protein	O
tyrosine	O
kinase	O
ZAP-70	B-protein
plays	O
an	O
important	O
role	O
in	O
T-cell	O
activation	O
and	O
development	O
.	O

Chromosomal	O
translocation	O
resulting	O
in	O
abnormal	O
expression	O
of	O
the	O
LAZ3/BCL6	B-DNA
gene	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
has	O
been	O
implicated	O
in	O
the	O
tumorigenesis	O
of	O
non-Hodgkin	O
lymphoma	O
(	O
NHL	O
)	O
.	O

The	O
clinical	O
course	O
and	O
the	O
laboratory	O
data	O
suggest	O
that	O
the	O
tachycardia	O
crises	O
are	O
the	O
consequence	O
of	O
a	O
hypersensitivity	O
of	O
the	O
heart	O
to	O
thyroid	O
hormones	O
,	O
associated	O
with	O
an	O
increased	O
number	O
of	O
T3	B-protein
nuclear	I-protein
receptor	I-protein
sites	O
in	O
lymphocytes	B-cell_type
.	O

We	O
show	O
for	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
,	O
as	O
well	O
as	O
human	B-cell_type
and	I-cell_type
mouse	I-cell_type
primary	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
that	O
this	O
inhibitory	O
effect	O
is	O
accompanied	O
by	O
an	O
impaired	O
nuclear	O
translocation	O
of	O
the	O
Rel	B-protein
proteins	I-protein
c-Rel	B-protein
,	O
RelA/p65	B-protein
and	O
NF-kappa	B-protein
B1/p50	I-protein
,	O
whereas	O
the	O
nuclear	O
appearance	O
of	O
RelB	B-protein
remains	O
unaffected	O
.	O

At	O
the	O
same	O
time	O
,	O
3-O-MG	O
transport	O
was	O
determined	O
in	O
the	O
same	O
subjects	O
.	O

Responses	O
to	O
jun-B	B-protein
were	O
not	O
related	O
to	O
age	O
,	O
sex	O
,	O
or	O
human	B-protein
leukocyte	I-protein
antigen	I-protein
status	O
.	O

The	O
primary	O
IL-13	B-protein
receptor	I-protein
complex	I-protein
on	O
human	B-cell_type
monocytes	I-cell_type
is	O
believed	O
to	O
be	O
a	O
heterodimer	O
comprised	O
of	O
the	O
IL-4R	B-protein
alpha	I-protein
chain	I-protein
and	O
the	O
IL-2R	B-protein
gamma	I-protein
chain	I-protein
(	B-protein
gamma	I-protein
(	I-protein
c	I-protein
)	I-protein
)	I-protein
-like	I-protein
molecule	I-protein
,	O
IL-13R	B-protein
alpha1	I-protein
.	O

Treatment	O
of	O
the	O
acute	B-cell_line
promyelocytic	I-cell_line
(	I-cell_line
APL	I-cell_line
)	I-cell_line
cell	I-cell_line
line	I-cell_line
NB4	B-cell_line
with	O
interferon	B-protein
alpha	I-protein
(	O
IFN	B-protein
(	I-protein
alpha	I-protein
)	I-protein
)	O
,	O
as	O
well	O
as	O
IFN	B-protein
(	I-protein
beta	I-protein
)	I-protein
and	I-protein
gamma	I-protein
,	O
results	O
in	O
an	O
increased	O
expression	O
of	O
the	O
transcripts	O
coding	O
for	O
retinoic-acid	B-protein
receptor	I-protein
type	I-protein
alpha	I-protein
(	O
RAR	B-protein
(	I-protein
alpha	I-protein
)	I-protein
)	O
and	O
the	O
leukemia-specific	B-protein
retinoic	I-protein
acid	I-protein
receptor	I-protein
PML-RAR	B-protein
.	O

This	O
minimal	B-DNA
promoter	I-DNA
exhibits	O
B-cell-specific	O
activity	O
and	O
contains	O
SP1	B-DNA
,	I-DNA
ETS	I-DNA
,	I-DNA
OCT	I-DNA
,	I-DNA
and	I-DNA
IKAROS/LYF-1	I-DNA
transcription	I-DNA
factor	I-DNA
motifs	I-DNA
.	O

Such	O
a	O
process	O
may	O
have	O
fundamental	O
implications	O
in	O
AIDS	O
pathogenesis	O
in	O
vivo	O
and	O
may	O
be	O
important	O
in	O
disease	O
progression	O
induced	O
by	O
opportunistic	O
infections	O
directly	O
or	O
indirectly	O
involving	O
macrophages	B-cell_type
.	O

High-dose	O
pulse	O
glucocorticoid	O
therapy	O
has	O
been	O
used	O
successfully	O
in	O
the	O
clinic	O
in	O
severe	O
pathological	O
conditions	O
for	O
about	O
20	O
years	O
.	O

We	O
previously	O
showed	O
that	O
PO-B	B-protein
DNA-binding	O
is	O
progressively	O
induced	O
during	O
differentiation	O
of	O
promyelomonocytic	B-cell_line
leukemic	I-cell_line
HL-60	I-cell_line
cells	I-cell_line
to	O
the	O
macrophage-like	B-cell_type
lineage	I-cell_type
(	O
with	O
phorbol	O
esters	O
)	O
.	O

To	O
further	O
explore	O
the	O
involvement	O
of	O
PI3-K	B-protein
in	O
T	O
cell	O
activation	O
,	O
we	O
created	O
a	O
set	O
of	O
potentially	O
dominant	B-DNA
negative	I-DNA
PI3-K	I-DNA
constructs	I-DNA
comprising	O
individual	O
or	O
tandem	B-DNA
domains	I-DNA
of	O
the	O
regulatory	B-protein
p85	I-protein
subunit	I-protein
and	O
tested	O
their	O
effect	O
on	O
downstream	O
signaling	O
events	O
like	O
Erk2	B-protein
activation	O
and	O
transcription	O
from	O
an	O
NFAT	B-DNA
(	I-DNA
nuclear	I-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells	I-DNA
)	I-DNA
element	I-DNA
taken	O
from	O
the	O
interleukin-2	B-DNA
promoter	I-DNA
.	O

Patterns	O
of	O
Pan	B-protein
expression	O
and	O
role	O
of	O
Pan	B-protein
proteins	I-protein
in	O
endocrine	O
cell	O
type-specific	O
complex	O
formation	O
.	O

Purified	O
bcl-2	B-protein
is	O
cleaved	O
by	O
HIV	B-protein
protease	I-protein
between	O
phenylalanine	O
112	O
and	O
alanine	O
113	O
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
expression	O
and	O
signal	O
transduction	O
in	O
HIV-1-infected	B-cell_type
cells	I-cell_type
.	O

Here	O
,	O
we	O
show	O
that	O
zinc	O
addition	O
in	O
a	O
serum-	O
and	O
lipopolysaccharide-free	O
cell	O
culture	O
system	O
leads	O
to	O
significantly	O
enhanced	O
levels	O
of	O
interleukin	B-protein
1	I-protein
beta	I-protein
(	O
IL-1	B-protein
beta	I-protein
)	O
and	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
and	O
to	O
expression	O
of	O
the	O
corresponding	O
mRNA	B-RNA
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O

N-formyl-methionyl-leucyl-phenylalanine	O
(	O
FMLP	O
)	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
induced	O
tyrosine	O
phosphorylation	O
of	O
42-	B-protein
and	I-protein
44-kDa	I-protein
proteins	I-protein
,	O
which	O
were	O
identified	O
as	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
(	O
ERK	B-protein
)	O
,	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Under	O
these	O
conditions	O
,	O
dexamethasone	O
had	O
a	O
minimal	O
effect	O
on	O
cell	O
growth	O
,	O
elicited	O
little	O
internucleosomal	O
DNA	O
fragmentation	O
,	O
and	O
induced	O
no	O
cell	O
cycle	O
perturbation	O
.	O

However	O
,	O
two	O
potent	O
immunosuppressive	O
agents	O
,	O
glucocorticoids	O
and	O
cyclosporin	O
A	O
,	O
also	O
inhibited	O
the	O
80-kDa	B-protein
protein	I-protein
.	O

Interphase	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
was	O
performed	O
with	O
2	O
YACs	B-DNA
flanking	O
the	O
CALM	B-DNA
region	I-DNA
,	O
a	O
YAC	B-DNA
contig	I-DNA
of	O
the	O
MLL	B-DNA
region	I-DNA
,	O
and	O
a	O
YAC	B-DNA
spanning	O
the	O
AF10	B-DNA
breakpoint	O
.	O

In	O
cells	O
preincubated	O
for	O
a	O
day	O
,	O
levels	O
of	O
FOS	B-RNA
mRNA	I-RNA
reach	O
a	O
maximum	O
20	O
min	O
after	O
the	O
addition	O
of	O
lectin	B-protein
and	O
decline	O
to	O
control	O
levels	O
over	O
the	O
next	O
3	O
hr	O
.	O

In	O
this	O
review	O
we	O
examine	O
the	O
structure	O
and	O
function	O
of	O
cytokine	B-protein
receptors	I-protein
and	O
the	O
signaling	O
pathways	O
involved	O
in	O
their	O
regulation	O
of	O
gene	O
expression	O
.	O

Furthermore	O
,	O
sodium	O
salicylate	O
blocked	O
the	O
LPS-induced	O
proteolytic	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
which	O
prevented	O
the	O
nuclear	O
translocation	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
.	O

In	O
vitro	O
effects	O
of	O
aldosterone	O
on	O
the	O
intracellular	O
concentrations	O
of	O
sodium	O
,	O
potassium	O
and	O
calcium	O
,	O
cell	O
volume	O
and	O
the	O
sodium-proton-antiport	B-protein
have	O
been	O
described	O
in	O
intact	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
(	O
HML	B-cell_type
)	O
.	O

CONCLUSIONS	O
:	O
Human	B-cell_type
ECs	I-cell_type
express	O
PPARalpha	B-protein
,	O
a	O
potentially	O
important	O
regulator	O
of	O
atherogenesis	O
through	O
its	O
transcriptional	O
control	O
of	O
VCAM-1	B-protein
gene	O
expression	O
.	O

It	O
will	O
further	O
elaborate	O
on	O
the	O
attempts	O
to	O
develop	O
successful	O
immunotherapy	O
and	O
drug	O
therapy	O
targeting	O
Ras	B-protein
expressing	O
tumors	O
.	O

Differential	O
interaction	O
of	O
nuclear	B-protein
factors	I-protein
with	O
the	O
leukocyte-specific	B-DNA
pp52	I-DNA
promoter	I-DNA
in	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

(	O
2E	O
)	O
-3-	O
[	O
5-	O
(	O
2	O
,	O
3-Dimethoxy-6-methyl-1	O
,	O
4-benzoquinoyl	O
)	O
]	O
-2-nonyl-2-	O
propenoic	O
acid	O
(	O
E3330	O
)	O
,	O
is	O
a	O
novel	O
agent	O
with	O
hepatoprotective	O
activity	O
.	O

Our	O
observations	O
suggest	O
that	O
both	O
the	O
enhancer	B-DNA
and	O
the	O
promoter	B-DNA
have	O
a	O
complex	O
tissue-specific	O
structure	O
whose	O
functional	O
interplay	O
potentiates	O
T-cell-specific	O
transcription	O
.	O

These	O
results	O
indicate	O
that	O
a	O
relatively	O
small	O
cis-acting	B-DNA
element	I-DNA
is	O
able	O
to	O
enhance	O
remodeling	O
of	O
promoter	O
chromatin	O
structure	O
resulting	O
in	O
increased	O
beta-globin	B-DNA
gene	I-DNA
expression	O
.	O

First	O
,	O
we	O
showed	O
that	O
viral	O
binding	O
induced	O
a	O
number	O
of	O
immunoregulatory	B-cell_type
genes	I-cell_type
(	O
IL-1beta	B-protein
,	O
A20	B-protein
,	O
NF-kappaB-p105/p50	B-protein
,	O
and	O
IkappaBalpha	B-protein
)	O
in	O
unactivated	O
monocytes	B-cell_type
and	O
that	O
neutralizing	B-protein
Abs	I-protein
to	O
the	O
major	O
HCMV	B-protein
glycoproteins	I-protein
,	O
gB	B-protein
(	O
UL55	B-protein
)	O
and	O
gH	B-protein
(	O
UL75	B-protein
)	O
,	O
inhibited	O
the	O
induction	O
of	O
these	O
genes	O
.	O

Involvement	O
of	O
G	B-protein
protein	I-protein
in	O
the	O
activation	O
of	O
MAPK	B-protein
pathway	O
by	O
TCC	B-protein
was	O
indicated	O
by	O
inhibition	O
of	O
Raf-1	B-protein
and	O
ERK1	B-protein
kinase	O
activity	O
,	O
as	O
well	O
as	O
the	O
DNA	O
synthesis	O
by	O
pretreatment	O
of	O
cells	O
with	O
pertussis	B-protein
toxin	I-protein
.	O

Recent	O
data	O
on	O
the	O
signals	O
initiated	O
after	O
cytokine	B-protein
receptor	I-protein
activation	O
on	O
eosinophils	B-cell_type
will	O
be	O
reviewed	O
.	O

Murine	B-protein
and	I-protein
human	I-protein
TCF-1	I-protein
displayed	O
a	O
95.5	O
%	O
overall	O
amino	O
acid	O
homology	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
indicate	O
that	O
MS-2beta	B-protein
and	O
MS-2gamma	B-protein
interact	O
with	O
nuclear	B-protein
factors	I-protein
that	O
are	O
induced	O
during	O
U937	B-cell_line
differentiation	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
transcriptional	O
activities	O
of	O
isolated	B-DNA
human	I-DNA
MCM	I-DNA
gene	I-DNA
promoters	I-DNA
.	O

Uncoupling	O
of	O
cell	O
cycle	O
arrest	O
from	O
the	O
expression	O
of	O
monocytic	O
differentiation	O
markers	O
in	O
HL60	B-cell_line
cell	I-cell_line
variants	I-cell_line
.	O

Given	O
the	O
important	O
role	O
of	O
the	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
in	O
the	O
development	O
and	O
physiology	O
of	O
the	O
breast	O
,	O
it	O
is	O
essential	O
to	O
delineate	O
the	O
mechanisms	O
responsible	O
for	O
its	O
failed	O
expression	O
in	O
some	O
breast	O
tumors	O
.	O

Dominant	O
negative	O
forms	O
of	O
Stat1alpha	B-protein
or	O
Stat3	B-protein
promoted	O
the	O
EPO	B-protein
-induced	O
erythroid	O
differentiation	O
of	O
UT-7/GM	B-cell_line
cells	I-cell_line
,	O
even	O
in	O
the	O
presence	O
of	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
,	O
although	O
this	O
cytokine	O
never	O
induced	O
erythroid	O
differentiation	O
of	O
the	O
parent	B-cell_line
UT-7/GM	I-cell_line
cells	I-cell_line
with	O
or	O
without	O
EPO	B-protein
.	O

The	O
LPS	O
response	O
was	O
also	O
more	O
rapid	O
,	O
as	O
it	O
was	O
already	O
evident	O
by	O
40	O
min	O
and	O
remained	O
sustained	O
for	O
up	O
to	O
3	O
h	O
.	O

We	O
have	O
investigated	O
the	O
mechanism	O
of	O
transactivation	O
mediated	O
by	O
the	O
CIITA	B-protein
activation	I-protein
domain	I-protein
by	O
studying	O
its	O
role	O
in	O
the	O
process	O
of	O
transcription	O
initiation	O
and	O
elongation	O
.	O

Experiments	O
using	O
inhibitors	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
protein	B-protein
kinase	I-protein
A	I-protein
,	O
and	O
tyrosine	O
kinase-dependent	O
pathways	O
revealed	O
that	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-1	B-protein
beta	I-protein
and	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
involves	O
activation	O
of	O
an	O
H7-inhibitable	O
pathway	O
.	O

The	O
insertion	O
of	O
multiple	O
copies	O
of	O
the	O
binding	B-DNA
site	I-DNA
for	O
the	O
former	O
or	O
latter	O
factor	O
into	O
a	O
heterologous	B-DNA
promoter	I-DNA
reduced	O
the	O
promoter	O
activity	O
to	O
one-tenth	O
or	O
one-third	O
,	O
respectively	O
.	O

Aberrant	O
splicing	O
of	O
the	O
TSG101	B-DNA
and	I-DNA
FHIT	I-DNA
genes	I-DNA
occurs	O
frequently	O
in	O
multiple	O
malignancies	O
and	O
in	O
normal	O
tissues	O
and	O
mimics	O
alterations	O
previously	O
described	O
in	O
tumours	O
.	O

Moreover	O
,	O
impaired	O
activation	O
of	O
NFkappaB	B-protein
does	O
not	O
appear	O
linked	O
to	O
a	O
reduction	O
of	O
TCRzeta	B-protein
expression	O
,	O
because	O
in	O
five	O
patients	O
,	O
normal	O
TCRzeta	B-protein
levels	O
were	O
present	O
although	O
kappaB	B-protein
binding	O
was	O
not	O
inducible	O
.	O

The	O
E2F	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
are	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
cell	O
cycle	O
progression	O
.	O

Therefore	O
,	O
we	O
have	O
investigated	O
its	O
role	O
in	O
primary	O
cultures	O
of	O
HIV-infected	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
by	O
using	O
neutralizing	O
anti-TNF-alpha	B-protein
antibodies	I-protein
or	O
TNF-alpha	B-protein
.	O

Subcellular	O
localization	O
analysis	O
in	O
various	O
cells	O
,	O
using	O
a	O
specific	B-protein
monoclonal	I-protein
antibody	I-protein
raised	O
against	O
SR-BP	B-protein
,	O
demonstrated	O
that	O
this	O
protein	O
was	O
associated	O
with	O
the	O
nuclear	O
envelope	O
.	O

In	O
the	O
E1a-positive	O
samples	O
,	O
the	O
average	O
of	O
E1a	O
copy	O
number	O
was	O
55	O
+/-	O
18/10	O
(	O
3	O
)	O
recovered	O
cells	O
.	O

We	O
investigated	O
whether	O
non-abortive	O
maternal	O
infections	O
would	O
compromise	O
fetal	O
brain	O
development	O
and	O
alter	O
hypothalamic-pituitary-adrenocortical	O
(	O
HPA	O
)	O
axis	O
functioning	O
when	O
adult	O
.	O

Comparison	O
of	O
the	O
different	O
combinations	O
of	O
GC	O
and	O
cytokines	B-protein
/LPS	O
revealed	O
differences	O
in	O
the	O
level	O
of	O
GC-dependent	O
enhancement	O
of	O
sialoadhesin	B-protein
expression	O
,	O
with	O
IFN-beta	B-protein
and	O
IL-4	B-protein
being	O
more	O
potent	O
than	O
IFN-gamma	B-protein
and	O
LPS	O
.	O

Polyclonal	B-cell_line
and	I-cell_line
clonal	I-cell_line
CTL	I-cell_line
that	O
were	O
generated	O
by	O
stimulating	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
with	O
an	O
HLA	B-cell_line
B8+	I-cell_line
homozygous	I-cell_line
LCL	I-cell_line
lysed	I-cell_line
T	I-cell_line
cell	I-cell_line
blasts	I-cell_line
pulsed	O
with	O
the	O
peptide	O
,	O
RAKFKQLLQ	O
;	O
lysis	O
of	O
certain	O
HLA	O
B8+	O
LCL	O
targets	O
was	O
associated	O
with	O
the	O
abundance	O
of	O
BZLF1	B-RNA
transcripts	I-RNA
.	O

The	O
gp160-induced	B-protein
NF-kappa	I-protein
B	I-protein
complex	I-protein
consists	O
of	O
p65	B-protein
,	O
p50	B-protein
and	O
c-rel	B-protein
proteins	I-protein
.	O

Recently	O
,	O
a	O
technique	O
of	O
clonal	O
analysis	O
has	O
been	O
devised	O
that	O
takes	O
advantage	O
of	O
a	O
highly	O
polymorphic	O
short	B-DNA
tandem	I-DNA
repeat	I-DNA
within	O
the	O
X-linked	B-DNA
human	I-DNA
androgen	I-DNA
receptor	I-DNA
(	I-DNA
AR	I-DNA
)	I-DNA
gene	I-DNA
,	O
resulting	O
in	O
a	O
heterozygosity	O
rate	O
approaching	O
90	O
%	O
.	O

In	O
contrast	O
,	O
two	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
,	O
ibuprofen	O
and	O
indomethacin	O
,	O
did	O
not	O
inhibit	O
LPS	O
induction	O
of	O
the	O
TF	B-DNA
gene	I-DNA
.	O

Increases	O
in	O
CAT	B-protein
activity	O
during	O
transient	O
expression	O
of	O
these	O
constructs	O
in	O
TPA-treated	B-cell_line
U-937	I-cell_line
cells	I-cell_line
could	O
be	O
assigned	O
to	O
the	O
region	O
(	O
-97	O
to	O
-20	O
)	O
of	O
the	O
promoter	B-DNA
that	O
contains	O
the	O
AP-1	B-DNA
binding	I-DNA
site	I-DNA
.	O

These	O
results	O
suggest	O
a	O
key	O
functional	O
role	O
of	O
PML	B-protein
in	O
early	O
hematopoiesis	O
and	O
late	O
erythropoiesis	O
:	O
the	O
latter	O
phenomenon	O
may	O
be	O
related	O
to	O
the	O
molecular	O
and	O
functional	O
interaction	O
of	O
PML	B-protein
with	O
pRb	B-protein
105	I-protein
.	O

Osteoclast	B-protein
markers	I-protein
accumulate	O
on	O
cells	O
developing	O
from	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
precursors	I-cell_type
.	O

Salicylates	O
inhibit	O
lipopolysaccharide-induced	O
transcriptional	O
activation	O
of	O
the	O
tissue	O
factor	O
gene	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

Transcriptional	O
activation	O
by	O
the	O
RFX5	B-protein
fusion	I-protein
protein	I-protein
could	O
be	O
restored	O
in	O
RJ2.2.5	B-cell_line
by	O
cotransfection	O
with	O
a	O
CIITA	B-DNA
expression	I-DNA
plasmid	I-DNA
.	O

The	O
formation	O
of	O
this	O
complex	O
also	O
requires	O
both	O
AP-1	B-DNA
sites	I-DNA
and	O
correlates	O
with	O
maximal	O
enhancer	B-DNA
activity	O
.	O

Basal	O
activity	O
of	O
a	O
3070	B-DNA
bp	I-DNA
CRH	I-DNA
promoter	I-DNA
fragment	I-DNA
was	O
only	O
seen	O
in	O
neuronal	O
and	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
divergent	O
effects	O
of	O
hemin	O
and	O
TPA	O
on	O
gene	O
expression	O
in	O
K562	B-cell_line
cells	I-cell_line
are	O
mediated	O
,	O
in	O
part	O
,	O
by	O
their	O
contrasting	O
effects	O
on	O
the	O
transcription	B-protein
factor	I-protein
NF-E2	B-protein
.	O

From	O
our	O
results	O
,	O
we	O
conclude	O
that	O
Rap1	B-protein
activation	O
in	O
platelets	B-cell_type
is	O
an	O
important	O
common	O
event	O
in	O
early	O
agonist-induced	O
signalling	O
,	O
and	O
that	O
this	O
activation	O
is	O
mediated	O
by	O
an	O
increased	O
intracellular	O
Ca2+	O
concentration	O

It	O
is	O
generally	O
accepted	O
that	O
Bcl-2	B-protein
exerts	O
its	O
antiapoptotic	O
effects	O
mainly	O
by	O
dimerizing	O
with	O
proapoptotic	O
members	O
of	O
the	O
Bcl-2	B-protein
family	I-protein
such	O
as	O
Bax	B-protein
and	O
Bad	B-protein
.	O

The	O
interleukin-10	B-protein
(	I-protein
IL-10	I-protein
)	I-protein
receptor	I-protein
is	O
another	O
member	O
of	O
the	O
IFN	B-protein
receptor	I-protein
family	I-protein
,	O
but	O
its	O
ligand	O
,	O
IL-10	B-protein
,	O
has	O
been	O
reported	O
to	O
induce	O
apoptosis	O
in	O
B-CLL	B-cell_line
cells	I-cell_line
.	O

The	O
Sp1	B-DNA
site	I-DNA
also	O
co-localizes	O
with	O
a	O
DNase	B-DNA
I	I-DNA
hypersensitive	I-DNA
site	I-DNA
.	O

GCA	O
is	O
self-sustained	O
in	O
temporal	O
arteries	O
engrafted	O
into	O
SCID	O
mice	O
,	O
providing	O
a	O
model	O
in	O
which	O
the	O
mechanisms	O
of	O
action	O
and	O
limitations	O
of	O
glucocorticoid	O
therapy	O
can	O
be	O
examined	O
in	O
vivo	O
.	O

In	O
vivo	O
genomic	O
DMS	O
footprinting	O
revealed	O
upstream	O
of	O
the	O
major	O
transcription	B-DNA
initiation	I-DNA
sites	I-DNA
,	O
the	O
presence	O
of	O
at	O
least	O
three	O
protein	B-DNA
binding	I-DNA
sites	I-DNA
,	O
two	O
of	O
which	O
were	O
constitutively	O
occupied	O
.	O

There	O
was	O
only	O
weak	O
inhibition	O
of	O
the	O
generation	O
of	O
enhancing	O
activity	O
by	O
the	O
corticosteroids	O
in	O
the	O
CR	O
asthmatic	O
individuals	O
.	O

IL-6	B-protein
-induced	O
apoptosis	O
,	O
but	O
not	O
macrophage-differentiation	O
,	O
was	O
blocked	O
by	O
continuously	O
expressed	O
BCL2	B-protein
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
selenium	O
,	O
an	O
integral	O
component	O
of	O
glutathione	B-protein
peroxidase	I-protein
(	O
GPX	B-protein
)	O
,	O
on	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Constitutive	O
STAT5	B-protein
activity	O
,	O
activated	O
through	O
an	O
unknown	O
pathway	O
not	O
including	O
JAK2	B-protein
or	O
EPOR	B-protein
,	O
may	O
act	O
in	O
concert	O
with	O
the	O
constitutive	O
PI3-kinase	B-protein
/PKB/Akt	B-protein
pathway	O
to	O
protect	O
the	O
EPO-independent	B-cell_line
HCD57-SREI	I-cell_line
cells	I-cell_line
from	O
apoptosis	O
and	O
promote	O
limited	O
proliferation	O
.	O

Protein	O
expression	O
paralleled	O
that	O
of	O
the	O
RNA	O
.	O

A	O
2-kb	B-DNA
VDR	I-DNA
cDNA	I-DNA
insert	I-DNA
(	O
including	O
the	O
complete	O
VDR	B-DNA
coding	I-DNA
region	I-DNA
)	O
was	O
cloned	O
in	O
an	O
antisense	O
orientation	O
into	O
the	O
EBV	O
episomal	O
vector	O
pMEP4	O
under	O
the	O
control	O
of	O
an	O
inducible	B-DNA
promoter	I-DNA
and	O
transfected	O
into	O
U937	B-cell_line
.	O

Nonadherent	O
neutrophils	B-cell_type
were	O
removed	O
by	O
sealing	O
and	O
inverting	O
the	O
culture	O
well	O
.	O

Nucleolin	B-protein
is	O
one	O
component	O
of	O
the	O
B	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
and	O
switch	B-protein
region	I-protein
binding	I-protein
protein	I-protein
,	O
LR1	B-protein
.	O

Moreover	O
,	O
Tax1	B-protein
activated	O
expression	O
of	O
two	O
other	O
transcription	B-protein
factors	I-protein
having	O
zinc	B-protein
finger	I-protein
motifs	I-protein
,	O
Egr-1	B-protein
and	O
Egr-2	B-protein
,	O
in	O
the	O
same	O
cells	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	O
of	O
PKC	B-protein
and	O
elevation	O
of	O
cAMP	O
leads	O
to	O
an	O
enhanced	O
AP-1	B-protein
transcriptional	O
activity	O
in	O
a	O
T-leukemia	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
suggesting	O
that	O
the	O
previously	O
observed	O
interaction	O
between	O
the	O
parallel	O
signal	O
transduction	O
pathways	O
may	O
have	O
functional	O
consequences	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

These	O
parameters	O
were	O
not	O
modified	O
by	O
Nef	B-protein
expression	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
whereas	O
stimulation	O
with	O
the	O
same	O
stimuli	O
resulted	O
in	O
partial	O
inhibition	O
of	O
LTR	B-DNA
activation	O
in	O
Nef+	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
.	O

As	O
a	O
first	O
step	O
toward	O
elucidating	O
the	O
function	O
of	O
Cbl	B-protein
in	O
TCR	B-protein
-initiated	O
signaling	O
,	O
we	O
evaluated	O
the	O
ability	O
of	O
wild-type	B-protein
Cbl	I-protein
or	O
a	O
transforming	O
Cbl	B-protein
mutant	I-protein
(	O
70Z/3	O
)	O
to	O
induce	O
transcriptional	O
activation	O
of	O
a	O
nuclear	B-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells	I-DNA
(	I-DNA
NFAT	I-DNA
)	I-DNA
element	I-DNA
derived	O
from	O
the	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL2	I-DNA
)	I-DNA
promoter	I-DNA
in	O
transiently	O
cotransfected	O
Jurkat-TAg	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Systemic	O
hGR	B-protein
levels	O
in	O
patients	O
with	O
Crohn	O
's	O
disease	O
(	O
CD	O
)	O
treated	O
with	O
steroids	O
(	O
66.6	O
+/-	O
61.0	O
dpm	O
mg-1	O
cytosol	B-protein
protein	I-protein
)	O
were	O
not	O
different	O
from	O
those	O
in	O
patients	O
with	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
(	O
56.1	O
+/-	O
51.6	O
dpm	O
mg-1	O
cytosol	B-protein
protein	I-protein
)	O
.	O

Earlier	O
studies	O
on	O
the	O
IL-2	B-protein
gene	O
expression	O
showed	O
that	O
overexpression	O
of	O
calcineurin	B-protein
(	O
CN	B-protein
)	O
,	O
a	O
Ca2+/calmodulin-dependent	B-protein
protein	I-protein
phosphatase	I-protein
,	O
can	O
stimulate	O
transcription	O
from	O
the	O
IL-2	B-DNA
promoter	I-DNA
through	O
the	O
NF-AT-binding	B-DNA
site	I-DNA
.	O

Competition	O
analysis	O
showed	O
that	O
the	O
anti-estrogen	O
tamoxifen	O
and	O
the	O
flavonoids	O
quercetin	O
and	O
rutin	O
competed	O
for	O
(	O
3H	O
)	O
-E2	O
binding	O
to	O
type-II	B-protein
EBS	I-protein
.	O

The	O
differences	O
between	O
wild-type	B-protein
and	I-protein
mutated	I-protein
receptors	I-protein
in	O
the	O
induction	O
of	O
apoptosis	O
were	O
not	O
related	O
to	O
levels	O
of	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
or	O
NF-	B-protein
kappaB	I-protein
activation	O
.	O

Southwestern	O
blotting	O
and	O
UV	O
cross-linking	O
studies	O
confirmed	O
that	O
the	O
BAT	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
were	O
Oct-1	B-protein
and	O
Oct-2	B-protein
.	O

In	O
healthy	O
subjects	O
,	O
the	O
mean	O
GC-R	B-protein
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	B-cell_type
of	O
the	O
GC-sensitive	O
group	O
were	O
2.89	O
+/-	O
1.23	O
fmol/10	O
(	O
6	O
)	O
cells	O
and	O
4.00	O
+/-	O
2.24	O
nM	O
,	O
respectively	O
.	O

Thus	O
increased	O
expression	O
of	O
GCRbeta	B-protein
could	O
account	O
for	O
glucocorticoid	O
insensitivity	O
.	O

FK506	O
,	O
an	O
immunosuppressant	O
,	O
inhibits	O
the	O
production	O
of	O
several	O
cytokines	B-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

ZAP-70	B-protein
will	O
then	O
be	O
able	O
to	O
effectively	O
control	O
phosphorylation	O
of	O
its	O
substrates	O
and	O
lead	O
to	O
gene	O
activation	O
.	O

Transfection	O
of	O
human	B-cell_line
promonocytic	I-cell_line
U-937	I-cell_line
cells	I-cell_line
with	O
an	O
HTLV-I	O
Tax	O
expression	O
vector	O
induced	O
galectin-3	B-protein
expression	O
in	O
this	O
cell	O
line	O
.	O

The	O
small	B-protein
GTP-binding	I-protein
protein	I-protein
Rho	I-protein
potentiates	O
AP-1	B-protein
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
addition	O
of	O
anti-CD28	B-protein
mAb	I-protein
to	O
anti-CD3-stimulated	B-cell_line
cells	I-cell_line
markedly	O
increased	O
IL-2	B-protein
production	O
in	O
both	O
cell	O
types	O
,	O
but	O
levels	O
of	O
IL-2	B-protein
in	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
remained	O
clearly	O
lower	O
than	O
those	O
of	O
adult	B-cell_type
T	I-cell_type
cells	I-cell_type
(	O
respective	O
mean	O
values	O
:	O
385	O
+/-	O
109	O
pg/ml	O
and	O
4494	O
+/-	O
1199	O
pg/ml	O
)	O
.	O

PDTC	O
,	O
apocynin	O
,	O
or	O
SKF525a	O
decreased	O
adhesion	O
of	O
monocytic	B-cell_line
U937	I-cell_line
cells	I-cell_line
to	O
TNF-treated	B-cell_line
HUVECs	I-cell_line
(	O
by	O
75	O
%	O
at	O
100	O
mumol/L	O
PDTC	O
)	O
.	O

Fas	B-protein
ligand	I-protein
induction	O
in	O
human	B-cell_type
NK	I-cell_type
cells	I-cell_type
is	O
regulated	O
by	O
redox	O
through	O
a	O
calcineurin-nuclear	B-protein
factors	I-protein
of	O
activated	O
T	O
cell-dependent	O
pathway	O
.	O

However	O
,	O
it	O
was	O
only	O
the	O
IL-2	B-DNA
promoter	I-DNA
whose	O
activation	O
by	O
Tpl-2	B-protein
was	O
fully	O
blocked	O
by	O
the	O
dominant	B-protein
negative	I-protein
mutant	I-protein
MEK1S218/222A	I-protein
and	O
the	O
MEK1/MEK2	O
inhibitor	O
PD098059	O
.	O

We	O
recently	O
identified	O
the	O
winged-helix	B-protein
transcription	I-protein
factor	I-protein
Trident	B-protein
and	O
described	O
its	O
expression	O
pattern	O
in	O
synchronized	B-cell_type
fibroblasts	I-cell_type
.	O

p45	B-RNA
mRNA	I-RNA
is	O
also	O
expressed	O
in	O
HL-60	B-cell_line
promyelocytes	I-cell_line
,	O
albeit	O
the	O
expression	O
level	O
is	O
much	O
lower	O
than	O
that	O
of	O
the	O
granulocyte	B-cell_type
fraction	I-cell_type
.	O

As	O
we	O
observed	O
that	O
activated	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
also	O
expressed	O
NFAT	B-protein
,	O
we	O
tested	O
the	O
antiinflammatory	O
properties	O
of	O
CsA	O
in	O
endothelial	B-cell_type
cells	I-cell_type
.	O

In	O
addition	O
,	O
IL-6	B-protein
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
bronchiolitis	O
obliterans	O
after	O
transplantation	O
.	O

Addition	O
of	O
exogenous	O
IL-2	B-protein
to	O
IL-10-treated	B-cell_line
cells	I-cell_line
significantly	O
reversed	O
the	O
antiproliferative	O
effects	O
of	O
IL-10	B-protein
.	O

Supershift	O
with	O
specific	O
antibodies	O
to	O
NF-kappa	B-protein
B	I-protein
subunits	I-protein
confirmed	O
that	O
the	O
inducible	O
retarded	O
bands	O
observed	O
in	O
the	O
EMSA	O
and	O
p65-p50	B-protein
heterodimer	I-protein
of	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
protein	I-protein
.	O

Activated	B-cell_type
platelets	I-cell_type
induce	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
secretion	O
and	O
surface	O
expression	O
of	O
intercellular	B-cell_type
adhesion	I-cell_type
molecule-1	I-cell_type
on	O
endothelial	B-cell_type
cells	I-cell_type
[	O
see	O
comments	O
]	O

In	O
this	O
study	O
,	O
we	O
discovered	O
a	O
novel	O
regulatory	B-DNA
element	I-DNA
located	O
at	O
-120	B-DNA
of	O
the	O
CD95L	B-DNA
promoter	I-DNA
which	O
contains	O
DNA	B-DNA
binding	I-DNA
sites	I-DNA
for	O
SP-1	B-protein
and	O
a	O
yet	O
unknown	O
inducible	B-protein
factor	I-protein
.	O

On	O
the	O
other	O
hand	O
,	O
stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
mitogens	O
or	O
antibodies	O
to	O
the	O
T-cell	O
receptor	O
(	O
TCR	O
)	O
-	O
CD3	B-protein
complex	O
resulted	O
in	O
the	O
down-regulation	O
of	O
transcriptional	O
factors	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
in	O
cells	O
expressing	O
the	O
nef	O
gene	O
compared	O
with	O
cells	O
not	O
expressing	O
the	O
nef	O
gene	O
.	O

Both	O
phosphorylation	O
and	O
proliferation	O
were	O
inhibited	O
by	O
IL-6	B-protein
neutralizing	I-protein
antibodies	I-protein
.	O

Interaction	O
of	O
HTLV-I	B-protein
Tax	I-protein
with	O
the	O
human	B-protein
proteasome	I-protein
:	O
implications	O
for	O
NF-kappa	B-protein
B	I-protein
induction	O
.	O

Both	O
IL-4	B-protein
and	O
anti-	O
CD40	B-protein
mAb	I-protein
induced	O
activation	O
of	O
phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PI3-kinase	B-protein
)	O
,	O
translocation	O
of	O
a	O
zeta	O
isoform	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
and	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

In	O
contrast	O
to	O
ionomycin	O
treatment	O
,	O
exposure	O
of	O
cells	O
to	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
plus	O
anti-CD28	B-protein
did	O
not	O
induce	O
NFATc	B-protein
,	O
indicating	O
that	O
under	O
these	O
conditions	O
,	O
interleukin-2	B-protein
synthesis	O
by	O
these	O
cells	O
is	O
apparently	O
independent	O
of	O
NFATc	B-protein
.	O

3	O
.	O

Stimulation	O
experiments	O
in	O
the	O
presence	O
of	O
protein	O
synthesis	O
inhibitor	O
,	O
cycloheximide	O
,	O
suggested	O
that	O
these	O
genes	O
were	O
activated	O
directly	O
by	O
IFNs	B-protein
.	O

Additionally	O
,	O
in	O
lymphocytes	B-cell_type
expressing	O
SOCS-3	B-protein
but	O
not	O
CIS	B-protein
,	O
IL-2	B-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
STAT5b	B-protein
was	O
markedly	O
reduced	O
,	O
while	O
there	O
was	O
only	O
a	O
weak	O
effect	O
on	O
IL-3-mediated	B-protein
STAT5b	I-protein
tyrosine	O
phosphorylation	O
.	O

One	O
HIV-1	O
variant	O
was	O
detected	O
containing	O
an	O
additional	O
binding	O
site	O
for	O
the	O
transcription	O
factor	O
Sp1	O
.	O

We	O
show	O
that	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
underlying	O
Ig	B-DNA
gene	I-DNA
extinction	O
can	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
a	O
lack	O
of	O
transcription	B-protein
factors	I-protein
that	O
are	O
essential	O
for	O
Ig	B-DNA
gene	I-DNA
transcription	O
.	O

The	O
TCF-1	B-protein
protein	O
was	O
detectable	O
in	O
all	O
samples	O
of	O
a	O
set	O
of	O
22	O
T-cell	B-cell_type
malignancies	I-cell_type
of	O
various	O
stages	O
of	O
maturation	O
,	O
but	O
was	O
absent	O
from	O
a	O
large	O
number	O
of	O
other	O
hematologic	B-cell_type
neoplasms	I-cell_type
.	O

cAMP-dependent	O
regulation	O
of	O
proenkephalin	O
by	O
JunD	B-protein
and	O
JunB	B-protein
:	O
positive	O
and	O
negative	O
effects	O
of	O
AP-1	B-protein
proteins	I-protein
.	O

Heat-shock	O
for	O
2	O
hours	O
at	O
42	O
degrees	O
C	O
,	O
or	O
the	O
administration	O
for	O
3	O
hours	O
of	O
100	O
or	O
150	O
microM	O
cadmium	O
chloride	O
,	O
inhibited	O
the	O
subsequent	B-cell_line
proliferation	I-cell_line
activity	I-cell_line
,	O
induced	O
the	O
expression	O
of	O
functional	O
differentiation	B-protein
markers	I-protein
,	O
and	O
caused	O
an	O
increase	O
in	O
the	O
amount	O
of	O
the	O
stress-responsive	B-protein
HSP70	I-protein
protein	I-protein
in	O
U-937	B-cell_line
human	I-cell_line
promonocytic	I-cell_line
cells	I-cell_line
.	O

alpha-IFN	B-protein
causes	O
dephosphorylation	O
of	O
pRb	B-protein
and	O
loss	O
of	O
p130	B-protein
phosphorylated	I-protein
Form	I-protein
3	I-protein
.	O

It	O
has	O
been	O
hypothesized	O
that	O
alpha-tcp	O
acts	O
as	O
an	O
anti-atherosclerotic	O
molecule	O
by	O
inhibiting	O
generation	O
of	O
oxidized	O
LDL	O
--	O
a	O
putative	O
triggering	O
molecule	O
in	O
the	O
atherosclerotic	O
process	O
.	O

This	O
cis	B-DNA
element	I-DNA
binds	O
a	O
protein	O
complex	O
referred	O
to	O
as	O
HRF	B-protein
(	O
heme-responsive	B-protein
factor	I-protein
)	O
,	O
which	O
is	O
greatly	O
enhanced	O
both	O
in	O
heme-treated	O
FLCs	B-cell_line
and	O
during	O
monocyte-to-macrophage	O
differentiation	O
.	O

Lt-4	B-protein
detected	O
40	O
kd	O
tax1	B-protein
antigen	I-protein
molecules	I-protein
in	O
most	O
HTLV-I-bearing	B-cell_line
cell	I-cell_line
lines	I-cell_line
except	O
one	O
cell	O
line	O
that	O
expressed	O
39	B-protein
kd	I-protein
tax1	I-protein
antigen	I-protein
.	O

A	O
PMA	B-DNA
responsive	I-DNA
element	I-DNA
was	O
localized	O
to	O
a	O
region	O
between	O
-319	B-DNA
and	I-DNA
-219	I-DNA
bp	I-DNA
upstream	I-DNA
of	O
the	O
initiation	O
codon	O
and	O
co-transfections	O
with	O
transcription	B-DNA
factor	I-DNA
expression	I-DNA
plasmids	I-DNA
for	O
AP-2	B-protein
and	O
Sp1	B-protein
resulted	O
in	O
augmented	O
ASM	O
promoter	O
activity	O
,	O
which	O
was	O
abolished	O
when	O
the	O
binding	B-DNA
sites	I-DNA
for	O
these	O
two	O
factors	O
were	O
deleted	O
.	O

The	O
expression	O
of	O
human	B-protein
PCD/DCoH	I-protein
in	O
the	O
liver	O
and	O
nonhepatic	B-cell_type
cells	I-cell_type
was	O
compared	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
.	O

The	O
RAR	B-protein
alpha	I-protein
rearranged	O
band	O
in	O
the	O
Southern	O
blot	O
analysis	O
and	O
a	O
chimaeric	B-protein
product	I-protein
of	O
PML-RAR	B-protein
alpha	I-protein
by	O
polymerase	O
chain	O
reaction	O
were	O
strongly	O
visible	O
before	O
ATRA	O
treatment	O
,	O
but	O
at	O
the	O
time	O
of	O
maximal	O
basophilia	O
both	O
of	O
them	O
were	O
markedly	O
diminished	O
.	O

Activation	O
of	O
p38	B-protein
MAPK	I-protein
correlates	O
closely	O
with	O
the	O
stimulation	O
of	O
T	O
cell	O
proliferation	O
.	O

These	O
two	O
anthracyclines	O
,	O
although	O
closely	O
related	O
in	O
their	O
structures	O
,	O
appeared	O
to	O
act	O
as	O
differentiation	O
inducers	O
by	O
distinct	O
mechanisms	O
.	O

In	O
the	O
present	O
studies	O
we	O
have	O
examined	O
the	O
signaling	O
pathways	O
by	O
which	O
this	O
monocyte-specific	O
response	O
is	O
induced	O
.	O

In	O
vitro	O
studies	O
identify	O
three	O
essential	O
elements	O
of	O
the	O
TATA-less	B-DNA
blr1	I-DNA
core	I-DNA
promoter	I-DNA
that	O
confer	O
cell	O
type-	O
and	O
differentiation-specific	O
expression	O
in	O
the	O
B	B-cell_type
cells	I-cell_type
of	O
both	O
humans	O
and	O
mice	O
,	O
a	O
functional	B-DNA
promoter	I-DNA
region	I-DNA
(	O
-36	O
with	O
respect	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
)	O
,	O
a	O
NF-kappaB	B-DNA
motif	I-DNA
(	O
+44	O
)	O
,	O
and	O
a	O
noncanonical	B-DNA
octamer	I-DNA
motif	I-DNA
(	O
+157	O
)	O
.	O

Recent	O
data	O
show	O
that	O
TCR/CD3	B-protein
stimulation	O
induces	O
activation	O
of	O
Stat5	B-protein
in	O
murine	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
these	O
transfected	O
CL-01	B-cell_line
cells	I-cell_line
,	O
CD40	O
:	O
CD40L	B-protein
engagement	O
and	O
exposure	O
to	O
IL-4	B-protein
synergistically	O
induced	O
gamma	O
3	O
ECS-dependent	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
activation	O
.	O

Moreover	O
,	O
in	O
the	O
presence	O
of	O
CIITA	B-protein
,	O
interactions	O
between	O
class	B-DNA
II	I-DNA
promoters	I-DNA
and	O
Bob1	B-protein
are	O
independent	O
of	O
the	O
octamer-binding	B-RNA
site	I-RNA
.	O

We	O
have	O
investigated	O
whether	O
this	O
antigen	O
is	O
a	O
target	O
structure	O
for	O
human	B-cell_type
T-lymphocytes	I-cell_type
.	O

NF-AT	B-protein
is	O
thought	O
to	O
consist	O
of	O
two	O
components	O
:	O
a	O
ubiquitous	B-protein
,	I-protein
inducible	I-protein
nuclear	I-protein
component	I-protein
that	O
we	O
have	O
identified	O
as	O
Fos	B-protein
and	O
Jun	B-protein
proteins	I-protein
,	O
and	O
a	O
preexisting	O
,	O
T	B-protein
cell-specific	I-protein
component	I-protein
(	O
NF-ATp	B-protein
)	O
which	O
is	O
the	O
target	O
for	O
the	O
immunosuppressive	O
agents	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
.	O

We	O
studied	O
the	O
effect	O
of	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
on	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
two	O
immediate	O
early	O
genes	O
c-fos	B-DNA
and	O
c-jun	B-DNA
.	O

However	O
,	O
the	O
histone	B-protein
deacetylase	I-protein
(	I-protein
HDAC	I-protein
)	I-protein
inhibitor	I-protein
trichostatin	O
A	O
readily	O
activates	O
an	O
RXR-RAR	B-DNA
reporter	I-DNA
construct	I-DNA
in	O
the	O
multipotent	O
EML	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
the	O
committed	O
MPRO	B-cell_type
promyelocytes	I-cell_type
,	O
indicating	O
that	O
differences	O
in	O
HDAC-containing	B-protein
repressor	I-protein
complexes	I-protein
in	O
these	O
two	O
closely	O
related	O
but	O
distinct	O
hematopoietic	B-cell_type
lineages	I-cell_type
might	O
account	O
for	O
the	O
differential	O
activation	O
of	O
the	O
RXR-RARalpha403	B-protein
heterodimers	I-protein
that	O
we	O
observed	O
at	O
these	O
different	O
stages	O
of	O
myeloid	O
development	O
.	O

Through	O
systematic	O
DNA	O
footprinting	O
of	O
the	O
TNF	O
(	O
encoding	O
tumour	O
necrosis	O
factor	O
,	O
TNF	O
)	O
promoter	O
region	O
,	O
we	O
have	O
identified	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
that	O
causes	O
the	O
helix-turn-helix	O
transcription	B-protein
factor	I-protein
OCT-1	O
to	O
bind	O
to	O
a	O
novel	O
region	O
of	O
complex	O
protein-DNA	O
interactions	O
and	O
alters	O
gene	O
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Alignment	O
of	O
the	O
selected	O
sequences	O
allowed	O
us	O
to	O
predict	O
a	O
consensus	O
sequence	O
for	O
binding	O
of	O
the	O
individual	O
homodimeric	B-protein
Rel-related	I-protein
proteins	I-protein
,	O
and	O
DNA-protein	O
binding	O
analysis	O
of	O
the	O
selected	O
DNA	O
sequences	O
revealed	O
sequence	O
specificity	O
of	O
the	O
proteins	O
.	O

Taken	O
together	O
,	O
this	O
review	O
supports	O
the	O
notion	O
that	O
the	O
development	O
of	O
lymphoid	O
malignancies	O
is	O
multifactorial	O
,	O
involving	O
genetic	O
alterations	O
as	O
well	O
as	O
dysregulated	O
cytokine	B-protein
expression	O
.	O

It	O
has	O
been	O
proposed	O
that	O
their	O
expression	O
is	O
controlled	O
by	O
the	O
non-clonal	O
,	O
or	O
innate	O
,	O
component	O
of	O
immunity	O
that	O
preceded	O
in	O
evolution	O
the	O
development	O
of	O
an	O
adaptive	O
immune	O
system	O
in	O
vertebrates	O
.	O

However	O
,	O
one	O
palindrome	B-DNA
,	O
either	O
alone	O
or	O
duplicated	O
,	O
or	O
the	O
overlapping	B-DNA
palindromes	I-DNA
did	O
not	O
respond	O
to	O
R	O
.	O

Confirmed	O
mutations	O
were	O
identified	O
in	O
28	O
%	O
of	O
the	O
families	O
studied	O
and	O
on	O
the	O
assumption	O
that	O
half	O
of	O
the	O
sporadic	O
cases	O
should	O
have	O
TSC2	B-DNA
mutations	I-DNA
,	O
a	O
crude	O
estimate	O
of	O
the	O
detection	O
rate	O
would	O
be	O
60	O
%	O
.	O

These	O
studies	O
are	O
the	O
first	O
to	O
determine	O
the	O
structure	O
and	O
organization	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
and	O
demonstrate	O
that	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
expression	O
can	O
be	O
regulated	O
by	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
via	O
induction	O
of	O
an	O
AP-2-like	B-protein
nuclear	I-protein
factor	I-protein
binding	O
to	O
upstream	B-DNA
promoter	I-DNA
elements	I-DNA
.	O

Specificity	O
of	O
ANG	B-protein
II	I-protein
-induced	O
NF-kappaB	B-protein
activation	O
was	O
ascertained	O
by	O
supershift	O
and	O
competition	O
experiments	O
.	O

An	O
ability	O
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
latent	I-protein
membrane	I-protein
protein	I-protein
LMP1	B-protein
to	O
enhance	O
the	O
survival	O
of	O
infected	B-cell_type
B	I-cell_type
cells	I-cell_type
through	O
upregulation	O
of	O
the	O
bcl-2	B-DNA
oncogene	I-DNA
was	O
first	O
suggested	O
by	O
experiments	O
involving	O
gene	O
transfection	O
and	O
the	O
selection	O
of	O
stable	O
LMP1+	B-cell_line
clones	I-cell_line
(	O
S.Henderson	O
,	O
M.	O
Rowe	O
,	O
C.Gregory	O
,	O
F.Wang	O
,	O
E.Kieff	O
,	O
and	O
A.Rickinson	O
,	O
Cell	O
65	O
:	O
1107-1115	O
,	O
1991	O
)	O
.	O

Furthermore	O
,	O
the	O
sharply	O
reduced	O
NF-AT	B-protein
activity	O
produced	O
by	O
co-transfecting	B-DNA
BKO	I-DNA
could	O
be	O
``	O
rescued	O
''	O
by	O
overexpression	O
of	O
transfected	O
B	B-protein
subunit	I-protein
,	O
suggesting	O
that	O
depletion	O
of	O
this	O
subunit	O
was	O
responsible	O
for	O
the	O
inhibition	O
.	O

This	O
gene	O
,	O
originally	O
named	O
AML1	B-DNA
,	O
is	O
a	O
human	O
homologue	O
of	O
the	O
Drosophila	B-DNA
gene	I-DNA
runt	I-DNA
that	O
controls	O
early	O
events	O
in	O
fly	O
embryogenesis	O
.	O

All	O
such	O
events	O
were	O
abrogated	O
by	O
treatment	O
with	O
LY294002	O
,	O
a	O
specific	O
inhibitor	O
of	O
PI3-kinase	B-protein
.	O

Interleukin-10	B-protein
(	O
IL-10	B-protein
)	O
protects	O
animals	O
from	O
lethal	O
endotoxemia	O
.	O

Based	O
on	O
these	O
results	O
,	O
we	O
propose	O
that	O
NTF	B-protein
and	O
OTF2	B-protein
interactions	O
(	O
both	O
with	O
their	O
cognate	B-DNA
DNA	I-DNA
elements	I-DNA
and	O
possibly	O
at	O
the	O
protein-protein	O
level	O
)	O
may	O
be	O
critical	O
to	O
B-cell-specific	O
expression	O
and	O
that	O
these	O
interactions	O
provide	O
additional	O
pathways	O
for	O
regulating	O
gene	O
expression	O
.	O

Of	O
six	O
flavonoids	O
tested	O
,	O
myricetin	O
was	O
found	O
to	O
strongly	O
inhibit	O
IKK	B-protein
kinase	O
activity	O
,	O
and	O
prevent	O
the	O
degradation	O
of	O
IkappaBalpha	B-protein
and	O
IkappaBbeta	B-protein
in	O
activated	O
endothelial	O
cells	O
.	O

Its	O
extracellular	O
domain	O
is	O
composed	O
of	O
four	O
cysteine-rich	B-protein
domains	I-protein
,	O
and	O
the	O
cytoplasmic	B-protein
region	I-protein
contains	O
a	O
death	B-protein
domain	I-protein
known	O
to	O
signal	O
apoptosis	O
.	O

The	O
molecular	O
basis	O
for	O
increased	O
IL-4	B-DNA
gene	I-DNA
expression	O
in	O
atopy	O
is	O
not	O
fully	O
understood	O
.	O

Transcriptional	O
activity	O
and	O
constitutive	O
nuclear	O
localization	O
of	O
the	O
ETS	B-protein
protein	I-protein
Elf-1	B-protein
.	O

In	O
humans	O
,	O
similar	O
effects	O
were	O
observed	O
with	O
homologous	O
members	O
of	O
the	O
CCAAT/enhancer-binding	B-protein
protein	I-protein
(	I-protein
C/EBP	I-protein
)	I-protein
family	I-protein
of	O
transcriptional	B-protein
regulators	I-protein
,	O
especially	O
the	O
human	O
homolog	O
of	O
chicken	B-protein
NF-M	I-protein
,	O
C/EBP-beta	B-protein
(	O
NF-IL6	B-protein
)	O
.	O

Regulation	O
of	O
IL-4	B-protein
expression	O
by	O
the	O
transcription	B-protein
factor	I-protein
JunB	B-protein
during	O
T	O
helper	O
cell	O
differentiation	O
.	O

In	O
addition	O
,	O
the	O
concentration	O
of	O
androgen	B-protein
receptors	I-protein
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
was	O
measured	O
,	O
in	O
both	O
the	O
follicular	O
and	O
luteal	O
phases	O
of	O
the	O
menstrual	O
cycle	O
,	O
basally	O
and	O
after	O
4	O
months	O
of	O
flutamide	O
treatment	O
.	O

To	O
evaluate	O
a	O
potential	O
mechanism	O
for	O
these	O
differences	O
in	O
function	O
,	O
we	O
evaluated	O
expression	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	I-protein
PKC	I-protein
)	I-protein
isoforms	I-protein
.	O

Interferons	B-protein
as	O
well	O
as	O
retinoids	O
inhibit	O
the	O
growth	O
of	O
NB4	B-cell_line
cells	I-cell_line
,	O
although	O
the	O
2	O
classes	O
of	O
compounds	O
do	O
not	O
significantly	O
interact	O
in	O
terms	O
of	O
anti-proliferative	O
activity	O
.	O

A	O
large	O
prospective	O
trial	O
is	O
needed	O
to	O
determine	O
if	O
one	O
or	O
more	O
of	O
these	O
biomarkers	O
,	O
is	O
predictive	O
of	O
breast	O
cancer	O
development	O
.	O

Peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
.	O

Furthermore	O
,	O
no	O
modification	O
of	O
the	O
suppressor	O
function	O
in	O
CEM	B-cell_line
C1	I-cell_line
cells	I-cell_line
by	O
dexamethasone	O
was	O
observed	O
.	O

The	O
transcription	B-protein
factor	I-protein
NF-ATc	B-protein
that	O
controls	O
gene	O
expression	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
embryonic	B-cell_type
cardiac	I-cell_type
cells	I-cell_type
is	O
expressed	O
in	O
three	O
prominent	O
isoforms	O
.	O

Activation	O
of	O
the	O
NF-kappaB	B-protein
pathway	O
by	O
inflammatory	O
stimuli	O
in	O
human	B-cell_type
neutrophils	I-cell_type
.	O

Mobility	O
shift	O
assays	O
showed	O
that	O
addition	O
of	O
anti-AIM	B-protein
mAb	I-protein
to	O
PMA-treated	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
markedly	O
enhanced	O
the	O
binding	O
activity	O
of	O
AP-1	B-protein
to	O
its	O
cognate	O
sequence	O
,	O
the	O
phorbol	B-DNA
ester	I-DNA
response	I-DNA
element	I-DNA
.	O

Whereas	O
GRalpha	B-protein
is	O
a	O
hormone-activated	O
transcription	B-protein
factor	I-protein
,	O
GRbeta	B-protein
does	O
not	O
bind	O
glucocorticoids	O
(	O
GCs	O
)	O
,	O
is	O
transcriptionally	O
inactive	O
,	O
and	O
is	O
a	O
potential	O
inhibitor	O
of	O
activated	O
GRalpha	B-protein
.	O

Furthermore	O
,	O
activation-dependent	O
tyrosine	O
phosphorylation	O
of	O
HS1	B-protein
was	O
not	O
required	O
for	O
NFAT	B-protein
transcriptional	O
activation	O
.	O

Multiple	O
TcR	B-protein
delta	I-protein
transcripts	I-protein
deriving	O
from	O
an	O
unrearranged	O
TcR	B-DNA
delta	I-DNA
gene	I-DNA
were	O
detected	O
in	O
both	O
polyclonal	B-cell_line
and	I-cell_line
clonal	I-cell_line
CD3-CD16+	I-cell_line
natural	I-cell_line
killer	I-cell_line
(	I-cell_line
NK	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Finally	O
,	O
potential	O
targets	O
of	O
regulation	O
by	O
the	O
zinc-finger	B-protein
transcription	I-protein
factor	I-protein
encoded	O
by	O
egr-1	B-DNA
include	O
the	O
interleukin-2	B-DNA
,	I-DNA
CD44	I-DNA
,	I-DNA
ICAM-1	I-DNA
,	I-DNA
and	I-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
genes	I-DNA
.	O

Rather	O
,	O
the	O
data	O
indicate	O
that	O
mitogen	O
increases	O
the	O
levels	O
of	O
a	O
nuclear	O
factor	O
(	O
s	O
)	O
that	O
dimerizes	O
with	O
CREB	B-protein
.	O

Interleukin-5	B-protein
(	O
IL-5	B-protein
)	O
,	O
which	O
is	O
produced	O
by	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
helper	I-cell_type
2	I-cell_type
(	I-cell_type
Th2	I-cell_type
)	I-cell_type
cells	I-cell_type
,	O
but	O
not	O
by	O
Th1	B-cell_type
cells	I-cell_type
,	O
plays	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
eosinophilia	O
in	O
asthma	O
.	O

Oct-2	B-RNA
mRNA	I-RNA
levels	O
and	O
both	O
Oct-2	B-protein
and	O
NF-kappa	B-protein
B	I-protein
proteins	I-protein
in	O
nuclear	O
extracts	O
were	O
not	O
altered	O
by	O
treatment	O
with	O
TGF-beta	B-protein
.	O

Members	O
of	O
this	O
family	O
have	O
been	O
isolated	O
from	O
invertebrates	O
as	O
well	O
as	O
vertebrates	O
.	O

At	O
the	O
same	O
time	O
there	O
was	O
no	O
change	O
in	O
the	O
level	O
of	O
expression	O
of	O
the	O
cell	B-protein
surface	I-protein
antigenes	I-protein
CD33	B-protein
,	O
CD34	B-protein
,	O
CD45	B-protein
,	O
CD71	B-protein
and	O
glycophorin	B-protein
A	I-protein
.	O

In	O
this	O
work	O
,	O
we	O
report	O
that	O
these	O
anergic	B-cell_line
T	I-cell_line
cells	I-cell_line
are	O
defective	O
in	O
their	O
ability	O
to	O
up-regulate	O
protein	O
binding	O
and	O
transactivation	O
at	O
two	O
critical	O
IL-2	B-DNA
DNA	I-DNA
enhancer	I-DNA
elements	I-DNA
:	O
NF-AT	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
;	O
a	O
sequence	O
that	O
binds	O
a	O
heterotrimeric	B-protein
NFATp	I-protein
,	I-protein
Fos	I-protein
,	I-protein
and	I-protein
Jun	I-protein
protein	I-protein
complex	I-protein
)	O
and	O
Activator	B-protein
Protein-1	I-protein
(	O
AP-1	B-protein
)	O
(	O
that	O
binds	O
Fos	B-protein
and	I-protein
Jun	I-protein
heterodimers	I-protein
)	O
.	O

Neutrophil	B-protein
elastase	I-protein
(	O
NE	B-protein
)	O
and	O
cathepsin	B-protein
G	I-protein
are	O
two	O
serine	B-protein
proteinases	I-protein
released	O
concomitantly	O
by	O
stimulated	O
polymorphonuclear	B-cell_type
neutrophils	I-cell_type
.	O

Eosinophils	B-cell_type
and	O
neutrophils	B-cell_type
are	O
closely	O
related	O
,	O
terminally	B-cell_type
differentiated	I-cell_type
cells	I-cell_type
that	O
in	O
vitro	O
undergo	O
constitutive	O
cell	O
death	O
by	O
apoptosis	O
.	O

We	O
show	O
that	O
induction	O
of	O
a	O
trimer	O
of	O
the	O
NFAT	B-DNA
and	I-DNA
Oct	I-DNA
sites	I-DNA
is	O
not	O
sensitive	O
to	O
phorbol	O
ester	O
treatment	O
,	O
and	O
that	O
mutations	O
in	O
the	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
have	O
no	O
effect	O
on	O
inducibility	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

The	O
implantation	O
of	O
trophoblast	B-cell_type
cells	I-cell_type
at	O
extrauterine	O
sites	O
still	O
results	O
in	O
decidualization	O
.	O

Substitution	O
mutations	O
,	O
which	O
abolished	O
binding	O
of	O
these	O
proteins	O
to	O
the	O
BR3	B-DNA
sequence	I-DNA
,	O
significantly	O
increased	O
hIL-5	B-DNA
promoter	I-DNA
activity	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Cortisol	O
resistance	O
in	O
acquired	O
immunodeficiency	O
syndrome	O
.	O

No	O
other	O
DNA	O
element	O
within	O
the	O
13-kb	B-DNA
human	I-DNA
c-fes	I-DNA
locus	I-DNA
contained	O
positive	B-DNA
cis-acting	I-DNA
elements	I-DNA
,	O
with	O
the	O
exception	O
of	O
a	O
weakly	O
active	O
region	O
within	O
the	O
3'-flanking	B-DNA
sequences	I-DNA
.	O

Expression	O
of	O
the	O
Tat	B-protein
protein	I-protein
of	O
HIV1	O
in	O
human	B-cell_line
promonocytic	I-cell_line
U937	I-cell_line
cells	I-cell_line
.	O

Moreover	O
,	O
induction	O
of	O
tyrosine	O
phosphorylation	O
appears	O
sufficient	O
per	O
se	O
to	O
initiate	O
a	O
complete	O
activation	O
programme	O
.	O

In	O
FCS-	B-cell_line
liquid-suspension	I-cell_line
culture	I-cell_line
supplemented	O
with	O
saturating	O
Ep	B-protein
level	O
and	O
low-dose	B-protein
IL-3/GM-CSF	I-protein
,	O
adult	O
HPC	B-cell_type
undergo	O
unilineage	O
erythropoietic	O
differentiation	O
:	O
Here	O
again	O
,	O
treatment	O
with	O
high-dose	O
RA	O
induces	O
a	O
shift	O
from	O
the	O
erythroid	O
to	O
granulocytic	O
differentiation	O
pathway	O
.	O

Recent	O
studies	O
,	O
however	O
,	O
demonstrate	O
that	O
the	O
transcribed	O
5'-untranslated	B-DNA
leader	I-DNA
region	I-DNA
(	O
5'-UTR	B-DNA
)	O
also	O
contains	O
important	O
transcriptional	B-DNA
elements	I-DNA
.	O

Physical	O
interaction	O
of	O
AML1	B-protein
with	O
BSAP	B-protein
correlates	O
with	O
functional	O
cooperativity	O
in	O
transfection	O
studies	O
where	O
AML1	B-protein
and	O
BSAP	B-protein
synergistically	O
activate	O
blk	B-DNA
promoter	O
transcription	O
by	O
more	O
than	O
50-fold	O
.	O

A-myb	B-protein
is	O
expressed	O
in	O
a	O
subpopulation	O
of	O
normal	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
activated	O
in	O
vivo	O
and	O
localised	O
in	O
the	O
germinal	O
center	O
of	O
peripheral	O
lymphoid	O
organs	O
and	O
is	O
not	O
detected	O
at	O
significant	O
levels	O
in	O
all	O
other	O
mature	O
or	O
immature	B-cell_type
haematopoietic	I-cell_type
populations	I-cell_type
studied	O
,	O
including	O
bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
,	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
granulocytes	B-cell_type
,	O
monocytes	B-cell_type
,	O
either	O
at	O
rest	O
or	O
after	O
in	O
vitro	O
activation	O
.	O

Estrogen	B-protein
receptor	I-protein
concentration	O
and	O
social	O
factors	O
as	O
predictors	O
of	O
natural	O
killer	O
cell	O
activity	O
in	O
early-stage	O
breast	O
cancer	O
patients	O
.	O

Ectopic	O
expression	O
of	O
the	O
dominant	O
negative	O
C/EBP	B-protein
protein	I-protein
LIP	I-protein
inhibited	O
HIV-1	O
mRNA	O
and	O
virus	O
production	O
in	O
activated	B-cell_line
U1	I-cell_line
cells	I-cell_line
,	O
demonstrating	O
that	O
C/EBP	B-protein
proteins	I-protein
are	O
required	O
for	O
provirus	O
induction	O
.	O

We	O
have	O
previously	O
shown	O
that	O
IL-6	B-protein
induces	O
activation	O
of	O
JAK1	B-protein
and	O
JAK2	B-protein
in	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Stimulation	O
of	O
a	O
human	B-cell_line
T-cell	I-cell_line
clone	I-cell_line
with	O
anti-CD3	B-protein
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
induces	O
NF-kappa	B-protein
B	I-protein
translocation	O
but	O
not	O
human	O
immunodeficiency	O
virus	O
1	O
enhancer-dependent	O
transcription	O
.	O

NAC	O
inhibited	O
interleukin-1	B-protein
(	O
IL-1	B-protein
beta	I-protein
)	O
-induced	O
,	O
but	O
not	O
basal	O
,	O
adhesion	O
with	O
50	O
%	O
inhibition	O
at	O
approximately	O
20	O
mM	O
.	O

In	O
an	O
attempt	O
to	O
identify	O
changes	O
in	O
gene	O
expression	O
that	O
accompany	O
the	O
T-cell	O
stimulation	O
defects	O
associated	O
with	O
the	O
loss	O
of	O
Rel	B-protein
,	O
we	O
have	O
examined	O
the	O
expression	O
of	O
cell	B-protein
surface	I-protein
activation	I-protein
markers	I-protein
and	O
cytokine	O
production	O
in	O
mitogen-stimulated	O
Rel-/-	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Cells	O
pretreated	O
with	O
dimaprit	O
showed	O
a	O
decrease	O
in	O
the	O
cAMP	O
response	O
to	O
subsequent	O
addition	O
of	O
H2	O
agonists	O
,	O
whereas	O
the	O
cAMP	O
response	O
to	O
prostaglandin	O
E2	O
remained	O
unaltered	O
.	O

Dexamethasone	O
,	O
up	O
to	O
a	O
concentration	O
of	O
1	O
mumol/L	O
,	O
neither	O
affected	O
significantly	O
the	O
release	O
of	O
granule	B-protein
enzymes	I-protein
nor	O
interfered	O
with	O
PAF	B-protein
binding	O
to	O
its	O
membrane	B-protein
receptors	I-protein
.	O

The	O
lymphotoxin	B-DNA
promoter	I-DNA
is	O
stimulated	O
by	O
HTLV-I	B-protein
tax	I-protein
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
human	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O

Interferon	B-protein
gamma	I-protein
induces	O
class	O
II	O
expression	O
in	O
this	O
glioblastoma	B-cell_line
cell	I-cell_line
line	I-cell_line
and	O
,	O
in	O
parallel	O
,	O
up-regulates	O
X1	O
and	O
X2	O
box	O
protein-DNA	O
interactions	O
,	O
while	O
all	O
other	O
interactions	O
remain	O
unchanged	O
.	O

Consistent	O
with	O
post-translational	O
regulation	O
,	O
no	O
change	O
in	O
total	O
level	O
of	O
CREB	B-protein
protein	O
was	O
observed	O
.	O

Suppression	O
of	O
human	O
anti-porcine	O
T-cell	O
immune	O
responses	O
by	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
II	I-DNA
transactivator	I-DNA
constructs	I-DNA
lacking	O
the	O
amino	O
terminal	O
domain	O
.	O

This	O
study	O
shows	O
that	O
expression	O
of	O
LMP1	B-protein
activates	O
transcription	O
from	O
p50/p65-	B-DNA
and	I-DNA
c-Rel-	I-DNA
responsive	I-DNA
promoters	I-DNA
,	O
and	O
that	O
this	O
activity	O
can	O
be	O
completely	O
inhibited	O
by	O
expression	O
of	O
a	O
dominant	O
inhibitory	B-protein
IkappaB	I-protein
mutant	I-protein
.	O

We	O
have	O
analysed	O
the	O
effect	O
of	O
mitogenic	O
lectins	O
on	O
c-Fos	B-protein
and	O
c-Jun	B-protein
protein	O
levels	O
as	O
well	O
as	O
on	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
binding	O
and	O
enhancer	O
activity	O
in	O
Jurkat	O
T-cells	O
.	O

These	O
findings	O
suggest	O
that	O
BCL-6	B-protein
may	O
play	O
a	O
role	O
in	O
regulating	O
differentiation	O
of	O
normal	O
germinal	B-cell_type
center	I-cell_type
B	I-cell_type
cells	I-cell_type
and	O
that	O
its	O
deregulated	O
expression	O
caused	O
by	O
rearrangements	O
may	O
contribute	O
to	O
lymphomagenesis	O
.	O

Resting	B-cell_type
monocytes	I-cell_type
contained	O
nuclear	B-protein
factors	I-protein
binding	O
to	O
the	O
AP-1	B-DNA
element	I-DNA
,	O
but	O
stimulation	O
of	O
monocytes	B-cell_type
with	O
LTB4	O
induced	O
greater	O
AP-1	B-protein
-binding	O
activity	O
of	O
nuclear	B-protein
proteins	I-protein
.	O

These	O
properties	O
suggest	O
that	O
TAFII105	B-protein
is	O
a	O
cell	O
type-specific	O
subunit	O
of	O
TFIID	B-protein
that	O
may	O
be	O
responsible	O
for	O
mediating	O
transcription	O
by	O
a	O
subset	O
of	O
activators	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Two	O
distinct	O
transcription	B-protein
factors	I-protein
that	O
bind	O
the	O
immunoglobulin	B-DNA
enhancer	I-DNA
microE5/kappa	B-DNA
2	I-DNA
motif	I-DNA
.	O

These	O
in	O
vitro	O
results	O
provide	O
a	O
preclinical	O
rationale	O
for	O
in	O
vivo	O
testing	O
of	O
TAM	O
,	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
,	O
and	O
breast	O
cancer	O
reactive	O
antibody-dependent	O
cellular	O
cytotoxicity	O
facilitating	O
antibody	O
in	O
patients	O
with	O
refractory	O
or	O
high	O
risk	O
breast	O
cancer	O
.	O

Abnormality	O
of	O
Oct-1	B-protein
DNA	O
binding	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
Sjogren	O
's	O
syndrome	O
patients	O
.	O

Type	B-protein
II	I-protein
estrogen	I-protein
binding	I-protein
sites	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
:	O
variations	O
during	O
the	O
menstrual	O
cycle	O
.	O

These	O
quantitative	O
,	O
if	O
not	O
qualitative	O
,	O
differences	O
between	O
signaling	O
initiated	O
by	O
these	O
two	O
ligands	O
for	O
CD28	B-protein
may	O
contribute	O
to	O
functional	O
differences	O
(	O
e.g.	O
Th1	O
or	O
Th2	O
differentiation	O
)	O
in	O
T	O
cell	O
responses	O
.	O

Tax	B-protein
has	O
been	O
shown	O
to	O
transactivate	O
several	O
cellular	B-DNA
genes	I-DNA
.	O

We	O
conclude	O
that	O
As2O3	O
treatment	O
is	O
an	O
effective	O
and	O
relatively	O
safe	O
drug	O
in	O
APL	O
patients	O
refractory	O
to	O
ATRA	O
and	O
conventional	O
chemotherapy	O
.	O

Further	O
deletional	O
and	O
alanine	O
mutagenesis	O
analyses	O
and	O
comparison	O
with	O
TRAF	B-DNA
binding	I-DNA
sequences	I-DNA
in	O
CD40	O
,	O
in	O
CD30	O
,	O
and	O
in	O
the	O
LMP1	B-protein
of	O
other	O
lymphycryptoviruses	O
provide	O
the	O
first	O
evidence	O
that	O
PXQXT/S	B-DNA
is	O
a	O
core	O
TRAF	B-DNA
binding	I-DNA
motif	I-DNA
.	O

It	O
is	O
not	O
known	O
whether	O
and	O
how	O
glucocorticoids	O
affect	O
the	O
function	O
of	O
the	O
inflammatory	O
infiltrate	O
or	O
why	O
the	O
disease	O
persists	O
subclinically	O
despite	O
chronic	O
treatment	O
.	O

We	O
show	O
,	O
however	O
,	O
that	O
the	O
presence	O
of	O
CIITA	B-protein
does	O
not	O
affect	O
the	O
stability	O
of	O
the	O
higher-order	O
protein	O
complex	O
formed	O
on	O
DNA	O
by	O
RFX	B-protein
,	O
X2BP	B-protein
and	O
NF-Y	B-protein
.	O

Involvement	O
of	O
Stat3	B-protein
in	O
interleukin-6	B-protein
-induced	O
IgM	B-protein
production	O
in	O
a	O
human	B-cell_line
B-cell	I-cell_line
line	I-cell_line
.	O

An	O
age-related	O
decrease	O
in	O
the	O
number	O
of	O
GR	B-protein
was	O
suggested	O
between	O
subjects	O
younger	O
than	O
20	O
years	O
and	O
elderly	O
subjects	O
;	O
there	O
was	O
no	O
apparent	O
seasonal	O
variation	O
in	O
GR	B-protein
.	O

We	O
report	O
a	O
65-year-old	O
woman	O
with	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
NHL	O
)	O
carrying	O
a	O
t	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
q27	I-DNA
;	I-DNA
q11	I-DNA
)	I-DNA
and	O
BCL6	B-DNA
rearrangement	O
in	O
the	O
affected	B-cell_type
cells	I-cell_type
.	O

We	O
previously	O
have	O
demonstrated	O
a	O
requirement	O
for	O
oxidative	O
events	O
during	O
cell	O
cycle	O
entry	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
have	O
hypothesised	O
that	O
reactive	O
oxygen	O
species	O
may	O
act	O
as	O
intracellular	O
signalling	O
agents	O
during	O
lymphocyte	O
activation	O
.	O

When	O
unstimulated	B-cell_line
HeLa	I-cell_line
cells	I-cell_line
are	O
ruptured	O
in	O
hypotonic	O
buffer	O
without	O
salt	O
or	O
detergent	O
,	O
immunoadsorption	O
of	O
either	O
STAT1	B-protein
or	O
STAT2	B-protein
from	O
the	O
resulting	O
cytosol	O
yields	O
coimmunoadsorption	O
of	O
the	O
other	O
STAT	B-protein
protein	I-protein
.	O

Third	O
,	O
a	O
coimmunoprecipitation	O
assay	O
showed	O
that	O
in	O
HTLV-1-infected	B-cell_line
human	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
,	O
Tax	B-protein
and	O
TFIIA	B-protein
were	O
associated	O
.	O

Differentiation-associated	O
expression	O
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
BZLF1	I-protein
transactivator	I-protein
protein	I-protein
in	O
oral	O
hairy	O
leukoplakia	O
.	O

The	O
viral	B-protein
protein	I-protein
Tax	I-protein
was	O
likely	O
responsible	O
for	O
this	O
higher	O
level	O
of	O
class	B-DNA
II	I-DNA
gene	I-DNA
transcription	O
,	O
as	O
purified	B-protein
Tax	I-protein
was	O
found	O
to	O
stimulate	O
both	O
genes	O
when	O
added	O
to	O
the	O
uninfected	O
cell	O
extract	O
or	O
in	O
reconstituted	O
systems	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
EBF	B-protein
represents	O
a	O
novel	O
regulator	O
of	O
B	O
lymphocyte-specific	O
gene	O
expression	O
.	O

Glucocorticoid	B-protein
receptor	I-protein
binding	O
in	O
three	O
different	O
cell	O
types	O
in	O
major	O
depressive	O
disorder	O
:	O
lack	O
of	O
evidence	O
of	O
receptor	O
binding	O
defect	O
.	O

Inhibition	O
of	O
RANTES	B-protein
expression	O
did	O
not	O
appear	O
to	O
be	O
secondary	O
to	O
IL-2	B-protein
inhibition	O
and	O
required	O
binding	O
to	O
the	O
intracellular	O
glucocorticoid	B-protein
receptor	I-protein
.	O

It	O
is	O
directly	O
implicated	O
in	O
the	O
emergence	O
of	O
the	O
age-related	O
immune	O
deficiency	O
.	O

Furthermore	O
,	O
PD98059	O
completely	O
blocked	O
the	O
TPA-induced	O
differentiation	O
of	O
ML-1	B-cell_line
cells	I-cell_line
,	O
as	O
assessed	O
by	O
a	O
number	O
of	O
features	O
associated	O
with	O
mononuclear	O
differentiation	O
including	O
changes	O
in	O
morphology	O
,	O
nonspecific	O
esterase	B-protein
activity	O
,	O
phagocytic	O
ability	O
,	O
NADPH	B-protein
oxidase	I-protein
activity	O
,	O
mitochondrial	O
respiration	O
,	O
and	O
c-jun	B-RNA
mRNA	I-RNA
inducibility	O
.	O

The	O
emergence	O
of	O
nuclear	B-protein
binding	I-protein
proteins	I-protein
was	O
investigated	O
using	O
interleukin-2	B-DNA
sequence	I-DNA
specific	I-DNA
oligonucleotide	I-DNA
probes	I-DNA
in	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

We	O
have	O
shown	O
that	O
the	O
c-Maf	B-protein
and	O
c-Myb	B-protein
transcription	I-protein
factors	I-protein
physically	O
interact	O
in	O
myeloid	O
cells	O
to	O
form	O
inhibitory	O
complexes	O
that	O
hinder	O
transactivation	O
of	O
c-Myb	B-DNA
target	I-DNA
genes	I-DNA
through	O
direct	O
binding	O
to	O
Myb	B-DNA
consensus	I-DNA
sites	I-DNA
.	O

GP	B-DNA
Ib	I-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
was	O
evaluated	O
by	O
transfection	O
of	O
human	B-cell_type
erythroleukemia	I-cell_type
cells	I-cell_type
with	O
reporter	O
plasmids	O
coding	O
for	O
the	O
enzyme	B-protein
,	O
luciferase	B-protein
.	O

In	O
summary	O
,	O
these	O
studies	O
show	O
that	O
the	O
amount	O
of	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
expression	O
has	O
a	O
marked	O
impact	O
on	O
the	O
level	O
of	O
activity	O
of	O
the	O
AC	O
cascade	O
from	O
the	O
membrane	O
through	O
to	O
the	O
nucleus	O
.	O

Inasmuch	O
as	O
these	O
features	O
implicate	O
enhanced	O
calcitriol	O
action	O
in	O
gut	O
and	O
bone	O
,	O
we	O
analyzed	O
the	O
vitamin	B-DNA
D	I-DNA
receptor	I-DNA
(	I-DNA
VDR	I-DNA
)	I-DNA
gene	I-DNA
to	O
ascertain	O
whether	O
an	O
abnormality	O
of	O
this	O
gene	O
marks	O
patients	O
with	O
intestinal	O
hyperabsorption	O
of	O
calcium	O
.	O

In	O
addition	O
,	O
recombinant	O
IL-1beta	B-protein
was	O
able	O
to	O
replace	O
MCM	O
for	O
the	O
inhibition	O
of	O
proliferation	O
and	O
down-regulation	O
of	O
AR	B-protein
and	O
PSA	B-protein
proteins	O
.	O

One	O
hundred	O
six	O
primary	O
breast	O
cancer	O
samples	O
were	O
analysed	O
for	O
c-erbB2	O
,	O
int-2	O
,	O
and	O
c-myc	O
gene	O
amplification	O
.	O

The	O
functional	O
domains	O
of	O
HS-40	B-DNA
were	O
also	O
mapped	O
.	O

Moreover	O
,	O
NF-ATp	B-protein
-/-	O
mice	O
older	O
than	O
6	O
weeks	O
show	O
an	O
2-5	O
fold	O
increase	O
in	O
number	O
of	O
lymphocytes	B-cell_type
.	O

Acetylation	O
and	O
modulation	O
of	O
erythroid	B-protein
Kruppel-like	I-protein
factor	I-protein
(	O
EKLF	B-protein
)	O
activity	O
by	O
interaction	O
with	O
histone	B-protein
acetyltransferases	I-protein
.	O

The	O
nervous	B-protein
system-derived	I-protein
(	I-protein
N-Oct	I-protein
)	I-protein
proteins	I-protein
bound	O
to	O
the	O
octamer	B-DNA
DNA	I-DNA
sequence	I-DNA
in	O
a	O
manner	O
which	O
is	O
indistinguishable	O
from	O
the	O
Oct-1	B-protein
and	O
Oct-2A	B-protein
proteins	I-protein
.	O

hGR	B-protein
levels	O
were	O
determined	O
from	O
isolated	O
cytosol	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
or	O
mucosal	O
biopsies	O
using	O
a	O
radioassay	O
with	O
[	O
3H	O
]	O
-dexamethasone	O
.	O

Treatment	O
with	O
dexamethasone	O
or	O
the	O
antiglucocorticoid	O
RU486	O
had	O
no	O
additional	O
effect	O
on	O
the	O
DNA-binding	O
capacity	O
when	O
receptor	O
preparations	O
were	O
maintained	O
at	O
0	O
C	O
(	O
no	O
activation	O
)	O
.	O

Inhibition	O
of	O
cytokine	B-protein
production	O
by	O
PBMC	B-cell_type
was	O
observed	O
also	O
when	O
other	O
inducers	O
were	O
used	O
(	O
staphylococci	O
,	O
silica	O
,	O
zymosan	O
)	O
.	O

Two	O
other	O
members	O
of	O
the	O
family	O
have	O
been	O
cloned	O
more	O
recently	O
,	O
A-myb	B-protein
and	O
B-myb	B-protein
,	O
which	O
show	O
sequence	O
homology	O
with	O
c-myb	B-DNA
in	O
several	O
domains	O
,	O
of	O
which	O
the	O
DNA	B-protein
binding	I-protein
domain	I-protein
as	O
well	O
as	O
other	O
regulatory	B-protein
domains	I-protein
.	O

Those	O
results	O
indicate	O
that	O
,	O
in	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
PKC	B-protein
activation	O
has	O
only	O
a	O
triggering	O
role	O
,	O
whereas	O
the	O
endogenously	O
secreted	O
TNF	B-protein
alpha	I-protein
plays	O
an	O
essential	O
role	O
in	O
the	O
quantitative	O
control	O
of	O
the	O
expression	O
of	O
IL-2R	B-protein
alpha	I-protein
chain	O
or	O
NF.kappa	B-protein
B	I-protein
activation	O
.	O

TCC	B-protein
also	O
stimulate	O
a	O
variety	O
of	O
cellular	O
activities	O
,	O
which	O
include	O
cytokine	B-protein
synthesis	O
,	O
proto-oncogene	B-DNA
activation	O
,	O
and	O
mitotic	O
signaling	O
.	O

Our	O
data	O
support	O
the	O
view	O
that	O
steroid-mediated	O
cell	O
death	O
occurs	O
by	O
a	O
process	O
requiring	O
direct	O
interaction	O
of	O
steroid-receptor	B-protein
complexes	I-protein
with	O
the	O
genome	O
.	O

Transcription	B-protein
factor	I-protein
AP-2	I-protein
activates	O
gene	O
expression	O
of	O
HTLV-I	O
.	O

This	O
report	O
represents	O
the	O
first	O
demonstration	O
that	O
a	O
multimerized	O
short	O
binding	O
motif	O
can	O
function	O
appropriately	O
in	O
transgenic	O
mice	O
.	O

of	O
33	O
PBMC	B-cell_type
specimens	O
from	O
healthy	O
adults	O
and	O
only	O
one	O
of	O
40	O
pediatric	O
samples	O
was	O
positive	O
(	O
at	O
a	O
low	O
level	O
)	O
for	O
adenovirus	B-DNA
DNA	I-DNA
by	O
nested	O
PCR	O
assay	O
.	O

NF-kappa	B-protein
B	I-protein
is	O
critical	O
for	O
T	O
lymphocyte	O
function	O
and	O
is	O
a	O
strong	O
inducer	O
of	O
HIV-LTR	B-DNA
activation	O
.	O

No	O
evidence	O
for	O
the	O
expression	O
of	O
the	O
progesterone	B-protein
receptor	I-protein
on	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
during	O
pregnancy	O
[	O
see	O
comments	O
]	O

The	O
interleukin	B-DNA
2	I-DNA
receptor	I-DNA
alpha-chain	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
is	O
a	O
key	O
regulator	O
of	O
lymphocyte	O
proliferation	O
.	O

NF-kappa	B-protein
B	I-protein
binds	O
to	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
region	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
and	O
contributes	O
to	O
the	O
inducibility	O
of	O
HIV-1	O
gene	O
expression	O
in	O
response	O
to	O
multiple	O
activating	O
agents	O
.	O

Despite	O
this	O
effect	O
,	O
steady	O
state	O
levels	O
of	O
HLA-DRalpha	B-protein
,	O
HLA-DRbeta	B-protein
,	O
and	O
invariant	B-protein
(	I-protein
Ii	I-protein
)	I-protein
chains	I-protein
were	O
equivalent	O
in	O
control	B-cell_type
and	I-cell_type
infected	I-cell_type
cells	I-cell_type
.	O

In	O
conclusion	O
,	O
our	O
results	O
identify	O
JNK	B-protein
as	O
a	O
target	O
of	O
antioxidant	O
agents	O
which	O
can	O
be	O
regulated	O
differentially	O
under	O
oxidant	O
and	O
antioxidant	O
conditions	O
.	O

CD44	O
is	O
a	O
ubiquitous	O
molecule	O
also	O
known	O
as	O
hyaluronic	O
acid	O
or	O
homing	O
receptor	O
.	O

Levels	O
of	O
occupied	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
protein	I-protein
increased	O
in	O
these	O
HL-60	B-cell_line
cells	I-cell_line
;	O
but	O
the	O
total	O
number	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
decreased	O
about	O
50	O
%	O
at	O
24	O
hours	O
and	O
returned	O
toward	O
normal	O
at	O
72	O
hours	O
.	O

Finally	O
,	O
immunoblot	O
analysis	O
of	O
nuclear	O
extracts	O
showed	O
decreased	O
or	O
absent	O
p65	B-protein
protein	I-protein
levels	O
.	O

Deletion	O
mutation	O
analysis	O
of	O
the	O
HIV-2	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
suggests	O
that	O
the	O
element	O
that	O
responds	O
to	O
CMV	O
transactivation	O
in	O
human	B-cell_type
CD4+	I-cell_type
lymphocytes	I-cell_type
is	O
either	O
a	O
diffuse	O
one	O
or	O
located	O
downstream	O
of	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
element	I-DNA
.	O

Hela	O
nuclear	O
extracts	O
contained	O
a	O
specific	B-protein
nuclear	I-protein
factor	I-protein
(	I-protein
s	I-protein
)	I-protein
binding	O
to	O
15-LO	B-DNA
promoter	I-DNA
DNA	I-DNA
which	O
are	O
distinct	O
from	O
those	O
derived	O
from	O
IL-13-treated	B-cell_line
human	I-cell_line
peripheral	I-cell_line
monocyte	I-cell_line
nuclear	O
extracts	O
.	O

Mutual	O
regulation	O
of	O
the	O
transcriptional	B-protein
activator	I-protein
NF-kappa	B-protein
B	I-protein
and	O
its	O
inhibitor	O
,	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
.	O

Despite	O
minimal	O
discrepancies	O
in	O
the	O
coding	B-DNA
region	I-DNA
,	O
there	O
are	O
striking	O
tissue-	O
and	O
cell	O
type-specific	O
differences	O
in	O
isoform	O
expression	O
patterns	O
.	O

Egr-1	B-protein
antisense	O
oligomers	O
in	O
the	O
culture	O
media	O
blocked	O
macrophage	O
differentiation	O
in	O
both	O
myeloid	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
normal	O
myeloblasts	B-cell_type
.	O

Nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
contains	O
Fos	B-protein
and	O
Jun	B-protein
.	O

The	O
kinetics	O
of	O
this	O
translocation	O
were	O
delayed	O
in	O
IL-7-treated	B-cell_line
as	O
compared	O
to	O
IL-2-treated	B-cell_line
cells	I-cell_line
.	O

To	O
evaluate	O
the	O
physiologic	O
plausibility	O
of	O
these	O
claims	O
,	O
we	O
compared	O
the	O
abundance	O
of	O
the	O
VDR	B-RNA
mRNA	I-RNA
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
between	O
different	O
VDR	B-protein
genotypes	I-protein
using	O
a	O
quantitative	O
reverse	O
transcribed	O
polymerase	O
chain	O
reaction-based	O
method	O
.	O

These	O
results	O
link	O
regulatory	B-protein
factors	I-protein
critical	O
to	O
T	O
cell	O
commitment	O
directly	O
to	O
HIV-1	O
replication	O
.	O

Here	O
,	O
we	O
have	O
studied	O
IL-2	B-protein
and	O
IL-4	B-protein
signaling	O
in	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
lacking	O
JAK3	B-protein
.	O

Additionally	O
,	O
E2F-1	B-protein
caused	O
massive	O
megakaryocyte	B-cell_type
accumulation	O
in	O
both	O
normal	O
and	O
ectopic	O
sites	O
,	O
first	O
evident	O
in	O
E15	O
embryonic	O
liver	O
.	O

A	O
novel	O
form	O
of	O
the	O
myeloid-specific	B-protein
zinc	I-protein
finger	I-protein
protein	I-protein
(	O
MZF-2	B-protein
)	O
.	O

Subsequently	O
binding	O
sites	O
have	O
been	O
demonstrated	O
in	O
the	O
plasma	O
membrane	O
of	O
human	B-cell_type
lymphocytes	I-cell_type
which	O
show	O
pharmacological	O
(	O
aldosterone	O
specificity	O
)	O
and	O
kinetic	O
(	O
high	O
turnover	O
)	O
properties	O
identical	O
with	O
those	O
of	O
the	O
rapid	O
aldosterone	O
effects	O
in	O
the	O
same	O
cells	O
.	O

Consistent	O
with	O
reduced	O
levels	O
of	O
Oct-1	B-protein
DNA	O
binding	O
activity	O
in	O
the	O
Rb-transformed	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
interleukin	B-protein
8	I-protein
expression	O
is	O
higher	O
in	O
these	O
cell	O
lines	O
.	O

Furthermore	O
,	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
two	O
molecules	O
of	O
NFATp	B-protein
bind	O
to	O
the	O
TNF-alpha	B-DNA
promoter	I-DNA
element	I-DNA
kappa	I-DNA
3	I-DNA
in	O
association	O
with	O
ATF-2	B-protein
and	O
Jun	B-protein
proteins	I-protein
bound	O
to	O
an	O
immediately	O
adjacent	O
cyclic	B-DNA
AMP	I-DNA
response	I-DNA
element	I-DNA
(	I-DNA
CRE	I-DNA
)	I-DNA
site	I-DNA
.	O

BACKGROUND	O
:	O
Alveolar	B-cell_type
macrophages	I-cell_type
play	O
a	O
key	O
role	O
in	O
the	O
initiation	O
of	O
the	O
inflammatory	O
reaction	O
of	O
allergic	O
asthma	O
.	O

In	O
cotransfection	O
experiments	O
we	O
show	O
that	O
all	O
the	O
isoforms	B-protein
are	O
able	O
to	O
activate	O
an	O
octamer	B-DNA
containing	O
promoter	B-DNA
element	I-DNA
in	O
fibroblasts	O
revealing	O
an	O
unexpected	O
functional	O
redundancy	O
.	O

FKBP	B-protein
has	O
been	O
shown	O
to	O
catalyze	O
the	O
interconversion	O
of	O
the	O
cis-	O
and	O
trans-rotamers	O
of	O
the	O
peptidyl-prolyl	B-protein
amide	I-protein
bond	I-protein
of	O
peptide	O
substrates	O
;	O
here	O
we	O
show	O
that	O
rapamycin	O
,	O
like	O
FK506	O
,	O
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
rotamase	O
activity	O
of	O
FKBP	B-protein
(	O
Ki	O
=	O
0.2	O
nM	O
)	O
.	O

The	O
CL	O
responses	O
of	O
IFN-U937	B-cell_line
cells	I-cell_line
and	O
peripheral	B-cell_type
blood	I-cell_type
human	I-cell_type
monocytes	I-cell_type
to	O
sensitized	B-cell_type
red	I-cell_type
cells	I-cell_type
,	O
platelets	B-cell_type
or	O
granulocytes	B-cell_type
were	O
then	O
compared	O
.	O

The	O
activation	O
by	O
p59fyn	B-protein
plus	O
PMA	B-protein
was	O
blocked	O
by	O
EGTA	O
and	O
by	O
the	O
immunosuppressant	O
drug	O
cyclosporin	O
A	O
.	O

cAMP	O
inducibility	O
of	O
transcriptional	B-protein
repressor	I-protein
ICER	B-protein
in	O
developing	O
and	O
mature	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1996	O
Jul	O
23	O
;	O
93	O
(	O
15	O
)	O
:	O
8154	O
]	O

These	O
transcriptional	O
regulators	O
in	O
turn	O
trigger	O
a	O
cascade	O
of	O
genetic	O
changes	O
that	O
ultimately	O
determine	O
the	O
course	O
of	O
the	O
cells	O
during	O
differentiation	O
.	O

This	O
induction	O
of	O
CAT	B-protein
activity	O
was	O
sensitive	O
to	O
dexamethasone	O
.	O

We	O
have	O
now	O
raised	O
a	O
monoclonal	B-protein
antibody	I-protein
to	O
document	O
expression	O
and	O
biochemistry	O
of	O
the	O
human	B-protein
TCF-1	I-protein
protein	I-protein
.	O

Following	O
EBV	O
infection	O
,	O
Epstein-Barr	O
nuclear	O
antigen	O
(	O
EBNA	B-protein
)	O
expression	O
could	O
be	O
detected	O
in	O
T	B-cell_type
rosetting	I-cell_type
CD4+	I-cell_type
and	I-cell_type
CD8+	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

In	O
addition	O
to	O
TNF	B-protein
,	O
LPS-induced	O
IL-6	O
and	O
spontaneous	O
IL-1ra	O
production	O
were	O
also	O
enhanced	O
.	O

Two	O
nuclear	B-protein
factor	I-protein
NF-IL6	I-protein
(	O
positions	O
-153	B-DNA
to	I-DNA
-145	I-DNA
and	O
-83	O
to	O
-75	O
)	O
and	O
one	O
nuclear	B-DNA
factor	I-DNA
NF-kappa	I-DNA
B	I-DNA
(	I-DNA
positions	I-DNA
-72	I-DNA
to	I-DNA
-63	I-DNA
)	I-DNA
motifs	I-DNA
are	O
present	O
within	O
this	O
fragment	O
.	O

We	O
conclude	O
that	O
cord	O
lymphocyte	O
activation	O
exhibits	O
an	O
adult-type	O
profile	O
.	O

Thrombin	B-protein
and	O
TRP	O
also	O
caused	O
translocation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
from	O
the	O
cytosol	O
to	O
the	O
plasma	O
membrane	O
.	O

p130	B-protein
,	O
predominantly	O
in	O
Form	O
1	O
,	O
and	O
hypophosphorylated	B-protein
pRb	I-protein
bind	O
an	O
E2F	B-DNA
DNA	I-DNA
binding	I-DNA
site	I-DNA
;	O
p130	B-protein
complexes	O
E2F-4	B-protein
,	O
whereas	O
pRb	B-protein
binds	O
both	O
E2F-4	O
and	O
E2F-1	B-protein
.	O

CCAAT/enhancer	B-protein
binding	I-protein
protein	I-protein
epsilon	I-protein
is	O
preferentially	O
up-regulated	O
during	O
granulocytic	O
differentiation	O
and	O
its	O
functional	O
versatility	O
is	O
determined	O
by	O
alternative	O
use	O
of	O
promoters	B-DNA
and	O
differential	O
splicing	O
.	O

Although	O
all	O
animals	O
20	O
and	O
47	O
days	O
after	O
infection	O
had	O
seroconverted	O
to	O
Ad5	O
,	O
virus	O
was	O
not	O
detected	O
in	O
these	O
groups	O
either	O
by	O
viral	O
plaque	O
assay	O
or	O
in	O
situ	O
hybridization	O
.	O

Additionally	O
,	O
IL-13	B-protein
suppresses	O
IL-2-induced	O
NK	O
cytolytic	O
and	O
proliferative	O
activities	O
although	O
less	O
efficiently	O
than	O
IL-4	B-protein
.	O

Recent	O
reports	O
have	O
characterized	O
these	O
cells	O
expressing	O
high	O
v-abl	B-DNA
kinase	O
activity	O
as	O
deficient	O
in	O
detectable	O
NF-kappaB	B-protein
DNA	O
binding	O
activity	O
and	O
low	O
level	O
RAG	B-DNA
gene	I-DNA
expression	O
.	O

Although	O
ICAM-1	B-protein
induction	O
was	O
unaffected	O
,	O
inhibitors	O
of	O
NADPH	B-protein
oxidase	I-protein
(	O
apocynin	O
)	O
or	O
cytochrome	B-protein
P-450	I-protein
(	O
SKF525a	O
)	O
suppressed	O
VCAM-1	B-protein
induction	O
by	O
TNF	O
,	O
revealing	O
that	O
several	O
radical-generating	O
systems	O
are	O
involved	O
in	O
its	O
regulation	O
.	O

Neither	O
FMLP	B-protein
nor	O
PAF	B-protein
activated	O
c-jun	B-protein
NH2-terminal	I-protein
MAPk	I-protein
(	O
JNKs	B-protein
)	O
.	O

We	O
propose	O
that	O
the	O
hydrophobic	B-protein
C-terminal	I-protein
tail	I-protein
of	O
CAML	B-protein
forms	O
its	O
effector	O
domain	O
,	O
thus	O
implicating	O
the	O
N-terminal	B-protein
hydrophilic	I-protein
domain	I-protein
in	O
a	O
regulatory	O
role	O
.	O

In	O
summary	O
,	O
we	O
developed	O
an	O
assay	O
for	O
the	O
quantitative	O
determination	O
of	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
in	O
small	O
human	O
tissue	O
samples	O
,	O
containing	O
as	O
little	O
as	O
50	O
ng	O
of	O
total	O
RNA	O
.	O

Anti-rheumatic	O
compound	O
aurothioglucose	O
inhibits	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
-induced	O
HIV-1	O
replication	O
in	O
latently	O
infected	O
OM10.1	B-cell_line
and	I-cell_line
Ach2	I-cell_line
cells	I-cell_line
.	O

We	O
have	O
previously	O
reported	O
that	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
contain	O
type	O
II	B-protein
estrogen	I-protein
binding	I-protein
sites	I-protein
(	O
type	B-protein
II	I-protein
EBS	I-protein
)	O
.	O

Interleukin	B-protein
1beta	I-protein
mediates	O
the	O
modulatory	O
effects	O
of	O
monocytes	B-cell_type
on	O
LNCaP	B-cell_type
human	I-cell_type
prostate	I-cell_type
cancer	I-cell_type
cells	I-cell_type
.	O

Overall	O
,	O
these	O
results	O
indicate	O
that	O
the	O
integrity	O
of	O
domain	B-protein
E	I-protein
is	O
necessary	O
and	O
sufficient	O
to	O
bind	O
steroid	O
ligands	O
,	O
agonists	O
or	O
antagonists	O
,	O
with	O
characteristics	O
similar	O
to	O
the	O
entire	O
native	O
MR	B-protein
.	O

We	O
show	O
that	O
repression	O
is	O
strongly	O
dependent	O
on	O
the	O
type	O
of	O
enhancer	B-DNA
present	O
in	O
the	O
reporter	B-DNA
plasmid	I-DNA
as	O
well	O
as	O
on	O
the	O
cell	B-cell_line
line	I-cell_line
tested	O
.	O

Elevated	O
numbers	O
of	O
circulating	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
CD3	B-protein
-directed	O
cytolysis	O
correlated	O
with	O
the	O
expression	O
of	O
oestrogen	B-protein
receptors	I-protein
independently	O
of	O
the	O
clinical/histological	O
parameters	O
.	O

Inefficient	O
DNA	O
replication	O
is	O
also	O
found	O
in	O
another	O
monocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
THP-1	B-cell_line

The	O
activation	O
of	O
NFAT	B-protein
was	O
also	O
impaired	O
by	O
expression	O
of	O
the	O
Itk	B-protein
mutant	I-protein
.	O

It	O
is	O
interesting	O
that	O
in	O
humans	O
and	O
rats	O
,	O
cortical	B-cell_type
thymocytes	I-cell_type
undergoing	O
negative	O
selection	O
can	O
still	O
induce	O
IL-2R	B-protein
alpha	I-protein
expression	O
and	O
even	O
be	O
rescued	O
in	O
vitro	O
,	O
if	O
exogenous	B-protein
IL-2	I-protein
is	O
provided	O
.	O

Transfection	O
of	O
an	O
AP-2	B-DNA
expression	I-DNA
construct	I-DNA
into	O
T-lymphocytes	B-cell_type
activated	O
gene	O
expression	O
from	O
the	O
HTLV-I	B-DNA
LTR	I-DNA
.	O

Exogenously	O
administered	O
IL-11	B-protein
substantially	O
reduced	O
,	O
in	O
a	O
dose-dependent	O
manner	O
,	O
the	O
intrapulmonary	O
accumulation	O
of	O
neutrophils	B-cell_type
and	O
the	O
lung	O
vascular	O
leak	O
of	O
albumin	B-protein
.	O

One	O
of	O
the	O
major	O
objectives	O
in	O
the	O
study	O
of	O
thrombogenesis	O
is	O
to	O
determine	O
the	O
mechanisms	O
by	O
which	O
a	O
hematopoietic	B-cell_type
progenitor	I-cell_type
is	O
activated	O
and	O
committed	O
to	O
the	O
megakaryocytic	B-cell_type
lineage	I-cell_type
.	O

In	O
these	O
cases	O
,	O
at	O
least	O
,	O
the	O
AML1	B-protein
expression	O
level	O
is	O
a	O
potential	O
regulator	O
for	O
myeloid	O
cell	O
differentiation	O
.	O

Activation	O
of	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
by	O
Treponema	B-protein
pallidum	I-protein
and	I-protein
Borrelia	I-protein
burgdorferi	I-protein
lipoproteins	I-protein
and	O
synthetic	O
lipopeptides	O
proceeds	O
via	O
a	O
pathway	O
distinct	O
from	O
that	O
of	O
lipopolysaccharide	O
but	O
involves	O
the	O
transcriptional	O
activator	O
NF-kappa	B-protein
B	I-protein
.	O

Viral	O
DNA	O
synthesis	O
and	O
late	O
gene	O
expression	O
were	O
found	O
to	O
be	O
defective	O
in	O
U937	B-cell_line
cells	I-cell_line
infected	O
with	O
E1B	B-protein
19K	I-protein
mutants	O
compared	O
with	O
wild-type	O
virus	O
.	O

These	O
results	O
can	O
not	O
be	O
explained	O
by	O
receptor	O
down-regulation	O
due	O
to	O
higher	O
levels	O
of	O
mineralocorticoids	O
in	O
PIH	O
;	O
a	O
hitherto	O
unknown	O
mineralocorticoid	O
may	O
,	O
thus	O
,	O
be	O
responsible	O
for	O
the	O
hypertension	O
and	O
altered	O
MR	B-protein
status	O
.	O

NK	B-cell_type
cells	I-cell_type
do	O
not	O
express	O
NFATc	B-protein
constitutively	O
,	O
but	O
NFATc	B-RNA
mRNA	I-RNA
accumulation	O
is	O
induced	O
in	O
these	O
cells	O
within	O
2	O
h	O
of	O
stimulation	O
with	O
CD16	O
ligands	O
.	O

However	O
,	O
NF-YB	B-protein
did	O
interact	O
with	O
the	O
C-terminal	B-protein
Tax1	I-protein
mutants	I-protein
M22	B-protein
(	O
130TL-AS	B-protein
)	O
and	O
M47	B-protein
(	O
319LL-RS	B-protein
)	O
.	O

Loss	O
of	O
both	O
cytolytic	O
susceptibility	O
and	O
sensitization	O
to	O
chemically	O
induced	O
apoptosis	O
was	O
coselected	O
during	O
in	O
vivo	O
selection	O
of	O
E1A-positive	B-cell_type
sarcoma	I-cell_type
cells	I-cell_type
for	O
increased	O
tumorigenicity	O
.	O

NF-kB	B-protein
levels	O
were	O
higher	O
in	O
unstimulated	B-cell_line
U1	I-cell_line
cells	I-cell_line
as	O
compared	O
to	O
the	O
parent	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	B-cell_line
.	O

It	O
also	O
appears	O
that	O
NF-kappaB	B-protein
suppression	O
by	O
RCC-S	O
may	O
contribute	O
to	O
the	O
immunosuppression	O
of	O
host	O
immunity	O
.	O

While	O
partial	O
variable	O
monosomy	O
of	O
loci	O
on	O
chromosome	B-DNA
17p	I-DNA
can	O
not	O
be	O
excluded	O
as	O
contributing	O
to	O
the	O
phenotype	O
in	O
this	O
patient	O
,	O
it	O
is	O
argued	O
that	O
the	O
major	O
likely	O
factor	O
is	O
partial	O
functional	O
disomy	O
of	O
sequences	O
on	O
Xp	B-DNA
in	O
cell	O
lineages	O
that	O
have	O
failed	O
to	O
inactivate	O
the	O
intact	O
X	B-DNA
chromosome	I-DNA
.	O

BASH	B-protein
becomes	O
tyrosine-phosphorylated	O
with	O
the	O
B	B-protein
cell	I-protein
Ag	I-protein
receptor	I-protein
(	O
BCR	B-protein
)	O
cross-link	O
or	O
by	O
coexpression	O
with	O
Syk	B-protein
and	O
Lyn	B-protein
and	O
associates	O
with	O
signaling	B-protein
molecules	I-protein
including	O
Syk	B-protein
and	O
a	O
putative	B-protein
chicken	I-protein
Shc	I-protein
homologue	I-protein
.	O

This	O
cDNA	B-DNA
clone	I-DNA
was	O
isolated	O
by	O
expression	O
cDNA	B-DNA
cloning	O
,	O
and	O
encodes	O
the	O
human	B-protein
c-Jun	I-protein
protein	I-protein
,	O
which	O
together	O
with	O
c-Fos	B-protein
forms	O
the	O
heterodimeric	B-protein
activator	I-protein
protein-1	I-protein
transcription	I-protein
complex	I-protein
.	O

GM-CSF	B-DNA
gene	I-DNA
activation	O
in	O
T	B-cell_type
cells	I-cell_type
is	O
known	O
to	O
involve	O
the	O
transcription	B-protein
factors	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
,	O
AP-1	B-protein
,	O
NFAT	B-protein
,	O
and	O
Sp1	O
.	O

Spi-B	B-protein
is	O
an	O
Ets	B-protein
transcription	I-protein
factor	I-protein
related	O
to	O
the	O
oncoprotein	B-protein
Spi-1/PU.1	B-protein
and	O
highly	O
expressed	O
in	O
B	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

Necrosis	O
was	O
excluded	O
by	O
propidium	O
iodide	O
staining	O
.	O

Moreover	O
,	O
supernatants	O
from	O
DEP-PAH-activated	B-cell_type
cells	I-cell_type
,	O
compared	O
with	O
those	O
of	O
controls	O
,	O
exhibited	O
a	O
significantly	O
enhanced	O
chemotactic	O
activity	O
for	O
neutrophils	B-cell_type
and	O
eosinophils	B-cell_type
,	O
which	O
was	O
significantly	O
inhibited	O
by	O
pretreatment	O
with	O
anti-IL-8	B-protein
and	O
anti-RANTES	B-protein
neutralizing	O
antibodies	O
,	O
respectively	O
.	O

However	O
,	O
compared	O
to	O
VD	O
,	O
their	O
antiproliferative	O
effect	O
is	O
up	O
to	O
30-fold	O
higher	O
on	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
even	O
up	O
to	O
300-fold	O
higher	O
on	O
human	B-cell_line
breast	I-cell_line
cancer	I-cell_line
MCF-7	I-cell_line
cells	I-cell_line
.	O

PU.1	B-protein
(	O
Spi-1	B-protein
)	O
and	O
C/EBP	B-protein
alpha	I-protein
regulate	O
expression	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
.	O

This	O
method	O
could	O
be	O
quite	O
useful	O
to	O
detect	O
not	O
only	O
CAG	B-DNA
repeats	I-DNA
in	O
SBMA	O
but	O
also	O
other	O
polymorphic	B-DNA
dinucleotide	I-DNA
and	O
trinucleotide	B-DNA
repeats	I-DNA
.	O

Because	O
HIV-1	O
requires	O
active	O
NF-kappa	B-protein
B	I-protein
for	O
efficient	O
transcription	O
,	O
we	O
tested	O
the	O
effect	O
of	O
HIV-1	O
infection	O
on	O
the	O
processing	O
of	O
the	O
human	B-protein
105K	I-protein
precursor	I-protein
.	O

DNA	O
mobility	O
shift	O
assay	O
revealed	O
specific	O
binding	O
of	O
nuclear	B-protein
protein	I-protein
(	O
s	O
)	O
from	O
LAM-	B-cell_line
,	I-cell_line
LPS-	I-cell_line
,	I-cell_line
or	I-cell_line
TNF-alpha-	I-cell_line
stimulated	I-cell_line
THP-1	I-cell_line
cells	I-cell_line
to	O
the	O
NF-IL6	O
motifs	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
phosphorylation	O
on	O
Rex	B-protein
function	O
by	O
using	O
a	O
protein	O
kinase	O
inhibitor	O
,	O
H-7	O
[	O
1-	O
(	O
5-isoquinolinyl-sulfonyl	O
)	O
-2-methylpiperazine	O
]	O
.	O

Deletion	O
of	O
this	O
region	O
or	O
internal	O
deletion	O
of	O
the	O
BOX1	B-protein
motif	I-protein
abrogated	O
IL-9	B-protein
-induced	O
cell	O
proliferation	O
and	O
signal	O
transduction	O
.	O

Estrogens	O
also	O
influence	O
production	O
of	O
mitogens	O
which	O
,	O
when	O
released	O
at	O
sites	O
of	O
vascular	O
injury	O
,	O
affect	O
vascular	O
remodeling	O
.	O

Infection	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
with	O
HIV-1	O
in	O
vitro	O
resulted	O
in	O
increased	O
interleukin-2	O
(	O
IL-2	O
)	O
secretion	O
in	O
response	O
to	O
T	O
cell	O
activation	O
via	O
the	O
CD3	B-protein
and	I-protein
CD28	I-protein
receptors	I-protein
.	O

Binding	O
of	O
superantigens	O
to	O
MHC	B-protein
class	I-protein
II	I-protein
molecules	I-protein
results	O
in	O
transduction	O
of	O
biochemical	O
signals	O
leading	O
to	O
cellular	O
activation	O
and	O
gene	O
expression	O
.	O

In	O
mammalian	O
cells	O
the	O
MAPK	B-protein
p38	I-protein
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cellular	O
responses	O
during	O
infection	O
through	O
its	O
effects	O
on	O
the	O
expression	O
of	O
proinflammatory	B-protein
molecules	I-protein
.	O

Epstein-Barr	O
virus	O
,	O
a	O
human	O
gammaherpesvirus	O
,	O
possesses	O
a	O
unique	O
set	O
of	O
latent	B-DNA
genes	I-DNA
whose	O
constitutive	O
expression	O
in	O
B	B-cell_type
cells	I-cell_type
leads	O
to	O
cell	O
growth	O
transformation	O
.	O

The	O
products	O
of	O
the	O
tumor	B-DNA
suppressor	I-DNA
genes	I-DNA
are	O
considered	O
to	O
function	O
as	O
specific	O
inhibitors	O
of	O
tumor	O
cell	O
growth	O
.	O

The	O
magnitude	O
and	O
kinetics	O
of	O
intracellular	O
ROI	O
were	O
similar	O
,	O
suggesting	O
that	O
there	O
were	O
no	O
differences	O
in	O
ROI-forming	O
mechanisms	O
or	O
antioxidative	O
capacities	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
deletion	O
in	O
NFATx1	B-protein
of	O
the	O
mapped	O
60	B-protein
residues	I-protein
leads	O
to	O
its	O
nuclear	O
translocation	O
independent	O
of	O
calcium	O
signaling	O
.	O

Here	O
we	O
show	O
that	O
in	O
a	O
MPC11	B-cell_line
plasmacytoma	I-cell_line
x	I-cell_line
fibroblast	I-cell_line
environment	I-cell_line
,	O
the	O
IgH	B-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
is	O
transcriptionally	O
inactive	O
.	O

Chicken	O
IL2	B-protein
contains	O
five	O
repeats	O
of	O
the	O
``	O
instability	O
''	O
motif	O
ATTTA	O
in	O
the	O
3'untranslated	B-DNA
region	I-DNA
in	O
exon	B-DNA
4	I-DNA
.	O

Upon	O
HBsAg	B-protein
stimulation	O
,	O
expression	O
of	O
IFN-gamma	B-protein
,	O
IL-2	B-protein
,	O
IL-4	B-protein
,	O
and	O
IL-10	B-protein
was	O
detected	O
in	O
41	O
%	O
,	O
8	O
%	O
,	O
41	O
%	O
,	O
and	O
50	O
%	O
of	O
the	O
patients	O
,	O
respectively	O
.	O

All	O
baseline	O
interview	O
and	O
testing	O
data	O
were	O
obtained	O
either	O
just	O
before	O
patients	O
were	O
discharged	O
from	O
the	O
hospital	O
,	O
or	O
at	O
their	O
first	O
outpatient	O
visit	O
,	O
within	O
two	O
weeks	O
of	O
discharge	O
.	O

This	O
review	O
focuses	O
on	O
interactions	O
during	O
thymocyte	B-cell_type
maturation	O
that	O
define	O
the	O
T	O
cell	O
repertoire	O
,	O
with	O
an	O
emphasis	O
placed	O
on	O
current	O
literature	O
within	O
this	O
field	O
.	O

Defective	O
translocation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
in	O
multidrug-resistant	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
confers	O
a	O
reversible	O
loss	O
of	O
phorbol	O
ester-induced	O
monocytic	O
differentiation	O
.	O

A	O
critical	O
issue	O
concerns	O
the	O
mechanism	O
by	O
which	O
CD14	B-protein
,	O
which	O
has	O
no	O
transmembrane	B-protein
domain	I-protein
,	O
transduces	O
its	O
signal	O
following	O
LPS	O
binding	O
.	O

Fibronectin	B-protein
synergized	O
with	O
anti-CD3	B-protein
antibody	I-protein
to	O
promote	O
CD4	B-protein
cell	O
proliferation	O
in	O
a	O
serum-free	O
culture	O
system	O
whereas	O
no	O
proliferation	O
was	O
observed	O
when	O
CD4	B-cell_line
cells	I-cell_line
were	O
cultured	O
with	O
anti-CD3	B-protein
alone	O
or	O
fibronectin	B-protein
alone	O
.	O

Fusion	O
of	O
anergic	B-cell_type
murine	I-cell_type
T	I-cell_type
cells	I-cell_type
to	O
human	B-cell_type
Jurkat	I-cell_type
T	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
and	O
formation	O
of	O
heterokaryons	B-cell_line
failed	O
to	O
result	O
in	O
a	O
complementation	O
of	O
this	O
signaling	O
defect	O
and	O
restoration	O
of	O
murine	B-RNA
IL-2	I-RNA
mRNA	I-RNA
inducibility	O
.	O

E2a-	O
Pbx1	B-protein
-induced	O
apoptosis	O
proceeded	O
through	O
a	O
BCL2	B-protein
-responsive	O
checkpoint	O
eventuating	O
in	O
PARP	B-protein
inactivation	O
but	O
did	O
require	O
p53	B-protein
.	O

Expression	O
of	O
c-fos	B-protein
and	I-protein
c-jun	I-protein
proteins	I-protein
and	O
AP-1	B-protein
binding	O
activity	O
during	O
cell	O
cycle	O
progression	O
of	O
HL60	B-cell_line
cells	I-cell_line
and	O
phytohemagglutinin-stimulated	B-cell_line
lymphocytes	I-cell_line
.	O

Stimulation	O
was	O
significantly	O
higher	O
when	O
lysates	O
were	O
heated	O
at	O
100	O
degrees	O
C	O
for	O
5	O
min	O
but	O
was	O
reduced	O
by	O
treatment	O
with	O
lysozyme	B-protein
or	O
protease	B-protein
.	O

Furthermore	O
,	O
CD40	B-protein
ligation	O
of	O
a	O
HLA-A2+	B-cell_line
,	I-cell_line
MelanA/MART1+	I-cell_line
MM	I-cell_line
cell	I-cell_line
line	I-cell_line
enhanced	O
its	O
susceptibility	O
to	O
specific	O
lysis	O
by	O
a	O
HLA-A2-restricted	B-cell_line
,	I-cell_line
MelanA/MART-1-specific	I-cell_line
CTL	I-cell_line
clone	I-cell_line
.	O

Energy	O
substrates	O
,	O
hormone	O
responses	O
and	O
glucocorticoid	O
binding	O
in	O
lymphocytes	B-cell_type
during	O
intense	O
physical	O
exercise	O
in	O
humans	O
following	O
phosphocreatine	O
administration	O
.	O

These	O
observations	O
suggest	O
that	O
protein	O
glycation	O
in	O
pancreatic	B-cell_type
beta	I-cell_type
cells	I-cell_type
,	O
which	O
occurs	O
in	O
vivo	O
under	O
chronic	O
hyperglycemia	O
,	O
suppresses	O
insulin	O
gene	O
transcription	O
and	O
thus	O
can	O
explain	O
part	O
of	O
the	O
beta	O
cell	O
glucose	O
toxicity	O
.	O

Two	O
groups	O
of	O
HMG	B-protein
box	I-protein
proteins	I-protein
are	O
distinguished	O
.	O

However	O
,	O
this	O
region	O
directed	O
extremely	O
low	O
reporter	O
mRNA	O
levels	O
relative	O
to	O
endogenous	O
IL-4	B-RNA
mRNA	I-RNA
,	O
suggesting	O
that	O
full	O
gene	O
activity	O
requires	O
additional	O
enhancer	B-DNA
elements	I-DNA
.	O

The	O
proteolytic	O
degradation	O
of	O
the	O
post-translationally	O
modified	O
I-kappa	B-protein
B	I-protein
is	O
known	O
to	O
be	O
mediated	O
by	O
the	O
26S	B-protein
proteasome	I-protein
complex	I-protein
.	O

Erythropoietin	B-protein
(	O
EPO	B-protein
)	O
and	O
its	O
receptor	O
(	O
EPOR	B-protein
)	O
are	O
required	O
for	O
the	O
development	O
of	O
mature	O
erythrocytes	O
.	O

The	O
CMAT	B-protein
protein	O
appears	O
to	O
be	O
a	O
novel	O
inducible	O
protein	O
involved	O
in	O
the	O
regulation	O
of	O
c-myb	B-DNA
expression	O
during	O
T-cell	O
activation	O
.	O

It	O
is	O
clear	O
from	O
various	O
studies	O
that	O
the	O
activity	O
of	O
the	O
NADPH	B-protein
oxidase	I-protein
can	O
be	O
modulated	O
through	O
the	O
regulation	O
of	O
the	O
GTP-GDP	O
state	O
of	O
Rac	B-protein
.	O

Comparison	O
of	O
HTLV-I	O
basal	O
transcription	O
and	O
expression	O
of	O
CREB/ATF-1/CREM	B-protein
family	I-protein
members	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Erythropoietin	B-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
Jak2	B-protein
,	O
STAT5A	B-protein
,	O
and	O
STAT5B	B-protein
in	O
primary	B-cell_type
cultured	I-cell_type
human	I-cell_type
erythroid	I-cell_type
precursors	I-cell_type
.	O

ZRE-B	B-DNA
is	O
therefore	O
not	O
part	O
of	O
the	O
R-	B-DNA
inducible	I-DNA
enhancer	I-DNA
.	O

Phase-2	O
neutrophil	O
adhesion	O
was	O
attenuated	O
by	O
an	O
anti-E-selectin	B-protein
mAb	I-protein
,	O
indicating	O
a	O
dominant	O
role	O
of	O
this	O
adhesion	O
molecule	O
in	O
the	O
late	O
phase	O
response	O
.	O

Through	O
these	O
actions	O
glucocorticosteroids	O
are	O
susceptible	O
to	O
modify	O
functions	O
of	O
cells	O
involved	O
in	O
the	O
allergic	O
inflammatory	O
response	O
.	O

Apoptotic	O
cells	O
within	O
atherosclerotic	O
plaques	O
may	O
allow	O
local	O
thrombin	B-protein
activation	O
,	O
thereby	O
contributing	O
to	O
disease	O
progression	O
.	O

Upregulation	O
of	O
interleukin	B-protein
6	I-protein
and	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
receptors	I-protein
by	O
transcription	B-protein
factor	I-protein
CCAAT	B-protein
enhancer	I-protein
binding	I-protein
protein	I-protein
alpha	I-protein
(	O
C/EBP	B-protein
alpha	I-protein
)	O
is	O
critical	O
for	O
granulopoiesis	O
.	O

The	O
effects	O
of	O
chemically	O
prepared	O
monochloramine	O
(	O
NH2Cl	O
)	O
on	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
and	O
PKC	B-protein
-mediated	O
cellular	O
responses	O
were	O
studied	O
in	O
elicited	B-cell_type
rat	I-cell_type
peritoneal	I-cell_type
neutrophils	I-cell_type
and	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

For	O
example	O
dendritic	B-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
can	O
be	O
found	O
in	O
colonies	O
of	O
GM-CSF-responsive	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
,	O
and	O
under	O
experimental	O
conditions	O
are	O
routinely	O
expanded	O
as	O
a	O
population	O
in	O
vitro	O
from	O
GM-CSF-responsive	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

PCR	O
analysis	O
of	O
spontaneous	B-cell_line
EBV-transformed	I-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
LCL	B-cell_line
)	O
from	O
three	O
individuals	O
with	O
primary	O
infection	O
showed	O
that	O
two	O
were	O
infected	O
with	O
type	O
A	O
and	O
one	O
with	O
type	O
B	O
EBV	O
.	O

In	O
order	O
to	O
understand	O
this	O
block	O
the	O
cascade	O
of	O
molecular	O
events	O
needs	O
to	O
be	O
characterized	O
.	O

[	O
Estrogen	B-protein
receptor	I-protein
content	O
of	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
]	O

Although	O
erythroid	B-cell_type
progenitors	I-cell_type
appear	O
to	O
be	O
the	O
principal	O
EPO-responsive	B-cell_type
cell	I-cell_type
type	I-cell_type
in	O
vivo	O
due	O
to	O
the	O
restricted	O
expression	O
of	O
the	O
EPOR	B-protein
,	O
many	O
growth	B-cell_line
factor-dependent	I-cell_line
cell	I-cell_line
lines	I-cell_line
expressing	O
the	O
EPOR	B-protein
can	O
respond	O
to	O
EPO	B-protein
by	O
activating	O
many	O
or	O
all	O
of	O
these	O
pathways	O
.	O

The	O
3'-CAGGTG	B-DNA
E-box	I-DNA
could	O
bind	O
USF	B-protein
proteins	I-protein
,	O
the	O
ubiquitous	B-protein
repressor	I-protein
ZEB	B-protein
,	O
or	O
the	O
basic	B-protein
helix-loop-helix	I-protein
proteins	I-protein
E2A	B-protein
and	O
HEB	B-protein
,	O
and	O
we	O
showed	O
that	O
a	O
competition	O
between	O
ZEB	B-protein
and	O
E2A/HEB	B-protein
proteins	I-protein
is	O
involved	O
in	O
the	O
silencer	O
activity	O
.	O

Immunostained	B-cell_type
tumor	I-cell_type
cells	I-cell_type
were	O
more	O
frequently	O
distributed	O
in	O
the	O
area	O
where	O
tumor	O
cell	O
infiltration	O
was	O
more	O
invasive	O
.	O

Inducible	O
expression	O
and	O
phosphorylation	O
of	O
coactivator	B-protein
BOB.1/OBF.1	I-protein
in	O
T	B-cell_type
cells	I-cell_type
[	O
see	O
comments	O
]	O

In	O
nonerythroid	B-cell_line
NIH3T3	I-cell_line
cells	I-cell_line
,	O
however	O
,	O
the	O
GATA	B-DNA
site	I-DNA
is	O
not	O
required	O
.	O

We	O
found	O
that	O
gelatinase	O
granules	O
,	O
defined	O
as	O
peroxidase-negative	O
granules	O
containing	O
gelatinase	B-protein
but	O
lacking	O
lactoferrin	B-protein
,	O
contain	O
50	O
%	O
of	O
total	O
cell	O
gelatinase	B-protein
,	O
with	O
the	O
remaining	O
residing	O
in	O
specific	O
granules	O
.	O

Using	O
in	O
vivo	O
genomic	O
footprinting	O
we	O
identified	O
interactions	O
in	O
B-cell	B-cell_line
lines	I-cell_line
at	O
the	O
octamer	B-DNA
site	I-DNA
and	O
the	O
Y	B-DNA
,	I-DNA
X1	I-DNA
,	I-DNA
and	I-DNA
X2	I-DNA
boxes	I-DNA
.	O

Therefore	O
,	O
a	O
STAT1	B-protein
transcription	B-protein
factor	I-protein
is	O
activated	O
by	O
IFN-gamma	B-protein
synthesized	O
and	O
released	O
upon	O
stimulation	O
of	O
T	B-cell_type
lymphocyte	I-cell_type
populations	I-cell_type
.	O

E3	B-protein
transcripts	I-protein
were	O
RA-inducible	O
in	O
HL60	B-cell_line
cells	I-cell_line
,	O
but	O
not	O
in	O
an	O
RA-resistant	B-cell_line
subclone	I-cell_line
,	O
HL60R	B-cell_line
,	O
that	O
harbors	O
a	O
mutated	O
RAR	B-DNA
alpha	I-DNA
gene	I-DNA
.	O

The	O
survival-promoting	O
activity	O
of	O
the	O
Bcl-2	B-protein
family	I-protein
of	O
proteins	O
appears	O
to	O
be	O
modulated	O
by	O
interactions	O
between	O
various	O
cellular	B-protein
proteins	I-protein
.	O

This	O
event	O
is	O
associated	O
with	O
induction	O
of	O
the	O
c-jun	B-DNA
early	I-DNA
response	I-DNA
gene	I-DNA
and	O
appearance	O
of	O
a	O
monocytic	O
phenotype	O
.	O

The	O
identification	O
of	O
carriers	O
is	O
of	O
substantial	O
clinical	O
importance	O
for	O
genetic	O
counseling	O
.	O

Sequences	O
related	O
to	O
the	O
TCF-1	B-DNA
alpha	I-DNA
binding	I-DNA
motif	I-DNA
(	O
5'-GGCACCCTTTGA-3	O
'	O
)	O
are	O
also	O
found	O
in	O
the	O
human	B-DNA
TCR	I-DNA
delta	I-DNA
(	O
and	O
possibly	O
TCR	B-DNA
beta	I-DNA
)	O
enhancers	B-DNA
.	O

Infected	O
AML	B-cell_type
blasts	I-cell_type
produced	O
between	O
2	O
and	O
6	O
ng	O
of	O
IL-12/10	O
(	O
6	O
)	O
cells	O
per	O
ml	O
per	O
48	O
hr	O
.	O

One	O
member	O
of	O
this	O
multigene	O
family	O
,	O
GATA-3	B-protein
,	O
is	O
most	O
abundantly	O
expressed	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
a	O
cellular	O
target	O
for	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
and	O
replication	O
.	O

In	O
astrocytes	B-cell_type
PDTC	O
also	O
dramatically	O
induces	O
the	O
NF	B-protein
kappaB-dependent	I-protein
enzyme	I-protein
,	O
iNOS	B-protein
,	O
supporting	O
the	O
physiologic	O
relevance	O
of	O
endogenous	O
NO	O
regulation	O
of	O
NF	B-protein
kappaB	I-protein
.	O

Interestingly	O
,	O
TGF-alpha	B-protein
production	O
by	O
eosinophils	B-cell_type
was	O
up-regulated	O
by	O
IL-3	B-protein
and	O
IL-5	B-protein
but	O
was	O
down-regulated	O
by	O
IL-4	B-protein
.	O

Protein	O
kinase	O
C	O
(	O
PKC	B-protein
)	O
depletion	O
generated	O
by	O
a	O
long-term	O
phorbol	O
12	O
myristate	O
13-acetate	O
treatment	O
had	O
weak	O
effects	O
on	O
proliferation	O
.	O

In	O
six	O
of	O
seven	O
patients	O
examined	O
,	O
inhibition	O
of	O
the	O
VLA-4/	O
VCAM-1	B-protein
pathway	O
resulted	O
in	O
greater	O
than	O
50	O
%	O
inhibition	O
of	O
transendothelial	O
migration	O
of	O
T-cells	B-cell_type
.	O

This	O
result	O
indicates	O
the	O
involvement	O
of	O
either	O
a	O
B-cell-specific	B-protein
cofactor	I-protein
or	O
a	O
specific	O
modification	O
of	O
a	O
cofactor	B-protein
or	O
the	O
Oct2	B-protein
protein	I-protein
in	O
Oct2	B-protein
-mediated	O
enhancer	O
activation	O
.	O

To	O
examine	O
the	O
role	O
of	O
mineralocorticoids	O
in	O
the	O
pathophysiology	O
of	O
PIH	O
,	O
we	O
studied	O
plasma	O
aldosterone	O
and	O
18-hydroxy-corticosterone	O
(	O
18-OH-B	O
)	O
levels	O
in	O
25	O
women	O
with	O
PIH	O
and	O
in	O
25	O
healthy	O
pregnant	O
women	O
.	O

The	O
levels	O
of	O
secreted	O
IL-1beta	B-protein
,	O
TNF-alpha	B-protein
,	O
and	O
IL-6	B-protein
during	O
24	O
h	O
of	O
stimulation	O
were	O
comparable	O
to	O
those	O
induced	O
by	O
Escherichia	O
coli	O
lipopolysaccharide	O
at	O
1	O
microg/ml	O
.	O

Interaction	O
of	O
sickle	B-cell_type
erythrocytes	I-cell_type
with	O
endothelial	B-cell_type
cells	I-cell_type
in	O
the	O
presence	O
of	O
endothelial	O
cell	O
conditioned	O
medium	O
induces	O
oxidant	O
stress	O
leading	O
to	O
transendothelial	O
migration	O
of	O
monocytes	B-cell_type
.	O

Lymphocyte	B-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
established	O
from	O
five	O
patients	O
with	O
vitamin	O
D-dependent	O
rickets	O
,	O
type	O
II	O
(	O
VDDR-II	O
)	O
.	O

Although	O
DOR1	B-protein
signaling	O
increased	O
[	O
Ca2+	O
]	O
i	O
,	O
deltorphin	O
enhanced	O
transcriptional	O
activity	O
of	O
the	O
NF-AT/AP-1-binding	B-DNA
site	I-DNA
via	O
a	O
mechanism	O
independent	O
of	O
calcineurin	B-protein
and	O
distinct	O
from	O
the	O
effects	O
of	O
elevated	O
[	O
Ca2+	O
]	O
i	O
.	O

As	O
such	O
it	O
serves	O
as	O
a	O
good	O
prototype	O
for	O
B	B-DNA
cell-specific	I-DNA
genes	I-DNA
whose	O
expression	O
begins	O
shortly	O
after	O
lineage	O
commitment	O
.	O

These	O
results	O
suggest	O
that	O
transformation	O
of	O
primary	B-cell_type
B	I-cell_type
cells	I-cell_type
with	O
EBV	O
induces	O
IL-12	B-protein
expression	O
potentially	O
through	O
LMP1	B-protein
expression	O
.	O

Immune	O
parameters	O
,	O
natural	B-cell_type
killer	I-cell_type
cell	I-cell_type
and	O
T	O
lymphocyte	O
functions	O
and	O
the	O
numbers	O
of	O
circulating	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
were	O
analysed	O
against	O
the	O
clinical	O
parameters	O
comprising	O
the	O
tumour	O
burden	O
,	O
the	O
stage	O
of	O
the	O
disease	O
and	O
the	O
expression	O
of	O
hormone	B-protein
receptors	I-protein
on	O
the	O
tumour	O
.	O

The	O
immunosuppressants	O
ciclosporin	O
and	O
FK506	O
block	O
the	O
Ca	O
(	O
2+	O
)	O
-dependent	O
signal-transduction	O
pathway	O
emanating	O
from	O
the	O
T-cell	B-protein
receptor	I-protein
,	O
thereby	O
inhibiting	O
the	O
activation	O
of	O
helper	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

These	O
proteins	O
are	O
differentially	O
expressed	O
in	O
human	B-cell_line
glioblastoma	I-cell_line
and	I-cell_line
neuroblastoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

We	O
found	O
that	O
transactivation	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
by	O
v-src	B-DNA
was	O
more	O
sensitive	O
to	O
mutations	O
of	O
the	O
proximal	O
,	O
rather	O
than	O
the	O
distal	O
,	O
kappa	B-DNA
B	I-DNA
element	I-DNA
.	O

To	O
explore	O
the	O
expression	O
of	O
adhesion	B-protein
molecules	I-protein
,	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
(	O
MCP-1	B-protein
)	O
,	O
and	O
Hsp60	B-protein
in	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
HUVECs	B-cell_type
)	O
,	O
Northern	O
blot	O
analyses	O
were	O
used	O
.	O

The	O
requirement	O
of	O
another	O
regulatory	B-DNA
element	I-DNA
called	O
CLE0	B-DNA
,	O
which	O
lies	O
downstream	O
of	O
the	O
-70	B-DNA
GATA	I-DNA
site	I-DNA
,	O
was	O
also	O
demonstrated	O
.	O

Physical	O
and	O
functional	O
interaction	O
between	O
the	O
human	B-protein
T-cell	I-protein
lymphotropic	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax1	I-protein
protein	I-protein
and	O
the	O
CCAAT	B-protein
binding	I-protein
protein	I-protein
NF-Y	B-protein
.	O

DNA	O
band-shift	O
assays	O
revealed	O
a	O
decrease	O
in	O
the	O
intensity	O
of	O
the	O
full	O
length	O
SP1	B-protein
/DNA	O
complex	O
and	O
an	O
increase	O
in	O
the	O
intensity	O
of	O
a	O
smaller	O
complex	O
due	O
to	O
the	O
binding	O
of	O
one	O
SP1	B-protein
cleavage	O
product	O
.	O

Tumor	O
cell	O
lines	O
with	O
a	O
defective	O
retinoblastoma	B-DNA
gene	I-DNA
are	O
unable	O
to	O
transcribe	O
the	O
HLA	B-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
in	O
response	O
to	O
IFN-gamma	B-protein
treatment	O
,	O
and	O
reconstitution	O
of	O
functional	O
Rb	B-protein
rescues	O
IFN-gamma-induced	O
class	B-DNA
II	I-DNA
gene	I-DNA
expression	O
.	O

These	O
results	O
demonstrate	O
that	O
Itk	B-protein
plays	O
a	O
role	O
in	O
IL-2	B-protein
production	O
,	O
indicating	O
a	O
critical	O
involvement	O
of	O
Itk	B-protein
in	O
the	O
initial	O
stage	O
of	O
T	O
cell	O
activation	O
by	O
mediating	O
signals	O
from	O
the	O
TCR/CD3	B-protein
complex	I-protein
,	O
CD2	B-protein
,	O
and	O
CD28	B-protein
.	O

Two	O
proteins	O
binding	O
the	O
kappa	B-DNA
B	I-DNA
sequence	I-DNA
,	O
NF-kappa	B-protein
B	I-protein
and	O
KBF1	B-protein
,	O
are	O
constitutively	O
expressed	O
in	O
IARC	B-cell_line
301	I-cell_line
nuclei	O
and	O
induced	O
by	O
PMA	O
and	O
PHA	B-protein
in	O
Jurkat	B-cell_line
.	O

Furthermore	O
,	O
we	O
found	O
that	O
cytoplasmic	O
acidification	O
facilitated	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
both	O
TNF	B-protein
alpha	I-protein
and	O
PKC	B-protein
,	O
by	O
a	O
mechanism	O
that	O
increases	O
NF-kappa	B-protein
B	I-protein
/I	B-protein
kappa	I-protein
B	I-protein
dissociation	O
without	O
affecting	O
the	O
NF-kappa	B-protein
B	I-protein
translocation	O
step	O
.	O

Antisense	O
inhibition	O
of	O
vitamin	B-protein
D	I-protein
receptor	I-protein
expression	O
induces	O
apoptosis	O
in	O
monoblastoid	B-cell_line
U937	I-cell_line
cells	I-cell_line
.	O

The	O
concentrations	O
required	O
for	O
50	O
%	O
displacement	O
of	O
17beta-	O
(	O
3H	O
)	O
estradiol	O
(	O
CB50	O
)	O
were	O
:	O
17beta-estradiol	O
,	O
1.34	O
nmol/L	O
;	O
diethylstilbestrol	O
,	O
1.46	O
nmol/L	O
;	O
daidzein	O
,	O
1.6	O
micromol/L	O
;	O
DG	O
,	O
14.7	O
micromol/L	O
;	O
genistein	O
,	O
0.154	O
micromol/L	O
;	O
GG	O
,	O
7.27	O
micromol/L	O
.	O

To	O
explore	O
the	O
receptor	O
signaling	O
pathways	O
involved	O
in	O
RA-induced	O
apoptosis	O
,	O
we	O
used	O
selective	O
ligands	O
for	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
(	O
RARs	O
;	O
RO13-7410	O
)	O
and	O
retinoid	B-protein
X	I-protein
receptors	I-protein
(	O
RXRs	B-protein
;	O
RO	O
25-6603	O
)	O
.	O

However	O
,	O
the	O
exact	O
cellular	O
mechanisms	O
underlying	O
this	O
anti-inflammatory	O
capacity	O
are	O
still	O
unknown	O
.	O

The	O
transcription	B-protein
factor	I-protein
HIV-TF1	B-protein
,	O
which	O
binds	O
to	O
a	O
region	O
about	O
60	B-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
enhancer	O
of	O
the	O
human	O
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
,	O
was	O
purified	O
from	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

The	O
Oct2	B-protein
transcription	B-protein
factor	I-protein
is	O
expressed	O
predominantly	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
and	O
plays	O
an	O
essential	O
role	O
during	O
the	O
terminal	O
phase	O
of	O
B	O
cell	O
differentiation	O
.	O

By	O
contrast	O
,	O
the	O
binding	O
activity	O
of	O
the	O
NF-kappa	B-protein
(	I-protein
B	I-protein
)	I-protein
and	O
EGR-1	B-protein
transcription	B-protein
factors	I-protein
was	O
little	O
affected	O
.	O

From	O
this	O
,	O
we	O
identified	O
a	O
number	O
of	O
variations	O
between	O
the	O
sequences	O
,	O
two	O
of	O
which	O
were	O
determined	O
to	O
be	O
associated	O
with	O
a	O
50	O
%	O
decrease	O
in	O
CAT	B-protein
activity	O
.	O

Increased	O
expression	O
of	O
Gs	B-protein
(	I-protein
alpha	I-protein
)	I-protein
enhances	O
activation	O
of	O
the	O
adenylyl	B-protein
cyclase	I-protein
signal	O
transduction	O
cascade	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
HLA	B-protein
class	I-protein
I	I-protein
-mediated	O
induction	O
of	O
cell	O
proliferation	O
correlates	O
with	O
inactivation	O
of	O
the	O
Rb	B-protein
protein	I-protein
in	O
the	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
Jurkat	I-cell_line
as	O
well	O
as	O
human	B-cell_type
aortic	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O

Gene	O
targeting	O
experiments	O
in	O
the	O
mouse	O
revealed	O
a	O
differential	O
dependency	O
of	O
fetal	O
and	O
adult	O
B-lymphopoiesis	O
on	O
this	O
transcription	B-protein
factor	I-protein
.	O

The	O
design	O
of	O
combination	O
hormonal	O
and	O
immunotherapeutic	O
protocols	O
for	O
breast	O
cancer	O
patients	O
may	O
be	O
facilitated	O
by	O
analysis	O
of	O
preclinical	O
in	O
vitro	O
model	O
systems	O
.	O

Initial	O
signaling	O
through	O
the	O
CD4	B-protein
receptor	I-protein
played	O
a	O
major	O
role	O
in	O
the	O
sensitization	O
of	O
HIV-infected	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
undergo	O
apoptosis	O
.	O

Clusters	O
of	O
genes	B-DNA
expressed	O
by	O
stromal	B-cell_type
cells	I-cell_type
and	O
lymphocytes	B-cell_type
in	O
the	O
breast	O
tumors	O
also	O
were	O
identified	O
in	O
this	O
analysis	O
.	O

One	O
(	O
site	B-DNA
B	I-DNA
)	O
contained	O
a	O
palindromic	B-DNA
sequence	I-DNA
with	O
homology	O
to	O
steroid/thyroid	B-DNA
hormone	I-DNA
response	I-DNA
elements	I-DNA
but	O
was	O
distinct	O
from	O
previously	O
described	O
binding	O
sites	O
of	O
this	O
class	O
.	O

The	O
role	O
of	O
E-proteins	B-protein
in	O
B-	O
and	O
T-lymphocyte	O
development	O
.	O

Inhibition	O
of	O
IL-1RI	B-protein
and	O
IL-1RII	O
mRNA	O
levels	O
by	O
IFN-gamma	B-protein
was	O
transcriptionally	O
mediated	O
,	O
and	O
correlated	O
directly	O
with	O
decreased	O
production	O
of	O
soluble	O
IL-1RII	B-protein
.	O

In	O
nuclear	O
run-on	O
analysis	O
,	O
such	O
tolerant	B-cell_type
cells	I-cell_type
show	O
only	O
a	O
low	O
degree	O
of	O
transcription	O
,	O
indicating	O
that	O
tolerance	O
operates	O
at	O
or	O
upstream	O
of	O
the	O
transcription	O
level	O
.	O

Another	O
component	O
of	O
the	O
AP-1	B-protein
transcription	I-protein
complex	I-protein
,	O
JunB	B-protein
,	O
is	O
shown	O
to	O
inhibit	O
activation	O
mediated	O
by	O
JunD	B-protein
.	O

They	O
involve	O
phosphorylation	O
and	O
proteolytic	O
reactions	O
and	O
seem	O
to	O
be	O
controlled	O
by	O
the	O
cells	O
'	O
redox	O
status	O
.	O

Thus	O
,	O
the	O
tyrosine	B-protein
kinase	I-protein
activated	O
by	O
G-CSF	B-protein
appears	O
to	O
directly	O
transduce	O
a	O
signal	O
to	O
a	O
protein	O
which	O
functions	O
as	O
a	O
transcriptional	B-protein
regulator	I-protein
.	O

Expression	O
of	O
MEK1-interfering	B-protein
mutants	I-protein
inhibited	O
the	O
stimulation	O
of	O
IL-2	B-DNA
promoter	I-DNA
-driven	O
transcription	O
and	O
blocked	O
the	O
ability	O
of	O
constitutively	O
active	O
Ras	B-protein
and	O
Raf-1	B-protein
to	O
costimulate	O
NF-AT	B-protein
activity	O
with	O
a	O
calcium	O
ionophore	O
.	O

The	O
effect	O
of	O
CD70	B-cell_line
transfectants	I-cell_line
was	O
dose	O
dependent	O
and	O
was	O
completely	O
blocked	O
by	O
anti-CD70	B-protein
mAb	I-protein
.	I-protein

Some	O
patients	O
with	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
develop	O
glucocorticoid	O
resistance	O
characterized	O
by	O
low	O
receptor	O
affinity	O
(	O
Kd	O
)	O
for	O
glucocorticoids	O
in	O
mononuclear	B-cell_type
,	O
cells	O
and	O
high	O
values	O
of	O
ACTH	O
and	O
cortisol	O
.	O

MDS1/EVI1	B-DNA
,	O
located	O
on	O
chromosome	B-DNA
3	I-DNA
band	I-DNA
q26	I-DNA
,	O
encodes	O
a	O
zinc-finger	B-protein
DNA-binding	I-protein
transcription	I-protein
activator	I-protein
not	O
detected	O
in	O
normal	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
but	O
expressed	O
in	O
several	O
normal	O
tissues	O
.	O

The	O
insertion	O
was	O
not	O
required	O
for	O
Fc	B-protein
gamma	I-protein
RII	I-protein
to	O
modulate	O
surface	B-protein
immunoglobulin	I-protein
-triggered	O
B-cell	O
activation	O
.	O

Activation	O
of	O
NK-kappa	B-protein
B	I-protein
and	O
upregulation	O
of	O
ICAM-1	B-protein
occurred	O
within	O
24	O
h	O
and	O
were	O
followed	O
at	O
48	O
to	O
72	O
h	O
by	O
upregulation	O
of	O
Bcl-2	B-protein
.	O

Cardiac	O
and	O
adrenergic	O
diseases	O
were	O
excluded	O
.	O

Finally	O
,	O
CD40	B-protein
ligation	O
induced	O
growth	O
inhibition	O
and	O
apoptosis	O
in	O
MM	O
.	O

The	O
glucocorticoid	B-protein
receptor	I-protein
cooperates	O
with	O
the	O
erythropoietin	B-protein
receptor	I-protein
and	O
c-Kit	B-protein
to	O
enhance	O
and	O
sustain	O
proliferation	O
of	O
erythroid	B-cell_type
progenitors	I-cell_type
in	O
vitro	O
.	O

Signaling	O
by	O
IL-2	B-protein
and	O
related	O
cytokines	B-protein
:	O
JAKs	B-protein
,	O
STATs	B-protein
,	O
and	O
relationship	O
to	O
immunodeficiency	O
.	O

Both	O
the	O
mutant	O
and	O
wild-type	O
strains	O
were	O
more	O
resistant	O
to	O
stress	O
when	O
in	O
stationary	O
phase	O
than	O
when	O
in	O
the	O
logarithmic	O
phase	O
of	O
growth	O
.	O

To	O
test	O
whether	O
this	O
putative	O
function	O
of	O
CD28	B-protein
is	O
mediated	O
via	O
a	O
particular	O
signaling	O
pathway	O
,	O
we	O
compared	O
early	O
signaling	O
events	O
initiated	O
in	O
resting	O
T	B-cell_type
cells	I-cell_type
by	O
the	O
stimulatory	B-protein
mAb	I-protein
BW	I-protein
828	I-protein
with	O
signals	O
triggered	O
by	O
the	O
nonstimulating	B-protein
CD28	I-protein
mAb	I-protein
9.3	I-protein
.	O

Activation	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
antigen	O
,	O
lectin	B-protein
,	O
or	O
a	O
combination	O
of	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
leads	O
to	O
the	O
induction	O
of	O
genes	O
for	O
a	O
set	O
of	O
lymphokines	B-protein
,	O
including	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
.	O

Activation	O
of	O
N-WASP	B-protein
by	O
IcsA	B-protein
unmasks	O
two	O
domains	O
acting	O
together	O
in	O
insertional	O
actin	B-protein
polymerization	O
.	O

The	O
CD34+	B-cell_line
myelomonocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
KG1	B-cell_line
differentiates	O
into	O
dendritic-like	O
cells	O
in	O
response	O
to	O
granulocyte-macrophage	B-protein
CSF	I-protein
plus	O
TNF-alpha	B-protein
,	O
or	O
PMA	O
(	O
with	O
or	O
without	O
the	O
calcium	O
ionophore	O
ionomycin	O
,	O
or	O
TNF-alpha	B-protein
)	O
,	O
with	O
different	O
stimuli	O
mediating	O
different	O
aspects	O
of	O
the	O
process	O
.	O

The	O
Thy-1	B-DNA
gene	I-DNA
promoter	I-DNA
resembles	O
a	O
``	B-DNA
housekeeping	I-DNA
''	I-DNA
promoter	I-DNA
in	O
that	O
it	O
is	O
located	O
within	O
a	O
methylation-free	B-DNA
island	I-DNA
,	O
lacks	O
a	O
canonical	B-DNA
TATA	I-DNA
box	I-DNA
,	O
and	O
displays	O
heterogeneity	O
in	O
the	O
5'-end	B-RNA
termini	I-RNA
of	O
the	O
mRNA	B-RNA
.	O

We	O
demonstrate	O
in	O
this	O
report	O
that	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
DNA	I-DNA
of	O
the	O
15-lox	B-DNA
gene	I-DNA
contains	O
sequences	O
which	O
down-regulate	O
its	O
activity	O
in	O
a	O
variety	O
of	O
non-erythroid	B-cell_line
cell	I-cell_line
lines	I-cell_line
but	O
not	O
in	O
two	O
erythroid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Initiation	B-protein
binding	I-protein
repressor	I-protein
,	O
a	O
factor	O
that	O
binds	O
to	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
of	O
the	O
histone	B-DNA
h5	I-DNA
gene	I-DNA
,	O
is	O
a	O
glycosylated	B-protein
member	I-protein
of	O
a	O
family	O
of	O
cell	B-protein
growth	I-protein
regulators	I-protein
[	O
corrected	O
]	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1996	O
Feb	O
;	O
16	O
(	O
2	O
)	O
:	O
735	O
]	O

A	O
PXQXT/S-containing	B-DNA
sequence	I-DNA
is	O
also	O
present	O
in	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
the	O
Hodgkin	O
's	O
disease	O
marker	O
,	O
CD30	B-protein
,	O
and	O
binds	O
TRAF3	B-protein
in	O
vitro	O
.	O

In	O
this	O
regard	O
,	O
intracellular	O
levels	O
of	O
c-fos	B-protein
appear	O
to	O
be	O
influential	O
.	O

The	O
5'-UTR	B-DNA
contains	O
binding	B-DNA
sites	I-DNA
for	O
the	O
transcription	B-protein
factors	I-protein
AP-1	O
,	O
NF-kappaB	B-protein
,	O
NF-AT	B-protein
,	O
IRF	B-protein
,	O
and	O
Sp1	B-protein
.	O

hLH-2	B-DNA
was	O
mapped	O
to	O
chromosome	B-DNA
9Q33-34.1	I-DNA
,	O
in	O
the	O
same	O
region	O
as	O
the	O
reciprocal	O
translocation	O
that	O
creates	O
the	O
BCR-ABL	B-protein
chimera	I-protein
of	O
the	O
Philadelphia	O
chromosome	O
(	O
Ph	O
'	O
)	O
,	O
the	O
hallmark	O
of	O
CML	O
;	O
hLH-2	B-DNA
was	O
retained	O
on	O
the	O
derivative	B-DNA
9	I-DNA
chromosome	I-DNA
and	O
is	O
therefore	O
centromeric	O
of	O
c-ABL	B-DNA
.	O

A	O
significant	O
2-4	O
fold	O
increase	O
of	O
c-fos	B-DNA
expression	O
was	O
observed	O
within	O
30	O
min	O
of	O
stimulation	O
with	O
IL-10	B-protein
(	O
p	O
<	O
0.01	O
)	O
.	O

High	O
affinity	O
binding	O
of	O
the	O
radioligand	O
with	O
an	O
apparent	O
Kd	O
of	O
approximately	O
0.1	O
nM	O
was	O
found	O
.	O

This	O
was	O
identified	O
as	O
the	O
mRNA	B-RNA
encoding	O
the	O
transcription	B-protein
factor	I-protein
egr-1	B-protein
,	O
which	O
is	O
expressed	O
with	O
fast	O
kinetics	O
in	O
T	B-cell_type
and	I-cell_type
NK	I-cell_type
cells	I-cell_type
upon	O
IL-2	B-protein
,	O
but	O
not	O
IL-12	B-protein
,	O
stimulation	O
.	O

Exogenous	O
IL-4	B-protein
could	O
overcome	O
the	O
apparent	O
Th2	O
differentiation	O
defect	O
in	O
seven	O
patients	O
but	O
was	O
without	O
effect	O
in	O
the	O
remaining	O
eight	O
patients	O
.	O

We	O
undertook	O
a	O
detailed	O
analysis	O
of	O
E2F	B-protein
DNA-binding	O
activities	O
and	O
their	O
cell	O
cycle	O
behavior	O
in	O
primary	O
human	O
T	B-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
,	O
stimuli	O
such	O
as	O
hyperosmotic	O
shock	O
or	O
phosphatase	O
inhibitors	O
,	O
which	O
use	O
PDTC-insensitive	O
pathways	O
,	O
induce	O
I	B-protein
kappaB	I-protein
alpha	O
degradation	O
in	O
1.3E2	B-cell_line
.	O

Interestingly	O
,	O
enhanced	O
expression	O
of	O
Spi-1	B-DNA
and	I-DNA
Fli-1	I-DNA
genes	I-DNA
already	O
was	O
detected	O
in	O
the	O
Ter	B-cell_line
119	I-cell_line
positive	I-cell_line
cell	I-cell_line
population	I-cell_line
of	O
transgenic	O
mice	O
spleen	O
in	O
vivo	O
.	O

We	O
have	O
previously	O
identified	O
a	O
new	O
transcription	B-protein
factor	I-protein
family	I-protein
(	O
the	O
MNP	B-protein
family	I-protein
)	O
whose	O
expression	O
is	O
crucial	O
for	O
the	O
induction	O
of	O
MIP-1	B-protein
alpha	I-protein
transcription	O
during	O
cellular	O
activation	O
and	O
in	O
transformed	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

Furthermore	O
,	O
analysis	O
with	O
cloned	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
indicated	O
that	O
G75	O
and	O
G76	O
were	O
not	O
cross-reactive	O
specificities	O
,	O
suggesting	O
a	O
key	O
role	O
for	O
the	O
N-terminal	B-protein
residues	I-protein
of	O
the	O
variant	O
peptide	O
in	O
dictating	O
specificities	O
.	O

In	O
this	O
first	O
study	O
of	O
TCR	B-protein
repertoire	I-protein
selection	O
for	O
an	O
EBV	B-protein
lytic	I-protein
antigen	I-protein
,	O
a	O
BZLF1	B-protein
-reactive	O
component	O
of	O
diverse	O
clonotypes	O
was	O
identified	O
in	O
primary	O
type	O
A	O
or	O
type	O
B	O
EBV	O
infection	O
which	O
was	O
sustained	O
in	O
the	O
EBV-specific	O
memory	O
response	O
throughout	O
life-long	O
infection	O
.	O

Two	O
other	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
CEM	B-cell_line
and	O
RPMI	B-cell_line
8402	I-cell_line
,	O
have	O
essentially	O
identical	O
deletions	O
.	O

Additionally	O
,	O
infected	B-cell_type
T	I-cell_type
cells	I-cell_type
displayed	O
lower	O
levels	O
of	O
CD45	B-protein
on	O
their	O
surfaces	O
.	O

The	O
approximate	O
locations	O
of	O
the	O
HSV-2	O
genes	O
encoding	O
HSV-2	O
type-specific	O
CD4+	B-protein
antigens	I-protein
have	O
been	O
determined	O
by	O
using	O
HSV-1	O
x	O
HSV-2	O
intertypic	O
recombinant	O
virus	O
and	O
include	O
the	O
approximate	O
map	O
regions	O
0.30	O
to	O
0.46	O
,	O
0.59	O
to	O
0.67	O
,	O
0.67	O
to	O
0.73	O
,	O
and	O
0.82	O
to	O
1.0	O
units	O
.	O

ZEBRA	B-protein
,	O
a	O
member	O
of	O
the	O
bZIP	B-protein
family	I-protein
of	O
DNA-binding	B-protein
proteins	I-protein
,	O
is	O
a	O
transcriptional	O
activator	O
capable	O
of	O
inducing	O
expression	O
from	O
viral	B-DNA
lytic	I-DNA
cycle	I-DNA
promoters	I-DNA
.	O

Further	O
,	O
in	O
transcriptional	O
assays	O
in	O
vivo	O
,	O
ICER	B-protein
inhibits	O
calcineurin	B-protein
-mediated	O
expression	O
of	O
the	O
interleukin	B-DNA
2	I-DNA
promoter	I-DNA
as	O
well	O
as	O
Tax	B-protein
-mediated	O
transactivation	O
of	O
the	O
human	B-DNA
T-lymphotropic	I-DNA
virus	I-DNA
type	I-DNA
I	I-DNA
(	I-DNA
HTLV-I	I-DNA
)	I-DNA
promoter	I-DNA
.	O

Our	O
results	O
demonstrate	O
the	O
regulation	O
of	O
STAT	B-protein
activity	O
by	O
a	O
signaling	O
pathway	O
that	O
regulates	O
the	O
T	O
cell	O
functional	O
phenotype	O
and	O
is	O
distinct	O
from	O
the	O
cytokine	B-protein
-activated	O
Janus	B-protein
kinase	I-protein
-STAT	B-protein
signaling	O
pathway	O
.	O

The	O
active	O
metabolite	O
of	O
vitamin	O
D	O
,	O
1	O
,	O
25	O
dihydroxyvitamin	O
D3	O
,	O
is	O
an	O
important	O
immunoregulatory	O
hormone	O
[	O
1	O
]	O
.	O

The	O
mediator	O
(	O
s	O
)	O
of	O
this	O
maturation	O
process	O
has	O
not	O
been	O
yet	O
defined	O
.	O

Interestingly	O
,	O
co-immunoprecipitation	O
analysis	O
also	O
revealed	O
that	O
Tax	B-protein
mutant	O
IEXC29S	B-protein
is	O
unable	O
to	O
interact	O
with	O
NGFI-A/Egr-1	B-protein
,	O
whereas	O
Tax	B-protein
mutant	O
IEXL320G	B-protein
is	O
able	O
to	O
interact	O
with	O
NGFI-A/Egr-1	B-protein
.	O

B-CLL	O
cells	O
do	O
express	O
receptors	O
for	O
interferon-alpha	B-protein
(	O
IFN-alpha	B-protein
)	O
and	O
IFN-gamma	B-protein
,	O
and	O
activation	O
of	O
both	O
has	O
been	O
shown	O
to	O
promote	O
B-CLL	O
survival	O
in	O
vitro	O
by	O
preventing	O
apoptosis	O
.	O

Constitutive	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
enhanced	O
granulopoiesis	O
,	O
and	O
neonatal	O
lethality	O
in	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
-deficient	O
mice	O
.	O

Moreover	O
,	O
Sp1	B-protein
and	O
Egr-1	B-protein
could	O
form	O
a	O
complex	O
with	O
kinetics	O
that	O
correlated	O
with	O
the	O
production	O
of	O
Egr-1	B-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
upon	O
PMA	O
stimulation	O
.	O

Different	O
sequence	O
requirements	O
for	O
expression	O
in	O
erythroid	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
cells	I-cell_type
within	O
a	O
regulatory	B-DNA
element	I-DNA
upstream	O
of	O
the	O
GATA-1	B-DNA
gene	I-DNA
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
detection	O
of	O
normal	O
CD40	B-protein
-induced	O
monocyte	O
activation	O
in	O
patients	O
with	O
CD40	B-protein
ligand+	O
hyper	O
IgM	B-protein
syndrome	O
in	O
whom	O
a	O
defect	O
in	O
CD40	B-protein
-induced	O
B	O
cell	O
activation	O
has	O
been	O
reported	O
.	O

The	O
c-rel	B-protein
protooncogene	I-protein
product	I-protein
represses	O
NF-kappa	B-protein
B	I-protein
p65	B-protein
-mediated	O
transcriptional	O
activation	O
of	O
the	O
long	O
terminal	O
repeat	O
of	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
effect	O
of	O
IL-4	B-protein
on	O
the	O
expression	O
of	O
cytokine	B-DNA
genes	I-DNA
in	O
monocytes	B-cell_type
evoked	O
by	O
other	O
T-helper	B-protein
cell	I-protein
cytokines	I-protein
:	O
IL-2	B-protein
,	O
IL-3	B-protein
,	O
and	O
GM-CSF	B-protein
.	O

Subsequent	O
studies	O
have	O
revealed	O
that	O
(	O
i	O
)	O
cytoplasmic	B-protein
RelA	I-protein
is	O
stably	O
associated	O
not	O
only	O
with	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
but	O
also	O
with	O
other	O
ankyrin	B-protein
motif-rich	I-protein
proteins	I-protein
including	O
the	O
products	O
of	O
the	O
NF-kappa	B-DNA
B2	I-DNA
(	I-DNA
p100	I-DNA
)	I-DNA
and	I-DNA
NF-kappa	I-DNA
B1	I-DNA
(	I-DNA
p105	I-DNA
)	I-DNA
genes	I-DNA
;	O
(	O
ii	O
)	O
in	O
contrast	O
to	O
RelA	B-protein
-I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
RelA-p100	B-protein
cytoplasmic	I-protein
complexes	I-protein
are	O
not	O
dissociated	O
following	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
activation	O
;	O
(	O
iii	O
)	O
p100	B-protein
functions	O
as	O
a	O
potent	O
inhibitor	O
of	O
RelA	B-protein
-mediated	O
transcription	O
in	O
vivo	O
;	O
(	O
iv	O
)	O
the	O
interaction	O
of	O
RelA	B-protein
and	O
p100	B-protein
involves	O
the	O
conserved	B-protein
Rel	I-protein
homology	I-protein
domain	I-protein
of	O
both	O
proteins	O
but	O
not	O
the	O
nuclear	B-protein
localization	I-protein
signal	I-protein
of	O
RelA	B-protein
,	O
which	O
is	O
required	O
for	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
binding	O
;	O
(	O
v	O
)	O
p100	B-protein
inhibition	O
of	O
RelA	B-protein
function	O
requires	O
the	O
C-terminal	B-protein
ankyrin	I-protein
motif	I-protein
domain	I-protein
,	O
which	O
mediates	O
cytoplasmic	O
retention	O
of	O
RelA	B-protein
;	O
and	O
(	O
vi	O
)	O
as	O
observed	O
with	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
nuclear	O
RelA	B-protein
stimulates	O
p100	B-RNA
mRNA	I-RNA
and	O
protein	O
expression	O
.	O

CTCF	B-protein
is	O
a	O
transcriptional	O
repressor	O
of	O
the	O
c-myc	O
gene	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

We	O
demonstrate	O
that	O
a	O
fusion	O
protein	O
composed	O
of	O
a	O
C-terminal	O
Hsp70	B-protein
peptide	O
and	O
the	O
p50	B-protein
subunit	I-protein
of	O
NF-kappaB	B-protein
was	O
directed	O
into	O
the	O
nucleus	O
of	O
cells	O
,	O
could	O
bind	O
DNA	O
specifically	O
,	O
and	O
activated	O
Igkappa	B-protein
expression	O
and	O
TNFalpha	B-protein
production	O
.	O

The	O
promoter	O
of	O
the	O
major	B-DNA
histocompatibility	I-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
DRA	B-DNA
contains	O
an	O
octamer	B-DNA
element	I-DNA
(	O
ATTTGCAT	O
)	O
that	O
is	O
required	O
for	O
efficient	O
DRA	B-DNA
expression	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

We	O
have	O
recently	O
characterised	O
a	O
new	O
factor	O
called	O
IK	B-protein
which	O
is	O
an	O
efficient	O
inhibitor	O
of	O
IFN-gamma	B-protein
induction	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
antigens	I-protein
expression	O
.	O

Activation	O
of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
alone	O
do	O
not	O
result	O
in	O
the	O
phosphorylation	O
and/or	O
degradation	O
of	O
IkB	B-protein
alpha	I-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
or	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O

Dependence	O
for	O
the	O
proliferative	O
response	O
to	O
erythropoietin	B-protein
on	O
an	O
established	O
erythroid	O
differentiation	O
program	O
in	O
a	O
human	B-cell_line
hematopoietic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
UT-7	B-cell_line
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
known	O
to	O
be	O
produced	O
at	O
sites	O
of	O
granulomatous	O
reactions	O
.	O

Abnormal	O
apoptosis	O
and	O
cell	O
cycle	O
progression	O
in	O
humans	O
exposed	O
to	O
methyl	O
tertiary-butyl	O
ether	O
and	O
benzene	O
contaminating	O
water	O
.	O

Human	B-cell_line
T-cell	I-cell_line
clones	I-cell_line
reactive	O
with	O
gC	B-protein
and	O
VP16	B-protein
are	O
reported	O
here	O
for	O
the	O
first	O
time	O
.	O

This	O
study	O
supports	O
previous	O
clinical	O
observations	O
that	O
patients	O
may	O
require	O
morning	O
through	O
evening	O
exposure	O
to	O
MP	O
to	O
optimize	O
efficacy	O
while	O
adrenal	O
suppression	O
is	O
being	O
minimized	O
.	O

Therefore	O
,	O
we	O
also	O
evaluated	O
activation	O
of	O
the	O
MAP	B-protein
kinase	I-protein
extracellular	I-protein
signal-regulated	I-protein
kinase	I-protein
(	I-protein
ERK	I-protein
)	I-protein
2	I-protein
by	O
the	O
phorbol	O
ester	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O

Among	O
genes	O
that	O
respond	O
to	O
these	O
transcription	B-protein
factors	I-protein
,	O
IL-2	B-RNA
mRNA	I-RNA
induction	O
was	O
suppressed	O
by	O
PF	O
,	O
whereas	O
IL-2R	B-RNA
(	I-RNA
alpha	I-RNA
)	I-RNA
chain	I-RNA
mRNA	I-RNA
induction	O
was	O
not	O
affected	O
.	O

The	O
deranged	O
cholesterol	O
feedback	O
mechanism	O
has	O
been	O
widely	O
recognised	O
in	O
initiation	O
as	O
well	O
as	O
progression	O
of	O
various	O
types	O
of	O
cancers	O
including	O
chronic	O
myeloid	O
leukaemia	O
(	O
CML	O
)	O
.	O

These	O
events	O
are	O
accompanied	O
by	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
RAG-1	B-RNA
and	I-RNA
RAG-2	I-RNA
RNAs	I-RNA
.	O

Regulation	O
of	O
E2F	B-protein
involves	O
its	O
interactions	O
with	O
other	O
cellular	B-protein
proteins	I-protein
,	O
including	O
the	O
retinoblastoma	B-protein
protein	I-protein
(	O
Rb	B-protein
)	O
,	O
the	O
Rb-related	B-protein
protein	I-protein
p107	B-protein
,	O
cyclin	B-protein
A	I-protein
,	O
and	O
cdk2	B-protein
.	O

The	O
hormone	B-protein
receptors	I-protein
of	O
the	O
primary	O
tumor	O
were	O
known	O
in	O
15	O
(	O
ER	B-protein
)	O
and	O
14	O
(	O
PR	B-protein
)	O
patients	O
,	O
respectively	O
.	O

The	O
chimeric	B-DNA
gene	I-DNA
,	I-DNA
AML1/ETO	B-DNA
(	I-DNA
MTG8	I-DNA
)	I-DNA
,	O
generated	O
in	O
t	B-DNA
(	I-DNA
8	I-DNA
;	I-DNA
21	I-DNA
)	I-DNA
acute	O
myeloid	O
leukemia	O
enhances	O
the	O
expression	O
of	O
Bcl-2	B-protein
.	O

Despite	O
the	O
absence	O
of	O
these	O
ER	O
peptides	O
,	O
the	O
TAP1-/-	B-cell_type
cells	I-cell_type
were	O
able	O
to	O
efficiently	O
cross-prime	B-cell_type
E1A-	I-cell_type
and	I-cell_type
E1B-specific	I-cell_type
CTLs	I-cell_type
following	O
immunization	O
of	O
syngeneic	O
mice	O
.	O

The	O
reduction	O
of	O
IkappaBalpha	B-protein
by	O
DZA	O
is	O
neither	O
involved	O
in	O
IkappaB	B-protein
kinase	I-protein
complex	I-protein
activation	O
nor	O
modulated	O
by	O
the	O
addition	O
of	O
homocysteine	O
.	O

The	O
authors	O
provide	O
the	O
results	O
of	O
studying	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
calcitriol	O
)	O
in	O
lymphocytes	B-cell_type
of	O
children	O
with	O
rickets	O
and	O
rickets-like	O
diseases	O
.	O

We	O
describe	O
a	O
slide	O
assay	O
that	O
allows	O
the	O
demonstration	O
of	O
antigens	B-protein
localized	O
in	O
the	O
nucleus	O
from	O
isolated	B-cell_type
white	I-cell_type
blood	I-cell_type
cells	I-cell_type
as	O
well	O
as	O
from	O
single	B-cell_type
tumor	I-cell_type
cells	I-cell_type
derived	O
from	O
malignant	O
effusions	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
these	O
transcription	B-protein
factors	I-protein
in	O
uninduced	O
and	O
LPS-induced	O
TF	B-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
monocytic	I-cell_type
THP-1	I-cell_type
cells	I-cell_type
.	O

Tuberculosis	O
and	O
chronic	O
hepatitis	O
B	O
virus	O
infection	O
in	O
Africans	O
and	O
variation	O
in	O
the	O
vitamin	B-DNA
D	I-DNA
receptor	I-DNA
gene	I-DNA
.	O

Recently	O
,	O
we	O
and	O
others	O
have	O
shown	O
that	O
thrombopoietin	B-protein
induces	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
Jak2	B-protein
and	O
other	O
proteins	O
in	O
human	B-cell_type
platelets	I-cell_type
and	O
BaF3	B-cell_line
cells	I-cell_line
,	O
genetically	O
engineered	O
to	O
express	O
c-Mpl	B-protein
,	O
a	O
receptor	O
for	O
thrombopoietin	B-protein
.	O

These	O
results	O
suggest	O
that	O
Oct-2	B-protein
participates	O
in	O
transcriptional	O
regulation	O
during	O
T-cell	B-cell_type
activation.	O
The	O
relatively	O
delayed	O
kinetics	O
of	O
Oct-2	B-protein
induction	O
suggests	O
that	O
Oct-2	B-protein
mediates	O
the	O
changes	O
in	O
gene	O
expression	O
which	O
occur	O
many	O
hours	O
or	O
days	O
following	O
antigen	O
stimulation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Rather	O
,	O
IFN-gamma	B-protein
antagonized	O
the	O
effect	O
of	O
IL-4	B-protein
and	O
suppressed	O
the	O
DC	B-cell_type
and	O
MGC	B-cell_type
formation	O
induced	O
by	O
GM-CSF	B-protein
+	O
IL-4	B-protein
and	O
M-CSF	B-protein
+	O
IL-4	B-protein
,	O
respectively	O
.	O

Elf-1	B-protein
binds	O
exclusively	O
to	O
the	O
underphosphorylated	O
form	O
of	O
Rb	B-protein
and	O
fails	O
to	O
bind	O
to	O
Rb	B-protein
mutants	I-protein
derived	O
from	O
patients	O
with	O
retinoblastoma	O
.	O

There	O
was	O
,	O
however	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
plasma	B-protein
sialyltransferase	I-protein
:	I-protein
cortisol	O
ratio	O
in	O
the	O
depressed	O
group	O
suggesting	O
an	O
inability	O
of	O
the	O
raised	O
cortisol	O
levels	O
to	O
induce	O
enzyme	O
expression	O
and	O
this	O
ratio	O
may	O
provide	O
a	O
useful	O
biochemical	O
marker	O
of	O
cortisol	O
receptor	O
function	O
.	O

Activation	O
of	O
macrophages	B-cell_type
by	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
transcription	O
of	O
genes	O
that	O
encode	O
for	O
proinflammatory	B-protein
regulators	I-protein
of	O
the	O
immune	O
response	O
.	O

Specific	O
NF-kappa	B-protein
B	I-protein
subunits	I-protein
act	O
in	O
concert	O
with	O
Tat	B-protein
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
.	O

A	O
critical	O
role	O
of	O
the	O
p75	B-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
(	O
p75TNF-R	B-protein
)	O
in	O
organ	O
inflammation	O
independent	O
of	O
TNF	B-protein
,	O
lymphotoxin	B-protein
alpha	I-protein
,	O
or	O
the	O
p55TNF-R	B-protein
.	I-protein

Cytomegalovirus	B-DNA
immediate	I-DNA
early	I-DNA
genes	I-DNA
upregulate	O
interleukin-6	B-protein
gene	O
expression	O
.	O

Surprisingly	O
,	O
this	O
was	O
the	O
case	O
even	O
when	O
an	O
antagonistic	B-protein
anti-TR55	I-protein
antibody	I-protein
was	O
used	O
.	O

We	O
show	O
here	O
that	O
IFN-alpha/beta	B-protein
act	O
directly	O
on	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
drive	O
Th1	O
development	O
,	O
bypassing	O
the	O
need	O
for	O
IL-12	B-protein
-induced	O
signaling	O
,	O
whereas	O
IFN-alpha	B-protein
can	O
not	O
substitute	O
IL-12	B-protein
for	O
mouse	O
Th1	O
development	O
.	O

We	O
found	O
that	O
in	O
both	O
cell	O
lines	O
,	O
both	O
phorbol	O
ester	O
and	O
TNF	B-protein
alpha	I-protein
were	O
able	O
to	O
activate	O
NF-kappa	B-protein
B	I-protein
.	O

Tissue	O
factor	O
expression	O
of	O
human	B-cell_type
monocytes	I-cell_type
is	O
suppressed	O
by	O
lysophosphatidylcholine	O
.	O

The	O
B3	B-protein
factor	I-protein
was	O
only	O
slightly	O
evident	O
in	O
nuclei	O
of	O
uninfected	B-cell_type
cells	I-cell_type
but	O
was	O
readily	O
detectable	O
in	O
nuclei	O
of	O
infected	B-cell_type
monocytes	I-cell_type
.	O

The	O
importance	O
of	O
BCL2	B-protein
and	O
Stat3	B-protein
on	O
IL-6	B-protein
-induced	O
macrophage-differentiation	O
and	O
apoptosis	O
was	O
studied	O
with	O
1A9-M	B-cell_line
cells	I-cell_line
expressing	O
human	B-protein
BCL2	I-protein
or	O
a	O
dominant-negative	O
form	O
of	O
Stat3	B-protein
,	O
respectively	O
.	O

Interestingly	O
,	O
the	O
DEX-mediated	O
IkappaBalpha	B-protein
induction	O
was	O
completely	O
inhibited	O
by	O
IL-2	B-protein
,	O
but	O
not	O
IL-4	B-protein
,	O
in	O
Th1	B-cell_type
cells	I-cell_type
,	O
while	O
the	O
reverse	O
profile	O
was	O
seen	O
in	O
Th2	B-cell_type
cells	I-cell_type
.	O

However	O
,	O
with	O
reduced	O
IL-13R	B-protein
alpha1	I-protein
expression	O
and	O
low	O
nuclear	O
STAT6	B-protein
activity	O
,	O
some	O
IL-13	B-protein
-induced	O
responses	O
were	O
unaltered	O
in	O
magnitude	O
in	O
MDMac	B-cell_line
.	O

Fetal	O
murine	O
thymus	O
exhibited	O
a	O
striking	O
concordance	O
of	O
endogenous	O
c-myb	B-DNA
expression	O
with	O
that	O
of	O
mouse	B-DNA
ADA	I-DNA
and	O
human	B-DNA
ADA	I-DNA
LCR	I-DNA
-directed	O
transgene	O
expression	O
.	O

These	O
findings	O
suggest	O
that	O
a	O
novel	O
AP-2-like	B-protein
transcription	I-protein
factor	I-protein
is	O
responsible	O
for	O
V-ATPase	B-protein
B	I-protein
subunit	I-protein
amplification	O
during	O
monocyte	O
differentiation	O
.	O

But	O
many	O
puzzles	O
of	O
the	O
drugs	O
remain	O
.	O

Phosphotyrosine	O
immunoprecipitation	O
followed	O
by	O
Western	O
blot	O
analysis	O
with	O
a	O
set	O
of	O
Jak	B-protein
kinase	I-protein
specific	I-protein
antibodies	I-protein
,	O
identified	O
p130	O
as	O
Jak2	B-protein
in	O
the	O
tax	B-protein
transformed	O
mouse	B-cell_line
fibroblastic	I-cell_line
cell	I-cell_line
line	I-cell_line
and	O
Jak3	B-protein
in	O
HTLV-1	B-cell_line
transformed	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

An	O
alternatively	O
spliced	O
isoform	O
of	O
the	O
Spi-B	B-protein
transcription	B-protein
factor	I-protein
.	O

Glucocorticoid-mediated	O
inhibition	O
of	O
interleukin-2	O
receptor	O
alpha	O
and	O
-beta	O
subunit	O
expression	O
by	O
human	O
T	O
cells	O
.	O

Deletions	O
or	O
mutations	O
in	O
this	O
element	O
reduced	O
the	O
serum	O
response	O
of	O
the	O
TSP	B-DNA
1	I-DNA
gene	I-DNA
by	O
80-90	O
%	O
.	O

Thus	O
,	O
the	O
cooperation	O
of	O
two	O
general	O
cellular	O
transcription	O
factors	O
may	O
allow	O
for	O
the	O
selective	O
downregulation	O
of	O
HIV	O
transcription	O
.	O

Negative	O
selection	O
in	O
the	O
cortex	O
appears	O
to	O
be	O
a	O
suicidal	O
inversion	O
of	O
antigen	O
responsiveness	O
:	O
instead	O
of	O
turning	O
on	O
IL-2	B-protein
expression	O
,	O
the	O
activated	B-cell_type
cell	I-cell_type
destroys	O
its	O
own	O
chromatin	B-DNA
.	O

Both	O
groups	O
showed	O
substantial	O
decreases	O
in	O
mineralocorticoid	O
(	O
MR	O
)	O
and	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
levels	O
in	O
the	O
hippocampus	O
,	O
a	O
limbic	O
brain	O
structure	O
critical	O
for	O
HPA	O
axis	O
regulation	O
,	O
whereas	O
GR	B-protein
concentrations	O
in	O
the	O
hypothalamus	O
were	O
unchanged	O
and	O
in	O
anterior	O
pituitary	O
were	O
slightly	O
increased	O
.	O

The	O
STAT	B-protein
proteins	I-protein
utilized	O
by	O
IL-7	B-protein
were	O
identical	O
to	O
those	O
induced	O
by	O
IL-2	B-protein
and	O
could	O
be	O
identified	O
as	O
various	O
STAT	B-protein
5	I-protein
isoforms	I-protein
.	O

Our	O
analyses	O
show	O
that	O
several	O
Oct2	B-protein
isoforms	I-protein
can	O
stimulate	O
from	O
a	O
remote	O
position	O
but	O
that	O
this	O
stimulation	O
is	O
restricted	O
to	O
B	B-cell_type
cells	I-cell_type
.	O

We	O
further	O
demonstrate	O
that	O
M-CSF	B-protein
increases	O
c-fos	B-RNA
mRNA	I-RNA
levels	O
in	O
human	B-cell_type
monocytes	I-cell_type
through	O
control	O
at	O
both	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

When	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
progesterone	O
they	O
released	O
a	O
soluble	B-protein
factor	I-protein
that	O
inhibited	O
cellular	O
immunoreactions	O
(	O
MLR	O
,	O
CRC	O
)	O
and	O
cellular	O
proliferation	O
as	O
measured	O
by	O
thymidine	O
incorporation	O
by	O
spleen-cell	B-cell_line
culture	I-cell_line
.	O

In	O
addition	O
,	O
the	O
erythroid-specific	B-protein
transcription	I-protein
factor	I-protein
NF-E1	B-protein
was	O
shown	O
to	O
be	O
expressed	O
coordinately	O
with	O
that	O
of	O
globin	B-protein
in	O
embryoid	B-cell_type
bodies	I-cell_type
.	O

We	O
have	O
isolated	O
cDNA	B-DNA
clones	I-DNA
of	O
myeloid	B-DNA
differentiation	I-DNA
primary	I-DNA
response	I-DNA
(	I-DNA
MyD	I-DNA
)	I-DNA
genes	I-DNA
,	O
activated	O
in	O
the	O
absence	O
of	O
de	O
novo	O
protein	O
synthesis	O
following	O
induction	O
for	O
differentiation	O
along	O
either	O
the	O
macrophage	B-cell_type
or	O
granulocyte	B-cell_type
lineage	I-cell_type
in	O
human	O
myeloblastic	B-cell_line
leukemia	I-cell_line
HL-60	I-cell_line
cells	I-cell_line
.	O

These	O
findings	O
demonstrate	O
that	O
interaction	O
of	O
both	O
subunits	O
of	O
the	O
heterodimeric	B-protein
NF-kappa	I-protein
B	I-protein
complex	I-protein
with	O
DNA	O
is	O
required	O
for	O
DNA	O
binding	O
and	O
transcriptional	O
activation	O
and	O
suggest	O
that	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
individual	O
rel-related	B-protein
proteins	I-protein
will	O
differ	O
dramatically	O
,	O
depending	O
on	O
the	O
specific	O
kappa	O
B	O
motifs	O
present	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
IKK	B-protein
complex	I-protein
,	O
but	O
not	O
p90	B-protein
(	I-protein
rsk	I-protein
)	I-protein
,	O
is	O
responsible	O
for	O
the	O
in	O
vivo	O
phosphorylation	O
of	O
IkappaBalpha	B-protein
mediated	O
by	O
the	O
co-activation	O
of	O
PKC	B-protein
and	O
calcineurin	B-protein
.	O

Stimulation	O
of	O
mouse	B-cell_type
B	I-cell_type
cells	I-cell_type
with	O
anti-IgM	B-protein
or	I-protein
IgD	I-protein
antibodies	I-protein
,	O
bacterial	O
lipopolysaccharide	O
,	O
phorbol	O
12-myristate	O
13-acetate	O
plus	O
ionomycin	O
,	O
or	O
CD40	B-protein
ligand	I-protein
led	O
to	O
a	O
five-fold	O
to	O
35-fold	O
decrease	O
in	O
BCL-6	B-RNA
mRNA	I-RNA
levels	O
.	O

CD40	B-protein
activation	O
of	O
B	B-cell_type
cells	I-cell_type
is	O
strongly	O
influenced	O
by	O
the	O
presence	O
of	O
cytokines	B-protein
.	O

Using	O
antibodies	O
in	O
an	O
electrophoretic	O
mobility	O
supershift	O
assay	O
,	O
one	O
of	O
these	O
complexes	O
was	O
shown	O
to	O
contain	O
NF-kappa	B-protein
B1	I-protein
and	O
RelA	B-protein
,	O
and	O
to	O
bind	O
with	O
higher	O
affinity	O
to	O
the	O
consensus	B-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
in	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O

Immunosuppressant	O
PG490	O
(	O
triptolide	O
)	O
inhibits	O
T-cell	B-protein
interleukin-2	I-protein
expression	O
at	O
the	O
level	O
of	O
purine-box/nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
T-cells	I-cell_type
and	O
NF-kappaB	B-protein
transcriptional	O
activation	O
.	O

Therefore	O
,	O
as	O
T	B-cell_type
cells	I-cell_type
progress	O
from	O
primary	O
TCR	B-protein
activation	O
through	O
IL-2	B-protein
-dependent	O
proliferation	O
,	O
followed	O
by	O
secondary	O
TCR	B-protein
stimulation	O
,	O
their	O
responsiveness	O
to	O
IFN-gamma	B-protein
varies	O
,	O
and	O
this	O
may	O
affect	O
their	O
ability	O
to	O
participate	O
in	O
an	O
ongoing	O
immune	O
response	O
.	O

Such	O
compounds	O
have	O
been	O
shown	O
to	O
favor	O
IgE	B-protein
production	O
,	O
bronchial	O
hyperresponsiveness	O
,	O
and	O
airway	O
inflammation	O
.	O

The	O
expression	O
of	O
genes	O
for	O
transcription	B-protein
factors	I-protein
involved	O
in	O
myeloid	O
differentiation	O
was	O
evaluated	O
by	O
Northern	O
blot	O
analysis	O
.	O

Here	O
we	O
demonstrate	O
that	O
AML1a	B-protein
,	O
which	O
solely	O
has	O
no	O
effects	O
as	O
a	O
transcriptional	O
regulator	O
,	O
dominantly	O
suppresses	O
transcriptional	O
activation	O
by	O
AML1b	B-protein
,	O
and	O
that	O
AML1a	B-protein
exhibits	O
the	O
higher	O
affinity	O
for	O
DNA-binding	O
than	O
AML1b	B-protein
.	O

Danazol	O
bound	O
to	O
these	O
sites	O
in	O
high	O
concentration	O
(	O
10	O
(	O
-6	O
)	O
M	O
,	O
clinical	O
serum	O
concentration	O
during	O
danazol	O
therapy	O
)	O
and	O
decreased	O
the	O
number	O
of	O
both	O
sites	O
.	O

The	O
gp160-mediated	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
CD4	B-cell_type
positive	I-cell_type
T	I-cell_type
cells	I-cell_type
may	O
be	O
involved	O
in	O
biological	O
effects	O
,	O
e.g.	O
,	O
enhanced	O
HIV	O
replication	O
,	O
hypergammaglobulinemia	O
,	O
increased	O
cytokine	B-protein
secretion	O
,	O
hypercellularity	O
in	O
bone	O
marrow	O
and	O
apoptosis	O
.	O

Our	O
results	O
suggest	O
that	O
activation	O
of	O
NF-kappaB	B-protein
occurs	O
through	O
a	O
Tax	B-protein
-independent	O
mechanism	O
in	O
leukemic	B-cell_type
cells	I-cell_type
of	O
ATL	O
patients	O
,	O
possibly	O
due	O
to	O
differential	O
NF-kappaB	B-protein
subunit	O
activation	O
.	O

Proliferation	O
in	O
response	O
to	O
TG	B-protein
was	O
observed	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
only	O
1	O
of	O
5	O
Hashimoto	O
patients	O
.	O

Autocrine	O
role	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
.	O

An	O
increased	O
growth	O
rate	O
of	O
these	O
Jurkat-tat	B-cell_line
cell	I-cell_line
lines	I-cell_line
as	O
compared	O
with	O
control	B-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
observed	O
.	O

CONCLUSIONS	O
:	O
Although	O
binding	B-protein
motifs	I-protein
and	O
actual	O
HLA	O
binding	O
can	O
be	O
detected	O
in	O
several	O
cases	O
,	O
the	O
generation	O
of	O
a	O
cellular	O
response	O
is	O
infrequent	O
,	O
confirming	O
that	O
HLA	O
binding	O
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
obtain	O
an	O
in	O
vitro	O
response	O
.	O

Treatment	O
of	O
PAEC	B-cell_line
exposed	O
to	O
xenogeneic	O
serum	O
with	O
the	O
NF-kappa	B-protein
B	I-protein
inhibitors	O
pyrrolidinedithiocarbamate	O
(	O
PDTC	O
,	O
25	O
microM	O
)	O
and	O
tosyl-phechloromethylketone	O
(	O
TPCK	O
,	O
25	O
microM	O
)	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
reduced	O
leukocyte	O
adhesion	O
in	O
respect	O
to	O
PAEC	B-cell_line
treated	O
with	O
human	O
serum	O
alone	O
.	O

bcl-2	B-protein
expression	O
is	O
increased	O
following	O
phorbol	O
ester	O
treatment	O
,	O
and	O
the	O
increased	O
expression	O
is	O
dependent	O
on	O
the	O
CRE	B-DNA
site	I-DNA
.	O

NF-kappaB	B-protein
activation	O
was	O
very	O
effective	O
when	O
cells	O
were	O
subjected	O
to	O
hyperthermia	O
before	O
being	O
treated	O
with	O
HOCl	O
.	O

CONCLUSION	O
:	O
Monocytes	B-cell_type
,	O
T	B-cell_type
cells	I-cell_type
,	O
and	O
B	B-cell_type
cells	I-cell_type
in	O
patients	O
express	O
transcripts	O
of	O
the	O
normal	O
wild	B-protein
type	I-protein
ER	I-protein
and	O
the	O
hormone	B-protein
binding	I-protein
domain	I-protein
variants	I-protein
in	O
vivo	O
.	O

Most	O
of	O
the	O
AP-1	B-protein
activity	O
could	O
be	O
eliminated	O
when	O
the	O
anti-AIM	B-protein
mAb	I-protein
was	O
added	O
to	O
the	O
culture	O
medium	O
in	O
the	O
presence	O
of	O
cycloheximide	O
,	O
suggesting	O
that	O
de	O
novo	O
protein	O
synthesis	O
is	O
crucial	O
for	O
the	O
induction	O
of	O
AP-1	B-protein
-binding	O
activity	O
.	O

In	O
contrast	O
,	O
CAT	B-DNA
gene	I-DNA
expression	O
directed	O
by	O
a	O
multimer	O
of	O
the	O
OCT-1	B-DNA
proximal	I-DNA
(	I-DNA
OCT-1p	I-DNA
)	I-DNA
-binding	I-DNA
site	I-DNA
was	O
equivalent	O
in	O
patient	O
and	O
controls	O
.	O

Briefly	O
,	O
we	O
found	O
that	O
1	O
)	O
rheumatoid	B-cell_type
synovial	I-cell_type
cells	I-cell_type
highly	O
expressed	O
CD44	B-protein
;	O
2	O
)	O
cross-linking	O
of	O
CD44	B-protein
markedly	O
but	O
transiently	O
augmented	O
VCAM-1	B-protein
expression	O
and	O
its	O
mRNA	O
transcription	O
much	O
more	O
than	O
did	O
IL-1beta	B-protein
and	O
TNF-alpha	O
;	O
3	O
)	O
hyaluronan	O
,	O
especially	O
when	O
fragmented	O
,	O
also	O
up-regulated	O
VCAM-1	B-protein
;	O
4	O
)	O
CD44	B-protein
activated	O
the	O
transcription	O
factor	O
AP-1	O
;	O
and	O
5	O
)	O
the	O
integrin	B-protein
-dependent	O
adhesive	O
function	O
of	O
RA	B-cell_type
synovial	I-cell_type
cells	I-cell_type
to	O
T	B-cell_type
cells	I-cell_type
was	O
also	O
amplified	O
by	O
CD44	B-protein
cross-linking	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
IFNs	B-protein
mediate	O
this	O
inhibition	O
has	O
not	O
been	O
defined	O
.	O

By	O
using	O
Jurkat	B-cell_line
and	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
we	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	O
of	O
two	O
second	O
messengers	O
of	O
the	O
TCR	B-protein
-initiated	O
signal	O
transduction	O
,	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
and	O
calcineurin	B-protein
,	O
results	O
in	O
the	O
synergistic	O
activation	O
of	O
the	O
IkappaBalpha	B-protein
kinase	I-protein
(	I-protein
IKK	I-protein
)	I-protein
complex	I-protein
but	O
not	O
of	O
another	O
putative	B-protein
IkappaBalpha	I-protein
kinase	I-protein
,	O
p90	B-protein
(	I-protein
rsk	I-protein
)	I-protein
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
evolutionarily	O
conserved	O
physical	O
interactions	O
between	O
Ets	B-protein
and	I-protein
NF-kappaB/NFAT	I-protein
proteins	I-protein
are	O
important	O
in	O
regulating	O
the	O
inducible	O
expression	O
of	O
T-cell	B-DNA
genes	I-DNA
and	O
viruses	O
.	O

T	O
cell	O
activation	O
and	O
ensuing	O
cellular	O
gene	O
activation	O
can	O
be	O
critical	O
for	O
HIV-1	O
replication	O
.	O

In	O
Jurkat	B-cell_line
cells	I-cell_line
this	O
effect	O
was	O
rapid	O
and	O
transient	O
,	O
but	O
in	O
Wurzburg	B-cell_line
cells	I-cell_line
the	O
response	O
was	O
slow	O
and	O
sustained	O
.	O

The	O
MHC	B-protein
class	I-protein
II	I-protein
transactivator	I-protein
(	O
CIITA	B-protein
)	O
requires	O
conserved	O
leucine	B-protein
charged	I-protein
domains	I-protein
for	O
interactions	O
with	O
the	O
conserved	O
W	B-DNA
box	I-DNA
promoter	I-DNA
element	I-DNA
.	O

Thus	O
,	O
type	O
2	O
effector	O
function	O
was	O
augmented	O
by	O
IL-4	B-protein
signals	O
transduced	O
through	O
a	O
chimeric	B-protein
receptor	I-protein
expressed	O
in	O
a	O
T	O
cell-specific	O
manner	O
.	O

Endothelial	O
cell	O
activation	O
and	O
leukocyte	O
infiltration	O
are	O
a	O
consistent	O
feature	O
of	O
discordant	O
xenograft	O
rejection	O
.	O

The	O
results	O
provide	O
a	O
distinct	O
and	O
more	O
specific	O
mechanism	O
for	O
E1A	B-protein
-mediated	O
immune	O
suppression	O
and	O
an	O
alternative	O
model	O
of	O
IFNgamma	B-protein
-driven	O
enhanceosome	O
formation	O
that	O
may	O
allow	O
for	O
other	O
adaptors	O
(	O
in	O
addition	O
to	O
p300/CBP	B-protein
)	O
to	O
link	O
Stat1	B-protein
to	O
the	O
basal	B-protein
transcription	I-protein
complex	I-protein
.	O

The	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
HIV-1-LTR	B-DNA
,	O
contains	O
binding	O
sites	O
for	O
several	O
cellular	O
transcription	O
factors	O
which	O
contribute	O
to	O
HIV-1	B-DNA
gene	I-DNA
expression	O
.	O

The	O
effects	O
of	O
these	O
substitutions	O
on	O
viral	O
replication	O
in	O
transfected	O
HeLa	B-cell_line
cells	I-cell_line
and	O
on	O
HIV	O
infection	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
or	O
continuous	B-cell_line
T-leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
evaluated	O
.	O

The	O
efficacy	O
of	O
the	O
activated	B-cell_type
LN	I-cell_type
cells	I-cell_type
is	O
augmented	O
when	O
the	O
sensitizing	O
tumor	O
is	O
a	O
genetically	B-cell_line
modified	I-cell_line
variant	I-cell_line
(	O
designated	O
D5G6	B-cell_line
)	O
that	O
secretes	O
granulocyte/macrophage-colony-stimulating	B-protein
factor	I-protein
.	O

RESULTS	O
:	O
No	O
significant	O
partial	O
correlations	O
of	O
the	O
number	O
of	O
the	O
peripheral	B-protein
blood	I-protein
mononuclear	I-protein
cell	I-protein
glucocorticoid	I-protein
receptors	I-protein
(	O
6821	O
+/-	O
5669	O
binding	O
sites	O
per	O
cell	O
)	O
and	O
the	O
affinity	O
(	O
Kd	O
:	O
16.5	O
+/-	O
13.51	O
nmol/L	O
)	O
for	O
the	O
glucocorticoid	B-protein
receptors	I-protein
with	O
the	O
symptom	O
score	O
(	O
placebo	O
:	O
4.3	O
+/-	O
2.45	O
pts	O
;	O
fluticasone	O
:	O
2.4	O
+/-	O
1.55	O
pts	O
)	O
after	O
active	O
treatment	O
were	O
found	O
.	O

Constitutive	O
nuclear	O
appearance	O
was	O
also	O
observed	O
for	O
NF-kB2/p52	O
.	O

The	O
PML	B-protein
gene	I-protein
product	I-protein
has	O
been	O
localized	O
to	O
subnuclear	B-cell_line
dot-like	I-cell_line
structures	I-cell_line
variously	O
termed	O
PODs	O
,	O
ND10s	O
,	O
Kr	O
bodies	O
,	O
or	O
PML	O
nuclear	O
bodies	O
(	O
PML	O
NBs	O
)	O
.	O

However	O
,	O
retroviral	O
transduction	O
of	O
GATA-3	B-protein
into	O
developing	B-cell_type
T	I-cell_type
cells	I-cell_type
induced	O
IL-5	B-protein
to	O
full	O
Th2	B-protein
levels	O
,	O
but	O
only	O
partially	O
restored	O
IL-4	B-protein
production	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
a	O
cDNA	B-DNA
,	O
CHEMR1	B-DNA
,	O
encoding	O
a	O
chemokine	B-protein
receptor	I-protein
with	O
a	O
homology	O
to	O
the	O
human	B-protein
C-C	I-protein
chemokine	I-protein
receptor	I-protein
,	O
CCR-4	B-protein
.	O

However	O
,	O
reintroduction	O
of	O
a	O
functional	O
5-LOX	B-protein
system	O
in	O
these	O
cells	O
allowed	O
ROI	O
production	O
and	O
5-LOX	B-protein
-dependent	O
NF-kappaB	B-protein
activation	O
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
,	O
an	O
oncogenic	O
human	O
herpesvirus	O
,	O
binds	O
to	O
and	O
infects	O
normal	B-cell_type
human	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
via	O
CD21	B-protein
,	O
the	O
CR2	B-protein
complement	I-protein
receptor	I-protein
.	O

All-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
induces	O
differentiation	O
of	O
HL60	B-cell_line
cells	I-cell_line
to	O
neutrophils	B-cell_type
and	O
is	O
used	O
to	O
treat	O
acute	O
promyelocytic	O
leukemia	O
.	O

The	O
role	O
of	O
Stat4	B-protein
in	O
species-specific	O
regulation	O
of	O
Th	O
cell	O
development	O
by	O
type	B-protein
I	I-protein
IFNs	I-protein
.	O

Furthermore	O
,	O
in	O
the	O
absence	O
of	O
exogenous	O
HGFs	B-protein
,	O
FL	B-cell_type
monocytic	I-cell_type
progenitors	I-cell_type
(	O
colony-forming	B-cell_type
unit	I-cell_type
monocyte	I-cell_type
[	O
CFU-M	B-cell_type
]	O
)	O
generate	O
large	O
colonies	O
exclusively	O
composed	O
of	O
monocytes-macrophages	O
;	O
these	O
colonies	O
are	O
absent	O
in	O
FCS-	O
clonogenic	O
culture	O
.	O

Yet	O
,	O
for	O
many	O
pathogens	O
,	O
the	O
molecules	O
that	O
induce	O
IL-12	B-protein
production	O
by	O
macrophages	B-cell_type
and	O
the	O
mechanisms	O
by	O
which	O
they	O
do	O
so	O
remain	O
undefined	O
.	O

ngal	O
gene	O
expression	O
was	O
found	O
at	O
moderate	O
levels	O
in	O
only	O
2	O
of	O
17	O
human	O
tissues	O
examined	O
,	O
breast	O
and	O
lung	O
.	O

We	O
show	O
that	O
the	O
BR3	B-DNA
sequence	O
contains	O
a	O
novel	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
located	O
at	O
positions	O
-90	O
to	O
-79	O
of	O
the	O
hIL-5	B-DNA
promoter	I-DNA
,	O
which	O
binds	O
Oct1	B-protein
,	O
octamer-like	B-protein
,	O
and	O
YY1	B-protein
nuclear	I-protein
factors	I-protein
.	O

Binding	O
experiments	O
,	O
using	O
COS-7	B-cell_line
cells	I-cell_line
transiently	O
transfected	O
with	O
PML-RAR	B-protein
and	O
the	O
normal	O
RAR	B-protein
alpha	I-protein
,	O
show	O
that	O
AM580	O
has	O
a	O
lower	O
affinity	O
than	O
ATRA	O
for	O
both	O
receptors	O
.	O

These	O
results	O
suggest	O
that	O
OTF-1	B-protein
,	O
without	O
OTF-2	B-protein
,	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
and	O
that	O
OTF-2	B-protein
alone	O
is	O
not	O
responsible	O
for	O
the	O
B-cell-specific	O
regulation	O
of	O
immunoglobulin	B-DNA
gene	I-DNA
expression	O
.	O

During	O
inflammatory	O
reactions	O
,	O
many	O
oxidative	O
species	O
are	O
produced	O
,	O
one	O
of	O
which	O
is	O
hypochlorous	O
acid	O
(	O
HOCl	O
)	O
,	O
which	O
is	O
responsible	O
for	O
the	O
microbicidal	O
effects	O
of	O
activated	O
human	B-cell_type
polymorphonuclear	I-cell_type
leukocytes	I-cell_type
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
presence	O
of	O
estrogen	O
type	O
I	O
(	O
high	O
affinity	O
,	O
low	O
capacity	O
)	O
and	O
type	O
II	O
(	O
low	O
affinity	O
,	O
high	O
capacity	O
)	O
binding	O
sites	O
in	O
human	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
the	O
effects	O
of	O
danazol	O
on	O
these	O
sites	O
.	O

Here	O
we	O
show	O
that	O
priming	O
of	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
selectively	O
enhances	O
IL-4	B-protein
expression	O
relative	O
to	O
IL-2	B-protein
expression	O
by	O
a	O
transcriptional	O
mechanism	O
involving	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	I-protein
NFAT	I-protein
)	I-protein
proteins	I-protein
.	O

The	O
distal	O
element	O
contains	O
the	O
5'-CC	O
(	O
A	O
+	O
T	O
)	O
6GG-3	O
'	O
consensus	O
sequence	O
characteristic	O
of	O
a	O
serum-response	O
element	O
(	O
SRE	O
)	O
.	O

Mutations	O
at	O
the	O
B2	B-DNA
site	O
abolish	O
this	O
transcriptional	O
activation	O
.	O

In	O
exerting	O
their	O
antiproliferative	O
effects	O
,	O
GCS	O
diffuse	O
into	O
target	B-cell_type
cells	I-cell_type
where	O
they	O
bind	O
their	O
cytoplasmic	B-protein
receptor	I-protein
,	O
which	O
in	O
turn	O
translocates	O
to	O
the	O
nucleus	O
where	O
it	O
inhibits	O
transcription	O
of	O
cytokine	B-DNA
genes	I-DNA
through	O
direct	O
binding	O
to	O
the	O
glucocorticoid	B-DNA
response	I-DNA
elements	I-DNA
(	O
GRE	B-DNA
)	O
,	O
which	O
are	O
located	O
in	O
the	O
promoter	O
region	O
of	O
cytokine	B-DNA
genes	I-DNA
or	O
,	O
alternatively	O
,	O
through	O
antagonism	O
of	O
the	O
action	O
of	O
transcription	B-protein
factors	I-protein
required	O
for	O
optimal	O
transcriptional	O
activation	O
.	O

The	O
myb	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
has	O
been	O
strongly	O
implicated	O
in	O
the	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
in	O
the	O
haematopoietic	O
system	O
.	O

Oligonucleotide	O
primers	O
based	O
on	O
the	O
murine	B-DNA
sequence	I-DNA
were	O
used	O
to	O
construct	O
a	O
quantitative	O
reverse	O
transcription-PCR	O
assay	O
for	O
gene	O
expression	O
.	O

In	O
addition	O
,	O
we	O
identify	O
a	O
major	O
PB1	B-protein
nuclear	I-protein
protein-binding	I-protein
complex	I-protein
that	O
is	O
not	O
present	O
in	O
resting	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
but	O
is	O
rapidly	O
induced	O
following	O
T-cell	O
activation	O
.	O

In	O
addition	O
,	O
ADP-activated	B-cell_type
platelets	I-cell_type
induced	O
MCP-1	O
and	O
ICAM-1	O
promoter-dependent	O
transcription	O
.	O

Human	O
herpesvirus	O
6	O
,	O
a	O
predominantly	O
T	O
lymphotropic	O
virus	O
,	O
has	O
been	O
recently	O
shown	O
to	O
infect	O
some	O
EBV-positive	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
to	O
induce	O
in	O
them	O
the	O
activation	O
of	O
the	O
EBV	O
lytic	O
cycle	O
.	O

These	O
results	O
indicate	O
that	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
,	O
including	O
the	O
phosphatase	B-protein
calcineurin	B-protein
,	O
participate	O
in	O
the	O
regulation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
a	O
cell	O
specific	O
fashion	O
and	O
synergize	O
with	O
PKC	B-protein
-dependent	O
and	O
-independent	O
pathways	O
at	O
the	O
level	O
of	O
IkB	B-protein
alpha	I-protein
phosphorylation	O
and	O
degradation	O
.	O

Expression	O
of	O
PILOT	B-protein
,	O
a	O
putative	O
transcription	B-protein
factor	I-protein
,	O
requires	O
two	O
signals	O
and	O
is	O
cyclosporin	O
A	O
sensitive	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
ZAP-70	B-protein
mutant	O
studied	O
here	O
could	O
be	O
phosphorylated	O
on	O
tyrosine	O
when	O
associated	O
to	O
the	O
TCR	B-protein
zeta	I-protein
chain	I-protein
and	O
was	O
able	O
to	O
bind	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
.	O

Activation	O
of	O
PKC	B-protein
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
certain	O
immediate	B-DNA
early	I-DNA
response	I-DNA
genes	I-DNA
,	O
and	O
in	O
the	O
present	O
studies	O
,	O
TPA	O
rapidly	O
induced	O
c-fos	B-DNA
and	O
c-jun	B-DNA
gene	I-DNA
expression	I-DNA
.	O

No	O
significant	O
difference	O
was	O
detected	O
in	O
the	O
activation	O
of	O
MAPK	B-protein
kinase-1	I-protein
that	O
is	O
induced	O
by	O
bufalin	O
in	O
wild-type	O
or	O
Bcl-2-overexpressed	B-cell_type
U937	I-cell_type
cells	I-cell_type
;	O
however	O
,	O
the	O
activation	O
of	O
MAPK	B-protein
by	O
bufalin	O
was	O
significantly	O
attenuated	O
in	O
the	O
cells	O
overexpressing	O
Bcl-2	B-protein
.	O

It	O
also	O
bound	O
to	O
the	O
purine-rich	B-DNA
CD3R	I-DNA
element	I-DNA
from	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
2	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
which	O
is	O
required	O
for	O
inducible	O
virus	O
expression	O
in	O
response	O
to	O
signalling	O
through	O
the	O
T-cell	B-protein
receptor	I-protein
.	O

This	O
identification	O
,	O
initially	O
made	O
by	O
microsequence	O
analysis	O
,	O
was	O
verified	O
by	O
showing	O
that	O
(	O
i	O
)	O
LR1	B-protein
-DNA	O
binding	O
activity	O
increased	O
in	O
B	B-cell_type
cells	I-cell_type
transfected	O
with	O
a	O
nucleolin	B-DNA
cDNA	I-DNA
expression	I-DNA
construct	I-DNA
;	O
(	O
ii	O
)	O
LR1	B-protein
-DNA	O
binding	O
activity	O
was	O
recognized	O
by	O
antibodies	O
raised	O
against	O
recombinant	B-protein
human	I-protein
nucleolin	I-protein
;	O
and	O
(	O
iii	O
)	O
in	O
B	B-cell_type
cells	I-cell_type
transfected	O
with	O
epitope-tagged	B-DNA
nucleolin	I-DNA
expression	I-DNA
constructs	I-DNA
,	O
the	O
LR1-DNA	B-protein
complex	I-protein
was	O
recognized	O
by	O
the	O
anti-tag	B-protein
antibody	I-protein
.	O

The	O
partial	B-DNA
cDNA	I-DNA
encodes	O
a	O
protein	O
which	O
is	O
homologous	O
to	O
the	O
C-terminal	B-protein
196	I-protein
amino	I-protein
acids	I-protein
of	O
the	O
36-kDa	B-protein
transcription	I-protein
factor	I-protein
,	O
YB-1	B-protein
.	O

Analysis	O
of	O
the	O
binding	O
proteins	O
employing	O
the	O
-605	O
motif	O
of	O
the	O
human	B-DNA
TNF	I-DNA
promoter	I-DNA
(	O
GGGGCTGTCCC	O
)	O
revealed	O
that	O
in	O
tolerant	O
cells	O
of	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
there	O
is	O
a	O
predominance	O
of	O
p50p50	B-protein
of	O
NF-kappa	B-protein
B	I-protein
.	O

The	O
current	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
underlying	O
immunosenescence	O
is	O
still	O
fragmentary	O
.	O

STAT5-	B-protein
and	I-protein
STAT1-related	I-protein
factors	I-protein
were	O
detected	O
in	O
ALL	O
and	O
STAT1-	B-protein
,	I-protein
STAT3-	I-protein
,	I-protein
and	I-protein
STAT5-related	I-protein
proteins	I-protein
were	O
present	O
in	O
nuclear	O
cell	O
extracts	O
from	O
AML	O
.	O

The	O
results	O
showed	O
that	O
in	O
hyper-	O
and	O
hypothyroid	O
patients	O
the	O
nuclear	O
affinity	O
(	O
Ka	O
)	O
for	O
T3	O
was	O
similar	O
to	O
that	O
of	O
normal	O
subjects	O
.	O

Proliferative	O
and	O
secretory	O
responses	O
in	O
androgen-sensitive	B-cell_type
prostate	I-cell_type
cancer	I-cell_type
LNCaP	I-cell_type
cells	I-cell_type
are	O
regulated	O
by	O
steroid	O
and	O
peptide	O
hormones	O
and	O
by	O
differentiation-promoting	O
substances	O
.	O

Expression	O
of	O
either	O
the	O
TCL1	B-DNA
oncogene	I-DNA
,	O
or	O
transcripts	O
from	O
its	O
homologue	O
MTCP1/c6.1B	B-DNA
,	O
in	O
leukaemic	O
and	O
non-leukaemic	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
ataxia	O
telangiectasia	O
patients	O
.	O

The	O
microA	B-DNA
motif	O
was	O
required	O
for	O
microB-dependent	B-DNA
enhancer	I-DNA
activity	O
,	O
which	O
suggests	O
that	O
a	O
minimal	B-DNA
B	I-DNA
cell-specific	I-DNA
enhancer	I-DNA
is	O
composed	O
of	O
both	O
the	O
PU.1	B-DNA
and	I-DNA
Ets-1	I-DNA
binding	I-DNA
sites	I-DNA
.	O

Expression	O
of	O
Spi-1	B-protein
in	O
these	O
cells	O
inhibited	O
this	O
ability	O
to	O
differentiate	O
and	O
rescued	O
the	O
cells	O
from	O
the	O
apoptotic	O
cell	O
death	O
program	O
normally	O
induced	O
upon	O
hEpo	B-protein
withdrawal	O
.	O

Cyclic	O
AMP	O
-responsive	B-DNA
element	I-DNA
-dependent	O
activation	O
of	O
Epstein-Barr	O
virus	O
zebra	B-DNA
promoter	I-DNA
by	O
human	O
herpesvirus	O
6	O
.	O

An	O
understanding	O
of	O
these	O
molecules	O
may	O
be	O
informative	O
about	O
negative	O
regulatory	O
circuits	O
that	O
can	O
potentially	O
limit	O
blood	O
cell	O
formation	O
.	O

The	O
half-life	O
of	O
c-jun	B-RNA
mRNA	I-RNA
was	O
similar	O
(	O
45-50	O
min	O
)	O
in	O
both	O
untreated	O
and	O
okadaic	B-cell_line
acid-induced	I-cell_line
cells	I-cell_line
.	O

Both	O
stimuli	O
induced	O
the	O
appearance	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
components	I-protein
(	O
c-Rel	B-protein
,	O
p65	B-protein
(	O
RelA	B-protein
)	O
,	O
and	O
p50	B-protein
(	O
NF-kappa	B-protein
B1	I-protein
)	O
)	O
and	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
activity	O
in	O
the	O
nucleus	O
.	O

UV-induced	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
blocked	O
by	O
CD3	B-protein
depletion	O
,	O
indicating	O
the	O
importance	O
of	O
such	O
cell	B-protein
surface	I-protein
molecules	I-protein
in	O
biological	O
responses	O
to	O
UV	O
.	O

In	O
contrast	O
,	O
the	O
cytoplasmic	O
levels	O
of	O
c-Rel	B-protein
and	O
Rel	B-protein
A	I-protein
were	O
normal	O
in	O
freshly	O
isolated	O
tumor-draining	O
LN	O
,	O
as	O
was	O
nuclear	O
kappaB	B-protein
DNA-binding	O
activity	O
induced	O
by	O
anti-CD3	B-protein
mAb	I-protein
or	O
phorbol	O
myristate	O
acetate	O
.	O

The	O
results	O
suggest	O
that	O
there	O
exists	O
a	O
functional	O
antagonism	O
between	O
VitD3	O
and	O
RA	O
that	O
may	O
have	O
important	O
implications	O
for	O
the	O
regulation	O
of	O
certain	O
immune	O
and	O
inflammatory	O
responses	O
through	O
their	O
inverse	O
effects	O
on	O
CD14	O
and	O
CD23	O
gene	O
expression	O
.	O

This	O
factor	O
consists	O
of	O
two	O
DNA-binding	B-protein
subunits	I-protein
of	O
relative	O
molecular	O
mass	O
50	O
,	O
000	O
(	O
50K	O
)	O
associated	O
with	O
two	O
65K	B-protein
subunits	I-protein
.	O

To	O
determine	O
whether	O
the	O
defect	O
in	O
the	O
patient	O
's	O
T	B-cell_type
lymphocytes	I-cell_type
involved	O
a	O
trans-acting	B-protein
factor	I-protein
common	O
to	O
the	O
affected	O
lymphokine	B-DNA
genes	I-DNA
,	O
we	O
examined	O
the	O
ability	O
of	O
nuclear	B-protein
factors	I-protein
from	O
the	O
patient	O
's	O
T	B-cell_type
lymphocytes	I-cell_type
to	O
bind	O
response	O
elements	O
present	O
in	O
the	O
regulatory	B-DNA
region	I-DNA
of	O
IL2	B-DNA
.	O

A	O
skewed	O
XCI	O
pattern	O
with	O
greater	O
than	O
75	O
%	O
amplification	O
of	O
1	O
allele	B-DNA
(	O
allele	B-DNA
ratio	O
>	O
3	O
:	O
1	O
)	O
was	O
found	O
in	O
22	O
(	O
9.1	O
%	O
)	O
of	O
242	O
control	O
subjects	O
.	O

Since	O
the	O
cells	O
were	O
not	O
treated	O
with	O
cytokines	B-protein
before	O
the	O
nuclear	B-protein
proteins	I-protein
were	O
extracted	O
,	O
we	O
conclude	O
that	O
these	O
factors	O
are	O
constitutively	O
activated	O
in	O
vivo	O
.	O

However	O
,	O
in	O
the	O
absence	O
of	O
tyrosine	B-protein
kinase	I-protein
activity	O
,	O
the	O
ability	O
of	O
NFkappaB	B-protein
to	O
stimulate	O
transcription	O
is	O
impaired	O
.	O

Functional	O
analysis	O
of	O
5	B-DNA
'	I-DNA
deletion	I-DNA
constructs	I-DNA
in	O
transfected	O
K562	B-cell_line
cells	I-cell_line
and	O
gel	O
mobility	O
shift	O
localized	O
the	O
major	O
phorbol	O
ester-responsive	O
motifs	O
in	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
promoter	O
to	O
a	O
cluster	O
of	O
activator	B-DNA
protein-2	I-DNA
(	I-DNA
AP-2	I-DNA
)	I-DNA
binding	I-DNA
consensus	I-DNA
sites	I-DNA
located	O
approximately	O
1.8	O
kb	O
5	O
'	O
from	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
.	O

Transcriptional	O
regulation	O
during	O
T-cell	B-cell_type
development	O
:	O
the	O
alpha	B-DNA
TCR	I-DNA
gene	I-DNA
as	O
a	O
molecular	O
model	O
.	O

A	O
transcription	O
start	O
site	O
is	O
located	O
approximately	O
4	O
kilobases	O
5	O
'	O
to	O
the	O
translation	B-DNA
initiation	I-DNA
codon	I-DNA
,	O
and	O
an	O
RNA	O
splice	O
of	O
3863	O
bases	O
occurs	O
in	O
the	O
5'-untranslated	B-DNA
region	I-DNA
to	O
generate	O
mature	B-RNA
HeLa	I-RNA
cell	I-RNA
mRNA	I-RNA
.	O

We	O
have	O
investigated	O
whether	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
and	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
these	O
two	O
pathways	O
lead	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Genetic	O
variation	O
in	O
cytokine	B-DNA
promoter	I-DNA
regions	I-DNA
is	O
postulated	O
to	O
influence	O
susceptibility	O
to	O
infection	O
,	O
but	O
the	O
molecular	O
mechanisms	O
by	O
which	O
such	O
polymorphisms	O
might	O
affect	O
gene	O
regulation	O
are	O
unknown	O
.	O

This	O
injury	O
was	O
significantly	O
inhibited	O
by	O
intravenous	O
pretreatment	O
of	O
the	O
mice	O
with	O
a	O
water-soluble	O
emulsion	O
of	O
alpha-tocopherol	O
.	O

After	O
20	O
h	O
of	O
stimulation	O
with	O
8-bromo-cAMP	O
,	O
AR	B-RNA
mRNA	I-RNA
was	O
upregulated	O
in	O
LNCaP	B-cell_line
but	O
not	O
in	O
either	O
PC-3	B-cell_line
or	O
DU-145	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Jun	B-protein
kinase	I-protein
then	O
facilitates	O
the	O
binding	O
of	O
c-Jun/c-Fos	B-protein
heterodimers	I-protein
to	O
the	O
AP-1	B-DNA
consensus	I-DNA
site	I-DNA
and	O
the	O
subsequent	O
transcriptional	O
activity	O
of	O
the	O
interleukin-2	B-DNA
promoter	I-DNA
.	O

This	O
event	O
is	O
probably	O
mediated	O
by	O
V-	O
(	O
D	O
)	O
-J	O
recombinase	O
activity	O
,	O
although	O
neither	O
locus	O
is	O
an	O
immunoglobulin	B-protein
or	O
a	O
T	B-protein
cell	I-protein
receptor	I-protein
.	O

A	O
nucleotide	O
substitution	O
within	O
a	O
recently	O
described	O
OAP40	B-DNA
element	I-DNA
located	O
just	O
upstream	O
of	O
an	O
NF-AT	B-DNA
site	I-DNA
(	O
P	B-DNA
sequence	I-DNA
)	O
appears	O
to	O
be	O
largely	O
responsible	O
for	O
the	O
increased	O
promotor	O
strength	O
of	O
this	O
particular	O
allelic	O
form	O
of	O
the	O
IL-4	B-DNA
promoter	I-DNA
.	O

Interaction	O
between	O
PU.1	B-protein
and	O
GATA-1	B-protein
requires	O
intact	O
DNA-binding	B-protein
domains	I-protein
in	O
both	O
proteins	O
.	O

Using	O
retinoids	O
with	O
different	O
receptor	O
binding	O
specificity	O
(	O
CD336	O
,	O
CD437	O
,	O
CD2019	O
,	O
CD367	O
)	O
,	O
dose-dependent	O
inhibition	O
of	O
IgE	B-protein
synthesis	O
was	O
shown	O
by	O
all	O
four	O
derivates	O
,	O
but	O
was	O
most	O
marked	O
by	O
an	O
RA	O
binding	O
the	O
alpha	B-protein
receptor	I-protein
with	O
high	O
specificity	O
.	O

Elevated	O
levels	O
of	O
several	O
inflammatory	B-protein
cytokines	I-protein
have	O
been	O
detected	O
in	O
the	O
sera	O
of	O
HIV-1-infected	O
individuals	O
.	O

All	O
factors	O
are	O
induced	O
in	O
the	O
nuclei	O
of	O
T	B-cell_type
cells	I-cell_type
upon	O
activation	O
with	O
mitogens	B-protein
but	O
not	O
with	O
exogenous	B-protein
IL-2	I-protein
growth	I-protein
factor	I-protein
.	O

The	O
simian	B-DNA
virus	I-DNA
40	I-DNA
early	I-DNA
promoter	I-DNA
is	O
also	O
synergistically	O
activated	O
by	O
the	O
Z/c-myb	B-protein
combination	I-protein
.	O

The	O
IL-3	B-protein
,	O
IL-5	B-protein
and	O
GM-CSF	B-protein
receptors	I-protein
share	O
a	O
common	B-protein
signal	I-protein
transducer	I-protein
that	O
possesses	O
no	O
intrinsic	B-protein
kinase	I-protein
domain	I-protein
.	O

Furthermore	O
,	O
PDTC	O
differentially	O
targeted	O
both	O
NFATp	B-protein
and	I-protein
NFATc	I-protein
family	I-protein
members	I-protein
,	O
inhibiting	O
the	O
transactivation	O
functions	O
of	O
NFATp	B-protein
and	O
mRNA	O
induction	O
of	O
NFATc	B-protein
.	O

The	O
Ribophorin	B-DNA
I-EVI1	I-DNA
fusion	I-DNA
in	O
particular	O
may	O
be	O
a	O
common	O
occurrence	O
in	O
t	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
3	I-DNA
)	I-DNA
.	O

However	O
,	O
there	O
are	O
other	O
effects	O
,	O
such	O
as	O
the	O
early	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
which	O
are	O
probably	O
derived	O
from	O
the	O
production	O
of	O
primary	O
DNA	O
breakage	O
by	O
some	O
anti-	O
topoisomerase	B-protein
drugs	O
.	O

Therefore	O
,	O
activation	O
of	O
Stat3	B-protein
is	O
essential	O
for	O
IL-6	B-protein
-induced	O
macrophage-differentiation	O
and	O
programmed	O
cell	O
death	O
in	O
this	O
model	O
.	O

Thus	O
two	O
different	O
anti-onco-genic	B-protein
transcription	I-protein
factors	I-protein
,	O
p53	B-protein
and	O
IRF-1	B-protein
,	O
are	O
required	O
for	O
distinct	O
apoptotic	O
pathways	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Tumor	B-cell_type
cells	I-cell_type
showed	O
an	O
overexpression	O
of	O
p53	B-protein
protein	I-protein
and	O
were	O
estrogen	B-protein
receptor	I-protein
-positive	O
.	O

Regulation	O
of	O
IkB	B-protein
alpha	I-protein
phosphorylation	O
by	O
PKC-	O
and	O
Ca	O
(	O
2+	O
)	O
-dependent	O
signal	O
transduction	O
pathways	O
.	O

Inhibition	O
with	O
monoclonal	B-protein
antibodies	I-protein
and	O
peptide	O
antagonists	O
inferred	O
that	O
this	O
was	O
due	O
to	O
reduced	O
expression	O
of	O
Ig	O
integrin	O
ligand	O
as	O
well	O
as	O
of	O
chemokines	B-protein
specifically	O
involved	O
in	O
these	O
events	O
.	O

In	O
addition	O
,	O
both	O
RelA	B-protein
and	O
c-Rel	B-protein
,	O
but	O
not	O
NF-kappa	B-protein
B1	I-protein
,	O
were	O
shown	O
to	O
transactivate	O
an	O
ICAM-1	B-DNA
kappa	I-DNA
B-reporter	I-DNA
construct	I-DNA
.	O

In	O
vivo	O
expanded	O
CD4+CD28null	B-cell_line
and	I-cell_line
CD8+CD28null	I-cell_line
T	I-cell_line
cells	I-cell_line
uniformly	O
lack	O
alpha-	B-protein
and	I-protein
beta-	I-protein
bound	I-protein
complexes	I-protein
,	O
resembling	O
the	O
pattern	O
seen	O
in	O
chronically	B-cell_type
activated	I-cell_type
cells	I-cell_type
and	O
not	O
of	O
senescent	B-cell_type
cells	I-cell_type
.	O

Thus	O
,	O
tyrosine	O
phosphorylation	O
is	O
an	O
important	O
and	O
perhaps	O
mandatory	O
proximal	O
step	O
in	O
the	O
activation	O
of	O
the	O
protein	B-protein
kinase	I-protein
C	I-protein
signaling	O
cascade	O
in	O
human	B-cell_type
B-lymphocyte	I-cell_type
precursors	I-cell_type
.	O

Interferon	B-protein
gamma	I-protein
activated	O
strongly	O
c-fos	B-DNA
and	O
weakly	O
c-jun	B-DNA
and	O
AP1	B-protein
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
constitutive	O
expression	O
of	O
bcl-xl	B-protein
but	O
not	O
bcl-2	B-protein
,	O
bcl-xs	B-protein
,	O
bak	B-protein
,	O
bad	B-protein
,	O
or	O
bax	B-protein
was	O
associated	O
with	O
apoptosis	O
resistance	O
after	O
IL-2	B-protein
deprivation	O
in	O
CTLL-2	B-cell_line
cells	I-cell_line
that	O
expressed	O
Tax	B-protein
.	O

1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
inhibited	O
CD23	B-protein
expression	O
in	O
U937	B-cell_line
cells	I-cell_line
,	O
yet	O
failed	O
to	O
modulate	O
CD23	B-protein
expression	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

We	O
have	O
found	O
that	O
Bcl-2	B-protein
overexpression	O
leads	O
to	O
the	O
prevention	O
of	O
chemotherapy	O
(	O
paclitaxel	O
)	O
-induced	O
expression	O
of	O
FasL	B-protein
and	O
blocks	O
paclitaxel-induced	O
apoptosis	O
.	O

Lymphocytes	B-cell_type
have	O
been	O
postulated	O
to	O
serve	O
as	O
a	O
site	O
of	O
adenoviral	O
persistence	O
based	O
upon	O
the	O
ability	O
to	O
isolate	O
adenovirus	O
from	O
tonsils	O
and	O
to	O
detect	O
adenovirus	O
DNA	O
by	O
Southern	O
blot	O
hybridization	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O

In	O
contrast	O
,	O
in	O
C57MG	B-cell_line
fibroblast	I-cell_line
cells	I-cell_line
,	O
lithium	O
inactivates	O
GSK-3beta	B-protein
and	O
induces	O
Tcf-controlled	O
transcription	O
.	O

The	O
signal	O
transduction	O
events	O
involved	O
in	O
gp120	B-protein
-mediated	O
enhancement	O
of	O
ICAM-1	B-protein
appear	O
to	O
involve	O
activation	O
of	O
both	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
tyrosine	B-protein
kinase	I-protein
,	O
because	O
inhibitors	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
tyrosine	B-protein
kinase	I-protein
abrogate	O
gp120	B-protein
-mediated	O
ICAM-1	B-protein
expression	O
in	O
both	O
astrocytes	B-cell_type
and	O
microglia	B-cell_type
.	O

A	O
regulatory	B-DNA
element	I-DNA
in	O
the	O
CD95	B-DNA
(	I-DNA
APO-1/Fas	I-DNA
)	I-DNA
ligand	I-DNA
promoter	I-DNA
is	O
essential	O
for	O
responsiveness	O
to	O
TCR	B-protein
-mediated	O
activation	O
.	O

Identification	O
of	O
a	O
herpesvirus	B-DNA
Saimiri	I-DNA
cis-acting	I-DNA
DNA	I-DNA
fragment	I-DNA
that	O
permits	O
stable	O
replication	O
of	O
episomes	O
in	O
transformed	O
T	B-cell_type
cells	I-cell_type
.	O

It	O
remains	O
open	O
whether	O
the	O
growth	O
retarding	O
property	O
of	O
the	O
EBNA2-oestrogen	B-protein
receptor	I-protein
fusion	I-protein
protein	I-protein
in	O
B	B-cell_line
cell	I-cell_line
lymphoma	I-cell_line
lines	I-cell_line
is	O
due	O
to	O
unphysiologically	O
high	O
expression	O
of	O
the	O
chimeric	B-protein
protein	I-protein
or	O
to	O
interference	O
with	O
a	O
cellular	O
programme	O
driving	O
proliferation	O
in	O
these	O
cell	B-cell_line
lines	I-cell_line
.	O

Here	O
we	O
report	O
an	O
analysis	O
of	O
the	O
transcription	O
factor	O
families	O
AP-1	O
,	O
Sp1	O
,	O
NF-kappaB	B-protein
,	O
and	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	O
STAT	B-protein
)	O
in	O
cancer	B-cell_type
patients	I-cell_type
'	I-cell_type
lymphocytes	I-cell_type
before	O
and	O
after	O
IL-2	B-protein
immunotherapy	O
,	O
as	O
assessed	O
by	O
a	O
gel-shift	O
assay	O
.	O

The	O
myeloid	B-protein
integrin	I-protein
CD11b	I-protein
is	O
expressed	O
selectively	O
on	O
the	O
surface	O
of	O
mature	B-cell_type
macrophages	I-cell_type
,	O
monocytes	B-cell_type
,	O
neutrophils	B-cell_type
,	O
and	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O

Inhibition	O
of	O
p105	B-protein
processing	O
by	O
NF-kappaB	B-protein
proteins	I-protein
in	O
transiently	B-cell_line
transfected	I-cell_line
cells	I-cell_line
.	O

In	O
contrast	O
mRNA	O
representing	O
pAT	O
591/EGR2	B-protein
was	O
not	O
expressed	O
in	O
these	O
cells	O
.	O

Platelet-activating	B-protein
factor	I-protein
is	O
a	O
potent	O
mediator	O
of	O
the	O
inflammatory	O
response	O
.	O

However	O
,	O
the	O
U937	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
which	O
is	O
fully	O
permissive	O
to	O
HIV	O
replication	O
,	O
is	O
known	O
to	O
express	O
only	O
low	O
levels	O
of	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
.	O

In	O
this	O
study	O
the	O
genetic	O
control	O
of	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
expression	O
during	O
the	O
transition	O
from	O
B	B-cell_type
cell	I-cell_type
to	O
plasma	B-cell_type
cell	I-cell_type
has	O
been	O
analyzed	O
.	O

Anti-	O
HBx	B-protein
antibody	O
titers	O
as	O
revealed	O
by	O
peptide	O
ELISAs	O
were	O
highest	O
and	O
most	O
frequent	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
and	O
usually	O
low	O
in	O
acutely	O
infected	O
patients	O
and	O
asymptomatic	O
carriers	O
.	O

Several	O
forms	O
of	O
EGR-1	B-protein
protein	I-protein
are	O
found	O
within	O
the	O
different	O
groups	O
of	O
cell	O
lines	O
,	O
and	O
the	O
binding	O
activity	O
to	O
DNA	B-DNA
consensus	I-DNA
sequences	I-DNA
was	O
investigated	O
.	O

The	O
functions	O
of	O
NFAT	B-protein
proteins	I-protein
are	O
directly	O
controlled	O
by	O
the	O
calcium-	B-protein
and	I-protein
calmodulin-	I-protein
dependent	I-protein
phosphatase	I-protein
calcineurin	B-protein
.	O

Activation	O
of	O
the	O
chimeric	B-protein
G-CSF-R/IL-7R	I-protein
alpha	I-protein
with	O
G-CSF	B-protein
resulted	O
in	O
a	O
full	O
proliferative	O
response	O
and	O
induced	O
the	O
phosphorylation	O
of	O
JAK1	B-protein
but	O
not	O
JAK2	B-protein
.	O

BOB.1/OBF.1	B-protein
was	O
phosphorylated	O
at	O
Ser184	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
and	O
this	O
modification	O
was	O
required	O
for	O
inducible	O
activation	O
.	O

Northern	O
blot	O
analysis	O
revealed	O
that	O
BLR2	B-RNA
mRNA	I-RNA
could	O
be	O
highly	O
stimulated	O
in	O
mitogen-	B-cell_line
and	I-cell_line
anti-CD3-treated	I-cell_line
peripheral	I-cell_line
blood	I-cell_line
lymphocytes	I-cell_line
.	O

These	O
results	O
indicate	O
that	O
the	O
presence	O
of	O
the	O
codon-10-variant	B-DNA
type	I-DNA
is	O
not	O
a	O
characteristic	O
of	O
breast	O
cancer	O
.	O

Transcription	B-protein
factor	I-protein
activation	O
and	O
functional	O
stimulation	O
of	O
human	B-cell_type
monocytes	I-cell_type
.	O

This	O
indicates	O
the	O
independency	O
of	O
the	O
CR	O
of	O
GR	B-protein
from	O
that	O
of	O
cortisol	O
.	O

Furthermore	O
,	O
NF90	B-protein
was	O
phosphorylated	O
in	O
a	O
double-stranded	B-RNA
RNA	I-RNA
-dependent	O
manner	O
likely	O
by	O
the	O
interferon-induced	O
,	O
double-stranded	B-protein
RNA-dependent	I-protein
protein	I-protein
kinase	I-protein
,	O
PKR	B-protein
.	O

Activating	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
binding	O
TPA	B-DNA
responsive	I-DNA
elements	I-DNA
(	O
TRE	B-DNA
)	O
are	O
located	O
downstream	O
of	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
in	O
the	O
U5	B-DNA
region	I-DNA
of	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
.	O

We	O
show	O
that	O
H-7-sensitive	O
pathways	O
regulate	O
STAT3	B-protein
DNA	O
binding	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

TAL1	B-protein
and	O
LIM-only	B-protein
proteins	I-protein
synergistically	O
induce	O
retinaldehyde	B-protein
dehydrogenase	I-protein
2	I-protein
expression	O
in	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
by	O
acting	O
as	O
cofactors	O
for	O
GATA3	B-protein
.	O

Abnormalities	O
for	O
one	O
or	O
both	O
probes	O
were	O
detected	O
in	O
83/95	O
samples	O
.	O

Nuclear	B-protein
factors	I-protein
from	O
unstimulated	O
,	O
but	O
not	O
from	O
activated	O
cells	O
,	O
bound	O
a	O
site	O
,	O
META	B-DNA
(	I-DNA
D-	I-DNA
)	I-DNA
,	O
adjacent	O
to	O
META	B-DNA
(	I-DNA
D+	I-DNA
)	I-DNA
.	O

Similarly	O
the	O
basal	O
as	O
well	O
as	O
TNF	B-protein
or	O
IL1-induced	O
activity	O
of	O
the	O
MHC	B-DNA
class	I-DNA
I	I-DNA
H-2Kb	I-DNA
promoter	I-DNA
can	O
be	O
inhibited	O
by	O
this	O
mutant	O
in	O
two	O
different	O
cell	B-cell_line
lines	I-cell_line
.	O

The	O
tumors	O
showed	O
high	O
radiosensitivity	O
.	O

A	O
cell	O
cycle	O
analysis	O
showed	O
that	O
the	O
constitutive	O
activation	O
of	O
Stat1alpha	B-protein
,	O
but	O
not	O
Stat3	B-protein
,	O
shortened	O
the	O
period	O
of	O
G0/G1	O
prolongation	O
caused	O
by	O
EPO	B-protein
stimulation	O
.	O

Pertussis	O
toxin	O
,	O
which	O
ADP-ribosylates	O
the	O
Gi	B-protein
proteins	I-protein
known	O
to	O
couple	O
to	O
the	O
C5a	B-protein
receptor	I-protein
,	O
produced	O
minimal	O
inhibition	O
of	O
C5a-induced	O
IL-8	B-protein
expression	O
and	O
had	O
little	O
effect	O
on	O
C5a-induced	O
calcium	O
mobilization	O
in	O
RAW264.7	B-cell_line
cells	I-cell_line
.	O

A	O
synthetic	O
thrombin	B-protein
receptor	I-protein
agonist	O
peptide	O
(	O
TRP	O
)	O
of	O
7	O
residues	O
(	O
SFLLRNP	O
)	O
was	O
found	O
to	O
be	O
as	O
effective	O
as	O
thrombin	B-protein
for	O
[	O
Ca2+	O
]	O
i	O
mobilization	O
,	O
and	O
both	O
agonists	O
induced	O
Ca2+	O
release	O
exclusively	O
from	O
internal	O
stores	O
.	O

In	O
lymphocytes	B-cell_type
activated	O
either	O
by	O
PHA	B-protein
or	O
OKT3	B-protein
(	O
but	O
not	O
in	O
resting	B-cell_type
cells	I-cell_type
)	O
,	O
a	O
50-kDa	B-protein
species	I-protein
cross-reacting	O
with	O
a	O
monoclonal	B-protein
antibody	I-protein
against	O
the	O
intestinal	B-protein
vitamin	I-protein
D	I-protein
receptor	I-protein
was	O
detected	O
.	O

We	O
report	O
here	O
that	O
a	O
DNA-binding	B-protein
factor	I-protein
containing	O
STAT1	B-protein
also	O
becomes	O
activated	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
or	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
although	O
not	O
until	O
1-2	O
h	O
after	O
stimulation	O
.	O

Glucocorticoids	O
(	O
GC	O
)	O
have	O
long	O
been	O
used	O
as	O
the	O
most	O
effective	O
agents	O
for	O
the	O
treatment	O
of	O
allergic	O
diseases	O
accompanied	O
by	O
eosinophilia	O
such	O
as	O
chronic	O
asthma	O
and	O
atopic	O
dermatitis	O
.	O

Erythroid-specific	B-DNA
genes	I-DNA
contain	O
binding	O
sites	O
for	O
NF-E1	B-protein
(	O
also	O
called	O
GF-1	B-protein
and	O
Eryf-1	B-protein
;	O
refs	O
1-3	O
respectively	O
)	O
,	O
the	O
principal	O
DNA-binding	B-protein
protein	I-protein
of	O
the	O
erythrocytic	B-cell_type
lineage	I-cell_type
.	O

These	O
observations	O
indicate	O
that	O
primary	O
T	O
cell	O
responses	O
detected	O
in	O
vitro	O
using	O
DC	B-cell_type
as	O
APC	B-cell_type
may	O
be	O
useful	O
to	O
characterize	O
the	O
potential	O
immunogenicity	O
of	O
viral	O
protein	O
epitopes	O
in	O
vivo	O
.	O

For	O
comparison	O
,	O
other	O
RBA	O
in	O
this	O
system	O
were	O
:	O
19-noraldosterone	O
,	O
20	O
%	O
;	O
18-deoxyaldosterone	O
,	O
5.8	O
%	O
;	O
18-deoxy-19-noraldosterone	O
,	O
4.7	O
%	O
;	O
18	O
,	O
21-anhydroaldosterone	O
,	O
0.37	O
%	O
;	O
17-isoaldosterone	O
,	O
7.6	O
%	O
and	O
apoaldosterone	O
,	O
4.3	O
%	O

Tumor	O
samples	O
,	O
obtained	O
from	O
129	O
patients	O
who	O
underwent	O
surgery	O
between	O
January	O
1987	O
and	O
December	O
1988	O
,	O
were	O
processed	O
for	O
staining	O
by	O
an	O
immunohistochemical	O
procedure	O
(	O
avidin-biotin	B-protein
complex	I-protein
)	O
.	O

CsA	O
does	O
not	O
interfere	O
with	O
the	O
synthesis	O
of	O
Rel	B-protein
proteins	I-protein
,	O
but	O
prevents	O
the	O
inducible	O
degradation	O
of	O
cytosolic	B-protein
NF-kappa	I-protein
B	I-protein
inhibitors	I-protein
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
upon	O
T	O
cell	O
activation	O
.	O

T	B-cell_type
lymphocytes	I-cell_type
express	O
several	O
low	B-protein
molecular	I-protein
weight	I-protein
transmembrane	I-protein
adaptor	I-protein
proteins	I-protein
that	O
recruit	O
src	B-protein
homology	I-protein
(	I-protein
SH	I-protein
)	I-protein
2	I-protein
domain-containing	I-protein
intracellular	I-protein
molecules	I-protein
to	O
the	O
cell	O
membrane	O
via	O
tyrosine-based	O
signaling	O
motifs	O
.	O

Because	O
of	O
the	O
efficient	O
binding	O
of	O
TG	B-protein
by	O
surrogate	B-protein
receptors	I-protein
on	O
non-T	B-cell_type
cells	I-cell_type
,	O
we	O
assessed	O
the	O
ability	O
of	O
such	O
cells	O
to	O
present	O
TG	B-protein
to	O
T	B-cell_type
cells	I-cell_type
.	O

When	O
transferred	O
to	O
a	O
potent	O
activator	O
,	O
transcriptional	O
stimulation	O
was	O
inhibited	O
efficiently	O
.	O

All	O
asthmatic	O
patients	O
showed	O
an	O
improvement	O
in	O
their	O
FEV1	O
values	O
after	O
corticosteroid	O
treatment	O
(	O
per	O
cent	O
of	O
predicted	O
value	O
68.28	O
+/-	O
4.93	O
versus	O
95.57	O
+/-	O
6.41	O
,	O
P	O
<	O
0.02	O
)	O
,	O
and	O
a	O
significant	O
decrease	O
for	O
glucocorticoid	B-protein
receptor	I-protein
mRNA	B-RNA
expression	O
(	O
P	O
<	O
0.02	O
)	O
was	O
observed	O
in	O
their	O
monocytes	O
.	O

Similar	O
to	O
LEF-1	B-protein
,	O
ALY	B-protein
can	O
stimulate	O
transcription	O
in	O
the	O
context	O
of	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	I-DNA
but	O
apparently	O
not	O
when	O
tethered	O
to	O
DNA	O
through	O
an	O
heterologous	B-protein
DNA-binding	I-protein
domain	I-protein
.	O

This	O
suggests	O
that	O
the	O
activation	O
mechanism	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
through	O
the	O
GM2/GC-box	B-DNA
sequence	I-DNA
is	O
different	O
from	O
that	O
of	O
genes	O
carrying	O
the	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
alone	O
.	O

Stepwise	O
deletions	O
into	O
the	O
proximal	B-DNA
promoter	I-DNA
also	O
revealed	O
that	O
the	O
CBF	B-protein
site	O
,	O
but	O
not	O
the	O
YY-1	B-DNA
site	I-DNA
,	O
was	O
required	O
for	O
efficient	O
induction	O
of	O
transcriptional	O
activation	O
.	O

Receptors	O
were	O
measured	O
by	O
radioreceptor	O
assay	O
.	O

Here	O
we	O
show	O
that	O
the	O
transcription	B-protein
factor	I-protein
RFX1	B-protein
can	O
bind	O
to	O
NRE	B-DNA
gamma	I-DNA
and	O
transactivate	O
the	O
core	B-DNA
promoter	I-DNA
through	O
this	O
site	O
.	O

Tat	B-protein
transactivation	O
mediated	O
by	O
the	O
kappa	B-DNA
B	I-DNA
domain	I-DNA
is	O
sufficient	O
to	O
allow	O
replication	O
of	O
TAR	B-DNA
-deleted	O
mutant	O
HIV-1	O
in	O
astrocytes	B-cell_type
.	O

Recent	O
work	O
from	O
several	O
laboratories	O
has	O
demonstrated	O
that	O
Rel/NF-kappa	B-protein
B	I-protein
transcription	B-protein
factors	I-protein
regulate	O
apoptosis	O
in	O
many	O
cell	O
types	O
.	O

Nevertheless	O
,	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
BA-induced	O
differentiation	O
remain	O
largely	O
unknown	O
.	O

Thrombin	B-protein
stimulated	O
tyrosine	O
phosphorylation	O
of	O
several	O
proteins	O
of	O
molecular	B-protein
mass	I-protein
40	I-protein
,	I-protein
42	I-protein
,	I-protein
70	I-protein
,	I-protein
120	I-protein
,	I-protein
and	I-protein
130	I-protein
kDa	I-protein
.	O

RESULTS	O
:	O
The	O
systemic	O
(	O
PBMC	O
)	O
hGR	B-protein
levels	O
of	O
corticosteroid-treated	O
IBD	O
patients	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
control	O
subjects	O
(	O
59.6	O
+/-	O
57.1	O
dpm	O
mg-1	O
cytosol	B-protein
protein	I-protein
vs	O
.	O

In	O
addition	O
,	O
they	O
suggested	O
that	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
is	O
under	O
the	O
control	O
of	O
not	O
only	O
NFAT	B-protein
but	O
also	O
a	O
second	O
factor	O
whose	O
activation	O
is	O
MEK	B-protein
-dependent	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
regulation	O
of	O
costimulation-induced	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
activation	O
in	O
primary	B-cell_type
mouse	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

A	O
3-bp	O
mutation	O
at	O
the	O
distal	O
Sp1-binding	B-DNA
site	I-DNA
not	O
only	O
eliminates	O
Sp1	B-protein
interaction	O
,	O
but	O
also	O
abolishes	O
most	O
of	O
the	O
VitD3	O
induction	O
of	O
CD14	B-protein
expression	O
.	O

This	O
may	O
have	O
implications	O
for	O
pathophysiological	O
conditions	O
that	O
involve	O
the	O
upregulation	O
of	O
these	O
molecules	O
(	O
e.g.	O
inflammation	O
and	O
atherosclerosis	O
)	O
.	O

Reporter	O
gene	O
assays	O
reveal	O
that	O
the	O
binding	O
of	O
c-Rel	B-protein
to	O
the	O
STAT5	B-protein
site	O
present	O
in	O
the	O
Fc	B-DNA
gammaR1	I-DNA
gene	I-DNA
leads	O
to	O
potent	O
transactivation	O
of	O
this	O
enhancer	O
.	O

Nevertheless	O
,	O
this	O
hyperaldosteronism	O
may	O
be	O
associated	O
with	O
hyponatremia	O
and	O
hyperkalemia	O
suggesting	O
PHA	O
related	O
to	O
the	O
major	O
importance	O
of	O
the	O
colon	O
for	O
the	O
absorption	O
of	O
sodium	O
.	O

Extracellular	O
generation	O
of	O
NO	O
(	O
NO	O
donor	O
)	O
did	O
not	O
effect	O
the	O
hyperadhesion	O
response	O
induced	O
by	O
the	O
initial	O
A/R	O
challenge	O
.	O

IkappaB	B-protein
alpha	I-protein
phosphorylation	O
on	O
Ser-32	O
and	O
Ser-36	O
is	O
followed	O
by	O
its	O
degradation	O
and	O
NF-kappaB	B-protein
activation	O
.	O

These	O
data	O
demonstrate	O
that	O
PML-RAR	B-protein
alpha	I-protein
and	O
PLZF-RAR	B-protein
alpha	I-protein
have	O
similar	O
(	O
inhibitory	O
)	O
effects	O
on	O
RA-independent	O
differentiation	O
and	O
opposite	O
(	O
stimulatory	O
or	O
inhibitory	O
)	O
effects	O
on	O
RA-dependent	O
differentiation	O
and	O
that	O
they	O
behave	O
in	O
vivo	O
as	O
RA-dependent	B-DNA
enhancers	I-DNA
or	O
inhibitors	O
of	O
RA-responsive	B-DNA
genes	I-DNA
,	O
respectively	O
.	O

We	O
have	O
selected	O
16	B-DNA
sequences	I-DNA
and	O
confirmed	O
their	O
down-regulation	O
along	O
the	O
TPA-induced	O
monocytic	O
differentiation	O
of	O
HL60	B-cell_line
cells	I-cell_line
.	O

These	O
findings	O
correlated	O
with	O
activation	O
of	O
the	O
IkappaBalpha	B-DNA
gene	I-DNA
and	O
blockade	O
of	O
the	O
nuclear	O
translocation	O
of	O
NFkappaB	B-protein
in	O
the	O
xenotransplanted	O
tissue	O
.	O

The	O
first	O
(	O
-445/-366	O
)	O
is	O
a	O
positive	O
element	O
active	O
in	O
both	O
basophils	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
.	O

These	O
values	O
were	O
determined	O
at	O
the	O
onset	O
of	O
clinical	O
symptoms	O
of	O
PIH	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
OCA-B	B-protein
is	O
a	O
tissue-	B-protein
,	I-protein
promoter-	I-protein
,	I-protein
and	I-protein
factor-specific	I-protein
coactivator	I-protein
and	O
that	O
OCA-B	B-protein
may	O
be	O
a	O
major	O
determinant	O
for	O
B	O
cell-specific	O
activation	O
of	O
immunoglobulin	B-DNA
promoters	I-DNA
.	O

Peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
were	O
isolated	O
by	O
density	O
centrifugation	O
methods	O
with	O
a	O
purity	O
of	O
>	O
90	O
%	O
and	O
were	O
cultured	O
in	O
RPMI	O
1640	O
medium	O
.	O

This	O
zinc-finger	B-protein
region	I-protein
,	O
which	O
is	O
thought	O
to	O
bind	O
DNA	O
in	O
a	O
sequence-specific	O
manner	O
,	O
is	O
similar	O
(	O
greater	O
than	O
80	O
%	O
on	O
the	O
amino	O
acid	O
level	O
)	O
to	O
two	O
previously	O
described	O
transcription	B-protein
factors	I-protein
pAT	B-protein
225/EGR1	I-protein
and	O
pAT	O
591/EGR2	B-protein
.	O

First	O
,	O
STAT4	B-protein
was	O
required	O
for	O
the	O
IL-12	B-protein
-dependent	O
transactivation	O
of	O
an	O
IRF-1	B-DNA
reporter	I-DNA
construct	I-DNA
,	O
and	O
second	O
,	O
STAT4	B-protein
binding	O
to	O
the	O
IRF-1	B-DNA
promoter	I-DNA
was	O
shown	O
using	O
EMSA	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
basis	O
for	O
NF-kappaB	B-protein
activation	O
in	O
freshly	B-cell_type
isolated	I-cell_type
leukemic	I-cell_type
cells	I-cell_type
from	O
ATL	O
patients	O
.	O

PMA	O
,	O
but	O
not	O
Ara-C	O
or	O
ceramides	O
,	O
activated	O
ERK	B-protein
MAPKS	I-protein
,	O
in	O
Jurkat	B-cell_line
and	O
EL4	B-cell_line
.	O

The	O
mechanisms	O
that	O
control	O
the	O
initial	O
induction	O
of	O
these	O
signals	O
upon	O
infection	O
are	O
poorly	O
understood	O
.	O

These	O
results	O
suggest	O
that	O
multiple	O
biochemical	O
pathways	O
are	O
involved	O
in	O
the	O
activation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
by	O
R24	B-protein
.	O

However	O
,	O
Nef	B-protein
does	O
not	O
affect	O
the	O
DNA-binding	O
activity	O
of	O
other	O
transcription	B-protein
factors	I-protein
implicated	O
in	O
HIV-1	O
regulation	O
,	O
including	O
SP-1	B-protein
,	O
USF	B-protein
,	O
URS	B-protein
,	O
and	O
NF-AT	B-protein
.	O

In	O
studies	O
initiated	O
to	O
evaluate	O
relationships	O
between	O
EBV	B-DNA
latent	I-DNA
genes	I-DNA
and	O
p53	B-protein
,	O
p53	B-protein
levels	O
were	O
found	O
to	O
increase	O
approximately	O
10-fold	O
4	O
to	O
5	O
days	O
after	O
EBV	O
infection	O
of	O
purified	O
resting	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
;	O
the	O
induced	O
p53	B-protein
was	O
transcriptionally	O
active	O
.	O

We	O
found	O
that	O
the	O
membrane	B-protein
proximal	I-protein
proline-rich	I-protein
domain	I-protein
and	O
adjacent	B-protein
16	I-protein
residues	I-protein
are	O
essential	O
for	O
both	O
hGM-CSF	B-protein
-dependent	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

Only	O
MCR	O
,	O
G	O
,	O
and	O
EIC	O
proved	O
significant	O
in	O
Cox	O
multivariate	O
analysis	O
.	O

In	O
contrast	O
to	O
IL-12	B-protein
,	O
no	O
up-regulation	O
of	O
IRF-1	B-protein
was	O
found	O
in	O
IL-4-stimulated	B-cell_line
cells	I-cell_line
,	O
and	O
IL-4	B-protein
did	O
not	O
block	O
IL-12	B-protein
-dependent	O
up-regulation	O
of	O
IRF-1	B-protein
.	O

Here	O
we	O
show	O
that	O
LMP-1	B-protein
induces	O
the	O
activity	O
of	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
,	O
a	O
dimer	O
of	O
Jun/Jun	B-protein
or	I-protein
Jun/Fos	I-protein
proteins	I-protein
.	O

Phytohemagglutinin	B-protein
(	O
PHA	B-protein
)	O
-induced	O
proliferation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
from	O
the	O
sensitive	O
but	O
not	O
the	O
resistant	O
asthmatic	O
patients	O
was	O
significantly	O
(	O
p	O
less	O
than	O
0.01	O
)	O
inhibited	O
by	O
dexamethasone	O
(	O
10	O
(	O
-7	O
)	O
mol/L	O
)	O
,	O
reflecting	O
a	O
shift	O
of	O
the	O
dose-response	O
curve	O
.	O

In	O
T	B-cell_type
cells	I-cell_type
stimulated	O
with	O
purified	O
phytohemagglutinin	B-protein
(	O
PHA-p	B-protein
)	O
and	O
4	O
beta-phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
addition	O
of	O
DM	O
to	O
the	O
cultures	O
resulted	O
in	O
a	O
60	O
%	O
reduction	O
in	O
IL-2R	B-protein
alpha	I-protein
and	O
a	O
30	O
%	O
reduction	O
in	O
IL-2R	B-protein
beta	I-protein
membrane	O
expression	O
compared	O
to	O
T	B-cell_type
cells	I-cell_type
cultured	O
in	O
the	O
absence	O
of	O
DM	O
(	O
p	O
<	O
0.01	O
)	O
.	O

(	O
2-Amino-3'-methoxyphenyl	O
)	O
oxanaphthalen-4-one	O
(	O
PD	O
98059	O
)	O
,	O
an	O
inhibitor	O
of	O
extracellular	O
signal-regulated	B-protein
protein	I-protein
kinase	I-protein
(	O
ERK	B-protein
)	O
activation	O
,	O
blocked	O
the	O
serine	O
phosphorylation	O
of	O
STAT3	B-protein
induced	O
by	O
chemotactic	B-protein
factors	I-protein
or	O
PMA	O
.	O

The	O
authors	O
used	O
a	O
Chinese	O
prescription	O
--	O
Liuwei	O
Dihuang	O
Pills	O
(	O
LDP	O
)	O
to	O
treat	O
the	O
patients	O
for	O
2	O
months	O
.	O

These	O
data	O
suggest	O
that	O
USF/c-Myc	B-protein
and	O
YY1	B-protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
HIV-1-replicative	O
cycle	O
,	O
by	O
modulating	O
both	O
the	O
viral	O
fusion/entry	O
process	O
and	O
viral	O
expression	O
.	O

Induction	O
of	O
a	O
functional	O
vitamin	B-protein
D	I-protein
receptor	I-protein
in	O
all-trans-retinoic	O
acid-induced	O
monocytic	O
differentiation	O
of	O
M2-type	B-cell_line
leukemic	I-cell_line
blast	I-cell_line
cells	I-cell_line
.	O

C5a-induced	O
reporter	B-DNA
gene	I-DNA
expression	O
was	O
abolished	O
by	O
introducing	O
mutations	O
into	O
the	O
kappaB	B-DNA
sites	I-DNA
and	O
by	O
coexpression	O
of	O
a	O
dominant	B-DNA
negative	I-DNA
IkappaBalpha	I-DNA
construct	I-DNA
resistant	O
to	O
agonist-induced	O
phosphorylation	O
.	O

We	O
used	O
histochemical	O
markers	O
to	O
define	O
the	O
immunophenotype	O
of	O
43	O
IDCs	O
with	O
respect	O
to	O
comedo	O
versus	O
noncomedo	O
status	O
and	O
patterns	O
of	O
angiogenesis	O
.	O

In	O
addition	O
,	O
LPS	O
stimulation	O
induced	O
the	O
binding	O
of	O
cognate	O
nuclear	B-protein
factors	I-protein
to	O
the	O
Egr-1	B-DNA
and	I-DNA
kappaB3	I-DNA
sites	I-DNA
,	O
which	O
were	O
identified	O
as	O
Egr-1	B-protein
and	O
p50/p65	B-protein
,	O
respectively	O
.	O

1-	O
(	O
5-Isoquinolinylsulphonyl	O
)	O
-2-methylpiperazine	O
dihydrochloride	O
(	O
H7	O
)	O
,	O
an	O
inhibitor	O
of	O
a	O
putative	O
STAT3	B-protein
serine	I-protein
kinase	I-protein
,	O
and	O
4-	O
(	O
4-fluorophenyl	O
)	O
-2-	O
(	O
4-methylsulphinylphenyl	O
)	O
-5-	O
(	O
4-pyridyl	O
)	O
1H-imidazole	O
(	O
SB	O
203580	O
)	O
,	O
an	O
inhibitor	O
of	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinase	I-protein
,	O
did	O
not	O
dampen	O
any	O
of	O
these	O
serine	O
phosphorylation	O
responses	O
.	O

Thus	O
,	O
changes	O
in	O
the	O
Sp1	B-DNA
binding	I-DNA
sites	I-DNA
had	O
the	O
most	O
dramatic	O
effects	O
on	O
SIVmac	O
replication	O
in	O
primary	B-cell_line
macrophage	I-cell_line
cultures	I-cell_line
.	O

We	O
identified	O
a	O
physical	O
interaction	O
between	O
Tax	B-protein
and	O
the	O
HsN3	B-protein
subunit	I-protein
of	O
the	O
human	B-protein
proteasome	I-protein
.	O

In	O
vitro	O
,	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
undergo	O
long-term	O
proliferation	O
when	O
activated	O
through	O
CD40	B-protein
,	O
a	O
protein	O
expressed	O
on	O
their	O
cell	O
surface	O
.	O

Our	O
results	O
demonstrate	O
that	O
1.3E2	B-cell_line
is	O
a	O
cellular	B-protein
transduction	I-protein
mutant	I-protein
exhibiting	O
a	O
defect	O
in	O
a	O
step	O
that	O
is	O
required	O
by	O
several	O
different	O
stimuli	O
to	O
activate	O
NF-kappaB	B-protein
.	O

The	O
hepatitis	B-DNA
B	I-DNA
virus	I-DNA
genome	I-DNA
encodes	O
a	O
transcriptional	B-protein
transactivator	I-protein
protein	I-protein
designated	O
HBxAg	B-protein
.	O

Additional	O
upstream	O
gene	O
segments	O
dramatically	O
affected	O
B29	B-protein
minimal	B-DNA
promoter	I-DNA
activity	O
.	O

The	O
chromosome	B-DNA
17	I-DNA
breakpoint	I-DNA
was	O
localized	O
to	O
intron	B-DNA
2	I-DNA
of	O
RARA	B-DNA
by	O
Southern	O
blotting	O
,	O
and	O
there	O
was	O
no	O
evidence	O
at	O
the	O
molecular	O
level	O
for	O
rearrangement	O
at	O
PML	B-DNA
locus	I-DNA
.	O

These	O
results	O
show	O
that	O
RCC-S	O
can	O
induce	O
in	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
the	O
same	O
phenotype	O
of	O
impaired	O
NF-kappaB	B-protein
activation	O
that	O
is	O
detected	O
in	O
T	B-cell_type
cells	I-cell_type
of	O
RCC	O
patient	O
.	O

Inhibition	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
in	O
vitro	O
by	O
a	O
novel	O
combination	O
of	O
anti-Tat	B-protein
single-chain	I-protein
intrabodies	I-protein
and	O
NF-kappa	O
B	O
antagonists	O
.	O

Here	O
we	O
cloned	O
the	O
murine	B-DNA
BCL6	I-DNA
(	I-DNA
mBCL6	I-DNA
)	I-DNA
cDNA	I-DNA
from	O
the	O
muscle	B-DNA
cDNA	I-DNA
library	I-DNA
using	O
the	O
human	B-DNA
BCL6	I-DNA
(	I-DNA
hBCL6	I-DNA
)	I-DNA
cDNA	I-DNA
as	O
a	O
probe	O
.	O

A	O
switch	O
from	O
human	B-protein
fetal	I-protein
(	I-protein
gamma	I-protein
)	I-protein
-to	O
adult	B-protein
(	I-protein
beta	I-protein
)	I-protein
-globin	I-protein
expression	O
occurs	O
within	O
erythroid	B-cell_type
precursor	I-cell_type
cells	I-cell_type
of	O
the	O
adult	B-cell_type
lineage	I-cell_type
.	O

This	O
chimera	O
transduced	O
IL-4	B-protein
-specific	O
signals	O
in	O
response	O
to	O
IL-2	B-protein
binding	O
and	O
dramatically	O
enhanced	O
type	O
2	O
responses	O
(	O
IL-4	B-protein
,	O
IL-5	B-protein
,	O
and	O
immunoglobulin	B-protein
E	I-protein
production	O
)	O
upon	O
in	O
vitro	O
TCR	B-protein
stimulation	O
or	O
in	O
vivo	O
antigen	O
challenge	O
.	O

Enhancement	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
replication	O
in	O
monocytes	B-cell_type
by	O
1	O
,	O
25-dihydroxycholecalciferol	O
.	O

Using	O
limiting-dilution	O
analysis	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
,	O
a	O
high	O
RAKFKQLLQ-specific	O
CTL	O
precursor	O
frequency	O
was	O
demonstrated	O
after	O
specific	O
peptide	O
or	O
autologous	O
lymphoblastoid	O
cell	O
line	O
stimulation	O
in	O
both	O
type	O
A	O
and	O
type	O
B	O
EBV	O
carriers	O
.	O

Our	O
results	O
imply	O
that	O
T	B-cell_type
cells	I-cell_type
need	O
to	O
maintain	O
a	O
certain	O
level	O
of	O
NF-kappaB	B-protein
transcriptional	O
activity	O
in	O
order	O
to	O
survive	O
;	O
up-	O
or	O
down-regulation	O
of	O
nuclear	B-protein
NF	I-protein
kappaB	I-protein
through	O
modulation	O
of	O
IkappaBalpha	B-protein
expression	O
by	O
cytokines	B-protein
or	O
DEX	O
may	O
lead	O
to	O
cell	O
survival	O
or	O
cell	O
death	O
,	O
respectively	O
.	O

When	O
the	O
HTLV-1	B-DNA
tax	I-DNA
gene	I-DNA
was	O
expressed	O
or	O
phorbol	O
myristake	O
acetate-A23187	O
stimulation	O
was	O
used	O
,	O
ICSAT	B-protein
expression	O
was	O
induced	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
which	O
otherwise	O
do	O
not	O
express	O
ICSAT	B-protein
.	O

Treatment	O
of	O
RWLeu-4	B-cell_line
cells	I-cell_line
with	O
VD3	O
induced	O
24R-hydroxylase	B-protein
activity	O
,	O
a	O
marker	O
of	O
vitamin	O
D3	O
responsiveness	O
in	O
many	O
tissues	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

In	O
vivo	O
transient	O
transfection	O
studies	O
utilizing	O
an	O
OTF-2	B-DNA
expression	I-DNA
vector	I-DNA
resulted	O
in	O
similar	O
findings	O
:	O
that	O
OTF-2	B-protein
protein	I-protein
enhanced	O
DRA	B-DNA
gene	I-DNA
transcription	O
,	O
and	O
that	O
this	O
effect	O
requires	O
an	O
intact	O
octamer	B-DNA
element	I-DNA
.	O

These	O
results	O
identify	O
a	O
new	O
signal	O
transduction	O
pathway	O
activated	O
by	O
GM-CSF	B-protein
and	O
provide	O
a	O
mechanism	O
for	O
rapid	O
activation	O
of	O
gene	O
expression	O
in	O
GM-CSF-stimulated	B-cell_type
PMN	I-cell_type
.	O

Although	O
retinoic	O
acid	O
(	O
RA	O
)	O
has	O
been	O
known	O
for	O
many	O
years	O
to	O
be	O
a	O
modulating	O
agent	O
that	O
plays	O
a	O
role	O
in	O
generating	O
both	O
granulocytes	B-cell_type
and	O
monocytes	B-cell_type
,	O
the	O
molecular	O
mechanism	O
underlying	O
this	O
role	O
has	O
not	O
been	O
defined	O
in	O
the	O
monoblast	B-cell_type
lineage	I-cell_type
.	O

The	O
putative	B-protein
intracellular	I-protein
receptors	I-protein
for	O
FK506	O
and	O
cyclosporin	O
are	O
cis-trans	O
prolyl	O
isomerases	O
.	O

Deletions	O
upstream	O
of	O
the	O
PRDII	B-DNA
element	I-DNA
increased	O
transcription	O
in	O
the	O
uninduced	O
extract	O
,	O
indicating	O
predominantly	O
negative	O
regulation	O
of	O
the	O
promoter	B-DNA
.	O

The	O
transgenic	O
mice	O
exhibited	O
abnormal	O
development	O
in	O
the	O
thymus	O
and	O
spleen	O
and	O
were	O
susceptible	O
to	O
infection	O
.	O

E3	B-protein
,	O
one	O
of	O
nine	O
sequences	O
identified	O
,	O
was	O
upregulated	O
in	O
an	O
immediate-early	O
manner	O
,	O
with	O
transcript	O
levels	O
peaking	O
after	O
60	O
minutes	O
exposure	O
to	O
RA	O
.	O

Several	O
neuroendocrine-immune	O
interactions	O
could	O
be	O
responsible	O
for	O
reduced	O
GR	B-protein
levels	O
with	O
age	O
and	O
sport	O
activity	O
in	O
man	O
.	O

The	O
effects	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
infection	O
on	O
cellular	O
differentiation	O
and	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
activity	O
have	O
been	O
investigated	O
in	O
a	O
new	O
model	O
of	O
myeloid	O
differentiation	O
.	O

Only	O
NF-AT1	B-protein
and	O
NF-AT4	B-protein
,	O
but	O
not	O
NF-AT2	B-protein
and	O
NF-AT3	B-protein
,	O
have	O
translocated	O
into	O
the	O
nuclei	O
in	O
IL-4-	B-cell_line
or	I-cell_line
IL-5-stimulated	I-cell_line
eosinophils	I-cell_line
.	O

In	O
comparison	O
to	O
K562	B-cell_line
,	O
nucleated	B-cell_line
erythroblasts	I-cell_line
from	O
adult	O
human	O
bone	O
marrow	O
exhibited	O
a	O
similar	O
but	O
nonidentical	O
pattern	O
of	O
nuclear	B-protein
factor	I-protein
binding	O
in	O
vivo	O
at	O
the	O
HS-40	B-DNA
region	O
.	O

Regulation	O
of	O
lymphoid-specific	B-DNA
immunoglobulin	I-DNA
mu	I-DNA
heavy	I-DNA
chain	I-DNA
gene	I-DNA
enhancer	I-DNA
by	O
ETS-domain	O
proteins	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
were	O
investigated	O
in	O
a	O
whole	O
cell	O
dexamethasone	O
binding	O
assay	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
.	O

The	O
functional	O
domains	O
of	O
the	O
murine	B-DNA
Thy-1	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

Our	O
studies	O
examined	O
this	O
interaction	O
in	O
normal	O
human	B-cell_type
monocytes	I-cell_type
.	O

These	O
phenomena	O
are	O
in	O
a	O
dose-dependent	O
manner	O
comparable	O
to	O
that	O
seen	O
with	O
rIL-12	B-protein
.	O

These	O
data	O
indicate	O
that	O
thrombin	B-protein
activates	O
endothelial	O
ICAM-1	B-protein
expression	O
and	O
polymorphonuclear	B-cell_type
leukocyte	I-cell_type
adhesion	O
by	O
NF-kappa	B-protein
Bp65	I-protein
binding	O
to	O
the	O
downstream	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
of	O
ICAM-1	B-DNA
promoter	I-DNA
after	O
proteolytically	O
activated	O
receptor-1	O
activation	O
.	O

Analysis	O
of	O
the	O
nuclear	O
extracts	O
with	O
antibodies	B-protein
directed	O
against	O
the	O
major	O
components	O
of	O
NF-kappa	B-protein
B	I-protein
the	O
p50	B-protein
and	I-protein
RelA	I-protein
(	I-protein
p65	I-protein
)	I-protein
proteins	I-protein
,	O
indicated	O
that	O
the	O
composition	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
similar	O
in	O
neonatal	B-cell_type
and	I-cell_type
adult	I-cell_type
cells	I-cell_type
.	O

No	O
positive	O
effect	O
of	O
the	O
duplicated	O
CTG-motif	B-DNA
could	O
be	O
detected	O
.	O

Lipopolysaccharide	O
is	O
a	O
potent	O
monocyte/macrophage-specific	O
stimulator	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
.	O

In	O
Rel-/-	B-cell_line
splenic	I-cell_line
T	I-cell_line
cell	I-cell_line
cultures	I-cell_line
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
ionomycin	O
,	O
the	O
levels	O
of	O
IL-3	O
,	O
IL-5	O
,	O
granulocyte-	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
,	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
and	O
gamma	B-protein
interferon	I-protein
(	O
IFN-gamma	B-protein
)	O
were	O
only	O
2-	O
to	O
3-fold	O
lower	O
compared	O
with	O
normal	O
T	O
cells	O
.	O

Inhibition	O
of	O
calcineurin	B-protein
by	O
the	O
immunosuppressive	O
drugs	O
cyclosporin	O
A	O
and	O
FK506	O
prevents	O
dephosphorylation	O
of	O
NFATp	B-protein
and	O
its	O
translocation	O
to	O
the	O
nucleus	O
.	O

Eosinophils	B-cell_type
were	O
isolated	O
from	O
the	O
peripheral	O
blood	O
of	O
healthy	O
donors	O
and	O
cultured	O
in	O
the	O
absence	O
or	O
presence	O
of	O
IL-3	B-protein
,	O
IL-4	B-protein
,	O
and	O
IL-5	B-protein
.	O

The	O
molecular	O
events	O
that	O
follow	O
and	O
that	O
transduce	O
signals	O
from	O
these	O
receptors	O
to	O
the	O
nucleus	O
are	O
still	O
poorly	O
defined	O
.	O

METHOD	O
OF	O
STUDY	O
:	O
For	O
assessment	O
of	O
IL	O
production	O
,	O
whole	O
peripheral	O
venous	O
blood	O
from	O
healthy	O
donors	O
was	O
stimulated	O
with	O
phorbol-myristate-acetate	O
and	O
ionomycine	O
.	O

Apoptosis	O
is	O
implicated	O
in	O
the	O
generation	O
and	O
resolution	O
of	O
inflammation	O
in	O
response	O
to	O
bacterial	O
pathogens	O
.	O

Functional	O
characterization	O
of	O
this	O
element	O
demonstrates	O
that	O
it	O
can	O
mediate	O
repression	O
when	O
linked	O
in	O
cis	O
to	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O

The	O
T-cell	B-DNA
receptor	I-DNA
(	I-DNA
TCR	I-DNA
)	I-DNA
beta-chain	I-DNA
promoters	I-DNA
have	O
been	O
characterized	O
as	O
nonstructured	B-DNA
basal	I-DNA
promoters	I-DNA
that	O
carry	O
a	O
single	O
conserved	O
ubiquitous	B-DNA
cyclic	I-DNA
AMP-responsive	I-DNA
element	I-DNA
.	O

p38	B-protein
and	O
p63	B-protein
may	O
provide	O
a	O
docking	O
site	O
for	O
Grb2	B-protein
,	O
thereby	O
linking	O
Grb2	B-protein
SH3-binding	I-protein
proteins	I-protein
SOS1	B-protein
,	O
SLP-76	B-protein
,	O
and	O
p120	B-protein
to	O
downstream	O
signalling	O
events	O
.	O

The	O
third	O
member	O
of	O
the	O
family	B-protein
,	O
A-myb	B-protein
,	O
shows	O
the	O
most	O
restricted	O
pattern	O
of	O
expression	O
,	O
suggesting	O
a	O
very	O
specific	O
role	O
for	O
this	O
transcription	B-protein
factor	I-protein
.	O

beta	B-protein
2-m	I-protein
increased	O
the	O
binding	O
to	O
the	O
HLA-A3	B-protein
molecule	I-protein
but	O
did	O
not	O
influence	O
the	O
binding	O
to	O
the	O
HLA-Cw*0702	B-protein
.	O

Despite	O
the	O
widespread	O
use	O
of	O
glucocorticoids	O
in	O
the	O
treatment	O
of	O
diseases	O
characterized	O
by	O
inflammation	O
,	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
these	O
hormones	O
exert	O
this	O
beneficial	O
effect	O
in	O
patients	O
with	O
asthma	O
remains	O
to	O
be	O
elucidated	O
.	O

LIF	B-protein
increased	O
steady-state	O
levels	O
of	O
HIV	B-RNA
mRNA	I-RNA
at	O
2.0	O
,	O
4.3	O
,	O
and	O
9.2	O
kB	O
.	O

The	O
current	O
work	O
describes	O
the	O
regulation	O
of	O
TNF	B-protein
in	O
human	B-cell_line
myelomonocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
after	O
PMA	O
stimulation	O
.	O

In	O
this	O
group	O
,	O
however	O
,	O
receptor	O
levels	O
and	O
morning	O
plasma	O
cortisol	O
values	O
showed	O
a	O
negative	O
correlation	O
,	O
indicating	O
a	O
subtle	O
down-regulatory	O
effect	O
.	O

Sodium	O
salicylate	O
and	O
aspirin	O
also	O
inhibited	O
NF-kappa	B-protein
B	I-protein
-dependent	O
transcription	O
from	O
the	O
Ig	B-DNA
kappa	I-DNA
enhancer	I-DNA
and	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
in	O
transfected	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Human	B-cell_type
monocytes	I-cell_type
isolated	O
from	O
peripheral	O
blood	O
of	O
healthy	O
donors	O
show	O
a	O
time-dependent	O
differentiation	O
into	O
macrophages	B-cell_type
upon	O
in	O
vitro	O
cultivation	O
,	O
closely	O
mimicking	O
their	O
in	O
vivo	O
migration	O
and	O
maturation	O
into	O
extravascular	O
tissues	O
.	O

However	O
,	O
the	O
concurrent	O
addition	O
of	O
iron	O
(	O
in	O
the	O
form	O
of	O
ferrous	O
or	O
ferric	O
chloride	O
and	O
other	O
iron	O
salts	O
)	O
reversed	O
the	O
inhibition	O
of	O
proliferation	O
caused	O
by	O
tepoxalin	O
.	O

These	O
data	O
shed	O
light	O
on	O
the	O
biochemical	O
and	O
molecular	O
mechanisms	O
regulating	O
human	O
granulocyte	O
apoptosis	O
and	O
,	O
in	O
particular	O
,	O
indicate	O
that	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
plays	O
a	O
crucial	O
role	O
in	O
regulating	O
the	O
physiological	O
cell	O
death	O
pathway	O
in	O
granulocytes	B-cell_type
.	O

A	O
protein	O
of	O
the	O
AP-1	B-protein
family	I-protein
is	O
a	O
component	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
.	O

Transient-transfection	O
assays	O
showed	O
that	O
bcl-x	B-DNA
promoter	I-DNA
was	O
transactivated	O
by	O
wild-type	B-protein
Tax	I-protein
.	O

Transfection	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
the	O
NF-kappaB	B-protein
subunits	I-protein
p50	B-protein
and	O
p65	B-protein
confers	O
resistance	O
against	O
Fas-mediated	O
apoptosis	O
.	O

The	O
T	B-protein
cell	I-protein
activation	I-protein
factor	I-protein
NF-ATc	B-protein
positively	O
regulates	O
HIV-1	O
replication	O
and	O
gene	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
forms	O
produced	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
have	O
a	O
predominantly	O
activating	O
effect	O
on	O
gene	O
expression	O
whereas	O
those	O
produced	O
in	O
neuronal	B-cell_type
cells	I-cell_type
have	O
a	O
predominantly	O
inhibitory	O
effect	O
and	O
can	O
repress	O
the	O
expression	O
of	O
both	O
the	O
herpes	B-DNA
simplex	I-DNA
virus	I-DNA
immediate-early	I-DNA
genes	I-DNA
and	O
the	O
cellular	B-DNA
tyrosine	I-DNA
hydroxylase	I-DNA
gene	I-DNA
.	O

Cutting	O
edge	O
:	O
expression	O
of	O
the	O
NF	B-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
in	O
eosinophils	B-cell_type
:	O
regulation	O
by	O
IL-4	B-protein
and	O
IL-5	B-protein
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
NFAT	B-protein
can	O
be	O
activated	O
and	O
IL-2	B-protein
can	O
be	O
produced	O
in	O
a	O
calcineurin	B-protein
independent	O
manner	O
.	O

Importantly	O
,	O
it	O
was	O
also	O
present	O
in	O
the	O
nucleus	O
of	O
HeLa	B-cell_line
cells	I-cell_line
,	O
which	O
lack	O
HNF1	B-protein
,	O
and	O
in	O
the	O
cytoplasm	O
of	O
fibroblasts	B-cell_type
that	O
have	O
little	O
or	O
no	O
tetrahydrobiopterin	B-protein
.	O

Recent	O
studies	O
have	O
reported	O
that	O
lymphocytes	B-cell_type
produce	O
,	O
transport	O
and	O
bind	O
dopamine	O
present	O
in	O
plasma	O
.	O

The	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
under	O
the	O
control	O
of	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
0.7	O
kb	O
was	O
strongly	O
induced	O
upon	O
activation	O
with	O
anti-CD3	B-protein
or	O
PHA	B-protein
plus	O
PMA	O
only	O
in	O
SCM-1-producer	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
through	O
a	O
cyclosporin	O
A-sensitive	O
mechanism	O
.	O

Identification	O
of	O
a	O
novel	B-protein
factor	I-protein
that	O
interacts	O
with	O
an	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
promoter	I-DNA
and	O
stimulates	O
transcription	O
in	O
conjunction	O
with	O
the	O
lymphoid	B-protein
cell-specific	I-protein
factor	I-protein
OTF2	B-protein
.	O

CONCLUSION	O
:	O
Our	O
results	O
show	O
that	O
the	O
tested	O
agents	O
(	O
except	O
indomethacin	O
)	O
are	O
inhibitors	O
of	O
the	O
T	O
cell-mediated	O
immune	O
response	O
,	O
as	O
expected	O
,	O
that	O
aspirin	O
is	O
an	O
effective	O
suppressor	O
of	O
adhesion	B-protein
molecule	I-protein
expression	O
,	O
and	O
that	O
all	O
three	O
agents	O
can	O
induce	O
Hsp60	B-protein
in	O
HUVECs	B-cell_type
.	O

Finally	O
,	O
we	O
show	O
that	O
one	O
of	O
the	O
isoforms	B-protein
encodes	O
the	O
previously	O
described	O
lymphoid-specific	B-protein
Oct2B	I-protein
protein	I-protein
which	O
has	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
the	O
function	O
of	O
the	O
octamer	B-DNA
motif	I-DNA
in	O
the	O
context	O
of	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
enhancer	I-DNA
.	O

Hence	O
,	O
the	O
present	O
results	O
show	O
that	O
STAT3	B-protein
serine	O
phosphorylation	O
can	O
be	O
regulated	O
independently	O
of	O
the	O
tyrosine	O
phosphorylation	O
of	O
this	O
molecule	O
.	O

This	O
suggests	O
that	O
mutated	B-protein
Ras	I-protein
activates	O
mechanisms	O
,	O
which	O
favor	O
tumor	O
growth	O
,	O
enhance	O
the	O
metastatic	O
capacity	O
of	O
tumors	O
or	O
modulate	O
tumor-specific	O
immune	O
responses	O
.	O

In	O
contrast	O
,	O
deletion	O
of	O
the	O
upstream	B-DNA
portion	I-DNA
of	O
the	O
delta	B-DNA
promoter	I-DNA
led	O
to	O
a	O
10	O
fold	O
decrease	O
in	O
expression	O
.	O

However	O
,	O
replication	O
of	O
EBV	O
in	O
vivo	O
is	O
controlled	O
primarily	O
by	O
host	O
immune	O
mechanisms	O
selecting	O
for	O
cells	O
that	O
are	O
not	O
permissive	O
for	O
viral	O
replication	O
as	O
the	O
result	O
of	O
a	O
particular	O
set	O
of	O
transcription	B-protein
factors	I-protein
.	O

Three	O
molecular	O
clones	O
of	O
HIV-1	O
,	O
derived	O
from	O
a	O
single	O
isolate	O
(	O
AL1	O
)	O
,	O
exhibited	O
distinct	O
replicative	O
and	O
cytopathic	O
properties	O
during	O
propagation	O
in	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

The	O
signal	O
transduction	O
events	O
triggered	O
by	O
cross-linking	O
of	O
the	O
CD40	B-protein
receptor	I-protein
have	O
been	O
widely	O
studied	O
in	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
but	O
little	O
is	O
known	O
about	O
signaling	O
following	O
CD40	B-protein
stimulation	O
of	O
monocytes	B-cell_type
and	O
resting	B-cell_line
tonsillar	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O

Evidence	O
for	O
lowered	O
induction	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
in	O
activated	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
during	O
aging	O
.	O

TS	O
activated	O
HSF	B-protein
,	O
which	O
was	O
associated	O
with	O
Hsp70	B-protein
overexpression	O
and	O
inhibition	O
of	O
NFkappaB	B-protein
binding	O
activity	O
and	O
TNFalpha	B-protein
release	O
.	O

These	O
results	O
confirm	O
and	O
extend	O
the	O
notion	O
of	O
the	O
functional	O
conservation	O
of	O
the	O
AIR-1	B-protein
gene	I-protein
product	I-protein
across	O
species	O
barriers	O
.	O

Analysis	O
of	O
intracellular	O
Ca2+	O
mobilization	O
suggested	O
that	O
the	O
CD3	B-protein
/	O
TcR	B-protein
-dependent	O
signal	O
transduction	O
was	O
impaired	O
in	O
PMA/Bt2cAMP-treated	B-cell_line
cells	I-cell_line
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
IL-4	B-protein
and	O
IL-10	B-protein
inhibit	O
IL-6	B-protein
production	O
by	O
different	O
mechanisms	O
in	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Nuclear	O
run-on	O
experiments	O
demonstrated	O
decreased	O
transcription	O
of	O
kappa	B-protein
L	I-protein
chain	I-protein
.	O

Other	O
cellular	O
parameters	O
,	O
such	O
as	O
glycosidase	O
activities	O
,	O
cytokine	B-protein
release	O
,	O
and	O
filament	O
expression	O
,	O
returned	O
to	O
levels	O
similar	O
to	O
that	O
observed	O
in	O
uninduced	B-cell_type
cells	I-cell_type
.	O

These	O
cells	O
,	O
stimulated	O
by	O
an	O
agonistic	O
monoclonal	O
antibody	O
against	O
CD40	B-protein
or	O
by	O
transfection	O
with	O
a	O
CD40L	B-DNA
expression	I-DNA
vector	I-DNA
,	O
secreted	O
p40	B-protein
and	O
showed	O
enhanced	O
p40	B-RNA
mRNA	I-RNA
expression	O
.	O

Immune	O
functions	O
,	O
clinical	O
parameters	O
and	O
hormone	O
receptor	O
status	O
in	O
breast	O
cancer	O
patients	O
.	O

These	O
results	O
reveal	O
a	O
new	O
link	O
between	O
the	O
dopamine	O
system	O
,	O
cytokine	B-protein
signaling	O
pathway	O
and	O
regulation	O
of	O
gene	O
expression	O
via	O
the	O
involvement	O
of	O
NF-kappaB	B-protein
in	O
T	B-cell_type
cells	I-cell_type
and	O
PBMC	B-cell_type
.	O

In	O
contrast	O
,	O
mutation	O
of	O
the	O
kappa	B-protein
B	I-protein
enhancer	I-protein
results	O
in	O
markedly	O
attenuated	O
activities	O
of	O
both	O
promoters	B-DNA
.	O

Induction	O
of	O
the	O
POU	B-protein
domain	I-protein
transcription	I-protein
factor	I-protein
Oct-2	B-protein
during	O
T-cell	B-cell_type
activation	O
by	O
cognate	O
antigen	O
.	O

The	O
development	O
of	O
ringed	B-cell_type
sideroblasts	I-cell_type
in	O
erythroid	B-cell_line
colonies	I-cell_line
by	O
iron	O
staining	O
and	O
their	O
X-inactivation	O
pattern	O
were	O
also	O
examined	O
.	O

In	O
addition	O
,	O
GST	B-protein
pull-down	O
experiments	O
demonstrated	O
a	O
physical	O
interaction	O
between	O
human	O
GATA-1	B-protein
and	O
C/EBPbeta	B-protein
.	O

When	O
the	O
erythroid	O
and	O
monocytic	O
differentiation	O
markers	O
were	O
analyzed	O
,	O
spi-1	B-protein
overexpression	O
resulted	O
in	O
opposite	O
effects	O
:	O
erythroid	O
differentiation	O
was	O
significantly	O
inhibited	O
in	O
spi-1	B-cell_line
transfectants	I-cell_line
,	O
while	O
spi-1	B-protein
overexpression	O
increased	O
the	O
monocytic	O
differentiation	O
of	O
cells	O
.	O

Interestingly	O
,	O
the	O
combination	O
of	O
the	O
RAR-selective	O
antagonist	O
and	O
9-cis	O
RA	O
resulted	O
in	O
partial	O
differentiation	O
and	O
apoptosis	O
of	O
HL-60	B-cell_line
and	I-cell_line
NB4	I-cell_line
cells	I-cell_line
,	O
whereas	O
the	O
RAR	B-protein
antagonist	O
completely	O
blocked	O
all-trans	O
RA-induced	O
differentiation	O
and	O
apoptosis	O
of	O
the	O
cells	O
.	O

The	O
allele-specific	O
expression	O
profiles	O
of	O
other	O
imprinted	B-DNA
genes	I-DNA
,	O
IGF2	B-DNA
and	O
H19	B-DNA
,	O
on	O
human	B-DNA
chromosome	I-DNA
11	I-DNA
were	O
constant	O
and	O
consistent	O
with	O
those	O
in	O
other	O
tissues	O
.	O

According	O
to	O
our	O
results	O
,	O
however	O
,	O
the	O
kinases	O
responsible	O
for	O
the	O
two	O
processes	O
are	O
distinct	O
entities	O
.	O

Nuclear	O
levels	O
of	O
NF-kappaB	B-protein
correlate	O
with	O
syncytium-forming	O
capacity	O
of	O
8e51	B-cell_line
cells	I-cell_line
,	O
expressing	O
a	O
defective	O
HIV	O
virus	O
.	O

NF-E1	B-protein
expression	O
seems	O
to	O
be	O
restricted	O
to	O
the	O
erythrocytic	B-cell_type
lineage	I-cell_type
.	O

This	O
exon	O
was	O
inserted	O
between	B-DNA
glutamine-rich	I-DNA
regions	I-DNA
2	I-DNA
and	I-DNA
3	I-DNA
,	O
carboxy	B-protein
terminal	I-protein
of	O
a	O
tentative	O
leucine-zipper	B-protein
structure	I-protein
.	O

Aldosterone-specific	B-protein
membrane	I-protein
receptors	I-protein
and	O
rapid	O
non-genomic	O
actions	O
of	O
mineralocorticoids	O
.	O

In	O
the	O
primary	B-cell_type
cells	I-cell_type
MDHM-induced	O
elevation	O
of	O
cytokine	B-RNA
mRNA	I-RNA
levels	O
was	O
preceded	O
by	O
a	O
downregulation	O
of	O
c-fos	B-DNA
expression	O
while	O
positive	O
c-jun	B-DNA
expression	O
was	O
not	O
modulated	O
.	O

Using	O
Ad	B-DNA
2/5	I-DNA
E1a-specific	I-DNA
primers	I-DNA
and	O
the	O
polymerase	O
chain	O
reaction	O
to	O
evaluate	O
DNA	O
recovered	O
from	O
freshly	O
isolated	O
nasal	O
and	O
bronchial	O
epithelium	O
recovered	O
by	O
brushing	O
,	O
E1a	B-DNA
sequences	I-DNA
were	O
detected	O
in	O
respiratory	O
epithelium	O
of	O
19	O
of	O
91	O
normals	O
(	O
21	O
%	O
)	O
.	O

1	O
.	O

Defensin	O
resistance	O
is	O
not	O
the	O
only	O
virulence	O
characteristic	O
controlled	O
by	O
the	O
PhoP-PhoQ	B-protein
regulon	I-protein
because	O
mutations	O
in	O
pagC	B-DNA
,	O
as	O
well	O
as	O
ones	O
in	O
the	O
phoP	B-DNA
locus	I-DNA
that	O
resulted	O
in	O
constitutive	O
pag	B-DNA
activation	O
(	O
phenotype	O
PhoPc	B-protein
)	O
,	O
had	O
no	O
effect	O
on	O
defensin	B-protein
resistance	O
,	O
even	O
though	O
they	O
rendered	O
the	O
organism	O
avirulent	O
and	O
deficient	O
in	O
survival	O
within	O
macrophages	B-cell_type
.	O

Activation	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
via	O
T	B-protein
cell	I-protein
receptor	I-protein
requires	O
a	O
Raf	B-protein
kinase	I-protein
and	O
Ca2+	O
influx	O
.	O

The	O
authors	O
investigated	O
whether	O
there	O
is	O
a	O
correlation	O
between	O
HER-2/neu	B-protein
expression	O
and	O
immunologic	O
parameters	O
representing	O
tumor	O
defense	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O

Nuclear	B-protein
factor-IL6	I-protein
activates	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

In	O
fetal	O
liver	O
of	O
PU.1-/-	O
mice	O
,	O
which	O
lack	O
lymphoid	B-cell_type
and	I-cell_type
myeloid	I-cell_type
cells	I-cell_type
,	O
expression	O
of	O
Btk	B-protein
was	O
reduced	O
two-	O
to	O
threefold	O
but	O
not	O
abolished	O
.	O

We	O
demonstrate	O
that	O
the	O
staphylococcal	B-protein
superantigens	I-protein
toxic	B-protein
shock	I-protein
syndrome	I-protein
toxin-1	I-protein
(	O
TSST-1	B-protein
)	O
and	O
staphylococcal	B-protein
enterotoxin	I-protein
A	I-protein
(	O
SEA	B-protein
)	O
activate	O
HIV-1-LTR	B-DNA
-driven	O
transcription	O
of	O
chloramphenicol	B-protein
acetyl	I-protein
transferase	I-protein
in	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	B-cell_line
.	O

Block	O
of	O
granulocytic	O
differentiation	O
of	O
32Dcl3	B-cell_line
cells	I-cell_line
by	O
AML1/ETO	B-DNA
(	I-DNA
MTG8	I-DNA
)	I-DNA
but	O
not	O
by	O
highly	O
expressed	O
Bcl-2	B-protein
.	O

TCF-1	B-protein
,	O
a	O
T	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
of	O
the	O
HMG	B-protein
box	I-protein
family	I-protein
,	O
interacts	O
with	O
sequence	B-DNA
motifs	I-DNA
in	O
the	O
TCR	B-DNA
beta	I-DNA
and	I-DNA
TCR	I-DNA
delta	I-DNA
enhancers	I-DNA
.	O

Analysis	O
of	O
whole-cell	O
lysates	O
by	O
antiphosphotyrosine	O
immunoblotting	O
showed	O
that	O
incubation	O
with	O
gamma	B-protein
interferon	I-protein
brought	O
about	O
specific	O
increases	O
in	O
phosphotyrosine	O
labeling	O
of	O
several	O
proteins	O
.	O

LSF	B-protein
(	O
also	O
known	O
as	O
LBP-1	B-protein
,	O
UBP	B-protein
,	O
and	O
CP-2	B-protein
)	O
has	O
been	O
shown	O
to	O
repress	O
LTR	O
transcription	O
in	O
vitro	O
,	O
but	O
transient	O
expression	O
of	O
LSF	B-protein
has	O
no	O
effect	O
on	O
LTR	B-DNA
activity	O
in	O
vivo	O
.	O

Using	O
a	O
novel	O
flow-cytometric	O
assay	O
,	O
we	O
were	O
able	O
to	O
identify	O
CD8	B-protein
(	I-protein
+	I-protein
)	I-protein
-T-cell	I-protein
epitopes	I-protein
(	O
by	O
IE-1	B-protein
peptide-specific	O
induction	O
of	O
cytokine	B-protein
synthesis	O
)	O
and	O
simultaneously	O
measure	O
the	O
frequency	O
of	O
cells	O
directed	O
against	O
them	O
.	O

This	O
activation	O
differed	O
substantially	O
from	O
that	O
mediated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
Ca2+	O
ionophore	O
or	O
produced	O
by	O
costimulation	O
with	O
antibodies	B-protein
against	O
the	O
T	B-protein
cell	I-protein
receptor-CD3	I-protein
complex	I-protein
and	O
to	O
CD28	B-protein
.	O

We	O
have	O
constructed	O
an	O
HIV-1	B-DNA
genome	I-DNA
carrying	O
the	O
cDNA	B-DNA
of	O
a	O
proteolysis-resistant	B-protein
nuclear	I-protein
factor-kappaB	I-protein
inhibitor	I-protein
(	O
IkappaB-alphaS32/36A	B-protein
)	O
in	O
the	O
nef	B-DNA
region	I-DNA
.	O

The	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
gene	I-DNA
has	O
been	O
studied	O
extensively	O
as	O
a	O
model	O
system	O
of	O
transcriptional	O
induction	O
during	O
T-lymphocyte	O
activation	O
.	O

These	O
studies	O
demonstrate	O
that	O
E2a-Pbx1	B-protein
initiates	O
programmed	O
cell	O
death	O
of	O
hematopoietic	B-cell_type
precursers	I-cell_type
by	O
a	O
mechanism	O
that	O
requires	O
its	O
chimeric	O
transcriptional	O
properties	O
,	O
but	O
,	O
unlike	O
other	O
nuclear	B-protein
oncoproteins	I-protein
,	O
is	O
independent	O
of	O
p53	B-protein
.	O

These	O
observations	O
suggest	O
a	O
biological	O
significance	O
for	O
different	O
mechanisms	O
of	O
IL-2	B-protein
activation	O
in	O
initiation	O
and	O
maintenance	O
of	O
the	O
cytokine	B-protein
repertoire	I-protein
found	O
in	O
the	O
mucosa	O
.	O

The	O
method	O
developed	O
can	O
be	O
adapted	O
to	O
characterize	O
and	O
identify	O
other	O
composite	B-DNA
elements	I-DNA
as	O
well	O
.	O

In	O
the	O
locus	B-DNA
control	I-DNA
region	I-DNA
(	O
LCR	B-DNA
)	O
of	O
the	O
beta-globin	B-DNA
locus	I-DNA
,	O
in	O
vivo	O
footprints	O
on	O
NF-E2	B-protein
(	O
or	O
AP-1	B-protein
)	O
and	O
GATA-1	B-DNA
motifs	I-DNA
remained	O
the	O
same	O
regardless	O
of	O
whether	O
the	O
fetal	O
or	O
the	O
adult	B-DNA
globin	I-DNA
genes	I-DNA
are	O
expressed	O
.	O

Sex	O
steroid	O
regulation	O
of	O
the	O
production	O
of	O
this	O
molecule	O
,	O
as	O
well	O
as	O
other	O
cytokines	B-protein
,	O
may	O
help	O
explain	O
the	O
gender-specific	O
differences	O
in	O
the	O
immune	O
system	O
,	O
including	O
autoimmunity	O
.	O

The	O
effects	O
of	O
a	O
competitive	O
progesterone	O
antagonist	O
(	O
RU486	O
)	O
and	O
a	O
specific	O
glucocorticoid	B-protein
receptor	I-protein
blocker	O
(	O
RU43044	O
)	O
were	O
tested	O
on	O
the	O
release	O
of	O
a	O
blocking	B-protein
factor	I-protein
by	O
progesterone-treated	B-cell_line
pregnancy	I-cell_line
lymphocytes	I-cell_line
.	O

4.	O
When	O
apoptotic	B-cell_type
lymphocytes	I-cell_type
from	O
exposed	O
individuals	O
were	O
compared	O
to	O
apoptotic	B-cell_type
lymphocytes	I-cell_type
from	O
the	O
control	O
group	O
,	O
statistically-significant	O
differences	O
between	O
each	O
mean	O
group	O
were	O
detected	O
(	O
26.4	O
+/-	O
1.8	O
and	O
12.1	O
+/-	O
1.3	O
,	O
respectively	O
)	O
,	O
indicating	O
an	O
increased	O
rate	O
of	O
apoptosis	O
in	O
80.5	O
%	O
of	O
exposed	O
individuals	O
(	O
P	O
<	O
0.0001	O
,	O
Mann-Whitney	O
U-Test	O
)	O
.	O

These	O
stimuli	O
result	O
in	O
phosphorylation	O
of	O
CREB	B-protein
at	O
serine	O
133	O
.	O

The	O
percentage	O
of	O
lavage	B-cell_type
T-lymphocytes	I-cell_type
expressing	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
was	O
significantly	O
greater	O
for	O
patients	O
with	O
tuberculosis	O
presenting	O
with	O
isolated	O
hilar	O
adenopathy	O
than	O
for	O
patients	O
with	O
pulmonary	O
infiltrates	O
and/or	O
cavities	O
.	O

The	O
gene	O
is	O
expressed	O
in	O
all	O
hematopoietic	B-cell_type
cells	I-cell_type
with	O
the	O
exception	O
of	O
T-cells	B-cell_type
and	O
plasma	B-cell_type
cells	I-cell_type
.	O

These	O
isoforms	O
(	O
elf-2a	B-protein
and	O
elf-2b	B-protein
)	O
contain	O
identical	O
RBTN-2	B-protein
binding	I-protein
regions	I-protein
and	O
DNA-binding	B-protein
domains	I-protein
.	O

TF	O
antigen	O
expression	O
as	O
elicited	O
by	O
LPS	O
was	O
also	O
lowered	O
by	O
lysoPC	O
.	O

GATA-3	B-protein
represses	O
gp91phox	B-DNA
gene	I-DNA
expression	O
in	O
eosinophil-committed	B-cell_line
HL-60-C15	I-cell_line
cells	I-cell_line
.	O

We	O
now	O
find	O
that	O
LMP1	B-protein
signaling	O
through	O
TRADD	B-protein
differs	O
from	O
TNFR1	B-protein
signaling	O
through	O
TRADD	B-protein
.	O

Expression	O
status	O
of	O
BCL-6	B-protein
and	O
syndecan-1	B-protein
identifies	O
distinct	O
histogenetic	O
subtypes	O
of	O
Hodgkin	O
's	O
disease	O
.	O

Moreover	O
,	O
supplementing	O
the	O
cultures	O
with	O
high	O
doses	O
of	O
IL-2	O
reverted	O
anti-	O
TNF-alpha	B-protein
inhibition	O
of	O
cell	O
proliferation	O
but	O
did	O
not	O
affect	O
the	O
inhibition	O
of	O
HIV	O
p24	B-protein
antigen	I-protein
release	O
or	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
the	O
same	O
cultures	O
.	O

The	O
minimal	O
promoter	O
of	O
the	O
human	B-DNA
B29	I-DNA
gene	I-DNA
is	O
contained	O
within	O
a	O
193-bp	B-DNA
region	I-DNA
5	O
'	O
of	O
these	O
multiple	B-DNA
start	I-DNA
sites	I-DNA
.	O

We	O
show	O
here	O
that	O
the	O
HIV-1	O
protease	O
can	O
process	O
p105	B-protein
and	O
increases	O
levels	O
of	O
active	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
complex	I-protein
.	O

We	O
evaluated	O
two	O
cytokine	O
systems	O
,	O
IL-2	B-protein
and	O
IFNgamma	B-protein
,	O
and	O
demonstrate	O
that	O
Nmi	B-protein
augments	O
STAT	B-protein
-mediated	O
transcription	O
in	O
response	O
to	O
these	O
cytokines	B-protein
.	O

Analogous	O
to	O
costimulation	O
via	O
CD28	B-protein
,	O
this	O
activity	O
is	O
mediated	O
through	O
activation	O
of	O
Rel/kappaB	B-protein
,	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
known	O
to	O
regulate	O
IL-2	B-protein
and	O
other	O
activation-inducible	B-protein
proteins	I-protein
.	O

ATRA	O
and	O
9-cis	O
RA	O
also	O
exert	O
their	O
effect	O
on	O
the	O
proliferation	O
of	O
primitive	B-cell_type
HPCs	I-cell_type
(	O
high-proliferative	B-cell_line
potential	I-cell_line
colony-forming	I-cell_line
cells	I-cell_line
[	O
HPP-CFCs	B-cell_line
]	O
)	O
and	O
putative	B-cell_type
hematopoietic	I-cell_type
stem	I-cell_type
cells	I-cell_type
(	O
HSCs	B-cell_type
;	O
assayed	O
in	O
Dexter-type	O
long-term	O
culture	O
)	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
a	O
potent	O
stimulator	O
of	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
,	O
causing	O
secretion	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
and	O
other	O
inflammatory	O
mediators	O
.	O

Using	O
as	O
a	O
probe	O
cysteamine	O
,	O
an	O
aminothiol	O
compound	O
with	O
both	O
antioxidant	O
and	O
antiproliferative	O
activity	O
,	O
we	O
have	O
identified	O
erk2	B-protein
,	O
a	O
key	O
element	O
of	O
the	O
MAP	O
kinase	O
pathway	O
,	O
as	O
being	O
responsive	O
to	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

Activation	O
of	O
helper	B-cell_type
T	I-cell_type
cells	I-cell_type
mediated	O
by	O
the	O
T	O
cell	O
receptor	O
induces	O
a	O
series	O
of	O
biochemical	O
events	O
.	O

Our	O
results	O
suggest	O
that	O
by	O
inhibiting	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
surface	O
expression	O
of	O
several	O
adhesion	B-protein
molecules	I-protein
can	O
be	O
modulated	O
and	O
that	O
tepoxalin	O
may	O
be	O
useful	O
in	O
treating	O
selected	O
adhesion	O
mediated	O
events	O
such	O
as	O
leukocyte	O
migration	O
or	O
atherosclerotic	O
plaque	O
formation	O
.	O

Negative	O
transcriptional	O
regulation	O
of	O
human	B-DNA
interleukin	I-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
by	O
glucocorticoids	O
through	O
interference	O
with	O
nuclear	B-protein
transcription	I-protein
factors	I-protein
AP-1	B-protein
and	O
NF-AT	B-protein
.	O

A	O
significant	O
rise	O
of	O
A10	B-protein
and	O
B27	B-protein
antigen	I-protein
incidence	O
compared	O
to	O
that	O
in	O
normal	O
subjects	O
allows	O
these	O
antigens	O
to	O
be	O
considered	O
genetic	O
markers	O
of	O
Icenko-Cushing	O
's	O
syndrome	O
.	O

As	O
documented	O
in	O
the	O
accompanying	O
paper	O
(	O
Klug	O
et	O
al.	O
,	O
this	O
issue	O
)	O
,	O
an	O
active	O
v-abl	B-protein
protein	I-protein
also	O
suppresses	O
the	O
activity	O
of	O
NF-kappa	B-protein
B/rel	I-protein
and	O
expression	O
controlled	O
by	O
the	O
kappa	B-DNA
intron	I-DNA
enhancer	I-DNA
.	O

A	O
nuclear	B-protein
factor-kappaB	I-protein
-mediated	O
phenomenon	O
.	O

Recently	O
,	O
the	O
egr-1	B-DNA
promoter	I-DNA
has	O
been	O
shown	O
to	O
be	O
highly	O
responsive	O
to	O
the	O
diverse	O
biochemical	O
signals	O
generated	O
by	O
antigen	O
and	O
cytokines	B-protein
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Immunohistochemically	O
,	O
the	O
immunoreaction	O
against	O
5	O
steroid	O
hormone	O
anti-sera	O
(	O
estradiol	O
,	O
estriol	O
,	O
cortisol	O
,	O
progesterone	O
and	O
testosterone	O
)	O
was	O
examined	O
in	O
39	O
cases	O
with	O
the	O
malignant	B-cell_type
soft	I-cell_type
tissue	I-cell_type
tumors	I-cell_type
(	O
fibrosarcoma	O
:	O
8	O
,	O
malignant	O
fibrous	O
histiocytoma	O
:	O
6	O
,	O
rhabdomyosarcoma	O
:	O
10	O
,	O
leiomyosarcoma	O
:	O
10	O
,	O
liposarcoma	O
:	O
5	O
)	O
.	O

The	O
class	B-DNA
II	I-DNA
transactivator	I-DNA
(	O
CIITA	B-DNA
)	O
is	O
necessary	O
for	O
both	O
constitutive	O
and	O
IFN-gamma	B-protein
induced	O
MHC	B-protein
class	I-protein
II	I-protein
expressions	O
.	O

The	O
A6H	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	O
)	O
recognizes	O
a	O
120	B-protein
,	I-protein
000-140	I-protein
,	I-protein
000	I-protein
MW	I-protein
antigen	I-protein
that	O
is	O
expressed	O
at	O
similar	O
densities	O
on	O
85-90	O
%	O
of	O
human	O
CD4+	B-cell_type
and	I-cell_type
CD8+	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
on	O
renal	O
cell	O
carcinomas	O
.	O

Triggering	O
of	O
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
by	O
the	O
anti-HLA-DR	B-protein
monoclonal	I-protein
antibody	I-protein
(	I-protein
mAb	I-protein
)	I-protein
L243	I-protein
significantly	O
(	O
P	O
<	O
0.05	O
)	O
and	O
differentially	O
enhanced	O
the	O
release	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
by	O
the	O
non-Hodgkin	B-cell_type
's	I-cell_type
lymphoma	I-cell_type
cells	I-cell_type
Ri-I	B-cell_line
,	O
Ci-I	B-cell_line
,	O
and	O
Sc-I	B-cell_line
,	O
which	O
are	O
at	O
a	O
distinct	O
stage	O
of	O
B-cell	O
differentiation	O
,	O
and	O
by	O
the	O
more	O
mature	O
Burkitt	B-cell_line
lymphoma	I-cell_line
cell	I-cell_line
Raji	I-cell_line
;	O
in	O
contrast	O
,	O
it	O
did	O
not	O
induce	O
TNF-alpha	B-protein
release	O
by	O
the	O
pre-B	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
Nalm-6	B-cell_line
and	O
BV173	B-cell_line
.	O

These	O
data	O
demonstrate	O
that	O
DMDTC	O
is	O
a	O
potent	O
immunosuppressive	O
compound	O
in	O
vitro	O
.	O

Elf-2	B-protein
,	O
a	O
rhombotin-2	B-protein
binding	I-protein
ets	I-protein
transcription	I-protein
factor	I-protein
:	O
discovery	O
and	O
potential	O
role	O
in	O
T	O
cell	O
leukemia	O
.	O

A	O
number	O
of	O
cytokines	B-protein
and	O
growth	B-protein
factors	I-protein
use	O
the	O
JAK	B-protein
-STAT	B-protein
pathway	O
to	O
signal	O
from	O
the	O
cell	O
membrane	O
to	O
the	O
nucleus	O
.	O

In	O
the	O
absence	O
of	O
tetracyclines	O
,	O
the	O
transfected	O
T	B-cell_type
cells	I-cell_type
were	O
shown	O
to	O
express	O
the	O
chimeric	B-protein
receptor	I-protein
on	O
the	O
cell	O
surface	O
and	O
could	O
be	O
activated	O
by	O
its	O
cognate	B-protein
Ag	I-protein
,	O
leading	O
to	O
the	O
secretion	O
of	O
IL-2	B-protein
.	O

In	O
the	O
present	O
study	O
,	O
we	O
utilized	O
RXR	B-protein
-and	O
RAR	B-protein
-specific	O
agonists	O
and	O
antagonists	O
to	O
determine	O
how	O
RA	O
overcomes	O
the	O
dominant-negative	O
activity	O
of	O
the	O
truncated	B-protein
RARalpha	I-protein
in	O
these	O
different	O
myeloid	O
developmental	O
stages	O
.	O

We	O
molecularly	O
cloned	O
a	O
new	O
Grb2	B-protein
family	I-protein
member	I-protein
,	O
named	O
Grf40	B-protein
,	O
containing	O
the	O
common	O
SH3-SH2-SH3	B-protein
motif	I-protein
.	O

A	O
yeast	O
two-hybrid	O
screen	O
identified	O
TES2	B-protein
interacting	I-protein
proteins	I-protein
,	O
including	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
death	I-protein
domain	I-protein
protein	I-protein
(	O
TRADD	B-protein
)	O
.	O

We	O
reasoned	O
that	O
selective	O
IFN	B-protein
responsiveness	O
of	O
the	O
first	O
STAT	B-protein
family	I-protein
member	I-protein
(	O
Stat1	B-protein
)	O
and	O
Stat1-dependent	B-DNA
immune-response	I-DNA
genes	I-DNA
such	O
as	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
)	O
,	O
IFN	B-protein
regulatory	I-protein
factor-1	I-protein
(	O
IRF-1	B-protein
)	O
,	O
and	O
Stat1	B-protein
itself	O
in	O
airway	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
provides	O
a	O
basis	O
for	O
detecting	O
cytokine	B-protein
signaling	O
abnormalities	O
in	O
inflammatory	O
airway	O
disease	O
.	O

This	O
reduction	O
was	O
accompanied	O
by	O
rapid	O
changes	O
in	O
the	O
cellular	O
adhesion	O
of	O
dimethyl	B-cell_line
sulfoxide-differentiated	I-cell_line
HL-60	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
stimulated	O
by	O
12-O-tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
.	O

The	O
palindromic	B-DNA
site	I-DNA
(	O
site	B-DNA
B	I-DNA
)	O
recognized	O
by	O
this	O
protein	O
is	O
related	O
to	O
the	O
palindromic	B-DNA
binding	I-DNA
sites	I-DNA
of	O
members	O
of	O
the	O
steroid/thyroid	B-protein
hormone	I-protein
receptor	I-protein
family	I-protein
.	O

Clusters	O
of	O
coexpressed	B-DNA
genes	I-DNA
identified	O
through	O
manipulations	O
of	O
mammary	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
in	O
vitro	O
also	O
showed	O
consistent	O
patterns	O
of	O
variation	O
in	O
expression	O
among	O
breast	O
tumor	O
samples	O
.	O

Cytotoxicity	B-protein
markers	I-protein
assessed	O
include	O
tumor	O
cell	O
killing	O
,	O
IL-1	B-protein
secretion	O
,	O
reactive	O
oxygen	O
intermediate	O
release	O
,	O
nitric	B-protein
oxide	I-protein
synthetase	I-protein
activity	O
as	O
measured	O
by	O
the	O
release	O
of	O
reactive	O
nitrogen	O
intermediates	O
,	O
complement	B-protein
receptor-1	I-protein
cell	I-protein
surface	I-protein
protein	I-protein
,	O
and	O
TNF-alpha	B-protein
protein	I-protein
presence	O
.	O

PU.1	B-protein
is	O
completely	O
absent	O
from	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
most	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
based	O
on	O
sensitive	O
RT-PCR	O
assays	O
.	O

However	O
,	O
we	O
found	O
that	O
RA	O
opposed	O
anti-apoptotic	O
effects	O
of	O
G-CSF	B-protein
and	O
GM-CSF	B-protein
on	O
CD34+	B-cell_type
cells	I-cell_type
(	O
G-CSF	B-protein
:	O
8	O
%	O
dead	B-cell_type
cells	I-cell_type
at	O
day	O
6	O
;	O
G-CSF	B-protein
+	O
RA	O
:	O
20	O
%	O
;	O
GM-CSF	B-protein
:	O
12	O
%	O
;	O
GM-CSF	B-protein
+	O
RA	O
:	O
27	O
%	O
)	O
.	O

Cross-linking	O
of	O
FcR	B-protein
with	O
immune	B-protein
complexes	I-protein
leads	O
,	O
first	O
to	O
activation	O
of	O
protein-tyrosine	B-protein
kinases	I-protein
.	O

PU.1	B-protein
seems	O
to	O
be	O
required	O
for	O
early	O
development	O
of	O
multiple	B-cell_type
hematopoietic	I-cell_type
lineages	I-cell_type
,	O
but	O
its	O
expression	O
in	O
mature	B-cell_type
cells	I-cell_type
is	O
preferentially	O
observed	O
in	O
cells	O
of	O
the	O
B-cell-and	B-cell_type
monocyte/macrophage-differentiation	I-cell_type
lineage	I-cell_type
.	O

In	O
this	O
article	O
,	O
transcriptional	O
regulation	O
of	O
the	O
archetypal	B-DNA
T-cell-specific	I-DNA
gene	I-DNA
,	O
alpha	B-DNA
TCR	I-DNA
,	O
is	O
discussed	O
.	O

These	O
include	O
(	O
5'-3	O
'	O
)	O
a	O
composite	O
NF-AT/	B-DNA
``	I-DNA
AP-1	I-DNA
''	I-DNA
element	I-DNA
,	O
a	O
CD28	B-DNA
response	I-DNA
element	I-DNA
,	O
an	O
AP-1	B-DNA
element	I-DNA
,	O
an	O
NF-AT	B-DNA
element	I-DNA
,	O
and	O
the	O
AP-1	B-DNA
part	I-DNA
of	I-DNA
an	I-DNA
AP-1/octamer	I-DNA
composite	I-DNA
element	I-DNA
.	O

In	O
addition	O
,	O
dibutyryl	O
cAMP	O
inhibited	O
cell	O
growth	O
in	O
a	O
dose-dependent	O
manner	O
,	O
whereas	O
histamine	O
failed	O
to	O
affect	O
proliferation	O
and	O
differentiation	O
of	O
U937	B-cell_line
cells	I-cell_line
.	O

The	O
extracts	O
were	O
compared	O
for	O
their	O
ability	O
to	O
retard	O
the	O
migration	O
of	O
radiolabeled	O
double	O
stranded	O
oligomers	O
representative	O
of	O
the	O
VDREs	B-DNA
of	O
the	O
human	B-DNA
osteocalcin	I-DNA
and	I-DNA
the	I-DNA
mouse	I-DNA
osteopontin	I-DNA
gene	I-DNA
promoters	I-DNA
.	O

We	O
conclude	O
that	O
soluble	O
TNF	O
receptors	O
can	O
inhibit	O
stimuli-induced	O
HIV-1	O
expression	O
and	O
NK-	B-protein
kappa	I-protein
B	I-protein
DNA-binding	O
activity	O
in	O
chronically	O
infected	B-cell_type
U1	I-cell_type
cells	I-cell_type
.	O

PKC-zeta	B-protein
belongs	O
to	O
this	O
family	O
and	O
is	O
known	O
to	O
be	O
an	O
important	O
step	O
in	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
other	O
cell	O
systems	O
.	O

The	O
mechanisms	O
by	O
which	O
beta-catenin	B-protein
undergoes	O
this	O
shift	O
in	O
location	O
and	O
participates	O
in	O
activation	O
of	O
gene	O
transcription	O
are	O
unknown	O
.	O

Moreover	O
,	O
Elf-1	B-protein
is	O
the	O
only	O
factor	O
present	O
in	O
activated	O
T-cell	O
nuclear	O
extracts	O
that	O
binds	O
to	O
these	O
sites	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

By	O
employing	O
a	O
derivative	O
E	B-DNA
box	I-DNA
that	O
binds	O
ZEB	B-protein
but	O
not	O
E2A	B-protein
,	O
we	O
have	O
shown	O
that	O
the	O
repressor	B-protein
is	O
active	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
the	O
IgH	B-DNA
enhancer	I-DNA
is	O
silenced	O
in	O
the	O
absence	O
of	O
binding	O
competition	O
by	O
bHLH	B-protein
proteins	I-protein
.	O

The	O
CRE	B-DNA
and	I-DNA
kappaB3	I-DNA
sites	I-DNA
in	O
region	B-DNA
II	I-DNA
together	O
conferred	O
strong	O
LPS	O
responsiveness	O
to	O
a	O
heterologous	B-DNA
promoter	I-DNA
,	O
whereas	O
individually	O
they	O
failed	O
to	O
provide	O
transcriptional	O
activation	O
.	O

A	O
T	B-protein
cell-specific	I-protein
protein	I-protein
Neg-1	B-protein
and	O
a	O
ubiquitous	B-protein
protein	I-protein
Neg-2	B-protein
binding	O
to	O
NRE-I	B-DNA
and	O
NRE-II	B-DNA
,	O
respectively	O
,	O
were	O
identified	O
.	O

During	O
the	O
treatment	O
with	O
As2O3	O
,	O
there	O
was	O
no	O
bone	O
marrow	O
depression	O
and	O
only	O
limited	O
side	O
effects	O
were	O
encountered	O
.	O

In	O
addition	O
,	O
antagonists	O
show	O
distinctly	O
different	O
requirements	O
for	O
efficient	O
binding	O
,	O
which	O
may	O
contribute	O
to	O
their	O
interference	O
in	O
the	O
ligand-inducible	O
transactivation	O
function	O
of	O
RAR	B-protein
alpha	I-protein
.	O

Glucocorticoid-induced	O
cell	O
death	O
requires	O
autoinduction	O
of	O
glucocorticoid	B-protein
receptor	I-protein
expression	O
in	O
human	B-cell_type
leukemic	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
binding	O
of	O
these	O
proteins	O
to	O
the	O
regulatory	O
region	O
of	O
IL-2	B-DNA
gene	I-DNA
in	O
vitro	O
and	O
stimulation	O
of	O
the	O
IL-2mRNA	B-RNA
synthesis	O
in	O
splenic	B-cell_line
T-lymphocytes	I-cell_line
culture	I-cell_line
in	O
normal	O
conditions	O
were	O
shown	O
.	O

In	O
hematopoietic	O
system	O
,	O
RA	O
and	O
RARs	B-protein
,	O
predominantly	O
RAR	B-protein
alpha	I-protein
may	O
play	O
key	O
roles	O
for	O
the	O
proliferation	O
and	O
differentiation	O
of	O
hematopoietic	B-cell_type
progenitors	I-cell_type
.	O

Serine	O
phosphorylation	O
of	O
STAT1	B-protein
and	O
STAT3	B-protein
was	O
seen	O
occasionally	O
in	O
other	O
leukemias	O
,	O
but	O
it	O
was	O
a	O
universal	O
finding	O
only	O
in	O
CLL	O
.	O

RESULTS	O
:	O
Therapeutic	O
concentrations	O
of	O
As2O3	O
(	O
1-2	O
microM	O
)	O
had	O
dual	O
effects	O
on	O
malignant	B-cell_type
lymphocytes	I-cell_type
:	O
1	O
)	O
inhibition	O
of	O
growth	O
through	O
adenosine	O
triphosphate	O
(	O
ATP	O
)	O
depletion	O
and	O
prolongation	O
of	O
cell	O
cycle	O
time	O
and	O
2	O
)	O
induction	O
of	O
apoptosis	O
.	O

Here	O
we	O
investigated	O
the	O
role	O
and	O
involvement	O
of	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF-alpha	B-protein
)	O
signal	B-protein
transducer	I-protein
molecules	I-protein
in	O
LPS	O
signaling	O
in	O
human	B-cell_type
dermal	I-cell_type
microvessel	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
HDMEC	B-cell_type
)	O
and	O
THP-1	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
.	O

The	O
integral	O
membrane	O
glycoprotein	B-protein
CD36	I-protein
appears	O
to	O
play	O
a	O
physiological	O
role	O
in	O
binding	O
and	O
uptake	O
of	O
Ox	O
LDL	O
by	O
monocyte-macrophages	B-cell_type
,	O
although	O
the	O
molecular	O
events	O
associated	O
with	O
CD36	B-protein
-Ox	O
LDL	O
interaction	O
are	O
unknown	O
.	O

NF-AT	B-protein
and	O
NF-kappaB	B-protein
were	O
not	O
significantly	O
induced	O
by	O
IL-2	B-protein
stimulation	O
.	O

These	O
findings	O
are	O
the	O
first	O
to	O
demonstrate	O
membrane	O
binding	O
of	O
aldosterone	O
being	O
compatible	O
with	O
major	O
aspects	O
of	O
its	O
nongenomic	O
effects	O
.	O

In	O
contrast	O
,	O
BRL49653	O
significantly	O
increased	O
MCP-1	B-protein
(	O
biotinylated	B-protein
MCP-1	I-protein
)	O
binding	O
to	O
THP-1	B-cell_type
cells	I-cell_type
,	O
whereas	O
RA	O
had	O
no	O
effect	O
.	O

To	O
gain	O
further	O
knowledge	O
of	O
the	O
IL-12R	B-protein
complex	I-protein
and	O
the	O
IL-12	B-protein
signal	O
transduction	O
pathway	O
in	O
cytotoxic	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
we	O
studied	O
a	O
number	O
of	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
had	O
been	O
transformed	O
to	O
permanent	O
growth	O
with	O
Herpesvirus	O
saimiri	O
,	O
an	O
oncogenic	O
virus	O
of	O
nonhuman	O
primates	O
.	O

Being	O
compatible	O
with	O
those	O
results	O
,	O
Azeptin	O
(	O
10	O
(	O
-5	O
)	O
M	O
)	O
suppressed	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
PBL	B-cell_type
,	O
HM	O
and	O
HF	B-cell_type
.	O

The	O
immunoregulatory	B-protein
properties	O
of	O
prolactin	O
,	O
a	O
pituitary	O
peptide	O
hormone	O
,	O
have	O
received	O
renewed	O
attention	O
.	O

In	O
each	O
case	O
,	O
cytogenetic	O
analysis	O
had	O
either	O
failed	O
or	O
had	O
shown	O
no	O
abnormalities	O
of	O
chromosome	B-DNA
20	I-DNA
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
following	O
incubation	O
of	O
L540	B-cell_line
cells	I-cell_line
(	O
Hodgkin	B-cell_line
's	I-cell_line
disease-derived	I-cell_line
,	I-cell_line
T	I-cell_line
cell-like	I-cell_line
,	I-cell_line
CD30+	I-cell_line
cells	I-cell_line
)	O
with	O
the	O
agonistic	B-protein
anti-CD30	I-protein
monoclonal	I-protein
antibodies	I-protein
(	O
mAb	B-protein
)	O
M44	B-protein
and	O
M67	B-protein
,	O
two	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
DNA	O
binding	O
activities	O
were	O
induced	O
in	O
nuclear	O
extracts	O
,	O
as	O
determined	O
in	O
gel	O
retardation	O
assays	O
.	O

These	O
effects	O
of	O
D-ribose	O
seemed	O
almost	O
irreversible	O
but	O
could	O
be	O
prevented	O
by	O
addition	O
of	O
1	O
mM	O
aminoguanidine	O
or	O
10	O
mM	O
N-acetylcysteine	O
,	O
thus	O
suggesting	O
that	O
glycation	O
and	O
reactive	O
oxygen	O
species	O
,	O
generated	O
through	O
the	O
glycation	O
reaction	O
,	O
serve	O
as	O
mediators	O
of	O
the	O
phenomena	O
.	O

The	O
IL-4-induced	B-protein
complex	I-protein
reacted	O
with	O
anti-STAT	B-protein
(	I-protein
signal	I-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	I-protein
6	I-protein
,	O
resulting	O
in	O
a	O
supershift	O
whereas	O
the	O
formation	O
of	O
the	O
IFN-gamma-induced	B-protein
complex	I-protein
was	O
inhibited	O
by	O
anti-STAT	B-protein
1	I-protein
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
ubiquitin	B-protein
-proteasome	B-protein
system	O
is	O
involved	O
in	O
the	O
process	O
;	O
however	O
,	O
the	O
specific	O
enzymes	B-protein
involved	O
and	O
the	O
mechanism	O
of	O
limited	O
proteolysis	O
,	O
in	O
which	O
half	O
of	O
the	O
molecule	O
is	O
spared	O
,	O
have	O
been	O
obscure	O
.	O

This	O
correlated	O
with	O
a	O
strong	O
reduction	O
of	O
BrdU	O
incorporation	O
after	O
24	O
h	O
of	O
TNFalpha	B-protein
treatment	O
.	O

These	O
results	O
add	O
a	O
different	O
perspective	O
to	O
the	O
molecular	O
interactions	O
through	O
which	O
LMP1	B-protein
,	O
TRADD	B-protein
,	O
and	O
RIP	B-protein
participate	O
in	O
B-lymphocyte	O
activation	O
and	O
growth	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
is	O
thought	O
to	O
exert	O
its	O
immunosuppressive	O
effects	O
by	O
inhibiting	O
the	O
expression	O
of	O
a	O
distinct	O
set	O
of	O
lymphokine	B-DNA
genes	I-DNA
which	O
are	O
induced	O
upon	O
T-cell	O
activation	O
,	O
among	O
them	O
the	O
gene	O
coding	O
for	O
interleukin-2	B-protein
.	O

We	O
found	O
a	O
constitutive	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
,	O
the	O
major	O
cytoplasmic	B-protein
inhibitor	I-protein
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
in	O
freshly	O
isolated	O
PBMC	B-cell_type
and	O
monocytes	B-cell_type
from	O
patients	O
with	O
tuberculosis	O
.	O

SHP2-interacting	B-protein
transmembrane	I-protein
adaptor	I-protein
protein	I-protein
(	O
SIT	B-protein
)	O
,	O
a	O
novel	O
disulfide-linked	B-protein
dimer	I-protein
regulating	O
human	O
T	O
cell	O
activation	O
.	O

Finally	O
,	O
a	O
novel	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
has	O
been	O
mapped	O
in	O
the	O
IL-3	B-DNA
promoter	I-DNA
between	O
nucleotide	O
-180	O
and	O
-210	O
that	O
leads	O
to	O
increased	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Characterization	O
of	O
5	B-DNA
'	I-DNA
end	I-DNA
of	I-DNA
human	I-DNA
thromboxane	I-DNA
receptor	I-DNA
gene	I-DNA
.	O

Activation	O
of	O
term	B-cell_type
infant	I-cell_type
cord	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
with	O
anti-CD3	B-protein
monoclonal	I-protein
antibodies	I-protein
resulted	O
in	O
up-regulation	O
of	O
both	O
c-jun	B-protein
and	O
c-fos	O
mRNAs	B-RNA
within	O
15	O
min	O
of	O
stimulation	O
.	O

In	O
chloramphenicol	B-protein
acetyltransferase	I-protein
assays	O
,	O
utilizing	O
the	O
transient	O
transfection	O
of	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
plasmid	I-DNA
containing	O
the	O
IL-6	B-DNA
gene	I-DNA
promoter	I-DNA
,	O
IL-4	B-protein
,	O
but	O
not	O
IL-10	B-protein
,	O
suppressed	O
the	O
transcriptional	O
activity	O
of	O
the	O
IL-6	O
gene	O
promoter	O
stimulated	O
by	O
PMA	O
and	O
LPS	O
.	O

Involvement	O
of	O
an	O
SAF-like	B-protein
transcription	I-protein
factor	I-protein
in	O
the	O
activation	O
of	O
serum	B-DNA
amyloid	I-DNA
A	I-DNA
gene	I-DNA
in	O
monocyte/macrophage	B-cell_type
cells	I-cell_type
by	O
lipopolysaccharide	O
.	O

Functional	O
analysis	O
of	O
monocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
transfected	O
with	O
plasmids	B-DNA
containing	O
various	O
lengths	O
of	O
TNF-alpha	B-DNA
promoter	I-DNA
localized	O
enhancer	B-DNA
elements	I-DNA
in	O
a	O
region	O
(	O
-182	B-DNA
to	I-DNA
-37	I-DNA
base	I-DNA
pairs	I-DNA
(	O
bp	O
)	O
)	O
that	O
were	O
required	O
for	O
optimal	O
transcription	O
of	O
the	O
TNF-alpha	B-DNA
gene	I-DNA
in	O
response	O
to	O
LPS	O
.	O

Using	O
a	O
yeast	O
two-hybrid	O
screen	O
to	O
identify	O
Syk	B-protein
kinases-interacting	I-protein
proteins	I-protein
(	O
SKIPs	B-protein
)	O
,	O
we	O
isolated	O
3BP2	B-protein
,	O
an	O
Abl	B-protein
SH3-interacting	I-protein
protein	I-protein
of	O
unknown	O
function	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
hXBP-1	B-protein
protein	I-protein
acts	O
as	O
a	O
transcription	B-protein
factor	I-protein
in	O
B	B-cell_type
cells	I-cell_type
.	O

The	O
B	B-protein
cell-specific	I-protein
nuclear	I-protein
factor	I-protein
OTF-2	B-protein
positively	O
regulates	O
transcription	O
of	O
the	O
human	B-DNA
class	I-DNA
II	I-DNA
transplantation	I-DNA
gene	I-DNA
,	O
DRA	B-DNA
.	O

A	O
nuclear	B-protein
factor	I-protein
NF-GM2	B-protein
that	O
interacts	O
with	O
a	O
regulatory	B-DNA
region	I-DNA
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
essential	O
for	O
its	O
induction	O
in	O
responses	O
to	O
T-cell	O
activation	O
:	O
purification	O
from	O
human	O
T-cell	B-cell_line
leukemia	I-cell_line
line	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
and	O
similarity	O
to	O
NF-kappa	B-protein
B	I-protein
.	O

In	O
addition	O
,	O
IFN-gamma	B-protein
enhanced	O
the	O
DNA-binding	O
activity	O
of	O
Stat1alpha	B-protein
.	O

Some	O
of	O
the	O
epitopes	O
were	O
detectable	O
only	O
by	O
immunoblotting	O
with	O
fusion	B-protein
proteins	I-protein
;	O
others	O
were	O
detectable	O
only	O
by	O
an	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
with	O
synthetic	O
peptides	O
.	O

On	O
several	O
occasions	O
we	O
have	O
observed	O
retrovirus-like	O
particles	O
(	O
RVLPs	O
)	O
by	O
transmission	O
electron	O
microscopy	O
(	O
EM	O
)	O
of	O
cultured	B-cell_line
T	I-cell_line
cells	I-cell_line
from	O
a	O
patient	O
with	O
MS	O
.	O

The	O
level	O
of	O
mRNA	O
expression	O
of	O
the	O
NM23	B-DNA
gene	I-DNA
is	O
significantly	O
lower	O
in	O
cell	B-cell_line
lines	I-cell_line
that	O
derive	O
from	O
more	O
infiltrating	O
primary	O
melanomas	O
than	O
in	O
cell	B-cell_line
lines	I-cell_line
obtained	O
from	O
less	O
infiltrating	O
tumours	O
.	O

The	O
presence	O
of	O
variants	O
did	O
not	O
correlate	O
with	O
disease	O
activity	O
or	O
medication	O
.	O

The	O
HTLV-I	B-DNA
LTR	I-DNA
contains	O
three	O
conserved	O
regulatory	B-DNA
elements	I-DNA
known	O
as	O
21	B-DNA
base	I-DNA
pair	I-DNA
repeats	I-DNA
which	O
are	O
required	O
for	O
stimulation	O
of	O
gene	O
expression	O
by	O
the	O
transactivator	B-protein
protein	I-protein
tax	B-protein
.	O

Cell-to-cell	O
contact	O
activates	O
in	O
vitro	O
binding	O
of	O
the	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
p50/p65	I-protein
heterodimer	I-protein
to	O
an	O
HIV-1	O
kappaB	O
oligonucleotide	O
.	O

These	O
results	O
describe	O
for	O
the	O
first	O
time	O
the	O
rapid	O
modulation	O
of	O
the	O
NT3R	B-protein
in	O
response	O
to	O
the	O
combined	O
influence	O
of	O
cold	O
exposure	O
and	O
reduced	O
circulating	O
T4	O
and	O
TSH	O
.	O

High-level	O
expression	O
in	O
nonproliferating	B-cell_type
B	I-cell_type
cells	I-cell_type
suggests	O
that	O
TCL1	B-protein
may	O
function	O
in	O
protecting	O
naive	B-cell_type
preactivated	I-cell_type
B	I-cell_type
cells	I-cell_type
from	O
apoptosis	O
.	O

Identification	O
of	O
more	O
specific	O
and	O
efficacious	O
inhibitors	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
might	O
prove	O
beneficial	O
for	O
the	O
treatment	O
of	O
cytokine-mediated	O
inflammatory	O
diseases	O
.	O

Platelet	B-protein
thromboxane	I-protein
receptors	I-protein
are	O
acutely	O
and	O
reversibly	O
upregulated	O
after	O
acute	O
myocardial	O
infarction	O
.	O

Prior	O
studies	O
have	O
shown	O
MCP-1	B-protein
expression	O
is	O
modulated	O
by	O
a	O
variety	O
of	O
ligands	O
that	O
act	O
through	O
extracellular	B-protein
receptors	I-protein
.	O

The	O
presence	O
of	O
an	O
active	O
CRE	B-DNA
site	I-DNA
in	O
the	O
bcl-2	B-DNA
promoter	I-DNA
implies	O
that	O
the	O
regulation	O
of	O
bcl-2	B-protein
expression	O
is	O
linked	O
to	O
a	O
signal	O
transduction	O
pathway	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
family	O
of	O
anti-inflammatory	O
agents	O
,	O
known	O
as	O
the	O
salicylates	O
,	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
activity	O
and	O
TF	B-DNA
gene	I-DNA
transcription	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
monocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
at	O
clinically	O
relevant	O
doses	O
.	O

Changes	O
in	O
PKC	B-protein
isoforms	I-protein
in	O
human	B-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
compared	O
with	O
blood	B-cell_type
monocytes	I-cell_type
.	O

This	O
induction	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
expression	O
is	O
transcriptionally	O
mediated	O
and	O
occurs	O
in	O
the	O
absence	O
of	O
synthesis	O
of	O
additional	O
protein	B-protein
factors	I-protein
.	O

The	O
transcription	B-protein
factors	I-protein
c-myb	B-protein
and	O
C/EBP	B-protein
alpha	I-protein
regulate	O
the	O
monocytic/myeloic	B-DNA
gene	I-DNA
MRP14	B-DNA
.	O

In	O
addition	O
,	O
we	O
observed	O
cell	O
type-specific	O
permissiveness	O
to	O
replication	O
of	O
some	O
mutant	O
viruses	O
.	O

The	O
expression	O
of	O
tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
,	O
the	O
principal	O
initiator	O
of	O
coagulation	O
,	O
is	O
increased	O
during	O
inflammation	O
and	O
atherosclerosis	O
.	O

Consequently	O
,	O
LMP-1	B-protein
triggers	O
the	O
activity	O
of	O
the	O
c-Jun	B-protein
N-terminal	I-protein
transactivation	I-protein
domain	I-protein
which	O
is	O
known	O
to	O
be	O
activated	O
upon	O
JNK	B-protein
-mediated	O
phosphorylation	O
.	O

Superantigens	B-protein
activate	O
HIV-1	O
gene	O
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

A	O
decrease	O
of	O
intracellular	O
sodium	O
or	O
potassium	O
occurred	O
during	O
incubation	O
without	O
aldosterone	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

Finally	O
,	O
oxidants	O
are	O
believed	O
to	O
promote	O
intestinal	B-cell_type
epithelial	I-cell_type
cell	I-cell_type
apoptosis	O
,	O
and	O
the	O
B-cell	B-protein
lymphoma/leukemia-2	I-protein
gene	I-protein
product	I-protein
is	O
believed	O
to	O
inhibit	O
this	O
phenomenon	O
in	O
an	O
antioxidant-dependent	O
manner	O
.	O

This	O
study	O
shows	O
that	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
cascade	O
is	O
blocked	O
when	O
anergy	O
is	O
induced	O
to	O
high	O
concentrations	O
of	O
soluble	O
peptide	O
.	O

Complementary	B-DNA
DNA	I-DNA
(	O
cDNA	B-DNA
)	O
encoding	O
a	O
human	B-protein
TFIID	I-protein
protein	I-protein
has	O
been	O
cloned	O
.	O

There	O
was	O
no	O
apparent	O
correlation	O
between	O
serum	O
testosterone	O
concentrations	O
and	O
androgen	B-protein
binding	I-protein
sites	I-protein
.	O

The	O
resulting	O
occupancy	O
displays	O
strong	O
similarities	O
with	O
the	O
one	O
observed	O
in	O
the	O
MHC	B-cell_type
class	I-cell_type
II-constitutive	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
represented	O
by	O
both	O
the	O
Burkitt	B-cell_line
lymphoma	I-cell_line
line	I-cell_line
Raji	I-cell_line
and	O
normal	B-cell_type
tonsil-	I-cell_type
derived	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Triggering	O
of	O
the	O
T-cell	B-protein
receptor-CD3	I-protein
complex	I-protein
activates	O
two	O
major	O
signal	O
cascades	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
(	O
i	O
)	O
Ca2+-dependent	O
signal	O
cascades	O
and	O
(	O
ii	O
)	O
protein	B-protein
kinase	I-protein
cascades	O
.	O

When	O
expressed	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
recombinant	O
NFAT1	B-protein
is	O
regulated	O
,	O
as	O
expected	O
,	O
by	O
the	O
calmodulin-dependent	B-protein
phosphatase	I-protein
calcineurin	B-protein
,	O
and	O
its	O
function	O
is	O
inhibited	O
by	O
the	O
immunosuppressive	O
agent	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

We	O
propose	O
that	O
Th1	O
development	O
can	O
be	O
considered	O
in	O
two	O
stages	O
,	O
capacitance	O
and	O
development	O
.	O

Recently	O
we	O
have	O
reported	O
that	O
the	O
Pax5	B-DNA
gene	I-DNA
is	O
subject	O
to	O
allele	B-DNA
-specific	O
regulation	O
during	O
B	O
cell	O
development	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
9S	B-protein
,	O
untransformed	B-protein
progestin	I-protein
,	I-protein
estrogen	I-protein
,	I-protein
androgen	I-protein
,	I-protein
and	I-protein
glucocorticoid	I-protein
receptor	I-protein
complexes	I-protein
in	O
rabbit	O
uterine	O
and	O
liver	O
cytosols	O
contain	O
a	O
59-kDa	B-protein
protein	I-protein
[	O
Tai	O
,	O
P.K.	O
,	O
Maeda	O
,	O
Y.	O
,	O
Nakao	O
,	O
K.	O
,	O
Wakim	O
,	O
N.G.	O
,	O
Duhring	O
,	O
J.L.	O
,	O
&	O
Faber	O
,	O
L.E.	O
(	O
1986	O
)	O
Biochemistry	O
25	O
,	O
5269-5275	O
]	O
.	O

This	O
review	O
focuses	O
on	O
the	O
molecular	O
actions	O
of	O
prolactin	O
in	O
the	O
immune	O
system	O
.	O

Analysis	O
of	O
MSR	B-DNA
promoter	I-DNA
activity	O
in	O
THP-1	B-cell_line
cells	I-cell_line
transfected	O
with	O
an	O
MSR	B-DNA
promoter-reporter	I-DNA
gene	I-DNA
construct	I-DNA
demonstrated	O
decreased	O
activity	O
of	O
the	O
MSR	B-DNA
promoter	I-DNA
in	O
IL-6	B-protein
-treated	O
THP-1	B-cell_line
macrophages	B-cell_type
.	O

Conditioned	O
medium	O
from	O
monocytes	B-cell_type
reduced	O
proliferation	O
in	O
a	O
dose-dependent	O
manner	O
.	O

This	O
difference	O
in	O
efficacy	O
,	O
which	O
correlates	O
with	O
the	O
compounds	O
'	O
anti-inflammatory	O
potency	O
in	O
vivo	O
,	O
may	O
be	O
explained	O
by	O
differences	O
in	O
structure	O
and	O
conformation	O
.	O

Induction	O
of	O
tyrosine	O
phosphorylation	O
and	O
T-cell	B-cell_type
activation	O
by	O
vanadate	O
peroxide	O
,	O
an	O
inhibitor	O
of	O
protein	B-protein
tyrosine	I-protein
phosphatases	I-protein
.	O

Involvement	O
of	O
NF-chi	B-protein
B	I-protein
and	O
NF-IL6	B-protein
in	O
induction	O
of	O
IL-6	B-protein
transcription	O
by	O
monocytes	O
was	O
demonstrated	O
using	O
deleted	O
forms	O
of	O
the	O
IL-6	B-DNA
promoter	I-DNA
.	O

Silencing	O
of	O
human	O
fetal	O
globin	B-protein
expression	O
is	O
impaired	O
in	O
the	O
absence	O
of	O
the	O
adult	B-protein
beta-globin	I-protein
gene	I-protein
activator	I-protein
protein	I-protein
EKLF	B-protein
.	O

Structure	O
function	O
analysis	O
of	O
vitamin	O
D	O
analogs	O
with	O
C-ring	O
modifications	O
.	O

(	O
4	O
)	O
Intrafollicular	B-cell_type
CD57+	I-cell_type
cells	I-cell_type
were	O
negative	O
for	O
Bcl-6	B-protein
,	O
indicating	O
heterogeneity	O
of	O
the	O
intrafollicular	B-cell_type
T-cell	I-cell_type
population	I-cell_type
.	O

The	O
reduction	O
paralleled	O
a	O
decrease	O
in	O
tyrosine	O
phosphorylation	O
of	O
endogenous	B-protein
wild-type	I-protein
Itk	I-protein
.	O

However	O
,	O
the	O
TPA	O
responsiveness	O
of	O
both	O
CMV	B-DNA
elements	I-DNA
proved	O
to	O
involve	O
synergistic	O
interactions	O
between	O
the	O
core	O
SRF	B-DNA
binding	I-DNA
site	I-DNA
(	O
CCATATATGG	O
)	O
and	O
the	O
adjacent	O
inverted	O
ETS	B-DNA
binding	I-DNA
motifs	I-DNA
(	O
TTCC	O
)	O
,	O
which	O
correlated	O
directly	O
with	O
formation	O
of	O
a	O
bound	O
tripartite	B-protein
complex	I-protein
containing	O
both	O
the	O
cellular	O
SRF	B-protein
and	O
ELK-1	B-protein
proteins	I-protein
.	O

Cytokines	B-protein
that	O
bind	O
to	O
the	O
common	O
gamma	B-protein
chain	I-protein
of	O
the	O
IL-2	B-protein
receptor	O
promote	O
the	O
survival	O
of	O
T	B-cell_type
cell	I-cell_type
blasts	I-cell_type
,	O
but	O
also	O
induce	O
proliferation	O
.	O

Cu2+	O
was	O
found	O
to	O
inhibit	O
the	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
induced	O
by	O
TNF-alpha	B-protein
,	O
TPA	O
,	O
or	O
H2O2	O
.	O

CholecystokininB	B-protein
receptor	I-protein
from	O
human	B-cell_line
Jurkat	I-cell_line
lymphoblastic	I-cell_line
T	I-cell_line
cells	I-cell_line
is	O
involved	O
in	O
activator	B-protein
protein-1	I-protein
-responsive	O
gene	O
activation	O
.	O

The	O
beta-casein	B-DNA
promoter	I-DNA
has	O
been	O
widely	O
used	O
to	O
monitor	O
the	O
activation	O
of	O
STAT	B-protein
(	I-protein
signal	I-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
)	I-protein
5	I-protein
since	O
STAT5	B-protein
was	O
originally	O
found	O
as	O
a	O
mediator	O
of	O
PRL-inducible	O
beta-casein	B-protein
expression	O
.	O

Mapping	O
of	O
the	O
structural	O
requirements	O
for	O
TRAF	B-protein
/RANK	B-protein
interaction	O
revealed	O
multiple	O
TRAF	B-protein
binding	I-protein
sites	I-protein
clustered	O
in	O
two	O
distinct	O
domains	O
in	O
the	O
RANK	B-protein
cytoplasmic	I-protein
tail	I-protein
.	O

Transient	O
overexpression	O
of	O
inactive	O
mutants	O
of	O
either	O
Raf-1	B-protein
or	O
JNK1	B-protein
showed	O
that	O
both	O
pathways	O
were	O
involved	O
in	O
kappa	O
B-dependent	O
IL-6	B-protein
promoter	O
activity	O
.	O

Also	O
no	O
significant	O
partial	O
correlations	O
of	O
the	O
levels	O
of	O
leukotriene	O
B4	O
(	O
45.6	O
+/-	O
105.3	O
ng/10	O
(	O
6	O
)	O
cells	O
)	O
produced	O
by	O
monocytes	B-cell_type
in	O
vitro	O
,	O
soluble	O
interleukin-2	B-protein
receptor	I-protein
(	O
734	O
+/-	O
237	O
ng/10	O
(	O
6	O
)	O
cells	O
)	O
released	O
by	O
lymphocytes	B-cell_type
in	O
vitro	O
and	O
cortisol	O
levels	O
(	O
571	O
+/-	O
236	O
ng/mL	O
)	O
in	O
plasma	O
with	O
the	O
symptom	O
score	O
after	O
active	O
treatment	O
were	O
found	O
.	O

The	O
ability	O
of	O
interferon	B-protein
alpha	I-protein
to	O
up-regulate	O
MNDA	B-RNA
mRNA	I-RNA
in	O
phorbol	O
ester	O
treated	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
is	O
consistent	O
with	O
the	O
observations	O
made	O
in	O
primary	B-cell_type
monocytes	I-cell_type
.	O

Since	O
LPS	O
and	O
anti-IgM	B-protein
were	O
unable	O
to	O
activate	O
RelB	B-protein
,	O
CD40	B-protein
appears	O
to	O
trigger	O
a	O
special	O
program	O
of	O
gene	O
expression	O
involved	O
in	O
the	O
proliferation	O
and/or	O
differentiation	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

These	O
results	O
indicate	O
that	O
Fc	B-protein
gamma	I-protein
R	I-protein
can	O
mediate	O
a	O
TNF-alpha	B-protein
-dependent	O
induction	O
of	O
HIV-1	B-DNA
gene	I-DNA
transcription	O
and	O
suggest	O
that	O
immune	B-protein
complexes	I-protein
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
HIV-1	O
infection	O
by	O
augmenting	O
viral	O
replication	O
in	O
monocytes	B-cell_type
.	O

Thus	O
,	O
c-Fos/c-Jun	B-protein
heterodimers	I-protein
might	O
contribute	O
to	O
the	O
repression	O
of	O
DRA	B-DNA
gene	I-DNA
expression	O
.	O

Thus	O
,	O
such	O
unique	O
activation	O
of	O
the	O
inhibitory	B-protein
p50/p50	I-protein
homodimer	I-protein
by	O
acute	O
ethanol	O
treatment	O
may	O
result	O
in	O
inhibition	O
rather	O
than	O
activation	O
of	O
NF-kappa	B-DNA
B-regulated	I-DNA
inflammatory	I-DNA
cytokine	I-DNA
genes	I-DNA
.	O

Single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
again	O
showed	O
the	O
heterozygous	O
status	O
of	O
the	O
twins	O
and	O
a	O
normal	O
pattern	O
in	O
their	O
parents	O
.	O

The	O
possibility	O
that	O
Oct-2a	B-protein
can	O
act	O
as	O
an	O
activator	O
and/or	O
a	O
repressor	O
may	O
have	O
important	O
consequences	O
for	O
the	O
function	O
of	O
Oct-2a	B-protein
in	O
B	O
cell	O
differentiation	O
and	O
other	O
developmental	O
processes	O
.	O

After	O
treatment	O
of	O
APL	B-cell_line
cells	I-cell_line
with	O
AM580	O
either	O
alone	O
or	O
in	O
combination	O
with	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
G-CSF	B-protein
)	O
,	O
the	O
compound	O
induces	O
granulocytic	O
maturation	O
,	O
as	O
assessed	O
by	O
determination	O
of	O
the	O
levels	O
of	O
leukocyte	B-RNA
alkaline	I-RNA
phosphatase	I-RNA
,	I-RNA
CD11b	I-RNA
,	I-RNA
CD33	I-RNA
,	I-RNA
and	I-RNA
G-CSF	I-RNA
receptor	I-RNA
mRNA	I-RNA
,	O
at	O
concentrations	O
that	O
are	O
10-	O
to	O
100-fold	O
lower	O
than	O
those	O
of	O
ATRA	O
necessary	O
to	O
produce	O
similar	O
effects	O
.	O

BLPs	B-protein
also	O
initiated	O
apoptosis	O
in	O
an	O
epithelial	B-cell_line
cell	I-cell_line
line	I-cell_line
transfected	O
with	O
hTLR2	B-protein
.	O

Acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
is	O
a	O
specific	O
type	O
of	O
acute	O
myeloid	O
leukemia	O
characterized	O
by	O
the	O
morphology	O
of	O
the	O
blast	B-cell_type
cells	I-cell_type
,	O
a	O
specific	O
t	O
(	O
15	O
;	O
17	O
)	O
translocation	O
,	O
and	O
risks	O
of	O
definite	O
coagulopathy	O
.	O

The	O
region	O
(	O
lining	O
or	O
sublining	O
)	O
,	O
cell	O
type	O
,	O
and	O
subcellular	O
distribution	O
(	O
cytoplasmic	O
or	O
nuclear	O
)	O
of	O
the	O
expression	O
of	O
C/EBP	B-protein
beta	I-protein
was	O
characterized	O
.	O

Most	O
importantly	O
,	O
we	O
show	O
a	O
Tax	B-protein
-dependent	O
correlation	O
between	O
expression	O
of	O
NFKB2	B-protein
(	O
p100	B-protein
)	O
and	O
processing	O
to	O
the	O
DNA	O
binding	O
NFKB2	B-protein
(	O
p52	B-protein
)	O
form	O
,	O
induction	O
of	O
c-Rel	B-protein
,	O
and	O
trans-activation	O
of	O
NF-kappa	B-protein
B	I-protein
-mediated	O
gene	O
expression	O
.	O

Signalling	O
via	O
CD28	B-protein
of	O
human	B-cell_line
naive	I-cell_line
neonatal	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

The	O
functional	O
synergy	O
between	O
IL-2	B-protein
and	O
IL-12	B-protein
is	O
also	O
associated	O
with	O
a	O
prominent	O
increase	O
in	O
STAT1	B-protein
and	O
STAT3	B-protein
serine	O
phosphorylation	O
over	O
that	O
observed	O
with	O
IL-12	B-protein
or	O
IL-2	B-protein
alone	O
.	O

We	O
find	O
that	O
mutation	O
of	O
these	O
elements	O
,	O
and	O
particularly	O
the	O
GATA	B-DNA
elements	I-DNA
,	O
results	O
in	O
a	O
decrease	O
or	O
complete	O
loss	O
of	O
DNase	B-protein
I	I-protein
hypersensitivity	O
.	O

Second	O
,	O
we	O
studied	O
the	O
effect	O
of	O
NAC	O
on	O
IgE	B-protein
synthesis	O
in	O
human	O
normal	O
B	O
cells	O
costimulated	O
with	O
IL-4	B-protein
and	O
anti-CD40	B-protein
mAb	I-protein
.	O

Because	O
binding	B-DNA
sites	I-DNA
for	O
B-cell-specific	B-protein
activator	I-protein
protein	I-protein
(	O
BSAP	B-protein
)	O
are	O
located	O
upstream	O
of	O
several	O
switch	O
regions	O
in	O
the	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
gene	I-DNA
cluster	I-DNA
,	O
BSAP	B-protein
might	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
germline	B-DNA
transcription	O
and	O
isotype	O
switching	O
.	O

Moreover	O
,	O
ectopic	B-protein
Id1	I-protein
repressed	O
E	B-DNA
(	I-DNA
gre	I-DNA
)	I-DNA
-directed	O
but	O
not	O
EA/S	B-DNA
-directed	O
MLV	O
transcription	O
in	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

These	O
data	O
provide	O
evidence	O
that	O
expression	O
of	O
the	O
human	B-DNA
IMPDH	I-DNA
type	I-DNA
II	I-DNA
gene	I-DNA
is	O
predominantly	O
regulated	O
by	O
the	O
nuclear	B-protein
factors	I-protein
ATF-2	B-protein
and	O
an	O
as	O
yet	O
unidentified	O
POS-binding	B-protein
protein	I-protein
.	O

The	O
levels	O
of	O
cAMP-dependent	B-protein
protein	I-protein
kinase	I-protein
and	O
Rap1	B-protein
were	O
assessed	O
by	O
Western	O
blot	O
analysis	O
,	O
immunostaining	O
,	O
and	O
computer-assisted	O
imaging	O
.	O

The	O
effects	O
of	O
Bcl-2	B-protein
can	O
be	O
overcome	O
,	O
at	O
least	O
partially	O
,	O
through	O
phosphorylation	O
of	O
Bcl-2	B-protein
.	O

The	O
adenoviral	O
technique	O
described	O
here	O
has	O
widespread	O
applicability	O
,	O
allowing	O
rapid	O
testing	O
of	O
the	O
effects	O
of	O
blocking	O
a	O
potential	O
therapeutic	O
target	O
in	O
either	O
cultures	O
of	O
normal	B-cell_type
cells	I-cell_type
or	O
in	O
the	O
diseased	O
tissue	O
itself	O
.	O

Maximal	O
LPS	O
induction	O
of	O
the	O
TF	B-DNA
promoter	I-DNA
required	O
the	O
two	O
AP-1	B-protein
sites	O
and	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
within	O
the	O
LPS	B-DNA
response	I-DNA
element	I-DNA
.	O

Potent	O
inhibition	O
of	O
HIV	O
type	O
1	O
replication	O
by	O
an	O
antiinflammatory	O
alkaloid	O
,	O
cepharanthine	O
,	O
in	O
chronically	B-cell_type
infected	I-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

Using	O
UT-7/GMT	B-cell_line
cells	I-cell_line
,	O
we	O
examined	O
how	O
TPO	B-protein
promotes	O
hemoglobinization	O
.	O

Expression	O
of	O
either	O
BZLF1	B-DNA
or	O
BRLF1	B-DNA
triggers	O
expression	O
of	O
the	O
other	O
immediate-early	B-protein
factor	I-protein
,	O
and	O
together	O
these	O
activators	O
act	O
individually	O
or	O
in	O
synergy	O
on	O
downstream	B-DNA
targets	I-DNA
to	O
activate	O
the	O
viral	O
lytic	O
cycle	O
.	O

Furthermore	O
,	O
GCRbeta	B-protein
expression	O
in	O
GC-insensitive	O
asthma	O
was	O
particularly	O
high	O
in	O
airway	O
T	B-cell_type
cells	I-cell_type
,	O
which	O
are	O
thought	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
pathogenesis	O
of	O
asthma	O
.	O

A	O
urinary	O
steroidogram	O
resulted	O
in	O
highly	O
elevated	O
tetrahydrocortisol	O
(	O
THF	O
:	O
13.3	O
mg/24h	O
;	O
N	O
:	O
1.4+/-0.8	O
)	O
with	O
no	O
increase	O
in	O
tetrahydrocortisone	O
(	O
THE	O
:	O
3.16	O
mg/24h	O
;	O
N	O
:	O
2.7+/-2.0	O
)	O
excretion	O
,	O
and	O
with	O
low	O
THE/THF	O
(	O
0.24	O
;	O
N	O
:	O
1.87+/-0.36	O
)	O
and	O
alpha	O
THF/THF	O
(	O
0.35	O
;	O
N	O
:	O
0.92+/-0.42	O
)	O
ratios	O
.	O

Peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
stimulated	O
with	O
PMA	O
/alphaCD28	B-protein
produced	O
IL-2	B-protein
in	O
the	O
presence	O
of	O
CsA	O
.	O

Expression	O
of	O
Id2	O
and	O
Id3	O
mRNA	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

The	O
endothelial	O
expression	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
,	O
E-selectin	B-protein
,	O
and	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
was	O
monitored	O
by	O
cell	O
surface	O
enzyme	O
immunoassays	O
or	O
flow	O
cytometry	O
,	O
and	O
steady-state	O
levels	O
of	O
VCAM-1	B-RNA
mRNA	I-RNA
were	O
assessed	O
by	O
Northern	O
blot	O
analysis	O
.	O

Precursor	O
frequency	O
of	O
anti-SSB	B-cell_line
T	I-cell_line
cells	I-cell_line
was	O
1	O
:	O
77	O
,	O
040	O
and	O
1	O
:	O
115	O
,	O
000	O
in	O
2	O
healthy	O
subjects	O
and	O
1	O
:	O
230	O
,	O
250	O
and	O
1	O
:	O
103	O
,	O
034	O
in	O
two	O
patients	O
with	O
SS	O
.	O

In	O
vitro	O
treatment	O
of	O
a	O
monocyte/macrophage	O
cell	O
line	O
with	O
CCl4	O
led	O
to	O
enhanced	O
NF-kappa	B-protein
B	I-protein
binding	O
and	O
an	O
increase	O
in	O
tumor	B-RNA
necrosis	I-RNA
factor-alpha	I-RNA
(	I-RNA
TNF-alpha	I-RNA
)	I-RNA
messenger	I-RNA
RNA	I-RNA
levels	O
.	O

In	O
three	O
families	O
the	O
autosomal	O
recessive	O
form	O
was	O
characterized	O
by	O
normal	B-protein
receptor	I-protein
as	O
well	O
as	O
hormone	O
data	O
in	O
both	O
parents	O
,	O
while	O
in	O
one	O
family	O
receptor	O
levels	O
in	O
both	O
parents	O
were	O
greatly	O
reduced	O
,	O
but	O
hormone	O
levels	O
were	O
normal	O
.	O

Stimulation	O
of	O
highly	B-cell_type
purified	I-cell_type
human	I-cell_type
T-cells	I-cell_type
via	O
CD2	B-protein
and	I-protein
CD28	I-protein
adhesion	I-protein
molecules	I-protein
induces	O
and	O
maintains	O
proliferation	O
for	O
more	O
than	O
3	O
weeks	O
.	O

A	O
solution	O
structure	O
for	O
the	O
non-sequence-specific	O
C-terminal	B-protein
HMG	I-protein
box	I-protein
of	O
HMG-1	B-protein
has	O
recently	O
been	O
proposed	O
.	O

These	O
stable	O
Jurkat	B-cell_line
cell	I-cell_line
clones	I-cell_line
provide	O
a	O
convenient	O
and	O
sensitive	O
tool	O
to	O
study	O
NFAT	B-protein
regulation	O
.	O

Regulation	O
of	O
the	O
vitellogenin	B-DNA
gene	I-DNA
B1	I-DNA
promoter	I-DNA
after	O
transfer	O
into	O
hepatocytes	B-cell_type
in	O
primary	O
cultures	O
.	O

While	O
LTRs	B-DNA
which	O
demonstrated	O
the	O
highest	O
activities	O
in	O
U-373	B-cell_line
MG	I-cell_line
cells	I-cell_line
also	O
yielded	O
high	O
activities	O
in	O
Jurkat	O
cells	O
,	O
the	O
LTRs	B-DNA
were	O
generally	O
more	O
active	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
when	O
compared	O
to	O
the	O
LAI	B-DNA
LTR	I-DNA
.	O

In	O
contrast	O
to	O
IL-2	B-protein
and	O
IFN-alpha	B-protein
,	O
IL-12	B-protein
induced	O
strong	O
tyrosine	O
phosphorylation	O
of	O
STAT4	B-protein
and	O
variable	O
weak	O
phosphorylation	O
of	O
STAT3	B-protein
.	O

One	O
of	O
these	O
activities	O
was	O
found	O
to	O
be	O
a	O
novel	O
,	O
less	O
abundant	O
,	O
Rb-	O
E2F	B-protein
complex	O
.	O

An	O
understanding	O
of	O
the	O
mechanistic	O
consequences	O
following	O
such	O
genetic	O
alterations	O
is	O
essential	O
to	O
an	O
understanding	O
of	O
the	O
development	O
of	O
these	O
lymphoid	O
neoplasms	O
.	O

The	O
functional	O
contribution	O
of	O
the	O
kappaB-Sp1	B-DNA
composite	I-DNA
site	I-DNA
in	O
P/I-inducible	B-DNA
fas	I-DNA
promoter	I-DNA
activation	O
was	O
verified	O
by	O
using	O
kappaB-	O
Sp1	B-protein
concatamers	O
(	O
-295	B-DNA
to	I-DNA
-286	I-DNA
)	O
in	O
a	O
thymidine	B-DNA
kinase	I-DNA
promoter-driven	I-DNA
reporter	I-DNA
construct	I-DNA
and	O
native	B-DNA
promoter	I-DNA
constructs	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
overexpressing	O
IkappaB-alpha	B-protein
.	O

The	O
knowledge	O
of	O
the	O
polyamine	O
pattern	O
in	O
breast	O
cancer	O
could	O
become	O
useful	O
in	O
clinical	O
practice	O
particularly	O
if	O
polyamine	O
metabolism	O
is	O
targeted	O
as	O
a	O
therapeutic	O
approach	O
.	O

We	O
have	O
now	O
characterized	O
factors	O
that	O
bind	O
to	O
an	O
enhancer	O
region	O
located	O
between	O
nucleotides	B-DNA
-170	I-DNA
and	I-DNA
-139	I-DNA
of	O
the	O
human	O
IL-2Rbeta	B-DNA
promoter	I-DNA
.	O

Although	O
CD40	B-protein
lacks	O
intrinsic	O
tyrosine	O
kinase	O
activity	O
,	O
its	O
ligation	O
induces	O
protein	O
tyrosine	O
phosphorylation	O
,	O
which	O
is	O
necessary	O
for	O
several	O
CD40	B-protein
-mediated	O
events	O
.	O

Relationship	O
between	O
glucocorticoid	B-protein
receptor	I-protein
and	O
response	O
to	O
glucocorticoid	O
therapy	O
in	O
ulcerative	O
colitis	O
.	O

Therefore	O
,	O
we	O
investigated	O
CD2	B-protein
and	O
CD3	B-protein
receptor	I-protein
-mediated	O
signalling	O
in	O
primary	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O

In	O
16HBE	B-cell_type
human	I-cell_type
bronchial	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
,	O
IL-8	B-protein
expression	O
is	O
regulated	O
predominantly	O
by	O
NF-kappaB	B-protein
,	O
and	O
PG490	O
but	O
not	O
cyclosporin	O
A	O
can	O
completely	O
inhibit	O
expression	O
of	O
IL-8	B-protein
.	O

RU-486	O
(	O
10	O
microM	O
)	O
,	O
which	O
prevents	O
translocation	O
of	O
ligated	O
hGR	B-protein
to	O
the	O
nucleus	O
by	O
inhibiting	O
dissociation	O
of	O
hGR	B-protein
from	O
heat	O
shock	O
protein	O
90	O
,	O
completely	O
aborted	O
the	O
effect	O
of	O
dexamethasone	O
on	O
adhesiveness	O
of	O
endothelial	B-cell_type
cells	I-cell_type
(	O
P	O
<	O
0.0005	O
,	O
n	O
=	O
3	O
)	O
.	O

1	B-DNA
,	I-DNA
25-Dihydroxyvitamin	I-DNA
D3	I-DNA
receptors	I-DNA
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
renal	O
insufficiency	O
.	O

By	O
using	O
PD98059	O
,	O
we	O
demonstrated	O
that	O
the	O
Raf1/MEK1/	O
ERK1/2	B-protein
pathway	O
did	O
not	O
affect	O
the	O
DNA	O
binding	O
of	O
NF-kappa	B-protein
B	I-protein
but	O
,	O
rather	O
,	O
acted	O
at	O
the	O
level	O
of	O
transcriptional	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

[	O
3H	O
]	O
Thymidine	O
incorporation	O
was	O
decreased	O
dose-dependently	O
by	O
dexamethasone	O
in	O
controls	O
and	O
patients	O
;	O
the	O
effect	O
was	O
significantly	O
blunted	O
(	O
P	O
less	O
than	O
0.05	O
)	O
in	O
group	O
1	O
patients	O
,	O
which	O
suggests	O
that	O
activation	O
of	O
glucocorticoid	B-protein
receptor	I-protein
is	O
impaired	O
as	O
a	O
result	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
abnormality	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

PD98059	O
inhibited	O
GM-CSF	B-protein
-dependent	O
proliferation	O
of	O
MO7e	B-cell_type
cells	I-cell_type
.	O

The	O
age-associated	O
immune	O
dysfunction	O
may	O
be	O
implicated	O
to	O
some	O
degree	O
in	O
the	O
extreme	O
susceptibility	O
of	O
the	O
elderly	O
to	O
infection	O
and	O
neoplasia	O
and	O
may	O
even	O
participate	O
in	O
various	O
aspects	O
of	O
senescence	O
.	O

A	O
nondegradable	O
mutant	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
blocked	O
both	O
FasL	B-protein
expression	O
and	O
apoptosis	O
induced	O
by	O
DNA	O
damage	O
but	O
not	O
Fas	B-protein
ligation	O
.	O

However	O
,	O
although	O
NFAT	B-protein
DNA	O
binding	O
is	O
similarly	O
induced	O
in	O
both	O
eTh1	B-cell_type
and	O
eTh2	B-cell_type
cells	I-cell_type
upon	O
antigen	O
stimulation	O
,	O
only	O
the	O
NFAT	B-protein
complexes	I-protein
present	O
in	O
eTh2	B-cell_type
cells	I-cell_type
are	O
able	O
to	O
mediate	O
high-level	O
transcription	O
,	O
and	O
relatively	O
little	O
NFAT	B-protein
transcriptional	O
activity	O
was	O
induced	O
in	O
eTh1	B-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
,	O
Egr-1	B-protein
expression	O
is	O
abrogated	O
in	O
group	B-cell_line
I	I-cell_line
Burkitt	I-cell_line
tumor	I-cell_line
cells	I-cell_line
,	O
irrespective	O
of	O
the	O
EBV	B-DNA
genome	I-DNA
carrying	O
status	O
.	O

The	O
addition	O
of	O
either	O
TNF	B-protein
alpha	I-protein
or	O
IL-2	B-protein
partially	O
recovered	O
cyclosporin	O
A-induced	O
IL-2R	B-protein
alpha	I-protein
inhibition	O
,	O
but	O
only	O
TNF	B-protein
alpha	I-protein
completely	O
recovered	O
NF.kappa	B-protein
B	I-protein
activation	O
.	O

In	O
addition	O
,	O
only	O
a	O
subset	O
of	O
the	O
NSAIDs	O
induced	O
HSP70	B-RNA
mRNA	I-RNA
species	I-RNA
.	O

We	O
also	O
found	O
that	O
IL-2	B-protein
protects	O
T	B-cell_line
cell	I-cell_line
clones	I-cell_line
from	O
IL-2	B-protein
deprivation	O
apoptosis	O
accompanying	O
active	O
proliferation	O
and	O
enhanced	O
expression	O
of	O
P53	B-protein
,	O
Rb	B-protein
and	O
Bcl-xL	B-protein
proteins	I-protein
.	O

Using	O
monoclonal	B-protein
antibodies	I-protein
(	O
mAbs	B-protein
)	O
and	O
flow	O
cytometry	O
,	O
we	O
studied	O
a	O
variety	O
of	O
surface	B-protein
receptors	I-protein
on	O
lymphocyte	B-cell_type
subpopulations	I-cell_type
of	O
workers	O
with	O
moderately	O
increased	O
body	O
burdens	O
of	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo-p-dioxin	O
(	O
TCDD	O
)	O
and	O
of	O
other	O
polychlorinated	O
dibenzo-p-dioxins	O
and	O
dibenzofurans	O
(	O
PCDD/PCDF	O
)	O
,	O
expressed	O
here	O
as	O
International-Toxicity	O
Equivalencies	O
(	O
I-TE	O
)	O
.	O

Sequences	O
upstream	O
and	O
downstream	O
from	O
the	O
TATA	B-DNA
box	I-DNA
were	O
found	O
to	O
contribute	O
to	O
elk-1	B-DNA
promoter	O
activity	O
.	O

This	O
influence	O
was	O
sufficient	O
for	O
establishment	O
of	O
antigen-induced	O
allergic	O
airway	O
hyperresponsiveness	O
on	O
a	O
disease-resistant	O
background	O

However	O
,	O
we	O
report	O
in	O
vitro	O
experimental	O
studies	O
in	O
which	O
IL-10	B-cell_line
primed	I-cell_line
leukocytes	I-cell_line
and	O
led	O
to	O
an	O
enhanced	O
production	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
upon	O
further	O
stimulation	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
stimulates	O
IL-2R	B-protein
alpha	I-protein
.	O

Western	O
blot	O
and	O
immunoprecipitation	O
studies	O
using	O
rabbit	B-protein
anti-C/EBP-epsilon	I-protein
antibodies	I-protein
raised	O
against	O
the	O
N-terminal	B-protein
portion	I-protein
of	O
C/EBP-epsilon	B-protein
(	O
amino	B-protein
acids	I-protein
1	I-protein
to	I-protein
115	I-protein
)	O
showed	O
that	O
C/EBP-epsilon	B-protein
is	O
a	O
32-kDa	B-protein
nuclear	I-protein
phosphoprotein	I-protein
.	O

Increased	O
intracellular	O
stores	O
of	O
latent	B-protein
NF-kappa	I-protein
B	I-protein
may	O
also	O
result	O
in	O
rapid	O
inducibility	O
of	O
NF-kappa	B-protein
B	I-protein
-dependent	O
cytokine	B-protein
gene	O
expression	O
.	O

These	O
data	O
suggest	O
that	O
EA-D	B-DNA
(	I-DNA
BMRF1	I-DNA
)	I-DNA
promoter	I-DNA
regulation	O
by	O
Z	B-protein
and	O
R	B-protein
is	O
cell	O
type	O
specific	O
and	O
appears	O
to	O
involve	O
different	O
mechanisms	O
in	O
each	O
cell	O
type	O
.	O

It	O
provides	O
a	O
transcriptional	O
activation	O
domain	O
which	O
,	O
unlike	O
Oct-1	B-protein
,	O
activates	O
an	O
mRNA-type	B-DNA
promoter	I-DNA
effectively	O
,	O
and	O
it	O
stabilizes	O
Oct-1	B-protein
on	O
the	O
Oct-1-responsive	B-DNA
octamer	I-DNA
sequence	I-DNA
ATGCAAAT	O
.	O

We	O
report	O
on	O
the	O
CTL	O
recognition	O
of	O
a	O
MHC	O
class	O
I-restricted	O
peptide	O
containing	O
a	O
cyclized	O
asparagine	O
(	O
succinimide	O
)	O
residue	O
.	O

Interaction	O
of	O
the	O
human	B-protein
T-cell	I-protein
lymphotropic	I-protein
virus	I-protein
type	I-protein
1	I-protein
tax	I-protein
transactivator	I-protein
with	O
transcription	B-protein
factor	I-protein
IIA	I-protein
.	O

Surprisingly	O
,	O
while	O
the	O
addition	O
of	O
phytohemagglutinin	B-protein
further	O
enhanced	O
the	O
induction	O
of	O
AP1	B-protein
,	O
the	O
addition	O
of	O
PMA	O
inhibited	O
it	O
.	O

Overexpression	O
of	O
TRAMP	B-protein
leads	O
to	O
two	O
major	O
responses	O
,	O
NF-kappaB	B-protein
activation	O
and	O
apoptosis	O
.	O

Dehydroepiandrosterone	O
modulation	O
of	O
lipopolysaccharide-stimulated	O
monocyte	O
cytotoxicity	O
.	O

Remarkably	O
,	O
the	O
expression	O
of	O
both	O
genes	O
is	O
downmodulated	O
during	O
erythroid	O
and	O
megakaryocytic	O
terminal	O
maturation	O
.	O

Like	O
G-CSF	B-protein
,	O
SB	O
247464	O
induced	O
tyrosine	O
phosphorylation	O
of	O
multiple	B-protein
signaling	I-protein
proteins	I-protein
and	O
stimulated	O
primary	B-cell_type
murine	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
to	O
form	O
granulocytic	B-cell_type
colonies	I-cell_type
in	O
vitro	O
.	O

Thus	O
,	O
NF-kappa	B-protein
B	I-protein
,	O
a	O
potent	O
transcriptional	O
activator	O
of	O
HIV	O
expression	O
,	O
is	O
also	O
involved	O
in	O
the	O
expression	O
of	O
RANTES	B-protein
,	O
a	O
chemokine	B-protein
that	O
blocks	O
infection	O
by	O
macrophage-tropic	O
strains	O
of	O
HIV	O
.	O

Transient	O
expression	O
assays	O
with	O
plasmids	O
containing	O
deleted	O
parts	O
of	O
the	O
LTR	B-DNA
region	I-DNA
linked	O
to	O
a	O
reporter	O
gene	O
showed	O
that	O
the	O
NF-kappaB	B-DNA
binding	I-DNA
site	I-DNA
was	O
essential	O
for	O
HIV-1	B-DNA
LTR	I-DNA
activity	O
in	O
CD40-stimulated	B-cell_line
B	I-cell_line
lymphocytes	I-cell_line
.	O

Two	O
stable	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
established	O
:	O
R59Z	B-cell_line
activator	I-cell_line
cells	I-cell_line
were	O
used	O
to	O
induce	O
lytic	O
EBV	O
expression	O
in	O
a	O
constitutive	O
manner	O
by	O
the	O
production	O
of	O
the	O
BZLF	B-protein
1	I-protein
trans-activator	I-protein
(	O
Zta	B-protein
)	O
.	O

Based	O
on	O
these	O
results	O
we	O
estimate	O
a	O
5-10	O
%	O
difference	O
in	O
virus	O
production	O
of	O
the	O
LTR	B-DNA
variants	I-DNA
when	O
compared	O
to	O
that	O
of	O
wild-type	O
.	O

Okadaic	O
acid	O
was	O
found	O
to	O
be	O
a	O
potent	O
inducer	O
of	O
AP1	B-protein
.	O

Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
monocytes	B-cell_type
to	O
express	O
a	O
variety	O
of	O
genes	O
by	O
activating	O
the	O
NF-kappaB/Rel	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
changes	O
in	O
endothelial	O
cell	O
glutathione	O
(	O
GSH	O
)	O
or	O
oxidized	O
glutathione	O
(	O
GSSG	O
)	O
can	O
alter	O
neutrophil	O
adhesivity	O
and	O
to	O
define	O
the	O
molecular	O
mechanism	O
that	O
underlies	O
this	O
GSSG/GSH-induced	O
adhesion	O
response	O
.	O

For	O
one	O
of	O
these	O
proteins	O
,	O
p57	B-protein
,	O
binding	O
to	O
the	O
IRES	B-DNA
correlates	O
with	O
translation	O
.	O

Addition	O
of	O
exogenous	O
TNF	B-protein
to	O
the	O
intermediate	B-cell_line
thymocyte	I-cell_line
cultures	I-cell_line
induces	O
NF-kappaB	B-protein
activity	O
and	O
is	O
sufficient	O
to	O
promote	O
HIV	O
replication	O
in	O
the	O
cocultures	O
with	O
TEC	B-cell_type
.	O

Activation	O
of	O
NF-kappaB	B-protein
in	O
Mycobacterium	O
tuberculosis	O
-induced	O
interleukin-2	B-protein
receptor	I-protein
expression	O
in	O
mononuclear	B-cell_type
phagocytes	I-cell_type
.	O

We	O
investigated	O
T	O
cell	O
reactivity	O
to	O
the	O
autoantigen	B-protein
SSB	I-protein
in	O
patients	O
with	O
SS	O
and	O
healthy	O
controls	O
.	O

The	O
breakpoints	O
of	O
most	O
transcript	O
deletions	O
coincide	O
with	O
genuine	O
or	O
cryptic	O
splice	B-DNA
site	I-DNA
sequences	I-DNA
,	O
suggesting	O
that	O
they	O
result	O
from	O
alternative	O
or	O
aberrant	O
splicing	O
.	O

Disruption	O
of	O
the	O
Jak1-binding	B-protein
proline-rich	I-protein
Box1	I-protein
region	I-protein
of	O
IL-4Ralpha	B-protein
abolished	O
signaling	O
by	O
this	O
chimeric	B-protein
receptor	I-protein
.	O

Cytokines	O
stimulate	O
granulopoiesis	O
through	O
signaling	O
via	O
receptors	O
whose	O
expression	O
is	O
controlled	O
by	O
lineage-specific	O
transcription	B-protein
factors	I-protein
.	O

Oestradiol	O
has	O
mitogenic	O
and	O
regulatory	O
effects	O
on	O
various	O
organs	O
and	O
cells	O
,	O
mediated	O
mainly	O
by	O
its	O
nuclear	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
.	O

The	O
decline	O
and	O
return	O
of	O
cortisol	O
concentrations	O
were	O
similar	O
between	O
MP	O
treatments	O
with	O
suppression	O
continuing	O
for	O
24	O
hours	O
.	O

We	O
have	O
recently	O
identified	O
and	O
cloned	O
TCF-1	B-protein
,	O
a	O
T	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
with	O
specificity	O
for	O
the	O
AACAAAG	O
motif	O
in	O
the	O
CD3	O
epsilon	O
enhancer	O
and	O
for	O
the	O
TTCAAAG	B-DNA
motif	I-DNA
in	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	I-DNA
.	O

Differentiation	O
in	O
response	O
to	O
all	O
analogs	O
was	O
shown	O
to	O
be	O
inhibited	O
by	O
1beta	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
HL	O
)	O
,	O
the	O
antagonist	O
to	O
the	O
nongenomic	O
activities	O
of	O
1	O
,	O
25D3	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
transcription	O
of	O
nuclear	B-DNA
protooncogenes	I-DNA
is	O
regulated	O
by	O
heat	O
shock	O
indicating	O
a	O
role	O
for	O
nuclear	B-DNA
protooncogenes	I-DNA
in	O
the	O
stress	O
response	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

Stimulation	O
of	O
DND39	B-cell_line
cells	I-cell_line
with	O
IL-4	B-protein
or	O
anti-CD40	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
activated	O
phosphatidylinositol	B-protein
3-kinase	I-protein
and	O
subsequently	O
induced	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
which	O
was	O
identified	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax	I-protein
protein	I-protein
induces	O
the	O
expression	O
of	O
STAT1	B-DNA
and	I-DNA
STAT5	I-DNA
genes	I-DNA
in	O
T-cells	B-cell_type
.	O

The	O
enzyme	O
might	O
therefore	O
be	O
a	O
potential	O
target	O
for	O
drug	O
therapy	O
under	O
conditions	O
of	O
active	O
DNA	O
replication	O
.	O

Cells	O
that	O
have	O
been	O
transformed	O
by	O
viruses	O
or	O
oncogenes	B-DNA
can	O
persist	O
only	O
if	O
they	O
manage	O
to	O
avoid	O
destruction	O
by	O
the	O
apoptotic	O
mechanisms	O
that	O
are	O
activated	O
on	O
transformation	O
and	O
that	O
contribute	O
to	O
maintain	O
cellular	O
homeostasis	O
.	O

The	O
biological	O
active	O
form	O
of	O
vitamin	O
D3	O
,	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VD	O
)	O
,	O
regulates	O
cellular	O
growth	O
and	O
differentiation	O
.	O

4.	O
Fluorescence	O
HPLC	O
showed	O
that	O
SMX-NHOH	O
and	O
SMX-NO	O
depleted	O
CYS	O
and	O
GSH	O
in	O
buffer	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
in	O
cells	O
and	O
plasma	O
.	O

For	O
this	O
purpose	O
,	O
mice	O
were	O
immunized	O
with	O
a	O
fusion	B-protein
protein	I-protein
including	O
the	O
sequence	O
Thr729-Lys984	B-protein
of	O
hMR	B-protein
.	O

Second	O
,	O
a	O
glutathione-S-transferase	O
(	O
GST	B-protein
)	O
affinity-binding	O
assay	O
showed	O
that	O
the	O
interaction	O
of	O
holo-	O
TFIIA	B-protein
with	O
GST-Tax	B-protein
was	O
20-fold	O
higher	O
than	O
that	O
observed	O
with	O
either	O
the	O
GST-Tax	B-protein
M32	I-protein
activation	I-protein
mutant	I-protein
or	O
the	O
GST	O
control	O
.	O

NF-kappa	B-protein
B	I-protein
is	O
involved	O
in	O
the	O
transcriptional	O
control	O
of	O
various	B-DNA
genes	I-DNA
that	O
act	O
as	O
extrinsic	O
and	O
intrinsic	O
survival	O
factors	O
for	O
T	B-cell_type
cells	I-cell_type
.	O

Primer	O
extension	O
analysis	O
of	O
C/EBP-epsilon	B-RNA
mRNA	I-RNA
detected	O
a	O
single	O
major	O
transcription	B-DNA
start	I-DNA
site	I-DNA
approximately	O
200	O
bp	O
upstream	O
of	O
the	O
start	B-DNA
codon	I-DNA
.	O

One	O
explanation	O
for	O
the	O
perpetuation	O
of	O
virus	O
infection	O
in	O
macrophages	B-cell_type
could	O
be	O
sustained	O
nuclear	O
NF-kappa	B-protein
B	I-protein
expression	O
.	O

By	O
Edman	O
sequencing	O
we	O
could	O
identify	O
a	O
caspase	O
3	O
cleavage	O
site	O
after	O
Asp584	O
(	O
D584AQPQAGR	O
)	O
,	O
generating	O
a	O
22-kDa	O
C-terminal	O
SP1	B-protein
protein	O
fragment	O
which	O
still	O
contains	O
the	O
DNA	O
binding	O
site	O
.	O

Our	O
previous	O
results	O
show	O
that	O
recombinant	B-protein
gp41	I-protein
(	O
aa565-647	B-protein
)	O
,	O
the	O
extracellular	B-protein
domain	I-protein
of	O
HIV-1	B-protein
transmembrane	I-protein
glycoprotein	I-protein
,	O
stimulates	O
interleukin-10	B-protein
(	O
IL-10	B-protein
)	O
production	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

In	O
vitro	O
apoptosis	O
induction	O
in	O
CLL	B-cell_line
cells	I-cell_line
was	O
delayed	O
in	O
response	O
to	O
GCs	O
,	O
but	O
not	O
to	O
other	O
apoptosis	O
inducers	O
.	O

In	O
contrast	O
to	O
the	O
type	B-protein
I	I-protein
receptor	I-protein
,	O
the	O
type	B-protein
II	I-protein
IL-1R	I-protein
has	O
a	O
small	O
cytoplasmic	B-protein
tail	I-protein
,	O
and	O
it	O
is	O
not	O
clear	O
whether	O
this	O
receptor	O
is	O
a	O
signal-transducing	B-protein
or	O
a	O
regulatory	B-protein
molecule	I-protein
.	O

This	O
method	O
was	O
successfully	O
extended	O
to	O
human	B-protein
retinoic	I-protein
X	I-protein
receptor	I-protein
alpha	I-protein
,	O
glucocorticoid	B-protein
receptor	I-protein
,	O
and	O
progesterone	B-protein
receptor	I-protein
,	O
thus	O
providing	O
a	O
basis	O
for	O
a	O
new	O
,	O
faster	O
assay	O
to	O
determine	O
simultaneously	O
the	O
affinity	O
and	O
conformation	O
of	O
receptors	O
when	O
bound	O
to	O
a	O
given	O
ligand	O
.	O

Furthermore	O
,	O
PU.1	B-protein
transactivates	O
the	O
M-CSF	B-DNA
receptor	I-DNA
promoter	I-DNA
in	O
nonmacrophage	B-cell_type
cells	I-cell_type
.	O

Transfection	O
of	O
EL-4	B-cell_line
cells	I-cell_line
with	O
the	O
IL-4	B-DNA
promoter-reporter	I-DNA
constructs	I-DNA
carrying	O
mutated	B-DNA
P-like	I-DNA
elements	I-DNA
showed	O
that	O
four	O
P-like	B-DNA
elements	I-DNA
,	O
CLE0	B-DNA
,	O
P	B-DNA
,	O
P2	B-DNA
and	O
P4	B-DNA
,	O
but	O
not	O
P3	B-DNA
,	O
were	O
required	O
for	O
optimal	O
activation	O
of	O
the	O
IL-4	B-DNA
promoter	I-DNA
.	O

In	O
addition	O
,	O
anti-CD29	B-protein
(	O
integrin	B-protein
beta	I-protein
1	I-protein
)	O
as	O
well	O
as	O
anti-VLA-5	B-protein
(	O
human	B-protein
fibronectin	I-protein
receptor	I-protein
)	O
antibodies	O
blocked	O
this	O
CD4	B-cell_line
cell	I-cell_line
activation	O
in	O
this	O
system	O
.	O

HLA-DR-	O
,	O
CD33+	O
,	O
CD56+	O
,	O
CD16-	O
myeloid/natural	O
killer	O
cell	O
acute	O
leukemia	O
:	O
a	O
previously	O
unrecognized	O
form	O
of	O
acute	O
leukemia	O
potentially	O
misdiagnosed	O
as	O
French-American-British	O
acute	O
myeloid	O
leukemia-M3	O
[	O
see	O
comments	O
]	O

Half-maximal	O
induction	O
of	O
GR	B-RNA
mRNA	I-RNA
and	O
protein	O
in	O
6TG1.1	B-cell_line
cells	I-cell_line
was	O
observed	O
between	O
10-100	O
nM	O
dexamethasone	O
,	O
and	O
inclusion	O
of	O
1	O
microM	O
RU	O
38486	O
completely	O
blocked	O
the	O
effects	O
of	O
100	O
nM	O
dexamethasone	O
,	O
demonstrating	O
that	O
positive	O
autoregulation	O
of	O
GR	B-protein
expression	O
in	O
6TG1.1	B-cell_line
cells	I-cell_line
is	O
a	O
receptor-mediated	O
response	O
.	O

Expression	O
was	O
confirmed	O
in	O
the	O
bone	O
marrow	O
with	O
a	O
reverse	O
transcription	O
PCR	O
assay	O
.	O

The	O
GC-R	B-protein
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	B-cell_type
of	O
the	O
GC-resistant	O
group	O
were	O
5.33	O
+/-	O
1.37	O
fmol/10	O
(	O
6	O
)	O
cells	O
and	O
3.20	O
+/-	O
1.39	O
nM	O
,	O
respectively	O
.	O

A	O
chromosomal	O
translocation	O
in	O
a	O
T-cell	O
leukemia	O
involving	O
the	O
short	B-DNA
arm	I-DNA
of	O
human	B-DNA
chromosome	I-DNA
11	I-DNA
at	O
band	B-DNA
11p15	I-DNA
disrupts	O
the	O
rhombotin	B-DNA
gene	I-DNA
.	O

Cytokines	B-protein
,	O
the	O
peptide	B-protein
hormones	I-protein
which	O
control	O
the	O
homeostasis	O
of	O
the	O
immune	O
system	O
and	O
also	O
play	O
a	O
fundamental	O
role	O
in	O
inflammatory	O
and	O
immune	O
mediated	O
reactions	O
,	O
have	O
been	O
involved	O
at	O
multiple	O
levels	O
in	O
the	O
pathogenesis	O
of	O
the	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
.	O

Role	O
of	O
the	O
camp	B-DNA
response	I-DNA
element	I-DNA
site	I-DNA
in	O
mediating	O
repression	O
by	O
the	O
upstream	B-DNA
regulatory	I-DNA
region	I-DNA
.	O

Immunocytochemistry	O
60	O
minutes	O
after	O
stimulation	O
revealed	O
that	O
NFkappaB	B-protein
was	O
located	O
in	O
the	O
cytoplasm	O
in	O
unstimulated	B-cell_type
cells	I-cell_type
;	O
however	O
,	O
the	O
addition	O
of	O
TNFalpha	B-protein
caused	O
NFkappaB	B-protein
to	O
translocate	O
into	O
the	O
nucleus	O
.	O

DNA-binding	O
and	O
transcriptional	O
regulatory	O
properties	O
of	O
hepatic	B-protein
leukemia	I-protein
factor	I-protein
(	O
HLF	B-protein
)	O
and	O
the	O
t	O
(	O
17	O
;	O
19	O
)	O
acute	B-protein
lymphoblastic	I-protein
leukemia	I-protein
chimera	I-protein
E2A-HLF	I-protein
.	O

Basing	O
on	O
these	O
experiments	O
,	O
trans-cellular	O
activation	O
of	O
EBV	O
was	O
tested	O
by	O
cocultivation	O
of	O
BZLF	B-cell_type
1-expressing	I-cell_type
R59Z	I-cell_type
activator	I-cell_type
cells	I-cell_type
with	O
the	O
R7-57	B-cell_line
reporter	I-cell_line
line	I-cell_line
.	O

Mutations	O
at	O
different	O
sites	O
within	O
this	O
proximal	B-DNA
promoter	I-DNA
region	I-DNA
abolished	O
the	O
promoter	O
activity	O
as	O
well	O
as	O
the	O
DNA	O
binding	O
.	O

Modulation	O
of	O
CD28	B-protein
expression	O
:	O
distinct	O
regulatory	O
pathways	O
during	O
activation	O
and	O
replicative	O
senescence	O
.	O

Additional	O
stimulation	O
of	O
the	O
CD3	B-protein
/TCR	B-protein
pathway	O
enhances	O
the	O
oxidative	O
and	O
apoptotic	O
effects	O
.	O

More	O
interestingly	O
,	O
transfection	O
experiments	O
with	O
CRE-CAT	B-DNA
plasmide	I-DNA
show	O
that	O
PGE2	O
activates	O
the	O
transcription	O
of	O
a	O
CRE-containing	B-DNA
promoter	I-DNA
.	O

In	O
the	O
present	O
report	O
,	O
we	O
identified	O
and	O
monitored	O
the	O
pocket	B-protein
protein-E2F	I-protein
complexes	I-protein
in	O
human	B-cell_type
primary	I-cell_type
B-lymphocytes	I-cell_type
after	O
activation	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
.	O

DNA	O
triplex	O
formation	O
selectively	O
inhibits	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
gene	I-DNA
expression	O
in	O
human	O
T	O
cells	O
.	O

Lymphoid	O
specific	O
gene	O
expression	O
of	O
the	O
adenovirus	B-DNA
early	I-DNA
region	I-DNA
3	I-DNA
promoter	I-DNA
is	O
mediated	O
by	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
motifs	I-DNA
.	O

Conversely	O
,	O
c-jun	B-protein
and	O
jun-B	B-protein
transfection	O
blunted	O
GR	B-protein
-dependent	O
transcription	O
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O

pIL-5	B-DNA
(	I-DNA
-511	I-DNA
)	I-DNA
Luc	I-DNA
was	O
transcribed	O
by	O
T-cell	B-cell_line
hybridomas	I-cell_line
derived	O
from	O
fusion	O
between	O
IL-5-producing	B-cell_line
T-cell	I-cell_line
clones	I-cell_line
and	O
an	O
IL-5	B-cell_line
gene-nonexpressing	I-cell_line
T-cell	I-cell_line
line	I-cell_line
,	O
but	O
not	O
by	O
hybridomas	B-cell_line
derived	O
from	O
IL-5-nonproducing	B-cell_line
T-cell	I-cell_line
clones	I-cell_line
.	O

Several	O
of	O
the	O
heterogeneous	O
clinical	O
manifestations	O
of	O
systemic	O
lupus	O
erythematosus	O
have	O
been	O
associated	O
with	O
specific	O
autoantibodies	B-protein
.	O

Furthermore	O
,	O
p50	B-protein
protein	O
was	O
detected	O
in	O
the	O
cytoplasm	O
of	O
all	O
lymphocytes	B-cell_type
.	O

Two	O
multicopy	B-DNA
basal	I-DNA
enhancer	I-DNA
motifs	I-DNA
within	O
the	O
SCMV	O
MIE	B-DNA
enhancer	I-DNA
,	O
namely	O
,	O
11	O
copies	O
of	O
the	O
16-bp	O
cyclic	B-DNA
AMP	I-DNA
response	I-DNA
element	I-DNA
(	O
CRE	B-DNA
)	O
and	O
3	O
copies	O
of	O
novel	O
17-bp	O
serum	B-DNA
response	I-DNA
factor	I-DNA
(	I-DNA
SRF	I-DNA
)	I-DNA
binding	I-DNA
sites	I-DNA
referred	O
to	O
as	O
the	O
SNE	B-DNA
(	O
SRF/NFkappaB-like	B-DNA
element	I-DNA
)	O
,	O
as	O
well	O
as	O
four	O
classical	O
NFkappaB	B-DNA
sites	I-DNA
within	O
the	O
HCMV	O
version	O
,	O
contribute	O
to	O
TPA	O
responsiveness	O
in	O
transient	O
assays	O
in	O
monocyte	B-cell_type
and	I-cell_type
T-cell	I-cell_type
types	I-cell_type
.	O

Comparative	O
analysis	O
identifies	O
conserved	O
tumor	B-DNA
necrosis	I-DNA
factor	I-DNA
receptor-associated	I-DNA
factor	I-DNA
3	I-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
human	B-DNA
and	I-DNA
simian	I-DNA
Epstein-Barr	I-DNA
virus	I-DNA
oncogene	I-DNA
LMP1	I-DNA
.	O

Thrombin	B-protein
activation	O
requires	O
assembly	O
of	O
a	O
prothrombinase	B-protein
complex	I-protein
of	O
activated	O
coagulation	B-protein
factors	I-protein
on	O
an	O
anionic	O
phospholipid	O
surface	O
,	O
classically	O
provided	O
by	O
activated	B-cell_type
platelets	I-cell_type
.	O

We	O
have	O
previously	O
shown	O
that	O
c-Jun	B-protein
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
rat	B-DNA
prolactin	I-DNA
(	I-DNA
rPRL	I-DNA
)	I-DNA
promoter	I-DNA
activity	O
induced	O
by	O
either	O
oncogenic	B-protein
Ras	I-protein
or	O
phorbol	O
esters	O
.	O

This	O
mechanism	O
may	O
contribute	O
to	O
delayed	O
progression	O
of	O
the	O
HIV-1	O
infection	O
in	O
vivo	O
.	O

BACKGROUND	O
:	O
Recent	O
data	O
suggest	O
that	O
the	O
regulation	O
of	O
class	O
switching	O
to	O
IgE	B-protein
by	O
cytokines	B-protein
is	O
mediated	O
by	O
STAT	B-protein
transcription	I-protein
factors	I-protein
.	O

To	O
better	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
suppression	O
by	O
CsA	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
this	O
drug	O
on	O
transcription	B-protein
factors	I-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

To	O
our	O
knowledge	O
,	O
this	O
represents	O
the	O
first	O
demonstration	O
that	O
phagocytic	O
stimuli	O
can	O
induce	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
human	B-cell_type
neutrophils	I-cell_type
.	O

The	O
results	O
show	O
the	O
presence	O
of	O
several	O
NF-kappaB	B-protein
family	I-protein
members	I-protein
,	I-protein
with	O
the	O
transactivating	O
RelA	B-protein
being	O
engaged	O
in	O
multiple	O
complexes	O
.	O

The	O
human	B-DNA
C/EBPepsilon	I-DNA
gene	I-DNA
is	O
transcribed	O
by	O
two	O
alternative	O
promoters	B-DNA
,	O
Palpha	B-DNA
and	O
Pbeta	B-DNA
.	O

We	O
demonstrated	O
in	O
earlier	O
studies	O
that	O
the	O
upstream	B-DNA
region	I-DNA
of	O
the	O
mouse	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
at	O
positions	O
between	O
-95	B-DNA
and	I-DNA
-73	I-DNA
is	O
essential	O
for	O
transcriptional	O
activation	O
in	O
response	O
to	O
PMA/A23187	O
.	O

Furthermore	O
overexpression	O
of	O
exogenous	B-protein
c-fos	I-protein
has	O
an	O
inhibitory	O
effect	O
on	O
GR	B-protein
-dependent	O
transcription	O
from	O
GRE	B-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

Leukotriene	O
B4	O
stimulates	O
c-fos	O
and	O
c-jun	O
gene	O
transcription	O
and	O
AP-1	B-protein
binding	O
activity	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

We	O
conclude	O
that	O
a	O
VDRE-binding	B-protein
protein	I-protein
(	O
s	O
)	O
,	O
distinct	O
from	O
IDBP	B-protein
and	O
present	O
in	O
nuclear	O
extract	O
of	O
cells	O
from	O
a	O
prototypical	B-cell_line
vitamin	I-cell_line
D-resistant	I-cell_line
NWP	I-cell_line
,	O
is	O
capable	O
of	O
inhibiting	O
normal	O
VDR-RXR	B-protein
heterodimer	O
binding	O
to	O
the	O
VDRE	B-DNA
.	O

We	O
conclude	O
that	O
NF-kappa	B-protein
B	I-protein
activation	O
could	O
constitute	O
one	O
of	O
the	O
mechanisms	O
whereby	O
the	O
expression	O
of	O
kappa	B-DNA
B-responsive	I-DNA
genes	I-DNA
is	O
enhanced	O
in	O
phagocytosing	B-cell_type
neutrophils	I-cell_type
.	O

In	O
this	O
study	O
,	O
the	O
IFN-gamma	B-protein
induction	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
expression	O
in	O
primary	O
cultures	O
of	O
thymic	B-cell_line
epithelial	I-cell_line
cells	I-cell_line
(	O
TEC	B-cell_line
)	O
was	O
analyzed	O
.	O

Inhibition	O
of	O
NF-kappaB	B-protein
activity	O
in	O
a	O
T	B-cell_line
cell	I-cell_line
hybridoma	I-cell_line
leads	O
to	O
decreased	O
FasL	B-protein
expression	O
and	O
apoptosis	O
upon	O
T	B-protein
cell	I-protein
receptor	I-protein
stimulation	O
.	O

Deletion	O
of	O
this	O
region	O
significantly	O
impaired	O
IL-9	B-protein
-induced	O
cell	O
growth	O
,	O
activation	O
of	O
JAK	B-protein
kinases	I-protein
,	O
insulin	B-protein
receptor	I-protein
substrate-2	I-protein
,	O
and	O
STAT3	B-protein
and	O
expression	O
of	O
early	B-DNA
response	I-DNA
genes	I-DNA
.	O

The	O
Bmax	O
in	O
these	O
subjects	O
significantly	O
increased	O
to	O
6.61	O
+/-	O
2.02	O
(	O
257.7	O
+/-	O
107.8	O
%	O
)	O
after	O
24	O
h	O
stimulation	O
with	O
concanavalin	O
A	O
(	O
p	O
<	O
0.01	O
)	O
,	O
while	O
the	O
Kd	O
change	O
was	O
not	O
significant	O
.	O

Finally	O
,	O
the	O
in	O
vitro	O
tyrosine	O
kinase	O
activity	O
associated	O
with	O
the	O
p210bcr-abl	B-protein
oncogene	I-protein
product	I-protein
was	O
decreased	O
approximately	O
50	O
%	O
by	O
VD3	O
treatment	O
.	O

Multifactor	O
cis-dominant	O
negative	O
regulation	O
of	O
IL-2	B-DNA
gene	I-DNA
expression	O
in	O
anergized	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
TCF-1	B-DNA
alpha	I-DNA
cDNA	I-DNA
contains	O
a	O
single	O
68-amino-acid	B-protein
domain	I-protein
that	O
is	O
homologous	O
to	O
a	O
region	O
conserved	O
among	O
high-mobility	B-protein
group	I-protein
(	O
HMG	B-protein
)	O
and	O
nonhistone	B-protein
chromosomal	I-protein
proteins	I-protein
.	O

Prior	O
analyses	O
have	O
demonstrated	O
that	O
the	O
enhancer	B-DNA
contains	O
a	O
28-bp	B-DNA
core	I-DNA
region	I-DNA
and	O
local	O
adjacent	O
augmentative	O
cis	B-DNA
elements	I-DNA
.	O

The	O
Km	O
and	O
Vmax	O
for	O
daidzein	O
and	O
genistein	O
were	O
9.0	O
and	O
7.7	O
micromol/L	O
,	O
and	O
0.7	O
and	O
1.6	O
micromol/	O
(	O
mg	O
protein.	O
min	O
)	O
,	O
respectively	O
.	O

The	O
transcription	B-protein
factor	I-protein
E2F	B-protein
activates	O
the	O
expression	O
of	O
multiple	O
genes	B-DNA
involved	O
in	O
cell	O
proliferation	O
,	O
such	O
as	O
c-myc	B-DNA
and	O
the	O
dihydrofolate	B-DNA
reductase	I-DNA
gene	I-DNA
.	O

CIITA	B-protein
-induced	O
occupation	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
promoters	I-DNA
is	O
independent	O
of	O
the	O
cooperative	O
stabilization	O
of	O
the	O
promoter-bound	B-protein
multi-protein	I-protein
complexes	I-protein
.	O

Expression	O
of	O
Tax	B-protein
protein	I-protein
in	O
19D	B-cell_line
and	O
9J	B-cell_line
resulted	O
in	O
transcription	O
of	O
the	O
endogenous	B-DNA
NF-kappa	I-DNA
B-dependent	I-DNA
granulocyte-macrophage	I-DNA
colony	I-DNA
stimulating	I-DNA
factor	I-DNA
gene	I-DNA
and	O
increased	O
basal	O
level	O
expression	O
of	O
transfected	O
NF-kappa	B-DNA
B-regulated	I-DNA
promoters	I-DNA
.	O

The	O
stimulation	O
of	O
viral	O
production	O
from	O
this	O
cell	O
line	O
occurs	O
only	O
if	O
these	O
cells	O
are	O
treated	O
with	O
granulocyte/macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
before	O
treatment	O
with	O
LPS	O
.	O

Bandshift	O
experiments	O
showed	O
that	O
in	O
an	O
early	O
stage	O
of	O
both	O
differentiation	O
pathways	O
(	O
14	O
days	O
)	O
,	O
the	O
94	O
kDa	O
STAT5B	B-protein
protein	I-protein
was	O
activated	O
by	O
both	O
IL-5	B-protein
(	O
eosinophil	B-cell_type
lineage	I-cell_type
)	O
and	O
GM-CSF	B-protein
(	O
neutrophil	B-cell_type
lineage	I-cell_type
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
number	O
of	O
GR	B-protein
per	O
cell	O
among	O
the	O
three	O
groups	O
(	O
FMS	O
:	O
6498	O
+/-	O
252	O
,	O
LBP	O
:	O
6625	O
+/-	O
284	O
,	O
controls	O
:	O
6576	O
+/-	O
304	O
)	O
,	O
but	O
the	O
dissociation	O
constant	O
(	O
Kd	O
)	O
of	O
the	O
FMS	O
(	O
14.5	O
+/-	O
0.9	O
nmol/l	O
)	O
and	O
LBP	O
(	O
14.7	O
+/-	O
1.3	O
nmol/l	O
)	O
subjects	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
controls	O
(	O
10.9	O
+/-	O
0.8	O
nmol/l	O
)	O
(	O
p	O
<	O
.05	O
)	O
.	O

In	O
addition	O
,	O
two	O
out	O
of	O
three	O
M10-expressing	B-cell_line
CEM	I-cell_line
clones	I-cell_line
were	O
also	O
resistant	O
to	O
highly	O
productive	O
infection	O
by	O
a	O
heterogeneous	O
HIV-1	O
pool	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
CD14+	B-cell_type
adherent	I-cell_type
human	I-cell_type
monocytes	I-cell_type
can	O
differentiate	O
into	O
CD1+relB+	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
by	O
the	O
combination	O
of	O
GM-CSF	B-protein
plus	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
and	O
that	O
they	O
differentiate	O
into	O
tartrate-resistant	B-cell_type
acid	I-cell_type
phosphatase	I-cell_type
(	I-cell_type
TRAP	I-cell_type
)	I-cell_type
-positive	I-cell_type
osteoclast-like	I-cell_type
multinucleated	I-cell_type
giant	I-cell_type
cells	I-cell_type
(	O
MGC	B-cell_type
)	O
by	O
the	O
combination	O
of	O
M-CSF	B-protein
plus	O
IL-4	B-protein
.	O

A	O
second	O
complex	O
contains	O
hsp90	B-protein
bound	O
to	O
p23	B-protein
plus	O
the	O
three	O
immunophilins	B-protein
and	O
some	O
hsp70	B-protein
.	O

NK	B-protein
cell	I-protein
NFAT	I-protein
is	O
present	O
in	O
the	O
cytosol	O
of	O
nonstimulated	B-cell_type
cells	I-cell_type
,	O
migrates	O
to	O
the	O
nucleus	O
upon	O
stimulation	O
,	O
and	O
can	O
associate	O
with	O
AP-1	B-protein
.	O

Solubilization	O
of	O
the	O
receptor	B-protein
protein	I-protein
from	O
membranes	O
by	O
high	O
salt	O
concentrations	O
(	O
1	O
M	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
)	O
was	O
not	O
achieved	O
.	O

Taken	O
together	O
,	O
DZA	O
promotes	O
the	O
proteolytic	O
degradation	O
of	O
IkappaBalpha	B-protein
,	O
but	O
not	O
IkappaBbeta	B-protein
,	O
resulting	O
in	O
an	O
increase	O
of	O
DNA	O
binding	O
activity	O
of	O
NF-kappaB	B-protein
in	O
the	O
nucleus	O
in	O
the	O
absence	O
of	O
its	O
transcriptional	O
activity	O
in	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
.	O

One	O
of	O
these	O
clones	O
,	O
pZVH14	B-DNA
,	O
activated	O
the	O
HIV	B-DNA
promoter	I-DNA
construct	I-DNA
containing	O
a	O
mutation	O
in	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
.	O

The	O
maximum	O
(	O
3H	O
)	O
-thymidine	O
incorporation	O
into	O
DNA	O
of	O
cord	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
all	O
preterms	O
,	O
with	O
or	O
without	O
NRDS	O
was	O
suppressed	O
when	O
compared	O
to	O
that	O
from	O
term	O
babies	O
or	O
adults	O
.	O

The	O
sites	O
and	O
their	O
corresponding	O
nuclear	O
binding	O
factors	O
include	O
:	O
NF-kappa	B-protein
B	I-protein
,	O
AP-1	B-protein
,	O
AP-3	B-protein
,	O
OCT-1	B-protein
,	O
and	O
NF-AT	B-protein
.	O

Monocytes	B-cell_type
were	O
effective	O
APC	B-cell_type
for	O
VZV	O
peptides	O
only	O
after	O
immunization	O
.	O

Cortivazol	O
is	O
a	O
phenylpyrazolo	O
glucocorticoid	O
of	O
high	O
potency	O
and	O
unusual	O
structure	O
.	O

Furthermore	O
,	O
the	O
ability	O
of	O
these	O
complexes	O
to	O
regulate	O
gene	O
expression	O
is	O
demonstrated	O
by	O
increased	O
transcription	O
from	O
an	O
AP-1	B-DNA
driven	I-DNA
reporter	I-DNA
construct	I-DNA
and	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
endogenous	B-DNA
AP-1	I-DNA
regulated	I-DNA
genes	I-DNA
.	O

NO	O
derived	O
from	O
nNOS	B-protein
in	O
glia	B-cell_type
inhibits	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF	B-protein
kappaB	I-protein
)	O
as	O
NOS	O
inhibitors	O
enhance	O
basal	O
NF	B-protein
kappaB	I-protein
activation	O
.	O

Evidence	O
for	O
distinct	O
intracellular	O
signaling	O
pathways	O
in	O
CD34+	B-cell_type
progenitor	I-cell_type
to	O
dendritic	O
cell	O
differentiation	O
from	O
a	O
human	O
cell	O
line	O
model	O
.	O

We	O
have	O
used	O
a	O
32P-labeled	O
oligonucleotide	O
derived	O
from	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
which	O
contains	O
a	O
tandem	O
repeat	O
of	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
binding	I-DNA
sequence	I-DNA
,	O
as	O
a	O
probe	O
in	O
a	O
gel	O
retardation	O
assay	O
to	O
study	O
this	O
transcription	B-protein
factor	I-protein
.	O

Protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
does	O
not	O
appear	O
to	O
play	O
a	O
role	O
in	O
the	O
alpha-tcp	O
effect	O
since	O
no	O
suppression	O
of	O
phosphorylation	O
of	O
PKC	B-protein
substrates	O
was	O
observed	O
.	O

The	O
finding	O
related	O
to	O
social	O
support	O
also	O
replicates	O
results	O
from	O
an	O
independent	O
sample	O
of	O
breast	O
cancer	O
patients	O
.	O

Within	O
the	O
above	O
region	O
,	O
the	O
fragment	O
spanning	O
nucleotides	B-DNA
-158	I-DNA
to	I-DNA
-90	I-DNA
was	O
required	O
for	O
optimal	O
transcription	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Patients	O
with	O
GC-insensitive	O
asthma	O
expressed	O
a	O
significantly	O
higher	O
number	O
of	O
GCRbeta-immunoreactive	B-cell_type
cells	I-cell_type
in	O
their	O
BAL	O
and	O
peripheral	O
blood	O
than	O
GC-sensitive	O
asthmatics	O
or	O
normal	O
control	O
subjects	O
.	O

NFATx1	B-protein
,	O
which	O
is	O
preferentially	O
expressed	O
in	O
the	O
thymus	O
and	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
,	O
is	O
one	O
of	O
four	O
members	O
of	O
the	O
NFAT	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

BOB.1/OBF.1	B-protein
can	O
efficiently	O
activate	O
octamer-dependent	O
promoters	O
in	O
fibroblasts	B-cell_type
;	O
however	O
,	O
it	O
fails	O
to	O
stimulate	O
octamer-dependent	B-DNA
enhancer	I-DNA
activity	O
.	O

Multiple	B-DNA
regulatory	I-DNA
elements	I-DNA
in	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
HIV	B-DNA
LTR	I-DNA
)	O
are	O
required	O
for	O
activation	O
of	O
HIV	O
gene	O
expression	O
.	O

We	O
also	O
present	O
evidence	O
that	O
IL-6	B-protein
kappa	I-protein
B	I-protein
binding	I-protein
factor	I-protein
II	I-protein
functions	O
as	O
a	O
repressor	O
specific	O
for	O
IL-6	B-DNA
kappa	I-DNA
B-related	I-DNA
kappa	I-DNA
B	I-DNA
motifs	I-DNA
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

In	O
both	O
activated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
activated	B-cell_line
tumorigenic	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
IL-2	B-protein
gene	O
expression	O
was	O
blocked	O
at	O
the	O
transcriptional	O
level	O
by	O
okadaic	O
acid	O
.	O

Interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
is	O
a	O
cytokine	B-protein
that	O
is	O
expressed	O
primarily	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Erythroid	O
colony	O
growth	O
was	O
also	O
inhibited	O
when	O
CD34+	B-cell_type
progenitors	I-cell_type
were	O
seeded	O
at	O
one	O
cell	O
per	O
well	O
,	O
suggesting	O
a	O
direct	O
action	O
of	O
RA	O
.	O

This	O
region	O
contains	O
two	O
binding	B-DNA
sites	I-DNA
for	O
the	O
Sp1	B-protein
transcription	I-protein
factor	I-protein
.	O

In	O
contrast	O
to	O
myeloid-related	B-cell_type
DC	I-cell_type
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
is	O
not	O
required	O
for	O
the	O
development	O
of	O
these	O
lymphoid-related	B-cell_type
DC	I-cell_type
in	O
vivo	O
or	O
in	O
vitro	O
.	O

These	O
results	O
suggest	O
that	O
the	O
SRG3	B-protein
protein	I-protein
is	O
involved	O
in	O
the	O
glucocorticoid-induced	O
apoptosis	O
in	O
the	O
thymoma	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Site-directed	O
mutagenesis	O
of	O
the	O
wild-type	B-DNA
IL-2R	I-DNA
alpha	I-DNA
kappa	I-DNA
B	I-DNA
enhancer	I-DNA
(	O
GGGGAATCTCCC	O
)	O
has	O
revealed	O
that	O
the	O
binding	O
of	O
p50	O
and	O
p55	B-protein
(	O
B2	B-protein
complex	I-protein
)	O
is	O
particularly	O
sensitive	O
to	O
alteration	O
of	O
the	O
5	B-DNA
'	I-DNA
triplet	I-DNA
of	O
deoxyguanosine	O
residues	O
.	O

This	O
pro-IL-16	B-protein
is	O
subsequently	O
processed	O
to	O
the	O
mature	O
cytokine	O
of	O
13	B-protein
kDa	I-protein
.	O

The	O
cyclosporin	B-protein
A	I-protein
(	I-protein
CsA	I-protein
)	I-protein
/FK506-sensitive	I-protein
nuclear	I-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
inducible	O
expression	O
of	O
cytokine	B-DNA
genes	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

Searching	O
of	O
B4-2	B-DNA
DNA	I-DNA
and	O
protein	O
sequences	O
against	O
various	O
databases	O
revealed	O
no	O
high	O
homology	O
to	O
other	O
sequences	O
.	O

However	O
,	O
these	O
studies	O
have	O
used	O
a	O
limited	O
number	O
of	O
known	O
kappa	O
B	O
DNA	O
motifs	O
,	O
and	O
the	O
question	O
of	O
the	O
optimal	O
DNA	O
sequences	O
preferred	O
by	O
each	O
homodimer	O
has	O
not	O
been	O
addressed	O
.	O

NF-kappa	B-protein
B	I-protein
binding	O
activity	O
can	O
be	O
detected	O
for	O
several	O
hours	O
after	O
stimulation	O
.	O

Dephosphorylation	O
of	O
4E-BP1	B-protein
was	O
also	O
observed	O
when	O
U-937	B-cell_line
cells	I-cell_line
were	O
induced	O
to	O
differentiate	O
into	O
monocytes/macrophages	B-cell_type
following	O
treatment	O
with	O
retinoic	O
acid	O
or	O
DMSO	O
.	O

Signal	O
transduction	O
pathways	O
in	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
stimulated	O
by	O
cytokines	B-protein
and	O
mediators	O
:	O
comparative	O
study	O
with	O
normal	B-cell_type
human	I-cell_type
neutrophils	I-cell_type
or	O
transformed	B-cell_line
cells	I-cell_line
and	O
the	O
putative	O
roles	O
in	O
functionality	O
and	O
cell	O
biology	O
.	O

In	O
vitro	O
studies	O
on	O
hematopoietic	O
control	O
mechanisms	O
have	O
been	O
hampered	O
by	O
the	O
heterogeneity	O
of	O
the	O
analyzed	O
cell	O
populations	O
,	O
ie	O
,	O
lack	O
of	O
lineage	O
specificity	O
and	O
developmental	O
stage	O
homogeneity	O
of	O
progenitor/precursor	B-cell_type
cells	I-cell_type
growing	O
in	O
culture	O
.	O

[	O
Glucocorticoid	B-protein
receptors	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
of	O
patients	O
with	O
bronchial	O
asthma	O
]	O

Additionally	O
,	O
activation	O
of	O
different	O
signal	O
transduction	O
pathways	O
in	O
C.	B-cell_type
pneumoniae-infected	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
was	O
shown	O
:	O
protein	O
tyrosine	O
phosphorylation	O
,	O
up-regulation	O
of	O
phosphorylated	O
p42/p44	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
,	O
and	O
NF-kappaB	B-protein
activation/translocation	O
occurred	O
within	O
10-15	O
min	O
.	O

These	O
studies	O
examined	O
the	O
ability	O
of	O
CMV	O
IE	O
gene	O
products	O
to	O
modulate	O
IL-6	B-protein
production	O
.	O

C5a	B-protein
induced	O
kappaB	B-protein
binding	O
activity	O
was	O
detected	O
15	O
min	O
after	O
agonist	O
stimulation	O
,	O
peaked	O
at	O
30-40	O
min	O
,	O
and	O
remained	O
detectable	O
at	O
2	O
h	O
.	O

In	O
summary	O
,	O
our	O
data	O
suggest	O
that	O
changes	O
in	O
the	O
composition	O
of	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
is	O
a	O
key	O
molecular	O
mechanism	O
for	O
increasing	O
IL-2	B-protein
transcription	O
and	O
may	O
underlie	O
the	O
phenomenon	O
of	O
costimulation	O
by	O
EC	B-cell_type
.	O

There	O
is	O
no	O
detectable	O
NF-AT	B-protein
protein	O
expression	O
in	O
the	O
nuclei	O
of	O
resting	B-cell_type
eosinophils	I-cell_type
.	O

Therefore	O
,	O
chromosome	B-DNA
bands	I-DNA
11p15	I-DNA
(	O
rhombotin	B-DNA
)	O
and	O
11p13	B-DNA
(	O
Rhom-2	B-DNA
)	O
are	O
consistent	O
sites	O
of	O
chromosome	O
translocation	O
in	O
T-cell	O
leukemia	O
,	O
with	O
the	O
11p15	B-DNA
target	I-DNA
more	O
rarely	O
involved	O
.	O

Functional	O
studies	O
with	O
IL-6	B-DNA
promoter	I-DNA
demonstrated	O
that	O
three	O
regions	O
are	O
the	O
targets	O
of	O
the	O
IFN-gamma	B-protein
and/or	O
TNF-alpha	B-protein
action	O
,	O
whereas	O
only	O
one	O
of	O
these	O
regions	O
seemed	O
to	O
be	O
implicated	O
in	O
LPS	O
activation	O
.	O

Lymphocyte	B-protein
glucocorticoid	I-protein
receptor	I-protein
binding	O
parameters	O
were	O
studied	O
in	O
15	O
severely	O
depressed	O
patients	O
during	O
depression	O
and	O
after	O
clinical	O
recovery	O
,	O
and	O
in	O
15	O
healthy	O
controls	O
.	O

The	O
complementary	B-DNA
DNAs	I-DNA
are	O
the	O
products	O
of	O
distinct	O
genes	O
,	O
yet	O
both	O
ITF-1	B-protein
and	O
ITF-2	B-protein
are	O
structurally	O
and	O
functionally	O
similar	O
.	O

We	O
compared	O
this	O
sensitivity	O
to	O
analogue	O
effects	O
on	O
VDR	B-protein
interacting	O
proteins	O
:	O
RXR	B-protein
,	O
GRIP-1	B-protein
,	O
and	O
DRIP205	B-protein
,	O
a	O
subunit	O
of	O
the	O
DRIP	B-protein
coactivator	I-protein
complex	I-protein
.	O

Peroxisome	B-protein
proliferator-activated	I-protein
receptors	I-protein
(	O
PPAR	B-protein
)	O
control	O
discrete	O
genes	O
involved	O
in	O
fatty	O
acid	O
and	O
lipid	O
metabolism	O
.	O

Although	O
a	O
number	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
the	O
control	O
of	O
the	O
cell	O
cycle	O
or	O
DNA	O
replication	O
have	O
been	O
shown	O
to	O
peak	O
in	O
S	O
phase	O
,	O
this	O
is	O
the	O
first	O
example	O
of	O
a	O
lineage-restricted	B-protein
transcription	I-protein
factor	I-protein
displaying	O
S	O
phase-specific	O
DNA	O
binding	O
activity	O
.	O

Extensive	O
mutagenesis	O
of	O
CIITA	B-protein
was	O
undertaken	O
to	O
identify	O
structural	O
motifs	O
required	O
for	O
function	O
.	O

BMT	O
inhibits	O
nuclear	O
translocation	O
of	O
both	O
HIV-1	B-protein
transactivator	I-protein
(	O
TAT	B-protein
)	O
and	O
the	O
cellular	B-protein
transcriptional	I-protein
nuclear	I-protein
factor-KB	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
resulting	O
in	O
the	O
suppression	O
of	O
HIV-1	O
replication	O
.	O

We	O
have	O
used	O
Western	O
blotting	O
to	O
investigate	O
the	O
presence	O
of	O
these	O
proteins	O
during	O
the	O
cell	O
cycles	O
of	O
two	O
different	O
cellular	B-cell_line
systems	I-cell_line
:	O
a	O
continuously	B-cell_line
growing	I-cell_line
myeloid	I-cell_line
leukemic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
HL60	B-cell_line
,	O
and	O
normal	B-cell_type
cells	I-cell_type
stimulated	O
into	O
cycle	O
,	O
phyto-	B-cell_line
hemagglutinin	I-cell_line
(	I-cell_line
PHA	I-cell_line
)	I-cell_line
-stimulated	I-cell_line
normal	I-cell_line
human	I-cell_line
peripheral	I-cell_line
blood	I-cell_line
lymphocytes	I-cell_line
(	O
PBL	B-cell_type
)	O
.	O

Here	O
we	O
have	O
investigated	O
the	O
transcriptional	O
regulation	O
of	O
the	O
gamma	B-protein
chain	I-protein
gene	O
by	O
analyzing	O
the	O
2.5-kilobase	B-DNA
sequence	I-DNA
upstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O

Induction	O
of	O
STAT3	B-protein
is	O
inhibited	O
by	O
both	O
the	O
serine/threonine	O
protein	O
kinase	O
inhibitor	O
H-7	O
and	O
the	O
immunosuppressive	O
drug	O
rapamycin	O
and	O
requires	O
de	O
novo	O
protein	O
synthesis	O
,	O
demonstrating	O
novel	O
coupling	O
between	O
sIg	B-protein
and	O
STAT	B-protein
proteins	I-protein
that	O
differs	O
from	O
the	O
classical	O
paradigm	O
for	O
STAT	B-protein
induction	O
by	O
cytokine	B-protein
receptors	I-protein
.	O

The	O
importance	O
of	O
the	O
internal	O
ATGs	O
to	O
Rex	B-protein
function	O
is	O
not	O
known	O
.	O

In	O
mammalian	B-cell_type
cells	I-cell_type
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
proteins	I-protein
have	O
been	O
purified	O
and	O
shown	O
to	O
be	O
the	O
inhibitors	O
of	O
NF-kappa	B-protein
B	I-protein
through	O
their	O
association	O
with	O
the	O
p65	B-protein
or	I-protein
c-Rel	I-protein
subunits	I-protein
.	O

Whereas	O
the	O
mechanism	O
of	O
nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
has	O
been	O
described	O
,	O
the	O
bacterial	O
ligands	O
required	O
are	O
poorly	O
understood	O
.	O

Although	O
both	O
promoters	O
lack	O
any	O
TATA	B-DNA
box	I-DNA
,	O
they	O
contain	O
two	O
CAAT	B-DNA
box-like	I-DNA
motifs	I-DNA
and	O
three	O
binding	B-DNA
sites	I-DNA
of	O
GA-binding	B-protein
protein	I-protein
(	I-protein
GABP	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
.	O

Furthermore	O
,	O
longer-term	O
potentiation	O
by	O
methylprednisolone	O
was	O
observed	O
in	O
maturing	B-cell_line
human	I-cell_line
monocyte-derived	I-cell_line
M	I-cell_line
phi	I-cell_line
,	O
with	O
greater	O
increases	O
in	O
5-day	O
M	B-cell_line
phi	I-cell_line
uptake	O
of	O
apoptotic	B-cell_type
cells	I-cell_type
being	O
observed	O
the	O
earlier	O
glucocorticoids	O
were	O
added	O
during	O
monocyte	O
maturation	O
into	O
M	B-cell_line
phi	I-cell_line
.	O

These	O
results	O
suggest	O
that	O
the	O
molecular	O
mechanism	O
of	O
HIV	O
inhibition	O
by	O
ascorbate	O
is	O
not	O
mediated	O
via	O
NF-kappa	B-protein
B	I-protein
inhibition	O
,	O
unlike	O
that	O
seen	O
with	O
other	O
antioxidants	O
.	O

Small	O
apolar	O
substitutions	O
(	O
11	O
alpha-methyl	O
,	O
11	O
alpha-fluoromethyl	O
)	O
did	O
not	O
markedly	O
decrease	O
the	O
affinity	O
for	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
,	O
but	O
larger	O
(	O
11	O
alpha-chloromethyl	O
or	O
11	O
alpha-	O
or	O
11	O
beta-phenyl	O
)	O
or	O
more	O
polar	O
substitutions	O
(	O
11	O
alpha-hydroxymethyl	O
,	O
11	O
alpha-	O
(	O
2-hydroxyethyl	O
]	O
decreased	O
the	O
affinity	O
to	O
less	O
than	O
5	O
%	O
of	O
that	O
of	O
1	O
alpha	O
,	O
25-OH	O
)	O
2D3	O
.	O

A	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
superfamily	I-protein
was	O
isolated	O
by	O
virtue	O
of	O
its	O
affinity	O
for	O
CAML	B-protein
.	O

Nucleotide	O
sequence	O
and	O
PCR	O
analyses	O
demonstrated	O
the	O
presence	O
of	O
novel	O
duplications	O
or	O
deletions	O
involving	O
the	O
NF-kappa	B-DNA
B	I-DNA
motif	I-DNA
.	O

The	O
inhibitory	O
effect	O
was	O
much	O
more	O
evident	O
with	O
higher	O
dose	O
(	O
more	O
than	O
10	O
(	O
-5	O
)	O
mol/L	O
)	O
and	O
it	O
was	O
also	O
reversed	O
by	O
RU38486	O
,	O
but	O
only	O
partially	O
.	O

Increased	O
mRNA	B-RNA
and	O
surface	O
expression	O
of	O
E-selectin	B-protein
,	O
ICAM-1	B-protein
,	O
and	O
VCAM-1	B-protein
were	O
noted	O
within	O
hours	O
.	O

We	O
studied	O
glucocorticosteroid	B-protein
receptor	I-protein
density	O
and	O
affinity	O
on	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
by	O
the	O
glucocorticosteroid	O
binding	O
assay	O
in	O
33	O
patients	O
with	O
SLE	O
who	O
had	O
taken	O
no	O
glucocorticosteroid	O
for	O
the	O
previous	O
6	O
months	O
and	O
in	O
32	O
healthy	O
controls	O
.	O

The	O
role	O
of	O
BSAP	B-protein
(	O
Pax-5	B-protein
)	O
in	O
B-cell	O
development	O
.	O

Deletion	O
constructs	O
of	O
the	O
pCD41	B-DNA
clone	I-DNA
demonstrated	O
that	O
ORF-A	B-protein
was	O
critical	O
for	O
the	O
HIV	B-DNA
LTR	I-DNA
activation	O
.	O

The	O
lack	O
of	O
steroid	O
binding	O
of	O
HBD	B-protein
mutants	O
with	O
the	O
Thr729-Leu765	B-protein
sequence	I-protein
deleted	O
[	O
Jalaguier	O
,	O
Mesnier	O
,	O
Leger	O
and	O
Auzou	O
(	O
1996	O
)	O
J.Steroid	O
Biochem.Mol.Biol.57	O
,	O
43-50	O
]	O
supports	O
this	O
hypothesis	O
.	O

The	O
physico-chemical	O
and	O
functional	O
parameters	O
of	O
the	O
low	B-protein
molecular	I-protein
nuclear	I-protein
proteins	I-protein
(	O
SP	B-protein
and	O
BP-	B-protein
14	I-protein
,	I-protein
18	I-protein
,	I-protein
19	I-protein
kDs	I-protein
)	O
isolated	O
from	O
splenic	B-cell_type
and	I-cell_type
brain	I-cell_type
cells	I-cell_type
of	O
immunized	O
rats	O
were	O
studied	O
.	O

Therefore	O
we	O
investigated	O
the	O
properties	O
and	O
function	O
of	O
the	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	O
FMS	O
patients	O
and	O
compared	O
the	O
results	O
with	O
those	O
of	O
healthy	O
persons	O
and	O
patients	O
with	O
chronic	O
low	O
back	O
pain	O
(	O
LBP	O
a	O
localized	O
pain	O
condition	O
)	O
.	O

We	O
provide	O
a	O
model	O
of	O
megakaryocytic	O
differentiation	O
in	O
which	O
expression	O
of	O
the	O
alpha2	B-DNA
integrin	I-DNA
gene	I-DNA
requires	O
signaling	O
via	O
the	O
MAP	B-protein
kinase	I-protein
pathway	O
to	O
activate	O
two	O
tandem	O
AP1	B-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
alpha2	B-DNA
integrin	I-DNA
enhancer	I-DNA
.	O

Characterization	O
of	O
CD40	B-protein
signaling	O
determinants	O
regulating	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activation	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

In	O
support	O
of	O
this	O
interpretation	O
,	O
mutation	O
of	O
putative	O
nuclear	B-protein
localization	I-protein
sequences	I-protein
decreased	O
nuclear	O
localization	O
and	O
increased	O
transcriptional	O
activation	O
by	O
membrane-bound	B-protein
DeltaE	I-protein
.	O

Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
rapidly	O
induces	O
TF	B-DNA
gene	I-DNA
transcription	O
in	O
monocytes	B-cell_type
.	O

Here	O
we	O
describe	O
methods	O
to	O
investigate	O
whether	O
and	O
how	O
signaling	O
agonists	O
induce	O
myeloid	O
differentiation	O
and	O
how	O
oncoproteins	B-protein
might	O
cause	O
AML	O
by	O
modulating	O
the	O
activity	O
of	O
transcription	B-protein
factors	I-protein
that	O
are	O
pivotal	O
for	O
normal	O
myeloid	O
development	O
.	O

The	O
inhibitory	O
effects	O
of	O
cepharanthine	O
on	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
-driven	O
gene	O
expression	O
and	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
activation	O
were	O
also	O
examined	O
.	O

One	O
of	O
these	O
subregions	O
,	O
NRE	B-DNA
gamma	I-DNA
,	O
is	O
active	O
in	O
both	O
HeLa	B-cell_line
cervical	I-cell_line
carcinoma	I-cell_line
cells	I-cell_line
and	O
Huh7	B-cell_line
hepatoma	I-cell_line
cells	I-cell_line
and	O
was	O
found	O
to	O
be	O
bound	O
by	O
a	O
protein	O
factor	O
present	O
in	O
both	O
cell	O
types	O
.	O

Representational	O
difference	O
analysis	O
has	O
been	O
used	O
to	O
isolate	O
cDNA	B-DNA
clones	I-DNA
corresponding	O
to	O
mRNA	B-RNA
species	I-RNA
activated	O
following	O
stable	O
expression	O
of	O
HOX11	B-protein
in	O
NIH	B-cell_line
3T3	I-cell_line
cells	I-cell_line
.	O

The	O
results	O
obtained	O
suggest	O
that	O
two	O
Ad12	B-DNA
E1A	I-DNA
domains	I-DNA
are	O
required	O
to	O
induce	O
resistance	O
of	O
the	O
cell	B-cell_line
lines	I-cell_line
to	O
NK	B-cell_type
cells	I-cell_type
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Exogenous	O
provision	O
of	O
NFkB	B-protein
rescued	O
IL2R	B-protein
alpha	O
expression	O
but	O
not	O
the	O
PTHrP	B-DNA
promoter	I-DNA
.	O

Induced	O
myeloid	O
differentiation	O
of	O
K562	B-cell_line
cells	I-cell_line
with	O
downregulation	O
of	O
erythroid	B-protein
and	I-protein
megakaryocytic	I-protein
transcription	I-protein
factors	I-protein
:	O
a	O
novel	O
experimental	O
model	O
for	O
hemopoietic	O
lineage	O
restriction	O
.	O

The	O
age	O
dependence	O
of	O
morphologic	O
risk	O
factors	O
appears	O
to	O
explain	O
the	O
high	O
local	O
failure	O
rate	O
seen	O
in	O
patients	O
younger	O
than	O
40	O
.	O

In	O
the	O
current	O
studies	O
,	O
IL-2	B-protein
production	O
by	O
T	B-cell_type
cells	I-cell_type
from	O
elderly	O
(	O
mean	O
78	O
years	O
)	O
and	O
young	O
(	O
mean	O
37	O
years	O
)	O
humans	O
was	O
measured	O
in	O
cultures	O
stimulated	O
with	O
PHA	B-protein
,	O
PHA	B-protein
plus	O
PMA	O
,	O
crosslinked	O
anti-CD3	O
mAB	O
OKT3	O
plus	O
PMA	O
,	O
or	O
PMA	O
plus	O
ionomycin	O
.	O

This	O
paper	O
aims	O
to	O
review	O
the	O
role	O
of	O
free	O
radical-induced	O
tissue	O
damage	O
and	O
antioxidant	O
defence	O
mechanisms	O
in	O
inflammatory	O
diseases	O
that	O
involve	O
pathogenic	O
processes	O
similar	O
to	O
the	O
periodontal	O
diseases	O
.	O

The	O
activity	O
of	O
A-MYB	B-protein
in	O
B	B-cell_type
and	I-cell_type
not	I-cell_type
T	I-cell_type
cells	I-cell_type
was	O
observed	O
when	O
either	O
an	O
artificial	O
construct	O
or	O
the	O
c-MYC	B-DNA
promoter	I-DNA
was	O
used	O
as	O
a	O
reporter	O
.	O

The	O
plasma	O
ANH	O
level	O
was	O
38	O
pmol/l	O
(	O
N	O
supine	O
:	O
5-25	O
)	O
.	O

Detection	O
of	O
minimal	O
residual	O
disease	O
in	O
a	O
patient	O
with	O
acute	O
promyelocytic	O
leukemia	O
by	O
RT-PCR	O
:	O
necessity	O
of	O
chemotherapy	O
following	O
ATRA	O
therapy	O
.	O

Remixing	O
of	O
purified	B-cell_type
T	I-cell_type
cells	I-cell_type
showed	O
that	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
do	O
not	O
suppress	O
LAI	O
replication	O
in	O
memory	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
that	O
memory	B-cell_type
T	I-cell_type
cells	I-cell_type
do	O
not	O
restore	O
LAI	O
expression	O
in	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

These	O
observations	O
suggest	O
that	O
a	O
so-far-unrecognized	O
SP-1	B-DNA
site	I-DNA
in	O
the	O
human	B-DNA
IL-1beta	I-DNA
promoter	I-DNA
may	O
participate	O
in	O
the	O
transcriptional	O
regulation	O
of	O
this	O
gene	O
in	O
keratinocytes	B-cell_type
.	O

CD27	B-protein
/CD70	O
interaction	O
enhanced	O
B	B-cell_type
cell	I-cell_type
proliferation	O
in	O
the	O
presence	O
of	O
IL-4	B-protein
or	O
IL-4	B-protein
plus	O
anti-CD40	B-protein
.	O

Multiple	O
transcription	B-protein
factors	I-protein
are	O
required	O
for	O
activation	O
of	O
human	B-DNA
interleukin	I-DNA
9	I-DNA
gene	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Mutation	O
of	O
the	O
hXBP-1	B-DNA
DNA	I-DNA
target	I-DNA
sequence	I-DNA
decreased	O
DR	B-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
in	O
vivo	O
.	O

With	O
Western	O
blotting	O
,	O
it	O
was	O
shown	O
that	O
nuclear	O
extracts	O
from	O
monocytes	B-cell_type
contained	O
p50	B-protein
and	O
p65	B-protein
protein	I-protein
in	O
response	O
to	O
LPS	O
and	O
IFN-gamma	B-protein
stimulation	O
.	O

The	O
GATA-3	B-protein
transcription	I-protein
factor	I-protein
is	O
required	O
for	O
development	O
of	O
the	O
T-cell	B-cell_line
lineage	I-cell_line
and	O
Th2	B-DNA
cytokine	I-DNA
gene	I-DNA
expression	O
in	O
CD4	B-cell_type
T-cells	I-cell_type
.	O

In	O
avian	O
erythroid	B-cell_type
progenitors	I-cell_type
,	O
steroid	O
hormones	O
cooperate	O
with	O
tyrosine	B-protein
kinase	I-protein
receptors	I-protein
to	O
induce	O
renewal	O
of	O
erythroid	B-cell_type
progenitors	I-cell_type
.	O

Promoter	O
deletion	O
studies	O
revealed	O
two	O
additional	O
NF-IL6	B-DNA
binding	I-DNA
sites	I-DNA
located	O
at	O
positions	O
-44	O
to	O
-36	O
(	O
C/EBP	B-protein
proximal	I-protein
)	O
and	O
-87	O
to	O
-79	O
(	O
C/EBP	B-protein
medial	I-protein
)	O
,	O
respectively	O
.	O

Heparin	O
is	O
a	O
polyanionic	O
glycosaminoglycan	O
(	O
GAG	O
)	O
that	O
can	O
bind	O
with	O
high	O
affinity	O
to	O
a	O
range	O
of	O
cytokines	B-protein
including	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
and	O
members	O
of	O
the	O
chemokine	B-protein
superfamily	I-protein
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
tissue-specific	O
expression	O
of	O
Th1/Th2-like	B-protein
cytokines	I-protein
has	O
remained	O
elusive	O
.	O

Activation	O
of	O
the	O
CD4	B-DNA
promoter	I-DNA
occurs	O
in	O
the	O
presence	O
of	O
the	O
viral	O
DNA	O
polymerase	O
inhibitor	O
phosphonoformic	O
acid	O
,	O
which	O
limits	O
expression	O
to	O
the	O
immediate-early	B-DNA
and	I-DNA
early	I-DNA
classes	I-DNA
of	I-DNA
viral	I-DNA
genes	I-DNA
.	O

Nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
T-cells	I-cell_type
(	O
NFAT-1	B-protein
)	O
is	O
a	O
transcription	B-protein
factor	I-protein
which	O
is	O
considered	O
to	O
be	O
an	O
important	O
regulator	O
in	O
early	O
T-cell	O
activation	O
.	O

Furthermore	O
,	O
no	O
induction	O
of	O
AP-1	B-protein
was	O
seen	O
in	O
A6H	B-protein
costimulated	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

A	O
fragment	O
extending	O
from	O
-643	B-DNA
to	I-DNA
+33	I-DNA
is	O
capable	O
of	O
controlling	O
the	O
tissue-specific	O
expression	O
of	O
the	O
CAT	B-DNA
gene	I-DNA
in	O
transfection	O
experiments	O
.	O

Northern	O
blot	O
experiments	O
demonstrate	O
further	O
that	O
TCF-1	B-RNA
alpha	I-RNA
mRNA	I-RNA
is	O
highly	O
tissue	O
specific	O
,	O
found	O
primarily	O
in	O
the	O
thymus	B-cell_line
or	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Importantly	O
,	O
constitutive	O
expression	O
of	O
Rev	B-protein
M10	I-protein
did	O
not	O
alter	O
the	O
secretion	O
of	O
interleukin	B-protein
2	I-protein
in	O
response	O
to	O
mitogen	O
stimulation	O
of	O
EL-4	B-cell_line
and	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Homology	O
between	O
nucleolin	B-protein
and	O
histone	B-protein
H1	I-protein
suggests	O
that	O
nucleolin	B-protein
may	O
alter	O
DNA	O
organization	O
in	O
response	O
to	O
cell	O
cycle	O
controls	O
,	O
and	O
the	O
nucleolin	B-protein
component	O
of	O
LR1	B-protein
may	O
therefore	O
function	O
to	O
organize	O
switch	B-DNA
regions	I-DNA
before	O
,	O
during	O
,	O
or	O
after	O
switch	O
recombination	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
patients	O
with	O
GC-insensitive	O
asthma	O
have	O
cytokine-induced	O
abnormalities	O
in	O
the	O
DNA	O
binding	O
capability	O
of	O
the	O
GCR	B-protein
.	O

Decreased	O
transcriptional	O
activation	O
by	O
N-terminal	B-protein
deletions	I-protein
of	O
CIITA	B-protein
is	O
correlated	O
directly	O
with	O
their	O
reduced	O
binding	O
to	O
TAFII32	B-protein
.	O

The	O
anti-oxidative	O
effect	O
of	O
BHA	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
thiol	O
,	O
but	O
not	O
glutathione	O
,	O
content	O
in	O
stimulated	B-cell_line
and	I-cell_line
unstimulated	I-cell_line
T	I-cell_line
cell	I-cell_line
,	O
whereas	O
TNF	B-protein
stimulation	O
itself	O
barely	O
modified	O
the	O
cellular	O
thiol	O
level	O
.	O

There	O
was	O
a	O
significant	O
negative	O
correlation	O
between	O
IC50S	O
of	O
prednisolone	O
and	O
increase-ratios	O
(	O
post/pre	O
ratio	O
)	O
of	O
Bmax	O
after	O
mitogen	B-protein
stimulation	O
(	O
p	O
<	O
0.05	O
)	O
.	O

PNU156804	O
action	O
is	O
restricted	O
to	O
some	O
signaling	O
pathways	O
;	O
it	O
does	O
not	O
affect	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
PMA	O
in	O
T	B-cell_type
cells	I-cell_type
but	O
blocks	O
that	O
induced	O
by	O
CD40	B-protein
cross-linking	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

Human	B-DNA
interferon	I-DNA
regulatory	I-DNA
factor	I-DNA
2	I-DNA
gene	I-DNA
.	O

We	O
found	O
that	O
the	O
TCL1	B-DNA
gene	I-DNA
was	O
overexpressed	O
in	O
the	O
PBLs	B-cell_type
of	O
an	O
AT	O
patient	O
with	O
a	O
large	B-cell_line
clonal	I-cell_line
T-cell	I-cell_line
population	I-cell_line
exhibiting	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
but	O
not	O
in	O
the	O
lymphocytes	B-cell_type
of	O
the	O
other	O
cases	O
.	O

On	O
electromobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
a	O
single	O
E2F-DNA	B-protein
binding	I-protein
complex	I-protein
was	O
detected	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
B	B-cell_type
cells	I-cell_type
and	O
monocytes	B-cell_type
which	O
was	O
shown	O
to	O
contain	O
E2F-4	B-protein
,	O
DP-1	B-protein
and	O
p130	B-protein
,	O
indicating	O
that	O
all	O
quiescent	B-cell_type
haemopoietic	I-cell_type
cells	I-cell_type
have	O
the	O
same	O
complex	O
.	O

The	O
bare	O
lymphocyte	O
syndrome	O
(	O
BLS	O
)	O
is	O
characterized	O
by	O
the	O
absence	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
transcription	O
and	O
humoral-	O
and	O
cellular-mediated	O
immune	O
responses	O
to	O
foreign	O
antigens	O
.	O

The	O
aim	O
of	O
this	O
research	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
a	O
causal	O
relationship	O
exists	O
between	O
the	O
level	O
of	O
expression	O
of	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
and	O
induction	O
of	O
the	O
adenylyl	B-protein
cyclase	I-protein
(	O
AC	O
)	O
cascade	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
mechanism	O
by	O
which	O
IL-10	B-protein
downregulates	O
expression	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
)	O
on	O
the	O
cell	O
surface	O
of	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
activated	O
with	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
.	O

A	O
somewhat	O
surprising	O
finding	O
however	O
was	O
a	O
very	O
strong	O
association	O
between	O
oncogene	B-DNA
amplification	O
and	O
dense	O
lymphocyte	O
infiltration	O
of	O
the	O
tumor	O
(	O
P	O
=	O
.05	O
)	O
.	O
This	O
correlation	O
is	O
even	O
stronger	O
when	O
only	O
high	O
levels	O
of	O
amplification	O
are	O
considered	O
,	O
either	O
for	O
each	O
oncogene	O
separately	O
(	O
P	O
=	O
.0048	O
)	O
or	O
in	O
combination	O
(	O
P	O
=	O
.0007	O
)	O
.	O

A	O
human	B-DNA
putative	I-DNA
lymphocyte	I-DNA
G0/G1	I-DNA
switch	I-DNA
gene	I-DNA
homologous	O
to	O
a	O
rodent	B-DNA
gene	I-DNA
encoding	O
a	O
zinc-binding	B-protein
potential	I-protein
transcription	I-protein
factor	I-protein
.	O

Cysteine	O
and	O
NAC	O
also	O
inhibit	O
NF-kappa	B-protein
B	I-protein
activity	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
chloramphenicol	B-protein
acetyl-transferase	I-protein
(	O
CAT	B-protein
)	O
gene	O
expression	O
under	O
control	O
of	O
NF-kappa	B-protein
B	I-protein
binding	B-DNA
sites	I-DNA
in	O
uninfected	B-cell_type
cells	I-cell_type
.	O

The	O
levels	O
of	O
c-jun	B-RNA
mRNA	I-RNA
was	O
elevated	O
4	O
to	O
7.5-fold	O
by	O
HU	O
within	O
2	O
h	O
.	O

The	O
composition	O
of	O
the	O
induced	O
nuclear	B-protein
NF-kappaB	I-protein
(	O
levels	O
of	O
p50	B-protein
and	O
RelA	B-protein
proteins	I-protein
)	O
was	O
similar	O
in	O
these	O
cell	O
types	O
.	O

Induction	O
of	O
IL-5	B-RNA
mRNA	I-RNA
upon	O
TCR	B-protein
and	O
IL-2R	B-protein
stimulation	O
was	O
totally	O
inhibited	O
by	O
dexamethasone	O
.	O

Additionally	O
,	O
to	O
determine	O
the	O
impact	O
of	O
RXR	B-protein
for	O
erythroid	O
cell	O
development	O
,	O
dominant	O
interfering	O
mutant	B-protein
RXRs	I-protein
,	O
lacking	O
the	O
transcriptional	O
activator	O
functions	O
AF-1	B-protein
and	O
AF-2	B-protein
,	O
or	O
AF-2	B-protein
only	O
,	O
or	O
the	O
entire	B-DNA
DNA-binding	I-DNA
domain	I-DNA
,	O
were	O
introduced	O
into	O
erythroid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
via	O
recombinant	O
retrovirus	O
vectors	O
and	O
analyzed	O
for	O
RXR	B-protein
-specific	O
effects	O
.	O

Here	O
we	O
report	O
that	O
the	O
formation	O
of	O
two	O
distinct	O
mitogen-inducible	B-protein
DNA-binding	I-protein
complexes	I-protein
,	O
the	O
kappa	B-protein
B	I-protein
complex	I-protein
within	O
the	O
HIV	B-DNA
enhancer	I-DNA
and	O
the	O
NFAT-1	B-protein
complex	I-protein
within	O
the	O
interleukin-2	B-DNA
enhancer	I-DNA
,	O
is	O
inhibited	O
in	O
the	O
presence	O
of	O
CsA	O
.	O

Multiple	O
functionally	O
important	O
EBF	B-DNA
and	I-DNA
E47	I-DNA
binding	I-DNA
sites	I-DNA
were	O
identified	O
in	O
the	O
lambda5	B-DNA
promoter/enhancer	I-DNA
region	I-DNA
,	O
indicating	O
that	O
lambda5	B-DNA
is	O
a	O
direct	O
genetic	O
target	O
for	O
these	O
transcription	B-protein
factors	I-protein
.	O

Lung	O
disease	O
associated	O
with	O
disorders	O
such	O
as	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
may	O
be	O
amenable	O
to	O
somatic	O
gene	O
therapy	O
in	O
which	O
there	O
is	O
delivery	O
of	O
the	O
normal	B-DNA
gene	I-DNA
directly	O
to	O
the	O
respiratory	O
epithelium	O
using	O
E1a-	O
adenovirus	O
(	O
Ad	O
)	O
type	O
2-	O
or	O
5-based	O
vectors	O
.	O

We	O
have	O
recently	O
cloned	O
the	O
carboxylesterase	B-DNA
upstream	I-DNA
sequence	I-DNA
and	O
showed	O
its	O
basal	B-DNA
promoter	I-DNA
activity	O
in	O
CHO	B-cell_line
cells	I-cell_line
.	O

Pit-1	B-protein
is	O
a	O
pituitary-specific	B-protein
transcription	I-protein
factor	I-protein
that	O
binds	O
to	O
and	O
transactivates	O
promoters	B-DNA
of	O
growth	B-DNA
hormone	I-DNA
and	I-DNA
prolactin	I-DNA
genes	I-DNA
.	O

The	O
Rel/NF-kappa	B-protein
B	I-protein
proteins	I-protein
,	O
p50	B-protein
,	O
p52	B-protein
,	O
p65	B-protein
,	O
c-Rel	B-protein
,	O
and	O
RelB	B-protein
,	O
constitute	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
the	O
positive	O
regulation	O
of	O
a	O
variety	O
of	O
genes	O
during	O
the	O
immune	O
response	O
.	O

The	O
immunomodulatory	O
cytokine	B-protein
IL-4	B-protein
affects	O
cells	O
of	O
most	O
hemopoietic	B-cell_type
lineages	I-cell_type
.	O

of	O
the	O
other	O
putative	O
regulatory	O
sites	O
was	O
occupied	O
in	O
vivo	O
,	O
indicating	O
that	O
they	O
may	O
not	O
be	O
functional	O
.	O

We	O
previously	O
identified	O
the	O
DNA	B-DNA
consensus	I-DNA
binding	I-DNA
site	I-DNA
recognized	O
by	O
the	O
two	O
DNA	B-protein
binding	I-protein
domains	I-protein
.	O

Here	O
,	O
we	O
report	O
that	O
cells	O
expressing	O
osteoclast	B-protein
markers	I-protein
differentiate	O
from	O
precursors	O
present	O
in	O
nonmobilized	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
,	O
without	O
the	O
addition	O
of	O
stromal	B-cell_type
cells	I-cell_type
,	O
growth	B-protein
factors	I-protein
,	O
cytokines	O
or	O
steroids	O
;	O
and	O
characterize	O
their	O
phenotype	O
.	O

Regulation	O
of	O
NFAT	B-protein
could	O
be	O
therefore	O
a	O
critical	O
element	O
in	O
the	O
polarization	O
to	O
eTh1	B-cell_type
or	O
eTh2	B-cell_type
.	O

p50	B-protein
is	O
translated	O
as	O
a	O
precursor	O
of	O
105	B-protein
kDa	I-protein
.	O

Thus	O
we	O
hypothesized	O
that	O
combinations	O
of	O
hypoxia	O
and	O
inflammatory	O
stimuli	O
may	O
differentially	O
regulate	O
expression	O
of	O
endothelial	B-protein
ICAM-1	I-protein
.	O

An	O
IRF-1	B-protein
-dependent	O
pathway	O
of	O
DNA	O
damage-induced	O
apoptosis	O
in	O
mitogen-activated	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

The	O
reason	O
that	O
only	O
certain	O
individuals	O
of	O
particular	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
haplotypes	I-protein
can	O
mount	O
T-cell	O
responses	O
against	O
a	O
given	O
antigen	O
of	O
pathogens	O
is	O
found	O
in	O
the	O
fact	O
that	O
T-cell	B-protein
receptors	I-protein
are	O
designed	O
to	O
recognize	O
18-20	O
residue-long	O
peptide	O
fragments	O
sandwiched	O
between	O
two	O
alpha-helices	B-protein
of	O
class	B-protein
I	I-protein
or	O
class	O
II	O
MHC	O
molecules	O
.	O

It	O
also	O
suggests	O
a	O
novel	O
specificity-conferring	O
mechanism	O
for	O
mineralocorticoid	O
action	O
at	O
the	O
membrane	O
level	O
.	O

Although	O
NF-AT	B-protein
has	O
not	O
been	O
cloned	O
or	O
purified	O
,	O
there	O
is	O
evidence	O
that	O
it	O
is	O
a	O
major	O
target	O
for	O
immunosuppression	O
by	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
(	O
refs	O
2-7	O
)	O
.	O

The	O
thyroid	O
function	O
was	O
normal	O
regarding	O
T4	O
,	O
free	O
T4	O
and	O
T3	O
,	O
TBG	O
,	O
radioiodine	O
uptake	O
,	O
TSH	O
and	O
T3	O
suppressibility	O
;	O
however	O
the	O
TSH	O
response	O
to	O
TRH	O
was	O
decreased	O
.	O

In	O
addition	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
decreased	O
the	O
abundance	O
of	O
a	O
specific	B-protein
DNA-protein	I-protein
complex	I-protein
formed	O
upon	O
incubation	O
of	O
nuclear	O
extracts	O
from	O
activated	O
lymphocytes	O
with	O
a	O
labeled	O
NF-kappa	B-protein
B	I-protein
DNA	I-protein
binding	I-protein
motif	I-protein
.	O

These	O
studies	O
indicate	O
that	O
iNO	O
attenuates	O
iNOS	B-protein
expression	O
in	O
macrophages	B-cell_type
and	O
inhibits	O
monocyte	O
adhesion	O
to	O
endothelial	B-cell_type
cells	I-cell_type
,	O
and	O
suggest	O
that	O
endogenously	O
derived	O
iNO	O
may	O
be	O
an	O
important	O
autoregulatory	O
inhibitor	O
of	O
vascular	O
inflammation	O

A20	O
can	O
be	O
regulated	O
by	O
the	O
NF-kappaB	B-protein
transcription	B-protein
factor	I-protein
,	O
which	O
is	O
known	O
to	O
be	O
activated	O
by	O
the	O
EBV	B-protein
LMP-1	I-protein
protein	I-protein
.	O

IFN	B-protein
regulatory	I-protein
factor	I-protein
1	I-protein
(	O
IRF-1	B-protein
)	O
is	O
a	O
transcription	B-protein
factor	I-protein
activated	O
by	O
either	O
CD40	B-protein
or	O
cytokines	B-protein
.	O

The	O
cDNA	B-DNA
clone	I-DNA
encodes	O
a	O
new	O
isoform	O
,	O
NFATc.beta	B-protein
,	O
of	O
the	O
NFAT	B-protein
gene	I-protein
family	I-protein
member	I-protein
NFATc	B-protein
(	O
designated	O
here	O
NFATc.alpha	B-protein
)	O
.	O

The	O
system	O
described	O
here	O
may	O
serve	O
as	O
a	O
model	O
for	O
studying	O
the	O
the	O
essential	B-DNA
genes	I-DNA
for	O
differentiation	O
of	O
normal	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
.	O

Constitutive	O
activation	O
of	O
different	O
Jak	B-protein
tyrosine	I-protein
kinases	I-protein
in	O
human	B-protein
T	I-protein
cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HTLV-1	I-protein
)	I-protein
tax	I-protein
protein	I-protein
or	O
virus-transformed	B-cell_line
cells	I-cell_line
.	O

Furthermore	O
,	O
pre-B	B-cell_line
cell	I-cell_line
and	I-cell_line
plasma	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
Spi-C	B-protein
-negative	O
,	O
suggesting	O
that	O
Spi-C	B-protein
might	O
be	O
a	O
regulatory	B-protein
molecule	I-protein
during	O
a	O
specific	O
phase	O
of	O
B	O
lymphoid	O
development	O
.	O

To	O
address	O
possible	O
mechanisms	O
that	O
could	O
explain	O
this	O
selective	O
activity	O
of	O
c-ErbB	B-protein
,	O
we	O
analyzed	O
the	O
ability	O
of	O
these	O
receptors	O
to	O
activate	O
the	O
different	O
members	O
of	O
the	O
Stat	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O

Immunoprecipitation	O
and	O
electrophoretic	O
mobility	O
shift	O
analysis	O
revealed	O
that	O
tyrosine	O
phosphorylation	O
of	O
JAK2	B-protein
and	O
activation	O
of	O
STAT5	B-protein
were	O
induced	O
upon	O
stimulation	O
with	O
hIL-5	B-protein
in	O
all	O
three	O
cell	O
types	O
,	O
while	O
STAT1	B-protein
activation	O
was	O
only	O
observed	O
in	O
eosinophils	B-cell_type
.	O

To	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
RANTES	B-protein
expression	O
,	O
the	O
RANTES	B-DNA
promoter	I-DNA
region	I-DNA
was	O
analyzed	O
by	O
transient	O
expression	O
and	O
gel-mobility	O
shift	O
assays	O
.	O

In	O
typical	O
AITL	O
,	O
some	O
neoplastic	O
cells	O
were	O
positive	O
for	O
Bcl-6	B-protein
,	O
showing	O
variable	O
degrees	O
of	O
staining	O
.	O

Binding	O
of	O
the	O
nuclear	O
factor	O
to	O
the	O
GAS	B-DNA
element	I-DNA
in	O
the	O
CAEV	B-DNA
LTR	I-DNA
is	O
inhibited	O
by	O
antibody	O
directed	O
against	O
STAT1	B-protein
(	O
p91/84	B-protein
)	O
.	O

We	O
have	O
tested	O
several	O
subregions	O
of	O
the	O
DR	B-DNA
enhancer	I-DNA
B	B-DNA
domain	I-DNA
,	O
either	O
alone	O
or	O
in	O
combination	O
,	O
for	O
their	O
capacity	O
to	O
transmit	O
the	O
R-activating	O
signal	O
to	O
the	O
rabbit	B-DNA
beta-globin	I-DNA
promoter	I-DNA
.	O

A	O
truncated	O
form	O
of	O
the	O
product	O
of	O
this	O
gene	O
translated	O
in	O
vitro	O
is	O
a	O
DNA-binding	B-protein
protein	I-protein
which	O
interacts	O
specifically	O
with	O
the	O
kappa	B-DNA
B	I-DNA
binding	I-DNA
site	I-DNA
found	O
in	O
many	O
inducible	B-DNA
genes	I-DNA
,	O
including	O
the	O
enhancer	O
in	O
human	O
immunodeficiency	O
virus	O
.	O

Inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
resulted	O
in	O
the	O
externalization	O
of	O
phosphatidylserine	O
,	O
induction	O
of	O
DNA	O
breaks	O
,	O
and	O
morphological	O
changes	O
consistent	O
with	O
apoptosis	O
.	O

Functional	O
characterization	O
of	O
the	O
murine	B-protein
homolog	I-protein
of	O
the	O
B	B-protein
cell-specific	I-protein
coactivator	I-protein
BOB.1/OBF.1	B-protein
.	O

All	O
patients	O
showed	O
insufficient	O
suppression	O
of	O
serum	O
cortisol	O
concentrations	O
in	O
the	O
overnight	O
1-mg	O
dexamethasone	O
test	O
.	O

Inhibition	O
of	O
NF-AT	B-protein
signal	O
transduction	O
events	O
by	O
a	O
dominant-negative	O
form	O
of	O
calcineurin	B-protein
.	O

V3-BH10	B-protein
neither	O
blocked	O
radiolabeled	O
IL-2	B-protein
binding	O
to	O
IL-2	B-protein
receptors	I-protein
nor	O
affected	O
tyrosyl	O
phosphorylation	O
of	O
several	O
cellular	B-protein
proteins	I-protein
(	O
p120	B-protein
,	O
p98	B-protein
,	O
p96	B-protein
,	O
p54	B-protein
,	O
and	O
p38	B-protein
)	O
,	O
which	O
is	O
immediately	O
induced	O
by	O
IL-2	B-protein
stimulation	O
.	O

Treatment	O
with	O
okadaic	O
acid	O
resulted	O
in	O
a	O
striking	O
increase	O
in	O
TNF-alpha	B-RNA
mRNA	I-RNA
transcripts	O
within	O
1	O
h	O
of	O
stimulation	O
and	O
large	O
amounts	O
of	O
TNF-alpha	B-protein
were	O
released	O
into	O
the	O
culture	O
media	O
.	O

Ectopic	O
ALF1	B-protein
and	O
E2A	B-protein
proteins	I-protein
required	O
intact	O
E	B-DNA
(	I-DNA
gre	I-DNA
)	I-DNA
motifs	I-DNA
for	O
mediating	O
transcriptional	O
activation	O
.	O

We	O
previously	O
demonstrated	O
increased	O
HTLV-1	O
transcription	O
following	O
CD2	O
but	O
not	O
CD3	O
receptor	O
cross-linking	O
.	O

The	O
pp52	B-DNA
promoter	I-DNA
contains	O
an	O
initiator	O
specifying	O
the	O
unique	O
5	B-DNA
'	I-DNA
terminus	I-DNA
of	O
pp52	B-RNA
mRNA	I-RNA
,	O
tandem	O
pairs	O
of	O
Ets	B-DNA
and	I-DNA
SP1	I-DNA
motifs	I-DNA
,	O
and	O
a	O
lone	B-DNA
C/EBP	I-DNA
motif	I-DNA
.	O

The	O
viral	B-protein
proteins	I-protein
are	O
believed	O
to	O
prolong	O
acute	O
and	O
persistent	O
adenovirus	O
infections	O
.	O

Resting	B-cell_type
B	I-cell_type
and	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
contain	O
high	O
levels	O
of	O
BCL-6	B-RNA
mRNA	I-RNA
.	O

Thus	O
,	O
although	O
CD3	B-protein
,	O
CD28	B-protein
,	O
and	O
CD2	O
activate	O
many	O
of	O
the	O
same	O
signaling	B-protein
molecules	I-protein
,	O
they	O
differed	O
in	O
their	O
capacity	O
to	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
HSI	B-protein
.	O

The	O
proteins	O
identified	O
have	O
molecular	O
weights	O
of	O
about	O
32	O
,	O
36	O
to	O
42	O
,	O
50	O
and	O
110	O
kD	O
.	O

Study	O
of	O
Aldh1	B-protein
gene	O
expression	O
during	O
spleen	O
development	O
showed	O
that	O
the	O
presence	O
of	O
Aldh1	B-RNA
mRNA	I-RNA
inversely	O
correlated	O
with	O
Hox11	B-protein
.	O

We	O
show	O
here	O
that	O
soluble	O
TN	B-protein
inhibits	O
proliferation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
response	O
to	O
alpha	B-protein
CD3	I-protein
Ab	I-protein
co-immobilized	O
with	O
the	O
extracellular	B-protein
matrix	I-protein
protein	I-protein
fibronectin	B-protein
(	O
FN	B-protein
)	O
.	O

The	O
regulation	O
of	O
the	O
production	O
or	O
activity	O
of	O
C/EBP	B-protein
beta	I-protein
,	O
to	O
inhibit	O
inflammatory	O
mediator	O
expression	O
by	O
synovial	B-cell_type
macrophages	I-cell_type
and	O
fibroblasts	B-cell_type
,	O
offers	O
a	O
novel	O
approach	O
to	O
therapeutic	O
intervention	O
.	O

A	O
novel	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
family	I-protein
transcription	I-protein
factor	I-protein
,	O
ICSAT/Pip/LSIRF	B-protein
,	O
that	O
negatively	O
regulates	O
the	O
activity	O
of	O
interferon-regulated	B-DNA
genes	I-DNA
.	O

In	O
addition	O
,	O
dual	O
colour	O
FISH	O
analysis	O
using	O
centromere	O
specific	O
probes	O
for	O
chromosomes	O
X	B-DNA
and	O
17	B-DNA
showed	O
that	O
the	O
breakpoints	O
on	O
both	O
chromosomes	B-DNA
lie	O
within	O
the	O
alphoid	O
arrays	O
,	O
making	O
interruption	O
of	O
a	O
locus	O
on	O
either	O
chromosome	O
unlikely	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
glucocorticoid	O
hormones	O
on	O
neutrophil	B-cell_type
-mediated	O
tumor	O
cell	O
cytostasis	O
and	O
found	O
that	O
hydrocortisone	O
and	O
a	O
synthetic	O
hormone	O
,	O
dexamethasone	O
(	O
Dex	O
)	O
,	O
inhibited	O
cytostasis	O
in	O
the	O
presence	O
or	O
absence	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
.	O

Redox	O
regulation	O
of	O
NF-kappa	B-protein
B	I-protein
has	O
been	O
implicated	O
in	O
the	O
activation	O
of	O
the	O
human	O
immuno-deficiency	O
virus	O
(	O
HIV	O
)	O
.	O

Indeed	O
,	O
the	O
combination	O
of	O
NE	B-protein
and	O
threshold	O
of	O
cathepsin	B-protein
G	I-protein
increased	O
the	O
binding	O
of	O
PAC-1	B-protein
approximately	O
5.5-fold	O
over	O
basal	O
values	O
measured	O
on	O
nontreated	B-cell_type
platelets	I-cell_type
,	O
whereas	O
this	O
binding	O
raised	O
only	O
by	O
approximately	O
3-fold	O
in	O
threshold	O
of	O
cathepsin	B-cell_type
G-stimulated	I-cell_type
platelets	I-cell_type
(	O
p	O
<	O
0.05	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
attempted	O
to	O
determine	O
whether	O
c-fos	B-DNA
expression	O
is	O
induced	O
by	O
radiotherapy	O
in	O
human	O
squamous	O
cell	O
carcinomas	O
of	O
the	O
head	O
and	O
neck	O
and	O
to	O
establish	O
a	O
possible	O
correlation	O
between	O
c-fos	B-DNA
expression	O
and	O
the	O
therapeutic	O
effects	O
of	O
radiation	O
therapy	O
.	O

We	O
previously	O
reported	O
that	O
Smad7	B-protein
is	O
an	O
activin	O
A-inducible	O
antagonist	O
of	O
activin	O
A-induced	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
HS-72	B-cell_line
cells	I-cell_line
.	O

The	O
ras	O
mutation	O
frequency	O
varies	O
between	O
95	O
%	O
in	O
pancreatic	O
cancer	O
and	O
5	O
%	O
in	O
breast	O
cancer	O
.	O

CONCLUSIONS	O
:	O
HCS	O
forcefully	O
blocks	O
the	O
production	O
of	O
IL-2	B-protein
;	O
the	O
IL-2R	B-protein
alpha-chain	I-protein
;	O
and	O
Jak1	O
,	O
Jak3	O
,	O
Stat1	O
,	O
Stat3	O
,	O
and	O
Stat5	O
expression	O
.	O

Heat	O
shock	O
caused	O
an	O
increase	O
in	O
c-fos	O
and	O
c-jun	O
mRNA	O
levels	O
and	O
a	O
decrease	O
in	O
c-myc	B-RNA
mRNA	I-RNA
levels	O
in	O
pre-B	B-cell_line
(	I-cell_line
Hyon	I-cell_line
)	I-cell_line
and	I-cell_line
T	I-cell_line
(	I-cell_line
DND-41	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
as	O
well	O
as	O
in	O
freshly	O
isolated	O
normal	O
human	O
thymocytes	O
.	O

Jak1	B-protein
,	O
Jak2	B-protein
,	O
and	O
Stat1	B-protein
were	O
immunoprecipitated	O
from	O
control	O
and	O
interferon-treated	B-cell_line
cells	I-cell_line
,	O
and	O
tyrosine	O
phosphorylation	O
of	O
these	O
proteins	O
,	O
detected	O
by	O
antiphosphotyrosine	O
immunoblotting	O
was	O
used	O
to	O
measured	O
their	O
activation	O
.	O

Dopamine	O
stimulates	O
expression	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
via	O
NF-kappaB	B-protein
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Sequence	O
homology	O
,	O
single	O
nucleotide	O
mutations	O
,	O
and	O
anti-CD28	B-protein
Ab	I-protein
stimulation	O
studies	O
established	O
that	O
the	O
NF-kappa	B-DNA
B-like	I-DNA
sequence	I-DNA
in	O
the	O
promoter	B-DNA
of	O
the	O
IL-8	B-DNA
gene	I-DNA
functioned	O
as	O
a	O
CD28	B-DNA
response	I-DNA
element	I-DNA
.	O

MZF-1	B-DNA
transcriptional	O
regulation	O
of	O
this	O
physiologically	B-DNA
relevant	I-DNA
promoter	I-DNA
was	O
assessed	O
in	O
both	O
hematopoietic	B-cell_line
and	O
nonhematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

PG490	O
inhibits	O
the	O
induction	O
of	O
DNA	O
binding	O
activity	O
at	O
the	O
purine-box/antigen	B-DNA
receptor	I-DNA
response	I-DNA
element	I-DNA
(	I-DNA
ARRE	I-DNA
)	I-DNA
/nuclear	I-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T-cells	I-DNA
(	I-DNA
NF-AT	I-DNA
)	I-DNA
target	I-DNA
sequence	I-DNA
but	O
not	O
at	O
the	O
NF-kappaB	B-DNA
site	I-DNA
.	O

In	O
this	O
study	O
we	O
analyzed	O
the	O
effect	O
of	O
CD40	B-protein
stimulation	O
on	O
the	O
activity	O
and	O
nuclear	O
appearance	O
of	O
Rel/nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
factors	I-protein
in	O
primary	B-cell_type
murine	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

The	O
former	O
two	O
substances	O
interact	O
with	O
T	B-cell_type
cells	I-cell_type
via	O
the	O
glucocorticoid	B-protein
and	I-protein
beta-adrenergic	I-protein
receptors	I-protein
respectively	O
.	O

Cross	O
talk	O
between	O
cell	O
death	O
and	O
cell	O
cycle	O
progression	O
:	O
BCL-2	B-protein
regulates	O
NFAT	B-protein
-mediated	O
activation	O
.	O

Initial	O
and	O
post-dexamethasone	O
in	O
vitro	O
fibroblast	O
binding	O
to	O
glucocorticoid	O
was	O
not	O
different	O
between	O
major	O
depressive	O
disorder	O
and	O
non-depressed	O
control	O
subjects	O
.	O

IL-2R	O
chains	O
were	O
measured	O
by	O
flow	O
cytometry	O
,	O
and	O
Jaks/Stats	B-protein
by	O
sodium	O
dodecyl	O
sulfate	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS-PAGE	O
)	O
and	O
Western	O
blot	O
.	O

Strikingly	O
,	O
despite	O
the	O
observed	O
repertoire	O
heterogeneity	O
,	O
all	O
clones	O
displayed	O
a	O
narrow	O
range	O
of	O
MHC	B-protein
/peptide	O
density	O
requirements	O
in	O
cytotoxicity	O
assays	O
(	O
ED50	O
between	O
9	O
and	O
36	O
nM	O
)	O
.	O

The	O
GR	B-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
in	O
aged	O
runner	O
was	O
65	O
%	O
of	O
the	O
control	O
.	O

Further	O
studies	O
were	O
carried	O
out	O
using	O
differential	O
RNA	O
display	O
(	O
DD	O
)	O
.	O

MTHC	B-cell_line
in	O
the	O
presence	O
of	O
TNF-alpha	B-protein
and	O
IL-4	B-protein
will	O
differentiate	O
into	O
cells	O
that	O
have	O
many	O
of	O
the	O
properties	O
of	O
macrophages	B-cell_type
.	O

Analysis	O
of	O
the	O
molecular	O
differences	O
between	O
primary	O
anaplastic	O
astrocytomas/glioblastomas	O
and	O
their	O
subsequent	O
recurrences	O
,	O
which	O
are	O
clinically	O
indistinguishable	O
,	O
may	O
provide	O
better	O
therapeutic	O
options	O
for	O
treatment	O
.	O

In	O
addition	O
,	O
the	O
procedure	O
described	O
herein	O
could	O
prove	O
useful	O
in	O
other	O
cell	O
types	O
that	O
express	O
high	O
levels	O
of	O
endogenous	B-protein
proteases	I-protein
.	O

Expression	O
of	O
dominant	B-protein
negative	I-protein
N17Rac	I-protein
also	O
prevents	O
TCR	B-protein
and	O
p21ras	B-protein
activation	O
of	O
NFAT	B-protein
,	O
but	O
without	O
interfering	O
with	O
the	O
ERK-2	B-protein
pathway	O
.	O

Second	O
,	O
TRE-DNA	B-protein
binding	I-protein
proteins	I-protein
sedimented	O
through	O
a	O
glycerol	O
density	O
gradient	O
at	O
rates	O
corresponding	O
to	O
proteins	O
of	O
native	O
molecular	O
weights	O
of	O
35	O
to	O
50	O
kD	O
and	O
110	O
kD	O
.	O

Ctx	B-protein
combined	O
with	O
TNFalpha	B-protein
or	O
IL-1beta	B-protein
to	O
produce	O
a	O
synergistic	O
increase	O
in	O
p24	B-protein
antigen	I-protein
production	O
in	O
U1	B-cell_line
promonocytic	I-cell_line
cells	I-cell_line
.	O

The	O
molecular	O
mechanisms	O
underlying	O
the	O
IL-7	B-protein
effect	O
involve	O
the	O
upregulation	O
of	O
the	O
DNA	O
binding	O
activity	O
of	O
NFAT	B-protein
(	O
60	O
%	O
)	O
and	O
AP-1	B-protein
(	O
120	O
%	O
)	O
,	O
without	O
affecting	O
the	O
activities	O
of	O
NFkappaB	B-protein
and	O
CD28RC	B-protein
,	O
which	O
was	O
confirmed	O
by	O
transfection	O
assays	O
.	O

In	O
lymph	O
nodes	O
,	O
expression	O
of	O
Bcl-6	B-protein
protein	O
is	O
restricted	O
to	O
germinal	B-cell_type
center	I-cell_type
(	I-cell_type
GC	I-cell_type
)	I-cell_type
B-cells	I-cell_type
and	O
10	O
%	O
to	O
15	O
%	O
of	O
CD3/CD4+	B-cell_type
intrafollicular	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Data	O
presented	O
provide	O
further	O
evidence	O
for	O
the	O
local	O
modulation	O
of	O
myelopoiesis	O
by	O
intracrine	O
mechanisms	O
.	O

N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
is	O
an	O
antioxidant	O
molecule	O
endowed	O
with	O
immunomodulatory	O
properties	O
.	O

Pax5	B-protein
is	O
predominantly	O
transcribed	O
from	O
only	O
one	O
of	O
its	O
two	O
alleles	B-DNA
in	O
early	B-cell_type
B-lymphoid	I-cell_type
progenitors	I-cell_type
and	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
while	O
it	O
transiently	O
switches	O
to	O
a	O
biallelic	O
mode	O
of	O
transcription	O
in	O
pre-B	B-cell_type
and	I-cell_type
immature	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Following	O
PCr	O
administration	O
we	O
observed	O
lower	O
blood	O
lactate	O
concentrations	O
and	O
different	O
patterns	O
of	O
some	O
enzyme	O
activities	O
,	O
less	O
pronounced	O
changes	O
in	O
plasma	B-protein
ACTH	I-protein
and	O
cortisol	O
concentrations	O
and	O
in	O
glucocorticoid	O
binding	O
in	O
lymphocytes	B-cell_type
,	O
but	O
no	O
changes	O
in	O
plasma	O
growth	O
hormone	O
concentrations	O
compared	O
to	O
the	O
placebo	O
.	O

Present	O
results	O
indicate	O
trancriptional	O
roles	O
of	O
STAT5	B-protein
and	O
functional	O
roles	O
of	O
ERK	B-protein
and/or	O
p38	B-protein
in	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
stimulated	O
by	O
physiological	O
receptor-mediated	O
agonists	O
GM-CSF	B-protein
and	O
FMLP	O
.	O

The	O
Id2	B-RNA
mRNA	I-RNA
was	O
abundantly	O
expressed	O
in	O
5/12	B-cell_line
T-cell	I-cell_line
and	O
3/4	B-cell_line
B-cell	I-cell_line
lines	I-cell_line
,	O
and	O
Id3	B-RNA
mRNA	I-RNA
was	O
detected	O
in	O
4/12	B-cell_line
T-cell	I-cell_line
and	O
3/4	B-cell_line
B-cell	I-cell_line
lines	I-cell_line
.	O

Involvement	O
of	O
Alu	B-DNA
sequences	I-DNA
in	O
the	O
cell-specific	O
regulation	O
of	O
transcription	O
of	O
the	O
gamma	B-protein
chain	I-protein
of	O
Fc	B-protein
and	O
T	B-protein
cell	I-protein
receptors	I-protein
.	O

Stimulation	O
of	O
neutrophil	B-cell_type
interleukin-8	B-protein
production	O
by	O
eosinophil	B-protein
granule	I-protein
major	I-protein
basic	I-protein
protein	I-protein
.	O

This	O
protein	O
was	O
named	O
elf-2	B-protein
because	O
its	O
DNA-binding	B-protein
domain	I-protein
is	O
virtually	O
identical	O
to	O
that	O
of	O
ets	B-protein
family	I-protein
member	I-protein
elf-1	B-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Gel	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
binding	O
of	O
Sp1	B-protein
and	O
AP-2	B-protein
to	O
the	O
LAL	B-DNA
promoter	I-DNA
is	O
increased	O
by	O
PMA	O
in	O
THP-1	B-cell_line
cells	I-cell_line
.	O

It	O
was	O
concluded	O
that	O
there	O
existed	O
hormonal	O
regulation	O
of	O
nuclear	B-protein
T3R	I-protein
,	O
and	O
up-regulation	O
was	O
seen	O
in	O
hypothyroidism	O
and	O
low	O
T3	O
syndrome	O
.	O

Thus	O
,	O
HTLV-I	B-protein
Tax	I-protein
,	O
HTLV-II	B-protein
Tax	I-protein
,	O
and	O
c-jun	B-protein
transactivate	O
PTHrP	B-protein
and	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
hypercalcemia	O
in	O
adult	O
T-cell	O
leukemia	O
.	O

Approximately	O
3	O
times	O
higher	O
levels	O
of	O
type	B-protein
II	I-protein
EBS	I-protein
were	O
found	O
in	O
the	O
periovulatory	O
period	O
with	O
respect	O
to	O
both	O
follicular	O
and	O
luteal	O
phases	O
.	O

RA	O
(	O
100	O
nM	O
)	O
induced	O
an	O
increase	O
in	O
the	O
percentage	O
of	O
dead	B-cell_type
cells	I-cell_type
from	O
24	O
%	O
to	O
44	O
%	O
at	O
day	O
6	O
(	O
p	O
<	O
0.05	O
,	O
n	O
=	O
6	O
)	O
as	O
compared	O
to	O
control	B-cell_type
cells	I-cell_type
cultured	O
in	O
medium	O
alone	O
.	O

NAC	O
inhibited	O
the	O
generation	O
of	O
Smu/Sepsilon	B-protein
switch	I-protein
fragments	I-protein
in	O
normal	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
costimulated	O
with	O
IL-4	B-protein
and	O
anti-CD40	B-protein
monoclonal	I-protein
antibody	I-protein
.	O

The	O
first	O
step	O
in	O
the	O
nuclear	O
import	O
process	O
is	O
recognition	O
of	O
a	O
nuclear	B-protein
localization	I-protein
sequence	I-protein
(	O
NLS	B-protein
)	O
within	O
the	O
karyophilic	B-protein
protein	I-protein
by	O
a	O
cytoplasmic	B-protein
receptor	I-protein
such	O
as	O
the	O
importin	B-protein
(	I-protein
karyopherin	I-protein
)	I-protein
-alpha	I-protein
subunit	I-protein
.	O

Whereas	O
mutations	O
in	O
the	O
GATA-3	B-protein
site	O
abolished	O
antigen-	O
or	O
cAMP-	O
stimulated	O
IL-5	O
promoter	O
activation	O
in	O
Th2	O
cells	O
,	O
ectopic	O
expression	O
of	O
GATA-3	B-protein
in	O
Th1	B-cell_type
cells	I-cell_type
or	O
in	O
a	O
non-lymphoid	B-cell_line
,	I-cell_line
non-IL-5-producing	I-cell_line
cell	I-cell_line
line	I-cell_line
activated	O
the	O
IL-5	B-DNA
promoter	I-DNA
.	O

The	O
thymic	O
cellularity	O
of	O
these	O
mice	O
was	O
significantly	O
decreased	O
.	O

Intranuclear	O
targeted	O
delivery	O
of	O
functional	O
NF-kappaB	B-protein
by	O
70	B-protein
kDa	I-protein
heat	I-protein
shock	I-protein
protein	I-protein
.	O

Therefore	O
,	O
the	O
human	B-protein
androgen	I-protein
receptor	I-protein
assay	O
(	O
HUMARA	O
)	O
was	O
used	O
to	O
determine	O
granulocyte	O
clonality	O
.	O

A	O
fusion	O
between	O
these	O
15	O
amino	O
acids	O
and	O
the	O
GAL4	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
was	O
capable	O
of	O
transactivating	O
reporters	O
driven	O
by	O
the	O
GAL4	B-DNA
DNA	I-DNA
binding	I-DNA
site	I-DNA
.	O

These	O
results	O
may	O
also	O
provide	O
a	O
clue	O
to	O
understanding	O
of	O
the	O
molecular	O
process	O
of	O
AIDS	O
pathogenesis	O
and	O
its	O
possible	O
biochemical	O
intervention	O
.	O

Thus	O
,	O
the	O
DRA	B-DNA
promoter	I-DNA
discriminates	O
against	O
OTF-1	B-protein
activation	O
at	O
the	O
level	O
of	O
DNA	O
binding	O
in	O
the	O
glioblastoma	B-cell_line
line	I-cell_line
.	O

Glucocorticoid	B-protein
receptor	I-protein
and	O
inhibition	O
of	O
3-O-methyl-D-glucose	O
uptake	O
by	O
glucocorticoids	O
in	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
from	O
normal	O
humans	O
:	O
correlation	O
between	O
receptor	O
level	O
and	O
hormone	O
effect	O
in	O
vitro	O
.	O

This	O
prompted	O
us	O
to	O
analyze	O
the	O
octamer-binding	B-protein
proteins	I-protein
in	O
the	O
latter	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
within	O
the	O
TCR	B-protein
/CD3	B-protein
signal	O
transduction	O
pathway	O
both	O
PKC	B-protein
and	O
calcineurin	B-protein
are	O
required	O
for	O
the	O
effective	O
activation	O
of	O
the	O
IKK	B-protein
complex	I-protein
and	O
NF-kappaB	B-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
rescued	O
B104	B-cell_line
cells	I-cell_line
from	O
death	O
induced	O
by	O
anti-IgM	B-protein
Ab	I-protein
,	O
but	O
did	O
not	O
affect	O
the	O
expression	O
of	O
Egr-1	B-protein
and	O
c-fos	B-RNA
mRNA	I-RNA
,	O
showing	O
that	O
CsA	O
and	O
FK506	O
affect	O
signal	O
transducers	O
differently	O
from	O
or	O
downstream	O
to	O
these	O
molecules	O
.	O

IL-2-	O
,	O
IL-12-	O
,	O
and	O
IFN-alpha-mediated	O
signaling	O
pathways	O
were	O
analyzed	O
in	O
primary	B-cell_type
NK	I-cell_type
cells	I-cell_type
and	O
in	O
the	O
NK3.3	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Progressive	O
expression	O
of	O
cell	B-protein
surface	I-protein
maturation-specific	I-protein
antigens	I-protein
of	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
was	O
induced	O
by	O
treatment	O
of	O
RWLeu-4	B-cell_line
cells	I-cell_line
with	O
VD3	O
for	O
24	O
to	O
72	O
h	O
at	O
doses	O
that	O
inhibited	O
cellular	O
proliferation	O
.	O

In	O
a	O
sample	O
from	O
one	O
of	O
the	O
patients	O
,	O
c-fos-positive	B-protein
lymphocytes	I-protein
were	O
identified	O
as	O
CD4	O
positive	O
and	O
CD8	O
negative	O
.	O

This	O
cellular	O
system	O
offers	O
the	O
advantage	O
that	O
MHC	B-protein
class	I-protein
II	I-protein
induction	O
is	O
studied	O
in	O
a	O
``	B-cell_type
physiologic	I-cell_type
''	I-cell_type
cell	I-cell_type
lineage	I-cell_type
that	O
,	O
as	O
a	O
result	O
of	O
this	O
expression	O
within	O
the	O
thymus	O
,	O
is	O
thought	O
to	O
participate	O
to	O
the	O
selection	O
and	O
maturation	O
of	O
the	O
T	B-cell_type
cells	I-cell_type
.	O

DOR1	B-protein
ligation	O
by	O
a	O
specific	O
DOR1	B-protein
agonist	O
,	O
deltorphin	O
,	O
augmented	O
IL-2	B-protein
secretion	O
by	O
synergizing	O
with	O
signals	O
from	O
TCR-CD3	B-protein
and	O
CD28	B-protein
.	O

To	O
determine	O
why	O
alveolar	B-cell_type
macrophages	I-cell_type
do	O
not	O
express	O
AP-1	B-protein
DNA	O
binding	O
activity	O
,	O
we	O
first	O
showed	O
that	O
there	O
was	O
not	O
a	O
decrease	O
in	O
expression	O
of	O
the	O
FOS	B-protein
and	I-protein
JUN	I-protein
proteins	I-protein
that	O
make	O
up	O
the	O
AP-1	B-protein
complex	O
.	O

While	O
the	O
activation	O
of	O
JAK2	B-protein
,	O
Shc	B-protein
,	O
Erk	B-protein
,	O
and	O
STAT5	B-protein
proteins	I-protein
correlated	O
with	O
hGM-CSF	B-protein
-mediated	O
cell	O
growth	O
,	O
cellular	O
differentiation	O
occurred	O
in	O
the	O
absence	O
of	O
activation	O
of	O
these	O
signal	O
transduction	O
pathways	O
.	O

Accordingly	O
,	O
immunoblot	O
experiments	O
showed	O
that	O
amongst	O
NF-kappa	B-protein
B	I-protein
/Rel	B-protein
proteins	I-protein
,	O
RelA	B-protein
and	O
p50	B-protein
are	O
mobilized	O
to	O
the	O
nucleus	O
following	O
microglial	O
cell	O
stimulation	O
with	O
A	O
beta	O
(	O
25-35	O
)	O
plus	O
IFN	B-protein
gamma	I-protein
.	O

Upon	O
PHA	B-protein
-stimulation	O
,	O
Id2	B-protein
expression	O
decreased	O
and	O
Id3	B-protein
levels	O
increased	O
with	O
biphasic	O
kinetics	O
.	O

In	O
B	B-cell_type
cells	I-cell_type
,	O
Egr-1	B-protein
therefore	O
plays	O
a	O
critical	O
role	O
in	O
integrating	O
the	O
short-lived	O
signal	O
delivered	O
by	O
triggering	O
of	O
the	O
Ag	B-protein
receptor	I-protein
into	O
phenotypic	O
changes	O
,	O
including	O
repression	O
of	O
CD95	B-protein
and	O
CD23	B-protein
transcription	O
.	O

Increased	O
oxidative	O
stress	O
and	O
subsequent	O
activation	O
of	O
the	O
transcription	O
factor	O
NF-kappaB	B-protein
has	O
been	O
linked	O
to	O
the	O
development	O
of	O
late	O
diabetic	O
complications	O
.	O

Activation	O
of	O
signaling	O
pathways	O
and	O
prevention	O
of	O
apoptosis	O
by	O
cytokines	B-protein
in	O
eosinophils	B-cell_type
.	O

In	O
contrast	O
to	O
the	O
differential	O
signaling	O
of	O
BW	B-protein
828	I-protein
and	O
9.3	B-protein
in	O
resting	O
T	O
cells	O
,	O
the	O
two	O
mAbs	O
exhibited	O
a	O
similar	O
pattern	O
of	O
early	O
signaling	O
events	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
Jurkat	B-cell_type
cells	I-cell_type
(	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
activation	O
,	O
association	O
of	O
phosphatidylinositol	B-protein
3-kinase	I-protein
with	O
CD28	B-protein
)	O
,	O
indicating	O
that	O
the	O
signaling	O
capacity	O
of	O
CD28	B-protein
changes	O
with	O
activation	O
.	O

Thus	O
,	O
Tax1	B-protein
was	O
suggested	O
to	O
replace	O
growth	O
signals	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
this	O
mechanism	O
.	O

We	O
therefore	O
determined	O
whether	O
corticosteroids	O
suppress	O
inflammation	O
by	O
inhibiting	O
endothelial	O
expression	O
of	O
adhesion	B-protein
molecules	I-protein
for	O
neutrophils	B-cell_type
(	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
)	O
.	O

The	O
number	O
of	O
glucocorticoid	B-protein
and	I-protein
mineralocorticoid	I-protein
binding	I-protein
sites	I-protein
was	O
increased	O
in	O
hypertensives	O
vs	O
normotensives	O
.	O

To	O
date	O
no	O
SOCS	B-protein
proteins	I-protein
have	O
been	O
specifically	O
implicated	O
in	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
signaling	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Role	O
of	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
in	O
cyclic	O
AMP	O
inhibition	O
of	O
NF-kappaB	B-protein
-mediated	O
transcription	O
.	O

The	O
catalytic	B-protein
domain	I-protein
of	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
,	O
but	O
not	O
its	O
regulatory	B-protein
domain	I-protein
,	O
is	O
sufficient	O
for	O
inducing	O
IL-2	B-protein
production	O
.	O

Members	O
of	O
the	O
cyclic	B-protein
adenosine	I-protein
monophosphate	I-protein
(	I-protein
cAMP	I-protein
)	I-protein
response	I-protein
element	I-protein
binding	I-protein
(	I-protein
CREB	I-protein
)	I-protein
/activating	I-protein
transcription	I-protein
factor	I-protein
1	I-protein
(	I-protein
ATF-1	I-protein
)	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
bind	O
three	O
21-bp	B-DNA
repeats	I-DNA
(	O
Tax-responsive	B-DNA
element-1	I-DNA
,	O
or	O
TRE-1	B-DNA
)	O
within	O
the	O
viral	B-DNA
promoter	I-DNA
and	O
are	O
important	O
for	O
basal	O
and	O
Tax-mediated	O
transcription	O
.	O

In	O
many	O
circumstances	O
it	O
is	O
difficult	O
to	O
distinguish	O
the	O
effects	O
of	O
CD28	B-protein
from	O
subsequent	O
actions	O
of	O
cytokines	B-protein
,	O
such	O
as	O
IL-2	B-protein
,	O
on	O
T	O
cell	O
proliferation	O
.	O

Tap	B-protein
:	O
a	O
novel	O
cellular	B-protein
protein	I-protein
that	O
interacts	O
with	O
tip	O
of	O
herpesvirus	O
saimiri	O
and	O
induces	O
lymphocyte	B-cell_type
aggregation	O
.	O

The	O
1311-base	B-DNA
pair	I-DNA
human	I-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
(	I-DNA
TNF	I-DNA
)	I-DNA
alpha	I-DNA
promoter	I-DNA
region	I-DNA
was	O
fused	O
to	O
the	O
luciferase	B-DNA
(	I-DNA
Luc	I-DNA
)	I-DNA
reporter	I-DNA
gene	I-DNA
and	O
studied	O
in	O
a	O
transient	O
transfection	O
system	O
in	O
three	O
TNF	B-cell_line
producing	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
the	O
U937	B-cell_line
macrophage	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
the	O
MLA	B-cell_line
144	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
and	O
the	O
729-6	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

This	O
event	O
is	O
also	O
triggered	O
under	O
various	O
other	O
conditions	O
of	O
biomedical	O
importance	O
.	O

The	O
effect	O
of	O
DM	O
on	O
expression	O
of	O
IL-2R	B-protein
alpha	I-protein
(	O
Tac	B-protein
,	O
p55	B-protein
,	O
CD25	B-protein
)	O
and	O
beta	B-DNA
(	I-DNA
p75	I-DNA
)	I-DNA
genes	I-DNA
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
was	O
examined	O
next	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

However	O
,	O
the	O
cellular	O
or	O
molecular	B-protein
factors	I-protein
responsible	O
for	O
a	O
delay	O
in	O
B-CLL	O
cell	O
death	O
are	O
unknown	O
.	O

Co-transfections	O
with	O
expression	B-DNA
plasmids	I-DNA
for	O
Sp1	B-protein
and	O
AP-2	B-protein
further	O
emphasized	O
the	O
important	O
role	O
of	O
these	O
transcription	B-protein
factors	I-protein
in	O
both	O
basal	O
and	O
PMA-enhanced	O
LAL	B-protein
expression	O
.	O

In	O
addition	O
,	O
amino	B-protein
acids	I-protein
346	I-protein
to	I-protein
543	I-protein
,	O
which	O
were	O
previously	O
defined	O
as	O
important	O
for	O
the	O
repressor	O
activity	O
of	O
the	O
GAL4-EBNA3C	B-protein
fusion	I-protein
proteins	I-protein
,	O
also	O
appear	O
to	O
be	O
necessary	O
for	O
the	O
repression	O
of	O
Cp	B-DNA
.	O

One	O
clone	O
(	O
DEG5	B-cell_line
)	O
also	O
exerted	O
a	O
high	O
and	O
specific	O
cytotoxicity	O
against	O
autologous	B-cell_line
cells	I-cell_line
pulsed	O
with	O
BCR1/25	O
.	O

IFN-gamma	B-protein
increased	O
the	O
surface	O
expression	O
of	O
class	B-protein
II	I-protein
molecules	I-protein
in	O
THP-1	B-cell_line
cells	I-cell_line
and	O
this	O
was	O
markedly	O
reduced	O
in	O
cells	O
infected	O
with	O
M.	O
tuberculosis	O
.	O

Human	B-DNA
cDNAs	I-DNA
encoding	O
subunits	O
of	O
these	O
factors	O
have	O
been	O
cloned	O
and	O
sequenced	O
.	O

The	O
core	O
GGAAs	O
of	O
the	O
muA	B-DNA
and	I-DNA
muB	I-DNA
sites	I-DNA
are	O
separated	O
by	O
30	O
nucleotides	O
,	O
suggesting	O
that	O
ETS	B-protein
proteins	I-protein
bind	O
to	O
these	O
sites	O
from	O
these	O
same	O
side	O
of	O
the	O
DNA	O
helix	O
.	O

We	O
previously	O
reported	O
the	O
purification	O
of	O
human	B-protein
PTF	I-protein
,	O
a	O
complex	O
of	O
four	B-protein
subunits	I-protein
,	O
and	O
the	O
molecular	O
cloning	O
and	O
characterization	O
of	O
PTF	B-protein
gamma	I-protein
and	I-protein
delta	I-protein
subunits	I-protein
.	O

Although	O
sequences	O
located	O
between	O
-559	O
and	O
-88	O
of	O
the	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
gene	I-DNA
were	O
dispensable	O
for	O
its	O
expression	O
on	O
enhancerless	B-DNA
plasmids	I-DNA
,	O
they	O
were	O
required	O
for	O
the	O
HS-40	B-DNA
enhancer	I-DNA
-mediated	O
activity	O
of	O
the	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
promoter	I-DNA
.	O

Further	O
examination	O
of	O
this	O
system	O
has	O
shown	O
that	O
the	O
inhibition	O
of	O
HSV-1	O
replication	O
by	O
the	O
antiviral	O
drug	O
acyclovir	O
does	O
not	O
inhibit	O
HSV-1-mediated	O
induction	O
of	O
HIV-1	O
provirus	O
.	O

Values	O
were	O
compared	O
with	O
those	O
of	O
patients	O
with	O
benign	O
tumors	O
(	O
n	O
=	O
4	O
)	O
,	O
or	O
undergoing	O
a	O
mammary	O
reduction	O
(	O
n	O
=	O
7	O
)	O
.	O

Experiments	O
conducted	O
with	O
different	O
HIV-1	B-DNA
LTR-based	I-DNA
vectors	I-DNA
suggested	O
that	O
PGE2-mediated	O
activation	O
effect	O
on	O
HIV-1	O
transcription	O
was	O
transduced	O
via	O
both	O
NF-kappaB-dependent	O
and	O
-independent	O
signaling	O
pathways	O
.	O

We	O
further	O
demonstrated	O
that	O
IL-2	B-protein
,	I-protein
-7	I-protein
,	I-protein
and	I-protein
-15	I-protein
induce	O
multiple	B-protein
STAT	I-protein
proteins	I-protein
,	O
including	O
STAT5a	B-protein
,	O
STAT5b	B-protein
,	O
STAT1	B-protein
alpha	I-protein
,	O
STAT3	B-protein
,	O
and	O
another	O
unidentified	O
Fc	B-protein
gamma	I-protein
RI	I-protein
GAS	I-protein
DNA-binding	I-protein
protein	I-protein
.	O

We	O
demonstrate	O
here	O
that	O
the	O
SLP-76	B-protein
linker	O
protein	O
interacts	O
with	O
both	O
nck	B-protein
,	O
an	O
adaptor	B-protein
protein	I-protein
,	O
and	O
Vav	B-protein
,	O
a	O
guanine	B-protein
nucleotide	I-protein
exchange	I-protein
factor	I-protein
for	O
Rho-family	B-protein
GTPases	I-protein
.	O

In	O
HeLa	B-cell_line
cells	I-cell_line
,	O
the	O
protein	O
was	O
almost	O
exclusively	O
localized	O
to	O
the	O
ribosome	O
salt	O
wash	O
fraction	O
of	O
cell	O
lysates	O
.	O

These	O
results	O
suggest	O
that	O
additional	O
factor	O
(	O
s	O
)	O
are	O
necessary	O
for	O
full	O
ER	B-protein
function	O
.	O

Using	O
transcription	O
analysis	O
,	O
such	O
as	O
multiplex	O
messenger	O
assays	O
,	O
we	O
show	O
here	O
that	O
natural	O
cytotoxicity	O
exerted	O
by	O
the	O
human	B-cell_line
NKL	I-cell_line
cell	I-cell_line
line	I-cell_line
correlates	O
with	O
mRNA	O
accumulation	O
of	O
very	B-protein
early	I-protein
activator	I-protein
protein	I-protein
(	I-protein
AP	I-protein
)	I-protein
-1	I-protein
transcription	B-DNA
factor	I-DNA
genes	I-DNA
such	O
as	O
JunB	B-DNA
,	O
FosB	B-DNA
and	O
c-Fos	B-DNA
.	O

Overexpression	O
of	O
p65	B-protein
increases	O
endogenous	O
I	B-protein
kappa	I-protein
B	I-protein
protein	O
in	O
both	O
carcinoma	B-cell_type
and	I-cell_type
lymphoid	I-cell_type
cells	I-cell_type
by	O
two	O
mechanisms	O
:	O
protein	O
stabilization	O
and	O
increased	O
transcription	O
of	O
I	B-RNA
kappa	I-RNA
B	I-RNA
mRNA	I-RNA
.	O

We	O
conclude	O
that	O
:	O
(	O
i	O
)	O
suppression	O
of	O
specific	O
transcription	B-protein
factor	I-protein
functions	O
can	O
potentially	O
serve	O
as	O
a	O
marker	O
of	O
exposure	O
to	O
oxidative	O
stress	O
and	O
its	O
effects	O
on	O
human	B-cell_type
lymphocytes	I-cell_type
;	O
(	O
ii	O
)	O
lipid	O
peroxidation	O
is	O
only	O
detectable	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
upon	O
exposure	O
to	O
weak	O
oxidative	O
stress	O
which	O
does	O
not	O
induce	O
catalase	B-protein
activity	O
;	O
(	O
iii	O
)	O
therefore	O
,	O
transcription	B-protein
factor	I-protein
DNA-binding	O
activities	O
are	O
more	O
sensitive	O
to	O
oxidative	O
stress	O
than	O
lipid	O
peroxidation	O
.	O

Human	O
immunodeficiency	O
virus-associated	O
Hodgkin	O
's	O
disease	O
derives	O
from	O
post-germinal	B-cell_type
center	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

We	O
used	O
an	O
adenoviral	O
technique	O
of	O
blocking	O
NF-kappaB	B-protein
through	O
overexpression	O
of	O
the	O
inhibitory	B-protein
subunit	I-protein
IkappaBalpha	B-protein
,	O
which	O
has	O
the	O
advantage	O
that	O
it	O
can	O
be	O
used	O
in	O
the	O
diseased	O
tissue	O
itself	O
,	O
with	O
>	O
90	O
%	O
of	O
the	O
synovial	B-cell_type
macrophages	I-cell_type
,	O
fibroblasts	B-cell_type
,	O
and	O
T	B-cell_type
cells	I-cell_type
infected	O
.	O

In	O
this	O
manuscript	O
,	O
we	O
demonstrate	O
that	O
Rex	B-protein
shuttles	O
between	O
the	O
nucleus	O
and	O
the	O
cytoplasm	O
and	O
that	O
its	O
activation	B-protein
domain	I-protein
constitutes	O
a	O
nuclear	B-protein
export	I-protein
signal	I-protein
that	O
specifies	O
efficient	O
transport	O
to	O
the	O
cytoplasm	O
.	O

Thus	O
p59fyn	B-protein
could	O
replace	O
the	O
calcium	O
ionophore	O
but	O
not	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O

In	O
Jurkat	B-cell_line
cells	I-cell_line
that	O
are	O
not	O
sensitive	O
to	O
H2O2-induced	O
NF-kappaB	B-protein
activation	O
,	O
H2O2	O
potentiated	O
NF-kappaB	B-protein
activation	O
in	O
the	O
presence	O
of	O
sustained	O
high	O
[	O
Ca2+	O
]	O
i	O
following	O
thapsigargin	O
treatment	O
.	O

These	O
findings	O
suggest	O
that	O
BASH	B-protein
is	O
involved	O
in	O
BCR	B-protein
-mediated	O
signal	O
transduction	O
and	O
could	O
play	O
a	O
critical	O
role	O
in	O
B	O
cell	O
development	O
in	O
the	O
bursa	O
.	O

Direct	O
analysis	O
of	O
sensorgrams	O
,	O
with	O
recombinant	B-protein
huGATA-3	I-protein
,	O
allowed	O
the	O
comparison	O
of	O
association	O
and	O
dissociation	O
profiles	O
of	O
the	O
three	O
DNA	B-DNA
regions	I-DNA
and	O
their	O
ranking	O
according	O
to	O
their	O
relative	O
affinities	O
.	O

The	O
dissociation	O
constant	O
(	O
Kd	O
)	O
and	O
maximum	O
binding	O
capacity	O
(	O
MBC	O
)	O
of	O
the	O
NT3R	B-protein
values	O
were	O
log	O
transformed	O
to	O
minimize	O
between-subject	O
variability	O
.	O

NF-kappa	B-protein
B	I-protein
is	O
a	O
protein	B-protein
complex	I-protein
which	O
functions	O
in	O
concert	O
with	O
the	O
tat-I	B-protein
gene	I-protein
product	I-protein
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
transcription	O
.	O

This	O
Tax1	B-protein
-induced	O
activation	O
of	O
cellular	B-DNA
genes	I-DNA
is	O
considered	O
to	O
be	O
a	O
critical	O
event	O
in	O
T-cell	O
transformation	O
by	O
HTLV-I	O
.	O

The	O
results	O
show	O
that	O
this	O
cytokine	B-protein
is	O
chicken	O
IL2	B-protein
and	O
not	O
IL15	B-protein
.	O

A	O
murine	B-protein
monoclonal	I-protein
antibody	I-protein
raised	O
to	O
an	O
unidentified	B-protein
estrogen	I-protein
receptor-related	I-protein
29-kDa	I-protein
protein	I-protein
selectively	O
recognized	O
these	O
proteins	O
as	O
well	O
as	O
a	O
more	O
basic	O
,	O
unphosphorylated	B-protein
27-kDa	I-protein
protein	I-protein
.	O

Cytoplasmic	O
protein	O
extracts	O
from	O
chronic	B-cell_type
myelogenous	I-cell_type
leukemia	I-cell_type
(	I-cell_type
CML	I-cell_type
)	I-cell_type
cells	I-cell_type
contained	O
an	O
activity	O
that	O
altered	O
the	O
electrophoretic	O
mobility	O
of	O
complexes	O
formed	O
between	O
nuclear	B-protein
proteins	I-protein
and	O
the	O
transcriptional	O
enhancers	O
of	O
interferon	O
(	O
IFN	O
)	O
-inducible	O
genes	O
.	O

Differentiation	O
of	O
T-helper	B-cell_type
lymphocytes	I-cell_type
:	O
selective	O
regulation	O
by	O
members	O
of	O
the	O
STAT	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

In	O
the	O
majority	O
of	O
patients	O
with	O
advanced	O
RCC	O
,	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
express	O
TCRzeta	B-protein
and	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
,	O
and	O
in	O
a	O
subset	O
,	O
reduced	O
levels	O
of	O
these	O
TCRzeta	B-protein
associated	I-protein
molecules	I-protein
are	O
seen	O
that	O
may	O
increase	O
during	O
cytokine	B-protein
-based	O
therapy	O
.	O

MAbs	O
against	O
the	O
dUTPase	B-protein
reacted	O
with	O
a	O
protein	O
of	O
approximately	O
31	O
kDa	O
in	O
12-O-tetradecanoyl-phorbol-13-acetate	B-cell_line
(	I-cell_line
TPA	I-cell_line
)	I-cell_line
-stimulated	I-cell_line
B	I-cell_line
cells	I-cell_line
harbouring	O
either	O
type	O
1	O
or	O
type	O
2	O
EBV	O
.	O

We	O
therefore	O
conclude	O
that	O
GATA-3	B-protein
specifically	O
binding	O
to	O
the	O
GATA	B-DNA
site	I-DNA
negatively	O
regulates	O
the	O
expression	O
of	O
the	O
gene	O
in	O
HL-60-C15	B-cell_line
cells	I-cell_line
.	O

In	O
this	O
study	O
,	O
we	O
observed	O
unexpectedly	O
by	O
immunohistochemical	O
,	O
Western	O
blotting	O
(	O
immunoblotting	O
)	O
,	O
and	O
Northern	O
(	O
RNA	O
)	O
blotting	O
assays	O
that	O
CD14	B-protein
is	O
expressed	O
at	O
high	O
density	O
in	O
human	B-cell_type
gingival	I-cell_type
fibroblasts	I-cell_type
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
NF-kappa	B-protein
B	I-protein
activation	O
might	O
constitute	O
one	O
of	O
the	O
mechanisms	O
underlying	O
the	O
inducible	O
expression	O
of	O
kappa	B-DNA
B-dependent	I-DNA
genes	I-DNA
in	O
microglia	B-cell_type
stimulated	O
by	O
A	O
beta	O
peptides	O
and	O
IFN	B-protein
gamma	I-protein
,	O
or	O
by	O
LPS	O
.	O

Mutation	O
of	O
the	O
IL-13	B-DNA
P	I-DNA
element	I-DNA
site	I-DNA
significantly	O
reduced	O
IL-13	B-protein
promoter	O
activity	O
in	O
response	O
to	O
T-cell	O
activation	O
.	O

We	O
propose	O
that	O
ALY	B-protein
mediates	O
context-dependent	O
transcriptional	O
activation	O
by	O
facilitating	O
the	O
functional	O
collaboration	O
of	O
multiple	B-protein
proteins	I-protein
in	O
the	O
TCR	B-protein
alpha	I-protein
enhancer	I-protein
complex	I-protein
.	O

Expression	O
of	O
IL-1alpha	B-protein
by	O
HTLV-I	O
productively	O
infected	B-cell_type
cells	I-cell_type
may	O
be	O
important	O
in	O
the	O
hypercalcemia	O
,	O
osteolytic	O
bone	O
lesions	O
,	O
neutrophilia	O
,	O
elevation	O
of	O
C-reactive	B-protein
protein	I-protein
,	O
and	O
fever	O
frequently	O
seen	O
in	O
patients	O
with	O
HTLV-I-induced	O
adult	O
T-cell	O
leukemia/lymphoma	O
.	O

Nuclear	O
run-on	O
experiments	O
showed	O
that	O
E3330	O
decreases	O
transcriptional	O
activation	O
of	O
TNF-alpha	B-DNA
gene	I-DNA
induced	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
stimulation	O
in	O
human	B-cell_type
peripheral	I-cell_type
monocytes	I-cell_type
.	O

Repeated	O
cold-air	O
exposures	O
increase	O
human	O
triiodothyronine	O
(	O
T3	O
)	O
plasma	O
clearance	O
rates	O
.	O

These	O
results	O
,	O
combined	O
with	O
previous	O
studies	O
,	O
suggest	O
that	O
the	O
Y	O
chromosome	O
in	O
great	O
apes	O
has	O
a	O
conserved	O
region	O
including	O
the	O
pseudoautosomal	B-DNA
region	I-DNA
and	O
the	O
testis-determining	O
region	O
.	O

Early	O
studies	O
in	O
murine	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
indicated	O
that	O
transcriptional	O
transactivation	O
functions	O
encoded	O
in	O
the	O
glucocorticoid	B-protein
receptor	I-protein
(	I-protein
GR	I-protein
)	I-protein
N-terminal	I-protein
domain	I-protein
are	O
required	O
for	O
glucocorticoid-mediated	O
apoptosis	O
.	O

These	O
findings	O
suggest	O
that	O
LTR	B-DNA
sequence	I-DNA
changes	O
can	O
significantly	O
affect	O
basal	O
LTR	B-DNA
function	O
and	O
transcription	B-protein
factor	I-protein
recruitment	O
,	O
which	O
may	O
,	O
in	O
turn	O
,	O
alter	O
the	O
course	O
of	O
viral	O
replication	O
in	O
cells	O
of	O
CNS	O
and	O
immune	O
system	O
origin	O
.	O

THP	O
and	O
DHA	O
markedly	O
decreased	O
the	O
levels	O
of	O
TNF-alpha	B-protein
and	O
IL-1	B-protein
beta	I-protein
in	O
the	O
circulation	O
of	O
mice	O
following	O
LPS	O
injection	O
.	O

Suppressive	O
effects	O
of	O
anti-inflammatory	O
agents	O
on	O
human	B-cell_type
endothelial	I-cell_type
cell	I-cell_type
activation	O
and	O
induction	O
of	O
heat	B-protein
shock	I-protein
proteins	I-protein
.	O

In	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
only	O
the	O
upstream	B-DNA
sequences	I-DNA
are	O
required	O
for	O
transactivation	O
by	O
the	O
Z/R	B-protein
combination	O
,	O
and	O
the	O
AP-1	B-protein
site	I-protein
is	O
dispensable	O
.	O

It	O
was	O
matched	O
by	O
an	O
inverse	O
correlation	O
between	O
lymphocyte	O
infiltration	O
and	O
blood-thyroid	O
hormone	O
concentration	O
,	O
urine	O
catecholamines	O
and	O
free	O
cortisol	O
excretion	O
and	O
fat/lean	O
body	O
mass	O
ratio	O
.	O

Translocated	B-protein
hormone/receptor	I-protein
complexes	I-protein
compete	O
for	O
a	O
limited	O
number	O
of	O
specific	O
nuclear	O
binding	O
sites	O
.	O

The	O
translocation	B-DNA
t	I-DNA
(	I-DNA
10	I-DNA
;	I-DNA
11	I-DNA
)	I-DNA
(	I-DNA
p13	I-DNA
;	I-DNA
q14	I-DNA
)	I-DNA
has	O
been	O
observed	O
in	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
as	O
well	O
as	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
is	O
a	O
hemopoietic	O
growth	O
factor	O
that	O
is	O
expressed	O
in	O
activated	O
T	O
cells	O
,	O
fibroblasts	O
,	O
macrophages	O
,	O
and	O
endothelial	O
cells	O
.	O

IL-2	B-protein
induced	O
less	O
STAT1	B-protein
alpha	I-protein
activation	O
and	O
IFN-alpha	B-protein
induced	O
greater	O
STAT5	B-protein
activation	O
in	O
NK3.3	B-cell_line
cells	I-cell_line
compared	O
with	O
preactivated	B-cell_line
primary	I-cell_line
NK	I-cell_line
cells	I-cell_line
.	O

The	O
transcription	B-protein
factor	I-protein
NF-ATc	B-protein
is	O
synthesized	O
in	O
three	O
prominent	O
isoforms	B-protein
.	O

Previously	O
,	O
we	O
have	O
shown	O
that	O
TAL1	B-protein
and	O
the	O
LIM-only	B-DNA
protein	I-DNA
gene	I-DNA
(	O
LMO	B-DNA
)	O
are	O
regularly	O
coactivated	O
in	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T-ALL	O
)	O
.	O

Moreover	O
,	O
anti-	O
STAT3	B-protein
antibodies	I-protein
specifically	O
precipitated	O
a	O
protein	O
of	O
92	B-protein
kDa	I-protein
that	O
becomes	O
phosphorylated	O
on	O
tyrosine	O
upon	O
lymphocyte	O
treatment	O
with	O
H2O2	O
.	O

Furthermore	O
,	O
compared	O
with	O
wild-type	B-protein
Id3	I-protein
,	O
an	O
Id3	B-protein
Asp5	I-protein
mutant	I-protein
(	O
mimicking	O
phosphorylation	O
)	O
is	O
unable	O
to	O
promote	O
cell	O
cycle	O
S	O
phase	O
entry	O
in	O
transfected	B-cell_line
fibroblasts	I-cell_line
,	O
whereas	O
an	O
Id3	B-protein
Ala5	I-protein
mutant	I-protein
(	O
ablating	O
phosphorylation	O
)	O
displays	O
an	O
activity	O
significantly	O
greater	O
than	O
that	O
of	O
wild-type	B-protein
Id3	I-protein
protein	I-protein
.	O

New	O
World	O
primates	O
such	O
as	O
the	O
squirrel	O
monkey	O
have	O
elevated	O
cortisol	O
levels	O
and	O
glucocorticoid	O
resistance	O
.	O

In	O
contrast	O
,	O
the	O
Rap1	B-protein
protein	I-protein
was	O
differentially	O
phosphorylated	O
when	O
using	O
15	O
micrograms/ml	O
of	O
the	O
C.	B-protein
Sub	I-protein
.	I-protein

By	O
using	O
70Z/3-derived	B-cell_line
pre-B-cell	I-cell_line
lines	I-cell_line
either	O
lacking	O
or	O
expressing	O
human	B-protein
CD14	I-protein
(	O
the	O
LPS	B-protein
receptor	I-protein
)	O
,	O
it	O
was	O
observed	O
that	O
expression	O
of	O
human	B-protein
CD14	I-protein
imparted	O
responsiveness	O
to	O
LPS	O
but	O
not	O
to	O
OspA	B-protein
or	O
spirochetal	B-protein
lipopeptides	I-protein
(	O
assessed	O
by	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
expression	O
of	O
surface	B-protein
immunoglobulin	I-protein
M	I-protein
)	O
.	O

FK506	O
suppressed	O
the	O
transcriptions	O
through	O
the	O
AP-1	B-DNA
or	O
kappa	B-DNA
B-like	I-DNA
sites	I-DNA
induced	O
by	O
PMA	O
plus	O
Ca	O
(	O
2+	O
)	O
-mobilizing	O
agents	O
,	O
but	O
not	O
those	O
induced	O
by	O
Ca	O
(	O
2+	O
)	O
-independent	O
stimuli	O
.	O

We	O
therefore	O
screened	O
a	O
T-cell	B-DNA
cDNA	I-DNA
library	O
under	O
low-stringency	O
conditions	O
with	O
a	O
probe	O
from	O
the	O
DNA	B-protein
binding	I-protein
domain	I-protein
of	O
Ets-1	B-protein
and	O
isolated	O
a	O
novel	B-protein
Ets	I-protein
family	I-protein
member	I-protein
,	O
Elf-1	B-protein
.	O

These	O
results	O
identify	O
LIF	B-protein
as	O
a	O
stimulus	O
of	O
HIV	O
replication	O
.	O

Identification	O
and	O
cloning	O
of	O
TCF-1	B-protein
,	O
a	O
T	B-protein
lymphocyte-specific	I-protein
transcription	I-protein
factor	I-protein
containing	O
a	O
sequence-specific	B-protein
HMG	I-protein
box	I-protein
.	O

Therefore	O
,	O
we	O
studied	O
the	O
CD40	B-protein
pathway	O
in	O
highly	O
purified	O
human	B-cell_type
monocytes	I-cell_type
and	O
resting	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
,	O
a	O
well	O
characterized	O
antioxidant	O
which	O
counteracts	O
the	O
effects	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
in	O
living	O
cells	O
,	O
prevented	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
H2O2	O
.	O

Proteolytic	O
activity	O
of	O
the	O
enzyme	B-protein
was	O
required	O
for	O
this	O
effect	O
since	O
diisopropyl	B-protein
fluorophosphate-thrombin	I-protein
failed	O
to	O
increase	O
[	O
Ca2+	O
]	O
i	O
.	O

Characterization	O
of	O
this	O
cDNA	B-DNA
clone	I-DNA
revealed	O
that	O
its	O
induction	O
was	O
dependent	O
on	O
LPS	O
activation	O
of	O
THP-1	B-cell_line
cells	I-cell_line
;	O
hence	O
,	O
the	O
name	O
LPS-induced	B-protein
TNF-alpha	I-protein
factor	I-protein
(	O
LITAF	B-protein
)	O
.	O

The	O
MZF-1	B-DNA
binding	I-DNA
sites	I-DNA
are	O
present	O
in	O
the	O
promoters	B-DNA
of	O
several	O
genes	B-DNA
expressed	O
during	O
myeloid	O
differentiation	O
,	O
including	O
the	O
CD34	B-DNA
promoter	I-DNA
.	O

Glucocorticoid	B-protein
receptor	I-protein
concentrations	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
(	O
MNL	B-cell_type
)	O
in	O
these	O
patients	O
were	O
comparable	O
with	O
those	O
in	O
both	O
other	O
patients	O
with	O
SLE	O
and	O
healthy	O
persons	O
.	O

Whereas	O
the	O
hypercalcemic	O
effect	O
for	O
ZK157202	O
is	O
also	O
increased	O
10-fold	O
,	O
ZK161422	O
has	O
the	O
same	O
calcium-mobilizing	O
potency	O
as	O
VD	O
.	O

Therefore	O
,	O
while	O
the	O
total	O
plasma	B-protein
sialyltransferase	I-protein
:	O
cortisol	O
ratio	O
reflects	O
HPA	O
axis	O
function	O
,	O
alterations	O
in	O
specific	O
isozyme	O
activity	O
may	O
also	O
be	O
associated	O
with	O
other	O
CNS	O
disease	O
states	O
.	O

To	O
define	O
the	O
mechanism	O
of	O
action	O
of	O
the	O
Nef	B-protein
protein	O
,	O
the	O
signal	O
transduction	O
pathways	O
which	O
may	O
be	O
affected	O
in	O
T	B-cell_type
cells	I-cell_type
by	O
constitutive	O
expression	O
of	O
the	O
nef	O
gene	O
were	O
examined	O
.	O

Nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
plays	O
a	O
broad	O
role	O
in	O
gene	O
regulation	O
,	O
but	O
it	O
is	O
not	O
evident	O
whether	O
NF-kappa	B-protein
B	I-protein
acts	O
as	O
a	O
messenger	O
system	O
for	O
germline	B-DNA
C	O
epsilon	O
transcription	O
.	O

The	O
primary	O
and	O
recurrent	O
tumors	O
in	O
Group	O
A	O
did	O
not	O
show	O
structural	O
alterations	O
in	O
the	O
p16	B-DNA
,	I-DNA
p15	I-DNA
or	I-DNA
CDK4	I-DNA
genes	I-DNA
,	O
whereas	O
homozygous	O
codeletion	O
of	O
p16	B-DNA
and	O
p15	B-DNA
was	O
observed	O
in	O
both	O
primary	O
and	O
recurrent	O
tumors	O
in	O
Group	O
B	O
.	O

Molecular	O
genetic	O
characterization	O
of	O
the	O
variant	B-DNA
allele	I-DNA
can	O
serve	O
as	O
a	O
primary	O
tool	O
for	O
diagnosis	O
and	O
subsequent	O
therapy	O
,	O
and	O
can	O
provide	O
a	O
basis	O
for	O
distinguishing	O
heterozygous	O
carriers	O
in	O
familial	O
androgen	O
resistance	O
.	O

TCF-1	B-protein
contained	O
a	O
single	O
DNA-binding	B-protein
HMG	I-protein
box	I-protein
most	O
closely	O
related	O
to	O
similar	O
boxes	O
in	O
the	O
putative	B-DNA
mammalian	I-DNA
sex-determining	I-DNA
gene	I-DNA
SRY	B-DNA
and	O
in	O
the	O
Schizosaccharomyces	B-DNA
pombe	I-DNA
Mc	I-DNA
mating	I-DNA
type	I-DNA
gene	I-DNA
.	O

One	O
protein	O
,	O
NF-GM2	B-protein
is	O
similar	O
to	O
the	O
transcription	B-protein
factor	I-protein
NF-kB	B-protein
.	O

This	O
A/R-induced	O
hyperadhesion	O
is	O
completely	O
prevented	O
by	O
a	O
previous	O
(	O
24	O
hours	O
earlier	O
)	O
exposure	O
of	O
HUVECs	B-cell_line
to	O
A/R	O
.	O

The	O
conversion	O
of	O
the	O
TCEd	B-DNA
to	O
a	O
'perfect	B-DNA
'	I-DNA
NF-kB	I-DNA
binding	I-DNA
site	I-DNA
leads	O
to	O
a	O
tighter	O
binding	O
of	O
NF-kB	B-protein
to	O
TCEd	B-DNA
DNA	I-DNA
and	O
,	O
as	O
a	O
functional	O
consequence	O
,	O
to	O
the	O
activity	O
of	O
the	O
'converted	B-DNA
'	I-DNA
TCEd	I-DNA
motifs	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O

The	O
PML/RAR	B-DNA
alpha	I-DNA
fusion	I-DNA
gene	I-DNA
resulting	O
from	O
the	O
t	B-DNA
(	I-DNA
15	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
translocation	I-DNA
is	O
a	O
specific	O
marker	O
for	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

In	O
comparison	O
,	O
UT-7	B-cell_line
Epo	I-cell_line
cells	I-cell_line
expressed	O
alpha-globin	O
and	O
higher	O
levels	O
of	O
gamma-globin	B-protein
(	O
5-fold	O
)	O
and	O
beta-globin	B-protein
(	O
from	O
barely	O
to	O
clearly	O
detectable	O
)	O
.	O

Anergy	O
is	O
a	O
major	O
mechanism	O
to	O
ensure	O
antigen-specific	O
tolerance	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
in	O
the	O
adult	O
.	O

We	O
have	O
now	O
used	O
this	O
assay	O
to	O
identify	O
another	O
export	O
factor	O
.	O

DTT	O
antagonized	O
and	O
BSO	O
enhanced	O
As2O3-induced	O
ATP	O
depletion	O
,	O
delta	O
psi	O
(	O
m	O
)	O
collapse	O
,	O
and	O
apoptosis	O
.	O

We	O
first	O
demonstrate	O
,	O
in	O
human	B-cell_line
and	I-cell_line
mouse	I-cell_line
intraspecies	I-cell_line
hybrids	I-cell_line
,	O
the	O
coordinate	O
suppression	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
,	O
Ii	B-protein
(	O
invariant	B-protein
chain	I-protein
)	O
and	O
HLA-DM	B-DNA
gene	I-DNA
transcription	O
,	O
and	O
the	O
release	O
of	O
the	O
silencing	O
by	O
the	O
addition	O
of	O
interferon	B-protein
gamma	I-protein
.	O

RAR	B-protein
alpha	I-protein
infected	B-cell_type
cells	I-cell_type
were	O
also	O
able	O
to	O
differentiate	O
into	O
mature	B-cell_type
macrophages	I-cell_type
in	O
the	O
both	O
of	O
long	O
term	O
culture	O
and	O
IL3	B-cell_line
colony	I-cell_line
.	O

Electrophoretic	O
mobility	O
shift	O
analyses	O
demonstrated	O
that	O
the	O
151-bp	B-DNA
region	I-DNA
contains	O
nuclear	B-DNA
protein	I-DNA
binding	I-DNA
sites	I-DNA
for	O
Sp1	B-protein
,	O
PU.1	B-protein
,	O
and/or	O
Elf-1	B-protein
,	O
and	O
a	O
novel	B-protein
factor	I-protein
.	O

We	O
have	O
analyzed	O
the	O
expression	O
and	O
activity	O
of	O
PU.1	B-protein
during	O
human	O
B-cell	O
development	O
using	O
a	O
panel	O
of	O
B-cell	B-cell_line
lines	I-cell_line
representing	O
different	O
stages	O
of	O
maturation	O
,	O
from	O
early	B-cell_line
precursors	I-cell_line
to	O
differentiated	B-cell_line
plasma	I-cell_line
cells	I-cell_line
.	O

Restriction	O
mapping	O
shows	O
that	O
the	O
transcription	B-DNA
unit	I-DNA
spans	O
approximately	O
35	O
kilobases	O
.	O

Hence	O
,	O
when	O
N-WASP	B-protein
is	O
activated	O
,	O
its	O
COOH-terminal	B-protein
domain	I-protein
feeds	O
barbed	O
end	O
growth	O
of	O
filaments	O
and	O
lowers	O
the	O
critical	O
concentration	O
at	O
the	O
bacterial	O
surface	O
.	O

Down-regulation	O
of	O
17beta-HSD	B-protein
IV	I-protein
mRNA	O
expression	O
was	O
associated	O
with	O
enhanced	O
estradiol	O
inactivation	O
by	O
U937	B-cell_line
cells	I-cell_line
,	O
suggesting	O
a	O
link	O
between	O
estrogenic	O
pathways	O
and	O
cell	O
proliferation	O
.	O

Pili	O
were	O
not	O
absolutely	O
required	O
for	O
binding	O
or	O
phagocytosis	O
of	O
P.	O
aeruginosa	O
.	O

The	O
proband	O
had	O
no	O
detectable	O
DPD	B-protein
activity	O
.	O

Transfection	O
of	O
kinase-deficient	O
mutants	O
of	O
IKKalpha	B-protein
and	O
IKKbeta	B-protein
into	O
either	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
or	I-cell_line
293	I-cell_line
cells	I-cell_line
also	O
inhibits	O
NF-kappaB	B-protein
-dependent	O
reporter	B-DNA
gene	I-DNA
expression	O
induced	O
by	O
Tax	B-protein
.	O

Various	O
extracellular	O
signals	O
induce	O
phosphorylation	O
and	O
rapid	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
to	O
release	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O

The	O
mechanisms	O
of	O
hormone-receptor	O
interactions	O
in	O
hypertension	O
are	O
activated	O
:	O
the	O
number	O
of	O
glucocorticoid	B-protein
and	I-protein
mineralocorticoid	I-protein
binding	I-protein
sites	I-protein
grows	O
in	O
hypertensive	O
patients	O
.	O

Phosphatidylserine	O
(	O
PS	O
)	O
,	O
another	O
anionic	O
glycerophospholipid	O
,	O
binds	O
to	O
mCD14	B-protein
with	O
lower	O
apparent	O
affinity	O
than	O
does	O
PtdIns	O
.	O

Transient-transfection	O
experiments	O
demonstrated	O
that	O
plasmids	B-DNA
containing	O
446	O
bp	O
of	O
c-fes	B-DNA
5'-flanking	I-DNA
sequences	I-DNA
linked	O
to	O
a	O
luciferase	O
reporter	O
gene	O
were	O
active	O
exclusively	O
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O

Dex	O
acted	O
directly	O
on	O
erythroid	B-cell_type
progenitors	I-cell_type
and	O
maintained	O
the	O
colony-forming	O
capacity	O
of	O
the	O
progenitor	B-cell_type
cells	I-cell_type
expanded	O
in	O
liquid	B-cell_line
cultures	I-cell_line
.	O

An	O
anti-IL-1	B-protein
beta	I-protein
antibody	I-protein
had	O
negligible	O
effects	O
on	O
HUVEC	B-protein
adhesion	I-protein
molecules	I-protein
,	O
PAI-1	B-protein
or	O
vWf	B-protein
production	O
.	O

Although	O
anti-CD28	B-protein
MoAb	I-protein
costimulation	O
enhances	O
all	O
of	O
the	O
above	O
signals	O
,	O
NF	O
kappa	O
B	O
and	O
IL-2	O
levels	O
remain	O
lower	O
than	O
in	O
adults	O
,	O
suggesting	O
the	O
need	O
for	O
further	O
activation	O
requirements	O
in	O
the	O
neonate	O
.	O

To	O
further	O
characterize	O
the	O
protein-DNA	O
interactions	O
mediating	O
IFN-beta	B-protein
induction	O
,	O
positive	B-protein
regulatory	I-protein
domain	I-protein
(	I-protein
PRD	I-protein
)	I-protein
II	I-protein
binding	I-protein
proteins	I-protein
were	O
purified	O
from	O
phorbol	O
ester	O
induced	O
Jurkat	B-cell_line
T-cells	I-cell_line
and	O
from	O
IFN	B-cell_line
primed	I-cell_line
,	I-cell_line
cycloheximide/polyinosinic-polycytidylic	I-cell_line
acid	I-cell_line
treated	I-cell_line
HeLa	I-cell_line
S3	I-cell_line
cells	I-cell_line
.	O

Adding	O
purified	O
NF-kappa	B-protein
B	I-protein
protein	I-protein
to	O
nuclear	O
extracts	O
from	O
cells	O
with	O
restricted	O
expression	O
overcomes	O
this	O
lack	O
of	O
binding	O
.	O

Cytokine	B-protein
effects	O
on	O
immunity	O
and	O
inflammation	O
often	O
depend	O
on	O
the	O
transcription	B-protein
factors	I-protein
termed	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	O
STATs	B-protein
)	O
,	O
so	O
STAT	B-protein
signaling	O
pathways	O
are	O
candidates	O
for	O
influencing	O
inflammatory	O
disease	O
.	O

We	O
compared	O
the	O
pattern	O
using	O
nuclear	O
extracts	O
from	O
human	O
brain	O
and	O
lymphocytes	B-cell_type
.	O

These	O
studies	O
indicate	O
that	O
A-myb	B-protein
plays	O
a	O
role	O
during	O
a	O
narrow	O
window	O
of	O
normal	B-cell_type
B	I-cell_type
cell	I-cell_type
differentiation	O
.	O

Treatment	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
with	O
the	O
cytokine	B-protein
IL-4	B-protein
(	O
IL-4	B-protein
)	O
,	O
in	O
the	O
absence	O
of	O
prior	O
activation	O
,	O
induces	O
a	O
weak	O
up-regulation	O
of	O
VDR	B-protein
expression	O
but	O
fails	O
to	O
generate	O
vitamin	B-protein
D-responsive	I-protein
element	I-protein
(	I-protein
VDRE	I-protein
)	I-protein
-reactive	I-protein
nuclear	I-protein
protein	I-protein
complexes	I-protein
or	O
to	O
initiate	O
the	O
genomic	O
transcription	O
of	O
25-hydroxyvitamin	B-protein
D3	I-protein
24-hydroxylase	I-protein
.	O

Level	O
of	O
gene	O
amplification	O
was	O
studied	O
by	O
Southern	O
and/or	O
slot	O
blot	O
techniques	O
.	O

We	O
tested	O
the	O
ability	O
of	O
human	B-DNA
TSP	I-DNA
1-chloramphenicol	I-DNA
acetyltransferase	I-DNA
constructs	I-DNA
to	O
respond	O
to	O
serum	O
in	O
stably	O
transfected	O
NIH-3T3	O
cells	O
.	O

Electrophoretic	O
mobility	O
shift	O
(	O
EMS	O
)	O
analyses	O
utilizing	O
oligonucleotides	O
homologous	O
to	O
each	O
of	O
the	O
21	B-DNA
bp	I-DNA
repeat	I-DNA
elements	I-DNA
reacted	O
with	O
nuclear	O
extracts	O
derived	O
from	O
cell	B-cell_line
lines	I-cell_line
of	O
lymphocytic	B-cell_type
,	I-cell_type
monocytic	I-cell_type
,	I-cell_type
neuronal	I-cell_type
,	I-cell_type
and	I-cell_type
glial	I-cell_type
cell	I-cell_type
origin	I-cell_type
have	O
demonstrated	O
differential	O
binding	O
of	O
cellular	B-protein
factors	I-protein
to	O
the	O
three	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
(	O
1-4	O
)	O
.	O

This	O
pattern	O
of	O
STAT	B-protein
protein	I-protein
phosphorylation	O
is	O
identical	O
to	O
IL-10	B-protein
receptor	I-protein
activation	O
on	O
normal	B-cell_type
cells	I-cell_type
and	O
similar	O
to	O
IFN-alpha	B-protein
(	O
STAT1	B-protein
and	O
STAT3	B-protein
)	O
and	O
IFN-gamma	B-protein
(	O
STAT1	B-protein
)	O
receptor	O
activation	O
in	O
CLL	B-cell_line
.	O

The	O
major	O
focus	O
of	O
this	O
research	O
is	O
to	O
define	O
the	O
cis	B-DNA
-acting	I-DNA
elements	I-DNA
which	O
are	O
required	O
for	O
the	O
formation	O
of	O
these	O
domains	O
of	O
unique	O
chromatin	O
structure	O
.	O

Here	O
we	O
investigate	O
the	O
hypothesis	O
that	O
low	O
shear-induced	O
activation	O
of	O
NF-kappaB	B-protein
is	O
responsible	O
for	O
enhanced	O
expression	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule	I-protein
(	O
VCAM-1	B-protein
)	O
resulting	O
in	O
augmented	O
endothelial	O
cell-monocyte	O
(	O
EC-Mn	O
)	O
adhesion	O
and	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
intracellular	O
oxidant	O
activity	O
.	O

These	O
results	O
show	O
that	O
PEBP2betaMYH11	B-protein
can	O
impair	O
neutrophil	O
development	O
and	O
provide	O
evidence	O
that	O
alterations	O
of	O
Pebp2	B-protein
can	O
contribute	O
to	O
the	O
genesis	O
of	O
myelodysplasia	O
.	O

We	O
examined	O
bone	O
marrow	O
cells	O
by	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
to	O
detect	O
residual	O
PML/RAR	B-cell_type
alpha	I-cell_type
mRNA-containing	I-cell_type
cells	I-cell_type
following	O
treatment	O
with	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
cytotoxic	O
chemotherapy	O
in	O
a	O
patient	O
with	O
APL	O
.	O

The	O
induced	O
differentiation	O
depends	O
on	O
the	O
simultaneous	O
(	O
vs.	O
sequential	O
)	O
presence	O
of	O
both	O
agents	O
.	O

Implications	O
for	O
regulation	O
of	O
immunoglobulin	B-protein
heavy	I-protein
chain	I-protein
expression	O
.	O

Suppression	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
by	O
human	B-DNA
class	I-DNA
II	I-DNA
trans-activator	I-DNA
constructs	I-DNA
lacking	O
the	O
N-terminal	B-protein
domain	I-protein
.	O

Serial	O
sectioning	O
of	O
6	O
micrometer	O
was	O
performed	O
using	O
a	O
cryostat	O
,	O
and	O
samples	O
were	O
immunohistochemically	O
stained	O
using	O
the	O
streptoavidin	B-protein
-biotin	B-protein
peroxidase	I-protein
method	O
and	O
a	O
monoclonal	O
antibody	O
against	O
c-fos	O
.	O

Interleukin-5	B-protein
(	O
IL-5	B-protein
)	O
is	O
produced	O
by	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
known	O
to	O
support	O
B	O
cell	O
growth	O
and	O
eosinophilic	O
differentiation	O
of	O
the	O
progenitor	B-cell_type
cells	I-cell_type
.	O

Both	O
GATA-1	B-protein
and	O
CACCC-binding	B-protein
proteins	I-protein
are	O
critical	O
for	O
the	O
developmentally	O
regulated	O
expression	O
of	O
erythroid-specific	B-DNA
genes	I-DNA
.	O

A	O
pair	O
of	O
restriction	B-DNA
fragment	I-DNA
length	I-DNA
polymorphisms	I-DNA
(	O
RFLPs	B-DNA
)	O
,	O
one	O
of	O
which	O
hybridizes	O
to	O
the	O
TCR	B-DNA
constant	I-DNA
region	I-DNA
C	I-DNA
beta	I-DNA
1	I-DNA
and	O
the	O
other	O
to	O
the	O
C	B-DNA
beta	I-DNA
2	I-DNA
gene	I-DNA
,	O
has	O
been	O
identified	O
,	O
suggesting	O
these	O
may	O
be	O
genotypic	O
markers	O
for	O
an	O
extended	O
region	O
of	O
the	O
TCR	B-DNA
beta	I-DNA
locus	I-DNA
.	O

The	O
involvement	O
of	O
p21	B-protein
(	I-protein
ras	I-protein
)	I-protein
in	O
the	O
regulation	O
of	O
calcium-dependent	O
signals	O
has	O
been	O
suggested	O
through	O
analysis	O
of	O
its	O
role	O
in	O
the	O
activation	O
of	O
NF-AT	B-protein
.	O

Reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
such	O
as	O
hydrogen	O
peroxide	O
serve	O
as	O
second	O
messengers	O
in	O
the	O
induction	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
,	O
and	O
hence	O
in	O
the	O
activation	O
and	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
in	O
human	B-cell_type
cells	I-cell_type
.	O

GCs	O
induce	O
apoptosis	O
in	O
neoplastic	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
;	O
and	O
,	O
defective	O
apoptosis	O
is	O
implicated	O
in	O
the	O
genesis	O
of	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
.	O

These	O
results	O
indicate	O
that	O
mitogenic	O
combinations	O
of	O
T	O
cell	O
activation	O
signals	O
are	O
integrated	O
at	O
the	O
level	O
of	O
NF-MATp35	B-protein
induction	O
.	O

Human	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
gene	O
regulation	O
in	O
phorbol	O
ester	O
stimulated	B-cell_line
T	I-cell_line
and	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Compared	O
to	O
the	O
control	O
group	O
,	O
fewer	O
depressed	O
subjects	O
down-regulated	O
Bmax	O
after	O
DEX	O
.	O

Mutations	O
of	O
this	O
site	O
that	O
destroyed	O
potential	O
ets	B-DNA
transcription	I-DNA
factor	I-DNA
binding	I-DNA
sites	I-DNA
had	O
reduced	O
transcriptional	O
activity	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
find	O
that	O
TPCK	O
virtually	O
abolishes	O
(	O
to	O
less	O
than	O
1	O
%	O
)	O
the	O
levels	O
of	O
NF	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	O
but	O
not	O
Oct-1	B-protein
)	O
found	O
in	O
nuclear	O
and	O
whole	O
cell	O
extracts	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
cytoplasmic	B-protein
domain	I-protein
of	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	I-protein
GM-CSF	I-protein
)	I-protein
receptor	I-protein
alpha	I-protein
subunit	I-protein
is	O
essential	O
for	O
both	O
GM-CSF	B-protein
-mediated	O
growth	O
and	O
differentiation	O
.	O

Single	B-protein
C	I-protein
motif-1	I-protein
(	I-protein
SCM-1	I-protein
)	I-protein
/lymphotactin	I-protein
is	O
a	O
C-type	B-protein
chemokine	I-protein
whose	O
expression	O
is	O
activation	O
dependent	O
,	O
cyclosporin	O
A	O
sensitive	O
and	O
restricted	O
to	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
double-negative	B-cell_type
thymocytes	I-cell_type
,	O
gammadelta-type	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
and	O
NK	B-cell_type
cells	I-cell_type
.	O

Patients	O
with	O
overt	O
hypo	O
-or	O
hyperthyroidism	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Chromosome	O
analysis	O
revealed	O
a	O
t	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
q27	I-DNA
;	I-DNA
q11	I-DNA
)	I-DNA
,	O
which	O
is	O
a	O
new	O
variant	O
translocation	O
of	O
t	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
q27	I-DNA
;	I-DNA
q32	I-DNA
)	I-DNA
.	O

This	O
was	O
not	O
observed	O
when	O
the	O
NFAT-1	B-DNA
mutant	I-DNA
LTR	I-DNA
was	O
activated	O
by	O
mitogen	B-protein
.	O

IL-10	B-protein
also	O
inhibited	O
expression	O
of	O
IL-2	B-protein
transcriptional	I-protein
regulators	I-protein
c-fos	B-protein
and	O
c-jun	B-protein
,	O
which	O
also	O
inhibit	O
other	O
cell	O
functions	O
.	O

These	O
results	O
suggest	O
a	O
novel	O
mechanism	O
by	O
which	O
integrin	B-protein
-mediated	O
cell	O
adhesion	O
can	O
modulate	O
the	O
magnitude	O
of	O
cytokine	B-protein
-induced	O
signal	O
transduction	O
pathways	O
,	O
thereby	O
amplifying	O
cellular	O
events	O
leading	O
to	O
monocyte	O
activation	O
and	O
inflammation	O
.	O

Our	O
results	O
suggest	O
that	O
reduced	O
IL-2	B-protein
production	O
by	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
specific	O
for	O
anti-CD3	B-protein
and	O
anti-CD3	B-protein
+	O
anti-CD28	B-protein
-mediated	O
stimulation	O
and	O
that	O
these	O
activators	O
can	O
not	O
effectively	O
activate	O
the	O
ROI	O
-NF-kappa	B-protein
B	I-protein
signalling	O
pathway	O
in	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Monoallelic	O
expression	O
of	O
Pax5	B-protein
:	O
a	O
paradigm	O
for	O
the	O
haploinsufficiency	O
of	O
mammalian	B-DNA
Pax	I-DNA
genes	I-DNA
?	O

Mycobacterium	O
tuberculosis	O
mannose-capped	O
lipoarabinomannan	O
can	O
induce	O
NF-kappaB	B-protein
-dependent	O
activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

Oct2	B-protein
expression	O
was	O
unable	O
to	O
stimulate	O
a	O
multimerized	B-DNA
octamer	I-DNA
enhancer	I-DNA
element	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
however	O
.	O

The	O
data	O
are	O
discussed	O
with	O
regard	O
to	O
their	O
potential	O
clinical	O
relevance	O
for	O
gastroenterology	O
.	O

In	O
vivo	O
,	O
this	O
could	O
lead	O
to	O
inappropriate	O
binding	O
of	O
cortisol	O
to	O
mineralocorticoid	O
receptors	O
.	O

Therefore	O
,	O
costimulation	O
by	O
alpha	B-protein
4	I-protein
beta	I-protein
1	I-protein
ligands	O
was	O
not	O
due	O
to	O
stabilization	O
of	O
the	O
interaction	O
of	O
the	O
cells	O
with	O
its	O
substrate	O
.	O

BACKGROUND	O
:	O
Abnormalities	O
in	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
-dependent	O
phosphorylation	O
system	O
have	O
been	O
recently	O
reported	O
in	O
patients	O
with	O
bipolar	O
disorder	O
.	O

The	O
OTF	O
interactions	O
we	O
observed	O
extended	O
over	O
the	O
heptamer	B-DNA
element	I-DNA
5'-CTCAGGA-3	O
'	O
,	O
and	O
it	O
seems	O
likely	O
that	O
the	O
binding	O
of	O
the	O
purified	B-protein
factors	I-protein
involves	O
cooperation	O
between	O
octamer	B-DNA
and	I-DNA
heptamer	I-DNA
sites	I-DNA
in	O
this	O
promoter	B-DNA
.	O

The	O
nuclear	O
pool	O
of	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
showed	O
a	O
higher	O
stability	O
than	O
cytosolic	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
and	O
was	O
partially	O
independent	O
of	O
the	O
resynthesis	O
of	O
the	O
protein	O
.	O

We	O
found	O
that	O
EPO	B-protein
did	O
not	O
activate	O
Stat1alpha	B-protein
or	O
Stat3	B-protein
in	O
UT-7/GM	B-cell_line
cells	I-cell_line
.	O

Thus	O
,	O
coupling	O
of	O
TCR-regulated	B-protein
PTKs	I-protein
to	O
downstream	O
signaling	O
pathways	O
requires	O
SLP-76	B-protein
.	O

In	O
addition	O
,	O
aspirin	O
and	O
indomethacin	O
,	O
but	O
not	O
CyA	O
,	O
induced	O
Hsp70	B-protein
expression	O
in	O
HUVECs	B-cell_type
that	O
correlated	O
with	O
induction	O
of	O
HSF-1	B-protein
activity	O
.	O

Conversely	O
,	O
classic	O
HD	O
(	O
CHD	O
)	O
is	O
heterogeneous	O
because	O
the	O
tumor	B-cell_type
cells	I-cell_type
of	O
a	O
fraction	O
of	O
CHD	O
display	O
the	O
BCL-6	B-protein
(	O
-	O
)	O
/	O
syn-1	B-protein
(	O
+	O
)	O
phenotype	O
of	O
post-GC	O
B-cells	O
,	O
whereas	O
another	O
fraction	O
of	O
CHD	O
is	O
constituted	O
by	O
a	O
mixture	O
of	O
tumor	B-cell_type
cells	I-cell_type
reflecting	O
the	O
GC	O
(	O
BCL-6	B-protein
(	O
+	O
)	O
/	O
syn-1	B-protein
(	O
-	O
)	O
)	O
or	O
post-GC	O
(	O
BCL-6	B-protein
(	O
-	O
)	O
/	O
syn-1	B-protein
(	O
+	O
)	O
)	O
phenotypes	O
.	O

IL-2R	B-protein
alpha	I-protein
is	O
rapidly	O
and	O
potently	O
induced	O
in	O
T	B-cell_type
cells	I-cell_type
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O

Inhibition	O
of	O
the	O
MAP	B-protein
kinase	I-protein
cascade	O
with	O
PD98059	O
,	O
a	O
specific	O
inhibitor	O
of	O
MAPK	B-protein
kinase	I-protein
1	I-protein
,	O
prevented	O
the	O
expression	O
of	O
the	O
alpha2	B-protein
integrin	I-protein
subunit	I-protein
in	O
cells	O
induced	O
to	O
become	O
megakaryocytic	O
.	O

When	O
mouse	B-cell_line
MPC11	I-cell_line
plasmacytoma	I-cell_line
cells	I-cell_line
,	O
in	O
which	O
the	O
IgH	B-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
is	O
active	O
,	O
are	O
fused	O
with	O
fibroblasts	B-cell_type
,	O
Ig	O
expression	O
is	O
extinguished	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Using	O
deletion	B-DNA
mutants	I-DNA
and	O
cis-cloned	O
synthetic	O
oligodeoxyribonucleotides	O
in	O
transient	O
expression	O
assays	O
,	O
nucleotide	O
sequences	O
responsible	O
for	O
this	O
effect	O
have	O
now	O
been	O
further	O
delimited	O
to	O
44	O
bp	O
located	O
from	O
-294	B-DNA
to	I-DNA
-251	I-DNA
bp	I-DNA
.	O

Cipro	O
did	O
not	O
affect	O
the	O
nuclear	B-protein
transcription	I-protein
factors	I-protein
AP-1	B-protein
or	O
NFIL-2A	B-protein
.	O

These	O
results	O
suggest	O
that	O
phosphorylated	B-protein
pRB	I-protein
is	O
constitutively	O
expressed	O
in	O
MM	B-cell_line
cells	I-cell_line
and	O
that	O
IL-6	B-protein
further	O
shifts	O
pRB	B-protein
from	O
its	O
dephosphorylated	O
to	O
its	O
phosphorylated	O
form	O
,	O
thereby	O
promoting	O
MM	O
cell	O
growth	O
via	O
two	O
mechanisms	O
;	O
by	O
decreasing	O
the	O
amount	O
of	O
E2F	O
bound	O
by	O
dephosphorylated	B-protein
pRB	I-protein
due	O
to	O
reduced	O
dephosphorylated	B-protein
pRB	I-protein
,	O
thereby	O
releasing	O
growth	O
arrest	O
;	O
and	O
by	O
upregulating	O
IL-6	B-protein
secretion	O
by	O
MM	B-cell_line
cells	I-cell_line
and	O
related	O
IL-6	B-protein
-mediated	O
autocrine	O
tumor	O
cell	O
growth	O
.	O

Invariably	O
,	O
the	O
BCL-6	B-protein
coding	O
region	O
is	O
intact	O
,	O
but	O
its	O
5	B-DNA
'	I-DNA
untranslated	I-DNA
region	I-DNA
is	O
replaced	O
with	O
sequences	O
from	O
the	O
translocation	B-DNA
partner	I-DNA
.	O

We	O
have	O
recently	O
identified	O
and	O
cloned	O
a	O
human	B-protein
transcription	I-protein
factor	I-protein
,	O
TCF-1	B-protein
,	O
that	O
binds	O
to	O
a	O
functional	O
element	O
in	O
the	O
T	O
lymphocyte-specific	O
enhancer	O
of	O
CD3-epsilon	O
.	O

The	O
in	O
vitro	O
kinase	O
activity	O
of	O
ZAP-70	B-protein
lacking	O
interdomain	B-protein
B	I-protein
was	O
markedly	O
reduced	O
,	O
but	O
the	O
kinase	O
activity	O
was	O
still	O
required	O
for	O
the	O
protein	O
's	O
in	O
vivo	O
activity	O
.	O

LMP1	B-protein
contains	O
two	O
domains	O
that	O
activate	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
,	O
one	O
through	O
interactions	O
with	O
TRAF	B-protein
proteins	I-protein
and	O
the	O
other	O
with	O
the	O
TRADD	B-protein
protein	I-protein
.	O

The	O
increased	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
observed	O
in	O
adherent	B-cell_type
monocytes	I-cell_type
was	O
accompanied	O
by	O
increases	O
in	O
mRNAs	B-RNA
of	O
the	O
early	B-DNA
growth	I-DNA
response	I-DNA
genes	I-DNA
c-fos	B-DNA
(	O
maximal	O
at	O
20	O
min	O
)	O
,	O
c-jun	O
,	O
and	O
EGR2	O
(	O
maximal	O
at	O
6-24	O
h	O
)	O
.	O

The	O
stability	O
of	O
c-Fos	B-protein
was	O
found	O
to	O
also	O
be	O
controlled	O
by	O
intracellular	O
signal	O
transduction	O
.	O

Ro	O
09-2210	O
was	O
also	O
able	O
to	O
block	O
antigen-induced	O
IL-2	B-protein
secretion	O
with	O
an	O
IC50	O
=	O
30	O
nM	O
,	O
but	O
was	O
considerably	O
less	O
potent	O
at	O
blocking	O
Ca2+	O
flux	O
stimulated	O
by	O
anti-CD3	B-protein
treatment	O
.	O

Glucocorticoid-induced	O
apoptosis	O
was	O
investigated	O
in	O
glucocorticoid-sensitive	B-cell_line
6TG1.1	I-cell_line
and	O
resistant	B-cell_line
ICR27TK.3	I-cell_line
human	B-cell_type
leukemic	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
protecting	O
cells	O
against	O
death	O
mediated	O
by	O
TNF	B-protein
We	O
show	O
here	O
that	O
NF-kappaB	B-protein
also	O
has	O
a	O
role	O
in	O
regulating	O
Fas	B-protein
/	O
APO-1	B-protein
/	O
CD95	B-protein
-mediated	O
death	O
,	O
a	O
major	O
pathway	O
of	O
peripheral	B-cell_type
T	I-cell_type
cell	I-cell_type
death	O
.	O

Activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
to	O
produce	O
cytokines	B-protein
is	O
regulated	O
by	O
the	O
counterbalance	O
of	O
protein-tyrosine	B-protein
kinases	I-protein
and	O
protein-tyrosine	O
phosphatases	O
,	O
many	O
of	O
which	O
have	O
a	O
high	O
degree	O
of	O
substrate	O
specificity	O
because	O
of	O
physical	O
association	O
with	O
their	O
targets	O
.	O

Four	O
of	O
6	O
cases	O
tested	O
showed	O
functional	O
NK	O
cell-mediated	O
cytotoxicity	O
,	O
suggesting	O
a	O
relationship	O
between	O
these	O
unique	O
CD33+	O
,	O
CD56+	O
,	O
CD16	B-protein
-acute	O
leukemias	O
and	O
normal	B-cell_type
CD56+	I-cell_type
,	I-cell_type
CD16-	I-cell_type
NK	I-cell_type
precursor	I-cell_type
cells	I-cell_type
.	O

Our	O
data	O
also	O
suggest	O
that	O
whilst	O
NF-kappa	B-protein
B	I-protein
may	O
be	O
an	O
essential	O
component	O
of	O
LMP1	B-protein
signal	O
transduction	O
,	O
other	O
cell-specific	B-protein
factors	I-protein
may	O
be	O
required	O
to	O
effect	O
some	O
functions	O
of	O
the	O
viral	B-protein
protein	I-protein
.	O

In	O
this	O
study	O
we	O
show	O
evidence	O
that	O
STAT3	B-protein
is	O
a	O
transcription	B-protein
factor	I-protein
whose	O
activity	O
is	O
modulated	O
by	O
H2O2	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
,	O
in	O
which	O
endogenous	O
catalase	B-protein
had	O
previously	O
been	O
inhibited	O
.	O

In	O
fact	O
,	O
transgenic	B-cell_line
bone	I-cell_line
marrow	I-cell_line
cells	I-cell_line
cocultured	O
with	O
a	O
bone	B-cell_line
marrow-derived	I-cell_line
stromal	I-cell_line
cell	I-cell_line
line	I-cell_line
revealed	O
an	O
altered	O
B-cell	B-cell_type
maturation	O
pattern	O
.	O

These	O
downstream	B-DNA
sequence	I-DNA
elements	I-DNA
,	O
termed	O
DSE	B-DNA
,	O
can	O
bind	O
both	O
AP-1	B-protein
and	O
CREB/ATF	B-protein
transcription	B-protein
factors	I-protein
.	O

IL-8	B-protein
,	O
a	O
potent	O
chemotactic	B-protein
factor	I-protein
for	O
neutrophil	B-cell_type
granulocytes	I-cell_type
and	O
lymphocytes	B-cell_type
,	O
is	O
a	O
proinflammatory	O
cytokine	O
secreted	O
by	O
a	O
variety	O
of	O
cell	O
types	O
,	O
including	O
T	B-cell_type
cells	I-cell_type
.	O

Incubation	O
of	O
endothelial	B-cell_type
cells	I-cell_type
with	O
oleate	O
for	O
72	O
hours	O
decreased	O
the	O
relative	O
proportions	O
of	O
saturated	O
(	O
palmitic	O
and	O
stearic	O
)	O
acids	O
in	O
total	O
cell	O
lipids	O
and	O
increased	O
the	O
proportions	O
of	O
oleate	O
in	O
total	O
cell	O
lipids	O
without	O
significantly	O
changing	O
the	O
relative	O
proportions	O
of	O
polyunsaturated	O
fatty	O
acids	O
.	O

Mapping	O
of	O
the	O
transcriptional	B-protein
repression	I-protein
domain	I-protein
of	O
the	O
lymphoid-specific	B-protein
transcription	I-protein
factor	I-protein
oct-2A	B-protein
.	O

Resolution	O
of	O
whole	O
cell	O
extract	O
through	O
two	O
chromatographic	O
steps	O
yields	O
a	O
single	O
protein	O
fraction	O
requiring	O
only	O
the	O
addition	O
of	O
TFIID	B-protein
for	O
the	O
initiation	O
of	O
transcription	O
at	O
RNA	B-DNA
polymerase	I-DNA
II	I-DNA
promoters	I-DNA
.	O

Exogenous	O
IL-2	B-protein
,	O
which	O
restitutes	O
the	O
proliferative	O
response	O
of	O
the	O
anti-CD3-	B-cell_line
and	I-cell_line
anti-CD28-treated	I-cell_line
Rel-/-	I-cell_line
T	I-cell_line
cells	I-cell_line
,	O
restores	O
production	O
of	O
IL-5	O
,	O
TNF-alpha	B-protein
,	O
and	O
IFN-gamma	B-protein
,	O
but	O
not	O
IL-3	B-protein
and	O
GM-CSF	B-protein
expression	O
to	O
approximately	O
normal	O
levels	O
.	O

Interleukin	O
6-induced	O
differentiation	O
of	O
a	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
into	O
IgM-secreting	B-cell_type
plasma	I-cell_type
cells	I-cell_type
is	O
mediated	O
by	O
c-fos	B-DNA
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
micromolar	O
concentrations	O
of	O
H2O2	O
can	O
induce	O
the	O
expression	O
and	O
replication	O
of	O
HIV-1	O
in	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

The	O
pattern	O
of	O
PML	B-protein
expression	O
in	O
normal	O
hematopoiesis	O
mimics	O
that	O
of	O
retinoblastoma	B-cell_type
pRb	B-protein
105	I-protein
.	O

In	O
the	O
sedentary	O
group	O
a	O
negative	O
correlation	O
was	O
present	O
between	O
GR	B-protein
binding	O
capacity	O
and	O
age	O
.	O

Increased	O
turnover	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
constitutive	O
NF-kappa	B-protein
B	I-protein
activity	O
in	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Phosphorylation	O
of	O
TRAF2	B-protein
inhibits	O
binding	O
to	O
the	O
CD40	B-protein
cytoplasmic	I-protein
domain	I-protein
.	O

Although	O
cadmium	O
caused	O
an	O
early	O
,	O
transient	O
stimulation	O
of	O
c-jun	B-DNA
and	O
c-fos	B-DNA
expression	O
and	O
AP-1	B-protein
binding	O
activity	O
,	O
heat-shock	O
failed	O
to	O
alter	O
both	O
protooncogene	B-DNA
expression	O
and	O
transcription	O
factor	O
binding	O
,	O
indicating	O
that	O
the	O
stress-induced	O
vimentin	B-protein
increase	O
was	O
not	O
the	O
result	O
of	O
AP-1	B-protein
-mediated	O
transcriptional	O
activation	O
.	O

When	O
tested	O
for	O
its	O
ability	O
to	O
block	O
calcineurin	B-protein
-dependent	O
signaling	O
in	O
Jurkat	O
cells	O
,	O
expression	O
of	O
this	O
``	B-DNA
B-subunit	I-DNA
knock-out	I-DNA
''	I-DNA
(	I-DNA
BKO	I-DNA
)	I-DNA
construct	I-DNA
suppressed	O
reporter	B-DNA
gene	I-DNA
activity	O
driven	O
by	O
NF-AT	B-protein
,	O
the	O
pivotal	O
promoter	B-DNA
element	I-DNA
for	O
interleukin	B-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
-2	I-DNA
gene	I-DNA
induction	O
.	O

Fusion	O
proteins	O
present	O
in	O
leukemic	B-cell_type
cells	I-cell_type
frequently	O
contain	O
a	O
new	O
amino	O
acid	O
at	O
the	O
fusion	B-protein
point	I-protein
.	O

Sequencing	O
of	O
the	O
GR	B-DNA
cDNA	I-DNA
and	O
gene	O
including	O
the	O
2.3-kb	O
coding	O
region	O
,	O
the	O
intron/exon	O
junctions	O
,	O
the	O
known	O
5'-regulatory	B-DNA
region	I-DNA
,	O
and	O
approximately	O
300	O
bp	O
of	O
the	O
3'-region	B-DNA
revealed	O
no	O
alterations	O
.	O

This	O
protein-protein	O
interaction	O
does	O
not	O
require	O
the	O
simultaneous	O
binding	O
of	O
Oct	B-protein
proteins	I-protein
to	O
DNA	O
,	O
and	O
high	O
resolution	O
footprinting	O
of	O
the	O
Oct	B-DNA
-DNA	O
interaction	O
reveals	O
that	O
binding	O
of	O
BOB.1/OBF.1	B-protein
to	O
Oct1	B-protein
or	O
Oct2	B-protein
does	O
not	O
alter	O
the	O
interaction	O
with	O
DNA	O
.	O

Anti-	O
CD28	B-protein
MoAb	I-protein
costimulation	O
increased	O
NF	B-protein
kappa	I-protein
B	I-protein
levels	O
in	O
neonates	O
,	O
albeit	O
to	O
levels	O
lower	O
than	O
that	O
of	O
adults	O
.	O

Following	O
discontinuation	O
of	O
glucocorticoid	O
drugs	O
GCR	B-protein
count	O
in	O
cortisol-dependent	O
BA	O
tends	O
to	O
rise	O
.	O

CIITA	B-protein
and	O
Bob1	B-protein
interact	O
with	O
proteins	O
that	O
bind	O
to	O
conserved	B-DNA
upstream	I-DNA
sequences	I-DNA
in	O
promoters	B-DNA
of	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
genes	I-DNA
and	O
octamer-binding	B-protein
transcription	I-protein
factors	I-protein
Oct-1	B-protein
and	O
Oct-2	B-protein
,	O
respectively	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
receptor	O
characteristics	O
in	O
Cushing	O
's	O
disease	O
patients	O
were	O
within	O
the	O
normal	O
range	O
.	O

In	O
contrast	O
,	O
anti-CD3	B-protein
and	O
anti-CD28	B-protein
stimulated	O
Rel-/-	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
which	O
fail	O
to	O
proliferate	O
,	O
make	O
little	O
or	O
no	O
detectable	O
cytokines	B-protein
.	O

Using	O
Scatchard	O
analysis	O
,	O
we	O
have	O
determined	O
the	O
dissociation	O
constants	O
of	O
homodimeric	B-protein
p49	I-protein
and	O
heterodimeric	B-protein
p49/p65	I-protein
for	O
binding	O
to	O
the	O
HIV	B-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
.	O

In	O
particular	O
,	O
TRAF6	B-protein
interacted	O
with	O
membrane-proximal	B-protein
determinants	I-protein
distinct	O
from	O
those	O
binding	O
TRAFs	B-protein
1	I-protein
,	I-protein
2	I-protein
,	I-protein
3	I-protein
,	I-protein
and	I-protein
5	I-protein
.	O

c-Fos	B-protein
protein	O
was	O
shown	O
essential	O
for	O
an	O
optimal	O
transactivation	O
of	O
the	O
HIV-1	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
by	O
Tat	B-protein
:	O
incubation	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
antisense	O
,	O
but	O
not	O
sense	O
,	O
c-fos	O
oligonucleotides	O
significantly	O
reduced	O
either	O
the	O
Tat	B-protein
-enhanced	O
expression	O
of	O
an	O
LTR-CAT	B-DNA
reporter	I-DNA
construct	I-DNA
or	O
the	O
levels	O
of	O
gag	B-protein
p24	I-protein
in	O
the	O
culture	O
supernatants	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
and	O
PBMC	B-cell_type
acutely	O
infected	O
with	O
HIV-1	O
.	O

Binding	O
is	O
,	O
however	O
,	O
readily	O
detected	O
when	O
the	O
3	O
'	O
G	O
is	O
replaced	O
by	O
a	O
C	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Formalin-fixed	O
paraffin	O
sections	O
were	O
used	O
for	O
immunostaining	O
of	O
Bcl-6	B-protein
.	O

The	O
present	O
work	O
demonstrates	O
that	O
the	O
glucocorticoid	O
dexamethasone	O
inhibits	O
TPA-induced	O
increases	O
in	O
c-jun	O
and	O
c-fos	O
mRNA	O
levels	O
in	O
U-937	B-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O

In	O
19	O
patients	O
with	O
a	O
malignant	O
breast	O
tumor	O
,	O
tumor	O
tissue	O
and	O
blood	O
were	O
taken	O
to	O
determine	O
the	O
eicosanoid	O
profile	O
and	O
platelet	B-cell_type
aggregation	O
.	O

Therapy	O
with	O
dexamethasone	O
was	O
successful	O
in	O
female	O
patients	O
with	O
acne	O
and	O
hirsutism	O
,	O
as	O
the	O
secondary	O
increase	O
in	O
the	O
production	O
of	O
adrenal	O
androgens	O
was	O
effectively	O
controlled	O
.	O

Stimulation	O
of	O
the	O
cAMP-dependent	O
signaling	O
pathway	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
the	O
proliferation	O
and	O
effector	O
functions	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

Bcl-2	B-protein
inhibits	O
apoptosis	O
induced	O
by	O
a	O
variety	O
of	O
stimuli	O
,	O
including	O
chemotherapy	O
drugs	O
and	O
glucocorticoids	O
.	O

One	O
,	O
located	O
at	O
-50	O
,	O
binds	O
members	O
of	O
the	O
CCACC/Sp1	B-protein
family	I-protein
and	O
the	O
other	O
,	O
located	O
at	O
-20	O
,	O
binds	O
the	O
erythroid	B-protein
factor	I-protein
GATA-1	I-protein
.	O

Both	O
have	O
been	O
shown	O
to	O
be	O
transcription	B-protein
factors	I-protein
.	O

Analysis	O
of	O
various	O
Tax	B-protein
mutants	I-protein
suggested	O
that	O
galectin-3	B-DNA
promoter	I-DNA
induction	O
is	O
dependent	O
on	O
activation	O
of	O
the	O
cyclic-AMP-responsive	B-protein
element	I-protein
binding	I-protein
protein/activation	I-protein
transcription	I-protein
factor	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
nuclear	B-protein
factor-kappa	I-protein
B/Rel	I-protein
induction	O
.	O

Interestingly	O
,	O
the	O
combination	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
RA	O
markedly	O
enhanced	O
the	O
levels	O
of	O
p27	B-protein
(	I-protein
KIP1	I-protein
)	I-protein
transcript	O
and	O
protein	O
as	O
compared	O
with	O
levels	O
induced	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
alone	O
.	O

IkappaBalpha	B-protein
was	O
degraded	O
normally	O
following	O
stimulation	O
in	O
both	O
normal	O
controls	O
and	O
T	B-cell_type
cells	I-cell_type
from	O
RCC	O
patients	O
.	O

The	O
purified	O
homodimer	B-protein
(	O
two	O
p50s	B-protein
)	O
of	O
the	O
DNA-binding	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
binds	O
the	O
B2	B-DNA
site	O
of	O
proenkephalin	O
relatively	O
better	O
than	O
does	O
the	O
heterotetramer	B-protein
(	O
two	O
p65s	B-protein
plus	O
two	O
p50s	B-protein
)	O
form	O
of	O
the	O
factor	O
.	O

Some	O
translocation	B-cell_type
cells	I-cell_type
proliferate	O
into	O
a	O
large	O
clone	O
and	O
may	O
develop	O
into	O
T	O
cell	O
prolymphocytic	O
leukaemia	O
(	O
T-PLL	O
)	O
.	O

Long-term	O
inositol	O
phosphate	O
release	O
,	O
but	O
not	O
tyrosine	B-protein
kinase	I-protein
activity	O
,	O
correlates	O
with	O
IL-2	B-protein
secretion	O
and	O
NF-AT	B-protein
induction	O
in	O
anti-CD3-activated	B-cell_line
peripheral	I-cell_line
human	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

CIITA	B-protein
B-cell-specific	B-DNA
promoter	I-DNA
suppression	O
in	O
MHC	B-cell_line
class	I-cell_line
II-silenced	I-cell_line
cell	I-cell_line
hybrids	I-cell_line
.	O

The	O
proto-oncogene	B-protein
products	I-protein
c-Fos	B-protein
and	O
c-Jun	B-protein
heterodimerize	O
through	O
their	O
leucine	B-protein
zippers	I-protein
to	O
form	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
.	O

Gel-shift	O
analysis	O
in	O
the	O
presence	O
of	O
EBNA2	B-protein
specific	O
monoclonal	O
antibodies	O
revealed	O
that	O
EBNA2	B-protein
is	O
a	O
component	O
of	O
the	O
third	O
complex	O
.	O

The	O
activity	O
of	O
the	O
enhancer	O
is	O
almost	O
completely	O
dependent	O
on	O
the	O
integrity	O
of	O
a	O
dimeric	B-DNA
GATA-1	I-DNA
binding	I-DNA
site	I-DNA
.	O

Cross-linking	O
CD40	B-protein
on	O
B	B-cell_type
cells	I-cell_type
preferentially	O
induces	O
stress-activated	B-protein
protein	I-protein
kinases	I-protein
rather	O
than	O
mitogen-activated	B-protein
protein	I-protein
kinases	I-protein
.	O

B	B-cell_type
cells	I-cell_type
derived	O
from	O
patients	O
with	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
(	O
X-SCID	O
)	O
are	O
deficient	O
in	O
gammac	O
and	O
provide	O
a	O
useful	O
model	O
in	O
which	O
to	O
dissect	O
the	O
role	O
of	O
this	O
subunit	O
in	O
IL-4	B-protein
-mediated	O
signaling	O
.	O

Efforts	O
to	O
pinpoint	O
the	O
exact	O
site	O
of	O
action	O
and	O
specificity	O
of	O
HePTP	B-protein
in	O
the	O
signaling	O
cascade	O
revealed	O
that	O
HePTP	B-protein
acts	O
directly	O
on	O
the	O
mitogen-activated	B-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinases	I-protein
Erk1	B-protein
and	I-protein
2	I-protein
and	O
consequently	O
reduces	O
the	O
magnitude	O
and	O
duration	O
of	O
their	O
catalytic	O
activation	O
in	O
intact	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

PMA	O
,	O
which	O
directly	O
activates	O
PKC	O
,	O
mimicked	O
the	O
effect	O
of	O
the	O
lectins	O
on	O
c-Fos	O
and	O
c-Jun	B-protein
,	O
but	O
elevation	O
of	O
either	O
intracellular	O
Ca2+	O
or	O
cAMP	O
levels	O
had	O
little	O
or	O
no	O
effect	O
.	O

The	O
magnitude	O
of	O
responsiveness	O
is	O
cell	O
type	O
dependent	O
.	O

We	O
report	O
here	O
that	O
the	O
nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
(	O
NFATp	B-protein
)	O
,	O
a	O
cyclosporin	B-protein
A	I-protein
(	I-protein
CsA	I-protein
)	I-protein
-sensitive	I-protein
factor	I-protein
that	O
regulates	O
the	O
transcription	O
of	O
several	O
cytokines	B-protein
,	O
mediates	O
CD16	B-protein
-induced	O
activation	O
of	O
cytokine	B-protein
genes	I-protein
in	O
human	B-cell_type
NK	I-cell_type
cells	I-cell_type
.	O

Previous	O
studies	O
have	O
indicated	O
that	O
the	O
expression	O
of	O
viral	O
oncoproteins	O
,	O
cell	O
transformation	O
,	O
or	O
phorbol	O
ester	O
treatment	O
of	O
cells	O
can	O
inhibit	O
alpha/beta	O
interferon	O
(	O
IFN-alpha/beta	O
)	O
-induced	O
gene	O
expression	O
.	O

Using	O
mRNA	O
differential	O
display	O
we	O
demonstrated	O
abnormally	O
high	O
expression	O
of	O
the	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	O
STAT1alpha	B-protein
)	O
in	O
monocytes	B-cell_type
from	O
the	O
proband	B-cell_line
II-2	I-cell_line
.	O

The	O
IL-2	B-DNA
gene	I-DNA
displays	O
both	O
T	O
cell	O
specific	O
and	O
inducible	O
expression	O
:	O
it	O
is	O
only	O
expressed	O
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
after	O
antigenic	O
or	O
mitogenic	O
stimulation	O
.	O

Looking	O
at	O
highly	O
purified	O
gangliosides	O
,	O
GD3	O
,	O
GD1a	O
,	O
GM3	O
,	O
GM2	O
,	O
and	O
GM1	O
were	O
all	O
effective	O
in	O
reducing	O
TNF	B-protein
production	O
in	O
PBMC	B-cell_type
,	O
and	O
in	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
by	O
factor	O
10	O
to	O
50	O
.	O

Analysis	O
of	O
IL-2R	B-protein
alpha	I-protein
expression	O
by	O
transient	O
transfection	O
of	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
constructs	I-DNA
into	O
the	O
HB24	B-cell_line
transfectants	I-cell_line
revealed	O
constitutive	O
expression	O
(	O
about	O
60	O
%	O
of	O
phytohemagglutinin-	B-cell_line
and	I-cell_line
phorbol	I-cell_line
ester-activated	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
)	O
that	O
was	O
dependent	O
on	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
in	O
the	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
.	O

Transfection	O
of	O
a	O
GRbeta	B-protein
expression	O
vector	O
alone	O
did	O
not	O
result	O
in	O
IL-2	B-DNA
promoter	I-DNA
repression	O
in	O
response	O
to	O
glucocorticoids	O
.	O

Antisera	O
to	O
Fos	B-protein
inhibits	O
NF-AT	B-protein
DNA	O
binding	O
as	O
does	O
an	O
oligonucleotide	O
containing	O
a	O
binding	B-DNA
site	I-DNA
for	I-DNA
AP1	I-DNA
.	O

The	O
receptor	O
from	O
OKT3	B-protein
and	O
OKT3	B-protein
+	O
phorbol	O
myristate	O
acetate	O
-activated	B-cell_type
lymphocytes	I-cell_type
exhibited	O
decreased	O
binding	O
to	O
DNA-cellulose	O
compared	O
to	O
PHA-activated	B-cell_type
lymphocytes	I-cell_type
.	O

Stimulation	O
of	O
human	B-cell_type
neutrophils	I-cell_type
with	O
chemoattractants	B-protein
FMLP	B-protein
or	O
platelet	B-protein
activating	I-protein
factor	I-protein
(	O
PAF	B-protein
)	O
results	O
in	O
different	O
but	O
overlapping	O
functional	O
responses	O
.	O

Therefore	O
we	O
conclude	O
that	O
flavonoids	O
may	O
be	O
of	O
therapeutic	O
value	O
for	O
vascular	O
disease	O
through	O
down	O
regulation	O
of	O
NFkappaB	B-protein
/IkappaB	B-protein
system	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Stress	O
response	O
of	O
senescent	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
:	O
reduced	O
hsp70	B-protein
is	O
independent	O
of	O
the	O
proliferative	O
block	O
.	O

Last	O
,	O
we	O
have	O
identified	O
two	O
open	B-DNA
reading	I-DNA
frames	I-DNA
(	O
ORFs	B-DNA
)	O
of	O
HHV-6	O
,	O
U86	B-DNA
and	O
U89	B-DNA
from	O
the	O
immediate-early	O
locus	O
A	O
,	O
that	O
can	O
transactivate	O
the	O
CD4	B-DNA
promoter	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O

Both	O
proteins	O
were	O
identified	O
by	O
peptide	O
microsequencing	O
,	O
and	O
a	O
complementary	B-DNA
DNA	I-DNA
encoding	O
the	O
histone	B-protein
deacetylase	I-protein
catalytic	I-protein
subunit	I-protein
(	O
HD1	B-protein
)	O
was	O
cloned	O
from	O
a	O
human	O
Jurkat	O
T	O
cell	O
library	O
.	O

Six	O
patients	O
were	O
reinvestigated	O
after	O
a	O
significant	O
weight	O
gain	O
.	O

By	O
using	O
the	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
(	O
JPX-9	B-cell_line
)	O
,	O
in	O
which	O
expression	O
of	O
the	O
Tax1	B-protein
is	O
inducible	O
,	O
we	O
showed	O
that	O
expression	O
of	O
mRNAs	B-RNA
for	O
Fra-1	B-protein
,	O
c-Jun	B-protein
,	O
and	O
JunD	B-protein
was	O
also	O
transactivated	O
by	O
Tax1	B-protein
.	O

In	O
contrast	O
to	O
IL-4	B-protein
,	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
had	O
no	O
demonstrable	O
effect	O
on	O
the	O
differentiation	O
of	O
monocytes	B-cell_type
.	O

Several	O
lines	O
of	O
evidence	O
suggest	O
disturbances	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
system	O
in	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

To	O
investigate	O
whether	O
both	O
lipoxygenase	B-protein
isoforms	I-protein
exhibit	O
a	O
similar	O
regulatory	O
response	O
toward	O
cytokine	B-protein
stimulation	O
,	O
we	O
studied	O
the	O
regulation	O
of	O
the	O
leukocyte-type	B-protein
12-lipoxygenase	I-protein
of	O
murine	B-cell_type
peritoneal	I-cell_type
macrophages	I-cell_type
by	O
interleukins	B-protein
and	O
found	O
that	O
the	O
activity	O
of	O
this	O
enzyme	B-protein
is	O
upregulated	O
in	O
a	O
dose-dependent	O
manner	O
when	O
the	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
the	O
IL-4	B-protein
or	O
IL-13	B-protein
but	O
not	O
by	O
IL-10	B-protein
.	O

It	O
was	O
concluded	O
that	O
the	O
DCS	O
is	O
characterized	O
by	O
diminished	O
biological	O
effects	O
of	O
adrenocortical	O
activity	O
,	O
while	O
the	O
DHS	O
,	O
by	O
augmented	O
biological	O
effects	O
of	O
adrenocortical	O
activity	O
.	O

The	O
A-myb	B-protein
transcription	I-protein
factor	I-protein
in	O
neoplastic	B-cell_type
and	I-cell_type
normal	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Direct	O
exposure	O
to	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo-p-dioxin	O
(	O
TCDD	O
)	O
increases	O
infectivity	O
of	O
human	B-cell_type
erythrocytes	I-cell_type
to	O
a	O
malarial	O
parasite	O
.	O

A	O
novel	O
genetic	O
system	O
to	O
isolate	O
a	O
dominant	B-protein
negative	I-protein
effector	I-protein
on	O
DNA-binding	O
activity	O
of	O
Oct-2	B-protein
.	O

T	B-cell_type
cells	I-cell_type
are	O
considered	O
to	O
be	O
unresponsive	O
to	O
testosterone	O
due	O
to	O
the	O
absence	O
of	O
androgen	B-protein
receptors	I-protein
(	O
AR	B-protein
)	O
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
redox	O
changes	O
in	O
vivo	O
on	O
the	O
differentiation	O
of	O
two	O
human	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
HL-60	B-cell_line
and	O
KG-1	B-cell_line
.	O

A	O
single	O
BCS	B-DNA
had	O
little	O
effect	O
either	O
on	O
the	O
minimal	O
B29	B-DNA
promoter	I-DNA
or	O
on	O
a	O
heterologous	O
promoter	O
.	O

These	O
agents	O
also	O
significantly	O
decreased	O
TNF	B-protein
-and	O
LPS-stimulated	O
increases	O
in	O
HUVEC	B-protein
surface	I-protein
VCAM-1	I-protein
.	O

All-trans	O
retinoic	O
acid	O
and	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
co-operate	O
to	O
promote	O
differentiation	O
of	O
the	O
human	B-cell_line
promyeloid	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
HL60	B-cell_line
to	O
monocytes	B-cell_type
.	O

One	O
type	O
,	O
EA/S	B-DNA
,	O
is	O
located	O
in	O
the	O
upstream	B-DNA
promoter	I-DNA
region	I-DNA
,	O
and	O
the	O
other	O
,	O
E	B-DNA
(	I-DNA
gre	I-DNA
)	I-DNA
,	O
is	O
located	O
in	O
a	O
tandem	B-DNA
repeat	I-DNA
with	O
enhancer	O
properties	O
.	O

This	O
triggering	O
leads	O
to	O
exocytosis	O
of	O
the	O
cytotoxic	B-cell_type
NK	I-cell_type
cell	I-cell_type
granules	I-cell_type
.	O

IL-2R	B-protein
alpha	I-protein
transcription	O
is	O
at	O
least	O
in	O
part	O
controlled	O
by	O
two	O
positive	B-protein
regulatory	I-protein
regions	I-protein
,	O
PRRI	B-DNA
and	O
PRRII	B-DNA
.	O

CsA	O
was	O
found	O
not	O
to	O
inhibit	O
lck	B-protein
gene	O
expression	O
,	O
nor	O
the	O
activity	O
of	O
the	O
lck	B-DNA
gene	I-DNA
product	O
.	O

A	O
mutation	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
in	O
primary	O
cortisol	O
resistance	O
.	O

This	O
effect	O
was	O
stronger	O
with	O
the	O
GAD-CREB	B-protein
fusion	I-protein
protein	I-protein
.	O

Sequence	O
analysis	O
revealed	O
the	O
presence	O
of	O
a	O
previously	O
unrecognized	B-DNA
composite	I-DNA
binding	I-DNA
site	I-DNA
for	O
both	O
the	O
Sp1	B-protein
and	O
NF-kappaB	B-protein
transcription	B-protein
factors	I-protein
at	O
positions	B-DNA
-295	I-DNA
to	I-DNA
-286	I-DNA
.	O

Interestingly	O
,	O
coincubation	O
of	O
35S-TR	B-protein
alpha	I-protein
1	I-protein
,	O
GH3	O
NE	O
,	O
and	O
unlabeled	O
TREp	B-DNA
resulted	O
in	O
not	O
only	O
the	O
35S-TR	B-protein
:	I-protein
TREp	I-protein
complex	I-protein
,	O
but	O
in	O
two	O
additional	O
more	O
greatly	O
retarded	O
complexes	O
containing	O
35S-TR	B-protein
alpha	I-protein
1	I-protein
and	O
comigrating	O
with	O
those	O
formed	O
by	O
GH3	O
extract	O
alone	O
.	O

The	O
preferential	O
induction	O
of	O
c-jun	B-DNA
by	O
H2O2	O
did	O
not	O
represent	O
redox	O
stabilization	O
of	O
mRNA	B-RNA
transcripts	I-RNA
,	O
and	O
oxidative	O
signals	O
closely	O
resembled	O
PHA/PMA	O
stimulation	O
by	O
effectively	O
transactivating	O
the	O
full	O
length	O
c-jun	B-DNA
promoter	O
via	O
the	O
proximal	B-DNA
jun1	I-DNA
tumor	I-DNA
promoter-responsive	I-DNA
element	I-DNA
(	I-DNA
TRE	I-DNA
)	I-DNA
-like	I-DNA
promoter	I-DNA
element	I-DNA
.	O

Finally	O
,	O
micromolar	O
amounts	O
of	O
pyrrolidine	O
dithiocarbamate	O
,	O
an	O
oxygen	O
radical	O
scavenger	O
that	O
efficiently	O
blocked	O
the	O
nuclear	O
appearance	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
T-lymphocytes	B-cell_type
,	O
also	O
inhibited	O
IL-2	B-protein
secretion	O
,	O
IL-2R	B-protein
alpha	I-protein
cell	O
surface	O
expression	O
,	O
and	O
T-cell	O
proliferation	O
.	O

Similarly	O
,	O
in	O
transfection	O
experiments	O
in	O
which	O
the	O
selective	B-DNA
kappa	I-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
were	O
used	O
to	O
drive	O
the	O
expression	O
of	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
construct	I-DNA
,	O
the	O
p65	B-DNA
-and	I-DNA
p50-selected	I-DNA
motifs	I-DNA
were	O
activated	O
only	O
in	O
the	O
presence	O
of	O
p65	B-protein
and	O
p50/65	B-protein
(	O
a	O
chimeric	B-protein
protein	I-protein
with	O
the	O
p50	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
and	O
p65	B-protein
activation	I-protein
domain	I-protein
)	O
expression	O
vectors	O
,	O
respectively	O
,	O
and	O
neither	O
demonstrated	O
a	O
significant	O
response	O
to	O
stimuli	O
that	O
induce	O
NF-kappa	B-protein
B	I-protein
activity	O
.	O

Using	O
interspecies	O
hybrids	O
,	O
the	O
segregation	O
of	O
human	B-DNA
chromosomes	I-DNA
allowed	O
us	O
to	O
establish	O
that	O
MHC	B-protein
class	I-protein
II	I-protein
extinction	O
is	O
linked	O
to	O
the	O
presence	O
in	O
the	O
hybrids	O
of	O
the	O
chromosomes	B-DNA
from	O
the	O
epithelial	B-cell_type
fusion	I-cell_type
partner	I-cell_type
.	O

The	O
activation	O
of	O
JNK	B-protein
by	O
classical	O
T	O
cell	O
stimuli	O
was	O
transient	O
,	O
whereas	O
that	O
mediated	O
by	O
PDTC	O
and	O
butylated	O
hydroxyanisole	O
(	O
but	O
not	O
N-acetylcysteine	O
)	O
was	O
sustained	O
.	O

Despite	O
a	O
wide	O
range	O
,	O
the	O
mean	O
GR	B-protein
count	O
and	O
affinity	O
in	O
MNC	B-cell_type
from	O
septic	O
patients	O
did	O
not	O
differ	O
from	O
those	O
in	O
normal	O
controls	O
,	O
suggesting	O
that	O
glucocorticoids	O
could	O
still	O
be	O
effective	O
in	O
the	O
hemodynamic	O
compensatory	O
phase	O
of	O
sepsis	O
.	O

The	O
IL-12	B-protein
nonresponsiveness	O
of	O
the	O
Th2	B-cell_line
clones	I-cell_line
was	O
further	O
evident	O
by	O
the	O
total	O
lack	O
of	O
IL-12	B-protein
-induced	O
phosphorylation	O
of	O
STAT4	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription-4	I-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
that	O
is	O
typically	O
involved	O
in	O
IL-12	B-protein
signaling	O
.	O

This	O
paper	O
reports	O
the	O
expression	O
of	O
IL-12R	B-protein
on	O
a	O
human	B-cell_line
gamma	I-cell_line
delta	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
that	O
responds	O
to	O
IL-12	B-protein
with	O
enhanced	O
cytolytic	O
activity	O
and	O
increased	O
expression	O
of	O
cytolytic	B-protein
effector	I-protein
molecules	I-protein
granzyme	B-protein
B	I-protein
and	O
perforin	B-protein
.	O

Engagement	O
of	O
the	O
T-cell	B-protein
receptor	I-protein
(	I-protein
TCR	I-protein
)	I-protein
-CD3	I-protein
complex	I-protein
induces	O
a	O
rapid	O
increase	O
in	O
the	O
activities	O
of	O
Src-family	B-protein
and	O
Syk/Zap-70-family	B-protein
kinases	I-protein
[	O
1	O
]	O
[	O
2	O
]	O
.	O

The	O
human	B-DNA
PAX-5	I-DNA
gene	I-DNA
was	O
recently	O
shown	O
to	O
participate	O
together	O
with	O
the	O
IgH	B-DNA
locus	I-DNA
in	O
the	O
chromosomal	O
translocation	O
t	B-DNA
(	I-DNA
9	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
p13	I-DNA
;	I-DNA
q32	I-DNA
)	I-DNA
.	O

IL-12	B-protein
and	O
IL-2	B-protein
can	O
stimulate	O
mitogen-	B-cell_type
or	I-cell_type
CD3-activated	I-cell_type
T	I-cell_type
cells	I-cell_type
to	O
proliferate	O
,	O
produce	O
IFN-gamma	B-protein
,	O
and	O
kill	O
tumor	B-cell_type
cells	I-cell_type
.	O

Here	O
we	O
demonstrate	O
that	O
B-1	B-cell_type
lymphocytes	I-cell_type
constitutively	O
express	O
nuclear	B-protein
activated	I-protein
STAT3	I-protein
,	O
which	O
is	O
not	O
expressed	O
by	O
unmanipulated	B-cell_type
conventional	I-cell_type
(	I-cell_type
B-2	I-cell_type
)	I-cell_type
lymphocytes	I-cell_type
.	O

Our	O
results	O
indicate	O
that	O
I	O
kappa	O
b	O
beta	O
,	O
but	O
not	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
is	O
required	O
for	O
the	O
signal-dependent	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
fibroblasts	B-cell_type
.	O

In	O
addition	O
,	O
vitamin	O
D-resistant	O
cell	O
nuclear	O
extract	O
contained	O
a	O
protein	O
(	O
s	O
)	O
which	O
was	O
bound	O
specifically	O
to	O
the	O
VDRE	B-DNA
and	O
was	O
capable	O
of	O
completely	O
inhibiting	O
VDR-RXR-VDRE	B-protein
complex	I-protein
formation	O
;	O
these	O
effects	O
were	O
not	O
demonstrated	O
with	O
nuclear	O
extract	O
from	O
the	O
wild	B-cell_line
type	I-cell_line
cell	I-cell_line
line	I-cell_line
or	O
with	O
the	O
post-nuclear	O
extract	O
of	O
the	O
vitamin	B-cell_line
D-resistant	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
have	O
investigated	O
IL-12	B-protein
expression	O
in	O
B	B-cell_type
cells	I-cell_type
during	O
in	O
vitro	O
transformation	O
with	O
EBV	O
.	O

The	O
absence	O
of	O
BSAP	B-protein
,	O
TCF-1	B-protein
,	O
and	O
GATA-3	B-protein
clearly	O
indicates	O
an	O
underlying	O
difference	O
between	O
H-RS	B-cell_line
cells	I-cell_line
and	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

In	O
keeping	O
with	O
this	O
finding	O
,	O
we	O
showed	O
that	O
apoptosis	O
of	O
U937	B-cell_line
cells	I-cell_line
is	O
characterized	O
by	O
the	O
rapid	O
disappearance	O
of	O
the	O
105	O
,	O
000-	O
to	O
110	O
,	O
000-molecular-weight	O
pRB	B-protein
forms	O
concomitantly	O
with	O
the	O
appearance	O
of	O
a	O
smear	O
of	O
immunoreactive	O
products	O
with	O
a	O
molecular	O
weight	O
of	O
greater	O
than	O
250	O
,	O
000	O
.	O

c-myc	B-protein
did	O
not	O
correlate	O
with	O
c-fos	B-protein
and	O
c-jun	B-protein
protein	O
expression	O
.	O

We	O
sought	O
to	O
determine	O
the	O
activities	O
of	O
various	O
environmental	O
estrogens	O
on	O
the	O
modulation	O
of	O
the	O
interleukin-1beta	B-DNA
(	I-DNA
IL-1beta	I-DNA
)	I-DNA
gene	I-DNA
in	O
a	O
model	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
hER	B-cell_line
+	I-cell_line
IL-1beta-CAT+	I-cell_line
.	O

IL-10-activated	B-protein
STAT1	I-protein
could	O
bind	O
to	O
the	O
GAS-motif	B-DNA
sequence	I-DNA
in	O
the	O
promoter	O
region	O
of	O
the	O
Fcgamma	B-protein
receptor	I-protein
,	O
but	O
not	O
to	O
that	O
in	O
the	O
promoter	B-DNA
region	I-DNA
of	O
the	O
COX-2	B-DNA
gene	I-DNA
,	O
whereas	O
IFN-gamma-activated	B-protein
STAT1	I-protein
and	O
STAT5	B-protein
could	O
bind	O
to	O
both	O
sequences	O
.	O

Our	O
data	O
also	O
demonstrate	O
that	O
NAC	O
increases	O
the	O
GSH-to-GSSG	O
ratio	O
within	O
the	O
EC	B-cell_type
suggesting	O
one	O
possible	O
mechanism	O
through	O
which	O
this	O
antioxidant	O
inhibits	O
agonist-induced	O
monocyte	O
adhesion	O
to	O
EC	B-cell_type
.	O

Thyroid	O
hormone	O
(	O
T3	O
)	O
alone	O
caused	O
similar	O
but	O
weaker	O
effects	O
.	O

Here	O
it	O
is	O
shown	O
that	O
microbial	B-protein
lipoproteins	I-protein
are	O
potent	O
stimulators	O
of	O
IL-12	B-protein
production	O
by	O
human	O
macrophages	B-cell_type
,	O
and	O
that	O
induction	O
is	O
mediated	O
by	O
Toll-like	B-protein
receptors	I-protein
(	O
TLRs	B-protein
)	O
.	O

The	O
PML	B-DNA
gene	I-DNA
is	O
fused	O
to	O
the	O
retinoic	B-DNA
acid	I-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
RAR	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
in	O
t	O
(	O
15	O
;	O
17	O
)	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
,	O
creating	O
a	O
PML-RAR	B-protein
alpha	I-protein
fusion	I-protein
oncoprotein	I-protein
.	O

Transcriptional	O
regulation	O
of	O
lysosomal	B-protein
acid	I-protein
lipase	I-protein
in	O
differentiating	O
monocytes	O
is	O
mediated	O
by	O
transcription	B-protein
factors	I-protein
Sp1	B-protein
and	O
AP-2	B-protein
.	O

There	O
were	O
no	O
notable	O
differences	O
in	O
the	O
ER	B-RNA
transcripts	I-RNA
between	O
patients	O
and	O
healthy	O
controls	O
.	O

Exposure	O
of	O
CML	B-cell_type
cells	I-cell_type
to	O
IFN-alpha	B-protein
diminished	O
the	O
effect	O
of	O
the	O
CML	B-protein
cytoplasmic	I-protein
proteins	I-protein
on	O
these	O
nuclear	B-protein
protein-DNA	I-protein
complexes	I-protein
.	O

Human	B-RNA
monocyte	I-RNA
IL-1	I-RNA
receptor	I-RNA
antagonist	I-RNA
(	I-RNA
IL-1ra	I-RNA
)	I-RNA
messenger	I-RNA
ribonucleic	I-RNA
acid	I-RNA
(	O
mRNA	O
)	O
expression	O
and	O
protein	O
secretion	O
are	O
inhibited	O
by	O
dexamethasone	O
.	O

It	O
was	O
evaluated	O
whether	O
any	O
of	O
the	O
variables	O
might	O
be	O
used	O
as	O
a	O
biomarker	O
of	O
effects	O
for	O
this	O
class	O
of	O
compounds	O
.	O

A	O
reporter	B-DNA
gene	I-DNA
under	O
the	O
control	O
of	O
a	O
T-cell	B-DNA
antigen	I-DNA
receptor	I-DNA
element	I-DNA
was	O
activated	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
by	O
antigen	O
receptor	O
triggering	O
or	O
by	O
a	O
combination	O
of	O
phorbol	O
myristate	O
acetate	O
,	O
which	O
activates	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
and	O
a	O
calcium	O
ionophore	O
.	O

Elevation	O
of	O
the	O
levels	O
of	O
circulating	B-protein
immune	I-protein
complexes	I-protein
frequently	O
accompanies	O
HIV-1	O
infection	O
and	O
is	O
a	O
prognostic	O
indicator	O
of	O
clinical	O
progression	O
from	O
asymptomatic	O
infection	O
to	O
AIDS	O
.	O

It	O
has	O
been	O
shown	O
that	O
this	O
E1B	B-protein
19K	I-protein
protein	I-protein
is	O
not	O
necessary	O
for	O
viral	O
DNA	O
replication	O
in	O
human	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
such	O
as	O
HeLa	B-cell_line
and	O
KB	B-cell_line
.	O

Putative	O
cis-acting	B-DNA
control	I-DNA
elements	I-DNA
present	O
within	O
a	O
300-bp	B-DNA
core	I-DNA
promoter	I-DNA
included	O
two	O
ets	B-DNA
sites	I-DNA
,	O
an	O
Sp1	B-DNA
site	I-DNA
,	O
tandem	O
E-box	B-DNA
domains	I-DNA
,	O
two	O
GATA-associated	B-DNA
sites	I-DNA
(	O
CACCC	O
)	O
,	O
an	O
AP-2	B-DNA
binding	I-DNA
site	I-DNA
,	O
and	O
a	O
GATA	B-DNA
element	I-DNA
at	O
-24	B-DNA
.	O

The	O
combined	O
treatment	O
resulted	O
in	O
more	O
durable	O
inhibition	O
of	O
HIV-1	O
replication	O
than	O
was	O
seen	O
with	O
the	O
NF-kappa	B-protein
B	I-protein
inhibitors	O
alone	O
or	O
the	O
anti-	O
Tat	B-protein
sFv	I-protein
intrabodies	I-protein
alone	O
.	O

29	O
asthma	O
patients	O
with	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
(	O
FEV1	O
)	O
<	O
70	O
%	O
predicted	O
were	O
studied	O
.	O

Transactivation	O
by	O
ETS1	B-protein
,	O
NFkappaB	B-protein
and	O
AP1	B-protein
is	O
synergistic	O
,	O
and	O
mutation	O
of	O
the	O
individual	O
binding	O
sites	O
reveals	O
that	O
the	O
transcriptional	O
activities	O
of	O
these	O
factors	O
are	O
interdependent	O
.	O

Signal	O
requirements	O
and	O
characterization	O
by	O
western	O
blots	O
and	O
DNA	O
sequencing	O
.	O

Finally	O
,	O
CD27	B-protein
cross-linking	O
resulted	O
in	O
the	O
up-regulation	O
of	O
positive	B-protein
regulatory	I-protein
domain	I-protein
I-binding	I-protein
factor-1	I-protein
.	O

This	O
putative	O
human	B-DNA
IL-2rE	I-DNA
,	O
designated	O
PRRIII	B-DNA
,	O
confers	O
IL-2	B-protein
responsiveness	O
on	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O

We	O
also	O
show	O
that	O
DFX	O
treatment	O
limits	O
the	O
in	O
vivo	O
activation	O
of	O
NF-kappaB	B-protein
,	O
a	O
transcription	B-protein
factor	I-protein
involved	O
in	O
both	O
TNF-alpha	B-protein
gene	O
transcription	O
and	O
TNF-alpha	B-protein
signalling	O
(	O
P	O
<	O
0.005	O
)	O
.	O

These	O
data	O
suggest	O
that	O
Tax	B-protein
stimulates	O
RNA	B-DNA
polymerase	I-DNA
III-dependent	I-DNA
gene	I-DNA
expression	O
by	O
accelerating	O
the	O
rate	O
and/or	O
extent	O
of	O
transcription	B-protein
initiation	I-protein
complex	I-protein
assembly	O
.	O

Hypoxia	O
causes	O
the	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
through	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
on	O
tyrosine	O
residues	O
.	O

Selective	O
phosphatase	O
inhibitors	O
for	O
protein	B-protein
phosphatase	I-protein
1	I-protein
(	O
PP1	B-protein
)	O
and	O
2A	B-protein
(	O
PP2A	B-protein
)	O
that	O
do	O
not	O
inhibit	O
calcineurin	B-protein
,	O
such	O
as	O
okadaic	O
acid	O
and	O
calyculin	O
A	O
,	O
also	O
inhibited	O
NFAT	B-protein
activation	O
with	O
IC50s	O
of	O
87	O
nM	O
and	O
4	O
nM	O
,	O
respectively	O
,	O
suggesting	O
that	O
okadaic	O
acid	O
and	O
related	O
inhibitors	O
may	O
block	O
NFAT	B-protein
activation	O
through	O
the	O
inhibition	O
of	O
PP1	B-protein
,	O
instead	O
of	O
PP2A	B-protein
.	O

Productive	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
causes	O
sustained	O
NF-kappaB	B-protein
DNA-binding	O
activity	O
in	O
chronically	O
infected	O
monocytic	O
cells	O
.	O

Elf-2b	B-protein
lacks	O
a	O
putative	B-protein
transactivation	I-protein
domain	I-protein
.	O

Apoptosis-resistant	B-cell_line
T	I-cell_line
cells	I-cell_line
have	O
a	O
deficiency	O
in	O
NF-kappaB	B-protein
-mediated	O
induction	O
of	O
Fas	B-protein
ligand	I-protein
transcription	O
.	O

Involvement	O
of	O
TNF	O
alpha	O
.	O

We	O
suggest	O
that	O
the	O
T	O
cell-specific	O
expression	O
of	O
the	O
IL-3	B-DNA
gene	I-DNA
is	O
partly	O
controlled	O
through	O
the	O
enhancer	O
by	O
cooperation	O
between	O
Oct	B-protein
and	I-protein
NFAT	I-protein
family	I-protein
proteins	I-protein
.	O

This	O
lysate	O
was	O
also	O
necessary	O
for	O
ER	B-protein
to	O
diminish	O
the	O
DNA-binding	O
activity	O
of	O
GATA-1	B-protein
.	O

Thus	O
,	O
constitutive	O
activation	O
of	O
Egr-1	B-protein
gene	O
is	O
invariably	O
associated	O
with	O
unrestricted	O
expression	O
of	O
viral	O
latent	O
genes	O
in	O
all	O
group	B-cell_line
III	I-cell_line
EBV	I-cell_line
genome	I-cell_line
carrying	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

We	O
examined	O
by	O
northern	O
hybridization	O
the	O
expression	O
of	O
Id2	B-RNA
and	I-RNA
Id3	I-RNA
mRNA	I-RNA
in	O
human	B-cell_line
leukemia/lymphoma	I-cell_line
lines	I-cell_line
and	O
patient	O
samples	O
,	O
as	O
well	O
as	O
resting	O
and	O
activated	B-cell_line
normal	I-cell_line
human	I-cell_line
lymphocytes	I-cell_line
from	O
peripheral	O
blood	O
(	O
PBL	B-cell_type
)	O
.	O

Glucocorticoids	O
are	O
known	O
to	O
downregulate	O
interleukin-1	B-protein
beta	I-protein
production	O
in	O
monocytic	B-cell_type
cells	I-cell_type
by	O
two	O
different	O
mechanims	O
:	O
direct	O
inhibition	O
of	O
the	O
gene	O
transcription	O
and	O
destabilization	O
of	O
the	O
preformed	O
interleukin-1	B-RNA
beta	I-RNA
mRNA	I-RNA
.	O

1	O
.	O

Since	O
the	O
DSE	B-DNA
and	O
TRE	B-DNA
sites	O
can	O
not	O
bind	O
CREB/ATF	B-protein
homodimers	I-protein
,	O
we	O
propose	O
a	O
mechanism	O
in	O
which	O
the	O
HIV-1	O
DSE	B-DNA
bind	O
heterodimers	B-protein
composed	O
of	O
both	O
AP-1	B-protein
and	I-protein
CREB/ATF	I-protein
proteins	I-protein
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
revealed	O
that	O
both	O
thiol	O
insufficiency	O
and	O
H2O2	O
treatment	O
suppressed	O
DNA-binding	O
activity	O
of	O
NFAT	B-protein
and	O
that	O
addition	O
of	O
thiol-reducing	O
compounds	O
reversed	O
or	O
even	O
enhanced	O
it	O
.	O

The	O
TH1-to-TH2	O
shift	O
may	O
be	O
responsible	O
for	O
the	O
stress-induced	O
susceptibility	O
of	O
the	O
organism	O
to	O
certain	O
infections	O
.	O

Cellular	O
disposition	O
of	O
sulphamethoxazole	O
and	O
its	O
metabolites	O
:	O
implications	O
for	O
hypersensitivity	O
.	O

Furthermore	O
,	O
expression	O
of	O
SHP-1	B-protein
phosphatase	I-protein
which	O
is	O
a	O
negative	O
regulator	O
of	O
cytokine	B-protein
receptor	I-protein
signaling	O
,	O
was	O
lost	O
in	O
most	O
IL-2	B-cell_line
independent	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
3/4	O
)	O
but	O
not	O
in	O
the	O
leukemic	O
ATLL	B-cell_type
cells	I-cell_type
(	O
0/3	O
)	O
.	O

To	O
examine	O
the	O
molecular	O
basis	O
of	O
constitutive	O
NF-kappaB	B-protein
DNA-binding	O
activity	O
in	O
HIV1	B-cell_type
-infected	I-cell_type
cells	I-cell_type
,	O
we	O
analyzed	O
the	O
phosphorylation	O
and	O
turnover	O
of	O
IkappaBalpha	B-protein
protein	O
,	O
the	O
activity	O
of	O
the	O
double-stranded	B-protein
RNA-dependent	I-protein
protein	I-protein
kinase	I-protein
(	O
PKR	B-protein
)	O
and	O
the	O
intracellular	O
levels	O
of	O
NF-kappaB	B-protein
subunits	I-protein
in	O
the	O
PLB-985	B-cell_line
and	O
U937	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
models	I-cell_line
.	O

In	O
this	O
study	O
multiple	O
NF-kappa	B-protein
B	I-protein
related	I-protein
polypeptides	I-protein
ranging	O
from	O
85	O
to	O
45	O
kDa	O
were	O
examined	O
for	O
their	O
capacity	O
to	O
interact	O
with	O
the	O
PRDII	B-DNA
regulatory	I-DNA
element	I-DNA
of	O
interferon	B-DNA
beta	I-DNA
and	O
were	O
shown	O
to	O
possess	O
distinct	O
intrinsic	O
DNA	O
binding	O
affinities	O
for	O
this	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
and	O
form	O
multiple	B-protein
DNA	I-protein
binding	I-protein
homo-	I-protein
and	I-protein
heterodimer	I-protein
complexes	I-protein
in	O
co-renaturation	O
experiments	O
.	O

IFN-gamma	B-protein
signaling	O
is	O
mediated	O
by	O
homodimeric	B-protein
STAT1	I-protein
protein	I-protein
.	O

Inhibition	O
of	O
lipopolysaccharide-induced	O
monocyte	B-protein
interleukin-1	I-protein
receptor	I-protein
antagonist	O
synthesis	O
by	O
cortisol	O
:	O
involvement	O
of	O
the	O
mineralocorticoid	B-protein
receptor	I-protein
.	O

The	O
viral	B-protein
trans-activators	I-protein
appear	O
to	O
target	O
specific	O
DNA	B-protein
binding	I-protein
protein	I-protein
such	O
as	O
NF-kB	B-protein
and	O
Sp1	B-protein
to	O
cis-acting	B-DNA
DNA	I-DNA
site	I-DNA
and	O
promote	O
lymphokine	B-DNA
gene	I-DNA
expression	O
without	O
TCR	B-protein
-mediated	O
stimulation	O
.	O

Thrombin	B-protein
stimulation	O
of	O
the	O
T	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
line	I-cell_line
Jurkat	I-cell_line
induced	O
a	O
transient	O
increase	O
in	O
[	O
Ca2+	O
]	O
i	O
.	O

It	O
is	O
assumed	O
that	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
acts	O
on	O
these	O
processes	O
by	O
phosphorylating	O
substrates	O
.	O

The	O
IL-2R	B-protein
alpha	I-protein
enhancer	O
binds	O
NF-kappa	B-protein
B	I-protein
poorly	O
and	O
is	O
only	O
weakly	O
activated	O
by	O
the	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
alone	O
.	O

Kinase	O
assays	O
showed	O
that	O
TNF	B-protein
elicited	O
a	O
rapid	O
but	O
short-lived	O
induction	O
of	O
IKK	B-protein
activity	O
with	O
a	O
3-fold	O
greater	O
effect	O
on	O
IKK-alpha	B-protein
than	O
on	O
IKK-beta	B-protein
,	O
peaking	O
at	O
5	O
min	O
.	O

Analogs	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
)	O
with	O
substitutions	O
on	O
C-11	O
were	O
synthesized	O
.	O

Human	O
immunodeficiency	O
virus-associated	O
Hodgkin	O
's	O
disease	O
(	O
HIV-HD	O
)	O
displays	O
several	O
peculiarities	O
when	O
compared	O
with	O
HD	O
of	O
the	O
general	O
population	O
.	O

For	O
cells	O
of	O
the	O
innate	O
immune	O
system	O
to	O
mount	O
a	O
host	O
defence	O
response	O
to	O
infection	O
,	O
they	O
must	O
recognize	O
products	O
of	O
microbial	O
pathogens	O
such	O
as	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
the	O
endotoxin	O
secreted	O
by	O
Gram-negative	O
bacteria	O
.	O

Many	O
environmental	O
factors	O
,	O
in	O
particular	O
,	O
proinflammatory	B-protein
cytokines	I-protein
and	O
growth	B-protein
factors	I-protein
,	O
can	O
exert	O
regulatory	O
effects	O
on	O
MSR	B-protein
expression	O
,	O
whereas	O
intracellular	O
accumulation	O
of	O
cholesterol	O
itself	O
does	O
not	O
influence	O
MSR	B-protein
levels	O
to	O
any	O
considerable	O
extent	O
.	O

In	O
parallel	O
,	O
NAC	O
was	O
shown	O
to	O
down-regulate	O
the	O
production	O
of	O
cytokines	B-protein
by	O
DC	B-cell_type
as	O
well	O
as	O
their	O
surface	O
expression	O
of	O
HLA-DR	B-protein
,	O
CD86	B-protein
(	O
B7-2	B-protein
)	O
,	O
and	O
CD40	B-protein
molecules	I-protein
both	O
at	O
the	O
basal	O
state	O
and	O
upon	O
LPS	O
activation	O
.	O

Analysis	O
of	O
a	O
series	O
of	O
5'-truncations	B-DNA
showed	O
several	O
peaks	O
of	O
basal	O
and	O
PMA	O
induced	O
activity	O
suggesting	O
the	O
presence	O
of	O
several	O
positive	B-DNA
and	O
negative	O
regulatory	O
elements	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
multiple	B-protein
Ets	I-protein
family	I-protein
members	I-protein
with	O
apparently	O
distinct	O
DNA	O
binding	O
specificities	O
regulate	O
differential	O
gene	O
expression	O
in	O
resting	B-cell_type
and	I-cell_type
activated	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
regulatory	O
mechanisms	O
of	O
the	O
human	B-DNA
and	I-DNA
murine	I-DNA
TNF	I-DNA
genes	I-DNA
are	O
discussed	O
.	O

We	O
confirm	O
that	O
binding	O
of	O
endogenous	O
NFkappaB	B-protein
and	O
AP1	B-protein
is	O
induced	O
following	O
PMA/ionomycin	O
treatment	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

Functional	O
expression	O
of	O
the	O
IL-2Ralpha	B-protein
on	O
mononuclear	B-cell_type
phagocytes	I-cell_type
in	O
M.	O
tuberculosis	O
infection	O
may	O
play	O
an	O
important	O
immunomodulatory	O
role	O
in	O
the	O
host	O
response	O
.	O

All	O
cases	O
tested	O
(	O
6/20	O
)	O
,	O
including	O
the	O
case	O
with	O
t	B-DNA
(	I-DNA
11	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
,	O
failed	O
to	O
differentiate	O
in	O
vitro	O
in	O
response	O
to	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
suggesting	O
that	O
these	O
cases	O
may	O
account	O
for	O
some	O
APLs	O
that	O
have	O
not	O
shown	O
a	O
clinical	O
response	O
to	O
ATRA	O
.	O

It	O
is	O
also	O
expressed	O
in	O
transformed	B-cell_line
B-cells	I-cell_line
.	O

We	O
demonstrate	O
here	O
that	O
the	O
expression	O
of	O
the	O
lysosomal	B-protein
enzyme	I-protein
acid	B-protein
sphingomyelinase	I-protein
(	O
ASM	O
;	O
E.C.3.1.4.12	O
)	O
is	O
induced	O
during	O
this	O
process	O
and	O
is	O
strongly	O
elevated	O
in	O
differentiated	O
THP-1	B-cell_line
cells	I-cell_line
,	O
as	O
well	O
as	O
in	O
differentiated	O
human	B-cell_type
mononuclear	I-cell_type
phagocytes	I-cell_type
.	O

The	O
synthesis	O
and	O
immunogenicity	O
of	O
varicella-zoster	B-protein
virus	I-protein
glycoprotein	I-protein
E	I-protein
and	O
immediate-early	B-protein
protein	I-protein
(	O
IE62	B-protein
)	O
expressed	O
in	O
recombinant	O
herpes	O
simplex	O
virus-1	O
.	O

Neutrophil	B-cell_type
maturation	O
and	O
the	O
role	O
of	O
retinoic	O
acid	O
.	O

These	O
in	O
vivo	O
anti-inflammatory	O
effects	O
of	O
IL-11	B-protein
were	O
associated	O
with	O
reduced	O
NF-kappaB	B-protein
activation	O
in	O
lung	O
,	O
reduced	O
levels	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluids	O
,	O
and	O
diminished	O
up-regulation	O
of	O
lung	B-protein
vascular	I-protein
ICAM-1	I-protein
.	O

In	O
contrast	O
,	O
tyrosine-phosphorylated	O
peptides	O
containing	O
Tyr374	O
or	O
Tyr396	O
did	O
not	O
interact	O
with	O
Stat3	B-protein
or	O
block	O
Stat3	B-protein
activation	O
.	O

To	O
identify	O
an	O
EBNA2	B-DNA
dependent	I-DNA
cis-acting	I-DNA
element	I-DNA
,	O
various	O
TP1	B-DNA
promoter-reporter	I-DNA
gene	I-DNA
constructs	I-DNA
were	O
transfected	O
in	O
the	O
absence	O
and	O
presence	O
of	O
an	O
EBNA2	B-DNA
expression	I-DNA
vector	I-DNA
into	O
the	O
established	O
B-cell	B-cell_line
line	I-cell_line
BL41-P3HR1	I-cell_line
.	O

Replication	O
of	O
type	O
1	O
human	O
immunodeficiency	O
viruses	O
containing	O
linker	O
substitution	O
mutations	O
in	O
the	O
-201	B-DNA
to	I-DNA
-130	I-DNA
region	I-DNA
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
.	O

Therefore	O
,	O
this	O
pathway	O
appears	O
as	O
a	O
crucial	O
step	O
in	O
the	O
initiation	O
of	O
early	O
T	O
cell	O
activation	O
events	O
.	O

Activation	O
of	O
CD34	B-protein
expression	O
in	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
is	O
dependent	O
on	O
the	O
presence	O
of	O
intact	O
MZF-1	B-DNA
binding	I-DNA
sites	I-DNA
.	O

This	O
induction	O
of	O
differentiation	O
is	O
accompanied	O
by	O
adherence	O
and	O
loss	O
of	O
proliferation	O
,	O
as	O
well	O
as	O
expression/repression	O
of	O
differentiation-associated	B-DNA
genes	I-DNA
.	O

HIV-1	O
harboring	O
mutations	O
within	O
two	O
C/EBP	B-DNA
sites	I-DNA
were	O
crippled	O
in	O
their	O
ability	O
to	O
replicate	O
in	O
U937	B-cell_line
promonocytic	I-cell_line
cells	I-cell_line
,	O
indicating	O
that	O
these	O
sites	O
are	O
required	O
for	O
replication	O
.	O

The	O
mitogen-induced	O
increase	O
of	O
c-Fos	B-protein
and	O
c-Jun	B-protein
immunoreactivity	O
was	O
inhibited	O
by	O
H-7	O
,	O
a	O
kinase	O
inhibitor	O
with	O
relatively	O
high	O
specificity	O
for	O
PKC	O
,	O
and	O
less	O
efficiently	O
by	O
H-8	O
,	O
a	O
structurally	O
related	O
kinase	O
inhibitor	O
less	O
active	O
on	O
PKC	O
,	O
but	O
more	O
active	O
on	O
cyclic	O
nucleotide-dependent	O
kinases	O
.	O

Since	O
anti-Ig	O
crosslinking	O
leads	O
to	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
and	O
an	O
increase	O
in	O
intracellular	O
calcium	O
level	O
,	O
Zp	B-DNA
was	O
tested	O
for	O
the	O
response	O
to	O
these	O
cellular	B-protein
factors	I-protein
.	O

IkappaB	B-protein
levels	O
in	O
MNC	B-cell_type
homogenates	O
increased	O
at	O
1	O
hr	O
,	O
peaked	O
at	O
2-4	O
hr	O
,	O
started	O
to	O
decrease	O
at	O
8	O
hr	O
,	O
and	O
returned	O
to	O
baseline	O
levels	O
at	O
24	O
hr	O
.	O

IL-10	B-protein
inhibited	O
translocation	O
of	O
NF-kappaB	B-protein
in	O
response	O
to	O
LPS	O
but	O
not	O
the	O
fungal	O
stimuli	O
.	O

When	O
such	O
cells	O
are	O
precultured	O
for	O
2	O
days	O
with	O
a	O
low	O
dose	O
of	O
LPS	O
(	O
20	O
ng/ml	O
)	O
followed	O
by	O
stimulation	O
with	O
a	O
high	O
dose	O
of	O
LPS	O
(	O
1	O
microgram/ml	O
)	O
,	O
expression	O
of	O
the	O
TNF	B-DNA
gene	I-DNA
is	O
minimal	O
,	O
i.e.	O
the	O
cells	O
are	O
tolerant	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

N-Acetylcysteine	O
treatment	O
attenuated	O
neutrophil	B-cell_type
adhesion	O
in	O
both	O
phases	O
,	O
which	O
indicated	O
a	O
role	O
for	O
GSH	O
in	O
the	O
adhesion	O
responses	O
.	O

Furthermore	O
,	O
IL-2	B-protein
and	O
IL-12	B-protein
synergistically	O
induced	O
IRF-1	B-protein
,	O
whereas	O
IFN-alpha	B-protein
and	O
IL-12	B-protein
did	O
not	O
.	O

We	O
analysed	O
FHIT	B-DNA
in	O
the	O
same	O
series	O
of	O
RNA	B-RNA
samples	I-RNA
and	O
detected	O
truncated	O
FHIT	B-RNA
transcripts	I-RNA
frequently	O
in	O
both	O
tumour	O
and	O
normal	O
tissues	O
.	O

The	O
protein	O
shows	O
significant	O
sequence	O
similarities	O
to	O
the	O
family	O
of	O
G-protein	B-protein
coupled	I-protein
chemokine	I-protein
receptors	I-protein
and	O
turned	O
out	O
to	O
be	O
identical	O
to	O
the	O
recently	O
described	O
receptor	B-protein
EBI1	I-protein
.	O

Neutrophil	O
maturation	O
was	O
impaired	O
in	O
PEBP2betaMYH11	B-protein
transgenic	O
mice	O
.	O

The	O
role	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
has	O
long	O
been	O
a	O
subject	O
of	O
controversy	O
.	O

In	O
contrast	O
,	O
the	O
binding	O
activities	O
of	O
AP-1	B-protein
and	O
GATA	B-protein
,	O
on	O
the	O
other	O
hand	O
,	O
are	O
increased	O
by	O
LDL	B-protein
.	O

Progesterone	O
effectively	O
blocked	O
a	O
broad	O
spectrum	O
of	O
K+	B-protein
channels	I-protein
,	O
reducing	O
both	O
Kv1.3	B-protein
and	O
charybdotoxin-resistant	B-protein
components	I-protein
of	O
KV	B-protein
current	O
and	O
KCa	B-protein
current	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
as	O
well	O
as	O
blocking	O
several	O
cloned	B-protein
KV	I-protein
channels	I-protein
expressed	O
in	O
cell	B-cell_line
lines	I-cell_line
.	O

This	O
intracellular	O
signaling	O
complex	O
potently	O
stimulates	O
kappa	O
B-directed	O
transcription	O
from	O
either	O
the	O
HIV-1	B-DNA
LTR	I-DNA
or	O
the	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
via	O
the	O
strong	O
transactivation	O
domain	O
present	O
in	O
p65	B-protein
.	O

The	O
hierarchy	O
of	O
transcriptional	O
control	O
in	O
B-cell	O
development	O
has	O
recently	O
been	O
analyzed	O
by	O
targeted	O
gene	O
inactivation	O
in	O
the	O
mouse	O
.	O

This	O
is	O
the	O
first	O
study	O
of	O
expression	O
of	O
all	O
family	O
members	O
at	O
the	O
protein	O
level	O
in	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

We	O
show	O
that	O
both	O
CREB	B-protein
isoforms	I-protein
are	O
expressed	O
in	O
many	B-cell_type
cell	I-cell_type
types	I-cell_type
and	O
mammalian	O
species	O
.	O

In	O
this	O
model	O
system	O
,	O
the	O
activities	O
of	O
late	B-DNA
promoter-reporter	I-DNA
fusions	I-DNA
are	O
measured	O
following	O
transient	O
transfection	O
into	O
tissue	B-cell_line
culture	I-cell_line
cells	I-cell_line
expressing	O
EBV	O
during	O
different	O
stages	O
of	O
the	O
lytic	O
cycle	O
.	O

However	O
,	O
signal	O
transduction	O
of	O
IL-10	B-protein
in	O
B	B-cell_type
cells	I-cell_type
is	O
poorly	O
understood	O
.	O

The	O
fusion	B-DNA
cDNA	I-DNA
results	O
from	O
an	O
interstitial	O
deletion	O
between	O
a	O
previously	O
unknown	B-DNA
locus	I-DNA
,	O
SIL	B-DNA
(	O
SCL	B-DNA
interrupting	I-DNA
locus	I-DNA
)	O
,	O
and	O
the	O
5	B-DNA
'	I-DNA
untranslated	I-DNA
region	I-DNA
of	O
SCL	B-protein
.	O

Our	O
results	O
suggest	O
that	O
PKA	B-protein
inhibits	O
T	O
cell	O
activation	O
by	O
interfering	O
with	O
multiple	O
events	O
along	O
the	O
two	O
signaling	O
pathways	O
operating	O
downstream	O
of	O
the	O
TCR	B-protein
and	O
the	O
CD28	B-protein
co-receptor	I-protein
molecules	I-protein
.	O

Human	B-cell_type
monocytes	I-cell_type
and	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
cultured	O
for	O
6	O
days	O
in	O
5	O
%	O
human	O
serum	O
expressed	O
PPARgamma	B-RNA
mRNA	I-RNA
and	O
protein	O
by	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
and	O
Western	O
blotting	O
,	O
respectively	O
.	O

The	O
Tat	B-protein
-mediated	O
increase	O
in	O
IL-2	B-DNA
promoter	I-DNA
activity	O
could	O
selectively	O
be	O
blocked	O
by	O
antisense	O
tat	O
or-unlike	O
the	O
analogous	O
effect	O
of	O
human	B-protein
T-cell	I-protein
lymphotropic	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax	I-protein
-by	O
cyclosporin	O
A	O
.	O

Purification	O
and	O
characterization	O
of	O
the	O
human	B-protein
SR	I-protein
31747A-binding	I-protein
protein	I-protein
.	O

However	O
,	O
continuous	O
treatments	O
with	O
subcytotoxic	O
concentrations	O
of	O
etoposide	O
(	O
0.15	O
microM	O
)	O
and	O
ICRF-193	O
(	O
0.3	O
microM	O
)	O
produced	O
several	O
similar	O
effects	O
,	O
namely	O
decreased	O
cell	O
proliferation	O
,	O
accumulation	O
of	O
cells	O
at	O
G2	O
,	O
increase	O
in	O
cell	O
mass	O
,	O
and	O
induction	O
of	O
differentiation	O
.	O

Signaling	O
through	O
the	O
lymphotoxin-beta	B-protein
receptor	I-protein
stimulates	O
HIV-1	O
replication	O
alone	O
and	O
in	O
cooperation	O
with	O
soluble	O
or	O
membrane-bound	B-protein
TNF-alpha	I-protein
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
supershift	O
assays	O
we	O
demonstrate	O
that	O
this	O
region	O
is	O
specifically	O
bound	O
by	O
Sp1	B-protein
and	O
AP-2	B-protein
.	O

The	O
main	O
feature	O
of	O
cellular	O
senescence	O
in	O
vitro	O
is	O
cessation	O
of	O
cell	O
proliferation	O
.	O

We	O
propose	O
that	O
,	O
while	O
maximum	O
inhibition	O
may	O
involve	O
interaction	O
with	O
both	O
transcription	B-protein
factors	I-protein
,	O
AP-1	B-protein
is	O
the	O
primary	O
target	O
of	O
Dex	O
.	O

Both	O
Dex	O
and	O
CsA	O
inhibited	O
the	O
binding	O
of	O
transcription	O
factors	O
AP-1	B-protein
and	O
NF-AT	B-protein
,	O
but	O
not	O
of	O
NF-kB	B-protein
and	O
OCT-1/OAF	B-protein
,	O
to	O
their	O
corresponding	O
sites	O
on	O
the	O
IL-2	B-DNA
gene	I-DNA
promoter	I-DNA
.	O

Both	O
C1	B-protein
and	O
C2	B-protein
proteins	I-protein
also	O
bind	O
to	O
a	O
similar	O
sequence	O
found	O
in	O
the	O
interleukin-2-receptor	B-DNA
alpha-subunit	I-DNA
enhancer	I-DNA
.	O

These	O
findings	O
support	O
a	O
pathway	O
by	O
which	O
LPS	O
stimulation	O
of	O
neutrophils	B-cell_type
results	O
in	O
activation	O
of	O
MKK3	B-protein
,	O
which	O
in	O
turn	O
activates	O
p38alpha	B-protein
MAPk	I-protein
,	O
ultimately	O
regulating	O
adhesion	O
,	O
NF-kappaB	B-protein
activation	O
,	O
enhanced	O
gene	O
expression	O
of	O
TNF-alpha	B-protein
,	O
and	O
regulation	O
of	O
TNF-alpha	B-protein
synthesis	O
.	O

The	O
gene	O
encodes	O
an	O
85-kDa	B-protein
protein	I-protein
,	O
designated	O
BASH	B-protein
(	O
B	B-protein
cell	I-protein
adaptor	I-protein
containing	I-protein
SH2	I-protein
domain	I-protein
)	O
,	O
that	O
contains	O
N-terminal	B-protein
acidic	I-protein
domains	I-protein
with	O
SH2	B-protein
domain-binding	I-protein
phosphotyrosine-based	I-protein
motifs	I-protein
,	O
a	O
proline-rich	B-protein
domain	I-protein
,	O
and	O
a	O
C-terminal	B-protein
SH2	I-protein
domain	I-protein
.	O

Given	O
the	O
deleterious	O
effects	O
to	O
the	O
host	O
of	O
TNF-alpha	B-protein
,	O
it	O
has	O
been	O
postulated	O
that	O
TNF-alpha	B-protein
gene	O
expression	O
must	O
be	O
tightly	O
regulated	O
.	O

Second	O
,	O
T	B-cell_type
cells	I-cell_type
,	O
which	O
lack	O
CD45	B-protein
and	O
can	O
not	O
signal	O
via	O
the	O
TCR	B-protein
,	O
supported	O
higher	O
levels	O
of	O
viral	O
replication	O
and	O
gene	O
expression	O
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
Vav	B-protein
leads	O
to	O
enhanced	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
activity	O
without	O
affecting	O
AP-1	B-protein
.	O

The	O
anaphylatoxins	B-protein
C5a	B-protein
and	O
C3a	B-protein
are	O
involved	O
in	O
the	O
regulation	O
of	O
cytokine	O
production	O
.	O

The	O
association	O
of	O
specific	O
HLA-DQ	B-DNA
alleles	I-DNA
with	O
autoimmunity	O
is	O
correlated	O
with	O
discrete	O
polymorphisms	O
in	O
the	O
HLA-DQ	B-DNA
sequence	I-DNA
that	O
are	O
localized	O
within	O
sites	O
suitable	O
for	O
peptide	O
recognition	O
.	O

This	O
is	O
the	O
third	O
patient	O
with	O
severe	O
FUra	O
toxicity	O
secondary	O
to	O
an	O
alteration	O
in	O
pyrimidine	O
catabolism	O
and	O
the	O
second	O
from	O
our	O
clinic	O
population	O
suggesting	O
that	O
the	O
frequency	O
of	O
this	O
genetic	O
defect	O
may	O
be	O
greater	O
than	O
previously	O
thought	O
.	O

The	O
ability	O
of	O
Qp	B-DNA
to	O
bind	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
proteins	I-protein
was	O
directly	O
demonstrated	O
by	O
electrophoretic	O
mobility-shift	O
assay	O
,	O
and	O
mutation	O
of	O
potential	O
STAT-binding	B-DNA
sites	I-DNA
reduced	O
Qp	B-DNA
responsiveness	O
to	O
Janus	B-protein
kinase	I-protein
(	I-protein
JAK	I-protein
)	I-protein
-1	I-protein
.	O

Electrophoretically	O
purified	O
p50	B-protein
alone	O
can	O
form	O
a	O
protein-DNA	B-protein
complex	I-protein
,	O
but	O
in	O
the	O
mixture	O
,	O
p50	B-protein
associates	O
preferentially	O
with	O
p65	B-protein
to	O
form	O
the	O
NF-GM2	B-protein
complex	I-protein
.	O

Our	O
results	O
,	O
although	O
limited	O
,	O
suggest	O
that	O
normal	O
individuals	O
can	O
express	O
both	O
the	O
wild-type	O
and	O
truncated	O
version	O
at	O
the	O
same	O
time	O
,	O
whereas	O
lupus	O
patients	O
only	O
express	O
either	O
the	O
wild-type	B-protein
or	I-protein
the	I-protein
truncated	I-protein
ER	I-protein
.	O

Therefore	O
we	O
analysed	O
the	O
expression	O
of	O
E2F	B-protein
-DNA	O
binding	O
activity	O
and	O
the	O
constituent	O
proteins	O
found	O
in	O
the	O
complexes	O
in	O
human	B-cell_type
primary	I-cell_type
haemopoietic	I-cell_type
cells	I-cell_type
of	O
various	O
lineages	O
.	O

Hormone	O
binding	O
specificity	O
was	O
assessed	O
by	O
competition	O
studies	O
with	O
various	O
steroid	O
ligands	O
.	O

The	O
ability	O
of	O
RFX1	B-protein
to	O
transactivate	O
the	O
core	B-DNA
promoter	I-DNA
raises	O
the	O
possibility	O
that	O
RFX1	B-protein
may	O
play	O
a	O
dual	O
role	O
in	O
regulating	O
HBV	O
gene	O
expression	O

The	O
bcl-2	B-DNA
gene	I-DNA
,	O
a	O
repressor	O
of	O
lymphocyte	B-cell_type
death	O
,	O
is	O
perhaps	O
the	O
best	O
understood	O
of	O
the	O
programmed	O
cell	O
death	O
associated	O
genes	O
.	O

The	O
reasons	O
for	O
the	O
dissimilar	O
oncogenicities	O
of	O
human	O
adenoviruses	O
and	O
human	O
papillomaviruses	O
(	O
HPV	O
)	O
in	O
humans	O
are	O
unknown	O
but	O
may	O
relate	O
to	O
differences	O
in	O
the	O
capacities	O
of	O
the	O
E1A	B-protein
and	O
E7	B-protein
proteins	I-protein
to	O
target	B-cell_type
cells	I-cell_type
for	O
rejection	O
by	O
the	O
host	B-cell_type
natural	I-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	I-cell_type
response	O
.	O

We	O
have	O
now	O
investigated	O
the	O
mechanism	O
of	O
action	O
of	O
a	O
new	O
analogue	O
of	O
UP	O
,	O
PNU156804	O
,	O
which	O
shows	O
a	O
more	O
favorable	O
activity	O
profile	O
than	O
UP	O
in	O
mice	O
.	O

The	O
most	O
extensively	O
studied	O
phenomenon	O
is	O
the	O
progressive	O
decline	O
in	O
the	O
proliferative	O
capacities	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
with	O
aging	O
.	O

Retinoic	O
acid	O
inhibits	O
CD40	B-protein
+	O
interleukin-4	B-protein
-mediated	O
IgE	B-protein
production	O
in	O
vitro	O
.	O

Normal	B-cell_type
RBC	I-cell_type
show	O
none	O
of	O
these	O
phenomena	O
.	O

Native	O
PTF	B-protein
beta	I-protein
,	O
in	O
either	O
protein	O
fractions	O
or	O
a	O
PTF-Oct-1-DNA	B-protein
complex	I-protein
,	O
can	O
be	O
recognized	O
by	O
polyclonal	B-protein
antibodies	I-protein
raised	O
against	O
recombinant	B-protein
PTF	I-protein
beta	I-protein
.	O

Cloning	O
a	O
cDNA	B-DNA
from	O
human	O
NK/T	B-cell_type
cells	I-cell_type
which	O
codes	O
for	O
a	O
protein	O
with	O
high	O
proline	O
content	O
.	O

Imbalance	O
of	O
these	O
T	B-cell_type
lymphocyte	I-cell_type
subsets	I-cell_type
has	O
been	O
implicated	O
in	O
immunological	O
diseases	O
including	O
allergy	O
,	O
inflammation	O
,	O
and	O
autoimmune	O
disease	O
.	O

The	O
hypothesis	O
to	O
be	O
tested	O
was	O
whether	O
or	O
not	O
humans	O
exhibit	O
a	O
similar	O
susceptibility	O
to	O
PCDDs/PCDFs	O
with	O
respect	O
to	O
the	O
surface	B-protein
receptors	I-protein
found	O
previously	O
to	O
respond	O
to	O
small	O
doses	O
of	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo-p-dioxin	O
(	O
TCDD	O
)	O
in	O
Callithrix	O
jacchus	O
.	O

A	O
protein	O
footprint	O
was	O
visible	O
over	O
this	O
region	O
of	O
the	O
c-myb	B-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
sequence	I-DNA
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
but	O
not	O
in	O
unactivated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Since	O
the	O
inhibition	O
of	O
Ca2+	O
redistribution	O
by	O
an	O
inhibitor	O
of	O
intracellular	O
Ca2+	O
mobilization	O
,	O
8-	O
(	O
diethylamino	O
)	O
-octyl-3	O
,	O
4	O
,	O
5-trimethoxybenzoate	O
hydrochloride	O
,	O
inhibited	O
TCR-induced	B-protein
FasL	I-protein
but	O
not	O
Fas	B-protein
,	O
the	O
expression	O
of	O
Fas	B-protein
appears	O
to	O
be	O
independent	O
of	O
Ca2+	O
mobilization	O
.	O

Accordingly	O
,	O
the	O
same	O
set	O
of	O
words	O
and	O
phrases	O
(	O
oligopeptides	O
)	O
appear	O
in	O
totally	O
unrelated	O
proteins	O
.	O

Five	O
patients	O
were	O
found	O
with	O
repeated	O
maximal	O
responses	O
to	O
adenovirus	B-protein
antigen	I-protein
;	O
in	O
one	O
of	O
these	O
adenovirus	B-DNA
nucleotide	I-DNA
sequences	I-DNA
were	O
present	O
in	O
a	O
synovial	O
biopsy	O
specimen	O
.	O

Retinoid-like	B-protein
receptors	I-protein
play	O
a	O
central	O
role	O
in	O
hormonal	O
responses	O
by	O
forming	O
heterodimers	B-protein
with	O
other	O
nuclear	B-protein
hormone	I-protein
receptors	I-protein
.	O

However	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
increased	O
the	O
number	O
of	O
cells	O
expressing	O
macrophage	B-protein
cell	I-protein
surface	I-protein
Ags	I-protein
,	O
including	O
CD14	B-protein
and	O
CD11b	B-protein
.	O

The	O
sequence	O
in	O
which	O
these	O
alterations	O
develop	O
is	O
unknown	O
.	O

The	O
proliferative	O
responses	O
of	O
purified	B-cell_type
CD4+	I-cell_type
or	I-cell_type
CD8+	I-cell_type
T	I-cell_type
cells	I-cell_type
are	O
suppressed	O
more	O
strongly	O
by	O
TPCK	O
when	O
anti-CD28	B-protein
rather	O
than	O
the	O
phorbol	O
ester	O
PMA	O
is	O
used	O
as	O
the	O
mitogenic	O
coactivator	B-protein
.	O

T-helper-cell	B-protein
determinants	I-protein
in	O
protein	B-protein
antigens	I-protein
are	O
preferentially	O
located	O
in	O
cysteine-rich	B-protein
antigen	I-protein
segments	I-protein
resistant	O
to	O
proteolytic	O
cleavage	O
by	O
cathepsin	B-protein
B	I-protein
,	I-protein
L	I-protein
,	I-protein
and	I-protein
D	I-protein
.	O

Freshly	O
isolated	O
monocytes	O
constitutively	O
expressed	O
high	O
levels	O
of	O
transcriptionally	B-protein
inactive	I-protein
p50	I-protein
homodimer	I-protein
which	O
decreased	O
with	O
time	O
in	O
culture	O
in	O
favor	O
of	O
the	O
transcriptionally	O
active	O
p50/p65	B-protein
and	I-protein
p50/RelB	I-protein
heterodimers	I-protein
.	O

Polyamines	O
in	O
human	O
breast	O
cancer	O
and	O
its	O
relations	O
to	O
classical	O
prognostic	O
features	O
:	O
clinical	O
implications	O
.	O

The	O
ERG2	B-protein
gene	I-protein
product	I-protein
has	O
been	O
identified	O
recently	O
as	O
the	O
molecular	O
target	O
of	O
SR	O
31747A	O
that	O
mediates	O
antiproliferative	O
effects	O
of	O
the	O
drug	O
in	O
yeast	O
.	O

However	O
,	O
cyclosporin	O
A	O
and	O
FK506	O
did	O
not	O
inhibit	O
Ca2+	O
mobilization	O
dependent	O
expression	O
of	O
c-fos	B-RNA
mRNA	I-RNA
indicating	O
that	O
only	O
a	O
subset	O
of	O
signalling	O
pathways	O
regulated	O
by	O
Ca2+	O
is	O
sensitive	O
to	O
these	O
drugs	O
.	O

Coactivation	O
by	O
OCA-B	B-protein
:	O
definition	O
of	O
critical	O
regions	O
and	O
synergism	O
with	O
general	O
cofactors	O
.	O

Circular	O
permutation	O
and	O
phasing	O
analyses	O
demonstrated	O
that	O
PU.1	B-protein
binding	O
but	O
not	O
TFE3	B-protein
or	O
Ets-1	B-protein
bends	O
mu	B-DNA
enhancer	I-DNA
DNA	I-DNA
toward	O
the	O
major	O
groove	O
.	O

Human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
(	O
Mo	B-cell_type
)	O
constitutively	O
display	O
the	O
beta-chain	O
of	O
the	O
receptor	O
for	O
IL-2	B-protein
,	O
whereas	O
expression	O
of	O
the	O
IL-2R	B-protein
alpha-chain	I-protein
is	O
not	O
constitutive	O
but	O
inducible	O
with	O
IL-2	B-protein
.	O

Analysis	O
of	O
Gal4-Elf-1	B-protein
fusion	I-protein
proteins	I-protein
revealed	O
that	O
the	O
N-terminal	O
86	O
amino	O
acids	O
of	O
Elf-1	B-protein
contain	O
a	O
transcriptional	B-protein
activation	I-protein
domain	I-protein
,	O
the	O
activity	O
of	O
which	O
is	O
attenuated	O
by	O
an	O
internal	B-protein
repression	I-protein
domain	I-protein
.	O

We	O
examined	O
the	O
contribution	O
of	O
the	O
two	O
isoforms	O
of	O
STAT5	B-protein
,	O
STAT5A	B-protein
and	O
STAT5B	B-protein
,	O
to	O
IL-2-	O
and	O
IL-7-induced	O
activation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphoblasts	I-cell_type
.	O

Hence	O
,	O
decreased	O
sensitivity	O
to	O
cortisol	O
is	O
associated	O
with	O
renin	B-protein
suppression	O
.	O

In	O
fibroblasts	B-cell_type
,	O
an	O
important	O
effector	O
for	O
the	O
Ras	B-DNA
oncogene	I-DNA
is	O
Phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PtdIns	B-protein
3-kinase	I-protein
)	O
.	O

The	O
low	O
frequency	O
with	O
which	O
these	O
Ig-expressing	B-cell_line
hybrids	I-cell_line
are	O
recovered	O
,	O
along	O
with	O
the	O
fact	O
that	O
cell	O
fusions	O
can	O
lead	O
to	O
chromosome	O
loss	O
,	O
led	O
us	O
to	O
propose	O
that	O
this	O
rare	O
phenotype	O
was	O
due	O
to	O
loss	O
of	O
a	O
T-cell-derived	B-protein
chromosome	I-protein
encoding	I-protein
a	I-protein
factor	I-protein
or	O
factors	O
with	O
gene	O
silencing	O
activity	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
cell	O
surface	O
molecules	O
in	O
these	O
responses	O
.	O

Chromosomal	O
translocations	O
involving	O
the	O
genes	O
encoding	O
the	O
alpha	B-protein
and	I-protein
beta	I-protein
subunits	I-protein
of	O
the	O
Pebp2/Cbf	B-protein
transcription	I-protein
factor	I-protein
have	O
been	O
associated	O
with	O
human	O
acute	O
myeloid	O
leukemia	O
and	O
the	O
preleukemic	O
condition	O
,	O
myelodysplasia	O
.	O

CD4+	B-cell_type
lymphocytes	I-cell_type
,	O
at	O
both	O
polyclonal	O
and	O
clonal	O
level	O
,	O
recognized	O
peptide	O
BCR1/25	O
in	O
an	O
HLA-DR	B-protein
--	O
restricted	O
fashion	O
on	O
presentation	O
by	O
autologous	B-cell_type
antigen-presenting	I-cell_type
cell	I-cell_type
(	O
APC	B-cell_type
)	O
or	O
by	O
APC	B-cell_type
expressing	O
the	O
HLA-DR11	B-protein
restricting	I-protein
molecule	I-protein
.	O

Because	O
STAT6	B-protein
activation	O
plays	O
an	O
essential	O
role	O
in	O
IL-4	B-protein
/	O
IL-13	B-protein
-induced	O
gene	O
expression	O
,	O
the	O
ability	O
of	O
IFN-beta	B-protein
and	O
IFN-gamma	B-protein
to	O
inhibit	O
STAT6	B-protein
activity	O
provides	O
an	O
explanation	O
for	O
how	O
IFNs	B-protein
can	O
suppress	O
IL-4	B-protein
/	O
IL-13	B-protein
-inducible	O
gene	O
expression	O
.	O

These	O
results	O
reveal	O
a	O
conserved	O
signaling	O
pathway	O
for	O
TLR2	B-protein
and	O
IL-1Rs	B-protein
and	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
the	O
inhibition	O
of	O
TLR2	B-protein
by	O
DN	O
variants	O
.	O

A	O
similar	O
comparison	O
with	O
protease-treated	O
extracts	O
prepared	O
from	O
Jurkat	B-cell_line
cells	I-cell_line
demonstrated	O
the	O
presence	O
of	O
the	O
band	O
1pk	O
activity	O
despite	O
an	O
absence	O
of	O
the	O
native	O
RFX	B-protein
activity	O
.	O

To	O
investigate	O
regulatory	O
networks	O
in	O
Legionella	O
pneumophila	O
,	O
the	O
gene	O
encoding	O
the	O
homolog	O
of	O
the	O
Escherichia	B-protein
coli	I-protein
stress	I-protein
and	I-protein
stationary-phase	I-protein
sigma	I-protein
factor	I-protein
RpoS	B-protein
was	O
identified	O
by	O
complementation	O
of	O
an	O
E.	O
coli	O
rpoS	B-DNA
mutation	O
.	O

We	O
also	O
show	O
that	O
mitogen	O
induction	O
of	O
the	O
interleukin-1	B-DNA
beta	I-DNA
converting	I-DNA
enzyme	I-DNA
(	I-DNA
ICE	I-DNA
)	I-DNA
gene	I-DNA
,	O
a	O
mammalian	B-protein
homologue	I-protein
of	O
the	O
Caenorhabditis	B-DNA
elegans	I-DNA
cell	I-DNA
death	I-DNA
gene	I-DNA
ced-3	B-DNA
,	O
is	O
IRF-1	B-protein
-dependent	O
.	O

At	O
the	O
2	O
microM	O
concentration	O
,	O
eosinophil	B-protein
cationic	I-protein
protein	I-protein
,	O
eosinophil-derived	O
neurotoxin	O
,	O
and	O
eosinophil	B-protein
peroxidase	I-protein
did	O
not	O
stimulate	O
significant	O
levels	O
of	O
IL-8	B-protein
production	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
AP-1	B-protein
site	O
and	O
a	O
distal	B-DNA
promoter	I-DNA
element	I-DNA
regulate	O
transcriptional	O
induction	O
of	O
collagenase-1	B-protein
during	O
monocytic	O
differentiation	O
.	O

No	O
upregulation	O
of	O
megakaryocyte	B-protein
or	I-protein
lymphoid	I-protein
markers	I-protein
occurred	O
.	O

To	O
investigate	O
the	O
potential	O
relevance	O
of	O
this	O
mechanism	O
in	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
,	O
we	O
examined	O
cytokine	B-protein
induction	O
by	O
leukocyte-platelet	O
adhesion	O
and	O
the	O
occurrence	O
of	O
leukocyte-platelet	O
conjugates	O
in	O
patients	O
with	O
AMI	O
.	O

Estrogen	B-cell_line
receptor	I-cell_line
positive	I-cell_line
(	I-cell_line
ER+	I-cell_line
:	I-cell_line
MCF-7	I-cell_line
)	I-cell_line
and	I-cell_line
negative	I-cell_line
(	I-cell_line
ER-	I-cell_line
:	I-cell_line
MDA-MB-231	I-cell_line
)	I-cell_line
human	I-cell_line
breast	I-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
utilized	O
to	O
evaluate	O
the	O
effects	O
of	O
tamoxifen	O
(	O
TAM	O
)	O
and	O
estradiol	O
(	O
E2	O
)	O
on	O
modulation	O
of	O
breast	O
cancer	O
target	O
susceptibility	O
to	O
lysis	O
by	O
lymphokine-activated	B-cell_type
killer	I-cell_type
(	I-cell_type
LAK	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O

Diamide	O
plus	O
BSO-induced	O
thiol/disulfide	O
imbalance	O
was	O
associated	O
with	O
a	O
biphasic	O
increase	O
in	O
neutrophil	B-cell_type
adhesion	O
to	O
HUVECs	B-cell_line
with	O
peak	O
responses	O
observed	O
at	O
15	O
minutes	O
(	O
phase	O
1	O
)	O
and	O
240	O
minutes	O
(	O
phase	O
2	O
)	O
.	O

Based	O
on	O
these	O
data	O
,	O
we	O
concluded	O
that	O
interdomain	B-protein
B	I-protein
regulates	O
but	O
is	O
not	O
required	O
for	O
ZAP-70	B-protein
signaling	O
function	O
leading	O
to	O
cellular	O
responses	O
.	O

Our	O
data	O
suggests	O
that	O
CoCl2-induced	O
cellular	O
signals	O
directing	O
increased	O
expression	O
of	O
VCAM-1	B-protein
in	O
HUVEC	B-cell_type
involve	O
downstream	O
activation	O
of	O
MAP	B-protein
kinase	I-protein
and	O
NF-kappaB	B-protein
,	O
while	O
the	O
phosphorylation	O
of	O
PECAM-1	B-protein
occurs	O
as	O
a	O
result	O
of	O
activation	O
of	O
PKC	B-protein
.	O

Comparison	O
of	O
tumor	O
specimen	O
from	O
MM	O
precursor	O
lesions	O
,	O
primary	O
tumors	O
,	O
and	O
metastases	O
revealed	O
that	O
CD40	B-protein
surface	O
expression	O
is	O
down-regulated	O
during	O
tumor	O
progression	O
.	O

Using	O
gene	O
targeting	O
,	O
we	O
generated	O
a	O
TNFRp55	B-protein
-deficient	O
mouse	O
strain	O
.	O

The	O
mechanism	O
by	O
which	O
TGF-beta	B-protein
inhibits	O
Ig	O
chain	O
synthesis	O
is	O
unclear	O
although	O
it	O
does	O
not	O
involve	O
inhibition	O
of	O
the	O
binding	O
of	O
NF-kappa	B-protein
B	I-protein
or	O
Oct-2	B-protein
to	O
their	O
respective	O
target	O
sequences	O
.	O

In	O
situ	O
hybridization	O
and	O
Northern	O
blot	O
analysis	O
suggest	O
that	O
Spi-B	B-protein
gene	O
expression	O
increases	O
during	O
B	O
cell	O
maturation	O
and	O
decreases	O
during	O
T	O
cell	O
maturation	O
.	O

Flow	O
cytometry	O
analysis	O
indicated	O
that	O
these	O
cells	O
were	O
expressing	O
high	O
levels	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
(	O
VCAM-1	B-protein
[	O
CD106	B-protein
]	O
)	O
,	O
a	O
110-kDa	O
member	O
of	O
the	O
immunoglobulin	B-protein
gene	I-protein
superfamily	I-protein
,	O
first	O
identified	O
on	O
endothelial	B-cell_type
cells	I-cell_type
stimulated	O
with	O
inflammatory	B-protein
cytokines	I-protein
.	O

Therefore	O
,	O
only	O
the	O
time	O
between	O
infection	O
and	O
eradication	O
remains	O
for	O
these	O
viruses	O
to	O
proliferate	O
.	O

Such	O
changes	O
clearly	O
can	O
not	O
be	O
explained	O
by	O
genomic	O
mechanisms	O
,	O
which	O
are	O
responsible	O
for	O
later	O
effects	O
than	O
the	O
membrane	O
related	O
rapid	O
responses	O
.	O

Tpl-2	B-protein
induces	O
IL-2	B-protein
expression	O
in	O
T-cell	B-cell_line
lines	I-cell_line
by	O
triggering	O
multiple	O
signaling	O
pathways	O
that	O
activate	O
NFAT	B-protein
and	O
NF-kappaB	B-protein
.	O

Haemopoietic	O
differentiation	O
is	O
ultimately	O
controlled	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
which	O
is	O
mediated	O
by	O
an	O
array	O
of	O
transcription	B-protein
factors	I-protein
.	O

Mechanisms	O
involved	O
in	O
the	O
inhibition	O
of	O
growth	O
of	O
a	O
human	B-cell_line
B	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
B104	B-cell_line
,	O
by	O
anti-MHC	B-protein
class	I-protein
II	I-protein
antibodies	I-protein
.	O

Effects	O
of	O
oxidative	O
stress	O
on	O
stimulation-dependent	O
signal	O
transduction	O
,	O
leading	O
to	O
IL-2	B-protein
expression	O
,	O
were	O
studied	O
.	O

Proliferation	O
,	O
as	O
measured	O
by	O
the	O
percentage	O
of	O
cells	O
in	O
cycle	O
appeared	O
normal	O
,	O
as	O
did	O
rearrangement	O
and	O
expression	O
of	O
the	O
TCR	B-protein
beta-chain	I-protein
.	O

The	O
earliest	O
lesion	O
in	O
the	O
development	O
of	O
an	O
atherosclerotic	O
plaque	O
is	O
the	O
fatty	O
streak	O
.	O

Our	O
results	O
identify	O
a	O
molecular	O
switch	O
for	O
lineage	O
specification	O
in	O
early	B-cell_type
lymphoid	I-cell_type
precursors	I-cell_type
of	O
humans	O
.	O

However	O
,	O
analysis	O
of	O
the	O
viral	B-DNA
control	I-DNA
elements	I-DNA
and	O
the	O
cellular	B-protein
factors	I-protein
that	O
regulate	O
adenoviral	O
gene	O
expression	O
in	O
lymphocytes	B-cell_type
has	O
not	O
been	O
reported	O
.	O

In	O
the	O
first	O
male	O
patient	O
,	O
the	O
number	O
of	O
receptors	O
was	O
very	O
low	O
,	O
while	O
the	O
affinity	O
was	O
lower	O
than	O
that	O
in	O
controls	O
.	O

Cell-specific	O
bifunctional	O
role	O
of	O
Jun	B-DNA
oncogene	I-DNA
family	I-DNA
members	I-DNA
on	O
glucocorticoid	B-protein
receptor	I-protein
-dependent	O
transcription	O
.	O

The	O
generation	O
of	O
cell-mediated	O
immunity	O
against	O
many	O
infectious	O
pathogens	O
involves	O
the	O
production	O
of	O
interleukin-12	B-protein
(	O
IL-12	B-protein
)	O
,	O
a	O
key	O
signal	O
of	O
the	O
innate	O
immune	O
system	O
.	O

The	O
distribution	O
of	O
myeloid	B-protein
lineage-associated	I-protein
cytokine	I-protein
receptors	I-protein
and	O
lysosomal	B-protein
proteins	I-protein
was	O
analyzed	O
in	O
human	B-cell_line
CD34+	I-cell_line
cord	I-cell_line
blood	I-cell_line
cell	I-cell_line
(	I-cell_line
CB	I-cell_line
)	I-cell_line
subsets	I-cell_line
at	O
different	O
stages	O
of	O
myeloid	O
commitment	O
by	O
reverse-transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
.	O

A	O
p56lck	B-protein
-independent	O
pathway	O
of	O
CD2	B-protein
signaling	O
involves	O
Jun	B-protein
kinase	I-protein
.	O

Association	O
between	O
expression	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
and	O
integration	O
of	O
human	O
T-cell-leukemia	O
virus	O
type	O
1	O
in	O
adult	B-cell_type
T-cell	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

As	O
HSF1	B-protein
can	O
function	O
as	O
both	O
an	O
activator	O
of	O
heat	B-DNA
shock	I-DNA
genes	I-DNA
and	O
a	O
repressor	O
of	O
non-heat	B-DNA
shock	I-DNA
genes	I-DNA
such	O
as	O
IL1B	O
and	O
c-	O
fos	O
,	O
we	O
have	O
examined	O
the	O
potential	O
role	O
of	O
HSF1	B-protein
in	O
the	O
effects	O
of	O
NSAIDs	O
on	O
gene	O
expression	O
in	O
a	O
human	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	I-cell_line
.	O

We	O
conclude	O
that	O
the	O
function	O
of	O
Stat6	B-protein
is	O
highly	O
dependent	O
on	O
promoter	O
context	O
and	O
that	O
this	O
factor	O
promotes	O
IL-4	B-protein
gene	O
expression	O
in	O
an	O
indirect	O
manner	O
.	O

The	O
adult	O
male	O
progeny	O
(	O
3	O
mo	O
old	O
)	O
of	O
both	O
experimental	O
groups	O
showed	O
increased	O
basal	O
plasma	O
corticosterone	O
levels	O
.	O

In	O
parallel	O
,	O
upregulation	O
of	O
the	O
lung	B-protein
vascular	I-protein
adhesion	I-protein
molecule	I-protein
,	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
,	O
was	O
greatly	O
reduced	O
by	O
intrapulmonary	O
instillation	O
of	O
phosphonate-containing	O
liposomes	O
.	O

Conversely	O
,	O
RS	B-cell_line
cells	I-cell_line
of	O
virtually	O
all	O
HIV-HD	O
express	O
the	O
EBV-encoded	B-protein
latent	I-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	O
LMP1	B-protein
)	O
,	O
which	O
,	O
being	O
functionally	O
homologous	O
to	O
CD40	B-protein
,	O
may	O
contribute	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
modulation	O
of	O
the	O
HIV-HD	O
phenotype	O
.	O

Soluble	B-protein
factors	I-protein
secreted	O
by	O
activated	B-cell_type
T-lymphocytes	I-cell_type
modulate	O
the	O
transcription	O
of	O
the	O
immunosuppressive	B-protein
cytokine	I-protein
TGF-beta	B-protein
2	I-protein
in	O
glial	B-cell_type
cells	I-cell_type
.	O

Thyroid	O
hormones	O
inhibit	O
[	O
3H	O
]	O
glycosaminoglycan	O
synthesis	O
by	O
cultured	B-cell_line
human	I-cell_line
dermal	I-cell_line
fibroblasts	I-cell_line
,	O
and	O
T3SO4	O
displayed	O
about	O
0.5	O
%	O
the	O
activity	O
of	O
T3	O
at	O
72	O
h	O
.	O

Translocation	B-DNA
breakpoints	I-DNA
in	O
three	O
patients	O
with	O
campomelic	O
dysplasia	O
and	O
autosomal	O
sex	O
reversal	O
map	O
more	O
than	O
130	O
kb	O
from	O
SOX9	B-DNA
.	O

Two	O
well-characterized	O
Ets	B-protein
family	I-protein
members	I-protein
,	O
Ets-1	B-protein
and	O
Ets-2	B-protein
,	O
are	O
reciprocally	O
expressed	O
during	O
T-cell	O
activation	O
.	O

We	O
also	O
report	O
that	O
in	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
,	O
an	O
E	O
(	O
2	O
)	O
receptor-positive	O
murine	O
monocytic	O
line	O
,	O
E	O
(	O
2	O
)	O
downregulates	O
cytokine-induced	O
TNF	B-protein
gene	O
expression	O
by	O
decreasing	O
the	O
activity	O
of	O
the	O
Jun	B-protein
NH	I-protein
(	I-protein
2	I-protein
)	I-protein
-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
.	O

Recently	O
,	O
we	O
reported	O
cases	O
of	O
angioimmunoblastic	O
T-cell	O
lymphoma	O
(	O
AITL	O
)	O
with	O
hyperplastic	O
GCs	O
(	O
AITL/GC	O
)	O
,	O
and	O
observed	O
that	O
borders	O
of	O
enlarged	O
GCs	O
were	O
ill	O
defined	O
,	O
with	O
features	O
suggestive	O
of	O
an	O
outward	O
migration	O
of	O
GC	B-cell_type
cells	I-cell_type
to	O
surrounding	O
interfollicular	O
zones	O
.	O

CD4	B-DNA
promoter	I-DNA
transactivation	O
by	O
human	O
herpesvirus	O
6	O
.	O

In	O
contrast	O
to	O
previous	O
results	O
obtained	O
using	O
polyclonal	O
antiseras	O
to	O
detect	O
Pan/	O
E2A	B-protein
proteins	I-protein
,	O
we	O
report	O
comparable	O
levels	O
of	O
Pan	B-protein
proteins	I-protein
in	O
GH/PRL-	B-cell_line
and	I-cell_line
insulin-producing	I-cell_line
,	I-cell_line
B-	I-cell_line
and	I-cell_line
T-lymphocyte	I-cell_line
cells	I-cell_line
.	O

These	O
findings	O
thus	O
reveal	O
the	O
presence	O
of	O
a	O
second	O
inducible	O
autoregulated	O
inhibitory	O
pathway	O
that	O
helps	O
ensure	O
the	O
rapid	O
but	O
transient	O
action	O
of	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
.	O

We	O
have	O
identified	O
an	O
E	B-DNA
box	I-DNA
around	O
-260	B-DNA
and	O
a	O
YY1	B-DNA
binding	I-DNA
site	I-DNA
around	O
-300	B-DNA
relative	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
a	O
strong	O
increase	O
of	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
after	O
triggering	O
of	O
HLA-DR	B-protein
antigens	I-protein
.	O

Stable	O
transfectants	O
of	O
HB24	B-DNA
were	O
established	O
that	O
expressed	O
high	O
levels	O
of	O
HB24	B-RNA
mRNA	I-RNA
and	O
possessed	O
an	O
altered	O
phenotype	O
suggestive	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Alternate	O
immune	O
system	O
targets	O
for	O
TCDD	O
:	O
lymphocyte	B-cell_type
stem	I-cell_type
cells	I-cell_type
and	O
extrathymic	B-cell_type
T-cell	I-cell_type
development	O
.	O

This	O
factor	O
is	O
Oct-1	B-protein
or	O
an	O
immunologically	B-protein
related	I-protein
octamer-binding	I-protein
protein	I-protein
,	O
and	O
it	O
plays	O
a	O
role	O
in	O
coordinating	O
the	O
activity	O
of	O
several	O
regulatory	B-DNA
elements	I-DNA
.	O

Together	O
,	O
these	O
findings	O
support	O
the	O
notion	O
that	O
chromatin	B-DNA
configuration	O
as	O
well	O
as	O
the	O
interplay	O
of	O
promoter	B-DNA
elements	I-DNA
mediate	O
proper	O
hormone-dependent	O
and	O
tissue-specific	O
expression	O
of	O
the	O
B1	B-DNA
vitellogenin	I-DNA
gene	I-DNA
.	O

We	O
report	O
that	O
certain	O
NF-AT	B-protein
(	I-protein
Rel	I-protein
)	I-protein
family	I-protein
members	I-protein
productively	O
bind	O
the	O
kappaB	B-DNA
regulatory	I-DNA
elements	I-DNA
,	O
synergize	O
with	O
NF-kappaB	B-protein
and	O
Tat	B-protein
in	O
transcriptional	O
activation	O
of	O
HIV-1	O
,	O
and	O
enhance	O
HIV-1	O
replication	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

DESIGN	O
:	O
Eighteen	O
hirsute	O
patients	O
with	O
regular	O
menses	O
were	O
studied	O
basally	O
and	O
during	O
treatment	O
with	O
125	O
mg	O
flutamide	O
,	O
three	O
times	O
per	O
day	O
for	O
12	O
months	O
.	O

But	O
signal	O
transduction	O
through	O
IFN-gammaR	B-protein
on	O
eosinophils	B-cell_type
remains	O
to	O
be	O
elucidated	O
.	O

Second	O
,	O
we	O
found	O
that	O
the	O
potentiating	O
activity	O
of	O
NE	B-protein
on	O
the	O
threshold	O
of	O
cathepsin	B-protein
G	I-protein
-induced	O
platelet	O
aggregation	O
was	O
strictly	O
dependent	O
on	O
the	O
presence	O
of	O
exogenous	B-protein
fibrinogen	I-protein
.	O

By	O
comparing	O
the	O
expression	O
of	O
genes	O
controlling	O
apoptosis	O
,	O
including	O
those	O
encoding	O
several	O
members	O
of	O
the	O
BCL-2	B-protein
family	I-protein
of	O
proteins	O
,	O
the	O
known	O
relative	O
resistance	O
of	O
EBV-immortalized	B-cell_line
B-cell	I-cell_line
lines	I-cell_line
to	O
apoptosis	O
induced	O
by	O
low	O
serum	O
was	O
found	O
to	O
correlate	O
with	O
expression	O
of	O
both	O
BCL-2	B-protein
and	O
A20	B-protein
.	O

While	O
in	O
vitro	O
administration	O
of	O
glucocorticoids	O
may	O
inhibit	O
concanavalin	O
A	O
(	O
Con	O
A	O
)	O
-	O
and	O
phytohemagglutinin	O
(	O
PHA	O
)	O
-induced	O
T-cell	O
proliferation	O
,	O
pokeweed	B-protein
mitogen	I-protein
(	O
PWM	B-protein
)	O
-driven	O
B-cell	O
mitogenesis	O
is	O
relatively	O
resistant	O
to	O
glucocorticoids	O
.	O

Our	O
results	O
indicate	O
that	O
not	O
only	O
the	O
reported	O
IL-2	B-DNA
NF-AT	I-DNA
and	I-DNA
NFIL-2A	I-DNA
sites	I-DNA
and	O
Ig	O
kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
but	O
also	O
the	O
IL-8	B-protein
AP-1	B-DNA
and	O
kappa	B-DNA
B-like	I-DNA
sites	I-DNA
are	O
terminals	O
of	O
FK506-sensitive	O
pathway	O
involving	O
Ca2+	O
mobilization	O
.	O

Ad5E1A	B-protein
-specific	O
CTL	O
activity	O
could	O
no	O
longer	O
be	O
isolated	O
from	O
mice	O
after	O
injection	O
of	O
Ad5E1A-peptide	O
,	O
indicating	O
that	O
tolerization	O
of	O
Ad5E1A	B-protein
-specific	O
CTL	O
activity	O
causes	O
the	O
enhanced	O
tumor	O
outgrowth	O
.	O

The	O
induction	O
of	O
IgE	B-protein
switching	O
in	O
B	B-cell_type
cells	I-cell_type
requires	O
several	O
signals	O
given	O
by	O
cytokines	B-protein
and	O
cell	O
contact-delivered	O
signals	O
.	O

We	O
searched	O
for	O
proteins	O
that	O
interact	O
with	O
Ras	B-protein
in	O
interleukin	B-cell_line
(	I-cell_line
IL	I-cell_line
)	I-cell_line
-2-stimulated	I-cell_line
or	I-cell_line
IL-2-deprived	I-cell_line
cells	I-cell_line
,	O
and	O
found	O
that	O
the	O
transcription	B-protein
factor	I-protein
Aiolos	B-protein
interacts	O
with	O
Ras	B-protein
.	O

[	O
Glucocorticoid	B-protein
receptors	I-protein
on	O
human	B-cell_type
peripheral	I-cell_type
mononuclear	I-cell_type
and	I-cell_type
polymorphonuclear	I-cell_type
leucocytes	I-cell_type
:	O
changes	O
in	O
patients	O
with	O
yang-deficiency	O
]	O

To	O
further	O
understand	O
the	O
molecular	O
and	O
nuclear	O
basis	O
for	O
this	O
synergism	O
,	O
we	O
have	O
explored	O
the	O
induction	O
of	O
DNA-binding	B-protein
proteins	I-protein
in	O
highly	O
purified	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
signaled	O
via	O
the	O
CD3	B-protein
and/or	O
CD2	B-protein
proteins	I-protein
.	O

This	O
cell-type	O
specific	O
induction	O
by	O
PMA	O
treatment	O
was	O
further	O
investigated	O
with	O
respect	O
to	O
transcriptional	O
control	O
.	O

This	O
activation	B-protein
domain	I-protein
of	O
CIITA	B-protein
interacts	O
with	O
the	O
32	B-protein
kDa	I-protein
subunit	I-protein
of	O
the	O
general	B-protein
transcription	I-protein
complex	I-protein
TFIID	B-protein
,	O
TAFII32	B-protein
.	O

Human	O
T	O
cell	O
activation	O
through	O
the	O
activation-inducer	B-protein
molecule/CD69	I-protein
enhances	O
the	O
activity	O
of	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
.	O

In	O
the	O
cell	B-cell_line
line	I-cell_line
HT93A	I-cell_line
,	O
which	O
is	O
capable	O
of	O
differentiating	O
towards	O
both	O
the	O
eosinophil	B-cell_type
and	O
neutrophil	O
lineages	O
in	O
response	O
to	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
C/EBPalpha	B-RNA
mRNA	I-RNA
expression	O
decreased	O
significantly	O
concomitant	O
with	O
eosinophilic	O
and	O
neutrophilic	O
differentiation	O
,	O
whereas	O
C/EBPbeta	B-protein
expression	O
was	O
markedly	O
increased	O
.	O

VitD3	O
induction	O
resulted	O
in	O
the	O
formation	O
of	O
VDR/RXR	B-protein
DNA-binding	I-protein
complexes	I-protein
on	O
both	O
VitD3	B-DNA
response	I-DNA
elements	I-DNA
and	O
RA	B-DNA
response	I-DNA
elements	I-DNA
(	O
RAREs	B-DNA
)	O
.	O

This	O
potent	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
-dependent	O
activation	O
does	O
not	O
require	O
monocytes	B-cell_type
or	O
accessory	B-cell_type
cells	I-cell_type
.	O

By	O
using	O
high	O
throughput	O
screening	O
of	O
microbial	O
broths	O
,	O
we	O
have	O
identified	O
a	O
compound	O
,	O
designated	O
Ro	O
09-2210	O
,	O
which	O
is	O
able	O
to	O
block	O
anti-CD3	B-protein
induced	O
peripheral	O
blood	O
T	O
cell	O
activation	O
with	O
an	O
IC50	O
=	O
40	O
nM	O
.	O

ETS1	B-protein
,	O
NFkappaB	B-protein
and	O
AP1	B-protein
synergistically	O
transactivate	O
the	O
human	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
.	O

Peroxisomal	B-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
(	O
PPARgamma	B-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
in	O
the	O
nuclear	O
receptor	O
superfamily	O
,	O
regulates	O
gene	O
expression	O
in	O
response	O
to	O
various	O
activators	O
,	O
including	O
15-deoxy-delta12	O
,	O
14-prostaglandin	O
J2	O
and	O
the	O
antidiabetic	O
agent	O
troglitazone	O
.	O

The	O
low	O
binding	O
affinity	O
of	O
squirrel	O
monkey	O
GR	B-protein
does	O
not	O
result	O
from	O
substitutions	O
in	O
the	O
receptor	O
,	O
because	O
squirrel	B-protein
monkey	I-protein
GR	I-protein
expressed	O
in	O
vitro	O
exhibits	O
high	O
affinity	O
.	O

The	O
study	O
population	O
included	O
the	O
affected	O
patient	O
(	O
proband	O
)	O
,	O
nine	O
of	O
her	O
blood	O
relatives	O
,	O
and	O
seven	O
healthy	O
volunteers	O
.	O

Leukotriene	O
B4	O
transcriptionally	O
activates	O
interleukin-6	B-protein
expression	O
involving	O
NK-chi	B-protein
B	I-protein
and	O
NF-IL6	B-protein
.	O

BCL-6	B-RNA
mRNA	I-RNA
levels	O
began	O
to	O
decrease	O
8	O
to	O
16	O
hours	O
after	O
stimulation	O
,	O
before	O
cells	O
entered	O
S	O
phase	O
.	O

The	O
viral	O
transcriptional	O
pattern	O
similar	O
to	O
that	O
of	O
nasopharyngeal	O
carcinoma	O
and	O
Hodgkin	O
's	O
disease	O
suggests	O
that	O
EBV	O
can	O
exploit	O
common	O
regulatory	O
mechanisms	O
for	O
gene	O
transcription	O
in	O
diverse	O
host	O
cell	O
types	O
.	O

This	O
ANG	B-protein
II	I-protein
effect	O
was	O
blocked	O
by	O
the	O
angiotensin	O
AT1	O
receptor	O
antagonist	O
losartan	O
.	O

Immunoprecipitation	O
experiments	O
failed	O
to	O
demonstrate	O
an	O
association	O
between	O
nuclear	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
and	O
NF-kappaB	B-protein
proteins	O
.	O

This	O
is	O
the	O
first	O
documented	O
case	O
of	O
female	O
twins	O
discordant	O
for	O
Fabry	O
disease	O
.	O

METHOD	O
:	O
For	O
this	O
purpose	O
,	O
the	O
number	O
and	O
affinity	O
of	O
GR	B-protein
in	O
peripheral	O
mononuclear	B-cell_type
leukocytes	I-cell_type
(	O
MNL	O
)	O
of	O
10	O
patients	O
with	O
PCOS	O
and	O
10	O
healthy	O
women	O
(	O
controls	O
)	O
were	O
determined	O
.	O

Epstein-Barr	O
virus	O
EBNA3C	B-protein
represses	O
Cp	B-DNA
,	O
the	O
major	O
promoter	O
for	O
EBNA	B-protein
expression	O
,	O
but	O
has	O
no	O
effect	O
on	O
the	O
promoter	O
of	O
the	O
cell	B-DNA
gene	I-DNA
CD21	I-DNA
.	O

Effects	O
of	O
alpha-lipoic	O
acid	O
and	O
dihydrolipoic	O
acid	O
on	O
expression	O
of	O
proto-oncogene	B-DNA
c-fos	I-DNA
.	O

These	O
genes	O
encode	O
proteins	O
that	O
form	O
the	O
dimeric	B-protein
complex	I-protein
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
,	O
which	O
is	O
active	O
as	O
a	O
transcriptional	B-protein
factor	I-protein
.	O

Immunofluorescence	O
studies	O
using	O
an	O
Ab	O
to	O
the	O
RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
subunit	I-protein
of	O
nuclear	O
factor-kappa	B-protein
B	I-protein
revealed	O
that	O
iNO	O
inhibited	O
the	O
activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
.	O

In	O
addition	O
,	O
the	O
ability	O
of	O
this	O
enzyme	B-protein
to	O
hydrolyse	O
PIP2	O
,	O
also	O
in	O
the	O
presence	O
of	O
genistein	O
,	O
implies	O
the	O
possibility	O
that	O
this	O
enzyme	O
can	O
exert	O
its	O
hydrolytic	O
activity	O
independently	O
of	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activation	O
.	O

Most	O
B	B-cell_line
lymphocyte	I-cell_line
lines	I-cell_line
expressed	O
negligible	O
levels	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
and	O
protein	O
;	O
however	O
;	O
analysis	O
of	O
a	O
lymphoid/myeloid	B-cell_line
somatic	I-cell_line
hybrid	I-cell_line
suggested	O
that	O
suppression	O
of	O
expression	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
in	O
B	B-cell_type
lymphocytes	I-cell_type
may	O
be	O
a	O
dominant	O
characteristic	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
interpretation	O
that	O
stimulation	O
of	O
Bcl-2	B-protein
expression	O
is	O
not	O
the	O
primary	O
target	O
of	O
AML1/ETO	B-DNA
.	O

Pretreatment	O
of	O
NK	B-cell_type
cells	I-cell_type
with	O
the	O
antioxidant	O
pyrrolidine	O
dithiocarbarmate	O
(	O
PDTC	O
)	O
leads	O
to	O
the	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
but	O
the	O
AP-1	B-protein
binding	O
to	O
DNA	O
was	O
superinduced	O
.	O

Due	O
to	O
its	O
location	O
within	O
this	O
cluster	O
and	O
its	O
biologic	O
role	O
in	O
Ig	O
class	O
switching	O
and	O
Th2	B-cell_line
cell	I-cell_line
differentiation	O
,	O
the	O
IL-4	B-DNA
gene	I-DNA
has	O
emerged	O
as	O
one	O
major	O
candidate	O
for	O
the	O
atopy	B-DNA
gene	I-DNA
.	O

Transcription	B-protein
factors	I-protein
,	O
such	O
as	O
NF	B-protein
kappa	I-protein
B	I-protein
and	O
AP-1	B-protein
,	O
are	O
activated	O
upon	O
stimulation	O
of	O
the	O
cells	O
with	O
several	O
chemoattractants	O
at	O
physiologically	O
relevant	O
concentrations	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
specific	O
antibodies	O
,	O
we	O
showed	O
that	O
CREB-1	B-protein
binds	O
specifically	O
to	O
the	O
-79	B-DNA
to	I-DNA
-52	I-DNA
region	I-DNA
of	O
the	O
CD4	B-DNA
promoter	I-DNA
.	O

The	O
discrepancy	O
in	O
the	O
degree	O
of	O
inhibition	O
by	O
membrane	O
extracts	O
and	O
NK	B-cell_type
cells	I-cell_type
with	O
mutant	B-protein
TNFRI	I-protein
suggests	O
that	O
additional	O
pathways	O
are	O
utilized	O
by	O
NK	B-cell_type
cells	I-cell_type
to	O
activate	O
EC	B-cell_type

Mutational	O
analysis	O
showed	O
that	O
optimal	O
transcriptional	O
activity	O
required	O
the	O
GATA	B-DNA
sequence	I-DNA
at	O
position	O
-24	B-DNA
,	O
and	O
gel-shift	O
assays	O
further	O
showed	O
that	O
the	O
GATA-2	B-protein
transcription	I-protein
factor	I-protein
,	O
but	O
not	O
GATA-1	B-protein
,	O
bound	O
to	O
this	O
region	O
of	O
the	O
PECAM-1	B-DNA
promoter	I-DNA
.	O

To	O
overcome	O
this	O
problem	O
,	O
we	O
have	O
exploited	O
the	O
observation	O
that	O
activated	O
human	B-cell_type
T	I-cell_type
cell	I-cell_type
blasts	I-cell_type
can	O
be	O
stimulated	O
via	O
the	O
CD28	B-protein
surface	I-protein
molecule	I-protein
in	O
the	O
absence	O
of	O
antigenic	O
challenge	O
;	O
thus	O
,	O
we	O
have	O
been	O
able	O
to	O
observe	O
the	O
response	O
of	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
CD28	B-protein
activation	O
in	O
isolation	O
.	O

These	O
data	O
support	O
the	O
positive	O
role	O
for	O
PGE2	O
on	O
some	O
immune	O
functions	O
.	O

Although	O
the	O
mechanism	O
of	O
HIV-1	O
activation	O
with	O
heat	O
shock	O
has	O
not	O
been	O
fully	O
elucidated	O
yet	O
,	O
it	O
is	O
presumed	O
PKC	B-protein
plays	O
an	O
important	O
role	O
in	O
HIV-1	O
activation	O
.	O

We	O
report	O
the	O
identification	O
of	O
a	O
T	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
,	O
TCF-1	B-protein
,	O
binding	O
to	O
this	O
element	O
.	O

Cystic	O
fibrosis	O
(	O
CF	O
)	O
patients	O
develop	O
progressive	O
cytokine	B-protein
-mediated	O
inflammatory	O
lung	O
disease	O
,	O
with	O
abundant	O
production	O
of	O
thick	O
,	O
tenacious	O
,	O
protease	B-protein
-and	O
oxidant-rich	O
purulent	O
airway	O
secretions	O
that	O
are	O
difficult	O
to	O
clear	O
even	O
with	O
physiotherapy	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
signaling	O
through	O
the	O
TNF	B-protein
receptor	O
family	O
member	O
,	O
the	O
lymphotoxin-beta	B-protein
(	I-protein
LT-beta	I-protein
)	I-protein
receptor	I-protein
(	O
LT-betaR	B-protein
)	O
,	O
also	O
regulates	O
HIV-1	O
replication	O
.	O

Tyrosine	O
phosphorylation	O
STAT1	B-protein
or	O
STAT3	B-protein
was	O
not	O
detected	O
in	O
human	B-cell_type
erythroid	I-cell_type
precursors	I-cell_type
after	O
stimulation	O
with	O
erythropoietin	B-protein
.	O

Constitutive	O
phosphorylation	O
of	O
Jak	B-protein
kinases	I-protein
may	O
facilitate	O
tumor	O
growth	O
in	O
both	O
HTLV-1	B-cell_type
infected	I-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
the	O
transgenic	O
mouse	O
model	O
.	O

Induction	O
of	O
activator	B-protein
protein	I-protein
(	I-protein
AP	I-protein
)	I-protein
-1	I-protein
and	O
nuclear	B-protein
factor-kappaB	I-protein
by	O
CD28	B-protein
stimulation	O
involves	O
both	O
phosphatidylinositol	B-protein
3-kinase	I-protein
and	O
acidic	B-protein
sphingomyelinase	I-protein
signals	O
.	O

The	O
major	O
transcription	O
factor	O
that	O
bound	O
to	O
the	O
oligonucleotide	O
was	O
confirmed	O
to	O
be	O
GABP	B-protein
by	O
supershift	O
and	O
competition	O
analysis	O
.	O

I	B-protein
kappa	I-protein
B	I-protein
proteins	I-protein
inhibit	O
DNA	O
binding	O
and	O
prevent	O
nuclear	O
uptake	O
of	O
NF-kappa	B-protein
B	I-protein
complexes	I-protein
.	O

The	O
active	O
compounds	O
did	O
not	O
inhibit	O
IL-1	B-protein
-induced	O
production	O
of	O
IL-6	B-protein
in	O
fibroblasts	B-cell_type
,	O
showing	O
the	O
cell	O
selectivity	O
of	O
the	O
effect	O
.	O

Cell	O
cycle	O
analysis	O
showed	O
shifts	O
in	O
the	O
distribution	O
of	O
cells	O
from	O
G1	O
to	O
S	O
phase	O
,	O
which	O
were	O
more	O
pronounced	O
after	O
cadmium	O
treatment	O
.	O

In	O
directing	O
the	O
synthesis	O
of	O
RNA	B-RNA
through	O
the	O
intervening	O
DNA	B-DNA
and	O
the	O
gene	O
by	O
a	O
tracking	O
and	O
transcription	O
mechanism	O
,	O
the	O
HS2	B-DNA
enhancer	I-DNA
may	O
(	O
i	O
)	O
open	O
up	O
the	O
chromatin	B-DNA
structure	I-DNA
of	O
a	O
gene	B-DNA
domain	I-DNA
and	O
(	O
ii	O
)	O
deliver	O
enhancer	B-protein
binding	I-protein
proteins	I-protein
to	O
the	O
promoter	O
sequence	O
where	O
they	O
may	O
stimulate	O
the	O
transcription	O
of	O
the	O
gene	O
at	O
the	O
cap	B-DNA
site	I-DNA
.	O

We	O
demonstrate	O
that	O
,	O
in	O
normal	O
human	O
T	B-cell_type
cells	I-cell_type
,	O
an	O
AP-1	B-protein
protein	I-protein
is	O
a	O
component	O
of	O
the	O
NF-AT	B-protein
protein	I-protein
complex	I-protein
.	O

Here	O
,	O
we	O
show	O
that	O
loss	O
of	O
GATA-3	B-protein
expression	O
by	O
developing	O
Th1	B-cell_type
cells	I-cell_type
requires	O
IL-12	B-protein
signaling	O
through	O
Stat4	B-protein
and	O
does	O
not	O
simply	O
result	O
from	O
an	O
absence	O
of	O
IL-4	B-protein
.	O

Alternatively	O
,	O
these	O
data	O
support	O
the	O
notion	O
that	O
neither	O
AP-1	B-protein
nor	O
the	O
c-myc	B-protein
protein	I-protein
are	O
involved	O
in	O
the	O
MDHM-induced	O
increase	O
in	O
IL-1	O
beta	O
,	O
IL-6	O
or	O
TNF	O
alpha	O
mRNA	O
levels	O
.	O

IgE	B-protein
synthesis	O
was	O
even	O
more	O
markedly	O
inhibited	O
by	O
RA	O
starting	O
at	O
concentrations	O
of	O
>	O
10	O
(	O
-14	O
)	O
mol/L	O
for	O
B	B-cell_type
cells	I-cell_type
and	O
>	O
10	O
(	O
-10	O
)	O
mol/L	O
for	O
PBMC	B-cell_type
.	O

CIITA	B-protein
is	O
a	O
positive	O
regulator	O
of	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
gene	I-DNA
transcription	O
that	O
has	O
been	O
found	O
to	O
be	O
defective	O
in	O
one	O
of	O
the	O
five	O
complementation	O
groups	O
of	O
class	B-cell_line
II	I-cell_line
major	I-cell_line
histocompatibility	I-cell_line
complex-negative	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

T-cell	O
activation	O
also	O
correlates	O
with	O
the	O
induction	O
of	O
the	O
factor	O
NF-kappa	B-protein
B	I-protein
which	O
binds	O
to	O
two	O
adjacent	O
sites	O
in	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O

We	O
previously	O
reported	O
that	O
the	O
role	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
in	O
NF-kappaB	B-protein
activation	O
by	O
proinflammatory	B-protein
cytokines	I-protein
was	O
cell	O
specific	O
.	O

Two	O
classes	O
of	O
LTR	O
size	O
variants	O
were	O
found	O
.	O

These	O
results	O
reveal	O
a	O
novel	O
activating	O
region	O
in	O
the	O
LMP1	B-protein
C-terminus	B-protein
and	O
identify	O
the	O
JAK	B-protein
/STAT	B-protein
pathway	O
as	O
a	O
target	O
of	O
this	O
viral	B-protein
integral	I-protein
membrane	I-protein
protein	I-protein
in	O
B	B-cell_type
cells	I-cell_type
.	O

YM268	O
facilitated	O
the	O
insulin-stimulated	O
triglyceride	O
accumulation	O
in	O
3T3-L1	B-cell_type
adipocytes	I-cell_type
and	O
increased	O
the	O
mRNA	O
expression	O
of	O
fatty	B-protein
acid-binding	I-protein
protein	I-protein
.	O

One	O
of	O
these	O
enhancers	B-DNA
is	O
,	O
in	O
part	O
,	O
identical	O
to	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
.	O

The	O
modulation	O
by	O
anti-LPS	B-protein
mAbs	I-protein
of	O
mCD14	B-protein
-mediated	O
LPS	O
uptake	O
was	O
associated	O
with	O
inhibition	O
of	O
LPS-induced	B-protein
nuclear	I-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
translocation	O
and	O
TNF-alpha	B-protein
secretion	O
in	O
CHO-CD14	B-cell_line
cells	I-cell_line
and	O
monocytes	O
,	O
respectively	O
,	O
while	O
mAb	O
enhancement	O
of	O
non-	O
mCD14	B-protein
-mediated	O
LPS	O
uptake	O
stimulated	O
these	O
activities	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
showed	O
that	O
each	O
of	O
the	O
cis-elements	B-DNA
bound	O
specific	O
protein	B-protein
factors	I-protein
.	O

Biosynthesis	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
is	O
predominantly	O
by	O
cells	O
of	O
the	O
monocytic	B-cell_type
lineage	I-cell_type
.	O

Through	O
this	O
mechanism	O
of	O
gene	O
regulation	O
,	O
YY1	B-protein
and	O
LSF	B-protein
could	O
contribute	O
to	O
the	O
establishment	O
and	O
maintenance	O
of	O
a	O
population	O
of	O
cells	O
stably	O
but	O
nonproductively	O
infected	O
with	O
HIV-1	O
.	O

The	O
production	O
of	O
both	O
cytokines	B-protein
,	O
measured	O
by	O
ELISA	O
tests	O
,	O
was	O
enhanced	O
in	O
monocytes	B-cell_type
.	O

Mononuclear	B-cell_type
leukocytes	I-cell_type
binding	O
to	O
glucocorticoid	O
correlated	O
significantly	O
with	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
binding	O
to	O
glucocorticoid	O
,	O
but	O
both	O
determinations	O
failed	O
to	O
differentiate	O
major	O
depressive	O
disorder	O
and	O
control	O
subjects	O
.	O

In	O
fact	O
,	O
NF-YA	B-RNA
mRNA	I-RNA
is	O
present	O
at	O
the	O
same	O
level	O
at	O
all	O
days	O
of	O
monocyte	O
cultivation	O
,	O
whereas	O
the	O
protein	O
is	O
absent	O
in	O
freshly	B-cell_type
isolated	I-cell_type
monocytes	I-cell_type
but	O
is	O
progressively	O
synthesized	O
during	O
the	O
maturation	O
process	O
.	O

Primary	O
(	O
partial	O
)	O
cortisol	B-protein
receptor	I-protein
resistance	O
was	O
previously	O
reported	O
in	O
a	O
total	O
of	O
7	O
patients	O
and	O
14	O
asymptomatic	O
family	O
members	O
.	O

Copyright	O
1997	O
Academic	O
Press	O
.	O

Therefore	O
,	O
we	O
investigated	O
whether	O
IVS1-10T	O
--	O
>	O
C	O
deleteriously	O
affected	O
BRCA1	B-DNA
splicing	O
or	O
expression	O
,	O
and	O
thereby	O
inactivated	O
the	O
other	O
BRCA1	B-DNA
allele	I-DNA
.	O

By	O
transfecting	O
tumor	O
cells	O
with	O
both	O
IL-12	B-DNA
and	I-DNA
B7.1	I-DNA
cDNAs	I-DNA
,	O
it	O
may	O
be	O
possible	O
to	O
use	O
these	O
modified	O
targets	O
as	O
vaccines	O
.	O

We	O
found	O
that	O
a	O
single	O
Ala	O
--	O
>	O
Asp	O
amino	O
acid	O
57	O
substitution	O
in	O
an	O
HLA-DQ3.2	O
molecule	O
regulated	O
binding	O
of	O
an	O
HSV-2	O
VP-16-derived	O
peptide	O
.	O

In	O
the	O
absence	O
of	O
a	O
cloned	O
MIBP1	B-DNA
gene	I-DNA
for	O
further	O
studies	O
,	O
we	O
hypothesize	O
that	O
RFX1	B-protein
acts	O
with	O
MIBP1	B-protein
to	O
negatively	O
regulate	O
the	O
core	O
promoter	O
activity	O
through	O
the	O
NRE	B-DNA
gamma	I-DNA
site	I-DNA
.	O

Cell	O
morphology	O
remained	O
essentially	O
the	O
same	O
in	O
serum-free	O
or	O
serum	O
containing	O
media	O
.	O

The	O
present	O
review	O
summarizes	O
these	O
findings	O
,	O
with	O
a	O
special	O
focus	O
on	O
our	O
own	O
studies	O
on	O
pluripotent	B-cell_line
endocrine	I-cell_line
cultures	I-cell_line
of	O
rat	O
pancreas	O
.	O

The	O
addition	O
of	O
mifepristone	O
or	O
caspase-3	O
inhibitor	O
could	O
partially	O
abrogate	O
GC-induced	O
apoptosis	O
as	O
well	O
as	O
GC-induced	O
inhibition	O
of	O
IL-1beta	B-protein
.	O

The	O
P	B-DNA
sequence	I-DNA
does	O
not	O
share	O
homology	O
with	O
the	O
5	B-DNA
'	I-DNA
upstream	I-DNA
sequence	I-DNA
of	O
the	O
IL-2	B-DNA
gene	I-DNA
,	O
even	O
though	O
surrounding	O
sequences	O
of	O
the	O
IL-4	B-DNA
gene	I-DNA
share	O
high	O
homology	O
with	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O

Coincidentally	O
,	O
a	O
deletion	O
of	O
this	O
region	O
enhanced	O
the	O
IL-2	B-protein
-induced	O
expression	O
of	O
beta-casein	B-protein
.	O

In	O
addition	O
,	O
stimulation	O
with	O
MBP	B-protein
prolonged	O
the	O
stability	O
of	O
IL-8	B-RNA
mRNA	I-RNA
.	O

In	O
neutrophils	O
undergoing	O
the	O
phagocytosis	O
of	O
opsonized	O
yeasts	O
,	O
the	O
onset	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
was	O
paralleled	O
by	O
a	O
decline	O
in	O
immunoreactive	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
protein	O
levels	O
,	O
and	O
the	O
cellular	O
I	B-protein
kappa	I-protein
B	I-protein
-alpha	O
pool	O
was	O
replenished	O
by	O
30	O
min	O
,	O
in	O
agreement	O
with	O
our	O
gel	O
shift	O
data	O
.	O

Overall	O
therefore	O
,	O
exposure	O
to	O
NSAIDs	O
leads	O
to	O
a	O
profound	O
switch	O
in	O
gene	O
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
,	O
with	O
suppression	O
of	O
genes	O
involved	O
in	O
macrophage	O
activation	O
and	O
induction	O
of	O
stress	B-DNA
genes	I-DNA
and	O
HSF1	B-protein
appears	O
to	O
play	O
a	O
regulatory	O
role	O
in	O
these	O
effects	O
.	O

These	O
findings	O
show	O
that	O
IL-13	B-protein
and	O
IL-4	B-protein
have	O
the	O
ability	O
to	O
regulate	O
NK	O
and	O
T	O
cell	O
activation	O
and	O
that	O
IL-13	B-protein
is	O
a	O
potent	O
regulator	O
of	O
STAT6	B-protein
and	O
JAK3	B-protein
in	O
these	O
cell	O
types	O
.	O

The	O
B3	B-protein
factor	I-protein
is	O
detected	O
in	O
the	O
cytosol	O
only	O
when	O
cells	O
are	O
HIV1-infected	O
.	O

Problems	O
of	O
antihypertensive	O
therapy	O
are	O
discussed	O
and	O
the	O
first	O
results	O
of	O
a	O
pilot	O
study	O
with	O
Urapidil	O
are	O
presented	O
.	O

We	O
evaluated	O
the	O
ability	O
of	O
eosinophil	B-protein
granule	I-protein
major	I-protein
basic	I-protein
protein	I-protein
(	O
MBP	B-protein
)	O
to	O
stimulate	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-8	I-protein
production	O
by	O
neutrophils	B-cell_type
.	O

Using	O
varying	O
conditions	O
,	O
three	O
distinct	O
complexes	O
were	O
shown	O
to	O
interact	O
specifically	O
with	O
the	O
NIP	B-DNA
region	I-DNA
,	O
although	O
only	O
one	O
correlates	O
with	O
repressor	O
activity	O
.	O

AML1a	B-protein
expression	O
was	O
associated	O
with	O
enhanced	O
sensitivity	O
to	O
megakaryocytic	O
differentiation	O
induced	O
by	O
phorbol	O
ester	O
.	O

In	O
selenium-deprived	B-cell_line
Jurkat	I-cell_line
and	O
ESb-L	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
,	O
supplementation	O
of	O
selenium	O
led	O
to	O
a	O
substantial	O
increase	O
of	O
GPX	B-protein
activity	O
.	O

Studies	O
of	O
the	O
mechanisms	O
that	O
enable	O
EBV	O
to	O
infect	O
nonactivated	O
,	O
noncycling	B-cell_type
B	I-cell_type
cells	I-cell_type
provide	O
compelling	O
evidence	O
for	O
a	O
sequence	O
of	O
events	O
in	O
which	O
EBV	O
binding	O
to	O
CD21	B-protein
on	O
purified	O
resting	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
rapidly	O
activates	O
the	O
NF-kappaB	B-protein
transcription	B-protein
factor	I-protein
,	O
which	O
,	O
in	O
turn	O
,	O
binds	O
to	O
and	O
mediates	O
transcriptional	O
activation	O
of	O
Wp	O
,	O
the	O
initial	O
viral	B-DNA
latent	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

In	O
T	B-cell_type
cells	I-cell_type
and	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
NF-kB	B-protein
is	O
bound	O
to	O
a	O
cytoplasmic	B-protein
proteic	I-protein
inhibitor	I-protein
,	O
the	O
IkB	B-protein
.	O

Mice	O
treated	O
with	O
antisense	O
to	O
NF-kappa	B-protein
B	I-protein
ODNs	O
showed	O
rapid	O
regression	O
of	O
transplanted	O
fibrosarcomas	O
.	O

Together	O
,	O
these	O
data	O
indicate	O
that	O
NF-kappaB	B-protein
activation	O
,	O
required	O
for	O
a	O
high	O
level	O
of	O
HIV	O
replication	O
in	O
thymocytes	B-cell_type
,	O
is	O
regulated	O
in	O
a	O
specific	O
manner	O
in	O
the	O
thymic	O
microenvironment	O
which	O
provides	O
the	O
necessary	O
cytokines	O
:	O
TNF	B-protein
,	O
IL-1	B-protein
,	O
and	O
IL-7	B-protein
.	O

TNF-alpha	B-RNA
mRNA	I-RNA
and	O
release	O
was	O
inhibited	O
even	O
if	O
IL-10	B-protein
was	O
added	O
up	O
to	O
8	O
h	O
after	O
cryptococcal	O
stimulation	O
.	O

CONCLUSIONS	O
:	O
Human	O
NK	O
cell	O
membrane-bound	O
LT	O
signals	O
across	O
species	O
via	O
TNFRI	B-protein
,	O
leading	O
to	O
NF-kappaB	B-protein
nuclear	O
translocation	O
and	O
transcription	O
of	O
E-selectin	B-protein
and	O
IL-8	B-protein
,	O
which	O
results	O
in	O
EC	B-cell_type
activation	O
.	O

We	O
have	O
hypothesized	O
that	O
such	O
defects	O
in	O
fetal/neonatal	O
T-cell	O
activation	O
may	O
be	O
due	O
to	O
lack	O
of	O
expression	O
of	O
the	O
transcriptional	B-protein
regulatory	I-protein
elements	I-protein
required	O
for	O
T-cell	O
activation	O
.	O

However	O
,	O
this	O
factor	O
appeared	O
when	O
the	O
CML	O
patients	O
achieved	O
complete	O
haematological	O
remission	O
(	O
CHR	O
)	O
through	O
alpha-interferon	B-protein
therapy	O
.	O

One	O
problem	O
in	O
using	O
these	O
clonality	O
analysis	O
methods	O
,	O
however	O
,	O
is	O
that	O
there	O
may	O
be	O
significant	O
variation	O
in	O
Lyonization	O
in	O
blood	B-cell_type
cells	I-cell_type
in	O
normal	O
individuals	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
decidualization	O
at	O
eutopic	O
and	O
ectopic	O
implantation	O
sites	O
.	O

Following	O
integration	O
into	O
the	O
host	O
cell	O
genome	O
,	O
HTLV-I	O
replication	O
is	O
regulated	O
by	O
both	O
host	O
and	O
viral	O
mechanisms	O
that	O
control	O
transcription	O
.	O

Previously	O
,	O
the	O
action	O
of	O
MC903	O
and	O
KH1060	O
was	O
presumed	O
to	O
be	O
mediated	O
by	O
the	O
nuclear	B-protein
vitamin	I-protein
D	I-protein
receptor	I-protein
(	O
VDRnuc	B-protein
)	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
is	O
an	O
etiologic	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

Agonistic	O
activity	O
of	O
a	O
CD40-specific	B-protein
single-chain	I-protein
Fv	I-protein
constructed	O
from	O
the	O
variable	B-protein
regions	I-protein
of	O
mAb	B-protein
G28-5	I-protein
.	O

Here	O
it	O
is	O
shown	O
that	O
the	O
HIV-1	O
viral	O
particle	O
contains	O
multiple	O
copies	O
of	O
the	O
vpr	B-protein
protein	I-protein
.	O

U937	B-cell_line
cells	I-cell_line
and	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
were	O
exposed	O
to	O
TS	O
,	O
binding	O
activities	O
of	O
the	O
respective	O
transcription	B-protein
factors	I-protein
were	O
analyzed	O
,	O
and	O
Hsp70	B-protein
expression	O
and	O
TNFalpha	B-protein
release	O
were	O
determined	O
in	O
parallel	O
.	O

To	O
further	O
elucidate	O
the	O
role	O
of	O
this	O
variant	O
octamer	B-DNA
motif	I-DNA
in	O
the	O
regulation	O
of	O
germline	B-DNA
transcription	O
from	O
the	O
unrearranged	O
kappa	B-DNA
locus	I-DNA
,	O
we	O
have	O
quantitated	O
the	O
relative	O
binding	O
affinity	O
of	O
Oct-1	B-protein
and	O
Oct-2	B-protein
for	O
the	O
variant	O
octamer	B-DNA
motif	I-DNA
and	O
determined	O
the	O
functional	O
role	O
of	O
this	O
octamer	B-DNA
motif	I-DNA
in	O
transcriptional	O
activation	O
.	O

Transcriptional	O
analysis	O
of	O
Epstein-Barr	O
virus	O
gene	O
expression	O
in	O
EBV-positive	O
gastric	O
carcinoma	O
:	O
unique	O
viral	O
latency	O
in	O
the	O
tumour	B-cell_type
cells	I-cell_type
.	O

These	O
results	O
indicate	O
that	O
histamine	O
activates	O
several	O
mechanisms	O
involved	O
in	O
the	O
induction	O
of	O
differentiation	O
,	O
such	O
as	O
cAMP	O
and	O
c-fos	B-DNA
production	O
,	O
but	O
fails	O
to	O
promote	O
differentiation	O
of	O
U937	B-cell_line
cells	I-cell_line
,	O
apparently	O
due	O
to	O
the	O
rapid	O
desensitization	O
of	O
H2	B-protein
receptors	I-protein
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
AMI	O
,	O
leukocyte-platelet	O
adhesion	O
is	O
increased	O
.	O

The	O
oestrogen	B-protein
receptor	I-protein
codon	B-DNA
10	I-DNA
polymorphism	O
detected	O
in	O
breast	O
cancer	O
is	O
also	O
present	O
in	O
non-malignant	B-cell_type
cells	I-cell_type
.	O

The	O
two	O
lines	O
also	O
expressed	O
comparable	O
levels	O
of	O
Epo-R	B-RNA
mRNA	I-RNA
while	O
the	O
number	O
of	O
Epo	B-protein
-binding	O
sites	O
on	O
UT-7	B-cell_line
Epo	I-cell_line
cells	I-cell_line
was	O
one-sixth	O
the	O
number	O
of	O
UT-7	B-cell_line
cells	I-cell_line
(	O
2400	O
+/-	O
3	O
vs.	O
13	O
,	O
800	O
+/-	O
300	O
)	O
.	O

Both	O
HIV-2	O
and	O
CMV	B-DNA
transactivators	I-DNA
enhance	O
HIV-2	O
gene	O
expression	O
by	O
transcriptional	O
activation	O
involving	O
transcript	O
initiation	O
as	O
well	O
as	O
elongation	O
,	O
with	O
CMV	B-DNA
transactivator	I-DNA
affecting	O
elongation	O
more	O
than	O
the	O
initiation	O
.	O

This	O
effect	O
is	O
largely	O
independent	O
of	O
the	O
CD2	O
:	O
lymphocyte	O
function-associated	O
Ag-3	O
pathway	O
.	O

Enzymatic	O
assay	O
of	O
alpha-galactosidase	B-protein
in	O
blood	B-cell_type
leucocytes	I-cell_type
,	O
skin	B-cell_type
fibroblasts	I-cell_type
,	O
Epstein-Barr	B-cell_line
virus	I-cell_line
transformed	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
hair	O
follicles	O
of	O
the	O
twins	O
and	O
their	O
parents	O
confirmed	O
the	O
heterozygous	O
status	O
of	O
the	O
twins	O
and	O
indicated	O
that	O
Fabry	O
disease	O
had	O
occurred	O
as	O
a	O
result	O
of	O
a	O
de	O
novo	O
mutation	O
.	O

Phosphoamino	O
acid	O
analysis	O
revealed	O
several	O
sets	O
of	O
proteins	O
with	O
different	O
phosphorylated	O
residues	O
Kinetic	O
analysis	O
of	O
the	O
phosphorylation	O
of	O
the	O
selected	O
proteins	O
was	O
performed	O
and	O
revealed	O
a	O
complex	O
group	O
of	O
transient	O
and	O
sustained	O
responses	O
to	O
cell	O
activation	O
.	O

Moreover	O
,	O
we	O
have	O
noticed	O
that	O
cysteine-containing	B-protein
T-cell	I-protein
determinants	I-protein
in	O
a	O
number	O
of	O
protein	B-protein
Ag	I-protein
are	O
particularly	O
rich	O
in	O
the	O
amino	O
acids	O
alanine	O
,	O
glycine	O
,	O
lysine	O
,	O
leucine	O
,	O
serine	O
,	O
threonine	O
,	O
and	O
valine	O
.	O

NF-AT	B-protein
does	O
not	O
directly	O
bind	O
to	O
this	O
element	O
.	O

Throughout	O
the	O
study	O
period	O
,	O
CD41	O
immunofluorescence	O
of	O
leukocytes	B-cell_type
(	O
flow	O
cytometry	O
)	O
revealed	O
increased	O
leukocyte-platelet	O
adhesion	O
in	O
patients	O
with	O
AMI	O
compared	O
with	O
control	O
patients	O
(	O
mean	O
+/-	O
SE	O
of	O
fluorescence	O
[	O
channels	O
]	O
before	O
PTCA	O
:	O
77	O
+/-	O
16	O
versus	O
35	O
+/-	O
9	O
;	O
P	O
=	O
.003	O
)	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
analyze	O
and	O
concilliate	O
the	O
reported	O
data	O
on	O
the	O
mechanism	O
of	O
action	O
of	O
estrogens	O
.	O

Following	O
PHA	B-protein
stimulation	O
of	O
PBL	B-cell_type
,	O
the	O
increase	O
in	O
AP-1	B-protein
activity	O
was	O
delayed	O
with	O
respect	O
to	O
the	O
augmentation	O
of	O
p39c-jun	B-protein
expression	O
.	O

Activation	O
of	O
the	O
human	B-DNA
delta-globin	I-DNA
gene	I-DNA
promoter	I-DNA
in	O
primary	B-cell_type
adult	I-cell_type
erythroid	I-cell_type
cells	I-cell_type
.	O

Hence	O
,	O
we	O
have	O
investigated	O
whether	O
Stat	B-protein
proteins	I-protein
are	O
present	O
in	O
platelets	B-cell_type
and	O
,	O
if	O
so	O
,	O
whether	O
they	O
become	O
tyrosine	O
phosphorylated	O
in	O
response	O
to	O
thrombopoietin	B-protein
.	O

Dysregulation	O
of	O
monocytic	B-protein
nuclear	I-protein
factor-kappa	I-protein
B	I-protein
by	O
oxidized	O
low-density	B-protein
lipoprotein	I-protein
.	O

Transactivation	O
by	O
CIITA	B-protein
was	O
extremely	O
sensitive	O
to	O
a	O
mutation	O
in	O
TBP	B-protein
that	O
in	O
yeast	O
is	O
known	O
to	O
abolish	O
VP16	B-protein
-mediated	O
transcription	O
but	O
leaves	O
basal	O
transcription	O
unaffected	O
.	O

The	O
N	B-DNA
element	I-DNA
could	O
independently	O
mediate	O
low	O
levels	O
of	O
transcription	O
in	O
both	O
B-cell	O
and	O
HeLa-cell	O
extracts	O
,	O
and	O
,	O
in	O
conjunction	O
with	O
the	O
octamer	B-DNA
element	I-DNA
,	O
it	O
can	O
promote	O
high	O
levels	O
of	O
transcription	O
in	O
B-cell	O
extracts	O
.	O

Other	O
experimental	O
strategies	O
have	O
implicated	O
BSAP	B-protein
in	O
the	O
control	O
of	O
cell	O
proliferation	O
,	O
isotype	O
switching	O
and	O
transcription	O
of	O
the	O
immunoglobulin	B-protein
heavy-chain	I-protein
gene	O
at	O
late	O
stages	O
of	O
B-cell	O
differentiation	O
.	O

Transient	O
stimulation	O
of	O
quiescent	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
with	O
either	O
a	O
cocktail	O
of	O
anti-CD40	B-protein
,	O
anti-IgM	B-protein
,	O
and	O
IL4	B-protein
,	O
or	O
EBV	O
results	O
in	O
the	O
rapid	O
expression	O
of	O
the	O
same	O
four	O
genes	O
,	O
suggesting	O
that	O
,	O
after	O
infection	O
,	O
EBV	O
exploits	O
the	O
normal	O
program	O
of	O
B-lymphocyte	B-cell_type
cell	O
cycle	O
activation	O
.	O

Ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
STATs	B-protein
promotes	O
their	O
homodimer	O
and	O
heterodimer	O
formation	O
and	O
subsequent	O
nuclear	O
translocation	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
classical	B-protein
AR	I-protein
present	O
in	O
splenic	B-cell_type
T	I-cell_type
cells	I-cell_type
are	O
not	O
active	O
in	O
the	O
genomic	O
pathway	O
.	O

Inhibitory	O
effect	O
of	O
E3330	O
,	O
a	O
novel	O
quinone	O
derivative	O
able	O
to	O
suppress	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
generation	O
,	O
on	O
activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
.	O

Treatment	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
mAb	B-protein
J393	I-protein
induced	O
tyrosine	O
phosphorylation	O
of	O
specific	O
protein	B-protein
substrates	I-protein
that	O
underwent	O
hyperphosphorylation	O
upon	O
antigen	B-protein
receptor	I-protein
costimulation	O
.	O

However	O
,	O
the	O
signaling	O
requirements	O
and	O
sensitivity	O
to	O
protein	O
synthesis	O
inhibitors	O
differ	O
considerably	O
.	O

Moreover	O
,	O
the	O
elevated	O
level	O
of	O
ER	B-protein
content	O
was	O
found	O
to	O
be	O
related	O
to	O
the	O
positive	O
antidsDNA	B-protein
antibody	I-protein
and	O
hypocomplementemia	O
.	O

Thus	O
,	O
the	O
glucocorticoid-induced	O
membrane	O
perturbation	O
,	O
the	O
possibility	O
to	O
inhibit	O
it	O
by	O
RU	O
486	O
,	O
and	O
the	O
inactivity	O
of	O
the	O
structurally	O
related	O
progesterone	O
,	O
refer	O
to	O
relatively	O
specific	O
binding	B-DNA
sites	I-DNA
for	O
the	O
glucocorticoids	O
in	O
the	O
membrane	O
of	O
erythrocyte	B-cell_type
ghosts	I-cell_type
.	O

The	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factor	I-protein
Egr-1	B-protein
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
along	O
the	O
macrophage	B-cell_type
lineage	I-cell_type
.	O

Different	O
cocktails	O
of	O
the	O
identified	O
ligands	O
were	O
added	O
to	O
sorted	B-cell_line
CD34+Thy-1+	I-cell_line
single	I-cell_line
cells	I-cell_line
.	O

Defining	O
therapeutic	O
targets	O
by	O
using	O
adenovirus	O
:	O
blocking	O
NF-kappaB	B-protein
inhibits	O
both	O
inflammatory	O
and	O
destructive	O
mechanisms	O
in	O
rheumatoid	O
synovium	O
but	O
spares	O
anti-inflammatory	B-protein
mediators	I-protein
.	O

Gel	O
electrophoretic	O
mobility	O
shift	O
assay	O
detected	O
an	O
induced	O
DNA-binding	O
activity	O
in	O
these	O
cells	O
in	O
response	O
to	O
LPS	O
.	O

Cdk2-dependent	O
phosphorylation	O
therefore	O
provides	O
a	O
switch	O
during	O
late	O
G1-to-S	O
phase	O
that	O
both	O
nullifies	O
an	O
early	O
G1	O
cell	O
cycle	O
regulatory	O
function	O
of	O
Id3	B-protein
and	O
modulates	O
its	O
target	O
bHLH	B-protein
specificity	O
.	O

We	O
now	O
demonstrate	O
that	O
nuclear	O
expression	O
of	O
human	O
c-Rel	B-protein
,	O
which	O
is	O
induced	O
by	O
either	O
phorbol	O
ester	O
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
with	O
delayed	O
kinetics	O
relative	O
to	O
p65	B-protein
,	O
markedly	O
represses	O
p65	B-protein
-mediated	O
activation	O
of	O
these	O
transcription	O
units	O
.	O

In	O
co-transfection	O
experiments	O
,	O
the	O
galectin-3	B-DNA
promoter	I-DNA
was	O
significantly	O
up-regulated	O
by	O
expression	B-DNA
vectors	I-DNA
encoding	O
the	O
40-kd	B-protein
Tax	I-protein
protein	I-protein
,	O
a	O
potent	O
transactivator	O
in	O
HTLV-I	O
.	O

Although	O
okadaic	O
acid	O
provides	O
a	O
potent	O
inductive	O
signal	O
for	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
it	O
did	O
not	O
induce	O
either	O
B	O
cell	O
proliferation	O
or	O
immunoglobulin	B-protein
secretion	O
.	O

A	O
cell	B-cell_line
culture	I-cell_line
system	I-cell_line
was	O
then	O
employed	O
that	O
permitted	O
the	O
differentiation	O
of	O
Th	B-protein
effectors	I-protein
from	O
resting	B-cell_type
memory	I-cell_type
T	I-cell_type
cells	I-cell_type
by	O
short	O
term	O
priming	O
.	O

Treatment	O
of	O
10	O
with	O
warm	O
HCl	O
furnished	O
19-chloro-4	O
,	O
21-dihydroxypregna-4	O
,	O
9	O
(	O
11	O
)	O
-diene-3	O
,	O
20-dione	O
(	O
13	O
)	O
.	O

Using	O
in	O
vitro	O
footprinting	O
and	O
gel	O
shift	O
assays	O
,	O
we	O
have	O
identified	O
four	O
distinct	O
binding	B-DNA
sites	I-DNA
for	O
nuclear	B-protein
proteins	I-protein
within	O
this	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
.	O

Like	O
other	O
enhancers	B-DNA
,	O
the	O
Ig	B-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
contains	O
several	O
short	O
sequence	B-DNA
motifs	I-DNA
that	O
bind	O
specific	B-protein
transcription	I-protein
factors	I-protein
.	O

IRF-2	B-DNA
gene	I-DNA
was	O
apparently	O
only	O
weakly	O
responsive	O
to	O
IFNs	B-protein
in	O
these	O
cells	O
.	O

Moreover	O
,	O
we	O
observed	O
constitutive	O
association	O
of	O
STAT3	B-protein
with	O
each	O
STAT5	B-protein
isomer	I-protein
.	O

N-acetyl-L-cysteine	O
inhibits	O
primary	O
human	O
T	O
cell	O
responses	O
at	O
the	O
dendritic	O
cell	O
level	O
:	O
association	O
with	O
NF-kappaB	B-protein
inhibition	O
.	O

New	O
strategies	O
that	O
attenuate	O
via	O
mechanisms	O
distinct	O
from	O
loss-of-function	O
are	O
needed	O
for	O
enhancing	O
the	O
safety	O
phenotype	O
of	O
viral	B-DNA
genome	I-DNA
.	O

Galectin-3	B-protein
is	O
widely	O
distributed	O
in	O
various	O
tissues	O
and	O
cell	O
types	O
and	O
is	O
expressed	O
in	O
many	O
leukocytes	B-cell_type
,	O
with	O
the	O
notable	O
exception	O
of	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

We	O
have	O
recently	O
shown	O
that	O
infection	O
of	O
Epstein-Barr	B-cell_line
virus	I-cell_line
(	I-cell_line
EBV	I-cell_line
)	I-cell_line
genome-positive	I-cell_line
B	I-cell_line
cells	I-cell_line
by	O
human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
results	O
in	O
the	O
expression	O
of	O
the	O
immediate-early	B-DNA
EBV	I-DNA
Zebra	I-DNA
gene	I-DNA
,	O
followed	O
by	O
virus	O
replication	O
(	O
L.Flamand	O
,	O
I.Stefanescu	O
,	O
D.V.Ablashi	O
,	O
and	O
J.Menezes	O
,	O
J.Virol.67	O
:	O
6768-6777	O
,	O
1993	O
)	O
.	O

Analyses	O
of	O
nuclear	O
translocation	O
of	O
individual	O
members	O
of	O
Rel	B-protein
proteins	I-protein
after	O
CD40	B-protein
induction	O
of	O
primary	B-cell_type
B	I-cell_type
cells	I-cell_type
showed	O
a	O
strong	O
and	O
long-lasting	O
accumulation	O
of	O
RelB	B-protein
and	O
,	O
less	O
pronounced	O
,	O
of	O
c-Rel	B-protein
.	O

This	O
research	O
may	O
make	O
feasible	O
manipulation	O
of	O
growth	O
and	O
differentiation	O
of	O
mammalian	B-cell_type
cells	I-cell_type
,	O
which	O
in	O
turn	O
would	O
have	O
profound	O
implication	O
in	O
biomedical	O
research	O
on	O
cell	O
and	O
gene	O
therapy	O
,	O
and	O
development	O
of	O
pharmaceutical	O
products	O
.	O

Two	O
other	O
sites	O
display	O
disparate	O
effects	O
on	O
IL-2	B-DNA
gene	I-DNA
expression	O
in	O
different	O
T	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
:	O
the	O
distal	B-DNA
purine	I-DNA
box	I-DNA
(	O
-291	B-DNA
to	I-DNA
-277	I-DNA
)	O
and	O
the	O
proximal	B-DNA
purine	I-DNA
box	I-DNA
sites	I-DNA
(	O
-145	B-DNA
to	I-DNA
-128	I-DNA
)	O
.	O

Because	O
STAT6	B-protein
activation	O
is	O
essential	O
for	O
IL-4	B-protein
-induced	O
gene	O
expression	O
,	O
we	O
examined	O
the	O
ability	O
of	O
type	O
I	O
and	O
type	O
II	O
IFNs	B-protein
to	O
regulate	O
activation	O
of	O
STAT6	B-protein
by	O
IL-4	B-protein
in	O
primary	B-cell_type
human	I-cell_type
monocytes	I-cell_type
.	O

Alveolar	B-cell_type
macrophages	I-cell_type
are	O
located	O
directly	O
in	O
the	O
surrounding	O
of	O
these	O
cells	O
,	O
so	O
that	O
we	O
suppose	O
an	O
interaction	O
between	O
epithelial	B-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
regarding	O
to	O
the	O
release	O
of	O
inflammatory	B-protein
mediators	I-protein
.	O

It	O
was	O
previously	O
demonstrated	O
that	O
stimulation	O
of	O
monocytic	O
cells	O
with	O
either	O
LPS	O
or	O
LAMPf	B-protein
led	O
to	O
a	O
series	O
of	O
common	O
downstream	O
signaling	O
events	O
,	O
including	O
the	O
activation	O
of	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
and	O
of	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
cascades	O
.	O

The	O
increased	O
level	O
of	O
PLC	B-protein
gamma	I-protein
1	I-protein
becomes	O
evident	O
after	O
90	O
min	O
of	O
IFN-beta	B-protein
treatment	O
and	O
is	O
still	O
detectable	O
after	O
24	O
h	O
.	O

These	O
results	O
provide	O
evidence	O
that	O
AML1	B-protein
proteins	O
play	O
a	O
role	O
in	O
erythroid	O
and	O
megakaryocytic	O
differentiation	O
.	O

Thus	O
,	O
inhibition	O
of	O
GSK-3beta	B-protein
is	O
insufficient	O
to	O
activate	O
Tcf-dependent	O
transcription	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

This	O
alteration	O
in	O
NFkappaB	B-protein
activation	O
occurred	O
in	O
the	O
presence	O
of	O
normal	O
expression	O
of	O
TCRzeta-associated	B-DNA
signaling	I-DNA
elements	I-DNA
.	O

Regions	O
of	O
low	O
base	O
order-dependent	O
stem-loop	O
potential	O
in	O
the	O
region	O
of	O
the	O
gene	O
are	O
defined	O
.	O

This	O
response	O
required	O
at	O
least	O
120	O
min	O
to	O
be	O
evident	O
and	O
supershift	O
experiments	O
revealed	O
that	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
contains	O
both	O
RelA	B-protein
and	O
p50	B-protein
.	O

After	O
cellular	O
activation	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
rapidly	O
degraded	O
in	O
concert	O
with	O
the	O
induced	O
nuclear	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

Further	O
characterization	O
of	O
these	O
cells	O
should	O
identify	O
factors	O
involved	O
in	O
the	O
growth	O
,	O
terminal	O
differentiation	O
and	O
activation	O
of	O
osteoclasts	B-cell_type
.	O

Activation	O
of	O
THP-1	B-cell_line
cells	I-cell_line
with	O
gamma-interferon	B-protein
(	O
gamma-IFN	B-protein
)	O
enhances	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
30-fold	O
,	O
blocks	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
suppression	O
of	O
its	O
synthesis	O
,	O
and	O
reduces	O
by	O
42.2	O
%	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
induction	O
of	O
its	O
degradation	O
.	O

Expression	O
of	O
the	O
class	B-protein
A	I-protein
macrophage	I-protein
scavenger	I-protein
receptor	I-protein
(	I-protein
MSR	I-protein
)	I-protein
contributes	O
to	O
the	O
uptake	O
of	O
modified	B-protein
low	I-protein
density	I-protein
lipoproteins	I-protein
(	I-protein
LDL	I-protein
)	I-protein
by	O
macrophages	B-cell_type
and	O
transformation	O
of	O
these	O
cells	O
into	O
lipid-laden	B-cell_type
foam	I-cell_type
cells	I-cell_type
,	O
which	O
characterize	O
atherosclerosis	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
inflammatory	O
effects	O
of	O
gamma-IFN	B-protein
signaling	O
could	O
play	O
a	O
role	O
in	O
foam	O
cell	O
formation	O
and	O
xanthomatosis	O
.	O

LP	B-cell_type
T	I-cell_type
cells	I-cell_type
exhibit	O
enhanced	O
IL-2	B-protein
secretion	O
when	O
activated	O
through	O
the	O
CD2	B-protein
pathway	O
.	O

Low	O
concentrations	O
of	O
RA	O
inhibiting	O
IgE	B-protein
synthesis	O
(	O
10	O
(	O
-10	O
)	O
mol/L	O
)	O
affected	O
neither	O
B-cell	O
proliferation	O
nor	O
the	O
production	O
of	O
IgA	B-protein
,	O
IgG	B-protein
,	O
and	O
IgM	B-protein
.	O

The	O
variant	O
Id-3L	B-protein
protein	I-protein
is	O
functionally	O
distinguishable	O
from	O
conventional	O
Id-3	B-protein
since	O
in	O
in	O
vitro	O
DNA	O
mobility	O
shift	O
assays	O
,	O
it	O
was	O
greatly	O
impaired	O
in	O
its	O
ability	O
to	O
abrogate	O
binding	O
of	O
the	O
basic	O
helix-loop-helix	B-protein
protein	I-protein
,	O
E47	B-protein
,	O
to	O
an	O
E	B-DNA
box	I-DNA
recognition	I-DNA
sequence	I-DNA
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
induces	O
immediate	O
effects	O
in	O
monocytes	O
by	O
activation	O
of	O
the	O
Janus	B-protein
kinase	I-protein
(	O
JAK2	B-protein
)	O
and	O
STAT	B-protein
transcription	I-protein
factor	I-protein
(	O
STAT5	B-protein
)	O
pathway	O
.	O

A	O
Taq	B-DNA
I	I-DNA
polymorphism	I-DNA
was	O
identified	O
which	O
enabled	O
chicken	O
IL2	B-protein
to	O
be	O
mapped	O
to	O
chromosome	B-DNA
4	I-DNA
,	O
linked	O
to	O
ANX5	B-DNA
,	O
with	O
synteny	O
with	O
mouse	B-DNA
chromosome	I-DNA
3	I-DNA
and	O
human	B-DNA
chromosome	I-DNA
4	I-DNA
.	O

The	O
effectiveness	O
of	O
this	O
approach	O
was	O
tested	O
by	O
immunizing	O
mice	O
with	O
human	O
group	O
C	O
adenoviruses	O
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-alpha	I-protein
controls	O
T-cell	O
activation	O
and	O
is	O
a	O
major	O
inducer	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-1	O
replication	O
in	O
chronically	B-cell_type
infected	I-cell_type
cells	I-cell_type
.	O

Expression	O
of	O
either	O
the	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
or	O
CREB	B-protein
fused	O
to	O
the	O
GAL4	B-protein
activation	I-protein
domain	I-protein
(	O
GAD	B-protein
)	O
in	O
this	O
strain	O
did	O
not	O
modify	O
the	O
expression	O
of	O
the	O
reporter	B-DNA
gene	I-DNA
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
NFKB2	B-protein
(	O
lyt-10	B-protein
)	O
and	O
c-Rel	B-protein
are	O
overexpressed	O
in	O
HTLV-I	O
infected	O
and	O
Tax-expressing	B-cell_type
cells	I-cell_type
and	O
,	O
together	O
,	O
account	O
for	O
the	O
majority	O
of	O
the	O
constitutive	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
these	O
cells	O
before	O
and	O
after	O
PMA	O
stimulation	O
.	O

Furthermore	O
,	O
GR	B-protein
number	O
failed	O
to	O
normalize	O
after	O
incubation	O
in	O
media	O
alone	O
or	O
IL-2	B-protein
and	O
IL-4	B-protein
.	O

Molecular	O
mechanisms	O
of	O
anoxia/reoxygenation-induced	O
neutrophil	O
adherence	O
to	O
cultured	B-cell_line
endothelial	I-cell_line
cells	I-cell_line
.	O

Our	O
results	O
lend	O
further	O
support	O
to	O
the	O
hypothesis	O
that	O
inflammatory	O
and	O
immune	O
responses	O
of	O
monocytes/macrophages	B-cell_type
may	O
be	O
modulated	O
at	O
the	O
molecular	O
level	O
by	O
signals	O
originating	O
from	O
tissue	B-cell_type
structural	I-cell_type
cells	I-cell_type
such	O
as	O
fibroblasts	B-cell_type
.	O

Here	O
we	O
identify	O
the	O
cell	B-protein
cycle	I-protein
regulator	I-protein
E2F	B-protein
as	O
an	O
IL-2	B-protein
target	O
in	O
T	O
lymphocytes	B-cell_type
and	O
PI3K	B-protein
as	O
the	O
critical	O
signaling	O
pathway	O
.	O

METHODS	O
:	O
A	O
panel	O
of	O
mAECA	B-protein
was	O
generated	O
from	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
of	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
,	O
using	O
Epstein-Barr	O
virus	O
transformation	O
.	O

In	O
addition	O
,	O
negative	O
correlations	O
were	O
observed	O
between	O
FECa2+	O
in	O
the	O
dense	O
tubules	O
and	O
age	O
.	O

BACKGROUND	O
:	O
In	O
vivo	O
regulation	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
by	O
glucocorticoids	O
provides	O
a	O
means	O
of	O
modulating	O
sensitivity	O
of	O
targeted	O
cells	O
.	O

In	O
group	B-cell_line
I	I-cell_line
BL	I-cell_line
cells	I-cell_line
,	O
containing	O
low	O
levels	O
of	O
NF-kappaB	B-protein
,	O
only	O
RBP	B-protein
binding	O
was	O
observed	O
in	O
EMSAs	O
,	O
whereas	O
NF-kappaB	B-protein
binding	O
could	O
be	O
demonstrated	O
in	O
EBV-transformed	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
containing	O
high	O
levels	O
of	O
activated	O
NF-kappaB	B-protein
.	O

We	O
could	O
also	O
show	O
Pu	B-DNA
box	I-DNA
-dependent	O
transactivation	O
of	O
a	O
reporter	O
gene	O
in	O
transient	O
transfections	O
in	O
these	O
cell	B-cell_line
lines	I-cell_line
.	O

Interferons	B-protein
up-regulate	O
STAT1	B-protein
,	O
STAT2	B-protein
,	O
and	O
IRF	B-protein
family	O
transcription	O
factor	O
gene	O
expression	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
.	O

Here	O
we	O
describe	O
the	O
molecular	O
cloning	O
of	O
SLAP-130	B-protein
,	O
a	O
SLP-76-associated	B-protein
phosphoprotein	I-protein
of	O
130	O
kDa	O
.	O

B	B-cell_type
cells	I-cell_type
were	O
prestimulated	O
with	O
SAC	O
for	O
48	O
hrs	O
.	O

Diminished	O
glucocorticoid	B-protein
receptors	I-protein
do	O
not	O
result	O
in	O
glucocorticoid	O
resistance	O
.	O

In	O
situ	O
DNA	O
binding	O
assay	O
determined	O
Stat3	B-protein
activation	O
predominantly	O
within	O
alveoli	O
.	O

Combinations	O
of	O
all-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
and	O
VD	O
,	O
in	O
some	O
cases	O
,	O
increased	O
this	O
effect	O
.	O

In	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
the	O
calcium/calmodulin-dependent	B-protein
serine/threonine	I-protein
phosphatase	I-protein
,	O
calcineurin	B-protein
,	O
plays	O
a	O
pivotal	O
role	O
in	O
transducing	O
membrane-associated	O
signals	O
to	O
the	O
nucleus	O
.	O

Analysis	O
of	O
myeloid-associated	B-DNA
genes	I-DNA
in	O
human	B-cell_type
hematopoietic	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

Expression	O
of	O
bcl-6	B-protein
protein	I-protein
in	O
normal	O
skin	O
and	O
epidermal	O
neoplasms	O
.	O

One	O
of	O
the	O
isolated	O
genes	O
,	O
that	O
for	O
retinaldehyde	B-protein
dehydrogenase	I-protein
2	I-protein
(	O
RALDH2	B-protein
)	O
,	O
was	O
regularly	O
expressed	O
in	O
most	O
of	O
the	O
T-ALL	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
coexpressed	O
TAL1	B-protein
and	O
LMO	B-protein
.	O

We	O
demonstrated	O
the	O
presence	O
of	O
a	O
polymorphism	O
in	O
the	O
promoter	B-DNA
region	I-DNA
of	O
the	O
IL-10	B-DNA
gene	I-DNA
and	O
four	O
in	O
the	O
TGF-beta	B-DNA
gene	I-DNA
promoters	I-DNA
(	O
3	O
in	O
TGF-beta1	B-DNA
and	O
1	O
in	O
TGF-beta2	B-DNA
)	O
.	O

Elf-1	B-protein
and	O
Stat5	B-protein
bind	O
to	O
a	O
critical	O
element	O
in	O
a	O
new	O
enhancer	O
of	O
the	O
human	B-DNA
interleukin-2	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1997	O
Apr	O
;	O
17	O
(	O
4	O
)	O
:	O
2351	O
]	O

RFX-B	B-DNA
complements	O
the	O
predominant	O
BLS	B-protein
complementation	I-protein
group	I-protein
(	O
group	B-protein
B	I-protein
)	O
and	O
was	O
found	O
to	O
be	O
mutant	O
in	O
cell	B-cell_line
lines	I-cell_line
from	O
this	O
BLS	O
group	O
.	O

In	O
infected	O
monocytes	B-cell_type
,	O
which	O
die	O
by	O
apoptosis	O
,	O
the	O
expression	O
of	O
CREB	B-protein
,	O
CTF	B-protein
,	O
and	O
OTF-2	B-protein
was	O
rather	O
suppressed	O
8	O
hours	O
after	O
infection	O
.	O

The	O
results	O
showed	O
that	O
intense	O
physical	O
exercise	O
led	O
not	O
only	O
to	O
increases	O
in	O
blood	O
hormone	O
concentrations	O
but	O
also	O
to	O
an	O
increase	O
in	O
the	O
density	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
.	O

Characterization	O
of	O
expression	O
of	O
the	O
gene	O
for	O
human	B-protein
pterin	I-protein
carbinolamine	I-protein
dehydratase/dimerization	I-protein
cofactor	I-protein
of	O
HNF1	B-protein
.	O

Liberated	O
NF-kappa	B-protein
B	I-protein
migrates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
binds	O
to	O
specific	B-DNA
promoter	I-DNA
sites	I-DNA
and	O
activates	O
gene	O
transcription	O
.	O

Two	O
clones	O
were	O
obtained	O
in	O
which	O
the	O
loss	O
of	O
NF-kappaB	B-protein
binding	O
activity	O
correlated	O
with	O
the	O
constitutive	O
expression	O
of	O
the	O
transgenic	O
IkappaBalpha	B-protein
.	O

Spi-1/PU.1	B-protein
is	O
a	O
myeloid-	B-protein
and	I-protein
B-cell	I-protein
specific	I-protein
transcription	I-protein
factor	I-protein
which	O
is	O
also	O
involved	O
in	O
Friend	O
virus-induced	O
murine	O
erythroleukemia	O
.	O

E1A	B-DNA
's	O
inhibition	O
of	O
IFN	B-protein
-MCP	O
has	O
the	O
net	O
effect	O
of	O
promoting	O
the	O
selective	O
NK	O
cell-mediated	O
clearance	O
of	O
Ad-infected	O
or	O
Ad-transformed	B-cell_line
human	I-cell_line
cells	I-cell_line
.	O

Translocations	O
involving	O
the	O
BCL-6	B-DNA
gene	I-DNA
are	O
common	O
in	O
the	O
diffuse	O
large	O
cell	O
subtype	O
of	O
non-Hodgkin	O
's	O
lymphoma	O
.	O

Some	O
of	O
these	O
proteins	O
(	O
referred	O
to	O
as	O
OTF-2	B-protein
)	O
are	O
lymphoid	O
specific	O
,	O
whereas	O
at	O
least	O
one	O
other	O
,	O
and	O
possibly	O
more	O
(	O
referred	O
to	O
as	O
OTF-1	B-protein
)	O
,	O
is	O
found	O
ubiquitously	O
in	O
all	O
cell	O
types	O
.	O

The	O
intracellular	O
parasite	O
Theileria	O
parva	O
secures	O
its	O
propagation	O
and	O
spreads	O
through	O
the	O
infected	O
animal	O
by	O
infecting	O
and	O
transforming	O
T	B-cell_type
cells	I-cell_type
,	O
inducing	O
their	O
continuous	O
proliferation	O
and	O
rendering	O
them	O
metastatic	O
.	O

A	O
long	O
period	O
of	O
clinical	O
latency	O
before	O
development	O
of	O
symptoms	O
is	O
characteristic	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
c-fos	B-DNA
upregulation	O
mediated	O
by	O
Tat	B-protein
might	O
play	O
a	O
significant	O
role	O
in	O
the	O
control	O
of	O
viral	O
gene	O
transactivation	O
.	O

Further	O
,	O
Vpr	B-protein
suppresses	O
expression	O
of	O
IL-2	B-protein
,	O
IL-10	B-protein
,	O
IL-12	B-protein
,	O
TNF	B-protein
alpha	I-protein
and	O
IL-4	B-protein
,	O
all	O
of	O
which	O
are	O
NF-kappa	B-protein
B	I-protein
-dependent	O
.	O

This	O
immunosuppressive	O
drug	O
is	O
known	O
to	O
prevent	O
T-cell	O
proliferation	O
,	O
but	O
the	O
precise	O
point	O
at	O
which	O
rapamycin	O
regulates	O
T-cell	O
cycle	O
progression	O
has	O
yet	O
to	O
be	O
elucidated	O
.	O

A	O
microB	B-protein
binding	I-protein
protein	I-protein
is	O
encoded	O
by	O
the	O
PU.1/Spi-1	B-DNA
proto-oncogene	I-DNA
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
MS-2	B-protein
mediates	O
induction	O
of	O
the	O
CD11b	B-DNA
gene	I-DNA
as	O
cells	O
of	O
the	O
monocytic	O
lineage	O
mature	O
.	O

Major	O
STAT	B-protein
complexes	I-protein
activated	O
by	O
G-CSF-R/IL-7R	B-protein
alpha	I-protein
contained	O
STAT1	B-protein
or	O
STAT5	B-protein
,	O
while	O
some	O
formation	O
of	O
STAT3-containing	B-protein
complexes	I-protein
was	O
also	O
seen	O
.	O

The	O
proliferative	O
activity	O
of	O
tumors	O
has	O
been	O
extensively	O
investigated	O
with	O
different	O
approaches	O
,	O
among	O
which	O
the	O
use	O
of	O
the	O
monoclonal	B-protein
antibody	I-protein
Ki-67	I-protein
represents	O
an	O
easy	O
and	O
reliable	O
means	O
of	O
assessing	O
cell	O
proliferation	O
.	O

Our	O
unexpected	O
observations	O
of	O
paternal	O
or	O
biallelic	O
expression	O
of	O
WT1	B-protein
in	O
fibroblasts	B-cell_type
and	O
lymphocytes	B-cell_type
,	O
together	O
with	O
the	O
previous	O
findings	O
of	O
maternal	O
or	O
biallelic	O
expression	O
in	O
placentae	O
and	O
brains	O
,	O
suggest	O
that	O
the	O
allele-specific	O
regulatory	O
system	O
of	O
WT1	B-protein
is	O
unique	O
and	O
may	O
be	O
controlled	O
by	O
a	O
putative	O
tissue-	O
and	O
individual-specific	O
modifier	O
.	O

In	O
both	O
cell	B-cell_line
lines	I-cell_line
,	O
n-acetyl-L-cysteine	O
(	O
NAC	O
)	O
,	O
a	O
potent	O
thiol	O
antioxidant	O
,	O
inhibited	O
the	O
triggering	O
of	O
the	O
nuclear	O
expression	O
of	O
NF-kappaB	B-protein
by	O
IL-4	B-protein
and	O
by	O
anti-CD40	B-protein
monoclonal	I-protein
antibody	I-protein
.	O

Using	O
Tax	B-protein
mutants	O
that	O
fail	O
to	O
activate	O
either	O
ATF	B-protein
-or	O
NF-kappaB-dependent	B-DNA
promoters	I-DNA
and	O
different	O
5	B-DNA
'	I-DNA
truncation	I-DNA
mutants	I-DNA
of	O
the	O
E2F-1	B-DNA
promoter	I-DNA
,	O
we	O
show	O
that	O
the	O
Tax	B-protein
-dependent	O
transcriptional	O
control	O
of	O
the	O
E2F1	B-DNA
gene	I-DNA
involves	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
ATF	B-DNA
binding	I-DNA
site	I-DNA
located	O
in	O
the	O
E2F-1	B-DNA
promoter	I-DNA
.	O

RESULTS	O
:	O
LPS	O
increased	O
NF-kappaB	B-protein
DNA	O
binding	O
and	O
TNF-alpha	B-protein
release	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

But	O
on	O
reporter	B-DNA
genes	I-DNA
with	O
nonoptimal	B-DNA
binding	I-DNA
sites	I-DNA
,	O
their	O
transcriptional	O
properties	O
diverged	O
and	O
E2A-HLF	B-protein
competitively	O
inhibited	O
activation	O
by	O
wild-type	B-protein
PAR	I-protein
proteins	I-protein
.	O

In	O
contrast	O
to	O
the	O
increase	O
of	O
C/EBP	O
epsilon	O
in	O
9-cis	O
RA-mediated	O
granulocytic	O
differentiation	O
,	O
the	O
DMSO-induced	O
differentiation	O
of	O
HL-60	B-cell_line
cells	I-cell_line
down	O
the	O
granulocytic	O
pathway	O
was	O
associated	O
with	O
an	O
initial	O
reduction	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
levels	O
.	O

Using	O
antibodies	O
against	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
NF-kappaB	B-protein
in	O
EMSAs	O
,	O
the	O
involvement	O
of	O
both	O
p50	B-protein
and	O
p65	B-protein
proteins	I-protein
was	O
further	O
demonstrated	O
.	O

The	O
electrophoretic	O
mobility	O
shift	O
assay	O
with	O
extracts	O
of	O
COS	B-cell_line
cells	I-cell_line
expressing	O
GATA-binding	B-protein
proteins	I-protein
showed	O
that	O
GATA-4	B-protein
has	O
the	O
highest	O
binding	O
affinity	O
to	O
the	O
-70	B-DNA
GATA	I-DNA
site	I-DNA
among	O
the	O
three	O
GATA-binding	B-protein
proteins	I-protein
.	O

Present	O
evidence	O
indicates	O
a	O
pathway	O
of	O
signal	O
transmission	O
in	O
T	B-cell_type
cells	I-cell_type
that	O
is	O
outlined	O
in	O
figure	O
1	O
.	O

For	O
this	O
purpose	O
,	O
we	O
transiently	O
transfected	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
the	O
reporter	B-DNA
plasmid	I-DNA
p	I-DNA
[	I-DNA
(	I-DNA
TRE	I-DNA
)	I-DNA
3-tk-Luc	I-DNA
]	I-DNA
and	O
found	O
that	O
CCK-8	O
was	O
able	O
to	O
dose-dependently	O
induce	O
luciferase	B-protein
expression	O
related	O
to	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
activation	O
with	O
a	O
maximal	O
response	O
identical	O
to	O
that	O
obtained	O
with	O
compounds	O
known	O
to	O
activate	O
AP-1	B-protein
complex	I-protein
(	O
quantitatively	O
,	O
the	O
same	O
level	O
of	O
induction	O
was	O
obtained	O
with	O
1	O
nM	O
12-O-tetradecanoylphorbol-13-acetate	O
,	O
100	O
microM	O
diacylglycerol	O
,	O
or	O
4	O
nM	O
epidermal	O
growth	O
factor	O
)	O
.	O

To	O
examine	O
transcriptional	O
regulation	O
of	O
cytokine	B-DNA
genes	I-DNA
by	O
CD15	O
engagement	O
,	O
a	O
CAT	O
plasmid	O
reporter	O
construct	O
containing	O
IL-1	B-DNA
beta	I-DNA
promoter/enhancer	I-DNA
sequences	I-DNA
was	O
introduced	O
into	O
MM6	B-cell_line
.	O

Phorbol	O
ester	O
or	O
specific	O
antigen	O
recognition	O
induced	O
HIV	B-DNA
LTR	I-DNA
transactivation	O
,	O
whereas	O
stimulation	O
with	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
or	O
antibody	O
to	O
CD3	B-protein
did	O
not	O
.	O

In	O
contrast	O
,	O
the	O
binding	O
activities	O
of	O
NF1	B-protein
and	O
Sp1	B-protein
were	O
not	O
affected	O
by	O
ER	B-protein
.	O

Rapid	O
Ca2+-mediated	O
activation	O
of	O
Rap1	B-protein
in	O
human	B-cell_type
platelets	I-cell_type
.	O

When	O
a	O
therapy	O
proves	O
effective	O
,	O
do	O
clinicians	O
truly	O
know	O
how	O
it	O
works	O
?	O
Even	O
with	O
a	O
therapy	O
as	O
specific	O
as	O
anti-TNF	B-protein
antibody	I-protein
,	O
it	O
is	O
not	O
clear	O
if	O
the	O
benefit	O
is	O
attributable	O
to	O
simple	O
binding	O
and	O
clearance	O
of	O
TNF-alpha	B-protein
or	O
to	O
binding	O
on	O
the	O
cell	O
surface	O
and	O
subsequent	O
deletion	O
of	O
the	O
activated	B-cell_type
macrophage	I-cell_type
.	O

Human	O
IL-5	B-protein
promoter/enhancer-luciferase	O
gene	O
construct	O
transfected	O
to	O
T-cell	B-cell_line
clones	I-cell_line
was	O
transcribed	O
on	O
either	O
TCR	B-protein
or	O
IL-2R	B-protein
stimulation	O
and	O
was	O
clearly	O
downregulated	O
by	O
dexamethasone	O
,	O
indicating	O
that	O
the	O
approximately	O
500-bp	B-DNA
human	I-DNA
IL-5	I-DNA
gene	I-DNA
segment	I-DNA
located	O
5	B-DNA
'	I-DNA
upstream	I-DNA
of	O
the	O
coding	O
region	O
contains	O
activation-inducible	B-DNA
enhancer	I-DNA
elements	I-DNA
responsible	O
for	O
the	O
regulation	O
by	O
GC	O
.	O

To	O
examine	O
the	O
effect	O
of	O
Trx	B-protein
in	O
intact	O
cells	O
,	O
we	O
performed	O
transient	O
assay	O
with	O
a	O
chloramphenicol	B-DNA
acetyltransferase-expressing	I-DNA
plasmid	I-DNA
under	O
the	O
control	O
of	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
and	O
an	O
effector	B-DNA
plasmid	I-DNA
expressing	O
human	B-protein
Trx	I-protein
.	O

The	O
Jak1	B-protein
,	I-protein
Jak2	I-protein
,	I-protein
Jak3	I-protein
,	I-protein
and	I-protein
Fes	I-protein
tyrosine	I-protein
kinases	I-protein
have	O
been	O
demonstrated	O
to	O
undergo	O
tyrosine	O
phosphorylation	O
in	O
response	O
to	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-4	I-protein
stimulation	O
in	O
different	O
cell	O
systems	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
in	O
myeloid	O
and	O
B	O
cell	O
extracts	O
,	O
PU.1	B-protein
forms	O
a	O
novel	O
,	O
specific	O
,	O
more	O
slowly	O
migrating	O
complex	O
(	O
PU-SF	B-protein
)	O
when	O
binding	O
the	O
GM-CSF	B-protein
receptor	I-protein
alpha	I-protein
promoter	O
PU.1	B-DNA
site	I-DNA
.	O

A	O
novel	O
HIV-1	O
isolate	O
containing	O
alterations	O
affecting	O
the	O
NF-kappa	B-DNA
B	I-DNA
element	I-DNA
.	O

They	O
also	O
indicate	O
that	O
abundant	O
TCL1	B-protein
expression	O
in	O
quiescent	B-cell_type
mantle	I-cell_type
zone	I-cell_type
B	I-cell_type
cells	I-cell_type
is	O
down-regulated	O
in	O
activated	O
germinal	B-cell_type
center	I-cell_type
follicular	I-cell_type
B	I-cell_type
cells	I-cell_type
in	O
parallel	O
to	O
the	O
known	O
expression	O
pattern	O
of	O
BCL-2	B-protein
.	O

Our	O
data	O
indicate	O
that	O
the	O
role	O
of	O
rpoS	B-DNA
in	O
L.	O
pneumophila	O
is	O
very	O
different	O
from	O
what	O
has	O
previously	O
been	O
reported	O
for	O
E.	O
coli	O
rpoS	B-DNA
.	O

METHODS	O
:	O
THP-1	B-cell_line
cells	I-cell_line
,	O
a	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
were	O
transfected	O
with	O
the	O
CMV	B-DNA
IE	I-DNA
genes	I-DNA
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
we	O
demonstrated	O
that	O
a	O
short	O
treatment	O
of	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
with	O
PGE2	O
induces	O
specific	O
binding	O
activity	O
to	O
CRE	B-DNA
and	O
AP-2	B-DNA
,	O
but	O
not	O
AP-1	B-DNA
,	I-DNA
DNA	I-DNA
elements	I-DNA
.	O

Here	O
we	O
describe	O
a	O
novel	O
regulatory	B-DNA
element	I-DNA
within	O
the	O
IL-2	B-DNA
promoter	I-DNA
located	O
immediately	O
upstream	O
of	O
the	O
nuclear	B-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cell	I-DNA
(	I-DNA
NFAT	I-DNA
)	I-DNA
domain	I-DNA
.	O

In	O
FL	O
,	O
follicles	O
were	O
densely	O
populated	O
,	O
and	O
their	O
borders	O
were	O
irregular	O
,	O
with	O
some	O
Bcl-6+	B-cell_type
cells	I-cell_type
in	O
the	O
interfollicular	O
zones	O
.	O

PU.1	B-protein
is	O
expressed	O
at	O
high	O
levels	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
mast	B-cell_type
cells	I-cell_type
,	O
megakaryocytes	B-cell_type
,	O
macrophages	B-cell_type
,	O
neutrophils	B-cell_type
,	O
and	O
immature	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
and	O
at	O
lower	O
levels	O
in	O
mature	B-cell_type
erythrocytes	I-cell_type
.	O

The	O
increases	O
in	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
induced	O
by	O
PA	O
or	O
anti-CD3	B-protein
mAb	I-protein
were	O
efficiently	O
abrogated	O
by	O
the	O
presence	O
of	O
propranolol	O
,	O
an	O
inhibitor	O
of	O
PA	O
phosphohydrolase	B-protein
and	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
.	O

Glucocorticoid	O
resistance	O
in	O
chronic	O
asthma	O
.	O

Anti-Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
autoantibodies	I-protein
are	O
associated	O
with	O
T	B-DNA
cell	I-DNA
receptor	I-DNA
beta	I-DNA
genes	I-DNA
in	O
systemic	O
lupus	O
erythematosus	O
patients	O
.	O

This	O
183-bp	B-DNA
region	I-DNA
was	O
both	O
cell	O
type	O
specific	O
and	O
responsive	O
to	O
two	O
distinct	O
stimuli	O
,	O
lipopolysaccharide	O
and	O
dibutyryl	O
cAMP	O
,	O
known	O
to	O
regulate	O
B7.1	B-protein
expression	O
.	O

The	O
OCT-1-binding	O
genotype	O
,	O
found	O
in	O
approximately	O
5	O
%	O
of	O
Africans	O
,	O
is	O
associated	O
with	O
fourfold	O
increased	O
susceptibility	O
to	O
cerebral	O
malaria	O
in	O
large	O
case-control	O
studies	O
of	O
West	O
African	O
and	O
East	O
African	O
populations	O
,	O
after	O
correction	O
for	O
other	O
known	O
TNF	O
polymorphisms	O
and	O
linked	O
HLA	B-DNA
alleles	I-DNA
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
regulating	O
this	O
early	O
inflammatory	O
response	O
.	O

Nuclear	O
p65	B-protein
and	O
c-Rel	B-protein
proteins	O
were	O
found	O
in	O
all	O
cell	O
types	O
including	O
lymphocytes	B-cell_type
.	O

The	O
level	O
of	O
SP140	B-RNA
mRNA	I-RNA
in	O
myeloid	B-cell_line
precursor	I-cell_line
cell	I-cell_line
lines	I-cell_line
HL60	B-cell_line
and	O
NB4	B-cell_line
markedly	O
increased	O
in	O
response	O
to	O
chemically	O
induced	O
cellular	O
differentiation	O
.	O

Finally	O
,	O
a	O
direct	O
interaction	O
between	O
RFX5	B-protein
and	O
CIITA	B-protein
was	O
detected	O
with	O
the	O
yeast	O
two-hybrid	O
and	O
far-Western	O
blot	O
assays	O
.	O

This	O
tight	O
correlation	O
between	O
c-jun	B-DNA
expression	O
,	O
the	O
generation	O
of	O
AP-1	B-protein
activity	O
,	O
and	O
differentiation	O
suggests	O
a	O
critical	O
role	O
for	O
this	O
gene	O
and	O
transcriptional	B-protein
complex	I-protein
during	O
this	O
process	O
.	O

These	O
studies	O
,	O
the	O
first	O
to	O
demonstrate	O
induction	O
of	O
LT	B-DNA
promoter	I-DNA
activity	O
over	O
basal	O
levels	O
,	O
indicate	O
that	O
HTLV-I	B-protein
tax	I-protein
causes	O
low-level	O
activation	O
of	O
both	O
endogenous	O
LT	B-protein
and	O
the	O
LT	B-DNA
promoter	I-DNA
,	O
at	O
least	O
in	O
part	O
through	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

We	O
detected	O
binding	O
for	O
the	O
EWS/FLI-1	O
peptide	O
and	O
for	O
5	O
RAS	O
peptides	O
(	O
1	O
wild	O
type	O
and	O
4	O
mutated	O
)	O
.	O

Freshly	O
isolated	O
cells	O
contain	O
high	O
levels	O
of	O
G0S2	B-RNA
mRNA	I-RNA
which	O
rapidly	O
decline	O
.	O

We	O
developed	O
mice	O
transgenic	O
for	O
human	O
CSF-1R	B-protein
because	O
mouse	O
CSF-1	B-protein
can	O
not	O
activate	O
human	O
CSF-1R	B-protein
.	O

The	O
differentiated	O
DC	B-cell_type
are	O
potent	O
presenters	O
of	O
antigen	O
in	O
mixed	O
lymphocyte	O
reactions	O
and	O
of	O
soluble	O
antigen	O
to	O
specific	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Expression	O
of	O
gamma-interferon	B-protein
inducible	I-protein
protein	I-protein
10	I-protein
(	O
IP-10	B-protein
)	O
,	O
a	O
STAT1alpha-responsive	B-DNA
gene	I-DNA
and	O
mediator	O
of	O
inflammatory	O
response	O
,	O
was	O
also	O
abnormally	O
expressed	O
in	O
the	O
monocytes	B-cell_type
from	O
II-2	B-cell_line
.	O

[	O
Changes	O
in	O
plasma	B-protein
interleukin-1	I-protein
and	O
their	O
possible	O
relationship	O
with	O
the	O
changes	O
in	O
glucocorticoid	B-protein
receptor	I-protein
in	O
aged	O
long-distance	O
runner	O
]	O

In	O
contrast	O
,	O
E1A-positive	B-cell_type
cells	I-cell_type
were	O
no	O
more	O
susceptible	O
to	O
injury-induced	O
necrosis	O
than	O
E1A-negative	B-cell_type
cells	I-cell_type
.	O

Both	O
r-hTBP-1	B-protein
and	O
rhu	B-protein
TNFR	I-protein
:	I-protein
Fc	I-protein
blocked	O
PMA	O
induction	O
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NK	I-protein
)	I-protein
-	I-protein
kappa	I-protein
B	I-protein
DNA-binding	O
activity	O
in	O
U1	B-cell_line
cells	I-cell_line
in	O
association	O
with	O
decreases	O
in	O
HIV-1	O
replication	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
effects	O
of	O
C3a	B-protein
and	O
C3a	B-protein
(	I-protein
desArg	I-protein
)	I-protein
on	O
gene	O
expression	O
and	O
protein	O
secretion	O
of	O
IL-6	B-protein
in	O
human	O
PBMCs	B-cell_type
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
LPS	O
or	O
IL-1beta	B-protein
.	O

In	O
addition	O
,	O
an	O
adenocarcinoma	B-protein
reactive	I-protein
human-mouse	I-protein
chimeric	I-protein
monoclonal	I-protein
antibody	I-protein
(	O
ING-1	B-protein
)	O
was	O
able	O
to	O
significantly	O
boost	O
in	O
vivo	O
generated	O
LAK	O
cell-mediated	O
lysis	O
of	O
control	B-cell_line
,	I-cell_line
E2-treated	I-cell_line
,	I-cell_line
and	I-cell_line
TAM-treated	I-cell_line
ER+	I-cell_line
and	I-cell_line
ER-	I-cell_line
cells	I-cell_line
.	O

To	O
approach	O
this	O
issue	O
,	O
we	O
used	O
CD36	B-protein
transfected	O
Chinese	B-cell_type
hampster	I-cell_type
ovary	I-cell_type
(	I-cell_type
CHO	I-cell_type
)	I-cell_type
cells	I-cell_type
,	O
exposed	O
them	O
to	O
Ox	O
LDL	O
,	O
and	O
determined	O
changes	O
in	O
the	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O

Accumulation	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
occurred	O
as	O
early	O
as	O
1	O
hour	O
after	O
exposure	O
of	O
NB4	B-cell_line
cells	I-cell_line
to	O
9-cis	O
RA	O
(	O
5	O
x	O
10	O
(	O
-7	O
)	O
mol/L	O
)	O
;	O
and	O
at	O
48	O
hours	O
,	O
levels	O
were	O
increased	O
by	O
5.1-fold	O
.	O

Taken	O
together	O
these	O
data	O
indicate	O
that	O
carboxylesterase	O
gene	O
transcription	O
in	O
THP-1	B-cell_line
cells	I-cell_line
starts	O
at	O
multiple	O
initiation	O
sites	O
and	O
that	O
Sp1	B-protein
and	O
IRBP	B-protein
may	O
be	O
critical	O
factors	O
for	O
modulating	O
the	O
differentiation-dependent	O
transcription	O
of	O
this	O
human	B-DNA
carboxylesterase	I-DNA
gene	I-DNA
.	O

CD36	B-protein
is	O
a	O
cell	O
surface	O
glycoprotein	B-protein
composed	O
of	O
a	O
single	O
polypeptide	O
chain	O
,	O
which	O
interacts	O
with	O
thrombospondin	B-protein
,	O
collagens	B-protein
type	I-protein
I	I-protein
and	I-protein
IV	I-protein
,	O
oxidized	O
low	B-protein
density	I-protein
lipoprotein	I-protein
,	O
fatty	O
acids	O
,	O
anionic	O
phospholipids	O
,	O
and	O
erythrocytes	B-cell_type
parasitized	O
with	O
Plasmodium	O
falciparum	O
.	O

Furthermore	O
,	O
CAT	B-protein
assays	O
using	O
mutated	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat-CAT	I-DNA
constructs	I-DNA
and	O
gel	O
shift	O
assays	O
demonstrate	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
NF-kappa	B-DNA
B	I-DNA
enhancer	I-DNA
.	O

The	O
molecular	O
mechanism	O
by	O
which	O
ATRA	O
increases	O
the	O
nuclear	O
abundance	O
of	O
a	O
functional	O
VDR	B-protein
is	O
still	O
unknown	O
,	O
but	O
our	O
data	O
clearly	O
indicate	O
that	O
the	O
M2	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
context	O
is	O
only	O
permissive	O
of	O
monocytic	O
differentiation	O
.	O

In	O
all	O
patients	O
a	O
marked	O
decrease	O
in	O
IL-2-producing	B-cell_type
cells	I-cell_type
and	O
a	O
significant	O
increase	O
in	O
well-differentiated	O
Th1	B-cell_type
cells	I-cell_type
that	O
produced	O
IFN-gamma	B-protein
but	O
not	O
IL-2	B-protein
were	O
evident	O
after	O
priming	O
with	O
anti-CD3	B-protein
and	O
anti-CD28	B-protein
.	O

As	O
occurs	O
for	O
HL-60	O
cell	O
differentiation	O
induced	O
by	O
high	O
phorbol	O
ester	O
concentration	O
,	O
the	O
ciprofibrate-induced	O
phorbol	O
ester-dependent	O
differentiation	O
of	O
HL-60	B-cell_line
cells	I-cell_line
proceeded	O
through	O
the	O
monocytic/macrophage	O
pathway	O
and	O
induced	O
the	O
phosphorylation	O
of	O
proteins	O
with	O
similar	O
molecular	O
weights	O
suggesting	O
that	O
increased	O
protein	B-protein
kinase	I-protein
C	I-protein
activity	O
may	O
be	O
involved	O
in	O
the	O
effect	O
.	O

In	O
particular	O
,	O
naturally	O
occurring	O
sequence	O
variation	O
impacted	O
transcription	B-protein
factor	I-protein
binding	O
to	O
an	O
activating	B-DNA
transcription	I-DNA
factor/cAMP	I-DNA
response	I-DNA
element	I-DNA
binding	I-DNA
(	I-DNA
ATF/CREB	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
(	O
located	O
between	O
the	O
LEF-1	B-DNA
and	I-DNA
distal	I-DNA
NF-kappaB	I-DNA
transcription	I-DNA
factor	I-DNA
binding	I-DNA
sites	I-DNA
)	O
that	O
we	O
identified	O
in	O
previous	O
studies	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
.	O

These	O
observations	O
provide	O
further	O
evidence	O
to	O
suggest	O
a	O
role	O
for	O
intracellular	O
oxidant	O
generation	O
as	O
a	O
regulatory	O
mechanism	O
during	O
cell	O
cycle	O
entry	O
,	O
and	O
establish	O
a	O
link	O
between	O
oxidative	O
signalling	O
and	O
other	O
aspects	O
of	O
the	O
intracellular	O
signalling	O
network	O
that	O
is	O
activated	O
in	O
response	O
to	O
mitogenic	O
stimulation	O
.	O

Because	O
dephosphorylated	B-protein
(	I-protein
activated	I-protein
)	I-protein
pRB	I-protein
blocks	O
transition	O
from	O
G1	O
to	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
whereas	O
phosphorylated	B-protein
(	I-protein
inactivated	I-protein
)	I-protein
pRB	I-protein
releases	O
this	O
growth	O
arrest	O
,	O
we	O
characterized	O
the	O
role	O
of	O
pRB	B-protein
in	O
IL-6	B-protein
-mediated	O
MM	O
cell	O
growth	O
.	O

T	B-cell_type
cells	I-cell_type
recognizing	O
antigens	O
encoded	O
within	O
map	O
units	O
0.67	O
to	O
0.73	O
of	O
HSV	B-DNA
DNA	I-DNA
are	O
frequently	O
recovered	O
from	O
herpetic	O
lesions	O
.	O

The	O
sense	O
sequence	O
(	O
sequence	O
III	O
)	O
of	O
the	O
X	B-DNA
gene	I-DNA
also	O
enhanced	O
the	O
expression	O
of	O
CD40	B-protein
antigen	I-protein
in	O
patients	O
with	O
hepatitis	O
B	O
.	O

Treatment	O
of	O
an	O
HTLV-I	B-cell_line
infected	I-cell_line
human	I-cell_line
T-cell	I-cell_line
line	I-cell_line
with	O
H-7	O
blocked	O
specifically	O
accumulation	O
of	O
the	O
unspliced	B-RNA
gag-pol	I-RNA
mRNA	I-RNA
,	O
resulting	O
in	O
the	O
decreased	O
Gag	B-protein
protein	I-protein
synthesis	O
that	O
corresponds	O
with	O
the	O
decreased	O
in	O
vivo	O
phosphorylation	O
of	O
Rex	B-protein
.	O

Thus	O
,	O
the	O
extinguishing	O
mechanism	O
is	O
effective	O
very	O
early	O
after	O
fusion	O
.	O

Finally	O
,	O
receptor	O
clusters	O
colocalized	O
with	O
ezrin/moesin/radixin	B-protein
proteins	I-protein
.	O

The	O
bipartite	B-protein
human	I-protein
interleukin-4	I-protein
(	I-protein
IL-4	I-protein
)	I-protein
receptor	I-protein
was	O
functionally	O
expressed	O
in	O
murine	B-cell_type
pro-B	I-cell_type
cells	I-cell_type
and	O
activated	O
by	O
human	B-protein
IL-4	I-protein
to	O
evoke	O
intracellular	O
signaling	O
.	O

Requirement	O
of	O
tyrosine	B-protein
kinase	I-protein
activation	O
for	O
the	O
anti-Ig	B-protein
-mediated	O
Zp	B-DNA
activation	O
was	O
also	O
demonstrated	O
through	O
the	O
use	O
of	O
the	O
tyrosine	O
kinase	O
inhibitor	O
herbimycin	O
.	O

Reverse	O
transcriptase	O
(	O
RT	O
)	O
assays	O
were	O
positive	O
in	O
purified	O
viral	O
material	O
from	O
both	O
LCLs	B-cell_line
.	O

The	O
effect	O
of	O
NAC	O
was	O
also	O
examined	O
on	O
deletional	O
switch	O
recombination	O
underlying	O
the	O
isotype	O
switch	O
to	O
IgE	B-protein
.	O

Oligonucleotides	O
containing	O
the	O
IL-13	B-protein
or	O
IL-4	B-DNA
P	I-DNA
element	I-DNA
sites	I-DNA
specifically	O
bound	O
the	O
transcriptional	B-protein
activator	I-protein
protein	I-protein
,	O
nuclear	B-protein
factor-activated	I-protein
T	I-protein
cells	I-protein
,	O
preformed	O
(	O
NF-ATp	B-protein
)	O
,	O
when	O
incubated	O
with	O
nuclear	O
protein	O
extracts	O
from	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
molecular	O
mechanism	O
underlying	O
IL-2	B-protein
transcriptional	O
blockade	O
in	O
anergic	B-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
is	O
not	O
fully	O
understood	O
.	O

Additional	O
major	O
protein-DNA	O
interactions	O
do	O
not	O
occur	O
within	O
the	O
promoter	O
region	O
after	O
T	O
lymphocyte	O
activation	O
,	O
indicating	O
a	O
requirement	O
for	O
additional	O
protein-protein	O
interactions	O
and/or	O
post-translational	O
modifications	O
of	O
pre-bound	B-protein
transcription	I-protein
factors	I-protein
to	O
account	O
for	O
the	O
observed	O
increase	O
in	O
IMPDH	O
type	O
II	O
gene	O
expression	O
.	O

In	O
addition	O
,	O
binding	O
studies	O
with	O
(	O
3H	O
)	O
dexamethasone	O
have	O
been	O
performed	O
to	O
determine	O
the	O
dissociation	O
constant	O
(	O
Kd	O
)	O
and	O
receptor	O
numbers	O
(	O
Ro	O
)	O
in	O
the	O
monocytes	B-cell_type
of	O
these	O
two	O
groups	O
of	O
subjects	O
.	O

Using	O
a	O
whole-cell	O
competitive	O
binding	O
assay	O
and	O
3H-dexamethasone	O
as	O
tracer	O
,	O
MNL	B-cell_type
of	O
abdominal	O
obese	O
subjects	O
were	O
found	O
to	O
have	O
4855	O
+/-	O
1389	O
sites/cell	O
which	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0.05	O
)	O
than	O
controls	O
(	O
6234	O
+/-	O
1568	O
sites/cell	O
)	O
,	O
although	O
no	O
significant	O
difference	O
was	O
found	O
in	O
the	O
mean	O
serum	O
cortisol	O
level	O
.	O

We	O
here	O
describe	O
the	O
genomic	O
organisation	O
(	O
3	O
exons	B-DNA
of	O
132	O
,	O
112	O
and	O
542	O
bp	O
and	O
2	O
introns	B-DNA
of	O
1211	O
and	O
378	O
bp	O
)	O
and	O
sequence	O
including	O
3	O
kb	O
of	O
DNA	O
from	O
the	O
immediate	O
5	B-DNA
'	I-DNA
upstream	I-DNA
region	I-DNA
of	O
the	O
human	B-DNA
eotaxin	I-DNA
gene	I-DNA
.	O

HIV-1	O
replication	O
was	O
increased	O
by	O
dopamine	O
,	O
which	O
correlated	O
with	O
the	O
increased	O
levels	O
of	O
HIV-1	O
transactivation	O
.	O

The	O
human	B-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
alpha	I-DNA
(	I-DNA
TNF-alpha	I-DNA
)	I-DNA
gene	I-DNA
is	O
one	O
of	O
the	O
earliest	O
genes	O
transcribed	O
after	O
the	O
stimulation	O
of	O
a	O
B	B-cell_type
cell	I-cell_type
through	O
its	O
antigen	B-protein
receptor	I-protein
or	O
via	O
the	O
CD-40	O
pathway	O
.	O

In	O
addition	O
,	O
BSAP	B-protein
was	O
found	O
to	O
be	O
the	O
only	O
abundant	O
DNA-binding	O
activity	O
of	O
B-cell	O
nuclear	O
extracts	O
that	O
interacts	O
with	O
the	O
CD19	B-DNA
promoter	I-DNA
.	O

Cytokine	B-protein
(	O
IL-2	B-protein
,	O
IL-6	B-protein
,	O
INF-gamma	B-protein
)	O
production	O
is	O
inhibited	O
95-100	O
%	O
by	O
concentrations	O
of	O
TPCK	O
that	O
totally	O
suppress	O
the	O
mitogenesis	O
of	O
CD4+	B-cell_type
or	I-cell_type
CD8+	I-cell_type
cells	I-cell_type
.	O

The	O
use	O
of	O
interferon-gamma-treated	B-cell_line
U937	I-cell_line
cells	I-cell_line
in	O
chemiluminescence	O
assays	O
to	O
detect	O
red	B-protein
cell	I-protein
,	I-protein
platelet	I-protein
and	I-protein
granulocyte	I-protein
antibodies	I-protein
of	O
potential	O
clinical	O
significance	O
.	O

Both	O
Kd	O
(	O
30.3+/-2.5	O
versus	O
19.2+/-2.4	O
nmol/L	O
)	O
and	O
IC50	O
values	O
(	O
15.5+/-1.8	O
versus	O
8.9+/-1.2	O
nmol/L	O
)	O
for	O
cortisol	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
lower	O
renin	B-protein
values	O
(	O
P	O
<	O
.03	O
)	O
.	O

Total	O
mRNA	B-RNA
was	O
extracted	O
from	O
T	B-cell_type
cells	I-cell_type
,	O
and	O
using	O
RT-PCR	O
,	O
changes	O
in	O
the	O
production	O
of	O
IL-2	B-protein
and	O
RA	B-protein
receptors	I-protein
(	O
RAR	B-protein
)	O
-	O
alpha	B-RNA
,	O
beta	B-RNA
,	O
gamma	B-RNA
mRNA	I-RNA
were	O
determined	O
.	O

HIV-1	O
infects	O
resting	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
but	O
remains	O
inactive	O
state	O
until	O
subsequent	O
cell	O
activation	O
.	O

BEAD-1	B-DNA
blocked	O
the	O
ability	O
of	O
the	O
TCR	B-DNA
delta	I-DNA
enhancer	I-DNA
(	O
Edelta	B-DNA
)	O
to	O
activate	O
a	O
promoter	O
when	O
located	O
between	O
the	O
two	O
in	O
a	O
chromatin-integrated	B-DNA
construct	I-DNA
.	O

Since	O
the	O
co-expression	O
with	O
a	O
dominant	O
negative	O
c-Fos	B-protein
abolished	O
the	O
responsiveness	O
to	O
TPA	O
,	O
we	O
conclude	O
that	O
activated	O
transcription	O
of	O
the	O
DRA	B-DNA
gene	I-DNA
depends	O
on	O
interactions	O
between	O
the	O
X2	B-DNA
box	I-DNA
and	O
NF-X2	B-DNA
,	O
which	O
contains	O
c-Fos	B-protein
.	O

On	O
the	O
basis	O
of	O
these	O
assays	O
,	O
all	O
N-Oct-factors	B-protein
were	O
found	O
to	O
be	O
distinct	O
from	O
the	O
ubiquitous	B-protein
Oct-1	I-protein
and	O
the	O
lymphoid-specific	B-protein
Oct-2A	I-protein
proteins	O
.	O

3.7	O
kilobases	O
upstream	O
of	O
the	O
murine	B-DNA
hematopoietic-specific	I-DNA
GATA-1	I-DNA
IE	I-DNA
promoter	I-DNA
.	O

MTBE	O
and	O
benzene-induced	O
apoptosis	O
is	O
attributed	O
to	O
a	O
discrete	O
block	O
within	O
the	O
cell	O
cycle	O
progression	O
.	O

Induction	O
of	O
endothelial	B-protein
adhesion	I-protein
molecules	I-protein
by	O
the	O
cytokine	B-protein
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF	B-protein
)	O
can	O
occur	O
independently	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
activation	O
of	O
a	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
(	O
PTK	B-protein
)	O
has	O
recently	O
been	O
implicated	O
in	O
the	O
upregulation	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
(	O
VCAM-1	B-protein
)	O
by	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
on	O
endothelial	B-cell_type
cells	I-cell_type
.	O

Surprisingly	O
,	O
overexpression	O
of	O
GRbeta	B-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
did	O
not	O
cause	O
significant	O
inhibition	O
of	O
GRalpha	B-protein
-induced	O
transactivation	O
of	O
a	O
GRE-dependent	B-DNA
luciferase	I-DNA
reporter	I-DNA
gene	I-DNA
either	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
studied	O
the	O
role	O
of	O
the	O
stromal-derived	B-protein
cytokine	I-protein
interleukin-7	I-protein
(	O
IL-7	B-protein
)	O
in	O
the	O
IL-2-gene	B-DNA
regulation	O
in	O
activated	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

To	O
investigate	O
further	O
,	O
we	O
then	O
purified	O
a	O
number	O
of	O
different	O
kinases	O
,	O
including	O
PKC	B-protein
,	O
PhK	B-protein
,	O
ZAP-70	B-protein
,	O
ERK	B-protein
,	O
and	O
MEK	B-protein
1	I-protein
(	O
a	O
MKK	B-protein
)	O
,	O
and	O
showed	O
that	O
Ro	O
09-2210	O
was	O
a	O
selective	O
inhibitor	O
of	O
MEK1	B-protein
in	O
vitro	O
(	O
IC50	O
=	O
59	O
nM	O
)	O
.	O

Plasma	O
TPO	B-protein
levels	O
are	O
regulated	O
by	O
the	O
platelet	O
and	O
megakaryocyte	O
mass	O
through	O
Mpl	B-protein
receptor	I-protein
binding	O
,	O
internalization	O
and	O
degradation	O
.	O

We	O
asked	O
whether	O
dexamethasone	O
(	O
Dex	O
)	O
and	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
inhibit	O
IL-2	B-DNA
gene	I-DNA
transcription	O
by	O
interfering	O
with	O
the	O
activity	O
of	O
nuclear	B-protein
proteins	I-protein
that	O
bind	O
to	O
the	O
IL-2	O
promoter	O
.	O

Furthermore	O
,	O
these	O
plasmids	B-DNA
were	O
not	O
active	O
in	O
RJ2.2.5	B-cell_line
,	O
an	O
in	O
vitro	O
mutagenized	O
derivative	O
of	O
Raji	B-cell_line
in	O
which	O
both	O
copies	O
of	O
CIITA	B-protein
are	O
defective	O
.	O

It	O
is	O
also	O
evident	O
that	O
association	O
of	O
X	B-protein
with	O
charged	O
phospholipid	O
surfaces	O
enhances	O
the	O
proteolytic	O
activation	O
of	O
this	O
zymogen	B-protein
by	O
increasing	O
recognition	O
and	O
susceptibility	O
of	O
the	O
sessile	O
peptide	O
bond	O
deduced	O
from	O
the	O
markedly	O
decreased	O
Km	O
and	O
increased	O
Kcat	O
.	O

It	O
is	O
most	O
likely	O
that	O
the	O
presence	O
of	O
a	O
silencer	B-DNA
contributes	O
to	O
the	O
more	O
stringent	O
activation	O
requirements	O
of	O
naive	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
results	O
suggest	O
that	O
the	O
IL-4RE	B-DNA
of	O
the	O
IL-4-inducible	B-DNA
gene	I-DNA
can	O
accommodate	O
both	O
IL-4-	B-protein
and	I-protein
IFN-gamma-activated	I-protein
factors	I-protein
,	O
such	O
as	O
STAT	B-protein
6	I-protein
and	O
STAT	B-protein
1	I-protein
,	O
either	O
in	O
homodimeric	B-protein
or	I-protein
heterodimeric	I-protein
forms	I-protein
and	O
the	O
binding	O
of	O
these	O
different	O
proteins	O
to	O
the	O
respective	O
promoter	O
may	O
play	O
a	O
potential	O
regulatory	O
role	O
in	O
the	O
IL-4	B-protein
-inducible	O
gene	O
expression	O
.	O

Examination	O
of	O
the	O
primary	O
amino	O
acid	O
sequence	O
of	O
this	O
protein	O
indicates	O
that	O
it	O
is	O
a	O
member	O
of	O
the	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
Stat	I-protein
)	I-protein
family	I-protein
of	O
DNA	B-protein
binding	I-protein
proteins	I-protein
,	O
hereby	O
designated	O
IL-4	B-protein
Stat	I-protein
.	O

Three	O
new	O
epitopes	O
were	O
identified	O
in	O
VP16	B-protein
,	O
a	O
tegument	B-protein
protein	I-protein
associated	O
with	O
VP22	B-protein
.	O

MNDA	B-protein
was	O
not	O
detected	O
in	O
normal	O
tissue	O
histiocytes	O
but	O
was	O
found	O
in	O
activated	B-cell_type
macrophages	I-cell_type
and	O
foreign	B-cell_type
body	I-cell_type
giant	I-cell_type
cells	I-cell_type
associated	O
with	O
inflammation	O
.	O

This	O
construct	O
was	O
stably	O
expressed	O
in	O
a	O
multipotent	B-cell_line
progenitor	I-cell_line
cell	I-cell_line
line	I-cell_line
transformed	O
by	O
the	O
Myb-Ets	B-protein
oncoprotein	I-protein
.	O

Previous	O
reports	O
have	O
suggested	O
the	O
CD28	B-protein
stimulation	O
contributes	O
to	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
by	O
up-regulating	O
the	O
activity	O
of	O
several	O
transcription	B-protein
factors	I-protein
,	O
including	O
AP-1	B-protein
and	O
nuclear	B-protein
factor-kappaB	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
/Rel	I-protein
family	I-protein
members	I-protein
as	O
well	O
as	O
an	O
uncharacterized	B-protein
transcription	I-protein
factor	I-protein
called	O
CD28	B-protein
response	O
complex	O
.	O

The	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
contains	O
binding	O
sites	O
for	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
and	O
the	O
constitutively	O
expressed	O
transcription	B-protein
factor	I-protein
Sp1	I-protein
,	O
both	O
of	O
which	O
are	O
highly	O
conserved	O
in	O
HIV	O
and	O
simian	O
immunodeficiency	O
virus	O
isolates	O
.	O

Immunoblot	O
and	O
flow	O
cytometry	O
analysis	O
revealed	O
a	O
limited	O
proteolysis	O
of	O
the	O
carboxyl	B-protein
terminus	I-protein
of	O
the	O
alphaIIb	B-protein
subunit	I-protein
heavy	I-protein
chain	I-protein
(	O
alphaIIbH	B-protein
)	O
,	O
as	O
judged	O
by	O
the	O
disappearance	O
of	O
the	O
epitope	O
for	O
the	O
monoclonal	B-protein
antibody	I-protein
PMI-1	I-protein
.	O

Rheumatoid	O
arthritis	O
synovial	O
tissue	O
was	O
examined	O
and	O
compared	O
with	O
osteoarthritis	O
tissue	O
for	O
the	O
presence	O
of	O
the	O
nuclear	B-protein
transcription	I-protein
factor	I-protein
C/EBP	I-protein
beta	I-protein
(	I-protein
NF-IL-6	I-protein
)	I-protein
.	O

Suppression	O
of	O
a	O
cellular	O
differentiation	O
program	O
by	O
phorbol	O
esters	O
coincides	O
with	O
inhibition	O
of	O
binding	O
of	O
a	O
cell-specific	B-protein
transcription	I-protein
factor	I-protein
(	O
NF-E2	B-protein
)	O
to	O
an	O
enhancer	B-DNA
element	I-DNA
required	O
for	O
expression	O
of	O
an	O
erythroid-specific	B-DNA
gene	I-DNA
.	O

The	O
immediate-early	O
gene	O
product	O
Egr-1	B-protein
regulates	O
the	O
human	B-DNA
interleukin-2	I-DNA
receptor	I-DNA
beta-chain	I-DNA
promoter	I-DNA
through	O
noncanonical	B-DNA
Egr	I-DNA
and	I-DNA
Sp1	I-DNA
binding	I-DNA
sites	I-DNA
.	O

Protein	O
kinase	O
inhibitor	O
H-7	O
blocks	O
accumulation	O
of	O
unspliced	B-RNA
mRNA	I-RNA
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
indicate	O
that	O
signaling	O
via	O
CD27	B-protein
on	O
B	B-cell_type
cells	I-cell_type
induces	O
IgE	B-protein
synthesis	O
,	O
in	O
cooperation	O
with	O
IL-4	B-protein
and	O
CD40	B-protein
signaling	O
,	O
by	O
promoting	O
the	O
generation	O
of	O
plasma	B-cell_type
cells	I-cell_type
through	O
up-regulation	O
of	O
positive	B-protein
regulatory	I-protein
domain	I-protein
I-binding	I-protein
factor-1	I-protein
.	O

Attenuation	O
of	O
HLA-DR	B-protein
expression	O
by	O
mononuclear	B-cell_type
phagocytes	I-cell_type
infected	O
with	O
Mycobacterium	O
tuberculosis	O
is	O
related	O
to	O
intracellular	O
sequestration	O
of	O
immature	B-protein
class	I-protein
II	I-protein
heterodimers	I-protein
.	O

Translocation	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
(	I-DNA
q27	I-DNA
;	I-DNA
q11	I-DNA
)	I-DNA
:	O
a	O
new	O
variant	O
translocation	O
in	O
a	O
patient	O
with	O
non-Hodgkin	O
's	O
lymphoma	O
of	O
B-cell	O
type	O
with	O
BCL6	B-DNA
rearrangement	O
.	O

To	O
elucidate	O
the	O
mechanism	O
of	O
GM-CSF	B-protein
gene	O
activation	O
,	O
we	O
have	O
purified	O
the	O
inducible	B-protein
factor	I-protein
NF-GM2	I-protein
from	O
the	O
nuclear	O
extract	O
of	O
stimulated	O
Jurkat	B-cell_line
cells	I-cell_line
on	O
the	O
basis	O
of	O
specific	O
DNA-binding	O
activity	O
.	O

In	O
contrast	O
to	O
their	O
inhibitory	O
effects	O
on	O
cytokine	B-protein
expression	O
,	O
GCS	O
up-regulate	O
cytokine	B-protein
receptor	I-protein
expression	O
that	O
correlates	O
with	O
enhanced	O
cytokine	B-protein
effects	O
on	O
target	B-cell_type
cells	I-cell_type
.	O

HLA-DM	B-protein
is	O
a	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
class	I-protein
II-like	I-protein
molecule	I-protein
that	O
facilitates	O
antigen	O
processing	O
by	O
catalyzing	O
the	O
exchange	O
of	O
invariant	O
chain-derived	O
peptides	O
(	O
CLIP	O
)	O
from	O
class	B-protein
II	I-protein
molecules	I-protein
for	O
antigenic	O
peptides	O
.	O

Inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
human	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
by	O
anetholdithiolthione	O
.	O

The	O
costimulatory	B-protein
molecule	I-protein
B7.1	I-protein
provides	O
a	O
second	O
signal	O
critical	O
for	O
T	O
cell	O
activation	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
gp41	B-protein
-induced	O
IL-10	B-protein
up-regulation	O
is	O
mediated	O
by	O
the	O
previously	O
described	O
synergistic	O
activation	O
of	O
cAMP	O
and	O
NF-kappaB	B-protein
pathways	O
.	O

The	O
interleukin	B-protein
2	I-protein
CD28-responsive	I-protein
complex	I-protein
contains	O
at	O
least	O
three	O
members	O
of	O
the	O
NF	B-protein
kappa	I-protein
B	I-protein
family	I-protein
:	O
c-Rel	B-protein
,	O
p50	B-protein
,	O
and	O
p65	B-protein
.	O

A	O
threonine	O
residue	O
at	O
position	B-protein
234	I-protein
,	O
previously	O
shown	O
to	O
be	O
important	O
for	O
CD40	B-protein
association	O
with	O
TNF	B-protein
receptor-associated	I-protein
factor	I-protein
2	I-protein
(	O
TRAF2	B-protein
)	O
,	O
TRAF3	B-protein
,	O
and	O
TRAF5	B-protein
,	O
was	O
not	O
required	O
for	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Chloramphenicol	B-DNA
acetyltransferase	I-DNA
expression	I-DNA
constructs	I-DNA
containing	O
regions	O
of	O
the	O
human	B-DNA
collagenase-1	I-DNA
promoter	I-DNA
were	O
stably	O
or	O
transiently	O
transfected	O
into	O
U937	B-cell_line
cells	I-cell_line
,	O
and	O
reporter	O
activity	O
was	O
assessed	O
at	O
various	O
times	O
after	O
the	O
onset	O
of	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-mediated	O
differentiation	O
.	O

In	O
fibroblasts	B-cell_type
from	O
patients	O
with	O
hereditary	O
hypercholesteremia	O
of	O
homozygous	O
type	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
did	O
not	O
exceed	O
10	O
%	O
of	O
their	O
content	O
in	O
normal	B-cell_type
cells	I-cell_type
.	O

Together	O
these	O
data	O
suggest	O
that	O
ETS1	B-protein
may	O
be	O
involved	O
in	O
mediating	O
the	O
increased	O
GM-CSF	B-protein
production	O
associated	O
with	O
T	B-cell_type
cell	I-cell_type
activation	O
.	O

In	O
addition	O
,	O
these	O
mAECA	B-protein
stimulated	O
the	O
nuclear	O
translocation	O
of	O
the	O
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
.	O

Finally	O
,	O
phorbol	O
12-myristate	O
13-acetate	O
increased	O
the	O
activity	O
of	O
both	O
the	O
core	O
and	O
the	O
969-bp	B-DNA
promoter	I-DNA
fragments	I-DNA
,	O
and	O
this	O
increase	O
was	O
abrogated	O
by	O
mutations	O
at	O
the	O
CRE	B-DNA
site	I-DNA
.	O

We	O
found	O
that	O
GIG18	B-DNA
was	O
rapidly	O
induced	O
to	O
comparable	O
levels	O
by	O
both	O
AR	B-protein
and	O
GR	B-protein
,	O
demonstrating	O
that	O
AR	B-protein
can	O
indeed	O
function	O
as	O
a	O
transcriptional	O
activator	O
in	O
S49	B-cell_line
cells	I-cell_line
and	O
,	O
moreover	O
,	O
that	O
GIG18	B-DNA
induction	O
may	O
be	O
a	O
marker	O
of	O
early	O
apoptotic	O
events	O
in	O
steroid-treated	O
cells	O
.	O

In	O
the	O
rare	O
hybrids	O
that	O
continue	O
to	O
express	O
Ig	O
,	O
all	O
other	O
tested	O
B	B-DNA
lymphocyte-specific	I-DNA
genes	I-DNA
also	O
remain	O
active	O
.	O

In	O
contrast	O
,	O
neither	O
the	O
RA-stimulated	O
,	O
RARE	B-DNA
-mediated	O
transcription	O
nor	O
the	O
induced	O
RAR-beta	B-protein
expression	O
was	O
suppressed	O
by	O
VitD3	O
,	O
suggesting	O
that	O
VitD3	O
selectively	O
inhibited	O
the	O
retinoid-induced	O
differentiation	O
program	O
but	O
not	O
the	O
RARE	B-DNA
-mediated	O
signal	O
.	O

Adult	O
lymphocytes	O
showed	O
an	O
equivalent	O
increase	O
in	O
mRNA	O
expression	O
of	O
c-fos	B-DNA
and	O
c-jun	B-DNA
(	O
140+/-25	O
and	O
155+/-31	O
%	O
)	O
at	O
30	O
min	O
post-	O
PHA	B-protein
stimulation	O
,	O
while	O
cord	B-cell_type
lymphocyte	I-cell_type
maximum	O
c-fos	O
and	O
c-jun	O
expression	O
(	O
82+/-6	O
and	O
142+/-12	O
%	O
)	O
occurred	O
at	O
15	O
min	O
post-	O
PHA	B-protein
stimulation	O
(	O
c-fos	B-DNA
,	O
p	O
=	O
0.0354	O
;	O
c-jun	B-DNA
,	O
p	O
=	O
0.0112	O
)	O
.	O

Ex	O
vivo	O
activation	O
of	O
tumor-draining	B-cell_type
lymph	I-cell_type
node	I-cell_type
T	I-cell_type
cells	I-cell_type
reverses	O
defects	O
in	O
signal	B-protein
transduction	I-protein
molecules	I-protein
.	O

BACKGROUND	O
:	O
Studies	O
from	O
our	O
laboratory	O
have	O
shown	O
that	O
the	O
earliest	O
stages	O
of	O
atherosclerosis	O
may	O
be	O
mediated	O
by	O
an	O
autoimmune	O
reaction	O
against	O
heat	B-protein
shock	I-protein
protein	I-protein
60	I-protein
(	O
Hsp60	B-protein
)	O
.	O

Retinoic	O
acid	O
treatment	O
of	O
irradiated	O
PML/RARalpha	B-protein
mice	O
enhanced	O
granulocyte	B-cell_type
recovery	O
.	O

Since	O
one	O
of	O
the	O
few	O
transcription	B-protein
factors	I-protein
which	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
monocyte	B-DNA
genes	I-DNA
is	O
the	O
macrophage-	B-protein
and	I-protein
B-cell-specific	I-protein
PU.1	I-protein
transcription	B-protein
factor	I-protein
,	O
we	O
investigated	O
whether	O
PU.1	B-protein
binds	O
and	O
activates	O
the	O
M-CSF	B-DNA
receptor	I-DNA
promoter	I-DNA
.	O

The	O
frequencies	O
of	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
directed	O
against	O
IE-1	B-protein
were	O
similar	O
to	O
those	O
directed	O
against	O
pp65	B-protein
in	O
donors	O
tested	O
with	O
known	O
pp65	B-protein
-derived	O
peptides	O
.	O

These	O
results	O
therefore	O
demonstrate	O
that	O
the	O
MHC	B-protein
class	I-protein
II	I-protein
gene	O
silencing	O
in	O
somatic	B-cell_line
cell	I-cell_line
hybrids	I-cell_line
is	O
due	O
to	O
an	O
active	O
suppression	O
of	O
one	O
of	O
the	O
promoters	B-DNA
of	O
the	O
CIITA	B-DNA
gene	I-DNA
,	O
mediated	O
by	O
the	O
epithelial	B-cell_type
cell	I-cell_type
fusion	I-cell_type
partner	I-cell_type
.	O

This	O
phenotype	O
is	O
distinct	O
from	O
that	O
of	O
G-CSF	O
receptor-/-	O
mice	O
,	O
suggesting	O
that	O
other	O
genes	O
are	O
likely	O
to	O
be	O
adversely	O
affected	O
by	O
loss	O
of	O
C/EBPalpha	B-protein
.	O

The	O
induction	O
of	O
these	O
genes	O
is	O
associated	O
with	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
-induced	O
T-cell	O
proliferation	O
.	O

Induction	O
of	O
new	O
CREB	B-protein
complexes	I-protein
implies	O
a	O
physiological	O
role	O
for	O
cAMP	O
in	O
mitogen	B-protein
activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

These	O
regulatory	B-DNA
elements	I-DNA
situated	O
downstream	O
of	O
transcription	O
interact	O
with	O
constitutive	O
and	O
inducible	O
transcription	B-protein
factors	I-protein
,	O
mediate	O
transmission	O
of	O
cellular	O
activation	O
signals	O
,	O
and	O
are	O
important	O
for	O
efficient	O
HIV-1	O
transcription	O
and	O
replication	O
.	O

Somewhat	O
unexpectedly	O
,	O
the	O
constitutive	O
p21ras	B-protein
activity	O
did	O
not	O
cause	O
an	O
increased	O
DNA	O
binding	O
of	O
transcription	B-protein
factors	I-protein
PEA1	B-protein
(	O
AP1	B-protein
)	O
,	O
PEA3	B-protein
,	O
Oct-2	B-protein
or	O
NF-kB	B-protein

Deletions	O
of	O
a	O
relatively	O
short	O
amino-	B-protein
(	I-protein
729-766	I-protein
)	I-protein
or	I-protein
carboxy-	I-protein
terminal	I-protein
(	I-protein
940-984	I-protein
)	I-protein
region	I-protein
of	O
the	O
HBD	B-protein
fragment	I-protein
eliminated	O
all	O
steroid-binding	O
properties	O
.	O

This	O
GAG	O
also	O
possesses	O
immunomodulatory	O
activity	O
in	O
vivo	O
and	O
can	O
antagonize	O
the	O
capacity	O
of	O
IFN-gamma	B-protein
to	O
induce	O
class	B-protein
II	I-protein
MHC	I-protein
antigen	I-protein
expression	O
,	O
and	O
to	O
up-regulate	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
,	O
by	O
cultured	B-cell_line
endothelial	I-cell_line
cells	I-cell_line
.	O

Activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
by	O
beta-amyloid	O
peptides	O
and	O
interferon-gamma	B-protein
in	O
murine	O
microglia	O
.	O

The	O
effect	O
of	O
the	O
steroid	O
is	O
mediated	O
by	O
its	O
binding	O
to	O
corticosteroid	B-protein
receptors	I-protein
.	O

In	O
most	O
cells	O
,	O
Rel/NF-kappa	B-protein
B	I-protein
transcription	B-protein
factors	I-protein
appear	O
to	O
mediate	O
survival	O
signals	O
that	O
protect	O
cells	O
from	O
apoptosis	O
;	O
however	O
,	O
under	O
some	O
circumstances	O
,	O
activation	O
of	O
these	O
factors	O
may	O
also	O
promote	O
apoptosis	O
.	O

Furthermore	O
,	O
concentrations	O
of	O
HU	O
below	O
250	O
microM	O
slightly	O
increased	O
the	O
5X	O
AP-1	B-protein
/CAT	B-protein
activity	O
.	O

In	O
mobility	O
shift	O
assays	O
,	O
a	O
nuclear	B-protein
factor	I-protein
from	O
THP-1	B-cell_line
and	O
U-937	B-cell_line
cells	I-cell_line
was	O
identified	O
that	O
binds	O
to	O
several	O
AP-2	B-DNA
response	I-DNA
elements	I-DNA
within	O
the	O
B2	B-DNA
promoter	I-DNA
,	O
but	O
does	O
not	O
react	O
with	O
AP-2	B-protein
antibodies	I-protein
,	O
and	O
has	O
a	O
DNA	B-DNA
sequence	I-DNA
binding	O
affinity	O
profile	O
that	O
differs	O
from	O
AP-2	B-protein
.	O

Differential	O
nuclear	O
localization	O
of	O
p50	B-protein
,	O
p52	B-protein
,	O
and	O
RelB	B-protein
proteins	O
in	O
human	B-cell_type
accessory	I-cell_type
cells	I-cell_type
of	O
the	O
immune	O
response	O
in	O
situ	O
.	O

OBJECTIVE	O
:	O
We	O
investigated	O
the	O
effect	O
of	O
DEP-PAHs	O
on	O
the	O
release	O
and	O
mRNA	B-RNA
expression	O
of	O
IL-8	B-protein
,	O
MCP-1	B-protein
,	O
and	O
RANTES	B-protein
by	O
PBMCs	B-cell_type
obtained	O
from	O
healthy	O
subjects	O
.	O

These	O
GATA/ER	B-protein
chimeric	I-protein
factors	I-protein
were	O
shown	O
to	O
be	O
hormone-inducible	B-protein
trans-activating	I-protein
proteins	I-protein
in	O
transient	O
transfection	O
assays	O
.	O

Although	O
less	O
potent	O
than	O
polyunsaturated	O
fatty	O
acids	O
in	O
inhibiting	O
endothelial	O
activation	O
,	O
oleic	O
acid	O
may	O
contribute	O
to	O
the	O
prevention	O
of	O
atherogenesis	O
through	O
selective	O
displacement	O
of	O
saturated	O
fatty	O
acids	O
in	O
cell	O
membrane	O
phospholipids	O
and	O
a	O
consequent	O
modulation	O
of	O
gene	O
expression	O
for	O
molecules	O
involved	O
in	O
monocyte	O
recruitment	O
.	O

Transient	O
expression	O
of	O
the	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
linked	O
to	O
serially	O
deleted	O
sequences	O
of	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
the	O
IL-9	B-DNA
gene	I-DNA
has	O
revealed	O
several	O
positive	O
and	O
negative	B-DNA
regulatory	I-DNA
elements	I-DNA
involved	O
in	O
the	O
basal	O
and	O
inducible	O
expression	O
of	O
the	O
IL-9	B-DNA
gene	I-DNA
in	O
C5MJ2	B-cell_line
cells	I-cell_line
.	O

To	O
investigate	O
the	O
mechanisms	O
responsible	O
for	O
tissue-specific	O
expression	O
of	O
the	O
IL-4	B-protein
gene	O
,	O
we	O
analyzed	O
nuclear	B-protein
factors	I-protein
binding	O
to	O
the	O
PRE-I	B-DNA
site	I-DNA
and	O
compared	O
the	O
binding	O
activities	O
of	O
these	O
factors	O
to	O
the	O
IL-4	B-protein
promoter	O
of	O
Th1	B-cell_type
and	I-cell_type
Th2	I-cell_type
cells	I-cell_type
.	O

The	O
CD8	B-protein
+	O
CD28	B-protein
+	O
population	O
showed	O
the	O
same	O
tendency	O
(	O
p	O
<	O
.01-.02	O
)	O
.	O

Additionally	O
,	O
Nef	B-cell_line
expressing	I-cell_line
cells	I-cell_line
were	O
transiently	O
transfected	O
with	O
a	O
plasmid	O
in	O
which	O
HIV-1	B-DNA
AP-1	I-DNA
DNA	I-DNA
recognition	I-DNA
sequences	I-DNA
were	O
cloned	O
downstream	O
of	O
the	O
chloramphenicol	B-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
gene	O
.	O

Although	O
much	O
is	O
understood	O
about	O
the	O
induction	O
of	O
genes	B-DNA
expressed	O
early	O
(	O
within	O
24	O
h	O
)	O
after	O
T-cell	O
activation	O
,	O
little	O
is	O
known	O
about	O
the	O
regulation	O
of	O
expression	O
of	O
genes	B-DNA
expressed	O
'late	O
'	O
(	O
three	O
or	O
more	O
days	O
)	O
post-stimulation	O
.	O

Our	O
data	O
suggest	O
that	O
CD30	B-protein
critically	O
regulates	O
the	O
CD40	B-protein
-mediated	O
differentiation	O
of	O
non-antigen-selected	B-cell_line
human	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O

Now	O
that	O
these	O
proteins	O
are	O
purified	O
and	O
cloned	O
,	O
the	O
major	O
goals	O
will	O
be	O
to	O
understand	O
their	O
role	O
and	O
the	O
roles	O
of	O
other	O
family	O
members	O
in	O
thymic	O
development	O
.	O

Stimulation	O
of	O
cells	O
with	O
IFN-alpha	B-protein
leads	O
to	O
the	O
assembly	O
of	O
IFN-stimulated	B-protein
gene	I-protein
factor	I-protein
3	I-protein
transcription	I-protein
factor	I-protein
complex	I-protein
formed	O
by	O
STAT1	B-protein
,	O
STAT2	B-protein
,	O
and	O
p48	B-protein
protein	I-protein
.	O

Structurally	O
related	O
divalent	O
cations	O
like	O
cobalt	O
,	O
nickel	O
,	O
and	O
mercury	O
also	O
partially	O
increase	O
monokine	O
secretion	O
but	O
to	O
a	O
much	O
lower	O
and	O
thus	O
insignificant	O
extent	O
.	O

Activator	B-protein
protein	I-protein
(	I-protein
AP	I-protein
)	I-protein
-1	I-protein
family	I-protein
proteins	I-protein
interacted	O
with	O
CLE0	B-DNA
,	O
P	O
,	O
P2	B-DNA
and	O
P4	B-DNA
.	O

GrpL	B-protein
can	O
be	O
coimmunoprecipitated	O
with	O
SLP-76	B-protein
but	O
not	O
with	O
Sos1	B-protein
or	O
Sos2	B-protein
from	O
Jurkat	B-cell_line
cell	I-cell_line
lysates	O
.	O

Four	O
of	O
six	O
truncating	O
mutations	O
were	O
novel	O
,	O
and	O
two	O
mutations	O
were	O
recurrent	O
.	O

Because	O
the	O
GATA-1	B-DNA
gene	I-DNA
is	O
known	O
to	O
transactivate	O
several	O
genes	O
specific	O
for	O
the	O
erythroid	B-cell_type
,	I-cell_type
megakaryocytic	I-cell_type
,	I-cell_type
and	I-cell_type
mastocytic/basophilic	I-cell_type
lineages	I-cell_type
,	O
we	O
studied	O
GATA-1	B-protein
expression	O
in	O
these	O
purified	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

Finally	O
,	O
we	O
show	O
that	O
the	O
B	O
cell	O
coactivator	B-protein
OBF-1/Bob1/OCA-B	B-protein
is	O
only	O
expressed	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
not	O
in	O
myeloid	B-cell_type
cells	I-cell_type
,	O
and	O
that	O
OBF-1/Bob1/OCA-B	B-protein
can	O
transactivate	O
the	O
PU.1	B-DNA
promoter	I-DNA
in	O
HeLa	B-cell_line
and	O
myeloid	B-cell_type
cells	I-cell_type
.	O

In	O
addition	O
,	O
a	O
human	B-cell_line
breast	I-cell_line
carcinoma	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
ZR-75-1	B-cell_line
)	O
,	O
which	O
expresses	O
the	O
progesterone	B-protein
receptor	I-protein
,	O
was	O
analysed	O
throughout	O
.	O

Thus	O
,	O
in	O
HIV	O
infection	O
,	O
elevated	O
cortisol	O
levels	O
suppress	O
cell-mediated	O
immunity	O
and	O
stimulate	O
humoral	O
immunity	O
,	O
whereas	O
this	O
response	O
is	O
not	O
detected	O
in	O
cortisol-resistant	O
patients	O
.	O

Interaction	O
to	O
DNA	O
induces	O
changes	O
in	O
the	O
transcription	O
rate	O
,	O
leading	O
to	O
either	O
gene	O
induction	O
or	O
gene	O
repression	O
.	O

The	O
IC50	O
of	O
alpha-tcp	O
on	O
an	O
IL-1	B-protein
-induced	O
response	O
was	O
45	O
microM	O
.	O

ISG15	B-RNA
mRNA	I-RNA
accumulation	O
in	O
U937	B-cell_line
cells	I-cell_line
is	O
not	O
detectable	O
before	O
6	O
h	O
of	O
IFN-alpha	B-protein
treatment	O
,	O
peaks	O
at	O
24	O
h	O
,	O
and	O
requires	O
protein	O
synthesis	O
.	O

We	O
have	O
shown	O
elsewhere	O
that	O
both	O
the	O
major	B-DNA
immediate-early	I-DNA
gene	I-DNA
(	O
MIE	B-DNA
)	O
and	O
lytic	O
cycle	O
infectious	O
progeny	O
virus	O
expression	O
can	O
be	O
induced	O
in	O
otherwise	O
nonpermissive	O
monocyte-like	B-cell_line
U-937	I-cell_line
cell	I-cell_line
cultures	I-cell_line
infected	O
with	O
either	O
human	O
CMV	O
(	O
HCMV	O
)	O
or	O
simian	O
CMV	O
(	O
SCMV	O
)	O
by	O
treatment	O
with	O
the	O
phorbol	O
ester	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

Finally	O
,	O
GM3	O
greatly	O
reduced	O
the	O
concentration	O
of	O
endogenous	O
GM-CSF	B-RNA
mRNA	I-RNA
induced	O
by	O
different	O
stimuli	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
but	O
did	O
not	O
affect	O
interleukin	B-RNA
3	I-RNA
mRNA	I-RNA
levels	O
in	O
the	O
same	O
cells	O
.	O

Indeed	O
,	O
erythroid	B-DNA
gene	I-DNA
expression	O
was	O
demonstrated	O
to	O
be	O
regulated	O
transcriptionally	O
by	O
ACLA	O
and	O
mainly	O
posttranscriptionally	O
by	O
DOX	O
.	O

NGAL	B-protein
levels	O
were	O
stratified	O
as	O
high	O
or	O
low	O
in	O
breast	O
cancers	O
from	O
a	O
cohort	O
of	O
node-positive	O
patients	O
with	O
known	O
outcome	O
.	O

Two	O
types	O
of	O
effector	O
cells	O
characterized	O
by	O
their	O
distinct	O
expression	O
of	O
cytokine	B-protein
profiles	O
have	O
been	O
described	O
.	O

Neither	O
deletion	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
nor	O
deletion	O
of	O
NFAT-1	B-protein
decreased	O
activation	O
of	O
viral	O
replication	O
by	O
phorbol	O
ester	O
.	O

Comparison	O
of	O
a	O
nearly	B-DNA
full-length	I-DNA
cDNA	I-DNA
sequence	I-DNA
with	O
the	O
corresponding	O
genomic	B-DNA
sequence	I-DNA
reveals	O
one	O
small	O
intron	O
and	O
an	O
open	B-DNA
reading	I-DNA
frame	I-DNA
in	O
the	O
second	O
exon	B-DNA
.	O

However	O
,	O
these	O
cells	O
have	O
been	O
impossible	O
to	O
generate	O
given	O
the	O
requirement	O
of	O
GATA-1	B-protein
for	O
Epo	B-protein
receptor	I-protein
expression	O
and	O
red	B-cell_type
cell	I-cell_type
viability	O
(	O
C.	O
Simon	O
and	O
S.	O
Orkin	O
,	O
unpublished	O
observations	O
)	O
.	O

An	O
activation-responsive	O
element	O
in	O
single	O
C	B-DNA
motif-1/lymphotactin	I-DNA
promoter	I-DNA
is	O
a	O
site	O
of	O
constitutive	O
and	O
inducible	O
DNA-protein	O
interactions	O
involving	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cell	I-protein
.	O

Such	O
findings	O
also	O
have	O
implications	O
regarding	O
the	O
clinical	O
use	O
of	O
lipid-lowering	O
agents	O
,	O
like	O
fibric	O
acids	O
,	O
which	O
can	O
activate	O
PPARalpha	B-protein
.	O

IL-4	B-protein
may	O
mediate	O
its	O
biological	O
effects	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
activating	O
a	O
tyrosine-phosphorylated	B-protein
DNA	I-protein
binding	I-protein
protein	I-protein
.	O

Pretreatment	O
with	O
actinomycin	O
D	O
and	O
cycloheximide	O
or	O
with	O
competing	O
ds-oligonucleotides	O
containing	O
the	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
or	O
activator	B-protein
protein-1	I-protein
cognate	B-DNA
DNA	I-DNA
sequences	I-DNA
significantly	O
attenuated	O
phase-2	O
response	O
,	O
suggesting	O
a	O
role	O
for	O
de	O
novo	O
macromolecule	O
synthesis	O
.	O

Requirements	O
for	O
induction	O
of	O
vitamin	O
D-mediated	O
gene	O
regulation	O
in	O
normal	B-cell_type
human	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

For	O
all	O
other	O
arginine	O
mutations	O
,	O
no	O
differences	O
in	O
affinity	O
were	O
detectable	O
.	O

Expression	O
of	O
DR3	B-protein
appears	O
to	O
be	O
restricted	O
to	O
tissues	O
enriched	O
in	O
lymphocytes	B-cell_type
.	O

Collectively	O
,	O
the	O
current	O
findings	O
open	O
new	O
perspectives	O
about	O
mechanisms	O
that	O
are	O
likely	O
to	O
regulate	O
gene	O
transcription	O
in	O
neutrophils	B-cell_type
.	O

Exposure	O
of	O
RWLeu-4	B-cell_line
cells	I-cell_line
to	O
VD3	O
also	O
inhibited	O
proliferation	O
and	O
DNA	O
synthesis	O
with	O
a	O
50	O
%	O
effective	O
dose	O
of	O
3.5-10	O
nM	O
within	O
72	O
h	O
;	O
in	O
addition	O
,	O
protein	O
and	O
RNA	O
synthesis	O
were	O
inhibited	O
by	O
VD3	O
treatment	O
.	O

We	O
provide	O
evidence	O
that	O
Zta	B-protein
up-regulation	O
of	O
p53	B-protein
leads	O
to	O
p53	B-protein
-mediated	O
interference	O
with	O
JAK	B-protein
/STAT	B-protein
activation	O
of	O
Qp	B-DNA
.	O

Expression	O
of	O
Bcl-xL	B-protein
and	O
adenovirus	B-protein
E1B	I-protein
19K	I-protein
did	O
not	O
interfere	O
with	O
anti-	O
Fas	B-protein
killing	O
.	O

Purified	B-cell_line
human	I-cell_line
peripheral	I-cell_line
T	I-cell_line
cells	I-cell_line
or	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
were	O
stimulated	O
with	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
expressing	O
either	O
human	B-protein
CD80	I-protein
(	O
CHO-CD80	B-protein
)	O
or	O
human	B-protein
CD86	I-protein
(	O
CHO-CD86	B-protein
)	O
or	O
with	O
anti-CD28	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	O
)	O
.	O

Finally	O
,	O
two	O
other	O
domains	O
,	O
located	O
at	O
positions	O
-460	O
and	O
-510	O
,	O
interact	O
with	O
proteins	O
that	O
are	O
only	O
present	O
in	O
megakaryocytic	B-cell_line
cells	I-cell_line
.	O

In	O
conclusion	O
,	O
three	O
different	O
cell-specific	O
pathways	O
lead	O
to	O
NF-kappaB	B-protein
activation	O
by	O
IL-1beta	B-protein
:	O
a	O
pathway	O
dependent	O
on	O
ROI	O
production	O
by	O
5-LOX	B-protein
in	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
an	O
ROI-	O
and	O
5-LOX	B-protein
-independent	O
pathway	O
in	O
epithelial	B-cell_type
cells	I-cell_type
,	O
and	O
a	O
pathway	O
requiring	O
ROI	O
production	O
by	O
NADPH	B-protein
oxidase	I-protein
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

The	O
experiments	O
reported	O
in	O
this	O
study	O
were	O
designed	O
to	O
address	O
the	O
signaling	O
events	O
triggered	O
by	O
TCR	B-protein
engagement	O
that	O
are	O
important	O
for	O
regulating	O
CD95	B-protein
ligand	I-protein
gene	O
expression	O
.	O

This	O
protein	O
also	O
binds	O
to	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
enhancer	I-DNA
mu	I-DNA
E1	I-DNA
site	I-DNA
.	O

Simple	O
activation	O
of	O
RXRs	B-protein
is	O
not	O
sufficient	O
to	O
induce	O
apoptosis	O
of	O
the	O
cells	O
.	O

Apoptosis	O
induced	O
by	O
DNA	O
damage	O
and	O
other	O
stresses	O
can	O
proceed	O
via	O
expression	O
of	O
Fas	B-protein
ligand	I-protein
(	O
FasL	B-protein
)	O
and	O
ligation	O
of	O
its	O
receptor	O
,	O
Fas	O
(	O
CD95	O
)	O
.	O

CIF	B-protein
inhibited	O
induction	O
of	O
either	O
construct	O
as	O
did	O
cyclosporine	O
,	O
which	O
is	O
known	O
to	O
block	O
activation	O
of	O
the	O
NFAT	B-protein
element	I-protein
.	O

Effects	O
of	O
DEP-PAHs	O
became	O
significant	O
at	O
7	O
hours	O
and	O
up	O
to	O
48	O
hours	O
time	O
culture	O
for	O
MCP-1	B-protein
,	O
and	O
up	O
to	O
24	O
hours	O
time	O
culture	O
for	O
IL-8	B-protein
and	O
RANTES	B-protein
.	O

These	O
results	O
suggest	O
that	O
Rho	B-protein
is	O
required	O
in	O
endothelial	B-cell_type
cells	I-cell_type
for	O
the	O
assembly	O
of	O
stable	O
adhesions	O
with	O
monocytes	B-cell_type
via	O
the	O
clustering	O
of	O
monocyte-binding	B-protein
receptors	I-protein
and	O
their	O
association	O
with	O
the	O
actin	O
cytoskeleton	O
,	O
independent	O
of	O
stress	O
fiber	O
formation	O
.	O

We	O
investigated	O
which	O
STAT	B-protein
complexes	I-protein
are	O
formed	O
upon	O
stimulation	O
of	O
B	B-cell_line
cell	I-cell_line
precursor	I-cell_line
acute	I-cell_line
lymphoblastic	I-cell_line
leukemia	I-cell_line
(	I-cell_line
BCP-ALL	I-cell_line
)	I-cell_line
cells	I-cell_line
with	O
IL-7	B-protein
.	O

Deletion	O
analysis	O
indicates	O
that	O
the	O
55	O
C-terminal	B-protein
amino	I-protein
acids	I-protein
of	O
the	O
LMP-1	B-protein
molecule	I-protein
,	O
but	O
not	O
its	O
TRAF	B-protein
interaction	I-protein
domain	I-protein
,	O
are	O
essential	O
for	O
AP-1	B-protein
activation	O
.	O

Immunoprecipitation	O
of	O
cell	O
extract	O
with	O
the	O
antiserum	O
against	O
the	O
mouse	B-protein
SRG3	I-protein
also	O
brought	O
down	O
a	O
195-kD	B-protein
protein	I-protein
that	O
could	O
be	O
recognized	O
by	O
an	O
antiserum	O
raised	O
against	O
human	B-protein
SWI2	I-protein
protein	I-protein
.	O

A	O
PMLRARalpha	B-DNA
transgene	I-DNA
initiates	O
murine	O
acute	O
promyelocytic	O
leukemia	O
.	O

We	O
report	O
here	O
that	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
acts	O
on	O
human	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
by	O
enhancing	O
binding	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
to	O
its	O
consensus	O
sequence	O
in	O
the	O
5	O
'	O
regulatory	O
enhancer	O
region	O
of	O
the	O
IL-2	B-DNA
receptor	I-DNA
alpha	I-DNA
chain	I-DNA
(	O
p55	B-protein
)	O
.	O

In	O
a	O
variety	O
of	O
other	O
cell	O
types	O
,	O
which	O
display	O
a	O
constitutive	O
Elk-1	B-protein
expression	O
,	O
HS	O
2	O
did	O
not	O
exist	O
,	O
suggesting	O
that	O
inducibility	O
of	O
elk-1	B-DNA
expression	O
is	O
associated	O
with	O
the	O
presence	O
of	O
HS	O
2	O
.	O

The	O
protein	O
was	O
found	O
in	O
untreated	B-cell_type
cells	I-cell_type
at	O
low	O
levels	O
,	O
whereas	O
induction	O
of	O
the	O
lytic	O
replication	O
cycle	O
by	O
TPA	O
treatment	O
or	O
by	O
providing	O
the	O
immediate	B-protein
early	I-protein
transactivator	I-protein
BZLF1	B-protein
in	O
trans	O
resulted	O
in	O
increased	O
expression	O
.	O

ATRA	O
did	O
not	O
activate	O
nuclear	O
factor	O
kappa	O
B	O
or	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
activation	O
pathways	O
,	O
suggesting	O
that	O
an	O
alternate	O
mechanism	O
is	O
involved	O
in	O
IRF-1	B-DNA
gene	I-DNA
activation	O
.	O

Mechanisms	O
of	O
transactivation	O
by	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells-1	I-protein
.	O

In	O
addition	O
,	O
treatment	O
of	O
these	O
nuclear	O
extracts	O
with	O
sodium	O
deoxycholate	O
restored	O
their	O
ability	O
to	O
form	O
the	O
heterodimer	B-protein
,	O
suggesting	O
the	O
presence	O
of	O
an	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
.	O

A	O
subset	O
of	O
B	B-cell_type
cell	I-cell_type
neoplasms	I-cell_type
expressing	O
MNDA	B-protein
included	O
hairy	O
cell	O
leukemia	O
,	O
parafollicular	O
(	O
monocytoid	O
)	O
B	O
cell	O
lymphoma	O
,	O
mantle	O
cell	O
lymphoma	O
,	O
and	O
small	O
lymphocytic	O
lymphoma	O
.	O

Adenovirus	B-protein
E1B	I-protein
19K	I-protein
protein	I-protein
is	O
required	O
for	O
efficient	O
DNA	O
replication	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O

Tax1	B-protein
strongly	O
activates	O
the	O
enhancer	O
activity	O
of	O
this	O
motif	O
,	O
in	O
both	O
epithelial	B-cell_line
HeLa	I-cell_line
and	O
lymphoid	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

The	O
signal	O
cascade	O
transducing	O
this	O
effect	O
is	O
not	O
yet	O
clear	O
.	O

Six	O
cases	O
of	O
AITL/GC	O
,	O
12	O
nonspecific	O
reactive	O
follicular	O
hyperplasia	O
(	O
FH	O
)	O
,	O
7	O
HIV	O
adenopathy	O
,	O
10	O
follicular	O
lymphoma	O
(	O
FL	O
)	O
,	O
and	O
8	O
typical	O
AITL	O
(	O
ie	O
,	O
AITL	O
without	O
GC	O
)	O
were	O
studied	O
.	O

The	O
GM-CSF	B-DNA
gene	I-DNA
is	O
not	O
expressed	O
in	O
resting	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
but	O
is	O
rapidly	O
induced	O
at	O
the	O
transcriptional	O
level	O
following	O
activation	O
through	O
the	O
cell	B-protein
surface	I-protein
T-cell	I-protein
receptor	I-protein
.	O

Interestingly	O
,	O
evidence	O
for	O
the	O
presence	O
of	O
B	B-cell_type
cells	I-cell_type
that	O
have	O
already	O
switched	O
to	O
IgE	B-protein
was	O
seen	O
in	O
PBMCs	B-cell_type
of	O
several	O
patients	O
with	O
asthma	O
or	O
HIE	O
.	O

C/EBPepsilon	B-RNA
mRNA	I-RNA
was	O
greatly	O
induced	O
during	O
in	O
vitro	O
granulocytic	O
differentiation	O
of	O
human	B-cell_type
primary	I-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O

This	O
phenomenon	O
has	O
been	O
termed	O
``	O
A/R	O
tolerance.	O
''	O

(	O
5	O
)	O
Some	O
neoplastic	O
cells	O
in	O
AITL	O
stained	O
for	O
Bcl-6	B-protein
,	O
suggesting	O
up-regulation	O
of	O
Bcl-6	B-protein
expression	O
in	O
this	O
tumor	O
.	O

After	O
preincubation	O
of	O
permeabilized	B-cell_line
cells	I-cell_line
with	O
a	O
Ran	B-protein
mutant	I-protein
that	O
can	O
not	O
hydrolyze	O
GTP	O
(	O
RanQ69L	B-protein
)	O
,	O
cytosol	O
supports	O
NFAT	B-protein
export	O
,	O
but	O
CRM1	B-protein
and	O
Ran	B-protein
alone	O
do	O
not	O
.	O

All	O
cells	O
tested	O
express	O
TAFII105	B-RNA
mRNA	I-RNA
,	O
but	O
only	O
B	B-cell_type
cells	I-cell_type
contain	O
significant	O
levels	O
of	O
protein	O
associated	O
with	O
TFIID	B-protein
.	O

When	O
submitted	O
to	O
an	O
in	O
vitro	O
CD4	B-protein
cross-linking	O
by	O
iHIV-1	O
,	O
PBMCs	B-cell_type
from	O
HIV-1-infected	O
patients	O
were	O
found	O
to	O
produce	O
virus	O
.	O

Further	O
,	O
in	O
normal	O
and	O
CD45-	B-cell_line
or	I-cell_line
Lck-deficient	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
Fas	O
stimulation	O
results	O
in	O
activation	O
of	O
Jun	B-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
,	O
a	O
proposed	O
mediator	O
of	O
stress	O
activation	O
pathways	O
.	O

Because	O
leukocyte-mediated	O
tissue	O
damage	O
is	O
an	O
important	O
component	O
of	O
the	O
pathologic	O
picture	O
in	O
ischemia/reperfusion	O
,	O
we	O
have	O
sought	O
mechanisms	O
by	O
which	O
PMNs	B-cell_type
are	O
directed	O
into	O
hypoxic	O
tissue	O
.	O

Although	O
three	O
sites	O
in	O
the	O
TNF-alpha	B-DNA
promoter	I-DNA
(	O
kappa	O
1	O
,	O
kappa	O
2	O
,	O
and	O
kappa	O
3	O
)	O
specifically	O
bind	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
in	O
lymphoid	O
nuclear	O
extracts	O
,	O
TNF-alpha	B-RNA
mRNA	I-RNA
induction	O
by	O
PMA	O
does	O
not	O
correlate	O
with	O
NF-kappa	B-protein
B	I-protein
binding	O
activities	O
displayed	O
by	O
different	O
T	B-cell_line
and	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Specific	O
nuclear	O
translocation	O
of	O
[	B-protein
3H	I-protein
]	I-protein
calcitriol/VDR	I-protein
was	O
found	O
to	O
be	O
time	O
dependent	O
reaching	O
a	O
maximum	O
of	O
approximately	O
2100	O
binding	O
sites/nucleus	O
after	O
3	O
h	O
of	O
incubation	O
in	O
HL60	B-cell_line
cells	I-cell_line
,	O
whereas	O
a	O
maximum	O
of	O
approximately	O
310	O
binding	O
sites/nucleus	O
was	O
found	O
after	O
3	O
h	O
in	O
PBL	B-cell_type
.	O

These	O
findings	O
also	O
highlight	O
the	O
potential	O
for	O
an	O
interplay	O
between	O
the	O
Notch	O
and	O
NF-kappaB	O
signaling	O
pathways	O
in	O
the	O
immune	O
system	O
.	O

In	O
fact	O
,	O
8e51	B-cell_line
cells	I-cell_line
that	O
had	O
almost	O
lost	O
their	O
syncytia-forming	O
capacity	O
were	O
found	O
to	O
contain	O
at	O
least	O
10	O
times	O
less	O
active	O
NF-kappaB	B-protein
DNA-binding	I-protein
complex	I-protein
than	O
the	O
actively	B-cell_type
fusing	I-cell_type
cells	I-cell_type
.	O

In	O
the	O
present	O
study	O
we	O
focused	O
on	O
the	O
pathophysiology	O
of	O
PIH	O
,	O
mainly	O
on	O
the	O
role	O
of	O
mineralocorticoids	O
,	O
reversed	O
blood	O
pressure	O
patterns	O
,	O
and	O
the	O
resulting	O
necessity	O
of	O
continuous	O
monitoring	O
of	O
the	O
preeclamptic	O
mother	O
.	O

LPS	O
is	O
not	O
able	O
to	O
induce	O
HIV-1	O
production	O
in	O
a	O
cloned	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Many	O
of	O
the	O
effects	O
of	O
CD40	B-protein
are	O
believed	O
to	O
be	O
achieved	O
through	O
altered	O
gene	O
expression	O
.	O

Furthermore	O
,	O
it	O
was	O
induced	O
in	O
lymphocytes	B-cell_type
activated	O
with	O
phorbol	O
ester	O
and	O
Ca2+	O
ionophore	O
within	O
30	O
min	O
after	O
stimulation	O
.	O

Two	O
anti-MHC	B-protein
class	I-protein
II	I-protein
Ab	I-protein
,	O
L227	B-protein
and	O
2.06	B-protein
,	O
inhibited	O
the	O
growth	O
of	O
B104	B-cell_line
cells	I-cell_line
,	O
although	O
2.06	B-protein
,	O
but	O
not	O
L227	B-protein
,	O
needed	O
to	O
be	O
further	O
cross-linked	O
with	O
a	O
goat	B-protein
anti-mouse	I-protein
IgG	I-protein
Ab	I-protein
(	O
GAM	B-protein
)	O
to	O
show	O
the	O
effect	O
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
we	O
showed	O
that	O
IL-10	B-protein
and	O
IL-4	B-protein
inhibited	O
LPS-induced	O
AP-1	B-protein
binding	O
activity	O
.	O

Unexpectedly	O
,	O
the	O
17q	B-DNA
breakpoints	I-DNA
in	O
four	O
CMPD1	O
translocation	O
cases	O
previously	O
analyzed	O
by	O
us	O
and	O
others	O
map	O
50	O
kb	O
or	O
more	O
from	O
SOX9	B-DNA
.	O

Activation	O
of	O
leukocytes	B-cell_type
by	O
proinflammatory	O
stimuli	O
selectively	O
initiates	O
intracellular	O
signal	O
transduction	O
via	O
sequential	O
phosphorylation	O
of	O
kinases	B-protein
.	O

In	O
contrast	O
,	O
NF-kappa	B-protein
B	I-protein
activity	O
was	O
not	O
detected	O
in	O
the	O
nucleus	O
following	O
long-term	O
expression	O
of	O
Tax	B-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

The	O
observed	O
failure	O
of	O
granulopoiesis	O
could	O
be	O
rescued	O
by	O
the	O
addition	O
of	O
soluble	O
IL-6	B-protein
receptor	I-protein
and	O
IL-6	B-protein
or	O
by	O
retroviral	O
transduction	O
of	O
G-CSF	B-protein
receptors	I-protein
,	O
demonstrating	O
that	O
loss	O
of	O
both	O
of	O
these	O
receptors	O
contributes	O
to	O
the	O
absolute	O
block	O
in	O
granulocyte	O
maturation	O
observed	O
in	O
C/EBPalpha-deficient	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
.	O

Groups	O
1	O
and	O
2	O
have	O
a	O
serine-rich	B-protein
region	I-protein
and	O
an	O
``	O
arginine	B-protein
element	I-protein
``	O
(	O
RRLPIF	B-protein
)	O
at	O
the	O
carboxyl	B-protein
terminus	I-protein
.	O

Lymphocytes	B-cell_type
have	O
been	O
postulated	O
to	O
serve	O
as	O
a	O
site	O
of	O
adenoviral	O
persistence	O
based	O
upon	O
the	O
ability	O
to	O
isolate	O
adenovirus	O
from	O
tonsils	O
and	O
to	O
detect	O
adenovirus	B-DNA
DNA	I-DNA
by	O
Southern	O
blot	O
hybridization	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O

NAC	O
also	O
inhibited	O
DC	O
responses	O
induced	O
by	O
CD40	B-protein
engagement	O
.	O

In	O
this	O
report	O
expression	O
profiles	O
and	O
activation	O
of	O
PKC	B-protein
were	O
analyzed	O
in	O
human	B-cell_line
Raji	I-cell_line
B	I-cell_line
lymphoblastoid	I-cell_line
cells	I-cell_line
.	O

However	O
,	O
in	O
contrast	O
with	O
TNF-alpha	B-protein
,	O
dopamine	O
treatment	O
did	O
not	O
affect	O
NF-kappaB	B-protein
DNA	O
binding	O
activity	O
nor	O
the	O
concentrations	O
of	O
p50	B-protein
,	O
p65	B-protein
and	O
IkappaB-alpha	B-protein
proteins	I-protein
,	O
which	O
suggests	O
a	O
distinct	O
NF-kappaB	B-protein
activation	O
mechanism	O
.	O

TRAF3	B-protein
is	O
a	O
negative	O
modulator	O
of	O
LMP1	B-protein
(	O
1-231	O
)	O
-mediated	O
NF-kappaB	B-protein
activation	O
.	O

Thus	O
,	O
GATA-1	B-protein
plays	O
important	O
in	O
vivo	O
roles	O
for	O
directing	O
definitive	O
hematopoietic	B-cell_type
progenitors	I-cell_type
to	O
differentiate	O
along	O
both	O
the	O
erythroid	O
and	O
megakaryocytic	O
pathways	O
.	O

This	O
study	O
indicates	O
that	O
activation	O
of	O
PKA	B-protein
reduces	O
the	O
induction	O
of	O
a	O
distinct	O
set	O
of	O
genes	B-DNA
in	O
monocytes	B-cell_type
and	O
endothelial	B-cell_type
cells	I-cell_type
by	O
inhibiting	O
NF-kappaB	B-protein
-mediated	O
transcription	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
induction	O
of	O
c-jun	B-DNA
transcription	O
by	O
okadaic	O
acid	O
is	O
controlled	O
primarily	O
by	O
a	O
transcriptional	O
mechanism	O
.	O

The	O
phenotype	O
of	O
RelB	B-protein
knockout	O
mice	O
implicates	O
this	O
member	O
of	O
the	O
NF	B-protein
kappa	I-protein
B/Rel	I-protein
family	I-protein
in	O
DC	B-cell_type
differentiation	O
.	O

The	O
other	O
factor	O
bound	O
to	O
a	O
putative	B-DNA
AP-1	I-DNA
recognition	I-DNA
sequence	I-DNA
predicted	O
for	O
the	O
HIV-1	O
NRE	B-DNA
.	O

Data	O
are	O
also	O
presented	O
to	O
suggest	O
that	O
the	O
redox	O
regulation	O
in	O
NF-kappaB	B-protein
activation	O
may	O
be	O
relevant	O
to	O
immune-related	O
diseases	O
and	O
to	O
aging	O
.	O

The	O
nuclear	O
distribution	O
of	O
GATA	B-protein
transcription	I-protein
factors	I-protein
in	O
murine	B-cell_type
haemopoietic	I-cell_type
cells	I-cell_type
was	O
examined	O
by	O
indirect	O
immunofluorescence	O
.	O

This	O
multiple	O
cytokine	B-protein
production	O
deficiency	O
could	O
not	O
be	O
restored	O
by	O
IL-2	B-protein
or	O
co-stimulatory	O
signals	O
provided	O
by	O
antigen-presenting	B-cell_type
cells	I-cell_type
(	O
APC	B-cell_type
)	O
.	O

Phenotypic	O
DC	B-cell_type
characteristics	O
of	O
KG1	B-cell_line
dendritic-like	I-cell_line
cells	I-cell_line
include	O
morphology	O
(	O
loosely	B-cell_type
adherent	I-cell_type
cells	I-cell_type
with	O
long	O
neurite	O
processes	O
)	O
,	O
MHC	B-protein
I+/	O
MHC	B-protein
IIbright/CD83+/CD86+/	O
CD14	B-protein
-	O
surface	O
Ag	O
expression	O
,	O
and	O
RelB	B-protein
and	O
DC	B-cell_type
-CK1	O
gene	O
expression	O
.	O

We	O
measured	O
effects	O
on	O
the	O
HIV-1	B-DNA
LTR	I-DNA
in	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
were	O
stimulated	O
with	O
antibodies	O
against	O
CD45	B-protein
and	O
in	O
those	O
that	O
lacked	O
the	O
expression	O
of	O
CD45	B-protein
on	O
their	O
surfaces	O
.	O

Western	O
Blot	O
analysis	O
using	O
antibodies	O
against	O
subunits	O
of	O
GTP-binding	B-protein
proteins	I-protein
indicated	O
that	O
Gq/G11	B-protein
richly	O
existed	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

SF	O
suppression	O
was	O
mediated	O
by	O
IL-4	B-protein
and	O
IL-10	B-protein
and	O
inhibition	O
of	O
IL-12	B-protein
expression	O
,	O
and	O
it	O
was	O
reversed	O
in	O
a	O
dominant	O
fashion	O
by	O
exogenous	O
IL-12	O
.	O

It	O
was	O
found	O
that	O
the	O
number	O
of	O
ER	B-protein
in	O
leucocytes	B-cell_type
was	O
significantly	O
increased	O
in	O
gynecomastia	O
(	O
Rs	O
of	O
leucocytes	B-cell_type
were	O
1054	O
+/-	O
254	O
sites/cell	O
)	O
.	O

In	O
contrast	O
,	O
p65	B-protein
delta	I-protein
,	O
a	O
naturally	O
occurring	O
splice	O
variant	O
,	O
fails	O
to	O
markedly	O
augment	O
I	B-protein
kappa	I-protein
B	I-protein
protein	O
levels	O
.	O

We	O
now	O
demonstrate	O
that	O
v-src	B-DNA
expression	O
correlates	O
with	O
nuclear	O
expression	O
of	O
a	O
kappa	B-protein
B	I-protein
binding	I-protein
complex	I-protein
similar	O
to	O
that	O
induced	O
by	O
phorbol	O
ester	O
and	O
ionomycin	O
,	O
as	O
detected	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
variety	O
of	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
.	O

Radiolabeled	B-protein
VDR	I-protein
disappeared	O
from	O
the	O
nuclear	O
compartment	O
with	O
a	O
halflife	O
of	O
approximately	O
30	O
min	O
if	O
cells	O
were	O
cultured	O
with	O
identical	O
concentrations	O
of	O
unlabeled	O
hormone	O
after	O
the	O
pulse	O
(	O
pulse/chase-experiments	O
)	O
.	O

Consistent	O
with	O
involvement	O
in	O
the	O
G0/G1	B-DNA
switch	I-DNA
,	O
the	O
protein	O
contains	O
potential	O
sites	O
for	O
phosphorylation	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
casein	B-protein
kinase	I-protein
II	I-protein
.	O

PU.1	B-protein
is	O
a	O
hematopoietic-specific	B-protein
Ets	I-protein
family	I-protein
transcription	I-protein
factor	I-protein
that	O
is	O
required	O
for	O
development	O
of	O
some	O
lymphoid	B-cell_type
and	I-cell_type
myeloid	I-cell_type
lineages	I-cell_type
.	O

Further	O
analysis	O
identified	O
three	O
elements	O
required	O
for	O
efficient	O
induction	O
,	O
referred	O
to	O
as	O
GM2	B-DNA
,	O
GC-box	B-DNA
and	O
conserved	B-DNA
lymphokine	I-DNA
element	I-DNA
(	O
CLE0	B-DNA
)	O
.	O

In	O
summary	O
,	O
we	O
have	O
identified	O
a	O
tissue-specific	B-DNA
regulatory	I-DNA
region	I-DNA
5	O
'	O
of	O
the	O
ecto-5'-NT	B-DNA
core	I-DNA
promoter	I-DNA
that	O
requires	O
the	O
presence	O
of	O
a	O
functional	O
CRE	B-DNA
site	I-DNA
within	O
the	O
basal	B-DNA
promoter	I-DNA
for	O
its	O
suppressive	O
activity	O
.	O

Finally	O
,	O
we	O
show	O
that	O
a	O
DNA	B-DNA
fragment	I-DNA
containing	O
the	O
human	B-DNA
GATA3	I-DNA
transcription	I-DNA
unit	I-DNA
,	O
3	B-DNA
kb	I-DNA
upstream	I-DNA
from	O
the	O
initiation	B-DNA
site	I-DNA
and	O
4	B-DNA
kb	I-DNA
downstream	I-DNA
from	O
the	O
polyadenylation	B-DNA
site	I-DNA
,	O
displays	O
T-cell	O
specificity	O
.	O

The	O
inflammatory	O
mediators	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
are	O
potent	O
activators	O
of	O
NF-kappaB	B-protein
.	O

Since	O
TNF	B-protein
is	O
one	O
of	O
the	O
major	O
inducers	O
of	O
various	O
adhesion	B-protein
molecules	I-protein
in	O
human	O
endothelial	O
cells	O
and	O
their	O
expression	O
is	O
known	O
to	O
require	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
we	O
examined	O
the	O
effect	O
of	O
PTPase	B-protein
inhibitors	O
on	O
the	O
TNF	B-protein
-mediated	O
induction	O
of	O
intracellular	B-protein
adhesion	I-protein
molecule	I-protein
(	I-protein
ICAM	I-protein
)	I-protein
-1	I-protein
,	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule	I-protein
(	I-protein
VCAM	I-protein
)	I-protein
-1	I-protein
and	O
endothelial	B-protein
leukocyte	I-protein
adhesion	I-protein
molecule	I-protein
(	I-protein
ELAM	I-protein
)	I-protein
-1	I-protein
.	O

CD8+	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
of	O
HIV-1	O
infected	O
individuals	O
produce	O
a	O
soluble	B-protein
factor	I-protein
that	O
efficiently	O
suppresses	O
HIV-1	O
replication	O
at	O
the	O
transcriptional	O
level	O
.	O

We	O
report	O
that	O
both	O
YY1	B-protein
and	O
LSF	B-protein
participate	O
in	O
the	O
formation	O
of	O
a	O
complex	O
that	O
recognizes	O
the	O
initiation	O
region	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
.	O

Stimulation	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
by	O
either	O
ligation	O
of	O
CD40	B-protein
Ag	I-protein
or	O
cross-linking	O
the	O
Ig	B-protein
receptor	I-protein
is	O
also	O
insufficient	O
to	O
render	O
B	B-cell_type
lymphocytes	I-cell_type
responsive	O
to	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

One	O
hundred	O
milligram	O
of	O
hydrocortisone	O
was	O
injected	O
intravenously	O
into	O
4	O
normal	O
subjects	O
.	O

Comparative	O
mapping	O
of	O
SRY	B-DNA
in	O
the	O
great	O
apes	O
.	O

IFN-gamma	O
production	O
is	O
strongly	O
decreased	O
by	O
HCSs	O
in	O
some	O
cases	O
,	O
but	O
not	O
in	O
others	O
.	O

Interleukin-7	B-protein
signaling	O
in	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
precursor	I-cell_line
acute	I-cell_line
lymphoblastic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
and	O
murine	B-cell_line
BAF3	I-cell_line
cells	I-cell_line
involves	O
activation	O
of	O
STAT1	B-protein
and	O
STAT5	B-protein
mediated	O
via	O
the	O
interleukin-7	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
.	O

Thus	O
,	O
cosignaling	O
via	O
the	O
LT-beta	B-protein
and	I-protein
TNF-alpha	I-protein
receptors	I-protein
is	O
probably	O
involved	O
in	O
the	O
modulation	O
of	O
HIV-1	O
replication	O
and	O
the	O
subsequent	O
determination	O
of	O
HIV-1	O
viral	O
burden	O
in	O
monocytes	B-cell_type
.	O

HIV-1	B-protein
Nef	I-protein
protein	I-protein
inhibits	O
the	O
recruitment	O
of	O
AP-1	B-protein
DNA-binding	O
activity	O
in	O
human	B-cell_type
T-cells	I-cell_type
.	O

This	O
implies	O
that	O
high	O
levels	O
of	O
IgE	B-protein
in	O
these	O
patients	O
either	O
results	O
from	O
B	B-cell_type
cells	I-cell_type
that	O
have	O
already	O
undergone	O
class	O
switching	O
,	O
from	O
Ig	O
class	O
switching	O
that	O
is	O
localized	O
to	O
target	O
tissues	O
,	O
or	O
both	O
.	O

The	O
expression	O
of	O
the	O
PML	B-DNA
gene	I-DNA
was	O
investigated	O
in	O
purified	O
early	O
hematopoietic	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
(	O
HPCs	B-cell_type
)	O
induced	O
to	O
unilineage	O
erythroid	O
or	O
granulocytic	O
differentiation	O
.	O

We	O
have	O
examined	O
the	O
influence	O
of	O
the	O
affinity	O
and	O
concentration	O
of	O
exogenous	O
peptide	O
and	O
the	O
density	O
of	O
specific	O
MHC	B-protein
molecules	I-protein
on	O
the	O
proliferation	O
of	O
a	O
CD4+	B-cell_line
,	I-cell_line
DQA1*0501/DQB1*0201	I-cell_line
(	I-cell_line
DQ2.1	I-cell_line
)	I-cell_line
-restricted	I-cell_line
,	I-cell_line
HSV-2-specific	I-cell_line
T	I-cell_line
cell	I-cell_line
clone	I-cell_line
.	O

In	O
order	O
to	O
characterize	O
the	O
cell	O
types	O
that	O
are	O
targets	O
for	O
this	O
immunoregulatory	O
hormone	O
,	O
we	O
have	O
evaluated	O
the	O
expression	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
on	O
peripheral	B-cell_type
blood	I-cell_type
T-lymphocytes	I-cell_type
and	O
those	O
recovered	O
from	O
the	O
lung	O
by	O
bronchoalveolar	O
lavage	O
from	O
patients	O
with	O
pulmonary	O
granulomatous	O
diseases	O
(	O
tuberculosis	O
and	O
sarcoidosis	O
)	O
and	O
from	O
normal	O
control	O
subjects	O
using	O
combined	O
autoradiographic	O
and	O
immunohistochemical	O
techniques	O
.	O

Furthermore	O
,	O
HIV-1	O
replication	O
is	O
cooperatively	O
stimulated	O
when	O
the	O
distinct	O
LT-betaR	B-protein
and	O
TNF	B-protein
receptor	I-protein
systems	I-protein
are	O
simultaneously	O
engaged	O
by	O
their	O
specific	O
ligands	O
.	O

Calcineurin	B-protein
stimulates	O
the	O
NF-kappa	B-DNA
B	I-DNA
element	I-DNA
by	O
enhancing	O
inactivation	O
of	O
I	B-protein
kappa	I-protein
B/MAD3	I-protein
,	O
an	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
thereby	O
increasing	O
the	O
amount	O
of	O
nuclear	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
activity	O
.	O

In	O
conclusion	O
,	O
MDHM-stimulated	O
induction	O
of	O
cytokine	B-RNA
mRNA	I-RNA
expression	O
was	O
accompanied	O
by	O
different	O
proto-oncogene	B-DNA
responses	O
in	O
PBMo	B-cell_type
and	O
THP-1	B-cell_line
cells	I-cell_line
.	O

There	O
are	O
four	O
putative	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
(	O
kappa	B-DNA
B-1	I-DNA
,	O
kappa	B-DNA
B-2	I-DNA
,	O
kappa	B-DNA
B-3	I-DNA
,	O
kappa	B-DNA
B-4	I-DNA
)	O
in	O
human	B-DNA
TNF-alpha	I-DNA
promoter	I-DNA
.	O

These	O
data	O
indicate	O
that	O
IL-4	B-protein
suppresses	O
the	O
induction	O
of	O
transcription	B-protein
factors	I-protein
in	O
human	B-cell_type
activated	I-cell_type
monocytes	I-cell_type
.	O

Tissue	O
specific	O
regulation	O
of	O
gene	O
expression	O
by	O
transcription	B-protein
factors	I-protein
is	O
a	O
fascinating	O
new	O
field	O
in	O
molecular	O
immunology	O
.	O

In	O
THP-1	B-cell_line
cells	I-cell_line
and	O
in	O
normal	O
PBM	B-cell_type
,	O
gamma-IFN	B-protein
inhibits	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
induction	O
of	O
24-hydroxylase	B-protein
mRNA	O
levels	O
without	O
reducing	O
mRNA	O
stability	O
,	O
suggesting	O
gamma-IFN	B-protein
inhibition	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
transactivating	O
function	O
.	O

Therefore	O
the	O
ACH-2	B-cell_line
cell	O
line	O
is	O
a	O
good	O
candidate	O
for	O
studying	O
the	O
effects	O
of	O
drugs	O
on	O
HIV-1	O
activation	O
.	O

CD2	B-protein
signalling	O
induces	O
phosphorylation	O
of	O
CREB	B-protein
in	O
primary	B-cell_type
lymphocytes	I-cell_type
.	O

In	O
parallel	O
,	O
Syk	B-protein
was	O
phosphorylated	O
on	O
tyrosine	O
,	O
while	O
Zap	B-protein
was	O
not	O
.	O

Butyric	O
acid	O
(	O
BA	O
)	O
is	O
known	O
to	O
induce	O
overexpression	O
of	O
fetal	B-protein
hemoglobin	I-protein
and	O
then	O
erythroid	O
differentiation	O
.	O

The	O
T-cell	B-protein
oncogenic	I-protein
protein	I-protein
HOX11	I-protein
activates	O
Aldh1	B-protein
expression	O
in	O
NIH	B-cell_line
3T3	I-cell_line
cells	I-cell_line
but	O
represses	O
its	O
expression	O
in	O
mouse	O
spleen	O
development	O
.	O

These	O
data	O
indicate	O
that	O
IL-11	B-protein
is	O
a	O
regulatory	B-protein
cytokine	I-protein
in	O
the	O
lung	O
and	O
that	O
,	O
like	O
other	O
members	O
of	O
this	O
family	O
,	O
its	O
anti-inflammatory	O
properties	O
appear	O
to	O
be	O
linked	O
to	O
its	O
suppression	O
of	O
NF-kappaB	B-protein
activation	O
,	O
diminished	O
production	O
of	O
TNF-alpha	B-protein
,	O
and	O
reduced	O
up-regulation	O
of	O
lung	B-protein
vascular	I-protein
ICAM-1	I-protein
.	O

C5a	B-protein
and	O
C3a	B-protein
stimulation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
resulted	O
in	O
nuclear	O
expression	O
of	O
a	O
DNA	O
binding	O
activity	O
with	O
specificity	O
to	O
the	O
kappaB	B-DNA
sequence	I-DNA
.	O

We	O
cloned	O
and	O
characterized	O
a	O
fork	B-DNA
head	I-DNA
cDNA	I-DNA
from	O
human	B-RNA
T	I-RNA
helper	I-RNA
cell	I-RNA
mRNA	I-RNA
using	O
differential	O
display	O
RT-PCR	O
.	O

In	O
addition	O
,	O
genistein	O
was	O
a	O
very	O
low-potency	O
agonist	O
,	O
having	O
an	O
EC50	O
of	O
1.5	O
microM	O
.	O

Here	O
,	O
cytokine	B-protein
-induced	O
activation	O
of	O
Stat3	B-protein
in	O
previously	O
activated	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
was	O
examined	O
using	O
Stat3	B-protein
antibodies	O
directed	O
against	O
different	O
regions	O
of	O
Stat3	B-protein
.	O

In	O
this	O
study	O
,	O
we	O
have	O
focused	O
on	O
atypical	O
PKC	B-protein
isoenzymes	I-protein
.	O

We	O
,	O
therefore	O
,	O
examined	O
glucocorticoid	B-protein
receptor	I-protein
characteristics	O
on	O
mononuclear	B-cell_type
leukocytes	I-cell_type
by	O
measuring	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
and	O
the	O
effect	O
of	O
dexamethasone	O
on	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
,	O
which	O
is	O
one	O
of	O
the	O
effects	O
of	O
glucocorticoid	B-protein
receptor	I-protein
activation	O
.	O

The	O
virus	O
with	O
four	O
Sp1	O
sites	O
did	O
outgrow	O
the	O
three	O
Sp1	O
virus	O
in	O
35	O
days	O
of	O
culture	O
and	O
CTG-monomer	O
virus	O
outcompeted	O
the	O
CTG-dimer	O
virus	O
in	O
42	O
days	O
.	O

The	O
results	O
were	O
compared	O
to	O
those	O
obtained	O
with	O
the	O
parental	B-cell_line
granulocyte-macrophage	I-cell_line
colony-stimulating	I-cell_line
factor	I-cell_line
(	I-cell_line
GM-CSF	I-cell_line
)	I-cell_line
-dependent	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
UT-7	B-cell_line
,	O
which	O
has	O
a	O
predominantly	O
megakaryoblastic	O
phenotype	O
and	O
is	O
unable	O
to	O
proliferate	O
continuously	O
in	O
the	O
presence	O
of	O
Epo	B-protein
.	O

In	O
contrast	O
,	O
it	O
is	O
also	O
becoming	O
clear	O
that	O
the	O
dysregulated	O
expression	O
of	O
proteins	O
that	O
are	O
not	O
genetically	O
altered	O
can	O
also	O
contribute	O
to	O
the	O
progression	O
of	O
lymphoid	O
malignancies	O
.	O

We	O
measured	O
steroid	O
mediated	O
lysis	O
,	O
receptor	O
number	O
and	O
induction	O
of	O
glutamine	B-protein
synthetase	I-protein
in	O
the	O
transfected	B-cell_line
cells	I-cell_line
.	O

Here	O
we	O
investigate	O
the	O
mechanism	O
by	O
which	O
PU.1	B-protein
interferes	O
with	O
erythroid	O
differentiation	O
.	O

Immunofluorescence	O
colocalization	O
of	O
both	O
estrogen	B-protein
and	O
progesterone	B-protein
receptors	I-protein
with	O
eosinophil	B-protein
cationic	I-protein
protein	I-protein
showed	O
that	O
approximately	O
70	O
%	O
of	O
positive	B-cell_type
cells	I-cell_type
were	O
eosinophils	B-cell_type
.	O

To	O
investigate	O
the	O
effect	O
of	O
treatment	O
with	O
a	O
pan	O
anti	B-protein
gamma/delta	I-protein
antibody	I-protein
,	O
lymphocytes	B-cell_type
were	O
incubated	O
for	O
3	O
hr	O
with	O
the	O
antibody	O
,	O
and	O
then	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-10	I-protein
,	O
IL-12	B-protein
and	O
progesterone-induced	B-protein
blocking	I-protein
factor	I-protein
(	O
PIBF	B-protein
)	O
expression	O
(	O
by	O
immuno-cytochemistry	O
)	O
as	O
well	O
as	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	I-cell_type
activity	O
were	O
determined	O
.	O

Adhesion	O
of	O
monocytoid	B-cell_line
U937	I-cell_line
cells	I-cell_line
to	O
LPS-treated	O
endothelial	O
cells	O
was	O
reduced	O
concomitantly	O
.	O

The	O
transcription	B-protein
factors	I-protein
active	O
at	O
the	O
IL-2	B-DNA
promoter	I-DNA
were	O
differentially	O
influenced	O
:	O
upon	O
down-modulation	O
of	O
okadaic	B-protein
acid-sensitive	I-protein
phosphatases	I-protein
,	O
transactivation	O
by	O
octamer	O
,	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
NF	B-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
proteins	I-protein
was	O
abrogated	O
,	O
while	O
transactivation	O
by	O
AP-1	B-protein
proteins	I-protein
was	I-protein
even	I-protein
enhanced	I-protein
.	I-protein

We	O
now	O
demonstrate	O
the	O
following	O
.	O

In	O
hyperthyroidism	O
nuclear	O
T3	O
maximal	O
binding	O
capacity	O
(	O
MBC	O
)	O
was	O
unaltered	O
,	O
whereas	O
in	O
hypothyroidism	O
the	O
MBC	O
was	O
significantly	O
increased	O
.	O

1	O
alpha	O
,	O
25-Dihydroxyvitamin	O
D3	O
(	O
VD	O
)	O
is	O
a	O
potent	O
inducer	O
of	O
monocytic	O
differentiation	O
of	O
both	O
normal	B-cell_type
and	I-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O

In	O
the	O
CD45-negative	B-cell_line
variant	I-cell_line
,	O
the	O
effect	O
of	O
pervanadate	O
on	O
tyrosine	O
phosphorylation	O
was	O
globally	O
decreased	O
and	O
some	O
phosphorylated	O
substrates	O
were	O
specifically	O
missing	O
.	O

Induction	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
by	O
low-density	B-protein
lipoprotein	I-protein
.	O

Monocytes	O
were	O
isolated	O
from	O
human	O
donors	O
.	O

The	O
Ets	B-protein
proteins	I-protein
share	O
a	O
conserved	O
Ets	B-protein
domain	I-protein
that	O
mediates	O
specific	O
DNA	O
binding	O
.	O

Treatment	O
of	O
HL-60	B-cell_line
cells	I-cell_line
with	O
both	O
TPA	O
and	O
cycloheximide	O
had	O
no	O
effect	O
on	O
the	O
rates	O
of	O
c-jun	B-DNA
transcription	O
.	O

Using	O
the	O
wild-type	B-protein
or	I-protein
mutated	I-protein
human	I-protein
retinoic	I-protein
acid	I-protein
receptor	I-protein
alpha	I-protein
as	O
a	O
model	O
,	O
kDa	O
values	O
determined	O
by	O
classical	O
competition	O
binding	O
assays	O
using	O
tritiated	O
ligands	O
are	O
in	O
agreement	O
with	O
those	O
measured	O
by	O
the	O
proteolytic	O
assay	O
.	O

To	O
characterize	O
the	O
human	B-DNA
elk-1	I-DNA
promoter	I-DNA
,	O
we	O
mapped	O
the	O
transcriptional	B-DNA
start	I-DNA
site	I-DNA
and	O
isolated	O
elk-1-specific	B-cell_line
genomic	I-cell_line
phage	I-cell_line
clones	I-cell_line
that	O
contained	O
extensive	O
upstream	B-DNA
and	I-DNA
downstream	I-DNA
sequences	I-DNA
.	O

These	O
findings	O
indicate	O
that	O
B29	B-DNA
gene	I-DNA
expression	O
is	O
controlled	O
by	O
the	O
complex	O
interplay	O
of	O
positive	O
and	O
negative	B-DNA
regulatory	I-DNA
elements	I-DNA
.	O

Induction	O
of	O
HL-60	B-cell_line
and	O
U-937	B-cell_line
cell	O
differentiation	O
into	O
monocytes/macrophages	B-cell_type
by	O
IFN-gamma	B-protein
or	O
PMA	O
results	O
in	O
a	O
dephosphorylation	O
and	O
consequent	O
activation	O
of	O
4E-BP1	B-protein
.	O

Nevertheless	O
,	O
relatively	O
high	O
,	O
pharmacological	O
concentrations	O
of	O
RA	O
(	O
1	O
to	O
10	O
&	O
mgr	O
;	O
M	O
)	O
overcome	O
these	O
differentiation	O
blocks	O
and	O
induce	O
terminal	O
granulocytic	O
differentiation	O
of	O
the	O
MPRO	B-cell_type
promyelocytes	I-cell_type
while	O
potentiating	O
interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
-induced	O
commitment	O
of	O
EML	B-cell_type
cells	I-cell_type
to	O
the	O
granulocyte/monocyte	O
lineage	O
.	O

We	O
also	O
show	O
that	O
the	O
IL-7	B-protein
-induced	O
enhancement	O
of	O
the	O
AP-1	B-protein
-DNA	O
binding	O
activity	O
is	O
not	O
cyclosporin	O
A-sensitive	O
.	O

We	O
found	O
that	O
the	O
relative	O
efficiency	O
of	O
the	O
enhancers	B-DNA
is	O
approximately	O
the	O
same	O
,	O
irrespective	O
of	O
the	O
type	O
of	O
promoter	B-DNA
used	O
,	O
i.e.	O
,	O
there	O
was	O
no	O
strong	O
preference	O
for	O
any	O
given	O
enhancer/	O
promoter	B-DNA
combination	O
.	O

We	O
report	O
here	O
the	O
cleavage	O
of	O
the	O
transcription	B-protein
factor	I-protein
SP1	B-protein
in	O
the	O
human	B-cell_line
Burkitt	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
BL60	I-cell_line
during	O
anti-IgM	B-protein
-induced	O
apoptosis	O
.	O

DNA	O
binding	O
specificity	O
of	O
complex	O
3	O
overlaps	O
with	O
that	O
of	O
upstream	B-protein
stimulatory	I-protein
factor	I-protein
but	O
is	O
clearly	O
distinct	O
.	O

We	O
show	O
that	O
a	O
cellular	O
reducing	O
catalyst	O
thioredoxin	B-protein
(	O
Trx	B-protein
)	O
plays	O
a	O
major	O
role	O
in	O
activation	O
of	O
the	O
DNA	O
binding	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
in	O
vitro	O
and	O
stimulation	O
of	O
transcription	O
from	O
the	O
NF	B-protein
kappa	I-protein
B	I-protein
-dependent	O
gene	O
expression	O
.	O

That	O
RA	O
promotes	O
both	O
neutrophil	O
and	O
monocyte	O
differentiation	O
has	O
implications	O
for	O
the	O
use	O
of	O
RA	O
and	O
D3	O
in	O
treatment	O
of	O
leukemias	O
and	O
provides	O
insight	O
into	O
mechanisms	O
whereby	O
RAR	O
,	O
VDR	B-protein
and	O
RXR	B-protein
facilitate	O
monocyte	O
differentiation	O
.	O

TCF-1	B-protein
alpha	I-protein
,	O
originally	O
identified	O
and	O
purified	O
through	O
its	O
binding	O
sites	O
on	O
the	O
HIV-1	B-DNA
promoter	I-DNA
,	O
was	O
found	O
to	O
bind	O
to	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	I-DNA
and	O
to	O
promoters	B-DNA
for	O
several	O
genes	B-DNA
expressed	O
at	O
significantly	O
earlier	O
stages	O
of	O
T-cell	O
development	O
than	O
the	O
TCR	B-DNA
alpha	I-DNA
gene	I-DNA
(	O
e.g.	O
,	O
p56lck	B-DNA
and	O
CD3	B-DNA
delta	I-DNA
)	O
.	O

In	O
the	O
current	O
studies	O
,	O
we	O
evaluated	O
the	O
combinatorial	O
effects	O
of	O
monocyte	O
adhesion	O
and	O
IFN-gamma	B-protein
on	O
intracellular	O
signaling	O
pathways	O
.	O

Inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
vitro	O
and	O
in	O
vivo	O
:	O
role	O
of	O
26S	B-protein
proteasome	I-protein
.	O

The	O
cDNA	O
contains	O
a	O
546-nucleotide	B-DNA
(	I-DNA
nt	I-DNA
)	I-DNA
open	I-DNA
reading	I-DNA
frame	I-DNA
(	O
ORF	B-DNA
)	O
that	O
codes	O
for	O
the	O
carboxyl-terminal	B-protein
180	I-protein
amino	I-protein
acids	I-protein
(	O
aa	O
)	O
of	O
the	O
recently	O
identified	O
fkhrl1	B-DNA
gene	I-DNA
.	O

We	O
have	O
recently	O
shown	O
that	O
both	O
phosphorylation	O
processes	O
require	O
T-cell	O
costimulation	O
.	O

The	O
human	B-DNA
and	I-DNA
mouse	I-DNA
GATA3	I-DNA
transcription	I-DNA
units	I-DNA
start	O
at	O
a	O
major	B-DNA
initiation	I-DNA
site	I-DNA
.	O

Transactivation	O
by	O
CIITA	B-protein
,	O
the	O
type	B-protein
II	I-protein
bare	I-protein
lymphocyte	I-protein
syndrome-associated	I-protein
factor	I-protein
,	O
requires	O
participation	O
of	O
multiple	O
regions	O
of	O
the	O
TATA	B-protein
box	I-protein
binding	I-protein
protein	I-protein
.	O

The	O
mAECA	B-protein
,	O
but	O
not	O
normal	B-protein
human	I-protein
IgG	I-protein
,	O
had	O
anti-human	O
aortic	O
EC	O
activity	O
.	O

Administration	O
of	O
dexamethasone	O
to	O
temporal	B-cell_line
artery-SCID	I-cell_line
chimeras	I-cell_line
for	O
1	O
wk	O
induced	O
a	O
partial	O
suppression	O
of	O
T	O
cell	O
and	O
macrophage	O
function	O
as	O
indicated	O
by	O
the	O
reduced	O
tissue	O
concentrations	O
of	O
IL-2	B-RNA
,	I-RNA
IL-1beta	I-RNA
,	I-RNA
and	I-RNA
IL-6	I-RNA
mRNA	I-RNA
,	O
and	O
by	O
the	O
diminished	O
expression	O
of	O
inducible	O
NO	B-protein
synthase	I-protein
.	O

These	O
data	O
implicate	O
TRAFs	B-protein
in	O
STP-C488	B-protein
-mediated	O
transformation	O
of	O
human	B-cell_type
lymphocytes	I-cell_type
and	O
rodent	O
fibroblasts	B-cell_type
.	O

Lavage	O
T-lymphocytes	O
from	O
patients	O
with	O
tuberculosis	O
or	O
with	O
sarcoidosis	O
,	O
but	O
not	O
those	O
from	O
normal	O
control	O
subjects	O
,	O
expressed	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
as	O
demonstrated	O
by	O
binding	O
of	O
[	O
3H	O
]	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
which	O
was	O
inhibited	O
by	O
the	O
presence	O
of	O
excess	O
unlabeled	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
but	O
not	O
by	O
the	O
presence	O
of	O
unlabeled	O
25	O
(	O
OH	O
)	O
D3	O
(	O
receptor-positive	B-cell_type
lymphocytes	I-cell_type
:	O
sarcoidosis	O
,	O
20	O
+/-	O
12	O
%	O
;	O
tuberculosis	O
,	O
31	O
+/-	O
17	O
%	O
)	O
.	O

(	O
3	O
)	O
Interfollicular	B-cell_type
Bcl-6+/CD3+	I-cell_type
cells	I-cell_type
in	O
AITL/GC	O
were	O
too	O
numerous	O
to	O
be	O
accounted	O
for	O
by	O
migration	O
alone	O
,	O
suggesting	O
local	O
proliferation	O
.	O

Second	O
,	O
in	O
contrast	O
to	O
recent	O
results	O
on	O
human	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
CIITA	B-protein
is	O
not	O
critically	O
involved	O
in	O
the	O
IFN-gamma	B-protein
-induced	O
up-regulation	O
of	O
MHC	B-DNA
class	I-DNA
I	I-DNA
genes	I-DNA
.	O

In	O
general	O
,	O
deletions	O
which	O
diminished	O
Cp	B-DNA
activity	O
resulted	O
in	O
induction	O
of	O
Wp	B-DNA
activity	O
,	O
consistent	O
with	O
suppression	O
of	O
Wp	B-DNA
activity	O
by	O
transcriptional	O
interference	O
from	O
Cp	B-DNA
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
the	O
age-related	O
hyporesponsiveness	O
can	O
not	O
be	O
attributed	O
to	O
a	O
skewing	O
of	O
the	O
T	O
cell	O
population	O
towards	O
a	O
memory	O
phenotype	O
in	O
the	O
elderly	O
.	O

Costimulation	O
through	O
CD28	B-protein
and/or	O
CD2	B-protein
did	O
not	O
modulate	O
the	O
CD3	B-protein
-dependent	O
phosphorylation	O
of	O
HS1	B-protein
.	O

The	O
first	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
human	B-cell_type
DC	I-cell_type
mediate	O
in	O
vitro	O
sensitization	O
of	O
naive	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
to	O
epitopes	B-protein
of	O
the	O
immediate	B-protein
early	I-protein
62	I-protein
(	I-protein
IE62	I-protein
)	I-protein
protein	I-protein
of	O
varicella	O
zoster	O
virus	O
(	O
VZV	O
)	O
.	O

Protein	B-protein
tyrosine	I-protein
kinase	I-protein
activity	O
,	O
NF-kappaB	B-protein
activity	O
,	O
and	O
the	O
synthesis	O
of	O
cytokine-specific	B-RNA
mRNA	I-RNA
were	O
inhibited	O
by	O
antioxidants	O
.	O

Although	O
inhibition	O
of	O
IL-4-driven	B-cell_line
germline	I-cell_line
C	I-cell_line
epsilon	I-cell_line
transcription	O
by	O
NAC	O
was	O
not	O
sufficient	O
,	O
the	O
agent	O
remarkably	O
diminished	O
anti-CD40	B-protein
mAb	I-protein
-mediated	O
up-regulation	O
of	O
germline	B-DNA
C	O
epsilon	O
transcription	O
.	O

The	O
human	B-DNA
IL-13	I-DNA
gene	I-DNA
was	O
located	O
12.5-kb	B-DNA
upstream	I-DNA
of	O
the	O
IL-4	B-DNA
gene	I-DNA
and	O
2-kb	B-DNA
downstream	I-DNA
of	O
a	O
CpG	B-DNA
island	I-DNA
.	O

We	O
conclude	O
that	O
CD28	B-protein
costimulation	O
can	O
cause	O
substantial	O
T	O
cell	O
proliferation	O
in	O
the	O
absence	O
of	O
IL-2	B-protein
,	O
which	O
is	O
driven	O
by	O
a	O
soluble	B-protein
factor	I-protein
independent	O
of	O
NF-AT	B-protein
transactivation	O
.	O

However	O
,	O
cell	B-cell_line
lines	I-cell_line
with	O
high	O
metastatic	O
potential	O
are	O
resistant	O
to	O
TNF	B-protein
in	O
vitro	O
.	O

Apoptosis	O
is	O
instrumental	O
in	O
the	O
processes	O
generating	O
the	O
diversity	O
of	O
the	O
B-cell	O
repertoire	O
.	O

Involvement	O
of	O
a	O
cellular	O
reducing	O
catalyst	O
thioredoxin	B-protein
.	O

Porcine	B-cell_line
aortic	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
PAEC	B-cell_line
)	O
were	O
incubated	O
for	O
1	O
hr	O
30	O
min	O
or	O
5	O
hr	O
with	O
10	O
%	O
homologous	O
porcine	O
serum	O
(	O
control	O
)	O
or	O
10	O
%	O
xenogeneic	O
human	O
serum	O
and	O
then	O
perfused	O
with	O
total	O
human	B-cell_type
leukocytes	I-cell_type
in	O
a	O
parallel	O
plate	O
flow	O
chamber	O
under	O
laminar	O
flow	O
(	O
1.5	O
dynes/cm2	O
)	O
.	O

RESULTS	O
--	O
Reactions	O
in	O
comedo	O
carcinomas	O
were	O
significantly	O
negative	O
for	O
estrogen	B-protein
receptor	I-protein
and	O
progesterone	B-protein
receptor	I-protein
,	O
and	O
positive	O
for	O
p53	B-protein
and	O
HER-2/neu	B-protein
more	O
often	O
than	O
the	O
noncomedo	O
variant	O
.	O

This	O
integrin-mediated	O
adhesion	O
controls	O
leukocyte	O
arrest	O
and	O
extravasation	O
during	O
the	O
onset	O
of	O
inflammatory	O
responses	O
.	O

Unlike	O
other	O
class	B-DNA
II	I-DNA
promoters	I-DNA
,	O
the	O
HLA-DR	B-DNA
alpha	I-DNA
(	I-DNA
DRA	I-DNA
)	I-DNA
promoter	I-DNA
also	O
contains	O
one	O
element	O
identical	O
to	O
the	O
``	B-DNA
octamer	I-DNA
''	I-DNA
motif	I-DNA
of	O
immunoglobulin	B-DNA
variable	I-DNA
region	I-DNA
promoters	I-DNA
that	O
is	O
responsible	O
for	O
B	O
cell-specific	O
transcription	O
.	O

Tuberculosis	O
has	O
emerged	O
as	O
an	O
epidemic	O
,	O
extended	O
by	O
the	O
large	O
number	O
of	O
individuals	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
.	O

AF-10	O
was	O
involved	O
in	O
5	O
of	O
6	O
evaluable	O
cases	O
,	O
including	O
1	O
case	O
without	O
detectable	O
CALM	B-DNA
or	O
MLL	O
rearrangement	O
.	O

Using	O
this	O
approach	O
,	O
we	O
identified	O
potential	O
NFAT	B-DNA
composite	I-DNA
elements	I-DNA
in	O
promoters	B-DNA
of	O
cytokine	B-DNA
genes	I-DNA
and	O
their	O
receptors	O
as	O
well	O
as	O
in	O
promoters	B-DNA
of	O
genes	O
for	O
AP-1	B-protein
family	I-protein
members	I-protein
,	O
Ca2+-binding	B-protein
proteins	I-protein
and	O
some	O
other	O
components	O
of	O
the	O
regulatory	O
network	O
operating	O
in	O
activated	B-cell_type
T-cells	I-cell_type
and	O
other	O
immune	B-cell_type
cells	I-cell_type
.	O

Human	O
C/EBP	B-DNA
epsilon	I-DNA
is	O
a	O
newly	O
cloned	O
gene	O
coding	O
for	O
a	O
CCAAT/enhancer	B-protein
binding	I-protein
protein	I-protein
that	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
myeloid	O
differentiation	O
.	O

To	O
approach	O
this	O
,	O
we	O
generated	O
a	O
luciferase	B-DNA
reporter	I-DNA
construct	I-DNA
containing	O
elements	O
of	O
the	O
CD95	B-protein
ligand	I-protein
promoter	O
.	O

Here	O
,	O
we	O
show	O
that	O
CD3	O
ligation	O
by	O
mAb	O
and	O
Staphylococcal	O
enterotoxin	O
(	O
SE	O
)	O
induce	O
a	O
rapid	O
,	O
gradually	O
accumulating	O
,	O
long-lasting	O
tyrosine	O
,	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	B-protein
(	O
but	O
not	O
Stat5	B-protein
)	O
in	O
allogen-specific	B-cell_line
human	I-cell_line
CD4+	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

This	O
induction	O
of	O
monocytic	O
differentiation	O
was	O
associated	O
with	O
transient	O
increases	O
in	O
c-jun	B-RNA
mRNA	I-RNA
levels	O
,	O
which	O
were	O
maximal	O
at	O
6	O
h	O
.	O

Subsequently	O
,	O
a	O
1.8	B-DNA
kilobase	I-DNA
(	I-DNA
kb	I-DNA
)	I-DNA
fragment	I-DNA
of	O
the	O
CIITA	B-DNA
promoter	I-DNA
was	O
isolated	O
and	O
sequenced	O
.	O

This	O
process	O
requires	O
calcium-dependent	O
dephosphorylation	O
of	O
NFAT	B-protein
caused	O
by	O
the	O
phosphatase	B-protein
calcineurin	B-protein
.	O

We	O
prepared	O
nuclear	O
extracts	O
from	O
two	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
which	O
increased	O
intracellular	O
free	O
calcium	O
levels	O
correlated	O
with	O
increased	O
phosphorylation	O
of	O
the	O
Ets-1	B-protein
protein	O
.	O

Antibodies	O
to	O
Stat6	B-protein
detected	O
a	O
unique	O
band	O
in	O
macaque	O
cell	O
lysates	O
.	O

Repression	O
of	O
class	O
II	O
transactivator	O
(	O
CIITA	B-DNA
)	O
mRNA	O
expression	O
is	O
detected	O
within	O
the	O
first	O
hours	O
of	O
IFN-gamma	B-protein
-HCMV	O
coincubation	O
and	O
results	O
in	O
the	O
absence	O
of	O
HLA-DR	B-protein
synthesis	O
.	O

GATA-3	B-protein
inhibits	O
Th1	B-protein
cytokines	I-protein
by	O
a	O
cell-intrinsic	O
mechanism	O
that	O
is	O
not	O
dependent	O
on	O
IL-4	B-protein
and	O
that	O
may	O
involve	O
repression	O
of	O
IL-12	B-protein
signaling	O
.	O

The	O
correlation	O
between	O
C5a-induced	O
kappaB	B-protein
binding	O
activity	O
and	O
IL-8	B-protein
gene	O
expression	O
was	O
examined	O
in	O
the	O
RAW264.7	B-cell_line
macrophage	I-cell_line
cells	I-cell_line
using	O
reporter	O
genes	O
directed	O
by	O
the	O
kappaB	B-DNA
sequence	I-DNA
from	O
IkappaBalpha	B-protein
and	O
IL-8	B-DNA
promoter	I-DNA
regions	I-DNA
.	O

Activation	O
of	O
Ras	O
and	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
pathway	O
by	O
terminal	B-protein
complement	I-protein
complexes	I-protein
is	O
G	B-protein
protein	I-protein
dependent	O
.	O

Here	O
we	O
have	O
therefore	O
examined	O
the	O
effect	O
of	O
the	O
phorbol	O
ester	O
PMA	O
(	O
phorbol	O
12-myristate	O
13-acetate	O
)	O
which	O
stimulates	O
PKC	B-protein
and	O
a	O
combination	O
of	O
the	O
adenosine	B-protein
receptor	I-protein
agonist	O
NECA	O
(	O
5'-	O
(	O
N-ethyl	O
)	O
-carboxamido	O
adenosine	O
)	O
and	O
forskolin	O
to	O
raise	O
cAMP	O
,	O
on	O
the	O
levels	O
of	O
c-Fos	B-protein
and	O
Jun	B-protein
and	O
on	O
the	O
binding	O
and	O
transcriptional	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
,	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
.	O

The	O
finding	O
that	O
Oct-2	B-protein
is	O
under	O
NF-kappaB	B-protein
control	O
highlights	O
an	O
important	O
cross-talk	O
mechanism	O
involving	O
two	O
distinct	O
transcription	B-protein
factor	I-protein
families	I-protein
that	O
regulate	O
B	B-cell_type
lymphocyte	I-cell_type
function	O
.	O

The	O
Ets	B-DNA
motifs	I-DNA
are	O
preferentially	O
bound	O
by	O
PU-1	B-protein
in	O
B	O
cell	O
extracts	O
from	O
all	O
stages	O
of	O
development	O
,	O
whereas	O
a	O
different	O
Ets	B-protein
family	I-protein
member	I-protein
reacts	O
with	O
these	O
motifs	O
in	O
T	O
cell	O
extracts	O
.	O

The	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
was	O
63	O
%	O
greater	O
in	O
the	O
morning	O
and	O
26	O
%	O
greater	O
in	O
the	O
afternoon	O
in	O
the	O
patients	O
with	O
PTSD	O
than	O
in	O
the	O
normal	O
subjects	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
DNA-binding	O
activity	O
primarily	O
consisting	O
of	O
the	O
classical	O
NF-kappa	B-protein
B	I-protein
heterodimer	I-protein
,	O
p50/RelA	B-protein
,	O
is	O
induced	O
in	O
phagocytosing	B-cell_type
neutrophils	I-cell_type
.	O

DNase	B-protein
I	I-protein
mapping	O
of	O
genomic	B-DNA
DNA	I-DNA
identified	O
a	O
hypersensitive	B-DNA
element	I-DNA
near	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
.	O

The	O
decrease	O
of	O
the	O
number	O
of	O
GCR	B-protein
in	O
asthmatics	O
,	O
we	O
think	O
,	O
is	O
related	O
to	O
heredity	O
and	O
repeated	O
attacks	O
of	O
asthma	O
.	O

ASA	O
was	O
found	O
to	O
inhibit	O
secretion	O
of	O
the	O
IL-12	B-protein
heterodimer	I-protein
as	O
well	O
as	O
p40	B-protein
monomer	I-protein
by	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

Total	O
RNA	O
was	O
isolated	O
from	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
and	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
determined	O
by	O
quantitative	O
competitive	O
reverse	O
transcription	O
PCR	O
.	O

Unlike	O
CIS	B-protein
,	O
SOCS-3	B-protein
was	O
rapidly	O
tyrosine	O
phosphorylated	O
in	O
response	O
to	O
IL-2	B-protein
.	O

DHEA	O
binding	O
sites	O
were	O
examined	O
using	O
a	O
whole-cell	O
binding	O
assay	O
in	O
a	O
human	B-cell_line
T	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
PEER	B-cell_line
,	O
revealing	O
that	O
a	O
single	O
class	O
of	O
high-affinity	O
binding	O
sites	O
for	O
DHEA	O
(	O
dissociation	O
constant	O
=	O
7.4	O
+/-	O
0.53	O
nmol/L	O
,	O
mean	O
+/-	O
SE	O
,	O
n	O
=	O
4	O
)	O
was	O
greatly	O
increased	O
when	O
treated	O
with	O
DHEA	O
,	O
phorbol-12-myristate-13-acetate	O
,	O
and	O
the	O
Ca2+	O
ionophore	O
A23187	O
.	O

Reduced	O
susceptibility	O
to	O
HIV-1	O
infection	O
of	O
ethyl-methanesulfonate-treated	B-cell_line
CEM	I-cell_line
subclones	I-cell_line
correlates	O
with	O
a	O
blockade	O
in	O
their	O
protein	B-protein
kinase	I-protein
C	I-protein
signaling	O
pathway	O
.	O

Northern	O
analysis	O
of	O
mRNA	O
from	O
hypoxic	O
ECs	B-cell_type
also	O
demonstrated	O
increased	O
levels	O
of	O
mRNA	B-RNA
for	O
macrophage	B-protein
chemotactic	I-protein
protein-1	I-protein
,	O
another	O
member	O
of	O
the	O
chemokine	B-protein
superfamily	I-protein
of	O
proinflammatory	B-protein
cytokines	I-protein
.	O

In	O
contrast	O
,	O
C3H	O
mice	O
inoculated	O
with	O
wild-type	O
Ad	O
recognized	O
an	O
epitope	O
mapping	O
within	O
E1B	B-DNA
.	O
When	O
inoculated	O
twice	O
with	O
Ad	O
vectors	O
lacking	O
both	O
E1A	B-DNA
and	O
E1B	B-DNA
,	O
no	O
immunorecessive	B-protein
epitopes	I-protein
were	O
recognized	O
.	O

In	O
CF	O
individuals	O
,	O
7	O
of	O
52	O
(	O
13	O
%	O
)	O
had	O
detectable	O
E1a	B-DNA
sequences	I-DNA
in	O
the	O
respiratory	O
epithelium	O
,	O
with	O
E1a	O
copy	O
number	O
in	O
the	O
positive	O
samples	O
of	O
80	O
+/-	O
21/10	O
(	O
3	O
)	O
recovered	O
cells	O
.	O

Control	O
of	O
NFATx1	B-protein
nuclear	O
translocation	O
by	O
a	O
calcineurin-regulated	B-protein
inhibitory	I-protein
domain	I-protein
.	O

We	O
find	O
that	O
in	O
the	O
absence	O
of	O
EKLF	B-protein
,	O
while	O
human	B-protein
beta-globin	I-protein
expression	O
is	O
dramatically	O
reduced	O
,	O
gamma-globin	B-RNA
transcripts	I-RNA
are	O
elevated	O
approximately	O
5-fold	O
.	O

Bcl-3	B-protein
may	O
therefore	O
aid	O
activation	O
of	O
select	O
NF-kappa	B-DNA
B-regulated	I-DNA
genes	I-DNA
,	O
including	O
those	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
.	O

Each	O
subject	O
group	O
was	O
divided	O
into	O
two	O
subgroups	O
according	O
to	O
PBMC	B-cell_type
sensitivity	O
to	O
prednisolone	O
in	O
a	O
mitogen	O
assay	O
procedure	O
;	O
i.e.	O
,	O
sensitive	O
(	O
IC50	O
<	O
381	O
ng/mL	O
)	O
and	O
resistant	O
(	O
IC50	O
>	O
381	O
ng/mL	O
)	O
groups	O
.	O

In	O
particular	O
,	O
Tax	B-protein
is	O
capable	O
of	O
modulating	O
the	O
expression	O
or	O
activity	O
of	O
various	O
host	O
transcription	B-protein
factors	I-protein
,	O
including	O
members	O
of	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
and	O
CREB/ATF	B-protein
families	I-protein
,	O
as	O
well	O
as	O
the	O
cellular	B-protein
factors	I-protein
HEB-1	B-protein
and	O
p67SRF	B-protein
.	O

As	O
cortisol	O
is	O
involved	O
in	O
the	O
physiological	O
regulation	O
of	O
cytokines	B-protein
,	O
a	O
study	O
was	O
conducted	O
to	O
examine	O
cytokine	B-protein
patterns	O
in	O
two	O
groups	O
of	O
hypercortisolemic	O
patients	O
,	O
one	O
with	O
normal	O
sensitivity	O
to	O
glucocorticoids	O
and	O
the	O
other	O
with	O
glucocorticoid	O
resistance	O
.	O

Moreover	O
,	O
ACH-2	B-cell_line
cells	I-cell_line
treated	O
with	O
HOCl	O
or	O
H2O2	O
released	O
tumour	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
in	O
the	O
supernatants	O
.	O

Mononuclear	B-cell_type
phagocytes	I-cell_type
are	O
exposed	O
to	O
fibrinous	O
provisional	O
matrix	O
throughout	O
migration	O
into	O
inflammatory	O
foci	O
,	O
so	O
this	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
fibrinogen	O
triggers	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factors	I-protein
.	O

Examination	O
of	O
IkappaB	B-protein
alpha	I-protein
regulation	O
revealed	O
that	O
TNF-alpha	B-protein
-mediated	O
degradation	O
of	O
IkappaB	B-protein
alpha	I-protein
in	O
both	O
memory	B-cell_type
and	I-cell_type
naive	I-cell_type
T	I-cell_type
cells	I-cell_type
from	O
the	O
elderly	O
was	O
severely	O
impaired	O
,	O
thus	O
contributing	O
to	O
the	O
lowered	O
induction	O
of	O
the	O
observed	O
NFkappaB	B-protein
.	O

Evidence	O
for	O
normal	O
vitamin	B-RNA
D	I-RNA
receptor	I-RNA
messenger	I-RNA
ribonucleic	I-RNA
acid	I-RNA
and	O
genotype	O
in	O
absorptive	O
hypercalciuria	O
.	O

Then	O
bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
from	O
transgenic	O
mice	O
were	O
plated	O
onto	O
MS-5	O
stromal	O
cells	O
expressing	O
the	O
membrane	B-protein
form	I-protein
of	O
human	B-protein
CSF-1	I-protein
(	O
2M-1	B-cell_line
cells	I-cell_line
)	O
in	O
order	O
to	O
combine	O
the	O
hematopoietic	O
supporting	O
properties	O
of	O
stromal	B-cell_type
cells	I-cell_type
and	O
the	O
proliferative	O
effects	O
of	O
CSF-1	B-protein
.	O

In	O
vivo	O
differentiation	O
therapy	O
with	O
retinoids	O
in	O
APL	O
patients	O
follows	O
strict	O
guidelines	O
related	O
both	O
to	O
the	O
APL	O
cell	O
and	O
the	O
biodisposal	O
of	O
all-trans	O
retinoic	O
acid	O
.	O

Pretreatment	O
(	O
or	O
up	O
to	O
15	O
minutes	O
posttreatment	O
)	O
relative	O
to	O
TNFalpha	B-protein
with	O
the	O
antioxidant	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
(	O
2	O
%	O
[	O
vol/vol	O
]	O
)	O
blocks	O
80	O
%	O
of	O
NF-kappaB	B-protein
-dependent	O
transcription	O
.	O

The	O
present	O
study	O
investigated	O
PPARalpha	B-protein
expression	O
in	O
human	B-cell_type
ECs	I-cell_type
and	O
their	O
regulation	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
revealed	O
three	O
specific	O
protein-DNA	B-protein
complexes	I-protein
formed	O
with	O
sequences	O
of	O
the	O
EBNA2	B-DNA
responsive	I-DNA
element	I-DNA
.	O

Here	O
we	O
summarize	O
studies	O
which	O
investigate	O
the	O
mechanism	O
by	O
which	O
these	O
cytokines	B-protein
selectively	O
reprogramme	O
gene	O
expression	O
in	O
T-lymphocytes	B-cell_type
.	O

Moreover	O
,	O
integrin	B-protein
-ligand	O
interactions	O
trigger	O
signaling	O
pathways	O
that	O
may	O
influence	O
leukocyte	O
phenotype	O
and	O
function	O
at	O
sites	O
of	O
inflammation	O
.	O

Unicellular-unilineage	B-cell_line
erythropoietic	I-cell_line
cultures	I-cell_line
:	O
molecular	O
analysis	O
of	O
regulatory	O
gene	O
expression	O
at	O
sibling	O
cell	O
level	O
.	O

The	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
initiates	O
both	O
extracellular	O
and	O
intracellular	O
regulatory	O
events	O
that	O
result	O
in	O
autoregulation	O
of	O
the	O
inflammatory	O
cascade	O
through	O
modulation	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
mediates	O
autocrine	O
and	O
paracrine	O
growth	O
of	O
multiple	B-cell_line
myeloma	I-cell_line
(	I-cell_line
MM	I-cell_line
)	I-cell_line
cells	I-cell_line
and	O
inhibits	O
tumor	O
cell	O
apoptosis	O
.	O

The	O
Epstein-Barr	B-protein
virus-encoded	I-protein
nuclear	I-protein
antigen	I-protein
EBNA-5	I-protein
accumulates	O
in	O
PML-containing	O
bodies	O
.	O

These	O
data	O
indicate	O
that	O
IL-10	B-protein
inhibits	O
IFN-gamma	B-protein
-induced	O
transcription	O
of	O
the	O
ICAM-1	B-DNA
gene	I-DNA
by	O
a	O
regulatory	O
mechanism	O
that	O
may	O
involve	O
NF-kappaB	B-protein
.	O

Highly	O
purified	O
monocytes	B-cell_type
were	O
incubated	O
with	O
IL-10	B-protein
for	O
60	O
to	O
90	O
minutes	O
before	O
the	O
addition	O
of	O
IFNgamma	B-protein
or	O
IFNalpha	B-protein
.	O

Glucocorticoids	O
promote	O
nonphlogistic	O
phagocytosis	O
of	O
apoptotic	B-cell_type
leukocytes	I-cell_type
.	O

RU	O
486	O
tested	O
at	O
an	O
equal	O
concentration	O
as	O
progesterone	O
significantly	O
inhibited	O
the	O
production	O
of	O
the	O
blocking	B-protein
factor	I-protein
,	O
while	O
RU	O
43044	O
was	O
without	O
effect	O
.	O

In	O
contrast	O
,	O
rolling	O
of	O
monocytes	B-cell_type
was	O
increased	O
by	O
IkappaB-alpha	B-protein
transfer	O
and	O
was	O
partly	O
mediated	O
by	O
P-selectin	B-protein
;	O
however	O
,	O
it	O
appeared	O
to	O
be	O
unaffected	O
by	O
the	O
inhibition	O
of	O
E-selectin	B-protein
induction	O
.	O

A	O
transcription	B-protein
factor	I-protein
,	O
NF-AT	B-protein
,	O
which	O
is	O
essential	O
for	O
early	O
T-cell	O
gene	O
activation	O
,	O
seems	O
to	O
be	O
a	O
specific	O
target	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
action	O
because	O
transcription	O
directed	O
by	O
this	O
protein	O
is	O
blocked	O
in	O
T	B-cell_type
cells	I-cell_type
treated	O
with	O
these	O
drugs	O
,	O
with	O
little	O
or	O
no	O
effect	O
on	O
other	O
transcription	B-protein
factors	I-protein
such	O
as	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
.	O

Whereas	O
T	B-cell_type
cells	I-cell_type
from	O
young	O
subjects	O
stimulated	O
with	O
cross-linked	B-protein
anti-CD3epsilon	I-protein
mAb	I-protein
OKT3	B-protein
plus	O
PMA	O
or	O
with	O
the	O
lectin	B-protein
PHA	B-protein
plus	O
PMA	O
demonstrated	O
considerable	O
increases	O
in	O
c-Fos	B-protein
protein	O
expression	O
,	O
the	O
expression	O
of	O
c-Fos	B-protein
but	O
not	O
c-Jun	B-protein
was	O
markedly	O
reduced	O
in	O
stimulated	O
T	B-cell_type
cells	I-cell_type
from	O
certain	O
elderly	O
subjects	O
.	O

The	O
existence	O
of	O
alternative	O
Pax-5	B-RNA
transcripts	I-RNA
was	O
confirmed	O
using	O
RNase	B-protein
protection	O
assays	O
.	O

The	O
malignant	B-cell_type
cells	I-cell_type
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
contain	O
a	O
reciprocal	O
chromosomal	O
translocation	O
that	O
fuses	O
the	O
promyelocytic	B-DNA
leukemia	I-DNA
gene	I-DNA
(	O
PML	O
)	O
with	O
the	O
retinoic	B-DNA
acid	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
(	O
RAR	B-protein
alpha	I-protein
)	O
.	O

Its	O
expression	O
was	O
always	O
restricted	O
to	O
the	O
nucleus	O
.	O

Two	O
transcriptional	O
elements	O
in	O
the	O
TSP	B-protein
1	I-protein
promoter	O
,	O
a	O
distal	O
element	O
at	O
-1280	O
and	O
a	O
proximal	O
element	O
at	O
-65	O
,	O
were	O
required	O
for	O
the	O
response	O
of	O
the	O
human	O
TSP	O
1	O
gene	O
to	O
serum	O
.	O

Overexpression	O
of	O
a	O
phosphorylation-defective	O
form	O
of	O
Rb	B-protein
inhibited	O
Elf-1	B-protein
-dependent	O
transcription	O
during	O
T	B-cell_type
cell	I-cell_type
activation	O
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
the	O
level	O
of	O
L.	O
pneumophila	O
RpoS	B-protein
increased	O
in	O
stationary	O
phase	O
.	O

These	O
conflicting	O
observations	O
may	O
be	O
due	O
to	O
different	O
effects	O
of	O
anti-inflammatory	O
agents	O
on	O
adhesion	O
molecule	O
and	O
Hsp	O
expression	O
in	O
EC	B-cell_type
,	O
respectively	O
.	O

Two	O
polyadenylation	O
sites	O
were	O
present	O
in	O
the	O
fourth	B-DNA
C	I-DNA
delta	I-DNA
exon	I-DNA
.	O

In	O
contrast	O
,	O
a	O
constitutively	O
active	O
SHP2-DeltaSH2	B-protein
had	O
no	O
statistically	O
significant	O
effect	O
(	O
although	O
it	O
caused	O
a	O
slight	O
augmentation	O
in	O
some	O
individual	O
experiments	O
)	O
.	O

All	O
fusions	O
splice	O
the	O
5	B-DNA
'	I-DNA
ends	I-DNA
of	O
the	O
3q21	B-DNA
genes	I-DNA
into	O
exon	B-DNA
2	I-DNA
of	O
the	O
EVI1	B-DNA
gene	O
,	O
an	O
event	O
that	O
is	O
similar	O
to	O
the	O
normal	O
intergenic	O
splicing	O
of	O
MDS1-EVI1	B-DNA
and	O
to	O
those	O
previously	O
documented	O
in	O
leukemias	O
with	O
t	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
21	I-DNA
)	I-DNA
and	O
t	B-DNA
(	I-DNA
3	I-DNA
;	I-DNA
12	I-DNA
)	I-DNA
,	O
in	O
which	O
acute	O
myelogenous	B-DNA
leukemia	I-DNA
1-EVI1	I-DNA
fusions	I-DNA
and	O
ETV6-EVI1	B-DNA
fusions	I-DNA
,	O
respectively	O
,	O
occur	O
.	O

Some	O
tegument-specific	B-cell_line
CD4	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
exhibited	O
cytotoxic	O
activity	O
against	O
HSV-infected	B-cell_type
cells	I-cell_type
.	O

AP-1	B-protein
,	O
the	O
polypeptide	O
product	O
of	O
c-jun	B-DNA
,	O
recognizes	O
and	O
binds	O
to	O
specific	O
DNA	O
sequences	O
and	O
stimulates	O
transcription	O
of	O
genes	B-DNA
responsive	O
to	O
certain	O
growth	O
factors	O
and	O
phorbol	O
esters	O
such	O
as	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

Involvement	O
of	O
the	O
N-terminal	B-protein
region	I-protein
of	O
the	O
human	B-protein
mineralocorticoid	I-protein
receptor	I-protein
hormone-binding	I-protein
domain	I-protein
in	O
agonist	O
and	O
antagonist	O
binding	O
as	O
revealed	O
by	O
a	O
new	B-protein
monoclonal	I-protein
antibody	I-protein
.	O

Higher-molecular-weight	B-protein
species	I-protein
of	O
NFATc	B-protein
(	O
of	O
110	O
and	O
140	O
kDa	O
)	O
were	O
also	O
detected	O
.	O

One-hybrid	O
assays	O
in	O
yeast	B-protein
isolated	I-protein
NF-ATp	I-protein
as	O
an	O
E1	B-protein
binding	I-protein
protein	I-protein
,	O
and	O
transfection	O
of	O
NF-ATp	B-protein
into	O
T	B-cell_line
and	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
strongly	O
enhanced	O
the	O
activation-dependent	B-protein
SCM-1	I-protein
promoter	O
activity	O
.	O

Here	O
we	O
demonstrate	O
a	O
link	O
between	O
the	O
p38	B-protein
pathway	O
and	O
a	O
member	O
of	O
the	O
myocyte-enhancer	B-protein
factor	I-protein
2	I-protein
(	I-protein
MEF2	I-protein
)	I-protein
group	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

Immunoprecipitation	O
of	O
the	O
gp	B-protein
160	I-protein
-induced	O
nuclear	O
extracts	O
with	O
polyclonal	B-protein
antibodies	I-protein
to	O
Fos	B-protein
and	O
Jun	B-protein
proteins	I-protein
indicates	O
that	O
AP-1	B-protein
complex	I-protein
is	O
comprised	O
of	O
members	O
of	O
these	O
family	O
of	O
proteins	O
.	O

Nuclear	B-protein
factor-kappaB	I-protein
induction	O
in	O
CD45RO+	B-cell_type
and	I-cell_type
CD45RA+	I-cell_type
T	I-cell_type
cell	I-cell_type
subsets	I-cell_type
during	O
aging	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
M-CSF	B-protein
on	O
potential	O
signaling	O
pathways	O
involving	O
expression	O
of	O
the	O
jun	B-DNA
and	I-DNA
fos	I-DNA
early	I-DNA
response	I-DNA
genes	I-DNA
.	O

By	O
titrating	O
the	O
oestrogen	O
concentration	O
in	O
these	O
stably	B-cell_line
transfected	I-cell_line
cells	I-cell_line
,	O
the	O
growth	O
retarding	O
and	O
the	O
transactivating	O
function	O
of	O
the	O
chimeric	B-protein
proteins	I-protein
could	O
not	O
be	O
dissociated	O
.	O

All	O
four	O
complexes	O
contain	O
CREB	B-protein
and	O
are	O
bound	O
to	O
the	O
cAMP	B-DNA
response	I-DNA
element	I-DNA
(	I-DNA
CRE	I-DNA
)	I-DNA
core	I-DNA
sequence	I-DNA
(	O
TGACGTCA	O
)	O
,	O
as	O
indicated	O
by	O
antibody	O
and	O
oligonucleotide	O
competition	O
experiments	O
.	O

Molecular	O
cues	O
delivered	O
by	O
the	O
microenvironment	O
frequently	O
act	O
in	O
an	O
instructive	O
fashion	O
by	O
initiating	O
intracellular	O
signaling	O
pathways	O
that	O
ultimately	O
target	O
a	O
select	O
group	O
of	O
transcription	B-protein
factors	I-protein
.	O

Acute	O
inflammatory	O
injury	O
in	O
rat	O
lung	O
induced	O
by	O
deposition	O
of	O
immunoglobulin	B-protein
G	I-protein
immune	I-protein
complexes	I-protein
requires	O
expression	O
of	O
cytokines	B-protein
and	O
chemokines	B-protein
as	O
well	O
as	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
.	O

These	O
results	O
suggest	O
that	O
the	O
inhibition	O
of	O
NF-kappaB	B-protein
activation	O
by	O
ASA	O
leads	O
to	O
down-regulation	O
of	O
IL-12	B-protein
production	O
and	O
inhibition	O
of	O
Th1	O
cell	O
development	O
.	O

Upon	O
activation	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
primary	B-cell_type
murine	I-cell_type
thymocytes	I-cell_type
with	O
phorbol	O
esters	O
and	O
ionomycin	O
,	O
BOB.1/OBF.1	B-protein
expression	O
and	O
transactivation	O
function	O
were	O
induced	O
.	O

Neither	O
heat	B-protein
shock	I-protein
protein	I-protein
reacts	O
directly	O
with	O
the	O
EC1	B-protein
antibody	I-protein
.	O

These	O
data	O
indicate	O
that	O
the	O
TRE-like	B-DNA
cAMP-responsive	I-DNA
DSE	I-DNA
sites	I-DNA
within	O
the	O
5'-untranslated	B-DNA
leader	I-DNA
can	O
mediate	O
the	O
transcriptional	O
cooperativity	O
between	O
TNFalpha	B-protein
and	O
the	O
cAMP	O
/PKA	B-protein
pathway	O
.	O

The	O
two	O
latter	O
signals	O
were	O
nevertheless	O
able	O
to	O
induce	O
NF-kappa	B-protein
B	I-protein
translocation	O
with	O
a	O
pattern	O
in	O
the	O
band-shift	O
assay	O
indistinguishable	O
from	O
that	O
observed	O
using	O
phorbol	O
ester	O
.	O

The	O
first	O
product	O
of	O
ascorbate	O
oxidation	O
,	O
the	O
ascorbate	O
free	O
radical	O
(	O
AFR	O
)	O
,	O
acts	O
in	O
biological	O
systems	O
mainly	O
as	O
an	O
oxidant	O
,	O
and	O
through	O
its	O
role	O
in	O
the	O
plasma	O
membrane	O
redox	O
system	O
exerts	O
different	O
effects	O
on	O
the	O
cell	O
.	O

In	O
neutrophils	B-cell_type
,	O
TNF-alpha	B-protein
caused	O
a	O
gliotoxin-inhibitable	O
activation	O
of	O
an	O
inducible	O
form	O
of	O
NF-kappaB	B-protein
,	O
a	O
response	O
that	O
may	O
underlie	O
the	O
ability	O
of	O
TNF-alpha	B-protein
to	O
delay	O
apoptosis	O
at	O
later	O
times	O
(	O
12-24	O
h	O
)	O
and	O
limit	O
its	O
early	O
killing	O
effect	O
.	O

All	O
patients	O
were	O
characterized	O
by	O
an	O
Addisonian	O
picture	O
(	O
weakness	O
,	O
weight	O
loss	O
,	O
hypotension	O
,	O
hyponatremia	O
,	O
and	O
intense	O
mucocutaneous	O
melanosis	O
)	O
.	O

The	O
transduction	O
pathway	O
leading	O
to	O
NF-kappaB	B-protein
activation	O
in	O
U937	B-cell_line
cells	I-cell_line
involved	O
the	O
intracellular	O
generation	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
as	O
demonstrated	O
by	O
the	O
concomitant	O
inhibitory	O
effects	O
of	O
antioxidants	O
on	O
NF-kappaB	B-protein
activation	O
and	O
the	O
emission	O
of	O
a	O
fluorescent	O
probe	O
reacting	O
intracellularly	O
with	O
hydrogen	O
peroxide	O
.	O

CONCLUSIONS	O
Hypercortisolaemia	O
does	O
not	O
down-regulate	O
the	O
lymphocyte	O
glucocorticoid	B-protein
receptors	I-protein
in	O
anorexia	O
nervosa	O
and	O
a	O
post-receptor	O
defect	O
might	O
be	O
involved	O
in	O
peripheral	O
tissue	O
resistance	O
to	O
the	O
effects	O
of	O
glucocorticoid	O
hormones	O
in	O
undernutrition	O
.	O

Two	O
tyrosines	O
(	O
Y113	O
and	O
Y128	O
)	O
fall	O
within	O
an	O
identical	O
five	O
amino-acid	O
motif	O
and	O
are	O
shown	O
to	O
be	O
phosphorylated	O
upon	O
TCR	B-protein
ligation	O
.	O

Many	O
of	O
these	O
events	O
are	O
dependent	O
upon	O
the	O
ability	O
of	O
CD40	B-protein
to	O
activate	O
the	O
transcription	O
factor	O
NF-kappa	B-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O

Although	O
there	O
have	O
been	O
a	O
number	O
of	O
reports	O
demonstrating	O
that	O
glucocorticoids	O
(	O
in	O
particular	O
dexamethasone	O
)	O
antagonize	O
the	O
eosinophil	O
life-prolonging	O
effects	O
of	O
hemopoietins	B-protein
,	O
direct	O
effects	O
of	O
dexamethasone	O
on	O
eosinophil	O
apoptosis	O
have	O
not	O
been	O
documented	O
.	O

Proliferation	O
of	O
the	O
K562	B-cell_line
cells	I-cell_line
was	O
also	O
suppressed	O
.	O

trans-activation	O
of	O
the	O
HIV	B-DNA
promoter	I-DNA
by	O
a	O
cDNA	O
and	O
its	O
genomic	O
clones	O
of	O
human	O
herpesvirus-6	O
.	O

Thus	O
,	O
IkappaB-alphaS32/36A	B-protein
offers	O
proof-of-principle	O
that	O
artifactually	O
gained	O
functions	O
,	O
when	O
used	O
to	O
attenuate	O
the	O
replication	O
of	O
live	O
HIV-1	O
,	O
can	O
be	O
stable	O
.	O

Few	O
,	O
if	O
any	O
,	O
studies	O
have	O
been	O
made	O
on	O
the	O
impact	O
of	O
these	O
compounds	O
on	O
the	O
immune	O
system	O
.	O

Cell-type-specific	O
regulation	O
of	O
the	O
human	B-DNA
tumor	I-DNA
necrosis	I-DNA
factor	I-DNA
alpha	I-DNA
gene	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
and	O
T	B-cell_type
cells	I-cell_type
by	O
NFATp	B-protein
and	O
ATF-2/JUN	B-protein
.	O

Monocytes	O
convert	O
25	O
(	O
OH	O
)	O
D3	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
to	O
24-hydroxylated	O
metabolites	O
more	O
polar	O
than	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

GR	B-protein
binding	O
capacity	O
was	O
higher	O
in	O
younger	O
subjects	O
than	O
in	O
older	O
ones	O
,	O
and	O
lower	O
in	O
the	O
group	O
of	O
athletes	O
than	O
in	O
the	O
younger	O
and	O
older	O
sedentary	O
subjects	O
.	O

Interestingly	O
,	O
although	O
mRNA	O
expression	O
of	O
Smad6	B-protein
was	O
induced	O
by	O
activin	O
A	O
in	O
HS-72	B-cell_line
cells	I-cell_line
,	O
Smad6	B-protein
showed	O
no	O
antagonistic	O
effect	O
on	O
activin	O
A-induced	O
growth	O
arrest	O
and	O
apoptosis	O
.	O

Although	O
recognized	O
as	O
fundamental	O
aspects	O
of	O
T	B-cell_type
lymphocyte	I-cell_type
development	O
,	O
only	O
recently	O
have	O
the	O
mechanisms	O
governing	O
positive	O
and	O
negative	O
selection	O
been	O
examined	O
at	O
a	O
molecular	O
level	O
.	O

In	O
spite	O
of	O
its	O
association	O
with	O
p50	B-protein
in	O
vitro	O
,	O
however	O
,	O
we	O
found	O
a	O
lymphoid	B-protein
cell-specific	I-protein
nuclear	I-protein
factor	I-protein
in	O
vivo	O
that	O
contains	O
c-Rel	B-protein
but	O
not	O
p50	B-protein
epitopes	I-protein
;	O
this	O
factor	O
,	O
termed	O
IL-6	B-protein
kappa	I-protein
B	I-protein
binding	I-protein
factor	I-protein
II	I-protein
,	O
appears	O
to	O
contain	O
the	O
c-Rel	B-protein
homodimer	I-protein
and	O
preferentially	O
recognizes	O
several	O
IL-6	B-DNA
kappa	I-DNA
B-related	I-DNA
kappa	I-DNA
B	I-DNA
motifs	I-DNA
.	O

In	O
the	O
transient-transfection	O
assay	O
,	O
ICP0	B-protein
,	O
but	O
not	O
ICP4	B-protein
,	O
activated	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
promoter	I-DNA
region	I-DNA
and	O
the	O
effect	O
of	O
ICP0	B-protein
was	O
greatly	O
enhanced	O
in	O
the	O
presence	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
binding	I-protein
proteins	I-protein
,	O
suggesting	O
that	O
induction	O
of	O
the	O
HIV-1	O
provirus	O
involves	O
cooperation	O
between	O
the	O
HSV-1-activated	B-protein
cellular	I-protein
factor	I-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
the	O
virus-encoded	B-protein
transactivator	I-protein
,	O
ICP0	B-protein
.	O

Thymic	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
mediate	O
negative	O
selection	O
at	O
a	O
relatively	O
late	O
stage	O
of	O
the	O
T-cell	O
developmental	O
pathway	O
.	O

Direct	O
assays	O
of	O
PKC	B-protein
activity	O
were	O
conducted	O
.	O

Activation	O
of	O
human	B-cell_type
macrophages	I-cell_type
by	O
mechanical	O
ventilation	O
in	O
vitro	O
.	O

p21ras	B-protein
initiates	O
Rac-1	B-protein
but	O
not	O
phosphatidyl	B-protein
inositol	I-protein
3	I-protein
kinase/PKB	I-protein
,	O
mediated	O
signaling	O
pathways	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

A	O
point	O
mutation	O
of	O
a	O
potential	O
phosphatidylinositol	B-DNA
3-kinase	I-DNA
(	I-DNA
PI3-K	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
(	O
Y731EAM	B-DNA
to	O
Y731EAC	B-DNA
)	O
in	O
70Z/3	B-protein
disrupted	O
the	O
association	O
of	O
PI3-K	B-protein
with	O
70Z/3	B-protein
,	O
but	O
did	O
not	O
reduce	O
the	O
induction	O
of	O
NFAT	B-protein
activity	O
,	O
suggesting	O
that	O
the	O
interaction	O
between	O
Cbl	B-protein
and	O
PI3-K	B-protein
is	O
not	O
required	O
in	O
the	O
70Z/3	B-protein
-mediated	O
induction	O
of	O
NFAT	B-protein
.	O

Retinoic	O
acid-induced	O
modulation	O
of	O
IL-2	B-RNA
mRNA	I-RNA
production	O
and	O
IL-2	B-protein
receptor	O
expression	O
on	O
T	B-cell_type
cells	I-cell_type
.	O

Finally	O
,	O
an	O
abbreviated	B-DNA
TSP	I-DNA
1	I-DNA
promoter/5'-flank	I-DNA
,	O
containing	O
the	O
SRE-	B-DNA
and	I-DNA
NF-Y-binding	I-DNA
sites	I-DNA
,	O
mediated	O
a	O
serum	O
response	O
that	O
was	O
close	O
in	O
magnitude	O
to	O
that	O
of	O
the	O
parent	B-DNA
promoter	I-DNA
.	O

Patients	O
with	O
HIV	O
infections	O
often	O
show	O
elevated	O
circulating	O
levels	O
of	O
cortisol	O
,	O
suggesting	O
some	O
misfunction	O
in	O
the	O
regulatory	O
systems	O
that	O
maintain	O
the	O
levels	O
of	O
this	O
critical	O
hormone	O
.	O

Ras	B-protein
-dependent	O
,	O
Ca2+-stimulated	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
by	O
a	O
constitutively	O
active	O
Cbl	B-protein
mutant	I-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

We	O
previously	O
identified	O
a	O
Fas	B-DNA
ligand	I-DNA
regulatory	I-DNA
element	I-DNA
(	O
FLRE	B-DNA
)	O
in	O
the	O
Fas	B-DNA
ligand	I-DNA
(	I-DNA
fasL	I-DNA
)	I-DNA
promoter	I-DNA
that	O
binds	O
Egr	B-protein
family	I-protein
proteins	I-protein
and	O
demonstrated	O
that	O
Egr-3	B-protein
(	O
PILOT	B-protein
)	O
but	O
not	O
Egr-1	B-protein
(	O
NGFI-A	B-protein
,	O
Krox-24	B-protein
,	O
Tis-8	B-protein
,	O
and	O
Zif-268	B-protein
)	O
induces	O
transcription	O
of	O
fasL	B-protein
.	O

Moreover	O
,	O
the	O
effects	O
of	O
IFN-gamma	B-protein
and	O
LPS	O
could	O
be	O
reproduced	O
by	O
priming	O
,	O
whereas	O
IFN-beta	B-protein
and	O
IL-4	B-protein
were	O
required	O
simultaneously	O
with	O
GC	O
.	O

Various	O
modes	O
of	O
basic	B-protein
helix-loop-helix	I-protein
protein	I-protein
-mediated	O
regulation	O
of	O
murine	O
leukemia	O
virus	O
transcription	O
in	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

There	O
is	O
increasing	O
evidence	O
that	O
IFN-alpha	B-protein
has	O
an	O
important	O
role	O
in	O
T-cell	O
biology	O
.	O

The	O
production	O
and	O
characterization	O
of	O
Jurkat	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
constitutively	O
express	O
functional	O
human	B-protein
immune	I-protein
deficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV-1	I-protein
)	I-protein
tat	I-protein
protein	I-protein
,	O
using	O
a	O
BK	O
virus	O
plasmid	O
expression	O
vector	O
and	O
HIV-1	B-DNA
tat	I-DNA
cDNA	I-DNA
,	O
is	O
described	O
.	O

Expression	O
cloning	O
of	O
c-Jun	B-protein
.	O

The	O
capacity	O
of	O
the	O
receptor	B-protein
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
low	O
in	O
Ro-VDR	B-cell_line
.	O

This	O
was	O
evidenced	O
by	O
the	O
ability	O
of	O
the	O
AP-1	B-DNA
site	I-DNA
to	O
compete	O
with	O
the	O
NF-AT	B-protein
site	O
for	O
binding	O
to	O
NF-AT	B-protein
and	O
by	O
the	O
capacity	O
of	O
immobilized	B-protein
anti-Jun	I-protein
and	O
anti-Fos	B-protein
antibodies	O
to	O
deplete	O
NF-AT	B-protein
-binding	O
activity	O
from	O
nuclear	O
extracts	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
requirements	O
for	O
induction	O
of	O
transcription	B-protein
factors	I-protein
reflected	O
the	O
requirements	O
for	O
the	O
secretion	O
of	O
multiple	O
cytokines	B-protein
,	O
including	O
IL-2	B-protein
,	O
TNF-alpha	B-protein
,	O
IFN-gamma	B-protein
,	O
and	O
granulocyte	B-protein
macrophage-CSF	I-protein
.	O

These	O
results	O
suggest	O
that	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
LTR	I-DNA
possesses	O
functional	O
redundancy	O
which	O
ensures	O
virus	O
replication	O
in	O
different	O
T-cell	B-cell_type
types	I-cell_type
and	O
is	O
capable	O
of	O
changing	O
depending	O
on	O
the	O
particular	O
combination	O
of	O
transcriptional	B-protein
factors	I-protein
present	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
PB1	B-DNA
element	I-DNA
alone	O
confers	O
inducibility	O
on	O
a	O
heterologous	O
promoter	O
following	O
transfection	O
into	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Although	O
the	O
growth	O
rate	O
was	O
normal	O
,	O
the	O
XP-B	B-cell_line
and	I-cell_line
XP-D	I-cell_line
cells	I-cell_line
contained	O
reduced	O
amounts	O
of	O
TFIIH	B-protein
.	O

Despite	O
its	O
reported	O
role	O
as	O
a	O
negative	O
regulator	O
of	O
transcription	O
,	O
Ig/EBP-1	B-protein
appears	O
to	O
exert	O
a	O
stimulatory	O
effect	O
on	O
this	O
promoter	B-DNA
.	O

Therefore	O
,	O
this	O
genetic	O
variant	O
,	O
which	O
predisposes	O
to	O
low	O
bone	O
mineral	O
density	O
in	O
many	O
populations	O
,	O
may	O
confer	O
resistance	O
to	O
certain	O
infectious	O
diseases	O
.	O

The	O
glucocorticoid	B-protein
receptor	I-protein
was	O
shown	O
to	O
repress	O
activity	O
of	O
both	O
the	O
RelA	B-protein
homodimer	I-protein
and	O
the	O
NF-kappa	B-protein
B1/RelA	I-protein
heterodimer	I-protein
.	O

Interferons	B-protein
induce	O
normal	O
and	O
aberrant	O
retinoic-acid	B-protein
receptors	I-protein
type	I-protein
alpha	I-protein
in	O
acute	B-cell_type
promyelocytic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
:	O
potentiation	O
of	O
the	O
induction	O
of	O
retinoid-dependent	O
differentiation	B-protein
markers	I-protein
.	O

The	O
class	B-protein
II	I-protein
transactivator	I-protein
(	O
CIITA	B-protein
)	O
and	O
B	B-protein
cell	I-protein
octamer-binding	I-protein
protein	I-protein
1/octamer-binding	I-protein
factor	I-protein
1/Oct	I-protein
coactivator	I-protein
from	O
B	B-cell_type
cells	I-cell_type
(	O
Bob1/OBF-1/OCA-B	B-protein
)	O
represent	O
two	O
B	B-protein
cell-specific	I-protein
transcriptional	I-protein
coactivators	I-protein
.	O

Gold	O
compounds	O
have	O
been	O
effectively	O
used	O
for	O
many	O
decades	O
in	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
.	O

The	O
biological	O
activity	O
of	O
11	O
alpha-methyl-1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
closely	O
resembled	O
that	O
of	O
the	O
natural	O
hormone	O
on	O
normal	O
and	O
leukemic	B-cell_type
cell	I-cell_type
proliferation	O
and	O
bone	O
resorption	O
,	O
whereas	O
its	O
in	O
vivo	O
effect	O
on	O
calcium	O
metabolism	O
of	O
the	O
rachitic	O
chick	O
was	O
about	O
50	O
%	O
of	O
that	O
of	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
.	O

Unlike	O
EKLF	B-protein
,	O
Sp1	B-protein
,	O
which	O
also	O
binds	O
to	O
CACCC	O
boxes	O
,	O
is	O
not	O
recruited	O
to	O
5'HS3	B-DNA
.	O

Co-transfection	O
experiments	O
confirm	O
that	O
Aiolos	B-protein
induces	O
Bcl-2	B-protein
expression	O
and	O
prevents	O
apoptosis	O
in	O
IL-2-deprived	B-cell_line
cells	I-cell_line
.	O

Upon	O
cellular	O
activation	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
phosphorylated	O
,	O
polyubiquitinated	O
,	O
and	O
degraded	O
in	O
the	O
proteasome	B-protein
.	O

BACKGROUND	O
:	O
The	O
class	B-protein
II	I-protein
transactivator	I-protein
(	O
CIITA	B-protein
)	O
is	O
a	O
bi-	B-protein
or	I-protein
multifunctional	I-protein
domain	I-protein
protein	I-protein
that	O
acts	O
as	O
a	O
transcriptional	B-protein
activator	I-protein
and	O
plays	O
a	O
critical	O
role	O
in	O
the	O
expression	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
.	O

Squirrel	O
monkeys	O
are	O
neotropical	O
primates	O
that	O
have	O
high	O
circulating	O
cortisol	O
to	O
compensate	O
for	O
expression	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GRs	B-protein
)	O
with	O
reduced	O
affinity	O
.	O

Furthermore	O
,	O
p65	B-protein
was	O
detected	O
in	O
the	O
nuclei	O
of	O
some	O
lymphocytes	B-cell_type
.	O

TNFRI	B-protein
has	O
been	O
recently	O
shown	O
to	O
activate	O
NF-kappaB	B-protein
through	O
association	O
with	O
TRADD	B-protein
,	O
RIP	B-protein
,	O
and	O
TRAF2	B-protein
;	O
activation	O
of	O
the	O
NF-kappaB-inducing	B-protein
kinase	I-protein
(	O
NIK	B-protein
)	O
;	O
activation	O
of	O
the	O
IkappaB	B-protein
alpha	I-protein
kinases	I-protein
(	O
IKKalpha	B-protein
and	O
IKKbeta	B-protein
)	O
;	O
and	O
phosphorylation	O
of	O
IkappaB	B-protein
alpha	I-protein
.	O

Alternative	O
polyadenylation	O
events	O
contribute	O
to	O
the	O
induction	O
of	O
NF-ATc	B-protein
in	O
effector	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
5	B-DNA
'	I-DNA
flanking	I-DNA
DNA	I-DNA
also	O
contains	O
a	O
cluster	O
of	O
three	O
binding	B-DNA
sites	I-DNA
for	O
the	O
GATA	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

The	O
NB	O
is	O
also	O
a	O
target	O
of	O
antibodies	B-protein
in	O
the	O
serum	O
of	O
patients	O
with	O
the	O
autoimmune	O
disease	O
primary	O
biliary	O
cirrhosis	O
.	O

To	O
further	O
identify	O
intracellular	O
signals	O
and	O
downstream	O
events	O
important	O
in	O
CD34+	B-cell_line
HPC	I-cell_line
--	O
>	O
DC	B-cell_type
differentiation	O
we	O
have	O
characterized	O
a	O
human	O
leukemic	O
cell	O
line	O
model	O
of	O
this	O
process	O
.	O

The	O
reduction	O
in	O
gene	O
expression	O
resulted	O
from	O
the	O
ability	O
of	O
IL-10	B-protein
to	O
suppress	O
IFN	B-protein
-induced	O
assembly	O
of	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
factors	I-protein
to	O
specific	B-DNA
promoter	I-DNA
motifs	I-DNA
on	O
IFNalpha-	B-DNA
and	I-DNA
IFNgamma-inducible	I-DNA
genes	I-DNA
.	O

IL-7	B-protein
also	O
delayed	O
the	O
decreases	O
in	O
the	O
levels	O
of	O
c-Myc	B-protein
,	O
Bcl-2	B-protein
,	O
and	O
Bcl-xL	B-protein
that	O
occur	O
upon	O
loss	O
of	O
v-Abl	B-protein
kinase	O
activity	O
.	O

One	O
of	O
the	O
cDNA	B-DNA
fragments	I-DNA
expressed	O
specifically	O
in	O
CD3	B-protein
-and	O
CD28	B-protein
-activated	B-cell_type
T	I-cell_type
cells	I-cell_type
was	O
designated	O
RP1	B-DNA
.	O

The	O
50	O
%	O
inhibitory	O
concentrations	O
of	O
MP	O
of	O
about	O
5	O
ng/ml	O
were	O
similar	O
for	O
both	O
regimens	O
.	O

The	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	I-DNA
LTR	I-DNA
)	I-DNA
region	I-DNA
of	O
HIV	B-DNA
proviral	I-DNA
DNA	I-DNA
contains	O
binding	O
sites	O
for	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
and	O
this	O
transcriptional	B-protein
activator	I-protein
appears	O
to	O
regulate	O
HIV	O
activation	O
.	O

Finally	O
,	O
when	O
using	O
Staphylococcus	O
aureus	O
or	O
platelet	B-protein
activating	I-protein
factor	I-protein
as	O
a	O
stimulus	O
,	O
gangliosides	O
were	O
able	O
to	O
suppress	O
TNF	B-protein
production	O
in	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
by	O
factor	O
5	O
to	O
10	O
,	O
as	O
well	O
.	O

These	O
data	O
demonstrate	O
the	O
efficiency	O
of	O
the	O
system	O
and	O
support	O
the	O
notion	O
that	O
numerous	O
genes	B-DNA
falling	O
into	O
those	O
categories	O
remain	O
unidentified	O
and	O
that	O
they	O
can	O
be	O
cloned	O
by	O
this	O
method	O
.	O

[	O
The	O
changes	O
in	O
glucocorticoid	O
receptors	O
in	O
peripheral	B-cell_type
leukocytes	I-cell_type
in	O
asthmatic	O
subjects	O
]	O

Finally	O
,	O
Scatchard	O
plot	O
analysis	O
demonstrated	O
the	O
presence	O
of	O
a	O
DHEA	O
receptor	O
in	O
monocytes	B-cell_type
,	O
suggesting	O
that	O
DHEA	O
effects	O
on	O
LPS-stimulated	B-cell_line
monocytes	I-cell_line
are	O
mediated	O
through	O
a	O
receptor-dependent	O
process	O
.	O

Expression	O
of	O
A-myb	B-DNA
,	O
but	O
not	O
c-myb	B-DNA
and	O
B-myb	B-DNA
,	O
is	O
restricted	O
to	O
Burkitt	O
's	O
lymphoma	O
,	O
sIg+	O
B-acute	O
lymphoblastic	O
leukemia	O
,	O
and	O
a	O
subset	O
of	O
chronic	O
lymphocytic	O
leukemias	O
.	O

The	O
mechanism	O
of	O
inhibition	O
is	O
related	O
to	O
the	O
surface	O
expression	O
of	O
several	O
cell	O
adhesion	B-protein
molecules	I-protein
.	O

CONCLUSION	O
:	O
Overall	O
,	O
the	O
results	O
suggest	O
that	O
NF-kappa	B-protein
B	I-protein
may	O
play	O
a	O
central	O
part	O
in	O
the	O
activation	O
of	O
infiltrating	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
chronic	O
rheumatoid	O
arthritis	O
.	O

These	O
results	O
demonstrate	O
another	O
level	O
of	O
regulation	O
within	O
the	O
NF-AT	B-protein
family	I-protein
that	O
can	O
contribute	O
to	O
cell	O
type-specific	O
gene	O
expression	O
.	O

The	O
HB9	B-DNA
homeodomain	I-DNA
is	O
most	O
similar	O
to	O
that	O
of	O
the	O
Drosophila	B-DNA
melanogaster	I-DNA
homeobox	I-DNA
gene	I-DNA
proboscipedia	B-DNA
.	O

We	O
utilized	O
CoCl2	O
as	O
a	O
mimetic	O
molecule	O
for	O
hypoxia	O
to	O
study	O
cellular	O
signaling	O
pathways	O
.	O

These	O
constructs	O
were	O
transfected	O
into	O
a	O
variety	O
of	O
cell	O
lines	O
,	O
either	O
alone	O
or	O
together	O
,	O
with	O
transcription	B-protein
factor	I-protein
expression	O
vectors	O
.	O

The	O
small	O
molecule	O
S9a	O
was	O
derived	O
from	O
an	O
established	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
inhibitor	O
(	O
Canventol	O
)	O
by	O
replacement	O
of	O
the	O
isopropylidine	O
group	O
with	O
a	O
phenyl	O
ring	O
.	O

We	O
show	O
that	O
the	O
lack	O
of	O
NF-YA	B-protein
protein	I-protein
is	O
due	O
to	O
posttranscriptional	O
regulation	O
and	O
not	O
to	O
a	O
specific	O
proteolytic	O
activity	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
p21	B-protein
(	I-protein
WAF1/CIP1	I-protein
)	I-protein
and	O
p27	B-protein
(	I-protein
KIP1	I-protein
)	I-protein
transcripts	O
were	O
induced	O
after	O
6	O
hours	O
'	O
exposure	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
then	O
decreased	O
to	O
basal	O
levels	O
over	O
48	O
hours	O
.	O

Vitamin	O
D	O
analogs	O
,	O
20-Epi-22-oxa-24a	O
,	O
26a	O
,	O
27a	O
,	O
-trihomo-1alpha	O
,	O
25	O
(	O
OH	O
)	O
2-vitamin	O
D3	O
,	O
1	O
,	O
24	O
(	O
OH	O
)	O
2-22-ene-24-cyclopropyl-vitamin	O
D3	O
and	O
1alpha	O
,	O
25	O
(	O
OH	O
)	O
2-lumisterol3	O
prime	O
NB4	B-cell_line
leukemia	I-cell_line
cells	I-cell_line
for	O
monocytic	O
differentiation	O
via	O
nongenomic	O
signaling	O
pathways	O
,	O
involving	O
calcium	O
and	O
calpain	O
.	O

SERCA	B-protein
activity	O
was	O
measured	O
as	O
the	O
thapsigargin	O
sensitive	O
,	O
Ca2+	O
dependent	O
and	O
ouabain	O
resistant	O
,	O
ATP	O
hydrolyses	O
in	O
platelet	O
membranes	O
.	O

The	O
T	O
cell	O
activation	O
is	O
initiated	O
by	O
interaction	O
of	O
specific	O
Ags	B-protein
with	O
TCR	B-protein
,	O
followed	O
by	O
activation	O
of	O
intracellular	O
biochemical	O
events	O
leading	O
to	O
activation	O
of	O
several	O
genes	O
.	O

Within	O
this	O
region	O
,	O
a	O
19-bp	B-DNA
nuclear	I-DNA
factor	I-DNA
binding	I-DNA
site	I-DNA
(	O
-570	B-DNA
to	I-DNA
-552	I-DNA
)	O
was	O
characterized	O
by	O
DNase	B-protein
I	I-protein
footprinting	O
and	O
electromobility	O
shift	O
assay	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
presence	O
of	O
constitutively	O
activated	O
STAT	B-protein
factors	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
acute	O
leukemia	O
.	O

Deletion	O
or	O
substitution	O
of	O
a	O
putative	B-protein
NF-kappaB	I-protein
binding	I-protein
site	I-protein
identified	O
in	O
the	O
bcl-x	B-DNA
promoter	I-DNA
significantly	O
decreased	O
Tax	B-protein
-induced	O
transactivation	O
.	O

We	O
have	O
examined	O
the	O
requirements	O
of	O
the	O
individual	O
E-boxes	B-DNA
in	O
MLV	O
transcriptional	O
regulation	O
.	O

Nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
a	O
critical	O
transcription	B-protein
factor	I-protein
for	O
maximal	O
expression	O
of	O
many	O
cytokines	B-protein
that	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
diseases	O
,	O
such	O
as	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
sepsis	O
syndrome	O
.	O

We	O
investigated	O
the	O
clinical	O
significance	O
of	O
glucocorticoid	B-protein
receptor	I-protein
determination	O
in	O
20	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
who	O
afterwards	O
developed	O
nephrotic	O
syndrome	O
.	O

On	O
the	O
other	O
hand	O
,	O
stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
mAb	B-protein
9.3	I-protein
increased	O
the	O
level	O
of	O
intracellular	O
Ca2+	O
and	O
triggered	O
the	O
activation	O
of	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
and	O
c-Raf-1	B-protein
,	O
but	O
was	O
unable	O
to	O
induce	O
the	O
binding	O
of	O
transcription	B-protein
factors	I-protein
to	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

The	O
T3-subjects	O
received	O
placebo	O
[	O
n	O
=	O
8	O
]	O
and	O
the	O
T3	O
+	O
subjects	O
received	O
T3	O
(	O
30	O
micrograms/d	O
)	O
[	O
n	O
=	O
8	O
]	O
in	O
a	O
double-blind	O
fashion	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
NF-kappaB	B-protein
may	O
be	O
required	O
for	O
human	O
CD34	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cell	I-cell_type
clonogenic	O
function	O
and	O
survival	O
.	O

Pindolol	O
was	O
inefficient	O
on	O
the	O
dysrhythmia	O
which	O
disappeared	O
with	O
carbimazole	O
and	O
relapsed	O
after	O
withdrawal	O
of	O
the	O
antithyroid	O
drug	O
.	O

Yet	O
,	O
IL-2	B-protein
-driven	O
proliferation	O
remained	O
profoundly	O
inhibited	O
,	O
suggesting	O
that	O
signaling	O
events	O
other	O
than	O
Jak3	B-protein
/Stat	B-protein
activation	O
had	O
also	O
been	O
changed	O
following	O
SE	B-protein
stimulation	O
.	O

Human	O
immunodeficiency	O
virus	O
type-2	O
gene	O
expression	O
:	O
two	O
enhancers	B-DNA
and	O
their	O
activation	O
by	O
T-cell	B-cell_type
activators	O
.	O

Two	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
mutants	I-protein
lacking	O
either	O
the	O
entire	O
catalytic	B-protein
domain	I-protein
or	O
the	O
entire	O
NH2	B-protein
regulatory	B-protein
domain	I-protein
were	O
generated	O
,	O
and	O
their	O
abilities	O
to	O
trigger	O
transactivation	O
of	O
the	O
TCR-regulated	B-DNA
nuclear	I-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells	I-DNA
(	I-DNA
NF-AT	I-DNA
)	I-DNA
region	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
were	O
compared	O
.	O

In	O
A20	B-cell_line
B	I-cell_line
cells	I-cell_line
,	O
the	O
TNF-alpha	B-DNA
gene	I-DNA
is	O
not	O
regulated	O
by	O
NFATp	B-protein
bound	O
to	O
the	O
kappa	B-DNA
3	I-DNA
element	I-DNA
.	O

Thymocytes	B-cell_type
expressed	O
four-	O
to	O
10-fold	O
greater	O
amounts	O
of	O
the	O
3.5	B-RNA
kb	I-RNA
transcript	I-RNA
than	O
other	O
tissues	O
.	O

The	O
DNA-binding	O
properties	O
of	O
two	B-protein
heat	I-protein
shock	I-protein
factors	I-protein
,	O
HSF1	B-protein
and	O
HSF3	B-protein
,	O
are	O
induced	O
in	O
the	O
avian	B-cell_line
erythroblast	I-cell_line
cell	I-cell_line
line	I-cell_line
HD6	B-cell_line
.	O

We	O
have	O
cloned	O
the	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	I-protein
LMP1	I-protein
)	I-protein
homologs	I-protein
from	O
the	O
simian	O
EBV	O
naturally	O
infecting	O
baboons	O
(	O
cercopithicine	O
herpesvirus	O
12	O
,	O
herpesvirus	O
papio	O
)	O
and	O
rhesus	O
monkeys	O
(	O
cercopithicine	O
herpesvirus	O
15	O
)	O
for	O
a	O
comparative	O
study	O
with	O
the	O
human	O
EBV	O
oncogene	O
.	O

Thus	O
,	O
STAT1	B-protein
may	O
be	O
a	O
useful	O
target	O
in	O
the	O
development	O
of	O
new	O
immunosuppressive	O
and	O
antineoplastic	O
agents	O
.	O

Prominent	O
protein	B-protein
kinase	I-protein
cascades	O
are	O
those	O
that	O
activate	O
mitogen-activated	B-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinases	I-protein
.	O

The	O
importance	O
of	O
the	O
central	B-protein
nervous	I-protein
system-enriched	I-protein
kappa	I-protein
B	I-protein
transcription	B-protein
factor	I-protein
in	O
the	O
regulation	O
of	O
HIV-1	O
expression	O
is	O
discussed	O
.	O

On	O
the	O
contrary	O
,	O
other	O
steroid	O
hormones	O
such	O
as	O
Tx	O
,	O
progesterone	O
,	O
and	O
testosterone	O
had	O
no	O
effect	O
.	O

Our	O
data	O
constitute	O
a	O
starting	O
point	O
for	O
studies	O
to	O
elucidate	O
the	O
molecular	O
mechanism	O
by	O
which	O
TGF-beta	B-protein
regulates	O
IgA	B-protein
production	O
.	O

Clone	B-DNA
pAT	I-DNA
133	I-DNA
identifies	O
a	O
gene	O
that	O
encodes	O
another	O
human	O
member	O
of	O
a	O
class	O
of	O
growth	B-DNA
factor-induced	I-DNA
genes	I-DNA
with	O
almost	O
identical	O
zinc-finger	B-protein
domains	I-protein
.	O

It	O
is	O
,	O
however	O
,	O
still	O
unclear	O
whether	O
LTB4	O
acts	O
in	O
this	O
regard	O
directly	O
or	O
indirectly	O
by	O
stimulating	O
the	O
release	O
of	O
chemotactic	O
and	O
inflammatory	B-protein
cytokines	I-protein
.	O

T-cell	O
prolymphocytic	O
leukemia	O
(	O
T-PLL	O
)	O
,	O
a	O
rare	O
form	O
of	O
mature	O
T-cell	O
leukemias	O
,	O
and	O
ataxia	O
telangiectasia	O
clonal	O
proliferation	O
,	O
a	O
related	O
condition	O
occurring	O
in	O
patients	O
suffering	O
from	O
ataxia	O
telangiectasia	O
,	O
have	O
been	O
associated	O
to	O
translocations	O
involving	O
the	O
14q32.1	B-DNA
or	O
Xq28	B-DNA
regions	I-DNA
,	O
where	O
are	O
located	O
the	O
TCL1	B-DNA
and	I-DNA
MTCP1	I-DNA
putative	I-DNA
oncogenes	I-DNA
,	O
respectively	O
.	O

The	O
Oct-2	B-protein
transcription	I-protein
factor	I-protein
is	O
a	O
member	O
of	O
the	O
POU	B-protein
(	I-protein
Pit-Oct-Unc	I-protein
)	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
and	O
is	O
expressed	O
only	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
and	O
in	O
neuronal	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
other	O
cell	O
types	O
.	O

Flutamide	O
affects	O
androgen	B-protein
receptor	I-protein
behavior	O
during	O
the	O
menstrual	O
cycle	O
.	O

Here	O
,	O
we	O
report	O
the	O
functional	O
expression	O
of	O
CD40	B-protein
on	O
human	O
malignant	O
melanomas	O
(	O
MMs	O
)	O
.	O

Both	O
canrenone	O
and	O
cortisol	O
were	O
inactive	O
as	O
ligands	O
up	O
to	O
concentrations	O
of	O
0.1	O
microM	O
.	O

Both	O
alpha-	O
and	O
beta-bound	O
complexes	O
are	O
found	O
only	O
in	O
lymphoid	O
tissues	O
,	O
in	O
CD28+	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
and	O
in	O
some	O
transformed	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

Transfection	O
with	O
C/EBP	B-protein
alpha	I-protein
revealed	O
a	O
massive	O
enhancement	O
of	O
the	O
MRP14	B-DNA
promoter	I-DNA
in	O
both	O
,	O
HL	B-cell_type
60	I-cell_type
cells	I-cell_type
(	O
granulocytic	O
differentiated	O
)	O
and	O
L132	B-cell_type
fibroblasts	I-cell_type
.	O

When	O
CD45RA+	B-cell_type
(	I-cell_type
naive	I-cell_type
)	I-cell_type
and	O
CD45RO+	B-cell_type
(	I-cell_type
memory	I-cell_type
)	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
were	O
directly	O
stimulated	O
with	O
H2O2	O
,	O
NF-kappaB	B-protein
nuclear	O
translocation	O
was	O
stronger	O
in	O
naive	B-cell_type
cells	I-cell_type
than	O
in	O
memory	B-cell_type
cells	I-cell_type
and	O
it	O
could	O
be	O
induced	O
with	O
lower	O
doses	O
.	O

These	O
mutants	O
were	O
used	O
to	O
demonstrate	O
that	O
the	O
ability	O
of	O
ZEBRA	B-protein
's	I-protein
wild	I-protein
type	I-protein
domain	I-protein
to	O
function	O
in	O
the	O
complex	O
biological	O
process	O
of	O
virus	O
activation	O
is	O
not	O
compromised	O
by	O
altering	O
its	O
position	O
within	O
the	O
protein	O
.	O

Thus	O
,	O
the	O
substitution	O
of	O
the	O
underlined	O
A	O
residue	O
to	O
a	O
C	O
within	O
the	O
GGGATTTCACC	B-DNA
motif	I-DNA
abolishes	O
its	O
T	O
cell-restricted	O
activity	O
and	O
leads	O
to	O
its	O
functioning	O
in	O
both	O
El4	B-cell_line
cells	I-cell_line
and	O
HeLa	B-cell_line
cells	I-cell_line
.	O

To	O
define	O
the	O
mechanism	O
underlying	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
protein	I-protein
recruitment	O
to	O
the	O
interleukin	B-protein
10	I-protein
(	I-protein
IL-10	I-protein
)	I-protein
receptor	I-protein
,	O
the	O
STAT	B-protein
proteins	I-protein
activated	O
by	O
IL-10	B-protein
in	O
different	O
cell	O
populations	O
were	O
first	O
defined	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

We	O
show	O
here	O
that	O
c-Raf	B-protein
,	O
which	O
is	O
at	O
the	O
helm	O
of	O
the	O
classic	O
MAP-	O
Erk	B-protein
cascade	O
,	O
contributes	O
to	O
IL-2	B-protein
induction	O
through	O
a	O
distal	B-DNA
enhancer	I-DNA
element	I-DNA
spanning	O
the	O
nucleotides	O
from	O
positions	O
-502	O
to	O
-413	O
in	O
front	O
of	O
the	O
transcriptional	O
start	O
site	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O

Further	O
,	O
complete	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
requires	O
at	O
least	O
two	O
signals	O
,	O
one	O
that	O
stimulates	O
an	O
increase	O
in	O
intracellular	O
calcium	O
and	O
one	O
that	O
stimulates	O
enzymatic	O
processes	O
including	O
kinases	O
.	O

Prolactin	O
activates	O
Stat5	B-protein
,	O
and	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
activates	O
Stat6	B-protein
.	O

In	O
vitro	O
transcription	O
studies	O
demonstrate	O
that	O
astrocyte-derived	B-protein
kappa	I-protein
B-binding	I-protein
factors	I-protein
activate	O
transcription	O
of	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
and	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
kappa	B-DNA
B	I-DNA
domain	I-DNA
.	O

The	O
methodology	O
employed	O
transient	O
transfection	O
of	O
HEK	B-cell_line
293	I-cell_line
cells	I-cell_line
with	O
a	O
cDNA	O
for	O
the	O
52-kDa	O
form	O
of	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
under	O
regulation	O
by	O
inducible	B-DNA
metallothionein	I-DNA
promoters	I-DNA
.	O

There	O
are	O
many	O
hypotheses	O
concerning	O
the	O
pathogenesis	O
of	O
endometriosis	O
,	O
though	O
no	O
single	O
theory	O
can	O
explain	O
all	O
cases	O
.	O

A	O
reduced	O
expression	O
of	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
(	O
VDR	O
)	O
in	O
parathyroid	O
glands	O
of	O
uremic	O
animals	O
and	O
humans	O
has	O
been	O
observed	O
.	O

Mutations	O
which	O
abrogated	O
the	O
gene-suppressive	O
activity	O
of	O
NRE	B-DNA
gamma	I-DNA
prevented	O
RFX1	B-protein
from	O
binding	O
to	O
NRE	B-DNA
gamma	I-DNA
.	O

This	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
inhibited	O
by	O
the	O
antioxidant	O
and	O
H2O2	O
scavenger	O
pyrrolidine	O
dithiocarbamate	O
and	O
the	O
proteasome	B-protein
inhibitor	O
PSI	O
.	O

[	O
Hormonal	O
metabolic	O
status	O
in	O
breast	O
cancer	O
patients	O
after	O
conservative	O
surgery	O
:	O
comparison	O
with	O
known	O
prognostic	O
criteria	O
]	O

We	O
have	O
also	O
observed	O
a	O
differential	O
expression	O
of	O
the	O
NF-YA	B-protein
subunit	I-protein
in	O
heme-treated	O
and	O
control	O
FLCs	B-cell_line
and	O
during	O
monocyte-to-macrophage	O
differentiation	O
.	O

In	O
malignant	O
tissues	O
,	O
polyamine	O
levels	O
were	O
significantly	O
higher	O
than	O
in	O
benign	O
tissues	O
.	O

We	O
conclude	O
that	O
cytokines	B-protein
,	O
which	O
signal	O
through	O
the	O
interferon	B-protein
family	I-protein
of	O
receptors	O
,	O
have	O
comparable	O
functional	O
effects	O
on	O
B-CLL	B-cell_line
cells	I-cell_line
.	O

A	O
small	O
,	O
nonpeptidyl	O
mimic	O
of	O
granulocyte-colony-stimulating	B-protein
factor	I-protein
[	O
see	O
commetns	O
]	O

It	O
has	O
been	O
shown	O
recently	O
that	O
in	O
wild-type	B-cell_line
CEM	I-cell_line
cells	I-cell_line
but	O
not	O
in	O
a	O
dex-resistant	B-cell_line
,	I-cell_line
glucocorticoid	I-cell_line
receptor	I-cell_line
(	I-cell_line
GR	I-cell_line
)	I-cell_line
-defective	I-cell_line
clone	I-cell_line
ICR-27	B-cell_line
TK-3	I-cell_line
,	O
dex	O
induces	O
GR	B-RNA
mRNA	I-RNA
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
PNU156804	O
does	O
not	O
block	O
significantly	O
the	O
induction	O
of	O
either	O
IL-2	B-protein
or	O
IL-2R	B-protein
alpha-	I-protein
and	I-protein
gamma-chains	I-protein
but	O
inhibits	O
IL-2	B-protein
-dependent	O
T	O
cell	O
proliferation	O
.	O

The	O
dominant	O
interference	O
activity	O
of	O
Ikaros	B-protein
isoforms	I-protein
unable	O
to	O
bind	O
DNA	O
and	O
their	O
effects	O
in	O
lymphocyte	O
development	O
suggest	O
that	O
Ikaros	B-protein
works	O
in	O
concert	O
with	O
other	O
factors	O
.	O

The	O
replacement	O
of	O
p50	B-protein
homodimers	I-protein
with	O
transcriptionally	O
active	O
heterodimers	O
following	O
time	O
in	O
culture	O
may	O
partially	O
explain	O
the	O
progressive	O
increase	O
in	O
susceptibility	O
of	O
monocytes	B-cell_type
to	O
HIV	O
infection	O
during	O
in	O
vitro	O
culture	O
.	O

Additionally	O
,	O
proposed	O
pathways	O
of	O
NF-kappaB	B-protein
activation	O
have	O
been	O
based	O
on	O
indirect	O
evidence	O
provided	O
by	O
experiments	O
which	O
used	O
antioxidants	O
to	O
inhibit	O
active	O
NF-kappaB	B-protein
formation	O
.	O

Although	O
the	O
role	O
of	O
CD28	B-protein
in	O
T	O
cell	O
costimulation	O
is	O
firmly	O
established	O
,	O
the	O
mechanisms	O
by	O
which	O
it	O
exerts	O
its	O
costimulatory	O
actions	O
are	O
less	O
clear	O
.	O

The	O
numbers	O
and	O
binding	O
affinities	O
of	O
these	O
receptors	B-protein
could	O
not	O
account	O
for	O
the	O
observed	O
difference	O
in	O
the	O
susceptibility	O
of	O
these	O
cells	O
to	O
functional	O
inhibition	O
by	O
dexamethasone	O
in	O
vitro	O
.	O

REVs	O
do	O
not	O
encode	O
a	O
transactivator	O
targeted	O
to	O
the	O
viral	B-DNA
LTR	I-DNA
,	O
and	O
cells	O
infected	O
with	O
Marek	O
's	O
disease	O
virus	O
,	O
a	O
herpesvirus	O
with	O
an	O
overlapping	O
host	O
range	O
,	O
do	O
not	O
express	O
factors	O
that	O
preferentially	O
enhance	O
expression	O
from	O
REV	O
or	O
avian	B-DNA
sarcoma/leukemia	I-DNA
virus	I-DNA
LTRs	I-DNA
.	O

In	O
this	O
study	O
,	O
a	O
combined	O
pharmacologic	O
and	O
genetic	O
strategy	O
using	O
two	O
PKC	B-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
inhibitors	O
,	O
pentoxifylline	O
(	O
PTX	O
)	O
and	O
Go-6976	O
,	O
and	O
a	O
stably	O
expressed	O
anti-Tat	B-protein
single-chain	I-protein
intracellular	I-protein
antibody	I-protein
(	O
sFv	B-protein
intrabody	I-protein
)	O
was	O
employed	O
to	O
obtain	O
cooperative	O
inhibition	O
of	O
both	O
HIV-1	O
LTR	B-DNA
-driven	O
gene	O
expression	O
and	O
HIV-1	O
replication	O
.	O

Binding	O
capacity	O
(	O
4978+/-391	O
versus	O
4131+/-321	O
sites/cell	O
)	O
,	O
Kd	O
values	O
for	O
dexamethasone	O
(	O
6.7+/-0.5	O
versus	O
5.7+/-0.3	O
nmol/L	O
)	O
,	O
and	O
IC50	O
values	O
for	O
dexamethasone	O
(	O
3.4+/-0.3	O
versus	O
3.1+/-0.2	O
nmol/L	O
)	O
and	O
cortisol	O
(	O
12.2+/-1.6	O
versus	O
9.5+/-0.3	O
nmol/L	O
)	O
were	O
not	O
significantly	O
different	O
.	O

The	O
implication	O
of	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
(	I-protein
s	I-protein
)	I-protein
,	O
protein	B-protein
kinase	I-protein
A	I-protein
and/or	O
protein	B-protein
kinase	I-protein
C	I-protein
was	O
highlighted	O
by	O
the	O
abrogation	O
of	O
the	O
ManLAM-mediated	O
activation	O
of	O
HIV-1	B-DNA
LTR-driven	I-DNA
gene	I-DNA
expression	O
using	O
herbimycin	O
A	O
and	O
H7	O
.	O

Glucocorticoids	O
induced	O
down-regulation	O
of	O
glucocorticoid	B-protein
receptor	I-protein
mRNA	O
expression	O
in	O
asthma	O
.	O

Similarly	O
,	O
D3-induced	O
monocyte	O
differentiation	O
of	O
normal	O
myeloid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
was	O
associated	O
with	O
increased	O
capacity	O
to	O
generate	O
E1	O
from	O
E2	O
.	O

Cloning	O
and	O
characterization	O
of	O
the	O
beta	B-protein
subunit	I-protein
of	O
human	B-protein
proximal	I-protein
sequence	I-protein
element-binding	I-protein
transcription	I-protein
factor	I-protein
and	O
its	O
involvement	O
in	O
transcription	O
of	O
small	B-DNA
nuclear	I-DNA
RNA	I-DNA
genes	I-DNA
by	O
RNA	B-protein
polymerases	I-protein
II	I-protein
and	I-protein
III	I-protein
.	O

The	O
transcriptional	B-DNA
regulatory	I-DNA
elements	I-DNA
of	O
many	O
inducible	B-DNA
T-cell	I-DNA
genes	I-DNA
contain	O
adjacent	O
or	O
overlapping	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
Ets	B-protein
and	I-protein
NF-kappaB/NFAT	I-protein
families	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

We	O
found	O
that	O
the	O
R-responsive	B-DNA
element	I-DNA
is	O
composed	O
of	O
four	O
protoenhancers	B-DNA
that	O
span	O
the	O
whole	O
B	B-DNA
domain	I-DNA
.	O

Coexpression	O
of	O
dominant	B-protein
negative	I-protein
Ras	I-protein
abrogated	O
the	O
basal	O
or	O
ionomycin-stimulated	O
,	O
70Z/3	B-protein
-mediated	O
NFAT	B-protein
activation	O
,	O
suggesting	O
a	O
functional	B-protein
Ras	I-protein
is	O
required	O
for	O
this	O
activation	O
.	O

Mineralocorticoid	O
effector	O
mechanisms	O
were	O
evaluated	O
in	O
29	O
patients	O
with	O
preeclampsia	O
and	O
in	O
25	O
uncomplicated	O
pregnancies	O
by	O
measurement	O
of	O
plasma	O
aldosterone	O
,	O
levels	O
of	O
mineralocorticoid	B-protein
receptor	I-protein
(	O
MR	B-protein
)	O
in	O
mononuclear	B-cell_type
leucocytes	I-cell_type
,	O
and	O
subtraction	O
potential	O
difference	O
(	O
SPD	O
;	O
rectal	O
minus	O
oral	O
values	O
)	O
.	O

Transcriptional	O
induction	O
of	O
the	O
RAR	B-RNA
(	I-RNA
alpha	I-RNA
)	I-RNA
and	I-RNA
PML-RAR	I-RNA
mRNAs	I-RNA
is	O
rapid	O
and	O
it	O
is	O
parallelled	O
by	O
an	O
increase	O
in	O
the	O
corresponding	O
proteins	O
.	O

Mutations	O
in	O
the	O
TSC2	B-DNA
gene	I-DNA
:	O
analysis	O
of	O
the	O
complete	O
coding	O
sequence	O
using	O
the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
.	O

Lineage-	O
and	O
stage-specific	O
expression	O
of	O
runt	B-protein
box	I-protein
polypeptides	I-protein
in	O
primitive	O
and	O
definitive	O
hematopoiesis	O
.	O

As	O
expected	O
,	O
the	O
distribution	O
of	O
atypical	B-protein
PKC-zeta	I-protein
was	O
unaffected	O
by	O
TPA	O
treatment	O
and	O
displayed	O
an	O
even	O
distribution	O
between	O
cytosol	O
and	O
membranes	O
.	O

We	O
have	O
examined	O
changes	O
in	O
HS1	B-protein
phosphorylation	O
after	O
differential	O
stimulation	O
of	O
CD3	B-protein
,	O
CD2	B-protein
,	O
and	O
CD28	B-protein
to	O
elucidate	O
its	O
role	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
to	O
further	O
delineate	O
the	O
signaling	O
pathways	O
recruited	O
by	O
these	O
receptors	O
.	O

Triggering	O
of	O
the	O
human	O
interleukin-6	O
gene	O
by	O
interferon-gamma	O
and	O
tumor	O
necrosis	O
factor-alpha	O
in	O
monocytic	O
cells	O
involves	O
cooperation	O
between	O
interferon	B-protein
regulatory	I-protein
factor-1	I-protein
,	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
and	O
Sp1	B-protein
transcription	B-protein
factors	I-protein
.	O

In	O
this	O
work	O
,	O
we	O
show	O
that	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
that	O
are	O
stimulated	O
through	O
the	O
TCR	B-protein
and	O
expanded	O
with	O
IL-2	B-protein
are	O
unresponsive	O
to	O
IFN-gamma	B-protein
,	O
as	O
determined	O
by	O
a	O
lack	O
of	O
activation	O
of	O
jak	B-protein
kinases	I-protein
and	O
the	O
transcription	B-protein
factor	I-protein
,	O
STAT1	B-protein
(	I-protein
alpha	I-protein
)	I-protein
,	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
.	O

The	O
role	O
of	O
HIV1	O
infection	O
in	O
the	O
expression	O
and	O
the	O
translocation	O
of	O
these	O
factors	O
is	O
discussed	O
.	O

Long-lasting	O
IL-2	B-protein
receptivity	O
is	O
associated	O
with	O
high-level	O
expression	O
of	O
the	O
inducible	O
IL-2	B-DNA
receptor	I-DNA
alpha	I-DNA
chain	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
that	O
is	O
regulated	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

In	O
epithelial	B-cell_type
cells	I-cell_type
,	O
the	O
Z	B-protein
transactivator	I-protein
alone	O
produced	O
maximal	O
stimulation	O
of	O
the	O
EA-D	B-DNA
promoter	I-DNA
;	O
the	O
effect	O
of	O
R	B-protein
and	O
Z	B-protein
together	O
was	O
no	O
greater	O
than	O
that	O
of	O
Z	B-protein
alone	O
.	O

At	O
>	O
0.5	O
micromol/L	O
,	O
genistein	O
inhibited	O
NK	O
cytotoxicity	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
.	O

We	O
have	O
tested	O
the	O
hypothesis	O
that	O
cellular	O
activation	O
events	O
occurring	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
monocytes	B-cell_type
and	O
mediated	O
through	O
translocation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
are	O
dependent	O
upon	O
the	O
constitutive	O
redox	O
status	O
of	O
these	O
cells	O
.	O

We	O
examined	O
the	O
allele-specific	O
expression	O
of	O
WT1	B-protein
in	O
cultured	O
human	B-cell_type
fibroblasts	I-cell_type
from	O
15	O
individuals	O
.	O

Both	O
the	O
DNA	B-protein
binding	I-protein
and	O
transactivation	B-protein
domains	I-protein
of	O
PU.1	B-protein
are	O
required	O
for	O
repression	O
and	O
both	O
domains	O
are	O
also	O
needed	O
to	O
block	O
terminal	O
differentiation	O
in	O
MEL	B-cell_line
cells	I-cell_line
.	O

Binding	O
of	O
the	O
drug	O
inhibits	O
isomerase	B-protein
activity	O
,	O
but	O
studies	O
with	O
other	O
prolyl	O
isomerase	B-protein
inhibitors	O
and	O
analysis	O
of	O
cyclosporin-resistant	B-cell_line
mutants	I-cell_line
in	O
yeast	O
suggest	O
that	O
the	O
effects	O
of	O
the	O
drug	O
result	O
from	O
the	O
formation	O
of	O
an	O
inhibitory	B-protein
complex	I-protein
between	O
the	O
drug	O
and	O
isomerase	B-protein
,	O
and	O
not	O
from	O
inhibition	O
of	O
isomerase	B-protein
activity	O
.	O

These	O
results	O
indicate	O
that	O
IL-6	B-protein
-induced	O
B-cell	O
differentiation	O
,	O
as	O
measured	O
by	O
IgM	B-protein
production	O
,	O
may	O
be	O
controlled	O
by	O
Stat3	B-protein
proteins	I-protein
.	O

Within	O
15	O
to	O
30	O
min	O
of	O
addition	O
of	O
M-CSF	B-protein
,	O
however	O
,	O
there	O
was	O
a	O
dramatic	O
coordinate	O
induction	O
of	O
these	O
genes	O
.	O

Chronic	O
rejection	O
of	O
transplanted	O
organs	O
is	O
manifested	O
as	O
atherosclerosis	O
of	O
the	O
blood	O
vessels	O
of	O
the	O
allograft	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
took	O
advantage	O
of	O
a	O
panel	O
of	O
CD8+	B-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
from	O
the	O
joint	O
of	O
a	O
rheumatoid	O
arthritis	O
patient	O
and	O
selected	O
for	O
their	O
reactivity	O
against	O
a	O
single	B-protein
MHC/peptide	I-protein
complex	I-protein
.	O

Comparison	O
of	O
primary	O
sensitization	O
of	O
naive	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
to	O
varicella-zoster	O
virus	O
peptides	O
by	O
dendritic	B-cell_type
cells	I-cell_type
in	O
vitro	O
with	O
responses	O
elicited	O
in	O
vivo	O
by	O
varicella	O
vaccination	O
.	O

RANTES	B-protein
(	O
regulated	B-protein
upon	I-protein
activation	I-protein
,	I-protein
normal	I-protein
T	I-protein
cell	I-protein
expressed	I-protein
and	I-protein
secreted	I-protein
)	O
is	O
a	O
cytokine	B-protein
that	O
belongs	O
to	O
the	O
beta-chemokine	B-protein
family	I-protein
;	O
it	O
is	O
chemoattractant	O
for	O
CD4+/CD45RO	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
it	O
is	O
produced	O
by	O
various	O
cell	O
types	O
including	O
CD8+	B-cell_type
and	I-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
as	O
well	O
as	O
monocytes/macrophages	B-cell_type
,	O
and	O
has	O
recently	O
been	O
shown	O
to	O
suppress	O
replication	O
of	O
macrophage-tropic	O
strains	O
of	O
HIV	O
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

This	O
phenomenon	O
is	O
mediated	O
,	O
in	O
part	O
,	O
through	O
inducible	O
expression	O
of	O
the	O
CXC	B-protein
chemokine	I-protein
,	O
interleukin-8	B-protein
(	O
IL-8	O
)	O
.	O

IL-7	B-protein
was	O
observed	O
to	O
induce	O
a	O
rapid	O
and	O
dose-dependent	O
tyrosine	O
phosphorylation	O
of	O
Jak	B-protein
1	I-protein
and	O
Jak	B-protein
3	I-protein
and	O
concomitantly	O
,	O
the	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
of	O
multiple	O
STAT	B-protein
proteins	I-protein
.	O

Clonality	O
analysis	O
of	O
refractory	O
anemia	O
with	O
ring	B-cell_type
sideroblasts	I-cell_type
:	O
simultaneous	O
study	O
of	O
clonality	O
and	O
cytochemistry	O
of	O
bone	B-cell_type
marrow	I-cell_type
progenitors	I-cell_type
.	O

Two	O
major	B-DNA
protein-binding	I-DNA
sites	I-DNA
within	O
the	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
have	O
been	O
identified	O
.	O

A	O
large	O
body	O
of	O
evidence	O
indicates	O
that	O
experimental	O
agents	O
which	O
raise	O
cellular	O
cAMP	O
levels	O
inhibit	O
T	O
cell	O
growth	O
and	O
division	O
.	O

A	O
new	O
homeobox	B-DNA
gene	I-DNA
,	O
HB24	B-DNA
,	O
has	O
been	O
isolated	O
from	O
a	O
human	O
B-lymphocyte	O
cDNA	O
library	O
.	O

Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-mediated	O
immune	O
responses	O
,	O
including	O
activation	O
of	O
monocytes	B-cell_type
,	O
macrophages	B-cell_type
,	O
and	O
endothelial	B-cell_type
cells	I-cell_type
,	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
Gram-negative	O
bacteria-induced	O
sepsis	O
syndrome	O
.	O

By	O
contrast	O
,	O
glucocorticoids	O
failed	O
to	O
inhibit	O
IFNalpha	B-protein
production	O
from	O
AIDS-GR	B-cell_type
monocytes	I-cell_type
(	O
approximately	O
20	O
%	O
inhibition	O
)	O
.	O

Inhibition	O
of	O
PKC	B-protein
by	O
the	O
isoquinoline	O
derivative	O
H7	O
abolishes	O
induction	O
of	O
M-CSF	B-protein
by	O
M-CSF	B-protein
.	O

Increased	O
expression	O
of	O
IFNgamma	B-protein
-induced	O
IP-10	B-RNA
mRNA	I-RNA
following	O
the	O
differentiation	O
of	O
U937	B-cell_line
cells	I-cell_line
was	O
mediated	O
largely	O
by	O
augmented	O
transcriptional	O
activity	O
of	O
the	O
gene	O
and	O
was	O
related	O
to	O
differentiation-dependent	O
changes	O
of	O
the	O
proteins	O
bound	O
to	O
IFN	B-DNA
stimulus	I-DNA
response	I-DNA
element	I-DNA
(	I-DNA
ISRE	I-DNA
)	I-DNA
and	O
kB	B-DNA
sites	I-DNA
,	O
suggesting	O
that	O
these	O
nuclear	B-protein
proteins	I-protein
may	O
determine	O
the	O
IP-10	B-RNA
mRNA	I-RNA
inducibility	O
by	O
IFNgamma	B-protein
.	O

Transcription	O
specific	O
differences	O
visualized	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
pattern	O
on	O
interphase	O
nuclei	O
of	O
different	O
cell	O
types	O
.	O

These	O
data	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
the	O
anti-inflammatory	O
effect	O
of	O
sesquiterpene	O
lactones	O
,	O
which	O
differs	O
from	O
that	O
of	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
indomethacin	O
and	O
acetyl	O
salicylic	O
acid	O
.	O

Regulation	O
of	O
the	O
beta-globin	B-DNA
locus	I-DNA
.	O

Cotransfection	O
of	O
CMV	B-DNA
IE	I-DNA
genes	I-DNA
and	O
IL-6	B-DNA
chloramphenicol	I-DNA
acetyl	I-DNA
transferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
or	I-DNA
IL-6	I-DNA
luciferase	I-DNA
constructs	I-DNA
were	O
used	O
to	O
study	O
IL-6	B-protein
promoter	O
activity	O
.	O

Deletion	O
of	O
this	O
sequence	O
abolishes	O
the	O
capacity	O
of	O
CD40	B-protein
to	O
induce	O
expression	O
of	O
CD23	B-protein
,	O
ICAM-1	B-protein
,	O
and	O
lymphotoxin-alpha	B-DNA
genes	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
.	O

Consequently	O
,	O
Tax	B-protein
can	O
activate	O
the	O
signaling	O
pathway	O
that	O
lead	O
to	O
the	O
release	O
of	O
E2F	B-protein
that	O
in	O
turn	O
induces	O
expression	O
of	O
factors	O
required	O
for	O
cell	O
cycle	O
progression	O
.	O

The	O
CpG	O
dinucleotide	O
in	O
this	O
element	B-DNA
is	O
selectively	O
methylated	O
in	O
Th2	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
other	O
cells	O
that	O
do	O
not	O
express	O
IFN-gamma	B-protein
,	O
and	O
methylation	O
markedly	O
reduces	O
transcription	B-protein
factor	I-protein
binding	O
.	O

Under	O
these	O
conditions	O
HUVEC	B-protein
adhesion	I-protein
molecules	I-protein
,	O
E-selectin	B-protein
,	O
VCAM-1	B-protein
and	O
ICAM-1	B-protein
,	O
were	O
increased	O
at	O
3	O
h	O
with	O
only	O
ICAM-1	B-protein
remaining	O
overexpressed	O
at	O
24	O
h	O
.	O

In	O
pre-B	B-cell_type
cells	I-cell_type
(	O
Ba/F3	O
)	O
,	O
the	O
transactivation	O
domain	O
of	O
Stat6	B-protein
was	O
IL-4	B-protein
regulated	O
,	O
independently	O
from	O
its	O
DNA	O
binding	O
function	O
.	O

It	O
was	O
found	O
that	O
the	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
expression	O
was	O
associated	O
with	O
the	O
de	O
novo	O
transcription	O
of	O
the	O
gene	O
encoding	O
the	O
CIITA	B-protein
trans-activator	I-protein
,	O
a	O
crucial	O
MHC	B-protein
class	I-protein
II	I-protein
gene	I-protein
regulatory	I-protein
factor	I-protein
.	O

MNDA	B-protein
was	O
not	O
detected	O
in	O
other	O
normal	O
bone	O
marrow	O
or	O
all	O
other	O
nonhematopoietic	B-cell_type
cells	I-cell_type
.	O

Association	O
of	O
the	O
interleukin-4	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
with	O
p47phox	O
,	O
an	O
activator	O
of	O
the	O
phagocyte	B-protein
NADPH	I-protein
oxidase	I-protein
in	O
B	B-cell_type
cells	I-cell_type
.	O

The	O
findings	O
suggest	O
that	O
when	O
SOCS-3	B-protein
is	O
rapidly	O
induced	O
by	O
IL-2	B-protein
in	O
T	B-cell_type
cells	I-cell_type
,	O
it	O
acts	O
to	O
inhibit	O
IL-2	B-protein
responses	O
in	O
a	O
classical	O
negative	O
feedback	O
loop	O
.	O

Levels	O
of	O
FOSB	B-RNA
mRNA	I-RNA
reach	O
a	O
maximum	O
40	O
min	O
after	O
the	O
addition	O
of	O
lectin	B-protein
and	O
decline	O
to	O
control	O
levels	O
over	O
the	O
next	O
6	O
hr	O
.	O

We	O
demonstrate	O
that	O
JunD	B-protein
,	O
a	O
component	O
of	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
complex	I-protein
,	O
activates	O
transcription	O
of	O
the	O
human	B-DNA
proenkephalin	I-DNA
gene	I-DNA
in	O
a	O
fashion	O
that	O
is	O
completely	O
dependent	O
upon	O
the	O
cAMP-dependent	B-protein
protein	I-protein
kinase	I-protein
,	O
protein	B-protein
kinase	I-protein
A	I-protein
.	O

Thus	O
,	O
defective	O
IL-2	B-DNA
gene	I-DNA
transcription	O
appears	O
to	O
be	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
a	O
selective	O
block	O
in	O
the	O
expression	O
of	O
the	O
AP-1	B-protein
Fos	I-protein
and	I-protein
Jun	I-protein
family	I-protein
members	I-protein
in	O
anergic	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

SAC	O
consistently	O
exhibited	O
a	O
dose-dependent	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
induced	O
by	O
both	O
TNF-alpha	B-protein
and	O
H2O2	O
.	O

In	O
addition	O
,	O
the	O
level	O
of	O
jun	B-protein
protein	I-protein
was	O
elevated	O
by	O
2	O
to	O
5-fold	O
within	O
4	O
h	O
in	O
HU	B-cell_line
treated	I-cell_line
cells	I-cell_line
.	O

These	O
data	O
indicate	O
that	O
,	O
in	O
contrast	O
to	O
most	O
LPS	O
effects	O
,	O
AP-1	B-protein
,	O
but	O
not	O
nuclear	B-protein
factor-kappaB	I-protein
,	O
mediates	O
LPS	O
induction	O
of	O
collagenase	B-protein
transcription	O
in	O
macrophagelike	B-cell_type
cells	I-cell_type
.	O

To	O
confirm	O
that	O
CCK	B-protein
(	I-protein
B	I-protein
)	I-protein
receptors	I-protein
are	O
involved	O
in	O
AP-1	B-protein
response	O
,	O
we	O
investigated	O
the	O
CCK-8	O
effect	O
on	O
interleukin-2	B-protein
expression	O
,	O
a	O
natural	O
endogenous	B-DNA
gene	I-DNA
regulated	O
by	O
several	O
factors	O
,	O
including	O
AP-1	B-protein
.	O

Sensitivity	O
against	O
various	O
enzyme	O
inhibitors	O
suggests	O
that	O
components	O
of	O
the	O
signal	O
transduction	O
pathway	O
are	O
shared	O
by	O
all	O
three	O
cytokines	B-protein
.	O

The	O
Syk	B-protein
-mediated	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
-induced	O
MAPK	B-protein
activation	O
was	O
detectable	O
within	O
1	O
min	O
of	O
receptor	O
stimulation	O
and	O
peaked	O
at	O
3-5	O
min	O
.	O

Prior	O
to	O
in	O
vivo	O
IL-2	B-protein
administration	O
,	O
the	O
typical	O
binding	O
pattern	O
of	O
transcription	B-protein
factors	I-protein
in	O
PBMC	B-cell_type
from	O
patients	O
resembled	O
that	O
seen	O
in	O
fresh	O
PBMC	B-cell_type
from	O
healthy	O
individuals	O
.	O

Endogenous	O
cortisol	O
has	O
no	O
effect	O
on	O
GCR	B-protein
level	O
estimated	O
by	O
3H-triamcinolone	O
acetonide	O
.	O

The	O
helix-loop-helix	B-protein
(	I-protein
HLH	I-protein
)	I-protein
proteins	I-protein
are	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
that	O
include	O
proteins	O
critical	O
to	O
differentiation	O
and	O
development	O
in	O
species	O
ranging	O
from	O
plants	O
to	O
mammals	O
.	O

Here	O
,	O
we	O
demonstrate	O
through	O
the	O
use	O
of	O
intracellular	O
staining	O
that	O
interleukin-1beta	B-protein
(	O
IL-1beta	B-protein
)	O
is	O
expressed	O
in	O
LCLs	B-cell_line
and	O
investigate	O
the	O
influence	O
of	O
the	O
individual	O
latent	B-protein
proteins	I-protein
on	O
the	O
expression	O
of	O
IL-1beta	B-protein
.	O

Nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
a	O
transcription	O
factor	O
that	O
binds	O
to	O
the	O
consensus	B-DNA
DNA	I-DNA
sequence	I-DNA
in	O
the	O
cis-acting	B-DNA
elements	I-DNA
of	O
various	B-DNA
genes	I-DNA
.	O

Within	O
the	O
upstream	B-DNA
promoter	I-DNA
region	I-DNA
of	O
Bcl-x	B-protein
,	O
a	O
potential	O
NF-kappaB-binding	B-DNA
sequence	I-DNA
was	O
found	O
to	O
support	O
NF-kappaB	B-protein
-dependent	O
transcriptional	O
activation	O
.	O

Along	O
with	O
our	O
previous	O
demonstration	O
of	O
both	O
physical	O
interactions	O
between	O
PTF	B-protein
gamma/PTF	I-protein
delta	I-protein
and	O
TBP	B-protein
and	O
the	O
involvement	O
of	O
TFIIIB90	B-protein
in	O
the	O
transcription	O
of	O
class	B-DNA
III	I-DNA
snRNA	I-DNA
genes	I-DNA
,	O
these	O
results	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
a	O
TBP-containing	B-protein
complex	I-protein
related	O
to	O
TFIIIB	B-protein
is	O
required	O
for	O
the	O
transcription	O
of	O
class	B-DNA
III	I-DNA
snRNA	I-DNA
genes	I-DNA
,	O
and	O
acts	O
through	O
weak	O
interaction	O
with	O
the	O
four-subunit	B-protein
PTF	I-protein
.	O

The	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
is	O
an	O
important	O
human	O
mediator	O
of	O
the	O
cellular	O
response	O
to	O
serum	O
,	O
growth	B-protein
factors	I-protein
,	O
and	O
phorbol	O
esters	O
such	O
as	O
12-O-tetradecanoyl-phorbol-13	O
acetate	O
(	O
TPA	O
)	O
.	O

Impaired	O
silencing	O
of	O
gamma-globin	B-protein
expression	O
identifies	O
EKLF	B-protein
as	O
the	O
first	O
transcription	B-protein
factor	I-protein
participating	O
quantitatively	O
in	O
the	O
gamma-globin	B-protein
to	O
beta-globin	B-protein
switch	O
.	O

Qualitatively	O
different	O
effects	O
were	O
observed	O
for	O
the	O
IL-1	B-protein
-induced	O
activation	O
of	O
stress-activated	B-protein
protein	I-protein
(	I-protein
SAP	I-protein
)	I-protein
kinases	I-protein
:	O
permanent	O
overexpression	O
of	O
IRAK	B-protein
did	O
not	O
affect	O
the	O
dose	O
dependence	O
but	O
prolonged	O
the	O
kinetics	O
of	O
IL-1	B-protein
-induced	O
activation	O
of	O
SAP	B-protein
kinases	I-protein
,	O
suggesting	O
that	O
this	O
signaling	O
branch	O
may	O
be	O
regulated	O
by	O
distinct	O
mechanisms	O
.	O

Previous	O
data	O
are	O
consistent	O
with	O
a	O
model	O
that	O
LMP1	B-protein
is	O
a	O
constitutively	B-protein
activated	I-protein
receptor	I-protein
that	O
transduces	O
signals	O
for	O
transformation	O
through	O
its	O
carboxyl-terminal	B-protein
cytoplasmic	I-protein
tail	I-protein
.	O

Treatment	O
with	O
two	O
different	O
schedules	O
of	O
oral	O
calcitriol	O
(	O
five	O
patients	O
with	O
0.5	O
microgram/day	O
for	O
1	O
month	O
and	O
four	O
patients	O
with	O
2	O
micrograms/day	O
for	O
7	O
days	O
)	O
did	O
not	O
change	O
VDR	B-protein
concentrations	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
recovery	O
of	O
proteins	O
mediating	O
signal	O
transduction	O
through	O
the	O
T	B-protein
cell	I-protein
receptor/CD3	I-protein
complex	I-protein
in	O
LN	B-cell_type
T	I-cell_type
cells	I-cell_type
activated	O
ex	O
vivo	O
was	O
associated	O
with	O
the	O
acquisition	O
of	O
antitumor	O
function	O
.	O

Indeed	O
,	O
binding	O
of	O
the	O
IgH	B-DNA
enhancer	I-DNA
to	O
either	O
intact	O
nuclear	O
matrix	O
preparations	O
or	O
to	O
MAR-BP1	B-protein
is	O
mutually	O
exclusive	O
to	O
NF-muNR	B-protein
binding	O
.	O

It	O
is	O
perhaps	O
possible	O
that	O
all	O
of	O
Stat4	B-protein
actions	O
on	O
Th1	O
development	O
may	O
be	O
exert	O
directly	O
by	O
Stat4	B-protein
at	O
the	O
IFN-gamma	B-DNA
gene	I-DNA
,	O
however	O
we	O
suggest	O
that	O
,	O
more	O
likely	O
,	O
Stat4	B-protein
may	O
act	O
to	O
induce	O
Th1	O
development	O
through	O
the	O
induction	O
of	O
other	O
non-cytokine	B-DNA
genes	I-DNA
,	O
whose	O
stable	O
expression	O
maintains	O
the	O
transcriptional	O
state	O
of	O
a	O
Th1	B-cell_type
cell	I-cell_type
.	O

Recent	O
studies	O
suggest	O
that	O
one	O
or	O
more	O
cytoplasmic	B-protein
serine	I-protein
kinases	I-protein
also	O
phosphorylate	O
STAT3	B-protein
and	O
are	O
necessary	O
for	O
maximal	O
gene	O
activation	O
.	O

TNFalpha	B-protein
cooperates	O
with	O
the	O
protein	B-protein
kinase	I-protein
A	I-protein
pathway	O
to	O
synergistically	O
increase	O
HIV-1	B-DNA
LTR	I-DNA
transcription	O
via	O
downstream	O
TRE-like	B-DNA
cAMP	I-DNA
response	I-DNA
elements	I-DNA
.	O

Inhibition	O
studies	O
indicate	O
that	O
specific	O
tyrosine	O
phosphorylation	O
following	O
PTK	B-protein
activation	O
is	O
involved	O
in	O
the	O
mobilization	O
of	O
the	O
transcription	B-protein
factor	I-protein
,	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
,	O
and	O
VCAM-1	B-RNA
mRNA	I-RNA
expression	O
.	O

To	O
substantiate	O
these	O
findings	O
we	O
initiated	O
an	O
intensified	O
culturing	O
procedure	O
and	O
were	O
able	O
to	O
establish	O
LCLs	B-cell_line
from	O
5	O
out	O
of	O
21	O
consecutive	O
MS	O
patients	O
and	O
1	O
out	O
of	O
13	O
consecutive	O
healthy	O
controls	O
.	O

These	O
findings	O
highlight	O
the	O
role	O
of	O
thrombin	B-protein
as	O
a	O
potential	O
regulator	O
of	O
T	B-cell_type
lymphocyte	I-cell_type
activation	O
.	O

Xenogeneic	O
human	O
serum	O
promotes	O
leukocyte	O
adhesion	O
to	O
porcine	O
endothelium	O
under	O
flow	O
conditions	O
,	O
possibly	O
through	O
the	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
.	O

We	O
hypothesize	O
that	O
interference	O
in	O
DNA-binding	O
activities	O
of	O
GATA-1	B-protein
and	O
CACCC-binding	B-protein
proteins	I-protein
is	O
the	O
mechanism	O
by	O
which	O
the	O
ER	B-protein
inhibits	O
regulation	O
of	O
these	O
genes	O
.	O

Synergism	O
between	O
the	O
CD3	O
antigen-	O
and	O
CD2	O
antigen-derived	O
signals	O
.	O

We	O
have	O
studied	O
the	O
regulation	O
of	O
sialoadhesin	B-protein
expression	O
in	O
vitro	O
and	O
show	O
that	O
glucocorticoids	O
(	O
GC	O
)	O
induce	O
sialoadhesin	B-protein
expression	O
on	O
freshly	O
isolated	O
rat	B-cell_type
macrophages	I-cell_type
and	O
the	O
rat	B-cell_line
macrophage	I-cell_line
cell	I-cell_line
line	I-cell_line
R2	I-cell_line
.	O

Department	O
of	O
lymphocytes	B-cell_type
from	O
hematopoietic	B-cell_type
stem	I-cell_type
cells	I-cell_type
is	O
controlled	O
,	O
in	O
part	O
,	O
by	O
the	O
activity	O
of	O
transcriptional	B-protein
regulatory	I-protein
proteins	I-protein
.	O

Disruption	O
of	O
alpha	O
beta	O
but	O
not	O
of	O
gamma	O
delta	O
T	O
cell	O
development	O
by	O
overexpression	O
of	O
the	O
helix-loop-helix	B-protein
protein	I-protein
Id3	B-protein
in	O
committed	B-cell_type
T	I-cell_type
cell	I-cell_type
progenitors	I-cell_type
.	O

However	O
,	O
the	O
reasons	O
for	O
these	O
changes	O
are	O
not	O
clear	O
.	O

Nuclear	O
transcription	O
studies	O
in	O
vitro	O
showed	O
that	O
LTB4	O
increased	O
the	O
transcription	O
of	O
the	O
c-fos	B-DNA
gene	I-DNA
7-fold	O
and	O
the	O
c-jun	B-DNA
gene	I-DNA
1.4-fold	O
.	O

IL-10	B-protein
appears	O
to	O
prevent	O
activation	O
of	O
NF-kappaB	B-protein
by	O
preserving	O
IkappaB-alpha	B-protein
protein	O
levels	O
,	O
leading	O
to	O
a	O
reduction	O
in	O
TNF-alpha	B-protein
release	O
.	O

The	O
complex	O
on	O
the	O
proximal	B-DNA
site	I-DNA
(	O
NF	B-protein
kappa	I-protein
B2	I-protein
)	O
appears	O
to	O
be	O
composed	O
of	O
p50	B-protein
and	O
relB	B-protein
.	O

In	O
mice	O
deficient	O
only	O
of	O
p52/NF-kappaB	B-protein
,	O
BLR1	B-protein
expression	O
was	O
unaffected	O
.	O

Its	O
expression	O
appears	O
to	O
be	O
activated	O
during	O
pro-B-cell	O
development	O
,	O
is	O
abundant	O
at	O
the	O
pre-B-	O
and	O
mature	O
B-cell	O
stages	O
,	O
but	O
is	O
absent	O
in	O
terminally	B-cell_type
differentiated	I-cell_type
plasma	I-cell_type
cells	I-cell_type
.	O

Moreover	O
,	O
we	O
provide	O
evidence	O
that	O
,	O
in	O
addition	O
to	O
a	O
glucocorticoid	B-protein
receptor	I-protein
-mediated	O
effect	O
,	O
the	O
mineralocorticoid	B-protein
receptor	I-protein
is	O
involved	O
in	O
the	O
inhibition	O
of	O
monocyte	O
IL-1ra	B-protein
secretion	O
by	O
cortisol	O
.	O

These	O
experiments	O
are	O
of	O
prime	O
importance	O
considering	O
that	O
CD4-expressing	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
represent	O
the	O
major	O
virus	O
reservoir	O
in	O
the	O
peripheral	O
blood	O
of	O
infected	O
individuals	O
.	O

Retroviral	O
induction	O
of	O
TIMP-1	B-protein
not	O
only	O
resulted	O
in	O
cell	O
survival	O
but	O
also	O
in	O
continued	O
DNA	O
synthesis	O
for	O
up	O
to	O
5	O
d	O
in	O
the	O
absence	O
of	O
serum	O
,	O
while	O
controls	O
underwent	O
apoptosis	O
.	O

The	O
presence	O
of	O
ras	O
mutations	O
has	O
been	O
correlated	O
with	O
a	O
poor	O
prognosis	O
and	O
negative	O
clinical	O
outcome	O
.	O

The	O
cells	O
used	O
were	O
the	O
BLIN-1	B-cell_line
pre-B	I-cell_line
cell	I-cell_line
line	I-cell_line
expressing	O
low	O
levels	O
of	O
cell	B-protein
surface	I-protein
mu	I-protein
heavy	I-protein
chain	I-protein
associated	O
with	O
surrogate	B-protein
light	I-protein
chain	I-protein
and	O
the	O
1E8	O
immature	O
B	O
cell	O
line	O
expressing	O
cell	B-protein
surface	I-protein
mu/kappa	I-protein
.	O

This	O
activity	O
was	O
dependent	O
on	O
the	O
SH2	B-protein
and	O
pleckstrin-homology	B-protein
domains	I-protein
of	O
3BP2	B-protein
,	O
and	O
required	O
functional	O
Syk	B-protein
kinases	I-protein
,	O
Ras	B-protein
,	O
and	O
calcineurin	B-protein
.	O

To	O
determine	O
the	O
mechanism	O
of	O
action	O
of	O
Ro	O
09-2210	O
,	O
we	O
set	O
up	O
a	O
transient	O
expression	O
system	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
using	O
a	O
variety	O
of	O
reporter	O
gene	O
constructs	O
and	O
showed	O
effective	O
inhibition	O
of	O
phorbol	O
ester/ionomycin-induced	O
NF-AT	B-protein
activation	O
and	O
anti-CD3	O
induced	O
NF-AT	B-protein
with	O
IC50	O
=	O
7.7	O
and	O
10	O
nM	O
,	O
respectively	O
.	O

Unlike	O
classical	O
NFkappaB	B-DNA
sites	I-DNA
,	O
neither	O
the	O
SNE	B-DNA
nor	O
the	O
SEE	B-DNA
motif	I-DNA
responded	O
to	O
phosphatase	O
inhibition	O
by	O
okadaic	O
acid	O
.	O

Involvement	O
of	O
intracellular	O
Ca2+	O
in	O
oxidant-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

We	O
also	O
identified	O
a	O
potent	O
inhibitory	B-protein
sequence	I-protein
within	O
its	O
N-terminal	B-protein
domain	I-protein
.	O

Functional	O
specificity	O
for	O
repression	O
matches	O
the	O
DNA	O
binding	O
specificity	O
of	O
complex	B-protein
3	I-protein
;	O
both	O
repressor	O
activity	O
and	O
complex	B-protein
3	I-protein
binding	O
require	O
the	O
consensus	B-DNA
sequence	I-DNA
CTCACNTNC	O
.	O

The	O
AML1	B-DNA
gene	I-DNA
on	O
chromosome	B-DNA
21	I-DNA
is	O
disrupted	O
in	O
the	O
(	B-DNA
8	I-DNA
;	I-DNA
21	I-DNA
)	I-DNA
(	I-DNA
q22	I-DNA
;	I-DNA
q22	I-DNA
)	I-DNA
and	I-DNA
(	I-DNA
3	I-DNA
;	I-DNA
21	I-DNA
)	I-DNA
(	I-DNA
q26	I-DNA
;	I-DNA
q22	I-DNA
)	I-DNA
translocations	I-DNA
associated	O
with	O
myelogenous	O
leukemias	O
and	O
encodes	O
a	O
DNA-binding	B-protein
protein	I-protein
.	O

By	O
promoter	O
function	O
analysis	O
,	O
we	O
show	O
that	O
the	O
SAA	B-DNA
promoter	I-DNA
sequence	I-DNA
between	O
-280	O
and	O
-226	O
can	O
confer	O
LPS	O
responsiveness	O
.	O

Consistent	O
with	O
the	O
failure	O
of	O
full-length	B-protein
BOB.1/OBF.1	I-protein
to	O
stimulate	O
octamer-dependent	B-DNA
enhancer	I-DNA
elements	I-DNA
in	O
non	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
the	O
GAL4	B-protein
fusions	I-protein
likewise	O
only	O
stimulate	O
from	O
a	O
promoter-proximal	O
position	O
.	O

However	O
,	O
induction	O
of	O
NF-AT	B-protein
,	O
which	O
has	O
the	O
same	O
signaling	O
requirements	O
as	O
c-Rel	B-protein
induction	O
,	O
was	O
not	O
inhibited	O
by	O
PF	O
.	O

We	O
report	O
here	O
that	O
phosphatidylinositol	O
(	O
PtdIns	O
)	O
,	O
phosphatidylinositol-4-phosphate	O
,	O
and	O
other	O
phosphatidylinositides	O
can	O
bind	O
to	O
mCD14	B-protein
.	O

These	O
two	O
DNA-protein	B-protein
complexes	I-protein
are	O
composed	O
of	O
at	O
least	O
four	O
host	O
proteins	O
(	O
p50	B-protein
,	O
p55	B-protein
,	O
p75	B-protein
,	O
p85	B-protein
)	O
,	O
each	O
of	O
which	O
shares	O
structural	O
similarity	O
with	O
the	O
v-rel	B-protein
oncogene	I-protein
product	I-protein
.	O

The	O
6-h	O
increase	O
in	O
PDGF	B-RNA
(	I-RNA
B	I-RNA
)	I-RNA
mRNA	I-RNA
was	O
adherence	O
dependent	O
,	O
and	O
in	O
addition	O
,	O
was	O
abrogated	O
when	O
the	O
cytoskeletal	O
integrity	O
was	O
compromised	O
by	O
cytochalasin	O
D	O
.	O

CONCLUSION	O
.	O

An	O
additional	O
distinguishing	O
characteristic	O
of	O
HTLV-I	O
infection	O
is	O
the	O
profound	O
state	O
of	O
viral	O
latency	O
that	O
is	O
present	O
in	O
circulating	O
primary	B-cell_type
leukemic	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Large	O
amounts	O
of	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
and	O
significant	O
quantities	O
of	O
NF-AT	B-protein
were	O
induced	O
in	O
SEA-activated	B-cell_line
CD4+	I-cell_line
spleen	I-cell_line
T	I-cell_line
cells	I-cell_line
,	O
whereas	O
Oct-1	O
and	O
Oct-2	O
DNA	O
binding	O
activity	O
was	O
similar	O
in	O
both	O
resting	O
and	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

p53	B-protein
and	O
p21/Cip1	B-protein
,	O
respectively	O
,	O
inhibit	O
the	O
expression	O
and	O
activation	O
of	O
PCNA	B-protein
,	O
whereas	O
p130	B-protein
and	O
pRb	B-protein
,	O
respectively	O
,	O
inhibit	O
the	O
expression	O
and	O
activation	O
of	O
E2F1	B-protein
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
membrane-proximal	B-protein
portion	I-protein
in	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
the	O
human	B-protein
IL-4R	I-protein
alpha	I-protein
(	O
hIL-4R	B-protein
alpha	I-protein
)	O
is	O
critical	O
for	O
proliferation	O
,	O
generation	O
of	O
germline	O
epsilon	O
transcript	O
,	O
and	O
activation	O
of	O
STAT6	B-protein
,	O
based	O
on	O
analyses	O
of	O
truncated	B-protein
hIL-4R	I-protein
alphas	I-protein
.	O

However	O
,	O
all	O
20	O
cases	O
lacked	O
the	O
t	O
(	O
15	O
;	O
17	O
)	O
and	O
17	O
cases	O
tested	O
lacked	O
the	O
promyelocytic/retinoic	B-RNA
acid	I-RNA
receptor	I-RNA
alpha	I-RNA
(	I-RNA
RAR	I-RNA
alpha	I-RNA
)	I-RNA
fusion	I-RNA
transcript	I-RNA
in	O
RT-PCR	O
assays	O
;	O
12	O
cases	O
had	O
46	O
,	O
XX	O
or	O
46	O
,	O
XY	O
karyotypes	O
,	O
whereas	O
2	O
cases	O
had	O
abnormalities	O
of	O
chromosome	B-DNA
17q	I-DNA
:	O
1	O
with	O
del	B-DNA
(	I-DNA
17	I-DNA
)	I-DNA
(	I-DNA
q25	I-DNA
)	I-DNA
and	O
the	O
other	O
with	O
t	B-DNA
(	I-DNA
11	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
(	I-DNA
q23	I-DNA
;	I-DNA
q21	I-DNA
)	I-DNA
and	O
the	O
promyelocytic	B-RNA
leukemia	I-RNA
zinc	I-RNA
finger/RAR	I-RNA
alpha	I-RNA
fusion	I-RNA
transcript	I-RNA
.	O

The	O
glucuronides	O
only	O
inhibited	O
NK	O
cytotoxicity	O
at	O
50	O
micromol/L	O
.	O

Processing	O
of	O
the	O
precursor	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
the	O
HIV-1	B-protein
protease	I-protein
during	O
acute	O
infection	O
.	O

Other	O
studies	O
further	O
demonstrate	O
that	O
the	O
jun-B	B-DNA
and	O
fra-1	B-DNA
genes	B-DNA
are	O
induced	O
by	O
TPA	O
in	O
both	O
HL-60/vinc	B-cell_line
and	O
HL-60/vinc/R	B-cell_line
cells	I-cell_line
,	O
whereas	O
c-fos	B-DNA
expression	O
is	O
attenuated	O
in	O
the	O
HL-60/vinc	O
line	O
.	O

A	O
mouse	B-DNA
ets-1	I-DNA
cDNA	I-DNA
clone	I-DNA
was	O
obtained	O
by	O
screening	O
a	O
mouse	O
thymus	O
cDNA	O
expression	O
library	O
with	O
a	O
double-stranded	B-DNA
oligonucleotide	I-DNA
probe	I-DNA
representing	O
20	O
bp	O
of	O
the	O
Moloney	O
murine	O
sarcoma	O
virus	O
(	O
MSV	O
)	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
.	O

NFAT	O
transcription	O
factors	O
play	O
a	O
central	O
role	O
in	O
initiating	O
T-cell	O
activation	O
through	O
the	O
induction	O
of	O
immediate-early	O
T-cell	O
specific	O
genes	O
including	O
interleukin-2	O
(	O
IL-2	B-protein
)	O
.	O

The	O
viral	B-protein
protein	I-protein
Tax	B-protein
induces	O
the	O
activation	O
and	O
nuclear	O
translocalization	O
of	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
,	O
which	O
is	O
proposed	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
transformation	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
HTLV-I	O
.	O

Activity	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
family	I-protein
with	O
associated	O
phosphorylation	O
of	O
c-Jun	B-protein
Y-peptide	I-protein
was	O
markedly	O
diminished	O
in	O
TPA-treated	B-cell_line
HL-60/vinc	I-cell_line
cells	I-cell_line
,	O
but	O
not	O
in	O
response	O
to	O
okadaic	O
acid	O
.	O

Because	O
CMV	O
is	O
also	O
associated	O
with	O
the	O
development	O
of	O
bronchiolitis	O
obliterans	O
after	O
transplantation	O
,	O
we	O
determined	O
whether	O
CMV	O
induces	O
IL-6	B-protein
gene	O
expression	O
.	O

CD3	B-protein
-epsilon	O
expression	O
is	O
controlled	O
by	O
a	O
downstream	B-DNA
T	I-DNA
lymphocyte-specific	I-DNA
enhancer	I-DNA
element	I-DNA
.	O

Up-regulation	O
of	O
RAR	B-protein
(	I-protein
alpha	I-protein
)	I-protein
and	O
PML-RAR	B-protein
gene	O
expression	O
by	O
IFN	B-protein
(	I-protein
alpha	I-protein
)	I-protein
is	O
accompanied	O
by	O
a	O
strong	O
potentiation	O
in	O
the	O
induction	O
of	O
2	O
retinoid-dependent	B-protein
granulocytic	I-protein
markers	I-protein
,	O
i.e.	O
,	O
granulocyte-colony-stimulating	B-RNA
factor	I-RNA
receptor	I-RNA
mRNA	I-RNA
and	O
leukocyte	B-protein
alkaline	I-protein
phosphatase	I-protein
.	O

1	O
)	O
There	O
exists	O
a	O
CR	O
of	O
GR	B-protein
in	O
human	B-cell_type
leukocytes	I-cell_type
,	O
PMN	B-cell_type
,	O
and	O
monocytes	B-cell_type
with	O
the	O
peak	O
values	O
from	O
0400	O
to	O
0800	O
hr	O
and	O
the	O
trough	O
values	O
between	O
2300	O
and	O
0000	O
hr	O
.	O

We	O
have	O
reported	O
previously	O
that	O
a	O
nuclear	O
NF-kappa	B-protein
B	I-protein
activity	O
was	O
present	O
in	O
freshly	O
extracted	O
human	B-cell_type
thymocytes	I-cell_type
in	O
the	O
absence	O
of	O
in	O
vitro	O
treatment	O
of	O
these	O
cells	O
.	O

Expression	O
of	O
mRNA	B-RNA
for	O
the	O
GATA-binding	B-protein
proteins	I-protein
in	O
human	B-cell_type
eosinophils	I-cell_type
and	O
basophils	B-cell_type
:	O
potential	O
role	O
in	O
gene	O
transcription	O
.	O

The	O
frequency	O
of	O
Oct2-positive	B-cell_line
clones	I-cell_line
was	O
1/15	O
,	O
000	O
in	O
both	O
libraries	O
.	O

The	O
mechanism	O
of	O
HS2	B-DNA
enhancer	I-DNA
function	O
is	O
not	O
known	O
.	O

To	O
identify	O
genes	O
that	O
are	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
after	O
stimulation	O
,	O
mRNA	O
from	O
T	B-cell_type
lymphocytes	I-cell_type
that	O
had	O
been	O
activated	O
by	O
the	O
simultaneous	O
stimulation	O
of	O
the	O
CD3	B-protein
and	O
CD28	B-protein
trigger	O
molecules	O
was	O
transcribed	O
for	O
a	O
differential	O
mRNA	O
display	O
analysis	O
into	O
cDNA	O
and	O
was	O
compared	O
with	O
cDNA	O
from	O
CD28	B-protein
-or	O
CD3	B-protein
-activated	O
or	O
resting	O
lymphocytes	B-cell_type
.	O

Site-directed	O
mutagenesis	O
further	O
demonstrated	O
that	O
the	O
enhancer	B-DNA
function	O
of	O
one	O
of	O
the	O
two	O
NF-E2/AP1	O
motifs	O
of	O
HS-40	B-DNA
is	O
mediated	O
through	O
its	O
binding	O
to	O
NF-E2	B-protein
but	O
not	O
AP1	B-protein
transcription	I-protein
factor	I-protein
.	O

Although	O
CD40	B-protein
ligand	I-protein
(	O
CD40L	B-protein
)	O
triggers	O
a	O
shift	O
from	O
dephosphorylated	O
to	O
phosphorylated	O
pRB	B-protein
and	O
proliferation	O
of	O
B	B-cell_type
cells	I-cell_type
,	O
the	O
addition	O
of	O
exogenous	O
IL-6	B-protein
to	O
CD40L	B-protein
-treated	O
B	B-cell_type
cells	I-cell_type
does	O
not	O
alter	O
either	O
pRB	B-protein
or	O
proliferation	O
,	O
as	O
observed	O
in	O
MM	B-cell_line
cells	I-cell_line
.	O

Furthermore	O
,	O
increasing	O
the	O
spacing	O
between	O
the	O
CRE	B-DNA
and	I-DNA
the	I-DNA
kappaB3	I-DNA
sites	I-DNA
completely	O
abolished	O
LPS	O
induction	O
,	O
suggesting	O
a	O
cooperative	O
interaction	O
between	O
c-Jun	B-protein
complexes	I-protein
and	O
p50/p65	B-protein
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
interplay	O
between	O
these	O
distinct	O
stimuli	O
is	O
not	O
clearly	O
delineated	O
.	O

Although	O
IL-10	B-protein
alone	O
did	O
not	O
induce	O
HIV-1	O
replication	O
,	O
in	O
the	O
presence	O
of	O
TNF-alpha	B-protein
,	O
IL-10	B-protein
markedly	O
enhanced	O
virion	O
production	O
from	O
a	O
chronically	O
infected	O
promonocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
U1	B-cell_line
)	O
and	O
in	O
acutely	O
infected	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
.	O

It	O
is	O
concluded	O
that	O
this	O
novel	O
culture	O
system	O
,	O
coupled	O
with	O
single-cell	O
RT-PCR	O
analysis	O
,	O
may	O
eliminate	O
the	O
ambiguities	O
intrinsic	O
to	O
molecular	O
studies	O
on	O
heterogeneous	O
populations	O
of	O
hematopoietic	B-cell_type
progenitors/precursors	I-cell_type
growing	O
in	O
culture	O
,	O
particularly	O
in	O
the	O
initial	O
stages	O
of	O
development	O
.	O

Synergistic	O
proinflammatory	O
effects	O
of	O
mechanical	O
stress	O
and	O
molecules	O
such	O
as	O
bacterial	B-protein
endotoxin	I-protein
were	O
observed	O
,	O
suggesting	O
that	O
mechanical	O
ventilation	O
might	O
be	O
particularly	O
deleterious	O
in	O
preinjured	O
or	O
infected	O
lungs	O
.	O

By	O
virtue	O
of	O
the	O
presence	O
of	O
CD4	B-protein
on	O
the	O
cell	O
surface	O
,	O
PLB-985	B-cell_line
cells	I-cell_line
were	O
chronically	O
infected	O
with	O
HIV-1	O
strain	O
IIIB	O
.	O

In	O
MM	B-cell_line
cells	I-cell_line
that	O
proliferated	O
in	O
response	O
to	O
IL-6	B-protein
,	O
exogenous	O
IL-6	B-protein
downregulated	O
dephosphorylated	B-protein
pRB	I-protein
and	O
decreased	O
dephosphorylated	O
pRB-E2F	B-protein
complexes	I-protein
.	O

Since	O
HUVECs	B-cell_line
released	O
superoxide	O
anions	O
in	O
response	O
to	O
TNF	O
,	O
and	O
H2O2	O
induces	O
VCAM-1	B-protein
,	O
PDTC	O
may	O
act	O
as	O
a	O
radical	O
scavenger	O
.	O

The	O
data	O
imply	O
the	O
existence	O
of	O
a	O
complex	O
family	O
of	O
NF-kappa	B-protein
B-like	I-protein
transcription	I-protein
factors	I-protein
.	O

Collectively	O
,	O
these	O
results	O
therefore	O
suggest	O
that	O
the	O
exclusive	O
Tax	B-protein
-induced	O
expression	O
of	O
VCAM-1	B-protein
on	O
T	B-cell_type
cells	I-cell_type
may	O
represent	O
a	O
pivotal	O
event	O
in	O
the	O
progression	O
of	O
HTLV-1-associated	O
diseases	O
.	O

227.0	O
+/-	O
90.8	O
dpm	O
mg-1	O
cytosol	B-protein
protein	I-protein
,	O
P	O
=	O
0.007	O
)	O
and	O
IBD	O
patients	O
not	O
receiving	O
glucocorticoid	O
treatment	O
(	O
179.7	O
+/-	O
171.3	O
dpm	O
mg-1	O
cytosol	B-protein
protein	I-protein
,	O
P	O
=	O
0.002	O
)	O
.	O

All	O
of	O
the	O
CLL	O
cases	O
except	O
two	O
(	O
96	O
%	O
)	O
were	O
negative	O
for	O
ER	B-protein
(	O
less	O
than	O
1	O
%	O
staining	O
;	O
less	O
than	O
4	O
fmol/mg	O
protein	O
)	O
.	O

Transient	O
transfection	O
experiments	O
with	O
expression	O
vectors	O
for	O
two	O
of	O
the	O
isoforms	O
demonstrated	O
that	O
the	O
32.2-kDa	B-protein
protein	I-protein
is	O
an	O
activator	O
of	O
transcription	O
of	O
granulocyte	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
receptor	I-DNA
promoter	I-DNA
,	O
while	O
the	O
14.3-kDa	B-protein
protein	I-protein
is	O
not	O
.	O

Mutation	O
of	O
the	O
E	B-DNA
box	I-DNA
abolished	O
USF/c-Myc	B-protein
-mediated	O
up-regulation	O
of	O
CXCR4	B-protein
promoter	O
activity	O
,	O
and	O
mutation	O
of	O
the	O
YY1	B-DNA
binding	I-DNA
site	I-DNA
was	O
associated	O
with	O
unresponsiveness	O
to	O
YY1	B-protein
-mediated	O
inhibition	O
.	O

Thus	O
,	O
our	O
data	O
indicate	O
that	O
Stat3	B-protein
and	O
Stat5	B-protein
may	O
be	O
involved	O
in	O
signal	O
transduction	O
after	O
ligand	O
binding	O
to	O
c-Mpl	B-protein
and	O
that	O
this	O
event	O
may	O
have	O
a	O
role	O
in	O
megakaryopoiesis/thrombopoiesis	O
or	O
possibly	O
a	O
mature	O
platelet	O
function	O
such	O
as	O
aggregation	O
.	O

Efficient	O
rescue	O
of	O
the	O
defect	O
requires	O
an	O
intact	O
GATA	B-DNA
element	I-DNA
in	O
the	O
distal	B-DNA
promoter	I-DNA
,	O
suggesting	O
autoregulatory	O
control	O
of	O
GATA-1	B-protein
transcription	O
.	O

In	O
conclusion	O
,	O
production	O
of	O
a	O
Th1	B-protein
cytokine	I-protein
,	O
IFN-gamma	B-protein
,	O
by	O
HBsAg	B-protein
-reactive	O
cells	O
was	O
associated	O
with	O
hepatocyte	O
damage	O
in	O
chronic	O
hepatitis	O
B	O
,	O
while	O
no	O
counteracting	O
effect	O
of	O
Th2	B-protein
cytokines	I-protein
produced	O
by	O
those	O
cells	O
was	O
observed	O
.	O

Reconstitution	O
of	O
Jak1	B-protein
expression	O
in	O
E1C3	B-cell_line
cells	I-cell_line
restored	O
the	O
ability	O
of	O
IL-4	B-protein
to	O
induce	O
IRS	B-DNA
and	O
Stat6	B-protein
tyrosine	O
phosphorylation	O
.	O

The	O
apparent	O
high	O
frequency	O
of	O
IL-12-nonresponsive	B-cell_line
Th	I-cell_line
cells	I-cell_line
within	O
the	O
allergen-specific	O
populations	O
in	O
atopic	O
patients	O
predicts	O
a	O
limited	O
skewing	O
potential	O
of	O
IL-12	B-protein
in	O
the	O
case	O
of	O
established	O
Th2	O
responses	O
,	O
but	O
only	O
affecting	O
newly	O
recruited	O
naive	O
Th	B-cell_line
cells	I-cell_line
.	O

One	O
interpretation	O
of	O
these	O
data	O
leads	O
to	O
a	O
model	O
in	O
which	O
the	O
peak	O
in	O
GATA-1	B-protein
DNA	O
binding	O
amplifies	O
the	O
effect	O
of	O
early	O
replication	O
on	O
the	O
activation	O
of	O
erythroid-specific	B-DNA
genes	I-DNA
at	O
the	O
same	O
time	O
as	O
preventing	O
activation	O
of	O
non-erythroid	B-DNA
genes	I-DNA
containing	O
GATA-responsive	B-DNA
elements	I-DNA
.	O

Calmodulin	O
antagonists	O
,	O
compound	O
R24571	O
and	O
trifluoperazine	O
,	O
blocked	O
the	O
Zp	B-DNA
activation	O
with	O
anti-Ig	B-protein
.	O

We	O
thus	O
report	O
a	O
hotspot	O
for	O
human	B-DNA
IFNGR1	I-DNA
small	I-DNA
deletions	I-DNA
that	O
confer	O
dominant	O
susceptibility	O
to	O
infections	O
caused	O
by	O
poorly	O
virulent	O
mycobacteria	O
.	O

Interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-4	I-protein
plays	O
an	O
important	O
role	O
in	O
IgE	B-protein
synthesis	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
in	O
Th2	O
differentiation	O
in	O
T	B-cell_line
cells	I-cell_line
.	O

This	O
study	O
evaluates	O
(	O
i	O
)	O
constitutive	O
levels	O
of	O
oncogene	B-DNA
and	O
p53	B-RNA
transcripts	I-RNA
in	O
chronic	O
phase	O
CML	O
patients	O
and	O
(	O
ii	O
)	O
their	O
modulations	O
subsequent	O
to	O
in	O
vivo	O
therapy	O
with	O
rIFN-alpha	B-protein
2c	I-protein
.	O

We	O
show	O
that	O
TLR2	B-protein
associates	O
with	O
the	O
high-affinity	B-protein
LPS	I-protein
binding	I-protein
protein	I-protein
membrane	O
CD14	B-protein
to	O
serve	O
as	O
an	O
LPS	B-protein
receptor	I-protein
complex	I-protein
,	O
and	O
that	O
LPS	O
treatment	O
enhances	O
the	O
oligomerization	O
of	O
TLR2	B-protein
.	O

We	O
investigated	O
the	O
ability	O
of	O
PRL	B-protein
and	O
IL-2	B-protein
to	O
activate	O
Stat	B-protein
proteins	I-protein
in	O
different	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Furthermore	O
a	O
dominant	B-protein
negative	I-protein
form	I-protein
of	O
AML1	B-protein
,	O
AML1a	B-protein
,	O
totally	O
suppressed	O
granulocytic	O
differentiation	O
otherwise	O
induced	O
by	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
when	O
AML1a	B-protein
was	O
overexpressed	O
in	O
32Dc13	B-cell_type
murine	I-cell_type
myeloid	I-cell_type
cells	I-cell_type
.	O

Treatment	O
of	O
the	O
more	O
immature	B-cell_line
B-cell	I-cell_line
line	I-cell_line
,	O
Ramos	B-cell_line
,	O
with	O
phorbol	O
esters	O
rescues	O
the	O
cells	O
from	O
calcium-dependent	O
apoptosis	O
.	O

Pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
is	O
an	O
inhibitor	O
of	O
NF	B-protein
kappaB	I-protein
in	O
most	O
cells	O
;	O
however	O
,	O
we	O
show	O
that	O
PDTC	O
is	O
also	O
a	O
potent	O
scavenger	O
of	O
NO	O
through	O
formation	O
of	O
mononitrosyl	O
iron	O
complexes	O
with	O
PDTC	O
.	O

Upon	O
antigen	O
stimulation	O
,	O
precursor	O
CD4+	B-cell_type
T	I-cell_type
helper	I-cell_type
(	I-cell_type
pTh	I-cell_type
)	I-cell_type
cells	I-cell_type
proliferate	O
and	O
differentiate	O
into	O
two	O
populations	O
of	O
effector	B-cell_type
cells	I-cell_type
(	O
eTh1	B-cell_type
and	O
eTh2	B-cell_type
)	O
,	O
each	O
one	O
expressing	O
a	O
specific	O
pattern	O
of	O
cytokines	B-protein
that	O
distinguishes	O
them	O
from	O
their	O
precursors	O
.	O

The	O
C-terminus	B-protein
has	O
a	O
putative	O
protein	B-protein
kinase	I-protein
C	I-protein
phosphorylation	I-protein
site	I-protein
.	O

Erythrocyte	O
polyamines	O
levels	O
were	O
identical	O
between	O
cancer	O
patients	O
and	O
controls	O
.	O

Atopy	O
,	O
which	O
predisposes	O
individuals	O
to	O
develop	O
asthma	O
,	O
severe	O
systemic	O
anaphylaxis	O
,	O
and	O
atopic	O
dermatitis	O
,	O
is	O
usually	O
associated	O
with	O
dramatically	O
elevated	O
total	O
serum	O
IgE	B-protein
levels	O
and	O
is	O
thought	O
to	O
be	O
controlled	O
by	O
a	O
major	O
susceptibility	B-DNA
gene	I-DNA
and	O
multiple	O
minor	O
susceptibility	B-DNA
genes	I-DNA
.	O

Thus	O
,	O
intact	O
microtubules	B-protein
are	O
essential	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-dependent	O
modulation	O
of	O
gene	O
transcription	O
.	O

In	O
erythroid	B-cell_line
K562	I-cell_line
cells	I-cell_line
in	O
which	O
the	O
HS2	B-DNA
enhancer	I-DNA
is	O
active	O
,	O
the	O
HS2	B-DNA
sequence	I-DNA
directs	O
the	O
synthesis	O
of	O
long	O
enhancer	O
transcripts	O
that	O
are	O
initiated	O
apparently	O
from	O
within	O
the	O
enhancer	B-DNA
and	O
elongated	O
through	O
the	O
intervening	O
DNA	O
into	O
the	O
cis-linked	B-DNA
CAT	I-DNA
gene	I-DNA
.	O

Passaging	O
of	O
the	O
NPC	B-cell_line
cell	I-cell_line
line	I-cell_line
HK666	I-cell_line
led	O
to	O
activation	O
of	O
expression	O
of	O
BZLF1	B-DNA
,	O
which	O
encodes	O
Zta	B-protein
and	O
loss	O
of	O
Qp	B-DNA
function	O
.	O

Plasma	O
cortisol	O
concentration	O
and	O
blood	O
leukocyte	O
content	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GCR	B-protein
)	O
were	O
assayed	O
in	O
20	O
patients	O
with	O
deficiency	O
syndromes	O
,	O
10	O
cold	O
in	O
property	O
(	O
deficiency-cold	O
)	O
,	O
the	O
other	O
10	O
hot	O
in	O
property	O
(	O
deficiency-heat	O
)	O
,	O
and	O
also	O
in	O
10	O
healthy	O
individuals	O
as	O
normal	O
control	O
for	O
the	O
purpose	O
of	O
investigating	O
the	O
nature	O
of	O
cold	O
and	O
heat	O
syndromes	O
.	O

In	O
addition	O
,	O
PPARgamma	B-RNA
mRNA	I-RNA
expression	O
in	O
U937	B-cell_line
cells	I-cell_line
increased	O
during	O
phorbol	O
12-myristate	O
13	O
acetate-induced	O
differentiation	O
.	O

Forty	O
animals	O
were	O
inoculated	O
intranasally	O
with	O
10	O
(	O
7.0	O
)	O
pfu	O
of	O
Ad5/animal	O
,	O
and	O
15	O
animals	O
inoculated	O
with	O
sterile	O
culture	O
media	O
served	O
as	O
controls	O
.	O

These	O
findings	O
reflect	O
the	O
properties	O
of	O
HSF1	B-protein
which	O
can	O
be	O
activated	O
to	O
at	O
least	O
two	O
DNA	B-protein
binding	I-protein
forms	I-protein
only	O
one	O
of	O
which	O
activates	O
heat	B-DNA
shock	I-DNA
promoters	I-DNA
and	O
suggest	O
that	O
individual	O
NSAID	O
family	O
members	O
may	O
differentially	O
induce	O
one	O
or	O
other	O
of	O
these	O
forms	O
.	O

We	O
have	O
now	O
elucidated	O
the	O
mechanism	O
by	O
which	O
CNI-1493	O
inhibits	O
macrophage	O
TNF	B-protein
synthesis	O
and	O
show	O
here	O
that	O
it	O
acts	O
through	O
suppression	O
of	O
TNF	B-protein
translation	O
efficiency	O
.	O

Immunocytochemical	O
analysis	O
of	O
MNDA	B-protein
in	O
tissue	O
sections	O
and	O
sorted	O
normal	O
bone	O
marrow	O
cells	O
documents	O
expression	O
only	O
in	O
maturing	O
normal	O
and	O
neoplastic	O
myelomonocytic	O
cells	O
and	O
a	O
subset	O
of	O
normal	O
and	O
neoplastic	O
B	O
lymphocytes	O
.	O

It	O
was	O
found	O
that	O
expression	O
of	O
wild-type	B-protein
RXR	I-protein
and	O
of	O
the	O
RXR	B-protein
mutants	I-protein
devoid	O
of	O
AF-1	B-protein
and/or	O
AF-2	B-protein
supported	O
a	O
transient	O
outgrowth	O
of	O
erythroid	B-cell_type
cells	I-cell_type
.	O

We	O
report	O
a	O
patient	O
with	O
acute	O
promyelocytic	O
leukaemia	O
who	O
developed	O
marked	O
basophilia	O
during	O
all-trans	O
retinoic	O
acid	O
treatment	O
.	O

We	O
conclude	O
that	O
PAF-receptor	O
antagonist	O
inhibits	O
the	O
CoCl2	O
-or	O
hypoxia-induced	O
increase	O
in	O
the	O
adhesion	O
of	O
SS	B-cell_type
RBC	I-cell_type
,	O
PECAM-1	B-protein
phosphorylation	O
,	O
and	O
the	O
concomitant	O
transendothelial	O
migration	O
of	O
monocytes	B-cell_type
.	O

However	O
IL-7	B-protein
,	O
a	O
crucial	O
factor	O
for	O
thymopoiesis	O
that	O
is	O
secreted	O
mainly	O
by	O
TEC	B-cell_type
,	O
is	O
a	O
necessary	O
cofactor	O
for	O
NF-kappaB	B-protein
activation	O
elicited	O
by	O
TNF	B-protein
or	O
IL-1	B-protein
.	O

To	O
tie	O
these	O
events	O
to	O
gene	O
activation	O
,	O
we	O
measured	O
NF-kappa	B-protein
B	I-protein
and	O
NF-AT	B-protein
activity	O
in	O
the	O
nucleus	O
after	O
anti-CD3	B-protein
stimulation	O
.	O

Interestingly	O
,	O
alteration	O
of	O
either	O
the	O
microB	B-DNA
or	O
E3	B-DNA
site	I-DNA
in	O
a	O
70-base-pair	B-DNA
fragment	I-DNA
of	O
the	O
IgH	B-DNA
enhancer	I-DNA
that	O
lacks	O
the	O
binding	O
site	O
for	O
OCTA	O
abolished	O
enhancer	O
activity	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
completely	O
.	O

Of	O
note	O
,	O
CD40	B-protein
-mediated	O
enhancement	O
of	O
IL-4	B-protein
-driven	O
germline	B-DNA
Cepsilon	O
transcription	O
was	O
markedly	O
decreased	O
by	O
NAC	O
or	O
by	O
a	O
decoy	O
oligodeoxynucleotide	O
for	O
NF-kappaB	B-protein
.	O

We	O
investigated	O
the	O
pattern	O
of	O
tal-1	B-protein
expression	O
in	O
purified	B-cell_type
human	I-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
by	O
in	O
situ	O
hybridization	O
and	O
reverse	B-protein
transcriptase	I-protein
polymerase	I-protein
chain	O
reaction	O
analysis	O
.	O

Interestingly	O
,	O
the	O
MnlI-AluI	B-DNA
fragment	I-DNA
could	O
suppress	O
the	O
basal-level	O
activity	O
of	O
the	O
conalbumin	B-DNA
promoter	I-DNA
in	O
both	O
Jurkat	B-cell_line
and	O
HeLa	B-cell_line
cells	I-cell_line
.	O

To	O
investigate	O
the	O
activity	O
of	O
a	O
single	O
transcription	B-protein
factor	I-protein
in	O
individual	B-cell_type
viable	I-cell_type
cells	I-cell_type
,	O
we	O
have	O
applied	O
an	O
assay	O
that	O
uses	O
the	O
fluorescence-activated	O
cell	O
sorter	O
to	O
quantitate	O
beta-galactosidase	B-protein
(	O
beta-gal	B-protein
)	O
.	O

p60	B-protein
phosphorylation	O
was	O
time	O
and	O
PMA	O
dose	O
dependent	O
,	O
and	O
was	O
induced	O
by	O
cell-permeable	O
diacylglycerol	O
,	O
but	O
not	O
by	O
inactive	O
phorbol	O
esters	O
.	O

Wild-type	O
and	O
chimeric	B-protein
HLF	I-protein
proteins	I-protein
also	O
bound	O
closely	O
related	O
sites	O
identified	O
previously	O
for	O
bZIP	B-protein
proteins	I-protein
of	O
both	O
the	O
proline	B-protein
-and	O
acidic	O
amino	O
acid-rich	O
(	O
PAR	B-protein
)	O
and	O
C/EBP	B-protein
subfamilies	I-protein
;	O
however	O
,	O
E2A-HLF	B-protein
proteins	O
were	O
significantly	O
less	O
tolerant	O
of	O
certain	O
deviations	O
from	O
the	O
HLF	B-DNA
consensus	I-DNA
binding	I-DNA
site	I-DNA
.	O

The	O
molecular	O
events	O
leading	O
to	O
enhanced	O
STAT1	B-protein
activation	O
and	O
cytokine	B-protein
responsiveness	O
concerned	O
both	O
Y701	B-protein
and	O
S727	B-protein
STAT1	I-protein
phosphorylation	O
.	O

The	O
reactivity	O
of	O
murine	B-protein
monoclonal	I-protein
antibodies	I-protein
,	O
anti-CD4-FITC	B-protein
,	O
anti-CD8-FITC	B-protein
,	O
anti-CD2-FITC	B-protein
and	O
anti-calla-FITC	B-protein
,	O
were	O
analyzed	O
using	O
flow	O
cytometry	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
the	O
activation-dependent	B-protein
cell	I-protein
surface	I-protein
markers	I-protein
CD25	B-protein
and	O
CD69	B-protein
was	O
within	O
normal	O
limits	O
.	O

A	O
large	O
amount	O
of	O
detailed	O
information	O
about	O
the	O
intracellular	B-protein
proteins	I-protein
regulating	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
the	O
cellular	O
response	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
has	O
emerged	O
recently	O
.	O

Transient	O
expression	O
of	O
NFATc.beta	B-protein
was	O
capable	O
of	O
activating	O
an	O
interleukin-2	B-DNA
NFAT-driven	I-DNA
reporter	I-DNA
gene	I-DNA
in	O
stimulated	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
in	O
a	O
CsA-sensitive	O
manner	O
.	O

Activation	O
of	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
by	O
the	O
LEF-1	B-protein
HMG	I-protein
protein	I-protein
on	O
nucleosome-assembled	B-DNA
DNA	I-DNA
in	O
vitro	O
.	O

We	O
had	O
previously	O
shown	O
that	O
the	O
drug	O
undecylprodigiosin	O
(	O
UP	O
)	O
blocks	O
human	B-cell_type
lymphocyte	I-cell_type
proliferation	O
in	O
vitro	O
.	O

Based	O
on	O
these	O
observations	O
,	O
it	O
is	O
possible	O
that	O
the	O
interaction	O
of	O
Sp	B-protein
and	O
ATF/CREB	B-protein
family	I-protein
members	I-protein
with	O
the	O
pp	B-DNA
repeat	I-DNA
during	O
basal	O
and	O
Tax	B-protein
-mediated	O
transcription	O
may	O
play	O
a	O
critical	O
role	O
in	O
viral	O
gene	O
expression	O
during	O
the	O
initial	O
stages	O
of	O
virus	O
infection	O
or	O
during	O
activation	O
of	O
a	O
latent	O
infection	O
.	O

The	O
proximity	O
of	O
hLH-2	B-DNA
to	O
the	O
breakpoint	O
on	O
chromosome	B-DNA
9	I-DNA
raises	O
the	O
possibility	O
of	O
cis-activation	O
by	O
the	O
t	B-DNA
(	I-DNA
9	I-DNA
;	I-DNA
22	I-DNA
)	I-DNA
(	I-DNA
q34	I-DNA
;	I-DNA
q11	I-DNA
)	I-DNA
translocation	I-DNA
.	O

The	O
binding	O
of	O
the	O
mAECA	B-protein
to	O
human	B-cell_type
aortic	I-cell_type
EC	I-cell_type
was	O
studied	O
by	O
immunohistochemistry	O
.	O

A	O
R-PK	B-DNA
DNA	I-DNA
fragment	I-DNA
extending	O
from	O
-870	O
to	O
+54	O
relative	O
to	O
the	O
cap	B-DNA
site	I-DNA
confers	O
erythroid	O
specificity	O
to	O
a	O
reporter	B-DNA
gene	I-DNA
.	O

The	O
specificity	O
of	O
HePTP	B-protein
correlated	O
with	O
its	O
physical	O
association	O
through	O
its	O
noncatalytic	O
N	B-protein
terminus	I-protein
with	O
Erk	B-protein
and	O
another	O
MAP	B-protein
kinase	I-protein
,	O
p38	B-protein
,	O
but	O
not	O
Jnk	B-protein
or	O
other	O
proteins	O
.	O

We	O
have	O
detected	O
variant	O
ER	B-protein
in	O
these	O
samples	O
and	O
have	O
compared	O
the	O
variant	O
profile	O
to	O
that	O
observed	O
in	O
breast	O
cancer	O
.	O

All	O
seven	O
IDCs	O
associated	O
with	O
Paget	O
's	O
disease	O
showed	O
positive	O
reactions	O
for	O
HER-2/neu	B-protein
.	O

This	O
led	O
to	O
the	O
hypothesis	O
that	O
some	O
of	O
the	O
Rel/NF-kappa	B-protein
B	I-protein
proteins	I-protein
were	O
key	O
nuclear	B-protein
factors	I-protein
in	O
functions	O
of	O
accessory	B-cell_type
cells	I-cell_type
of	O
the	O
immune	O
response	O
.	O

This	O
nuclear	B-protein
complex	I-protein
was	O
activated	O
by	O
LPS	O
with	O
kinetics	O
that	O
preceded	O
induction	O
of	O
the	O
TF	B-DNA
gene	I-DNA
.	O

The	O
cytokine	B-protein
-dependent	O
upregulation	O
of	O
the	O
murine	B-protein
macrophage	I-protein
12-lipoxygenase	I-protein
and	O
its	O
induction	O
during	O
experimental	O
anemia	O
suggests	O
its	O
close	O
relatedness	O
with	O
the	O
human	B-protein
reticulocyte-type	I-protein
15-lipoxygenase	I-protein
despite	O
their	O
differences	O
in	O
the	O
positional	O
specificity	O
of	O
arachidonic	O
acid	O
oxygenation	O
.	O

Coexpression	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
Sp1	B-protein
occurs	O
in	O
the	O
heterologous	B-cell_type
DC-T-cell	I-cell_type
syncytia	I-cell_type
that	O
are	O
induced	O
by	O
HIV-1	O
.	O

These	O
results	O
provide	O
compelling	O
links	O
between	O
the	O
efficiency	O
of	O
the	O
20-epi	O
analogue	O
in	O
inducing	O
VDR	B-protein
/DRIP	O
interactions	O
,	O
transactivation	O
in	O
vitro	O
,	O
and	O
its	O
enhanced	O
ability	O
to	O
induce	O
cellular	O
differentiation	O
.	O

Lymphocytes	B-cell_type
were	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
more	O
sensitive	O
to	O
the	O
direct	O
cytotoxic	O
effects	O
of	O
SMX-NO	O
than	O
neutrophils	B-cell_type
.	O

These	O
results	O
indicated	O
that	O
ATL	B-cell_line
cells	I-cell_line
constitutively	O
overexpress	O
the	O
L-selectin	B-DNA
gene	I-DNA
that	O
can	O
be	O
transactivated	O
by	O
HTLV-1	O
Tax	B-protein
.	O

Single	O
cell	O
assay	O
of	O
a	O
transcription	B-protein
factor	I-protein
reveals	O
a	O
threshold	O
in	O
transcription	O
activated	O
by	O
signals	O
emanating	O
from	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
a	O
portion	O
of	O
the	O
ER	B-protein
upstream	B-DNA
regulatory	I-DNA
region	I-DNA
from	O
the	O
ER-positive	B-cell_line
MCF-7	I-cell_line
and	O
the	O
ER-negative	B-cell_line
MDA-MB-231	I-cell_line
breast	I-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
to	O
determine	O
if	O
sequence	O
alterations	O
in	O
this	O
region	O
account	O
for	O
the	O
ER	B-protein
-negative	O
phenotype	O
of	O
some	O
tumors	O
.	O

Three	O
of	O
these	O
mutants	O
contained	O
targeted	O
disruptions	O
of	O
potential	O
functional	O
motifs	O
:	O
the	O
acidic	B-protein
activation	I-protein
domain	I-protein
,	O
a	O
putative	O
GTP-binding	B-protein
motif	I-protein
and	O
two	O
leucine	B-protein
charged	I-protein
domains	I-protein
(	O
LCD	B-protein
motifs	I-protein
)	O
.	O

We	O
suggest	O
that	O
in	O
young	O
subjects	O
Type	B-protein
II	I-protein
receptors	I-protein
are	O
initially	O
up-regulated	O
by	O
dexamethasone	O
,	O
and	O
then	O
down-regulated	O
,	O
while	O
in	O
aged	O
subjects	O
an	O
up-regulation	O
can	O
not	O
be	O
achieved	O
,	O
as	O
suggested	O
by	O
the	O
higher	O
values	O
of	O
plasma	O
cortisol	O
usually	O
found	O
in	O
aging	O
subjects	O
.	O

IL-12	B-protein
induced	O
STAT4	B-protein
and	O
IL-2	B-protein
and	O
IL-15	B-protein
induced	O
STAT5	B-protein
binding	O
to	O
the	O
GAS	B-DNA
elements	I-DNA
.	O

These	O
findings	O
therefore	O
suggest	O
that	O
the	O
HTLV-I	B-DNA
enhancer	I-DNA
contains	O
multiple	B-DNA
functional	I-DNA
elements	I-DNA
,	O
including	O
binding	O
sites	O
for	O
at	O
least	O
CREB-	B-protein
and	I-protein
NF-kappa	I-protein
B-like	I-protein
factors	I-protein
,	O
which	O
synergistically	O
cooperate	O
in	O
activation	O
of	O
the	O
HTLV-I	B-DNA
enhancer	I-DNA
in	O
response	O
to	O
p40tax	B-protein
.	O

Activation	O
of	O
CD4	B-cell_type
positive	I-cell_type
T	I-cell_type
cells	I-cell_type
is	O
a	O
primary	O
requirement	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
entry	O
,	O
efficient	O
HIV	O
replication	O
,	O
and	O
progression	O
to	O
AIDS	O
,	O
Utilizing	O
CD4	B-cell_line
positive	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
purified	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
normal	O
individuals	O
,	O
we	O
have	O
demonstrated	O
that	O
native	B-protein
envelope	I-protein
glycoproteins	I-protein
of	O
HIV	O
,	O
gp	B-protein
160	I-protein
,	O
can	O
induce	O
activation	O
of	O
transcription	B-protein
factor	I-protein
,	I-protein
activated	I-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
.	O

The	O
genetic	O
elements	O
and	O
regulatory	O
mechanisms	O
responsible	O
for	O
human	B-DNA
interleukin	I-DNA
9	I-DNA
(	I-DNA
IL-9	I-DNA
)	I-DNA
gene	I-DNA
expression	O
in	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
leukemia	I-cell_line
virus	I-cell_line
type	I-cell_line
I-transformed	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
C5MJ2	B-cell_line
,	O
were	O
investigated	O
.	O

A	O
15-base	O
oligonucleotide	O
,	O
GM3	O
,	O
was	O
targeted	O
to	O
a	O
purine-rich	B-DNA
region	I-DNA
in	O
the	O
GM-CSF	B-DNA
proximal	I-DNA
promoter	I-DNA
,	O
which	O
overlaps	O
the	O
kappaB	B-DNA
element	I-DNA
.	O

Lt-4	B-protein
reacted	O
with	O
all	O
HTLV-I-bearing	B-cell_line
cell	I-cell_line
lines	I-cell_line
tested	O
and	O
five	O
out	O
of	O
eight	O
simian	B-cell_line
cell	I-cell_line
lines	I-cell_line
bearing	O
STLV-I	O
,	O
but	O
not	O
with	O
an	O
HTLV-II-bearing	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Tissue-specific	O
expression	O
of	O
interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
is	O
mediated	O
via	O
cis-acting	B-DNA
elements	I-DNA
located	O
within	O
315	O
base	O
pairs	O
of	O
the	O
transcription	B-DNA
start	I-DNA
.	O

Thrombopoietin	B-protein
is	O
known	O
to	O
be	O
essential	O
for	O
megakaryocytopoiesis	O
and	O
thrombopoiesis	O
.	O

Protein	B-protein
kinase	I-protein
B	I-protein
(	O
c-Akt	B-protein
)	O
,	O
phosphatidylinositol	B-protein
3-kinase	I-protein
,	O
and	O
STAT5	B-protein
are	O
activated	O
by	O
erythropoietin	B-protein
(	O
EPO	B-protein
)	O
in	O
HCD57	B-cell_line
erythroid	I-cell_line
cells	I-cell_line
but	O
are	O
constitutively	O
active	O
in	O
an	O
EPO-independent	B-cell_line
,	I-cell_line
apoptosis-resistant	I-cell_line
subclone	I-cell_line
(	O
HCD57-SREI	B-cell_line
cells	I-cell_line
)	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
each	O
Tax1	B-protein
-inducible	O
transcriptional	O
pathway	O
in	O
T-cell	O
transformation	O
,	O
we	O
introduced	O
Tax1	B-protein
mutants	I-protein
with	O
different	O
trans-activating	O
phenotypes	O
into	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
by	O
retroviral	O
vectors	O
.	O

Tax	B-protein
was	O
transfected	O
into	O
HTLV-I-negative	B-cell_line
human	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O

The	O
element	O
worked	O
in	O
either	O
orientation	O
and	O
could	O
mediate	O
EBNA2	B-protein
dependent	O
transactivation	O
on	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O

The	O
Fy	O
(	O
a-b-	O
)	O
phenotype	O
is	O
the	O
predominant	O
one	O
in	O
populations	O
of	O
black	O
people	O
and	O
also	O
occurs	O
in	O
other	O
populations	O
,	O
including	O
some	O
non-Ashkenazi	O
Jewish	O
groups	O
.	O

We	O
demonstrate	O
here	O
that	O
pretreatment	O
with	O
PAO	O
results	O
in	O
the	O
inhibition	O
of	O
NFkappaB	B-protein
induction	O
in	O
TNF-alpha	B-protein
treated	O
T	B-cell_type
cells	I-cell_type
,	O
suggesting	O
a	O
role	O
for	O
PAO-sensitive	B-protein
phosphatase	I-protein
in	O
the	O
activation	O
of	O
the	O
NFkappaB	B-protein
via	O
this	O
pathway	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

We	O
show	O
here	O
that	O
AM580	O
,	O
a	O
stable	O
retinobenzoic	O
derivative	O
originally	O
synthesized	O
as	O
a	O
RAR	B-protein
alpha	I-protein
agonist	O
,	O
is	O
a	O
powerful	O
inducer	O
of	O
granulocytic	O
maturation	O
in	O
NB4	B-cell_line
,	O
an	O
APL-derived	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
and	O
in	O
freshly	B-cell_type
isolated	I-cell_type
APL	I-cell_type
blasts	I-cell_type
.	O

Our	O
data	O
suggest	O
that	O
SAC	O
may	O
act	O
via	O
antioxidant	O
mechanisms	O
to	O
block	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Activation	O
of	O
PPARgamma	B-protein
may	O
play	O
a	O
role	O
in	O
the	O
induction	O
of	O
differentiation	O
of	O
macrophages	B-cell_type
to	O
foam	B-cell_type
cells	I-cell_type
that	O
are	O
associated	O
with	O
atherosclerotic	O
lesions	O
.	O

Both	O
sIgM-	O
and	O
sIgD-crosslinking	O
with	O
antibodies	O
induced	O
elevation	O
of	O
cAMP	O
levels	O
,	O
phosphatidylinositol	O
turnover	O
,	O
PKC	B-protein
activation	O
and	O
expression	O
of	O
Egr-1	B-RNA
and	I-RNA
c-fos	I-RNA
mRNA	I-RNA
,	O
although	O
sIgM	B-protein
-crosslinking	O
was	O
more	O
effective	O
than	O
sIgD	B-protein
-crosslinking	O
,	O
presumably	O
due	O
to	O
the	O
higher	O
expression	O
of	O
sIgM	B-protein
than	O
of	O
sIgD	B-protein
.	O

As	O
p65	B-protein
complexes	I-protein
are	O
transcriptionally	O
active	O
in	O
comparison	O
to	O
the	O
p50	O
homodimer	O
,	O
this	O
novel	O
finding	O
may	O
provide	O
insight	O
on	O
the	O
origin	O
of	O
abnormal	B-protein
cytokine	I-protein
or	O
other	O
gene	O
transcription	O
in	O
SLE	O
patients	O
.	O

CaMKIV/	B-protein
Gr	I-protein
signaling	O
is	O
associated	O
with	O
transcriptional	O
activation	O
of	O
c-fos	B-DNA
but	O
is	O
independent	O
of	O
p21ras	B-DNA
or	O
calcineurin	B-protein
.	O

CD40	B-protein
ligation	O
leads	O
to	O
B	O
cell	O
activation	O
events	O
such	O
as	O
proliferation	O
,	O
Ig	O
secretion	O
,	O
isotype	O
switching	O
,	O
and	O
up-regulation	O
of	O
cell	B-protein
surface	I-protein
molecules	I-protein
,	O
as	O
well	O
as	O
the	O
generation	O
of	O
memory	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

The	O
active	O
metabolite	O
of	O
vitamin	O
D	O
,	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
]	O
,	O
is	O
a	O
potent	O
regulator	O
of	O
human	O
monocyte/macrophage	O
function	O
in	O
vitro	O
.	O

The	O
role	O
of	O
Aiolos	B-DNA
,	O
a	O
lymphoid-restricted	B-DNA
and	I-DNA
structurally	I-DNA
related	I-DNA
gene	I-DNA
,	O
in	O
lymphoid	O
differentiation	O
is	O
discussed	O
.	O

These	O
results	O
should	O
contribute	O
to	O
a	O
better	O
understanding	O
of	O
the	O
regulation	O
of	O
IL3	B-protein
gene	O
expression	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Transcriptional	O
regulation	O
of	O
the	O
gene	O
encoding	O
the	O
human	B-protein
C-type	I-protein
lectin	I-protein
leukocyte	I-protein
receptor	I-protein
AIM/CD69	B-protein
and	O
functional	O
characterization	O
of	O
its	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha-responsive	I-DNA
elements	I-DNA
.	O

Effect	O
of	O
environmental	O
estrogens	O
on	O
IL-1beta	B-DNA
promoter	I-DNA
activity	O
in	O
a	O
macrophage	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

The	O
activation	O
of	O
Janus	B-protein
protein	I-protein
tyrosine	I-protein
kinases	I-protein
(	O
Jak	B-protein
)	O
and	O
STAT	B-protein
(	I-protein
signal	I-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
)	I-protein
proteins	I-protein
has	O
recently	O
been	O
linked	O
to	O
the	O
signal	O
transduction	O
mechanism	O
of	O
several	O
cytokines	B-protein
.	O

Mutants	O
of	O
type	O
5	O
adenovirus	O
(	O
Ad5	O
)	O
with	O
reiterated	B-DNA
DNA	I-DNA
sequences	I-DNA
in	O
the	O
E1a	B-DNA
region	I-DNA
appeared	O
in	O
a	O
human	B-cell_line
T-lymphocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Molt-4	B-cell_line
,	O
persistently	O
infected	O
with	O
H5sub304	O
,	O
a	O
deletion/substitution	O
mutant	O
that	O
has	O
a	O
wild-type	O
phenotype	O
in	O
viral	O
replication	O
.	O

We	O
were	O
,	O
therefore	O
,	O
interested	O
in	O
examining	O
mutated	O
CIITA	B-DNA
constructs	I-DNA
for	O
their	O
effect	O
on	O
porcine	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
.	O

This	O
revealed	O
that	O
NF-kappaB	B-protein
generation	O
was	O
sensitive	O
to	O
chloroquine	O
,	O
an	O
inhibitor	O
of	O
acidic	B-protein
sphingomyelinase	I-protein
,	O
but	O
not	O
to	O
the	O
phosphatidylinositol	B-protein
3-kinase	I-protein
inhibitor	O
,	O
wortmannin	O
.	O

Northern	O
blotting	O
experiments	O
indicated	O
that	O
regulation	O
predominantly	O
occurred	O
at	O
the	O
mRNA	O
level	O
.	O

IL-1beta	B-protein
stimulation	O
of	O
epithelial	B-cell_type
cells	I-cell_type
did	O
not	O
generate	O
any	O
ROIs	O
and	O
NF-kappaB	B-protein
induction	O
was	O
not	O
influenced	O
by	O
5-LOX	B-protein
inhibitors	O
.	O

HMG-I	B-protein
binds	O
to	O
GATA	B-DNA
motifs	I-DNA
:	O
implications	O
for	O
an	O
HPFH	O
syndrome	O
.	O

USF/c-Myc	B-protein
enhances	O
,	O
while	O
Yin-Yang	B-protein
1	I-protein
suppresses	O
,	O
the	O
promoter	O
activity	O
of	O
CXCR4	B-protein
,	O
a	O
coreceptor	B-protein
for	O
HIV-1	O
entry	O
.	O

The	O
close	O
homology	O
of	O
the	O
basic	B-protein
region/leucine	I-protein
zipper	I-protein
(	O
bZIP	B-protein
)	O
DNA-binding	O
and	O
dimerization	B-protein
domain	I-protein
of	O
HLF	B-protein
to	O
that	O
of	O
the	O
CES-2	B-protein
cell-death	I-protein
specification	I-protein
protein	I-protein
of	O
Caenorhabditis	O
elegans	O
suggests	O
a	O
model	O
of	O
leukaemogenesis	O
in	O
which	O
E2A-HLF	B-protein
blocks	O
an	O
early	O
step	O
within	O
an	O
evolutionarily	O
conserved	O
cell-death	O
pathway	O
.	O

Human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	I-cell_line
was	O
treated	O
with	O
E.	O
chaffeensis	O
which	O
had	O
been	O
preincubated	O
with	O
human	O
anti-E.	O
chaffeensis	O
serum	O
for	O
2	O
h	O
,	O
and	O
the	O
levels	O
of	O
cytokine	B-RNA
mRNAs	I-RNA
were	O
evaluated	O
by	O
competitive	O
reverse	O
transcription-PCR	O
.	O

The	O
data	O
demonstrate	O
a	O
remarkable	O
qualitative	O
and	O
quantitative	O
heterogeneity	O
of	O
the	O
humoral	O
HBx	B-protein
immune	O
response	O
which	O
can	O
be	O
monitored	O
by	O
HBx	B-protein
-specific	O
peptide	O
ELISAs	O
.	O

Opposing	O
effects	O
of	O
glucocorticoids	O
on	O
the	O
rate	O
of	O
apoptosis	O
in	O
neutrophilic	B-cell_type
and	I-cell_type
eosinophilic	I-cell_type
granulocytes	I-cell_type
.	O

We	O
recently	O
confirmed	O
the	O
existence	O
of	O
gelatinase	O
granules	O
as	O
a	O
subpopulation	O
of	O
peroxidase-negative	O
granules	O
by	O
double-labeling	O
immunogold	O
electron	O
microscopy	O
on	O
intact	O
cells	O
and	O
by	O
subcellular	O
fractionation	O
.	O

PML	B-protein
is	O
expressed	O
in	O
diverse	O
tissues	O
and	O
cell	O
lines	O
and	O
localized	O
in	O
the	O
nucleus	O
with	O
a	O
typical	O
speckled	O
pattern	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
a	O
novel	O
function	O
of	O
iNO	O
is	O
to	O
terminate	O
inflammatory	O
processes	O
.	O

Isolation	O
of	O
a	O
candidate	O
repressor/activator	O
,	O
NF-E1	B-protein
(	O
YY-1	B-protein
,	O
delta	B-protein
)	O
,	O
that	O
binds	O
to	O
the	O
immunoglobulin	B-DNA
kappa	I-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
and	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
mu	I-DNA
E1	I-DNA
site	I-DNA
.	O

Association	O
of	O
the	O
newly	O
synthesized	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
with	O
p65	B-protein
restores	O
intracellular	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
activity	O
and	O
prolongs	O
the	O
survival	O
of	O
this	O
labile	O
inhibitor	O
.	O

Adenovirus	O
can	O
establish	O
persistent	O
infections	O
which	O
may	O
reactivate	O
and	O
cause	O
disease	O
in	O
immunocompromised	O
hosts	O
.	O

These	O
results	O
suggest	O
that	O
interferon	B-protein
gamma	I-protein
functions	O
on	O
a	O
poised	B-DNA
promoter	I-DNA
by	O
altering	O
weak	O
,	O
nonproductive	O
interactions	O
at	O
the	O
X	B-DNA
boxes	I-DNA
to	O
strong	O
interactions	O
.	O

Here	O
we	O
show	O
that	O
fludarabine	O
,	O
but	O
not	O
the	O
immunosuppressant	O
cyclosporine	O
A	O
,	O
inhibits	O
the	O
cytokine	B-protein
-induced	O
activation	O
of	O
STAT1	B-protein
and	O
STAT1	B-protein
-dependent	O
gene	O
transcription	O
in	O
normal	B-cell_type
resting	I-cell_type
or	I-cell_type
activated	I-cell_type
lymphocytes	I-cell_type
.	O

Although	O
the	O
mutant	O
strain	O
was	O
able	O
to	O
kill	O
HL-60-	B-cell_type
and	I-cell_type
THP-1-derived	I-cell_type
macrophages	I-cell_type
,	O
it	O
could	O
not	O
replicate	O
within	O
a	O
protozoan	O
host	O
,	O
Acanthamoeba	O
castellanii	O
.	O

Stimulation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
through	O
their	O
antigen	B-protein
receptor	I-protein
leads	O
to	O
the	O
appearance	O
of	O
several	O
transcription	B-protein
factors	I-protein
,	O
including	O
NF-AT	B-protein
and	O
NF-kappa	B-protein
B	I-protein
,	O
which	O
are	O
involved	O
in	O
regulating	O
genes	O
required	O
for	O
immunologic	O
activation	O
.	O

To	O
determine	O
whether	O
enhancer	B-DNA
elements	I-DNA
in	O
addition	O
to	O
the	O
highly	O
conserved	O
octamer	B-DNA
(	I-DNA
OCTA	I-DNA
)	I-DNA
-nucleotide	I-DNA
motif	I-DNA
are	O
important	O
for	O
lymphoid-specific	O
expression	O
of	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
gene	I-DNA
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
mutating	O
the	O
binding	B-DNA
site	I-DNA
for	O
a	O
putative	B-protein
additional	I-protein
lymphoid-specific	I-protein
transcription	I-protein
factor	I-protein
,	O
designated	O
NF-microB	B-protein
,	O
in	O
the	O
murine	B-DNA
IgH	I-DNA
enhancer	I-DNA
.	O

For	O
measuring	O
the	O
contribution	O
of	O
macrophages	B-cell_type
to	O
the	O
release	O
of	O
inflammatory	B-protein
mediators	I-protein
by	O
bronchial	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
,	O
we	O
established	O
an	O
in	O
vitro	O
model	O
of	O
co-cultured	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
(	O
BM	B-cell_type
)	O
and	O
BEAS-2B	B-cell_line
cells	I-cell_line
in	O
a	O
transwell	O
system	O
(	O
Costar	O
)	O
.	O

This	O
factor	O
also	O
inhibited	O
the	O
synthesis	O
of	O
anti-DNP	B-protein
antibodies	I-protein
by	O
a	O
mouse	B-cell_line
hybridoma	I-cell_line
and	O
diminished	O
the	O
proportion	O
of	O
cells	O
in	O
phase	O
S	O
.	O

These	O
results	O
suggest	O
that	O
haemoglobin	O
production	O
in	O
UT-7	B-cell_line
cells	I-cell_line
is	O
limited	O
by	O
a	O
deficiency	O
of	O
erythroid-specific	B-protein
aminolaevulinic	I-protein
acid	I-protein
synthase	I-protein
(	O
ALAS-E	B-protein
)	O
activity	O
or	O
globin	O
synthesis	O
as	O
a	O
consequence	O
of	O
their	O
immaturity	O
as	O
a	O
multipotential	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

One	O
of	O
the	O
protoenhancers	B-DNA
contains	O
the	O
overlapping	B-DNA
palindromes	I-DNA
5'-TTGTCCcgtGGACAAaTGTCC-3'	O
.	O

Using	O
purified	O
recombinant	O
p50	B-protein
,	O
p65	B-protein
,	O
and	O
c-Rel	B-protein
proteins	I-protein
,	O
optimal	O
DNA-binding	O
motifs	O
were	O
selected	O
from	O
a	O
pool	O
of	O
random	O
oligonucleotides	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
demonstrate	O
that	O
dysfunction	O
of	O
these	O
genes	B-DNA
also	O
occurs	O
during	O
recurrence	O
of	O
glial	O
tumors	O
that	O
were	O
highly	O
malignant	O
at	O
first	O
presentation	O
.	O

Concomitant	O
with	O
receptor	O
oligomerization	O
,	O
the	O
IL-1R-associated	B-protein
kinase	I-protein
(	I-protein
IRAK	I-protein
)	I-protein
is	O
recruited	O
to	O
the	O
TLR2	B-protein
complex	O
.	O

In	O
monocytes	B-cell_type
,	O
lipopolysaccharide	O
induces	O
synthesis	O
and	O
activity	O
of	O
the	O
85-kDa	O
cytosolic	B-protein
phospholipase	I-protein
A2	I-protein
.	O

Furthermore	O
,	O
the	O
physical	O
interaction	O
of	O
Tax	B-protein
with	O
p100	B-protein
leads	O
to	O
the	O
inhibition	O
of	O
Tax	B-protein
-induced	O
activation	O
of	O
the	O
HTLV-I	O
and	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeats	I-DNA
,	O
reflecting	O
p100	B-protein
-mediated	O
cytoplasmic	O
sequestration	O
of	O
the	O
normally	O
nuclearly	O
expressed	O
Tax	B-protein
protein	I-protein
.	O

The	O
sequence	O
of	O
the	O
smallest	O
subunit	O
describes	O
a	O
novel	O
gene	O
,	O
termed	O
RFX-B	B-DNA
.	O

Deletion	O
of	O
interdomain	B-protein
B	I-protein
did	O
not	O
affect	O
the	O
ability	O
of	O
ZAP-70	B-protein
to	O
bind	O
to	O
the	O
receptor	O
.	O

The	O
Janus	B-cell_line
kinase-1-deficient	I-cell_line
cell	I-cell_line
line	I-cell_line
U4A	I-cell_line
expresses	O
HLA-DR	B-RNA
alpha	I-RNA
mRNA	I-RNA
in	O
response	O
to	O
NK	O
cell	O
activation	O
,	O
and	O
HLA-DR	B-DNA
alpha	I-DNA
promoter	I-DNA
constructs	I-DNA
transfected	O
into	O
these	O
cells	O
are	O
induced	O
by	O
NK	B-cell_line
cells	I-cell_line
but	O
not	O
IFN-gamma	B-protein
.	O

We	O
have	O
investigated	O
the	O
induction	O
of	O
these	O
genes	O
by	O
macrophage-CSF	B-protein
(	O
M-CSF	B-protein
)	O
in	O
human	B-cell_type
monocytes	I-cell_type
that	O
do	O
not	O
proliferate	O
in	O
response	O
to	O
M-CSF	B-protein
but	O
require	O
the	O
factor	O
for	O
optimal	O
cell	O
differentiation	O
.	O

We	O
therefore	O
conclude	O
that	O
common	O
polymorphisms	O
within	O
the	O
VDR	B-DNA
3'-UTR	I-DNA
do	O
not	O
influence	O
message	O
stability	O
.	O

Furthermore	O
,	O
the	O
same	O
cell	B-cell_line
lines	I-cell_line
were	O
resistant	O
to	O
cytolytic	O
action	O
of	O
other	O
cytotoxic	B-protein
proteins	I-protein
secreted	O
by	O
LAK	B-cell_line
cells	I-cell_line
.	O

Binding	O
of	O
c-Rel	B-protein
to	O
STAT5	B-DNA
target	I-DNA
sequences	I-DNA
in	O
HTLV-I-transformed	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Treatment	O
of	O
immunoprecipitated	O
NFATp	B-protein
from	O
untreated	O
HT-2	B-cell_line
cells	I-cell_line
with	O
calcineurin	B-protein
resulted	O
in	O
the	O
dephosphorylation	O
of	O
NFATp	B-protein
,	O
demonstrating	O
that	O
NFATp	B-protein
is	O
an	O
in	O
vitro	O
substrate	O
for	O
calcineurin	B-protein
.	O

Superantigens	B-protein
also	O
increased	O
viral	O
protein	O
secretion	O
from	O
the	O
granulocyte-macrophage	B-cell_line
colony-stimulating	I-cell_line
factor-pretreated	I-cell_line
chronically	I-cell_line
infected	I-cell_line
human	I-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
U1	I-cell_line
.	O

On	O
the	O
other	O
hand	O
,	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
-induced	O
signals	O
are	O
blocked	O
by	O
rapamycin	O
but	O
not	O
by	O
FK506	O
.	O

Lymphoid	O
differentiation	O
is	O
one	O
of	O
the	O
best	O
studied	O
examples	O
of	O
mammalian	O
development	O
.	O

In	O
addition	O
,	O
HU	O
stimulates	O
the	O
synthesis	O
of	O
fetal	B-protein
hemoglobin	I-protein
in	O
sickle	O
cell	O
anemia	O
patients	O
.	O

RFX-B	B-DNA
is	O
the	O
gene	O
responsible	O
for	O
the	O
most	O
common	O
cause	O
of	O
the	O
bare	O
lymphocyte	O
syndrome	O
,	O
an	O
MHC	B-protein
class	I-protein
II	I-protein
immunodeficiency	O
[	O
published	O
erratum	O
appears	O
in	O
Immunity	O
1999	O
Mar	O
;	O
10	O
(	O
3	O
)	O
:	O
399	O
]	O

To	O
identify	O
potential	O
cellular	O
homologues	O
of	O
cyclosporin	O
A	O
that	O
might	O
regulate	O
calcium	O
signalling	O
,	O
we	O
have	O
cloned	O
human	O
genes	O
encoding	O
cyclophilin	B-protein
B-binding-proteins	I-protein
using	O
the	O
yeast	O
two-hybrid	O
system	O
.	O

However	O
,	O
the	O
two	O
SH2	B-protein
domains	I-protein
of	O
SHP1	B-protein
did	O
not	O
facilitate	O
its	O
recognition	O
of	O
ZAP-70	B-protein
and	O
Syk	B-protein
as	O
substrates	O
in	O
intact	O
cells	O
.	O

Furthermore	O
,	O
S9a	O
and	O
AZT	O
in	O
combination	O
,	O
at	O
noncytoxic	O
concentrations	O
strongly	O
inhibited	O
HIV-1	O
replication	O
that	O
was	O
more	O
than	O
additive	O
and	O
substantially	O
prolonged	O
the	O
appearance	O
of	O
virus	O
both	O
in	O
acutely	B-cell_type
infected	I-cell_type
CD4+	I-cell_type
lymphocytes	I-cell_type
(	O
SupT	B-cell_line
)	O
in	O
culture	O
and	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
infected	O
with	O
a	O
primary	O
HIV-1	O
isolate	O
.	O

Several	O
DNA-binding	B-protein
complexes	I-protein
were	O
detected	O
on	O
RAREs	B-DNA
in	O
undifferentiated	B-cell_type
cells	I-cell_type
.	O

Our	O
results	O
suggest	O
that	O
CaMKIV	B-protein
may	O
represent	O
a	O
physiologically	O
relevant	O
CREB	B-protein
kinase	I-protein
in	O
T	B-cell_type
cells	I-cell_type
and	O
that	O
the	O
enzyme	O
is	O
also	O
required	O
to	O
ensure	O
normal	O
expansion	O
of	O
T	B-cell_type
cells	I-cell_type
in	O
the	O
thymus	O
.	O

Rat	O
spleen	O
and	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
express	O
progesterone	B-protein
receptors	I-protein
whose	O
concentration	O
is	O
increased	O
greatly	O
during	O
the	O
early	O
phase	O
of	O
pregnancy	O
.	O

The	O
viral	B-protein
encoded	I-protein
protein	I-protein
tax	B-protein
,	O
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
oncogenesis	O
.	O

Elevated	O
cAMP	O
did	O
not	O
prevent	O
nuclear	O
translocation	O
of	O
p50/p65	B-protein
and	O
c-Rel/p65	B-protein
heterodimers	I-protein
,	O
decrease	O
nuclear	O
translocation	O
of	O
p65	B-protein
,	O
or	O
significantly	O
modify	O
TNFalpha	B-protein
-induced	O
phosphorylation	O
of	O
p65	B-protein
.	O

We	O
demonstrate	O
that	O
one	O
target	O
of	O
this	O
positive/negative	O
regulation	O
in	O
vivo	O
is	O
the	O
alpha4	B-protein
integrin	I-protein
,	O
which	O
play	O
a	O
key	O
role	O
in	O
normal	O
hematopoiesis	O
and	O
function	O
of	O
mature	B-cell_type
leukocytes	I-cell_type
.	O

ZEBRA	B-protein
activation	O
can	O
be	O
replaced	O
by	O
a	O
heterologous	B-protein
acidic	I-protein
,	I-protein
proline-rich	I-protein
,	I-protein
or	I-protein
glutamine-rich	I-protein
activation	I-protein
domain	I-protein
.	O

Furthermore	O
,	O
myricetin	O
was	O
also	O
found	O
to	O
inhibit	O
NFkappaB	B-protein
activity	O
correlated	O
with	O
suppression	O
of	O
monocyte	O
adhesion	O
to	O
ECV304	B-cell_line
cells	I-cell_line
.	O

The	O
retinoblastoma	B-protein
gene	I-protein
product	I-protein
(	O
pRB	B-protein
)	O
plays	O
an	O
important	O
role	O
in	O
controlling	O
both	O
cell	O
release	O
from	O
the	O
G1	O
phase	O
and	O
apoptosis	O
.	O

Therefore	O
we	O
studied	O
the	O
expression	O
pattern	O
of	O
LAZ3/BCL6	B-protein
by	O
in	O
situ	O
hybridization	O
with	O
synthetic	O
oligonucleotide	O
probes	O
in	O
frozen	O
tissue	O
sections	O
from	O
five	O
reactive	O
lymph	O
nodes	O
and	O
38	O
B	O
cell	O
and	O
non-B	O
NHL	O
.	O

In	O
this	O
study	O
we	O
report	O
on	O
the	O
establishment	O
and	O
characterization	O
of	O
two	O
novel	O
lymphoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
CRO-AP/3	B-cell_line
and	O
CRO-AP/5	B-cell_line
)	O
which	O
carry	O
infection	O
by	O
human	O
herpesvirus	O
type-8	O
(	O
HHV-8	O
)	O
and	O
have	O
derived	O
from	O
AIDS-related	O
primary	O
effusion	O
lymphoma	O
(	O
PEL	B-cell_line
)	O
.	O

However	O
,	O
treatment	O
of	O
HL-60	B-cell_line
cells	I-cell_line
with	O
PDBu	O
induced	O
the	O
rapid	O
expression	O
of	O
the	O
apoptosis	B-protein
suppressor	I-protein
protein	I-protein
Bcl-xL	B-protein
,	O
whereas	O
the	O
expression	O
of	O
this	O
protein	O
remained	O
unaltered	O
in	O
DMSO-treated	O
cells	O
.	O

These	O
data	O
provide	O
the	O
first	O
demonstration	O
in	O
vivo	O
that	O
activation	O
of	O
a	O
protein	B-protein
phosphatase	I-protein
can	O
inactivate	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
and	O
suggest	O
one	O
possible	O
explanation	O
for	O
mechanism-based	O
toxicities	O
associated	O
with	O
FK-506	O
and	O
CsA	O
by	O
demonstrating	O
that	O
these	O
drugs	O
can	O
inhibit	O
the	O
calcineurin	B-protein
-dependent	O
activation	O
of	O
a	O
virtually	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
.	O

Binding	O
characteristics	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
in	O
multiple	O
sclerosis	O
.	O

PU.1	B-protein
(	O
spi-1	B-protein
)	O
,	O
a	O
member	O
of	O
the	O
Ets	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
,	O
is	O
predominantly	O
expressed	O
in	O
myeloid	B-cell_type
and	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
activates	O
many	O
B	B-DNA
cell	I-DNA
and	I-DNA
myeloid	I-DNA
genes	I-DNA
,	O
and	O
is	O
critical	O
for	O
development	O
of	O
both	O
of	O
these	O
lineages	O
.	O

Abnormal	O
activation	O
of	O
NFkappaB	B-protein
is	O
also	O
present	O
in	O
>	O
50	O
%	O
of	O
patients	O
and	O
may	O
also	O
revert	O
to	O
normal	O
during	O
IL-2/	O
IFN	B-protein
alpha	I-protein
-based	O
treatment	O
.	O

In	O
the	O
past	O
few	O
years	O
,	O
there	O
has	O
been	O
some	O
progress	O
in	O
defining	O
the	O
tyrosine	O
kinases	O
that	O
are	O
activated	O
by	O
the	O
IL-3/IL-5/GM-CSF	B-protein
receptor	I-protein
beta-subunit	I-protein
in	O
eosinophils	B-cell_type
.	O

Azeptin	O
dose-dependently	O
suppressed	O
both	O
DNA	O
and	O
protein	O
synthesis	O
in	O
human	B-cell_type
gingival	I-cell_type
fibroblasts	I-cell_type
(	O
HF	B-cell_type
)	O
and	O
also	O
suppressed	O
blastogenesis	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
.	O
Generation	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
interleukin	B-protein
1-beta	I-protein
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
and	O
interleukin-6	B-protein
from	O
10	O
(	O
-5	O
)	O
M	O
Azeptin-treated	O
PBL	B-cell_type
and	O
human	B-cell_type
monocytes	I-cell_type
(	O
HM	B-cell_type
)	O
was	O
decreased	O
to	O
approximately	O
1/3	O
to	O
2/3	O
of	O
the	O
control	O
levels	O
.	O

Furthermore	O
,	O
the	O
ability	O
to	O
suppress	O
IL-1RI	O
and	O
IL-1RII	B-protein
mRNA	O
levels	O
was	O
not	O
unique	O
to	O
IFN-gamma	B-protein
because	O
IL-10	B-protein
also	O
inhibited	O
expression	O
of	O
these	O
genes	O
in	O
IL-4/IL-13-stimulated	B-cell_line
monocytes	I-cell_line
.	O

Estrogen	O
and	O
progesterone	O
induction	O
of	O
survival	O
of	O
monoblastoid	B-cell_type
cells	I-cell_type
undergoing	O
TNF-alpha	B-protein
-inuced	O
apoptosis	O
.	O

LMP1	B-protein
needs	O
only	O
11	O
amino	O
acids	O
to	O
activate	O
NF-kappaB	B-protein
or	O
synergize	O
with	O
TRADD	B-protein
in	O
NF-kappaB	B-protein
activation	O
,	O
while	O
TNFR1	B-protein
requires	O
approximately	O
70	O
residues	O
.	O

Our	O
findings	O
support	O
the	O
recently	O
determined	O
calcineurin	B-protein
X-ray	O
crystal	O
structure	O
,	O
provide	O
evidence	O
that	O
calcineurin	B-protein
is	O
the	O
only	O
CsA-sensitive	B-protein
component	I-protein
limiting	O
signaling	O
from	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
to	O
the	O
nucleus	O
,	O
and	O
suggest	O
a	O
means	O
to	O
render	O
cells	O
and	O
tissues	O
resistant	O
to	O
the	O
toxic	O
side	O
effects	O
of	O
CsA	O
and	O
FK506	O
.	O

EBV-encoded	B-protein
nuclear	I-protein
antigen	I-protein
(	I-protein
EBNA	I-protein
)	I-protein
-1	I-protein
is	O
expressed	O
,	O
whereas	O
the	O
immunogenic	O
and	O
proliferative	O
EBNAs	B-protein
are	O
not	O
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-alpha	I-protein
-induced	O
HIV-1	O
replication	O
in	O
OM10.1	B-cell_line
or	O
Ach2	B-cell_line
cells	I-cell_line
was	O
significantly	O
inhibited	O
by	O
non-cytotoxic	O
doses	O
of	O
AuTG	O
(	O
>	O
10	O
microM	O
in	O
OM10.1	O
cells	O
and	O
>	O
25	O
F.M	O
in	O
Ach2	B-cell_line
cells	I-cell_line
)	O
,	O
while	O
25	O
microM	O
of	O
the	O
counter-anion	B-protein
thioglucose	I-protein
(	O
TG	B-protein
)	O
or	O
gold	O
compound	O
containing	O
divalent	O
gold	O
ion	O
,	O
HAuCl3	O
,	O
had	O
no	O
effect	O
.	O

Androgen	O
receptor	O
blockade	O
might	O
be	O
potentiated	O
by	O
a	O
reduction	O
of	O
serum	O
androgens	O
.	O

Heterogeneous	O
expression	O
of	O
the	O
lipocalin	B-protein
NGAL	I-protein
in	O
primary	O
breast	O
cancers	O
.	O

Substitution	O
of	O
the	O
optimized	O
peptide	O
sequence	O
into	O
the	O
natural	O
calcineurin	B-protein
docking	I-protein
site	I-protein
increased	O
the	O
calcineurin	B-protein
responsiveness	O
of	O
NFAT	B-protein
.	O

In	O
addition	O
to	O
its	O
rapid	O
time	O
course	O
the	O
unique	O
characteristics	O
of	O
this	O
new	O
pathway	O
for	O
steroid	O
action	O
include	O
a	O
10000-fold	O
selectivity	O
for	O
aldosterone	O
over	O
cortisol	O
and	O
the	O
ineffectiveness	O
of	O
spironolactones	O
,	O
classical	O
mineralocorticoid	O
antagonists	O
,	O
as	O
antagonists	O
of	O
the	O
response	O
.	O

In	O
smoking	O
menopausal	O
patients	O
,	O
lymphocyte	O
infiltration	O
was	O
found	O
to	O
be	O
higher	O
than	O
in	O
non-smokers	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Previous	O
studies	O
showed	O
that	O
the	O
first	O
ATG	O
of	O
the	O
rex	B-DNA
gene	I-DNA
is	O
critical	O
for	O
Rex	B-protein
production	O
and	O
function	O
.	O

In	O
addition	O
to	O
these	O
elements	O
,	O
we	O
identified	O
a	O
second	O
regulatory	B-DNA
element	I-DNA
,	O
the	O
N	B-DNA
element	I-DNA
with	O
the	O
sequence	O
5'-GGAACCTCCCCC-3'	O
.	O

The	O
M-CSF	B-protein
receptor	I-protein
was	O
first	O
detectable	O
in	O
the	O
myeloid-committed	B-cell_line
CD34+Thy-l-CD45RA+	I-cell_line
subset	I-cell_line
.	O

The	O
CD2	B-protein
T	I-protein
lymphocyte	I-protein
glycoprotein	I-protein
surface	I-protein
molecule	I-protein
mediates	O
both	O
cell	O
to	O
cell	O
adhesion	O
and	O
T	O
cell	O
activation	O
,	O
two	O
processes	O
that	O
are	O
involved	O
in	O
the	O
spread	O
of	O
HIV	O
infection	O
.	O

Exposing	O
HUVECs	B-cell_line
to	O
A/R	O
induces	O
an	O
increase	O
in	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
in	O
HUVEC	O
nuclei	O
within	O
4	O
hours	O
.	O

The	O
GH-induced	O
inhibitory	O
effect	O
was	O
also	O
observed	O
using	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
and	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
.	O

c-Fos	B-protein
and	O
c-Jun	B-protein
are	O
also	O
found	O
in	O
this	O
CD28RE/AP-1-specific	B-protein
complex	I-protein
.	O

Genetic	O
characterization	O
of	O
transactivation	O
of	O
the	O
human	B-DNA
T-cell	I-DNA
leukemia	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
promoter	I-DNA
:	O
Binding	O
of	O
Tax	B-protein
to	O
Tax-responsive	B-DNA
element	I-DNA
1	I-DNA
is	O
mediated	O
by	O
the	O
cyclic	B-protein
AMP-responsive	I-protein
members	I-protein
of	O
the	O
CREB/ATF	B-protein
family	I-protein
of	O
transcription	O
factors	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
CD40	B-protein
-mediated	O
cell	O
survival	O
proceeds	O
through	O
NF-kappaB	B-protein
-dependent	O
up-regulation	O
of	O
Bcl-2	B-protein
family	I-protein
members	I-protein
.	O

METHODS	O
:	O
Protein	O
production	O
in	O
supernatants	O
was	O
assessed	O
by	O
ELISA	O
,	O
and	O
mRNA	B-RNA
expression	O
was	O
evaluated	O
by	O
semiquantitative	O
RT-PCR	O
.	O

Crossreactive	O
recognition	O
of	O
viral	O
,	O
self	O
,	O
and	O
bacterial	O
peptide	O
ligands	O
by	O
human	B-cell_type
class	I-cell_type
I-restricted	I-cell_type
cytotoxic	I-cell_type
T	I-cell_type
lymphocyte	I-cell_type
clonotypes	I-cell_type
:	I-cell_type
implications	O
for	O
molecular	O
mimicry	O
in	O
autoimmune	O
disease	O
.	O

The	O
role	O
of	O
interleukin-11	B-protein
(	O
IL-11	B-protein
)	O
was	O
evaluated	O
in	O
the	O
IgG	B-protein
immune	I-protein
complex	I-protein
model	O
of	O
acute	O
lung	O
injury	O
in	O
rats	O
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
NFAT	B-DNA
binding	I-DNA
site	I-DNA
is	O
mediated	O
by	O
a	O
complex	O
comprising	O
a	O
member	O
of	O
the	O
NFAT	B-protein
group	O
and	O
AP-1	B-protein
family	I-protein
proteins	I-protein
.	O

Human	O
T	O
cell	O
leukemia	O
virus-I	O
(	O
HTLV-I	O
)	O
Tax	B-protein
-mediated	O
apoptosis	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
requires	O
an	O
enhanced	O
intracellular	O
prooxidant	O
state	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
a	O
novel	O
Ets-related	B-protein
transcription	I-protein
factor	I-protein
,	O
Elf-1	B-protein
,	O
binds	O
specifically	O
to	O
two	B-DNA
purine-rich	I-DNA
motifs	I-DNA
in	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
.	O

This	O
region	O
binds	O
an	O
inducible	O
,	O
T-cell-specific	B-protein
factor	I-protein
over	O
its	O
5	B-DNA
'	I-DNA
end	I-DNA
,	O
a	O
site	O
that	O
is	O
necessary	O
for	O
the	O
expression	O
of	O
IL-3	B-protein
in	O
the	O
absence	O
of	O
other	O
upstream	O
elements	O
.	O

In	O
unstimulated	O
THP-1	B-cell_line
,	O
CRE-binding	B-protein
protein	I-protein
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
c-Jun	B-protein
complexes	I-protein
were	O
found	O
to	O
bind	O
to	O
the	O
CRE	B-DNA
site	I-DNA
.	O

We	O
found	O
that	O
this	O
latently	O
infected	O
cell	O
line	O
with	O
heat	O
shock	O
at	O
42	O
degrees	O
C	O
for	O
2	O
h	O
resulted	O
in	O
a	O
high	O
level	O
of	O
HIV-1	O
production	O
without	O
addition	O
of	O
any	O
cytokines	B-protein
.	O

Eosinophils	B-cell_type
infiltrating	O
hamster	O
cutaneous	O
wounds	O
were	O
found	O
to	O
express	O
TGFs	B-protein
sequentially	O
.	O

Capacitance	O
would	O
simply	O
involve	O
expression	O
of	O
IL-12R	B-protein
beta	I-protein
1	I-protein
and	I-protein
beta	I-protein
2	I-protein
subunits	I-protein
,	O
regulated	O
by	O
TCR	O
,	O
IL-4	B-protein
and	O
IFNs	B-protein
.	O

Pretreatment	O
of	O
PBMCs	B-cell_type
with	O
pertussis	B-protein
toxin	I-protein
blocked	O
the	O
functions	O
of	O
C3a	B-protein
and	O
C3a	B-protein
(	I-protein
desArg	I-protein
)	I-protein
,	O
indicating	O
that	O
the	O
actions	O
of	O
these	O
two	O
molecules	O
are	O
mediated	O
by	O
a	O
G	B-protein
protein	I-protein
-coupled	O
pathway	O
.	O

Human	B-DNA
IL4	I-DNA
promoter	I-DNA
-mediated	O
transcription	O
is	O
downregulated	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
stimulated	O
with	O
the	O
NF-kappa	B-protein
B-activating	I-protein
cytokine	I-protein
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
and	O
suppressed	O
in	O
RelA-overexpressing	B-cell_line
cells	I-cell_line
.	O

PROBLEM	O
:	O
Due	O
to	O
the	O
lack	O
of	O
classical	B-protein
HLA	I-protein
antigens	I-protein
on	O
the	O
trophoblast	O
,	O
fetal	B-protein
antigens	I-protein
are	O
possibly	O
presented	O
in	O
a	O
non	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	O
MHC	B-protein
)	O
restricted	O
way	O
.	O

Moreover	O
,	O
EGF	O
treatment	O
induced	O
Stat3	B-protein
phosphorylation	O
in	O
cells	O
transfected	O
with	O
the	O
intact	O
chimeric	B-protein
EGF-gp130	I-protein
receptor	I-protein
along	O
with	O
induction	O
of	O
DNA-mobility	O
shift	O
of	O
a	O
classical	B-DNA
interferon-gamma-activated	I-DNA
site	I-DNA
.	O

These	O
simian	O
EBV	O
share	O
considerable	O
genetic	O
,	O
biologic	O
,	O
and	O
epidemiologic	O
features	O
with	O
human	O
EBV	O
,	O
including	O
virus-induced	O
tumorigenesis	O
.	O

To	O
delineate	O
the	O
regulatory	O
mechanisms	O
of	O
human	O
IL-5	B-protein
synthesis	O
,	O
we	O
established	O
allergen-specific	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
from	O
asthmatic	O
patients	O
.	O

Thus	O
,	O
our	O
data	O
establish	O
that	O
ATF/CREB	B-protein
factors	I-protein
functionally	O
modulate	O
histone	B-DNA
H4	I-DNA
gene	I-DNA
transcription	O
at	O
distal	B-DNA
and	I-DNA
proximal	I-DNA
promoter	I-DNA
elements	I-DNA
.	O

Interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
is	O
exclusively	O
expressed	O
by	O
activated	B-cell_type
T	I-cell_type
and	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
,	O
a	O
function	O
that	O
is	O
tightly	O
controlled	O
both	O
in	O
a	O
lineage-specific	O
and	O
in	O
a	O
stimulation-dependent	O
manner	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
IL-10	B-protein
on	O
the	O
activation	O
of	O
HIV-1	O
from	O
infected	B-cell_type
monocytes	I-cell_type
and	O
macrophages	B-cell_type
.	O

The	O
BCL6	B-DNA
gene	I-DNA
encodes	O
a	O
95-kDa	B-protein
protein	I-protein
containing	O
six	O
C-terminal	B-protein
zinc-finger	I-protein
motifs	I-protein
and	O
an	O
N-terminal	B-protein
POZ	I-protein
domain	I-protein
,	O
suggesting	O
that	O
it	O
may	O
function	O
as	O
a	O
transcription	B-protein
factor	I-protein
.	O

This	O
40-kDa	O
polypeptide	O
is	O
able	O
to	O
interact	O
with	O
the	O
tumor	B-protein
suppressor	I-protein
p16	B-protein
(	I-protein
INK4A	I-protein
)	I-protein
.	O

The	O
ability	O
to	O
induce	O
anergy	O
in	O
antigen-specific	B-cell_type
T	I-cell_type
cells	I-cell_type
has	O
potential	O
therapeutic	O
value	O
for	O
altering	O
pathologic	O
immune	O
responses	O
.	O

In	O
addition	O
,	O
the	O
transcription	B-protein
factor	I-protein
Stat-3	B-protein
was	O
tyrosine	O
phosphorylated	O
in	O
the	O
cytoplasm	O
and	O
subsequently	O
translocated	O
to	O
the	O
cell	O
nucleus	O
.	O

Addition	O
of	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
the	O
octamer	B-DNA
consensus	I-DNA
to	O
Jurkat	B-cell_line
T	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
inhibited	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
secretion	O
to	O
a	O
degree	O
similar	O
to	O
that	O
observed	O
with	O
a	O
mutated	B-DNA
octamer	I-DNA
site	I-DNA
in	O
the	O
IL-2	B-DNA
enhancer	I-DNA
.	O

No	O
NF-IL-6	B-protein
binding	O
activity	O
was	O
detected	O
in	O
the	O
same	O
nuclear	O
extracts	O
.	O

The	O
T3	O
-group	O
showed	O
no	O
change	O
in	O
MBC	O
over	O
the	O
study	O
.	O

Further	O
evidence	O
suggests	O
that	O
Nef	B-protein
inhibits	O
NF-kappa	B-protein
B	I-protein
induction	O
by	O
interfering	O
with	O
a	O
signal	O
derived	O
from	O
the	O
T-cell	B-protein
receptor	I-protein
complex	I-protein
.	O

Dissociation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
from	O
Ig	B-protein
kappa	I-protein
B	I-protein
by	O
cytokine	O
and	O
LPS	O
stimulation	O
,	O
and	O
possibly	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
may	O
represent	O
a	O
common	O
pathway	O
to	O
induction	O
of	O
the	O
TF	B-DNA
and	I-DNA
other	I-DNA
inflammatory	I-DNA
genes	I-DNA
.	O

Downregulation	O
of	O
Wilms	B-DNA
'	I-DNA
tumor	I-DNA
gene	I-DNA
(	O
WT1	B-DNA
)	O
is	O
not	O
a	O
prerequisite	O
for	O
erythroid	O
or	O
megakaryocytic	O
differentiation	O
of	O
the	O
leukemic	B-cell_line
cell	I-cell_line
line	I-cell_line
K562	I-cell_line
.	O

Moderate	O
body	O
mass	O
,	O
relatively	O
low	O
fat	O
level	O
and	O
positive	O
receptor	O
status	O
are	O
among	O
factors	O
of	O
good	O
prognosis	O
in	O
breast	O
cancer	O
of	O
early	O
stages	O
.	O

Although	O
the	O
intact	O
beta	B-DNA
interferon	I-DNA
promoter	I-DNA
was	O
only	O
weakly	O
stimulated	O
by	O
phorbol	O
ester	O
or	O
TNF-alpha	B-protein
,	O
multimers	O
of	O
the	O
PRDII	B-DNA
NF-kappa	I-DNA
B-binding	I-DNA
domain	I-DNA
were	O
inducible	O
by	O
both	O
agents	O
.	O

Anti-CD2	B-protein
receptor	I-protein
antibodies	I-protein
activate	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Finally	O
,	O
recombinant	O
GHF-1	B-protein
interacted	O
directly	O
with	O
c-Jun	B-protein
but	O
not	O
c-Fos	B-protein
proteins	I-protein
.	O

Cotransfection	O
studies	O
with	O
this	O
cDNA	B-DNA
indicate	O
that	O
it	O
can	O
repress	O
basal	B-DNA
promoter	I-DNA
activity	O
.	O

Indeed	O
,	O
IL-10	B-protein
,	O
like	O
IFN-gamma	B-protein
,	O
was	O
able	O
to	O
significantly	O
reduce	O
the	O
amount	O
of	O
B-CLL	O
cell	O
death	O
caused	O
by	O
hydrocortisone-induced	O
apoptosis	O
.	O

Neutrophils	O
pretreated	O
with	O
NH2Cl	O
(	O
30-50	O
microM	O
)	O
showed	O
a	O
marked	O
decrease	O
in	O
the	O
respiratory	O
burst	O
activity	O
induced	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
which	O
is	O
a	O
potent	O
PKC	B-protein
activator	O
.	O

PMA	O
and	O
TNF	B-protein
alpha	I-protein
induced	O
activation	O
of	O
(	B-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
in	O
human	O
Jurkat	B-cell_line
T-cells	I-cell_line
was	O
partially	O
inhibited	O
by	O
ADT	O
(	O
0.1	O
mM	O
)	O
pretreatment	O
.	O

Blood	O
samples	O
were	O
obtained	O
prior	O
to	O
the	O
injection	O
and	O
at	O
1	O
,	O
2	O
,	O
4	O
,	O
8	O
and	O
24	O
hr	O
after	O
the	O
injection	O
.	O

The	O
E2A-HLF	B-DNA
fusion	I-DNA
gene	I-DNA
,	O
generated	O
by	O
t	B-DNA
(	I-DNA
17	I-DNA
;	I-DNA
19	I-DNA
)	I-DNA
(	I-DNA
q22	I-DNA
;	I-DNA
p13	I-DNA
)	I-DNA
in	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
,	O
encodes	O
a	O
chimeric	B-protein
transcription	I-protein
factor	I-protein
in	O
which	O
the	O
trans-activating	B-protein
domains	I-protein
of	O
E2A	B-protein
are	O
fused	O
to	O
the	O
DNA-	B-protein
binding	I-protein
and	I-protein
dimerization	I-protein
domains	I-protein
of	O
hepatic	B-protein
leukemic	I-protein
factor	I-protein
(	O
HLF	B-protein
)	O
.	O

[	O
The	O
value	O
of	O
the	O
clinical	O
test	O
of	O
glucocorticoid	B-protein
receptors	I-protein
of	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
in	O
patients	O
with	O
chronic	O
pulmonary	O
heart	O
disease	O
]	O

Enhancement	O
of	O
HIV-1	O
replication	O
is	O
related	O
in	O
part	O
to	O
increased	O
DNA-binding	O
activity	O
of	O
cellular	B-protein
transcription	I-protein
factors	I-protein
such	O
as	O
NF-kappa	B-protein
B	I-protein
.	O

Our	O
findings	O
also	O
suggest	O
one	O
possible	O
immunological	O
variable	O
involved	O
,	O
with	O
potential	O
clinical	O
significance	O
,	O
for	O
this	O
patient	O
population	O
.	O

Disturbance	O
of	O
both	O
the	O
immune	O
surveillance	O
as	O
well	O
as	O
viral	B-DNA
gene	I-DNA
regulation	O
may	O
result	O
in	O
EBV-associated	O
disease	O
.	O

In	O
addition	O
,	O
we	O
identified	O
a	O
novel	O
E2F-like	B-DNA
sequence	I-DNA
in	O
human	B-DNA
MCM6	I-DNA
promoter	I-DNA
which	O
cooperates	O
with	O
the	O
authentic	O
E2F	B-DNA
sites	I-DNA
in	O
E2F	B-protein
-dependent	O
regulation	O
.	O

The	O
IL-4	B-protein
receptor	I-protein
alpha-chain	I-protein
cytoplasmic	I-protein
domain	I-protein
is	O
sufficient	O
for	O
activation	O
of	O
JAK-1	B-protein
and	O
STAT6	B-protein
and	O
the	O
induction	O
of	O
IL-4	B-protein
-specific	O
gene	O
expression	O
.	O

3	O
.	O

Estrone	O
potentiates	O
myeloid	O
cell	O
differentiation	O
:	O
a	O
role	O
for	O
17	B-protein
beta-hydroxysteroid	I-protein
dehydrogenase	I-protein
in	O
modulating	O
hemopoiesis	O
.	O

Establishment	O
and	O
characterization	O
of	O
EBV-positive	B-cell_line
and	I-cell_line
EBV-negative	I-cell_line
primary	I-cell_line
effusion	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
harbouring	O
human	O
herpesvirus	O
type-8	O
.	O

A	O
nongenomic	O
mechanism	O
for	O
progesterone-mediated	O
immunosuppression	O
:	O
inhibition	O
of	O
K+	B-protein
channels	I-protein
,	O
Ca2+	O
signaling	O
,	O
and	O
gene	O
expression	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

The	O
different	O
response	O
of	O
myeloid	O
cells	O
ectopically	O
expressing	O
the	O
normal	O
or	O
the	O
fusion	B-protein
protein	I-protein
to	O
G-CSF	B-protein
and	O
TGF-beta1	B-protein
could	O
depend	O
on	O
the	O
different	O
transactivation	O
properties	O
of	O
these	O
proteins	O
resulting	O
in	O
divergent	O
expression	O
of	O
downstream	B-DNA
genes	I-DNA
regulated	O
by	O
the	O
two	O
proteins	O
.	O

NF-kappa	B-protein
B	I-protein
controls	O
expression	O
of	O
inhibitor	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
:	O
evidence	O
for	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

The	O
mutation	O
may	O
have	O
implications	O
for	O
some	O
physiological	O
roles	O
of	O
DARC	B-protein
and	O
be	O
of	O
interest	O
in	O
malaria	O
research	O
and	O
in	O
studies	O
of	O
population	O
genetics	O
.	O

No	O
difference	O
in	O
plasma	O
cortisol	O
was	O
found	O
between	O
the	O
patients	O
and	O
the	O
healthy	O
subjects	O
(	O
P	O
>	O
0.05	O
)	O
.	O

RNase	B-protein
treatment	O
prior	O
to	O
hybridization	O
considerably	O
reduces	O
the	O
size	O
of	O
this	O
signals	O
.	O

In	O
all	O
cell	B-cell_line
lines	I-cell_line
where	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
binding	O
to	O
a	O
receptor	B-protein
was	O
detectable	O
,	O
the	O
receptor	B-protein
had	O
the	O
typical	O
sedimentation	O
coefficient	O
of	O
3.7	O
S	O
on	O
sucrose	O
density	O
gradient	O
analysis	O
.	O

Further	O
results	O
,	O
in	O
which	O
beta-gal	B-protein
activity	O
is	O
correlated	O
with	O
NF-AT	B-protein
-binding	O
activity	O
,	O
indicate	O
that	O
the	O
concentration	O
of	O
NF-AT	B-protein
must	O
exceed	O
a	O
critical	O
threshold	O
before	O
transcription	O
initiates	O
.	O

Thus	O
,	O
the	O
transcriptional	O
activity	O
of	O
TCF-1	B-protein
alpha	I-protein
appears	O
to	O
depend	O
on	O
the	O
TCF-2	B-protein
alpha	I-protein
and	O
T	B-protein
alpha	I-protein
1	I-protein
(	O
CREB	B-protein
)	O
transcription	B-protein
factors	I-protein
and	O
the	O
context	O
of	O
its	O
binding	O
site	O
within	O
the	O
TCR	B-DNA
alpha	I-DNA
enhancer	I-DNA
.	O

Activation	O
and	O
expression	O
of	O
the	O
nuclear	B-protein
factors	I-protein
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
NFATp	B-protein
and	O
NFATc	B-protein
,	O
in	O
human	B-cell_type
natural	I-cell_type
killer	I-cell_type
cells	I-cell_type
:	O
regulation	O
upon	O
CD16	B-protein
ligand	O
binding	O
.	O

Regulation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
and	O
its	O
inhibitor	O
I	B-protein
kappa	I-protein
B-alpha/MAD-3	I-protein
in	O
monocytes	B-cell_type
by	O
Mycobacterium	O
tuberculosis	O
and	O
during	O
human	O
tuberculosis	O
.	O

In	O
the	O
transgenic	O
mice	O
,	O
all	O
the	O
lymphoid	O
tissues	O
examined	O
showed	O
a	O
dramatic	O
reduction	O
in	O
the	O
number	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
(	O
B	B-cell_type
cells	I-cell_type
)	O
.	O

We	O
review	O
the	O
control	O
of	O
expression	O
of	O
the	O
Tissue	B-DNA
Factor	I-DNA
(	I-DNA
TF	I-DNA
)	I-DNA
gene	I-DNA
and	O
the	O
function	O
of	O
the	O
TF	B-protein
protein	I-protein
.	O

Modulation	O
of	O
the	O
expression	O
of	O
the	O
IFN-gamma	B-protein
receptor	I-protein
beta-chain	I-protein
controls	O
responsiveness	O
to	O
IFN-gamma	B-protein
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Human	O
cytomegalovirus	O
induces	O
interleukin-8	B-protein
production	O
by	O
a	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
THP-1	B-cell_line
,	O
through	O
acting	O
concurrently	O
on	O
AP-1-	B-DNA
and	I-DNA
NF-kappaB-binding	I-DNA
sites	I-DNA
of	O
the	O
interleukin-8	B-DNA
gene	I-DNA
.	O

Both	O
drugs	O
dose-dependently	O
inhibited	O
LPS-induced	B-protein
TF	I-protein
and	O
TNF-alpha	B-protein
synthesis	O
at	O
the	O
mRNA	B-RNA
and	O
the	O
protein	O
level	O
,	O
and	O
reduced	O
PGE2	B-protein
production	O
.	O

The	O
MHC	B-protein
class	I-protein
II	I-protein
homologous	I-protein
proteins	I-protein
HLA-DMA	B-protein
and	O
HLA-DMB	B-protein
function	O
in	O
the	O
loading	O
of	O
peptides	O
onto	O
class	B-protein
II	I-protein
molecules	I-protein
.	O

Conserved	O
upstream	O
promoter	O
sequences	O
regulate	O
this	O
tissue-specific	O
expression	O
of	O
class	B-DNA
II	I-DNA
genes	I-DNA
.	O

These	O
findings	O
support	O
the	O
conclusion	O
that	O
the	O
interaction	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
with	O
its	O
receptor	O
on	O
T-lymphocytes	B-cell_type
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
granulomatous	O
reactions	O
,	O
but	O
because	O
these	O
receptors	O
are	O
expressed	O
on	O
different	O
lymphocyte	B-cell_type
populations	I-cell_type
,	O
the	O
net	O
effect	O
of	O
this	O
potent	O
immunoregulatory	B-protein
molecule	I-protein
is	O
likely	O
different	O
in	O
sarcoidosis	O
and	O
tuberculosis	O
.	O

Transcriptional	O
control	O
by	O
META	B-DNA
parallels	O
that	O
of	O
several	O
lymphokine	B-DNA
genes	I-DNA
,	O
being	O
specific	O
to	O
T	B-cell_type
cells	I-cell_type
,	O
dependent	O
on	O
their	O
activation	O
,	O
and	O
inhibited	O
by	O
the	O
immunosuppressive	O
drug	O
cyclosporine	O
(	O
CsA	O
)	O
.	O

We	O
investigated	O
the	O
regulation	O
of	O
thymidine	B-protein
kinase	I-protein
in	O
phytohemagglutinin-stimulated	B-cell_line
normal	I-cell_line
human	I-cell_line
lymphocytes	I-cell_line
and	O
in	O
the	O
p16-negative	B-cell_line
human	I-cell_line
acute	I-cell_line
lymphoblastic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
MOLT-4	B-cell_line
and	O
CEM	B-cell_line
.	O

Strains	O
with	O
mutations	O
in	O
either	O
gene	O
of	O
the	O
regulatory	B-DNA
pair	I-DNA
(	O
phoP	B-DNA
[	O
transcriptional	B-DNA
activator	I-DNA
]	O
or	O
phoQ	B-DNA
[	O
membrane	B-protein
sensor	I-protein
kinase	I-protein
]	O
)	O
had	O
increased	O
sensitivities	O
to	O
defensin	B-protein
.	O

Unlike	O
full-sized	O
NOTCH1	B-protein
,	O
two	O
such	O
truncated	O
forms	O
of	O
the	O
protein	O
either	O
lacking	O
a	O
major	O
portion	O
of	O
the	O
extracellular	B-protein
domain	I-protein
(	O
DeltaE	B-protein
)	O
or	O
consisting	O
only	O
of	O
the	O
intracellular	B-protein
domain	I-protein
(	O
ICN	B-protein
)	O
were	O
found	O
to	O
activate	O
transcription	O
in	O
cultured	O
cells	O
,	O
presumably	O
through	O
RBP-Jkappa	B-protein
response	O
elements	O
within	O
DNA	O
.	O

Distinctive	O
gene	O
expression	O
patterns	O
in	O
human	B-cell_type
mammary	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
and	O
breast	O
cancers	O
.	O

In	O
this	O
study	O
,	O
we	O
propose	O
a	O
novel	O
function	O
for	O
CD44	O
.	O

Transcription	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type-1	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
genome	I-DNA
is	O
regulated	O
in	O
part	O
by	O
cellular	B-protein
factors	I-protein
and	O
is	O
stimulated	O
by	O
activation	O
of	O
latently	B-cell_type
infected	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Neuronal	B-protein
(	I-protein
type	I-protein
I	I-protein
)	I-protein
nitric	I-protein
oxide	I-protein
synthase	I-protein
regulates	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
activity	O
and	O
immunologic	B-protein
(	I-protein
type	I-protein
II	I-protein
)	I-protein
nitric	I-protein
oxide	I-protein
synthase	I-protein
expression	O
.	O

Mononuclear	B-cell_type
phagocytes	I-cell_type
play	O
an	O
important	O
role	O
in	O
atherosclerosis	O
and	O
its	O
sequela	O
plaque	O
rupture	O
in	O
part	O
by	O
their	O
secretion	O
of	O
matrix	B-protein
metalloproteinases	I-protein
(	O
MMPs	B-protein
)	O
,	O
including	O
MMP-9	B-protein
.	O

These	O
results	O
suggest	O
that	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
are	O
exposed	O
to	O
oxidative	O
stress-inducing	O
signals	O
during	O
delivery	O
and/or	O
are	O
inherently	O
more	O
sensitive	O
to	O
NF-kappa	B-protein
B	I-protein
activating	O
signals	O
than	O
adult	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

We	O
have	O
demonstrated	O
that	O
the	O
cross-linking	O
of	O
cell	B-protein
surface	I-protein
CD4	I-protein
by	O
gp120-anti-gp120	B-protein
immune	I-protein
complexes	I-protein
or	O
heat-inactivated	O
HIV-1	O
(	O
iHIV-1	O
)	O
is	O
sufficient	O
to	O
trigger	O
activation	O
signals	O
leading	O
to	O
virus	O
reactivation	O
(	O
9	O
)	O
.	O

Morphological	O
studies	O
demonstrated	O
characteristic	O
features	O
of	O
erythroid	O
differentiation	O
and	O
maturation	O
.	O

Here	O
we	O
report	O
that	O
sustained	O
high	O
concentrations	O
of	O
Ca2+	O
,	O
but	O
not	O
transient	O
pulses	O
,	O
are	O
required	O
to	O
maintain	O
NF-AT	B-protein
transcription	B-protein
factors	I-protein
in	O
the	O
nucleus	O
,	O
where	O
they	O
participate	O
in	O
Ca2+-dependent	O
induction	O
of	O
genes	B-DNA
required	O
for	O
lymphocyte	B-cell_type
activation	O
and	O
proliferation	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
a	O
third	O
component	O
is	O
necessary	O
for	O
gene	O
activation	O
and	O
that	O
this	O
third	O
component	O
may	O
vary	O
with	O
cell	O
type	O
.	O

Epstein-Barr	O
virus	O
latent	B-protein
membrane	I-protein
protein-1	I-protein
triggers	O
AP-1	B-protein
activity	O
via	O
the	O
c-Jun	B-protein
N-terminal	O
kinase	O
cascade	O
.	O

This	O
may	O
occur	O
through	O
the	O
ability	O
of	O
IL-10	B-protein
to	O
induce	O
expression	O
of	O
the	O
gene	O
,	O
suppressor	O
of	O
cytokine	B-protein
signaling	I-protein
3	I-protein
(	O
SOCS3	B-protein
)	O
.	O

3	O
)	O
In	O
Cushing	O
's	O
syndrome	O
,	O
the	O
CR	O
of	O
GR	B-protein
was	O
normal	O
in	O
spite	O
of	O
the	O
fact	O
that	O
the	O
CR	O
of	O
plasma	O
cortisol	O
was	O
disturbed	O
.	O

Selective	O
expression	O
of	O
an	O
interleukin-12	B-protein
receptor	I-protein
component	I-protein
by	O
human	B-cell_type
T	I-cell_type
helper	I-cell_type
1	I-cell_type
cells	I-cell_type
.	O

The	O
amino	B-protein
terminus	I-protein
contains	O
an	O
unusual	O
repeat	O
of	O
38	O
consecutive	O
glutamine	O
residues	O
and	O
an	O
X-Thr-Pro	B-protein
repeat	I-protein
.	O

Tyloxapol	O
(	O
0.05	O
to	O
0.1	O
%	O
wt/vol	O
)	O
effectively	O
scavenges	O
the	O
oxidant	O
hypochlorous	O
acid	O
(	O
HOCl	O
;	O
1	O
to	O
7.5	O
mM	O
)	O
in	O
vitro	O
,	O
and	O
protects	O
from	O
HOCl-mediated	O
lung	O
injury	O
in	O
rats	O
.	O

We	O
also	O
discuss	O
our	O
recent	O
findings	O
that	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
IFNs	I-protein
suppress	O
IL-4	B-protein
/	O
IL-13	B-protein
-inducible	O
gene	O
expression	O
by	O
inhibiting	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
STAT6	B-protein
.	O

Subsequent	O
cloning	O
of	O
TCF-1	B-protein
identified	O
three	O
splice	B-protein
alternatives	I-protein
.	O

Regulation	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
:	O
effects	O
of	O
glucocorticoid	O
treatment	O
,	O
Cushing	O
's	O
disease	O
and	O
ketoconazole	O
.	O

Interleukin-1	B-protein
beta	I-protein
(	O
IL-1beta	B-protein
)	O
is	O
one	O
of	O
the	O
most	O
important	O
inflammatory	B-protein
mediators	I-protein
in	O
human	O
inflammatory	O
and	O
immunological	O
diseases	O
.	O

It	O
had	O
previously	O
been	O
thought	O
that	O
ZEBRA	B-protein
's	O
capacity	O
to	O
disrupt	O
EBV	O
latency	O
resided	O
primarily	O
in	O
its	O
ability	O
to	O
activate	O
transcription	O
of	O
genes	O
that	O
encode	O
products	O
required	O
for	O
lytic	O
replication	O
.	O

The	O
human	B-DNA
IL-16	I-DNA
gene	I-DNA
consists	O
of	O
seven	O
exons	B-DNA
and	O
six	O
introns	B-DNA
.	O

The	O
effects	O
mediated	O
by	O
a	O
combined	O
stimulation	O
of	O
cAMP	O
-and	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
-dependent	O
pathways	O
have	O
been	O
investigated	O
in	O
different	O
cellular	O
systems	O
,	O
and	O
it	O
has	O
been	O
shown	O
that	O
they	O
may	O
complement	O
each	O
other	O
in	O
activating	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

The	O
human	B-protein
T	I-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
TCF-1	B-protein
alpha	I-protein
plays	O
a	O
key	O
role	O
in	O
the	O
tissue-specific	O
activation	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
C	O
alpha	O
enhancer	O
and	O
binds	O
to	O
pyrimidine-rich	B-DNA
elements	I-DNA
(	O
5'-PyCTTTG-3	O
'	O
)	O
present	O
in	O
a	O
variety	O
of	O
other	O
T	B-DNA
cell-specific	I-DNA
control	I-DNA
regions	I-DNA
.	O

Hepatic	B-cell_type
microsomes	I-cell_type
and	O
isolated	B-cell_type
hepatocytes	I-cell_type
in	O
short	O
term	O
culture	O
desulfate	O
T3	O
sulfate	O
(	O
T3SO4	O
)	O
.	O

Given	O
the	O
reported	O
long-range	O
cis-inactivating	O
effect	O
of	O
the	O
XIST	B-DNA
gene	I-DNA
in	O
early	O
embryonic	O
development	O
and	O
the	O
lack	O
of	O
requirement	O
of	O
X-chromosome-specific	B-DNA
elements	I-DNA
for	O
propagating	O
the	O
inactive	O
state	O
,	O
there	O
exists	O
the	O
possibility	O
of	O
cis	O
inactivation	O
of	O
autosomal	O
material	O
after	O
de	O
novo	O
translocation	O
to	O
an	O
inactive	B-DNA
X	I-DNA
chromosome	I-DNA
(	O
Xi	B-DNA
)	O
in	O
differentiated	B-cell_type
cells	I-cell_type
.	O

At	O
high	O
concentration	O
of	O
NE	O
,	O
all	O
of	O
the	O
TR	B-protein
bound	O
to	O
TREp	B-DNA
was	O
more	O
greatly	O
retarded	O
than	O
in	O
the	O
absence	O
of	O
NE	O
.	O

We	O
propose	O
that	O
a	O
generally	O
permissive	O
enhancer/	O
promoter	B-DNA
interaction	O
is	O
of	O
evolutionary	O
benefit	O
for	O
higher	O
eukaryotes	O
:	O
by	O
enhancer	O
shuffling	O
,	O
genes	O
could	O
be	O
easily	O
brought	O
under	O
a	O
new	O
type	O
of	O
inducibility/cell	O
type	O
specificity	O
.	O

Kinase	O
activity	O
was	O
reduced	O
in	O
lysates	O
preadsorbed	O
using	O
an	O
antibody	B-protein
specific	O
for	O
CaM	B-protein
kinase	I-protein
II	I-protein
.	O

To	O
further	O
define	O
the	O
effects	O
of	O
dexamethasone	O
at	O
the	O
molecular	O
level	O
,	O
we	O
prepared	O
a	O
series	O
of	O
deleted	O
c-jun	B-DNA
promoter	I-DNA
fragments	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
gene	I-DNA
.	O

Phosphatidylinositides	O
bind	O
to	O
plasma	B-protein
membrane	I-protein
CD14	I-protein
and	O
can	O
prevent	O
monocyte	O
activation	O
by	O
bacterial	O
lipopolysaccharide	O
.	O

RARs	B-protein
and	O
RXRs	B-protein
form	O
heterodimers	B-protein
and	O
regulate	O
retinoid-mediated	O
gene	O
expression	O
.	O

TIMP-1	B-protein
suppression	O
of	O
PCD	O
is	O
not	O
due	O
to	O
metalloproteinase	B-protein
inhibition	O
,	O
as	O
reduction	O
and	O
alkylation	O
of	O
the	O
TIMP-1	B-protein
did	O
not	O
abolish	O
this	O
activity	O
.	O

Elevated	O
cyclic	O
AMP	O
inhibits	O
NF-kappaB	B-protein
-mediated	O
transcription	O
in	O
human	O
monocytic	O
cells	O
and	O
endothelial	O
cells	O
.	O

Uneven	O
X	B-DNA
inactivation	O
in	O
a	O
female	O
monozygotic	O
twin	O
pair	O
with	O
Fabry	O
disease	O
and	O
discordant	O
expression	O
of	O
a	O
novel	O
mutation	O
in	O
the	O
alpha-galactosidase	B-DNA
A	I-DNA
gene	I-DNA
.	O

CD23	B-protein
expression	O
and	O
IgE	B-protein
synthesis	O
by	O
IL-4	B-protein
were	O
augmented	O
in	O
Ile50-bearing	B-cell_line
PBMC	I-cell_line
,	O
compared	O
with	O
those	O
bearing	O
Val50	O
.	O

Here	O
we	O
report	O
that	O
human	B-cell_type
leukaemia	I-cell_type
cells	I-cell_type
carrying	O
the	O
translocation	O
t	B-DNA
(	I-DNA
17	I-DNA
;	I-DNA
19	I-DNA
)	I-DNA
rapidly	O
died	O
by	O
apoptosis	O
when	O
programmed	O
to	O
express	O
a	O
dominant-negative	O
suppressor	O
of	O
the	O
fusion	O
protein	O
E2A-HLF	B-protein
,	O
indicating	O
that	O
the	O
chimaeric	B-protein
oncoprotein	I-protein
probably	O
affects	O
cell	O
survival	O
rather	O
than	O
cell	O
growth	O
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
a	O
human	O
herpesvirus	O
which	O
latently	O
infects	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

Previous	O
studies	O
have	O
identified	O
H-7-sensitive	O
kinase	O
pathways	O
that	O
regulate	O
STAT3	B-protein
DNA	O
binding	O
.	O

B	B-cell_type
lymphocytes	I-cell_type
from	O
the	O
peripheral	O
blood	O
of	O
patients	O
with	O
chronic	O
lymphocytic	O
leukaemia	O
(	O
CLL	O
)	O
were	O
analysed	O
for	O
the	O
nuclear	O
presence	O
and	O
DNA	O
binding	O
of	O
a	O
panel	O
of	O
transcription	B-protein
factors	I-protein
which	O
are	O
involved	O
in	O
the	O
gene	O
control	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

The	O
second	O
(	O
-365/-264	O
)	O
binds	O
to	O
nuclear	B-protein
factors	I-protein
,	O
which	O
appear	O
to	O
be	O
different	O
in	O
basophils	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
,	O
and	O
acts	O
as	O
a	O
negative	O
element	O
in	O
basophils	B-cell_type
and	O
as	O
a	O
positive	O
one	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Role	O
for	O
a	O
novel	O
5	B-DNA
'	I-DNA
palindromic	I-DNA
octamer	I-DNA
sequence	I-DNA
.	O

That	O
the	O
signal	O
transduction	O
pathways	O
used	O
by	O
the	O
cytokines	B-protein
IL-2	B-protein
and	O
IL-15	B-protein
are	O
identical	O
would	O
suggest	O
that	O
these	O
cytokines	B-protein
have	O
redundant	O
roles	O
in	O
lymphoid	O
development	O
;	O
instead	O
,	O
IL-2	B-protein
is	O
the	O
guardian	O
of	O
thymus-derived	O
T-cell	O
homeostasis	O
,	O
while	O
interleukin-15	B-protein
promotes	O
extrathymic	O
development	O
of	O
T	B-cell_type
and	I-cell_type
NK	I-cell_type
cells	I-cell_type
.	O

This	O
review	O
discusses	O
the	O
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
in	O
general	O
and	O
the	O
association	O
of	O
NF-kappaB	B-protein
activation	O
with	O
cellular/molecular	O
events	O
of	O
renal	O
inflammation	O
and	O
fibrosis	O

Freshly	O
isolated	O
monocytes	O
treated	O
with	O
the	O
protein	O
phosphatase	O
inhibitor	O
okadaic	O
acid	O
secreted	O
high	O
levels	O
of	O
IL-6	B-protein
protein	I-protein
,	O
which	O
coincided	O
with	O
enhanced	O
binding	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
as	O
well	O
as	O
with	O
phosphorylation	O
and	O
activation	O
of	O
the	O
ERK1/2	B-protein
and	I-protein
JNK	I-protein
proteins	I-protein
.	O

Positive	O
induction	O
of	O
GR	B-RNA
mRNA	I-RNA
might	O
be	O
one	O
of	O
the	O
earliest	O
crucial	O
steps	O
in	O
the	O
lysis	O
of	O
normal	B-cell_line
and	I-cell_line
dex-resistant	I-cell_line
CEM	I-cell_line
cells	I-cell_line
,	O
or	O
might	O
serve	O
as	O
a	O
marker	O
for	O
the	O
process	O
.	O

Here	O
we	O
demonstrate	O
that	O
these	O
analogs	O
,	O
as	O
well	O
as	O
the	O
6-cis-locked	O
conformer	O
,	O
1alpha	B-cell_line
,	I-cell_line
25-dihydroxy-lumisterol3	I-cell_line
(	I-cell_line
JN	I-cell_line
)	I-cell_line
prime	I-cell_line
NB4	I-cell_line
cells	I-cell_line
for	O
monocytic	O
differentiation	O
.	O

In	O
contrast	O
,	O
there	O
was	O
no	O
regulation	O
by	O
glucocorticoids	O
of	O
either	O
the	O
CD8	B-protein
or	O
CD4	B-protein
antigens	I-protein
in	O
the	O
leukemic	B-cell_line
clone	I-cell_line
CEM	I-cell_line
C1	I-cell_line
.	O

To	O
identify	O
transcription	B-protein
factors	I-protein
binding	O
to	O
PRE-I	B-DNA
,	O
we	O
screened	O
a	O
cDNA	B-DNA
expression	I-DNA
library	I-DNA
from	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
isolated	O
a	O
cDNA	B-DNA
encoding	O
nuclear	B-protein
factor	I-protein
(	B-protein
NF	I-protein
)	I-protein
-IL6	I-protein
(	O
also	O
known	O
as	O
C/EBP	B-protein
beta	I-protein
)	O
.	O

DG	O
and	O
GG	O
were	O
synthesized	O
using	O
3-methylcholanthrene-induced	O
rat	O
liver	O
microsomes	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
was	O
to	O
explore	O
the	O
down-regulation	O
of	O
the	O
glucocorticoid	B-protein
receptors	I-protein
during	O
hypercortisolaemia	O
in	O
anorexia	O
nervosa	O
.	O

Interestingly	O
,	O
Oct1	O
and	O
NF-AT	O
DNA	O
binding	O
activity	O
were	O
not	O
affected	O
by	O
cysteamine	O
treatment	O
,	O
suggesting	O
that	O
oxidative	O
signalling	O
processes	O
operate	O
in	O
a	O
selective	O
manner	O
.	O

CONCLUSION	O
:	O
These	O
results	O
indicate	O
that	O
(	O
1	O
)	O
IgE	B-protein
production	O
in	O
asthma	O
and	O
HIE	O
usually	O
is	O
associated	O
with	O
elevated	O
levels	O
of	O
IL-4	B-protein
,	O
but	O
not	O
IL-13	B-protein
,	O
in	O
the	O
peripheral	O
blood	O
;	O
(	O
2	O
)	O
the	O
increased	O
sera	O
IL-4	B-protein
levels	O
in	O
asthma	O
and	O
HIE	O
are	O
not	O
sufficient	O
to	O
induce	O
Stat6	B-protein
activation	O
in	O
PBMCs	B-cell_type
;	O
and	O
(	O
3	O
)	O
evidence	O
of	O
switch	O
recombination	O
to	O
epsilon	O
may	O
be	O
detected	O
in	O
isolated	O
cases	O
of	O
elevated	O
IgE	B-protein
.	O

Taken	O
together	O
,	O
these	O
findings	O
strongly	O
suggest	O
that	O
SR-BP	B-protein
represents	O
the	O
molecular	O
target	O
for	O
SR	O
31747A	O
in	O
mammalian	O
tissues	O
,	O
which	O
could	O
be	O
critical	O
for	O
T	O
cell	O
proliferation	O
.	O

c-Maf	B-protein
induces	O
monocytic	O
differentiation	O
and	O
apoptosis	O
in	O
bipotent	B-cell_type
myeloid	I-cell_type
progenitors	I-cell_type
.	O

Activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
and	O
kappaB	B-protein
-dependent	O
transcriptional	O
activity	O
was	O
enhanced	O
in	O
the	O
presence	O
of	O
activated	B-cell_type
platelets	I-cell_type
.	O

Moreover	O
,	O
anti-TNF-alpha	B-protein
inhibited	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
-driven	O
transcription	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
in	O
primary	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
response	O
to	O
activation	O
,	O
either	O
in	O
the	O
presence	O
or	O
the	O
absence	O
of	O
HIV-1	B-protein
Tat	I-protein
.	O

A	O
polyclonal	O
antiserum	O
raised	O
against	O
recombinant	B-protein
B4-2	I-protein
recognizes	O
a	O
32-34	B-protein
kDa	I-protein
protein	I-protein
in	O
lymphocytes	B-cell_type
.	O

They	O
fail	O
to	O
induce	O
mRNA	B-RNA
of	O
TNF-alpha	B-protein
after	O
3	O
h	O
of	O
culture	O
.	O

Aims	O
of	O
the	O
study	O
were	O
to	O
(	O
1	O
)	O
assess	O
the	O
potential	O
role	O
of	O
the	O
expression	O
of	O
these	O
genes	O
in	O
the	O
maintenance	O
and	O
expansion	O
of	O
the	O
neoplastic	B-cell_line
clones	I-cell_line
and	O
(	O
2	O
)	O
search	O
for	O
constitutional	O
losses	O
or	O
rearrangements	O
of	O
one	O
allele	B-DNA
followed	O
by	O
a	O
deletion	O
of	O
the	O
second	O
allele	B-DNA
of	O
the	O
same	O
genes	O
in	O
the	O
leukemic	B-cell_type
cells	I-cell_type
.	O

This	O
shift	O
is	O
apparently	O
not	O
caused	O
by	O
a	O
recruitment	O
phenomenon	O
,	O
because	O
in	O
FCS+	B-cell_line
culture	I-cell_line
,	O
the	O
total	O
number	O
of	O
colonies	O
is	O
not	O
significantly	O
modified	O
by	O
RA	O
addition	O
.	O

Tax	B-protein
,	O
the	O
viral	B-protein
protein	I-protein
,	O
is	O
thought	O
to	O
be	O
crucial	O
in	O
the	O
development	O
of	O
the	O
disease	O
,	O
since	O
it	O
transforms	O
healthy	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
vitro	O
and	O
induces	O
tumors	O
in	O
transgenic	O
animals	O
.	O

Since	O
expression	O
of	O
the	O
viruses	O
is	O
in	O
large	O
part	O
regulated	O
by	O
the	O
sequence	B-DNA
elements	I-DNA
in	O
their	O
long	B-DNA
terminal	I-DNA
repeats	I-DNA
(	O
LTRs	B-DNA
)	O
,	O
this	O
study	O
was	O
directed	O
to	O
an	O
analysis	O
of	O
the	O
regulatory	B-DNA
elements	I-DNA
in	O
the	O
HIV-2	B-DNA
LTR	I-DNA
.	O

In	O
contrast	O
,	O
increased	O
expressions	O
of	O
C/EBPbeta	B-protein
and	O
MZF-1	B-RNA
mRNA	I-RNA
occurred	O
with	O
neutrophilic	O
differentiation	O
.	O

This	O
may	O
explain	O
the	O
strong	O
cyto-differentiating	O
potential	O
of	O
AM580	O
in	O
PML-RAR-containing	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Indeed	O
,	O
monocytes	B-cell_type
pretreated	O
with	O
IL-10	B-protein
are	O
able	O
so	O
inhibit	O
NF-kappa	B-protein
B	I-protein
nuclear	O
activity	O
in	O
purified	O
T	B-cell_type
lymphocytes	I-cell_type
stimulated	O
with	O
OKT3	B-protein
.	O

Allelic	O
variations	O
of	O
the	O
vitamin	B-DNA
D	I-DNA
receptor	I-DNA
(	I-DNA
VDR	I-DNA
)	I-DNA
gene	I-DNA
have	O
been	O
associated	O
with	O
the	O
risk	O
of	O
developing	O
prostate	O
cancer	O
in	O
men	O
and	O
osteoporosis	O
in	O
postmenopausal	O
women	O
.	O

However	O
,	O
CD80	B-protein
and	O
CD86	B-protein
also	O
induce	O
distinct	O
signal	O
transduction	O
pathways	O
including	O
the	O
tyrosine	O
phosphorylation	O
of	O
CD28	B-protein
and	O
phospholipase	B-protein
Cgamma1	I-protein
and	O
the	O
SH2	B-protein
-dependent	O
association	O
of	O
phosphoinositide	B-protein
3-kinase	I-protein
with	O
CD28	B-protein
.	O

A	O
carboxy	B-DNA
terminal	I-DNA
Tax	I-DNA
deletion	I-DNA
mutant	I-DNA
was	O
deficient	O
in	O
transactivation	O
of	O
both	O
the	O
PTHrP	B-DNA
and	I-DNA
IL2R	I-DNA
alpha	I-DNA
promoters	I-DNA
but	O
not	O
the	O
HTLV-I	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
.	O

Stimulation	O
of	O
cells	O
leads	O
to	O
a	O
rapid	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
which	O
is	O
presumed	O
to	O
be	O
important	O
for	O
the	O
subsequent	O
degradation	O
.	O

RESULTS	O
:	O
We	O
identified	O
5	O
protein	B-DNA
binding	I-DNA
regions	I-DNA
(	O
BRs	B-DNA
)	O
located	O
within	O
the	O
proximal	B-DNA
hIL-5	I-DNA
promoter	I-DNA
.	O

CD20	B-protein
is	O
a	O
B-lineage-specific	B-DNA
gene	I-DNA
expressed	O
at	O
the	O
pre-B-cell	O
stage	O
of	O
B-cell	O
development	O
that	O
disappears	O
on	O
differentiation	O
to	O
plasma	B-cell_type
cells	I-cell_type
.	O

We	O
hypothesize	O
that	O
an	O
unknown	O
gene	O
or	O
genes	O
in	O
linkage	O
with	O
the	O
polymorphisms	B-DNA
is	O
(	O
are	O
)	O
responsible	O
for	O
the	O
relationship	O
between	O
risk	O
of	O
prostate	O
cancer	O
and	O
VDR	B-protein
polymorphisms	B-DNA
.	O

Enhancing	O
effect	O
of	O
17	O
beta-estradiol	O
on	O
human	O
NK	O
cell	O
activity	O
.	O

The	O
v-erb	B-DNA
A	I-DNA
oncogene	I-DNA
of	O
avian	O
erythroblastosis	O
virus	O
is	O
a	O
mutated	O
and	O
virally	O
transduced	O
copy	O
of	O
a	O
host	B-DNA
cell	I-DNA
gene	I-DNA
encoding	O
a	O
thyroid	B-protein
hormone	I-protein
receptor	I-protein
.	O

These	O
data	O
suggest	O
that	O
inhibition	O
of	O
NFkappaB	B-protein
activation	O
may	O
provide	O
a	O
molecular	O
approach	O
to	O
increase	O
apoptosis	O
sensitivity	O
in	O
anticancer	O
treatment	O
.	O

Inducible	O
expression	O
of	O
E2a-Pbx1	B-protein
resulted	O
in	O
cell	O
death	O
with	O
the	O
morphologic	O
and	O
molecular	O
features	O
of	O
apoptosis	O
.	O

In	O
contrast	O
,	O
even	O
at	O
doses	O
as	O
high	O
as	O
100	O
U/ml	O
,	O
IL-10	B-protein
inhibited	O
TNF-alpha	B-protein
release	O
in	O
response	O
to	O
C.	O
albicans	O
by	O
only	O
50	O
%	O
.	O

Furthermore	O
,	O
Id3	B-protein
impedes	O
expression	O
of	O
recombination	O
activating	O
genes	O
and	O
downregulates	O
pre-Talpha	B-RNA
mRNA	I-RNA
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
can	O
induce	O
growth	O
inhibition	O
and	O
G1	O
arrest	O
of	O
UF-1	B-cell_line
cells	I-cell_line
,	O
resulting	O
in	O
differentiation	O
of	O
these	O
cells	O
toward	O
granulocytes	B-cell_type
.	O

Tumor-derived	B-protein
soluble	I-protein
products	I-protein
from	O
cultured	O
RCC	O
explants	O
inhibit	O
NFkappaB	B-protein
activity	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
healthy	O
volunteers	O
,	O
despite	O
a	O
normal	O
level	O
of	O
stimulus-induced	O
IkappaBalpha	B-protein
degradation	O
in	O
these	O
cells	O
.	O

Thus	O
,	O
decreased	O
proteasome	B-protein
-mediated	O
degradation	O
may	O
be	O
central	O
to	O
immune	O
dysfunction	O
that	O
accompanies	O
aging	O
.	O

Cepharanthine	O
is	O
a	O
biscoclaurine	O
alkaloid	O
isolated	O
from	O
Stephania	O
cepharantha	O
Hayata	O
and	O
has	O
been	O
shown	O
to	O
have	O
antiinflammatory	O
,	O
antiallergic	O
,	O
and	O
immunomodulatory	O
activities	O
in	O
vivo	O
.	O

The	O
latter	O
one	O
appears	O
to	O
be	O
mediated	O
by	O
a	O
rapidly	O
calcium-dependent	B-protein
induced	I-protein
gene	I-protein
product	I-protein
.	O

In	O
vivo	O
genomic	O
footprinting	O
had	O
also	O
revealed	O
cell-specific	O
binding	O
of	O
protein	O
,	O
presumably	O
Sp1	B-protein
,	O
to	O
these	O
regions	O
.	O

We	O
provide	O
evidence	O
here	O
that	O
virtually	O
all	O
human	B-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
express	O
NF-kappaB	B-protein
that	O
can	O
be	O
activated	O
by	O
exposure	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
a	O
variety	O
of	O
cytokines	B-protein
,	O
eg	O
,	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
,	O
interleukin-3	B-protein
,	O
and	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
.	O

Three	O
aspects	O
of	O
the	O
involvement	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
pathogenesis	O
were	O
examined	O
.	O

While	O
PKC	B-protein
depletion	O
did	O
not	O
alter	O
the	O
NF-kappa	B-protein
B	I-protein
level	O
,	O
treatment	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
with	O
H-89	O
or	O
herbimycin	O
A	O
provoked	O
a	O
decrease	O
in	O
the	O
NF-kappa	B-protein
B	I-protein
level	O
.	O

This	O
increase	O
in	O
mobility	O
was	O
attributable	O
to	O
dephosphorylation	O
,	O
as	O
lambda	O
phosphatase	O
treatment	O
could	O
convert	O
the	O
slower	B-protein
migrating	I-protein
forms	I-protein
into	O
the	O
corresponding	B-protein
faster	I-protein
mobility	I-protein
forms	I-protein
.	O

Within	O
2	O
hours	O
,	O
this	O
resulted	O
in	O
increased	O
mRNA	O
for	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
,	I-protein
1	I-protein
beta	I-protein
,	O
IL-8	B-protein
,	O
and	O
monocyte	B-protein
chemoattractant	I-protein
protein	I-protein
(	I-protein
MCP	I-protein
)	I-protein
-1	I-protein
in	O
unfractionated	O
leukocytes	B-cell_type
.	O

The	O
downstream	O
regulatory	O
region	O
contains	O
a	O
cyclic	B-DNA
AMP-responsive	I-DNA
element	I-DNA
(	O
CRE	B-DNA
)	O
.	O

M2	B-cell_line
leukemic	I-cell_line
blast	I-cell_line
cells	I-cell_line
behave	O
differently	O
because	O
they	O
undergo	O
monocytic	O
differentiation	O
with	O
both	O
the	O
differentiation	O
inducers	O
.	O

Adherent	O
cells	O
were	O
counted	O
by	O
digital	O
image	O
analysis	O
.	O

CAML	B-protein
appears	O
to	O
be	O
a	O
new	O
participant	O
in	O
the	O
calcium-signal	O
transduction	O
pathway	O
,	O
implicating	O
cyclophilin	B-protein
B	I-protein
in	O
calcium	O
signalling	O
,	O
even	O
in	O
the	O
absence	O
of	O
cyclosporin	O
.	O

TF	O
expression	O
by	O
circulating	B-cell_type
monocytes	I-cell_type
is	O
associated	O
with	O
thrombotic	O
and	O
inflammatory	O
complications	O
in	O
a	O
variety	O
of	O
diseases	O
.	O

Stimulation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
by	O
zinc	O
and	O
related	O
cations	O
.	O

In	O
previous	O
work	O
,	O
we	O
identified	O
an	O
essential	O
site	O
in	O
the	O
c-sis/PDGF-B	B-DNA
promoter	I-DNA
,	O
Tax-responsive	B-DNA
element	I-DNA
1	I-DNA
(	O
TRE1	B-DNA
)	O
,	O
necessary	O
for	O
transactivation	O
by	O
Tax	B-protein
.	O

Certain	O
interactions	O
between	O
TBP	B-protein
and	O
general	B-protein
factors	I-protein
that	O
are	O
specifically	O
required	O
for	O
acidic	B-protein
activation	I-protein
domains	I-protein
were	O
also	O
required	O
for	O
CIITA	B-protein
-mediated	O
transactivation	O
to	O
reach	O
its	O
full	O
potential	O
.	O

Few	O
known	O
genes	B-DNA
(	O
IL-2	B-protein
,	O
members	O
of	O
the	O
IL-8	B-DNA
family	I-DNA
,	O
interferon-gamma	B-DNA
)	O
are	O
induced	O
in	O
T	B-cell_type
cells	I-cell_type
only	O
through	O
the	O
combined	O
effect	O
of	O
phorbol	O
myristic	O
acetate	O
(	O
PMA	O
)	O
and	O
a	O
Ca	O
(	O
2+	O
)	O
-ionophore	O
,	O
and	O
expression	O
of	O
only	O
these	O
genes	B-DNA
can	O
be	O
fully	O
suppressed	O
by	O
Cyclosporin	O
A	O
(	O
CyA	O
)	O
.	O

A	O
mechanism	O
for	O
the	O
antiinflammatory	O
effects	O
of	O
corticosteroids	O
:	O
the	O
glucocorticoid	B-protein
receptor	I-protein
regulates	O
leukocyte	O
adhesion	O
to	O
endothelial	B-cell_type
cells	I-cell_type
and	O
expression	O
of	O
endothelial-leukocyte	B-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
and	O
intercellular	B-protein
adhesion	I-protein
molecule	I-protein
1	I-protein
.	O

p21ras	B-protein
is	O
activated	O
by	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
and	O
then	O
co-ordinates	O
important	O
signaling	O
pathways	O
for	O
T	B-protein
lymphocyte	I-protein
activation	O
.	O

Thus	O
,	O
the	O
gamma	B-DNA
3	I-DNA
ECS	I-DNA
is	O
an	O
inducible	O
promoter	O
containing	O
cis	B-DNA
elements	I-DNA
that	O
critically	O
mediate	O
CD40L	B-protein
and	O
IL-4	B-protein
-triggered	O
transcriptional	O
activation	O
of	O
the	O
human	B-DNA
C	I-DNA
gamma	I-DNA
3	I-DNA
gene	I-DNA
.	O

The	O
elevation	O
in	O
intracellular	O
calcium	O
that	O
is	O
induced	O
by	O
interactions	O
at	O
the	O
antigen	B-protein
receptor	I-protein
leads	O
to	O
the	O
activation	O
of	O
the	O
calcium-dependent	B-protein
phosphatase	I-protein
calcineurin	B-protein
.	O

The	O
promoter	B-DNA
of	O
the	O
TP1	B-DNA
gene	I-DNA
was	O
chosen	O
as	O
a	O
model	O
system	O
to	O
study	O
the	O
molecular	O
mechanism	O
of	O
EBNA2	B-protein
mediated	O
transactivation	O
.	O

T	B-cell_type
cell	I-cell_type
activation	O
results	O
in	O
high	O
levels	O
of	O
HIV	O
replication	O
and	O
is	O
thought	O
to	O
be	O
one	O
mechanism	O
leading	O
to	O
the	O
conversion	O
from	O
latent	O
to	O
active	O
viral	O
infection	O
.	O

DZA	O
inhibits	O
the	O
transcriptional	O
activity	O
of	O
NF-kappaB	B-protein
through	O
the	O
hindrance	O
of	O
p65	B-protein
(	O
Rel-A	B-protein
)	O
phosphorylation	O
without	O
reduction	O
of	O
its	O
nuclear	O
translocation	O
and	O
DNA	O
binding	O
activity	O
.	O

Data	O
regarding	O
the	O
processes	O
by	O
which	O
these	O
cytokines	B-protein
transduce	O
signals	O
from	O
the	O
cell	O
membrane	O
to	O
the	O
nucleus	O
are	O
becoming	O
increasingly	O
complex	O
.	O

Both	O
truncated	O
forms	O
also	O
bound	O
to	O
the	O
transcription	B-protein
factor	I-protein
RBP-Jkappa	I-protein
in	O
extracts	O
prepared	O
from	O
human	B-cell_line
and	I-cell_line
murine	I-cell_line
T-ALL	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Constitutive	O
expression	O
in	O
vivo	O
of	O
Fos	B-protein
,	O
and	O
to	O
a	O
lesser	O
extent	O
Fra-1	B-protein
,	O
eliminates	O
the	O
requirement	O
for	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
stimulation	O
,	O
leaving	O
NF-AT	B-protein
-directed	O
transcription	O
responsive	O
to	O
calcium	O
ionophore	O
alone	O
.	O

For	O
example	O
,	O
the	O
analysis	O
of	O
only	O
1	O
signaling	B-protein
molecule	I-protein
may	O
allow	O
patients	O
with	O
significant	O
defects	O
in	O
T-cell	O
signaling	O
to	O
go	O
unnoticed	O
.	O

The	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
GCH	O
is	O
under	O
investigation	O
,	O
but	O
is	O
has	O
been	O
noted	O
that	O
they	O
exert	O
immune	O
activity	O
via	O
the	O
genomic	O
pathway	O
.	O

These	O
results	O
suggested	O
that	O
the	O
two	O
subunits	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
the	O
c-Rel	B-protein
protein	I-protein
have	O
different	O
roles	O
in	O
different	O
cell	O
types	O
during	O
B	O
cell	O
immunopoiesis	O
.	O

However	O
,	O
neither	O
TNF	B-protein
or	O
LPS	O
stimulated	O
VCAM-1	B-protein
expression	O
in	O
HUAECs	B-cell_type
.	O

Human	B-DNA
and	I-DNA
mouse	I-DNA
Rhom-2	I-DNA
are	O
highly	O
conserved	O
and	O
,	O
like	O
rhombotin	B-DNA
,	O
encode	O
two	O
tandem	B-DNA
cysteine-rich	I-DNA
LIM	I-DNA
domains	I-DNA
.	O

Reactivation	O
of	O
Kaposi	O
's	O
sarcoma-associated	O
herpesvirus	O
infection	O
from	O
latency	O
by	O
expression	O
of	O
the	O
ORF	B-protein
50	I-protein
transactivator	I-protein
,	O
a	O
homolog	O
of	O
the	O
EBV	B-protein
R	I-protein
protein	I-protein
.	O

We	O
therefore	O
investigated	O
the	O
effects	O
of	O
cysteine	O
and	O
related	O
thiols	O
on	O
HIV-1	O
replication	O
and	O
NF-kappa	B-protein
B	I-protein
expression	O
.	O

When	O
HL60	B-cell_line
cells	I-cell_line
or	O
normal	O
myeloid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
were	O
exposed	O
to	O
exogenous	O
E1	O
they	O
became	O
more	O
sensitive	O
to	O
the	O
differentiation-inducing	O
effects	O
of	O
D3	O
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
endothelial	O
hypoxia	O
provides	O
a	O
novel	O
,	O
proteasome	B-protein
-dependent	O
stimulus	O
for	O
ICAM-1	B-protein
induction	O
.	O

We	O
have	O
purified	O
a	O
new	O
T-cell-specific	B-protein
factor	I-protein
,	O
TCF-1	B-protein
alpha	I-protein
,	O
that	O
is	O
implicated	O
in	O
the	O
activation	O
of	O
genes	O
encoding	O
a	O
major	O
component	O
of	O
the	O
human	B-protein
T-cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
.	O

The	O
use	O
of	O
the	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
(	O
PTK	B-protein
)	O
-specific	O
inhibitor	O
herbimycin	O
A	O
dramatically	O
decreased	O
cellular	O
proliferation	O
without	O
altering	O
the	O
activity	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus-1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
HIV-1	B-DNA
LTR	I-DNA
)	O
,	O
a	O
promoter	B-DNA
largely	O
dependent	O
on	O
the	O
binding	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-	B-protein
kappa	I-protein
B	I-protein
)	O
.	O

Interleukin-1	B-protein
stimulated	O
U-937	B-cell_line
cell	I-cell_line
adhesion	O
to	O
and	O
VCAM-1	B-protein
surface	O
expression	O
in	O
both	O
HUVECs	B-cell_type
and	O
HUAECs	B-cell_type
.	O

In	O
addition	O
,	O
the	O
65-kD	B-protein
protein	I-protein
associated	O
with	O
the	O
p50	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
and	O
the	O
kappa	B-DNA
B	I-DNA
probe	I-DNA
to	O
form	O
a	O
complex	O
with	O
the	O
same	O
electrophoretic	O
mobility	O
as	O
the	O
NF-kappa	B-protein
B-DNA	I-protein
complex	I-protein
.	O

r-hTBP-1	B-protein
and	O
rhu	B-protein
TNFR	I-protein
:	I-protein
Fc	I-protein
also	O
decreased	O
p24	B-protein
antigen	I-protein
synthesized	O
by	O
U1	B-cell_line
cells	I-cell_line
in	O
response	O
to	O
other	O
stimuli	O
,	O
including	O
phytohemagglutinin	B-protein
(	I-protein
PHA	I-protein
)	I-protein
-induced	I-protein
supernatant	I-protein
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
,	O
interleukin-6	B-protein
,	O
and	O
TNF	B-protein
.	O

Tepoxalin	O
also	O
inhibited	O
the	O
secretion	O
of	O
a	O
NF-kappa	B-protein
B	I-protein
regulated	I-protein
chemokine	I-protein
,	O
IL-8	B-protein
,	O
a	O
known	O
inducer	O
of	O
CD11b/CD18	B-protein
expression	O
.	O

The	O
therapeutic	O
potential	O
of	O
drugs	O
that	O
block	O
the	O
induction	O
of	O
cyclooxygenase-2	B-protein
has	O
been	O
emphasized	O
.	O

Whether	O
the	O
putative	O
new	O
retrovirus	O
(	O
es	O
)	O
and	O
EBV	O
have	O
any	O
causal	O
relationship	O
to	O
MS	O
is	O
still	O
not	O
known	O
,	O
but	O
the	O
findings	O
support	O
this	O
possibility	O
.	O

Furthermore	O
,	O
the	O
NFKB2	B-protein
precursor	O
is	O
physically	O
associated	O
with	O
c-Rel	B-protein
and	O
with	O
Tax	B-protein
in	O
HTLV-I	B-cell_type
infected	I-cell_type
cells	I-cell_type
.	O

3BP2	B-protein
was	O
selectively	O
expressed	O
in	O
hematopoietic/lymphoid	O
tissues	O
and	O
bound	O
via	O
its	O
SH2	B-protein
domain	I-protein
activated	I-protein
Syk-family	I-protein
kinases	I-protein
in	O
mammalian	B-cell_type
cells	I-cell_type
,	O
including	O
in	O
antigen	B-cell_type
receptor-stimulated	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Mutation	O
of	O
the	O
consensus	B-DNA
AP-1/CRE	I-DNA
site	I-DNA
within	O
ZII	B-DNA
abolished	O
the	O
inducibility	O
of	O
Zp	B-DNA
by	O
HHV-6	O
,	O
whereas	O
positioning	O
of	O
the	O
ZII	B-DNA
domain	I-DNA
upstream	O
of	O
the	O
beta-globin	B-DNA
minimal	I-DNA
promoter	I-DNA
conferred	O
responsiveness	O
following	O
HHV-6	O
infection	O
.	O

Five	O
cellular	B-protein
proteins	I-protein
(	O
p52	B-protein
,	O
p57	B-protein
,	O
p70	B-protein
,	O
p72	B-protein
,	O
and	O
p100	B-protein
)	O
cross-link	O
the	O
EMCV	O
IRES	B-DNA
or	O
fragments	O
of	O
the	O
IRES	B-DNA
.	O

Deregulation	O
of	O
TCL1	B-DNA
is	O
the	O
first	O
event	O
in	O
the	O
initiation	O
of	O
malignancy	O
in	O
these	O
types	O
of	O
leukemias	O
and	O
represents	O
a	O
potential	O
tool	O
for	O
clinical	O
evaluation	O
.	O

PtdIns	O
binding	O
to	O
mCD14	B-protein
can	O
be	O
blocked	O
by	O
anti-CD14	B-protein
monoclonal	I-protein
antibodies	I-protein
that	O
inhibit	O
LPS	O
-mCD14	B-protein
binding	O
,	O
and	O
PtdIns	O
can	O
inhibit	O
both	O
LPS	O
-mCD14	B-protein
binding	O
and	O
LPS-induced	O
responses	O
in	O
monocytes	B-cell_type
.	O

The	O
induction	O
of	O
STAT	B-protein
activity	O
was	O
inhibited	O
completely	O
by	O
pretreatment	O
with	O
either	O
cycloheximide	O
or	O
cyclosporin	O
A	O
,	O
thus	O
indicating	O
that	O
the	O
induction	O
was	O
due	O
to	O
a	O
secondary	B-protein
factor	I-protein
produced	O
by	O
the	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O

L-selectin	B-protein
is	O
an	O
adhesion	O
molecule	O
of	O
the	O
selectin	O
family	O
that	O
mediates	O
the	O
initial	O
step	O
of	O
leukocyte	O
adhesion	O
to	O
vascular	O
endothelium	O
.	O

Most	O
viruses	O
can	O
not	O
compete	O
with	O
the	O
various	O
immune	O
mechanisms	O
and	O
become	O
eliminated	O
in	O
the	O
course	O
of	O
infection	O
.	O

Analysis	O
of	O
IL-2	B-protein
and	O
IL-2R	B-protein
alpha	I-protein
expression	O
demonstrated	O
that	O
the	O
perturbation	O
of	O
the	O
proliferation	O
response	O
was	O
not	O
attributable	O
to	O
an	O
abnormal	O
expression	O
of	O
these	O
genes	O
.	O

TNF-alpha	B-RNA
RNA	I-RNA
was	O
undetectable	O
in	O
U937	B-cell_line
cells	I-cell_line
,	O
whereas	O
a	O
low	O
constitutive	O
level	O
was	O
detected	O
in	O
U9-IIIB	B-cell_line
cells	I-cell_line
.	O

Apart	O
from	O
clear-cut	O
defects	O
in	O
the	O
synthesis	O
of	O
mRNAs	B-RNA
for	O
Th2-type	B-protein
lymphokines	I-protein
,	O
such	O
as	O
IL-4	B-protein
,	O
IL-5	B-protein
,	O
IL-10	B-protein
and	O
IL-13	B-protein
,	O
in	O
primary	O
and	O
secondary	O
stimulations	O
of	O
spleen	B-cell_type
cells	I-cell_type
in	O
vitro	O
,	O
of	O
a	O
distinct	O
impaired	O
deletion	O
of	O
V	B-cell_line
beta	I-cell_line
11+/CD4+	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
from	O
these	O
mice	O
was	O
detected	O
after	O
superantigen	O
injection	O
.	O

Translocation	O
of	O
NF-kappa	B-protein
B	I-protein
p50/p65	B-protein
was	O
also	O
observed	O
following	O
stimulation	O
of	O
CR1	B-protein
or	O
CR3	B-protein
of	O
uninfected	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
from	O
HIV-seronegative	O
donors	O
.	O

They	O
are	O
particularly	O
abundant	O
in	O
lymphoid	O
tissues	O
and	O
are	O
thought	O
to	O
be	O
critical	O
for	O
the	O
transcription	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Interferon-alpha	B-protein
induction	O
of	O
STATs1	B-protein
,	I-protein
-3	I-protein
DNA	O
binding	O
and	O
growth	O
arrest	O
is	O
independent	O
of	O
Lck	B-protein
and	O
active	O
mitogen-activated	B-protein
kinase	I-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

In	O
this	O
review	O
,	O
Paul	O
Scholl	O
and	O
Raif	O
Geha	O
discuss	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
mechanisms	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
signaling	O
and	O
analyse	O
their	O
role	O
in	O
human	O
B-cell	B-cell_type
activation	O
.	O

We	O
determined	O
the	O
mechanism	O
of	O
NF-kappaB	B-protein
suppression	O
in	O
T	B-cell_type
cells	I-cell_type
of	O
RCC	O
patient	O
and	O
determined	O
whether	O
supernatant	O
fluid	O
from	O
RCC	O
explants	O
(	O
RCC-S	O
)	O
induced	O
the	O
same	O
phenotype	O
of	O
NF-kappaB	B-protein
suppression	O
in	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
that	O
is	O
observed	O
in	O
patient	O
T	B-cell_type
cells	I-cell_type
.	O

Substitution	O
mutations	O
in	O
this	O
consensus	B-DNA
sequence	I-DNA
eliminate	O
binding	O
of	O
the	O
inducible	B-protein
factor	I-protein
.	O

Sex	O
and	O
age	O
distribution	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
normal	O
human	O
subjects	O
.	O

The	O
expression	O
of	O
cell	O
surface	O
markers	O
including	O
the	O
interleukin	B-protein
2	I-protein
receptor	I-protein
alpha	I-protein
(	I-protein
IL-2R	I-protein
alpha	I-protein
)	I-protein
chain	I-protein
(	O
CD25	B-protein
)	O
,	O
CD69	B-protein
and	O
L-selectin	B-protein
(	O
CD62	B-protein
)	O
is	O
normal	O
in	O
mitogen-activated	B-cell_line
Rel-/-	I-cell_line
T	I-cell_line
cells	I-cell_line
,	O
but	O
cytokine	B-protein
production	O
is	O
impaired	O
.	O

Interleukin-3	B-protein
expression	O
by	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
involves	O
an	O
inducible	O
,	O
T-cell-specific	B-protein
factor	I-protein
and	O
an	O
octamer	B-protein
binding	I-protein
protein	I-protein
.	O

Overexpression	O
of	O
dominant	O
negative	O
forms	O
of	O
IKKalpha	B-protein
and	I-protein
-beta	I-protein
demonstrates	O
that	O
only	O
IKKbeta	B-protein
is	O
the	O
target	O
for	O
PKC	B-protein
and	O
calcineurin	B-protein
.	O

IL-7	B-protein
did	O
not	O
maintain	O
v-Abl	B-protein
-mediated	O
differentiation	O
arrest	O
of	O
the	O
pre-B	B-cell_type
cells	I-cell_type
,	O
as	O
activation	O
of	O
NF-kappaB	B-protein
and	O
RAG	B-DNA
gene	I-DNA
transcription	O
was	O
unaffected	O
by	O
IL-7	B-protein
.	O

With	O
the	O
use	O
of	O
immunohistochemistry	O
,	O
bcl-6	B-protein
protein	I-protein
was	O
shown	O
to	O
stain	O
intensely	O
on	O
normal	B-cell_line
prickle	I-cell_line
cells	I-cell_line
,	O
but	O
none	O
to	O
only	O
slightly	O
on	O
epidermal	B-cell_type
basal	I-cell_type
cells	I-cell_type
.	O

LNCaP	B-cell_line
cells	I-cell_line
were	O
shown	O
to	O
express	O
the	O
IL-1beta	B-protein
receptor	O
type	O
1	O
,	O
which	O
transduces	O
IL-1beta	B-protein
signal	O
.	O

Erythropoietin	O
(	O
Epo	O
)	O
is	O
essential	O
for	O
the	O
later	O
stages	O
of	O
erythropoiesis	O
,	O
acting	O
to	O
promote	O
cell	O
survival	O
and	O
proliferation	O
,	O
but	O
its	O
role	O
in	O
differentiation	O
remains	O
to	O
be	O
defined	O
.	O

NH2	B-protein
-terminal	O
amino	O
acid	O
sequence	O
analysis	O
identified	O
the	O
140-kDa	B-protein
surface	I-protein
antigen	I-protein
for	O
mAb	B-protein
J393	I-protein
as	O
CD43/leukosialin	B-protein
,	O
the	O
major	O
sialoglycoprotein	B-protein
of	O
leukocytes	B-cell_type
.	O

The	O
activation	O
of	O
this	O
nuclear	O
factor	O
is	O
qualitatively	O
different	O
in	O
rheumatoid	B-cell_type
synovial	I-cell_type
T	I-cell_type
cells	I-cell_type
to	O
that	O
in	O
other	O
forms	O
of	O
non-rheumatoid	O
arthritis	O
(	O
for	O
example	O
,	O
osteoarthritis	O
,	O
spondyloarthropathies	O
)	O
.	O

HIV-1	O
replication	O
was	O
determined	O
by	O
p24	B-protein
antigen	I-protein
level	O
.	O

The	O
calcium	O
ionophore-induced	O
c-myc	B-DNA
suppression	O
,	O
however	O
,	O
strictly	O
requires	O
de	O
novo	O
protein	O
synthesis	O
.	O

The	O
GM-CSF	B-DNA
promoter	I-DNA
,	O
modified	O
in	O
this	O
way	O
to	O
be	O
ETS1	B-protein
specific	O
,	O
is	O
fully	O
responsive	O
to	O
PMA/ionomycin	O
induction	O
,	O
in	O
addition	O
to	O
ETS1	B-protein
transactivation	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
ionomycin	O
.	O

The	O
tax	O
gene	O
product	O
of	O
the	O
type	O
I	O
human	O
T-cell	O
leukemia	O
virus	O
(	O
HTLV-I	O
)	O
transactivates	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
through	O
activation	O
of	O
an	O
enhancer	O
termed	O
CD28	B-DNA
responsive	I-DNA
element	I-DNA
(	O
CD28RE	B-DNA
)	O
.	O

Mycobacterium	O
tuberculosis	O
and	O
its	O
components	O
are	O
strong	O
signals	O
to	O
activate	O
monocytes	B-cell_type
to	O
production	O
of	O
cytokines	B-protein
.	O

A	O
single	B-DNA
point	I-DNA
mutation	I-DNA
in	O
the	O
SRE	B-DNA
completely	O
abrogated	O
the	O
responsiveness	O
to	O
tat/S	B-DNA
.	O

We	O
first	O
isolated	O
two	O
overlapping	O
cosmids	B-DNA
encoding	O
human	B-protein
CIITA	I-protein
which	O
,	O
when	O
co-transfected	O
,	O
are	O
able	O
to	O
restore	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
in	O
a	O
B-lymphoblastoid	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
B-LCL	B-cell_line
)	O
defective	O
for	O
CIITA	B-protein
.	O

Other	O
applications	O
involve	O
the	O
introduction	O
of	O
other	O
GATA-binding	B-protein
protein	I-protein
family	I-protein
members	I-protein
to	O
determine	O
whether	O
they	O
rescue	O
the	O
mutation	O
.	O

In	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
NK	I-cell_type
cells	I-cell_type
,	O
genistein	O
at	O
<	O
0.5	O
micromol/L	O
and	O
DG	O
and	O
GG	O
at	O
0.1-10	O
micromol/L	O
enhanced	O
NK	O
cell-mediated	O
K562	B-cell_line
cancer	I-cell_line
cell	I-cell_line
killing	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
exogenous	O
PGE2	O
mimics	O
the	O
NF-kappaB	B-protein
inhibitory	O
effect	O
of	O
FCM	O
.	O

Bacterially	O
expressed	O
RP1	B-protein
protein	I-protein
revealed	O
specific	O
binding	O
to	O
wild-type	B-protein
but	O
not	O
to	O
mutated	B-protein
APC	I-protein
protein	I-protein
.	O

Positive-pressure	O
mechanical	O
ventilation	O
supports	O
gas	O
exchange	O
in	O
patients	O
with	O
respiratory	O
failure	O
but	O
is	O
also	O
responsible	O
for	O
significant	O
lung	O
injury	O
.	O

This	O
CD16	B-protein
-induced	O
FasL	B-protein
expression	O
was	O
suppressed	O
by	O
oxidative	O
stress	O
,	O
including	O
thiol	O
deprivation	O
or	O
treatment	O
with	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
.	O

Here	O
we	O
report	O
the	O
characterization	O
of	O
a	O
nuclear	B-protein
complex	I-protein
from	O
human	O
monocytic	B-cell_type
cells	I-cell_type
that	O
bound	O
to	O
a	O
kappa	B-DNA
B-like	I-DNA
site	I-DNA
,	O
5'-CGGAGTTTCC-3	B-DNA
'	I-DNA
,	O
in	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
the	O
human	B-DNA
TF	I-DNA
gene	I-DNA
.	O

Uncontrolled	O
replication	O
of	O
a	O
virus	O
,	O
which	O
is	O
harmful	O
to	O
the	O
host	O
is	O
also	O
disadvantageous	O
to	O
the	O
virus	O
.	O

Role	O
of	O
AP-1-	B-protein
and	I-protein
octamer-binding	I-protein
proteins	I-protein
in	O
control	O
of	O
IL3	B-protein
gene	O
expression	O
.	O

We	O
further	O
demonstrate	O
that	O
Tax1	B-protein
specifically	O
activated	O
the	O
NF-Y-responsive	B-DNA
DQbeta	I-DNA
promoter	I-DNA
,	O
as	O
well	O
as	O
a	O
minimal	B-DNA
promoter	I-DNA
which	O
contains	O
only	O
the	O
Y-box	B-DNA
element	I-DNA
.	O

[	O
Molecular	O
mechanism	O
of	O
cytokine	B-DNA
gene	I-DNA
expression	O
in	O
Th1	B-cell_line
and	O
Th2	B-cell_line
]	O

The	O
NF-kappa	B-protein
B	I-protein
inhibitor	O
,	O
tepoxalin	O
,	O
suppresses	O
surface	O
expression	O
of	O
the	O
cell	B-protein
adhesion	I-protein
molecules	I-protein
CD62E	B-protein
,	O
CD11b/CD18	B-protein
and	O
CD106	B-protein
.	O

Since	O
peripheral	B-cell_type
blood	I-cell_type
T-lymphocytes	I-cell_type
express	O
cryptic	B-protein
epitopes	I-protein
for	O
mAb	B-protein
J393	I-protein
,	O
these	O
findings	O
demonstrate	O
the	O
existence	O
of	O
a	O
tightly	O
regulated	O
CD43	B-protein
-mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	B-cell_type
T-cell	I-cell_type
lineages	I-cell_type
.	O

Recent	O
studies	O
have	O
revealed	O
that	O
interactions	O
between	O
transcription	B-protein
factors	I-protein
play	O
an	O
important	O
role	O
in	O
regulation	O
of	O
gene	O
expression	O
in	O
eukaryotic	B-cell_type
cells	I-cell_type
.	O

OM10.1	B-cell_line
,	O
a	O
promyelocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
latently	O
infected	O
with	O
HIV-1	O
,	O
has	O
been	O
developed	O
as	O
a	O
model	O
for	O
studying	O
the	O
mechanism	O
of	O
viral	O
latency	O
and	O
the	O
activation	O
of	O
virus	O
expression	O
.	O

The	O
affinity	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
Kd	O
)	O
was	O
strikingly	O
decreased	O
(	O
9.36	O
+/-	O
3.44	O
nM	O
in	O
group	O
1	O
;	O
3.2	O
+/-	O
1.5	O
nM	O
in	O
group	O
2	O
;	O
2.0	O
+/-	O
0.8	O
nM	O
in	O
controls	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O

Thus	O
,	O
IL-12	B-protein
appears	O
to	O
be	O
a	O
critical	O
factor	O
in	O
the	O
generation	O
and	O
maintenance	O
of	O
chronic	O
inflammatory	O
conditions	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
human	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
and	I-DNA
enhancer	I-DNA
also	O
encompass	O
binding	O
sites	O
for	O
core-binding	B-protein
factor	I-protein
(	O
CBF	B-protein
)	O
.	O

These	O
two	O
proteins	O
physically	O
interact	O
with	O
each	O
other	O
and	O
mutually	O
inhibit	O
their	O
respective	O
biological	O
functions	O
.	O

In	O
addition	O
,	O
these	O
data	O
suggest	O
that	O
transcriptional	O
activation	O
of	O
RE/AP	B-protein
is	O
not	O
mediated	O
by	O
NFAT	B-protein
,	O
because	O
activation	O
of	O
a	O
NFAT	B-protein
reporter	O
is	O
not	O
affected	O
by	O
the	O
addition	O
of	O
CTLA4Ig	O
.	O

The	O
GS	O
strain	O
transactivated	O
the	O
promoter	B-DNA
in	O
both	O
stimulated	O
and	O
resting	O
T	B-cell_type
cells	I-cell_type
,	O
while	O
the	O
Z29	O
strain	O
increased	O
HIV	B-DNA
promoter	I-DNA
activity	O
only	O
in	O
stimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Analysis	O
of	O
these	O
PBLs	B-cell_type
revealed	O
that	O
activation	O
of	O
the	O
NF-kappaB	B-protein
pathway	O
is	O
sufficient	O
to	O
promote	O
the	O
growth	O
response	O
to	O
IL-2	B-protein
.	O

We	O
have	O
also	O
investigated	O
A-myb	B-DNA
expression	O
in	O
49	O
fresh	O
cases	O
of	O
B	O
leukemias	O
.	O

Therefore	O
,	O
we	O
compared	O
the	O
nucleotide	B-DNA
sequences	I-DNA
of	O
the	O
CD11a	B-DNA
,	I-DNA
CD11b	I-DNA
,	I-DNA
and	I-DNA
CD11c	I-DNA
gene	I-DNA
promoters	I-DNA
to	O
identify	O
common	O
elements	O
that	O
might	O
contribute	O
to	O
inducible	O
expression	O
.	O

Inhibition	O
of	O
T	O
cell	O
activation	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
exerts	O
a	O
suppressive	O
effect	O
on	O
the	O
induction	O
of	O
these	O
NF-kappa	B-DNA
B-controlled	I-DNA
cytokine	I-DNA
promoters	I-DNA
.	O

c-Myb	B-DNA
and	O
Ets	B-protein
proteins	I-protein
synergize	O
to	O
overcome	O
transcriptional	O
repression	O
by	O
ZEB	B-protein
.	O

These	O
included	O
both	O
p50/p50	B-protein
and	O
p50/p65	B-protein
dimers	I-protein
,	O
recognized	O
by	O
specific	B-protein
antibodies	I-protein
in	O
EMSA	O
.	O

Some	O
patients	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
have	O
elevated	O
plasma	O
cortisol	O
concentrations	O
and	O
show	O
failure	O
to	O
suppress	O
cortisol	O
secretion	O
upon	O
administration	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
yet	O
they	O
do	O
not	O
have	O
Cushingoid	O
features	O
.	O

This	O
increased	O
adhesion	O
was	O
suppressed	O
by	O
the	O
addition	O
of	O
anti-CD18	B-protein
antibody	I-protein
(	O
157.6+/-25.1	O
cells/mm2	O
,	O
n	O
=	O
8	O
,	O
P	O
<	O
0.01	O
)	O
and	O
by	O
pretreatment	O
with	O
10	O
(	O
-7	O
)	O
M	O
dexamethasone	O
(	O
207.9+/-31.5	O
cells/mm2	O
,	O
n	O
=	O
10	O
,	O
P	O
<	O
0.01	O
)	O
.	O

A	O
high	O
expression	O
of	O
WT1	B-DNA
has	O
been	O
detected	O
in	O
a	O
range	O
of	O
acute	O
leukemias	O
,	O
and	O
WT1	B-DNA
is	O
downregulated	O
during	O
induced	O
differentiation	O
of	O
some	O
leukemic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

For	O
this	O
purpose	O
,	O
we	O
used	O
three	O
main	O
approaches	O
.	O

The	O
POU	B-protein
transcription	I-protein
factors	I-protein
Oct-1	B-protein
and	O
Oct-2	B-protein
regulate	O
the	O
activity	O
of	O
octamer-dependent	B-DNA
promoters	I-DNA
,	O
including	O
those	O
that	O
direct	O
transcription	O
from	O
rearranged	O
immunoglobulin	B-protein
genes	I-protein
.	O

In	O
HIV-infected	O
patients	O
,	O
such	O
enhancement	O
may	O
further	O
impair	O
host	O
immunity	O
and	O
could	O
accelerate	O
the	O
course	O
of	O
HIV	O
disease	O
.	O

CD14	B-protein
-mediated	O
signal	O
pathway	O
of	O
Porphyromonas	O
gingivalis	O
lipopolysaccharide	O
in	O
human	B-cell_type
gingival	I-cell_type
fibroblasts	I-cell_type
.	O

To	O
characterize	O
the	O
role	O
of	O
these	O
P-like	B-DNA
elements	I-DNA
and	O
their	O
binding	B-protein
factors	I-protein
in	O
the	O
native	B-DNA
promoter	I-DNA
,	O
we	O
did	O
transient	O
transfection	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
.	O

Moreover	O
GM-CSF	B-protein
was	O
able	O
to	O
induce	O
JAK2	B-protein
and	O
p93fes	B-protein
catalytic	O
activity	O
.	O

Like	O
a	O
delayed-type	O
hypersensitivity	O
response	O
,	O
the	O
rheumatoid	O
synovium	O
represents	O
an	O
effector	O
site	O
.	O

This	O
suggests	O
that	O
CHEMR1	B-DNA
may	O
be	O
a	O
receptor	O
for	O
unidentified	O
C-C	B-protein
chemokine	I-protein
or	O
a	O
low-affinity	O
receptor	O
for	O
MIP-1alpha	B-protein
.	O

The	O
findings	O
in	O
the	O
human	B-cell_line
multiple	I-cell_line
myeloma	I-cell_line
cell	I-cell_line
lines	I-cell_line
represent	O
the	O
first	O
examples	O
of	O
B	B-cell_type
cells	I-cell_type
with	O
downregulated	O
PU.1	B-protein
expression	O
and	O
apparently	O
contradict	O
observations	O
in	O
the	O
murine	O
system	O
in	O
which	O
PU.1	B-protein
is	O
expressed	O
and	O
active	O
in	O
plasmacytoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
extent	O
to	O
which	O
analog	O
activity	O
was	O
increased	O
after	O
cotreatment	O
with	O
RA	O
was	O
inversely	O
related	O
to	O
potency	O
.	O

METHOD	O
:	O
They	O
measured	O
the	O
number	O
of	O
lymphocyte	B-protein
cytosolic	I-protein
glucocorticoid	I-protein
receptors	I-protein
and	O
plasma	O
cortisol	O
concentrations	O
in	O
15	O
consecutively	O
admitted	O
male	O
combat	O
Vietnam	O
veterans	O
with	O
PTSD	O
and	O
in	O
a	O
normal	O
comparison	O
group	O
of	O
11	O
subjects	O
.	O

These	O
findings	O
and	O
other	O
related	O
results	O
are	O
reviewed	O
here	O
.	O

Calcitriol	O
:	O
a	O
hematolymphopoietrope	O
?	O
[	O
editorial	O
]	O

The	O
function	O
of	O
SSB	B-cell_line
T	I-cell_line
cells	I-cell_line
in	O
controls	O
remains	O
to	O
be	O
defined	O
.	O

An	O
acute	B-DNA
myeloid	I-DNA
leukemia	I-DNA
gene	I-DNA
,	O
AML1	B-DNA
,	O
regulates	O
transcriptional	O
activation	O
and	O
hemopoietic	O
myeloid	O
cell	O
differentiation	O
antagonistically	O
by	O
two	O
alternative	O
spliced	O
forms	O
.	O

The	O
magnitude	O
of	O
the	O
thrombin	B-protein
response	O
in	O
the	O
different	O
cell	O
types	O
paralleled	O
the	O
expression	O
of	O
the	O
thrombin	B-RNA
receptor	I-RNA
mRNA	I-RNA
.	O

In	O
addition	O
to	O
the	O
existing	O
isoform	O
(	O
Pax-5	B-protein
,	O
which	O
we	O
have	O
named	O
Pax-5a	B-protein
)	O
,	O
we	O
have	O
isolated	O
three	O
new	O
isoforms	O
,	O
Pax-5b	B-protein
,	O
Pax-5d	B-protein
,	O
and	O
Pax-5e	B-protein
,	O
from	O
murine	O
spleen	O
and	O
B-lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
using	O
library	O
screenings	O
and	O
polymerase	O
chain	O
reaction	O
amplification	O
.	O

Activation	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
enhancer	I-DNA
is	O
not	O
dependent	O
on	O
NFAT-1	B-protein
.	O

TNF-alpha	B-protein
was	O
able	O
to	O
increase	O
expression	O
of	O
the	O
HIV	B-DNA
LTR	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
,	O
but	O
in	O
monocytic	B-cell_type
cells	I-cell_type
,	O
TNF-alpha	B-protein
did	O
not	O
induce	O
the	O
HIV	B-DNA
LTR	I-DNA
above	O
a	O
constitutive	O
level	O
of	O
activity	O
.	O

Binding	B-DNA
sites	I-DNA
at	O
the	O
core	O
region	O
show	O
little	O
conservation	O
with	O
consensus	B-DNA
sites	I-DNA
.	O

In	O
addition	O
,	O
in	O
vivo	O
footprint	O
analysis	O
showed	O
the	O
putative	O
X	B-DNA
and	I-DNA
Y	I-DNA
boxes	I-DNA
to	O
be	O
occupied	O
by	O
transcription	B-protein
factors	I-protein
in	O
wild-type	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
but	O
not	O
in	O
RFX-deficient	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

The	O
absence	O
of	O
slow	O
migrating	O
forms	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
following	O
stimulation	O
suggests	O
that	O
the	O
phosphorylation	O
does	O
not	O
necessarily	O
constitute	O
the	O
signal-induced	O
event	O
which	O
targets	O
the	O
molecule	O
for	O
proteolysis	O
.	O

EMS	O
analyses	O
performed	O
with	O
nuclear	O
extracts	O
from	O
Tax-expressing	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
and	O
HTLV-I-transformed	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
demonstrate	O
that	O
Tax	B-protein
prevents	O
the	O
formation	O
of	O
U1	B-DNA
(	O
U1A/U1B	B-DNA
)	O
and	O
U2	B-DNA
DNA-protein	B-protein
complexes	I-protein
.	O

When	O
cultured	O
in	O
RPMI	O
1640	O
medium	O
containing	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
most	O
YJ	B-cell_line
cells	I-cell_line
were	O
myeloblastoid	O
with	O
a	O
small	O
number	O
of	O
the	O
cells	O
having	O
eosinophilic	O
granules	O
.	O

17beta-estradiol	O
(	O
E2	O
)	O
markedly	O
enhanced	O
lipopolysaccharide	O
-	O
(	O
LPS	O
)	O
induced	O
IL-1beta	B-DNA
promoter	I-DNA
-driven	O
CAT	B-protein
activity	O
in	O
a	O
dose-dependent	O
manner	O
.	O

However	O
,	O
V3-BH10	B-protein
enhanced	O
IL-2	B-protein
-induced	B-RNA
mRNA	I-RNA
expression	O
of	O
c-fos	B-DNA
but	O
not	O
c-myc	B-DNA
or	O
junB	B-DNA
.	O

We	O
have	O
determined	O
how	O
the	O
phosphorylation	O
of	O
the	O
retinoblastoma	B-protein
family	I-protein
(	O
pRb	B-protein
,	O
p107	B-protein
,	O
and	O
p130	B-protein
)	O
is	O
governed	O
in	O
individual	O
cell	O
cycle	O
phases	O
of	O
Daudi	B-cell_line
B-cells	I-cell_line
during	O
cell	O
cycle	O
exit	O
triggered	O
by	O
alpha-interferon	B-protein
(	O
alpha-IFN	B-protein
)	O
.	O

These	O
results	O
suggest	O
that	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
IFN-beta	B-protein
can	O
activate	O
other	O
transcription	B-protein
factor	I-protein
(	O
s	O
)	O
distinct	O
from	O
ISGF3	B-protein
to	O
regulate	O
PLC	B-protein
gamma	I-protein
1	I-protein
expression	O
.	O

In	O
addition	O
,	O
SE	B-protein
can	O
induce	O
an	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
nonresponsive	O
state	O
and	O
apoptosis	O
.	O

In	O
1991	O
,	O
we	O
demonstrated	O
,	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
that	O
3	O
different	O
factors	O
(	O
termed	O
B1	B-protein
,	O
B2	B-protein
and	O
B3	B-protein
)	O
with	O
affinity	O
for	O
the	O
KB-enhancer	B-DNA
target	I-DNA
sequence	I-DNA
were	O
specifically	O
detected	O
in	O
nuclear	O
extracts	O
from	O
HIV1-infected	B-cell_type
monocytes	I-cell_type
and	O
macrophages	B-cell_type
.	O

X-linked	O
spinal	O
and	O
bulbar	O
muscular	O
atrophy	O
(	O
SBMA	O
)	O
,	O
an	O
adult-onset	O
form	O
of	O
motor	O
neuron	O
disease	O
,	O
was	O
recently	O
reported	O
to	O
be	O
caused	O
by	O
amplification	O
of	O
the	O
CAG	O
repeats	O
in	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
.	O

By	O
examining	O
in	O
vitro-differentiated	B-cell_line
embryonic	I-cell_line
stem	I-cell_line
cells	I-cell_line
,	O
we	O
showed	O
previously	O
that	O
in	O
the	O
absence	O
of	O
GATA-1	B-protein
,	O
committed	B-cell_line
erythroid	I-cell_line
precursors	I-cell_line
fail	O
to	O
complete	O
maturation	O
and	O
instead	O
undergo	O
apoptosis	O
.	O

Daidzein	O
and	O
genistein	O
glucuronides	O
in	O
vitro	O
are	O
weakly	O
estrogenic	O
and	O
activate	O
human	B-cell_type
natural	I-cell_type
killer	I-cell_type
cells	I-cell_type
at	O
nutritionally	O
relevant	O
concentrations	O
.	O

Here	O
,	O
we	O
show	O
that	O
this	O
diversity	O
can	O
be	O
partitioned	O
on	O
the	O
basis	O
of	O
crossreactive	O
cytotoxicity	O
patterns	O
involving	O
the	O
recognition	O
of	O
a	O
self	O
peptide-RSKFRQIV-located	O
in	O
a	O
serine/threonine	B-protein
kinase	I-protein
and	O
a	O
bacterial	O
peptide-RRKYKQII-located	O
in	O
Staphylococcus	B-protein
aureus	I-protein
replication	I-protein
initiation	I-protein
protein	I-protein
.	O

Tat-binding	B-protein
protein	I-protein
7	I-protein
is	O
a	O
subunit	O
of	O
the	O
26S	B-protein
protease	I-protein
.	O

Eosinophil	B-protein
granule	I-protein
major	I-protein
basic	I-protein
protein	I-protein
(	O
MBP	B-protein
)	O
is	O
expressed	O
exclusively	O
in	O
eosinophils	B-cell_type
and	O
basophils	B-cell_type
in	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

We	O
used	O
phenolic	O
,	O
lipid-soluble	O
,	O
chain-breaking	O
antioxidants	O
(	O
butylated	O
hydroxyanisole	O
(	O
BHA	O
)	O
,	O
nordihydroquairetic	O
acid	O
,	O
or	O
alpha-tocopherol	O
(	O
vitamin	O
E	O
)	O
to	O
show	O
that	O
peroxyl	O
radical	O
scavenging	O
in	O
unstimulated	B-cell_line
and	I-cell_line
PMA-	I-cell_line
or	I-cell_line
TNF-stimulated	I-cell_line
cells	I-cell_line
blocks	O
the	O
functions	O
depending	O
on	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
the	O
immunosuppressive	O
effect	O
of	O
oxLDLs	B-protein
might	O
operate	O
via	O
a	O
dysregulation	O
of	O
the	O
T-lymphocyte	B-cell_type
activation	O
mechanisms	O
.	O

Human	B-cell_type
phagocytes	I-cell_type
recognize	O
bacterial	O
LPS	O
(	O
endotoxin	O
)	O
through	O
membrane	B-protein
CD14	I-protein
(	O
mCD14	B-protein
)	O
,	O
a	O
proinflammatory	B-protein
LPS	I-protein
receptor	I-protein
.	O

Transcriptional	O
activation	O
of	O
the	O
macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
gene	I-DNA
by	O
IL-2	B-protein
is	O
associated	O
with	O
secretion	O
of	O
bioactive	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
protein	I-protein
by	O
monocytes	B-cell_type
and	O
involves	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
.	O

Damage	O
to	O
the	O
genes	O
encoding	O
proteins	O
that	O
function	O
in	O
intracellular	O
signaling	O
,	O
transcription	O
,	O
or	O
regulation	O
of	O
the	O
cell	O
cycle	O
has	O
been	O
identified	O
and	O
linked	O
at	O
varying	O
degrees	O
to	O
the	O
progression	O
of	O
certain	O
lymphoid	O
malignancies	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
-induced	O
maturation	O
mediated	O
by	O
the	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
alpha	I-protein
(	O
RAR	B-protein
alpha	I-protein
)	O
has	O
been	O
implicated	O
in	O
myeloid	O
development	O
.	O

Transforming	B-protein
growth	I-protein
factor-beta	I-protein
(	O
TGF-beta	B-protein
)	O
inhibits	O
B	B-cell_type
cell	I-cell_type
Ig	B-protein
secretion	O
and	O
reduces	O
B	B-cell_type
cell	I-cell_type
membrane	O
Ig	B-protein
expression	O
.	O

BSAP	B-protein
has	O
been	O
identified	O
previously	O
as	O
a	O
transcription	B-protein
factor	I-protein
that	O
is	O
expressed	O
at	O
early	O
,	O
but	O
not	O
late	O
,	O
stages	O
of	O
B-cell	O
differentiation	O
.	O

However	O
,	O
these	O
two	O
decoy	O
oligodeoxynucleotides	O
together	O
almost	O
completely	O
abrogated	O
IL-4	B-protein
-induced	O
germline	B-DNA
Cepsilon	O
transcription	O
.	O

Both	O
inducible	O
complexes	O
persisted	O
for	O
at	O
least	O
3	O
weeks	O
.	O

Highly	O
polarized	O
HLA	B-protein
class	I-protein
II	I-protein
antigen	I-protein
processing	O
and	O
presentation	O
by	O
human	B-cell_type
intestinal	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O

PPARalpha	O
activators	O
inhibit	O
cytokine-induced	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
expression	O
in	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O

Leukocyte	B-cell_type
populations	I-cell_type
,	O
hormone	B-protein
receptors	I-protein
and	O
apoptosis	O
in	O
eutopic	O
and	O
ectopic	O
first	O
trimester	O
human	O
pregnancies	O
.	O

Host	O
control	O
of	O
HIV-1	O
parasitism	O
in	O
T	B-cell_type
cells	I-cell_type
by	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
.	O

The	O
binding	O
sites	O
and	O
partial	O
proteolysis	O
profile	O
of	O
this	O
protein	O
are	O
indistinguishable	O
from	O
those	O
of	O
the	O
erythroid	B-protein
protein	I-protein
;	O
also	O
,	O
NF-E1	B-RNA
messenger	I-RNA
RNA	I-RNA
is	O
the	O
same	O
size	O
in	O
both	O
the	O
megakaryocytic	B-cell_line
and	I-cell_line
erythroid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Its	O
N-terminal	B-protein
125	I-protein
amino	I-protein
acids	I-protein
function	O
as	O
an	O
independent	B-protein
transcriptional	I-protein
activation	I-protein
domain	I-protein
.	O

VASP	O
is	O
not	O
involved	O
in	O
Shigella	O
movement	O
,	O
and	O
the	O
function	O
of	O
profilin	B-protein
does	O
not	O
require	O
its	O
binding	O
to	O
proline-rich	B-protein
regions	I-protein
.	O

However	O
,	O
stimulation	O
of	O
B-cells	B-cell_type
from	O
B-CLL	O
patients	O
under	O
conditions	O
which	O
induced	O
differentiation	O
into	O
plasma	B-cell_type
cells	I-cell_type
was	O
associated	O
with	O
induction	O
of	O
Bcd	B-DNA
gene	O
expression	O
.	O

In	O
contrast	O
,	O
APC	B-cell_type
pulsed	O
with	O
Ala-substituted	O
peptides	O
430-444	O
,	O
442A	O
or	O
433-442A	O
at	O
neutral	O
pH	O
failed	O
to	O
stimulate	O
the	O
T	B-cell_line
cell	I-cell_line
clone	I-cell_line
,	O
while	O
APC	B-cell_type
pulsed	O
at	O
acidic	O
pH	O
and	O
subsequently	O
washed	O
led	O
to	O
successful	O
T	O
cell	O
activation	O
.	O

NF-AT	B-protein
induction	O
may	O
require	O
two	O
activation-dependent	O
events	O
:	O
the	O
CsA-sensitive	O
translocation	O
of	O
a	O
pre-existing	O
component	O
and	O
the	O
CsA-resistant	O
synthesis	O
of	O
a	O
nuclear	B-protein
component	I-protein
.	O

Chemokines	B-protein
refer	O
to	O
a	O
rapidly	O
expanding	O
family	O
of	O
small	O
cytokines	B-protein
whose	O
primary	O
function	O
is	O
recruitment	O
of	O
leukocytes	O
to	O
inflammatory	O
sites	O
.	O

Many	O
transcription	B-protein
factors	I-protein
contain	O
similar	O
structural	B-protein
protein	I-protein
sequences	I-protein
,	O
and	O
we	O
have	O
used	O
an	O
RT-PCR-based	O
approach	O
to	O
isolate	O
sequences	O
,	O
from	O
transcription	B-protein
factor	I-protein
gene	O
families	O
which	O
share	O
similar	O
domains	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
the	O
activation	O
of	O
NF-kappaB	B-protein
by	O
LPS	O
in	O
a	O
promonocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
U937	B-cell_line
)	O
followed	O
a	O
rather	O
slow	O
kinetics	O
,	O
depending	O
on	O
the	O
rate	O
of	O
IkappaB-alpha	B-protein
inhibitor	O
hydrolysis	O
.	O

These	O
effects	O
are	O
controlled	O
by	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
,	O
a	O
member	O
of	O
the	O
steroid	B-protein
hormone	I-protein
receptor	I-protein
family	I-protein
.	O

To	O
characterize	O
the	O
protein-DNA	O
interactions	O
important	O
for	O
the	O
developmental	O
control	O
of	O
the	O
human	B-DNA
beta-globin	I-DNA
locus	I-DNA
,	O
we	O
analyzed	O
by	O
in	O
vivo	O
dimethyl	O
sulfate	O
footprinting	O
erythroid	B-cell_type
cells	I-cell_type
expressing	O
either	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
developmental	O
program	O
.	O

Recently	O
,	O
we	O
have	O
reported	O
that	O
the	O
histogenesis	O
of	O
HD	O
of	O
the	O
general	O
population	O
may	O
be	O
assessed	O
by	O
monitoring	O
the	O
expression	O
pattern	O
of	O
BCL-6	B-protein
,	O
a	O
transcription	B-protein
factor	I-protein
expressed	O
in	O
germinal	B-cell_line
center	I-cell_line
(	I-cell_line
GC	I-cell_line
)	I-cell_line
B	I-cell_line
cells	I-cell_line
,	O
and	O
of	O
CD138/syndecan-1	B-protein
(	O
syn-1	B-protein
)	O
,	O
a	O
proteoglycan	O
associated	O
with	O
post-GC	O
,	O
terminal	O
B-cell	B-cell_type
differentiation	O
.	O

Additionally	O
,	O
no	O
tyrosine	O
phosphorylation	O
of	O
HS1	B-protein
was	O
induced	O
by	O
mitogenic	B-cell_type
pairs	I-cell_type
of	O
anti-CD2	B-protein
mAbs	I-protein
capable	O
of	O
activating	O
the	O
transcription	B-protein
factor	I-protein
NFAT	I-protein
(	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
)	O
.	O

Differential	O
phosphorylation	O
and	O
consequent	O
differential	O
activation	O
of	O
both	O
separate	O
and	O
overlapping	O
STAT	B-protein
proteins	I-protein
by	O
IL-2	B-protein
,	O
IL-12	B-protein
,	O
and	O
IFN-alpha	B-protein
may	O
provide	O
a	O
molecular	O
basis	O
for	O
the	O
similarities	O
and	O
differences	O
in	O
the	O
actions	O
of	O
these	O
cytokines	B-protein
on	O
NK	B-cell_type
cells	I-cell_type
.	O

The	O
p21ras	B-protein
small	I-protein
GTP	I-protein
binding	I-protein
proteins	I-protein
participate	O
in	O
signal	O
transduction	O
from	O
cell	O
surface	O
receptors	O
and	O
affect	O
neoplastic	O
transformation	O
and	O
development	O
in	O
many	O
different	O
cell	O
types	O
.	O

When	O
added	O
pulsewise	O
to	O
immature	B-cell_type
cells	I-cell_type
,	O
differentiation	O
was	O
accelerated	O
while	O
more	O
mature	B-cell_type
cells	I-cell_type
underwent	O
premature	O
cell	O
death	O
.	O

This	O
indicated	O
that	O
the	O
dUTPase	O
is	O
expressed	O
during	O
EBV	O
replication	O
and	O
reactivation	O
.	O

The	O
gene	O
has	O
41	B-DNA
small	I-DNA
exons	I-DNA
spanning	O
45	B-DNA
kb	I-DNA
of	O
genomic	B-DNA
DNA	I-DNA
and	O
encoding	O
a	O
5.5	B-RNA
kb	I-RNA
mRNA	I-RNA
.	O

Understanding	O
the	O
cis-	B-protein
and	I-protein
transacting	I-protein
factors	I-protein
that	O
regulate	O
the	O
tissue-specific	O
expression	O
of	O
PECAM-1	B-protein
should	O
increase	O
our	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
vascular-specific	O
gene	O
expression	O
is	O
achieved	O
.	O

The	O
MNDA	B-RNA
mRNA	I-RNA
level	O
in	O
the	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
also	O
unaffected	O
by	O
the	O
latter	O
four	O
agents	O
.	O

The	O
levels	O
of	O
p56lck	B-protein
and	O
p59fyn	B-protein
were	O
lower	O
in	O
tumor-draining	O
than	O
in	O
normal	B-cell_type
LN	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
production	O
of	O
tyrosine-phosphorylated	B-protein
substrates	I-protein
was	O
markedly	O
depressed	O
following	O
anti-CD3	B-protein
stimulation	O
.	O

Thus	O
,	O
Tap	B-protein
is	O
likely	O
to	O
be	O
an	O
important	O
cellular	O
mediator	O
of	O
Tip	B-protein
function	O
in	O
T	O
cell	O
transformation	O
by	O
herpesvirus	O
saimiri	O
.	O

An	O
unknown	O
event	O
might	O
be	O
involved	O
in	O
GC-resistance	O
of	O
CRF	O
.	O

GR	B-protein
binding	O
parameters	O
were	O
analyzed	O
in	O
relation	O
to	O
the	O
results	O
of	O
the	O
combined	O
dexamethasone	O
-CRH	B-protein
test	O
,	O
which	O
reflects	O
corticosteroid	O
receptor	O
function	O
at	O
the	O
hypothalamus	O
,	O
in	O
30	O
patients	O
and	O
9	O
controls	O
.	O

Consistent	O
with	O
a	O
role	O
for	O
bcl-xL	B-protein
in	O
mediating	O
GATA-1	B-protein
-induced	O
erythroid	O
cell	O
survival	O
,	O
in	O
vitro-differentiated	B-cell_line
bcl-xL-/-	I-cell_line
embryonic	I-cell_line
stem	I-cell_line
cells	I-cell_line
fail	O
to	O
generate	O
viable	O
mature	O
definitive	O
erythroid	B-cell_type
cells	I-cell_type
,	O
a	O
phenotype	O
resembling	O
that	O
of	O
GATA-1	B-DNA
gene	I-DNA
disruption	O
.	O

Seventeen	O
cases	O
revealed	O
distinct	O
immunostaining	O
against	O
at	O
least	O
1	O
of	O
the	O
5	O
steroid	O
hormones	O
.	O

Egr-1	O
and	O
the	O
serum	O
response	O
factor	O
were	O
found	O
to	O
interact	O
specifically	O
with	O
the	O
intronic	B-DNA
sequence	I-DNA
at	O
+265	O
and	O
+448	O
,	O
respectively	O
.	O

All	O
these	O
motifs	O
are	O
essential	O
and	O
collectively	O
control	O
transcriptional	O
activity	O
.	O

This	O
suggests	O
that	O
NF-kappa	B-protein
B	I-protein
expression	O
may	O
be	O
necessary	O
for	O
the	O
maintenance	O
of	O
the	O
malignant	O
phenotype	O
and	O
provides	O
a	O
therapeutic	O
approach	O
for	O
HTLV-I-associated	O
disease	O
.	O

Finally	O
,	O
we	O
did	O
not	O
observed	O
either	O
up-regulation	O
or	O
antagonism	O
of	O
GcR	B-protein
by	O
ketoconazole	O
treatment	O
,	O
at	O
the	O
time	O
that	O
cortisol	O
levels	O
of	O
patients	O
with	O
Cushing	O
's	O
disease	O
were	O
reduced	O
.	O

We	O
have	O
investigated	O
several	O
molecular	O
pathways	O
that	O
are	O
known	O
to	O
be	O
activated	O
by	O
IL-2	B-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

To	O
determine	O
the	O
contribution	O
of	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
the	O
IL-7	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
(	O
IL-7R	B-protein
alpha	I-protein
)	O
to	O
activation	O
of	O
STAT	B-protein
proteins	I-protein
,	O
transfectants	O
of	O
the	O
murine	B-cell_line
pro-B	I-cell_line
cell	I-cell_line
line	I-cell_line
BAF3	I-cell_line
were	O
made	O
that	O
express	O
chimeric	B-protein
receptors	I-protein
consisting	O
of	O
the	O
extracellular	B-protein
domain	I-protein
of	O
human	B-protein
granulocyte	I-protein
colony-stimulating	I-protein
factor	I-protein
receptor	I-protein
(	O
G-CSF-R	B-protein
)	O
and	O
the	O
transmembrane	B-protein
and	I-protein
intracellular	I-protein
domains	I-protein
of	O
human	B-protein
IL-7R	I-protein
alpha	I-protein
.	O

Overexpression	O
of	O
SIT	B-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
downmodulates	O
T	O
cell	O
receptor-	O
and	O
phytohemagglutinin-mediated	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
by	O
interfering	O
with	O
signaling	O
processes	O
that	O
are	O
probably	O
located	O
upstream	O
of	O
activation	O
of	O
phospholipase	B-protein
C	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
ER	B-protein
alpha	I-protein
(	O
referred	O
to	O
throughout	O
as	O
ER	B-protein
)	O
on	O
DNA-binding	O
activities	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
regulating	O
the	O
expression	O
of	O
erythroid-specific	B-DNA
genes	I-DNA
,	O
and	O
,	O
in	O
particular	O
,	O
the	O
histone	B-DNA
H5	I-DNA
gene	I-DNA
.	O

rel	B-protein
Is	O
rapidly	O
tyrosine-phosphorylated	O
following	O
granulocyte-colony	B-protein
stimulating	I-protein
factor	I-protein
treatment	O
of	O
human	O
neutrophils	O
.	O

In	O
summary	O
,	O
glucocorticoid	B-protein
receptor	I-protein
determination	O
in	O
patients	O
with	O
lupus	O
nephritis	O
may	O
be	O
a	O
predictive	O
clue	O
for	O
assessing	O
responsiveness	O
to	O
glucocorticoid	O
therapy	O
.	O

CONCLUSION	O
:	O
Cytomegalovirus	B-protein
immediate	I-protein
early	I-protein
gene	I-protein
products	I-protein
significantly	O
enhanced	O
expression	O
of	O
IL-6	B-protein
in	O
LPS-stimulated	O
cells	O
.	O

Also	O
co-transfections	O
of	O
the	O
wild-type	B-DNA
promoter	I-DNA
construct	I-DNA
with	O
an	O
AP-1/c-jun	B-DNA
expression	I-DNA
vector	I-DNA
resulted	O
in	O
augmented	O
basal	O
and	O
PMA-induced	O
promoter	O
activity	O
.	O

Alteration	O
of	O
a	O
single	O
serine	O
in	O
the	O
basic	B-protein
domain	I-protein
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
ZEBRA	I-protein
protein	I-protein
separates	O
its	O
functions	O
of	O
transcriptional	O
activation	O
and	O
disruption	O
of	O
latency	O
.	O

The	O
selective	O
expression	O
and	O
regulation	O
of	O
the	O
IL-12R	B-protein
beta	I-protein
2	I-protein
subunit	I-protein
may	O
help	O
to	O
understand	O
the	O
basis	O
of	O
Th1/Th2	O
differentiation	O
and	O
may	O
provide	O
therapeutic	O
options	O
for	O
altering	O
the	O
Th1/Th2	O
balance	O
in	O
several	O
immuno-pathological	O
conditions	O
such	O
as	O
autoimmune	O
diseases	O
and	O
allergies	O
.	O

Through	O
activation	O
of	O
this	O
and	O
other	O
NF-Y	B-protein
driven	O
promoters	B-DNA
,	O
the	O
Tax1	B-protein
-NF-Y	B-protein
interaction	O
may	O
play	O
a	O
critical	O
role	O
in	O
causing	O
cellular	O
transformation	O
and	O
HTLV-1	O
pathogenesis	O
.	O

Using	O
tetanus	B-cell_type
toxoid	I-cell_type
specific	I-cell_type
and	I-cell_type
HLA-DR-restricted	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
we	O
show	O
that	O
polarized	B-cell_type
intestinal	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
directed	O
to	O
express	O
HLA-DR	B-protein
molecules	I-protein
are	O
able	O
to	O
initiate	O
class	O
II	O
processing	O
only	O
after	O
internalization	O
of	O
antigen	O
from	O
their	O
apical	O
surface	O
.	O

Analyses	O
of	O
the	O
regulation	O
of	O
IkappaBalpha	B-protein
in	O
TNF-alpha-treated	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
from	O
young	O
and	O
elderly	O
donors	O
revealed	O
severely	O
compromised	O
degradation	O
of	O
IkappaBalpha	B-protein
in	O
T	B-cell_type
cells	I-cell_type
from	O
the	O
elderly	O
.	O

The	O
unusual	O
CD56+	B-cell_type
CD16-	I-cell_type
eGLs	I-cell_type
present	O
in	O
large	O
numbers	O
in	O
late	O
secretory	O
phase	O
eutopic	O
endometrium	O
were	O
highly	O
purified	O
(	O
>	O
98	O
%	O
)	O
by	O
immunomagnetic	O
separation	O
.	O

Expression	O
of	O
CD30	B-protein
by	O
these	O
cells	O
is	O
induced	O
by	O
CD40L	B-protein
but	O
is	O
inhibited	O
by	O
B	O
cell	O
receptor	O
coengagement	O
and/or	O
exposure	O
to	O
IL-6	B-protein
and	O
IL-12	B-protein
.	O

Molecular	O
characterization	O
and	O
pattern	O
of	O
tissue	O
expression	O
of	O
the	O
gene	O
for	O
neutrophil	B-protein
gelatinase-associated	I-protein
lipocalin	I-protein
from	O
humans	O
.	O

This	O
raises	O
the	O
possibility	O
that	O
androgen	B-protein
receptors	I-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
differ	O
from	O
those	O
in	O
genital	B-cell_type
skin	I-cell_type
fibroblasts	I-cell_type
.	O

The	O
adenovirus	B-DNA
E1B	I-DNA
19K	I-DNA
gene	I-DNA
plays	O
an	O
essential	O
role	O
in	O
transformation	O
of	O
primary	B-cell_type
rodent	I-cell_type
cells	I-cell_type
in	O
cooperation	O
with	O
E1A	B-protein
and	O
in	O
the	O
inhibition	O
of	O
apoptosis	O
during	O
lytic	O
infection	O
.	O

Our	O
data	O
suggest	O
that	O
nNOS	B-protein
in	O
astrocytes	B-cell_type
regulates	O
NF	B-protein
kappaB	I-protein
activity	O
and	O
iNOS	B-protein
expression	O
,	O
and	O
indicate	O
a	O
novel	O
regulatory	O
role	O
for	O
nNOS	B-protein
in	O
tonically	O
suppressing	O
central	O
nervous	O
system	O
,	O
NF	B-DNA
kappaB-regulated	I-DNA
genes	I-DNA
.	O

Second	O
,	O
recombinant	B-protein
LEF-1	I-protein
is	O
shown	O
to	O
activate	O
HIV-1	O
transcription	O
on	O
chromatin-assembled	B-DNA
DNA	I-DNA
in	O
vitro	O
.	O

Monocytic	O
differentiation	O
of	O
HL-60	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
correlates	O
with	O
the	O
induction	O
of	O
Bcl-xL	B-protein
.	O

By	O
in	O
vitro	O
transcription	O
assays	O
,	O
DM	O
regulated	O
IL-2R	B-protein
alpha	I-protein
gene	O
expression	O
at	O
a	O
transcriptional	O
level	O
while	O
transcription	O
of	O
IL-2R	B-DNA
beta	I-DNA
gene	I-DNA
was	O
unaffected	O
by	O
DM	O
.	O

The	O
C-terminal	B-protein
domain	I-protein
of	O
the	O
precursor	O
is	O
rapidly	O
degraded	O
,	O
forming	O
the	O
mature	B-protein
p50	I-protein
subunit	I-protein
consisted	O
of	O
the	O
N-terminal	B-protein
region	I-protein
of	O
the	O
molecule	O
.	O

Arsenic	O
contents	O
in	O
hair	O
and	O
nail	O
were	O
increased	O
,	O
and	O
the	O
peak	O
content	O
of	O
arsenic	O
could	O
reach	O
2.5	O
to	O
2.7	O
microg/g	O
tissue	O
at	O
CR	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
thrombin	B-protein
and	O
TRP	O
enhanced	O
CD69	B-protein
expression	O
and	O
interleukin	B-protein
2	I-protein
production	O
induced	O
by	O
T	B-protein
cell	I-protein
receptor	I-protein
cross-linking	O
in	O
both	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
peripheral	O
blood	O
lymphocytes	B-cell_type
.	O

Lineage-specific	O
expression	O
is	O
controlled	O
at	O
the	O
level	O
of	O
mRNA	O
transcription	O
.	O

Various	O
stimuli	O
of	O
T	B-cell_type
cells	I-cell_type
that	O
induce	O
the	O
activity	O
of	O
TAD-A	B-protein
also	O
enhance	O
the	O
activity	O
of	O
TAD-B	B-protein
,	O
but	O
,	O
unlike	O
TAD-A	B-protein
,	O
TAD-B	B-protein
remains	O
unphosphorylated	O
by	O
protein	O
from	O
12-O-tetradecanoyl	B-cell_line
12-phorbol	I-cell_line
13-acetate-stimulated	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

When	O
32Dcl3	B-cell_line
cells	I-cell_line
expressing	O
exogenous	O
Bcl-2	B-protein
were	O
induced	O
to	O
differentiate	O
,	O
the	O
onset	O
of	O
morphological	O
differentiation	O
was	O
delayed	O
.	O

Influence	O
of	O
estradiol	O
and	O
tamoxifen	O
on	O
susceptibility	O
of	O
human	B-cell_line
breast	I-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
to	O
lysis	O
by	O
lymphokine-activated	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O

IL-1	B-DNA
beta	I-DNA
and	I-DNA
IL-6	I-DNA
genes	I-DNA
contain	O
AP-1	B-DNA
binding	I-DNA
sites	I-DNA
as	O
regulatory	B-DNA
elements	I-DNA
,	O
the	O
AP-1	B-protein
protein	O
being	O
composed	O
of	O
c-jun	B-protein
and	I-protein
c-fos	I-protein
gene	I-protein
products	I-protein
.	O

Considering	O
that	O
nuclear	B-protein
regulatory	I-protein
factor-kappa	I-protein
beta	I-protein
(	B-protein
NF-kappa	I-protein
B	I-protein
)	I-protein
/Rel	I-protein
is	O
a	O
common	O
regulatory	B-protein
element	I-protein
of	O
the	O
promoter	B-DNA
region	I-DNA
of	O
the	O
inflammatory	B-DNA
cytokine	I-DNA
genes	I-DNA
,	O
herein	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
acute	O
ethanol	O
affects	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

One	O
clone	O
(	O
C3/5	B-cell_line
,	I-cell_line
CD3	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
,	I-cell_line
CD4	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
,	I-cell_line
CD8	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
)	O
was	O
selected	O
for	O
further	O
analysis	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
in	O
relation	O
to	O
age	O
and	O
to	O
sport	O
activity	O
.	O

The	O
data	O
show	O
that	O
hypertension	O
in	O
preeclamptic	O
women	O
can	O
be	O
treated	O
by	O
Urapidil	O
without	O
side	O
effects	O
or	O
reflex-tachycardia	O
.	O

A	O
signal	O
transduction	O
pathway	O
activated	O
by	O
many	O
cytokines	B-protein
has	O
recently	O
been	O
elaborated	O
.	O

Copyright	O
1997	O
Academic	O
Press	O
.	O

PHA	B-protein
-induced	O
kappaB-dependent	O
reporter	O
activity	O
was	O
,	O
however	O
,	O
effectively	O
blocked	O
by	O
a	O
dominant	O
negative	O
form	O
of	O
Raf-1	B-protein
,	O
suggesting	O
a	O
critical	O
role	O
for	O
a	O
Raf	B-protein
kinase	I-protein
.	O

In	O
contrast	O
,	O
other	O
viral	O
and	O
cellular	O
products	O
have	O
not	O
been	O
influenced	O
by	O
the	O
level	O
of	O
H-7	O
used	O
.	O

In	O
addition	O
to	O
contributing	O
to	O
the	O
understanding	O
of	O
DLCL	O
pathogenesis	O
,	O
the	O
identification	O
of	O
BCL-6	B-protein
lesions	O
may	O
have	O
relevant	O
clinical	O
implications	O
.	O

These	O
results	O
suggest	O
that	O
herpes	B-protein
simplex	I-protein
tegument	I-protein
proteins	I-protein
are	O
processed	O
for	O
antigen	O
presentation	O
in	O
vivo	O
and	O
are	O
possible	O
candidate	O
compounds	O
for	O
herpes	O
simplex	O
vaccines	O
.	O

A	O
novel	B-cell_type
B-cell	I-cell_type
derived	O
(	O
Bcd	B-DNA
)	O
oncogene	B-DNA
has	O
been	O
isolated	O
from	O
the	O
peripheral	O
blood	O
lymphocytes	O
of	O
one	O
B-cell	O
chronic	O
lymphocytic	O
leukemia	O
(	O
B-CLL	O
)	O
patient	O
using	O
DNA	O
transfer	O
and	O
a	O
mouse	O
tumorigenicity	O
assay	O
.	O

Both	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
could	O
be	O
anergized	O
by	O
the	O
autopresentation	O
of	O
native	O
peptide	O
since	O
anergy	O
was	O
induced	O
in	O
cultures	O
lacking	O
fresh	O
antigen-presenting	B-cell_type
cells	I-cell_type
.	O

Activity	O
of	O
the	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
of	O
the	O
interleukin-2	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
in	O
somatic	B-cell_line
cell	I-cell_line
hybrids	I-cell_line
is	O
accompanied	O
by	O
the	O
nuclear	O
localization	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
induction	O
mechanism	O
of	O
SAA	B-DNA
gene	I-DNA
in	O
THP-1	B-cell_line
monocyte/macrophage	I-cell_line
cells	I-cell_line
which	O
play	O
a	O
critical	O
role	O
in	O
the	O
development	O
of	O
atherosclerotic	O
fatty	O
streak	O
and	O
plaque	O
formation	O
.	O

Nonspecific	O
protein	B-protein
kinase	I-protein
inhibition	O
inhibited	O
NF-kappaB	B-protein
activation	O
and	O
TNF-alpha	B-protein
release	O
,	O
while	O
specific	O
PKC	B-protein
inhibition	O
with	O
Bis	O
had	O
no	O
effect	O
on	O
LPS-induced	O
NF-kappaB	B-protein
DNA	O
binding	O
or	O
TNF-alpha	B-protein
release	O
.	O

Low	O
levels	O
of	O
c-jun	B-protein
transcripts	I-protein
were	O
detectable	O
in	O
resting	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O

3-deazaadenosine	O
,	O
a	O
S-adenosylhomocysteine	B-protein
hydrolase	I-protein
inhibitor	O
,	O
has	O
dual	O
effects	O
on	O
NF-kappaB	B-protein
regulation	O
.	O

When	O
stably	O
introduced	O
into	O
primary	B-cell_type
erythroblasts	I-cell_type
or	O
conditionally	B-cell_line
transformed	I-cell_line
erythroid	I-cell_line
progenitors	I-cell_line
cells	I-cell_line
,	O
exogenous	O
GATA-2/ER	B-protein
promoted	O
proliferation	O
and	O
inhibited	O
terminal	O
differentiation	O
in	O
an	O
estrogen-dependent	O
manner	O
.	O

Furthermore	O
,	O
this	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
accumulation	O
did	O
not	O
require	O
synthesis	O
of	O
new	O
protein	B-protein
factors	I-protein
because	O
9-cis	O
RA	O
induced	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
accumulation	O
in	O
the	O
absence	O
of	O
new	O
protein	O
synthesis	O
.	O

Abnormalities	O
in	O
the	O
p16	B-DNA
,	I-DNA
p15	I-DNA
and	I-DNA
CDK4	I-DNA
genes	I-DNA
that	O
regulate	O
transition	O
through	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
have	O
been	O
implicated	O
in	O
the	O
malignant	O
progression	O
of	O
astrocytomas	O
.	O

In	O
the	O
four	O
representative	O
mutants	O
investigated	O
,	O
the	O
DNA	B-DNA
reiterations	I-DNA
all	O
started	O
within	O
a	O
six-base-pair	B-DNA
consensus	I-DNA
sequence	I-DNA
,	O
G	O
(	O
or	O
C	O
)	O
CTGTG	O
,	O
located	O
in	O
the	O
second	O
exon	B-DNA
of	O
the	O
E1a	B-DNA
region	I-DNA
(	O
at	O
nt	O
1333	O
,	O
1367	O
,	O
or	O
1419	O
)	O
.	O

We	O
have	O
recently	O
shown	O
that	O
the	O
expression	O
of	O
Tax	B-protein
protected	O
the	O
mouse	B-cell_line
T-cell	I-cell_line
line	I-cell_line
CTLL-2	I-cell_line
against	O
apoptosis	O
induced	O
by	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
deprivation	O
and	O
converted	O
its	O
growth	O
from	O
being	O
IL-2	B-protein
dependent	O
to	O
being	O
IL-2	B-protein
independent	O
.	O

Stimulation	O
of	O
interleukin-1	B-DNA
gene	I-DNA
transcription	O
may	O
be	O
caused	O
by	O
the	O
stimulation	O
of	O
transcription	B-protein
factor	I-protein
activities	O
,	O
including	O
those	O
of	O
AP-1	B-protein
,	O
by	O
these	O
protein	B-protein
phosphatase	I-protein
inhibitors	O
.	O

A	O
less	O
pronounced	O
reduction	O
in	O
lambda	B-protein
L	I-protein
chain	I-protein
and	O
microH	B-protein
chain	I-protein
was	O
also	O
noted	O
.	O

Cell-mediated	O
immunity	O
plays	O
an	O
essential	O
role	O
in	O
the	O
control	O
of	O
infection	O
with	O
the	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
.	O

When	O
the	O
EKLF-/-	B-cell_line
cells	I-cell_line
were	O
injected	O
into	O
blastocysts	O
,	O
they	O
did	O
not	O
contribute	O
at	O
a	O
detectable	O
level	O
to	O
the	O
mature	O
erythrocyte	O
compartment	O
of	O
the	O
chimeric	O
animals	O
,	O
based	O
on	O
analysis	O
of	O
glucose	B-protein
phosphate	I-protein
isomerase-1	I-protein
(	I-protein
GPI-1	I-protein
)	I-protein
isozymes	I-protein
and	O
hemoglobins	O
that	O
distinguish	O
ES	B-cell_type
cell-derived	I-cell_type
erythrocytes	I-cell_type
from	O
host	O
blastocyst-derived	B-cell_type
erythrocytes	I-cell_type
.	O

Results	O
of	O
this	O
study	O
indicate	O
that	O
a	O
sustained	O
elevated	O
[	O
Ca2+	O
]	O
i	O
is	O
a	O
significant	O
factor	O
in	O
oxidant-induced	O
NF-kappaB	B-protein
activation	O
.	O

TCF-1	B-protein
consists	O
of	O
two	O
polypeptides	O
of	O
about	O
50	O
kD	O
and	O
105	O
kD	O
;	O
the	O
former	O
seems	O
to	O
be	O
related	O
to	O
the	O
50	B-protein
kD	I-protein
polypeptide	I-protein
of	O
NF-kB	B-protein
.	O

The	O
expression	O
of	O
many	O
genes	O
for	O
which	O
products	O
are	O
involved	O
in	O
inflammation	O
is	O
controlled	O
by	O
the	O
transcriptional	B-protein
regulator	I-protein
nuclear	I-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
.	O

Many	O
studies	O
show	O
that	O
monoamine	B-protein
oxidase	I-protein
B	I-protein
in	O
blood	B-cell_type
cells	I-cell_type
is	O
a	O
biological	O
marker	O
for	O
personality	O
characteristics	O
such	O
as	O
sensation	O
seeking	O
.	O

The	O
resulting	O
diminished	O
phosphorylation	O
of	O
c-Jun	B-protein
and	O
JunD	B-protein
at	O
their	O
NH	B-protein
(	I-protein
2	I-protein
)	I-protein
-termini	I-protein
decreases	O
the	O
ability	O
of	O
these	O
nuclear	O
proteins	O
to	O
autostimulate	O
the	O
expression	O
of	O
the	O
c-Jun	B-DNA
and	I-DNA
JunD	I-DNA
genes	I-DNA
,	O
thus	O
leading	O
to	O
lower	O
production	O
of	O
c-Jun	B-protein
and	O
JunD	B-protein
.	O

The	O
ds	O
phosphorothioate	O
oligonucleotides	O
probably	O
compete	O
for	O
binding	O
of	O
specific	O
transcription	O
factors	O
and	O
may	O
provide	O
anti-viral	O
,	O
immunosuppressive	O
,	O
or	O
other	O
therapeutic	O
effects	O
.	O

Monocyte	O
adhesion	O
and	O
receptor	O
cross-linking	O
induced	O
stress	O
fiber	O
assembly	O
,	O
and	O
inhibitors	O
of	O
myosin	B-protein
light	I-protein
chain	I-protein
kinase	I-protein
prevented	O
this	O
response	O
but	O
did	O
not	O
affect	O
receptor	O
clustering	O
.	O

A	O
few	O
viruses	O
,	O
like	O
the	O
Herpesviruses	O
or	O
the	O
papillomaviruses	O
,	O
however	O
,	O
have	O
developed	O
a	O
sophisticated	O
strategy	O
for	O
persisting	O
lifelong	O
,	O
usually	O
asymptomatically	O
in	O
the	O
host	O
,	O
hiding	O
from	O
the	O
immune	O
system	O
and	O
producing	O
infectious	O
progeny	O
at	O
the	O
same	O
time	O
.	O

In	O
vitro	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
expression	O
by	O
antisense	O
oligodeoxynucleotides	O
(	O
ODNs	O
)	O
inhibited	O
growth	O
of	O
these	O
culture-adapted	B-cell_line
Tax-transformed	I-cell_line
fibroblasts	I-cell_line
as	O
well	O
as	O
an	O
HTLV-I-transformed	B-cell_line
human	I-cell_line
lymphocyte	I-cell_line
line	I-cell_line
.	O

In	O
contrast	O
,	O
intracytoplasmic	O
TNFalpha	B-protein
levels	O
were	O
strongly	O
reduced	O
in	O
transfected	B-cell_line
clones	I-cell_line
.	O

Dendritic	B-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
are	O
potent	O
APC	B-cell_type
during	O
primary	O
and	O
secondary	O
immune	O
responses	O
.	O

TNF	B-protein
alpha	I-protein
did	O
not	O
activate	O
cAMP	O
production	O
and	O
its	O
signal	O
was	O
not	O
modulated	O
by	O
cAMP	O
activators	O
.	O

Apparently	O
normal	O
at	O
birth	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
-/-	O
mice	O
exhibit	O
severe	O
runting	O
,	O
skin	O
defects	O
,	O
and	O
extensive	O
granulopoiesis	O
postnatally	O
,	O
typically	O
dying	O
by	O
8	O
days	O
.	O

The	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	I-protein
M-CSF	I-protein
)	I-protein
receptor	I-protein
is	O
expressed	O
in	O
a	O
tissue-specific	O
fashion	O
from	O
two	O
distinct	O
promoters	B-DNA
in	O
monocytes/macrophages	B-cell_type
and	O
the	O
placenta	O
.	O

In	O
addition	O
,	O
extracellular	B-protein
factor	I-protein
(	O
s	O
)	O
released	O
by	O
X-ray-treated	B-cell_line
human	I-cell_line
colonic	I-cell_line
carcinoma	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
HT29	B-cell_line
)	O
might	O
activate	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
of	O
HIV-1	O
in	O
non-irradiated	B-cell_line
HT29	I-cell_line
cells	I-cell_line
.	O

Since	O
APL	B-cell_line
cells	I-cell_line
do	O
not	O
express	O
HLA	B-protein
class	I-protein
II	I-protein
molecules	I-protein
,	O
we	O
tested	O
in	O
two	O
donors	O
(	O
D.E.	O
and	O
C.H.R.	O
)	O
and	O
in	O
patients	O
S.R.and	O
P.G.whether	O
the	O
use	O
of	O
9-mer	O
peptides	O
(	O
BCR1/9	O
)	O
would	O
generate	O
a	O
CD8	B-protein
/HLA	B-protein
class	I-protein
I	I-protein
-restricted	O
response	O
.	O

These	O
cells	O
,	O
however	O
,	O
were	O
viable	O
and	O
showed	O
a	O
complete	O
respiratory	O
burst	O
upon	O
arachidonic	O
acid	O
stimulation	O
,	O
which	O
induces	O
the	O
respiratory	O
burst	O
by	O
a	O
PKC	B-protein
-independent	O
mechanism	O
.	O

The	O
data	O
also	O
indicate	O
that	O
CD2	B-protein
receptor	O
activation	O
and	O
phytohemagglutinin	B-protein
plus	O
phorbol	O
12-myristate	O
13-acetate	O
stimulation	O
augment	O
T	O
cell	O
IL3	B-protein
gene	O
expression	O
through	O
the	O
same	O
cis-	O
and	O
trans-activating	O
signals	O
.	O

NF-kappaB	B-protein
in	O
MNC	B-cell_type
nuclear	O
extracts	O
decreased	O
at	O
1	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
4	O
hr	O
,	O
gradually	O
increased	O
at	O
8	O
hr	O
and	O
returned	O
back	O
to	O
baseline	O
levels	O
at	O
24	O
hr	O
.	O

The	O
mechanism	O
of	O
this	O
effect	O
is	O
that	O
Bcl-2	B-protein
prevents	O
the	O
nuclear	O
translocation	O
of	O
NFAT	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
lymphocytes	I-protein
,	O
a	O
transcription	B-protein
factor	I-protein
activated	O
by	O
microtubule	B-protein
damage	O
)	O
by	O
binding	O
and	O
sequestering	O
calcineurin	O
,	O
a	O
calcium-dependent	O
phosphatase	O
that	O
must	O
dephosphorylate	O
NFAT	B-protein
to	O
move	O
to	O
the	O
nucleus	O
.	O

Packaging	O
of	O
viral	O
particles	O
,	O
integration	O
into	O
the	O
target	O
genome	O
,	O
and	O
stability	O
of	O
the	O
integrated	O
provirus	O
are	O
not	O
affected	O
by	O
the	O
LTR	B-DNA
modification	O
.	O

Interferon-gamma-induced	B-protein
factor	I-protein
binding	O
to	O
the	O
interleukin-4-responsive	B-DNA
element	I-DNA
of	O
CD23b	B-DNA
promoter	I-DNA
in	O
human	B-cell_type
tonsillar	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
:	O
role	O
in	O
transient	O
up-regulation	O
of	O
the	O
interleukin-4-induced	B-RNA
CD23b	I-RNA
mRNA	I-RNA
.	O

NM23	B-protein
was	O
identified	O
in	O
a	O
system	O
of	O
murine	B-cell_line
melanoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
in	O
which	O
an	O
inverse	O
relationship	O
was	O
found	O
between	O
NM23	B-protein
expression	O
and	O
metastatic	O
ability	O
.	O

Such	O
repression	O
imposes	O
a	O
requirement	O
for	O
both	O
c-Myb	B-protein
and	O
Ets	B-protein
for	O
transcriptional	O
activity	O
,	O
providing	O
one	O
explanation	O
for	O
why	O
synergy	O
between	O
these	O
factors	O
is	O
important	O
.	O

Moreover	O
,	O
platelet-activating	B-protein
factor	I-protein
was	O
capable	O
of	O
inducing	O
transcription	O
of	O
the	O
nuclear	B-DNA
proto-oncogenes	I-DNA
c-fos	B-DNA
and	O
c-jun	B-DNA
.	O

The	O
range	O
of	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
expression	O
produced	O
was	O
found	O
to	O
mimic	O
a	O
physiologically	O
relevant	O
spectrum	O
of	O
G	B-protein
(	I-protein
S	I-protein
)	I-protein
alpha	I-protein
expression	O
in	O
membranes	O
derived	O
from	O
human	O
tissues	O
and	O
rat	O
brain	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
altered	O
CCAAT	B-DNA
box	I-DNA
(	O
CCAAC	O
)	O
and	O
the	O
lack	O
of	O
an	O
EKLF	B-DNA
binding	I-DNA
site	I-DNA
in	O
delta-globin	B-protein
contribute	O
to	O
its	O
low	O
level	O
of	O
expression	O
in	O
the	O
hAEC	B-cell_line
model	I-cell_line
as	O
well	O
.	O

In	O
another	O
group	O
of	O
28	O
patients	O
(	O
three	O
individuals	O
from	O
the	O
first	O
group	O
)	O
,	O
the	O
frequency	O
of	O
abnormal	O
NFkappaB	B-protein
activation	O
was	O
studied	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
after	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
phorbol	O
myristate	O
acetate/ionomycin	O
or	O
anti-CD3	B-protein
monoclonal	I-protein
antibody	I-protein
.	O

Oxidative	O
stress	O
suppresses	O
transcription	B-protein
factor	I-protein
activities	O
in	O
stimulated	B-cell_type
lymphocytes	I-cell_type
.	O

Human	O
intestinal	B-cell_type
epithelial	I-cell_type
cell	I-cell_type
inflammatory	O
responses	O
to	O
amebic	O
infection	O
were	O
inhibited	O
by	O
the	O
intraluminal	O
administration	O
of	O
an	O
antisense	O
oligonucleotide	O
to	O
the	O
human	B-protein
p65	I-protein
subunit	I-protein
of	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
,	O
and	O
the	O
role	O
of	O
neutrophils	O
in	O
tissue	O
damage	O
observed	O
with	O
amebiasis	O
was	O
studied	O
by	O
depleting	O
neutrophils	B-cell_type
from	O
SCID-HU-INT	O
mice	O
.	O

Paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	B-protein
dynamics	O
kill	O
cells	O
in	O
a	O
Fas	B-protein
/Fas	B-protein
ligand	I-protein
(	O
FasL	B-protein
)	O
-dependent	O
manner	O
;	O
antibody	O
to	O
FasL	B-protein
inhibits	O
paclitaxel-induced	O
apoptosis	O
.	O

Deletion	O
of	O
the	O
EBNA2-dependent	B-DNA
enhancer	I-DNA
located	O
upstream	O
of	O
Cp	B-DNA
resulted	O
in	O
a	O
ca.	O
two-	O
to	O
fivefold	O
reduction	O
in	O
Cp	B-DNA
activity	O
in	O
the	O
LCLs	B-cell_line
assayed	O
.	O

Furthermore	O
,	O
CD28	B-protein
coligation	O
fails	O
to	O
enhance	O
IL-2	B-DNA
promoter-reporter	I-DNA
or	O
RE/AP	B-protein
construct	O
expression	O
in	O
CD2-activated	B-cell_type
LPMC	I-cell_type
.	O

We	O
also	O
showed	O
that	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
and	O
to	O
a	O
lesser	O
extent	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
,	O
secreted	O
within	O
the	O
coculture	O
,	O
induce	O
NF-kappaB	B-protein
activity	O
and	O
a	O
correlative	O
LTR	B-DNA
transactivation	O
.	O

Recently	O
,	O
it	O
was	O
suggested	O
that	O
activation	O
of	O
the	O
alpha	B-protein
isoform	I-protein
of	O
PPAR	B-protein
by	O
the	O
potent	O
proinflammatory	O
mediator	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
enhanced	O
degradation	O
of	O
this	O
eicosanoid	O
,	O
offersuggesting	O
a	O
new	O
aspect	O
of	O
down-regulation	O
of	O
inflammation	O
.	O

Whereas	O
the	O
previously	O
described	O
isoform	B-protein
NF-ATc/A	I-protein
contains	O
a	O
relatively	O
short	O
C	B-protein
terminus	I-protein
,	O
the	O
longer	O
isoforms	O
,	O
B	B-protein
and	O
C	B-protein
,	O
span	O
extra	O
C-terminal	O
peptides	O
of	O
128	O
and	O
246	O
aa	O
,	O
respectively	O
.	O

Interleukin	B-protein
2	I-protein
and	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
signals	O
converge	O
upon	O
serine	O
727	O
.	O

The	O
number	O
of	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
in	O
human	B-cell_type
peripheral	I-cell_type
leucocytes	I-cell_type
in	O
13	O
men	O
with	O
gynecomastia	O
were	O
measured	O
by	O
radioligand	O
binding	O
method.	O
The	O
results	O
were	O
compared	O
with	O
those	O
of	O
13	O
sex-and	O
age-matched	O
healthy	O
subjects	O
.	O

This	O
silencer	O
is	O
inactive	O
in	O
the	O
most	O
immature	B-cell_type
DN	I-cell_type
thymocytes	I-cell_type
,	O
which	O
probably	O
use	O
a	O
distinct	O
silencer	O
mechanism	O
to	O
down-regulate	O
CD4	B-DNA
gene	I-DNA
expression	O
.	O

Impaired	O
cortisol	O
binding	O
to	O
glucocorticoid	B-protein
receptors	I-protein
in	O
hypertensive	O
patients	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
Mycoplasma	B-protein
fermentans	I-protein
lipid-associated	I-protein
membrane	I-protein
proteins	I-protein
(	O
LAMPf	B-protein
)	O
induce	O
the	O
production	O
of	O
high	O
levels	O
of	O
IL-8	B-protein
by	O
THP-1	B-cell_line
(	I-cell_line
human	I-cell_line
monocyte	I-cell_line
)	I-cell_line
cells	I-cell_line
and	O
PMN	B-cell_type
at	O
the	O
same	O
extent	O
as	O
LPS	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
the	O
short	O
life	O
span	O
was	O
ameliorated	O
by	O
introduction	O
into	O
the	O
EKLF-/-	B-cell_line
ES	I-cell_line
cells	I-cell_line
of	O
a	O
human	B-DNA
LCR/gamma-globin	I-DNA
gene	I-DNA
,	O
as	O
evidenced	O
by	O
the	O
presence	O
of	O
ES	B-cell_type
cell-derived	I-cell_type
reticulocytes	I-cell_type
as	O
well	O
as	O
mature	B-cell_type
erythrocytes	I-cell_type
in	O
the	O
blood	O
of	O
the	O
chimeric	O
animals	O
.	O

The	O
inducible	B-protein
C1	I-protein
protein	I-protein
was	O
partially	O
purified	O
by	O
three	O
chromatographic	O
steps	O
and	O
characterized	O
by	O
u.v.	O
cross-linking	O
as	O
a	O
47	B-protein
kDa	I-protein
protein	I-protein
.	O

The	O
NF90	B-protein
protein	O
was	O
found	O
to	O
be	O
expressed	O
not	O
only	O
in	O
T-cells	B-cell_type
,	O
but	O
also	O
in	O
nonimmune	B-cell_line
HeLa	I-cell_line
cells	I-cell_line
.	O

Integration	O
of	O
the	O
signals	O
generated	O
by	O
TCR	B-protein
and	O
CD28	B-protein
engagement	O
occurs	O
along	O
this	O
pathway	O
,	O
which	O
then	O
bifurcates	O
to	O
induce	O
I	B-protein
kappa	I-protein
B	I-protein
phosphorylation	O
and	O
NF-kappa	B-protein
B	I-protein
activation	O
on	O
the	O
one	O
hand	O
,	O
and	O
JNK	B-protein
activation	O
and	O
c-Jun	B-protein
phosphorylation	O
on	O
the	O
other	O
.	O

Surprisingly	O
,	O
expression	O
of	O
neither	O
BHRF1	B-protein
nor	O
Bcl-2	B-protein
in	O
a	O
B-cell	B-cell_line
line	I-cell_line
,	O
BJAB	B-cell_line
,	O
protected	O
the	O
cells	O
from	O
anti-Fas-mediated	O
apoptosis	O
even	O
though	O
they	O
increased	O
the	O
survival	O
of	O
serum-starved	B-cell_type
cells	I-cell_type
.	O

Relative	O
expressions	O
of	O
SERCA	B-protein
2	O
and	O
3	O
isoforms	O
and	O
Ras-related	B-protein
protein	I-protein
(	I-protein
Rap	I-protein
)	I-protein
1	I-protein
in	O
platelet	O
membranes	O
were	O
determined	O
by	O
Western	O
immunoblots	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
two	O
tyrosines	O
,	O
Tyr-113	O
and	O
Tyr-128	O
,	O
of	O
SLP-76	B-protein
are	O
required	O
for	O
its	O
binding	O
to	O
Vav	B-protein
,	O
both	O
in	O
vitro	O
and	O
in	O
intact	B-cell_type
cells	I-cell_type
.	O

The	O
binding	O
of	O
these	O
gamma	B-cell_type
delta	I-cell_type
T	I-cell_type
cells	I-cell_type
serves	O
as	O
a	O
signal	O
for	O
abrogation	O
of	O
oral	O
tolerance	O
to	O
ingested	B-protein
proteins	I-protein
setting	O
in	O
motion	O
a	O
series	O
of	O
immune	O
responses	O
directed	O
against	O
the	O
small	O
intestinal	O
epithelium	O
of	O
CD	O
patients	O
.	O

NF-kappa	B-protein
B	I-protein
binding	O
activity	O
was	O
absent	O
in	O
several	O
SLE	O
patients	O
who	O
were	O
not	O
receiving	O
any	O
medication	O
,	O
including	O
corticosteroids	O
.	O

Previously	O
,	O
we	O
have	O
reported	O
that	O
DHEA	O
and	O
synthetic	O
analogs	O
of	O
DHEA	O
can	O
be	O
modest	O
inhibitors	O
of	O
HIV-1	O
IIIB	O
replication	O
in	O
phytohemagglutinin-stimulated	B-cell_line
peripheral	I-cell_line
blood	I-cell_line
lymphocyte	I-cell_line
cultures	I-cell_line
.	O

However	O
,	O
the	O
precise	O
factors	O
that	O
mediate	O
this	O
induction	O
mechanism	O
remain	O
unknown	O
.	O

Recent	O
experiments	O
suggest	O
that	O
Ikaros	B-protein
and	O
Aiolos	B-protein
set	O
B	O
cell	O
antigen-receptor	O
(	O
BCR	O
)	O
-	O
and	O
TCR-mediated	O
signaling	O
thresholds	O
and	O
that	O
the	O
molecules	O
exist	O
within	O
T	B-cell_type
cells	I-cell_type
in	O
nuclear	B-protein
complexes	I-protein
that	O
contain	O
nucleosome	O
remodeling	O
and	O
histone	B-protein
deacetylase	I-protein
activities	O
.	O

Transcription	B-protein
factor	I-protein
GATA-3	I-protein
is	O
differentially	O
expressed	O
in	O
murine	B-cell_line
Th1	I-cell_line
and	I-cell_line
Th2	I-cell_line
cells	I-cell_line
and	O
controls	O
Th2-specific	O
expression	O
of	O
the	O
interleukin-5	B-DNA
gene	I-DNA
.	O

We	O
show	O
that	O
increased	O
transcription	O
of	O
the	O
NF-IL6	B-DNA
gene	I-DNA
is	O
responsible	O
,	O
at	O
least	O
in	O
part	O
,	O
for	O
induction	O
of	O
NF-IL6	B-RNA
mRNA	I-RNA
following	O
activation	O
of	O
U937	B-cell_line
promonocytic	I-cell_line
cells	I-cell_line
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
bufalin	O
,	O
which	O
is	O
an	O
active	O
principle	O
of	O
Chinese	O
medicine	O
,	O
chan'su	O
,	O
caused	O
apoptosis	O
in	O
human	B-cell_line
leukemia	I-cell_line
U937	I-cell_line
cells	I-cell_line
by	O
anomalous	O
activation	O
of	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
via	O
the	O
signaling	O
pathway	O
of	O
Ras	B-protein
,	O
Raf-1	B-protein
,	O
and	O
MAPK	B-protein
kinase-1	I-protein
.	O

Chlamydia	O
pneumoniae	O
is	O
an	O
important	O
respiratory	O
pathogen	O
.	O

(	O
i	O
)	O
Acute	O
transfection	O
and	O
expression	O
of	O
EBNA-2	B-protein
under	O
control	O
of	O
simian	B-DNA
virus	I-DNA
40	I-DNA
or	I-DNA
Moloney	I-DNA
murine	I-DNA
leukemia	I-DNA
virus	I-DNA
promoters	I-DNA
resulted	O
in	O
increased	O
LMP1	B-protein
expression	O
in	O
P3HR-1-infected	B-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
and	O
the	O
P3HR-1	B-cell_line
or	O
Daudi	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Hence	O
,	O
PPAR	B-protein
can	O
positively	O
or	O
negatively	O
influence	O
TH	O
action	O
depending	O
on	O
TRE	B-DNA
structure	O
and	O
THR	B-protein
isotype	I-protein
.	O

Overexpression	O
of	O
WT1	B-DNA
in	O
some	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
confers	O
resistance	O
to	O
differentiation	O
induction	O
.	O

In	O
contrast	O
,	O
somatic	O
cell	O
fusion	O
between	O
clone	B-cell_line
13	I-cell_line
and	O
RJ2.2.5	B-cell_line
restored	O
expression	O
of	O
the	O
HLA-DQ	B-DNA
haplotype	O
encoded	O
by	O
the	O
RJ2.2.5	B-DNA
DQB	I-DNA
gene	I-DNA
.	O

Recombinant	O
c-Jun	B-protein
and	O
c-Fos	B-protein
were	O
ubiquitinylated	O
by	O
the	O
ubiquitin	B-protein
carrier	I-protein
enzymes	I-protein
E214K	B-protein
,	O
E220K	B-protein
,	O
or	O
E232K	B-protein
in	O
the	O
presence	O
of	O
the	O
ubiquitin-activating	B-protein
enzyme	I-protein
,	O
E1	B-protein
.	O

Moreover	O
,	O
cyclosporine	O
,	O
at	O
concentrations	O
readily	O
accomplished	O
in	O
clinical	O
practice	O
,	O
was	O
found	O
to	O
inhibit	O
the	O
emergence	O
of	O
these	O
DNA-binding	B-protein
proteins	I-protein
in	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
signaled	O
via	O
cell	O
surface	O
proteins	O
implicated	O
in	O
antigen-dependent	O
T	O
cell	O
activation	O
and	O
in	O
T	B-cell_type
cells	I-cell_type
stimulated	O
by	O
mobilization	O
of	O
cellular	O
calcium	O
and	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O

Regulation	O
of	O
fas-ligand	O
expression	O
during	O
activation-induced	O
cell	O
death	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
via	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
.	O

NAC	O
may	O
be	O
considered	O
for	O
the	O
treatment	O
of	O
HIV-1-infected	O
individuals	O
.	O

Since	O
C3a	B-protein
has	O
been	O
shown	O
to	O
induce	O
PGE2	O
production	O
by	O
monocytes	B-cell_type
,	O
and	O
PGE2	O
has	O
been	O
shown	O
to	O
influence	O
cytokine	O
production	O
,	O
we	O
investigated	O
the	O
potential	O
role	O
of	O
PGE2	O
in	O
C3a	B-protein
-mediated	O
enhancement	O
of	O
LPS-	O
and	O
IL-1beta-induced	O
IL-6	O
production	O
.	O

We	O
show	O
here	O
that	O
the	O
minimum	O
region	O
of	O
the	O
ferritin	B-DNA
H-gene	I-DNA
promoter	I-DNA
that	O
is	O
able	O
to	O
confer	O
transcriptional	O
regulation	O
by	O
heme	O
in	O
FLCs	B-cell_line
to	O
a	O
reporter	B-DNA
gene	I-DNA
is	O
77	B-DNA
nucleotides	I-DNA
upstream	I-DNA
of	O
the	O
TATA	B-DNA
box	I-DNA
.	O

Interestingly	O
,	O
this	O
15-amino	B-protein
acid	I-protein
transactivation	I-protein
sequence	I-protein
is	O
well	O
conserved	O
in	O
NFAT	B-protein
family	I-protein
proteins	I-protein
,	O
although	O
the	O
sequences	O
contiguous	O
to	O
the	O
carboxyl-terminal	B-protein
regions	I-protein
of	O
the	O
NFAT	B-protein
family	I-protein
are	O
much	O
less	O
conserved	O
.	O

The	O
kinetics	O
of	O
expression	O
suggest	O
that	O
the	O
high	O
initial	O
levels	O
are	O
caused	O
by	O
the	O
isolation	O
procedure	O
,	O
and	O
do	O
not	O
reflect	O
constitutive	O
expression	O
.	O

Although	O
CD28	B-protein
is	O
constitutively	O
expressed	O
,	O
its	O
expression	O
is	O
transiently	O
down-regulated	O
following	O
T	O
cell	O
activation	O
and	O
declines	O
progressively	O
with	O
in	O
vitro	O
senescence	O
.	O

Transcriptional	O
inhibition	O
by	O
interleukin-6	B-protein
of	O
the	O
class	B-protein
A	I-protein
macrophage	I-protein
scavenger	I-protein
receptor	I-protein
in	O
macrophages	B-cell_type
derived	O
from	O
human	B-cell_type
peripheral	I-cell_type
monocytes	I-cell_type
and	O
the	O
THP-1	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Studies	O
of	O
pluripotent	B-cell_line
islet	I-cell_line
cultures	I-cell_line
.	O

Structure-function	O
studies	O
of	O
the	O
GATA-1	B-protein
protein	O
could	O
be	O
greatly	O
simplified	O
and	O
a	O
larger	O
number	O
of	O
mutants	O
studied	O
.	O

As	O
determined	O
by	O
tyrosine	O
phosphorylation	O
,	O
nuclear	O
translocation	O
and	O
binding	O
to	O
an	O
hSIE-oligonucleotide	O
probe	O
,	O
IL-2	B-protein
and	O
IL-15	B-protein
activated	O
the	O
slowly	O
migrating	O
isoform	O
,	O
Stat3alpha	B-protein
.	O

They	O
are	O
rapidly	O
activated	O
by	O
various	O
cytokines	B-protein
,	O
hormones	O
,	O
and	O
growth	O
factors	O
.	O

We	O
thus	O
conclude	O
that	O
PTPases	B-protein
play	O
a	O
crucial	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
signal	O
transduction	O
culminating	O
in	O
T-lymphocyte	B-cell_type
activation	O
.	O

[	O
The	O
trend	O
of	O
molecular	O
biology	O
study	O
on	O
eosinophils	B-cell_type
]	O

Pretreatment	O
of	O
cultured	B-cell_type
human	I-cell_type
ECs	I-cell_type
with	O
the	O
PPARalpha	B-protein
activators	O
fenofibrate	O
or	O
WY14643	O
inhibited	O
TNF-alpha-induced	B-protein
VCAM-1	I-protein
in	O
a	O
time-	O
and	O
concentration-dependent	O
manner	O
,	O
an	O
effect	O
not	O
seen	O
with	O
PPARgamma	B-protein
activators	O
.	O

We	O
conclude	O
that	O
a	O
specific	O
nuclear	O
translocation	O
mechanism	O
exists	O
for	O
calcitriol	O
in	O
both	O
cell	O
types	O
examined	O
,	O
most	O
likely	O
due	O
to	O
translocation	O
of	O
receptor	B-protein
proteins	I-protein
after	O
hormone	O
binding	O
.	O

Furthermore	O
,	O
this	O
signaling	O
pathway	O
appears	O
not	O
to	O
rely	O
on	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O

The	O
human	B-DNA
IL-4	I-DNA
gene	I-DNA
,	O
of	O
10	O
kilobases	O
,	O
is	O
composed	O
of	O
four	O
exons	B-DNA
and	O
three	O
introns	B-DNA
.	O

IL-4	B-protein
,	O
a	O
product	O
of	O
the	O
T-helper	B-cell_type
0	I-cell_type
(	I-cell_type
Th0	I-cell_type
)	I-cell_type
and	I-cell_type
2	I-cell_type
(	I-cell_type
Th2	I-cell_type
)	I-cell_type
subset	I-cell_type
,	O
was	O
originally	O
described	O
as	O
a	O
B-cell	B-protein
stimulatory	I-protein
factor	I-protein
and	O
has	O
subsequently	O
been	O
found	O
to	O
suppress	O
IL-1	O
alpha	O
,	O
IL-1	O
beta	O
,	O
IL-6	O
,	O
IL-8	O
,	O
and	O
TNF-alpha	O
gene	O
expression	O
in	O
monocytes	B-cell_type
stimulated	O
with	O
LPS	O
,	O
and	O
to	O
upregulate	O
IL-1	B-DNA
receptor	I-DNA
antagonist	I-DNA
(	I-DNA
IL1-RA	I-DNA
)	I-DNA
gene	I-DNA
expression	O
.	O

Instead	O
,	O
ATF-2	B-protein
and	O
Jun	B-protein
proteins	I-protein
bind	O
to	O
the	O
composite	B-DNA
kappa	I-DNA
3/CRE	I-DNA
site	I-DNA
and	O
NFATp	B-protein
binds	O
to	O
a	O
newly	O
identified	O
second	O
NFAT	B-DNA
site	I-DNA
centered	O
at	O
-76	B-DNA
nucleotides	I-DNA
relative	O
to	O
the	O
TNF-alpha	B-DNA
transcription	I-DNA
start	I-DNA
site	I-DNA
.	O

Here	O
,	O
we	O
show	O
that	O
SE	B-protein
induce	O
dynamic	O
changes	O
in	O
the	O
expression	O
of	O
and	O
signal	O
transduction	O
through	O
the	O
IL-2	B-protein
receptor	I-protein
(	I-protein
IL-2R	I-protein
)	I-protein
beta	I-protein
and	I-protein
gamma	I-protein
chains	I-protein
(	O
IL-2R	B-protein
beta	I-protein
and	O
IL-2R	B-protein
gamma	I-protein
)	O
in	O
human	B-cell_line
antigen-specific	I-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O

Effects	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
on	O
the	O
human	B-cell_line
chronic	I-cell_line
myelogenous	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
RWLeu-4	B-cell_line
.	O

Identification	O
of	O
transcription	B-protein
factors	I-protein
expressed	O
during	O
ATRA-induced	O
neutrophil	O
differentiation	O
of	O
HL60	B-cell_line
cells	I-cell_line
.	O

BASH	B-protein
,	O
a	O
novel	B-protein
signaling	I-protein
molecule	I-protein
preferentially	O
expressed	O
in	O
B	B-cell_type
cells	I-cell_type
of	O
the	O
bursa	O
of	O
Fabricius	O
.	O

Ligand	O
binding	O
and	O
activation	O
of	O
the	O
IL-10	B-protein
receptor	I-protein
expressed	O
on	O
B-CLL	B-cell_line
cells	I-cell_line
results	O
in	O
the	O
phosphorylation	O
of	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
1	I-protein
(	O
STAT1	B-protein
)	O
and	O
STAT3	B-protein
proteins	O
.	O

The	O
JAK	B-protein
/STAT	B-protein
pathway	O
is	O
one	O
of	O
the	O
signaling	O
pathways	O
implicated	O
in	O
mediating	O
biological	O
responses	O
induced	O
by	O
these	O
cytokines	B-protein
.	O

The	O
active	O
material	O
partitioned	O
into	O
the	O
phenol	O
layer	O
on	O
hot	O
aqueous	O
phenol	O
extraction	O
.	O

We	O
have	O
also	O
characterized	O
the	O
genomic	B-protein
mBob1	I-protein
clone	I-protein
.	O

Neither	O
DNA	O
fragmentation	O
nor	O
the	O
morphology	O
of	O
apoptosis	O
was	O
observed	O
.	O

The	O
functional	O
significance	O
of	O
c-Rel	B-protein
involvement	O
in	O
the	O
CD28-responsive	B-protein
complex	I-protein
is	O
demonstrated	O
by	O
transient	O
transfection	O
analysis	O
,	O
where	O
cotransfection	O
of	O
c-Rel	B-protein
augments	O
the	O
level	O
of	O
expression	O
of	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
gene	I-DNA
linked	O
to	O
the	O
CD28-responsive	B-DNA
element	I-DNA
.	O

One	O
gene	O
of	O
interest	O
is	O
the	O
glycoprotein	B-DNA
IIb	I-DNA
(	I-DNA
GPIIb	I-DNA
)	I-DNA
gene	I-DNA
;	O
GPIIb	B-DNA
,	O
the	O
alpha	B-protein
subunit	I-protein
of	O
the	O
platelet	B-protein
cytoadhesin	I-protein
GPIIb-IIIa	I-protein
,	O
is	O
produced	O
in	O
megakaryocytes	B-cell_line
at	O
an	O
early	O
stage	O
of	O
the	O
differentiation	O
,	O
whereas	O
the	O
other	O
subunit	O
of	O
this	O
complex	O
,	O
GPIIIa	B-protein
,	O
is	O
expressed	O
in	O
other	O
cells	O
.	O

Thus	O
,	O
Elf-1	B-protein
is	O
able	O
to	O
stimulate	O
gene	O
transcription	O
which	O
may	O
be	O
required	O
for	O
the	O
development	O
and	O
activity	O
of	O
lymphocytes	B-cell_type
.	O

COS-1	B-cell_line
cells	I-cell_line
,	O
co-expressing	O
the	O
human	O
IL-10R	B-protein
and	O
individual	O
STAT	B-protein
proteins	I-protein
,	O
confirmed	O
a	O
preference	O
of	O
the	O
IL-10R	B-protein
for	O
STAT3	B-protein
and	O
STAT1	B-protein
.	O

This	O
defect	O
in	O
maturation	O
resulted	O
in	O
a	O
transgene	O
dose-dependent	O
reduction	O
in	O
peripheral	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
with	O
the	O
CD8	B-cell_type
lineage	I-cell_type
being	O
more	O
severely	O
affected	O
.	O

The	O
regulation	O
of	O
gene	O
expression	O
during	O
lymphocyte	B-cell_type
differentiation	O
is	O
a	O
complex	O
process	O
involving	O
interactions	O
between	O
multiple	B-DNA
positive	I-DNA
and	I-DNA
negative	I-DNA
transcriptional	I-DNA
regulatory	I-DNA
elements	I-DNA
.	O

The	O
present	O
study	O
,	O
using	O
highly	O
enriched	O
human	B-protein
CD34+	I-protein
as	O
well	O
as	O
Lin-	B-cell_line
murine	I-cell_line
bone	I-cell_line
marrow	I-cell_line
progenitor	I-cell_line
cells	I-cell_line
,	O
demonstrates	O
a	O
potent	O
inhibitory	O
effect	O
of	O
9-cis-RA	O
on	O
burst-forming	O
unit-erythroid	O
(	O
BFU-E	O
)	O
colony	O
formation	O
regardless	O
of	O
the	O
cytokine	B-protein
stimulating	O
growth	O
.	O

Because	O
extinction	O
of	O
IL-12	B-protein
signaling	O
in	O
early	O
Th2	O
development	O
could	O
potentially	O
be	O
important	O
in	O
imprinting	O
a	O
more	O
permanent	O
Th2	O
phenotype	O
on	O
a	O
population	O
of	O
T	B-cell_type
cells	I-cell_type
,	O
we	O
have	O
also	O
examined	O
various	O
parameters	O
regulating	O
the	O
IL-12	B-protein
signaling	O
pathway	O
.	O

Fos	O
proteins	O
are	O
not	O
needed	O
for	O
this	O
reconstitution	O
,	O
and	O
although	O
JunB	B-protein
is	O
not	O
functional	O
,	O
it	O
can	O
participate	O
in	O
the	O
NF-AT	B-protein
DNA	I-protein
binding	I-protein
complex	I-protein
.	O

Both	O
encode	O
proteins	O
that	O
bind	O
specifically	O
to	O
a	O
cAMP	B-DNA
response	I-DNA
element	I-DNA
in	I-DNA
vitro	I-DNA
.	O

NFAT4/x	B-protein
was	O
very	O
weakly	O
expressed	O
in	O
unstimulated	O
cells	O
,	O
and	O
its	O
level	O
did	O
not	O
increase	O
upon	O
treatment	O
with	O
activating	O
agents	O
.	O

It	O
may	O
be	O
familial	O
or	O
secondary	O
to	O
abnormal	O
renal	O
sodium	O
handling	O
.	O

Transient	O
transfection	O
studies	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
an	O
E	O
(	O
2	O
)	O
receptor-negative	O
line	O
,	O
suggest	O
that	O
E	O
(	O
2	O
)	O
inhibits	O
TNF	B-protein
gene	O
expression	O
through	O
an	O
effect	O
mediated	O
by	O
estrogen	B-protein
receptor	I-protein
beta	I-protein
(	O
ERbeta	B-protein
)	O
.	O

Although	O
the	O
exact	O
mechanism	O
by	O
which	O
HTLV-I	O
contributes	O
to	O
leukemogenesis	O
is	O
still	O
unclear	O
,	O
the	O
Tax	B-protein
protein	I-protein
is	O
thought	O
to	O
play	O
a	O
major	O
role	O
in	O
this	O
process	O
.	O

Induction	O
of	O
the	O
pro-myelocytic	B-DNA
leukaemia	I-DNA
gene	I-DNA
by	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
interferons	I-protein
.	O

This	O
finding	O
may	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
the	O
reasons	O
for	O
the	O
prevalence	O
of	O
lupus	O
in	O
females	O
and	O
of	O
the	O
estrogenic	O
effects	O
on	O
SLE	O
disease	O
activity	O
.	O

In	O
addition	O
,	O
the	O
combination	O
of	O
a	O
NF	B-DNA
kappa	I-DNA
B/rel	I-DNA
binding	I-DNA
site	I-DNA
and	O
the	O
STAT6	B-DNA
response	I-DNA
element	I-DNA
conferred	O
IL-4	B-protein
inducibility	O
to	O
a	O
heterologous	B-DNA
minimal	I-DNA
promoter	I-DNA
,	O
while	O
the	O
individual	O
sites	O
had	O
no	O
effect	O
.	O

Glucocorticoids	O
are	O
important	O
for	O
maintaining	O
cellular	O
and	O
humoral	O
homeostasis	O
and	O
are	O
key	O
mediators	O
of	O
neuroendocrine-immune	O
regulatory	O
interactions	O
.	O

Our	O
data	O
suggest	O
that	O
although	O
CD45	B-protein
and	O
Lck	B-protein
are	O
not	O
required	O
for	O
Fas	B-protein
signaling	O
,	O
JNK	B-protein
activation	O
may	O
play	O
an	O
important	O
role	O
transducing	O
distal	O
signals	O
that	O
lead	O
to	O
apoptosis	O
after	O
Fas	B-protein
ligation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
identified	O
a	O
cellular	O
context	O
(	O
the	O
interleukin-2	B-cell_line
[	I-cell_line
IL-2	I-cell_line
]	I-cell_line
-dependent	I-cell_line
HT-2	I-cell_line
line	I-cell_line
)	O
in	O
which	O
the	O
EPO	B-protein
stimulation	O
of	O
the	O
EPOR	B-protein
fails	O
to	O
support	O
cellular	O
proliferation	O
,	O
STAT-5	B-protein
induction	O
,	O
or	O
MAPK	B-protein
activation	O
,	O
despite	O
efficient	O
phosphorylation	O
of	O
the	O
EPOR	B-protein
and	O
JAK2	B-protein
and	O
inhibition	O
of	O
apoptosis	O
after	O
withdrawal	O
of	O
IL-2	B-protein
.	O

They	O
act	O
at	O
a	O
point	O
in	O
activation	O
that	O
lies	O
between	O
receptor	O
ligation	O
and	O
the	O
transcription	O
of	O
early	B-DNA
genes	I-DNA
.	O

We	O
identified	O
this	O
92-kDa	B-protein
protein	I-protein
as	O
STAT5	B-protein
,	O
but	O
not	O
as	O
STATs1	B-protein
,	I-protein
3	I-protein
,	I-protein
and	I-protein
6	I-protein
nor	O
c-fes	B-protein
and	O
vav	B-protein
protooncogene	I-protein
products	I-protein
,	O
and	O
demonstrated	O
its	O
translocation	O
to	O
the	O
nucleus	O
,	O
enhancement	O
of	O
specific	O
DNA	O
binding	O
capacity	O
,	O
and	O
potentiation	O
of	O
trancriptional	O
activity	O
by	O
GM-CSF	B-protein
.	O

Several	O
lines	O
of	O
evidence	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
(	O
EBNA-2	B-protein
)	O
or	O
leader	B-protein
protein	I-protein
(	O
EBNA-LP	B-protein
)	O
affects	O
expression	O
of	O
the	O
EBV	B-protein
latent	I-protein
infection	I-protein
membrane	I-protein
protein	I-protein
LMP1	B-protein
.	O

We	O
analysed	O
mRNA	O
from	O
18	O
unrelated	O
cases	O
of	O
TSC	O
for	O
TSC2	B-DNA
mutations	I-DNA
using	O
the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
.	O

Cells	O
expressing	O
the	O
E1A	B-protein
oncoprotein	I-protein
were	O
selectively	O
killed	O
by	O
unstimulated	B-cell_line
NK	I-cell_line
cells	I-cell_line
,	O
while	O
the	O
same	O
parental	B-cell_type
cells	I-cell_type
but	O
expressing	O
the	O
HPV	O
type	O
16	O
(	O
HPV-16	O
)	O
or	O
HPV-18	O
E7	B-protein
oncoprotein	I-protein
were	O
resistant	O
to	O
NK	O
cell	O
lysis	O
.	O

Inhibition	O
of	O
NF-kappaB	B-protein
transcriptional	O
activity	O
and	O
promotion	O
of	O
IkappaBalpha	B-protein
degradation	O
.	O

It	O
was	O
inhibited	O
at	O
1	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
2-4	O
hr	O
,	O
started	O
to	O
increase	O
at	O
8	O
hr	O
,	O
and	O
returned	O
to	O
basal	O
levels	O
at	O
24	O
hr	O
.	O

No	O
effect	O
was	O
seen	O
with	O
non	O
transfected	B-cell_line
cells	I-cell_line
or	O
with	O
cells	O
transfected	O
with	O
a	O
control	O
plasmid	O
.	O

These	O
results	O
indicate	O
that	O
the	O
adhesion	O
of	O
RA	B-cell_type
synovial	I-cell_type
cells	I-cell_type
to	O
matrices	O
such	O
as	O
hyaluronic	O
acid	O
through	O
CD44	B-protein
could	O
up-regulate	O
VCAM-1	B-protein
expression	O
and	O
VCAM-1	B-protein
-mediated	O
adhesion	O
to	O
T	B-cell_type
cells	I-cell_type
,	O
which	O
might	O
in	O
turn	O
cause	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
and	O
synovial	B-cell_type
cells	I-cell_type
in	O
RA	O
synovitis	O
.	O

Furthermore	O
,	O
cycloheximide	O
displayed	O
a	O
similar	O
capacity	O
to	O
enhance	O
TNF-alpha	B-protein
induced	O
neutrophil	O
apoptosis	O
even	O
at	O
time	O
points	O
when	O
cycloheximide	O
alone	O
had	O
no	O
pro-apoptotic	O
effect	O
,	O
suggesting	O
that	O
NF-kappaB	B-protein
may	O
regulate	O
the	O
production	O
of	O
protein	O
(	O
s	O
)	O
which	O
protect	O
neutrophils	B-cell_type
from	O
the	O
cytotoxic	O
effects	O
of	O
TNF-alpha	B-protein
.	O

Two	O
tandem	O
AP1	B-DNA
binding	I-DNA
sites	I-DNA
with	O
dyad	O
symmetry	O
are	O
required	O
for	O
enhancer	O
activity	O
and	O
for	O
DNA-protein	B-protein
complex	I-protein
formation	O
with	O
members	O
of	O
the	O
c-fos/c-jun	B-protein
family	I-protein
.	O

The	O
slight	O
increase	O
in	O
the	O
percentage	O
of	O
CD4+CD45R0+	B-cell_type
cells	I-cell_type
remained	O
significant	O
even	O
after	O
covariant	O
analysis	O
taking	O
age-related	O
changes	O
into	O
account	O
.	O

Treatment	O
with	O
DMSO	O
resulted	O
in	O
the	O
elevation	O
of	O
the	O
apoptosis	B-protein
effector	I-protein
Bax	B-protein
,	O
whereas	O
treatment	O
with	O
PDBu	O
did	O
not	O
significantly	O
alter	O
the	O
levels	O
of	O
this	O
protein	O
.	O

Interleukin-12	B-protein
is	O
produced	O
in	O
response	O
to	O
infection	O
with	O
bacteria	O
or	O
parasites	O
or	O
to	O
bacterial	O
constituents	O
such	O
as	O
LPS	O
in	O
monocytes/macrophages	B-cell_type
and	O
dendritic	B-cell_type
cells	I-cell_type
,	O
and	O
also	O
generated	O
by	O
the	O
interaction	O
between	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
antigen-presenting	B-cell_type
cells	I-cell_type
via	O
CD40-CD40	B-protein
ligand	I-protein
(	O
CD40L	B-protein
)	O
.	O

We	O
have	O
used	O
charybdotoxin	O
,	O
a	O
known	O
inhibitor	O
of	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-dependent	I-protein
K+	I-protein
channels	I-protein
,	O
to	O
study	O
the	O
role	O
of	O
these	O
channels	O
in	O
lymphocyte	O
activation	O
and	O
mitogenesis	O
.	O

This	O
review	O
will	O
discuss	O
the	O
mechanisms	O
by	O
which	O
Ras	B-protein
expressing	O
tumors	O
are	O
able	O
to	O
evade	O
destruction	O
by	O
the	O
immune	O
system	O
and	O
enhance	O
their	O
growth	O
and	O
metastatic	O
potential	O
.	O

Accessory	O
molecules	O
play	O
a	O
crucial	O
role	O
in	O
the	O
development	O
of	O
the	O
T	O
cell	O
response	O
to	O
antigenic	O
challenge	O
.	O

The	O
relationship	O
between	O
the	O
immunohistochemical	O
findings	O
and	O
the	O
antitumor	O
effect	O
at	O
a	O
radiation	O
dose	O
of	O
20	O
Gy	O
was	O
examined	O
on	O
the	O
corresponding	O
H	O
&	O
E-stained	O
sections	O
.	O

Site-directed	O
mutational	O
studies	O
demonstrate	O
that	O
Site	B-DNA
I	I-DNA
and	O
Site	B-DNA
IV	I-DNA
together	O
support	O
ATF1-	O
and	O
CREB-induced	O
trans-activation	O
of	O
the	O
H4	B-DNA
promoter	I-DNA
.	O

Colinear	O
triplex	O
formation	O
acts	O
as	O
a	O
selective	O
transcriptional	O
repressor	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
and	O
may	O
have	O
potential	O
therapeutic	O
application	O
in	O
cases	O
of	O
undesirable	O
overexpression	O
of	O
this	O
protein	O
.	O

RT-PCR	O
demonstrated	O
that	O
NL	B-cell_type
of	O
both	O
subtypes	O
expressed	O
EBNAI	B-protein
of	O
the	O
QUK	O
splice	O
pattern	O
,	O
the	O
latent	B-protein
membrane	I-protein
proteins	I-protein
,	O
LMP1	B-protein
and	I-protein
2	I-protein
and	O
the	O
BamHI	B-RNA
A	I-RNA
rightward	I-RNA
transcripts	I-RNA
in	O
the	O
absence	O
of	O
EBNA2	B-RNA
mRNAs	I-RNA
,	O
compatible	O
with	O
the	O
latency	O
type	O
II	O
pattern	O
.	O

In	O
this	O
study	O
we	O
examined	O
the	O
direct	O
effects	O
of	O
glucocorticoids	O
on	O
eosinophil	B-cell_type
and	O
neutrophil	B-cell_type
apoptosis	O
in	O
light	O
of	O
their	O
common	O
therapeutic	O
use	O
as	O
anti-inflammatory	O
and	O
anti-allergic/hypereosinophilic	O
agents	O
.	O

Although	O
mutation	O
of	O
either	O
Y113	O
and	O
Y128	O
has	O
a	O
minimal	O
effect	O
on	O
SLP-76	B-protein
function	O
,	O
mutation	O
of	O
both	O
residues	O
decreases	O
significantly	O
the	O
ability	O
of	O
SLP-76	B-protein
to	O
promote	O
T	O
cell	O
activation	O
.	O

Using	O
a	O
recently	O
developed	O
transfection	O
technique	O
,	O
we	O
demonstrate	O
that	O
in	O
primary	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
,	O
stimulation	O
of	O
a	O
548	B-DNA
bp	I-DNA
IL-2	I-DNA
promoter-luciferase	I-DNA
reporter	I-DNA
construct	I-DNA
by	O
phorbol	O
ester	O
and	O
calcium	O
ionophore	O
is	O
reversed	O
by	O
dexamethasone	O
to	O
a	O
similar	O
extent	O
as	O
in	O
Jurkat	O
T	O
lymphoma	O
cells	O
transfected	O
with	O
a	O
GRalpha	B-protein
expression	O
vector	O
.	O

Comparison	O
of	O
constitutive	O
and	O
inducible	O
transcriptional	O
enhancement	O
mediated	O
by	O
kappa	B-DNA
B-related	I-DNA
sequences	I-DNA
:	O
modulation	O
of	O
activity	O
in	O
B	B-cell_type
cells	I-cell_type
by	O
human	B-DNA
T-cell	I-DNA
leukemia	I-DNA
virus	I-DNA
type	I-DNA
I	I-DNA
tax	I-DNA
gene	I-DNA
.	O

All	O
tissues	O
and	O
cells	O
studied	O
expressed	O
both	O
wild-type	B-protein
ER	I-protein
and	O
variant	B-protein
species	I-protein
.	O

The	O
myeloid-cell-specific	B-DNA
c-fes	I-DNA
promoter	I-DNA
is	O
regulated	O
by	O
Sp1	B-protein
,	O
PU.1	B-protein
,	O
and	O
a	O
novel	O
transcription	B-protein
factor	I-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Here	O
we	O
show	O
that	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
by	O
Tpl-2	B-protein
is	O
inhibited	O
by	O
mutant	B-protein
signaling	I-protein
molecules	I-protein
that	O
inhibit	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
or	O
the	O
calcineurin	B-protein
/NFAT	B-protein
pathways	O
and	O
is	O
promoted	O
by	O
combinations	O
of	O
signaling	B-protein
molecules	I-protein
that	O
activate	O
these	O
pathways	O
.	O

A	O
novel	O
human	B-DNA
homeobox	I-DNA
gene	I-DNA
distantly	O
related	O
to	O
proboscipedia	B-DNA
is	O
expressed	O
in	O
lymphoid	O
and	O
pancreatic	O
tissues	O
.	O

Differanisole	O
A	O
,	O
3	O
,	O
5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic	O
acid	O
,	O
inhibited	O
growth	O
of	O
human	B-cell_type
myeloid	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

Recent	O
biochemical	O
studies	O
have	O
shown	O
that	O
p65	B-protein
and	O
p50	B-protein
form	O
the	O
prototypical	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
,	O
which	O
is	O
rapidly	O
translocated	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
during	O
T-cell	O
activation	O
.	O

In	O
summary	O
,	O
our	O
results	O
suggest	O
that	O
IE-1	B-protein
is	O
far	O
more	O
important	O
as	O
a	O
CD8	O
(	O
+	O
)	O
-T-cell	O
target	O
than	O
current	O
opinion	O
suggests	O
.	O

This	O
pattern	O
of	O
distribution	O
is	O
,	O
thus	O
far	O
,	O
unique	O
to	O
the	O
GATA	B-protein
transcription	I-protein
factors	I-protein
and	O
suggests	O
a	O
protein-protein	O
interaction	O
with	O
other	O
components	O
of	O
the	O
nuclear	O
bodies	O
via	O
the	O
GATA	B-protein
zinc	I-protein
finger	I-protein
domain	I-protein
.	O

Functional	O
studies	O
showed	O
a	O
2.5-fold	O
increase	O
in	O
promoter	O
activity	O
when	O
this	O
19-bp	B-DNA
binding	I-DNA
site	I-DNA
was	O
deleted	O
in	O
the	O
reporter	B-DNA
constructs	I-DNA
IL-1beta	B-protein
/CAT	B-protein
and	O
IL-1beta	B-protein
/SV40	B-DNA
promoter	I-DNA
/CAT	B-protein
.	O

Here	O
,	O
we	O
report	O
that	O
differentiated	B-cell_type
B	I-cell_type
cells	I-cell_type
contain	O
a	O
novel	O
substoichiometric	O
TAF	B-protein
of	O
105	O
kDa	O
not	O
found	O
associated	O
with	O
TFIID	B-protein
isolated	O
from	O
other	O
cell	O
types	O
.	O

Similar	O
transfection	O
analysis	O
of	O
the	O
-66	B-DNA
to	I-DNA
-59	I-DNA
region	I-DNA
of	O
the	O
CD11b	B-DNA
promoter	I-DNA
showed	O
Sp3	B-protein
-dependent	O
expression	O
.	O

However	O
,	O
although	O
Wnt	O
signals	O
are	O
known	O
to	O
inhibit	O
the	O
activity	O
of	O
the	O
negative	B-protein
regulatory	I-protein
protein	I-protein
kinase	I-protein
glycogen	B-protein
synthase	I-protein
kinase-3beta	I-protein
(	O
GSK-3beta	B-protein
)	O
,	O
resulting	O
in	O
increased	O
levels	O
of	O
beta-catenin	B-protein
,	O
we	O
find	O
no	O
evidence	O
for	O
involvement	O
of	O
GSK-3beta	B-protein
in	O
Tcf-mediated	O
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

We	O
performed	O
an	O
analysis	O
of	O
the	O
mechanisms	O
by	O
which	O
two	O
PKC	B-protein
inhibitors	O
,	O
Calphostin	O
C	O
and	O
Staurosporine	O
,	O
prevent	O
the	O
FN	B-protein
-induced	O
IL-1beta	B-protein
response	O
.	O

DNA	O
band-shift	O
analysis	O
reveals	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
glial	O
cells	O
that	O
differs	O
from	O
that	O
present	O
in	O
T	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

Retinoic	O
acid	O
activates	O
interferon	B-protein
regulatory	I-protein
factor-1	I-protein
gene	O
expression	O
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O

Using	O
antigen	O
peptide	O
analogs	O
with	O
different	O
mutations	O
of	O
known	O
DQ2-anchor	O
residues	O
,	O
T	O
cell	O
response	O
was	O
reduced	O
in	O
an	O
peptide-affinity	O
and	O
-	O
concentration	O
specific	O
manner	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	B-protein
)	O
is	O
a	O
transcriptional	B-protein
activator	I-protein
that	O
binds	O
to	O
sequences	O
in	O
the	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
promoter	I-DNA
and	O
is	O
thought	O
to	O
be	O
largely	O
responsible	O
for	O
the	O
T	O
cell-specific	O
inducibility	O
of	O
IL-2	B-protein
expression	O
.	O

Interleukin-13	B-protein
(	O
IL-13	B-protein
)	O
and	O
IL-4	B-protein
are	O
cytokines	O
produced	O
by	O
T	O
cells	O
that	O
are	O
encoded	O
by	O
the	O
q23-31	O
region	O
of	O
human	O
chromosome	O
5	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
constitutes	O
the	O
first	O
indication	O
that	O
NF-kappaB	B-protein
activation	O
may	O
underlie	O
the	O
action	O
of	O
proinflammatory	O
stimuli	O
towards	O
human	O
neutrophil	O
gene	O
expression	O
and	O
,	O
as	O
such	O
,	O
adds	O
a	O
new	O
facet	O
to	O
our	O
understanding	O
of	O
neutrophil	B-cell_type
biology	I-cell_type
.	O

The	O
D3	O
analogs	O
MC903	O
,	O
EB1089	O
and	O
KH1060	O
were	O
more	O
potent	O
inducers	O
of	O
monocyte	O
differentiation	O
.	O

UV-induced	O
CYP1A1	B-protein
gene	O
expression	O
in	O
human	O
cells	O
is	O
mediated	O
by	O
tryptophan	O
.	O

These	O
observations	O
imply	O
that	O
TCF-1	B-protein
is	O
involved	O
in	O
the	O
control	O
of	O
several	O
T	B-DNA
cell-specific	I-DNA
genes	I-DNA
and	O
might	O
thus	O
play	O
an	O
important	O
role	O
in	O
the	O
establishment	O
and	O
maintenance	O
of	O
the	O
mature	B-cell_type
T	I-cell_type
cell	I-cell_type
phenotype	I-cell_type
.	O

The	O
MBP	B-protein
-selected	O
line	O
could	O
likewise	O
be	O
rendered	O
unresponsive	O
by	O
incubation	O
with	O
supraoptimal	O
concentrations	O
of	O
immunodominant	O
peptide	O
and	O
anergy	O
induction	O
was	O
accompanied	O
by	O
IL-10	B-protein
release	O
.	O

The	O
ratio	O
of	O
BCL2+	B-cell_type
to	O
CD3+	B-cell_type
cells	I-cell_type
in	O
ectopic	O
pregnancy	O
was	O
0.41	O
.	O

PML	B-protein
appears	O
to	O
be	O
transcriptionally	O
regulated	O
by	O
class	B-protein
I	I-protein
and	I-protein
II	I-protein
interferons	I-protein
,	O
which	O
raises	O
the	O
possibility	O
that	O
interferons	O
modulate	O
the	O
function	O
and	O
growth	O
and	O
differentiation	O
potential	O
of	O
normal	O
myeloid	B-cell_type
cells	I-cell_type
and	O
precursors	O
by	O
activating	O
PML	B-protein
-dependent	O
pathways	O
.	O

When	O
isolated	O
PBMC	B-cell_type
were	O
first	O
cultured	O
for	O
20	O
h	O
in	O
the	O
presence	O
of	O
IL-10	B-protein
on	O
Teflon	O
to	O
prevent	O
adherence	O
,	O
washed	O
to	O
remove	O
IL-10	B-protein
and	O
then	O
further	O
cultured	O
in	O
plastic	O
dishes	O
for	O
an	O
additional	O
20	O
h	O
in	O
the	O
presence	O
of	O
LPS	O
or	O
IL-1beta	B-protein
,	O
an	O
enhanced	O
release	O
of	O
TNF	B-protein
was	O
observed	O
.	O

High	O
concentrations	O
of	O
either	O
compound	O
(	O
1	O
)	O
drastically	O
reduced	O
the	O
number	O
of	O
primary	O
HPP-CFC	B-cell_line
colonies	I-cell_line
and	O
totally	O
abolished	O
their	O
recloning	O
capacity	O
and	O
(	O
2	O
)	O
inhibited	O
HSC	B-cell_type
proliferation	O
.	O

Both	O
within	O
and	O
among	O
these	O
SLE	O
patients	O
,	O
frequent	O
polyomavirus	O
reactivations	O
were	O
observed	O
that	O
could	O
not	O
be	O
explained	O
by	O
certain	O
rearrangements	O
of	O
the	O
noncoding	O
control	O
regions	O
,	O
nor	O
by	O
corticosteroid	O
treatment	O
.	O

Cells	O
were	O
separated	O
from	O
blood	O
samples	O
on	O
a	O
Ficoll	O
gradient	O
and	O
incubated	O
with	O
different	O
concentrations	O
of	O
[	O
3H	O
]	O
testosterone	O
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
400-fold	O
excess	O
of	O
unlabelled	O
testosterone	O
.	O

In	O
addition	O
,	O
no	O
CIITA	B-protein
protein	O
is	O
detectable	O
in	O
clone	B-cell_line
13	I-cell_line
nuclear	O
extracts	O
.	O

Observations	O
such	O
as	O
these	O
encourage	O
the	O
speculation	O
that	O
there	O
may	O
be	O
subtle	O
differences	O
in	O
the	O
regulation	O
of	O
HIV-1	O
and	O
HIV-2	O
expression	O
that	O
may	O
be	O
relevant	O
to	O
the	O
possible	O
longer	O
latency	O
and	O
reduced	O
pathogenicity	O
of	O
HIV-2	O
.	O

Intron-exon	O
organization	O
and	O
functional	O
analysis	O
of	O
5'-flanking	B-DNA
region	I-DNA
.	O

S9a	O
inhibited	O
TNF-alpha	B-protein
promoter-driven	O
reporter	B-DNA
gene	I-DNA
activity	O
.	O

Murine	B-DNA
fra-1	I-DNA
was	O
highly	O
homologous	O
to	O
rat	B-DNA
and	I-DNA
human	I-DNA
fra-1	I-DNA
.	O

HL-60	B-cell_line
cells	I-cell_line
constitutively	O
expressing	O
an	O
Egr-1	B-DNA
transgene	I-DNA
(	O
HL-60Egr-1	B-DNA
)	O
could	O
be	O
induced	O
for	O
macrophage	B-cell_type
,	O
but	O
not	O
granulocyte	B-cell_type
,	O
differentiation	O
.	O

We	O
have	O
identified	O
a	O
putative	O
transcription	B-protein
factor	I-protein
,	O
designated	O
PILOT	B-protein
,	O
with	O
an	O
identical	O
dual	O
signal	O
requirement	O
for	O
expression	O
.	O

While	O
ICN	B-protein
appeared	O
primarily	O
in	O
the	O
nucleus	O
,	O
DeltaE	B-protein
localized	O
to	O
cytoplasmic	O
and	O
nuclear	O
membranes	O
,	O
suggesting	O
that	O
intranuclear	O
localization	O
is	O
not	O
essential	O
for	O
oncogenesis	O
or	O
transcriptional	O
activation	O
.	O

These	O
AP-2	B-DNA
and	O
AP-1	B-DNA
sites	I-DNA
were	O
each	O
modified	O
with	O
a	O
double	O
point	O
mutation	O
.	O

The	O
information	O
obtained	O
from	O
these	O
cell	B-cell_line
lines	I-cell_line
has	O
also	O
been	O
used	O
in	O
arguments	O
for	O
a	O
lymphoid	O
origin	O
of	O
H-RS	B-cell_line
cells	I-cell_line
in	O
tissue	O
despite	O
the	O
frequent	O
absence	O
of	O
lymphoid	B-protein
markers	I-protein
and	O
Ig/TcR	B-DNA
gene	I-DNA
rearrangements	I-DNA
in	O
these	O
cells	O
.	O

Using	O
ATL-16T	B-cell_line
cells	I-cell_line
which	O
express	O
IL-5	B-RNA
mRNA	I-RNA
,	O
we	O
have	O
identified	O
a	O
region	O
,	O
within	O
the	O
human	B-DNA
IL-5	I-DNA
gene	I-DNA
promoter	I-DNA
,	O
that	O
regulates	O
IL-5	B-DNA
gene	I-DNA
transcription	O
.	O

Expression	O
of	O
the	O
mBCL6	B-DNA
gene	I-DNA
was	O
ubiquitously	O
detected	O
in	O
adult	O
mouse	O
tissues	O
including	O
lymphatic	O
organs	O
.	O

The	O
mechanism	O
of	O
corticosteroid	O
resistance	O
in	O
bronchial	O
asthma	O
has	O
been	O
studied	O
by	O
determining	O
the	O
rank	O
order	O
of	O
potency	O
for	O
different	O
corticosteroids	O
in	O
inhibiting	O
the	O
generation	O
of	O
a	O
3	O
kD	O
molecule	O
from	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
isolated	O
from	O
corticosteroid-sensitive	O
(	O
CS	O
)	O
and	O
corticosteroid-resistant	O
(	O
CR	O
)	O
asthmatic	O
subjects	O
,	O
which	O
augments	O
leukotriene	O
B4	O
(	O
LTB4	B-protein
)	O
generation	O
by	O
human	B-cell_type
neutrophils	I-cell_type
(	O
PMN	B-cell_type
)	O
stimulated	O
by	O
calcium	O
ionophore	O
.	O

We	O
and	O
others	O
have	O
previously	O
shown	O
that	O
the	O
nuclear	B-protein
protein	I-protein
,	O
Ets-1	B-protein
,	O
is	O
phosphorylated	O
in	O
a	O
calcium-dependent	O
manner	O
after	O
ligation	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
M	O
on	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

In	O
this	O
report	O
we	O
have	O
asked	O
which	O
region	O
(	O
s	O
)	O
of	O
the	O
steroid	B-protein
receptor	I-protein
are	O
important	O
for	O
mediating	O
lysis	O
in	O
leukemic	B-cell_type
T	I-cell_type
lymphoblasts	I-cell_type
.	O

METHODS	O
:	O
The	O
authors	O
evaluated	O
tarsal	O
and	O
bulbar	O
conjunctival	O
biopsies	O
from	O
seven	O
patients	O
with	O
severe	O
and	O
symptomatic	O
VKC	O
for	O
the	O
presence	O
of	O
estrogen	B-protein
and	O
progesterone	B-protein
receptors	I-protein
by	O
using	O
monoclonal	B-protein
antibodies	I-protein
with	O
a	O
peroxidase-antiperoxidase	O
technique	O
.	O

The	O
HSFE	B-DNA
induced	O
an	O
area	O
of	O
enhanced	O
DNase	B-protein
1	I-protein
hypersensitivity	O
extending	O
from	O
the	O
transcriptional	O
start	O
site	O
to	O
-300bp	O
of	O
the	O
artificial	B-DNA
promoter	I-DNA
and	O
significantly	O
increased	O
the	O
proportion	O
of	O
beta-globin	B-DNA
promoters	I-DNA
in	O
an	O
open	O
chromatin	O
configuration	O
.	O

These	O
insights	O
in	O
the	O
molecular	O
events	O
that	O
are	O
involved	O
in	O
TCF/LEF	B-protein
function	O
in	O
these	O
organisms	O
may	O
eventually	O
lead	O
to	O
the	O
understanding	O
of	O
the	O
function	O
of	O
these	O
HMG	B-protein
box	I-protein
proteins	I-protein
in	O
lymphoid	O
development	O

This	O
detection	O
suggested	O
a	O
preferential	O
activation	O
of	O
p50/c-Rel	B-protein
in	O
medullary	B-cell_type
thymocytes	I-cell_type
,	O
whereas	O
p50/p65	B-protein
was	O
present	O
in	O
both	O
cortical	O
and	O
medullary	O
regions	O
of	O
human	O
thymus	O
lobules	O
.	O

Moreover	O
,	O
PMA	O
caused	O
the	O
dephosphorylation	O
of	O
Tyk2	B-protein
but	O
not	O
of	O
Jak1	B-protein
,	O
which	O
was	O
activated	O
by	O
IFN	B-protein
.	O

Granzyme	O
B	O
gene	O
transcription	O
is	O
induced	O
in	O
activated	O
lymphocytes	B-cell_type
upon	O
antigenic	O
stimulation	O
,	O
and	O
several	O
regulatory	B-DNA
regions	I-DNA
including	O
CBF	B-protein
,	O
AP-1	B-protein
,	O
and	O
Ikaros	B-DNA
binding	I-DNA
sites	I-DNA
have	O
been	O
shown	O
to	O
be	O
essential	O
in	O
the	O
control	O
of	O
granzyme	B-DNA
B	I-DNA
promoter	I-DNA
activation	O
.	O

One	O
hour	O
pulse-treatment	O
with	O
3	O
microM	O
etoposide	O
caused	O
topoisomerase	B-protein
associated	O
,	O
primary	O
DNA	O
breakage	O
,	O
which	O
was	O
rapidly	O
followed	O
by	O
apoptosis	O
.	O

Extracellular-regulated	B-protein
kinase	I-protein
1/2	I-protein
,	O
Jun	B-protein
N-terminal	I-protein
kinase	I-protein
,	O
and	O
c-Jun	B-protein
are	O
involved	O
in	O
NF-kappa	B-protein
B	I-protein
-dependent	O
IL-6	B-protein
expression	O
in	O
human	O
monocytes	O
.	O

Although	O
IL-2	B-protein
and	O
IFN-alpha	B-protein
activated	O
STAT1	B-protein
alpha	I-protein
and	O
STAT5	B-protein
,	O
IL-2	B-protein
predominantly	O
activated	O
STAT5	B-protein
,	O
while	O
IFN-alpha	B-protein
predominantly	O
activated	O
STAT1	B-protein
alpha	I-protein
.	O

Activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
by	O
Gardnerella	O
vaginalis	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
To	O
further	O
analyze	O
the	O
neonatal	O
immune	O
response	O
to	O
an	O
antigenic	O
challenge	O
such	O
as	O
blood	O
transfusion	O
,	O
c-fos	O
and	O
c-jun	O
mRNA	O
expression	O
were	O
analyzed	O
in	O
twelve	O
in-vitro-stimulated	O
normal	O
cord	O
blood	O
and	O
ten	O
in-vitro-stimulated	B-cell_type
normal	I-cell_type
adult	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocyte	I-cell_type
samples	I-cell_type
.	O

LPS-induced	O
NF-kappaB	B-protein
activation	O
was	O
not	O
inhibited	O
by	O
a	O
dominant	O
negative	O
mutant	O
of	O
TRAF2	B-protein
that	O
is	O
involved	O
in	O
TNF	B-protein
signaling	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
interpretation	O
that	O
glucocorticoid-mediated	O
autoregulation	O
of	O
GR	O
expression	O
is	O
a	O
tissue-specific	O
primary	O
transcriptional	O
response	O
.	O

Both	O
CIITA	B-protein
and	O
Bob1	B-protein
increase	O
the	O
expression	O
from	O
the	O
DRA	B-DNA
promoter	I-DNA
,	O
which	O
is	O
a	O
prototypic	O
class	B-DNA
II	I-DNA
promoter	I-DNA
.	O

Within	O
2	O
to	O
4	O
h	O
of	O
PMA	O
exposure	O
,	O
steady	O
state	O
levels	O
of	O
TNF	B-RNA
mRNA	I-RNA
are	O
markedly	O
elevated	O
in	O
all	O
myelomonocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
studied	O
.	O

These	O
results	O
support	O
a	O
model	O
for	O
viral	B-DNA
promoter	I-DNA
switching	O
during	O
the	O
initial	O
stages	O
of	O
infection	O
in	O
which	O
Wp	O
activity	O
leads	O
to	O
the	O
expression	O
of	O
EBNA	B-protein
2	I-protein
,	O
followed	O
by	O
activation	O
of	O
Cp	B-DNA
through	O
the	O
EBNA	B-DNA
2-dependent	I-DNA
enhancer	I-DNA
.	O

The	O
hydrophobic	B-protein
domain	I-protein
is	O
homologous	O
to	O
three	O
yeast	O
polypeptides	O
,	O
suggesting	O
that	O
this	O
higher	B-DNA
eukaryotic	I-DNA
gene	I-DNA
could	O
have	O
evolved	O
from	O
recombination	O
between	O
a	O
gene	O
that	O
encoded	O
a	O
soluble	B-protein
nuclear	I-protein
protein	I-protein
and	O
a	O
membrane	B-DNA
protein	I-DNA
gene	I-DNA
similar	O
to	O
those	O
in	O
yeast	O
.	O

Fcgamma	B-protein
receptor	I-protein
-mediated	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
activation	O
in	O
monocytes	B-cell_type
is	O
independent	O
of	O
Ras	B-protein
.	O

In	O
several	O
cell	O
types	O
,	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and/or	O
activating	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
has	O
been	O
demonstrated	O
to	O
be	O
extremely	O
important	O
in	O
blocking	O
apoptosis	O
.	O

Two	O
of	O
these	O
were	O
not	O
cell	O
type	O
specific	O
,	O
but	O
the	O
third	O
was	O
detected	O
only	O
in	O
EBNA2	B-protein
positive	O
cell	O
extracts	O
.	O

A	O
comparison	O
of	O
in	O
situ	O
hybridization	O
to	O
EBV	B-DNA
DNA	I-DNA
and	O
viral	B-protein
capsid	I-protein
antigen	I-protein
staining	O
with	O
BZ1	B-protein
reactivity	O
suggested	O
that	O
BZLF1	B-protein
expression	O
precedes	O
rampant	O
virus	O
replication	O
.	O

Deletion	O
of	O
the	O
glucocorticoid	O
response	O
elements	O
located	O
at	O
ca.	B-DNA
bp	I-DNA
-850	I-DNA
upstream	O
of	O
Cp	B-DNA
did	O
not	O
result	O
in	O
a	O
significant	O
loss	O
in	O
activity	O
.	O

We	O
now	O
report	O
that	O
EC	B-cell_type
costimulation	O
causes	O
increased	O
levels	O
of	O
IL-2	B-RNA
mRNA	I-RNA
as	O
a	O
result	O
of	O
increased	O
IL-2	B-protein
transcription	O
in	O
PBL	B-cell_type
.	O

These	O
observations	O
suggest	O
a	O
mechanism	O
by	O
which	O
SP-A	B-protein
plays	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
some	O
lung	O
conditions	O
and	O
point	O
to	O
potential	O
therapeutic	O
measures	O
that	O
could	O
be	O
used	O
to	O
prevent	O
SP-A	B-protein
induced	O
inflammation	O
in	O
the	O
lung	O
.	O

Cell	O
proliferation	O
of	O
CEM-C7	B-cell_line
cells	O
cultured	O
in	O
both	O
serum-free	O
media	O
has	O
been	O
sustained	O
for	O
3	O
mo	O
.	O

PPARgamma	B-protein
induces	O
the	O
expression	O
of	O
many	O
genes	B-DNA
involved	O
in	O
lipid	O
anabolism	O
,	O
including	O
the	O
adipocyte	B-protein
fatty	I-protein
acid	I-protein
binding	I-protein
protein	I-protein
(	O
aP2	B-protein
)	O
,	O
and	O
is	O
a	O
key	O
regulator	O
of	O
adipocyte	B-cell_type
differentiation	O
.	O

The	O
stimulation	O
of	O
interleukin-1	B-protein
alpha	I-protein
production	O
by	O
okadaic	O
acid	O
was	O
more	O
modest	O
than	O
that	O
of	O
interleukin-1	B-protein
beta	I-protein
.	O

Overexpression	O
of	O
full-length	O
SCL	B-protein
protein	I-protein
in	O
the	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
SupT1	O
and	O
Raji	O
,	O
did	O
not	O
alter	O
cell	O
phenotype	O
and	O
there	O
was	O
no	O
evidence	O
for	O
autoregulation	O
of	O
SCL	B-protein
transcription	O
.	O

Our	O
findings	O
suggest	O
that	O
leukocyte-platelet	O
adhesion	O
contributes	O
to	O
the	O
regulation	O
of	O
inflammatory	O
responses	O
in	O
AMI	O
.	O

Furthermore	O
,	O
we	O
observed	O
the	O
association	O
of	O
p47phox	O
with	O
the	O
hIL-4R	B-protein
alpha	I-protein
in	O
B	B-cell_type
cells	I-cell_type
derived	O
from	O
a	O
normal	O
donor	O
.	O

The	O
tyrosine	O
kinase	O
activity	O
in	O
the	O
anti-	O
Itk	B-protein
immunoprecipitate	O
was	O
significantly	O
activated	O
upon	O
these	O
stimulations	O
.	O

The	O
induction	O
of	O
this	O
promoter	O
was	O
confirmed	O
in	O
COS7	B-cell_line
cells	I-cell_line
.	O

Although	O
overexpressed	O
Egr-1	B-protein
was	O
ineffective	O
,	O
overexpressed	O
Egr-2	B-protein
was	O
as	O
potent	O
as	O
Egr-3	B-protein
in	O
inducing	O
fasL	B-DNA
promoter-dependent	I-DNA
reporter	I-DNA
constructs	I-DNA
in	O
T	O
cell	O
hybridomas	O
and	O
HeLa	O
cells	O
,	O
and	O
both	O
up-regulated	O
endogenous	O
fasL	B-RNA
mRNA	I-RNA
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O

The	O
effect	O
of	O
temperature	O
,	O
beta	B-protein
2-microglobulin	I-protein
(	O
beta	B-protein
2-m	I-protein
)	O
and	O
fetal	O
calf	O
serum	O
(	O
FCS	O
)	O
on	O
the	O
binding	O
and	O
the	O
stability	O
of	O
the	O
HLA/peptide	B-protein
complex	I-protein
was	O
studied	O
.	O

LBR	B-protein
's	O
nucleoplasmic	B-protein
domain	I-protein
is	O
encoded	O
by	O
exons	B-DNA
1-4	I-DNA
,	O
and	O
its	O
hydrophobic	B-protein
domain	I-protein
,	O
with	O
eight	O
putative	O
transmembrane	B-protein
segments	I-protein
,	O
is	O
encoded	O
by	O
exons	B-DNA
5-13	I-DNA
.	O

PMA	O
induction	O
increases	O
the	O
level	O
of	O
a	O
number	O
of	O
specific	B-protein
binding	I-protein
complexes	I-protein
relative	O
to	O
the	O
resting	B-cell_type
cells	I-cell_type
.	O

A	O
role	O
for	O
changes	O
in	O
immunophilins	B-protein
,	O
causing	O
glucocorticoid	O
resistance	O
in	O
neotropical	O
primates	O
,	O
is	O
supported	O
by	O
the	O
following	O
:	O
the	O
changes	O
in	O
FKBP51	B-protein
and	O
FKBP52	B-protein
were	O
observed	O
in	O
cells	O
from	O
other	O
neotropical	O
primates	O
with	O
glucocorticoid	O
resistance	O
;	O
the	O
elevated	O
level	O
of	O
FKBP51	B-protein
was	O
reflected	O
in	O
an	O
abundance	O
of	O
FKBP51	B-protein
in	O
heat	B-protein
shock	I-protein
protein	I-protein
90	I-protein
complexes	I-protein
in	O
SML	B-cell_type
;	O
when	O
cytosols	O
of	O
SML	B-cell_type
and	O
L929	B-cell_line
cells	I-cell_line
were	O
mixed	O
,	O
the	O
decrease	O
in	O
GR	O
binding	O
was	O
associated	O
with	O
incorporation	O
of	O
FKBP51	B-protein
into	O
GR	B-protein
heterocomplexes	I-protein
;	O
the	O
effect	O
of	O
SML	B-cell_type
cytosol	O
on	O
GR	O
binding	O
was	O
reproduced	O
with	O
cytosol	O
from	O
COS	B-cell_line
cells	I-cell_line
expressing	O
squirrel	O
monkey	O
FKBP51	B-protein
;	O
and	O
both	O
the	O
effect	O
of	O
SML	B-cell_type
cytosol	O
on	O
GR	O
binding	O
and	O
the	O
incorporation	O
of	O
FKBP51	B-protein
into	O
GR	B-protein
heterocomplexes	I-protein
were	O
blocked	O
by	O
FK506	O
.	O

This	O
factor	O
has	O
a	O
DNA-binding	O
specificity	O
similar	O
to	O
that	O
of	O
NF-kappa	B-protein
B	I-protein
but	O
is	O
unrelated	O
to	O
this	O
or	O
other	O
Rel	B-protein
proteins	I-protein
by	O
functional	O
and	O
biochemical	O
criteria	O
.	O

MHC	B-protein
class	I-protein
II	I-protein
signaling	O
in	O
B-cell	B-cell_type
activation	O
[	O
see	O
comments	O
]	O

We	O
previously	O
identified	O
the	O
P	B-DNA
sequence	I-DNA
as	O
a	O
critical	O
regulatory	B-DNA
element	I-DNA
of	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
.	O

All	O
human	O
adenoviruses	O
transform	O
rodent	B-cell_type
cells	I-cell_type
in	O
vitro	O
,	O
but	O
only	O
cells	O
transformed	O
by	O
serotypes	O
belonging	O
to	O
subgroups	O
A	O
(	O
Ad12	O
)	O
and	O
B	O
(	O
Ad3	O
)	O
are	O
tumorigenic	O
for	O
immunocompetent	O
animals	O
.	O

To	O
study	O
the	O
molecular	O
mechanisms	O
of	O
transcriptional	O
control	O
of	O
CD95L	B-protein
expression	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
we	O
investigated	O
the	O
human	B-DNA
CD95L	I-DNA
promoter	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

This	O
factor	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
a	O
variety	O
of	O
cell	O
types	O
but	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	B-DNA
Ig	I-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
in	O
non-B	B-cell_type
cells	I-cell_type
,	O
perhaps	O
due	O
to	O
a	O
non-permissive	O
chromatin	B-DNA
structure	O
of	O
the	O
Ig	B-DNA
heavy	I-DNA
chain	I-DNA
locus	I-DNA
.	O

We	O
show	O
here	O
that	O
DTCs	O
inhibited	O
both	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
synthesis	O
and	O
membrane	O
expression	O
of	O
antigens	B-protein
which	O
are	O
induced	O
during	O
T-cell	O
activation	O
.	O

p21	B-protein
(	I-protein
ras	I-protein
)	I-protein
,	O
a	O
guanine	B-protein
nucleotide	I-protein
binding	I-protein
factor	I-protein
,	O
mediates	O
T-cell	O
signal	O
transduction	O
through	O
PKC	B-protein
-dependent	O
and	O
PKC	B-protein
-independent	O
pathways	O
.	O

In	O
conclusion	O
,	O
strong	O
c-myc	B-RNA
mRNA	I-RNA
expression	O
was	O
observed	O
on	O
epithelial	B-cell_type
cells	I-cell_type
of	O
labial	O
salivary	O
glands	O
from	O
patients	O
with	O
primary	O
SS	O
.	O

These	O
are	O
prominent	O
enzymes	B-protein
in	O
the	O
endocytic	O
pathway	O
through	O
which	O
soluble	B-protein
protein	I-protein
Ag	I-protein
enter	O
APC	B-protein
,	O
and	O
resistant	B-protein
segments	I-protein
in	O
Ag	B-protein
may	O
,	O
therefore	O
,	O
be	O
expected	O
to	O
contain	O
more	O
T-cell	B-protein
determinants	I-protein
than	O
susceptible	B-protein
segments	I-protein
.	O

DNA-binding	O
activities	O
(	O
determined	O
by	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
of	O
three	O
transcription	B-protein
factors	I-protein
:	O
NFkappaB	B-protein
,	O
AP-1	B-protein
and	O
NFAT	B-protein
,	O
were	O
abolished	O
in	O
the	O
lymphocytes	B-cell_type
by	O
all	O
three	O
modes	O
of	O
oxidative	O
stress	O
.	O

Although	O
devoid	O
of	O
any	O
effect	O
by	O
itself	O
,	O
a	O
mutant	B-protein
p53	I-protein
cooperated	O
with	O
Spi-1	B-protein
and	O
EpoR	B-protein
(	I-protein
R129C	I-protein
)	I-protein
to	O
reinforce	O
both	O
phenotypes	O
.	O

Fast	O
in	O
vitro	O
effects	O
of	O
aldosterone	O
on	O
the	O
Na+/H	B-protein
(	I-protein
+	I-protein
)	I-protein
-exchanger	I-protein
,	O
inositoltrisphosphate	O
generation	O
and	O
corresponding	O
specific	O
binding	O
to	O
plasma	O
membranes	O
at	O
Kd-values	O
of	O
approximately	O
0.1	O
nM	O
have	O
been	O
found	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
and	O
vascular	B-cell_type
smooth	I-cell_type
muscle	I-cell_type
cells	I-cell_type
.	O

On	O
the	O
contrary	O
,	O
the	O
release	O
of	O
MCP-1	B-protein
was	O
significantly	O
inhibited	O
,	O
also	O
in	O
a	O
dose-dependent	O
manner	O
.	O

Triggering	O
of	O
complement	B-protein
receptors	I-protein
CR1	B-protein
(	O
CD35	B-protein
)	O
and	O
CR3	B-protein
(	O
CD11b/CD18	B-protein
)	O
induces	O
nuclear	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
(	O
p50/p65	B-protein
)	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
enhances	O
viral	O
replication	O
in	O
HIV-infected	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

The	O
sexual	O
difference	O
in	O
the	O
incidence	O
of	O
autoimmune	O
diseases	O
has	O
remained	O
an	O
enigma	O
for	O
many	O
years	O
.	O

Phosphoinositide	B-protein
3-kinase	I-protein
(	O
PI	B-protein
3-kinase	I-protein
)	O
is	O
activated	O
by	O
a	O
diverse	O
set	O
of	O
receptors	O
that	O
determine	O
T-cell	O
function	O
,	O
including	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
,	O
the	O
costimulatory	B-protein
receptor	I-protein
CD28	I-protein
,	O
and	O
negative	B-protein
regulators	I-protein
of	O
T-cell	O
activation	O
such	O
as	O
CTLA-4	B-protein
.	O

Here	O
,	O
we	O
investigate	O
the	O
role	O
of	O
Rho	B-protein
in	O
regulating	O
the	O
distribution	O
of	O
the	O
monocyte-binding	B-protein
receptors	I-protein
E-selectin	B-protein
,	O
ICAM-1	B-protein
,	O
and	O
VCAM-1	B-protein
in	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O

The	O
induction	O
of	O
immediate	B-DNA
early	I-DNA
genes	I-DNA
in	O
cells	O
of	O
the	O
immune	O
system	O
is	O
critical	O
to	O
determining	O
the	O
ultimate	O
outcome	O
of	O
exposure	O
to	O
antigen	O
.	O

We	O
also	O
observed	O
that	O
cell	B-cell_type
surface	I-cell_type
CD4	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD3	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
cells	I-cell_type
with	O
rearranged	B-DNA
TCR	I-DNA
genes	I-DNA
developed	O
from	O
Id3-transduced	B-cell_line
but	O
not	O
from	O
control-transduced	B-cell_line
pre-T	I-cell_line
cells	I-cell_line
in	O
an	O
FTOC	B-cell_line
.	O

The	O
56-59-kilodalton	B-protein
protein	I-protein
identified	O
in	O
untransformed	B-protein
steroid	I-protein
receptor	I-protein
complexes	I-protein
is	O
a	O
unique	B-protein
protein	I-protein
that	O
exists	O
in	O
cytosol	O
in	O
a	O
complex	O
with	O
both	O
the	O
70-	B-protein
and	I-protein
90-kilodalton	I-protein
heat	I-protein
shock	I-protein
proteins	I-protein
.	O

Tyloxapol	O
inhibits	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappa	I-protein
B	I-protein
(	O
NK-kappa	B-protein
B	I-protein
)	O
,	O
reduces	O
resting	O
secretion	O
of	O
the	O
cytokine	B-protein
interleukin-8	B-protein
(	O
IL-8	B-protein
)	O
in	O
cultured	B-cell_line
human	I-cell_line
monocytes	I-cell_line
,	O
and	O
inhibits	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-stimulated	O
release	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
IL-1	B-protein
beta	I-protein
,	O
IL-6	B-protein
,	O
IL-8	B-protein
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
,	O
and	O
the	O
eiconsanoids	O
thromboxane	O
A2	O
and	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
.	O

Furthermore	O
,	O
the	O
most	O
important	O
trans-acting	B-protein
factors	I-protein
of	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
(	O
e.g	O
.	O
NF-kB	B-protein
,	O
NF-AT	B-protein
and	O
STAT	B-protein
families	I-protein
)	O
and	O
their	O
functional	O
importance	O
are	O
described	O
.	O

It	O
is	O
expressed	O
on	O
a	O
subpopulation	O
of	O
macrophages	B-cell_type
in	O
lymphoid	O
tissues	O
and	O
in	O
chronic	O
inflammation	O
(	O
e.g.	O
,	O
during	O
autoimmune	O
diseases	O
)	O
.	O

We	O
identified	O
a	O
region	O
of	O
the	O
c-myb	B-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
sequence	I-DNA
that	O
increased	O
c-myb	B-DNA
expression	O
during	O
T-cell	O
activation	O
.	O

TCP	O
succinate	O
(	O
200	O
microM	O
,	O
24	O
h	O
)	O
reduced	O
TNF-induced	B-protein
VCAM-1	I-protein
and	O
E-selectin	B-protein
expression	O
from	O
a	O
specific	O
mean	O
fluorescence	O
intensity	O
of	O
151	O
+/-	O
28	O
to	O
12	O
+/-	O
4	O
channels	O
and	O
from	O
225	O
+/-	O
38	O
to	O
79	O
+/-	O
21	O
channels	O
,	O
respectively	O
.	O

Transient	O
expression	O
assays	O
linked	O
Zta	B-protein
expression	O
to	O
the	O
down-regulation	O
of	O
Qp	B-DNA
.	O

The	O
concentration	O
of	O
c-fos	B-RNA
,	I-RNA
c-jun	I-RNA
,	I-RNA
c-myc	I-RNA
,	I-RNA
junB	I-RNA
,	I-RNA
and	I-RNA
fra-1	I-RNA
mRNAs	I-RNA
was	O
increased	O
in	O
activated	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
incubated	O
with	O
ciprofloxacin	O
compared	O
to	O
that	O
in	O
untreated	O
controls	O
.	O

The	O
C-terminal	B-protein
half	I-protein
of	O
human	B-protein
MZF-2	I-protein
,	O
carrying	O
the	O
zinc	B-protein
finger	I-protein
domains	I-protein
,	O
was	O
completely	O
identical	O
with	O
that	O
of	O
human	B-protein
MZF-1	I-protein
,	O
whereas	O
the	O
N-terminal	B-protein
half	I-protein
of	O
MZF-2	B-protein
was	O
different	O
from	O
the	O
corresponding	O
region	O
of	O
human	O
MZF-1	B-protein
,	O
and	O
was	O
coded	O
by	O
distinct	O
exons	B-DNA
.	O

The	O
potential	O
clinical	O
usefulness	O
of	O
these	O
CL	O
assays	O
was	O
suggested	O
by	O
the	O
ability	O
of	O
both	O
monocytes	B-cell_type
and	O
IFN-U937	B-cell_line
cells	I-cell_line
to	O
respond	O
to	O
red	B-cell_type
cells	I-cell_type
,	O
platelets	B-cell_type
or	O
granulocytes	B-cell_type
sensitized	O
with	O
sera	O
from	O
pregnant	O
women	O
whose	O
babies	O
had	O
either	O
haemolytic	O
disease	O
of	O
the	O
newborn	O
(	O
HDN	O
)	O
,	O
alloimmune	O
thrombocytopenia	O
or	O
alloimmune	O
neutropenia	O
respectively	O
.	O

The	O
augmentation	O
of	O
B	O
cell	O
proliferation	O
by	O
CD70	O
transfectants	O
was	O
apparent	O
in	O
CD27+	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
but	O
was	O
mild	O
in	O
CD27-	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Thirteen	O
of	O
15	O
patients	O
with	O
SS	O
and	O
4/17	O
controls	O
were	O
HLA-DR3	B-protein
positive	O
,	O
with	O
no	O
apparent	O
association	O
of	O
HLA-DR3	B-protein
with	O
SSB	B-protein
reactivity	O
in	O
controls	O
.	O

CRISP-3	B-protein
is	O
pre-B	O
cell-specific	O
,	O
Nov1	B-DNA
is	O
plasma	O
B	O
cell-specific	O
and	O
Nov2	B-DNA
is	O
B	O
cell-specifically	O
expressed	O
.	O

A	O
specific	O
p38	B-protein
MAPk	I-protein
inhibitor	O
(	O
SK	O
&	O
F	O
86002	O
)	O
blocked	O
superoxide	O
anion	O
production	O
in	O
response	O
to	O
FMLP	B-protein
and	O
reduced	O
adhesion	O
and	O
chemotaxis	O
in	O
response	O
to	O
PAF	B-protein
or	O
FMLP	B-protein
.	O

To	O
identify	O
cellular	B-protein
proteins	I-protein
binding	O
to	O
TRE-1	B-DNA
in	O
a	O
Tax	B-protein
-dependent	O
manner	O
,	O
this	O
strain	O
was	O
also	O
used	O
to	O
screen	O
a	O
library	O
of	O
human	B-DNA
cDNAs	I-DNA
fused	O
to	O
GAD	B-protein
.	O

Thus	O
,	O
both	O
NF-kappa	B-protein
B-binding	I-protein
complexes	I-protein
are	O
needed	O
for	O
optimal	O
viral	O
transcription	O
.	O

Thus	O
,	O
the	O
novel	O
enhancer	O
element	O
identified	O
in	O
this	O
study	O
is	O
probably	O
a	O
target	O
site	O
for	O
both	O
positive	B-protein
and	I-protein
negative	I-protein
factors	I-protein
.	O

Two	O
different	O
proteins	O
which	O
independently	O
bound	O
to	O
neighboring	O
sequences	O
within	O
the	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
(	O
NRE	B-DNA
)	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
were	O
detected	O
in	O
the	O
nuclear	O
extract	O
of	O
a	O
virus-infected	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

The	O
down-regulation	O
of	O
RANTES	B-protein
expression	O
by	O
glucocorticoids	O
in	O
T	B-cell_type
cells	I-cell_type
may	O
directly	O
contribute	O
to	O
the	O
efficacy	O
of	O
these	O
agents	O
in	O
suppressing	O
cellular	O
infiltration	O
and	O
to	O
their	O
anti-inflammatory	O
properties	O
.	O

Collectively	O
this	O
study	O
shows	O
that	O
expression	O
of	O
the	O
Btk	B-DNA
gene	I-DNA
is	O
regulated	O
by	O
the	O
combined	O
action	O
of	O
Sp1-	B-protein
and	I-protein
PU.1-family	I-protein
members	I-protein
.	O

NGFI-B/nur77	B-protein
and	O
its	O
related	O
genes	O
constitute	O
a	O
family	O
and	O
the	O
NGFI-B/nur77	B-protein
family	I-protein
consists	O
of	O
three	O
subtypes	O
,	O
named	O
nur77	B-protein
alpha	I-protein
,	O
nur77	B-protein
beta	I-protein
,	O
nur77	B-protein
gamma	I-protein
.	O

The	O
NFAT-controlled	B-DNA
luciferase	I-DNA
gene	I-DNA
system	I-DNA
distinguishes	O
CIF	B-protein
from	O
other	O
T	O
cell	O
inhibitory	O
activities	O
present	O
in	O
colostrum	O
,	O
in	O
particular	O
,	O
TGF	B-protein
beta	I-protein
1	I-protein
and	O
TGF	B-protein
beta	I-protein
2	I-protein
and	O
the	O
glucocorticoids	O
.	O

Spi-1/PU.1	B-DNA
proto-oncogene	B-DNA
induces	O
opposite	O
effects	O
on	O
monocytic	O
and	O
erythroid	O
differentiation	O
of	O
K562	B-cell_line
cells	I-cell_line
.	O

Certain	O
subpopulations	O
of	O
lymphocytes	B-cell_type
synthesize	O
and	O
secrete	O
biologically	O
active	O
prolactin	O
,	O
which	O
suggests	O
that	O
prolactin	O
can	O
act	O
as	O
an	O
autocrine	O
and/or	O
paracrine	O
factor	O
to	O
modulate	O
the	O
activities	O
of	O
cells	O
of	O
the	O
immune	O
system	O
.	O

HIV-1	B-protein
tat	I-protein
induces	O
the	O
expression	O
of	O
a	O
new	O
hematopoietic	B-protein
cell-specific	I-protein
transcription	I-protein
factor	I-protein
and	O
downregulates	O
MIP-1	B-DNA
alpha	I-DNA
gene	I-DNA
expression	O
in	O
activated	B-cell_type
T-cells	I-cell_type
.	O

No	O
up-regulation	O
of	O
hTR	B-protein
beta	I-protein
1	I-protein
was	O
seen	O
in	O
hypothyroid	O
relative	O
to	O
euthyroid	O
patients	O
.	O

Leukemic	O
blasts	O
in	O
the	O
majority	O
of	O
cases	O
shared	O
unique	O
morphologic	O
features	O
(	O
deeply	O
invaginated	O
nuclear	O
membranes	O
,	O
scant	O
cytoplasm	O
with	O
fine	O
azurophilic	O
granularity	O
,	O
and	O
finely	O
granular	O
Sudan	O
black	O
B	O
and	O
myeloperoxidase	B-protein
cytochemical	O
reactivity	O
)	O
that	O
were	O
remarkably	O
similar	O
to	O
those	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
;	O
particularly	O
the	O
microgranular	B-protein
variant	I-protein
(	O
FAB	B-protein
AML-M3v	I-protein
)	O
.	O

Expression	O
of	O
ATF-2	B-protein
in	O
S.	O
cerevisiae	O
did	O
not	O
activate	O
TRE-1	B-DNA
in	O
the	O
presence	O
of	O
Tax	B-protein
.	O

Assays	O
using	O
monocytes	B-cell_type
or	O
IFN-U937	B-cell_line
cells	I-cell_line
were	O
of	O
comparable	O
sensitivity	O
for	O
detection	O
of	O
antibodies	B-protein
against	O
all	O
three	O
types	O
of	O
target	O
cell	O
.	O

To	O
this	O
aim	O
,	O
allergen-specific	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
(	O
TCC	B-cell_line
)	O
were	O
generated	O
from	O
the	O
peripheral	O
blood	O
of	O
three	O
atopic	O
patients	O
,	O
and	O
their	O
cytokine	B-protein
profiles	O
were	O
analyzed	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
impact	O
of	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
sequence	O
diversity	O
on	O
LTR-directed	B-DNA
gene	I-DNA
expression	O
in	O
cells	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
and	O
immune	O
system	O
,	O
we	O
amplified	O
and	O
cloned	O
LTRs	B-DNA
from	O
proviral	B-DNA
DNA	I-DNA
in	O
HIV-1-infected	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
.	O

Abnormalities	O
of	O
cyclic	O
adenosine	O
monophosphate	O
signaling	O
in	O
platelets	B-cell_type
from	O
untreated	O
patients	O
with	O
bipolar	O
disorder	O
.	O

E3330	O
inhibited	O
this	O
induced	O
promoter	O
activity	O
in	O
a	O
dose-dependent	O
manner	O
.	O

These	O
results	O
provide	O
evidence	O
for	O
differential	O
regulation	O
of	O
the	O
promoter	O
function	O
of	O
CPO	B-protein
gene	O
between	O
erythroid	B-cell_type
and	I-cell_type
nonerythroid	I-cell_type
cells	I-cell_type
.	O

To	O
determine	O
whether	O
oxidative	O
stress	O
dependent	O
NF-kappaB	B-protein
activation	O
is	O
evident	O
in	O
patients	O
with	O
diabetic	O
nephropathy	O
we	O
used	O
an	O
Electrophoretic	O
Mobility	O
Shift	O
Assay	O
based	O
semiquantitative	O
detection	O
system	O
which	O
enabled	O
us	O
to	O
determine	O
NF-kappaB	B-protein
activation	O
in	O
ex	O
vivo	O
isolated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

Androgen	B-protein
binding	I-protein
sites	I-protein
in	O
peripheral	B-cell_type
human	I-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
of	O
healthy	O
males	O
and	O
females	O
.	O

To	O
investigate	O
the	O
molecular	O
mechanism	O
of	O
the	O
inhibitory	O
effect	O
on	O
transcriptional	O
or	O
post-transcriptional	O
regulation	O
of	O
IL-6	B-DNA
gene	I-DNA
expression	O
by	O
IL-4	B-protein
and	O
IL-10	B-protein
,	O
we	O
studied	O
IL-6	B-protein
production	O
,	O
expression	O
level	O
of	O
IL-6	B-RNA
mRNA	I-RNA
,	O
IL-6	B-protein
promoter	O
activity	O
,	O
transcriptional	O
activity	O
of	O
NF-kappaB	B-protein
and	O
NF-IL-6	B-protein
,	O
and	O
IL-6	B-RNA
mRNA	I-RNA
stability	O
in	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
THP-1	B-cell_line
and	O
U937	B-cell_line
,	O
stimulated	O
by	O
PMA	O
and	O
LPS	O
in	O
the	O
absence	O
or	O
the	O
presence	O
of	O
IL-4	B-protein
or	O
IL-10	B-protein
.	O

However	O
,	O
in	O
contrast	O
to	O
human	B-cell_type
lymphocytes	I-cell_type
,	O
IFN-gamma	B-protein
production	O
was	O
inhibited	O
and	O
IFN-gamma	B-RNA
mRNA	I-RNA
levels	O
were	O
unaffected	O
at	O
24	O
h	O
and	O
only	O
slightly	O
upregulated	O
at	O
48	O
and	O
72	O
h	O
of	O
culture	O
in	O
murine	B-cell_type
splenocytes	I-cell_type
incubated	O
with	O
cipro	O
(	O
20	O
micrograms/ml	O
)	O
.	O

In	O
addition	O
,	O
the	O
product	O
of	O
the	O
proto-oncogene	B-DNA
c-rel	I-DNA
can	O
bind	O
to	O
similar	O
DNA	O
motifs	O
by	O
itself	O
or	O
as	O
a	O
heterodimer	O
with	O
p50	B-protein
or	O
p65	B-protein
.	O

The	O
regulation	O
of	O
human	B-protein
IL-1beta	I-protein
gene	O
expression	O
has	O
been	O
studied	O
for	O
several	O
years	O
,	O
and	O
a	O
few	O
regulatory	B-DNA
elements	I-DNA
have	O
been	O
discovered	O
in	O
the	O
promoter	B-DNA
region	I-DNA
.	O

Two	O
families	O
of	O
transcription	B-protein
factors	I-protein
that	O
are	O
required	O
for	O
normal	O
hematopoiesis	O
are	O
c-Myb	B-protein
and	O
Ets	B-protein
.	O

Although	O
monocytic	O
cells	O
can	O
provide	O
a	O
reservoir	O
for	O
viral	O
production	O
in	O
vivo	O
,	O
their	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
transcription	O
can	O
be	O
either	O
latent	O
,	O
restricted	O
,	O
or	O
productive	O
.	O

The	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
alpha	I-protein
(	O
PPARalpha	B-protein
)	O
ligand	O
WY	O
14	O
,	O
643	O
does	O
not	O
interfere	O
with	O
leukotriene	O
B4	O
induced	O
adhesion	O
of	O
neutrophils	B-cell_type
to	O
endothelial	B-cell_type
cells	I-cell_type
.	O

The	O
resultant	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
DH42	B-cell_line
,	O
was	O
hygromycin	O
resistant	O
,	O
contained	O
VDR	B-DNA
cDNA	I-DNA
,	O
expressed	O
fewer	O
VDRs	B-protein
than	O
controls	O
,	O
and	O
showed	O
a	O
substantial	O
decrease	O
in	O
antiproliferative	O
response	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

Inhibition	O
of	O
the	O
differentiation	O
of	O
human	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
lines	I-cell_line
by	O
redox	O
changes	O
induced	O
through	O
glutathione	O
depletion	O
.	O

This	O
dominant-negative	B-protein
acting	I-protein
Stat-3	I-protein
isoform	I-protein
significantly	O
inhibited	O
apoptosis	O
induced	O
by	O
ligation	O
of	O
MHC-I	B-protein
.	O

TCL1	B-protein
protein	O
expression	O
is	O
restricted	O
to	O
tumor	O
cells	O
in	O
AIDS	O
IBLP	O
tissue	O
samples	O
analyzed	O
with	O
immunohistochemical	O
staining	O
.	O

Human	B-cell_type
peripheral	I-cell_type
B	I-cell_type
cells	I-cell_type
became	O
capable	O
of	O
constitutively	O
producing	O
p40	O
by	O
in	O
vitro	O
transformation	O
with	O
EBV	O
,	O
coincident	O
with	O
the	O
expression	O
of	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	O
LMP1	B-protein
)	O
of	O
EBV	O
.	O

The	O
-45	B-DNA
site	I-DNA
is	O
an	O
E	B-DNA
box	I-DNA
that	O
binds	O
basic	B-protein
helix-loop-helix-zipper	I-protein
proteins	I-protein
whereas	O
the	O
-160	B-DNA
site	I-DNA
is	O
a	O
composite	B-DNA
PU.1	I-DNA
and	I-DNA
Pip	I-DNA
binding	I-DNA
site	I-DNA
.	O

During	O
the	O
differentiation	O
of	O
naive	B-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
isolated	O
from	O
T	O
cell	O
receptor	O
transgenic	O
mice	O
,	O
GATA-3	B-protein
gene	O
expression	O
was	O
up-regulated	O
in	O
developing	O
Th2	B-cell_type
cells	I-cell_type
,	O
but	O
was	O
down-regulated	O
in	O
Th1	B-cell_type
cells	I-cell_type
,	O
and	O
antigen-	B-cell_type
or	I-cell_type
cAMP-activated	I-cell_type
Th2	I-cell_type
cells	I-cell_type
(	O
but	O
not	O
Th1	B-cell_type
cells	I-cell_type
)	O
expressed	O
the	O
GATA-3	B-protein
protein	I-protein
.	O

These	O
stimuli	O
also	O
induced	O
the	O
stress-activated	O
kinase	O
pathway	O
(	O
SAPK	B-protein
/JNK	B-protein
)	O
,	O
which	O
was	O
required	O
for	O
the	O
maximal	O
induction	O
of	O
apoptosis	O
.	O

Nevertheless	O
,	O
its	O
properties	O
seem	O
to	O
be	O
most	O
extensively	O
exploited	O
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Pretreatment	O
of	O
monocytes	B-cell_type
with	O
IFN-beta	B-protein
or	O
IFN-gamma	B-protein
,	O
but	O
not	O
IL-1	B-protein
,	O
IL-2	B-protein
,	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
,	O
granulocyte/macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
,	O
IL-6	B-protein
,	O
or	O
transforming	O
growth	O
factor	O
beta	O
suppressed	O
activation	O
of	O
STAT6	B-protein
by	O
IL-4	B-protein
.	O

Finally	O
,	O
RNA	O
from	O
activated	B-cell_type
lymphocytes	I-cell_type
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
using	O
oligonucleotide	O
primers	O
flanking	O
the	O
196	B-DNA
base	I-DNA
pair	I-DNA
long	I-DNA
region	I-DNA
encoding	O
the	O
DNA-binding	B-protein
domain	I-protein
of	O
the	O
human	B-protein
intestinal	I-protein
receptor	I-protein
.	O

In	O
contrast	O
,	O
ligand	O
activation	O
of	O
c-Kit	B-protein
was	O
unable	O
to	O
induce	O
any	O
of	O
these	O
effects	O
in	O
the	O
same	O
cells	O
.	O

Lymphocyte	O
activation	O
results	O
in	O
the	O
upregulation	O
of	O
Fas	B-protein
expression	O
and	O
the	O
acquisition	O
of	O
sensitivity	O
to	O
FasL	B-protein
-mediated	O
apoptosis	O
.	O

Recent	O
findings	O
suggest	O
an	O
involvement	O
of	O
reactive	O
oxygen	O
species	O
in	O
the	O
pathway	O
of	O
TPA	O
and	O
protein	B-protein
kinase	I-protein
C	I-protein
leading	O
to	O
expression	O
of	O
c-fos	B-RNA
and	I-RNA
c-jun	I-RNA
mRNA	I-RNA
.	O

Activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
THP-1	B-cell_line
cells	I-cell_line
by	O
SP-A	B-protein
doses	O
as	O
low	O
as	O
1	O
microgram/ml	O
occurred	O
within	O
30	O
min	O
of	O
SP-A	B-protein
treatment	O
,	O
peaked	O
at	O
60	O
min	O
,	O
and	O
then	O
declined	O
.	O

This	O
nonresponsiveness	O
occurs	O
because	O
of	O
a	O
lack	O
of	O
expression	O
of	O
the	O
beta-	B-protein
chain	I-protein
(	O
accessory	O
factor	O
)	O
of	O
the	O
IFN-gamma	B-protein
receptor	I-protein
,	O
while	O
at	O
the	O
same	O
time	O
maintaining	O
IFN-gamma	B-protein
receptor	I-protein
alpha-chain	I-protein
expression	O
.	O

To	O
analyze	O
the	O
signal	O
transduction	O
mechanisms	O
induced	O
by	O
RA	O
,	O
we	O
first	O
compared	O
the	O
effects	O
of	O
PMA	O
and	O
RA	O
on	O
the	O
expression	O
of	O
genes	O
which	O
are	O
known	O
to	O
be	O
regulated	O
during	O
monocytic	O
differentiation	O
.	O

The	O
survival	O
rate	O
of	O
tal-1	B-DNA
transgenic	O
animals	O
was	O
much	O
lower	O
as	O
compared	O
with	O
control	O
mice	O
.	O

The	O
mean	O
number	O
of	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
receptors	I-protein
was	O
significantly	O
lower	O
in	O
aged	O
subjects	O
than	O
in	O
controls	O
(	O
respectively	O
,	O
198	O
+/-	O
96	O
and	O
272	O
+/-	O
97	O
receptors	B-protein
/cell	O
for	O
type	B-protein
I	I-protein
,	O
and	O
1	O
,	O
794	O
+/-	O
803	O
and	O
3	O
,	O
339	O
+/-	O
918	O
for	O
type	O
II	B-protein
receptors	I-protein
)	O
.	O

Therefore	O
,	O
IRF-1	B-protein
may	O
be	O
an	O
important	O
contributor	O
to	O
IL-12	B-protein
signaling	O
,	O
and	O
we	O
speculate	O
that	O
the	O
defective	O
IL-12	B-protein
responses	O
seen	O
in	O
IRF	B-protein
-1-/-	O
mice	O
might	O
be	O
attributable	O
,	O
in	O
part	O
,	O
to	O
the	O
absence	O
of	O
this	O
transcription	B-protein
factor	I-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Sublethal	O
levels	O
of	O
oxidative	O
stress	O
stimulate	O
transcriptional	O
activation	O
of	O
c-jun	B-DNA
and	O
suppress	O
IL-2	B-DNA
promoter	I-DNA
activation	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

In	O
this	O
paper	O
we	O
have	O
investigated	O
the	O
role	O
of	O
Egr-1	B-protein
in	O
B	O
cell	O
growth	O
regulation	O
by	O
examining	O
the	O
gene	O
expression	O
in	O
a	O
panel	O
of	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
including	O
both	O
EBV	B-DNA
genome	I-DNA
negative	O
and	O
EBV	B-cell_line
carrying	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Furthermore	O
,	O
the	O
two	O
VDR	B-DNA
3'-UTR	I-DNA
haplotypes	O
conferred	O
an	O
identical	O
half-life	O
on	O
a	O
heterologous	B-DNA
beta-globin	I-DNA
reporter	I-DNA
gene	I-DNA
,	O
in	O
an	O
in	O
vitro	O
assay	O
.	O

The	O
loss	O
of	O
conventional	O
responsiveness	O
is	O
probably	O
caused	O
by	O
alterations	O
at	O
the	O
level	O
of	O
signaling	O
,	O
and	O
may	O
be	O
a	O
manifestation	O
of	O
the	O
physiological	O
state	O
that	O
is	O
a	O
precondition	O
for	O
selection	O
.	O

Results	O
were	O
expressed	O
as	O
a	O
median	O
(	O
interquartile	O
range	O
)	O
.	O

Increased	O
labeling	O
of	O
these	O
proteins	O
occurred	O
to	O
similar	O
extents	O
in	O
control	B-cell_type
cells	I-cell_type
and	O
in	O
cells	O
that	O
had	O
been	O
infected	O
with	O
L.	O
donovani	O
for	O
16	O
h	O
.	O

This	O
translocation	O
process	O
coupled	O
to	O
the	O
subsequent	O
active	O
maintenance	O
of	O
NFAT	B-protein
in	O
the	O
nucleus	O
compartment	O
is	O
critical	O
for	O
the	O
induction	O
of	O
expression	O
of	O
several	O
genes	O
encoding	O
cytokines	B-protein
and	O
membrane	B-protein
proteins	I-protein
that	O
modulate	O
immune	O
responses	O
.	O

The	O
method	O
is	O
based	O
on	O
the	O
coamplification	O
of	O
VDR	B-DNA
cDNA	I-DNA
and	O
an	O
internal	O
standard	O
consisting	O
of	O
known	O
concentrations	O
of	O
a	O
human	B-DNA
VDR	I-DNA
CDNA	I-DNA
mutated	O
at	O
a	O
BglII	B-DNA
restriction	I-DNA
site	I-DNA
;	O
the	O
interassay	O
coefficient	O
of	O
variation	O
is	O
11	O
%	O
.	O

50	O
%	O
HCS	O
downregulates	O
the	O
alpha-chain	B-protein
and	O
slightly	O
upregulates	O
the	O
beta-chain	B-protein
.	O

These	O
syncytia	O
lack	O
activated	B-cell_type
cells	I-cell_type
as	O
determined	O
by	O
an	O
absence	O
of	O
staining	O
for	O
Ki-67	O
cell	O
cycle	O
antigen	O
.	O

Inhibition	O
of	O
IL-1R	B-DNA
gene	I-DNA
expression	O
by	O
IFN-gamma	B-protein
and	O
IL-10	B-protein
was	O
not	O
due	O
to	O
down-regulation	O
of	O
surface	B-protein
IL-4R	I-protein
because	O
pretreatment	O
with	O
these	O
cytokines	O
did	O
not	O
decrease	O
the	O
number	O
of	O
IL-4	B-protein
binding	O
sites	O
per	O
cell	O
.	O

These	O
data	O
show	O
that	O
human	B-protein
PCD/DCoH	I-protein
is	O
not	O
only	O
present	O
in	O
cells	O
where	O
tetrahydrobiopterin	B-protein
is	O
synthesized	O
or	O
HNF1	B-protein
is	O
present	O
but	O
is	O
a	O
widely	O
distributed	O
protein	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
showed	O
the	O
induction	O
of	O
a	O
CsA-resistant	B-protein
NFAT	I-protein
complex	I-protein
in	O
the	O
nuclear	O
extracts	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
stimulated	O
with	O
PMA	O
plus	O
alphaCD28	B-protein
.	O

Despite	O
their	O
similar	O
effects	O
the	O
drugs	O
bind	O
to	O
two	O
different	O
cytosolic	B-protein
protein	I-protein
,	O
cyclophilin	B-protein
and	O
FKBP	B-protein
respectively	O
,	O
which	O
raises	O
the	O
possibility	O
that	O
they	O
have	O
different	O
modes	O
of	O
action	O
.	O

METHODS	O
:	O
Ten	O
atopic	O
asthmatic	O
subjects	O
were	O
treated	O
with	O
FP	O
250	O
microg	O
twice	O
daily	O
for	O
4	O
weeks	O
.	O

These	O
findings	O
demonstrate	O
that	O
TGF-beta	B-protein
decreases	O
B	O
lymphocyte	O
Ig	B-protein
secretion	O
by	O
inhibiting	O
the	O
synthesis	O
of	O
Ig	B-RNA
mRNA	I-RNA
and	O
inhibiting	O
the	O
switch	O
from	O
the	O
membrane	B-RNA
form	I-RNA
to	O
the	O
secreted	B-RNA
forms	I-RNA
of	O
mu	B-RNA
and	I-RNA
gamma	I-RNA
mRNA	I-RNA
.	O

During	O
the	O
course	O
of	O
serious	O
bacterial	O
infections	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
believed	O
to	O
interact	O
with	O
macrophage	B-protein
receptors	I-protein
,	O
resulting	O
in	O
the	O
generation	O
of	O
inflammatory	O
mediators	O
and	O
systemic	O
symptoms	O
including	O
hemodynamic	O
instability	O
and	O
shock	O
.	O

Potential	O
sites	O
for	O
transcription	B-protein
factors	I-protein
AP1	B-protein
,	O
AP2	B-protein
,	O
and	O
AP3	B-protein
are	O
consistent	O
with	O
rapid	O
transcriptional	O
activation	O
in	O
response	O
to	O
inducing	O
agents	O
.	O

Nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
a	O
pleiotropic	B-protein
transcription	I-protein
factor	I-protein
which	O
is	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
several	O
specific	O
genes	O
.	O

However	O
,	O
in	O
vivo	O
,	O
not	O
only	O
CSF	B-protein
but	O
also	O
many	O
other	O
cytokines	B-protein
are	O
produced	O
under	O
various	O
conditions	O
.	O

Although	O
little	O
is	O
known	O
to	O
date	O
concerning	O
the	O
regulation	O
of	O
gene	O
transcription	O
in	O
neutrophils	B-cell_type
,	O
it	O
is	O
noteworthy	O
that	O
many	O
of	O
these	O
genes	O
depend	O
on	O
the	O
activation	O
of	O
transcription	B-protein
factors	I-protein
,	O
such	O
as	O
NF-kappaB	B-protein
,	O
for	O
inducible	O
expression	O
.	O

The	O
transcription	B-protein
factor	I-protein
,	O
NF-kappaB	B-protein
,	O
is	O
important	O
for	O
T-cell	O
activation	O
,	O
B-cell	O
maturation	O
,	O
and	O
human	O
immunodeficiency	O
virus	O
transcription	O
and	O
plays	O
a	O
role	O
in	O
alternatively	O
mediating	O
and	O
protecting	O
against	O
apoptosis	O
in	O
a	O
variety	O
of	O
cell	O
types	O
.	O

The	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
regulates	O
genes	O
involved	O
in	O
inflammation	O
,	O
cell	O
proliferation	O
,	O
and	O
cell	O
differentiation	O
.	O

Since	O
a	O
mutation	O
of	O
CBP	B-protein
abolishing	O
HAT	O
activity	O
is	O
almost	O
as	O
active	O
as	O
wild-type	B-protein
CBP	I-protein
in	O
T	B-cell_type
cells	I-cell_type
,	O
functions	O
of	O
CBP/p300	B-protein
other	O
than	O
histone	O
acetylation	O
appear	O
to	O
control	O
the	O
NF-AT	B-protein
-dependent	O
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

In	O
addition	O
,	O
Tax	B-protein
also	O
stimulates	O
the	O
transcription	O
of	O
the	O
E2F-1	B-DNA
gene	I-DNA
itself	O
.	O

These	O
clones	O
were	O
tested	O
for	O
their	O
recognition	O
of	O
BCR1/25	O
.	O

The	O
increased	O
NO	O
production	O
during	O
the	O
second	O
A/R	O
insult	O
reduces	O
PMN	O
adhesion	O
most	O
likely	O
by	O
reducing	O
the	O
intracellular	O
oxidant	O
stress	O
induced	O
by	O
A/R	O
.	O

No	O
difference	O
of	O
VDR	B-protein
retention	O
in	O
pulse	O
and	O
pulse/chase-experiments	O
was	O
seen	O
in	O
PBL	B-cell_type
,	O
where	O
VDR	B-protein
halflife	O
was	O
approximately	O
30	O
min	O
.	O

While	O
growing	O
either	O
with	O
or	O
without	O
albumin	O
,	O
the	O
several	O
clonal	B-cell_line
lines	I-cell_line
of	O
CEM	B-cell_line
cells	O
displayed	O
growth	O
similar	O
to	O
serum-supplemented	O
cultures	O
.	O

Functional	O
studies	O
demonstrated	O
that	O
transcriptional	O
activation	O
of	O
a	O
plasmid	B-DNA
containing	O
multimerized	B-DNA
kappaB	I-DNA
sites	I-DNA
by	O
p65	B-protein
was	O
inhibited	O
by	O
agents	O
that	O
elevate	O
cAMP	O
and	O
by	O
overexpression	O
of	O
the	O
catalytic	B-protein
subunit	I-protein
of	O
PKA	B-protein
.	O

PI	B-protein
3-kinase	I-protein
also	O
regulates	O
the	O
activity	O
of	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
,	O
the	O
40S	B-protein
ribosomal	I-protein
protein	I-protein
S6	I-protein
kinase	I-protein
,	O
a	O
response	O
that	O
is	O
abrogated	O
by	O
the	O
macrolide	O
rapamycin	O
.	O

BSAP	B-protein
is	O
unique	O
among	O
the	O
transcription	B-protein
factors	I-protein
that	O
regulate	O
epsilon	O
germline	B-DNA
expression	O
,	O
because	O
it	O
is	O
B	O
cell	O
specific	O
,	O
and	O
is	O
at	O
the	O
merging	O
point	O
of	O
two	O
signalling	O
pathways	O
that	O
are	O
critical	O
for	O
IgE	B-protein
switching	O
.	O

Regulation	O
of	O
sialoadhesin	B-protein
expression	O
on	O
rat	B-cell_type
macrophages	I-cell_type
.	O

Furthermore	O
,	O
we	O
demonstrated	O
by	O
western	O
blot	O
analysis	O
that	O
neutrophils	B-cell_type
express	O
an	O
alternatively	O
spliced	O
variant	O
of	O
the	O
pituitary	B-protein
transcription	I-protein
factor	I-protein
Pit-1	B-protein
,	O
designated	O
Pit-1b	B-protein
.	O

Anaerobic	O
threshold	O
(	O
AT	O
)	O
was	O
determined	O
from	O
the	O
point	O
of	O
departure	O
of	O
the	O
ventilatory	O
response	O
from	O
linearity	O
and	O
from	O
the	O
sudden	O
increase	O
in	O
venous	O
blood	O
lactate	O
concentrations	O
during	O
MPE	O
.	O

We	O
have	O
carried	O
out	O
experiments	O
to	O
define	O
the	O
nature	O
of	O
the	O
higher	B-protein
affinity	I-protein
CVZ	I-protein
binding	I-protein
site	I-protein
.	O

In	O
this	O
study	O
,	O
the	O
influence	O
of	O
the	O
sequences	O
located	O
between	B-DNA
-3134	I-DNA
and	I-DNA
-2987	I-DNA
on	O
the	O
transcriptional	O
activity	O
of	O
the	O
proIL-1beta	B-DNA
gene	I-DNA
in	O
LPS-stimulated	B-cell_line
Raw	I-cell_line
264.7	I-cell_line
cells	I-cell_line
was	O
examined	O
in	O
detail	O
.	O

The	O
present	O
paper	O
studies	O
the	O
expression	O
of	O
the	O
NM23.H1	B-DNA
gene	I-DNA
in	O
cell	B-cell_line
lines	I-cell_line
which	O
derive	O
from	O
primary	O
or	O
metastatic	O
human	O
malignant	O
melanomas	O
in	O
relation	O
to	O
staging	O
,	O
infiltration	O
degree	O
,	O
lymphocytic	O
infiltration	O
,	O
cell	O
morphology	O
,	O
cell	O
pigmentation	O
,	O
karyotype	O
,	O
and	O
disease-free	O
survival	O
.	O

These	O
factors	O
are	O
present	O
in	O
nuclear	O
extracts	O
prepared	O
from	O
both	O
induced	O
and	O
uninduced	O
THP-1	B-cell_line
cells	I-cell_line
.	O

In	O
addition	O
,	O
we	O
supplemented	O
one	O
group	O
of	O
individuals	O
with	O
a	O
daily	O
oral	O
replacement	O
dose	O
of	O
T3	O
to	O
isolate	O
the	O
influence	O
of	O
serum	O
thyroxine	O
(	O
T4	O
)	O
and	O
thyrotropin	O
(	O
TSH	O
)	O
levels	O
on	O
receptor	O
kinetics	O
.	O

Such	O
tests	O
may	O
become	O
useful	O
diagnostic	O
tools	O
.	O

As	O
expected	O
,	O
these	O
transgenic	O
mice	O
developed	O
splenomegaly	O
due	O
to	O
the	O
massive	O
amplification	O
of	O
Ter	B-cell_line
119	I-cell_line
positive	I-cell_line
erythroid	I-cell_line
nucleated	I-cell_line
cells	I-cell_line
expressing	O
T	B-protein
antigen	I-protein
.	O

One	O
p21ras	B-protein
effector	O
pathway	O
involves	O
the	O
MAP	B-protein
kinase	I-protein
ERK-2	B-protein
,	O
and	O
we	O
have	O
examined	O
its	O
role	O
in	O
NFAT	B-protein
regulation	O
.	O

However	O
,	O
more	O
recent	O
studies	O
in	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
have	O
suggested	O
that	O
the	O
N-terminal	B-protein
domain	I-protein
is	O
not	O
necessary	O
for	O
steroid-regulated	O
apoptosis	O
and	O
that	O
GR	B-protein
-mediated	O
transrepression	O
may	O
be	O
the	O
more	O
critical	O
mechanism	O
.	O

Gel-shift	O
assay	O
was	O
also	O
examined	O
to	O
show	O
the	O
formation	O
of	O
Stat1alpha-DNA	B-protein
complexes	I-protein
.	O

Abnormal	O
renal	O
tubular	O
phosphate	O
transport	O
is	O
considered	O
to	O
be	O
the	O
primary	O
defect	O
in	O
X-linked	O
hypophosphatemic	O
rickets	O
(	O
XLH	O
)	O
.	O

K+	O
channel	O
blockade	O
by	O
progesterone	O
is	O
specific	O
;	O
other	O
steroid	O
hormones	O
had	O
little	O
or	O
no	O
effect	O
,	O
although	O
the	O
progesterone	O
antagonist	O
RU	O
486	O
also	O
blocked	O
KV	B-protein
and	O
KCa	B-protein
channels	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
VD-responsive	B-DNA
genes	I-DNA
are	O
induced	O
by	O
ATRA	O
treatment	O
of	O
Kasumi-1	B-cell_line
cells	I-cell_line
,	O
suggesting	O
that	O
the	O
genetic	O
program	O
underlying	O
monocytic	O
differentiation	O
is	O
activated	O
.	O

The	O
5'-UTR	B-DNA
also	O
interacts	O
with	O
a	O
specific	O
nucleosome	B-protein
that	O
is	O
rapidly	O
displaced	O
during	O
transcriptional	O
activation	O
of	O
the	O
latent	O
provirus	O
.	O

Using	O
deletion	B-DNA
constructs	I-DNA
,	O
we	O
have	O
defined	O
an	O
active	B-DNA
promoter	I-DNA
region	I-DNA
of	O
1056	O
bp	O
.	O

We	O
have	O
cloned	O
the	O
mouse	O
and	O
human	O
GATA-1	B-DNA
genes	I-DNA
.	O

We	O
have	O
shown	O
that	O
an	O
estradiol-dependent	O
activation	O
of	O
human	O
T	O
cell	O
leukemia	O
virus-I	O
Tax	B-protein
leads	O
to	O
the	O
inhibition	O
of	O
cell	O
proliferation	O
and	O
to	O
the	O
induction	O
of	O
apoptosis	O
.	O

We	O
observed	O
that	O
FK506	O
suppressed	O
the	O
transcription	O
of	O
a	O
chemotactic	B-protein
cytokine	I-protein
,	O
interleukin-8	B-protein
(	O
IL-8	B-protein
)	O
in	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
(	O
Ca2+	O
)	O
ionophore	O
(	O
ionomycin	O
)	O
.	O

In	O
contrast	O
to	O
peptide	O
vaccination	O
,	O
immunization	O
with	O
adenovirus	O
,	O
expressing	O
Ad5E1A	B-protein
,	O
induced	O
Ad5E1A	B-protein
-specific	O
immunity	O
and	O
prevented	O
the	O
outgrowth	O
of	O
Ad5E1A	B-protein
-expressing	O
tumors	O
.	O

The	O
other	O
two	O
SR	O
patients	O
had	O
an	O
abnormally	O
low	O
GR	B-protein
number	O
with	O
normal	O
binding	O
affinity	O
that	O
was	O
not	O
limited	O
to	O
T	B-cell_type
cells	I-cell_type
.	O

This	O
dispersed	O
localization	O
of	O
a	O
group	O
of	O
functionally	O
related	O
gene	O
provides	O
insights	O
into	O
the	O
molecular	O
mechanism	O
of	O
human	B-DNA
genome	I-DNA
evolution	O
and	O
their	O
possible	O
involvement	O
in	O
human	O
diseases	O
.	O

In	O
addition	O
,	O
a	O
significant	O
correlation	O
was	O
noted	O
between	O
the	O
degree	O
of	O
inhibition	O
of	O
lymphocyte	O
proliferation	O
(	O
IC50	O
)	O
and	O
the	O
binding	O
affinity	O
of	O
dexamethasone	O
to	O
the	O
GCR	B-protein
.	O

Secretion	O
of	O
myeloid	B-protein
cell-derived	I-protein
cytokines	I-protein
may	O
both	O
increase	O
virus	O
production	O
and	O
contribute	O
to	O
AIDS-associated	O
disorders	O
.	O

Two	O
mutants	O
displayed	O
differential	O
activity	O
between	O
the	O
two	O
promoters	B-DNA
,	O
activating	O
transcription	O
with	O
the	O
W-X-Y	B-DNA
but	I-DNA
not	I-DNA
the	I-DNA
X-Y	I-DNA
elements	I-DNA
.	O

Cyclosporin	O
A-resistant	O
transactivation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
requires	O
activity	O
of	O
okadaic	B-protein
acid-sensitive	I-protein
serine/threonine	I-protein
phosphatases	I-protein
.	O

Furthermore	O
,	O
while	O
PMA	O
activation	O
was	O
inhibited	O
by	O
the	O
PKC	B-protein
inhibitor	O
staurosporin	O
,	O
the	O
TNF	B-protein
alpha	I-protein
effect	O
was	O
unchanged	O
.	O

A	O
common	O
feature	O
of	O
all	O
stages	O
of	O
atherosclerosis	O
is	O
inflammation	O
of	O
the	O
vessel	O
wall	O
.	O

This	O
sequence	B-DNA
motif	I-DNA
is	O
a	O
binding	O
site	O
for	O
nuclear	B-protein
proteins	I-protein
,	O
the	O
so-called	O
octamer	B-protein
transcription	I-protein
factors	I-protein
(	O
Oct	B-protein
or	O
OTF	B-protein
factors	I-protein
)	O
.	O

Recently	O
we	O
reported	O
that	O
all-trans-retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
a	O
potent	O
and	O
highly	O
specific	O
inducer	O
of	O
CD38	B-protein
expression	O
in	O
human	B-cell_type
promyelocytic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

These	O
data	O
are	O
the	O
first	O
to	O
define	O
the	O
molecular	O
weight	O
of	O
the	O
membrane	B-protein
receptor	I-protein
for	O
aldosterone	O
.	O

In	O
contrast	O
,	O
NK	O
activity	O
was	O
not	O
affected	O
by	O
pretreatment	O
of	O
the	O
effector	O
cells	O
with	O
the	O
proteasome	B-protein
inhibitor	O
N-acetyl-leu-leu-norleucinal	O
which	O
selectively	O
inhibits	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Other	O
bacterial	O
toxins	O
,	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF	B-protein
)	O
,	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
,	O
T	B-protein
cell	I-protein
mitogens	I-protein
,	O
UV	O
light	O
,	O
gamma	O
rays	O
and	O
oxidative	O
stress	O
were	O
reported	O
to	O
induce	O
NF-kappa	B-protein
B	I-protein
.	O

Globin	B-protein
chains	I-protein
(	O
alpha	B-protein
,	O
beta	B-protein
and	O
gamma	B-protein
)	O
were	O
clearly	O
detectable	O
by	O
affinity	O
chromatography	O
in	O
UT-7	B-protein
Epo	I-protein
but	O
not	O
in	O
UT-7	B-cell_line
cells	I-cell_line
.	O

Here	O
,	O
we	O
describe	O
the	O
isolation	O
and	O
detailed	O
characterization	O
of	O
the	O
murine	B-protein
homolog	I-protein
.	O

In	O
a	O
Jurkat	B-cell_line
cell	I-cell_line
model	I-cell_line
of	O
T-cell	O
activation	O
an	O
interleukin-2	B-DNA
promoter/reporter	I-DNA
gene	I-DNA
construct	I-DNA
was	O
activated	O
by	O
antigen	B-protein
receptor	I-protein
agonism	O
in	O
combination	O
with	O
the	O
lymphokine	B-protein
interleukin-1	B-protein
.	O

Characterization	O
of	O
HB24	B-DNA
expression	O
in	O
lymphoid	O
and	O
select	O
developing	O
tissues	O
was	O
performed	O
by	O
in	O
situ	O
hybridization	O
.	O

This	O
process	O
is	O
shown	O
to	O
evolve	O
independently	O
of	O
the	O
presence	O
of	O
TNF	B-protein
,	O
lymphotoxin	B-protein
alpha	I-protein
,	O
or	O
the	O
p55TNF-R	B-protein
,	O
although	O
coexpression	O
of	O
a	O
human	B-DNA
TNF	I-DNA
transgene	I-DNA
accelerated	O
pathology	O
.	O

Sequence	O
analyses	O
of	O
cDNA	B-DNA
clones	I-DNA
indicated	O
that	O
these	O
transcripts	O
encode	O
proteins	O
differing	O
only	O
at	O
their	O
amino	B-protein
termini	I-protein
,	O
and	O
likely	O
represent	O
alternatively	O
spliced	O
isoforms	O
.	O

These	O
results	O
show	O
that	O
Spi-1/	O
PU.1	B-protein
requires	O
signals	O
emanating	O
from	O
specific	O
cytokine	O
and	O
growth	O
factor	O
receptors	O
to	O
affect	O
the	O
survival	O
,	O
proliferation	O
and	O
differentiation	O
control	O
of	O
primary	B-cell_type
erythroblasts	I-cell_type
.	O

Furthermore	O
,	O
the	O
effect	O
of	O
12-O-tetradecanoyl	O
phorbol	O
13-acetate	O
and	O
ionomycin	O
,	O
which	O
synergized	O
to	O
fully	O
activate	O
c-Jun	B-protein
N-terminal	I-protein
kinase	I-protein
,	O
was	O
also	O
sensitive	O
to	O
inhibition	O
by	O
forskolin	O
.	O

Costimulation	O
with	O
anti-CD28	B-protein
MoAb	I-protein
greatly	O
enhanced	O
the	O
proliferative	O
response	O
of	O
neonatal	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
levels	O
equivalent	O
to	O
those	O
of	O
adult	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
whereas	O
adult	B-cell_type
T	I-cell_type
cells	I-cell_type
showed	O
only	O
slight	O
increases	O
.	O

Mutations	O
in	O
the	O
AT	B-DNA
box	I-DNA
or	O
in	O
the	O
BSAP	B-DNA
sites	I-DNA
did	O
not	O
affect	O
CD19	B-protein
reporter	B-DNA
construct	I-DNA
activity	O
,	O
while	O
a	O
mutation	O
of	O
the	O
GC	B-DNA
box	I-DNA
reduced	O
it	O
modestly	O
,	O
and	O
a	O
PyG	B-DNA
box	I-DNA
mutation	O
reduced	O
it	O
dramatically	O
.	O

Furthermore	O
,	O
PML	B-protein
and	O
pRb	B-protein
105	I-protein
were	O
co-immunoprecipitated	O
in	O
cellular	O
lysates	O
derived	O
from	O
erythroid	B-cell_type
precursors	I-cell_type
indicating	O
that	O
this	O
functional	O
interaction	O
may	O
have	O
a	O
biochemical	O
basis	O
.	O

PU.1/Pip	B-protein
and	O
basic	B-protein
helix	I-protein
loop	I-protein
helix	I-protein
zipper	I-protein
transcription	I-protein
factors	I-protein
interact	O
with	O
binding	B-DNA
sites	I-DNA
in	O
the	O
CD20	B-DNA
promoter	I-DNA
to	O
help	O
confer	O
lineage-	O
and	O
stage-specific	O
expression	O
of	O
CD20	B-protein
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

The	O
eukaryotic	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
participates	O
in	O
many	O
parts	O
of	O
the	O
genetic	O
program	O
mediating	O
T	B-cell_type
lymphocyte	I-cell_type
activation	O
and	O
growth	O
.	O

Translational	O
initiation	O
of	O
encephalomyocarditis	B-RNA
virus	I-RNA
(	I-RNA
EMCV	I-RNA
)	I-RNA
mRNA	I-RNA
occurs	O
by	O
ribosomal	O
entry	O
into	O
the	O
5	B-DNA
'	I-DNA
nontranslated	I-DNA
region	I-DNA
of	O
the	O
EMCV	B-RNA
mRNA	I-RNA
,	O
rather	O
than	O
by	O
ribosomal	O
scanning	O
.	O

Pathogenesis	O
of	O
atherosclerosis	O
.	O

Various	O
antioxidants	O
,	O
such	O
as	O
pyrrolidine	O
dithiocarbamate	O
,	O
p-bromophenacyl-bromide	O
and	O
nordihydroguaiaretic	O
acid	O
could	O
strongly	O
reduce	O
NF-kappaB	B-protein
translocation	O
,	O
demonstrating	O
the	O
importance	O
of	O
oxidative	O
species	O
in	O
the	O
transduction	O
mechanism	O
.	O

Involvement	O
of	O
phosphatidylinositol	B-protein
3-kinase	I-protein
in	O
NFAT	B-protein
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

PG490	O
inhibits	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
expression	O
by	O
normal	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
antibody	O
to	O
CD3	B-protein
(	O
IC50	O
of	O
10	O
ng/ml	O
)	O
,	O
and	O
with	O
PMA	O
and	O
ionomycin	O
(	O
Iono	O
,	O
IC50	O
of	O
40	O
ng/ml	O
)	O
.	O

Lastly	O
,	O
we	O
demonstrate	O
a	O
selective	O
inhibition	O
of	O
p24	B-protein
production	O
by	O
HIV-infected	B-cell_type
human	I-cell_type
macrophages	I-cell_type
when	O
treated	O
with	O
AO	O
to	O
PKC-zeta	B-protein
.	O

The	O
AP-1	B-DNA
mutant	I-DNA
constructs	I-DNA
also	O
showed	O
delayed	O
transcriptional	O
activation	O
in	O
PMA-treated	B-cell_line
fibroblasts	I-cell_line
.	O

PBL	B-cell_type
constitutively	O
express	O
c-jun	B-protein
transcripts	I-protein
,	O
and	O
the	O
level	O
of	O
c-jun	B-RNA
mRNA	I-RNA
is	O
not	O
altered	O
by	O
PHA	B-protein
activation	O
in	O
the	O
absence	O
or	O
presence	O
of	O
EC	B-cell_type
.	O

Most	O
were	O
located	O
in	O
the	O
carboxyterminal	B-protein
half	I-protein
of	O
the	O
HBxAg	B-protein
protein	I-protein
.	O

mBob1	B-protein
is	O
B-cell	O
restricted	O
,	O
and	O
is	O
found	O
in	O
all	O
B-cell	B-cell_line
lines	I-cell_line
representing	O
different	O
stages	O
of	O
B-cell	O
differentiation	O
.	O

Rescue	O
by	O
cytokines	B-protein
of	O
apoptotic	O
cell	O
death	O
induced	O
by	O
IL-2	B-protein
deprivation	O
of	O
human	B-cell_line
antigen-specific	I-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
.	O

L227	B-protein
induced	O
an	O
increase	O
in	O
intracellular	O
free	O
Ca2+	O
concentration	O
(	O
[	O
Ca2+	O
]	O
i	O
)	O
from	O
the	O
intracellular	O
pool	O
and	O
little	O
or	O
no	O
protein	O
tyrosine	O
phosphorylation	O
,	O
phosphatidyl	O
inositol	O
turnover	O
,	O
or	O
expression	O
of	O
Egr-1	B-RNA
mRNA	I-RNA
,	O
whereas	O
2.06	B-protein
plus	O
GAM	B-protein
induced	O
an	O
increase	O
in	O
[	O
Ca2+	O
]	O
i	O
from	O
both	O
the	O
intracellular	O
and	O
,	O
in	O
particular	O
,	O
the	O
extracellular	O
pools	O
.	O

InterleUkin	B-protein
2	I-protein
expression	O
requires	O
several	O
transcription	B-protein
factors	I-protein
of	O
which	O
nuclear	O
translocation	O
of	O
NFAT	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
)	O
and	O
NFAT	B-protein
-mediated	O
transactivation	O
were	O
impaired	O
by	O
BCL-2	B-protein
.	O

Deletion	O
analysis	O
showed	O
that	O
expression	O
from	O
the	O
DM	B-DNA
promoters	I-DNA
is	O
dependent	O
on	O
the	O
conserved	O
S-X-Y	B-DNA
region	I-DNA
.	O

LPMC	B-cell_type
exhibited	O
increased	O
IL-2	B-protein
production	O
in	O
response	O
to	O
CD28	B-protein
costimulation	O
,	O
compared	O
with	O
cells	O
activated	O
through	O
CD2	B-protein
alone	O
.	O

In	O
a	O
series	O
of	O
electrophoretic	O
mobility	O
shift	O
assays	O
with	O
protein	O
extracts	O
of	O
highly	B-cell_line
polarized	I-cell_line
Th2	I-cell_line
clones	I-cell_line
from	O
atopics	O
and	O
Th1	B-cell_line
clones	I-cell_line
from	O
controls	O
we	O
compared	O
DNA-binding	O
activities	O
at	O
the	O
two	O
NFAT-binding	B-DNA
elements	I-DNA
P0	B-DNA
and	O
P1	B-DNA
of	O
the	O
crucial	O
proximal	O
human	O
IL-4	B-DNA
promoter	I-DNA
.	O

Nevertheless	O
,	O
none	O
of	O
the	O
genes	O
originally	O
thought	O
to	O
be	O
regulated	O
by	O
Oct2	B-protein
were	O
affected	O
in	O
their	O
expression	O
in	O
Oct2-deficient	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

In	O
EMSAs	O
,	O
this	O
substitution	O
results	O
in	O
a	O
markedly	O
enhanced	O
affinity	O
for	O
sequence-specific	O
complexes	O
exhibiting	O
an	O
AP-1	B-protein
specificity	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
how	O
this	O
viral	B-protein
protein	I-protein
induces	O
a	O
persistent	O
rather	O
than	O
transient	O
NF-kappaB	B-protein
response	O
.	O

Cross-linking	O
of	O
this	O
lymphocyte-specific	B-protein
protein	I-protein
,	O
designated	O
TACI	B-protein
(	O
transmembrane	B-protein
activator	I-protein
and	I-protein
CAML-interactor	I-protein
)	O
,	O
on	O
the	O
surface	O
of	O
transfected	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
with	O
TACI-specific	B-protein
antibodies	I-protein
led	O
to	O
activation	O
of	O
the	O
transcription	B-protein
factors	I-protein
NF-AT	B-protein
,	O
AP-1	B-protein
,	O
and	O
NFkappaB	B-protein
.	O

During	O
normal	O
T-cell	O
activation	O
,	O
IkappaBalpha	B-protein
is	O
rapidly	O
phosphorylated	O
,	O
ubiquitinated	O
,	O
and	O
degraded	O
by	O
the	O
26S	B-protein
proteasome	I-protein
,	O
thus	O
permitting	O
the	O
release	O
of	O
functional	O
NF-kappaB	B-protein
.	O

Staurosporine	O
,	O
a	O
nonspecific	O
inhibitor	O
of	O
PKC	B-protein
,	O
partially	O
blocked	O
TPA-induced	O
adherence	O
and	O
growth	O
inhibition	O
and	O
concomitantly	O
prevented	O
TPA-induced	O
c-fos	O
and	O
c-jun	O
gene	O
expression	O
.	O

Binding	O
of	O
c-Rel	B-protein
to	O
the	O
Fc	B-DNA
gammaR1	I-DNA
STAT	I-DNA
site	I-DNA
also	O
occurs	O
in	O
human	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
immortalized	O
with	O
HTLV-I	O
in	O
vitro	O
and	O
is	O
correlated	O
with	O
enhanced	O
levels	O
of	O
proliferation	O
of	O
these	O
cells	O
.	O

Immunocytochemistry	O
identified	O
the	O
cells	O
in	O
the	O
infiltrate	O
as	O
cytotoxic	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Similarly	O
,	O
the	O
complexes	O
binding	O
the	O
consensus	B-DNA
AP-1	I-DNA
TRE	I-DNA
and	O
jun	B-DNA
TRE-like	I-DNA
motifs	I-DNA
in	O
cells	O
exposed	O
to	O
oxidative	O
signals	O
or	O
PHA/PMA	O
were	O
indistinguishable	O
,	O
being	O
composed	O
of	O
c-Fos	B-protein
,	O
c-Jun	B-protein
,	O
and	O
JunD	B-protein
.	O

HIV	O
does	O
not	O
replicate	O
in	O
naive	B-cell_type
CD4	I-cell_type
T	I-cell_type
cells	I-cell_type
stimulated	O
with	O
CD3/CD28	B-protein
.	O

Functional	O
antagonism	O
between	O
vitamin	O
D3	O
and	O
retinoic	O
acid	O
in	O
the	O
regulation	O
of	O
CD14	O
and	O
CD23	O
expression	O
during	O
monocytic	O
differentiation	O
of	O
U-937	B-cell_line
cells	I-cell_line
.	O

Clinical	O
CR	O
was	O
achieved	O
in	O
nine	O
of	O
10	O
(	O
90	O
%	O
)	O
patients	O
treated	O
with	O
As2O3	O
alone	O
and	O
in	O
the	O
remaining	O
five	O
patients	O
treated	O
by	O
the	O
combination	O
of	O
As2O3	O
and	O
low-dose	O
chemotherapeutic	O
drugs	O
or	O
ATRA	O
.	O

Recent	O
findings	O
suggest	O
an	O
involvement	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
signal	O
transduction	O
pathways	O
leading	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Lymphocyte	B-cell_line
cell	I-cell_line
lines	I-cell_line
from	O
vitamin	O
D-dependent	O
rickets	O
type	O
II	O
show	O
functional	O
defects	O
in	O
the	O
1	B-protein
alpha	I-protein
,	I-protein
25-dihydroxyvitamin	I-protein
D3	I-protein
receptor	I-protein
.	O

Quantitative	O
immunohistochemical	O
analysis	O
of	O
mononuclear	B-cell_type
infiltrates	I-cell_type
in	O
breast	O
carcinomas	O
--	O
correlation	O
with	O
tumour	O
differentiation	O
.	O

The	O
inhibition	O
by	O
PDTC	O
was	O
reversible	O
unless	O
glutathione	O
synthesis	O
was	O
blocked	O
by	O
buthionine	O
sulfoximine	O
.	O

Dimers	O
encoded	O
by	O
HLA-DR	B-protein
haplotypes	O
may	O
be	O
the	O
primary	B-DNA
restriction	I-DNA
elements	I-DNA
for	O
lectin-like	O
,	O
gliadin	O
peptides	O
while	O
the	O
degree	O
of	O
immune	O
suppression	O
(	O
or	O
lack	O
thereof	O
)	O
to	O
ingested	O
gliadins	O
is	O
governed	O
by	O
inherited	O
HLA-DQ	B-DNA
haplotypes	O
.	O

These	O
data	O
suggest	O
that	O
selenium	O
supplementation	O
may	O
be	O
used	O
to	O
modulate	O
the	O
expression	O
of	O
NF-kappa	B-DNA
B	I-DNA
target	I-DNA
genes	I-DNA
and	O
HIV-1	O
.	O

Our	O
studies	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
CD3	B-protein
antigen-derived	O
signals	O
and	O
CD2	B-protein
antigen	I-protein
-derived	O
signals	O
are	O
synergistic	O
in	O
inducing	O
the	O
emergence	O
of	O
transcription	B-protein
factors	I-protein
that	O
bind	O
to	O
the	O
NF-AT1	B-DNA
,	I-DNA
AP-1	I-DNA
,	I-DNA
and	I-DNA
NF-kB	I-DNA
sites	I-DNA
located	O
in	O
the	O
promoter/enhancer	B-DNA
region	I-DNA
of	O
the	O
IL-2	B-protein
gene	O
.	O

This	O
activation	O
was	O
not	O
observed	O
in	O
undifferentiated	O
embryocarcinoma	O
F9	O
cells	O
.	O

Subsequent	O
analysis	O
of	O
the	O
human	B-DNA
ICAM-1	I-DNA
promoter	I-DNA
has	O
revealed	O
that	O
both	O
12-O-tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
and	O
tumour	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
upregulate	O
ICAM-1	B-protein
expression	O
through	O
the	O
presence	O
of	O
a	O
nuclear	B-DNA
factor	I-DNA
(	I-DNA
NF-kappa	I-DNA
B	I-DNA
)	I-DNA
target	I-DNA
sequence	I-DNA
(	O
TGGAAATTCC	O
)	O
.	O

Reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
and	O
Northern	O
analyses	O
confirmed	O
that	O
normal	O
and	O
leukemic	O
myeloid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
expressed	O
mRNA	B-RNA
for	O
the	O
type	O
I	O
and	O
IV	O
isoforms	O
of	O
17	B-protein
beta-hydroxysteroid	I-protein
dehydrogenase	I-protein
.	O

This	O
may	O
be	O
due	O
to	O
the	O
fact	O
that	O
T	B-cell_type
cells	I-cell_type
treated	O
with	O
IL-2	B-protein
contained	O
those	O
located	O
in	O
S	O
+	O
G2/M	O
phases	O
of	O
the	O
cell	O
cycle	O
,	O
whereas	O
the	O
vast	O
majority	O
of	O
T	B-cell_type
cells	I-cell_type
treated	O
with	O
IFN-alpha/beta	B-protein
were	O
located	O
in	O
G0/G1	O
phase	O
.	O

We	O
show	O
that	O
transcription	O
of	O
the	O
BLR2	B-DNA
gene	I-DNA
could	O
be	O
specifically	O
induced	O
in	O
Epstein-Barr	B-cell_line
virus	I-cell_line
negative	I-cell_line
BL	I-cell_line
41	I-cell_line
cells	I-cell_line
via	O
estrogen-mediated	O
activation	O
of	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
,	O
a	O
key	O
regulator	O
of	O
viral	B-DNA
and	I-DNA
cellular	I-DNA
genes	I-DNA
in	O
immortalized	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

Immunoprecipitation	O
analysis	O
revealed	O
that	O
unde3r	O
these	O
circumstances	O
,	O
Calphostin	O
C	O
inhibited	O
the	O
production	O
of	O
IL-1beta	B-protein
protein	I-protein
,	O
whereas	O
Staurosporine	O
allowed	O
protein	O
production	O
,	O
but	O
inhibited	O
its	O
secretion	O
.	O

Sequence	O
analyses	O
show	O
that	O
this	O
protein	O
has	O
significant	O
homology	O
with	O
the	O
human	B-DNA
cytomegalovirus	I-DNA
UL44	I-DNA
gene	I-DNA
coding	O
for	O
the	O
ICP36	B-protein
family	I-protein
of	O
early-late-class	B-protein
phosphoprotein	I-protein
.	O

The	O
expression	O
of	O
activated	O
p21	B-protein
(	I-protein
ras	I-protein
)	I-protein
negatively	O
regulated	O
the	O
induction	O
of	O
IE	B-DNA
genes	I-DNA
by	O
calcium	O
ionophore	O
.	O

This	O
study	O
has	O
investigated	O
DHEA	O
modulation	O
of	O
LPS-induced	O
monocyte	O
cytotoxicity	O
.	O

Moreover	O
,	O
a	O
CIITA	B-protein
protein	I-protein
in	O
which	O
both	O
functional	O
alpha-helices	B-protein
have	O
been	O
deleted	O
displays	O
a	O
dominant	O
negative	O
phenotype	O
.	O

Comparison	O
of	O
these	O
sequences	O
to	O
those	O
required	O
to	O
mediate	O
virus	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
the	O
gene	O
reveal	O
significant	O
differences	O
,	O
and	O
thus	O
,	O
the	O
sequence	O
requirements	O
for	O
PMA	O
induction	O
are	O
distinct	O
from	O
those	O
that	O
mediate	O
induction	O
by	O
virus	O
or	O
LPS	O
.	O

Moreover	O
,	O
both	O
in	O
cell	O
lines	O
and	O
in	O
primary	O
leukemia	O
cells	O
that	O
are	O
resistant	O
towards	O
induction	O
of	O
apoptosis	O
by	O
DILs	B-protein
and	O
doxorubicin	O
,	O
antagonization	O
of	O
NFkappaB	B-protein
activity	O
partially	O
restored	O
apoptosis	O
sensitivity	O
.	O

These	O
data	O
provide	O
important	O
fundamental	O
insights	O
into	O
the	O
molecular	O
mechanisms	O
by	O
which	O
the	O
c-Jun	B-protein
delta-domain	I-protein
functions	O
as	O
a	O
modulatory	O
switch	O
and	O
further	O
imply	O
that	O
the	O
functional	O
role	O
of	O
c-Jun	B-protein
is	O
dictated	O
by	O
cell-specific	O
influences	O
and	O
the	O
delta-domain	B-protein
motif	I-protein
.	O

In	O
only	O
four	O
patients	O
sodium	O
in	O
HML	B-cell_type
without	O
incubation	O
was	O
elevated	O
compared	O
with	O
the	O
range	O
for	O
normal	O
persons	O
.	O

These	O
results	O
suggested	O
that	O
the	O
bound	B-protein
kinase	I-protein
is	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
LPS	O
by	O
inducing	O
the	O
phosphorylation	O
of	O
the	O
C-terminal	B-protein
region	I-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
subsequent	O
dissociation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
.	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
complex	I-protein
.	O

CONCLUSION	O
:	O
IL-5	B-protein
synthesis	O
by	O
human	B-cell_type
helper	I-cell_type
T	I-cell_type
cells	I-cell_type
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O

Next	O
,	O
we	O
demonstrated	O
that	O
these	O
viral	O
ligands	O
directly	O
up-regulated	O
monocyte	O
gene	O
expression	O
upon	O
their	O
binding	O
to	O
their	O
appropriate	O
cellular	O
receptors	O
.	O

We	O
report	O
here	O
that	O
this	O
activation	O
of	O
HIV	O
replication	O
takes	O
place	O
at	O
the	O
transcriptional	O
level	O
through	O
activation	O
of	O
the	O
Rel/NF-kappaB	B-protein
transcription	B-protein
factors	I-protein
.	O

PRRIII	B-DNA
contains	O
a	O
Stat	B-DNA
protein	I-DNA
binding	I-DNA
site	I-DNA
that	O
overlaps	O
with	O
an	O
EBS	B-DNA
motif	I-DNA
(	O
GASd/EBSd	B-DNA
)	O
.	O

Binding	O
site	O
selection	O
revealed	O
that	O
the	O
alternating	B-protein
RCGCRYGCGY	I-protein
consensus	I-protein
constitutes	O
high-affinity	O
IBR/F	B-DNA
binding	I-DNA
sites	I-DNA
and	O
that	O
the	O
direct-repeat	B-DNA
palindrome	I-DNA
TGCGCATGCGCA	O
is	O
the	O
optimal	B-DNA
site	I-DNA
.	O

Similar	O
to	O
IL-4	B-protein
,	O
IL-13	B-RNA
mRNA	I-RNA
expression	O
was	O
highest	O
in	O
T-cell	B-cell_line
populations	I-cell_line
enriched	O
for	O
cells	O
that	O
had	O
previously	O
been	O
primed	O
in	O
vivo	O
or	O
in	O
vitro	O
,	O
indicating	O
that	O
priming	O
increases	O
the	O
expression	O
of	O
the	O
IL-13	B-DNA
and	I-DNA
IL-4	I-DNA
genes	I-DNA
in	O
a	O
coordinate	O
manner	O
.	O

To	O
deepen	O
our	O
understanding	O
of	O
this	O
protein	O
,	O
we	O
characterized	O
its	O
expression	O
in	O
human	O
tissues	O
and	O
cells	O
.	O

Inhibition	O
of	O
Rho	B-protein
activity	O
with	O
C3	B-protein
transferase	I-protein
or	O
N19RhoA	B-protein
,	O
a	O
dominant	O
negative	O
RhoA	B-protein
mutant	I-protein
,	O
reduced	O
the	O
adhesion	O
of	O
monocytes	B-cell_type
to	O
activated	O
endothelial	B-cell_type
cells	I-cell_type
and	O
inhibited	O
their	O
spreading	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
a	O
more	O
sensitive	O
and	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assay	O
was	O
developed	O
to	O
detect	O
adenovirus	B-DNA
DNA	I-DNA
.	O

Furthermore	O
,	O
Ikaros-null	B-cell_type
thymocytes	I-cell_type
hyperproliferate	O
in	O
response	O
to	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
signaling	O
;	O
within	O
days	O
after	O
their	O
appearance	O
in	O
the	O
thymus	O
,	O
clonally	O
expanding	O
populations	O
are	O
detected	O
.	O

Lymphocyte	O
glucocorticoid	B-protein
receptor	I-protein
binding	O
during	O
depression	O
and	O
after	O
clinical	O
recovery	O
.	O

Although	O
mutation	O
occurs	O
specifically	O
in	O
B	B-cell_type
cells	I-cell_type
during	O
the	O
germinal	O
center	O
reaction	O
,	O
it	O
remains	O
a	O
matter	O
of	O
debate	O
whether	O
the	O
mutation	O
machinery	O
also	O
targets	O
non-Ig	B-DNA
genes	I-DNA
.	O

External	O
stimuli	O
,	O
including	O
those	O
that	O
activate	O
T	B-cell_type
cells	I-cell_type
,	O
result	O
in	O
nuclear	O
translocation	O
of	O
active	O
NF-kappa	B-protein
B	I-protein
.	O

PDTC	O
strongly	O
inhibited	O
low	O
shear-induced	O
activation	O
of	O
NF-kappaB	B-protein
,	O
expression	O
of	O
VCAM-1	B-protein
,	O
and	O
EC-Mn	O
adhesion	O
.	O

The	O
present	O
study	O
demonstrates	O
the	O
existence	O
of	O
kappa	B-protein
B-specific	I-protein
binding	I-protein
factors	I-protein
present	O
in	O
human	B-cell_type
glial	I-cell_type
astrocytes	I-cell_type
that	O
differ	O
from	O
prototypical	O
NF-kappa	B-protein
B	I-protein
.	O

These	O
domains	O
,	O
which	O
have	O
been	O
characterized	O
as	O
DNase	B-DNA
I	I-DNA
hypersensitive	I-DNA
sites	I-DNA
(	O
HSs	B-DNA
)	O
,	O
comprise	O
the	O
active	O
elements	O
of	O
the	O
LCR	B-DNA
.	O

These	O
studies	O
identify	O
EGR1	B-protein
as	O
an	O
intermediary	O
linking	O
BCR	B-protein
-derived	O
signals	O
to	O
the	O
induction	O
of	O
CD44	B-protein
.	O

In	O
addition	O
,	O
an	O
inhibitor	O
of	O
PKC	B-protein
blocked	O
both	O
activated	O
ras	B-protein
and	O
phorbol	O
ester	O
stimulation	O
,	O
suggesting	O
a	O
role	O
for	O
ras	B-protein
upstream	O
of	O
PKC	B-protein
.	O

We	O
screened	O
TSG101	B-DNA
for	O
somatic	O
mutations	O
in	O
DNA	O
and	O
RNA	O
samples	O
isolated	O
from	O
a	O
variety	O
of	O
common	O
human	O
malignancies	O
,	O
EBV-immortalised	B-cell_type
B-cells	I-cell_type
,	O
and	O
normal	O
lung	O
parenchyma	O
.	O

DNA-protein	O
crosslinking	O
studies	O
have	O
revealed	O
that	O
the	O
more	O
rapidly	O
migrating	O
B2	B-protein
complex	I-protein
contains	O
both	O
p50	B-protein
and	O
p55	B-protein
while	O
the	O
more	O
slowly	O
migrating	O
B1	B-protein
complex	I-protein
is	O
composed	O
of	O
p50	B-protein
,	O
p55	B-protein
,	O
p75	B-protein
,	O
and	O
p85	B-protein
.	O

Furthermore	O
,	O
LTalpha	B-protein
was	O
secreted	O
in	O
NK	B-cell_line
:	I-cell_line
EC	I-cell_line
co-cultures	I-cell_line
.	O

Pervanadate	B-protein
activated	I-protein
NF-kappa	I-protein
B	I-protein
,	O
as	O
shown	O
by	O
an	O
increase	O
in	O
DNA-binding	O
activity	O
of	O
this	O
transcription	B-protein
factor	I-protein
.	O

Here	O
we	O
show	O
that	O
the	O
murine	B-DNA
PU.1	I-DNA
promoter	I-DNA
is	O
also	O
specifically	O
and	O
highly	O
functional	O
in	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
as	O
well	O
.	O

The	O
human	O
C/EBP-epsilon	B-protein
protein	O
exhibited	O
strong	O
and	O
specific	O
binding	O
to	O
double-stranded	B-DNA
DNA	I-DNA
containing	I-DNA
consensus	I-DNA
C/EBP	I-DNA
sites	I-DNA
.	O

The	O
novel	O
Ets	B-protein
protein	I-protein
was	O
most	O
closely	O
related	O
to	O
PU.1	B-protein
and	O
Spi-B	B-protein
within	O
the	O
DNA	B-DNA
binding	I-DNA
Ets	I-DNA
domain	I-DNA
and	O
was	O
therefore	O
named	O
Spi-C	B-protein
.	O

Induction	O
of	O
this	O
distal	B-DNA
IL-2	I-DNA
enhancer	I-DNA
differs	O
from	O
induction	O
of	O
the	O
proximal	B-DNA
IL-2	I-DNA
promoter-enhancer	I-DNA
,	O
since	O
it	O
is	O
induced	O
by	O
phorbol	O
esters	O
alone	O
and	O
independent	O
from	O
Ca2+	O
signals	O
.	O

The	O
interactions	O
of	O
Hsp60-specific	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
arterial	O
endothelial	B-cell_type
cells	I-cell_type
(	O
EC	B-cell_type
)	O
require	O
expression	O
of	O
both	O
Hsp60	B-protein
and	O
certain	O
adhesion	B-protein
molecules	I-protein
shown	O
to	O
be	O
induced	O
simultaneously	O
in	O
EC	B-cell_type
by	O
mechanical	O
and	O
other	O
types	O
of	O
stress	O
.	O

Protein-tyrosine	O
kinase	O
activation	O
is	O
required	O
for	O
lipopolysaccharide	O
induction	O
of	O
interleukin	B-protein
1beta	I-protein
and	O
NFkappaB	B-protein
activation	O
,	O
but	O
not	O
NFkappaB	B-protein
nuclear	O
translocation	O
.	O

Endothelial	B-cell_type
cells	I-cell_type
(	O
EC	B-cell_type
)	O
act	O
as	O
APC	O
for	O
resting	B-cell_type
PBL	I-cell_type
in	O
vitro	O
,	O
and	O
may	O
have	O
important	O
roles	O
in	O
vivo	O
in	O
the	O
pathogenesis	O
of	O
allograft	O
rejection	O
and	O
delayed	O
hypersensitivity	O
.	O

Moreover	O
,	O
our	O
findings	O
suggest	O
that	O
the	O
level	O
of	O
STAT3	B-protein
phosphorylation	O
is	O
balanced	O
between	O
a	O
staurosporine-sensitive	B-protein
kinase	I-protein
(	O
s	O
)	O
and	O
PP2A	B-protein
.	O

Some	O
criteria	O
which	O
can	O
be	O
used	O
to	O
define	O
steroid-resistant	O
bronchial	O
asthma	O
are	O
listed	O
here	O
.	O

Live-attenuated	O
human	O
immunodeficiency	O
viruses	O
(	O
HIVs	O
)	O
are	O
candidates	O
for	O
Acquired	O
Immunodeficiency	O
Syndrome	O
(	O
AIDS	O
)	O
vaccine	O
.	O

MyD88	B-protein
,	O
originally	O
isolated	O
as	O
a	O
myeloid	O
differentiation	O
primary	B-DNA
response	I-DNA
gene	I-DNA
,	O
is	O
shown	O
to	O
act	O
as	O
an	O
adaptor	O
in	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
signaling	O
by	O
interacting	O
with	O
both	O
the	O
IL-1	B-protein
receptor	I-protein
complex	I-protein
and	O
IL-1	B-protein
receptor-associated	I-protein
kinase	I-protein
(	O
IRAK	B-protein
)	O
.	O

T-cell	O
proliferation	O
studies	O
were	O
performed	O
using	O
highly	O
purified	O
human	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

These	O
findings	O
indicate	O
that	O
corticosteroid	O
resistance	O
in	O
bronchial	O
asthma	O
can	O
not	O
be	O
explained	O
by	O
abnormalities	O
in	O
corticosteroid	O
receptor	O
characteristics	O
.	O

Inhibition	O
of	O
STAT6	B-protein
activity	O
is	O
not	O
evident	O
unless	O
cells	O
are	O
preincubated	O
with	O
IFN	B-protein
for	O
at	O
least	O
1	O
h	O
before	O
IL-4	B-protein
stimulation	O
.	O

Additional	O
size	O
heterogeneity	O
of	O
both	O
NFATc	B-protein
and	O
NFATp	B-protein
results	O
from	O
phosphorylation	O
.	O

These	O
inhibitory	O
effects	O
of	O
c-Rel	B-protein
correlate	O
with	O
its	O
DNA-binding	O
activity	O
but	O
not	O
with	O
its	O
ability	O
to	O
heterodimerize	O
with	O
p50	B-protein
,	O
suggesting	O
that	O
c-Rel	B-protein
inhibition	O
involves	O
competition	O
with	O
p50/p65	B-protein
for	O
occupancy	O
of	O
the	O
kappa	O
B	O
enhancer	O
element	O
.	O

As2O3	O
was	O
administered	O
intravenously	O
at	O
the	O
dose	O
of	O
10	O
mg/d	O
.	O

Downregulation	O
of	O
LPS-induced	B-protein
AP-1	I-protein
was	O
accompanied	O
,	O
and	O
thus	O
possibly	O
explained	O
,	O
by	O
a	O
reduced	O
expression	O
at	O
mRNA	B-RNA
level	O
of	O
the	O
two	O
major	O
components	O
of	O
the	O
AP-1	B-protein
complex	I-protein
,	O
namely	O
c-fos	B-DNA
and	O
c-jun	B-DNA
as	O
determined	O
by	O
Northern	O
experiments	O
.	O

(	O
iv	O
)	O
No	O
other	O
EBV	B-DNA
genes	I-DNA
were	O
required	O
for	O
EBNA-2	B-protein
transactivation	O
of	O
LMP1	B-protein
since	O
cotransfection	O
of	O
recombinant	B-DNA
EBNA-2	I-DNA
expression	I-DNA
vectors	I-DNA
and	O
genomic	O
LMP1	B-DNA
DNA	I-DNA
fragments	I-DNA
enhanced	O
LMP1	B-protein
expression	O
in	O
the	O
EBV-negative	B-cell_line
B-lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
BJAB	B-cell_line
,	O
Louckes	B-cell_line
,	O
and	O
BL30	B-cell_line
.	O

Moreover	O
,	O
the	O
effects	O
of	O
rapamycin	O
on	O
,	O
and	O
the	O
role	O
of	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
in	O
,	O
IL-2	B-protein
and	O
PI	B-protein
3-kinase	I-protein
activation	O
of	O
E2Fs	B-protein
have	O
not	O
been	O
characterized	O
.	O

Here	O
we	O
demonstrate	O
that	O
CD28RE	B-DNA
binds	O
an	O
inducible	O
protein	O
with	O
a	O
molecular	O
mass	O
of	O
approximately	O
35	O
kDa	O
called	O
nuclear	B-protein
factor	I-protein
of	I-protein
mitogenic-activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-MATp35	B-protein
)	O
that	O
is	O
clearly	O
different	O
from	O
the	O
known	O
NF-	B-protein
kappaB/Rel	I-protein
family	I-protein
members	I-protein
.	O

A	O
potentially	O
more	O
common	O
pharmacogenetic	O
syndrome	O
.	O

Finally	O
,	O
the	O
ManLAM-mediated	O
activation	O
of	O
HIV-1	B-DNA
LTR	I-DNA
transcription	O
was	O
found	O
to	O
be	O
independent	O
of	O
the	O
autocrine	O
or	O
paracrine	O
action	O
of	O
endogenous	B-protein
TNF-alpha	I-protein
.	O

One	O
of	O
the	O
cellular	O
targets	O
of	O
the	O
trans-activating	O
effects	O
of	O
Tax	O
is	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
,	O
pleiotropic	B-protein
regulators	I-protein
of	O
immunoregulatory	O
,	O
cytokine	O
and	O
viral	O
gene	O
expression	O
.	O

These	O
data	O
suggest	O
that	O
SLP-76	B-protein
recruits	O
a	O
negative	O
regulator	O
,	O
SLAP-130	B-protein
,	O
as	O
well	O
as	O
positive	O
regulators	O
of	O
signal	O
transduction	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Differential	O
autoregulation	O
of	O
glucocorticoid	B-protein
receptor	I-protein
expression	O
in	O
human	B-cell_line
T-	I-cell_line
and	I-cell_line
B-cell	I-cell_line
lines	I-cell_line
.	O

Recently	O
,	O
investigators	O
have	O
hypothesized	O
that	O
CD14	B-protein
-mediated	O
signaling	O
is	O
effected	O
through	O
a	O
receptor-associated	O
tyrosine	B-protein
kinase	I-protein
(	O
TK	O
)	O
,	O
suggesting	O
a	O
multicomponent	O
receptor	O
model	O
of	O
LPS	O
signaling	O
.	O

Positive	O
autoregulation	O
of	O
GR	B-protein
expression	O
was	O
also	O
observed	O
in	O
glucocorticoid-resistant	B-cell_line
CEM-C1	I-cell_line
cells	I-cell_line
,	O
which	O
contain	O
functional	O
GR	B-protein
,	O
but	O
whose	O
growth	O
is	O
unaffected	O
by	O
glucocorticoids	O
.	O

Quantitative	O
assays	O
demonstrated	O
a	O
direct	O
temporal	O
relationship	O
between	O
LMP-1	B-protein
protein	I-protein
levels	O
and	O
active	O
NF-kappaB	B-protein
during	O
the	O
time	O
course	O
of	O
infection	O
.	O

For	O
most	O
lymphokine	B-DNA
genes	I-DNA
,	O
a	O
combination	O
of	O
phorbol	O
esters	O
(	O
phorbol	O
12-myristate	O
13	O
acetate	O
,	O
PMA	O
)	O
and	O
calcium	O
ionophores	O
(	O
A23187	O
)	O
is	O
required	O
for	O
their	O
maximal	O
induction	O
.	O

Wortmannin	O
did	O
not	O
interfere	O
with	O
NFAT	B-protein
activation	O
,	O
although	O
it	O
inhibited	O
PI3-K	B-protein
and	O
Erk2	B-protein
activation	O
in	O
the	O
same	O
experiment	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
LITAF	B-protein
plays	O
an	O
important	O
role	O
in	O
the	O
activation	O
of	O
the	O
human	B-DNA
TNF-alpha	I-DNA
gene	I-DNA
and	O
proposes	O
a	O
new	O
mechanism	O
to	O
control	O
TNF-alpha	B-protein
gene	O
expression	O
.	O

The	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
requires	O
engagement	O
of	O
the	O
T	B-protein
cell	I-protein
receptor/CD3	I-protein
complex	I-protein
and	O
co-stimulatory	B-protein
molecules	I-protein
,	O
and	O
results	O
in	O
the	O
triggering	O
of	O
several	O
signaling	O
pathways	O
which	O
lead	O
rapidly	O
to	O
the	O
nuclear	O
translocation	O
of	O
several	O
transcription	B-protein
factors	I-protein
,	O
such	O
as	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
and	O
NF-AT	B-protein
.	O

This	O
suppressive	O
effect	O
was	O
also	O
seen	O
in	O
IL-2	B-protein
-driven	O
cell	O
growth	O
of	O
CD8-positive	B-cell_type
lymphocytes	I-cell_type
purified	O
from	O
7-day	B-cell_type
PHA-blasts	I-cell_type
,	O
indicating	O
that	O
CD4	B-protein
molecules	I-protein
were	O
not	O
required	O
for	O
the	O
suppression	O
.	O

In	O
this	O
report	O
we	O
have	O
examined	O
the	O
efficacy	O
of	O
the	O
gold	O
compound	O
AuTG	O
as	O
an	O
inhibitor	O
of	O
HIV	O
replication	O
in	O
latently	O
infected	O
OM10.1	B-cell_line
and	I-cell_line
Ach2	I-cell_line
cells	I-cell_line
.	O

Consistent	O
with	O
the	O
diagnosis	O
of	O
PEL	B-cell_line
,	O
both	O
CRO-AP/3	B-cell_line
and	O
CRO-AP/5	B-cell_line
expressed	O
indeterminate	O
(	O
i.e.	O
non-B	O
,	O
non-T	O
)	O
phenotypes	O
although	O
immunogenotypic	O
studies	O
documented	O
their	O
B-cell	B-cell_type
origin	I-cell_type
.	O

Activity	O
against	O
macrovascular	B-cell_line
EC	I-cell_line
(	O
HUVEC	B-cell_line
)	O
and	O
microvascular	B-cell_line
EC	I-cell_line
(	O
human	B-cell_line
bone	I-cell_line
marrow	I-cell_line
EC	I-cell_line
immortalized	I-cell_line
by	I-cell_line
SV40	I-cell_line
)	O
antigens	O
was	O
detected	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
.	O

We	O
propose	O
that	O
the	O
activation	O
of	O
an	O
NFAT	O
kinase	O
by	O
PDTC	O
could	O
be	O
responsible	O
for	O
the	O
rapid	O
shuttling	O
of	O
the	O
NFAT	B-protein
,	O
therefore	O
transiently	O
converting	O
the	O
sustained	O
transactivation	O
of	O
this	O
transcription	B-protein
factor	I-protein
that	O
occurs	O
during	O
lymphocyte	O
activation	O
,	O
and	O
show	O
that	O
c-Jun	B-protein
NH2-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
can	O
act	O
by	O
directly	O
phosphorylating	O
NFATp	B-protein
.	O

The	O
two	O
structurally	O
distinct	O
immunophilin-drug	B-protein
complexes	I-protein
bind	O
to	O
,	O
and	O
inhibit	O
,	O
the	O
phosphatase	B-protein
activity	O
of	O
calcineurin	B-protein
.	O

A	O
factor	O
with	O
apparently	O
indistinguishable	O
sequence	O
specificity	O
can	O
be	O
induced	O
in	O
many	O
other	O
cell	O
types	O
,	O
where	O
it	O
is	O
used	O
to	O
regulate	O
inducible	O
gene	O
expression	O
.	O

The	O
29-kDa	B-protein
proteins	I-protein
were	O
confirmed	O
to	O
be	O
phosphorylated	O
forms	O
of	O
HSP27	B-protein
by	O
immunoprecipitation	O
studies	O
.	O

We	O
have	O
examined	O
early	O
signal	O
transduction	O
pathways	O
recruited	O
following	O
T	O
cell	O
stimulation	O
with	O
either	O
CD80	B-protein
or	O
CD86	B-protein
.	O

The	O
finding	O
of	O
clonal	O
eosinophilia	O
in	O
a	O
patient	O
presenting	O
with	O
IHES	O
indicates	O
that	O
such	O
patients	O
may	O
have	O
,	O
in	O
reality	O
,	O
a	O
low-grade	O
clonal	O
disorder	O
that	O
can	O
be	O
distinguished	O
from	O
reactive	O
eosinophilias	O
by	O
HUMARA	B-DNA
analysis	O
.	O

One	O
of	O
the	O
potential	O
advantages	O
of	O
autologous	O
PBSCT	O
is	O
the	O
possibility	O
that	O
peripheral	B-cell_type
blood	I-cell_type
stem	I-cell_type
cells	I-cell_type
(	O
PBSC	B-cell_type
)	O
are	O
less	O
likely	O
to	O
be	O
contaminated	O
by	O
leukemic	B-cell_type
cells	I-cell_type
than	O
bone	O
marrow	O
grafts	O
.	O

Thus	O
,	O
it	O
is	O
not	O
unexpected	O
that	O
this	O
versatile	O
cellular	O
homeostatic	O
switch	O
would	O
be	O
affected	O
by	O
a	O
variety	O
of	O
viral	O
pathogens	O
,	O
which	O
have	O
evolved	O
mechanisms	O
to	O
utilize	O
various	O
aspects	O
of	O
Rel/NF-kappa	B-protein
B	I-protein
activity	O
to	O
facilitate	O
their	O
replication	O
,	O
cell	O
survival	O
and	O
possibly	O
evasion	O
of	O
immune	O
responses	O
.	O

Reporter	O
gene	O
experiments	O
finally	O
showed	O
that	O
transcription	O
from	O
promoters	O
of	O
STAT5	B-protein
target	O
genes	O
can	O
be	O
specifically	O
induced	O
by	O
challenging	O
cells	O
with	O
IL-4	B-protein
,	O
and	O
that	O
both	O
STAT5a	B-protein
and	O
STAT5b	B-protein
can	O
contribute	O
to	O
IL-4	B-protein
-triggered	O
transcriptional	O
control	O
.	O

In	O
the	O
present	O
study	O
we	O
demonstrate	O
that	O
also	O
the	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
family	I-protein
members	I-protein
STAT1	B-protein
p91	I-protein
and	O
STAT3	B-protein
p92	I-protein
and	O
the	O
product	O
of	O
the	O
c-fps/fes	B-DNA
protooncogene	I-DNA
become	O
tyrosine-phosphorylated	O
upon	O
GM-CSF	B-protein
stimulation	O
and	O
physically	O
associated	O
with	O
both	O
GM-CSF	B-protein
receptor	O
beta	O
common	O
subunit	O
and	O
JAK2	B-protein
.	O

These	O
results	O
provided	O
evidence	O
that	O
c-Myc	B-protein
and	O
E1A	B-protein
activated	O
the	O
NK	O
cell	O
induced	O
cytolysis	O
at	O
a	O
post-triggering	O
stage	O
of	O
NK	O
cell-target	O
cell	O
interaction	O
.	O

Constitutive	O
expression	O
of	O
human	B-protein
colony-stimulating	I-protein
factor-1	I-protein
receptor	I-protein
(	O
CSF-1R	B-protein
)	O
confers	O
long-lasting	O
CSF-1	B-protein
-dependent	O
proliferation	O
to	O
mouse	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
differentiation	O
of	O
T	B-cell_type
cells	I-cell_type
into	O
functionally	O
diverse	O
subpopulations	O
is	O
controlled	O
in	O
part	O
,	O
by	O
transcriptional	O
activation	O
and	O
silencing	O
;	O
however	O
,	O
little	O
is	O
known	O
in	O
detail	O
about	O
the	O
proteins	O
that	O
influence	O
this	O
developmental	O
process	O
.	O

Characterisation	O
of	O
regulatory	O
sequences	O
at	O
the	O
Epstein-Barr	B-DNA
virus	I-DNA
BamHI	I-DNA
W	I-DNA
promoter	I-DNA
.	O

Female	O
family	O
members	O
were	O
also	O
studied	O
to	O
identify	O
heterozygote	O
carriers	O
.	O

In	O
an	O
extended	O
family	O
we	O
were	O
able	O
to	O
study	O
an	O
aunt	O
and	O
her	O
newborn	O
daughter	O
,	O
who	O
were	O
both	O
also	O
biochemically	O
affected	O
but	O
clinically	O
asymptomatic	O
.	O

As	O
a	O
homodimer	O
JunB	B-protein
is	O
unable	O
to	O
bind	O
the	O
enhancer	O
;	O
however	O
in	O
the	O
presence	O
of	O
c-Fos	B-protein
,	O
high-affinity	O
binding	O
is	O
observed	O
.	O

RESULTS	O
:	O
Interleukin-6	B-protein
protein	I-protein
and	O
mRNA	O
production	O
were	O
significantly	O
increased	O
in	O
cells	O
transfected	O
with	O
the	O
CMV	B-DNA
IE	I-DNA
genes	I-DNA
and	O
stimulated	O
with	O
LPS	O
compared	O
to	O
LPS-stimulated	B-cell_line
control	I-cell_line
cells	I-cell_line
.	O

Cell-type-specific	O
transactivation	O
of	O
the	O
parathyroid	B-DNA
hormone-related	I-DNA
protein	I-DNA
gene	I-DNA
promoter	I-DNA
by	O
the	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
I	I-protein
(	I-protein
HTLV-I	I-protein
)	I-protein
tax	I-protein
and	O
HTLV-II	B-protein
tax	I-protein
proteins	I-protein
.	O

LOX-1	B-protein
is	O
an	O
endothelial	B-protein
receptor	I-protein
for	O
oxidized	B-protein
low-density	I-protein
lipoprotein	I-protein
that	O
plays	O
essential	O
roles	O
in	O
atherogenesis	O
.	O

Replication	O
of	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV-1	O
)	O
is	O
highly	O
dependent	O
on	O
the	O
state	O
of	O
activation	O
of	O
the	O
infected	B-cell_type
cells	I-cell_type
and	O
is	O
modulated	O
by	O
interactions	O
between	O
viral	B-protein
and	I-protein
host	I-protein
cellular	I-protein
factors	I-protein
.	O

1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
were	O
expressed	O
to	O
a	O
greater	O
extent	O
on	O
CD8+	B-cell_type
T-lymphocytes	I-cell_type
than	O
on	O
CD4+	B-cell_type
T-lymphocytes	I-cell_type
in	O
sarcoidosis	O
,	O
whereas	O
a	O
greater	O
proportion	O
of	O
CD4+	B-cell_type
than	O
of	O
CD8+	B-cell_type
T-lymphocytes	I-cell_type
from	O
patients	O
with	O
tuberculosis	O
were	O
receptor-positive	O
.	O

These	O
STAT	B-protein
proteins	I-protein
were	O
detected	O
by	O
using	O
the	O
IFN-gamma-activated	B-DNA
sequence	I-DNA
(	O
GAS	B-DNA
)	O
and	O
related	O
oligonucleotides	O
as	O
probes	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

We	O
have	O
previously	O
reported	O
that	O
the	O
activation	O
of	O
Syk	B-protein
is	O
less	O
dependent	O
on	O
the	O
Src	B-protein
family	I-protein
kinase	I-protein
Lck	B-protein
than	O
the	O
activation	O
of	O
Zap	B-protein
.	O

Interdomain	B-protein
B	I-protein
in	O
ZAP-70	B-protein
regulates	O
but	O
is	O
not	O
required	O
for	O
ZAP-70	B-protein
signaling	O
function	O
in	O
lymphocytes	B-cell_type
.	O

Other	O
factors	O
are	O
implicated	O
in	O
immortalization	O
of	O
common	B-cell_type
marmoset	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
may	O
also	O
be	O
critical	O
in	O
the	O
transformation	O
of	O
human	B-cell_type
lymphocytes	I-cell_type
and	O
rodent	B-cell_type
fibroblasts	I-cell_type
.	O

IL-10	B-protein
also	O
prevented	O
the	O
upregulation	O
of	O
the	O
G1	B-protein
cyclins	I-protein
D2	B-protein
and	O
D3	B-protein
,	O
proteins	O
necessary	O
for	O
entry	O
and	O
progression	O
through	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

PURPOSE	O
:	O
Sex-related	O
influences	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
vernal	O
keratoconjunctivitis	O
(	O
VKC	O
)	O
,	O
an	O
allergic	O
eosinophilic	O
disease	O
.	O

Increased	O
levels	O
of	O
GR	B-RNA
mRNA	I-RNA
were	O
noticed	O
as	O
early	O
as	O
3	O
h	O
after	O
treatment	O
.	O

To	O
investigate	O
the	O
role	O
of	O
Stat6	B-protein
in	O
regulating	O
IL-4	B-protein
transcription	O
,	O
we	O
used	O
Stat6	B-protein
-deficient	O
Jurkat	O
T	B-cell_type
cells	I-cell_type
with	O
different	O
intact	O
IL-4	B-DNA
promoter	I-DNA
constructs	I-DNA
in	O
cotransfection	O
assays	O
.	O

Assuming	O
that	O
9-cis-retinoic	O
acid	O
(	O
9-cis-RA	O
)	O
inhibits	O
TCR-mediated	O
apoptosis	O
,	O
nur77	B-protein
may	O
cause	O
apoptosis	O
by	O
monomer	O
in	O
the	O
absence	O
of	O
9-cis-RA	O
and	O
may	O
inhibit	O
apoptosis	O
by	O
heterodimer	O
with	O
RXR	B-protein
in	O
the	O
presence	O
of	O
9-cis-RA	O
.	O

The	O
short	O
truncated	O
analog	O
433-442A	O
binds	O
very	O
poorly	O
at	O
both	O
acidic	O
and	O
neutral	O
pH	O
.	O

These	O
studies	O
support	O
the	O
idea	O
that	O
superoxide	O
anion	O
radical	O
plays	O
a	O
role	O
in	O
the	O
expression	O
of	O
c-fos	B-RNA
mRNA	I-RNA
.	O

1-	O
(	O
5-Isoquinolinyl	O
sulfonyl	O
)	O
-2-methylpiperazine	O
,	O
an	O
inhibitor	O
of	O
PKC	B-protein
,	O
inhibited	O
the	O
anti-Ig	B-protein
inducibility	O
of	O
Zp	B-DNA
.	O

Although	O
no	O
qualitative	O
difference	O
was	O
observed	O
between	O
specific	O
granules	O
and	O
gelatinase	B-protein
granules	O
with	O
respect	O
to	O
cytochrome	B-protein
b558	I-protein
and	O
Mac-1	B-protein
,	O
stimulation	O
of	O
the	O
neutrophil	B-cell_type
with	O
FMLP	B-protein
resulted	O
in	O
a	O
selective	O
mobilization	O
of	O
the	O
least	O
dense	O
peroxidase-negative	O
granules	O
,	O
ie	O
,	O
gelatinase	B-protein
granules	O
,	O
which	O
,	O
in	O
concert	O
with	O
secretory	O
vesicles	O
,	O
furnish	O
the	O
plasma	O
membrane	O
with	O
Mac-1	B-protein
and	O
cytochrome	B-protein
b558	I-protein
.	O

Intracellular	O
calcium	O
appears	O
to	O
be	O
most	O
critical	O
in	O
the	O
1	O
,	O
25D3-priming	O
stage	O
of	O
differentiation	O
,	O
while	O
calpain	B-protein
is	O
essential	O
in	O
the	O
TPA	O
maturation	O
response	O
.	O

Cytokines	B-protein
,	O
IL-2	B-protein
,	O
IL-4	B-protein
,	O
IL-6	B-protein
,	O
IL-7	B-protein
,	O
IL-12	B-protein
,	O
and	O
IL-15	B-protein
are	O
key	O
regulators	O
of	O
human	O
peripheral	O
blood	O
T	O
and	O
NK	O
cell	O
activation	O
and	O
differentiation	O
but	O
the	O
precise	O
mechanisms	O
that	O
give	O
rise	O
to	O
their	O
differential	O
activities	O
within	O
these	O
cells	O
are	O
not	O
clear	O
.	O

The	O
cloned	B-cell_line
cell	I-cell_line
lines	I-cell_line
are	O
derived	O
from	O
12-day	O
fetal	O
liver	O
and	O
are	O
transformed	O
with	O
a	O
truncated	O
form	O
of	O
c-myb	B-DNA
,	O
which	O
lacks	O
the	O
normal	O
autoregulatory	B-DNA
sequences	I-DNA
.	O

Surfactant	O
suppresses	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
human	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Signal	O
transduction	O
through	O
tyrosine	O
kinase	O
activation	O
may	O
lead	O
to	O
altered	O
gene	O
expression	O
,	O
as	O
J393/	O
CD43	B-protein
ligation	O
prompted	O
decreases	O
in	O
the	O
nuclear	O
localization	O
of	O
the	O
transcriptional	B-protein
regulatory	I-protein
protein	I-protein
NF-kappaB	B-protein
and	O
proteins	O
binding	O
the	O
interferon-inducible	B-DNA
regulatory	I-DNA
element	I-DNA
.	O

In	O
addition	O
to	O
the	O
onset	O
of	O
differentiation	O
,	O
cell	O
death	O
was	O
induced	O
with	O
typical	O
apoptotic	O
features	O
.	O

Similar	O
to	O
induction	O
of	O
cytolytic	O
susceptibility	O
and	O
in	O
contrast	O
to	O
other	O
E1A	B-protein
activities	O
,	O
cellular	O
sensitization	O
to	O
chemically	O
induced	O
apoptosis	O
depended	O
on	O
high-level	O
E1A	B-protein
oncoprotein	B-protein
expression	O
.	O

Transient	O
transfection	O
of	O
a	O
B	O
lymphoma	O
line	O
resulted	O
in	O
up	O
to	O
89	O
%	O
reduction	O
of	O
constitutive	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
within	O
5	O
days	O
and	O
suppression	O
of	O
HLA-DRA	B-RNA
mRNA	I-RNA
synthesis	O
.	O

In	O
contrast	O
,	O
in	O
vivo	O
footprints	O
on	O
GT	B-DNA
(	I-DNA
CACCC	I-DNA
)	I-DNA
motifs	I-DNA
differed	O
between	O
the	O
cells	O
expressing	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
program	O
.	O

The	O
region	O
downstream	O
of	O
the	O
enhancer	B-DNA
(	O
DEN	B-DNA
)	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
of	O
the	O
mink	O
cell	O
focus-forming	O
murine	O
leukemia	O
virus	O
is	O
important	O
for	O
viral	O
pathogenicity	O
.	O

The	O
work	O
reported	O
here	O
was	O
instigated	O
to	O
identify	O
additional	O
VDR	B-protein
3'-UTR	B-DNA
polymorphisms	O
that	O
may	O
have	O
functional	O
significance	O
and	O
to	O
then	O
test	O
whether	O
these	O
genetic	O
variants	O
alter	O
message	O
stability	O
.	O

This	O
result	O
suggests	O
that	O
the	O
cAMP	B-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
,	O
CREB	B-protein
,	O
is	O
involved	O
in	O
the	O
protein-TRE-DNA	B-protein
complex	I-protein
and	O
in	O
mediating	O
the	O
Tax	B-protein
response	O
.	O

Expression	O
of	O
v-src	B-DNA
in	O
T	B-cell_type
cells	I-cell_type
correlates	O
with	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

Inhibition	O
of	O
cyclooxygenase-2	B-protein
expression	O
by	O
4-trifluoromethyl	O
derivatives	O
of	O
salicylate	O
,	O
triflusal	O
,	O
and	O
its	O
deacetylated	O
metabolite	O
,	O
2-hydroxy-4-trifluoromethylbenzoic	O
acid	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
,	O
unlike	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
is	O
constitutively	O
phosphorylated	O
and	O
resynthesized	O
as	O
a	O
hypophosphorylated	B-protein
form	I-protein
.	O

Decreased	O
concentration	O
of	O
1	B-protein
,	I-protein
25-dihydroxyvitamin	I-protein
D3	I-protein
receptors	I-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
of	O
patients	O
with	O
X-linked	O
hypophosphatemic	O
rickets	O
:	O
effect	O
of	O
phosphate	O
supplementation	O
.	O

In	O
parallel	O
,	O
the	O
inhibitory	O
effect	O
of	O
dexamethasone	O
on	O
3-O-methyl-D-glucose	O
uptake	O
was	O
assayed	O
in	O
the	O
corresponding	O
mononuclear	B-cell_type
leukocytes	I-cell_type
.	O

High-risk	O
patients	O
can	O
be	O
recognized	O
morphologically	O
.	O

More	O
than	O
50	O
%	O
of	O
TPO-treated	B-cell_line
UT-7/GMT	I-cell_line
cells	I-cell_line
positively	O
stained	O
for	O
Hb	B-protein
.	O

Since	O
T	B-cell_type
cells	I-cell_type
normally	O
express	O
Bcl-2	B-protein
and	O
Bcl-xL	B-protein
following	O
activation	O
,	O
their	O
inability	O
to	O
block	O
Fas	B-protein
-mediated	O
apoptosis	O
may	O
allow	O
for	O
the	O
elimination	O
of	O
self-reactive	B-cell_type
cells	I-cell_type
and	O
the	O
appropriate	O
regulation	O
of	O
immune	O
responses	O
.	O

RESULTS	O
:	O
The	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
from	O
the	O
six	O
nonresponders	O
,	O
five	O
responders	O
,	O
and	O
ten	O
healthy	O
controls	O
were	O
4922	O
(	O
range	O
,	O
4484-5643	O
)	O
,	O
3413	O
(	O
range	O
,	O
3183-4450	O
)	O
,	O
and	O
3610	O
(	O
range	O
,	O
2594-3979	O
)	O
binding	O
sites/cell	O
,	O
respectively	O
.	O

We	O
have	O
identified	O
a	O
``	B-protein
two-handed	I-protein
''	I-protein
zinc	I-protein
finger	I-protein
protein	I-protein
,	O
denoted	O
ZEB	B-protein
,	O
the	O
DNA-binding	O
specificity	O
of	O
which	O
mimics	O
that	O
of	O
the	O
cellular	B-protein
repressor	I-protein
.	O

Repeated	O
karyotypic	O
studies	O
on	O
peripheral	B-cell_type
blood	I-cell_type
lymphocyte	I-cell_type
cultures	I-cell_type
showed	O
only	O
46	O
,	O
X	O
,	O
-Y	O
,	O
t	O
(	O
Y	O
;	O
15	O
)	O
(	O
q12	O
;	O
p13	O
)	O
.	O

Evidence	O
is	O
provided	O
here	O
that	O
the	O
nuclear	O
component	O
of	O
human	B-protein
NF-AT	I-protein
contains	O
the	O
phorbol	B-protein
ester-inducible	I-protein
transcription	I-protein
factor	I-protein
AP1	I-protein
(	O
Jun/Fos	B-protein
)	O
.	O

The	O
inability	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
to	O
suppress	O
its	O
synthesis	O
in	O
macrophages	B-cell_type
contrasts	O
with	O
the	O
tight	O
control	O
of	O
its	O
production	O
in	O
macrophage	O
precursors	O
,	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
(	O
PBM	B-cell_type
)	O
.	O

Tepoxalin	O
is	O
a	O
new	O
dual	O
cyclooxygenase/5-lipoxygenase	O
anti-inflammatory	O
compound	O
currently	O
under	O
clinical	O
investigation	O
.	O

CL-01	B-cell_line
cells	I-cell_line
are	O
IgM	B-protein
+	O
IgD	B-protein
+	O
CD30	B-protein
+	O
and	O
switch	O
to	O
IgG	B-protein
,	O
IgA	B-protein
,	O
and	O
IgE	B-protein
when	O
exposed	O
to	O
CD40L	B-protein
and	O
IL-4	B-protein
.	O

This	O
new	O
site	O
plays	O
a	O
critical	O
role	O
in	O
the	O
calcium-mediated	O
,	O
cyclosporin	O
A-sensitive	O
induction	O
of	O
TNF-alpha	B-protein
in	O
both	O
A20	B-cell_line
B	I-cell_line
cells	I-cell_line
and	O
Ar-5	B-cell_line
cells	I-cell_line
.	O

When	O
single-point	O
mutation	O
was	O
introduced	O
to	O
each	O
GC	B-DNA
box	I-DNA
,	O
EBS	B-DNA
,	O
and	O
GT	B-DNA
box	I-DNA
in	O
PFP9a20	B-DNA
,	O
at	O
least	O
3-fold	O
less	O
CAT	B-protein
activity	O
was	O
observed	O
in	O
CTLL-R8	B-cell_line
cells	I-cell_line
.	O

In	O
addition	O
,	O
sodium	O
salicylate	O
and	O
additional	O
NSAIDs	O
used	O
at	O
concentrations	O
that	O
activate	O
HSF1	B-protein
also	O
inhibited	O
the	O
expression	O
of	O
other	O
monocytic	B-DNA
genes	I-DNA
(	O
TNF-alpha	B-DNA
,	O
IL-1beta	B-DNA
,	O
IL-6	B-DNA
,	O
IL-8	B-DNA
,	O
IL-10	B-DNA
,	O
ICAM-1	B-DNA
)	O
activated	O
by	O
exposure	O
to	O
a	O
pro-inflammatory	O
stimulus	O
(	O
lipopolysaccharide	O
,	O
LPS	O
)	O
.	O

Moreover	O
,	O
there	O
is	O
no	O
cooperation	O
or	O
synergy	O
between	O
R	B-protein
and	O
EB1	B-protein
when	O
activating	O
the	O
B	B-DNA
domain	I-DNA
(	O
ZRE-B	B-DNA
plus	O
the	O
R-responsive	B-DNA
element	I-DNA
)	O
positioned	O
as	O
an	O
enhancer	B-DNA
.	O

Both	O
IL-2	B-protein
and	O
IL-7	B-protein
induced	O
substantial	O
amounts	O
of	O
STAT5A	B-protein
/STAT5B	B-protein
heterodimerization	O
.	O

In	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
activated	O
by	O
phorbol-12-myristate-13-acetate	O
and	O
phytohemagglutinin	B-protein
,	O
CCK-8	O
induced	O
IL-2	O
expression	O
.	O

A	O
transcription	B-protein
factor	I-protein
NF	B-protein
kappa	I-protein
B	I-protein
,	O
which	O
regulates	O
expression	O
of	O
various	O
cellular	O
genes	O
involved	O
in	O
immune	O
responses	O
and	O
viral	B-DNA
genes	I-DNA
including	O
HIV	O
,	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
as	O
a	O
complex	O
with	O
an	O
inhibitory	B-protein
protein	I-protein
I	I-protein
kappa	I-protein
B	I-protein
.	O

Importantly	O
,	O
culture	O
of	O
MM	B-cell_line
cells	I-cell_line
with	O
RB	O
antisense	O
,	O
but	O
not	O
RB	O
sense	O
,	O
oligonucleotide	O
(	O
ODN	O
)	O
triggered	O
IL-6	B-protein
secretion	O
and	O
proliferation	O
in	O
MM	B-cell_line
cells	I-cell_line
;	O
however	O
,	O
proliferation	O
was	O
only	O
partially	O
inhibited	O
by	O
neutralizing	O
anti-IL-6	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
MoAb	B-protein
)	O
.	O

The	O
increase	O
in	O
AP-1	B-protein
-binding	O
activity	O
was	O
accompanied	O
by	O
the	O
marked	O
stimulation	O
of	O
the	O
transcription	O
of	O
c-fos	B-protein
but	O
not	O
that	O
of	O
c-jun	B-protein
.	O

We	O
also	O
demonstrated	O
that	O
fresh	O
leukemic	B-cell_type
cells	I-cell_type
,	O
whatever	O
their	O
stage	O
of	O
differentiation	O
,	O
as	O
well	O
as	O
myelomonocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
respond	O
to	O
VD	O
by	O
an	O
increase	O
in	O
RXR	B-protein
alpha	I-protein
levels	O
.	O

Altogether	O
,	O
these	O
results	O
indicate	O
that	O
the	O
IL-10	B-protein
-induced	O
up-regulation	O
of	O
cytokine	B-protein
production	O
depends	O
on	O
the	O
prevention	O
of	O
monocyte	O
adherence	O
by	O
red	B-cell_type
cells	I-cell_type
in	O
the	O
whole	O
blood	O
assays	O
or	O
by	O
cultures	O
of	O
PBMC	B-cell_type
on	O
Teflon	O
.	O

In	O
both	O
transiently	B-cell_line
cotransfected	I-cell_line
human	I-cell_line
cells	I-cell_line
and	O
stable	O
chromatin-integrated	B-cell_line
yeast	I-cell_line
cells	I-cell_line
,	O
c-Myb	B-protein
strongly	O
transactivated	B-DNA
reporter	I-DNA
constructs	I-DNA
that	O
contained	O
polymerized	B-DNA
core	I-DNA
sequences	I-DNA
.	O

The	O
molecular	O
basis	O
for	O
restricted	O
cytokine	B-protein
expression	O
by	O
T	B-cell_type
helper	I-cell_type
1	I-cell_type
(	I-cell_type
Th1	I-cell_type
)	I-cell_type
and	I-cell_type
T	I-cell_type
helper	I-cell_type
2	I-cell_type
(	I-cell_type
Th2	I-cell_type
)	I-cell_type
cells	I-cell_type
is	O
unclear	O
.	O

Therefore	O
,	O
HIV-1-induced	O
cell	O
fusion	O
brings	O
together	O
factors	O
that	O
upregulate	O
virus	O
transcription	O
.	O

Binding	O
of	O
activated	B-cell_type
platelets	I-cell_type
induces	O
IL-1	B-protein
beta	I-protein
,	O
IL-8	B-protein
,	O
and	O
MCP-1	B-protein
in	O
leukocytes	B-cell_type
.	O

We	O
have	O
now	O
investigated	O
the	O
effect	O
of	O
oxLDLs	B-protein
on	O
blast	O
differentiation	O
,	O
on	O
IL-2	B-protein
synthesis	O
and	O
on	O
the	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
system	O
in	O
activated	O
lymphocytes	O
.	O

Grf40	B-protein
binds	O
to	O
the	O
SH2	B-protein
domain-containing	I-protein
leukocyte	I-protein
protein	I-protein
of	O
76	O
kD	O
(	O
SLP-76	B-protein
)	O
via	O
its	O
SH3	O
domain	O
more	O
tightly	O
than	O
Grb2	B-protein
.	O

The	O
different	O
patterns	O
of	O
p50	B-protein
,	O
p52	B-protein
and	O
RelB	B-protein
protein	O
nuclear	O
localization	O
may	O
provide	O
insight	O
into	O
their	O
different	O
roles	O
during	O
the	O
immune	O
response	O
in	O
vivo	O
.	O

However	O
,	O
we	O
show	O
that	O
JunB	B-protein
binds	O
directly	O
to	O
the	O
P1	B-DNA
site	I-DNA
and	O
synergizes	O
with	O
c-Maf	B-protein
to	O
activate	O
an	O
IL-4	B-DNA
luciferase	I-DNA
reporter	I-DNA
gene	I-DNA
.	O

Northern	O
blot	O
analysis	O
of	O
L132	B-cell_type
cells	I-cell_type
transfected	O
with	O
the	O
C/EBP	B-protein
alpha	I-protein
expression	O
vector	O
demonstrate	O
that	O
C/EBP	B-protein
alpha	I-protein
is	O
sufficient	O
to	O
enhance	O
MRP14	B-protein
expression	O
in	O
the	O
context	O
of	O
the	O
whole	O
genome	O
.	O

Central	B-cell_type
nervous	I-cell_type
system-derived	I-cell_type
cells	I-cell_type
express	O
a	O
kappa	O
B-binding	O
activity	O
that	O
enhances	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
in	O
vitro	O
and	O
facilitates	O
TAR	B-DNA
-independent	O
transactivation	O
by	O
Tat	B-protein
.	O

Xenogeneic	O
human	O
serum	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
increased	O
the	O
number	O
of	O
adherent	B-cell_type
leukocytes	I-cell_type
as	O
compared	O
with	O
porcine	O
serum	O
.	O

We	O
report	O
here	O
that	O
the	O
second	O
alteration	O
,	O
at	O
threonine	O
78	O
,	O
also	O
plays	O
an	O
important	O
,	O
although	O
more	O
indirect	O
,	O
role	O
:	O
alteration	O
of	O
the	O
sequence	O
at	O
threonine	O
78	O
such	O
that	O
it	O
resembles	O
that	O
of	O
c-erb	B-protein
A	I-protein
can	O
act	O
as	O
an	O
intragenic	O
suppressor	O
and	O
can	O
partially	O
restore	O
function	O
to	O
a	O
v-erb	B-protein
A	I-protein
protein	I-protein
rendered	O
defective	O
due	O
to	O
a	O
mutation	O
at	O
position	B-protein
61	I-protein
.	O

gamma-Interferon	B-protein
-induced	O
resistance	O
to	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2	O
D3	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
macrophages	B-cell_type
:	O
a	O
mechanism	O
for	O
the	O
hypercalcemia	O
of	O
various	O
granulomatoses	O
.	O

Our	O
previous	O
studies	O
(	O
Chen	O
,	O
H.M.	O
,	O
Ray-Gallet	O
,	O
D.	O
,	O
Zhang	O
,	O
P.	O
,	O
Hetherington	O
,	O
C.J.	O
,	O
Gonzalez	O
,	O
D.A.	O
,	O
Zhang	O
,	O
D.-E.	O
,	O
Moreau-Gachelin	O
,	O
F.	O
,	O
and	O
Tenen	O
,	O
D.G.	O
(	O
1995	O
)	O
Oncogene	O
11	O
,	O
1549-1560	O
)	O
demonstrate	O
that	O
the	O
PU.1	B-DNA
promoter	I-DNA
directs	O
cell	B-DNA
type-specific	I-DNA
reporter	I-DNA
gene	I-DNA
expression	O
in	O
myeloid	O
cell	O
lines	O
,	O
and	O
that	O
PU.1	B-protein
activates	O
its	O
own	O
promoter	O
in	O
an	O
autoregulatory	O
loop	O
.	O

Inhibition	O
of	O
cytokine	B-protein
production	O
was	O
gene	O
selective	O
and	O
not	O
due	O
to	O
general	O
effects	O
on	O
protein	O
synthesis	O
.	O

When	O
cultured	O
on	O
bone	O
,	O
VR+	B-cell_line
,	I-cell_line
TRAP+	I-cell_line
cells	I-cell_line
of	O
low	O
multinuclearity	O
appear	O
and	O
cover	O
up	O
to	O
50	O
%	O
of	O
the	O
surface	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
utilized	O
a	O
mutant	B-cell_line
Jak1-deficient	I-cell_line
HeLa	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
E1C3	B-cell_line
,	O
and	O
its	O
parental	B-cell_line
Jak1-expressing	I-cell_line
counterpart	I-cell_line
,	O
1D4	B-cell_line
,	O
to	O
analyze	O
the	O
role	O
of	O
Jak1	B-protein
in	O
mediating	O
IL-4-induced	O
tyrosine	O
phosphorylation	O
events	O
.	O

Induction	O
of	O
relA	B-protein
(	I-protein
p65	I-protein
)	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
subunit	I-protein
expression	O
during	O
differentiation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
to	O
macrophages	B-cell_type
.	O

Although	O
,	O
the	O
level	O
of	O
MNDA	B-RNA
mRNA	I-RNA
in	O
primary	B-cell_type
monocytes	I-cell_type
is	O
very	O
low	O
it	O
was	O
up-regulated	O
at	O
6	O
h	O
following	O
the	O
addition	O
of	O
interferon	B-protein
alpha	I-protein
.	O

The	O
in	O
vitro	O
transendothelial	O
migration	O
of	O
circulating	B-cell_type
filarial	I-cell_type
antigen-specific	I-cell_type
T-cells	I-cell_type
was	O
examined	O
in	O
Wuchereria	O
banerofti	O
infection	O
.	O

Activation	O
of	O
the	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
after	O
antigen	O
recognition	O
is	O
a	O
critical	O
event	O
for	O
T	O
cell	O
proliferation	O
and	O
effector	O
function	O
.	O

In	O
previous	O
studies	O
,	O
it	O
was	O
shown	O
that	O
the	O
fusion	O
region	O
of	O
the	O
pml/RAR-alpha	B-protein
protein	I-protein
,	O
expressed	O
by	O
acute	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
(	I-cell_line
APL	I-cell_line
)	I-cell_line
cells	I-cell_line
,	O
can	O
be	O
specifically	O
recognized	O
in	O
vitro	O
by	O
donor	O
(	O
D.	O
E.	O
)	O
CD4	B-cell_line
T	I-cell_line
cells	I-cell_line
in	O
a	O
HLA	B-protein
class	I-protein
II	I-protein
DR11-restricted	O
fashion	O
.	O

To	O
understand	O
the	O
mechanism	O
by	O
which	O
PRL	B-protein
regulates	O
the	O
biphasic	O
expression	O
of	O
IRF-1	B-protein
,	O
we	O
cloned	O
the	O
rat	B-DNA
IRF-1	I-DNA
gene	I-DNA
and	O
functionally	O
characterized	O
the	O
IRF-1	B-DNA
promoter	I-DNA
.	O

Recent	O
studies	O
show	O
that	O
human	B-cell_type
osteoclasts	I-cell_type
develop	O
in	O
vitro	O
from	O
hematopoietic	B-cell_type
cells	I-cell_type
;	O
however	O
,	O
special	O
cultures	O
conditions	O
and/or	O
cytokine	O
mobilized	O
peripheral	O
blood	O
are	O
apparently	O
required	O
.	O

Previous	O
work	O
has	O
shown	O
that	O
C/EBP	B-DNA
sites	I-DNA
and	O
C/EBP	B-protein
transcriptional	I-protein
activators	I-protein
are	O
necessary	O
for	O
HIV-1	B-DNA
LTR	I-DNA
activity	O
in	O
monocytes/macrophages	B-cell_type
.	O

In	O
peripheral	O
blood	O
lymphocytes	O
,	O
expression	O
of	O
Trident	B-RNA
mRNA	I-RNA
was	O
absent	O
,	O
but	O
could	O
be	O
induced	O
upon	O
stimulation	O
with	O
mitogens	O
in	O
vitro	O
.	O

BACKGROUND	O
.	O

We	O
,	O
therefore	O
,	O
conclude	O
that	O
signals	O
generated	O
by	O
the	O
convergence	O
of	O
the	O
MAPK	B-protein
and	O
the	O
calcineurin	B-protein
/NFAT	B-protein
pathway	O
are	O
necessary	O
and	O
sufficient	O
for	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
by	O
Tpl-2	B-protein
.	O

In	O
CRF	O
patients	O
,	O
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	B-cell_type
of	O
the	O
GC-sensitive	O
group	O
were	O
6.04	O
+/-	O
2.35	O
fmol/10	O
(	O
6	O
)	O
cells	O
and	O
3.49	O
+/-	O
1.72	O
nM	O
,	O
respectively	O
,	O
while	O
those	O
in	O
PBMC	B-cell_type
of	O
the	O
GC-resistant	O
group	O
were	O
5.13	O
+/-	O
2.31	O
fmol/10	O
(	O
6	O
)	O
cells	O
and	O
4.04	O
+/-	O
1.62	O
nM	O
,	O
respectively	O
.	O

Likewise	O
,	O
the	O
level	O
of	O
expression	O
of	O
the	O
erythroid	B-protein
transcription	I-protein
factors	I-protein
GATA-1	B-protein
,	O
GATA-2	B-protein
,	O
NF-E2	B-protein
,	O
SCL	B-protein
and	O
RBTN2	B-protein
,	O
all	O
expressed	O
in	O
untreated	O
K562	B-cell_line
cells	I-cell_line
,	O
did	O
not	O
increase	O
during	O
sodium	O
phenylacetate	O
induced	O
erythroid	O
differentiation	O
.	O

Unexpectedly	O
,	O
the	O
presence	O
of	O
nuclear	B-protein
I	I-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
did	O
not	O
inhibit	O
NF-kappaB	B-protein
binding	O
to	O
DNA	O
and	O
this	O
phenomenon	O
was	O
not	O
due	O
to	O
the	O
presence	O
of	O
IkappaBbeta	B-protein
at	O
the	O
nuclear	O
level	O
.	O

Expression	O
of	O
the	O
human	B-protein
RAR-alpha	I-protein
in	O
receptor-negative	B-cell_line
erythroblasts	I-cell_line
conferred	O
RA-induced	O
regulation	O
of	O
differentiation	O
to	O
the	O
otherwise	O
unresponsive	B-cell_type
cells	I-cell_type
,	O
thus	O
showing	O
that	O
the	O
RAR-alpha	B-protein
is	O
essential	O
for	O
the	O
RA	O
effect	O
.	O

Specific	O
families	O
of	O
receptors	B-protein
,	O
kinases	B-protein
,	O
transcription	B-protein
factors	I-protein
,	O
and	O
cysteine	B-protein
proteases	I-protein
,	O
termed	B-protein
caspases	I-protein
,	O
are	O
involved	O
in	O
the	O
apoptotic	O
cascade	O
leading	O
to	O
proteolysis	O
of	O
specific	O
substrates	O
and	O
to	O
morphological	O
changes	O
associated	O
with	O
programmed	O
cell	O
death	O
.	O

The	O
promoter	B-DNA
of	O
the	O
CD19	B-DNA
gene	I-DNA
is	O
a	O
target	O
for	O
the	O
B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
BSAP	B-protein
.	O

Receptor	B-RNA
transcripts	I-RNA
were	O
4.6	O
kilobases	O
(	O
kb	O
)	O
,	O
and	O
no	O
variant	O
sizes	O
were	O
observed	O
.	O

This	O
effect	O
was	O
confirmed	O
in	O
COS-7	O
cells	O
transfected	O
with	O
the	O
cDNA	O
of	O
CCK	B-protein
(	I-protein
B	I-protein
)	I-protein
receptor	I-protein
cloned	O
from	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Point	O
mutations	O
of	O
either	O
the	O
PU.1	B-DNA
site	I-DNA
or	O
the	O
C/EBP	B-DNA
site	I-DNA
that	O
abolish	O
the	O
binding	O
of	O
the	O
respective	O
factors	O
result	O
in	O
a	O
significant	O
decrease	O
of	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
in	O
myelomonocytic	B-cell_type
cells	I-cell_type
only	O
.	O

CONCLUSIONS	O
:	O
Flutamide	O
is	O
effective	O
in	O
the	O
treatment	O
of	O
hirsutism	O
but	O
requires	O
constant	O
surveillance	O
of	O
liver	O
function	O
.	O

Thus	O
these	O
results	O
suggest	O
a	O
direct	O
contribution	O
of	O
EBV	O
to	O
chronic	O
rheumatoid	O
arthritis	O
pathogenesis	O
.	O

The	O
similar	O
actions	O
of	O
IL-10R	B-protein
and	O
IL-6R	B-protein
on	O
the	O
induction	O
of	O
endogenous	O
IL-6-responsive	B-DNA
genes	I-DNA
were	O
demonstrated	O
in	O
hepatoma	B-cell_type
cells	I-cell_type
stably	O
expressing	O
the	O
IL-10R	B-protein
.	O

Evaluation	O
of	O
monoclonal	O
anti-D	O
reagents	O
using	O
D	B-cell_line
variant	I-cell_line
cells	I-cell_line
.	O

The	O
transcription	B-protein
factors	I-protein
Sp1	B-protein
and	O
PU.1	B-protein
prime	I-protein
the	O
CD11b	B-DNA
promoter	I-DNA
,	O
but	O
the	O
nature	O
of	O
the	O
factors	O
responsible	O
for	O
its	O
inducible	O
expression	O
are	O
unknown	O
.	O

Selection	O
of	O
optimal	O
kappa	O
B/Rel	O
DNA-binding	O
motifs	O
:	O
interaction	O
of	O
both	O
subunits	O
of	O
NF-kappa	B-protein
B	I-protein
with	O
DNA	O
is	O
required	O
for	O
transcriptional	O
activation	O
.	O

Monocyte	O
apoptosis	O
was	O
determined	O
by	O
four	O
independent	O
methods	O
,	O
including	O
annexin-V	O
staining	O
,	O
TUNEL	O
,	O
DNA-laddering	O
,	O
and	O
typical	O
morphology	O
by	O
means	O
of	O
transmission	O
electron	O
microscopy	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
demonstrated	O
that	O
the	O
-300	O
region	O
of	O
the	O
IL-1beta	B-protein
promoter	O
,	O
which	O
contains	O
a	O
nuclear	B-DNA
factor-kappaB	I-DNA
(	I-DNA
NF-kappaB	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
,	O
contained	O
a	O
functional	B-DNA
RBP	I-DNA
binding	I-DNA
site	I-DNA
.	O

Recently	O
,	O
a	O
unique	O
inhibitory	O
role	O
of	O
NFAT1	B-protein
in	O
IL-4	B-DNA
gene	I-DNA
control	O
was	O
shown	O
in	O
the	O
mouse	O
.	O

Appearance	O
of	O
the	O
STAT1	B-protein
factor	O
is	O
significantly	O
reduced	O
in	O
the	O
presence	O
of	O
cyclosporin	O
A	O
,	O
and	O
blocked	O
by	O
cycloheximide	O
,	O
indicating	O
that	O
its	O
activation	O
is	O
dependent	O
upon	O
a	O
protein	O
(	O
s	O
)	O
synthesized	O
in	O
response	O
to	O
initial	O
signaling	O
events	O
.	O

B-cell-specific	O
transcription	O
of	O
this	O
gene	O
was	O
dependent	O
on	O
the	O
octamer	B-DNA
element	I-DNA
5'-ATGCAAAG-3	O
'	O
,	O
located	O
in	O
the	O
upstream	B-DNA
region	I-DNA
of	O
this	O
promoter	B-DNA
and	O
in	O
the	O
promoters	B-DNA
of	O
all	O
other	O
immunoglobulin	B-DNA
heavy-	I-DNA
and	I-DNA
light-chain	I-DNA
genes	I-DNA
.	O

Our	O
results	O
indicate	O
that	O
ATRA	O
as	O
well	O
as	O
VD	O
efficiently	O
increases	O
the	O
nuclear	O
abundance	O
of	O
VD	B-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
and	O
promotes	O
monocytic	O
differentiation	O
.	O

Interleukin-7	B-protein
can	O
induce	O
the	O
activation	O
of	O
Jak	B-protein
1	I-protein
,	O
Jak	B-protein
3	I-protein
and	O
STAT	B-protein
5	I-protein
proteins	I-protein
in	O
murine	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
overall	O
effect	O
of	O
heat	O
shock	O
on	O
c-myc	B-RNA
mRNA	I-RNA
level	O
,	O
however	O
,	O
was	O
a	O
marked	O
inhibition	O
of	O
its	O
transcription	O
.	O

We	O
also	O
observed	O
hematopoiesis	O
outside	O
of	O
the	O
bone	O
marrow	O
in	O
the	O
affected	O
mutant	O
mice	O
.	O

IL-2	B-protein
production	O
by	O
CsA-treated	B-cell_line
cells	I-cell_line
is	O
therefore	O
dramatically	O
reduced	O
.	O

Compared	O
to	O
benign	O
tumor	O
or	O
mammary	O
reduction	O
test	O
material	O
the	O
eicosanoid	O
profile	O
of	O
tissue	O
obtained	O
from	O
malignant	O
mammary	O
tumors	O
showed	O
important	O
differences	O
.	O

They	O
may	O
represent	O
immunoregulatory	B-cell_type
cells	I-cell_type
,	O
and	O
further	O
analysis	O
of	O
these	O
cells	O
,	O
and	O
a	O
comparison	O
to	O
those	O
found	O
in	O
patients	O
with	O
SS	O
,	O
may	O
elucidate	O
normal	O
immunoregulation	O
and	O
the	O
derangements	O
that	O
lead	O
to	O
Sjogren	O
's	O
syndrome	O
.	O

Cells	O
with	O
nuclear	O
p50	B-protein
were	O
negative	O
for	O
the	O
CD38	B-protein
,	O
CD20	B-protein
and	O
CD2	B-protein
markers	I-protein
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
mediates	O
a	O
wide	O
variety	O
of	O
disease	O
states	O
including	O
septic	O
shock	O
,	O
acute	O
and	O
chronic	O
inflammation	O
,	O
and	O
cachexia	O
.	O

Thus	O
,	O
3BP2	B-protein
is	O
an	O
important	O
adaptor	O
that	O
may	O
couple	O
activated	O
Zap-70/Syk	B-protein
to	O
a	O
LAT-containing	B-protein
signaling	I-protein
complex	I-protein
involved	O
in	O
TCR-mediated	O
gene	O
transcription	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
NF-kappa	B-protein
B	I-protein
plays	O
a	O
crucial	O
role	O
in	O
ensuring	O
the	O
differentiation	O
and	O
survival	O
of	O
thymocytes	B-cell_type
in	O
the	O
early	O
stages	O
of	O
their	O
development	O
.	O

Half-life	O
(	O
t1/2	O
)	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
in	O
T	B-cell_type
lymphocytes	I-cell_type
was	O
short	O
(	O
1	O
hour	O
)	O
as	O
determined	O
by	O
measuring	O
decay	O
of	O
the	O
message	O
after	O
addition	O
of	O
actinomycin	O
D	O
.	O

Interestingly	O
,	O
the	O
expression	O
level	O
of	O
p27Kip1	B-RNA
mRNA	I-RNA
was	O
maximal	O
in	O
resting	B-cell_type
Go	I-cell_type
T-cells	I-cell_type
and	O
rapidly	O
declined	O
following	O
anti-CD3	B-protein
activation	O
.	O

By	O
biochemical	O
fractionation	O
and	O
reconstitution	O
,	O
we	O
showed	O
that	O
RanBP1	B-protein
restores	O
nuclear	O
export	O
after	O
the	O
RanQ69L	B-protein
preincubation	O
.	O

Significantly	O
,	O
the	O
CBF	B-DNA
sites	I-DNA
are	O
in	O
each	O
case	O
contained	O
within	O
the	O
minimum	O
essential	B-DNA
core	I-DNA
regions	I-DNA
required	O
for	O
inducible	O
activation	O
of	O
transcription	O
.	O

The	O
consequences	O
of	O
p80c-rel	B-protein
tyrosine	O
phosphorylation	O
are	O
not	O
yet	O
known	O
;	O
however	O
,	O
tyrosine-phosphorylated	O
p80c-rel	B-protein
is	O
capable	O
of	O
binding	O
to	O
DNA	O
,	O
and	O
G-CSF	B-protein
stimulation	O
results	O
in	O
an	O
increase	O
in	O
the	O
amount	O
of	O
p80c-rel	B-protein
which	O
binds	O
to	O
DNA	O
.	O

We	O
determined	O
whether	O
the	O
interaction	O
of	O
SS	B-cell_type
RBC	I-cell_type
with	O
cultured	O
endothelial	B-cell_type
cells	I-cell_type
induced	O
cellular	O
oxidant	O
stress	O
that	O
would	O
culminate	O
in	O
expression	O
of	O
cell	B-protein
adhesion	I-protein
molecules	I-protein
(	O
CAMs	B-protein
)	O
involved	O
in	O
the	O
adhesion	O
and	O
diapedesis	O
of	O
monocytes	B-cell_type
and	O
the	O
adherence	O
of	O
SS	B-cell_type
reticulocytes	I-cell_type
.	O

The	O
adherence	O
of	O
monocytes	B-cell_type
to	O
activated	O
endothelium	O
is	O
an	O
early	O
event	O
in	O
atherogenesis	O
.	O

Although	O
a	O
role	O
of	O
p16	B-protein
in	O
this	O
regulation	O
has	O
been	O
presumed	O
,	O
there	O
is	O
no	O
proof	O
so	O
far	O
that	O
loss	O
of	O
this	O
tumor	B-DNA
suppressor	I-DNA
gene	I-DNA
really	O
affects	O
E2F	B-protein
-mediated	O
regulations	O
.	O

This	O
induction	O
was	O
abolished	O
by	O
PD-135	O
,	O
158	O
.	O

In	O
vivo	O
,	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
,	O
less	O
frequently	O
,	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
may	O
completely	O
lose	O
CD28	B-protein
surface	O
expression	O
during	O
chronic	O
infections	O
and	O
with	O
aging	O
.	O

Stable	O
expression	O
of	O
transdominant	B-protein
Rev	I-protein
protein	I-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
inhibits	O
human	O
immunodeficiency	O
virus	O
replication	O
.	O

As	O
the	O
expression	O
level	O
of	O
the	O
RP1	B-DNA
gene	I-DNA
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
a	O
spectrum	O
of	O
tumor-derived	B-cell_line
cell	I-cell_line
lines	I-cell_line
correlates	O
with	O
the	O
proliferative	O
status	O
of	O
the	O
cells	O
,	O
members	O
of	O
the	O
EB1-like	B-DNA
gene	I-DNA
family	I-DNA
may	O
not	O
only	O
be	O
involved	O
in	O
the	O
tumorigenesis	O
of	O
colorectal	O
cancers	O
but	O
may	O
also	O
play	O
a	O
role	O
in	O
the	O
proliferative	O
control	O
of	O
normal	B-cell_type
cells	I-cell_type
.	O

Both	O
Stat3	B-protein
-activation	O
and	O
Stat3	B-protein
-independent	O
BCL2	B-protein
downregulation	O
are	O
important	O
for	O
interleukin-6	B-protein
-induced	O
apoptosis	O
of	O
1A9-M	B-cell_line
cells	I-cell_line
.	O

We	O
show	O
that	O
triggering	O
of	O
CD40	B-protein
signaling	O
pathway	O
(	O
s	O
)	O
by	O
CD40	B-protein
ligands	I-protein
expressed	O
on	O
L	B-cell_type
cells	I-cell_type
led	O
to	O
strong	O
activation	O
of	O
an	O
NF-kappaB-controlled	B-DNA
beta-globin	I-DNA
reporter	I-DNA
gene	I-DNA
in	O
primary	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
from	O
transgenic	O
mice	O
.	O

Western	O
blot	O
analysis	O
confirmed	O
the	O
presence	O
of	O
C/EBP	B-protein
beta	I-protein
in	O
these	O
cells	O
.	O

cells/tube	O
in	O
the	O
assay	O
volume	O
0.25	O
ml	O
were	O
found	O
to	O
be	O
optimal	O
.	O

Involvement	O
in	O
the	O
potentiation	O
of	O
platelet	O
aggregation	O
.	O

The	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
contains	O
an	O
important	O
functional	O
site	O
between	O
positions	O
-53	O
and	O
-41	O
as	O
identified	O
by	O
deletion	O
analysis	O
of	O
reporter	B-DNA
constructs	I-DNA
.	O

Both	O
limiting-component	O
transcription	O
assays	O
and	O
DNA	O
binding	O
assays	O
identified	O
the	O
class	B-protein
III	I-protein
gene	I-protein
transcription	I-protein
factor	I-protein
TFIIIB	B-protein
as	O
the	O
principle	O
target	O
of	O
Tax	B-protein
activity	O
.	O

The	O
expression	O
of	O
CD4	B-protein
,	O
a	O
marker	O
for	O
T-derived	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
,	O
was	O
not	O
significantly	O
different	O
in	O
serum-free	O
medium	O
.	O

Additionally	O
,	O
mutated	B-protein
Ras	I-protein
can	O
also	O
serve	O
as	O
a	O
primary	O
target	O
for	O
the	O
development	O
of	O
immunotherapy	O
or	O
drug	O
therapy	O
.	O

Here	O
we	O
studied	O
minimal	O
residual	O
disease	O
(	O
MRD	O
)	O
of	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
who	O
have	O
PML/RAR	B-protein
alpha	I-protein
or	O
AML1/ETO	B-protein
as	O
well	O
as	O
the	O
phenotypic	O
analysis	O
of	O
lymphocyte	B-cell_type
subsets	I-cell_type
involved	O
in	O
antitumor	O
immunity	O
.	O

These	O
results	O
show	O
that	O
NH2Cl	O
inhibits	O
PKC	B-protein
-mediated	O
cellular	O
responses	O
through	O
inhibition	O
of	O
the	O
inducible	O
PKC	B-protein
activity	O
.	O

Although	O
NAC	O
reduced	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activation	O
in	O
EC	B-cell_type
as	O
measured	O
by	O
gel-shift	O
assays	O
using	O
an	O
oligonucleotide	B-DNA
probe	I-DNA
corresponding	O
to	O
the	O
consensus	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
of	O
the	O
VCAM-1	B-DNA
gene	I-DNA
(	O
VCAM-NF-kappa	B-protein
B	I-protein
)	O
,	O
the	O
antioxidant	O
had	O
no	O
appreciable	O
effect	O
when	O
an	O
oligomer	O
corresponding	O
to	O
the	O
consensus	B-DNA
NF-kappa	I-DNA
B	I-DNA
binding	I-DNA
site	I-DNA
of	O
the	O
E-selectin	B-DNA
gene	I-DNA
(	O
E-selectin	B-protein
-NF-kappa	B-protein
B	I-protein
)	O
was	O
used	O
.	O

In	O
contrast	O
,	O
semiquantitative	O
RT-PCR	O
analysis	O
of	O
RNA	O
from	O
reticulocytes	B-cell_type
of	O
the	O
same	O
chimeric	O
animals	O
suggested	O
that	O
the	O
ES	B-cell_type
cell-derived	I-cell_type
reticulocytes	I-cell_type
were	O
present	O
at	O
a	O
level	O
of	O
6	O
%	O
to	O
8	O
%	O
.	O

Flavonoids	O
are	O
a	O
group	O
of	O
naturally-occurring	O
phenolic	O
compounds	O
in	O
the	O
plant	O
kingdom	O
,	O
and	O
many	O
flavonoids	O
are	O
found	O
with	O
vascular	O
protective	O
properties	O
.	O

In	O
particular	O
,	O
Western	O
,	O
supershift	O
,	O
and	O
promoter	O
deletion	O
analyses	O
suggested	O
a	O
role	O
for	O
CCAAT/enhancer-binding	B-DNA
protein-beta	I-DNA
(	I-DNA
C/EBP-beta	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
between	O
-2010	B-DNA
and	I-DNA
-1954	I-DNA
in	O
regulating	O
transcription	O
of	O
collagenase-1	B-protein
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
supernatant	O
from	O
activated	B-cell_type
T-lymphocytes	I-cell_type
is	O
able	O
to	O
induce	O
the	O
transcription	O
of	O
a	O
potent	O
cytokine	B-protein
,	O
TGF-beta	B-protein
2	I-protein
in	O
glial	B-cell_type
cells	I-cell_type
.	O

Nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
,	O
a	O
mediator	O
of	O
lipopolysaccharide	O
effects	O
.	O

The	O
base	O
exchange	O
at	O
-509	O
(	O
from	O
the	O
transcription	O
initiation	O
site	O
)	O
in	O
the	O
TGF-beta	B-DNA
promoter	I-DNA
also	O
linked	O
to	O
elevated	O
total	O
IgE	B-protein
(	O
p	O
<	O
0.01	O
)	O
.	O

Coupling	O
of	O
the	O
upstream	B-DNA
beta	I-DNA
globin	I-DNA
sequence	I-DNA
from	O
approximately	O
-500	O
to	O
-250	O
bp	O
to	O
the	O
truncated	O
delta	B-DNA
promoter	I-DNA
fragment	O
led	O
to	O
complete	O
extinction	O
of	O
transcription	O
activity	O
,	O
consistent	O
with	O
a	O
negative	O
regulatory	O
effect	O
of	O
the	O
beta	B-DNA
globin	I-DNA
gene	I-DNA
upstream	I-DNA
element	I-DNA
(	O
s	O
)	O
.	O

Acute	O
megakaryoblastic	O
leukemia	O
(	O
AML-M7	O
)	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
's	O
syndrome	O
(	O
TMD	O
)	O
are	O
characterized	O
by	O
rapid	O
growth	O
of	O
abnormal	B-cell_type
blast	I-cell_type
cells	I-cell_type
which	O
express	O
megakaryocytic	B-protein
markers	I-protein
.	O

These	O
results	O
suggest	O
that	O
the	O
temporal	O
control	O
of	O
c-Jun	B-protein
and	O
c-Fos	B-protein
may	O
be	O
regulated	O
through	O
the	O
ubiquitinylation	O
pathways	O
,	O
and	O
the	O
ubiquitinylation	O
of	O
c-Jun	B-protein
and	O
c-Fos	B-protein
may	O
in	O
turn	O
be	O
regulated	O
in	O
response	O
to	O
the	O
heterodimerization	O
between	O
them	O
and	O
the	O
cooperation	O
between	O
E220K	B-protein
and	O
E3	O
mediated	O
polyubiquitinylation	O
.	O

In	O
three	O
unrelated	O
Japanese	O
children	O
with	O
combined	O
pituitary	O
hormone	O
deficiency	O
,	O
we	O
identified	O
three	O
point	O
mutations	O
in	O
the	O
Pit-1	B-DNA
gene	I-DNA
,	O
Pro24Leu	B-DNA
,	O
Arg143Gln	B-DNA
,	O
and	O
Arg271Trp	B-DNA
,	O
located	O
on	O
the	O
major	B-DNA
transactivation	I-DNA
region	I-DNA
,	O
POU-specific	B-DNA
domain	I-DNA
,	O
and	O
POU-homeodomain	B-DNA
,	O
respectively	O
.	O

Interleukin-2	O
(	O
IL-2	B-protein
)	O
promoter	O
activity	O
stimulated	O
by	O
cross-linking	O
of	O
CD2	B-protein
,	O
TCR	B-protein
/CD3	O
,	O
and	O
CD28	B-protein
with	O
antibodies	B-protein
was	O
significantly	O
reduced	O
by	O
transient	O
expression	O
of	O
an	O
Itk	B-protein
mutant	I-protein
lacking	O
the	O
kinase	O
activity	O
.	O

We	O
show	O
that	O
in	O
B-lymphocyte	B-cell_type
precursors	I-cell_type
,	O
irradiation	O
with	O
gamma-rays	O
leads	O
to	O
(	O
i	O
)	O
stimulation	O
of	O
phosphatidylinositol	O
turnover	O
;	O
(	O
ii	O
)	O
downstream	O
activation	O
by	O
covalent	O
modification	O
of	O
multiple	O
serine-specific	B-protein
protein	I-protein
kinases	I-protein
,	O
including	O
protein	B-protein
kinase	I-protein
C	I-protein
;	O
and	O
(	O
iii	O
)	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
.	O

Bcl-2	B-protein
-mediated	O
drug	O
resistance	O
:	O
inhibition	O
of	O
apoptosis	O
by	O
blocking	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
lymphocytes	I-protein
(	O
NFAT	B-protein
)	O
-induced	O
Fas	B-protein
ligand	O
transcription	O
.	O

Western	O
blot	O
analysis	O
of	O
nuclear	O
extracts	O
showed	O
that	O
the	O
impaired	O
DNA-protein	O
interactions	O
in	O
anergic	B-cell_line
T	I-cell_line
cells	I-cell_line
were	O
associated	O
with	O
poor	O
expression	O
of	O
the	O
inducible	O
AP-1	B-protein
family	O
members	O
c-Fos	B-protein
,	O
FosB	B-protein
,	O
and	O
JunB	B-protein
.	O

Inhibition	O
of	O
HIV-1	O
replication	O
by	O
combination	O
of	O
a	O
novel	O
inhibitor	O
of	O
TNF-alpha	B-protein
with	O
AZT	O
.	O

BACKGROUND	O
:	O
A	O
delicate	O
balance	O
between	O
positive	O
and	O
negative	O
regulatory	O
mechanisms	O
during	O
T-cell	O
activation	O
determines	O
the	O
specificity	O
and	O
magnitude	O
of	O
an	O
immune	O
response	O
.	O

The	O
local	O
cellular	O
immune	O
response	O
to	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
is	O
important	O
in	O
the	O
control	O
of	O
recurrent	O
HSV	O
infection	O
.	O

The	O
organized	O
structure	O
of	O
the	O
secondary	O
lymphoid	O
tissues	O
is	O
thought	O
to	O
enhance	O
the	O
sensitivity	O
of	O
antigen	O
recognition	O
and	O
to	O
support	O
proper	O
regulation	O
of	O
the	O
activation	O
and	O
maturation	O
of	O
the	O
antigen-responsive	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

The	O
effects	O
of	O
GDSP	O
on	O
pancreatic	O
weight	O
,	O
serum	B-protein
amylase	I-protein
and	I-protein
lipase	I-protein
,	O
morphologic	O
changes	O
in	O
the	O
pancreas	O
,	O
neutrophil	O
infiltration	O
,	O
and	O
nuclear	B-protein
factor	I-protein
KB	I-protein
(	O
NF-KB	B-protein
)	O
activation	O
were	O
measured	O
in	O
rats	O
infused	O
with	O
supramaximal	O
dose	O
of	O
cerulein	O
(	O
5	O
(	O
g/kg/h	O
)	O
for	O
6	O
h	O
.	O

TCF-1	B-RNA
mRNA	I-RNA
was	O
originally	O
found	O
to	O
be	O
expressed	O
in	O
a	O
T	O
cell-specific	O
fashion	O
within	O
a	O
set	O
of	O
human	B-cell_line
and	I-cell_line
mouse	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

RESULTS	O
:	O
With	O
the	O
exception	O
of	O
indomethacin	O
,	O
the	O
used	O
immunosuppressive	O
and	O
anti-inflammatory	O
agents	O
significantly	O
inhibited	O
T	O
cell	O
proliferation	O
in	O
response	O
to	O
influenza	B-protein
virus	I-protein
antigen	I-protein
in	O
a	O
dose-dependent	O
manner	O
.	O

Having	O
previously	O
shown	O
that	O
Ca	O
(	O
2+	O
)	O
-	O
and	O
PKC-dependent	O
pathways	O
synergize	O
by	O
accelerating	O
the	O
degradation	O
of	O
IkB	B-protein
alpha	I-protein
,	O
we	O
focused	O
on	O
the	O
regulation	O
of	O
IkB	B-protein
alpha	I-protein
phosphorylation	O
.	O

Critical	O
role	O
for	O
IL-6	B-protein
.	O

A	O
differentiation-associated	O
pattern	O
of	O
BZLF1	B-protein
expression	O
was	O
observed	O
,	O
BZ1	B-protein
reacting	O
with	O
nuclei	O
of	O
the	O
upper	O
spinous	O
layer	O
of	O
the	O
lesion	O
.	O

Here	O
,	O
we	O
tested	O
whether	O
the	O
potency	O
of	O
one	O
class	O
of	O
compounds	O
,	O
20-epi	O
analogues	O
,	O
to	O
induce	O
myeloid	O
cell	O
differentiation	O
,	O
is	O
because	O
of	O
direct	O
molecular	O
effects	O
on	O
vitamin	B-protein
D	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
.	O

A	O
mAb	B-protein
,	O
R24	B-protein
,	O
that	O
reacts	O
specifically	O
with	O
a	O
cell	O
surface	O
ganglioside	O
(	O
GD3	O
)	O
has	O
been	O
demonstrated	O
to	O
stimulate	O
proliferation	O
of	O
T	B-cell_type
cells	I-cell_type
derived	O
from	O
human	O
peripheral	O
blood	O
.	O

Thus	O
,	O
cells	O
with	O
the	O
properties	O
of	O
both	O
macrophages	B-cell_type
and	O
DC	B-cell_type
can	O
be	O
derived	O
from	O
a	O
single	O
type	O
of	O
GM-CSF-responsive	B-cell_type
progenitor	I-cell_type
cell	I-cell_type
.	O

Similarities	O
between	O
the	O
effects	O
of	O
dexamethasone	O
and	O
RU486	O
suggest	O
that	O
the	O
antiglucocorticoid	O
properties	O
of	O
RU486	O
do	O
not	O
occur	O
at	O
the	O
level	O
of	O
specific	O
DNA	O
binding	O
.	O

In	O
addition	O
,	O
AR	B-protein
are	O
not	O
detectable	O
on	O
the	O
surface	O
of	O
intact	B-cell_type
T	I-cell_type
cells	I-cell_type
when	O
using	O
anti-AR	B-protein
antibodies	I-protein
directed	O
against	O
the	O
amino	B-protein
and	I-protein
carboxy	I-protein
terminus	I-protein
of	O
the	O
AR	B-protein
,	O
although	O
T	B-cell_type
cells	I-cell_type
contain	O
AR	B-protein
,	O
as	O
revealed	O
by	O
reverse	O
transcription-polymerase	O
chain	O
reactions	O
and	O
Western	O
blotting	O
.	O

Interestingly	O
,	O
an	O
enhanced	O
frequency	O
of	O
CD16	B-protein
and	O
CD68	O
(	O
+	O
)	O
cells	O
among	O
the	O
CD14	O
(	O
+	O
)	O
cells	O
was	O
observed	O
in	O
the	O
presence	O
of	O
IL-10	B-protein
,	O
independently	O
of	O
the	O
pre-culture	O
conditions	O
of	O
the	O
PBMC	B-cell_type
.	O

Here	O
,	O
we	O
have	O
characterized	O
the	O
structural	O
and	O
cell-specific	O
requirements	O
for	O
this	O
c-Jun	B-protein
inhibitory	O
response	O
,	O
and	O
we	O
show	O
that	O
this	O
c-Jun	B-protein
inhibitory	O
response	O
mapped	O
to	O
the	O
rPRL	B-DNA
footprint	I-DNA
II	I-DNA
repressor	I-DNA
site	I-DNA
,	O
was	O
pituitary-specific	O
and	O
required	O
the	O
c-Jun	B-protein
delta-domain	I-protein
.	O

The	O
distribution	O
of	O
immunoglobulin	O
M	O
(	O
IgM	O
)	O
-	O
,	O
IgD-	O
,	O
and	O
IgG-positive	O
cells	O
and	O
the	O
expression	O
patterns	O
of	O
Ki-67	O
,	O
CD23	O
,	O
or	O
bcl-2	O
and	O
bcl-6	O
gene	O
products	O
in	O
the	O
follicles	O
with	O
GC	O
formation	O
in	O
the	O
liver	O
of	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
were	O
similar	O
to	O
those	O
of	O
lymph	O
nodes	O
,	O
indicating	O
that	O
B	B-cell_type
cells	I-cell_type
are	O
activated	O
,	O
proliferated	O
,	O
and	O
differentiated	O
in	O
the	O
ILFs	O
with	O
GC	O
formation	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
.	O

The	O
two	O
isozymes	B-protein
show	O
little	O
amino	O
acid	O
identity	O
in	O
their	O
N-terminal	B-protein
signal	I-protein
sequences	I-protein
but	O
have	O
considerable	O
sequence	O
identity	O
in	O
the	O
C-terminal	B-protein
two-thirds	I-protein
of	O
their	O
proteins	O
.	O

RESULTS	O
:	O
Cord	O
lymphocytes	O
revealed	O
a	O
greater	O
proliferation	O
rate	O
with	O
PHA	B-protein
and	O
alphaCD3	B-protein
than	O
adult	O
lymphocytes	O
(	O
p	O
=	O
0.0081	O
and	O
0.0023	O
,	O
respectively	O
)	O
.	O

Treatment	O
of	O
HL-60	B-cell_line
eosinophilic	I-cell_line
sublines	I-cell_line
with	O
either	O
interleukin-5	B-protein
or	O
butyric	O
acid	O
increased	O
the	O
expression	O
of	O
GATA-1	B-RNA
mRNA	I-RNA
concomitant	O
with	O
the	O
expression	O
of	O
eosinophil-specific	B-DNA
genes	I-DNA
,	O
whereas	O
levels	O
of	O
GATA-2	B-RNA
mRNA	I-RNA
remained	O
relatively	O
constant	O
.	O

This	O
implicates	O
that	O
the	O
SRG3	B-DNA
may	O
play	O
an	O
important	O
regulatory	O
role	O
during	O
T	O
cell	O
development	O
in	O
thymus	O
.	O

Because	O
the	O
translation	O
rate	O
is	O
an	O
important	O
determinant	O
of	O
cell	O
proliferation	O
,	O
we	O
have	O
investigated	O
translation	O
initiation	O
during	O
human	B-cell_type
myeloid	I-cell_type
cell	I-cell_type
differentiation	O
using	O
the	O
HL-60	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
and	O
the	O
U-937	B-cell_line
monoblastic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Furthermore	O
,	O
we	O
did	O
not	O
observe	O
any	O
qualitative	O
differences	O
between	O
the	O
effect	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
on	O
six	O
different	O
transcription	B-protein
factors	I-protein
which	O
suggests	O
that	O
these	O
drugs	O
may	O
interfere	O
with	O
the	O
activity	O
of	O
a	O
novel	O
Ca2+	O
dependent	O
step	O
that	O
regulates	O
several	O
transcription	B-protein
factors	I-protein
.	O

Since	O
the	O
okadaic	O
acid	O
,	O
a	O
potent	O
protein	O
phosphatase	O
inhibitor	O
,	O
prolongs	O
the	O
induction	O
of	O
the	O
binding	O
activity	O
,	O
phosphorylation	O
events	O
are	O
likely	O
to	O
occur	O
.	O

We	O
now	O
show	O
that	O
this	O
differential	O
rescue	O
by	O
specific	O
cytokines	B-protein
in	O
Th	B-cell_type
cells	I-cell_type
correlates	O
with	O
the	O
level	O
of	O
IkappaBalpha	B-protein
that	O
is	O
regulated	O
by	O
DEX	O
and	O
cytokines	B-protein
.	O

Positive	O
regulators	O
of	O
the	O
lineage-specific	O
transcription	B-protein
factor	I-protein
GATA-1	B-protein
in	O
differentiating	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
.	O

Human	O
T-cell	O
leukemia	O
virus	O
types	O
I	O
(	O
HTLV-I	O
)	O
and	O
II	O
(	O
HTLV-II	O
)	O
have	O
two	O
nonstructural	B-DNA
trans-acting	I-DNA
regulatory	I-DNA
genes	I-DNA
,	O
tax	B-DNA
and	O
rex	B-DNA
,	O
located	O
in	O
the	O
3	B-DNA
'	I-DNA
region	I-DNA
of	O
the	O
viral	B-DNA
genome	I-DNA
.	O

The	O
treatment	O
of	O
human	B-cell_type
tonsillar	I-cell_type
T-lymphocytes	I-cell_type
with	O
4-phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
resulted	O
in	O
about	O
two	O
fold	O
increase	O
in	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
number	O
,	O
without	O
any	O
significant	O
change	O
in	O
the	O
receptor	O
affinity	O
.	O

We	O
can	O
now	O
study	O
regulatory	O
regions	O
and	O
functional	O
domains	O
of	O
the	O
protein	O
in	O
the	O
context	O
of	O
a	O
true	O
erythroid	O
environment	O
,	O
experiments	O
that	O
have	O
not	O
been	O
possible	O
heretofore	O
.	O

In	O
the	O
second	O
approach	O
,	O
we	O
tested	O
the	O
generality	O
of	O
this	O
phenomenon	O
by	O
transiently	O
expressing	O
LMP1	B-protein
from	O
a	O
strong	O
constitutively	O
active	O
promoter	O
in	O
a	O
range	O
of	O
different	O
cell	O
types	O
.	O

In	O
RAW264.7	B-cell_line
cells	I-cell_line
,	O
the	O
binding	O
was	O
constitutive	O
,	O
however	O
,	O
in	O
bone	B-cell_line
marrow-derived	I-cell_line
macrophages	I-cell_line
binding	O
activity	O
was	O
shown	O
to	O
be	O
interferon-gamma	B-protein
inducible	O
.	O

In	O
addition	O
,	O
the	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
partially	O
suppressed	O
.	O

Phosphorylation	O
and	O
degradation	O
of	O
the	O
cytoplasmic	B-protein
inhibitor	I-protein
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
are	O
crucial	O
regulatory	O
events	O
in	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
DNA-binding	O
activity	O
.	O

Furthermore	O
,	O
NF-kappaB	B-protein
transcriptional	I-protein
factor	I-protein
of	O
aggregated	O
cells	O
had	O
approximately	O
40-fold	O
higher	O
activity	O
than	O
that	O
of	O
parental	B-cell_type
cells	I-cell_type
.	O

However	O
,	O
stimulation	O
with	O
IL-2	B-protein
resulted	O
in	O
Jak3	B-protein
and	O
STAT5	B-protein
phosphorylation	O
in	O
both	O
leukemic	B-cell_type
ATLL	I-cell_type
cells	I-cell_type
and	O
IL-2-dependent	B-cell_line
lines	I-cell_line
.	O

To	O
clarify	O
the	O
presence	O
of	O
histamine	B-protein
receptor	I-protein
and	O
its	O
transmembrane	O
mechanism	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
we	O
investigated	O
the	O
effects	O
of	O
agonists	O
or	O
antagonists	O
of	O
histamine	B-protein
receptor	I-protein
subtypes	O
and	O
bacterial	O
toxins	O
on	O
intracellular	O
concentration	O
of	O
Ca2+	O
[	O
Ca2+	O
]	O
i	O
)	O
,	O
[	O
3H	O
]	O
pyrilamine	O
binding	O
and	O
c-fos	B-RNA
mRNA	I-RNA
expression	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
cloned	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

These	O
findings	O
suggest	O
that	O
Zp	B-DNA
responds	O
directly	O
to	O
changes	O
in	O
the	O
activity	O
of	O
both	O
PKC	B-protein
and	O
calcium/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
.	O

These	O
results	O
indicate	O
that	O
DNA	O
binding	O
by	O
VDR	B-protein
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
mediate	O
IL-2	B-protein
repression	O
.	O

These	O
analyses	O
demonstrated	O
that	O
the	O
[	O
3H	O
]	O
aldosterone-	O
MBP-HBD	B-protein
complex	I-protein
is	O
at	O
least	O
associated	O
with	O
hsp90	B-protein
in	O
reticulocyte	O
lysate	O
and	O
that	O
the	O
HBD	B-protein
of	O
hMR	B-protein
is	O
sufficient	O
to	O
bind	O
hsp90	B-protein
.	O

We	O
report	O
the	O
characterization	O
of	O
the	O
cis-	B-DNA
and	I-DNA
trans-acting	I-DNA
elements	I-DNA
involved	O
in	O
the	O
tissue-specific	O
activity	O
of	O
the	O
L	B-DNA
gene	I-DNA
erythroid	I-DNA
promoter	I-DNA
.	O

Chemoattractants	O
stimulate	O
the	O
expression	O
of	O
several	O
inflammatory	B-protein
cytokines	I-protein
and	O
chemokines	B-protein
,	O
which	O
in	O
turn	O
may	O
activate	O
their	O
respective	O
receptors	O
and	O
initiate	O
an	O
autocrine	O
regulatory	O
mechanism	O
for	O
persistent	O
cytokine	B-protein
and	O
chemokine	B-protein
gene	O
expression	O
.	O

The	O
human	B-DNA
CD19	I-DNA
gene	I-DNA
has	O
been	O
cloned	O
,	O
and	O
several	O
BSAP-binding	B-DNA
sites	I-DNA
have	O
been	O
mapped	O
by	O
in	O
vitro	O
protein-DNA	O
binding	O
studies	O
.	O

Base-pair	O
substitutions	O
in	O
the	O
TF	B-DNA
site	I-DNA
indicated	O
that	O
the	O
presence	O
of	O
a	O
cytosine	O
at	O
position	B-protein
1	I-protein
precluded	O
binding	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

Glucocorticoids	O
are	O
well	O
known	O
for	O
their	O
effects	O
on	O
the	O
vitality	O
and	O
function	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

However	O
,	O
a	O
physical	O
interaction	O
between	O
calcineurin	B-protein
and	O
NFATp	B-protein
has	O
not	O
been	O
demonstrated	O
.	O

However	O
,	O
inhibition	O
of	O
protein	O
synthesis	O
with	O
cycloheximide	O
anytime	O
during	O
the	O
first	O
18	O
h	O
of	O
steroid	O
treatment	O
was	O
as	O
effective	O
in	O
blocking	O
chromatin	O
fragmentation	O
as	O
inhibition	O
for	O
the	O
entire	O
period	O
,	O
suggesting	O
that	O
synthesis	O
of	O
a	O
component	O
with	O
a	O
rapid	O
turnover	O
rate	O
is	O
required	O
.	O

MIP-1	B-protein
alpha	I-protein
is	O
a	O
secreted	O
chemokine	B-protein
which	O
can	O
inhibit	O
hematopoietic	B-cell_type
stem	I-cell_type
cells	I-cell_type
and	O
modulate	O
inflammatory	O
responses	O
.	O

The	O
activation	O
is	O
rapid	O
and	O
transient	O
and	O
is	O
mediated	O
through	O
a	O
cyclosporin	O
A-insensitive	O
pathway	O
.	O

We	O
further	O
show	O
that	O
Nmi	B-protein
interacts	O
with	O
all	O
STATs	B-protein
except	O
Stat2	B-protein
.	O

Transient	O
tranfection	O
of	O
a	O
promyelocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
NB4	B-cell_line
)	O
with	O
a	O
C/EBP-epsilon	B-DNA
expression	I-DNA
plasmid	I-DNA
increased	O
cell	O
growth	O
by	O
sevenfold	O
,	O
while	O
antisense	O
C/EBP-epsilon	B-protein
caused	O
a	O
fivefold	O
decrease	O
in	O
clonal	O
growth	O
of	O
these	O
cells	O
.	O

EBNA2	B-protein
-dependent	O
transcriptional	O
induction	O
of	O
the	O
IFN-beta	B-DNA
promoter	I-DNA
occurred	O
in	O
EBV-negative	B-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
,	O
indicating	O
that	O
other	O
EBV	B-DNA
genes	I-DNA
were	O
not	O
required	O
for	O
the	O
induction	O
of	O
IFN-beta	B-protein
synthesis	O
.	O

Spi-B	B-protein
and	O
PU.1	B-protein
are	O
hematopoietic-specific	B-protein
transcription	I-protein
factors	I-protein
that	O
constitute	O
a	O
subfamily	O
of	O
the	O
Ets	B-protein
family	I-protein
of	O
DNA-binding	B-protein
proteins	I-protein
.	O

AG-490	O
also	O
inhibited	O
IL-2	B-protein
-mediated	O
proliferative	O
growth	O
in	O
human	O
T	B-cell_type
cells	I-cell_type
with	O
an	O
IC50	O
)	O
=	O
25	O
microM	O
that	O
was	O
partially	O
recoverable	O
.	O

Here	O
we	O
report	O
that	O
the	O
type	B-protein
II	I-protein
IL-1R	I-protein
does	O
not	O
mediate	O
gene	O
activation	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Involvement	O
of	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
pathways	O
in	O
interleukin-8	B-protein
production	O
by	O
human	B-cell_type
monocytes	I-cell_type
and	O
polymorphonuclear	B-cell_type
cells	I-cell_type
stimulated	O
with	O
lipopolysaccharide	O
or	O
Mycoplasma	B-protein
fermentans	I-protein
membrane	I-protein
lipoproteins	I-protein
.	O

Our	O
results	O
emphasize	O
the	O
multiple	O
levels	O
at	O
which	O
NFAT-dependent	O
transactivation	O
is	O
regulated	O
,	O
and	O
predict	O
significant	O
differences	O
in	O
the	O
architecture	O
of	O
cooperative	O
transcription	B-protein
complexes	I-protein
containing	O
different	O
NFAT-family	B-protein
proteins	I-protein
.	O

Two	O
of	O
these	O
regions	O
,	O
BR3	B-DNA
and	O
BR4	B-DNA
located	O
at	O
positions	O
-102	O
to	O
-73	O
,	O
have	O
not	O
previously	O
been	O
described	O
as	O
regulators	O
of	O
IL-5	B-protein
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Further	O
characterization	O
of	O
gelatinase	O
granules	O
has	O
been	O
hampered	O
by	O
poor	O
separation	O
of	O
specific	O
and	O
gelatinase	O
granules	O
on	O
both	O
two-layer	O
Percoll	O
gradients	O
and	O
sucrose	O
gradients	O
.	O

Altogether	O
,	O
the	O
CD4	B-DNA
gene	I-DNA
is	O
regulated	O
by	O
several	O
positive	O
and	O
negative	O
regulatory	O
mechanisms	O
which	O
come	O
into	O
play	O
in	O
a	O
developmentally	O
coordinated	O
manner	O
.	O

TCF-1	B-protein
alpha	I-protein
is	O
currently	O
unique	O
among	O
the	O
newly	O
emerging	O
family	O
of	O
DNA-binding	B-protein
regulatory	I-protein
proteins	I-protein
that	O
share	O
the	O
HMG	B-protein
motif	I-protein
in	O
that	O
it	O
is	O
a	O
highly	B-protein
tissue-specific	I-protein
RNA	I-protein
polymerase	I-protein
II	I-protein
transcription	B-protein
factor	I-protein
.	O

Immunoblot	O
analysis	O
and	O
immunoperoxidase	O
staining	O
of	O
infected	O
cell	O
monolayers	O
demonstrated	O
vector	O
expression	O
of	O
VZV	B-protein
proteins	I-protein
.	O

We	O
have	O
cloned	O
a	O
group	O
of	O
cDNAs	B-DNA
representing	O
mRNAs	B-RNA
that	O
are	O
rapidly	O
induced	O
following	O
adherence	O
of	O
human	B-cell_type
monocytes	I-cell_type
.	O

In	O
order	O
to	O
determine	O
the	O
cis-acting	B-DNA
elements	I-DNA
necessary	O
for	O
both	O
basal	O
and	O
phorbol	O
12-myristate-13	O
acetate	O
(	O
PMA	O
)	O
-enhanced	O
promoter	O
activity	O
,	O
we	O
performed	O
deletion	O
analysis	O
and	O
reporter	B-DNA
gene	I-DNA
assays	O
.	O

In	O
this	O
report	O
we	O
show	O
induction	O
of	O
MNP-1	B-protein
in	O
Jurkat	B-cell_line
T-cells	I-cell_line
expressing	O
HIV-1	B-protein
tat	I-protein
.	O

The	O
involvement	O
of	O
p23	B-protein
,	O
hsp90	B-protein
,	O
and	O
immunophilins	B-protein
in	O
the	O
assembly	O
of	O
progesterone	B-protein
receptor	I-protein
complexes	I-protein
.	O

Crkl	B-protein
,	O
an	O
SH2/SH3	B-protein
adapter	I-protein
protein	I-protein
,	O
becomes	O
coimmunoprecipitated	O
specifically	O
with	O
STAT5	B-protein
from	O
erythropoietin-stimulated	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
;	O
although	O
it	O
was	O
shown	O
to	O
become	O
associated	O
with	O
c-Cbl	B-protein
in	O
the	O
studies	O
using	O
cell	B-cell_line
lines	I-cell_line
.	O

Synergistic	O
induction	O
of	O
the	O
IL-6	B-DNA
gene	I-DNA
by	O
IFN-gamma	B-protein
and	O
TNF-alpha	B-protein
,	O
in	O
monocytic	B-cell_type
cells	I-cell_type
,	O
involved	O
cooperation	O
between	O
the	O
IRF-1	B-protein
and	O
NF	B-protein
kappa	I-protein
B	I-protein
p65	I-protein
homodimers	I-protein
with	O
concomitant	O
removal	O
of	O
the	O
negative	O
effect	O
of	O
the	O
retinoblastoma	B-DNA
control	I-DNA
element	I-DNA
present	O
in	O
the	O
IL-6	B-DNA
promoter	I-DNA
.	O

GA-binding	B-protein
protein	I-protein
factors	I-protein
,	O
in	O
concert	O
with	O
the	O
coactivator	B-protein
CREB	I-protein
binding	I-protein
protein/p300	I-protein
,	O
control	O
the	O
induction	O
of	O
the	O
interleukin	B-DNA
16	I-DNA
promoter	I-DNA
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

These	O
data	O
provide	O
further	O
information	O
on	O
the	O
molecular	O
events	O
occurring	O
in	O
immune	B-cell_type
cells	I-cell_type
generated	O
through	O
in	O
vivo	O
and	O
in	O
vitro	O
administration	O
of	O
IL-2	B-protein
,	O
and	O
further	O
document	O
that	O
there	O
is	O
not	O
a	O
precise	O
congruence	O
between	O
PBMC	B-cell_type
activated	O
in	O
vivo	O
and	O
in	O
vitro	O
by	O
IL-2	B-protein
.	O

Measurement	O
of	O
the	O
transcriptional	O
activity	O
of	O
the	O
HIV-1	B-DNA
promoter	I-DNA
after	O
transient	O
transfection	O
of	O
the	O
HIV-1	B-DNA
provirus	I-DNA
DNA	I-DNA
or	O
of	O
long	B-DNA
terminal	I-DNA
repeat-luciferase	I-DNA
constructs	I-DNA
showed	O
a	O
positive	O
correlation	O
between	O
the	O
transcriptional	O
and	O
the	O
replication	O
defects	O
for	O
most	O
mutants	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
signaling	O
pathway	O
from	O
Fc	B-protein
receptors	I-protein
leading	O
to	O
expression	O
of	O
different	O
genes	O
important	O
to	O
leukocyte	O
biology	O
,	O
initiates	O
with	O
tyrosine	B-protein
kinases	I-protein
and	O
requires	O
MAPK	B-protein
activation	O
;	O
but	O
in	O
contrast	O
to	O
other	O
tyrosine	B-protein
kinase	I-protein
receptors	I-protein
,	O
FcR	B-protein
-mediated	O
MAPK	B-protein
activation	O
does	O
not	O
involve	O
Ras	B-protein
and	O
Raf	B-protein
.	O

Analysis	O
of	O
truncated	O
LTRs	B-DNA
confirmed	O
that	O
inhibition	O
of	O
LTR	B-DNA
activation	O
was	O
not	O
mediated	O
through	O
NF-kappa	B-protein
B	I-protein
-binding	O
activity	O
but	O
through	O
the	O
region	O
containing	O
the	O
negative	B-DNA
responding	I-DNA
elements	I-DNA
(	O
NREs	B-DNA
)	O
.	O

Induction	O
of	O
NF-MATp35	B-protein
was	O
shown	O
to	O
depend	O
on	O
de	O
novo	O
protein	O
synthesis	O
and	O
was	O
restricted	O
to	O
T	B-cell_type
cells	I-cell_type
that	O
received	O
a	O
mitogenic	O
combination	O
of	O
T	O
cell	O
stimuli	O
,	O
not	O
necessarily	O
including	O
CD28	B-protein
signaling	O
.	O

E2F-1	B-protein
expression	O
in	O
megakaryocytes	B-cell_type
blocked	O
differentiation	O
during	O
maturation	O
,	O
resulting	O
in	O
severe	O
thrombocytopenia	O
.	O

METHODS	O
:	O
E.	O
histolytica	O
infection	O
was	O
established	O
in	O
human	O
intestinal	O
xenografts	O
in	O
severe	O
combined	O
immunodeficient	O
(	O
SCID-HU-INT	O
)	O
mice	O
.	O

Phosphorylation	O
of	O
the	O
IkappaB	B-protein
cytoplasmic	I-protein
inhibitors	I-protein
,	O
IkappaBalpha	B-protein
,	O
IkappaBbeta	B-protein
,	O
and	O
IkappaBepsilon	B-protein
,	O
by	O
these	O
kinases	O
triggers	O
proteolytic	O
degradation	O
and	O
the	O
release	O
of	O
NF-kappaB/Rel	B-protein
proteins	I-protein
into	O
the	O
nucleus	O
.	O

Therefore	O
,	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
may	O
be	O
an	O
effective	O
strategy	O
for	O
acquired	O
immunodeficiency	O
syndrome	O
therapy	O
.	O

Nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells-family	I-protein
proteins	I-protein
(	O
NFAT1/NFATp	B-protein
,	O
NFATc	B-protein
,	O
NFAT3	B-protein
,	O
and	O
NFAT4/NFATx/NFATc3	B-protein
)	O
play	O
a	O
key	O
role	O
in	O
the	O
transcription	O
of	O
cytokine	B-DNA
genes	I-DNA
and	O
other	O
genes	O
during	O
the	O
immune	O
response	O
.	O

In	O
an	O
analysis	O
of	O
the	O
molecular	O
mechanism	O
by	O
which	O
IL-2	B-protein
message	O
was	O
generated	O
,	O
we	O
showed	O
that	O
a	O
fibronectin	B-protein
-VLA-5	O
fibronectin	B-protein
receptor	I-protein
interaction	O
may	O
contribute	O
an	O
independent	O
signal	O
distinct	O
from	O
the	O
CD3	B-protein
pathway	O
of	O
activation	O
by	O
the	O
induction	O
of	O
an	O
AP-1	B-protein
transcriptional	I-protein
factor	I-protein
.	O

However	O
,	O
anti-	O
CD45	B-protein
antibodies	O
inhibit	O
these	O
effects	O
in	O
cells	O
from	O
infected	O
individuals	O
.	O

YT-N17	B-cell_line
contained	O
11.8	O
fmol/mg	O
protein	O
of	O
estrogen	B-protein
receptor	I-protein
(	O
mean	O
of	O
two	O
independent	O
assays	O
)	O
,	O
a	O
value	O
which	O
was	O
5-10-fold	O
higher	O
than	O
that	O
of	O
other	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Membrane-associated	B-protein
lymphotoxin	I-protein
on	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
activates	O
endothelial	B-cell_type
cells	I-cell_type
via	O
an	O
NF-kappaB	B-protein
-dependent	O
pathway	O
.	O

The	O
transendothelial	O
migration	O
of	O
monocytes	B-cell_type
was	O
inhibited	O
by	O
an	O
antibody	O
to	O
PECAM-1	B-protein
.	O

The	O
clinical	O
benefits	O
of	O
salicylates	O
in	O
the	O
treatment	O
of	O
several	O
diseases	O
,	O
including	O
atherosclerosis	O
and	O
rheumatoid	O
arthritis	O
,	O
may	O
be	O
related	O
to	O
their	O
ability	O
to	O
reduce	O
monocyte	O
gene	O
expression	O
.	O

Human	O
vaginal	O
fluid	O
specimens	O
had	O
comparable	O
properties	O
,	O
which	O
correlated	O
with	O
their	O
bacterial	O
content	O
.	O

Expression	O
of	O
GrpL	B-protein
is	O
restricted	O
to	O
hematopoietic	O
tissues	O
,	O
and	O
it	O
is	O
distinguished	O
from	O
Grb2	B-protein
by	O
having	O
a	O
proline-rich	B-protein
region	I-protein
.	O

An	O
in	O
vitro	O
surrogate	O
of	O
IL-2	B-protein
immunotherapy	O
is	O
the	O
incubation	O
of	O
fresh	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
from	O
healthy	O
individuals	O
in	O
IL-2	B-protein
for	O
several	O
days	O
,	O
resulting	O
in	O
the	O
production	O
of	O
lymphokine	B-protein
-activated	O
killer	O
(	O
LAK	O
)	O
activity	O
in	O
these	O
cultures	O
.	O

In	O
a	O
non-parametric	O
test	O
(	O
Kruskal-Wallis	O
)	O
a	O
strong	O
negative	O
association	O
was	O
found	O
between	O
high	O
levels	O
of	O
c-erbB2	B-DNA
amplification	O
and	O
absence	O
of	O
estrogen	O
receptor	O
(	O
ER	O
)	O
(	O
P	O
=	O
.0009	O
)	O
or	O
progesterone	B-protein
receptor	I-protein
(	O
PR	B-protein
)	O
(	O
P	O
=	O
.011	O
)	O
expression	O
.	O

Mineralocorticoid	O
effector	O
mechanism	O
in	O
preeclampsia	O
.	O

One	O
such	O
example	O
is	O
the	O
excessive	O
expression	O
of	O
``	B-protein
normal	I-protein
''	I-protein
lymphokines	I-protein
of	O
cytokines	B-protein
which	O
accompanies	O
many	O
lymphoproliferative	O
diseases	O
.	O

Effects	O
of	O
overexpression	O
of	O
IL-1	B-protein
receptor-associated	I-protein
kinase	I-protein
on	O
NFkappaB	B-protein
activation	O
,	O
IL-2	B-protein
production	O
and	O
stress-activated	O
protein	O
kinases	O
in	O
the	O
murine	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
EL4	I-cell_line
.	O

In	O
these	O
studies	O
,	O
we	O
have	O
identified	O
DNA	B-DNA
sequences	I-DNA
and	O
specific	O
protein	O
interactions	O
necessary	O
for	O
transcriptional	O
regulation	O
of	O
the	O
human	B-DNA
prointerleukin	I-DNA
1	I-DNA
beta	I-DNA
(	I-DNA
proIL-1	I-DNA
beta	I-DNA
)	I-DNA
gene	I-DNA
.	O

Modulation	O
of	O
normal	O
erythroid	O
differentiation	O
by	O
the	O
endogenous	O
thyroid	O
hormone	O
and	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
:	O
a	O
possible	O
target	O
for	O
v-erbA	B-DNA
oncogene	I-DNA
action	O
.	O

Many	O
of	O
these	O
may	O
be	O
created	O
by	O
alternative	O
splicing	O
of	O
a	O
primary	B-RNA
transcript	I-RNA
of	O
one	O
Oct	O
factor	O
gene	O
and	O
may	O
serve	O
a	O
specific	O
function	O
in	O
the	O
fine	O
tuning	O
of	O
gene	O
expression	O
.	O

Consistent	O
with	O
this	O
result	O
,	O
these	O
cell	O
lines	O
expressed	O
increased	O
levels	O
of	O
mRNAs	B-RNA
encoding	O
the	O
AP-1	B-protein
proteins	I-protein
,	O
c-Fos	B-protein
,	O
Fra-1	B-protein
,	O
c-Jun	B-protein
,	O
JunB	B-protein
,	O
and	O
JunD	B-protein
.	O

Mitogen	O
induction	O
of	O
the	O
electrophoretic	B-protein
mobility	I-protein
shift	I-protein
assay	I-protein
complexes	I-protein
is	O
not	O
accounted	O
for	O
by	O
protein	O
phosphorylation	O
or	O
by	O
induction	O
of	O
CREB	B-protein
.	O

Fos	B-protein
kinase	I-protein
phosphorylates	O
c-Fos	B-protein
at	O
a	O
site	O
near	O
the	O
C-terminus	B-protein
,	O
as	O
well	O
as	O
a	O
peptide	O
derived	O
from	O
this	O
region	O
(	O
residues	B-protein
359-370	I-protein
,	O
RKGSSSNEPSSD	B-protein
)	O
,	O
and	O
Fos	O
peptide	O
competitively	O
inhibited	O
c-Fos	B-protein
phosphorylation	O
.	O

A	O
structure-function	O
analysis	O
demonstrated	O
that	O
induction	O
of	O
apoptosis	O
was	O
not	O
a	O
dominant-negative	O
effect	O
of	O
the	O
E2a	B-protein
moiety	I-protein
but	O
,	O
rather	O
,	O
required	O
the	O
DNA-binding	B-protein
homeodomain	I-protein
of	O
Pbx1	B-protein
.	O

Mutations	O
of	O
the	O
CRE	B-DNA
site	I-DNA
that	O
result	O
in	O
loss	O
of	O
CREB	B-protein
binding	O
also	O
lead	O
to	O
loss	O
of	O
functional	O
activity	O
of	O
the	O
bcl-2	O
promoter	O
in	O
transient-transfection	O
assays	O
.	O

These	O
data	O
are	O
the	O
first	O
to	O
show	O
a	O
connection	O
between	O
FGF-1	B-protein
signaling	O
and	O
NF-kappaB	B-protein
activation	O
outside	O
of	O
embryonic	O
development	O
.	O

Biphasic	O
control	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
induced	O
by	O
the	O
triggering	O
of	O
HLA-DR	B-protein
antigens	I-protein
expressed	O
on	O
B	B-cell_type
cells	I-cell_type
.	O

In	O
parallel	O
,	O
increased	O
levels	O
of	O
transcripts	O
for	O
IP-10	B-protein
,	O
a	O
murine	O
homologue	O
in	O
the	O
chemokine	B-protein
family	I-protein
related	O
to	O
IL-8	B-protein
,	O
were	O
observed	O
in	O
hypoxic	O
lung	O
tissue	O
.	O

ATF1	B-protein
and	O
CREB	B-protein
trans-activate	O
a	O
cell	B-DNA
cycle	I-DNA
regulated	I-DNA
histone	I-DNA
H4	I-DNA
gene	I-DNA
at	O
a	O
distal	B-DNA
nuclear	I-DNA
matrix	I-DNA
associated	I-DNA
promoter	I-DNA
element	I-DNA
.	O

To	O
evaluate	O
the	O
effect	O
of	O
UV	O
light	O
on	O
cytochrome	B-protein
P4501A1	I-protein
gene	O
expression	O
,	O
we	O
studied	O
the	O
induction	O
of	O
CYP1A1	B-RNA
mRNA	I-RNA
by	O
UV	O
irradiation	O
of	O
cultured	B-cell_line
human	I-cell_line
keratinocytes	I-cell_line
(	O
HaCaT	B-cell_line
cell	I-cell_line
line	I-cell_line
)	O
,	O
primary	B-cell_type
human	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
and	O
mouse	B-cell_line
Hepa-1	I-cell_line
cells	I-cell_line
.	O

These	O
data	O
indicate	O
a	O
highly	O
polarized	O
functional	O
architecture	O
for	O
antigen	O
processing	O
and	O
presentation	O
by	O
intestinal	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
,	O
and	O
suggest	O
that	O
the	O
functional	O
outcome	O
of	O
antigen	O
processing	O
by	O
the	O
intestinal	O
epithelium	O
is	O
both	O
dependent	O
on	O
the	O
cellular	O
surface	O
at	O
which	O
the	O
foreign	O
antigen	O
is	O
internalized	O
and	O
by	O
the	O
underlying	O
degree	O
of	O
mucosal	O
inflammation	O

NFAT	B-protein
binding	O
to	O
the	O
calcineurin	B-protein
catalytic	I-protein
domain	I-protein
was	O
inhibited	O
by	O
the	O
calcineurin	B-protein
autoinhibitory	I-protein
domain	I-protein
and	O
the	O
RII	O
substrate	O
peptide	O
,	O
which	O
bind	O
in	O
the	O
calcineurin	B-protein
active	I-protein
site	I-protein
,	O
as	O
well	O
as	O
by	O
the	O
NFAT	B-protein
docking	O
site	O
peptide	O
,	O
which	O
binds	O
to	O
a	O
region	O
of	O
calcineurin	B-protein
distinct	O
from	O
the	O
active	B-protein
site	I-protein
.	O

ras	B-protein
protein	I-protein
activity	O
is	O
essential	O
for	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
signal	O
transduction	O
.	O

Furthermore	O
,	O
transient-cotransfection	O
assay	O
demonstrated	O
that	O
PU.1	B-protein
(	O
and	O
not	O
Elf-1	B-protein
)	O
can	O
transactivate	O
the	O
c-fes	B-DNA
promoter	I-DNA
in	O
nonmyeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Interrelations	O
between	O
the	O
hypothalamic-pituitary-adrenal	O
system	O
(	O
HPA	O
)	O
and	O
the	O
immune	O
system	O
represent	O
a	O
well-documented	O
biological	O
phenomenon	O
.	O

Treatment	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
the	O
selective	O
PKC	B-protein
inhibitor	O
GF109203X	O
abrogates	O
the	O
PMA-induced	O
IkB	B-protein
alpha	I-protein
phosphorylation/degradation	O
irrespective	O
of	O
activation	O
of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
,	O
but	O
not	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IkB	B-protein
alpha	I-protein
induced	O
by	O
TNF-alpha	B-protein
,	O
a	O
PKC	B-protein
-independent	O
stimulus	O
.	O

Immune	O
response	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
to	O
HBx-antigen	B-protein
of	O
hepatitis	O
B	O
virus	O
.	O

Both	O
IL-2	B-protein
and	O
IL-4	B-protein
bind	O
to	O
receptors	O
containing	O
the	O
common	B-protein
gamma	I-protein
chain	I-protein
and	O
JAK3	B-protein
.	O

mNFATc	B-protein
complexed	O
with	O
AP-1	B-protein
bound	O
specifically	O
to	O
the	O
murine	B-protein
IL-2	I-protein
NFAT	I-protein
recognition	I-protein
sequence	I-protein
and	O
activated	O
transcription	O
from	O
the	O
co-transfected	B-DNA
IL-2	I-DNA
promoter	I-DNA
in	O
COS-7	B-cell_line
cells	I-cell_line
.	O

To	O
do	O
this	O
,	O
wild-type	O
and	O
mutant	O
forms	O
of	O
the	O
CD4	B-protein
cytoplasmic	I-protein
tail	I-protein
were	O
stably	O
expressed	O
in	O
the	O
lymphoblastoid	B-cell_line
T-cell	I-cell_line
line	I-cell_line
A2.01	B-cell_line
.	O

TCF-1	B-protein
belonged	O
to	O
a	O
novel	O
family	O
of	O
genes	O
that	O
contain	O
the	O
so-called	O
high	O
mobility	B-DNA
group	I-DNA
1	I-DNA
(	I-DNA
HMG	I-DNA
)	I-DNA
box	I-DNA
.	O

Although	O
the	O
exact	O
etiology	O
of	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
remains	O
unresolved	O
,	O
immune	O
reactions	O
are	O
believed	O
to	O
be	O
the	O
central	O
pathogenic	O
mechanisms	O
.	O

Finally	O
,	O
TPA	O
addition	O
to	O
monocytes	B-cell_type
infected	O
with	O
HIV-1	O
inhibited	O
HIV-1	O
replication	O
,	O
as	O
determined	O
by	O
reverse	B-protein
transcriptase	I-protein
assays	O
,	O
in	O
a	O
concentration-dependent	O
manner	O
.	O

The	O
complexes	B-protein
consisted	O
of	O
p50/p50	B-protein
homodimers	I-protein
and	O
p50/p65	O
heterodimers	O
.	O

Transient	O
expression	O
experiments	O
of	O
5'-deletion	B-DNA
fragments	I-DNA
of	O
the	O
CD36	B-DNA
promoter	I-DNA
coupled	O
to	O
luciferase	B-protein
demonstrated	O
that	O
as	O
few	O
as	O
158	B-DNA
base	I-DNA
pairs	I-DNA
upstream	I-DNA
from	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
were	O
sufficient	O
to	O
direct	O
the	O
monocyte-specific	O
transcription	O
of	O
the	O
reporter	B-DNA
gene	I-DNA
.	O

In	O
this	O
study	O
,	O
various	O
sets	O
of	O
somatic	B-cell_line
cell	I-cell_line
hybrids	I-cell_line
,	O
generated	O
by	O
the	O
fusion	O
of	O
epithelial	B-cell_line
cell	I-cell_line
lines	I-cell_line
with	O
B-lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
were	O
analyzed	O
for	O
the	O
expression	O
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
class	I-protein
II	I-protein
antigens	I-protein
.	O

This	O
suggests	O
that	O
diverse	O
agents	O
thought	O
to	O
activate	O
NF-kappa	B-protein
B	I-protein
by	O
distinct	O
intracellular	O
pathways	O
might	O
all	O
act	O
through	O
a	O
common	O
mechanism	O
involving	O
the	O
synthesis	O
of	O
ROI	O
.	O

Sp3	B-protein
mediates	O
transcriptional	O
activation	O
of	O
the	O
leukocyte	B-DNA
integrin	I-DNA
genes	I-DNA
CD11C	B-DNA
and	O
CD11B	B-DNA
and	O
cooperates	O
with	O
c-Jun	O
to	O
activate	O
CD11C	B-DNA
.	O

The	O
effect	O
of	O
GH	O
appears	O
to	O
occur	O
in	O
an	O
autocrine	O
fashion	O
,	O
since	O
the	O
inhibitory	O
effect	O
on	O
TNF-alpha	B-protein
secretion	O
by	O
constitutive	O
GH	O
production	O
could	O
be	O
abolished	O
in	O
the	O
presence	O
of	O
anti-hGH	B-protein
mAb	I-protein
.	O

We	O
have	O
demonstrated	O
earlier	O
that	O
the	O
crosslinkage	O
of	O
the	O
CD3/TCR	B-protein
complex	I-protein
with	O
the	O
CD2	B-protein
antigen	I-protein
results	O
in	O
the	O
proliferation	O
of	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

This	O
phenomenon	O
,	O
which	O
is	O
independent	O
of	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
,	O
is	O
associated	O
with	O
HIV	O
replication	O
,	O
and	O
is	O
thus	O
likely	O
to	O
explain	O
at	O
least	O
in	O
part	O
the	O
perpetuation	O
of	O
HIV	O
infection	O
in	O
monocytes	B-cell_type
.	O

The	O
treatment	O
with	O
the	O
ACE	O
inhibitor	O
captopril	O
led	O
to	O
activation	O
of	O
hormone-receptor	O
interactions	O
.	O

The	O
cells	O
were	O
then	O
stimulated	O
for	O
6	O
h	O
.	O

No	O
specific	O
translocation	O
into	O
the	O
nuclear	O
compartment	O
was	O
seen	O
when	O
isolated	O
nuclei	O
were	O
incubated	O
in	O
[	O
3H	O
]	O
calcitriol	O
.	O

The	O
patients	O
'	O
plasma	O
cortisol	O
concentrations	O
were	O
normal	O
or	O
slightly	O
elevated	O
.	O

The	O
results	O
showed	O
that	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
ER	B-protein
content	O
of	O
lymphocytes	B-cell_type
from	O
the	O
controls	O
and	O
that	O
from	O
patients	O
with	O
SLE	O
.	O

The	O
evolutionarily	B-DNA
conserved	I-DNA
sequence	I-DNA
upstream	O
of	O
the	O
human	B-protein
Ig	I-protein
heavy	I-protein
chain	I-protein
S	I-protein
gamma	I-protein
3	I-protein
region	I-protein
is	O
an	O
inducible	B-DNA
promoter	I-DNA
:	O
synergistic	O
activation	O
by	O
CD40	B-protein
ligand	I-protein
and	O
IL-4	B-protein
via	O
cooperative	O
NF-kappa	B-DNA
B	I-DNA
and	I-DNA
STAT-6	I-DNA
binding	I-DNA
sites	I-DNA
.	O

In	O
addition	O
,	O
unwanted	O
and	O
potentially	O
hazardous	O
specificities	O
may	O
be	O
elicited	O
when	O
using	O
synthetic	O
peptides	O
in	O
subunit	O
vaccines	O
in	O
which	O
succinimide	O
residues	O
may	O
form	O
spontaneously	O
during	O
storage	O
or	O
chemical	O
synthesis	O
.	O

Functional	O
IL-12	B-protein
is	O
a	O
heterodimer	B-protein
composed	O
of	O
two	O
distinct	O
subunits	O
that	O
are	O
encoded	O
by	O
separate	O
genes	O
on	O
different	O
chromosomes	O
.	O

In	O
addition	O
,	O
nuclear	O
extracts	O
of	O
the	O
mAECA-treated	B-cell_line
EC	I-cell_line
were	O
analyzed	O
for	O
the	O
induction	O
of	O
translocation	O
of	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
,	O
using	O
a	O
specific	O
NF-kappaB	B-protein
oligoprobe	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Escape	O
of	O
human	O
cytomegalovirus	O
from	O
HLA-DR	B-protein
-restricted	O
CD4	O
(	O
+	O
)	O
T-cell	O
response	O
is	O
mediated	O
by	O
repression	O
of	O
gamma	B-protein
interferon	I-protein
-induced	O
class	B-protein
II	I-protein
transactivator	I-protein
expression	O
.	O

Immunohistochemical	O
and	O
ultrastructural	O
studies	O
were	O
performed	O
to	O
support	O
the	O
diagnosis	O
.	O

This	O
activity	O
requires	O
regions	O
of	O
SLP-76	B-protein
that	O
mediate	O
protein-protein	O
interactions	O
with	O
other	O
molecules	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
suggesting	O
that	O
SLP-76	B-protein
-associated	O
proteins	O
also	O
function	O
to	O
regulate	O
signal	O
transduction	O
.	O

Additional	O
mapping	O
studies	O
indicated	O
that	O
defined	O
deletions	O
of	O
C-terminal	O
70Z/3	B-protein
sequences	O
affected	O
to	O
a	O
variable	O
degree	O
its	O
ability	O
to	O
stimulate	O
NFAT	B-protein
activity	O
.	O

HIV-1	O
infection	O
of	O
myeloid	B-cell_type
cells	I-cell_type
can	O
lead	O
to	O
the	O
expression	O
of	O
surface	B-protein
receptors	I-protein
associated	O
with	O
cellular	O
activation	O
and/or	O
differentiation	O
that	O
increase	O
the	O
responsiveness	O
of	O
these	O
cells	O
to	O
cytokines	B-protein
secreted	O
by	O
neighboring	O
cells	O
as	O
well	O
as	O
to	O
bacteria	O
or	O
other	O
pathogens	O
.	O

Autologous	O
peripheral	B-cell_type
blood	I-cell_type
stem	I-cell_type
cell	I-cell_type
transplantation	O
(	O
PBSCT	O
)	O
is	O
replacing	O
autologous	O
bone	O
marrow	O
transplantation	O
(	O
BMT	O
)	O
in	O
the	O
treatment	O
of	O
leukemia	O
.	O

Stat5	B-protein
and	O
Stat6	B-protein
are	O
transcription	B-protein
factors	I-protein
active	O
in	O
mammary	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
and	O
immune	O
cells	O
.	O

In	O
both	O
cases	O
,	O
peptide	O
presentation	O
to	O
T	B-cell_type
cells	I-cell_type
via	O
class	B-protein
II	I-protein
molecules	I-protein
was	O
restricted	O
to	O
the	O
basolateral	O
surface	O
.	O

The	O
role	O
of	O
the	O
protooncogene	B-DNA
c-fos	I-DNA
in	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
6	I-protein
-induced	O
B	O
cell	O
differentiation	O
was	O
assessed	O
.	O

BACKGROUND	O
:	O
Inhibition	O
of	O
complement	O
in	O
small	O
animal	O
models	O
of	O
xenotransplantation	O
has	O
demonstrated	O
graft	O
infiltration	O
with	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cells	I-cell_type
and	O
monocytes	O
associated	O
with	O
endothelial	B-cell_type
cell	I-cell_type
(	O
EC	B-cell_type
)	O
activation	O
.	O

Expression	O
and	O
role	O
of	O
PML	B-DNA
gene	I-DNA
in	O
normal	O
adult	O
hematopoiesis	O
:	O
functional	O
interaction	O
between	O
PML	B-protein
and	I-protein
Rb	I-protein
proteins	I-protein
in	O
erythropoiesis	O
.	O

Expression	O
of	O
an	O
active	O
form	O
of	O
Ras	B-protein
,	O
Ras	B-protein
(	I-protein
G12V	I-protein
)	I-protein
,	O
suppressed	O
the	O
IL-2	B-protein
-induced	O
beta-casein	B-protein
and	O
OSM	B-protein
gene	O
expression	O
,	O
and	O
the	O
negative	O
effect	O
of	O
Ras	B-protein
is	O
mediated	O
by	O
the	O
region	O
between	O
-105	B-DNA
and	I-DNA
-193	I-DNA
in	O
the	O
beta-casein	B-DNA
promoter	I-DNA
.	O

Bronchoalveolar	B-cell_type
lavage	I-cell_type
(	I-cell_type
BAL	I-cell_type
)	I-cell_type
cells	I-cell_type
and	O
peripheral	O
blood	O
mononuclear	B-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
were	O
examined	O
for	O
GCRbeta	B-protein
immunoreactivity	O
using	O
a	O
GCRbeta-specific	B-protein
antibody	I-protein
by	O
immunohistochemical	O
staining	O
.	O

Ionomycin	O
induced	O
synergistic	O
activation	O
of	O
NFAT	B-protein
in	O
cells	O
expressing	O
p85	B-protein
mutants	I-protein
that	O
contained	O
the	O
C-terminal	B-protein
SH2	I-protein
domain	I-protein
.	O

Thyroid	B-protein
hormone	I-protein
receptors	I-protein
form	O
distinct	O
nuclear	B-protein
protein-dependent	I-protein
and	I-protein
independent	I-protein
complexes	I-protein
with	O
a	O
thyroid	B-DNA
hormone	I-DNA
response	I-DNA
element	I-DNA
.	O

The	O
HIV-1	O
mutant	O
virus	O
containing	O
both	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
and	I-DNA
NFAT-1	I-DNA
deletion	I-DNA
was	O
able	O
to	O
replicate	O
although	O
at	O
a	O
much	O
decreased	O
growth	O
rate	O
,	O
while	O
the	O
deletion	O
of	O
NFAT-1	B-protein
alone	O
increased	O
the	O
viral	O
growth	O
rate	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Thus	O
,	O
IVS1-10T	O
--	O
>	O
C	O
is	O
not	O
harmful	O
to	O
BRCA1	B-DNA
function	O
,	O
and	O
is	O
classified	O
a	O
benign	O
polymorphism	O
.	O

Inorganic	O
lead	O
(	O
Pb	O
)	O
is	O
a	O
ubiquitous	O
environmental	O
contaminant	O
that	O
produces	O
a	O
variety	O
of	O
effects	O
on	O
humoral	O
and	O
cell	O
mediated	O
immune	O
responses	O
.	O

Expression	O
and	O
genomic	O
configuration	O
of	O
GM-CSF	B-protein
,	O
IL-3	B-protein
,	O
M-CSF	B-protein
receptor	I-protein
(	O
C-FMS	B-protein
)	O
,	O
early	B-DNA
growth	I-DNA
response	I-DNA
gene-1	I-DNA
(	O
EGR-1	B-DNA
)	O
and	O
M-CSF	B-DNA
genes	I-DNA
in	O
primary	O
myelodysplastic	O
syndromes	O
.	O

Transfection	O
experiments	O
showed	O
that	O
both	O
Stat1alpha	B-protein
and	O
Stat3	B-protein
inhibited	O
the	O
induction	O
by	O
EPO	B-protein
of	O
gamma-globin	B-RNA
and	I-RNA
erythroid-specific	I-RNA
5-aminolevulinate	I-RNA
synthetase	I-RNA
transcripts	I-RNA
,	O
resulting	O
in	O
a	O
reduction	O
of	O
the	O
percentage	O
of	O
hemoglobin-positive	B-cell_type
cells	I-cell_type
.	O

This	O
result	O
fits	O
well	O
into	O
the	O
general	O
observation	O
of	O
stress-induced	O
down-regulation	O
of	O
immune	O
responses	O
.	O

The	O
MNDA	B-RNA
mRNA	I-RNA
level	O
in	O
primary	B-cell_type
granulocytes	I-cell_type
was	O
unaffected	O
by	O
addition	O
of	O
interferon	B-protein
alpha	I-protein
and	O
other	O
agents	O
including	O
interferon	B-protein
gamma	I-protein
,	O
endotoxin	B-protein
,	O
poly	B-protein
(	I-protein
I	I-protein
)	I-protein
.poly	I-protein
(	I-protein
C	I-protein
)	I-protein
,	O
and	O
FMLP	B-protein
.	O

Surprisingly	O
,	O
G28-5	B-protein
sFv	I-protein
was	O
a	O
potent	O
CD40	B-protein
agonist	I-protein
that	O
rapidly	O
crosslinked	O
CD40	B-protein
on	O
the	O
cell	O
surface	O
but	O
did	O
not	O
crosslink	O
CD40-Ig	B-protein
in	O
solution	O
.	O

In	O
2	O
complex	O
translocations	O
,	O
none	O
of	O
the	O
three	O
genes	O
was	O
rearranged	O
.	O

Gangliosides	O
suppress	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
production	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Renal	O
cell	O
carcinoma-derived	O
gangliosides	O
suppress	O
nuclear	B-protein
factor-kappaB	I-protein
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

C3	O
transferase	O
and	O
cytochalasin	O
D	O
did	O
not	O
alter	O
the	O
expression	O
levels	O
of	O
monocyte-binding	B-protein
receptors	I-protein
on	O
endothelial	B-cell_type
cells	I-cell_type
,	O
but	O
did	O
inhibit	O
clustering	O
of	O
E-selectin	B-protein
,	O
ICAM-1	B-protein
,	O
and	O
VCAM-1	B-protein
on	O
the	O
cell	O
surface	O
induced	O
by	O
monocyte	O
adhesion	O
or	O
cross-linking	B-protein
antibodies	I-protein
.	O

The	O
nuclear	O
localization	O
of	O
Delta19	B-DNA
definitively	O
demonstrates	O
that	O
the	O
mechanisms	O
by	O
which	O
beta-catenin	B-protein
localizes	O
in	O
the	O
nucleus	O
are	O
completely	O
independent	O
of	O
LEF/TCF	B-protein
factors	I-protein
.	O

Finally	O
,	O
we	O
were	O
able	O
to	O
generate	O
a	O
specific	O
CD8+	B-cell_line
CTL	I-cell_line
line	I-cell_line
against	O
a	O
K-RAS	O
mutated	O
peptide	O
.	O

Transfectants	B-cell_line
grown	O
in	O
the	O
presence	O
of	O
tetracycline	O
contained	O
about	O
15	O
,	O
000	O
receptors/cell	O
,	O
a	O
value	O
approximately	O
equal	O
to	O
basal	O
level	O
GR	B-protein
expression	O
in	O
glucocorticoid-sensitive	B-cell_line
6TG1.1	I-cell_line
cells	I-cell_line
before	O
steroid	O
treatment	O
.	O

Human	B-cell_line
leukemia	I-cell_line
HL60	I-cell_line
cells	I-cell_line
respond	O
to	O
the	O
presence	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25D3	O
)	O
by	O
expressing	O
a	O
number	O
of	O
markers	O
of	O
the	O
monocyte/macrophage	O
phenotype	O
and	O
become	O
arrested	O
predominantly	O
in	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Because	O
candidiasis	O
and	O
cryptococcosis	O
are	O
common	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-infected	O
persons	O
,	O
the	O
effect	O
of	O
Cryptococcus	O
neoformans	O
and	O
Candida	O
albicans	O
on	O
HIV	O
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
was	O
examined	O
.	O

In	O
the	O
majority	O
of	O
cell	B-cell_line
lines	I-cell_line
studied	O
,	O
the	O
regulation	O
of	O
ferritin	B-protein
expression	O
was	O
exerted	O
mostly	O
at	O
the	O
translational	O
level	O
.	O

The	O
link	O
between	O
cellular	O
production	O
of	O
such	O
important	O
mediators	O
of	O
inflammation	O
and	O
the	O
antioxidant	O
(	O
AO	O
)	O
thiols	O
,	O
cysteine	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
,	O
is	O
discussed	O
and	O
it	O
is	O
hypothesised	O
that	O
NF-kappa	B-protein
B	I-protein
antagonists	O
may	O
offer	O
important	O
therapeutic	O
benefits	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
reconstitution	O
of	O
a	O
cell-free	O
processing	O
system	O
and	O
demonstrate	O
directly	O
that	O
:	O
(	O
a	O
)	O
the	O
ubiquitin	B-protein
-proteasome	B-protein
system	O
is	O
involved	O
in	O
processing	O
of	O
the	O
intact	O
p105	B-protein
precursor	O
,	O
(	O
b	O
)	O
conjugation	O
of	O
ubiquitin	B-protein
to	O
the	O
precursor	O
is	O
an	O
essential	O
intermediate	O
step	O
in	O
the	O
processing	O
,	O
(	O
c	O
)	O
the	O
recently	O
discovered	O
novel	O
species	O
of	O
the	O
ubiquitin-carrier	B-protein
protein	I-protein
,	O
E2-F1	B-protein
,	O
that	O
is	O
involved	O
in	O
the	O
conjugation	O
and	O
degradation	O
of	O
p53	B-protein
,	O
is	O
also	O
required	O
for	O
the	O
limited	O
processing	O
of	O
the	O
p105	B-protein
precursor	I-protein
,	O
and	O
(	O
d	O
)	O
a	O
novel	O
,	O
approximately	O
320-kDa	B-protein
species	I-protein
of	O
ubiquitin-protein	B-protein
ligase	I-protein
,	O
is	O
involved	O
in	O
the	O
process	O
.	O

Absolute	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
are	O
very	O
low	O
with	O
an	O
estimated	O
one	O
molecule	O
of	O
mRNA	B-RNA
being	O
present	O
in	O
a	O
mononuclear	B-cell_type
blood	I-cell_type
cell	I-cell_type
or	O
thyrocyte	B-cell_type
.	O

These	O
effects	O
were	O
characterized	O
by	O
a	O
marked	O
reduction	O
in	O
CD11b	B-protein
integrin	B-protein
expression	O
on	O
the	O
surface	O
of	O
treated	B-cell_line
cells	I-cell_line
.	O

In	O
contrast	O
,	O
nondividing	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
normal	O
individuals	O
did	O
not	O
express	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
;	O
with	O
stimulation	O
of	O
proliferation	O
of	O
these	O
cells	O
,	O
accumulation	O
of	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
increased	O
markedly	O
.	O

Impaired	O
fetal	B-cell_type
thymocyte	I-cell_type
development	O
after	O
efficient	O
adenovirus-mediated	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Transcription	B-protein
factors	I-protein
of	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
--	O
basic	O
research	O
and	O
clinical	O
perspectives	O
for	O
gastroenterology	O
.	O

In	O
summary	O
,	O
the	O
expression	O
of	O
E1A	B-protein
gene	I-protein
products	I-protein
inhibited	O
IFN	B-protein
-MCP	O
independently	O
of	O
virus	O
infection	O
.	O

Metabolic	O
labeling	O
combined	O
with	O
pulse-chase	O
experiments	O
and	O
biochemical	O
analysis	O
showed	O
that	O
the	O
majority	O
of	O
class	B-protein
II	I-protein
molecules	I-protein
in	O
infected	O
cells	O
became	O
resistant	O
to	O
endoglycosidase	B-protein
H	I-protein
,	O
consistent	O
with	O
normal	O
Golgi	O
processing	O
.	O

Calcium	O
dependent	O
activation	O
of	O
the	O
NF-AT	B-protein
transcription	I-protein
factor	I-protein
by	O
p59fyn	B-protein
.	O

These	O
findings	O
illustrate	O
gain-of-function	O
as	O
a	O
feasible	O
strategy	O
for	O
developing	O
safer	O
live-attenuated	O
HIVs	O
to	O
be	O
tested	O
as	O
candidates	O
for	O
AIDS	O
vaccine	O
.	O

METHODS	O
:	O
Purified	B-cell_type
peripheral	I-cell_type
eosinophils	I-cell_type
were	O
stimulated	O
with	O
IFN-gamma	B-protein
at	O
37	O
degrees	O
C	O
for	O
1-60	O
min	O
.	O

Here	O
we	O
describe	O
the	O
ability	O
of	O
these	O
factors	O
to	O
interact	O
with	O
a	O
site	O
(	O
GM5	B-DNA
)	O
,	O
located	O
within	O
the	O
CLE0	B-DNA
element	I-DNA
,	O
-47	B-DNA
to	I-DNA
-40	I-DNA
upstream	I-DNA
of	O
the	O
GM-CSF	B-DNA
transcription	I-DNA
initiation	I-DNA
site	I-DNA
.	O

Flow	O
cytometric	O
and	O
morphological	O
analyses	O
demonstrated	O
that	O
the	O
addition	O
of	O
CD70	O
transfectants	O
to	O
B	B-cell_line
cell	I-cell_line
cultures	I-cell_line
remarkably	O
promoted	O
differentiation	O
into	O
plasma	B-cell_type
cells	I-cell_type
in	O
the	O
presence	O
of	O
IL-4	B-protein
and	O
CD40	B-protein
signaling	O
.	O

Although	O
all	O
MRD-positive	O
patients	O
in	O
LT	O
remission	O
are	O
still	O
until	O
now	O
event-free	O
,	O
3	O
of	O
the	O
7	O
MRD-positive	O
(	O
MRD+	O
)	O
patients	O
in	O
ST	O
remission	O
soon	O
relapsed	O
.	O

We	O
also	O
show	O
that	O
calcineurin	B-protein
associated	O
with	O
the	O
N-terminal	B-protein
domain	I-protein
of	O
NFATx1	B-protein
at	O
multiple	B-protein
docking	I-protein
sites	I-protein
and	O
caused	O
a	O
reduction	O
of	O
size	O
,	O
indicative	O
of	O
dephosphorylation	O
,	O
in	O
NFATx1	B-protein
.	O

These	O
data	O
suggest	O
that	O
,	O
in	O
this	O
inflammatory	O
model	O
,	O
initial	O
activation	O
of	O
NF-kappaB	B-protein
occurs	O
in	O
alveolar	B-cell_type
macrophages	I-cell_type
and	O
the	O
ensuing	O
production	O
of	O
TNF-alpha	B-protein
may	O
propagate	O
NF-kappaB	B-protein
activation	O
to	O
other	O
cell	O
types	O
in	O
the	O
lung	O
.	O

Kappa	B-protein
B-specific	I-protein
DNA	I-protein
binding	I-protein
proteins	I-protein
are	O
differentially	O
inhibited	O
by	O
enhancer	O
mutations	O
and	O
biological	O
oxidation	O
.	O

The	O
proximal	O
regulatory	O
element	O
of	O
the	O
interferon-gamma	B-DNA
promoter	I-DNA
mediates	O
selective	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Within	O
this	O
region	O
,	O
we	O
have	O
identified	O
several	O
sequences	O
that	O
are	O
implicated	O
in	O
DNA	O
protein	O
interactions	O
as	O
shown	O
in	O
DNAse	B-protein
I	I-protein
footprints	O
and	O
gel	O
mobility	O
shift	O
assays	O
.	O

Further	O
,	O
deletion	O
of	O
the	O
hGATA-3	B-DNA
transcriptional	I-DNA
activation	I-DNA
domain	I-DNA
abolished	O
GATA-dependent	O
HIV-1	O
trans-activation	O
,	O
showing	O
that	O
the	O
stimulation	O
of	O
viral	O
transcription	O
observed	O
is	O
a	O
direct	O
effect	O
of	O
cotransfected	B-protein
hGATA-3	I-protein
.	O

NF-kappaB	B-protein
activation	O
by	O
LMP1	B-protein
(	O
1-231	O
)	O
is	O
likely	O
to	O
be	O
mediated	O
by	O
TRAF1	B-protein
/TRAF2	B-protein
heteroaggregates	O
since	O
TRAF1	B-protein
is	O
unique	O
among	O
the	O
TRAFs	B-protein
in	O
coactivating	O
NF-kappaB	B-protein
with	O
LMP1	B-protein
(	O
1-231	O
)	O
,	O
a	O
TRAF2	B-protein
dominant-negative	O
mutant	O
can	O
block	O
LMP1	B-protein
(	O
1-231	O
)	O
-mediated	O
NF-kappaB	B-protein
activation	O
as	O
well	O
as	O
TRAF1	B-protein
coactivation	O
,	O
and	O
30	O
%	O
of	O
TRAF2	B-protein
is	O
associated	O
with	O
TRAF1	B-protein
in	O
EBV-transformed	O
B	O
cells	O
.	O

Double	O
staining	O
revealed	O
that	O
these	O
interfollicular	B-cell_type
Bcl-6+	I-cell_type
cells	I-cell_type
in	O
AITL/GC	O
were	O
Bcl6+/CD3+/CD20-/CD57-	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

However	O
,	O
its	O
interactions	O
with	O
these	O
histone	B-protein
acetyltransferases	I-protein
are	O
not	O
equivalent	O
,	O
as	O
CBP	B-protein
and	O
p300	B-protein
,	O
but	O
not	O
P/CAF	B-protein
,	O
utilize	O
EKLF	B-protein
as	O
a	O
substrate	O
for	O
in	O
vitro	O
acetylation	O
within	O
its	O
trans-	O
activation	B-protein
region	I-protein
.	O

Two	O
distinct	O
pathways	O
of	O
interleukin-5	B-protein
synthesis	O
in	O
allergen-specific	B-cell_line
human	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
are	O
suppressed	O
by	O
glucocorticoids	O
.	O

The	O
point	O
mutations	O
resulted	O
in	O
a	O
2.5-	O
to	O
3-fold	O
reduction	O
of	O
CAT	B-protein
activity	O
.	O

Quantitation	O
of	O
beta	B-RNA
1	I-RNA
triiodothyronine	I-RNA
receptor	I-RNA
mRNA	I-RNA
in	O
human	O
tissues	O
by	O
competitive	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
.	O

Similarly	O
,	O
an	O
excess	O
of	O
FK506	O
is	O
needed	O
to	O
revert	O
rapamycin-mediated	O
inhibition	O
of	O
IL-2	B-protein
-induced	O
proliferation	O
.	O

The	O
activation	O
of	O
STAT3	B-protein
was	O
not	O
found	O
in	O
human	B-cell_type
eosinophils	I-cell_type
,	O
monocytes	B-cell_type
,	O
and	O
HL-60	B-cell_line
cells	I-cell_line
,	O
although	O
the	O
STAT3	B-protein
protein	I-protein
was	O
expressed	O
in	O
these	O
cells	O
.	O

During	O
treatment	O
with	O
Hm	B-protein
,	O
K562	B-cell_line
cells	I-cell_line
constitutively	O
expressed	O
c-myb	B-RNA
mRNA	I-RNA
,	O
and	O
50	O
%	O
of	O
them	O
began	O
to	O
synthesize	O
hemoglobin	B-protein
(	O
Hb	B-protein
)	O
.	O

Tissue	O
and	O
cell-type	O
specific	O
expression	O
of	O
the	O
tuberous	B-DNA
sclerosis	I-DNA
gene	I-DNA
,	O
TSC2	B-DNA
,	O
in	O
human	O
tissues	O
.	O

Differences	O
in	O
pre-	O
and	O
postoperative	O
values	O
of	O
cancer	O
patients	O
were	O
seen	O
in	O
plasma	O
RIA	O
values	O
:	O
PGE2	O
and	O
6-k-PGF1	O
alpha	O
were	O
significantly	O
higher	O
preoperatively	O
when	O
compared	O
with	O
postoperatively	O
,	O
however	O
,	O
such	O
differences	O
were	O
seen	O
in	O
the	O
control	O
groups	O
as	O
well	O
.	O

In	O
this	O
paper	O
,	O
we	O
show	O
that	O
HCMV	O
down	O
regulates	O
gamma	O
interferon	O
(	O
IFN-gamma	B-protein
)	O
-induced	O
HLA-DR	B-protein
expression	O
in	O
U373	B-cell_line
MG	I-cell_line
astrocytoma	I-cell_line
cells	I-cell_line
due	O
to	O
a	O
defect	O
downstream	O
of	O
STAT1	B-protein
phosphorylation	O
and	O
nuclear	O
translocation	O
.	O

In	O
the	O
present	O
study	O
,	O
by	O
using	O
an	O
in	O
vitro	O
model	O
,	O
we	O
examined	O
whether	O
stimulation	O
with	O
interleukin-6	B-protein
(	I-protein
IL-6	I-protein
)	I-protein
,	O
an	O
immunoregulatory	B-protein
,	O
multipotential	B-protein
cytokine	I-protein
,	O
modulates	O
the	O
expression	O
and	O
activities	O
of	O
the	O
MSR	B-protein
in	O
macrophages	B-cell_type
.	O

Furthermore	O
,	O
ectopic	O
expression	O
of	O
EBF	B-protein
in	O
HeLa	B-cell_line
cells	I-cell_line
activated	O
a	O
B29	B-DNA
promoter-controlled	I-DNA
reporter	I-DNA
construct	I-DNA
13-fold	O
and	O
induced	O
a	O
low	O
level	O
of	O
expression	O
from	O
the	O
endogenous	B-DNA
B29	I-DNA
gene	I-DNA
.	O

We	O
employed	O
electromobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
to	O
screen	O
for	O
the	O
presence	O
of	O
proteins	O
capable	O
of	O
binding	O
to	O
the	O
vitamin	B-DNA
D	I-DNA
response	I-DNA
element	I-DNA
(	O
VDRE	B-DNA
)	O
.	O

This	O
investigation	O
was	O
undertaken	O
to	O
determine	O
the	O
composition	O
of	O
StatG	B-protein
in	O
mature	B-cell_type
normal	I-cell_type
human	I-cell_type
myeloid	I-cell_type
cells	I-cell_type
,	O
i.e	O
.	O
polymorphonuclear	B-cell_type
neutrophilic	I-cell_type
granulocytes	I-cell_type
(	O
PMN	B-cell_type
)	O
.	O

The	O
protein	O
expressed	O
by	O
the	O
v-erb	B-DNA
A	I-DNA
oncogene	I-DNA
binds	O
to	O
DNA	O
and	O
acts	O
as	O
a	O
dominant	O
negative	O
inhibitor	O
of	O
both	O
the	O
thyroid	B-protein
hormone	I-protein
receptor	I-protein
and	O
the	O
closely	O
related	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
.	O

U937	O
cells	O
transfected	O
with	O
the	O
human	O
full-length	B-DNA
IL-1beta	I-DNA
promoter	I-DNA
connected	O
to	O
a	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
were	O
submitted	O
to	O
transcription	O
assays	O
,	O
Northern	O
blotting	O
,	O
and	O
DNA	O
electrophoresis	O
mobility	O
gel	O
shift	O
assays	O
.	O

The	O
maximal	O
effect	O
is	O
observed	O
at	O
the	O
IL-10	B-protein
concentration	O
of	O
20	O
U/ml	O
.	O

In	O
addition	O
,	O
X-ray	O
activation	O
of	O
HIV-1	B-DNA
LTR	I-DNA
in	O
transiently	O
or	O
stably	O
transfected	O
cell	B-cell_line
lines	I-cell_line
is	O
inhibited	O
by	O
a	O
potent	O
antioxidant	O
drug	O
,	O
pyrrolidine	O
dithiocarbamate	O
and	O
by	O
another	O
drug	O
,	O
known	O
for	O
its	O
role	O
in	O
the	O
trapping	O
of	O
growth	B-protein
factors	I-protein
,	O
suramin	O
.	O

Presentation	O
of	O
viral	O
peptide	O
and	O
protein	O
segregated	O
with	O
DQA1	B-DNA
allele	I-DNA
,	O
because	O
cell	O
lines	O
bearing	O
DQA1*0501/DQB1*0201	B-protein
heterodimers	I-protein
presented	O
antigen	O
in	O
proliferation	O
and	O
cytotoxicity	O
assays	O
much	O
more	O
efficiently	O
than	O
cell	B-cell_line
lines	I-cell_line
bearing	O
DQA1*0201/DQB1*0201	B-protein
.	O

Engagement	O
of	O
any	O
of	O
these	O
receptors	O
induces	O
the	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
a	O
shared	O
group	O
of	O
intracellular	B-protein
signaling	I-protein
proteins	I-protein
,	O
including	O
Vav	B-protein
,	O
Cbl	B-protein
,	O
p85	B-protein
phosphoinositide	I-protein
3-kinase	I-protein
,	O
and	O
the	O
Src	B-protein
family	I-protein
kinases	I-protein
Lck	B-protein
and	O
Fyn	B-protein
.	O

With	O
the	O
aim	O
of	O
gaining	O
insight	O
into	O
the	O
function	O
of	O
context-dependent	B-protein
activation	I-protein
domains	I-protein
,	O
we	O
cloned	O
ALY	B-protein
,	O
a	O
novel	O
LEF-1-interacting	B-protein
protein	I-protein
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
corresponding	O
mutations	O
in	O
murine	O
calcineurin	B-protein
render	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
signal	O
transduction	O
cascade	O
CsA	O
resistant	O
in	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

A	O
PMA	B-DNA
responsive	I-DNA
element	I-DNA
has	O
been	O
identified	O
between	O
-182	B-DNA
bp	I-DNA
and	O
-107	B-DNA
bp	I-DNA
upstream	O
of	O
the	O
major	B-DNA
transcription	I-DNA
start	I-DNA
site	I-DNA
.	O

Truncation	O
of	O
the	O
beta	B-DNA
globin	I-DNA
promoter	I-DNA
led	O
to	O
a	O
2-3	O
fold	O
increase	O
in	O
promoter	O
activity	O
.	O

Although	O
four	O
specific	O
complexes	O
can	O
be	O
detected	O
binding	O
to	O
this	O
sequence	O
,	O
only	O
one	O
of	O
these	O
complexes	O
is	O
specific	O
for	O
both	O
the	O
CD28RE	B-DNA
and	O
the	O
adjacent	B-DNA
AP-1	I-DNA
site	I-DNA
.	O

Precise	O
deletion	O
of	O
the	O
exons	O
suggests	O
that	O
they	O
are	O
alternatively	O
spliced	O
transcripts	O
.	O

Thus	O
,	O
we	O
could	O
trace	O
the	O
deficit	O
of	O
the	O
mutant	B-cell_type
cells	I-cell_type
to	O
an	O
inefficient	O
NF-kappaB	B-protein
activation	O
,	O
evidencing	O
a	O
relevant	O
role	O
for	O
NF-kappaB	B-protein
in	O
the	O
regulation	O
of	O
FasL	B-protein
expression	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
finding	O
that	O
functionally	O
distinct	O
isoforms	O
of	O
STAT5	B-protein
are	O
activated	O
during	O
the	O
early	O
and	O
late	O
differentiation	O
stages	O
of	O
granulocytes	O
suggests	O
that	O
they	O
might	O
be	O
involved	O
in	O
regulating	O
different	O
biological	O
functions	O
in	O
these	O
cells	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
monovalent	O
gold	O
compound	O
AuTG	O
is	O
a	O
potentially	O
useful	O
drug	O
for	O
the	O
treatment	O
of	O
patients	O
infected	O
with	O
HIV	O
.	O

LAM	B-protein
and	O
LPS	O
were	O
potent	O
inducers	O
of	O
IL-6	B-DNA
gene	I-DNA
expression	O
in	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O

Results	O
of	O
preliminary	O
studies	O
,	O
many	O
of	O
which	O
were	O
conducted	O
by	O
Dr.	O
Dezube	O
,	O
suggest	O
that	O
use	O
of	O
this	O
agent	O
in	O
combination	O
with	O
antiretroviral	O
compounds	O
may	O
prove	O
useful	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
HIV-1	O
infection	O
.	O

Tyrosine	O
kinases	O
are	O
not	O
required	O
for	O
lipopolysaccharide-mediated	O
nuclear	O
translocation	O
of	O
NFkappaB	B-protein
.	O

The	O
effects	O
of	O
CsA	O
on	O
endothelial	B-cell_type
cells	I-cell_type
were	O
also	O
detected	O
at	O
the	O
chromatin	B-DNA
structure	O
level	O
,	O
as	O
DNasel	B-DNA
hypersensitive	I-DNA
sites	I-DNA
within	O
both	O
the	O
GM-CSF	B-protein
enhancer	O
and	O
the	O
E-selectin	B-DNA
promoter	I-DNA
were	O
suppressed	O
by	O
CsA	O
.	O

Cross-priming	O
of	O
CTL	O
responses	O
in	O
vivo	O
does	O
not	O
require	O
antigenic	O
peptides	O
in	O
the	O
endoplasmic	O
reticulum	O
of	O
immunizing	B-cell_type
cells	I-cell_type
.	O

Cortisol	O
and	O
various	O
synthetic	O
glucocorticoids	O
bind	O
to	O
the	O
GR	B-protein
with	O
one-site	O
kinetics	O
.	O

Transient	O
expression	O
of	O
CD69	B-DNA
promoter-based	I-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
in	O
K562	B-cell_line
cells	I-cell_line
indicated	O
that	O
the	O
proximal	B-DNA
promoter	I-DNA
region	I-DNA
spanning	O
positions	O
-78	O
to	O
+16	O
contained	O
the	O
cis-acting	B-DNA
sequences	I-DNA
necessary	O
for	O
basal	O
and	O
phorbol	O
12-myristate	O
13-acetate-inducible	O
transcription	O
of	O
the	O
CD69	B-DNA
gene	I-DNA
.	O

This	O
represents	O
the	O
first	O
report	O
of	O
NFAT	B-protein
in	O
endothelial	B-cell_type
cells	I-cell_type
and	O
suggests	O
mechanisms	O
by	O
which	O
CsA	O
could	O
function	O
as	O
an	O
antiinflammatory	O
agent	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
an	O
etiological	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

These	O
results	O
indicated	O
that	O
,	O
in	O
abdominal	O
obesity	O
,	O
the	O
GR	B-protein
binding	O
capacity	O
in	O
MNL	B-cell_type
is	O
influenced	O
by	O
the	O
changes	O
in	O
glucose	O
transport	O
.	O

We	O
have	O
used	O
this	O
MTHC	B-cell_line
system	I-cell_line
to	O
analyze	O
differences	O
in	O
gene	O
expression	O
as	O
the	O
cells	O
mature	O
along	O
the	O
DC	B-cell_type
and	O
macrophage	B-cell_type
pathways	I-cell_type
.	O

Here	O
we	O
report	O
the	O
presence	O
of	O
a	O
factor	O
with	O
the	O
mobility	O
and	O
sequence-specific	O
DNA-binding	O
characteristics	O
of	O
EF1	B-protein
at	O
low	O
abundance	O
in	O
a	O
wide	O
variety	O
of	O
non-erythroid	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O

These	O
data	O
indicate	O
that	O
IL-4	B-protein
signaling	O
occurs	O
in	O
the	O
absence	O
of	O
of	O
JAK3	B-protein
,	O
but	O
is	O
comparatively	O
inefficient	O
.	O

The	O
tax	B-protein
gene	I-protein
product	I-protein
(	O
HTLV-I	B-protein
p40tax	I-protein
and	O
HTLV-II	B-protein
p37tax	I-protein
)	O
is	O
the	O
transcriptional	O
activator	O
of	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O

Our	O
data	O
provide	O
evidence	O
that	O
the	O
differential	O
responses	O
in	O
gene	O
expression	O
and	O
cell	O
activation	O
seen	O
in	O
primary	O
NK	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
on	O
direct	O
stimulation	O
with	O
different	O
cytokines	B-protein
may	O
be	O
a	O
direct	O
result	O
of	O
distinct	O
activation	O
of	O
STAT	B-protein
transcription	I-protein
factors	I-protein
.	O

An	O
interleukin-4-induced	B-protein
transcription	I-protein
factor	I-protein
:	O
IL-4	B-protein
Stat	I-protein
.	O

The	O
Epstein-Barr	O
virus	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	O
LMP1	B-protein
)	O
is	O
essential	O
for	O
the	O
transformation	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
into	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

However	O
,	O
in	O
vitro	O
clonal	O
growth	O
assays	O
performed	O
on	O
peripheral	O
blood	O
from	O
transgenic	O
versus	O
control	O
mice	O
revealed	O
a	O
marked	O
reduction	O
of	O
myeloid	B-cell_type
progenitors	I-cell_type
,	O
especially	O
in	O
those	O
responding	O
to	O
granulocyte/	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
.	O

Decreased	O
IL-12	B-protein
production	O
and	O
Th1	O
cell	O
development	O
by	O
acetyl	O
salicylic	O
acid-mediated	O
inhibition	O
of	O
NF-kappaB	B-protein
.	O

Different	O
glucocorticoid	O
hormones	O
(	O
GCH	O
)	O
show	O
differences	O
in	O
the	O
intensity	O
and	O
in	O
the	O
kinetics	O
of	O
their	O
immunomodulating	O
activity	O
.	O

Octamer	B-protein
binding	I-protein
factors	I-protein
and	O
their	O
coactivator	B-protein
can	O
activate	O
the	O
murine	B-DNA
PU.1	I-DNA
(	I-DNA
spi-1	I-DNA
)	I-DNA
promoter	I-DNA
.	O

Transient	O
transfection	O
studies	O
performed	O
in	O
COS7	B-cell_line
cells	I-cell_line
revealed	O
that	O
the	O
newly	O
synthesized	O
p105	B-protein
protein	O
appears	O
to	O
be	O
more	O
rapidly	O
processed	O
compared	O
to	O
its	O
accumulated	O
form	O
that	O
is	O
already	O
associated	O
with	O
the	O
processed	O
product	O
p50	B-protein
.	O

A	O
21.4-kb	B-DNA
DNA	I-DNA
clone	I-DNA
,	O
pZVB70	B-DNA
,	O
showed	O
the	O
highest	O
transactivating	O
ability	O
,	O
while	O
two	O
other	O
DNA	B-DNA
fragments	I-DNA
,	O
pZVB10	B-DNA
(	O
6.2	O
kb	O
)	O
and	O
pZVH14	B-DNA
(	O
8.7	O
kb	O
)	O
,	O
showed	O
lower	O
activity	O
.	O

We	O
show	O
that	O
an	O
inhibitor	O
of	O
protein	B-protein
phosphatases	I-protein
(	O
PPs	B-protein
)	O
PP1/PP2A	B-protein
,	O
calyculin	B-protein
A	I-protein
,	O
induces	O
(	O
i	O
)	O
phosphorylation	O
of	O
STAT3	B-protein
on	O
serine	O
and	O
threonine	O
residues	O
,	O
(	O
ii	O
)	O
inhibition	O
of	O
STAT3	B-protein
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
,	O
and	O
(	O
iii	O
)	O
relocation	O
of	O
STAT3	B-protein
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O

The	O
requirement	O
for	O
TNF	B-protein
is	O
further	O
confirmed	O
by	O
the	O
observation	O
that	O
the	O
inability	O
of	O
the	O
intermediate	B-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD3	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
thymocytes	I-cell_type
to	O
replicate	O
the	O
virus	O
is	O
associated	O
with	O
a	O
defect	O
in	O
TNF	B-protein
production	O
during	O
their	O
interaction	O
with	O
TEC	B-cell_type
and	O
correlates	O
with	O
the	O
absence	O
of	O
nuclear	O
NF-kappaB	B-protein
activity	O
in	O
these	O
freshly	B-cell_type
isolated	I-cell_type
thymocytes	I-cell_type
.	O

A	O
particular	O
allele	O
has	O
an	O
unusually	O
high	O
transcriptional	O
activity	O
.	O

Oestrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
analysis	O
in	O
B-cell	O
chronic	O
lymphocytic	O
leukemia	O
:	O
correlation	O
of	O
biochemical	O
and	O
immunocytochemical	O
methods	O
.	O

The	O
results	O
show	O
that	O
the	O
CYP1A1	B-RNA
mRNA	I-RNA
level	O
induced	O
by	O
UV	O
in	O
the	O
presence	O
of	O
tryptophan	O
was	O
higher	O
than	O
that	O
induced	O
by	O
UV	O
alone	O
in	O
both	O
HaCaT	B-cell_line
cells	I-cell_line
and	O
lymphocytes	B-cell_type
after	O
3	O
h	O
of	O
incubation	O
post-UV	O
irradiation	O
.	O

Pharmacologic	O
control	O
of	O
trans-gene	O
expression	O
in	O
gene-modified	B-cell_line
T	I-cell_line
cells	I-cell_line
will	O
not	O
only	O
facilitate	O
new	O
approaches	O
to	O
the	O
study	O
of	O
different	O
aspects	O
of	O
T	O
cell	O
biology	O
,	O
but	O
will	O
also	O
provide	O
the	O
basis	O
for	O
new	O
gene	O
therapy	O
strategies	O
.	O

In	O
contrast	O
,	O
p107	B-protein
is	O
dephosphorylated	O
and	O
is	O
then	O
depleted	O
from	O
cells	O
as	O
they	O
exit	O
the	O
cell	O
cycle	O
.	O

SCL	B-protein
and	O
related	O
hemopoietic	B-protein
helix-loop-helix	I-protein
transcription	I-protein
factors	I-protein
.	O

Loss	O
of	O
heterozygosity	O
in	O
PB	B-cell_type
granulocytes	I-cell_type
would	O
be	O
masked	O
by	O
the	O
presence	O
of	O
significant	O
numbers	O
of	O
normal	B-cell_type
granulocytes	I-cell_type
not	O
derived	O
from	O
the	O
malignant	B-cell_line
clone	I-cell_line
.	O

The	O
effect	O
of	O
the	O
Tat	B-protein
protein	I-protein
constitutively	O
expressed	O
by	O
these	O
cells	O
upon	O
their	O
differentiation	O
was	O
then	O
evaluated	O
by	O
looking	O
for	O
the	O
expression	O
of	O
the	O
c-fos	B-DNA
and	O
of	O
the	O
c-fms	B-DNA
proto-oncogenes	I-DNA
which	O
are	O
linked	O
to	O
the	O
differentiation	O
of	O
myelomonoblastic	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
the	O
phosphorylation	O
status	O
of	O
TRAF2	B-protein
had	O
significant	O
effects	O
on	O
the	O
ability	O
of	O
the	O
protein	O
to	O
bind	O
to	O
CD40	B-protein
,	O
as	O
evidenced	O
by	O
our	O
observations	O
that	O
the	O
CD40	B-protein
cytoplasmic	I-protein
domain	I-protein
interacted	O
preferentially	O
with	O
underphosphorylated	O
TRAF2	B-protein
and	O
that	O
phosphatase	B-protein
treatment	O
significantly	O
enhanced	O
the	O
binding	O
of	O
TRAF2	B-protein
to	O
CD40	B-protein
.	O

The	O
mechanism	O
underlying	O
this	O
association	O
is	O
so	O
far	O
not	O
explored	O
.	O

When	O
the	O
wild-type	B-protein
hGR	I-protein
and	O
hGR-Ile	B-protein
729	I-protein
were	O
expressed	O
in	O
COS-1	B-cell_line
cells	I-cell_line
and	O
assayed	O
for	O
[	O
3H	O
]	O
-Dexamethasone	O
binding	O
,	O
the	O
dissociation	O
constants	O
were	O
0.799	O
+/-	O
0.068	O
and	O
1.54	O
+/-	O
0.06	O
nM	O
(	O
mean	O
+/-	O
SEM	O
)	O
(	O
P	O
<	O
0.01	O
)	O
,	O
respectively	O
.	O

Concentration	O
of	O
receptors	O
of	O
hormonal	O
form	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
found	O
to	O
be	O
minimal	O
in	O
lymphocytes	B-cell_type
under	O
conditions	O
of	O
chronic	O
kidney	O
insufficiency	O
,	O
while	O
their	O
expression	O
,	O
after	O
the	O
dioxyvit	O
action	O
,	O
was	O
detected	O
only	O
in	O
patients	O
with	O
glomerulonephritis	O
.	O

The	O
affected	O
tyrosine	O
residue	O
located	O
at	O
the	O
C	B-protein
terminus	I-protein
of	O
the	O
DNA	B-protein
binding	I-protein
protein	I-protein
is	O
evolutionarily	O
strongly	O
conserved	O
among	O
the	O
members	O
of	O
the	O
HMG	B-protein
box	I-protein
containing	I-protein
proteins	I-protein
.	O

The	O
protein-tyrosine	B-protein
kinase	I-protein
ZAP-70	B-protein
is	O
implicated	O
,	O
together	O
with	O
the	O
Src	B-protein
kinase	I-protein
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
,	O
in	O
controlling	O
the	O
early	O
steps	O
of	O
the	O
T-cell	O
antigen	O
receptor	O
(	O
TCR	B-protein
)	O
signaling	O
cascade	O
.	O

In	O
murine	B-cell_line
Ba/F3	I-cell_line
cells	I-cell_line
transfected	O
with	O
the	O
human	B-protein
G-CSFR	I-protein
and	O
NFS-60	B-cell_line
cells	I-cell_line
constitutively	O
expressing	O
the	O
murine	B-protein
G-CSFR	I-protein
,	O
G-CSF	B-protein
induced	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
Jak1	B-protein
,	O
Jak2	B-protein
,	O
and	O
Tyk2	B-protein
.	O

For	O
these	O
reasons	O
,	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
the	O
GPIIb	B-DNA
gene	I-DNA
was	O
used	O
to	O
identify	O
the	O
regions	O
that	O
interact	O
with	O
DNA-binding	B-protein
nuclear	I-protein
factors	I-protein
.	O

These	O
data	O
suggest	O
that	O
IL-4	B-DNA
promoter	I-DNA
activity	O
is	O
normally	O
down-regulated	O
by	O
an	O
NRE	B-DNA
via	O
repression	O
of	O
the	O
enhancer	B-DNA
positive	I-DNA
regulatory	I-DNA
element	I-DNA
.	O

Supplementing	O
the	O
data	O
on	O
the	O
processing	O
of	O
pro-IL-16	B-protein
,	O
our	O
results	O
indicate	O
the	O
complexity	O
of	O
IL-16	B-protein
expression	O
,	O
which	O
is	O
tightly	O
controlled	O
at	O
the	O
transcriptional	O
and	O
posttranslational	O
levels	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Cloning	O
of	O
a	O
human	B-DNA
homeobox	I-DNA
gene	I-DNA
that	O
resembles	O
a	O
diverged	B-DNA
Drosophila	I-DNA
homeobox	I-DNA
gene	I-DNA
and	O
is	O
expressed	O
in	O
activated	O
lymphocytes	B-cell_type
.	O

The	O
gene	O
expression	O
of	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
-inducible	I-protein
protein	I-protein
10	I-protein
(	O
IP-10	B-protein
)	O
(	O
a	O
CXC	B-protein
chemokine	I-protein
)	O
was	O
markedly	O
augmented	O
by	O
the	O
IFNgamma	B-protein
treatment	O
in	O
PMA	O
-or	O
RA-differentiated	O
U937	B-cell_line
cells	I-cell_line
,	O
but	O
only	O
marginally	O
in	O
undifferentiated	O
or	O
VitD3-treated	B-cell_line
cells	I-cell_line
.	O

Because	O
monocytes	B-cell_type
and	O
macrophages	O
are	O
important	O
mediators	O
of	O
Th1-type	O
responses	O
,	O
such	O
as	O
delayed-type	O
hypersensitivity	O
,	O
we	O
sought	O
to	O
determine	O
if	O
IL-10	B-protein
could	O
directly	O
mediate	O
inhibition	O
of	O
IFNgamma-	O
and	O
IFNalpha-induced	O
gene	O
expression	O
in	O
these	O
cells	O
.	O

Human	B-cell_line
CD3-CD16+	I-cell_line
natural	I-cell_line
killer	I-cell_line
cells	I-cell_line
express	O
the	O
hGATA-3	B-protein
T	I-protein
cell	I-protein
transcription	I-protein
factor	I-protein
and	O
an	O
unrearranged	O
2.3-kb	B-protein
TcR	I-protein
delta	I-protein
transcript	I-protein
.	O

We	O
also	O
find	O
significant	O
differences	O
in	O
activation	O
of	O
germline	B-DNA
and	O
V	B-DNA
region	I-DNA
promoters	I-DNA
by	O
kappa	B-DNA
enhancers	I-DNA
.	O

To	O
assess	O
the	O
transcription	O
regulatory	O
function	O
of	O
MZF-1	B-DNA
,	O
the	O
full-length	O
MZF-1	B-DNA
coding	O
region	O
was	O
fused	O
to	O
the	O
DNA	B-protein
binding	I-protein
domain	I-protein
of	O
the	O
yeast	B-protein
transactivator	I-protein
GAL4	I-protein
.	O

We	O
describe	O
two	O
female	O
monozygotic	O
(	O
MZ	O
)	O
twins	O
heterozygous	O
for	O
Fabry	O
disease	O
,	O
an	O
X	O
linked	O
disorder	O
resulting	O
from	O
the	O
deficient	O
activity	O
of	O
alpha-galactosidase	B-protein
A	I-protein
.	O

The	O
mean	O
concentrations	O
necessary	O
to	O
cause	O
50	O
%	O
inhibition	O
of	O
lymphocyte	O
proliferation	O
(	O
IC50s	O
)	O
for	O
the	O
steroid-sensitive	O
group	O
ranged	O
from	O
2	O
x	O
10	O
(	O
-10	O
)	O
mol/L	O
for	O
budesonide	O
to	O
7	O
x	O
10	O
(	O
-8	O
)	O
mol/L	O
for	O
hydrocortisone	O
,	O
whereas	O
the	O
mean	O
IC50s	O
for	O
the	O
steroid-resistant	O
group	O
ranged	O
from	O
approximately	O
2	O
x	O
10	O
(	O
-8	O
)	O
mol/L	O
for	O
budesonide	O
to	O
greater	O
than	O
10	O
(	O
-6	O
)	O
mol/L	O
for	O
hydrocortisone	O
.	O

Addition	O
of	O
GM-CSF	B-protein
to	O
this	O
basic	O
cocktail	O
consistently	O
increased	O
the	O
clonogenic	O
capacity	O
of	O
single	B-cell_line
CD34+Thy-1+	I-cell_line
cells	I-cell_line
,	O
and	O
this	O
effect	O
was	O
further	O
enhanced	O
(	O
up	O
to	O
72.3	O
+/-	O
4.3	O
%	O
on	O
day	O
7	O
)	O
by	O
the	O
inclusion	O
of	O
TNF-alpha	B-protein
.	O

A	O
recent	O
clinical	O
therapeutic	O
initiative	O
has	O
been	O
the	O
use	O
of	O
chemical	O
agents	O
which	O
induce	O
the	O
leukaemic	B-cell_type
cells	I-cell_type
to	O
overcome	O
their	O
block	O
in	O
differentiation	O
.	O

Transfection	O
of	O
trans-dominant	B-DNA
negative	I-DNA
expression	I-DNA
vectors	I-DNA
of	O
ras	B-DNA
and	O
raf	B-DNA
,	O
together	O
with	O
AP-1-dependent	B-DNA
reporter	I-DNA
constructs	I-DNA
,	O
as	O
well	O
as	O
Western	O
blot	O
analysis	O
using	O
anti-ERK	B-protein
(	I-protein
extracellular	I-protein
signal-regulated	I-protein
kinase	I-protein
)	I-protein
antibodies	I-protein
,	O
indicated	O
that	O
the	O
Ras/Raf/ERK	O
pathway	O
did	O
not	O
appear	O
to	O
mediate	O
the	O
effect	O
of	O
the	O
antioxidant	O
.	O

Overexpression	O
of	O
beta-adrenergic	O
receptor	O
kinase	O
1	O
carboxyl-terminal	O
peptide	O
in	O
JY25	B-cell_line
cells	I-cell_line
also	O
inhibited	O
Raf-1	B-protein
and	O
ERK1	B-protein
activity	O
,	O
indicating	O
a	O
direct	O
involvement	O
of	O
G	O
betagamma	O
subunits	O
in	O
the	O
signal	O
transduction	O
generated	O
through	O
activation	O
of	O
MAPK	B-protein
pathway	O
by	O
TCC	B-protein
assembly	O
in	O
the	O
plasma	O
membrane	O
.	O

RESULTS	O
.	O

Truncated	B-protein
c-Jun	I-protein
and	I-protein
c-Fos	I-protein
mutant	I-protein
proteins	I-protein
including	O
wbJun	B-protein
and	O
wbFos	B-protein
were	O
also	O
ubiquitinylated	O
under	O
the	O
same	O
conditions	O
,	O
suggesting	O
the	O
sites	O
of	O
ubiquitinylation	O
are	O
located	O
within	O
the	O
dimerization	B-protein
and	I-protein
DNA	I-protein
binding	I-protein
domains	I-protein
of	O
c-Jun	B-protein
and	O
c-Fos	B-protein
.	O

The	O
percentage	O
of	O
the	O
OKT8+	B-cell_line
suppressor/cytotoxic	I-cell_line
T	I-cell_line
cells	I-cell_line
increased	O
when	O
the	O
inflammation	O
expanded	O
from	O
scanty	O
to	O
moderate	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

These	O
results	O
demonstrate	O
the	O
selective	O
role	O
of	O
GATA-4	B-protein
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IL-5	B-DNA
gene	I-DNA
in	O
a	O
circumstance	O
where	O
multiple	O
members	O
of	O
the	O
GATA-binding	B-protein
proteins	I-protein
are	O
expressed	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
in	O
vivo	O
,	O
despite	O
an	O
efficient	O
entry	O
of	O
the	O
virus	O
in	O
all	O
the	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
subpopulations	I-cell_type
,	O
a	O
high	O
viral	O
load	O
may	O
be	O
generated	O
exclusively	O
within	O
the	O
mature	B-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CD8	I-cell_type
(	I-cell_type
-	I-cell_type
)	I-cell_type
CD3	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
subset	I-cell_type
of	I-cell_type
thymocytes	I-cell_type
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
glucocorticoid	O
hormone	O
inhibition	O
of	O
neutrophil	B-cell_type
-mediated	O
tumor	O
cell	O
cytostasis	O
is	O
at	O
least	O
partially	O
due	O
to	O
a	O
lowering	O
of	O
the	O
ligand	O
binding	O
avidity	O
of	O
beta2	B-protein
integrin	I-protein
on	O
the	O
neutrophil	B-cell_type
surface	O
.	O

We	O
show	O
that	O
the	O
myeloid	O
and	O
B	B-protein
cell	I-protein
transcription	I-protein
factor	I-protein
PU.1	B-protein
binds	O
specifically	O
to	O
this	O
site	O
.	O

Growth	O
experiments	O
demonstrated	O
that	O
diethylstilbestrol	O
(	O
DES	O
)	O
tamoxifen	O
(	O
TAM	O
)	O
,	O
quercetin	O
and	O
rutin	O
exerted	O
a	O
reversible	O
dose-dependent	O
inhibition	O
of	O
cell	O
proliferation	O
in	O
the	O
range	O
of	O
concentrations	O
between	O
10	O
nM	O
and	O
10	O
microM	O
.	O

Regulation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
in	O
stably	O
transfected	O
Jurkat	B-cell_line
cell	I-cell_line
clones	I-cell_line
.	O

Growth	B-protein
factor	I-protein
receptors	I-protein
play	O
an	O
important	O
role	O
in	O
hematopoiesis	O
.	O

Cyclosporin	O
A	O
inhibits	O
early	O
mRNA	O
expression	O
of	O
G0/G1	B-DNA
switch	I-DNA
gene	I-DNA
2	I-DNA
(	O
G0S2	B-DNA
)	O
in	O
cultured	B-cell_line
human	I-cell_line
blood	I-cell_line
mononuclear	I-cell_line
cells	I-cell_line
.	O

The	O
frequency	O
,	O
distribution	O
,	O
and	O
nature	O
of	O
these	O
mutations	O
were	O
similar	O
to	O
those	O
resulting	O
from	O
the	O
Ig	O
hypermutation	O
process	O
.	O

Sensitivity	O
for	O
induction	O
of	O
apoptosis	O
was	O
markedly	O
increased	O
by	O
these	O
treatments	O
in	O
apoptosis	O
sensitive	O
cell	B-cell_line
lines	I-cell_line
.	O

Elf-1	B-protein
is	O
a	O
lymphoid-specific	B-protein
Ets	I-protein
transcription	I-protein
factor	I-protein
that	O
regulates	O
inducible	O
gene	O
expression	O
during	O
T	B-cell_type
cell	I-cell_type
activation	O
.	O

NF-kappaB	O
nuclear	O
translocation	O
is	O
secondary	O
to	O
the	O
phosphorylation	O
and	O
subsequent	O
degradation	O
of	O
the	O
NF-kappaB	B-protein
inhibitory	I-protein
molecule	I-protein
IkappaBalpha	B-protein
.	O

These	O
observations	O
indicate	O
that	O
during	O
chronic	O
HIV	O
infection	O
of	O
U937	B-cell_line
cells	I-cell_line
,	O
continuous	O
NF-kappa	B-protein
B	I-protein
(	O
p50/p65	B-protein
)	O
translocation	O
results	O
in	O
p105	O
promoter	O
upregulation	O
with	O
subsequent	O
cytosolic	O
NF-kappa	B-protein
B	I-protein
accumulation	O
,	O
ready	O
for	O
further	O
translocation	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
human	O
THP-1	B-cell_line
promonocytic	I-cell_line
cells	I-cell_line
,	O
engineered	O
by	O
gene	O
transfer	O
to	O
constitutively	O
produce	O
human	O
growth	O
hormone	O
(	O
hGH	O
)	O
,	O
secreted	O
depressed	O
amounts	O
of	O
TNF-alpha	B-protein
in	O
response	O
to	O
challenge	O
by	O
LPS	O
.	O

Although	O
common	O
members	O
of	O
the	O
apoptotic	O
cascade	O
are	O
shared	O
between	O
different	O
cell	O
types	O
,	O
it	O
appears	O
that	O
cell-specific	B-protein
factors	I-protein
can	O
influence	O
the	O
response	O
to	O
a	O
given	O
apoptotic	O
stimuli	O
.	O

Here	O
we	O
extend	O
those	O
results	O
by	O
showing	O
that	O
the	O
position	O
of	O
the	O
ZEBRA	B-protein
activation	I-protein
domain	I-protein
or	O
a	O
heterologous	O
replacement	O
domain	O
does	O
not	O
influence	O
its	O
ability	O
to	O
function	O
in	O
the	O
disruption	O
of	O
EBV	O
latency	O
.	O

We	O
suspect	O
that	O
the	O
C/EBP	B-DNA
epsilon	I-DNA
promoter/enhancer	I-DNA
contains	O
a	O
retinoic	B-DNA
acid-response	I-DNA
element	I-DNA
that	O
is	O
directly	O
stimulated	O
by	O
retinoids	O
.	O

DNA-protein	O
binding	O
assays	O
with	O
nuclear	O
extracts	O
from	O
induced	O
cells	O
demonstrate	O
a	O
high	B-protein
molecular	I-protein
weight	I-protein
complex	I-protein
on	O
the	O
enhancer	B-DNA
.	O

Similarly	O
,	O
interferons	O
could	O
act	O
on	O
APL	B-cell_type
cells	I-cell_type
,	O
alone	O
or	O
in	O
combination	O
with	O
all-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
especially	O
if	O
the	O
PML/RAR	B-RNA
alpha	I-RNA
fusion	I-RNA
transcript	I-RNA
that	O
results	O
from	O
the	O
t	B-DNA
(	I-DNA
15	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
is	O
induced	O
by	O
interferon	B-protein
.	O

HTLV-1	B-protein
Tax	I-protein
induces	O
expression	O
of	O
various	O
immediate	B-DNA
early	I-DNA
serum	I-DNA
responsive	I-DNA
genes	I-DNA
.	O

We	O
may	O
find	O
that	O
one	O
region	O
of	O
the	O
protein	O
is	O
required	O
for	O
embryonic	O
expression	O
and	O
another	O
for	O
adult	O
globin	B-DNA
gene	I-DNA
expression	O
.	O

Additionally	O
,	O
we	O
showed	O
that	O
pentazocine	O
,	O
a	O
competitive	O
inhibitor	O
of	O
SR	O
31747A	O
binding	O
,	O
also	O
prevents	O
the	O
immunosuppressive	O
effect	O
of	O
SR	O
31747A	O
.	O

The	O
mechanisms	O
underlying	O
these	O
rapid	O
effects	O
of	O
aldosterone	O
on	O
electrolytes	O
have	O
been	O
extensively	O
studied	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
,	O
which	O
thus	O
may	O
represent	O
valuable	O
tools	O
in	O
the	O
delineation	O
of	O
the	O
receptor-effector	O
mechanisms	O
involved	O
.	O

These	O
results	O
indicate	O
that	O
lymphocyte-specific	O
factors	O
binding	O
to	O
the	O
TCEd	B-DNA
are	O
involved	O
in	O
the	O
control	O
of	O
T	O
cell	O
specific-transcription	O
of	O
the	O
Il-2	B-DNA
gene	I-DNA
.	O

IL-2	B-protein
induced	O
the	O
binding	O
of	O
Stat5a	B-protein
and	I-protein
b	I-protein
proteins	I-protein
to	O
the	O
human	B-DNA
GASd	I-DNA
element	I-DNA
.	O

We	O
have	O
focused	O
on	O
the	O
study	O
of	O
the	O
signal	O
transduction	O
pathways	O
triggered	O
by	O
CD23	B-protein
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
the	O
promonocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
.	O

The	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
antioxidants	O
and	O
specific	O
protease	O
inhibitors	O
may	O
provide	O
a	O
pharmacological	O
basis	O
for	O
interfering	O
with	O
these	O
acute	O
processes	O
.	O

A	O
5.5-kilobase	B-DNA
genomic	I-DNA
clone	I-DNA
contained	O
the	O
full-length	O
CD14	B-DNA
coding	I-DNA
sequence	I-DNA
and	O
4.2	B-DNA
kilobases	I-DNA
of	I-DNA
5'-upstream	I-DNA
sequence	I-DNA
.	O

Therefore	O
,	O
monokine	O
induction	O
is	O
a	O
zinc-specific	O
effect	O
influenced	O
by	O
the	O
physicochemical	O
properties	O
of	O
the	O
ion	O
.	O

This	O
suggests	O
that	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
CD40	B-protein
-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
can	O
occur	O
independently	O
of	O
TRAF2	B-protein
and	O
TRAF5	B-protein
association	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
E	O
(	O
2	O
)	O
downregulates	O
TNF	B-protein
production	O
is	O
presently	O
unknown	O
.	O

Either	O
a	O
genetic	O
or	O
pharmacologic	O
blockade	O
of	O
HL-60	O
differentiation	O
prohibited	O
these	O
inductive	O
effects	O
.	O

Their	O
corresponding	O
plasma	O
cortisol	O
levels	O
were	O
assessed	O
.	O

Although	O
negative	O
regulation	O
by	O
dimethyl	O
sulfoxide	O
takes	O
place	O
even	O
when	O
protein	O
synthesis	O
is	O
inhibited	O
by	O
cycloheximide	O
,	O
the	O
phorbol	O
myristate	O
acetate	O
effect	O
is	O
blocked	O
to	O
some	O
extent	O
only	O
by	O
cycloheximide	O
.	O

Here	O
,	O
we	O
propose	O
gain-of-function	O
to	O
be	O
used	O
simultaneously	O
with	O
loss-of-function	O
as	O
a	O
novel	O
approach	O
for	O
attenuating	O
HIV-1	O
.	O

The	O
results	O
show	O
unequivocal	O
evidence	O
of	O
non-	O
Ig	B-DNA
gene	I-DNA
hypermutation	O
in	O
germinal	B-cell_type
center	I-cell_type
B	I-cell_type
cells	I-cell_type
and	O
provide	O
fresh	O
insights	O
into	O
the	O
process	O
of	O
hypermutation	O
and	O
lymphomagenesis	O
.	O

A	O
general	O
correlation	O
between	O
induction	O
of	O
GR	B-RNA
mRNA	I-RNA
and	O
lysis	O
of	O
the	O
normal	O
and	O
dex-resistant	B-cell_line
cells	I-cell_line
was	O
found	O
.	O

3.	O
SMX-NHOH	O
and	O
SMX-NO	O
were	O
rapidly	O
reduced	O
back	O
to	O
the	O
parent	O
compound	O
by	O
cysteine	O
(	O
CYS	O
)	O
,	O
GSH	O
,	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
cells	I-cell_type
and	O
plasma	O
,	O
suggesting	O
that	O
this	O
is	O
an	O
important	O
and	O
ubiquitous	B-protein
bioinactivation	O
mechanism	O
.	O

Deoxycorticosterone	O
acetate	O
had	O
an	O
intermediate	O
activity	O
with	O
an	O
apparent	O
Kd	O
of	O
100	O
nM	O
.	O

IL-12	B-protein
-induced	O
activation	O
of	O
NK	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
occurs	O
in	O
the	O
absence	O
of	O
immediate-early	B-DNA
activation	I-DNA
gene	I-DNA
expression	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
activation	O
of	O
CREB/ATF	B-protein
and	O
AP-1	B-protein
transcription	I-protein
factors	I-protein
by	O
PGN	O
or	O
by	O
any	O
other	O
component	O
of	O
Gram-positive	O
bacteria	O
.	O

This	O
pathway	O
resulted	O
in	O
the	O
induction	O
of	O
the	O
transcription	B-protein
factors	I-protein
NF-kappa	B-protein
B	I-protein
,	O
NF-AT	B-protein
,	O
and	O
proteins	O
binding	O
to	O
the	O
CD28	B-protein
response	O
element	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

However	O
,	O
NF-kappa	B-protein
B	I-protein
activation	O
was	O
insufficient	O
for	O
CD40	B-protein
-mediated	O
up-regulation	O
of	O
B7-1	B-protein
,	O
Fas	B-protein
,	O
and	O
CD23	B-protein
.	O

Since	O
induction	O
of	O
the	O
IL-2	B-protein
receptor	I-protein
alpha	I-protein
subunit	I-protein
is	O
a	O
hallmark	O
of	O
lymphocyte	B-cell_type
activation	O
,	O
we	O
suggest	O
that	O
p21ras	B-protein
naturally	O
triggers	O
B	B-cell_type
cell	I-cell_type
activation	O
.	O

We	O
further	O
demonstrate	O
the	O
impact	O
of	O
platelet-activating	B-protein
factor	I-protein
binding	O
to	O
B	B-cell_type
cells	I-cell_type
by	O
measuring	O
platelet-activating	B-protein
factor	I-protein
induced	O
arachidonic	O
acid	O
release	O
and	O
5-hydroxyeicosatetraenoic	O
acid	O
production	O
.	O

Transient	O
transfection	O
studies	O
demonstrate	O
further	O
that	O
TCR	B-protein
-stimulated	O
activation	O
of	O
the	O
Ras	B-protein
signaling	O
pathway	O
is	O
required	O
for	O
optimal	O
activation	O
of	O
CD95	B-protein
ligand	I-protein
.	O

It	O
was	O
also	O
determined	O
,	O
using	O
electrophoresis	O
mobility	O
shift	O
assays	O
,	O
that	O
M.	O
tuberculosis	O
ManLAM	O
led	O
to	O
the	O
nuclear	O
translocation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	I-protein
.	O

PPARgamma	B-protein
has	O
also	O
been	O
implicated	O
recently	O
in	O
the	O
biology	O
of	O
monocytes	O
and	O
in	O
cell-cycle	O
regulation	O
and	O
cancer	O
.	O

Switching	O
is	O
hampered	O
by	O
CD30	B-protein
coengagement	O
,	O
possibly	O
through	O
interference	O
with	O
the	O
CD40	B-protein
-mediated	O
NF-kappaB	B-protein
-dependent	O
transcriptional	O
activation	O
of	O
downstream	B-DNA
C	I-DNA
(	I-DNA
H	I-DNA
)	I-DNA
genes	I-DNA
.	O

In	O
both	O
cell	O
lines	O
LIF	B-protein
increased	O
NF-kB	B-protein
activity	O
.	O

Acquisition	O
of	O
HSF3	B-protein
DNA-binding	O
activity	O
in	O
HD6	B-cell_line
cells	I-cell_line
is	O
accompanied	O
by	O
oligomerization	O
from	O
a	O
non-DNA-binding	B-protein
dimer	I-protein
to	O
a	O
DNA-binding	B-protein
trimer	I-protein
,	O
whereas	O
the	O
effect	O
of	O
heat	O
shock	O
on	O
HSF1	B-protein
is	O
oligomerization	O
of	O
an	O
inert	B-protein
monomer	I-protein
to	O
a	O
DNA-binding	B-protein
trimer	I-protein
.	O

Impaired	O
myelopoiesis	O
in	O
vivo	O
was	O
shown	O
by	O
stressing	O
these	O
mice	O
with	O
sublethal	O
irradiation	O
.	O

The	O
expression	O
of	O
p45	B-protein
megakaryocytic	B-cell_type
lineage	I-cell_type
cells	I-cell_type
,	O
p45	B-RNA
mRNA	I-RNA
is	O
transcribed	O
only	O
from	O
aNF-E2	B-DNA
promoter	I-DNA
.	O

Finally	O
,	O
gel	O
mobility	O
shift	O
assays	O
demonstrated	O
the	O
nuclear	O
translocation	O
of	O
proteins	O
specifically	O
bound	O
to	O
these	O
two	O
NF-kappaB	B-DNA
motifs	I-DNA
,	O
confirming	O
that	O
VCAM-1	B-protein
was	O
induced	O
on	O
Tax-expressing	B-cell_line
cells	I-cell_line
in	O
a	O
kappaB	B-protein
-dependent	O
manner	O
.	O

Furthermore	O
,	O
using	O
DNA	B-DNA
templates	I-DNA
containing	O
two	O
copies	O
of	O
the	O
PRDII	B-DNA
domain	I-DNA
linked	O
to	O
the	O
rabbit	B-DNA
beta	I-DNA
globin	I-DNA
gene	I-DNA
,	O
the	O
purified	O
polypeptides	O
specifically	O
stimulated	O
NF-kappa	B-protein
B	I-protein
dependent	O
transcription	O
in	O
an	O
in	O
vitro	O
reconstitution	O
assay	O
as	O
heterodimers	O
but	O
not	O
as	O
p50	B-protein
homodimers	I-protein
.	O

In	O
concert	O
with	O
the	O
coactivator	B-protein
CREB	I-protein
binding	I-protein
protein/p300	I-protein
,	O
which	O
interacts	O
with	O
GABPalpha	B-protein
,	O
the	O
binding	O
of	O
GABPalpha	B-protein
and	O
-beta	B-protein
to	O
the	O
dyad	B-DNA
symmetry	I-DNA
element	I-DNA
controls	O
the	O
induction	O
of	O
IL-16	B-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

Since	O
1988	O
,	O
several	O
families	O
of	O
functionally	O
important	O
T	B-protein
cell	I-protein
transcription	I-protein
factors	I-protein
have	O
been	O
identified	O
.	O

CONCLUSION	O
:	O
Mutated	B-DNA
human	I-DNA
CIITA	I-DNA
constructs	I-DNA
are	O
potent	O
suppressors	O
of	O
porcine	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
.	O

In	O
transgenic	O
mice	O
,	O
elevated	O
JunB	B-protein
levels	O
caused	O
increased	O
expression	O
of	O
several	O
Th2	B-protein
cytokines	I-protein
in	O
developing	O
Th1	B-cell_type
cells	I-cell_type
.	O

A	O
cell	B-DNA
type-specific	I-DNA
enhancer	I-DNA
in	O
the	O
human	B-DNA
B7.1	I-DNA
gene	I-DNA
regulated	O
by	O
NF-kappaB	B-protein
.	O

Finally	O
,	O
despite	O
impaired	O
Rel-A	B-protein
translocation	O
,	O
T	B-cell_type
cells	I-cell_type
were	O
capable	O
of	O
transcribing	O
IL-2	B-protein
.	O

These	O
changes	O
in	O
the	O
enhancer	B-DNA
element	I-DNA
were	O
identified	O
in	O
the	O
original	O
AL1	O
virus	O
stock	O
.	O

IL-1beta	B-protein
transcription	O
was	O
abrogated	O
;	O
in	O
contrast	O
,	O
TGF-beta1	B-RNA
mRNA	I-RNA
synthesis	O
was	O
steroid	O
resistant	O
.	O

The	O
spi-1	B-cell_line
transfected	I-cell_line
cells	I-cell_line
showed	O
reduced	O
growth	O
rates	O
and	O
reduced	O
clonogenic	O
cell	O
growth	O
.	O

The	O
findings	O
suggest	O
that	O
a	O
novel	B-DNA
proto-oncogene	I-DNA
in	O
the	O
vicinity	O
of	O
TCR	B-DNA
alpha/delta	I-DNA
is	O
involved	O
in	O
this	O
translocation	O
.	O

Jak3	B-protein
is	O
constitutively	O
associated	O
with	O
CD40	B-protein
,	O
and	O
this	O
interaction	O
requires	O
a	O
proline-rich	B-protein
sequence	I-protein
in	O
the	O
membrane-proximal	B-protein
region	I-protein
of	O
CD40	B-protein
.	O

Recombinant	O
I	O
kappa	O
B-alpha	O
(	O
MAD-3	B-protein
)	O
inhibited	O
the	O
DNA	O
binding	O
activity	O
of	O
p65	B-protein
,	O
p49/p65	B-protein
,	O
and	O
p50/p65	B-protein
but	O
stimulated	O
the	O
binding	O
of	O
NFKB2	B-protein
(	O
p49	B-protein
)	O
or	O
NFKB1	O
(	O
p50	O
)	O
.	O

Characterization	O
of	O
cytokine	B-protein
differential	O
induction	O
of	O
STAT	B-protein
complexes	I-protein
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
and	I-cell_type
NK	I-cell_type
cells	I-cell_type
.	O

The	O
antibody	B-protein
D07	I-protein
revealed	O
marked	O
overexpression	O
of	O
p53	B-protein
protein	I-protein
in	O
only	O
one	O
tumor	O
.	O

We	O
examined	O
whether	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
resistance	O
develops	O
as	O
PBM	B-cell_type
differentiate	O
to	O
macrophages	B-cell_type
or	O
with	O
macrophage	O
activation	O
.	O

METHODS	O
:	O
Methods	O
used	O
in	O
this	O
study	O
include	O
DNase	B-protein
I	I-protein
footprint	O
assays	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
and	O
functional	O
analysis	O
by	O
mammalian	O
cell	O
transfection	O
involving	O
deletion	O
analysis	O
and	O
site-directed	O
mutagenesis	O
.	O

Thrombin	B-protein
activation	O
was	O
also	O
seen	O
with	O
apoptotic	B-cell_type
human	I-cell_type
VSMCs	I-cell_type
(	O
AUC	O
of	O
211	O
+/-	O
8	O
nmol	O
x	O
min/L	O
;	O
PT	O
of	O
103	O
+/-	O
4	O
nmol/L	O
)	O
and	O
was	O
inhibited	O
by	O
annexin	O
V	O
(	O
P	O
<	O
.0001	O
for	O
AUC	O
and	O
PT	O
)	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
stimulation	O
of	O
human	B-cell_type
neutrophils	I-cell_type
is	O
known	O
to	O
result	O
in	O
activation	O
of	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
(	O
MAPk	B-protein
)	O
;	O
however	O
,	O
the	O
upstream	B-protein
activator	I-protein
(	O
s	O
)	O
of	O
p38	B-protein
MAPk	I-protein
is	O
unknown	O
,	O
and	O
consequences	O
of	O
p38	B-protein
MAPk	I-protein
activation	O
remain	O
largely	O
undefined	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
involvement	O
of	O
the	O
Jak/Stat	B-protein
pathway	O
in	O
the	O
signaling	O
of	O
eosinophils	B-cell_type
after	O
IFN-gammaR	B-protein
conjugation	O
by	O
the	O
ligand	O
binding	O
.	O

Further	O
dissection	O
of	O
the	O
317	B-DNA
base	I-DNA
pair	I-DNA
region	I-DNA
demonstrates	O
that	O
,	O
whereas	O
all	O
317	B-DNA
base	I-DNA
pairs	I-DNA
are	O
required	O
for	O
expression	O
in	O
megakaryocytes	B-cell_type
,	O
only	O
the	O
5	B-DNA
'	I-DNA
62	I-DNA
base	I-DNA
pairs	I-DNA
are	O
needed	O
for	O
erythroid-specific	O
reporter	O
expression	O
.	O

This	O
observation	O
suggests	O
that	O
physical	O
linkage	O
to	O
XIC/XIST	B-DNA
does	O
not	O
lead	O
to	O
de	O
novo	O
inactivation	O
of	O
autosomal	O
material	O
.	O

This	O
function	O
is	O
mediated	O
through	O
two	O
repression	B-protein
domains	I-protein
and	O
is	O
dependent	O
upon	O
the	O
promoter	O
context	O
and	O
cell	O
type	O
.	O

Cycles	O
remained	O
ovulatory	O
.	O

They	O
bind	O
in	O
vitro	O
respectively	O
ATF-1	B-protein
and	O
NF-Y	B-protein
proteins	I-protein
.	O

Lipopolysaccharide	O
is	O
one	O
of	O
the	O
most	O
potent	O
trigger	O
substances	O
for	O
monocytes	O
and	O
macrophages	O
causing	O
secretion	O
of	O
inflammatory	B-protein
mediators	I-protein
such	O
as	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
and	O
interleukin-1	B-protein
.	O

LPS	O
is	O
also	O
shown	O
to	O
dramatically	O
increase	O
HIV-1	O
production	O
from	O
a	O
chronically	B-cell_line
infected	I-cell_line
monocyte/macrophage-like	I-cell_line
cloned	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
U1	B-cell_line
,	O
which	O
produces	O
very	O
low	O
levels	O
of	O
HIV-1	O
at	O
baseline	O
.	O

Protein	O
latency	O
expression	O
was	O
determined	O
by	O
immunocytochemistry	O
.	O

Upon	O
cotransfection	O
into	O
non-T	B-cell_type
cells	I-cell_type
,	O
TCF-1	B-protein
could	O
transactivate	O
through	O
its	O
cognate	O
motif	O
.	O

We	O
find	O
that	O
TCL1	B-protein
is	O
expressed	O
in	O
the	O
majority	O
of	O
AIDS	O
IBLP	O
tumors	O
examined	O
.	O

Inhibition	O
of	O
NO	B-protein
synthase	I-protein
(	O
NOS	B-protein
)	O
during	O
the	O
second	O
A/R	O
challenge	O
prevents	O
the	O
development	O
of	O
A/R	O
tolerance	O
with	O
respect	O
to	O
PMN	O
adhesion	O
.	O

These	O
observations	O
demonstrate	O
that	O
CD4	B-protein
signaling	O
mediates	O
HIV-induced	O
apoptosis	O
by	O
a	O
mechanism	O
independent	O
of	O
Fas	B-protein
-Fas	B-protein
ligand	I-protein
interaction	O
,	O
does	O
not	O
require	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
signaling	O
,	O
and	O
may	O
involve	O
a	O
critical	O
region	O
for	O
CD4	B-protein
dimerization	O
.	O

Using	O
the	O
DNA	O
affinity	O
precipitation	O
assay	O
,	O
we	O
observed	O
that	O
Tax1	B-protein
is	O
able	O
to	O
efficiently	O
induce	O
the	O
binding	O
of	O
Rel	O
,	O
whereas	O
PMA	O
is	O
not	O
.	O

This	O
finding	O
suggests	O
that	O
the	O
BZLF1	B-DNA
promoter	I-DNA
may	O
be	O
regulated	O
by	O
the	O
degree	O
of	O
squamous	O
differentiation	O
.	O

Tyrosine	O
phosphorylation	O
of	O
this	O
protein	O
could	O
also	O
be	O
induced	O
in	O
Balb/c3T3	B-cell_line
cells	I-cell_line
using	O
a	O
supernatant	O
from	O
the	O
B	B-cell_line
line	I-cell_line
,	O
which	O
was	O
associated	O
with	O
induction	O
of	O
cell	O
proliferation	O
.	O

Novel	O
aldosterone	B-protein
receptors	I-protein
:	O
specificity-conferring	O
mechanism	O
at	O
the	O
level	O
of	O
the	O
cell	O
membrane	O
.	O

We	O
overexpressed	O
AML1a	B-protein
(	O
without	O
the	O
transcription-activating	B-protein
domain	I-protein
)	O
and	O
AML1b	B-protein
(	O
with	O
the	O
domain	O
)	O
proteins	O
in	O
K562	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
,	O
which	O
can	O
be	O
induced	O
to	O
differentiate	O
into	O
hemoglobin-producing	B-cell_type
cells	I-cell_type
and	O
megakaryocytes	B-cell_type
.	O

Here	O
,	O
we	O
report	O
that	O
LPS	O
induces	O
IKK	B-protein
activity	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
THP-1	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
.	O

Neutrophil	B-cell_type
maturation	O
occurs	O
in	O
well	O
defined	O
morphological	O
stages	O
that	O
correlate	O
with	O
the	O
acquisition	O
of	O
molecular	B-protein
markers	I-protein
associated	O
with	O
neutrophil	O
function	O
.	O

A	O
constitutive	O
NF-kappa	B-protein
B	I-protein
activity	O
has	O
been	O
reported	O
in	O
mature	B-cell_type
macrophages	I-cell_type
.	O

Our	O
studies	O
suggest	O
that	O
this	O
form	O
of	O
acute	O
leukemia	O
may	O
arise	O
from	O
transformation	O
of	O
a	O
precursor	O
cell	O
common	O
to	O
both	O
the	O
myeloid	B-cell_type
and	I-cell_type
NK	I-cell_type
cell	I-cell_type
lineages	I-cell_type
;	O
thus	O
we	O
propose	O
the	O
designation	O
myeloid/NK	O
acute	O
leukemia	O
.	O

Constitutive	O
expression	O
c-fos	B-RNA
,	I-RNA
c-jun	I-RNA
,	I-RNA
and	I-RNA
NF	I-RNA
kappa	I-RNA
B	I-RNA
mRNA	I-RNA
is	O
in	O
nucleated	B-cell_type
fetal	I-cell_type
blood	I-cell_type
cells	I-cell_type
and	O
up-regulation	O
of	O
c-fos	B-protein
and	O
c-jun	B-protein
with	O
anti-CD3	B-protein
stimulation	O
.	O

We	O
have	O
purified	O
the	O
RFX	B-protein
complex	I-protein
and	O
sequenced	O
its	O
three	O
subunits	O
.	O

Mutations	O
in	O
these	O
liver-enriched	B-protein
transcription	I-protein
factors	I-protein
result	O
in	O
two	O
forms	O
of	O
early-onset	O
type	O
2	O
diabetes	O
(	O
maturity-onset	O
diabetes	O
of	O
the	O
young	O
[	O
MODY	O
]	O
)	O
,	O
MODY3	O
and	O
MODY1	O
,	O
which	O
are	O
characterized	O
by	O
impaired	O
glucose-stimulated	O
insulin	O
secretion	O
,	O
early	O
disease	O
onset	O
,	O
and	O
autosomal	O
dominant	O
inheritance	O
.	O

Screening	O
of	O
a	O
library	O
of	O
compounds	O
using	O
transactivation	O
and	O
AP-1	B-protein
transrepression	O
models	O
in	O
transiently	O
transfected	O
cells	O
identified	O
dissociated	O
glucocorticoids	O
,	O
which	O
exert	O
strong	O
AP-1	B-protein
inhibition	O
but	O
little	O
or	O
no	O
transactivation	O
.	O

Pharmacological	O
control	O
of	O
antigen	O
responsiveness	O
in	O
genetically	B-cell_line
modified	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

Furthermore	O
,	O
recombinant	O
TIMP-1	B-protein
,	O
but	O
not	O
TIMP-2	B-protein
or	O
a	O
synthetic	O
metalloproteinase	O
inhibitor	O
(	O
BB-94	O
)	O
,	O
confers	O
resistance	O
to	O
apoptosis	O
induced	O
by	O
both	O
CD95-dependent	O
and	O
-independent	O
(	O
cold	O
shock	O
,	O
serum	O
deprivation	O
,	O
and	O
gamma-radiation	O
)	O
pathways	O
in	O
TIMP-1-negative	B-cell_line
BL	I-cell_line
lines	I-cell_line
.	O

Here	O
we	O
show	O
that	O
JunB	B-protein
,	O
but	O
not	O
the	O
other	O
Jun	B-protein
family	I-protein
members	I-protein
,	O
was	O
selectively	O
induced	O
in	O
Th2	B-cell_type
cells	I-cell_type
and	O
not	O
in	O
Th1	B-cell_type
cells	I-cell_type
during	O
differentiation	O
.	O

Compared	O
with	O
monocytes	O
in	O
suspension	O
or	O
adherent	O
on	O
plastic	O
surfaces	O
,	O
monocytes	O
adherent	O
to	O
fibronectin	B-protein
or	O
RGD	O
exhibited	O
a	O
greater	O
than	O
threefold	O
increase	O
in	O
steady	O
state	O
levels	O
of	O
IFN-gamma-induced	B-RNA
mRNA	I-RNA
for	O
the	O
high	B-protein
affinity	I-protein
Fc	I-protein
gammaRI	I-protein
receptor	I-protein
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Pretreatment	O
of	O
the	O
endothelium	O
with	O
dexamethasone	O
inhibited	O
leukocyte	O
adhesion	O
;	O
this	O
may	O
be	O
due	O
in	O
part	O
to	O
the	O
suppression	O
of	O
NFkappaB	B-protein
entry	O
into	O
the	O
nucleus	O
.	O

We	O
conclude	O
that	O
FMS	O
patients	O
have	O
a	O
mild	O
hypocortisolemia	O
,	O
increased	O
cortisol	O
feedback	O
resistance	O
in	O
combination	O
probably	O
with	O
a	O
reduced	O
CRH	O
synthesis	O
or	O
release	O
in	O
the	O
hypothalamus	O
.	O

Bcd	B-DNA
transcripts	O
were	O
detected	O
in	O
all	O
normal	O
PBL	B-cell_type
samples	O
tested	O
but	O
not	O
in	O
several	O
malignant	B-cell_line
human	I-cell_line
B-cell	I-cell_line
lines	I-cell_line
and	O
not	O
in	O
50	O
%	O
of	O
B-cells	B-cell_type
from	O
B-CLL	O
patients	O
.	O

Binding	O
of	O
HIV-TF1	B-protein
to	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
activated	O
transcription	O
from	O
the	O
HIV	B-DNA
promoter	I-DNA
in	O
vitro	O
.	O

Intriguingly	O
,	O
surface	O
expression	O
of	O
LT-alpha1beta2	B-protein
is	O
up-regulated	O
on	O
a	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
acutely	O
infected	O
with	O
HIV-1	O
,	O
suggesting	O
a	O
positive	O
feedback	O
loop	O
between	O
HIV-1	O
infection	O
,	O
LT-alpha1beta2	B-protein
expression	O
,	O
and	O
HIV-1	O
replication	O
.	O

T	B-cell_type
cells	I-cell_type
infiltrating	O
a	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
lesion	O
from	O
a	O
HLA	O
DQ	O
2	O
,	O
7	O
individual	O
yielded	O
a	O
virus-specific	B-cell_line
CD4+	I-cell_line
clone	I-cell_line
restricted	O
by	O
DQ2	B-protein
.	O

The	O
Janus	B-protein
family	I-protein
tyrosine	I-protein
kinase	I-protein
Jak3	B-protein
is	O
the	O
only	O
signaling	O
molecule	O
known	O
to	O
be	O
associated	O
with	O
gamma	B-protein
c	I-protein
,	O
so	O
it	O
was	O
hypothesized	O
that	O
defects	O
in	O
Jak3	B-protein
might	O
cause	O
an	O
XSCID-like	O
phenotype	O
.	O

MR	B-protein
count	O
was	O
significantly	O
(	O
P	O
less	O
than	O
0.0005	O
)	O
decreased	O
in	O
the	O
PIH	O
group	O
(	O
148	O
+/-	O
9	O
binding	O
sites/cell	O
)	O
compared	O
with	O
the	O
control	O
group	O
(	O
300	O
+/-	O
17	O
binding	O
sites/cell	O
;	O
mean	O
+/-	O
SEM	O
)	O
.	O

Transfection	O
studies	O
reveal	O
that	O
the	O
I	B-RNA
kappa	I-RNA
B-alpha	I-RNA
mRNA	I-RNA
and	O
the	O
encoded	O
protein	O
are	O
potently	O
induced	O
by	O
NF-kappa	B-protein
B	I-protein
and	O
by	O
homodimers	O
of	O
p65	B-protein
and	O
of	O
c-Rel	B-protein
.	O

Whereas	O
CD36	B-protein
and	O
mEI	B-protein
were	O
expressed	O
in	O
all	O
hematopoetic	B-cell_line
cell	I-cell_line
lines	I-cell_line
containing	O
Oct2	B-protein
,	O
.	O

In	O
a	O
cotransfection	O
assay	O
,	O
the	O
Tax	B-protein
protein	I-protein
of	O
both	O
HTLV-I	O
and	O
HTLV-II	O
specifically	O
activated	O
transcription	O
from	O
the	O
IL-1alpha	B-DNA
promoter	I-DNA
in	O
an	O
uninfected	B-cell_line
Jurkat	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

In	O
addition	O
,	O
DNA-binding	O
activities	O
of	O
Jun-Fos	B-protein
heterodimers	I-protein
were	O
observed	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
during	O
the	O
course	O
of	O
natural	O
cytotoxicity	O
.	O

When	O
breast	O
cancers	O
were	O
examined	O
for	O
NGAL	O
mRNA	O
and	O
protein	O
levels	O
,	O
they	O
were	O
found	O
to	O
exhibit	O
heterogeneous	O
expression	O
.	O

NF-kappaB	B-protein
functions	O
as	O
both	O
a	O
proapoptotic	B-protein
and	I-protein
antiapoptotic	I-protein
regulatory	I-protein
factor	I-protein
within	O
a	O
single	O
cell	O
type	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
atypical	B-protein
PKC	I-protein
isoenzymes	I-protein
,	O
including	O
PKC-zeta	B-protein
,	O
participate	O
in	O
the	O
signal	O
transduction	O
pathways	O
by	O
which	O
HIV	O
infection	O
results	O
in	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
.	O

In	O
cells	O
of	O
nonhematopoietic	B-cell_type
lineage	I-cell_type
,	O
human	B-cell_type
endothelial	I-cell_type
and	O
HeLa	B-cell_type
cells	I-cell_type
,	O
the	O
GP	B-DNA
Ib	I-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
was	O
no	O
greater	O
than	O
background	O
levels	O
obtained	O
with	O
promoterless	B-DNA
constructs	I-DNA
.	O

Paradoxical	O
priming	O
effects	O
of	O
IL-10	B-protein
on	O
cytokine	B-protein
production	O
.	O

In	O
earlier	O
studies	O
,	O
we	O
have	O
identified	O
the	O
transcription	B-protein
factors	I-protein
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
as	O
molecular	O
targets	O
for	O
oxidative	O
signalling	O
processes	O
during	O
cell	O
cycle	O
entry	O
,	O
and	O
have	O
shown	O
that	O
oxidative	O
signalling	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
early	O
changes	O
in	O
gene	O
expression	O
during	O
the	O
G0	O
to	O
G1	O
phase	O
transition	O
.	O

Before	O
and	O
after	O
treatment	O
,	O
the	O
patients	O
underwent	O
fiberoptic	O
bronchoscopy	O
with	O
endobronchial	O
biopsy	O
and	O
sampling	O
of	O
venous	O
blood	O
for	O
measurements	O
of	O
GR	B-RNA
mRNA	I-RNA
levels	O
.	O

Within	O
the	O
context	O
of	O
a	O
complex	B-DNA
enhancer	I-DNA
and	O
LCR	B-DNA
,	O
c-Myb	B-protein
can	O
act	O
as	O
an	O
organizer	O
of	O
thymocyte-specific	B-DNA
gene	I-DNA
expression	O
via	O
a	O
single	O
binding	O
site	O
.	O

Glucocorticoid-resistance	O
in	O
peripheral-blood	B-cell_type
lymphocytes	I-cell_type
does	O
not	O
correlate	O
with	O
number	O
of	O
affinity	O
of	O
glucocorticoid-receptors	B-protein
in	O
chronic	O
renal	O
failure	O
patients	O
.	O

The	O
genomic	O
actions	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
are	O
mediated	O
by	O
the	O
intracellular	O
vitamin	B-protein
D	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
.	O

The	O
kinases	O
that	O
couple	O
ligand	O
binding	O
to	O
tyrosine	O
phosphorylation	O
of	O
cellular	B-protein
substrates	I-protein
by	O
the	O
G-CSFR	O
with	O
activation	O
of	O
specific	O
functional	O
programs	O
are	O
largely	O
unknown	O
.	O

Constitutive	O
activations	O
of	O
PKB/Akt	B-protein
,	O
STAT5a	B-protein
,	O
and	O
STAT5b	B-protein
were	O
noted	O
in	O
these	O
EPO-independent	B-cell_line
cells	I-cell_line
.	O

The	O
c-jun	B-DNA
gene	I-DNA
expression	O
was	O
very	O
transient	O
and	O
was	O
not	O
detectable	O
by	O
60	O
min	O
after	O
M-CSF	B-protein
addition	O
.	O

Thus	O
,	O
qualitative	O
differences	O
in	O
the	O
capacity	O
to	O
regulate	O
these	O
factors	O
could	O
not	O
be	O
shown	O
in	O
fetal	B-cell_type
blood	I-cell_type
cells	I-cell_type
.	O

Platelet-activating	B-protein
factor	I-protein
induces	O
phospholipid	O
turnover	O
,	O
calcium	O
flux	O
,	O
arachidonic	O
acid	O
liberation	O
,	O
eicosanoid	O
generation	O
,	O
and	O
oncogene	B-DNA
expression	O
in	O
a	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Kaposi	O
's	O
sarcoma	O
(	O
KS	O
)	O
-associated	O
herpesvirus	O
(	O
KSHV	O
)	O
,	O
or	O
human	O
herpesvirus	O
8	O
,	O
is	O
a	O
lymphotropic	O
virus	O
strongly	O
linked	O
to	O
several	O
AIDS-related	O
neoplasms	O
.	O

Ubiquitinylation	O
of	O
transcription	B-protein
factors	I-protein
c-Jun	B-protein
and	O
c-Fos	B-protein
using	O
reconstituted	B-protein
ubiquitinylating	I-protein
enzymes	I-protein
.	O

A	O
chimeric	O
IL-6	B-protein
receptor	I-protein
,	O
comprised	O
of	O
the	O
intracellular	B-protein
tail	I-protein
of	O
the	O
IL-6	B-protein
receptor	I-protein
subunit	I-protein
gp130	B-protein
fused	O
to	O
the	O
extracellular	B-protein
domain	I-protein
of	O
the	O
epidermal	B-protein
growth	I-protein
factor	I-protein
(	I-protein
EGF	I-protein
)	I-protein
receptor	I-protein
,	O
was	O
stably	O
transfected	O
into	O
SKW6.4	B-cell_line
cells	I-cell_line
.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
enhanced	O
NF-kappa	B-protein
B	I-protein
expression	O
caused	O
by	O
free	O
radical	O
production/oxidative	O
stress	O
may	O
modulate	O
liver	O
injury	O
,	O
perhaps	O
through	O
an	O
effect	O
on	O
cytotoxic	B-protein
cytokine	I-protein
synthesis	O
.	O

A	O
central	O
role	O
for	O
a	O
single	B-DNA
c-Myb	I-DNA
binding	I-DNA
site	I-DNA
in	O
a	O
thymic	B-DNA
locus	I-DNA
control	I-DNA
region	I-DNA
.	O

In	O
contrast	O
,	O
interleukin-1beta-converting	O
enzyme	O
family	O
protease	O
inhibitors	O
Ac-DEVD-CHO	O
and	O
CrmA	O
blocked	O
Fas	B-protein
-mediated	O
apoptosis	O
.	O

When	O
the	O
human	B-DNA
epsilon-	I-DNA
or	I-DNA
beta-globin	I-DNA
genes	I-DNA
driven	O
by	O
the	O
dominant	B-DNA
control	I-DNA
region	I-DNA
(	O
DCR	B-DNA
)	O
are	O
introduced	O
into	O
this	O
system	O
,	O
the	O
human	B-DNA
epsilon-globin	I-DNA
gene	I-DNA
,	O
in	O
contrast	O
to	O
the	O
beta-globin	B-DNA
gene	I-DNA
,	O
is	O
not	O
deregulated	O
by	O
the	O
presence	O
of	O
the	O
DCR	B-DNA
and	O
is	O
expressed	O
strictly	O
as	O
an	O
embryonic	B-DNA
gene	I-DNA
.	O

In	O
fertile	O
women	O
remarkable	O
changes	O
in	O
androgen	B-protein
binding	I-protein
sites	I-protein
were	O
seen	O
in	O
the	O
course	O
of	O
the	O
menstrual	O
cycle	O
,	O
with	O
a	O
significant	O
increase	O
in	O
the	O
immediate	O
preovulatory	O
period	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
roles	O
of	O
Stat1alpha	B-protein
and	O
Stat3	B-protein
in	O
EPO	B-protein
-induced	O
erythroid	O
differentiation	O
.	O

The	O
mechanism	O
by	O
which	O
NF-ATc	B-protein
enters	O
the	O
nucleus	O
is	O
unknown	O
,	O
and	O
although	O
it	O
appears	O
to	O
require	O
calcineurin	B-protein
,	O
NF-ATc	B-protein
has	O
not	O
yet	O
been	O
shown	O
to	O
be	O
an	O
in	O
vivo	O
substrate	O
of	O
calcineurin	B-protein
.	O

Binding	O
of	O
erythroid	B-protein
and	I-protein
non-erythroid	I-protein
nuclear	I-protein
proteins	I-protein
to	O
the	O
silencer	B-DNA
of	O
the	O
human	B-DNA
epsilon-globin-encoding	I-DNA
gene	I-DNA
.	O

By	O
promoter	O
deletion	O
and	O
mutation	O
analyses	O
,	O
we	O
established	O
this	O
region	O
as	O
a	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
.	O

Dexamethasone	O
inhibited	O
IL-2	B-protein
-induced	O
T	B-cell_type
cell	I-cell_type
proliferation	O
by	O
30	O
%	O
-88	O
%	O
,	O
relative	O
to	O
its	O
concentration	O
within	O
the	O
cultures	O
.	O

CD15	O
cross-linking	O
also	O
concomitantly	O
increased	O
interleukin-1	B-RNA
beta	I-RNA
(	I-RNA
IL-1	I-RNA
beta	I-RNA
)	I-RNA
mRNA	I-RNA
,	O
while	O
no	O
apparent	O
change	O
was	O
observed	O
in	O
the	O
levels	O
of	O
beta-actin	B-RNA
mRNA	I-RNA
,	O
indicating	O
specificity	O
.	O

The	O
Arp2/3	B-protein
complex	I-protein
is	O
essential	O
in	O
initiation	O
of	O
actin	B-protein
assembly	O
and	O
Shigella	O
movement	O
,	O
as	O
previously	O
observed	O
for	O
Listeria	O
monocytogenes	O
.	O

PNU156804	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
is	O
due	O
to	O
the	O
inhibition	O
of	O
the	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
and	O
I	B-protein
kappa	I-protein
B-beta	I-protein
.	O

TNF-alpha	O
signaling	O
leads	O
to	O
a	O
rapid	O
depletion	O
of	O
cellular	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
pools	O
.	O

Three	O
DNA	O
clones	O
containing	O
HHV-6	B-DNA
(	I-DNA
GS	I-DNA
)	I-DNA
genomic	I-DNA
fragments	I-DNA
transactivated	O
the	O
HIV	B-DNA
promoter	I-DNA
in	O
cotransfected	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Gel	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
specific	O
DNA-protein	B-protein
complexes	I-protein
can	O
be	O
formed	O
with	O
each	O
element	O
,	O
and	O
that	O
there	O
are	O
cell-specific	O
differences	O
in	O
factors	O
,	O
which	O
bind	O
to	O
the	O
SP-1-like	B-DNA
element	I-DNA
between	O
MEL	B-cell_line
and	I-cell_line
NIH3T3	I-cell_line
cells	I-cell_line
.	O

Functional	O
synergy	O
between	O
Raf	B-protein
and	O
calcineurin	B-protein
.	O

A	O
later	O
result	O
of	O
inhibition	O
of	O
this	O
activation	O
pathway	O
by	O
p21	B-protein
(	I-protein
ras	I-protein
)	I-protein
was	O
down-regulation	O
of	O
the	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
and	O
subsequent	O
coordinate	O
reductions	O
in	O
IL-2	B-DNA
gene	I-DNA
expression	O
and	O
protein	O
production	O
.	O

Activation	O
of	O
STAT5	B-protein
by	O
IL-4	B-protein
relies	O
on	O
Janus	B-protein
kinase	I-protein
function	O
but	O
not	O
on	O
receptor	O
tyrosine	O
phosphorylation	O
,	O
and	O
can	O
contribute	O
to	O
both	O
cell	O
proliferation	O
and	O
gene	O
regulation	O
.	O

These	O
results	O
indicate	O
that	O
cepharanthine	O
is	O
a	O
highly	O
potent	O
inhibitor	O
of	O
HIV-1	O
replication	O
in	O
a	O
chronically	B-cell_line
infected	I-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

We	O
questioned	O
whether	O
one	O
can	O
use	O
the	O
limited	O
expression	O
of	O
lymphoid	B-protein
markers	I-protein
or	O
the	O
limited	O
gene	O
rearrangement	O
to	O
conclude	O
that	O
H-RS	B-cell_line
cells	I-cell_line
have	O
a	O
lymphoid	O
origin	O
,	O
because	O
these	O
markers	O
may	O
be	O
aberrant	O
in	O
tumor	B-cell_type
cells	I-cell_type
.	O

BACKGROUND	O
:	O
IL-5	B-protein
controls	O
development	O
of	O
eosinophilia	O
and	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
allergic	O
diseases	O
.	O

Gel	O
retardation	O
assays	O
,	O
using	O
a	O
32P-probe	O
containing	O
the	O
HIV-1	O
NF-kB	B-protein
probe	O
and	O
nuclear	O
extracts	O
from	O
PMA-treated	B-cell_type
cells	I-cell_type
,	O
showed	O
significantly	O
reduced	O
induction	O
of	O
nuclear	B-protein
NF-kB	I-protein
binding	I-protein
proteins	I-protein
in	O
these	O
two	O
subclones	O
compared	O
with	O
wild	B-protein
type	I-protein
CEM	I-protein
and	O
a	O
control	O
subclone	O
.	O

We	O
have	O
isolated	O
TFIIH	B-protein
from	O
cells	O
derived	O
from	O
a	O
patient	O
(	O
XP11BE	O
)	O
who	O
carries	O
this	O
frameshift	O
mutation	O
(	O
TFIIHmut	B-protein
)	O
and	O
from	O
the	O
mother	O
of	O
this	O
patient	O
(	O
TFIIHwt	B-protein
)	O
to	O
determine	O
the	O
biochemical	O
consequences	O
of	O
the	O
mutation	O
.	O

When	O
introduced	O
into	O
interleukin	B-protein
3	I-protein
(	O
IL-3	B-protein
)	O
-dependent	O
mouse	O
pro-B	B-cell_type
lymphocytes	I-cell_type
,	O
E2A-HLF	B-protein
prevents	O
apoptosis	O
induced	O
by	O
growth	B-protein
factor	I-protein
deprivation	O
,	O
suggesting	O
that	O
IL-3	B-protein
mediates	O
cell	O
survival	O
through	O
activation	O
of	O
a	O
transcription	B-protein
factor	I-protein
whose	O
activity	O
can	O
be	O
constitutively	O
replaced	O
by	O
the	O
chimeric	B-protein
oncoprotein	I-protein
.	O

These	O
observations	O
suggest	O
a	O
second	O
pathway	O
leading	O
to	O
NF-kappa	B-protein
B	I-protein
induction	O
,	O
in	O
which	O
processing	O
of	O
the	O
precursors	O
rather	O
than	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
plays	O
a	O
major	O
role	O
.	O

Using	O
a	O
radiolabeled	O
chemical	O
probe	O
,	O
we	O
here	O
purified	O
a	O
target	O
of	O
SR	O
31747A	O
and	O
called	O
it	O
SR	B-protein
31747A-binding	I-protein
protein	I-protein
(	O
SR-BP	B-protein
)	O
.	O

Seven	O
preterms	O
developed	O
neonatal	O
respiratory	O
distress	O
syndrome	O
(	O
NRDS	O
)	O
.	O

Chronic	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
infection	O
of	O
myeloid	B-cell_type
cells	I-cell_type
disrupts	O
the	O
autoregulatory	O
control	O
of	O
the	O
NF-kappaB/Rel	B-protein
pathway	O
via	O
enhanced	O
IkappaBalpha	B-protein
degradation	O
.	O

Triflusal	O
and	O
HTB	O
may	O
exert	O
beneficial	O
effects	O
in	O
processes	O
in	O
which	O
de	O
novo	O
COX-2	B-protein
expression	O
is	O
involved	O
and	O
,	O
in	O
a	O
broader	O
sense	O
,	O
in	O
pathological	O
situations	O
in	O
which	O
genes	O
under	O
nuclear	B-protein
factor-kappaB	I-protein
control	O
are	O
up-regulated	O
.	O

Furthermore	O
,	O
hirudin	O
and	O
anti-thrombin	B-protein
III	I-protein
inhibited	O
the	O
thrombin-induced	O
[	O
Ca2+	O
]	O
i	O
rise	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

The	O
pAT	B-DNA
133	I-DNA
gene	I-DNA
is	O
immediately	O
induced	O
,	O
with	O
FOS	B-protein
-like	O
kinetics	O
,	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
in	O
fibroblasts	B-cell_type
.	O

Progesterone	O
suppression	O
of	O
pregnancy	B-cell_type
lymphocytes	I-cell_type
is	O
not	O
mediated	O
by	O
glucocorticoid	O
effect	O
.	O

This	O
stimulation	O
is	O
abrogated	O
by	O
mutations	O
affecting	O
the	O
E2F-binding	B-DNA
sites	I-DNA
.	O

We	O
showed	O
here	O
by	O
mobility-shift	O
assay	O
that	O
T-cell	B-cell_line
lines	I-cell_line
transformed	O
with	O
the	O
virus	O
contained	O
high	O
levels	O
of	O
AP-1	B-protein
activities	O
.	O

The	O
second	O
was	O
to	O
suppress	O
the	O
permanent	O
NF-kappaB	B-protein
translocation	O
induced	O
by	O
HIV-1	O
replication	O
itself	O
in	O
chronically	B-cell_line
infected	I-cell_line
U937	I-cell_line
cells	I-cell_line
,	O
using	O
a	O
specific	O
proteasome	O
inhibitor	O
(	O
Z-LLL-H	O
)	O
.	O

In	O
addition	O
,	O
assay	O
of	O
PBMC	B-cell_type
by	O
the	O
adenovirus-specific	O
PCR	O
may	O
help	O
detect	O
early	O
invasive	O
disease	O
and	O
warrants	O
further	O
evaluation	O
.	O

Moreover	O
,	O
the	O
mechanism	O
of	O
action	O
of	O
BHRF1	B-protein
resembled	O
that	O
of	O
Bcl-2	B-protein
and	O
Bcl-xL	B-protein
as	O
it	O
inhibited	O
TNF-	O
and	O
anti-Fas-induced	O
activation	O
of	O
two	O
enzymes	O
participating	O
in	O
the	O
apoptosis	O
pathway	O
,	O
cytosolic	B-protein
phospholipase	I-protein
A2	I-protein
and	O
caspase-3/CPP32	B-protein
,	O
but	O
did	O
not	O
interfere	O
with	O
the	O
activation	O
of	O
NF-kappaB-like	B-protein
transcription	I-protein
factors	I-protein
.	O

Since	O
most	O
of	O
the	O
actions	O
of	O
vitamin	O
D	O
are	O
mediated	O
by	O
its	O
receptors	O
(	O
VDR	B-protein
)	O
,	O
abnormalities	O
of	O
VDR	B-protein
have	O
been	O
postulated	O
in	O
XLH	O
.	O

V3	B-protein
loop	I-protein
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
suppresses	O
interleukin	B-protein
2	I-protein
-induced	O
T	O
cell	O
growth	O
[	O
published	O
erratum	O
appears	O
in	O
AIDS	O
Res	O
Hum	O
Retroviruses	O
1997	O
May	O
1	O
;	O
13	O
(	O
7	O
)	O
:	O
633	O
]	O

Structure/function	O
analysis	O
of	O
various	O
Oct-2a	B-protein
effector	I-protein
regions	I-protein
in	O
the	O
context	O
of	O
the	O
GAL4	B-protein
DNA-binding	I-protein
domain	I-protein
revealed	O
that	O
Oct-2a	B-protein
contains	O
two	O
functionally	O
different	O
activation	B-protein
domains	I-protein
at	O
the	O
N	B-protein
and	I-protein
the	I-protein
C	I-protein
termini	I-protein
.	O

Interferon	O
augments	O
PML	B-protein
and	O
PML/RAR	B-protein
alpha	I-protein
expression	O
in	O
normal	O
myeloid	B-cell_type
and	O
acute	B-cell_type
promyelocytic	I-cell_type
cells	I-cell_type
and	O
cooperates	O
with	O
all-trans	O
retinoic	O
acid	O
to	O
induce	O
maturation	O
of	O
a	O
retinoid-resistant	B-cell_line
promyelocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

mRNA	B-RNA
expression	O
was	O
identified	O
after	O
RNA	O
extraction	O
using	O
RNAzol	O
and	O
analysed	O
after	O
reverse	B-protein
transcriptase	I-protein
,	O
by	O
polymerase	O
chain	O
reaction	O
using	O
a	O
semiquantitative	O
competitive	O
hybridization	O
assay	O
.	O

We	O
have	O
investigated	O
the	O
protein	O
binding	O
characteristics	O
and	O
functional	O
importance	O
of	O
the	O
ACT-1-activating	B-DNA
region	I-DNA
of	O
the	O
IL-3	B-protein
promoter	O
.	O

RFX5	B-protein
and	O
CIITA	B-protein
associate	O
to	O
form	O
a	O
complex	O
capable	O
of	O
activating	O
transcription	O
from	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
promoters	I-DNA
.	O

Negative	O
selection	O
refers	O
to	O
the	O
deletion	O
or	O
inactivation	O
of	O
potentially	O
autoreactive	B-cell_type
thymocytes	I-cell_type
.	O

Human	B-protein
interleukin-13	I-protein
activates	O
the	O
interleukin-4-dependent	B-protein
transcription	I-protein
factor	I-protein
NF-IL4	B-protein
sharing	O
a	O
DNA	B-protein
binding	I-protein
motif	I-protein
with	O
an	O
interferon-gamma-induced	B-protein
nuclear	I-protein
binding	I-protein
factor	I-protein
.	O

CONCLUSION	O
:	O
The	O
results	O
in	O
this	O
study	O
confirm	O
the	O
potency	O
of	O
the	O
inhaled	O
corticosteroid	O
FP	O
and	O
provide	O
evidence	O
for	O
a	O
considerable	O
tissue-specific	O
interindividual	O
variation	O
in	O
the	O
expression	O
of	O
the	O
GR	B-protein
.	O

We	O
have	O
developed	O
a	O
reporter	O
assay	O
to	O
begin	O
characterizing	O
the	O
mechanisms	O
that	O
regulate	O
late	O
gene	O
expression	O
in	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
.	O

cis-acting	B-DNA
sequences	I-DNA
required	O
for	O
inducible	O
interleukin-2	B-DNA
enhancer	I-DNA
function	O
bind	O
a	O
novel	O
Ets-related	B-protein
protein	I-protein
,	O
Elf-1	B-protein
.	O

Transfection	O
of	O
cells	O
with	O
full	O
length	O
E2A	B-DNA
cDNA	I-DNA
leads	O
to	O
appearance	O
of	O
protein	O
co-migrating	O
with	O
the	O
73	B-protein
kDa	I-protein
protein	I-protein
on	O
SDS	O
gel	O
electrophoresis	O
and	O
co-migrating	O
with	O
LEF1/BCF1	B-protein
on	O
mobility	O
shift	O
analysis	O
.	O

These	O
results	O
suggest	O
that	O
monoclonal	O
integration	O
of	O
HTLV-1	O
provirus	O
to	O
the	O
genome	O
of	O
T	B-cell_type
cell	I-cell_type
,	O
especially	O
the	O
number	O
of	O
integration	O
sites	O
,	O
is	O
one	O
of	O
the	O
factors	O
for	O
induction	O
of	O
ICAM-1	B-protein
molecules	I-protein
.	O

In	O
contrast	O
to	O
transcriptional	O
activation	O
in	O
PBMC	B-cell_type
,	O
EMSA	O
revealed	O
that	O
CD28	B-protein
coligation	O
of	O
CD2-activated	B-cell_type
LPMC	I-cell_type
does	O
not	O
result	O
in	O
increased	O
binding	O
of	O
trans-factors	O
to	O
the	O
CD28RE	B-DNA
,	O
nor	O
did	O
Western	O
blots	O
detect	O
changes	O
in	O
I-kappaBalpha	B-protein
or	O
I-kappaBbeta	B-protein
levels	O
following	O
CD28	B-protein
coligation	O
.	O

IL-4	B-protein
had	O
no	O
significant	O
effect	O
on	O
HIV	O
reverse	O
transcription	O
.	O

Seventeen	O
microsatellite	B-DNA
markers	I-DNA
that	O
span	O
the	O
common	O
deleted	O
region	O
were	O
used	O
to	O
search	O
for	O
loss	O
of	O
heterozygosity	O
in	O
granulocyte	B-DNA
DNA	I-DNA
.	O

In	O
the	O
studies	O
described	O
in	O
this	O
report	O
,	O
we	O
demonstrated	O
a	O
physical	O
interaction	O
between	O
multiple	O
Ets	B-protein
and	I-protein
NF-kappaB/NFAT	I-protein
proteins	I-protein
both	O
in	O
vitro	O
and	O
in	O
activated	B-cell_type
normal	I-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Inhibition	O
of	O
LITAF	B-RNA
mRNA	I-RNA
expression	O
in	O
THP-1	B-cell_line
cells	I-cell_line
resulted	O
in	O
a	O
reduction	O
of	O
TNF-alpha	B-protein
transcripts	O
.	O

TNFalpha	B-protein
decreased	O
(	O
P	O
<	O
0.001	O
)	O
,	O
while	O
IL-10	B-protein
increased	O
(	O
P	O
<	O
0.001	O
)	O
,	O
the	O
concentration	O
of	O
dexamethasone	O
binding	O
sites	O
in	O
these	O
cells	O
,	O
with	O
no	O
discernible	O
effect	O
on	O
their	O
binding	O
affinity	O
.	O

Using	O
a	O
structure-function	O
mutagenesis	O
approach	O
,	O
two	O
tyrosine	O
residues	O
(	O
Tyr427	O
and	O
Tyr477	O
)	O
in	O
the	O
intracellular	B-protein
domain	I-protein
of	O
the	O
murine	O
IL-10	B-protein
receptor	O
were	O
found	O
to	O
be	O
redundantly	O
required	O
for	O
receptor	O
function	O
and	O
for	O
activation	O
of	O
Stat3	B-protein
but	O
not	O
for	O
Stat1	B-protein
or	O
Stat5	B-protein
.	O

The	O
IL-2Ralpha	B-DNA
promoter	I-DNA
containing	O
the	O
nuclear	B-DNA
factor	I-DNA
kappa	I-DNA
B	I-DNA
(	I-DNA
NF-kappaB	I-DNA
)	I-DNA
site	I-DNA
was	O
transcriptionally	O
induced	O
by	O
M.	O
tuberculosis	O
and	O
this	O
NF-kappaB	B-protein
site	O
could	O
confer	O
inducibility	O
to	O
a	O
heterologous	B-DNA
herpes	I-DNA
thymidine	I-DNA
kinase	I-DNA
(	I-DNA
TK	I-DNA
)	I-DNA
promoter	I-DNA
by	O
M.	O
tuberculosis	O
.	O

Overall	O
,	O
our	O
data	O
indicate	O
that	O
Calphostin	O
C	O
prevents	O
the	O
transcription	O
of	O
the	O
IL-1beta	B-DNA
gene	I-DNA
thereby	O
inhibiting	O
protein	O
synthesis	O
.	O

In	O
addition	O
,	O
we	O
looked	O
at	O
the	O
modulation	O
of	O
nuclear	B-protein
factors	I-protein
binding	O
specifically	O
to	O
the	O
AP-1	B-DNA
element	I-DNA
after	O
LTB4	O
stimulation	O
.	O

These	O
results	O
suggest	O
that	O
PI3-K	B-protein
is	O
involved	O
in	O
NFAT	B-protein
activation	O
through	O
a	O
complex	O
adaptor	O
function	O
of	O
its	O
regulatory	B-protein
subunit	I-protein
and	O
that	O
its	O
lipid	B-protein
kinase	I-protein
activity	O
is	O
dispensable	O
for	O
this	O
effect	O
.	O

Overexpression	O
of	O
BXB	B-protein
,	O
a	O
constitutive	O
active	O
version	O
of	O
c-Raf	B-protein
,	O
and	O
of	O
further	O
members	O
of	O
the	O
Ras	B-protein
-	O
Raf	B-protein
-	O
Erk	B-protein
signal	O
cascade	O
exerted	O
an	O
increase	O
of	O
GABP	B-protein
-mediated	O
promoter-enhancer	O
induction	O
.	O

The	O
number	O
and	O
affinity	O
of	O
glucocorticoid	O
binding	O
sites	O
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
of	O
patients	O
with	O
atopic	O
dermatitis	O
(	O
AD	O
)	O
and	O
healthy	O
controls	O
were	O
determined	O
under	O
baseline	O
conditions	O
and	O
after	O
a	O
defined	O
oral	O
glucocorticoid	O
treatment	O
.	O

Thus	O
,	O
hTLR2	B-protein
is	O
a	O
molecular	O
link	O
between	O
microbial	O
products	O
,	O
apoptosis	O
,	O
and	O
host	O
defense	O
mechanisms	O
.	O

However	O
,	O
its	O
activity	O
becomes	O
lower	O
in	O
the	O
double-positive	O
and	O
a	O
fraction	O
of	O
the	O
CD4+	B-cell_type
CD8int/-	I-cell_type
cell	I-cell_type
population	I-cell_type
,	O
indicating	O
that	O
an	O
additional	O
enhancer	O
,	O
located	O
in	O
either	O
the	O
first	B-DNA
or	I-DNA
the	I-DNA
third	I-DNA
intron	I-DNA
of	O
the	O
CD4	B-DNA
gene	I-DNA
,	O
is	O
required	O
for	O
CD4	B-DNA
gene	I-DNA
expression	O
in	O
this	O
population	O
.	O

The	O
induction	O
of	O
IgE	B-protein
by	O
IL-4	B-protein
and	O
IL-13	B-protein
occurs	O
through	O
the	O
activation	O
of	O
the	O
intracellular	B-protein
signal-transducing	I-protein
protein	I-protein
Stat6	I-protein
,	O
whereas	O
the	O
inhibition	O
of	O
IgE	B-protein
class	O
switching	O
by	O
interferon-y	B-protein
(	O
IFN-gamma	B-protein
)	O
occurs	O
through	O
the	O
activation	O
of	O
Statl	B-protein
.	O

Here	O
we	O
describe	O
an	O
alternative	O
approach	O
,	O
based	O
on	O
in	O
vitro	O
stimulation	O
with	O
epitope	B-cell_line
peptide-loaded	I-cell_line
dendritic	I-cell_line
cells	I-cell_line
(	O
DCs	B-cell_line
)	O
,	O
which	O
allows	O
one	O
to	O
probe	O
the	O
CTL	O
repertoire	O
for	O
any	O
individual	O
reactivity	O
of	O
choice	O
;	O
this	O
method	O
proved	O
significantly	O
more	O
efficient	O
than	O
stimulation	O
with	O
peptide	O
alone	O
.	O

These	O
findings	O
further	O
extended	O
our	O
previous	O
data	O
regarding	O
EBV	O
latency	O
in	O
gastric	B-cell_type
carcinoma	I-cell_type
cells	I-cell_type
at	O
the	O
protein	O
level	O
,	O
and	O
have	O
affirmed	O
that	O
the	O
programme	O
of	O
viral	O
gene	O
expression	O
in	O
the	O
tumour	O
more	O
closely	O
resembles	O
'latency	O
I	O
'	O
represented	O
by	O
Burkitt	O
's	O
lymphoma	O
than	O
'latency	O
II	O
'	O
represented	O
by	O
the	O
majority	O
of	O
nasopharyngeal	O
carcinomas	O
.	O

Cellular	O
regulation	O
of	O
BZLF1	B-protein
transcription	O
is	O
therefore	O
thought	O
to	O
play	O
a	O
key	O
role	O
in	O
regulating	O
the	O
stringency	O
of	O
viral	O
latency	O
.	O

IL-2	B-protein
and	O
IL-7	B-protein
were	O
equivalent	O
in	O
their	O
ability	O
to	O
induce	O
tyrosine	O
phosphorylation	O
of	O
STAT5A	B-protein
and	O
STAT5B	B-protein
and	O
to	O
facilitate	O
binding	O
of	O
these	O
STATs	B-protein
to	O
an	O
immobilized	B-DNA
GAS	I-DNA
element	I-DNA
.	O

Central	O
to	O
the	O
bone-sparing	O
effect	O
of	O
estrogen	O
(	O
E	O
(	O
2	O
)	O
)	O
is	O
its	O
ability	O
to	O
block	O
the	O
monocytic	O
production	O
of	O
the	O
osteoclastogenic	B-protein
cytokine	I-protein
TNF-alpha	I-protein
(	O
TNF	B-protein
)	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
AP-1	B-DNA
site	I-DNA
at	O
-150	B-DNA
bp	I-DNA
represents	O
a	O
major	O
,	O
if	O
not	O
the	O
only	O
,	O
site	O
of	O
PKC	B-protein
responsiveness	O
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

In	O
addition	O
,	O
alpha	B-protein
G2S	I-protein
exhibited	O
increased	O
expression	O
of	O
CD11b	B-protein
and	O
CD54	B-protein
,	O
while	O
alpha	B-cell_line
B5A	I-cell_line
cells	I-cell_line
showed	O
increased	O
expression	O
of	O
CD102	B-protein
,	O
suggesting	O
that	O
RXR-alpha	B-protein
has	O
a	O
role	O
in	O
regulating	O
expression	O
of	O
cell	B-protein
adhesion	I-protein
molecules	I-protein
in	O
U937	B-cell_line
cells	I-cell_line
.	O

To	O
understand	O
the	O
mechanism	O
of	O
leukemic	B-cell_type
cell	I-cell_type
infiltration	O
into	O
organs	O
,	O
we	O
studied	O
the	O
expression	O
and	O
regulation	O
of	O
L-selectin	B-RNA
mRNA	I-RNA
in	O
fresh	O
leukemic	B-cell_type
cells	I-cell_type
of	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
patients	O
and	O
investigated	O
the	O
response	O
of	O
the	O
L-selectin	B-DNA
promoter	I-DNA
to	O
human	B-protein
T-cell	I-protein
lymphotropic	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HTLV-1	I-protein
)	I-protein
Tax	I-protein
,	O
which	O
is	O
a	O
viral	B-protein
transcriptional	I-protein
transactivator	I-protein
.	O

Glucocorticoids	O
(	O
GCS	O
)	O
profoundly	O
inhibit	O
several	O
aspects	O
of	O
T	O
cell	O
immunity	O
largely	O
through	O
inhibition	O
of	O
cytokine	B-protein
expression	O
at	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

The	O
monoclonal	B-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
J393	B-protein
induces	O
apoptosis	O
in	O
Jurkat	B-cell_line
T-cells	I-cell_line
.	O

In	O
this	O
study	O
,	O
a	O
series	O
of	O
Burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
(	I-cell_line
BL	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
assayed	O
for	O
their	O
expression	O
of	O
tissue	B-protein
inhibitor	I-protein
of	I-protein
metalloproteinases	I-protein
(	I-protein
TIMP	I-protein
)	I-protein
-1	I-protein
.	O

Finally	O
,	O
recovered	O
protein	O
was	O
identified	O
as	O
genuine	O
huGATA-3	B-protein
by	O
SDS-PAGE	O
,	O
Western	O
blotting	O
,	O
and	O
bandshift	O
assays	O
.	O

Here	O
we	O
show	O
that	O
contrary	O
to	O
previous	O
reports	O
,	O
PU.1	B-protein
and	O
Spi-B	B-protein
have	O
very	O
different	O
expression	O
patterns	O
.	O

Monocyte	O
arrest	O
and	O
transmigration	O
on	O
inflamed	O
endothelium	O
in	O
shear	O
flow	O
is	O
inhibited	O
by	O
adenovirus-mediated	O
gene	O
transfer	O
of	O
IkappaB-alpha	B-protein
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

After	O
the	O
treatment	O
with	O
the	O
regimen	O
of	O
Kidney-tonifying	O
and	O
Qi-invigorating	O
,	O
the	O
GCR	B-protein
of	O
the	O
aged	O
persons	O
and	O
rats	O
was	O
enhanced	O
,	O
and	O
in	O
this	O
way	O
,	O
the	O
function	O
of	O
the	O
aged	O
adrenal	O
cortex	O
was	O
improved	O
.	O

We	O
conclude	O
that	O
okadaic	O
acid-induced	O
IL-6	B-protein
gene	O
expression	O
is	O
at	O
least	O
partly	O
mediated	O
through	O
the	O
ERK1/2	B-protein
and	O
JNK	B-protein
pathway-dependent	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
transcriptional	O
capacity	O
.	O

The	O
independence	O
of	O
intracellular	O
electrolytes	O
from	O
aldosterone	O
despite	O
a	O
normal	O
number	O
of	O
mineralocorticoid	B-protein
receptors	I-protein
may	O
reflect	O
an	O
impairment	O
of	O
the	O
mineralocorticoid	O
effector	O
mechanism	O
in	O
the	O
HML	B-cell_type
of	O
patients	O
with	O
essential	O
hypertension	O
.	O

Here	O
we	O
demonstrate	O
that	O
hexamethylene	O
bisacetamide	O
(	O
HMBA	O
)	O
induced	O
K562	B-cell_line
cells	I-cell_line
to	O
differentiate	O
along	O
a	O
third	O
pathway	O
.	O

This	O
review	O
will	O
focus	O
on	O
the	O
conversion	O
of	O
the	O
unprimed	O
eosinophil	O
phenotype	O
in	O
the	O
peripheral	O
blood	O
of	O
normal	O
individuals	O
to	O
the	O
primed	O
phenotype	O
found	O
in	O
the	O
peripheral	O
blood	O
and	O
tissues	O
of	O
allergic	O
patients	O
,	O
a	O
phenomenon	O
called	O
priming	O
.	O

Complete	O
suppression	O
of	O
AP-1	B-protein
activity	O
was	O
observed	O
in	O
Con	B-cell_line
A-treated	I-cell_line
,	I-cell_line
proliferating	I-cell_line
thymocytes	I-cell_line
.	O

The	O
two	O
proteins	O
interact	O
with	O
one	O
another	O
through	O
their	O
putative	O
helix-loop-helix	B-protein
motifs	I-protein
and	O
each	O
possesses	O
a	O
distinct	O
domain	O
that	O
dictates	O
transcription	O
activation	O
.	O

Our	O
results	O
suggest	O
that	O
while	O
transfection	O
analyses	O
offer	O
an	O
adequate	O
approximation	O
of	O
the	O
effects	O
of	O
the	O
LS	O
mutations	O
,	O
the	O
analysis	O
of	O
viral	O
replication	O
using	O
a	O
mutant	O
viral	O
stock	O
presents	O
a	O
more	O
accurate	O
picture	O
,	O
which	O
is	O
sometimes	O
at	O
variance	O
with	O
the	O
transfection	O
results	O
.	O

Such	O
repressive	O
function	O
is	O
similar	O
to	O
that	O
seen	O
in	O
IRF-2	B-protein
or	O
ICSBP	B-protein
.	O

The	O
X-inactivation	O
patterns	O
of	O
circulating	O
PMNCs	B-cell_type
and	O
T	B-cell_type
lymphocytes	I-cell_type
as	O
well	O
as	O
individual	O
granulocyte	B-cell_line
colonies	I-cell_line
grown	O
in	O
vitro	O
from	O
bone	O
marrow	O
cells	O
were	O
analyzed	O
.	O

To	O
determine	O
the	O
role	O
of	O
AP-2	B-protein
in	O
the	O
regulation	O
of	O
the	O
HTLV-I	B-DNA
LTR	I-DNA
gene	O
expression	O
,	O
we	O
used	O
an	O
AP-2	B-DNA
cDNA	I-DNA
in	O
DNA	O
binding	O
and	O
transient	O
expression	O
assays	O
.	O

T	B-cell_type
cells	I-cell_type
were	O
separated	O
into	O
CD4	B-cell_type
and	O
CD8	B-cell_type
.	O

Nor	O
was	O
fragmentation	O
observed	O
after	O
treatment	O
with	O
RU38486	O
,	O
indicating	O
that	O
repression	O
of	O
AP-1	B-protein
activity	O
is	O
not	O
involved	O
.	O

To	O
test	O
this	O
latter	O
possibility	O
,	O
a	O
chimeric	B-protein
receptor	I-protein
containing	O
the	O
extracellular	B-protein
domain	I-protein
of	O
c-kit	B-protein
(	O
the	O
stem	B-protein
cell	I-protein
factor	I-protein
(	I-protein
SCF	I-protein
)	I-protein
receptor	I-protein
)	O
and	O
the	O
cytoplasmic	B-protein
and	I-protein
transmembrane	I-protein
domains	I-protein
of	O
the	O
IL-4R	B-protein
alpha	I-protein
chain	I-protein
was	O
generated	O
.	O

In	O
vivo	O
footprinting	O
and	O
mutational	O
analysis	O
of	O
the	O
proximal	B-DNA
CD19	I-DNA
promoter	I-DNA
reveal	O
important	O
roles	O
for	O
an	O
SP1/Egr-1	B-DNA
binding	I-DNA
site	I-DNA
and	O
a	O
novel	O
site	O
termed	O
the	O
PyG	B-DNA
box	I-DNA
.	O

Tax	B-protein
corresponds	O
to	O
a	O
40-kDa	B-protein
transforming	I-protein
protein	I-protein
from	O
the	O
pathogenic	O
retrovirus	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
that	O
activates	O
nuclear	O
expression	O
of	O
the	O
NF-kappaB/Rel	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
by	O
an	O
unknown	O
mechanism	O
.	O

Oxidative	O
stress	O
obtained	O
by	O
the	O
addition	O
of	O
H2O2	O
to	O
the	O
culture	O
medium	O
of	O
J.Jhan	B-cell_line
or	O
U937	B-cell_line
cells	I-cell_line
could	O
not	O
by	O
itself	O
induce	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Moreover	O
,	O
the	O
inverse	O
changes	O
in	O
the	O
expression	O
of	O
CRH	B-protein
in	O
the	O
hypothalamus	O
and	O
spleens	O
of	O
arthritic	O
rats	O
were	O
paralleled	O
by	O
similar	O
inverse	O
changes	O
in	O
NF-IL6beta	B-protein
expression	O
in	O
these	O
organs	O
.	O

In	O
agar	O
cultures	O
,	O
47.10	B-cell_line
cells	I-cell_line
form	O
7-	O
and	O
14-day	O
colonies	O
in	O
response	O
to	O
a	O
cocktail	O
of	O
granulocyte/macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
2.5	O
ng/mL	O
)	O
,	O
interleukin-3	B-protein
(	O
1	O
ng/mL	O
)	O
,	O
and	O
mouse	O
CSF-1	B-protein
(	O
10	O
ng/mL	O
)	O
.	O

In	O
vivo	O
footprinting	O
identified	O
protected	O
regions	O
over	O
the	O
known	O
high	O
affinity	O
B	B-DNA
cell	I-DNA
lineage-specific	I-DNA
activator	I-DNA
protein	I-DNA
(	I-DNA
BSAP	I-DNA
)	I-DNA
site	I-DNA
,	O
the	O
low	B-DNA
affinity	I-DNA
BSAP	I-DNA
site	I-DNA
,	O
a	O
SP1/Egr-1	B-DNA
site	I-DNA
termed	O
the	O
CD19	B-DNA
GC	I-DNA
box	I-DNA
,	O
and	O
two	O
novel	O
sites	O
named	O
the	O
AT	B-DNA
box	I-DNA
and	O
PyG	B-DNA
box	I-DNA
.	O

Thus	O
,	O
our	O
data	O
suggest	O
that	O
TPO	B-protein
has	O
a	O
distinct	O
action	O
on	O
erythropoiesis	O
.	O

The	O
negative-acting	B-DNA
sequences	I-DNA
repress	O
enhancer	O
activity	O
in	O
a	O
position-	O
and	O
orientation-independent	O
manner	O
at	O
the	O
pre-B-cell	O
stage	O
.	O

We	O
now	O
demonstrate	O
that	O
parasite-induced	O
NF-kappaB	B-protein
activation	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
survival	O
of	O
T.	B-cell_type
parva-transformed	I-cell_type
T	I-cell_type
cells	I-cell_type
by	O
conveying	O
protection	O
against	O
an	O
apoptotic	O
signal	O
that	O
accompanies	O
parasite-mediated	O
transformation	O
.	O

This	O
modification	O
of	O
a	O
previously	O
described	O
protocol	O
simplifies	O
and	O
reduces	O
laboratory	O
work	O
and	O
allows	O
assay	O
reproducibility	O
to	O
be	O
controlled	O
more	O
reliably	O
.	O

The	O
suppression	O
of	O
T	B-cell_type
cell	I-cell_type
function	O
and	O
NF	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
expression	O
by	O
serine	O
protease	O
inhibitors	O
is	O
blocked	O
by	O
N-acetylcysteine	O
.	O

The	O
functional	O
analysis	O
of	O
the	O
IL-8	B-DNA
gene	I-DNA
revealed	O
that	O
both	O
AP-1-	B-DNA
and	I-DNA
NF-kappaB	I-DNA
factor-binding	I-DNA
elements	I-DNA
were	O
involved	O
in	O
conferring	O
the	O
responsiveness	O
to	O
CMV	O
.	O

From	O
a	O
murine	B-DNA
B-cell	I-DNA
cDNA-library	I-DNA
we	O
have	O
cloned	O
a	O
cDNA	B-DNA
encoding	O
the	O
murine	B-protein
B-cell	I-protein
specific	I-protein
coactivator	I-protein
mBob1	B-protein
.	O

[	O
Regulatory	O
effect	O
of	O
insulin	B-protein
on	O
glucocorticoid	B-protein
receptor	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
leukocytes	I-cell_type
]	O

The	O
transcription	B-protein
factor	I-protein
GATA-1	B-protein
is	O
expressed	O
in	O
a	O
subset	O
of	O
hemopoietic	B-cell_type
cells	I-cell_type
,	O
where	O
it	O
mediates	O
the	O
cell-type	O
specific	O
expression	O
of	O
several	O
genes	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
human	B-DNA
GM-CSF	I-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
directs	O
reporter	B-DNA
gene	I-DNA
activity	O
in	O
a	O
tissue-specific	O
fashion	O
in	O
myelomonocytic	B-cell_type
cells	I-cell_type
,	O
which	O
correlates	O
with	O
its	O
expression	O
pattern	O
as	O
analyzed	O
by	O
reverse	O
transcription	O
PCR	O
.	O

Construction	O
and	O
biological	O
characterization	O
of	O
an	O
interleukin-12	B-protein
fusion	I-protein
protein	I-protein
(	O
Flexi-12	B-protein
)	O
:	O
delivery	O
to	O
acute	B-cell_type
myeloid	I-cell_type
leukemic	I-cell_type
blasts	I-cell_type
using	O
adeno-associated	O
virus	O
.	O

In	O
contrast	O
,	O
STAT3	B-protein
activation	O
is	O
induced	O
in	O
B-2	B-cell_type
cells	I-cell_type
after	O
antigen	O
receptor	O
engagement	O
in	O
a	O
delayed	O
fashion	O
(	O
after	O
3	O
h	O
)	O
.	O

The	O
inhibition	O
of	O
B104	B-cell_line
cell	I-cell_line
growth	O
induced	O
by	O
anti-MHC	B-protein
class	I-protein
II	I-protein
Ab	I-protein
was	O
Ca	O
(	O
2+	O
)	O
-independent	O
and	O
not	O
inhibited	O
by	O
actinomycin	O
D	O
or	O
cyclosporin	O
A	O
,	O
and	O
cell	O
cycle	O
arrest	O
at	O
the	O
G2/M	O
interphase	O
was	O
not	O
observed	O
.	O

Monofactorial	O
analysis	O
identified	O
the	O
following	O
factors	O
to	O
be	O
correlated	O
with	O
increased	O
risk	O
:	O
moderate/marked	O
mononuclear	O
cell	O
reaction	O
(	O
MCR	O
)	O
,	O
high	O
histologic	O
grade	O
(	O
G	O
)	O
,	O
extensive	O
intraductal	O
component	O
(	O
EIC	O
)	O
,	O
tumor	O
necrosis	O
,	O
macroscopic	O
multiplicity	O
,	O
estrogen	B-protein
receptor	I-protein
negativity	O
,	O
anatomic	O
tumor	O
size	O
,	O
age	O
younger	O
than	O
40	O
years	O
,	O
and	O
vascular	O
invasion	O
.	O

Likewise	O
,	O
NF-AT1	B-RNA
mRNA	I-RNA
and	O
NF-AT4	B-RNA
mRNA	I-RNA
have	O
been	O
detected	O
in	O
resting	B-cell_type
eosinophils	I-cell_type
,	O
and	O
their	O
levels	O
can	O
be	O
significantly	O
up-regulated	O
by	O
the	O
Th2-associated	B-protein
cytokines	I-protein
IL-4	B-protein
and	O
IL-5	B-protein
.	O

H2O2-induced	O
NF-kappaB	B-protein
activation	O
in	O
Wurzburg	B-cell_line
cells	I-cell_line
was	O
not	O
influenced	O
by	O
the	O
presence	O
of	O
extracellular	O
EGTA	O
but	O
was	O
totally	O
inhibited	O
in	O
cells	O
that	O
were	O
loaded	O
with	O
esterified	O
EGTA	O
.	O

Emphasis	O
is	O
given	O
to	O
recent	O
information	O
about	O
the	O
molecular	O
mechanisms	O
of	O
prolactin	O
receptor	O
signal	O
transduction	O
,	O
and	O
the	O
signaling	B-protein
molecules	I-protein
and	O
prolactin-inducible	B-DNA
target	I-DNA
genes	I-DNA
that	O
participate	O
in	O
these	O
responses	O
.	O

Because	O
of	O
the	O
theoretical	O
potential	O
of	O
such	O
sequences	O
supporting	O
replication	O
of	O
E1a-	O
Ad	O
vectors	O
,	O
human	O
gene	O
therapy	O
protocols	O
for	O
CF	O
utilizing	O
such	O
vectors	O
should	O
consider	O
evaluating	O
study	O
individuals	O
for	O
the	O
presence	O
of	O
Ad	B-DNA
2/5	I-DNA
E1a	I-DNA
sequences	I-DNA
in	O
the	O
respiratory	O
epithelium	O
.	O

ADT	O
,	O
a	O
pro-glutathione	O
antioxidant	O
,	O
was	O
observed	O
to	O
be	O
capable	O
of	O
modulating	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Altogether	O
,	O
the	O
data	O
do	O
not	O
provide	O
any	O
evidence	O
to	O
support	O
an	O
assumption	O
that	O
moderately	O
increased	O
body	O
burdens	O
of	O
PCDDs/PCDFs	O
in	O
adults	O
induce	O
decreases	O
in	O
the	O
cellular	O
components	O
of	O
the	O
human	O
immune	O
system	O
.	O

GDSP	O
significantly	O
inhibited	O
edema	O
formation	O
,	O
neutrophil	O
infiltration	O
,	O
acinar	O
cell	O
damage	O
,	O
and	O
plasma	B-protein
lipase	I-protein
and	O
amylase	B-protein
increases	O
caused	O
by	O
cerulein	O
.	O

Both	O
Sp1	B-protein
and	O
Sp3	B-protein
bound	O
to	O
the	O
5	B-DNA
'	I-DNA
portion	I-DNA
of	O
this	O
region	O
,	O
whereas	O
a	O
PMA-inducible	B-protein
factor	I-protein
(	O
PIF	B-protein
)	O
mainly	O
bound	O
to	O
its	O
3	B-DNA
'	I-DNA
portion	I-DNA
and	O
bound	O
to	O
the	O
Sp	B-DNA
binding	I-DNA
motifs	I-DNA
as	O
well	O
.	O

Of	O
even	O
more	O
interest	O
,	O
IkappaBalpha	B-protein
overexpression	O
inhibited	O
the	O
production	O
of	O
matrix	B-protein
metalloproteinases	I-protein
1	I-protein
and	I-protein
3	I-protein
while	O
not	O
affecting	O
their	O
tissue	O
inhibitor	O
.	O

This	O
phenomenon	O
is	O
due	O
to	O
mutually	O
exclusive	O
binding	O
of	O
NF-ATp	B-protein
and	O
NF-kappa	B-protein
B	I-protein
to	O
the	O
P	B-DNA
sequence	I-DNA
,	O
an	O
element	O
located	O
69	B-DNA
bp	I-DNA
upstream	I-DNA
of	O
the	O
IL4	B-DNA
transcription	I-DNA
initiation	I-DNA
site	I-DNA
.	O

This	O
study	O
adds	O
GM-CSF	B-protein
to	O
a	O
growing	O
list	O
of	O
cytokines	B-protein
and	O
receptors	O
that	O
are	O
regulated	O
by	O
CBF	B-protein
and	O
which	O
control	O
the	O
growth	O
,	O
differentiation	O
,	O
and	O
activation	O
of	O
hemopoietic	B-cell_type
cells	I-cell_type
.	O

Consistent	O
with	O
the	O
requirement	O
for	O
PC4	B-protein
in	O
the	O
reconstituted	O
system	O
,	O
OCA-B	B-protein
was	O
found	O
to	O
interact	O
directly	O
with	O
PC4	B-protein
.	O

Alone	O
,	O
PMA	O
and	O
calcium	O
ionophore	O
A23187	O
did	O
not	O
affect	O
,	O
but	O
together	O
stimulated	O
,	O
like	O
phytohaemagglutinin	B-protein
(	O
PHA	B-protein
)	O
,	O
leucine	O
and	O
,	O
in	O
particular	O
,	O
thymidine	O
incorporation	O
.	O

These	O
results	O
suggest	O
that	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
both	O
Dex	O
and	O
CsA	O
inhibited	O
IL-2	B-DNA
gene	I-DNA
transcription	O
through	O
interference	O
with	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
and	O
NF-AT	B-protein
.	O

We	O
refer	O
to	O
the	O
kappa	B-protein
B-binding	I-protein
,	I-protein
truncated	I-protein
protein	I-protein
as	O
p50B	B-protein
by	O
analogy	O
with	O
p50-NF-kappa	B-protein
B	I-protein
and	O
to	O
the	O
full-length	O
protein	O
as	O
p97	B-protein
.	O

Composite	B-DNA
elements	I-DNA
are	O
regulatory	B-DNA
modules	I-DNA
of	O
promoters	B-DNA
or	O
enhancers	B-DNA
that	O
consist	O
of	O
binding	O
sites	O
of	O
two	O
different	O
but	O
synergizing	O
transcription	B-protein
factors	I-protein
.	O

Two	O
distinct	O
signal	O
transmission	O
pathways	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
are	O
inhibited	O
by	O
complexes	O
formed	O
between	O
an	O
immunophilin	B-protein
and	O
either	O
FK506	O
or	O
rapamycin	O
.	O

Treatment	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
with	O
IFN-alpha	B-protein
,	O
IL-2	B-protein
,	O
IL-12	B-protein
,	O
and	O
IL-15	B-protein
upregulated	O
IL-2Ralpha	B-protein
,	O
c-myc	B-DNA
,	O
and	O
pim-1	B-DNA
gene	I-DNA
expression	O
.	O

The	O
effect	O
appeared	O
within	O
30	O
min	O
and	O
returned	O
to	O
basal	O
levels	O
after	O
2	O
h	O
.	O

Because	O
monocytes	B-cell_type
play	O
a	O
pivotal	O
role	O
in	O
the	O
pathophysiology	O
of	O
intravascular	O
coagulation	O
activation	O
through	O
their	O
ability	O
to	O
synthesize	O
tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
,	O
we	O
asked	O
(	O
1	O
)	O
whether	O
monocyte	O
TF	B-protein
activation	O
occurs	O
in	O
cardiac	O
transplant	O
recipients	O
and	O
(	O
2	O
)	O
whether	O
monocyte	O
TF	B-protein
expression	O
is	O
affected	O
by	O
treatment	O
with	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

HLA-DR	O
typing	O
was	O
by	O
polymerase	O
chain	O
reaction	O
and	O
sequence	O
specific	O
oligonucleotide	O
typing	O
.	O

These	O
results	O
demonstrate	O
that	O
multiple	O
X1	O
box-specific	O
DNA-binding	O
activities	O
exist	O
in	O
all	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
but	O
the	O
presence	O
of	O
an	O
actively	O
binding	O
RFX	B-protein
species	O
correlates	O
with	O
class	O
II	O
transcription	O
.	O

To	O
date	O
,	O
a	O
large	O
number	O
of	O
receptors	O
for	O
IL-12	B-protein
have	O
been	O
found	O
only	O
on	O
PBMC	B-cell_type
following	O
activation	O
with	O
PHA	B-protein
or	O
IL-2	B-protein
.	O

At	O
variance	O
,	O
in	O
PAEC	B-cell_line
incubated	O
with	O
the	O
homologous	O
serum	O
,	O
NF-kappa	B-protein
B	I-protein
was	O
strictly	O
localized	O
in	O
the	O
cell	O
cytoplasm	O
.	O

The	O
antigenic	O
specificities	O
of	O
lesion-derived	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
are	O
quite	O
diverse	O
and	O
include	O
at	O
least	O
10	O
epitopes	O
.	O

These	O
studies	O
have	O
prompted	O
our	O
interest	O
in	O
the	O
dynamics	O
of	O
other	O
transcription	B-protein
factor	I-protein
changes	O
during	O
HL-60	O
differentiation	O
.	O

NF-kappa	B-protein
B/Rel	I-protein
proteins	I-protein
have	O
been	O
shown	O
to	O
physically	O
interact	O
with	O
both	O
AP-1	B-protein
and	I-protein
Sp1	I-protein
proteins	I-protein
.	O

Multiple	O
p21ras	B-protein
effector	O
pathways	O
regulate	O
nuclear	O
factor	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Mice	O
generated	O
by	O
gene	O
targeting	O
to	O
lack	O
MyD88	B-protein
have	O
defects	O
in	O
T	O
cell	O
proliferation	O
as	O
well	O
as	O
induction	O
of	O
acute	O
phase	O
proteins	O
and	O
cytokines	B-protein
in	O
response	O
to	O
IL-1	B-protein
.	O

Activation	O
of	O
human	B-cell_line
CD4	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

Regulation	O
of	O
interleukin-2	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
expression	O
and	O
nuclear	B-protein
factor.kappa	I-protein
B	I-protein
activation	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

One	O
of	O
the	O
proteins	O
that	O
binds	O
to	O
these	O
sites	O
is	O
TRAF2	B-protein
,	O
a	O
signal	B-protein
transduction	I-protein
molecule	I-protein
that	O
is	O
also	O
utilized	O
by	O
TNFR1	B-protein
to	O
mediate	O
the	O
activation	O
of	O
several	O
downstream	O
kinases	B-protein
and	O
transcription	B-protein
factors	I-protein
.	O

We	O
have	O
now	O
studied	O
Trident	B-protein
expression	O
in	O
cell	B-cell_line
lines	I-cell_line
,	O
differentiating	B-cell_type
thymocytes	I-cell_type
and	O
in	O
lymphocytes	O
derived	O
from	O
peripheral	O
blood	O
.	O

Although	O
no	O
germ-line	O
BRCA1	B-DNA
mutation	O
was	O
observed	O
,	O
6	O
of	O
the	O
18	O
male	O
breast	O
cancer	O
cases	O
(	O
33	O
%	O
)	O
carried	O
truncating	O
mutations	O
in	O
the	O
BRCA2	B-DNA
gene	O
.	O

IL-4	B-protein
and	O
IL-13	B-protein
up-regulated	O
the	O
expression	O
of	O
both	O
genomic	O
and	O
spliced	O
HIV	B-RNA
mRNA	I-RNA
in	O
monocytes	B-cell_type
cultured	O
on	O
Teflon	O
,	O
as	O
determined	O
by	O
Northern	O
analysis	O
and	O
p24	B-protein
Ag	I-protein
assay	O
.	O

In	O
addition	O
,	O
this	O
analysis	O
suggests	O
a	O
common	O
step	O
in	O
the	O
signaling	O
pathways	O
that	O
trigger	O
I	B-protein
kappaB	I-protein
alpha	I-protein
,	O
I	B-protein
kappaB	I-protein
beta	I-protein
,	O
and	O
I	B-protein
kappaB	I-protein
epsilon	I-protein
degradation	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
obtained	O
peripheral	O
venous	O
blood	O
samples	O
in	O
20	O
patients	O
with	O
AMI	O
before	O
and	O
daily	O
for	O
5	O
days	O
after	O
direct	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
(	O
PTCA	O
)	O
and	O
in	O
20	O
patients	O
undergoing	O
elective	O
PTCA	O
.	O

Treatment	O
of	O
cells	O
expressing	O
the	O
chimeric	B-protein
receptor	I-protein
kit/IL-4R	B-protein
alpha	I-protein
with	O
SCF	B-protein
induces	O
activation	O
of	O
the	O
IL-4R	B-protein
alpha-associated	I-protein
kinase	I-protein
JAK-1	B-protein
and	O
the	O
transcription	B-protein
factor	I-protein
STAT6	B-protein
.	O

Possible	O
mechanisms	O
by	O
which	O
these	O
proteins	O
may	O
regulate	O
transcription	O
of	O
the	O
epsilon-globin-encoding	B-DNA
gene	I-DNA
in	O
erythroid	B-cell_type
and	I-cell_type
non-erythroid	I-cell_type
cells	I-cell_type
are	O
discussed	O
.	O

Our	O
finding	O
that	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
or	O
antibody	B-protein
to	I-protein
CD3	I-protein
is	O
not	O
sufficient	O
to	O
induce	O
HIV	B-DNA
enhancer	I-DNA
-dependent	O
transcription	O
in	O
cloned	B-cell_line
T	I-cell_line
cells	I-cell_line
contrasts	O
with	O
results	O
obtained	O
in	O
most	O
lymphoblastoid	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
and	O
indicates	O
that	O
normal	O
T	B-cell_type
lymphocytes	I-cell_type
differ	O
from	O
tumoral	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
terms	O
of	O
requirements	O
for	O
HIV	B-DNA
LTR	I-DNA
activation	O
.	O

JunB	B-protein
-control	O
of	O
IL-4	B-protein
expression	O
is	O
mediated	O
by	O
the	O
phosphorylation	O
of	O
JunB	B-protein
at	O
Thr102	O
and-	O
104	O
by	O
JNK	B-protein
MAP	I-protein
kinase	I-protein
.	O

A	O
2.3-kb	B-protein
LCR	I-protein
in	O
the	O
human	B-DNA
adenosine	I-DNA
deaminase	I-DNA
(	I-DNA
ADA	I-DNA
)	I-DNA
gene	I-DNA
first	I-DNA
intron	I-DNA
,	O
which	O
controls	O
expression	O
in	O
thymocytes	B-cell_type
,	O
is	O
composed	O
of	O
a	O
200-bp	B-DNA
enhancer	I-DNA
domain	I-DNA
and	O
extended	O
flanking	O
sequences	O
that	O
facilitate	O
activation	O
from	O
within	O
chromatin	B-DNA
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

A	O
new	O
human	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
with	O
an	O
eosinophilic	O
phenotype	O
,	O
designated	O
YJ	B-cell_line
,	O
was	O
established	O
from	O
the	O
peripheral	B-cell_type
blood	I-cell_type
cells	I-cell_type
of	O
a	O
patient	O
with	O
chronic	O
myelomonocytic	O
leukemia	O
(	O
CMMoL	O
)	O
with	O
eosinophilia	O
.	O

DN	O
constructs	O
of	O
myeloid	B-protein
differentiation	I-protein
protein	I-protein
,	O
IRAK	B-protein
,	O
TNF	B-protein
receptor-associated	I-protein
factor	I-protein
6	I-protein
,	O
and	O
NF-kappaB-inducing	B-protein
kinase	I-protein
,	O
when	O
coexpressed	O
with	O
TLR2	B-protein
,	O
abrogate	O
TLR2	B-protein
-mediated	O
NF-kappaB	B-protein
activation	O
.	O

Fibrinogen	B-protein
activates	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factors	I-protein
in	O
mononuclear	B-cell_type
phagocytes	I-cell_type
.	O

Adhesion	O
to	O
extracellular	O
matrices	O
is	O
known	O
to	O
modulate	O
leukocyte	O
activation	O
,	O
although	O
the	O
mechanisms	O
are	O
not	O
fully	O
understood	O
.	O

LMP1	B-protein
expression	O
induces	O
phenotypic	O
changes	O
resembling	O
B	O
cell	O
activation	O
,	O
such	O
as	O
cell	O
size	O
increase	O
and	O
up-regulation	O
of	O
cell	B-protein
surface	I-protein
activation	I-protein
markers	I-protein
.	O

A	O
concatenated	O
form	O
of	O
Epstein-Barr	B-DNA
viral	I-DNA
DNA	I-DNA
in	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
induced	O
by	O
transfection	O
with	O
BZLF1	B-protein
.	O

The	O
kinetics	O
of	O
induced	O
differentiation	O
are	O
consistent	O
with	O
a	O
G1	O
specific	O
cellular	O
response	O
to	O
initiate	O
the	O
metabolic	O
cascade	O
culminating	O
in	O
cell	O
differentiation	O
.	O

As	O
a	O
bioassay	O
for	O
glucocorticoid	O
action	O
we	O
also	O
measured	O
dexamethasone	O
suppressibility	O
of	O
mitogen-stimulated	O
incorporation	O
of	O
[	O
3H	O
]	O
thymidine	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
binding	O
of	O
several	O
B	B-protein
cell-specific	I-protein
transcription	I-protein
factors	I-protein
,	O
essential	O
for	O
IgH	B-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
activity	O
,	O
is	O
lacking	O
,	O
which	O
may	O
explain	O
3	O
'	O
enhancer	O
inactivity	O
,	O
although	O
the	O
binding	O
of	O
repressors	O
can	O
not	O
be	O
excluded	O
.	O

In	O
all	O
the	O
subjects	O
,	O
dexamethasone	O
was	O
able	O
to	O
suppress	O
plasma	O
cortisol	O
.	O

Compared	O
with	O
IL-2	B-protein
,	O
CD3	B-protein
ligation	O
induces	O
a	O
delayed	O
Stat3	B-protein
binding	O
to	O
oligonucleotide	O
probes	O
from	O
the	O
ICAM-1	B-protein
and	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
.	O

Four	O
NFAT-like	B-DNA
elements	I-DNA
exist	O
within	O
the	O
enhancer	O
.	O

In	O
a	O
fourth	O
cell	B-cell_line
line	I-cell_line
,	O
A1-VDR	B-cell_line
,	O
the	O
receptor	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
had	O
a	O
low	O
binding	O
capacity	O
and	O
25	B-protein
(	I-protein
OH	I-protein
)	I-protein
D3-24-hydroxylase	I-protein
activity	O
was	O
not	O
detectable	O
.	O

We	O
demonstrate	O
that	O
Pb	O
at	O
physiologically	O
relevant	O
concentrations	O
activates	O
NF-kappa	B-protein
B	I-protein
in	O
primary	B-cell_type
human	I-cell_type
CD4+	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Expression	O
of	O
luciferase	B-protein
in	O
these	O
cells	O
was	O
induced	O
by	O
phorbol	O
myristate	O
acetate	O
plus	O
a	O
calcium	O
ionophore	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Simultaneously	O
,	O
T	B-cell_type
lymphocyte	I-cell_type
subsets	I-cell_type
and	O
NK	B-cell_type
cells	I-cell_type
from	O
the	O
peripheral	O
blood	O
(	O
PB	O
)	O
and	O
bone	O
marrow	O
(	O
BM	O
)	O
were	O
investigated	O
by	O
flow	O
cytometric	O
analysis	O
.	O

Redox	O
signals	O
and	O
NF-kappaB	B-protein
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Twenty-two	O
differences	O
from	O
the	O
human	O
sequence	O
were	O
found	O
in	O
the	O
N-terminal	B-protein
region	I-protein
(	O
amino	B-protein
acids	I-protein
1-421	I-protein
)	O
of	O
the	O
squirrel	O
monkey	O
receptor	O
.	O

The	O
activation	O
of	O
PKC	B-protein
with	O
PMA	O
or	O
1-oleoyl-2-acetyl-sn-glycerol	O
could	O
mimic	O
the	O
TCR	B-protein
signal	O
by	O
inducing	O
the	O
expression	O
of	O
Fas	B-protein
but	O
not	O
FasL	O
.	O

These	O
findings	O
suggest	O
that	O
PRE-I	B-DNA
may	O
play	O
a	O
role	O
in	O
the	O
differential	O
regulation	O
of	O
IL-4	B-DNA
gene	I-DNA
expression	O
levels	O
.	O

Through	O
the	O
same	O
or	O
a	O
reciprocal	O
mechanism	O
,	O
states	O
associated	O
with	O
chronic	O
hyperactivity	O
or	O
hypoactivity	O
of	O
the	O
stress	O
system	O
might	O
influence	O
the	O
susceptibility	O
of	O
an	O
individual	O
to	O
certain	O
autoimmune	O
,	O
allergic	O
,	O
infectious	O
,	O
or	O
neoplastic	O
diseases	O
.	O

When	O
cotransfected	O
with	O
the	O
HIV	B-DNA
LTR	I-DNA
CAT	I-DNA
into	O
CV-1	B-cell_line
cells	I-cell_line
,	O
both	O
the	O
pCD41	B-DNA
and	O
pGD41	B-DNA
clones	O
trans-activated	O
the	O
HIV	B-DNA
LTR	I-DNA
.	O

Stimulation	O
of	O
resting	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
with	O
the	O
CD28-specific	B-protein
mAb	I-protein
BW	I-protein
828	I-protein
induces	O
proliferation	O
and	O
cytokine	B-protein
synthesis	O
without	O
further	O
requirement	O
for	O
TCR	B-protein
coengagement	O
.	O

Acquisition	O
of	O
heat	O
shock	O
factor	O
2	O
(	O
HSF2	O
)	O
DNA	O
binding	O
activity	O
is	O
accompanied	O
by	O
induced	O
transcription	O
of	O
heat	B-DNA
shock	I-DNA
genes	I-DNA
in	O
hemin-treated	O
K562	B-cell_line
cells	I-cell_line
undergoing	O
erythroid	O
differentiation	O
.	O

This	O
cooperative	O
function	O
may	O
account	O
for	O
the	O
divergent	O
effects	O
of	O
LSF	B-protein
previously	O
observed	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Surprisingly	O
,	O
the	O
PMA-ionomycin-induced	O
synthesis	O
of	O
NFATc	B-protein
that	O
was	O
detected	O
by	O
immunoprecipitation	O
was	O
not	O
mirrored	O
in	O
the	O
DNA	O
binding	O
assays	O
:	O
nearly	O
all	O
of	O
the	O
activity	O
was	O
due	O
to	O
NFATp	B-protein
.	O

One	O
cDNA	B-DNA
clone	I-DNA
of	O
a	O
primary	O
response	O
gene	O
,	O
expressed	O
upon	O
macrophage	O
differentiation	O
,	O
encoded	O
for	O
Egr-1	B-protein
,	O
a	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factor	I-protein
.	O

Transcriptional	O
induction	O
of	O
collagenase-1	B-protein
in	O
differentiated	B-cell_line
monocyte-like	I-cell_line
(	I-cell_line
U937	I-cell_line
)	I-cell_line
cells	I-cell_line
is	O
regulated	O
by	O
AP-1	B-protein
and	O
an	O
upstream	B-DNA
C/EBP-beta	I-DNA
site	I-DNA
.	O

Early	B-protein
B	I-protein
cell	I-protein
factor	I-protein
(	O
EBF	B-protein
)	O
and	O
E47	B-protein
participate	O
in	O
the	O
transcriptional	O
control	O
of	O
early	O
B	O
lymphocyte	O
differentiation	O
.	O

Copyright	O
1999	O
Wiley-Liss	O
,	O
Inc	O
.	O

The	O
data	O
presented	O
strongly	O
support	O
a	O
role	O
for	O
this	O
transcription	B-protein
factor	I-protein
in	O
B-cell	O
differentiation	O
and	O
perhaps	O
in	O
B-cell	O
transformation	O
in	O
some	O
neoplasias	O
.	O

These	O
findings	O
further	O
support	O
our	O
previous	O
observations	O
on	O
the	O
distinct	O
regulation	O
of	O
expression	O
of	O
the	O
human	B-DNA
HLA-DQ	I-DNA
class	I-DNA
II	I-DNA
subset	I-DNA
,	O
which	O
may	O
be	O
thus	O
controlled	O
at	O
the	O
posttranscriptional	O
level	O
by	O
a	O
CIITA	B-protein
-independent	O
mechanism	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
the	O
antiapoptotic	O
effects	O
is	O
unclear	O
.	O

Cellular	O
redox	O
status	O
influences	O
both	O
cytotoxic	O
and	O
NF-kappa	O
B	O
activation	O
in	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O

Cytosols	O
were	O
prepared	O
from	O
lymphocytes	O
of	O
24	O
healthy	O
pregnant	O
women	O
(	O
11	O
first	O
,	O
10	O
second	O
and	O
three	O
third	O
trimester	O
)	O
,	O
seven	O
healthy	O
non-pregnant	O
women	O
,	O
nine	O
women	O
with	O
recurrent	O
spontaneous	O
abortion	O
,	O
and	O
six	O
healthy	O
men	O
.	O

Thus	O
,	O
it	O
is	O
hypothesized	O
that	O
elevated	O
TNF-alpha	B-protein
is	O
primarily	O
responsible	O
for	O
promoting	O
tumor	O
progression	O
.	O

Finally	O
,	O
these	O
studies	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
molecular	O
pathogenesis	O
of	O
X-SCID	O
is	O
due	O
primarily	O
to	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
-mediated	O
defects	O
in	O
the	O
IL-7	B-protein
/IL-7R	B-protein
system	O

The	O
tissular	O
patterns	O
of	O
CIITA	O
and	O
MHC	O
class	O
II	O
gene	O
expression	O
are	O
tightly	O
correlated	O
:	O
CIITA	B-RNA
mRNA	I-RNA
is	O
highly	O
expressed	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
and	O
is	O
induced	O
by	O
interferon	B-protein
gamma	I-protein
(	O
IFN-gamma	B-protein
)	O
in	O
macrophage	B-cell_line
and	I-cell_line
epithelial	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Musculin	O
protein	O
is	O
closely	O
related	O
to	O
human	B-protein
ABF-1	I-protein
,	O
which	O
is	O
expressed	O
in	O
activated	O
B	B-cell_type
cells	I-cell_type
,	O
and	O
to	O
epicardin/capsulin/Pod-1	B-protein
,	O
which	O
is	O
expressed	O
in	O
branchial	B-cell_type
myoblasts	I-cell_type
,	O
visceral	O
and	O
urogenital	O
mesoderm	O
and	O
epicardium	O
.	O

Synergism	O
required	O
an	O
intact	O
GR	B-protein
DNA-binding	I-protein
domain	I-protein
,	O
whereas	O
amino-	B-protein
or	I-protein
carboxyl-terminal	I-protein
domains	I-protein
were	O
dispensable	O
.	O

Interestingly	O
,	O
triggering	O
of	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
complex	I-protein
or	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
with	O
phorbol	O
esters	O
also	O
induces	O
phosphorylation	O
of	O
serine	O
727	O
but	O
without	O
simultaneously	O
inducing	O
STAT3	B-protein
tyrosine	O
phosphorylation	O
or	O
DNA	O
binding	O
.	O

Reconstitution	O
of	O
T	O
cell	O
antigen	O
receptor-induced	O
Erk2	B-protein
kinase	I-protein
activation	O
in	O
Lck-negative	B-cell_line
JCaM1	I-cell_line
cells	I-cell_line
by	O
Syk	B-protein
.	O

JunB	B-protein
also	O
upregulated	O
IL-4	B-protein
expression	O
in	O
response	O
to	O
immunization	O
.	O

Receptor	O
characteristics	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
were	O
evaluated	O
by	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
.	O

Regulation	O
by	O
Egr-1	B-protein
,	O
c-Jun	B-protein
,	O
and	O
NF-kappaB	B-protein
transcription	B-protein
factors	I-protein
.	O

Although	O
their	O
precise	O
mechanism	O
of	O
action	O
remains	O
to	O
be	O
elucidated	O
,	O
glucocorticoids	O
represent	O
the	O
most	O
effective	O
therapy	O
in	O
the	O
treatment	O
of	O
asthma	O
.	O

This	O
protein	O
is	O
most	O
similar	O
to	O
the	O
105-kDa	O
precursor	O
polypeptide	O
of	O
p50-NF-kappa	B-protein
B	I-protein
.	O

Afternoon	O
ACTH	O
and	O
cortisol	O
concentrations	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
three	O
groups	O
.	O

The	O
combined	O
data	O
lend	O
additional	O
support	O
to	O
the	O
proposal	O
that	O
spirochetal	B-protein
lipoproteins	I-protein
and	O
LPS	O
initiate	O
monocyte	O
activation	O
via	O
different	O
cell	O
surface	O
events	O
but	O
that	O
the	O
signaling	O
pathways	O
ultimately	O
converge	O
to	O
produce	O
qualitatively	O
similar	O
cellular	O
responses	O
.	O

We	O
found	O
that	O
two	O
IL-1alpha	B-DNA
kappaB-like	I-DNA
sites	I-DNA
(	O
positions	O
-1	B-DNA
,	I-DNA
065	I-DNA
to	I-DNA
-1	I-DNA
,	I-DNA
056	I-DNA
and	O
+646	B-DNA
to	I-DNA
+655	I-DNA
)	O
specifically	O
formed	O
a	O
complex	O
with	O
NF-kappaB	B-protein
-containing	O
nuclear	O
extract	O
from	O
MT-2	B-cell_line
cells	I-cell_line
and	O
that	O
NF-kappaB	B-protein
bound	O
with	O
higher	O
affinity	O
to	O
the	O
3	B-DNA
'	I-DNA
NF-kappaB	I-DNA
binding	I-DNA
site	I-DNA
than	O
to	O
the	O
5	B-DNA
'	I-DNA
NF-kappaB	I-DNA
site	I-DNA
.	O

Thus	O
,	O
C.	O
neoformans	O
and	O
C.	O
albicans	O
enhance	O
HIV	O
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
through	O
a	O
TNF-alpha-	O
and	O
NF-kappaB-dependent	O
mechanism	O
.	O

Using	O
plasmids	O
containing	O
sense	O
or	O
antisense	B-DNA
RXR-alpha	I-DNA
sequences	I-DNA
under	O
the	O
control	O
of	O
an	O
inducible	O
promoter	O
,	O
we	O
generated	O
stably	O
transfected	O
cell	O
lines	O
which	O
expressed	O
either	O
increased	O
or	O
decreased	O
levels	O
of	O
RXR-alpha	B-protein
,	O
respectively	O
.	O

The	O
secondary	O
lymphoid	O
tissues	O
are	O
located	O
at	O
strategic	O
sites	O
where	O
foreign	B-protein
antigens	I-protein
can	O
be	O
efficiently	O
brought	O
together	O
with	O
immune	B-cell_type
system	I-cell_type
regulatory	I-cell_type
and	I-cell_type
effector	I-cell_type
cells	I-cell_type
.	O

TRAMP	B-protein
is	O
abundantly	O
expressed	O
on	O
thymocytes	B-cell_type
and	O
lymphocytes	B-cell_type
.	O

A	O
DNA	B-DNA
probe	I-DNA
that	O
spanned	O
a	O
domain	O
conserved	O
among	O
the	O
proto-oncogene	B-DNA
c-rel	I-DNA
,	O
the	O
Drosophila	B-protein
morphogen	I-protein
dorsal	I-protein
,	O
and	O
the	O
p50	B-protein
DNA	I-protein
binding	I-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
was	O
generated	O
from	O
Jurkat	B-DNA
T	I-DNA
cell	I-DNA
complementary	I-DNA
DNA	I-DNA
with	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
degenerate	O
oligonucleotides	O
.	O

The	O
E3-dependent	O
ubiquitinylation	O
of	O
c-Jun	B-protein
was	O
inhibited	O
upon	O
the	O
heterodimerization	O
of	O
c-Jun	B-protein
with	O
c-Fos	B-protein
.	O

Using	O
Northern	O
blotting	O
,	O
RNase	B-protein
protection	O
assay	O
,	O
and	O
nuclear	O
run-on	O
analyses	O
,	O
we	O
show	O
that	O
the	O
up-regulation	O
of	O
ASM	O
expression	O
is	O
regulated	O
mainly	O
at	O
the	O
level	O
of	O
transcription	O
and	O
that	O
new	O
protein	O
synthesis	O
is	O
required	O
for	O
enhanced	O
ASM	O
activity	O
.	O

We	O
examined	O
the	O
effect	O
of	O
Tax	B-protein
activity	O
on	O
the	O
growth	O
of	O
the	O
interleukin-2	B-cell_line
(	I-cell_line
IL-2	I-cell_line
)	I-cell_line
-dependent	I-cell_line
T-cell	I-cell_line
line	I-cell_line
CTLL-2	B-cell_line
.	O

HTLV-1	O
infection	O
causes	O
an	O
adult	O
T	O
cell	O
leukemia	O
in	O
humans	O
.	O

Mutation	O
of	O
the	O
PU.1	B-DNA
site	I-DNA
did	O
not	O
significantly	O
affect	O
promoter	O
activity	O
.	O

Tamoxifen	O
,	O
an	O
oestrogen	O
antagonist	O
,	O
has	O
been	O
given	O
in	O
some	O
patients	O
with	O
CLL	O
and	O
Hodgkin	O
's	O
disease	O
,	O
with	O
dramatic	O
response	O
in	O
single	O
cases	O
.	O

Also	O
,	O
an	O
induction	O
specific	B-protein
DNA	I-protein
binding	I-protein
protein	I-protein
was	O
purified	O
from	O
HeLa	B-cell_line
cells	I-cell_line
that	O
interacted	O
with	O
the	O
(	O
AAGTGA	O
)	O
4	O
tetrahexamer	B-DNA
sequence	I-DNA
and	O
the	O
PRDI	B-DNA
domain	I-DNA
.	O

The	O
interaction	O
of	O
the	O
Oct2	B-protein
transcription	I-protein
factor	I-protein
with	O
the	O
cognate	B-DNA
octamer	I-DNA
motif	I-DNA
ATGCAAAT	O
is	O
a	O
critical	O
determinant	O
of	O
the	O
lymphoid-specific	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

In	O
the	O
present	O
study	O
we	O
have	O
performed	O
electrophoretic	O
mobility-shift	O
assays	O
to	O
investigate	O
the	O
pattern	O
of	O
protein	O
binding	O
to	O
a	O
150	B-DNA
bp	I-DNA
fragment	I-DNA
of	O
the	O
proximal	B-DNA
5'-flanking	I-DNA
region	I-DNA
of	O
the	O
human	B-DNA
monoamine	I-DNA
oxidase	I-DNA
B	I-DNA
gene	I-DNA
.	O

That	O
PKC-zeta	B-protein
is	O
specific	O
in	O
regulating	O
NF-kappa	B-protein
B	I-protein
is	O
concluded	O
from	O
the	O
inability	O
of	O
PKC-zeta	B-protein
(	I-protein
mut	I-protein
)	I-protein
to	O
interfere	O
with	O
the	O
basal	O
or	O
phorbol	O
myristate	O
acetate-inducible	O
CREB	B-protein
-or	O
AP1	B-protein
-dependent	O
transcriptional	O
activity	O
.	O

Increased	O
levels	O
of	O
replication	O
of	O
the	O
HIV	O
type	O
1	O
are	O
observed	O
after	O
the	O
activation	O
of	O
infected	B-cell_type
T	I-cell_type
cells	I-cell_type
through	O
the	O
TCR	B-protein
.	O

Interleukin	O
2	O
(	O
IL-2	B-protein
)	O
is	O
an	O
important	O
lymphokine	B-protein
required	O
in	O
the	O
process	O
of	O
T	O
cell	O
activation	O
,	O
proliferation	O
,	O
clonal	O
expansion	O
and	O
differentiation	O
.	O

Thus	O
CTL	B-cell_line
clones	I-cell_line
that	O
recognized	O
the	O
viral	O
,	O
self	O
,	O
and	O
bacterial	O
peptides	O
expressed	O
a	O
highly	O
restricted	O
alphabeta	O
TCR	B-protein
phenotype	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Staphylococcal	B-protein
enterotoxins	I-protein
modulate	O
interleukin	B-protein
2	I-protein
receptor	I-protein
expression	O
and	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B-protein
protein-tyrosine	I-protein
kinase	I-protein
3	I-protein
(	O
Jak3	B-protein
)	O
and	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	O
Stat	B-protein
proteins	I-protein
)	O
.	O

Histamine	O
modulates	O
the	O
expression	O
of	O
c-fos	B-DNA
through	O
cyclic	O
AMP	O
production	O
via	O
the	O
H2	B-protein
receptor	I-protein
in	O
the	O
human	B-cell_line
promonocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
.	O

The	O
role	O
of	O
Cbl-b	B-protein
is	O
unclear	O
,	O
however	O
.	O

Differanisole	O
A	O
and	O
9-cis	O
retinoic	O
acid	O
(	O
9cisRA	O
)	O
synergistically	O
inhibited	O
the	O
growth	O
and	O
induced	O
functional	O
and	O
morphologic	O
differentiation	O
of	O
HL-60	B-cell_line
and	I-cell_line
NB4	I-cell_line
cells	I-cell_line
,	O
whereas	O
the	O
combined	O
treatment	O
with	O
differanisole	O
A	O
and	O
all-trans	O
retinoic	O
acid	O
or	O
1alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
was	O
less	O
effective	O
.	O

However	O
,	O
in	O
vitro	O
mutagenesis	O
of	O
the	O
HTLV-I	O
rex	B-DNA
gene	I-DNA
has	O
provided	O
indirect	O
evidence	O
which	O
suggests	O
that	O
p21rex	B-protein
,	O
and	O
by	O
analogy	O
HTLV-II	O
p24rex	B-protein
,	O
results	O
from	O
initiation	O
at	O
an	O
internal	O
AUG	O
of	O
the	O
tax/rex	B-RNA
mRNA	I-RNA
.	O

Following	O
irradiation	O
,	O
PML/RARalpha	B-protein
transgenic	O
mice	O
,	O
as	O
compared	O
with	O
controls	O
,	O
more	O
rapidly	O
depressed	O
peripheral	O
white	O
blood	O
cell	O
and	O
granulocyte	O
counts	O
.	O

They	O
can	O
stimulate	O
proliferation	O
and	O
activate	O
transcription	O
of	O
over-lapping	O
sets	O
of	O
genes	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

Retroviral	O
mediated	O
transfer	O
and	O
expression	O
of	O
exogenous	B-DNA
genes	I-DNA
in	O
primary	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
:	O
assaying	O
for	O
a	O
viral	O
transactivator	B-protein
activity	O
in	O
normal	B-cell_type
and	I-cell_type
malignant	I-cell_type
cells	I-cell_type
.	O

The	O
corresponding	O
region	O
in	O
the	O
second	O
AIDS	O
retrovirus	O
,	O
HIV-2	O
,	O
contains	O
a	O
conserved	O
and	O
a	O
divergent	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
binding	I-DNA
site	I-DNA
.	O

Treatment	O
of	O
a	O
T-lymphocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
with	O
micromolar	O
concentrations	O
of	O
HOCl	O
promoted	O
the	O
appearance	O
of	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
(	O
the	O
heterodimer	B-protein
p50/p65	I-protein
)	O
in	O
the	O
nucleus	O
of	O
the	O
cells	O
,	O
even	O
in	O
the	O
absence	O
of	O
de	O
novo	O
protein	O
synthesis	O
.	O

Eight	O
patients	O
with	O
dermatomyositis/polymyositis	O
were	O
examined	O
to	O
determine	O
whether	O
the	O
number	O
of	O
GR	B-protein
in	O
MNL	B-cell_type
could	O
be	O
down-regulated	O
by	O
their	O
cognate	O
ligands	O
.	O

To	O
better	O
understand	O
the	O
assembly	O
mechanism	O
for	O
the	O
progesterone	B-protein
receptor	I-protein
(	O
PR	B-protein
)	O
,	O
we	O
have	O
developed	O
cell-free	O
systems	O
for	O
studying	O
interactions	O
of	O
PR	B-protein
,	O
hsp90	B-protein
,	O
and	O
other	O
associated	B-protein
proteins	I-protein
.	O

The	O
values	O
of	O
plasma	O
aldosterone	O
and	O
18-OH-B	O
were	O
also	O
low	O
.	O

This	O
finding	O
supports	O
a	O
polyclonal	O
reactive	O
process	O
as	O
the	O
underlying	O
etiology	O
for	O
palmar	O
fibromatosis	O
.	O

While	O
there	O
was	O
a	O
significant	O
increase	O
in	O
plasma	O
cortisol	O
levels	O
in	O
the	O
depressed	O
group	O
,	O
there	O
were	O
no	O
changes	O
in	O
the	O
lymphocyte	O
GR	B-protein
binding	O
parameters	O
(	O
K	O
(	O
m	O
)	O
and	O
Bmax	O
)	O
.	O

Preclinical	O
and	O
clinical	O
studies	O
demonstrate	O
the	O
potential	O
use	O
of	O
TPO	B-protein
in	O
a	O
variety	O
of	O
contexts	O
,	O
but	O
it	O
is	O
too	O
early	O
to	O
evaluate	O
its	O
benefit	O
in	O
reducing	O
platelet	O
transfusion	O
.	O

In	O
the	O
presence	O
of	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
cellular	O
activation	O
associated	O
with	O
stimulation	O
of	O
such	O
a	O
progression	O
appears	O
to	O
be	O
sufficient	O
for	O
the	O
up-regulation	O
of	O
VDR	B-protein
message	O
and	O
protein	O
and	O
necessary	O
for	O
the	O
establishment	O
of	O
VDRE	B-protein
binding	I-protein
complexes	I-protein
and	O
the	O
induction	O
of	O
24-hydroxylase	B-protein
message	O
.	O

We	O
report	O
here	O
that	O
Ox	O
LDL	O
enhanced	O
DNA	O
binding	O
activity	O
of	O
nuclear	O
extracts	O
to	O
an	O
NF-kappaB	B-DNA
sequence	I-DNA
following	O
activation	O
of	O
CD36-producing	B-cell_line
CHO	I-cell_line
cells	I-cell_line
with	O
the	O
proinflammatory	B-protein
cytokine	I-protein
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O

Here	O
we	O
describe	O
the	O
functional	O
characterization	O
of	O
this	O
promoter	O
and	O
identification	O
of	O
the	O
factors	O
in	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
that	O
regulate	O
its	O
activity	O
.	O

It	O
is	O
suggested	O
that	O
constitutive	O
expression	O
of	O
c-myb	B-RNA
mRNA	I-RNA
is	O
necessary	O
for	O
Hm	B-protein
-induced	O
differentiation	O
,	O
and	O
that	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
c-myb	B-RNA
mRNA	I-RNA
induced	O
by	O
antisense	B-RNA
myb	I-RNA
RNA	I-RNA
expression	O
suppresses	O
Hm	B-protein
-induced	O
differentiation	O
.	O

The	O
total	O
populations	O
of	O
CD4	B-protein
+	O
,	O
CD8	B-protein
+	O
and	O
CD56	B-protein
+	O
[	O
possible	O
T-cell	B-cell_type
and	O
natural	B-cell_type
killer	I-cell_type
(	O
T/NK	B-cell_type
)	O
populations	O
]	O
in	O
the	O
BM	O
of	O
ST	O
patients	O
and	O
MRD+/LT	O
patients	O
were	O
significantly	O
(	O
p	O
<	O
.01	O
)	O
low	O
.	O

The	O
RAKFKQLLQ-specific	O
CTL	O
precursor	O
frequencies	O
in	O
all	O
5	O
persons	O
were	O
at	O
least	O
as	O
dominant	O
as	O
those	O
observed	O
with	O
two	O
other	O
EBV-associated	B-protein
,	I-protein
HLA-B8-restricted	I-protein
latent	I-protein
epitopes	I-protein
,	O
FLRGRAYGL	O
and	O
QAKWRLQTL	O
.	O

We	O
therefore	O
propose	O
that	O
IL-2	B-protein
receptor	I-protein
signal	O
transduction	O
does	O
not	O
depend	O
on	O
equimolar	O
heterodimerization	O
of	O
JAK1	B-protein
and	O
JAK3	B-protein
following	O
IL-2	B-protein
-induced	O
heterodimerization	O
of	O
IL-2R	B-protein
beta	I-protein
and	O
IL-2R	B-protein
gamma	I-protein
.	O

The	O
Rho	B-protein
family	O
of	O
small	B-protein
GTP-binding	I-protein
proteins	I-protein
is	O
involved	O
in	O
the	O
regulation	O
of	O
cytoskeletal	O
structure	O
,	O
gene	O
transcription	O
,	O
specific	O
cell	O
fate	O
development	O
,	O
and	O
transformation	O
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
,	O
we	O
propose	O
that	O
the	O
enhanced	O
intestinal	O
calcium	O
absorption	O
invariably	O
seen	O
in	O
absorptive	O
hypercalciuria	O
and	O
attendant	O
symptoms	O
of	O
this	O
disorder	O
are	O
not	O
attributable	O
to	O
mutations	O
of	O
the	O
VDR	B-protein
and	O
are	O
not	O
linked	O
to	O
a	O
common	O
VDR	B-DNA
genotype	I-DNA
.	O

Constitutive	O
expression	O
of	O
Id3	B-protein
completely	O
blocks	O
development	O
of	O
CD34+	B-cell_type
cells	I-cell_type
into	O
T	B-cell_type
cells	I-cell_type
in	O
a	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O

It	O
wat	O
found	O
that	O
the	O
contents	O
of	O
leucocytic	B-protein
ER	I-protein
in	O
climacteric	O
syndrome	O
patients	O
were	O
significantly	O
lower	O
than	O
normal	O
child-bearing-age	O
women	O
.	O

A	O
nuclear	B-protein
membrane	I-protein
protein	I-protein
related	O
to	O
yeast	B-protein
sterol	I-protein
isomerase	I-protein
.	O

Gel	O
shift	O
assays	O
demonstrated	O
SP1	O
and	O
Egr-1	B-protein
binding	O
to	O
the	O
CD19	B-DNA
GC	I-DNA
box	I-DNA
,	O
while	O
unknown	O
nuclear	O
proteins	O
bound	O
the	O
PyG	B-DNA
and	I-DNA
AT	I-DNA
boxes	I-DNA
.	O

The	O
structural	O
classes	O
of	O
transcription	B-protein
factors	I-protein
are	O
described	O
and	O
basic	O
methods	O
for	O
detection	O
and	O
analysis	O
of	O
transcription	B-protein
factors	I-protein
are	O
detailed	O
.	O

These	O
results	O
reveal	O
a	O
central	O
role	O
for	O
CaMKIV/Gr	B-protein
as	O
a	O
Ca	O
(	O
2+	O
)	O
-regulated	O
activator	O
of	O
gene	O
transcription	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

However	O
,	O
a	O
minority	O
of	O
LYSP100	B-DNA
nuclear	O
dots	O
exactly	O
colocalized	O
with	O
PML	B-cell_type
and	O
SP100	B-protein
.	O

Stat6	B-protein
had	O
a	O
transactivation	O
domain	O
which	O
was	O
about	O
10-fold	O
stronger	O
than	O
that	O
of	O
Stat5	B-protein
.	O

Moreover	O
,	O
the	O
high	O
expression	O
level	O
of	O
c-myc	B-DNA
,	O
characteristic	O
of	O
the	O
parental	O
MPC11	B-cell_line
cells	I-cell_line
carrying	O
the	O
t	B-DNA
(	I-DNA
12	I-DNA
;	I-DNA
15	I-DNA
)	I-DNA
translocation	I-DNA
,	O
is	O
down-regulated	O
in	O
the	O
hybrids	O
to	O
that	O
in	O
unfused	O
fibroblasts	B-cell_type
.	O

This	O
RFLP	B-DNA
pair	I-DNA
occurs	O
in	O
76	O
%	O
of	O
patients	O
with	O
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
precipitins	O
,	O
84	O
%	O
of	O
anti-	O
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
-positive	O
patients	O
lacking	O
La	B-protein
(	I-protein
SSB	I-protein
)	I-protein
precipitins	B-protein
,	O
but	O
only	O
41	O
%	O
of	O
the	O
patients	O
lacking	O
both	O
precipitins	B-protein
(	O
P	O
=	O
0.0004	O
)	O
.	O

In	O
U937	B-cell_line
and	I-cell_line
Jurkat	I-cell_line
T	I-cell_line
lymphoid	I-cell_line
cells	I-cell_line
,	O
the	O
inducibility	O
of	O
the	O
different	O
hybrid	B-DNA
promoters	I-DNA
by	O
TNF-alpha	B-protein
or	O
phorbol	O
ester	O
varied	O
in	O
a	O
cell	O
type-	O
and	O
promoter	O
context-specific	O
manner	O
;	O
the	O
levels	O
of	O
gene	O
activity	O
of	O
NF-kappa	B-DNA
B-containing	I-DNA
plasmids	I-DNA
correlated	O
directly	O
with	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
DNA-binding	O
activity	O
.	O

In	O
transient	O
transfection	O
assays	O
,	O
both	O
multicopy	O
NFAT	B-protein
-and	O
IL-2	B-DNA
promoter-beta-galactosidase	I-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
could	O
be	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
/alpha-	O
CD28	B-protein
stimulation	O
,	O
and	O
this	O
activation	O
was	O
resistant	O
to	O
CsA	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
induction	O
of	O
apoptosis	O
by	O
GC	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Depending	O
on	O
costimulatory	O
signals	O
,	O
SE	B-protein
induce	O
either	O
proliferation	O
or	O
anergy	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

HB24	B-DNA
is	O
likely	O
to	O
have	O
an	O
important	O
role	O
in	O
lymphocytes	B-cell_type
as	O
well	O
as	O
in	O
certain	O
developing	O
tissues	O
.	O

Increase	O
of	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
transcription	O
involves	O
the	O
enhanced	O
binding	O
of	O
the	O
transcription	O
factor	O
NF-kappa	B-protein
B	I-protein
to	O
its	O
consensus	B-DNA
sequence	I-DNA
in	O
the	O
5'-regulatory	B-DNA
region	I-DNA
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
.	O

The	O
50	O
%	O
inhibitory	O
concentrations	O
of	O
MP	O
values	O
for	O
adrenal	O
suppression	O
were	O
about	O
1	O
ng/ml	O
.	O

[	O
Changes	O
in	O
leucocytic	O
estrogen	B-protein
receptor	I-protein
levels	O
in	O
patients	O
with	O
climacteric	O
syndrome	O
and	O
therapeutic	O
effect	O
of	O
liuwei	O
dihuang	O
pills	O
]	O

So	O
far	O
,	O
there	O
are	O
no	O
drugs	O
or	O
therapy	O
available	O
that	O
can	O
provide	O
protection	O
against	O
HIV-1	O
latency	O
reactivation	O
.	O

The	O
activation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	B-protein
(	I-protein
STAT	I-protein
)	I-protein
proteins	I-protein
in	O
a	O
primary	O
TCR	B-protein
-mediated	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
have	O
been	O
explored	O
.	O

In	O
the	O
human	O
,	O
this	O
may	O
also	O
occur	O
via	O
IFN-alpha	B-protein
,	O
which	O
is	O
able	O
to	O
activate	O
Stat4	B-protein
.	O

Nuclear	B-protein
factor-kappaB	I-protein
-dependent	O
induction	O
of	O
interleukin-8	B-protein
gene	O
expression	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
:	O
evidence	O
for	O
an	O
antioxidant	O
sensitive	O
activating	O
pathway	O
distinct	O
from	O
nuclear	O
translocation	O
.	O

Expression	O
of	O
p13MTCP1	B-protein
is	O
restricted	O
to	O
mature	O
T-cell	O
proliferations	O
with	O
t	O
(	O
X	O
;	O
14	O
)	O
translocations	O
.	O

Cell-cycle	O
analysis	O
showed	O
that	O
the	O
growth-inhibitory	O
effect	O
of	O
DES	O
,	O
TAM	O
or	O
quercetin	O
was	O
due	O
to	O
a	O
blocking	O
effect	O
in	O
the	O
G0-G1	O
phases	O
.	O

At	O
the	O
level	O
of	O
the	O
genomic	B-DNA
TNF	I-DNA
gene	I-DNA
,	O
a	O
DNase	B-DNA
I	I-DNA
hypersensitive	I-DNA
site	I-DNA
is	O
detected	O
within	O
the	O
TNF	B-DNA
promoter	I-DNA
between	O
-200	O
to	O
-100	O
bp	O
relative	O
to	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
.	O

We	O
previously	O
identified	O
and	O
analyzed	O
a	O
45-nucleotide	B-DNA
sequence	I-DNA
(	O
downstream	B-DNA
regulatory	I-DNA
element	I-DNA
1	I-DNA
[	O
DRE	B-DNA
1	I-DNA
]	O
)	O
,	O
+195	B-DNA
to	I-DNA
+240	I-DNA
,	O
at	O
the	O
boundary	O
of	O
the	O
R/U5	B-DNA
region	I-DNA
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
which	O
is	O
required	O
for	O
HTLV-I	O
basal	O
transcription	O
.	O

Consecutive	O
IL-1beta-	B-RNA
,	I-RNA
IL-6-	I-RNA
and	I-RNA
TNF-alpha-mRNA	I-RNA
were	O
elevated	O
(	O
up	O
to	O
1.9	O
+/-	O
0.58-fold	O
)	O
.	O

The	O
congenital	O
absence	O
of	O
the	O
receptor	O
results	O
in	O
a	O
bleeding	O
disorder	O
associated	O
with	O
``	B-cell_type
giant	I-cell_type
''	I-cell_type
platelets	I-cell_type
,	O
a	O
condition	O
linking	O
the	O
expression	O
of	O
the	O
complex	O
to	O
platelet	O
morphogenesis	O
.	O

In	O
chronic	O
bronchitis	O
,	O
few	O
cells	O
were	O
GCRbeta-positive	B-cell_type
and	O
their	O
numbers	O
did	O
not	O
differ	O
significantly	O
from	O
normal	O
control	O
subjects	O
.	O

As	O
a	O
target	O
for	O
DNA	O
methylation	O
and	O
for	O
binding	O
of	O
transcription	B-protein
factors	I-protein
that	O
mediate	O
or	O
impede	O
transcription	O
,	O
this	O
element	O
appears	O
to	O
play	O
a	O
central	O
role	O
in	O
controlling	O
IFN-gamma	B-protein
expression	O
.	O

Transcription	O
of	O
a	O
minimal	B-DNA
promoter	I-DNA
from	O
the	O
NF-IL6	B-DNA
gene	I-DNA
is	O
regulated	O
by	O
CREB/ATF	B-protein
and	O
SP1	B-protein
proteins	I-protein
in	O
U937	B-cell_line
promonocytic	I-cell_line
cells	I-cell_line
.	O

So	O
far	O
,	O
we	O
have	O
identified	O
five	O
potential	O
targets	O
for	O
Oct2	B-protein
:	O
the	O
membrane	B-protein
glycoprotein	I-protein
CD36	B-protein
,	O
the	O
cysteine-rich	B-protein
secreted	I-protein
protein	I-protein
3	I-protein
(	O
CRISP-3	B-protein
)	O
,	O
a	O
mouse	O
homolog	O
of	O
the	O
human	B-protein
monocyte/neutrophil	I-protein
elastase	I-protein
inhibitor	I-protein
(	O
mEI	B-protein
)	O
and	O
two	O
unknown	O
cDNA	B-DNA
sequences	I-DNA
Nov1	B-DNA
and	O
Nov2	B-DNA
.	O

Two	O
splice	O
alternatives	O
were	O
identified	O
that	O
were	O
not	O
previously	O
observed	O
in	O
human	B-protein
TCF-1	I-protein
.	O

Besides	O
,	O
there	O
was	O
also	O
a	O
linear	O
correlation	O
between	O
the	O
number	O
of	O
GCR	B-protein
and	O
the	O
age	O
of	O
the	O
initial	O
attack	O
of	O
asthma	O
.	O

Studies	O
on	O
the	O
biological	O
activity	O
of	O
triiodothyronine	O
sulfate	O
.	O

Constitutive	O
association	O
of	O
JAK1	B-protein
and	O
STAT5	B-protein
in	O
pro-B	B-cell_type
cells	I-cell_type
is	O
dissolved	O
by	O
interleukin-4	B-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
both	O
proteins	O
.	O

Contribution	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
Sp1	B-DNA
binding	I-DNA
motifs	I-DNA
to	O
the	O
replicative	O
capacity	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
:	O
distinct	O
patterns	O
of	O
viral	O
growth	O
are	O
determined	O
by	O
T-cell	B-cell_type
types	I-cell_type
.	O

After	O
24	O
h	O
incubation	O
the	O
decrease	O
of	O
these	O
values	O
increased	O
respectively	O
to	O
43.5	O
+/-	O
19.0	O
,	O
56.1	O
+/-	O
20.7	O
and	O
80.2	O
+/-	O
15.5	O
(	O
P	O
less	O
than	O
0.05	O
,	O
P	O
less	O
than	O
0.01	O
and	O
P	O
less	O
than	O
0.01	O
compared	O
with	O
control	O
)	O
.	O

Amino	O
acid	O
sequences	O
of	O
all	O
proteins	O
are	O
essays	O
written	O
in	O
the	O
same	O
language	O
.	O

Moreover	O
,	O
the	O
apoptotic	O
process	O
was	O
not	O
related	O
to	O
Fas	B-protein
-Fas	B-protein
ligand	I-protein
interaction	O
;	O
however	O
,	O
an	O
antagonistic	O
anti-Fas	O
MAb	O
(	O
ZB-4	O
)	O
enhanced	O
apoptosis	O
in	O
HIV-infected	B-cell_type
cells	I-cell_type
without	O
inducing	O
apoptosis	O
in	O
uninfected	B-cell_type
cells	I-cell_type
.	O

Differential	O
effects	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
inhibitors	O
on	O
fibronectin	B-protein
-induced	O
interleukin-beta	B-DNA
gene	I-DNA
transcription	O
,	O
protein	O
synthesis	O
and	O
secretion	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

Initial	O
experiments	O
indicated	O
that	O
a	O
50	O
%	O
decrease	O
in	O
VDR	B-protein
levels	O
was	O
associated	O
with	O
a	O
2-fold	O
increase	O
in	O
cell	O
proliferation	O
and	O
a	O
similar	O
rise	O
in	O
c-myc	B-RNA
mRNA	I-RNA
expression	O
.	O

When	O
these	O
patient	O
cells	O
were	O
further	O
stimulated	O
by	O
IL-2	B-protein
in	O
vitro	O
,	O
additional	O
differences	O
in	O
STAT	B-protein
induction	O
patterns	O
were	O
noted	O
.	O

For	O
this	O
purpose	O
,	O
81	O
pentadecamer	O
peptides	O
covering	O
the	O
complete	O
491-amino-acid	B-protein
sequence	I-protein
of	O
IE-1	B-protein
were	O
tested	O
on	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
of	O
anti-HCMV	O
immunoglobulin	O
G-seropositive	O
donors	O
.	O

The	O
latter	O
class	O
of	O
events	O
is	O
blocked	O
in	O
lymphocytes	B-cell_type
by	O
the	O
immunosuppressive	O
drugs	O
cyclosporin	O
A	O
and	O
FK506	O
,	O
which	O
inhibit	O
calcineurin	B-protein
,	O
a	O
Ca2+-activated	B-protein
serine/threonine	I-protein
phosphatase	I-protein
necessary	O
for	O
the	O
nuclear	O
import	O
of	O
NF-AT	B-protein
transcription	B-protein
factors	I-protein
.	O

Finally	O
,	O
chromosomal	O
localization	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
revealed	O
that	O
LITAF	B-protein
mapped	O
to	O
chromosome	B-DNA
16p12-16p13.3	I-DNA
.	O

Although	O
the	O
-20	O
GATA	B-DNA
binding	I-DNA
site	I-DNA
(	O
AGATAA	O
)	O
is	O
also	O
a	O
potential	O
TFIID	B-DNA
binding	I-DNA
site	I-DNA
,	O
it	O
does	O
not	O
bind	O
TFIID	B-protein
.	O

The	O
effects	O
of	O
RA	O
on	O
IL-2-alpha	O
receptor	O
expression	O
was	O
determined	O
by	O
flow	O
cytometry	O
on	O
T	B-cell_type
cells	I-cell_type
.	O

Constitutively	O
active	O
MAPKK-1	B-protein
fully	O
activates	O
ERK-2	B-protein
and	O
the	O
transcription	B-protein
factor	I-protein
Elk-1	B-protein
,	O
but	O
does	O
not	O
substitute	O
for	O
activated	O
p21ras	B-protein
and	O
synergize	O
with	O
calcium	O
/calcineurin	B-protein
signals	O
to	O
induce	O
NFAT	B-protein
.	O

Pivotal	O
role	O
for	O
the	O
NFIL3/E4BP4	B-protein
transcription	I-protein
factor	I-protein
in	O
interleukin	B-protein
3	I-protein
-mediated	O
survival	O
of	O
pro-B	B-cell_type
lymphocytes	I-cell_type
.	O

Both	O
FMLP	B-protein
and	O
PAF	B-protein
activated	I-protein
MAP	I-protein
kinase	I-protein
kinase-3	I-protein
(	O
MKK3	B-protein
)	O
,	O
a	O
known	O
activator	O
of	O
p38	B-protein
MAPk	I-protein
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
AG-490	O
inhibits	O
the	O
JAK3	B-protein
-mediated	O
Type	O
II	O
signaling	O
pathway	O
but	O
not	O
the	O
T	B-cell_type
cell	I-cell_type
receptor-derived	O
Type	O
I	O
pathway	O
and	O
possesses	O
therapeutic	O
potential	O
for	O
T	B-cell_type
cell	I-cell_type
-derived	O
pathologies	O
such	O
as	O
graft-versus-host	O
disease	O
,	O
allergy	O
,	O
and	O
autoimmune	O
disorders	O
.	O

Therefore	O
,	O
initiation	O
of	O
the	O
EBV	O
lytic	O
cycle	O
by	O
the	O
ZEBRA	B-protein
protein	I-protein
requires	O
a	O
function	O
in	O
addition	O
to	O
transcriptional	O
activation	O
;	O
a	O
change	O
of	O
serine	O
186	O
to	O
alanine	O
in	O
the	O
DNA-binding	B-protein
domain	I-protein
of	O
ZEBRA	B-protein
abolished	O
this	O
additional	O
function	O
and	O
uncovered	O
a	O
new	O
role	O
for	O
the	O
ZEBRA	B-protein
protein	I-protein
in	O
disruption	O
of	O
EBV	O
latency	O
.	O

Abundant	O
expression	O
of	O
erythroid	B-RNA
transcription	I-RNA
factor	I-RNA
P45	I-RNA
NF-E2	I-RNA
mRNA	I-RNA
in	O
human	B-cell_type
peripheral	I-cell_type
granurocytes	I-cell_type
.	O

IL-4	B-protein
secreted	O
by	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
a	O
pleiotropic	B-protein
cytokine	I-protein
affecting	O
growth	O
and	O
differentiation	O
of	O
diverse	O
cell	O
types	O
such	O
as	O
T	B-cell_type
cells	I-cell_type
,	O
B	B-cell_type
cells	I-cell_type
,	O
and	O
mast	B-cell_type
cells	I-cell_type
.	O

Induction	O
of	O
HIV-1-	O
LTR	B-DNA
-driven	O
transcription	O
in	O
THP-1	B-cell_line
cells	I-cell_line
by	O
superantigens	B-protein
was	O
associated	O
with	O
the	O
induction	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
DNA-binding	O
activity	O
.	O

A	O
comparison	O
with	O
known	O
proteins	O
in	O
Genbank	O
revealed	O
that	O
all	O
three	O
S6	B-protein
peptides	O
match	O
the	O
predicted	O
sequence	O
of	O
TBP7	B-protein
,	O
Tat-binding	B-protein
protein	I-protein
7	I-protein
.	O

The	O
authors	O
revealed	O
alterations	O
in	O
the	O
functional	O
activity	O
of	O
the	O
indicated	O
endocrine	O
glands	O
depending	O
on	O
the	O
intensity	O
of	O
bronchial	O
patency	O
disorders	O
and	O
the	O
nature	O
of	O
the	O
therapeutic	O
measures	O
carried	O
out	O
.	O

To	O
clarify	O
the	O
etiological	O
relationship	O
between	O
the	O
two	O
variants	O
,	O
we	O
analyzed	O
responsiveness	O
to	O
IL-4	B-protein
of	O
transfectants	O
with	O
four	O
kinds	O
of	O
IL-4Ralpha	B-protein
carrying	O
either	O
Val	O
or	O
Ile	O
at	O
50	B-protein
and	O
either	O
Gln	O
or	O
Arg	O
at	O
551	B-protein
.	O

However	O
,	O
examination	O
of	O
proteasome	B-protein
activity	O
in	O
these	O
T	B-cell_type
cells	I-cell_type
using	O
fluorogenic	O
peptide	O
assays	O
revealed	O
a	O
significant	O
age-related	O
decline	O
in	O
chymotryptic	O
activity	O
.	O

We	O
show	O
here	O
that	O
in	O
circulating	B-cell_type
monocytes	I-cell_type
,	O
NF-Y	B-protein
binding	O
activity	O
is	O
not	O
detected	O
on	O
the	O
CCAAT	B-DNA
motif	I-DNA
present	O
in	O
the	O
promoters	B-DNA
of	I-DNA
genes	I-DNA
such	O
as	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
,	O
gp91-phox	B-DNA
,	O
mig	B-DNA
,	O
and	O
fibronectin	O
,	O
whereas	O
during	O
macrophage	O
differentiation	O
,	O
a	O
progressive	O
increase	O
in	O
NF-Y	B-protein
binding	O
activity	O
is	O
observed	O
on	O
these	O
promoters	O
.	O

Production	O
of	O
IL-2	B-protein
requires	O
the	O
formation	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
the	O
IL-2-gene	B-DNA
regulation	O
.	O

However	O
,	O
the	O
intensity	O
of	O
p65	B-protein
labeling	O
was	O
much	O
higher	O
in	O
several	O
thymocytes	B-cell_type
from	O
the	O
medulla	O
.	O

Comparison	O
of	O
KG1	B-cell_line
to	O
the	O
PMA-unresponsive	B-cell_line
subline	I-cell_line
KG1a	I-cell_line
reveals	O
differences	O
in	O
expression	O
of	O
TNF	B-protein
receptors	I-protein
1	I-protein
and	I-protein
2	I-protein
;	O
PKC	B-protein
isoforms	I-protein
alpha	I-protein
,	I-protein
beta	I-protein
I	I-protein
,	I-protein
beta	I-protein
II	I-protein
,	I-protein
and	I-protein
mu	I-protein
;	O
and	O
RelB	B-protein
,	O
suggesting	O
that	O
these	O
components/pathways	O
are	O
important	O
for	O
DC	B-cell_type
differentiation	O
.	O

Class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
(	I-DNA
class	I-DNA
II	I-DNA
)	I-DNA
genes	I-DNA
are	O
regulated	O
in	O
a	O
B-cell-specific	O
and	O
gamma	O
interferon-inducible	O
fashion	O
.	O

This	O
region	O
contains	O
binding	B-DNA
sites	I-DNA
for	O
several	O
transcription	B-protein
factors	I-protein
,	O
including	O
the	O
STAT	B-protein
family	I-protein
and	O
NF-IL6	B-protein
,	O
and	O
the	O
expression	O
of	O
LOX-1	B-protein
was	O
upregulated	O
by	O
several	O
cytokines	B-protein
.	O

of	O
the	O
constructs	O
influenced	O
the	O
anti-CD3-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
TCR	B-protein
zeta-chain	I-protein
or	O
phospholipase	B-protein
Cgamma1	I-protein
,	O
indicating	O
that	O
Src	B-protein
family	I-protein
kinase	I-protein
function	O
was	O
intact	O
.	O

We	O
suggest	O
that	O
HIV-1	O
infection	O
of	O
myeloid	B-cell_type
cells	I-cell_type
induces	O
IFN	B-protein
production	O
and	O
PKR	B-protein
activity	O
,	O
which	O
in	O
turn	O
contribute	O
to	O
enhanced	O
IkappaBalpha	B-protein
phosphorylation	O
and	O
subsequent	O
degradation	O
.	O

RESULTS	O
:	O
In	O
patients	O
,	O
both	O
total	O
and	O
free	O
plasma	O
cortisol	O
concentrations	O
were	O
higher	O
than	O
in	O
the	O
normal	O
women	O
,	O
as	O
was	O
their	O
urinary	O
free	O
cortisol	O
;	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
per	O
cell	O
(	O
Ro	O
)	O
and	O
the	O
binding	O
affinity	O
(	O
Kd	O
)	O
for	O
dexamethasone	O
were	O
,	O
however	O
,	O
not	O
significantly	O
different	O
(	O
Ro	O
:	O
7687	O
+/-	O
1750	O
vs	O
7347	O
+/-	O
1285	O
sites/cell	O
;	O
Kd	O
:	O
7.7	O
+/-	O
2.4	O
vs	O
7.4	O
+/-	O
1.7	O
nM	O
at	O
24	O
degrees	O
C	O
)	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
whether	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
signaling	O
pathway	O
contributes	O
to	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
-induced	O
mononuclear	O
differentiation	O
in	O
the	O
human	B-cell_line
myeloblastic	I-cell_line
leukemia	I-cell_line
ML-1	I-cell_line
cells	I-cell_line
.	O

Immunoblot	O
analyses	O
and	O
metabolic	O
labeling	O
with	O
[	O
32P	O
]	O
orthophosphate	O
show	O
that	O
CsA	O
alters	O
NFATp	B-protein
migration	O
on	O
SDS-polyacrylamide	O
gel	O
electrophoresis	O
by	O
increasing	O
its	O
phosphorylation	O
level	O
without	O
affecting	O
subcellular	O
distribution	O
.	O

The	O
maintenance	O
of	O
lymphocyte	O
homeostasis	O
by	O
apoptosis	O
is	O
a	O
critical	O
regulatory	O
mechanism	O
in	O
the	O
normal	O
immune	O
system	O
.	O

Using	O
this	O
assay	O
system	O
,	O
we	O
have	O
evaluated	O
the	O
contributions	O
of	O
ligand	O
binding	O
and	O
heat	O
activation	O
to	O
DNA	O
binding	O
by	O
these	O
glucocorticoid	B-protein
receptors	I-protein
.	O

Interleukin-9	B-protein
receptor	I-protein
(	I-protein
IL-9R	I-protein
)	I-protein
complex	I-protein
consists	O
of	O
a	O
ligand-specific	B-protein
alpha	I-protein
chain	I-protein
and	O
IL-2R	B-protein
gamma	I-protein
chain	I-protein
.	O

Furthermore	O
,	O
addition	O
of	O
the	O
recombinant	O
NF-Y	B-protein
A	B-protein
subunit	I-protein
restores	O
NF-Y	B-protein
binding	O
.	O

1	O
,	O
25-Dihydroxyvitamin	O
D3	O
induces	O
differentiation	O
of	O
a	O
retinoic	B-cell_line
acid-resistant	I-cell_line
acute	I-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
UF-1	B-cell_line
)	O
associated	O
with	O
expression	O
of	O
p21	B-protein
(	I-protein
WAF1/CIP1	I-protein
)	I-protein
and	O
p27	B-protein
(	I-protein
KIP1	I-protein
)	I-protein
.	O

Retinoid	B-protein
X	I-protein
receptor	I-protein
and	O
c-cerbA/thyroid	B-protein
hormone	I-protein
receptor	I-protein
regulate	O
erythroid	O
cell	O
growth	O
and	O
differentiation	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
the	O
effects	O
of	O
DZA	O
on	O
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
regulation	O
.	O

The	O
EGR1	B-DNA
binding	I-DNA
motif	I-DNA
was	O
shown	O
to	O
be	O
necessary	O
for	O
stimulus-induced	O
expression	O
of	O
a	O
CD44	B-protein
promoter-chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
construct	I-DNA
in	O
nontransformed	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
and	O
was	O
required	O
for	O
transactivation	O
by	O
an	O
EGR1	B-DNA
expression	I-DNA
vector	I-DNA
in	O
a	O
B-cell	B-cell_line
line	I-cell_line
.	O

An	O
E2F-4/p130	B-protein
complex	I-protein
was	O
detected	O
in	O
representative	O
samples	O
of	O
all	O
FAB	B-protein
types	O
analysed	O
.	O

Here	O
,	O
we	O
studied	O
whether	O
PPARalpha	B-protein
activation	O
(	O
by	O
means	O
of	O
the	O
selective	O
agonist	O
WY	O
14	O
,	O
643	O
)	O
of	O
endothelial	B-cell_type
cells	I-cell_type
,	O
pivotal	O
in	O
the	O
regulation	O
of	O
inflammatory	O
responses	O
,	O
interfered	O
with	O
LTB4	O
induced	O
adhesion	O
of	O
PMN	B-cell_type
neutrophil	I-cell_type
granulocytes	I-cell_type
in	O
vitro	O
.	O

Monocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
normal	O
peripheral	O
blood	O
monocytes	O
were	O
infected	O
with	O
HIV-1	O
in	O
vitro	O
and	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
F	B-protein
(	I-protein
ab	I-protein
'	I-protein
)	I-protein
2	I-protein
fragments	I-protein
of	O
monoclonal	B-protein
anti-CR1	I-protein
or	O
anti-CR3	B-protein
Abs	I-protein
or	O
with	O
C3	B-protein
fragments	I-protein
.	O

It	O
is	O
concluded	O
that	O
topoisomerase	O
II	O
inhibitors	O
may	O
induce	O
the	O
differentiation	O
of	O
promonocytic	O
cells	O
,	O
independently	O
of	O
their	O
capacity	O
to	O
cause	O
DNA	O
strand	O
breaks	O
.	O

All	O
three	O
stimuli	O
induced	O
IL-10	B-protein
production	O
in	O
PBMC	B-cell_type
,	O
although	O
over	O
10-fold	O
less	O
IL-10	B-protein
was	O
released	O
in	O
response	O
to	O
C.	O
neoformans	O
compared	O
with	O
LPS	O
and	O
C.	O
albicans	O
.	O

No	O
such	O
increase	O
was	O
observed	O
in	O
control	O
U937	B-cell_line
cells	I-cell_line
.	O

Western	O
blotting	O
of	O
NK	B-cell_type
cell	I-cell_type
and	O
membrane	O
extracts	O
detected	O
the	O
presence	O
of	O
Lymphotoxin-alpha	B-protein
(	O
LTalpha	B-protein
)	O
but	O
not	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
.	O

A	O
defect	O
in	O
gammac	O
leads	O
to	O
the	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
characterized	O
by	O
a	O
block	O
in	O
T	O
cell	O
differentiation	O
.	O

The	O
pathological	O
alteration	O
of	O
this	O
cytokine	O
pathway	O
leading	O
to	O
NF-kappaB	B-protein
activation	O
by	O
Tax	B-protein
may	O
play	O
a	O
central	O
role	O
in	O
HTLV-1-mediated	O
transformation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
clinically	O
manifested	O
as	O
the	O
adult	O
T-cell	O
leukemia	O

While	O
all	O
the	O
M10-expressing	B-cell_line
cell	I-cell_line
lines	I-cell_line
remained	O
infectable	O
by	O
HIV-1	O
,	O
these	O
same	O
cells	O
failed	O
to	O
support	O
a	O
productive	O
replication	O
cycle	O
when	O
infected	O
with	O
a	O
cloned	O
isolate	O
of	O
HIV-1	O
.	O

SLP-76	B-protein
(	O
SH2	B-protein
domain	I-protein
leukocyte	I-protein
protein	I-protein
of	O
76	O
kDa	O
)	O
is	O
a	O
recently	O
identified	O
substrate	O
of	O
the	O
TCR-stimulated	B-protein
protein	I-protein
tyrosine	B-protein
kinases	I-protein
that	O
functions	O
in	O
the	O
signal	O
transduction	O
cascade	O
linking	O
the	O
TCR	B-protein
with	O
IL-2	B-protein
gene	O
expression	O
.	O

After	O
16	O
hr	O
of	O
exposure	O
to	O
SE	B-protein
,	O
the	O
expression	O
of	O
IL-2R	B-protein
beta	I-protein
remained	O
low	O
,	O
while	O
that	O
of	O
IL2R	B-protein
alpha	I-protein
and	O
IL2R	B-protein
gamma	I-protein
was	O
further	O
up-regulated	O
,	O
and	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
Jak3	B-protein
and	O
Stat	B-protein
proteins	I-protein
was	O
partly	O
normalized	O
.	O

In	O
transfection	O
assays	O
,	O
TRADD	B-protein
and	O
TES2	B-protein
synergistically	O
mediated	O
high-level	O
NF-kappaB	B-protein
activation	O
.	O

Because	O
previous	O
work	O
has	O
demonstrated	O
that	O
T	B-cell_type
cells	I-cell_type
from	O
elderly	O
individuals	O
may	O
display	O
normal	O
proliferative	O
responses	O
when	O
activated	O
via	O
the	O
anti-CD2	B-protein
pathway	O
,	O
c-jun	O
and	O
jun	O
B	O
mRNA	O
expression	O
was	O
also	O
studied	O
in	O
anti-CD2-activated	B-cell_line
purified	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Both	O
Drosophila	O
Toll	B-protein
and	O
the	O
IL-1	O
receptor	O
are	O
known	O
to	O
signal	O
through	O
the	O
NF-kappaB	B-protein
pathway	O
.	O

In	O
the	O
absence	O
of	O
tetracycline	O
,	O
GR	B-RNA
mRNA	I-RNA
and	O
protein	O
expression	O
increased	O
2-3-fold	O
,	O
and	O
cells	O
expressed	O
48	O
,	O
000	O
receptors	O
,	O
a	O
level	O
nearly	O
equivalent	O
to	O
that	O
present	O
in	O
6TG1.1	B-cell_line
cells	I-cell_line
after	O
18	O
h	O
of	O
autoinduction	O
.	O

We	O
observed	O
in	O
the	O
present	O
study	O
that	O
lysoPC	O
(	O
1	O
to	O
10	O
micromol/L	O
)	O
dose-dependently	O
reduced	O
TF	B-protein
activity	O
in	O
human	B-cell_type
monocytes	I-cell_type
,	O
as	O
elicited	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Switching	O
the	O
cells	O
to	O
the	O
nonpermissive	O
temperature	O
led	O
to	O
a	O
marked	O
increase	O
in	O
globin	B-DNA
gene	I-DNA
expression	O
and	O
concomitant	O
decrease	O
in	O
expression	O
of	O
Spi-1	B-protein
,	O
Fli-1	B-protein
,	O
and	O
megakaryocytic	B-DNA
genes	I-DNA
in	O
an	O
erythropoietin	B-protein
-dependent	O
manner	O
.	O

CD28	B-protein
is	O
an	O
important	O
costimulatory	B-protein
molecule	I-protein
in	O
the	O
activation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Thus	O
,	O
this	O
Alu	B-DNA
repeat	I-DNA
(	O
90	O
%	O
identical	O
to	O
Alu	B-DNA
consensus	I-DNA
sequences	I-DNA
)	O
has	O
evolved	O
to	O
become	O
both	O
a	O
positive	O
and	O
negative	O
regulator	O
.	O

Furthermore	O
,	O
we	O
have	O
demonstrated	O
that	O
both	O
C/EBPbeta	B-protein
and	O
GATA-1	B-protein
can	O
bind	O
simultaneously	O
to	O
the	O
C/EBP-	O
and	O
GATA-binding	B-DNA
sites	I-DNA
in	O
the	O
MBP	B-DNA
promoter	I-DNA
.	O

Sequence	O
analysis	O
of	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
the	O
CD69	B-DNA
gene	I-DNA
revealed	O
the	O
presence	O
of	O
a	O
potential	O
TATA	B-DNA
element	I-DNA
30	B-DNA
base	I-DNA
pairs	I-DNA
upstream	I-DNA
of	O
the	O
major	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
and	O
several	O
putative	O
binding	O
sequences	O
for	O
inducible	O
transcription	B-protein
factors	I-protein
(	O
NF-kappa	B-protein
B	I-protein
,	O
Egr-1	B-protein
,	O
AP-1	B-protein
)	O
,	O
which	O
might	O
mediate	O
the	O
inducible	O
expression	O
of	O
this	O
gene	O
.	O

We	O
propose	O
that	O
HePTP	B-protein
plays	O
a	O
negative	O
role	O
in	O
antigen	O
receptor	O
signaling	O
by	O
specifically	O
regulating	O
MAP	B-protein
kinases	I-protein
in	O
the	O
cytosol	O
and	O
at	O
early	O
time	O
points	O
of	O
T	O
cell	O
activation	O
before	O
the	O
activation-induced	O
expression	O
of	O
nuclear	B-protein
dual-specific	I-protein
MAP	I-protein
kinase	I-protein
phosphatases	I-protein
.	O

EMS	O
analyses	O
utilizing	O
a	O
series	O
of	O
mutated	B-DNA
pp	I-DNA
repeat	I-DNA
elements	I-DNA
demonstrate	O
that	O
the	O
nucleotide	O
sequence	O
requirements	O
for	O
U1	B-DNA
(	O
U1A/U1B	B-DNA
)	O
and	O
U2	B-DNA
formation	O
are	O
separable	O
from	O
those	O
required	O
for	O
C1-C3	B-DNA
formation	O
.	O

We	O
found	O
that	O
leukemic	B-cell_type
cells	I-cell_type
from	O
ATL	O
patients	O
,	O
like	O
HTLV-I-infected	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
,	O
display	O
constitutive	O
NF-kappaB	B-protein
DNA	O
binding	O
activity	O
and	O
increased	O
degradation	O
of	O
IkappaBalpha	B-protein
(	O
an	O
inhibitor	O
of	O
NF-kappaB	B-protein
)	O
.	O

Of	O
the	O
5	O
virus	O
carriers	O
,	O
4	O
were	O
infected	O
with	O
type	O
A	O
and	O
1	O
with	O
type	O
B	O
EBV	O
.	O

This	O
study	O
used	O
a	O
high	O
titer	O
anti-38	O
,	O
000-M	O
(	O
r	O
)	O
serum	O
to	O
screen	O
bacteriophage	B-DNA
lambda	I-DNA
cDNA	I-DNA
expression	O
libraries	O
and	O
identified	O
human	B-cell_type
islet	I-cell_type
and	O
placental	B-cell_line
clones	I-cell_line
encoding	O
jun-B	B-protein
,	O
the	O
nuclear	B-protein
transcription	I-protein
protein	I-protein
,	O
of	O
predicted	O
38	O
,	O
000	O
M	O
(	O
r	O
)	O
.	O

Large	O
or	O
polar	O
substitutions	O
on	O
C-11	O
of	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
thus	O
impair	O
the	O
binding	O
of	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
but	O
increase	O
the	O
affinity	O
to	O
vitamin	B-protein
D-binding	I-protein
protein	I-protein
.	O

Both	O
of	O
these	O
events	O
were	O
blocked	O
by	O
preincubation	O
of	O
the	O
cells	O
with	O
FK506	O
,	O
a	O
calcineurin	B-protein
inhibitor	O
,	O
consistent	O
with	O
the	O
hypothesis	O
that	O
NFATp	B-protein
is	O
a	O
calcineurin	B-protein
substrate	O
in	O
cells	O
.	O

These	O
include	O
the	O
Ikaros	B-protein
,	O
LKLF	B-protein
,	O
and	O
GATA3	B-protein
zinc-finger	I-protein
proteins	I-protein
;	O
the	O
Ets	B-protein
,	O
CREB/ATF	B-protein
,	O
and	O
NF-kappa	B-protein
B/Rel/NFAT	I-protein
transcription	I-protein
factors	I-protein
;	O
the	O
Stat	B-protein
proteins	I-protein
;	O
and	O
HMG	B-protein
box	I-protein
transcription	I-protein
factors	I-protein
such	O
as	O
LEF1	B-protein
,	O
TCF1	B-protein
,	O
and	O
Sox4	B-protein
.	O

IL-2	B-DNA
gene	I-DNA
transcription	O
is	O
affected	O
by	O
several	O
nuclear	B-protein
proteins	I-protein
.	O

Supernatants	O
from	O
these	O
cultures	O
were	O
assayed	O
for	O
secreted	O
TGF-alpha	B-protein
and	O
TGF-beta1	B-protein
using	O
TGF	B-protein
-specific	O
ELISAs	O
.	O

By	O
using	O
a	O
reverse	O
transcription-PCR-based	O
approach	O
and	O
a	O
set	O
of	O
primers	O
specific	O
for	O
the	O
DNA-binding	B-DNA
domains	I-DNA
of	O
highly	O
homologous	O
members	O
of	O
the	O
C/EBP	B-protein
family	I-protein
of	O
transcriptional	B-protein
regulators	I-protein
,	O
we	O
have	O
cloned	O
a	O
novel	B-DNA
human	I-DNA
gene	I-DNA
encoding	O
a	O
member	O
of	O
the	O
C/EBP	B-DNA
gene	I-DNA
family	I-DNA
,	O
identified	O
as	O
the	O
human	O
homolog	O
of	O
CRP1	B-protein
,	O
C/EBP-epsilon	B-protein
.	O

Conversely	O
,	O
several	O
cytokines	B-protein
modulate	O
the	O
levels	O
of	O
HIV	O
expression	O
in	O
infected	O
cells	O
of	O
both	O
T	B-cell_type
lymphocytic	I-cell_type
and	I-cell_type
mononuclear	I-cell_type
phagocytic	I-cell_type
lineage	I-cell_type
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
a	O
CCAAT	B-DNA
site	I-DNA
located	O
upstream	O
of	O
the	O
PU.1	B-DNA
site	I-DNA
between	O
positions	O
-70	O
and	O
-54	O
is	O
involved	O
in	O
positive-negative	O
regulation	O
of	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
.	O

Cytomegalovirus	O
(	O
CMV	O
)	O
infection	O
induced	O
interleukin-8	B-protein
(	O
IL-8	B-protein
)	O
gene	O
transcription	O
in	O
a	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
THP-1	B-cell_line
cells	I-cell_line
,	O
leading	O
to	O
IL-8	B-protein
secretion	O
.	O

These	O
data	O
suggest	O
that	O
Rho	B-protein
potentiates	O
AP-1	B-protein
transcription	O
during	O
T-cell	O
activation	O

NFAT	B-protein
proteins	I-protein
constitute	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
mediating	O
signal	O
transduction	O
.	O

In	O
this	O
study	O
,	O
c-myc	B-RNA
protooncogene	I-RNA
mRNA	I-RNA
expression	O
in	O
29	O
labial	O
minor	O
salivary	O
gland	O
biopsies	O
from	O
patients	O
with	O
primary	O
SS	O
and	O
15	O
controls	O
was	O
examined	O
using	O
in	O
situ	O
hybridization	O
histochemistry	O
.	O

Whereas	O
IL-4	B-protein
appears	O
to	O
repress	O
functional	O
IL-12	B-protein
signaling	O
through	O
inhibition	O
of	O
IL-12R	B-protein
beta	I-protein
2	I-protein
expression	O
,	O
IFN-gamma	B-protein
in	O
the	O
mouse	O
,	O
and	O
IFN-alpha	B-protein
in	O
the	O
human	O
appear	O
to	O
induce	O
IL-12R	B-protein
beta	I-protein
2	I-protein
expression	O
and	O
promote	O
IL-12	B-protein
responsiveness	O
.	O

HTLV-I	O
encodes	O
a	O
potent	O
transactivator	B-protein
protein	O
termed	O
Tax	B-protein
that	O
appears	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
process	O
of	O
T-cell	O
immortalization	O
.	O

These	O
results	O
can	O
not	O
be	O
explained	O
by	O
receptor	O
down-regulation	O
due	O
to	O
higher	O
level	O
of	O
mineralocorticoids	O
of	O
the	O
zona	O
glomerulosa	O
.	O

CD30	B-protein
is	O
a	O
recently	O
described	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor/nerve	I-protein
growth	I-protein
factor	I-protein
receptor	I-protein
superfamily	I-protein
.	O

This	O
could	O
partly	O
be	O
explained	O
by	O
the	O
antenatal	O
steroid	O
treatment	O
.	O

Our	O
results	O
indicate	O
that	O
p24rex	B-protein
of	O
HTLV-II	O
is	O
not	O
initiated	O
at	O
an	O
internal	O
AUG	O
and	O
that	O
the	O
internal	O
methionine	O
codons	O
are	O
not	O
crucial	O
to	O
the	O
function	O
of	O
the	O
rex	B-DNA
gene	I-DNA
and	O
,	O
ultimately	O
,	O
the	O
transforming	O
properties	O
of	O
the	O
virus	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
ATL	B-cell_line
cells	I-cell_line
overexpressed	O
that	O
L-selectin	B-RNA
mRNA	I-RNA
and	O
that	O
the	O
level	O
was	O
aberrantly	O
upregulated	O
after	O
PMA	O
stimulation	O
.	O

This	O
observation	O
was	O
made	O
despite	O
normal	O
cytoplasmic	O
levels	O
of	O
the	O
Rel-A	B-protein
protein	I-protein
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Interleukin-7	B-protein
upregulates	O
the	O
interleukin-2-gene	B-DNA
expression	O
in	O
activated	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
at	O
the	O
transcriptional	O
level	O
by	O
enhancing	O
the	O
DNA	O
binding	O
activities	O
of	O
both	O
nuclear	O
factor	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
activator	B-protein
protein-1	I-protein
.	O

Glucocorticoids	O
kill	O
certain	O
types	O
of	O
lymphoblasts	B-cell_type
,	O
but	O
the	O
mechanisms	O
are	O
unknown	O
.	O

Since	O
both	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
have	O
been	O
reported	O
to	O
be	O
important	O
in	O
the	O
induction	O
of	O
the	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha	I-DNA
(	I-DNA
TNF-alpha	I-DNA
)	I-DNA
gene	I-DNA
we	O
examined	O
the	O
effects	O
of	O
okadaic	O
acid	O
on	O
TNF-alpha	B-RNA
mRNA	I-RNA
levels	O
.	O

To	O
study	O
their	O
differential	O
activation	O
properties	O
,	O
we	O
linked	O
the	O
isolated	O
effector	B-protein
domains	I-protein
to	O
the	O
GAL4	B-protein
DNA-binding	I-protein
domain	I-protein
.	O

Spi-B	B-protein
expression	O
is	O
very	O
abundant	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
both	O
Spi-B	B-RNA
mRNA	I-RNA
and	O
protein	O
are	O
detected	O
in	O
some	O
T	B-cell_type
cells	I-cell_type
.	O

Human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
,	O
a	O
betaherpesvirus	O
,	O
is	O
a	O
pathogen	O
which	O
escapes	O
immune	O
recognition	O
through	O
various	O
mechanisms	O
.	O

Basal	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
in	O
MNL	B-cell_type
was	O
significantly	O
reduced	O
in	O
anorexia	O
nervosa	O
as	O
well	O
as	O
in	O
Cushing	O
's	O
patients	O
compared	O
to	O
control	O
subjects	O
(	O
p	O
<	O
.001	O
)	O
and	O
was	O
diminished	O
by	O
dexamethasone	O
to	O
an	O
extent	O
similar	O
to	O
control	O
subjects	O
in	O
patients	O
with	O
anorexia	O
nervosa	O
,	O
but	O
significantly	O
(	O
p	O
<	O
.001	O
)	O
less	O
in	O
those	O
with	O
Cushing	O
's	O
disease	O
.	O

In	O
contrast	O
,	O
fixed	O
tissue	O
macrophages	B-cell_type
express	O
detectable	O
HIV	B-protein
proteins	I-protein
,	O
indicating	O
permanent	O
virus	O
transcription	O
.	O

Furthermore	O
,	O
biologic	O
functions	O
are	O
modulated	O
,	O
in	O
that	O
the	O
hormone	O
inhibits	O
proliferation	O
in	O
a	O
subset	O
of	O
the	O
activated	O
B	B-cell_type
cells	I-cell_type
.	O

Variation	O
of	O
glucocorticoids	O
in	O
healthy	O
aged	O
subjects	O
and	O
athletes	O
has	O
been	O
shown	O
.	O

She	O
had	O
generalized	O
lymphadenopathy	O
and	O
the	O
bone	O
marrow	O
was	O
infiltrated	O
by	O
lymphoma	B-cell_type
cells	I-cell_type
at	O
presentation	O
.	O

These	O
results	O
appear	O
to	O
indicate	O
that	O
suppression	O
of	O
cytokine	B-protein
and	O
NO	O
generation	O
by	O
Azeptin	O
results	O
at	O
least	O
partially	O
from	O
the	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

IEF-1	B-protein
,	O
a	O
pancreatic	O
beta-cell	O
type-specific	O
complex	O
believed	O
to	O
regulate	O
insulin	O
expression	O
,	O
is	O
demonstrated	O
to	O
consist	O
of	O
at	O
least	O
two	O
distinct	O
species	O
,	O
one	O
of	O
which	O
does	O
not	O
contain	O
Pan	B-protein
molecules	I-protein
.	O

Tax	B-protein
does	O
not	O
bind	O
directly	O
to	O
DNA	O
but	O
rather	O
deregulates	O
the	O
activity	O
of	O
cellular	B-protein
transcription	I-protein
factors	I-protein
.	O

The	O
induced	O
differentiation	O
occurs	O
with	O
down-regulation	O
of	O
c-fos	B-protein
protein	I-protein
and	O
an	O
accompanying	O
up-regulation	O
of	O
RB	B-protein
protein	I-protein
expression	O
,	O
consistent	O
with	O
a	O
possible	O
need	O
for	O
up-regulated	O
RB	B-protein
expression	O
to	O
maintain	O
a	O
given	O
differentiated	O
phenotype	O
and	O
suppress	O
transcriptional	B-protein
activators	I-protein
that	O
might	O
typically	O
be	O
associated	O
with	O
proliferation	O
.	O

TCF/LEF	B-protein
proteins	I-protein
have	O
recently	O
been	O
found	O
to	O
constitute	O
a	O
downstream	O
component	O
of	O
the	O
Wingless/Wnt	O
signal	O
transduction	O
pathway	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
IFN-alpha	B-protein
,	O
IL-2	B-protein
,	O
IL-12	B-protein
,	O
and	O
IL-15	B-protein
have	O
overlapping	O
activities	O
on	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

We	O
measured	O
the	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
nuclear	O
extracts	O
by	O
gel	O
shift	O
analysis	O
.	O

Recently	O
,	O
CD40	B-protein
also	O
has	O
been	O
shown	O
to	O
be	O
expressed	O
by	O
mesenchymal	B-cell_type
cells	I-cell_type
,	O
including	O
human	B-cell_type
fibroblasts	I-cell_type
.	O

Furthermore	O
,	O
when	O
human	B-protein
IL-2R	I-protein
beta	I-protein
was	O
stably	O
expressed	O
in	O
murine	B-cell_line
BA/F3	I-cell_line
cells	I-cell_line
,	O
robust	O
IL-2	B-protein
-induced	O
proliferation	O
and	O
JAK3	B-protein
activation	O
occurred	O
without	O
detectable	O
involvement	O
of	O
either	O
JAK1	B-protein
,	O
JAK2	B-protein
or	O
TYK2	B-protein
.	O

PRL	B-protein
and	O
IL-2	B-protein
receptor	O
activation	O
are	O
both	O
linked	O
to	O
the	O
Jak/Stat	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
)	O
pathway	O
.	O

During	O
T-cell	O
activation	O
,	O
c-myb	B-DNA
expression	O
is	O
induced	O
and	O
much	O
of	O
the	O
increase	O
in	O
expression	O
occurs	O
at	O
the	O
transcriptional	O
level	O
.	O

The	O
molecule	O
bound	O
CD40	B-protein
with	O
a	O
high	O
affinity	O
(	O
2.2	O
nM	O
)	O
and	O
was	O
a	O
monomer	O
in	O
solution	O
.	O

We	O
isolated	O
a	O
novel	O
subline	O
,	O
UT-7/GMT	B-cell_line
,	O
from	O
the	O
human	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
UT-7/GM	I-cell_line
(	O
N.	O
Komatsu	O
,	O
et	O
al.	O
,	O
Blood	O
,	O
89	O
:	O
4021-4033	O
,	O
1997	O
)	O
.	O

Inefficient	O
termination	O
of	O
antigen	O
responses	O
in	O
NF-ATp	B-protein
-deficient	O
mice	O
.	O

Dex	O
inhibited	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
the	O
AP-1	B-DNA
,	O
but	O
not	O
the	O
NF-AT	B-DNA
and	O
NF-kB	B-DNA
plasmids	I-DNA
.	O

Surfactant	B-protein
protein	I-protein
A	I-protein
activates	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
THP-1	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

The	O
TT-selected	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
could	O
be	O
rendered	O
unresponsive	O
to	O
its	O
dominant	O
epitope	O
in	O
a	O
dose-dependent	O
manner	O
(	O
IC50	O
=	O
0.03	O
microg/ml	O
)	O
.	O

However	O
,	O
a	O
role	O
for	O
NF-kappaB	B-protein
in	O
human	B-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
has	O
not	O
been	O
described	O
.	O

Similarly	O
,	O
a	O
kinase-deficient	B-protein
mutant	I-protein
of	O
NIK	B-protein
(	O
NF-kappaB-inducing	B-protein
kinase	I-protein
)	O
,	O
which	O
represents	O
an	O
upstream	O
kinase	O
in	O
the	O
TNF-alpha	O
and	O
IL-1	O
signaling	O
pathways	O
leading	O
to	O
IKKalpha	B-protein
and	O
IKKbeta	B-protein
activation	O
,	O
blocks	O
Tax	B-protein
induction	O
of	O
NF-kappaB	B-protein
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
inhibit	O
the	O
production	O
of	O
IL-2	B-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

It	O
has	O
been	O
found	O
that	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
of	O
the	O
peripheral	O
blood	O
of	O
healthy	O
elderly	O
subjects	O
increases	O
,	O
while	O
the	O
number	O
of	O
mineralocorticoid	O
receptors	O
decreases	O
.	O

The	O
molecular	O
mechanisms	O
of	O
the	O
effects	O
of	O
IL-4	B-protein
and	O
IL-13	B-protein
on	O
HIV	O
infection	O
in	O
human	B-cell_type
monocytes	I-cell_type
as	O
they	O
matured	O
into	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
over	O
7	O
days	O
were	O
investigated	O
using	O
HIV-1	O
(	O
BaL	O
)	O
,	O
and	O
low	O
passage	O
clinical	O
strains	O
.	O

Experiments	O
with	O
a	O
blocking	O
antibody	O
to	O
IL-4R	B-protein
alpha	I-protein
showed	O
that	O
this	O
chain	O
remains	O
an	O
essential	O
component	O
of	O
the	O
IL-13	B-protein
receptor	I-protein
complex	I-protein
on	O
MDMac	B-cell_line
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
the	O
phosphorylation	O
of	O
TRAF2	B-protein
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
regulating	O
signaling	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
influence	O
the	O
CD40	B-protein
-TRAF2	B-protein
interaction	O
.	O

Using	O
semiquantitative	O
RT-PCR	O
,	O
we	O
found	O
a	O
striking	O
increase	O
in	O
IL-6	B-RNA
mRNA	I-RNA
levels	O
only	O
in	O
resuscitated	O
HS	O
,	O
with	O
peak	O
levels	O
observed	O
1	O
h	O
after	O
initiation	O
of	O
resuscitation	O
.	O

The	O
positive	O
region	O
can	O
be	O
divided	O
into	O
an	O
upstream	B-DNA
and	I-DNA
a	I-DNA
downstream	I-DNA
regulatory	I-DNA
region	I-DNA
.	O

PKC	B-protein
activation	O
only	O
induced	O
Fas	B-protein
expression	O
in	O
cells	O
expressing	O
wild-type	O
TDAG51	B-DNA
.	O

Consistent	O
with	O
the	O
binding	O
data	O
,	O
the	O
same	O
mutations	O
in	O
the	O
GAS	B-DNA
element	I-DNA
eliminate	O
responsiveness	O
to	O
IFN-gamma	B-protein
in	O
the	O
context	O
of	O
both	O
a	O
functional	O
CAEV	B-DNA
LTR	I-DNA
and	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O

In	O
addition	O
to	O
increasing	O
our	O
understanding	O
of	O
the	O
molecular	O
pathways	O
that	O
regulate	O
T	O
cell	O
development	O
and	O
function	O
,	O
these	O
results	O
have	O
suggested	O
novel	O
targets	O
for	O
genetic	O
and	O
pharmacological	O
manipulation	O
of	O
T	O
cell	O
immunity	O
.	O

It	O
is	O
conceivable	O
that	O
GC	O
exert	O
their	O
anti-inflammatory	O
capacity	O
in	O
various	O
diseases	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
induction	O
of	O
apoptosis	O
in	O
monocytes	B-cell_type
.	O

The	O
combination	O
of	O
the	O
immune	B-protein
costimulatory	I-protein
molecule	I-protein
B7.1	B-protein
and	O
IL-12	B-protein
has	O
been	O
shown	O
to	O
be	O
synergistic	O
for	O
T	O
cell	O
activation	O
.	O

Differanisole	O
A	O
,	O
a	O
novel	O
antitumor	O
antibiotic	O
,	O
enhances	O
growth	O
inhibition	O
and	O
differentiation	O
of	O
human	B-cell_type
myeloid	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
induced	O
by	O
9-cis	O
retinoic	O
acid	O
.	O

p38	O
also	O
forms	O
a	O
complex	O
with	O
the	O
tyrosine	B-protein
kinase	I-protein
csk	I-protein
in	O
stimulated	B-cell_type
cells	I-cell_type
and	O
is	O
a	O
substrate	O
for	O
the	O
kinase	B-protein
.	O

These	O
factors	O
act	O
synergistically	O
to	O
activate	O
transcription	O
,	O
and	O
this	O
synergy	O
is	O
required	O
for	O
transcription	O
of	O
at	O
least	O
several	O
important	O
hematopoietic	B-DNA
genes	I-DNA
.	O

Hypoxia	O
enhances	O
induction	O
of	O
endothelial	B-protein
ICAM-1	I-protein
:	O
role	O
for	O
metabolic	O
acidosis	O
and	O
proteasomes	B-protein
.	O

We	O
show	O
here	O
that	O
in	O
addition	O
to	O
the	O
strong	B-protein
N-terminal	I-protein
trans-activation	I-protein
domain	I-protein
,	O
TAD-A	B-protein
,	O
which	O
is	O
common	O
to	O
all	O
three	O
NF-ATc	B-protein
isoforms	I-protein
,	O
NF-ATc/C	B-protein
contains	O
a	O
second	O
trans-activation	B-protein
domain	I-protein
,	O
TAD-B	B-protein
,	O
in	O
its	O
C-terminal	O
peptide	O
.	O

Furthermore	O
,	O
expression	O
of	O
physiological	O
levels	O
of	O
Bcl-x	B-cell_type
protected	I-cell_type
B	I-cell_type
cells	I-cell_type
from	O
Fas-mediated	O
apoptosis	O
in	O
the	O
absence	O
of	O
NF-kappaB	B-protein
signaling	O
.	O

However	O
,	O
Spi-C	B-protein
may	O
represent	O
a	O
novel	O
subgroup	O
within	O
the	O
Ets	B-protein
protein	I-protein
family	I-protein
,	O
as	O
it	O
differed	O
significantly	O
from	O
Spi-B	B-protein
and	O
PU.1	B-protein
within	O
helix	B-protein
1	I-protein
of	O
the	O
Ets	B-protein
domain	I-protein
.	O

To	O
investigate	O
the	O
effects	O
of	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV-1	I-protein
)	I-protein
Tat	I-protein
on	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
expression	O
,	O
we	O
used	O
IL-2	B-DNA
promoter-chloramphenicol	I-DNA
acetyltransferase	I-DNA
constructs	I-DNA
and	O
IL-2-secreting	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
as	O
a	O
model	O
system	O
.	O

We	O
report	O
an	O
unusual	O
case	O
of	O
a	O
55	O
year	O
old	O
Japanese	O
woman	O
with	O
a	O
seminoma	O
but	O
relatively	O
normal	O
menses	O
.	O

In	O
T	O
cell	O
areas	O
,	O
p50	B-protein
,	O
p52	B-protein
,	O
and	O
RelB	B-protein
were	O
found	O
in	O
the	O
nuclei	O
of	O
HLA-DR+	B-cell_line
cells	I-cell_line
with	O
an	O
antigen-presenting	O
cell	O
(	O
APC	O
)	O
morphology	O
.	O

In	O
transient	O
cotransfection	O
experiments	O
,	O
dominant	O
negative	O
mutants	O
of	O
the	O
IL-1	B-protein
signaling	O
pathway	O
,	O
including	O
MyD88	B-protein
,	O
IRAK	B-protein
,	O
IRAK2	B-protein
,	O
and	O
TRAF6	B-protein
inhibited	O
both	O
IL-1	B-protein
-and	O
LPS-induced	O
NF-kappaB	B-protein
-luciferase	B-protein
activity	O
.	O

By	O
immunocytochemistry	O
,	O
25	O
+/-	O
7	O
%	O
of	O
the	O
human	B-cell_type
neutrophils	I-cell_type
were	O
shown	O
to	O
express	O
immunoreactive	B-protein
GH	I-protein
,	O
whereas	O
eosinophils	B-cell_type
were	O
negative	O
.	O

The	O
mechanisms	O
by	O
which	O
the	O
effects	O
of	O
IL-2	B-protein
are	O
propagated	O
within	O
cells	O
are	O
not	O
understood	O
.	O

The	O
role	O
of	O
p16	B-protein
in	O
the	O
E2F-dependent	B-protein
thymidine	I-protein
kinase	I-protein
regulation	O
.	O

Stimulation	O
of	O
NK	B-cell_type
cells	I-cell_type
with	O
CD16	B-protein
ligands	O
induces	O
NFAT	B-protein
-like	O
DNA	O
binding	O
activity	O
in	O
the	O
nuclear	O
extracts	O
from	O
these	O
cells	O
,	O
as	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

--	O
Vegeto	O
,	O
E.	O
,	O
Pollio	O
,	O
G.	O
,	O
Pellicciari	O
,	O
C.	O
,	O
Maggi	O
,	O
A	O
.	O

The	O
cDNA	B-DNA
has	O
an	O
open	B-DNA
reading	I-DNA
frame	I-DNA
of	O
900	B-DNA
amino	I-DNA
acids	I-DNA
capable	O
of	O
encoding	O
a	O
97-kDa	B-protein
protein	I-protein
.	O

Binding	O
of	O
these	O
factors	O
to	O
ZII	B-DNA
was	O
prevented	O
by	O
oligonucleotides	O
containing	O
CRE	B-DNA
but	O
not	O
by	O
AP-1	B-DNA
consensus	I-DNA
sequences	I-DNA
.	O

Lymphocytes	B-cell_type
from	O
patients	O
who	O
have	O
received	O
anti-estrogen	O
therapy	O
show	O
similar	O
enhancement	O
of	O
Ig-secreting	B-cell_type
cells	I-cell_type
after	O
PWM	B-protein
stimulation	O
.	O

It	O
contains	O
six	O
repeats	O
of	O
the	O
Kruppel-like	B-protein
zinc-finger	I-protein
motif	I-protein
that	O
are	O
completely	O
identical	O
to	O
those	O
of	O
hBCL6	B-protein
,	O
indicating	O
that	O
the	O
BCL6	B-DNA
gene	I-DNA
is	O
well	O
conserved	O
between	O
humans	O
and	O
mice	O
.	O

However	O
,	O
while	O
HUVECs	B-cell_line
contained	O
endothelial	O
NOS	B-protein
protein	I-protein
,	O
no	O
inducible	O
NOS	B-protein
was	O
detected	O
in	O
either	O
tolerant	O
or	O
nontolerant	B-cell_type
cells	I-cell_type
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
a	O
commonly	O
prescribed	O
anti-inflammatory	O
drug	O
,	O
acetyl	O
salicylic	O
acid	O
(	O
ASA	O
)	O
,	O
on	O
IL-12	B-protein
production	O
and	O
Th1	O
cell	O
development	O
.	O

We	O
have	O
previously	O
shown	O
that	O
in	O
T	B-cell_type
cells	I-cell_type
the	O
PI3-K	B-protein
inhibitor	O
,	O
wortmannin	O
,	O
interferes	O
with	O
activation	O
of	O
the	O
mitogen-activated	B-protein
kinase	I-protein
,	O
Erk2	B-protein
,	O
after	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TcR	B-protein
)	O
stimulation	O
.	O

Circadian	O
rhythm	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
leukocytes	I-cell_type
and	O
their	O
reactivity	O
to	O
glucocorticoids	O
.	O

Transactivation	O
of	O
PTHrP	B-protein
by	O
Tax	B-protein
was	O
seen	O
in	O
T	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
B-cell	B-cell_line
lines	I-cell_line
or	O
fibroblasts	B-cell_line
.	O

Our	O
results	O
implicate	O
NFIL3/E4BP4	B-protein
(	O
nuclear	B-protein
factor	I-protein
regulated	I-protein
by	I-protein
IL-3/adenovirus	I-protein
E4	I-protein
promoter	I-protein
binding	I-protein
protein	I-protein
)	O
in	O
a	O
distinct	O
growth	O
factor-regulated	O
signaling	O
pathway	O
that	O
is	O
responsible	O
for	O
the	O
survival	O
of	O
early	B-cell_type
B-cell	I-cell_type
progenitors	I-cell_type
,	O
and	O
whose	O
alteration	O
by	O
E2A-HLF	B-protein
leads	O
to	O
childhood	O
B	O
lineage	O
leukemia	O
.	O

PCR	B-DNA
fragments	I-DNA
were	O
cloned	O
,	O
sequenced	O
,	O
clustered	O
into	O
homologous	O
groups	O
,	O
and	O
the	O
group	O
sequences	O
searched	O
on	O
the	O
GenBank	O
database	O
.	O

The	O
expression	O
of	O
active	O
NF-kappa	B-protein
B	I-protein
might	O
therefore	O
also	O
be	O
regulated	O
by	O
the	O
extent	O
of	O
processing	O
of	O
p105	B-protein
.	O

The	O
three-dimensional	O
positioning	O
of	O
immunoglobulin	B-DNA
(	I-DNA
Ig	I-DNA
)	I-DNA
genes	I-DNA
within	O
the	O
nucleus	O
of	O
human	B-cell_type
cells	I-cell_type
was	O
investigated	O
using	O
in	O
situ	O
hybridization	O
and	O
confocal	O
microscopy	O
.	O

Furthermore	O
,	O
we	O
evaluated	O
the	O
mineralocorticoid	B-protein
receptor	I-protein
(	O
MR	B-protein
)	O
status	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
in	O
the	O
2	O
groups	O
.	O

Nuclear	O
run-on	O
experiments	O
showed	O
that	O
THP	O
inhibited	O
transcription	O
of	O
the	O
IL-1	B-DNA
beta	I-DNA
gene	I-DNA
.	O

A	O
clone	O
of	O
U937	B-cell_line
cells	I-cell_line
was	O
selected	O
which	O
expressed	O
Fc	B-protein
receptor	I-protein
I	I-protein
(	O
Fc	B-protein
gamma	I-protein
RI	I-protein
)	O
and	O
which	O
,	O
after	O
incubation	O
with	O
IFN-gamma	B-protein
for	O
72	O
h	O
,	O
was	O
capable	O
of	O
generating	O
high	O
levels	O
of	O
lucigenin-enhanced	O
CL	O
.	O

The	O
three	O
jun	B-DNA
genes	I-DNA
showed	O
a	O
similar	O
time	O
course	O
in	O
their	O
induction	O
by	O
PMA	O
,	O
maximal	O
mRNA	O
levels	O
being	O
reached	O
after	O
60	O
min	O
of	O
induction	O
.	O

Binding	O
of	O
ER	B-protein
to	O
an	O
estrogen	B-DNA
response	I-DNA
element	I-DNA
was	O
enhanced	O
by	O
addition	O
of	O
rabbit	O
reticulocyte	O
lysate	O
.	O

Activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
induces	O
an	O
NF-kappa	B-protein
B	I-protein
-like	O
binding	O
activity	O
to	O
the	O
B2	B-DNA
site	O
,	O
concomitant	O
with	O
activation	O
of	O
the	O
proenkephalin	B-DNA
promoter	I-DNA
.	O

However	O
,	O
the	O
cellular	O
functions	O
and	O
its	O
role	O
in	O
inflammation	O
,	O
for	O
example	O
,	O
rheumatoid	O
synovitis	O
,	O
are	O
currently	O
unknown	O
.	O

The	O
highly	O
specific	O
granulomonocyte-associated	B-protein
lysosomal	I-protein
proteins	I-protein
myeloperoxidase	B-protein
(	O
MPO	B-protein
)	O
and	O
lysozyme	B-protein
(	O
LZ	B-protein
)	O
,	O
as	O
well	O
as	O
the	O
transcription	B-protein
factor	I-protein
PU.1	B-protein
,	O
were	O
already	O
detectable	O
in	O
the	O
most	O
immature	O
CD34+Thy-1+	B-cell_line
subset	I-cell_line
.	O

Interestingly	O
,	O
tg	B-cell_type
epsilon26	I-cell_type
thymocytes	I-cell_type
expressed	O
GATA-3	B-protein
and	O
TCF-1	B-protein
,	O
but	O
not	O
LEF-1	B-protein
and	O
PEBP-2alpha	B-protein
,	O
among	O
T	B-protein
cell-specific	I-protein
transcription	I-protein
factors	I-protein
that	O
are	O
involved	O
in	O
early	O
T	O
cell	O
development	O
,	O
indicating	O
that	O
GATA-3	B-protein
and	O
TCF-1	B-protein
expressed	O
during	O
thymocyte	O
development	O
do	O
not	O
necessarily	O
determine	O
the	O
cell	O
fate	O
into	O
T	B-cell_type
cell	I-cell_type
lineage	I-cell_type
.	O

A	O
specific	O
,	O
retarded	O
band	O
containing	O
VDR-RXR	B-protein
was	O
identified	O
when	O
wild	O
type	O
cell	O
but	O
not	O
when	O
vitamin	O
D-resistant	O
cell	O
nuclear	O
extract	O
was	O
used	O
in	O
the	O
binding	O
reaction	O
with	O
either	O
probe	O
.	O

In	O
nonlymphoid	B-cell_type
cells	I-cell_type
,	O
the	O
epidermal	B-protein
growth	I-protein
factor	I-protein
receptor	I-protein
displayed	O
increased	O
tyrosine	O
phosphorylation	O
within	O
seconds	O
of	O
UV	O
irradiation	O
.	O

HLA	O
Class	O
II	O
dependency	O
was	O
investigated	O
using	O
anti-Class	B-protein
II	I-protein
monoclonal	I-protein
antibodies	I-protein
.	O

Findings	O
that	O
xenogeneic	O
serum	O
promotes	O
leukocyte-endothelium	O
interaction	O
possibly	O
through	O
NF-kappa	B-protein
B	I-protein
activation	O
might	O
be	O
relevant	O
for	O
designing	O
future	O
therapeutic	O
strategies	O
aimed	O
at	O
prolonging	O
xenograft	O
survival	O
.	O

Secretion	O
of	O
ILs	B-protein
was	O
blocked	O
with	O
monensine	O
.	O

This	O
viral	O
reactivation	O
was	O
associated	O
with	O
increased	O
NF-kappaB	B-protein
nuclear	O
translocation	O
in	O
patients	O
'	O
PBMCs	B-cell_type
.	O

Furthermore	O
,	O
the	O
dephosphorylated	O
NF-AT1	B-protein
can	O
be	O
rapidly	O
rephosphorylated	O
when	O
the	O
cells	O
are	O
incubated	O
with	O
cyclosporin	O
A	O
,	O
an	O
immunosuppressant	O
inhibiting	O
the	O
serine/threonine	B-protein
phosphatase	I-protein
calcineurin	B-protein
.	O

However	O
,	O
the	O
inducible	O
degradation	O
of	O
p105	B-protein
is	O
not	O
coupled	O
with	O
the	O
generation	O
of	O
p50	B-protein
.	O

Critical	O
cytoplasmic	B-protein
domains	I-protein
of	O
human	B-protein
interleukin-9	I-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
in	O
interleukin	B-protein
-9-mediated	O
cell	O
proliferation	O
and	O
signal	O
transduction	O
.	O

These	O
results	O
imply	O
a	O
potential	O
role	O
of	O
the	O
anaphylatoxins	B-protein
C5a	B-protein
and	O
C3a	B-protein
in	O
regulating	O
leukocytes	O
gene	O
expression	O
through	O
G	O
protein-coupled	O
transcription	O
factor	O
activation	O
.	O

Apoptosis	O
and	O
growth	O
inhibition	O
in	O
malignant	B-cell_type
lymphocytes	I-cell_type
after	O
treatment	O
with	O
arsenic	O
trioxide	O
at	O
clinically	O
achievable	O
concentrations	O
[	O
see	O
comments	O
]	O

The	O
larger	O
crossreacting	O
protein	O
exhibited	O
an	O
electrophoretic	O
mobility	O
of	O
80	O
kDa	O
,	O
was	O
localized	O
in	O
the	O
cell	O
cytosol	O
,	O
and	O
appeared	O
to	O
be	O
specific	O
for	O
activated	B-cell_type
lymphocytes	I-cell_type
since	O
it	O
was	O
not	O
detected	O
in	O
several	O
other	O
human	B-cell_type
cells	I-cell_type
including	O
monocytes	B-cell_type
.	O

The	O
three	O
compartments	O
are	O
thought	O
to	O
be	O
of	O
common	O
endodermal	O
origin	O
;	O
in	O
contrast	O
to	O
earlier	O
hypotheses	O
,	O
which	O
suggested	O
that	O
the	O
endocrine	O
compartment	O
was	O
of	O
neuroectodermal	O
origin	O
.	O

The	O
Oct	O
1	O
transcription	B-protein
factor	I-protein
,	O
and	O
a	O
very	O
close	O
homologue	O
,	O
KIAA0144	B-DNA
,	O
was	O
identified	O
using	O
the	O
POU	O
family	O
primers	O
.	O

The	O
level	O
of	O
ongoing	O
HIV-1	O
replication	O
within	O
an	O
individual	O
is	O
critical	O
to	O
HIV-1	O
pathogenesis	O
.	O

Identification	O
of	O
transcriptional	B-protein
suppressor	I-protein
proteins	I-protein
that	O
bind	O
to	O
the	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

IL-4	B-protein
stimulated	O
nuclear	B-protein
factor-kappaB	I-protein
nuclear	O
translocation	O
and	O
binding	O
before	O
enhancement	O
of	O
HIV	B-RNA
RNA	I-RNA
expression	O
.	O

Multiple	O
proteins	O
interact	O
with	O
the	O
nuclear	B-DNA
inhibitory	I-DNA
protein	I-DNA
repressor	I-DNA
element	I-DNA
in	O
the	O
human	B-DNA
interleukin-3	I-DNA
promoter	I-DNA
.	O

A	O
difference	O
in	O
the	O
time	O
course	O
of	O
appearance	O
of	O
NFAT-1	B-protein
activity	O
between	O
T-lymphocytes	B-cell_type
and	O
non-T-lymphocytes	B-cell_type
was	O
revealed	O
.	O

Its	O
expression	O
is	O
restricted	O
to	O
a	O
few	O
cell	O
types	O
,	O
including	O
monocyte/macrophages	B-cell_type
.	O

Inhibition	O
of	O
TNF-alpha	B-protein
production	O
by	O
THP-1-hGH-transfected	B-cell_line
cells	I-cell_line
cultured	O
in	O
the	O
presence	O
of	O
LPS	O
is	O
dependent	O
on	O
a	O
selective	O
pathway	O
,	O
since	O
no	O
inhibition	O
of	O
TNF-alpha	B-protein
production	O
was	O
observed	O
when	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
PMA	O
.	O

Glucocorticoid	O
effects	O
were	O
assessed	O
in	O
vivo	O
by	O
depletion	O
of	O
endogenous	O
glucocorticoids	O
after	O
oral	O
administration	O
of	O
1.5	O
g	O
metyrapone	O
(	O
MET	O
)	O
and	O
subsequent	O
glucocorticoid	O
replacement	O
,	O
and	O
in	O
vitro	O
by	O
incubation	O
of	O
the	O
cells	O
with	O
different	O
doses	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
.	O

These	O
data	O
indicate	O
that	O
tumor	B-cell_type
cells	I-cell_type
of	O
NLPHD	O
uniformly	O
display	O
a	O
GC	O
B-cell	O
phenotype	O
,	O
whereas	O
the	O
phenotype	O
of	O
tumor	B-cell_type
cells	I-cell_type
of	O
CHD	O
appears	O
to	O
be	O
modulated	O
by	O
the	O
surrounding	O
cellular	O
background	O
,	O
particularly	O
CD40L+	B-cell_type
reactive	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
,	O
treatment	O
with	O
both	O
okadaic	O
acid	O
and	O
cycloheximide	O
was	O
associated	O
with	O
stabilization	O
(	O
t	O
1/2	O
=	O
90	O
min	O
)	O
of	O
c-jun	B-protein
transcripts	I-protein
.	O

LIF	B-protein
induces	O
the	O
production	O
of	O
other	O
cytokines	B-protein
in	O
monocytes	O
but	O
its	O
effects	O
on	O
HIV	O
replication	O
were	O
not	O
inhibited	O
by	O
antibodies	B-protein
to	O
IL-1	B-protein
,	O
TNF	B-protein
,	O
or	O
IL-6	B-protein
.	O

Previously	O
,	O
transcription	O
of	O
the	O
c-fos	B-DNA
gene	I-DNA
has	O
been	O
reported	O
to	O
be	O
transactivated	O
by	O
the	O
viral	B-protein
transcription	I-protein
factor	I-protein
,	O
Tax1	B-protein
.	O

NMR	O
analysis	O
demonstrated	O
the	O
presence	O
of	O
three	O
alpha-helices	B-protein
(	O
Val10-Gln22	B-protein
,	O
Glu30-Leu41	B-protein
and	O
Phe50-Tyr65	B-protein
)	O
connected	O
by	O
loop	B-protein
regions	I-protein
(	O
Ser23-Ala49	B-protein
and	O
Leu42-Pro49	B-protein
)	O
.	O

The	O
upstream	B-DNA
regulatory	I-DNA
element	I-DNA
could	O
confer	O
T-cell	O
specificity	O
to	O
the	O
GATA-3	B-DNA
promoter	I-DNA
activity	O
,	O
and	O
analysis	O
of	O
this	O
region	O
revealed	O
a	O
707-base	B-DNA
pair	I-DNA
silencer	I-DNA
that	O
drastically	O
inhibited	O
GATA-3	B-DNA
promoter	I-DNA
activity	O
in	O
non-T-cells	B-cell_type
.	O

When	O
activated	O
,	O
glucocorticoid	B-protein
receptors	I-protein
form	O
a	O
dimer	B-protein
and	O
bind	O
to	O
DNA	O
after	O
migration	O
into	O
the	O
nucleus	O
.	O

Moreover	O
,	O
tyrosine-phosphorylated	B-protein
LAT/pp36/38	I-protein
in	O
detergent	O
lysates	O
prepared	O
from	O
anti-CD3	B-cell_type
stimulated	I-cell_type
T	I-cell_type
cells	I-cell_type
associated	O
with	O
Grb2	B-protein
but	O
not	O
GrpL	B-protein
.	O

Individual	O
mutation	O
of	O
the	O
DBF	O
or	O
AP3-L	B-DNA
site	O
as	O
well	O
as	O
the	O
double	O
mutation	B-DNA
AP-1	I-DNA
(	I-DNA
III	I-DNA
)	I-DNA
/AP3-L	I-DNA
did	O
not	O
affect	O
HIV-1	O
replication	O
compared	O
to	O
that	O
of	O
the	O
wild-type	O
virus	O
.	O

Th1	O
cell-mediated	O
immune	O
responses	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
inflammatory	O
autoimmune	O
diseases	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
human	B-cell_type
NK	I-cell_type
cells	I-cell_type
activate	O
porcine	O
EC	B-cell_type
in	O
vitro	O
,	O
which	O
results	O
in	O
adhesion	B-protein
molecule	I-protein
expression	O
and	O
cytokine	B-protein
secretion	O
.	O

Deletional	O
and	O
site-directed	O
mutagenesis	O
revealed	O
the	O
presence	O
of	O
multiple	O
functionally	O
critical	O
cis	B-DNA
elements	I-DNA
within	O
this	O
region	O
,	O
one	O
of	O
which	O
was	O
a	O
nuclear	B-DNA
factor	I-DNA
(	I-DNA
NF	I-DNA
)	I-DNA
-kappaB	I-DNA
consensus	I-DNA
sequence	I-DNA
.	O

Out	O
current	O
findings	O
suggest	O
that	O
further	O
investigations	O
are	O
warranted	O
to	O
elucidate	O
the	O
possible	O
linkage	O
of	O
ER	B-DNA
codon	I-DNA
10	I-DNA
polymorphism	O
to	O
physiological	O
and	O
pathological	O
conditions	O
.	O

In	O
contrast	O
to	O
the	O
transient	O
NF-kappa	B-protein
B	I-protein
activation	O
induced	O
by	O
phorbol	O
ester	O
,	O
the	O
permanent	O
NF-kappa	B-protein
B	I-protein
translocation	O
induced	O
by	O
HIV	O
infection	O
was	O
not	O
dependent	O
on	O
PKC	B-protein
isoenzymes	I-protein
alpha	I-protein
and	I-protein
beta	I-protein
as	O
shown	O
by	O
the	O
use	O
of	O
a	O
specific	O
inhibitor	O
(	O
GF	O
109203X	O
)	O
.	O

B	B-cell_type
lymphocytes	I-cell_type
and	O
macrophages	O
express	O
closely	O
related	O
immunoglobulin	B-protein
G	I-protein
(	I-protein
IgG	I-protein
)	I-protein
Fc	I-protein
receptors	I-protein
(	O
Fc	B-protein
gamma	I-protein
RII	I-protein
)	O
that	O
differ	O
only	O
in	O
the	O
structures	O
of	O
their	O
cytoplasmic	B-protein
domains	I-protein
.	O

We	O
demonstrate	O
here	O
that	O
a	O
third	O
region	O
encompassing	O
a	O
proline	B-protein
rich	I-protein
sequence	I-protein
within	O
the	O
33	O
bp	O
repetitive	O
stretch	O
of	O
LMP1	B-protein
's	O
C-terminus	B-protein
is	O
required	O
for	O
the	O
activation	O
of	O
Janus	B-protein
kinase	I-protein
3	I-protein
(	O
JAK3	B-protein
)	O
.	O

However	O
,	O
the	O
lysis	O
pathway	O
in	O
the	O
dex-resistant	B-cell_line
cells	I-cell_line
is	O
defective	O
in	O
that	O
dex-resistant	B-cell_line
clones	I-cell_line
needed	O
significantly	O
more	O
cortivazol	O
than	O
the	O
normal	B-cell_line
cells	I-cell_line
for	O
lysis	O
of	O
the	O
cells	O
.	O

Fludarabine	O
caused	O
a	O
specific	O
depletion	O
of	O
STAT1	B-protein
protein	I-protein
(	O
and	O
mRNA	O
)	O
but	O
not	O
of	O
other	O
STATs	B-protein
.	O

Synergistic	O
transactivation	O
of	O
the	O
BMRF1	B-DNA
promoter	I-DNA
by	O
the	O
Z/c-myb	B-protein
combination	I-protein
appears	O
to	O
involve	O
direct	O
binding	O
by	O
the	O
Z	B-protein
protein	I-protein
but	O
not	O
the	O
c-myb	B-protein
protein	I-protein
.	O

Murine	B-protein
and	I-protein
human	I-protein
T-lymphocyte	I-protein
GATA-3	I-protein
factors	I-protein
mediate	O
transcription	O
through	O
a	O
cis-regulatory	B-DNA
element	I-DNA
within	O
the	O
human	B-DNA
T-cell	I-DNA
receptor	I-DNA
delta	I-DNA
gene	I-DNA
enhancer	I-DNA
.	O

OCA-B	B-protein
stimulates	O
the	O
transcription	O
from	O
an	O
IgH	B-DNA
promoter	I-DNA
in	O
conjunction	O
with	O
either	O
Oct-1	B-protein
or	O
Oct-2	B-protein
but	O
shows	O
no	O
significant	O
effect	O
on	O
the	O
octamer	B-DNA
/	O
Oct	B-DNA
-dependent	O
transcription	O
of	O
the	O
ubiquitously	B-DNA
expressed	I-DNA
histone	I-DNA
H2B	I-DNA
promoter	I-DNA
and	O
the	O
transcription	O
of	O
USF-	B-DNA
and	I-DNA
Sp1-regulated	I-DNA
promoters	I-DNA
.	O

MZF-2	B-RNA
mRNA	I-RNA
was	O
expressed	O
in	O
myeloid	O
cells	O
,	O
particularly	O
in	O
the	O
cells	O
committed	O
to	O
the	O
neutrophilic	B-cell_type
lineage	I-cell_type
,	O
and	O
down-regulated	O
by	O
G-CSF	B-protein
.	O

CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
costimulated	O
with	O
the	O
A6H	B-protein
mAb	I-protein
upregulated	O
CD80	B-protein
,	O
CD86	B-protein
,	O
CD71	B-protein
,	O
interleukin-2	B-protein
(	I-protein
IL-2	I-protein
)	I-protein
R	I-protein
alpha	I-protein
,	O
IL-2R	B-protein
beta	I-protein
and	O
IL-2R	B-protein
gamma	I-protein
,	O
while	O
no	O
corresponding	O
up-regulation	O
of	O
these	O
cell	B-protein
surface	I-protein
molecules	I-protein
was	O
seen	O
in	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

We	O
observed	O
that	O
after	O
LPS	O
stimulation	O
of	O
human	B-cell_type
monocytes	I-cell_type
,	O
TNF-alpha	B-protein
increased	O
to	O
798+/-67	O
pg/mL	O
(	O
p	O
<	O
.001	O
versus	O
control	O
)	O
.	O

Furthermore	O
,	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
the	O
kinetics	O
of	O
the	O
two	O
phosphorylation	O
events	O
are	O
essentially	O
similar	O
.	O

Conversely	O
,	O
SCL	B-protein
expression	O
was	O
up-regulated	O
by	O
Epo	B-protein
and	O
further	O
increased	O
by	O
haemin	O
and	O
delta-ALA	O
.	O

Here	O
we	O
show	O
that	O
both	O
a	O
FasL-	B-DNA
and	I-DNA
a	I-DNA
consensus	I-DNA
NF-kappaB-	I-DNA
reporter	I-DNA
construct	I-DNA
are	O
inefficiently	O
induced	O
in	O
these	O
cells	O
compared	O
to	O
wild-type	B-cell_type
cells	I-cell_type
.	O

The	O
NF-kappa	B-protein
B	I-protein
family	I-protein
of	O
transcription	B-protein
proteins	I-protein
represents	O
multiple	O
DNA	O
binding	O
,	O
rel	B-protein
related	I-protein
polypeptides	I-protein
that	O
contribute	O
to	O
regulation	O
of	O
genes	O
involved	O
in	O
immune	O
responsiveness	O
and	O
inflammation	O
,	O
as	O
well	O
as	O
activation	O
of	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O

Coexpression	O
of	O
the	O
class	B-protein
II	I-protein
transactivator	I-protein
CIITA	I-protein
in	O
these	O
cells	O
,	O
which	O
stimulates	O
highly	O
efficient	O
class	O
II	O
processing	O
without	O
the	O
characteristic	O
decline	O
in	O
barrier	O
function	O
seen	O
in	O
polarized	O
monolayers	O
treated	O
with	O
the	O
proinflammatory	B-protein
cytokine	I-protein
gamma-IFN	I-protein
,	O
facilitates	O
antigen	O
processing	O
from	O
the	O
basolateral	O
surface	O
.	O

In	O
contrast	O
,	O
all	O
other	O
NF-kappa	B-protein
B	I-protein
/I	O
kappa	O
B	O
molecules	O
tested	O
are	O
relatively	O
stable	O
in	O
both	O
cell-types	O
.	O

Expression	O
of	O
IkappaBalpha	B-protein
in	O
the	O
nucleus	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Four	O
specific	O
protein-DNA	B-protein
complexes	I-protein
were	O
detected	O
after	O
incubation	O
of	O
nuclear	O
extracts	O
(	O
NE	O
)	O
from	O
T3-responsive	B-cell_line
pituitary	I-cell_line
(	I-cell_line
GH3	I-cell_line
)	I-cell_line
cells	I-cell_line
with	O
a	O
TREp-containing	B-DNA
DNA	I-DNA
fragment	I-DNA
.	O

Transcription	B-protein
factor	I-protein
IID	I-protein
(	O
TFIID	B-protein
)	O
binds	O
to	O
the	O
TATA	B-DNA
box	I-DNA
promoter	I-DNA
element	I-DNA
and	O
regulates	O
the	O
expression	O
of	O
most	O
eukaryotic	B-DNA
genes	I-DNA
transcribed	O
by	O
RNA	B-protein
polymerase	I-protein
II	I-protein
.	O

cDNA	B-DNA
microarrays	I-DNA
and	O
a	O
clustering	O
algorithm	O
were	O
used	O
to	O
identify	O
patterns	O
of	O
gene	O
expression	O
in	O
human	B-cell_type
mammary	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
growing	O
in	O
culture	O
and	O
in	O
primary	O
human	O
breast	O
tumors	O
.	O

IL-2	B-protein
gene	O
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
requires	O
both	O
TCR	O
and	O
costimulatory	O
signals	O
.	O

The	O
AML1	B-protein
antisense	O
oligodeoxynucleotide	O
but	O
not	O
the	O
sense	O
oligomer	O
recovered	O
its	O
differentiation-inducing	O
capacity	O
in	O
the	O
presence	O
of	O
butyrate	O
.	O

The	O
recent	O
discovery	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
reviewed	O
and	O
several	O
potential	O
pathways	O
for	O
cytokine	B-protein
-induced	O
periodontal	O
tissue	O
damage	O
,	O
mediated	O
by	O
NF-kappa	B-protein
B1	I-protein
are	O
discussed	O
.	O

Treatment	O
with	O
E2	O
was	O
also	O
associated	O
with	O
a	O
time-dependent	O
decrease	O
in	O
the	O
mRNA	O
level	O
of	O
the	O
proapoptotic	B-protein
Nip-2	I-protein
protein	I-protein
,	O
supporting	O
the	O
hypothesis	O
that	O
hormone	O
responsiveness	O
of	O
U937	B-cell_line
cells	I-cell_line
is	O
mediated	O
by	O
target	O
gene	O
transcription	O
.	O

We	O
examined	O
the	O
effects	O
of	O
IFN-gamma	B-protein
on	O
both	O
basal	O
and	O
IL-4	B-protein
/	O
IL-13	B-protein
-induced	O
IL-1R	B-DNA
gene	I-DNA
expression	O
in	O
primary	B-cell_type
monocytes	I-cell_type
.	O

The	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	B-cell_line
mimics	O
PAM	B-cell_type
in	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
and	O
sensitivity	O
to	O
exogenous	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

Glycation-dependent	O
,	O
reactive	O
oxygen	O
species-mediated	O
suppression	O
of	O
the	O
insulin	O
gene	O
promoter	O
activity	O
in	O
HIT	B-cell_type
cells	I-cell_type
.	O

Pretreatment	O
with	O
IFN-gamma	B-protein
potentiates	O
the	O
IFN-alpha	B-protein
-induced	O
protection	O
,	O
but	O
IFN-gamma	B-protein
alone	O
does	O
not	O
have	O
any	O
antiviral	O
activity	O
.	O

Some	O
subgroups	O
displayed	O
a	O
direct	O
correlation	O
between	O
infiltration	O
and	O
sex-binding	B-protein
globulin	I-protein
,	O
cholesterol	O
,	O
luteinizing	O
hormone	O
in	O
blood	O
,	O
and	O
lean	O
body	O
mass	O
.	O

Specific	O
complex	O
formation	O
between	O
the	O
type	B-protein
II	I-protein
bare	I-protein
lymphocyte	I-protein
syndrome-associated	I-protein
transactivators	I-protein
CIITA	B-protein
and	O
RFX5	B-protein
.	O

The	O
phosphorothioate	O
oligonucleotides	O
specifically	O
bound	O
either	O
octamer	B-protein
transcription	I-protein
factor	I-protein
or	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
.	O

In	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
which	O
exemplify	O
an	O
intermediate	O
stage	O
of	O
B-cell	O
differentiation	O
,	O
a	O
reduced	O
expression	O
and	O
activity	O
were	O
observed	O
.	O

Here	O
,	O
we	O
have	O
readdressed	O
the	O
issue	O
of	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
specific	O
for	O
the	O
72-kDa	B-protein
major	I-protein
immediate-early	I-protein
protein	I-protein
(	O
IE-1	B-protein
)	O
,	O
which	O
is	O
nonstructural	O
but	O
is	O
found	O
very	O
early	O
and	O
throughout	O
the	O
replicative	O
cycle	O
.	O

During	O
humoral	O
immune	O
responses	O
,	O
B-lymphocyte	O
activation	O
is	O
followed	O
by	O
differentiation	O
along	O
either	O
the	O
plasma	O
cell	O
pathway	O
or	O
the	O
memory	O
B-cell	O
pathway	O
.	O

Recently	O
,	O
we	O
have	O
reported	O
that	O
the	O
histogenesis	O
of	O
B-cell	B-cell_type
lymphomas	I-cell_type
may	O
be	O
assessed	O
by	O
monitoring	O
the	O
expression	O
pattern	O
of	O
BCL-6	B-protein
,	O
a	O
transcription	B-protein
factor	I-protein
expressed	O
in	O
germinal	B-cell_type
center	I-cell_type
(	I-cell_type
GC	I-cell_type
)	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
and	O
CD138/syndecan-1	B-protein
(	O
syn-1	B-protein
)	O
,	O
a	O
proteoglycan	O
associated	O
with	O
post-GC	O
,	O
terminal	O
B-cell	O
differentiation	O
.	O

We	O
demonstrate	O
that	O
CaMKIV/Gr	B-protein
reconstitutes	O
the	O
capacity	O
of	O
the	O
cytosolic	O
component	O
of	O
NFAT	B-protein
to	O
direct	O
transcription	O
from	O
NFAT	B-DNA
sites	I-DNA
in	O
non-	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
induction	O
of	O
promoters	B-DNA
dependent	O
on	O
these	O
elements	O
is	O
inhibitable	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
tacrolimus	O
(	O
FK-506	O
)	O
.	O

The	O
subunits	O
of	O
this	O
heterodimer	B-protein
have	O
been	O
cloned	O
,	O
and	O
NF90	B-protein
was	O
found	O
to	O
encode	O
a	O
protein	O
containing	O
two	O
domains	O
that	O
are	O
predicted	O
to	O
form	O
motifs	O
capable	O
of	O
binding	O
to	O
double-stranded	B-RNA
RNA	I-RNA
.	O

Lymphocytes	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
have	O
diminished	O
receptor	O
density	O
;	O
thus	O
,	O
patients	O
with	O
RA	O
should	O
show	O
partial	O
resistance	O
to	O
glucocorticoids	O
.	O

These	O
findings	O
suggest	O
the	O
involvement	O
of	O
HB9	B-DNA
in	O
regulating	O
gene	O
transcription	O
in	O
lymphoid	O
and	O
pancreatic	O
tissues	O
.	O

Eosinophil	B-cell_type
priming	O
by	O
cytokines	B-protein
:	O
from	O
cellular	O
signal	O
to	O
in	O
vivo	O
modulation	O
.	O

Thus	O
a	O
primary	O
effect	O
of	O
these	O
immunosuppressive	O
reagents	O
is	O
to	O
control	O
the	O
subcellular	O
localization	O
of	O
the	O
NF-AT	B-protein
family	O
of	O
transcription	B-protein
factors	I-protein
.	O

In	O
addition	O
,	O
EL-4	B-cell_type
cells	I-cell_type
incubated	O
with	O
ciprofloxacin	O
showed	O
an	O
early	O
peak	O
and	O
more	O
activated	O
nuclear	O
factor	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
(	O
NFAT-1	B-protein
)	O
as	O
compared	O
to	O
control	O
cells	O
without	O
antibiotics	O
.	O

Inhibition	O
of	O
the	O
transfer	O
of	O
tyrosine	O
phosphoryl	O
groups	O
onto	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
prevented	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
degradation	O
and	O
NF-kappa	B-protein
B	I-protein
binding	O
.	O

These	O
results	O
indicate	O
that	O
RA	O
directly	O
inhibits	O
the	O
erythroid	O
differentiation	O
program	O
at	O
the	O
level	O
of	O
early	O
adult	O
HPC	B-cell_type
,	O
and	O
may	O
lead	O
to	O
a	O
shift	O
from	O
the	O
erythroid	O
to	O
granulocytic	O
differentiation	O
pathway	O
.	O

These	O
data	O
suggest	O
that	O
in	O
pregnancy	O
,	O
lymphocyte	O
progesterone	O
acts	O
on	O
specific	O
progesterone	B-protein
receptors	I-protein
and	O
glucocorticoid	B-protein
binding	I-protein
sites	I-protein
are	O
not	O
involved	O
.	O

The	O
X	B-DNA
box	I-DNA
region	I-DNA
is	O
critical	O
for	O
directing	O
the	O
expression	O
of	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
genes	I-DNA
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

The	O
OCA-B	O
and	O
VP16	B-protein
interactions	O
with	O
the	O
Oct-1	B-protein
POU	I-protein
domain	I-protein
are	O
sufficiently	O
different	O
to	O
permit	O
OCA-B	B-protein
and	O
VP16	B-protein
to	O
bind	O
the	O
Oct-1	B-protein
POU	I-protein
domain	I-protein
simultaneously	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
the	O
XP-B	B-cell_line
and	I-cell_line
XP-D	I-cell_line
lymphoblastoid	I-cell_line
cells	I-cell_line
do	O
not	O
have	O
impaired	O
RNA	O
transcription	O
activity	O
.	O

In	O
the	O
mouse	B-cell_line
Th2	I-cell_line
D10	I-cell_line
cells	I-cell_line
and	O
in	O
the	O
human	B-cell_line
Th2	I-cell_line
clones	I-cell_line
,	O
POS-1	B-protein
(	O
designated	O
POS-1b	B-protein
)	O
contains	O
NF-IL6beta	B-protein
,	O
Jun	B-protein
,	O
and	O
NF-ATc/p	B-protein
.	O

IL-2	B-protein
-induced	O
beta-casein	B-protein
expression	O
was	O
enhanced	O
by	O
dexamethasone	O
,	O
and	O
this	O
synergistic	O
effect	O
of	O
Dexamethasone	O
requires	O
the	O
sequence	O
between	O
-155	B-DNA
and	I-DNA
-193	I-DNA
in	O
the	O
beta-casein	B-DNA
promoter	I-DNA
.	O

They	O
determine	O
the	O
outcome	O
of	O
an	O
antigenic	O
response	O
toward	O
humoral	O
or	O
cell-mediated	O
immunity	O
.	O

Function	O
and	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
immune	O
system	O
.	O

In	O
contrast	O
,	O
activated	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
older	O
individuals	O
show	O
a	O
significant	O
reduction	O
in	O
the	O
induction	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
in	O
response	O
to	O
the	O
same	O
stimuli	O
.	O

Another	O
LTR	B-DNA
size	I-DNA
variation	I-DNA
was	O
observed	O
in	O
four	O
patients	O
in	O
a	O
region	O
just	O
upstream	O
of	O
the	O
NF-kappa	B-DNA
B	I-DNA
enhancer	I-DNA
.	O

However	O
,	O
the	O
combined	O
stimulation	O
did	O
not	O
result	O
in	O
enhanced	O
p50	B-protein
and	O
p65	B-protein
protein	I-protein
expression	O
.	O

However	O
,	O
the	O
growth	O
of	O
most	O
mutated	O
viruses	O
was	O
suppressed	O
in	O
primary	B-cell_type
rhesus	I-cell_type
monkey	I-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
(	O
SIVmacMER	O
approximately	O
2xNFkappaB	B-protein
approximately	O
substNFkappaB	B-protein
>	O
deltaNFkappaB	B-protein
>	O
deltaNFkappaB	B-protein
deltaSpl234	B-protein
approximately	O
deltaNFkappaBdeltaSpl	B-protein
>	O
deltaSpl234	B-protein
approximately	O
substSpl2	B-protein
>	O
substSp23	B-protein
approximately	O
substSp34	B-protein
approximately	O
substSpl234	B-protein
>	O
or	O
=	O
SIVmac239	O
)	O
.	O

Proteins	O
in	O
the	O
first	O
group	O
contain	O
multiple	O
HMG	B-protein
boxes	I-protein
,	O
are	O
non-sequence-specific	O
,	O
and	O
recognize	O
structural	O
features	O
as	O
found	O
in	O
cruciform	B-DNA
DNA	I-DNA
and	O
cross-over	B-DNA
DNA	I-DNA
.	O

The	O
E1A	B-DNA
and	I-DNA
hexon	I-DNA
primers	I-DNA
amplified	O
DNA	O
from	O
representative	O
adenoviral	O
serotypes	O
in	O
all	O
six	O
adenoviral	O
groups	O
(	O
A-F	O
)	O
.	O

Therefore	O
,	O
Tax	B-protein
appears	O
to	O
inhibit	O
the	O
interaction	O
of	O
Sp	B-protein
family	I-protein
members	I-protein
with	O
the	O
pp	B-DNA
repeat	I-DNA
.	O

NLS	B-protein
peptide-mediated	O
disruption	O
of	O
the	O
nuclear	O
import	O
of	O
these	O
transcription	B-protein
factors	I-protein
results	O
in	O
inhibition	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
IL-2	O
gene	O
expression	O
,	O
processes	O
dependent	O
on	O
NF-kappa	B-protein
B	I-protein
or	O
the	O
combination	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
AP-1	B-protein
,	O
and	O
NFAT	B-protein
.	O

Northern	O
blot	O
analyses	O
indicated	O
a	O
highly	O
restricted	O
mRNA	O
expression	O
pattern	O
,	O
with	O
the	O
strongest	O
expression	O
occurring	O
in	O
promyelocyte	B-cell_line
and	I-cell_line
late-myeloblast-like	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Like	O
in	O
Th2	B-cell_line
clones	I-cell_line
,	O
suppressed	O
NFAT-	O
P0	B-DNA
complex	O
formation	O
was	O
observed	O
also	O
at	O
the	O
polyclonal	O
level	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
of	O
three	O
of	O
five	O
severe	O
atopic	O
dermatitis	O
patients	O
with	O
strongly	O
elevated	O
serum	O
IgE	B-protein
levels	O
,	O
but	O
not	O
in	O
control	O
PBMC	B-cell_type
.	O

The	O
function	O
of	O
LEF-1	B-protein
is	O
dependent	O
,	O
in	O
part	O
,	O
on	O
the	O
HMG	B-protein
domain	I-protein
that	O
induces	O
a	O
sharp	O
bend	O
in	O
the	O
DNA	O
helix	O
,	O
and	O
on	O
an	O
activation	B-protein
domain	I-protein
that	O
stimulates	O
transcription	O
only	O
in	O
a	O
specific	O
context	O
of	O
other	O
enhancer-binding	B-protein
proteins	I-protein
.	O

Thus	O
,	O
c-erbA/TR	B-protein
appears	O
to	O
act	O
as	O
a	O
binary	O
switch	O
affecting	O
erythroid	B-cell_type
cell	I-cell_type
fate	I-cell_type
:	O
unliganded	O
c-erbA/TR	B-protein
supports	O
growth	O
while	O
ligand-activated	O
c-erbA/TR	B-protein
induces	O
differentiation	O
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
commitment	O
of	O
progenitors	O
to	O
the	O
eosinophil	B-cell_type
lineage	I-cell_type
has	O
not	O
been	O
determined	O
.	O

We	O
then	O
investigated	O
if	O
HCMV	O
binding	O
also	O
resulted	O
in	O
the	O
translation	O
and	O
secretion	O
of	O
cytokines	B-protein
.	O

However	O
,	O
analysis	O
of	O
deletion	B-DNA
mutants	I-DNA
localized	O
nearly	O
all	O
of	O
the	O
promoter	O
activity	O
to	O
a	O
short	O
region	O
(	O
-73	B-DNA
to	I-DNA
-16	I-DNA
)	O
that	O
did	O
not	O
include	O
the	O
cluster	O
of	O
c-Myb	B-DNA
sites	I-DNA
.	O

Internal	O
ribosomal	O
binding	O
requires	O
a	O
cis-acting	B-DNA
element	I-DNA
termed	O
the	O
internal	B-DNA
ribosomal	I-DNA
entry	I-DNA
site	I-DNA
(	O
IRES	B-DNA
)	O
.	O

Dexamethasone	O
inhibited	O
LPS-induced	O
bioactive	O
IL-12	B-protein
production	O
in	O
a	O
dose-dependent	O
fashion	O
and	O
at	O
physiologically	O
relevant	O
concentrations	O
;	O
it	O
had	O
no	O
effect	O
on	O
IL-10	B-protein
secretion	O
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
events	O
linked	O
to	O
T-cell	O
activation	O
,	O
in	O
addition	O
to	O
NF-kappa	B-protein
B	I-protein
translocation	O
per	O
se	O
,	O
induce	O
functional	O
interactions	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
with	O
the	O
HIV	B-DNA
enhancer	I-DNA
.	O

CD40	B-protein
ligation	O
on	O
MM	O
by	O
CD40L-transfected	B-cell_line
murine	I-cell_line
L-cells	I-cell_line
or	O
by	O
a	O
soluble	O
CD40L	B-protein
fusion	I-protein
protein	I-protein
up-regulated	O
their	O
expression	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
and	O
MHC	B-protein
class	I-protein
I	I-protein
and	I-protein
class	I-protein
II	I-protein
molecules	I-protein
and	O
their	O
secretion	O
of	O
IL-6	B-protein
,	O
IL-8	B-protein
,	O
tumor	B-protein
necrosis	I-protein
factor-a	I-protein
,	O
and	O
granulocyte	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
and	O
also	O
induced	O
a	O
rapid	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor	I-protein
kappaB	I-protein
.	O

Recent	O
evidence	O
indicates	O
that	O
the	O
rate	O
of	O
progression	O
of	O
the	O
HIV-1	O
disease	O
is	O
significantly	O
reduced	O
in	O
thalassaemia	O
major	O
patients	O
upon	O
treatment	O
with	O
high	O
doses	O
of	O
desferrioxamine	O
(	O
DFX	O
)	O
.	O

Virus	O
stocks	O
obtained	O
from	O
these	O
experiments	O
exhibited	O
a	O
continuum	O
of	O
replicative	O
capacities	O
in	O
different	O
human	B-cell_type
T-cell	I-cell_type
types	I-cell_type
depending	O
on	O
which	O
element	B-DNA
(	O
s	O
)	O
was	O
present	O
in	O
the	O
LTR	B-DNA
.	O

Thus	O
,	O
STAT3	B-protein
may	O
play	O
a	O
role	O
in	O
B	O
cell	O
antigen-specific	O
signaling	O
responses	O
,	O
and	O
its	O
constitutive	O
activation	O
is	O
associated	O
with	O
a	O
normal	O
cell	O
population	O
exhibiting	O
intrinsic	O
proliferative	O
behavior	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
is	O
an	O
etiological	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

The	O
second	O
male	O
patient	O
had	O
slight	O
hypertension	O
without	O
hypokalemia	O
.	O

This	O
activity	O
is	O
further	O
inducible	O
in	O
activated	O
T	B-cell_type
cells	I-cell_type
,	O
but	O
not	O
in	O
fibroblasts	B-cell_type
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D2	O
production	O
by	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
alveolar	B-cell_type
macrophages	I-cell_type
recovered	O
by	O
lavage	O
from	O
normocalcemic	O
patients	O
with	O
tuberculosis	O
.	O

Stimulation	O
with	O
different	O
GC	O
at	O
therapeutic	O
concentrations	O
resulted	O
in	O
monocyte	O
apoptosis	O
in	O
a	O
time-	O
and	O
dose-dependent	O
manner	O
.	O

This	O
was	O
followed	O
by	O
a	O
gradual	O
decline	O
to	O
the	O
basal	O
level	O
by	O
24	O
h	O
.	O

Low	O
levels	O
of	O
c-jun	B-RNA
transcripts	I-RNA
were	O
detectable	O
in	O
untreated	B-cell_line
HL-60	I-cell_line
leukemic	I-cell_line
cells	I-cell_line
,	O
increased	O
significantly	O
by	O
6	O
h	O
,	O
and	O
reached	O
near	O
maximal	O
levels	O
by	O
24	O
h	O
of	O
exposure	O
to	O
32	O
nM	O
TPA	O
.	O

These	O
results	O
indicate	O
that	O
IL-4	B-protein
and	O
ligation	O
of	O
CD40	B-protein
induce	O
NF-kappa	B-protein
B	I-protein
expression	O
via	O
at	O
least	O
a	O
mechanism	O
dependent	O
on	O
the	O
PI3-kinase	B-protein
pathway	O
and	O
suggest	O
that	O
NF-kappa	B-protein
B	I-protein
sensitive	O
to	O
NAC	O
may	O
play	O
a	O
role	O
in	O
regulating	O
germline	B-DNA
C	O
epsilon	O
transcription	O
.	O

The	O
tumor	B-cell_type
cells	I-cell_type
in	O
most	O
cases	O
of	O
Hodgkin	O
's	O
disease	O
(	O
HD	O
)	O
have	O
been	O
recently	O
recognized	O
to	O
originate	O
from	O
the	O
B-cell	B-cell_type
lineage	I-cell_type
,	O
but	O
their	O
precise	O
differentiation	O
stage	O
is	O
not	O
fully	O
clarified	O
.	O

Cell	O
sorter	O
analysis	O
of	O
CD11b+	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
revealed	O
similar	O
CD11b+	B-cell_type
populations	I-cell_type
in	O
transgenic	O
and	O
control	O
mice	O
.	O

The	O
transcriptional	O
activity	O
of	O
both	O
domains	O
is	O
strongly	O
potentiated	O
by	O
interactions	O
with	O
distinct	O
B	B-protein
cell-specific	I-protein
coactivators	I-protein
.	O

We	O
demonstrate	O
that	O
although	O
the	O
individual	O
components	O
of	O
this	O
element	O
do	O
not	O
respond	O
to	O
IL-2	B-protein
,	O
together	O
they	O
form	O
a	O
composite	O
element	O
capable	O
of	O
conferring	O
IL-2	B-protein
responsiveness	O
to	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O

These	O
cells	O
showed	O
reduced	O
numbers	O
of	O
binding	B-protein
sites	I-protein
with	O
little	O
alteration	O
in	O
apparent	O
affinity	O
between	O
ligand	O
and	O
receptor	O
.	O

The	O
aberrant	O
activation	O
of	O
AP-1	B-protein
by	O
gp160	B-protein
in	O
CD4	B-cell_type
positive	I-cell_type
T	I-cell_type
cells	I-cell_type
could	O
result	O
in	O
up-regulation	O
of	O
cytokines	B-protein
containing	O
AP-1	B-DNA
sites	I-DNA
,	O
e.g	O
.	O
interleukin-3	B-protein
and	O
granulocyte	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
,	O
and	O
concurrently	O
lead	O
to	O
T	B-cell_type
cell	I-cell_type
unresponsiveness	O
by	O
inhibiting	O
interleukin-2	B-protein
secretion	O
.	O

Active	O
suppression	O
of	O
the	O
class	B-DNA
II	I-DNA
transactivator-encoding	I-DNA
AIR-1	I-DNA
locus	I-DNA
is	O
responsible	O
for	O
the	O
lack	O
of	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
expression	O
observed	O
during	O
differentiation	O
from	O
B	B-cell_type
cells	I-cell_type
to	O
plasma	B-cell_type
cells	I-cell_type
.	O

Using	O
the	O
technique	O
of	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
with	O
RNA	O
isolated	O
from	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
of	O
the	O
patient	O
and	O
of	O
controls	O
,	O
no	O
evidence	O
was	O
found	O
that	O
IVS1-10TC	O
abnormally	O
disrupted	O
mRNA	B-RNA
splicing	O
or	O
caused	O
the	O
absence	O
of	O
BRCA1	B-RNA
mRNA	I-RNA
.	O

Correspondingly	O
,	O
RNase	B-protein
treatment	O
had	O
no	O
effect	O
on	O
hybridization	O
pattern	O
at	O
all	O
.	O

Much	O
attention	O
has	O
focused	O
on	O
the	O
series	O
of	O
sequence	O
elements	O
upstream	O
of	O
the	O
transcriptional	B-DNA
initiation	I-DNA
site	I-DNA
in	O
the	O
U3	B-DNA
region	I-DNA
of	O
the	O
LTR	B-DNA
including	O
the	O
Sp1	B-protein
and	O
NF-kappaB	B-protein
binding	B-DNA
sites	I-DNA
.	O

Differential	O
regulation	O
of	O
4E-BP1	B-protein
and	O
4E-BP2	B-protein
,	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
during	O
human	B-cell_type
myeloid	I-cell_type
cell	I-cell_type
differentiation	O
.	O

The	O
system	O
is	O
based	O
on	O
the	O
use	O
of	O
an	O
oligomerized	O
NFAT-1	B-protein
binding	O
motif	O
that	O
directs	O
transcription	B-protein
of	I-protein
SV40	I-protein
T-antigen	I-protein
in	O
transgenic	O
mice	O
.	O

These	O
findings	O
show	O
that	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
is	O
necessary	O
to	O
activate	O
the	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
,	O
while	O
KBF1	B-protein
by	O
itself	O
is	O
not	O
sufficient	O
.	O

Photoaffinity	O
labeling	O
of	O
plasma	B-protein
membrane	I-protein
receptors	I-protein
for	O
aldosterone	O
from	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O

Amplified	O
c-erbB2	B-DNA
gene	I-DNA
sequences	I-DNA
were	O
present	O
in	O
21.5	O
%	O
of	O
all	O
samples	O
.	O

Calcineurin	B-protein
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
inactivate	O
I	B-protein
kappa	I-protein
B/MAD3	I-protein
,	O
an	O
inhibitor	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

TCF-1	B-protein
belongs	O
to	O
the	O
family	O
of	O
transcription-regulating	B-protein
proteins	I-protein
which	O
share	O
a	O
region	O
of	O
homology	O
termed	O
the	O
HMG-box	B-protein
.	O

Differential	O
regulation	O
of	O
the	O
Janus	B-protein
kinase	I-protein
-STAT	B-protein
pathway	O
and	O
biologic	O
function	O
of	O
IL-13	B-protein
in	O
primary	B-cell_type
human	I-cell_type
NK	I-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
:	O
a	O
comparative	O
study	O
with	O
IL-4	B-protein
.	O

UV	O
irradiation	O
and	O
H2O2	O
treatment	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
induce	O
protein	O
tyrosine	O
phosphorylation	O
and	O
Ca2+	O
signals	O
similar	O
to	O
those	O
observed	O
following	O
biological	O
stimulation	O
.	O

Fibrinogen	B-protein
also	O
caused	O
activation	O
of	O
AP-1	B-protein
,	O
but	O
not	O
SP1	B-protein
or	O
cAMP	B-protein
response	I-protein
element-binding	I-protein
protein	I-protein
(	I-protein
CREB	I-protein
)	I-protein
factors	I-protein
.	O

The	O
lung	B-cell_type
macrophage	I-cell_type
was	O
identified	O
as	O
the	O
main	O
cellular	O
source	O
for	O
critical	O
inflammatory	B-protein
mediators	I-protein
such	O
as	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
the	O
chemokines	B-protein
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-8	I-protein
and	I-protein
-6	I-protein
,	O
and	O
matrix	B-protein
metalloproteinase-9	I-protein
in	O
this	O
model	O
system	O
of	O
mechanical	O
ventilation	O
.	O

Cross-linking	O
CD19	B-protein
on	O
early	O
human	B-cell_type
B	I-cell_type
lineage	I-cell_type
cells	I-cell_type
induces	O
the	O
formation	O
of	O
a	O
CD19/Vav/phosphatidylinositol-3	B-protein
kinase	I-protein
complex	I-protein
,	O
tyrosine	O
phosphorylation	O
of	O
CD19	B-protein
and	O
Vav	B-protein
,	O
and	O
activation	O
of	O
the	O
Ras	B-protein
pathway	O
.	O

Stimulation	O
of	O
CD40	B-protein
on	O
immunogenic	O
human	O
malignant	O
melanomas	O
augments	O
their	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocyte	I-cell_type
-mediated	O
lysis	O
and	O
induces	O
apoptosis	O
.	O

Transgene	O
expression	O
did	O
not	O
affect	O
the	O
thymic	O
development	O
,	O
but	O
led	O
to	O
lowered	O
numbers	O
of	O
splenic	O
T	B-cell_type
cells	I-cell_type
and	O
to	O
a	O
dramatic	O
decrease	O
in	O
the	O
ex	O
vivo	O
proliferative	O
response	O
of	O
splenic	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Our	O
data	O
provide	O
the	O
first	O
demonstration	O
that	O
IL-12	B-protein
-mediated	O
activation	O
of	O
T	B-cell_type
and	I-cell_type
NK	I-cell_type
cells	I-cell_type
does	O
not	O
involve	O
expression	O
of	O
members	O
of	O
the	O
immediate-early	B-DNA
activation	I-DNA
genes	I-DNA
family	I-DNA
(	O
egr-1	B-DNA
,	O
c-fos	B-DNA
,	O
and	O
junB	B-DNA
)	O
,	O
AP-1	B-protein
transcriptional	O
activity	O
,	O
or	O
bcl-2	B-DNA
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
observed	O
that	O
curcumin	O
(	O
50	O
microM	O
)	O
inhibited	O
proliferation	O
of	O
rat	B-cell_type
thymocytes	I-cell_type
stimulated	O
with	O
concanavalin	O
A	O
(	O
Con	O
A	O
)	O
as	O
well	O
as	O
that	O
of	O
human	B-cell_type
Jurkat	I-cell_type
lymphoblastoid	I-cell_type
cells	I-cell_type
in	O
the	O
logarithmic	O
growth	O
phase	O
.	O

HIV-1	O
activation	O
and	O
expression	O
was	O
quantitated	O
by	O
reverse	B-protein
transcriptase	I-protein
assay	O
.	O

Activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
elevation	O
of	O
cAMP	O
interact	O
synergistically	O
to	O
raise	O
c-Fos	B-protein
and	O
AP-1	B-protein
activity	O
in	O
Jurkat	O
cells	O
.	O

Cyclosporin	O
A	O
and	O
FK506	O
inhibit	O
T-	O
and	O
B-cell	O
activation	O
and	O
other	O
processes	O
essential	O
to	O
an	O
effective	O
immune	O
response	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
synergy	O
between	O
SLP-76	B-protein
and	O
Vav	B-protein
in	O
regulating	O
IL-2	B-DNA
gene	I-DNA
expression	O
reflects	O
the	O
cooperation	O
between	O
different	O
signaling	O
pathways	O
.	O

While	O
Jurkat	B-cell_line
cells	I-cell_line
co-expressed	O
two	O
discrete	O
cell-surface	B-protein
isoforms	I-protein
of	O
CD43	B-protein
,	O
recognized	O
by	O
mAb	B-protein
J393	I-protein
and	O
mAb	B-protein
G10-2	I-protein
,	O
respectively	O
,	O
only	O
J393/CD43	B-protein
signaled	O
apoptosis	O
.	O

Taken	O
together	O
,	O
ciprofloxacin	O
increased	O
the	O
levels	O
of	O
immediate-early	B-RNA
transcripts	I-RNA
,	O
enhanced	O
IL-2	B-protein
and	O
metallothionein	B-protein
promoter	O
induction	O
,	O
and	O
upregulated	O
AP-1	B-protein
concentrations	O
in	O
primary	B-cell_type
lymphocytes	I-cell_type
,	O
reflecting	O
a	O
program	O
commonly	O
observed	O
in	O
mammalian	O
stress	O
responses	O
.	O

Sequence-specific	O
DNA	O
binding	O
of	O
the	O
B-cell-specific	B-protein
coactivator	I-protein
OCA-B	B-protein
.	O

These	O
findings	O
may	O
provide	O
clues	O
toward	O
understanding	O
the	O
involvement	O
of	O
cAMP	O
signaling	O
in	O
the	O
pathogenesis	O
of	O
bipolar	O
disorder	O
.	O

Among	O
them	O
,	O
both	O
the	O
activation	O
of	O
PKC/Ras-	O
and	O
CaM/CN-mediated	O
pathways	O
play	O
a	O
central	O
role	O
in	O
the	O
signal	O
transduction	O
of	O
cytokine	B-DNA
gene	I-DNA
expression	O
.	O

In	O
MDMs	B-cell_type
,	O
an	O
upregulation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
synthesis	O
as	O
well	O
as	O
the	O
appearance	O
of	O
a	O
novel	O
M	O
(	O
r	O
)	O
40	O
,	O
000	O
form	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
were	O
also	O
observed	O
.	O

We	O
have	O
recently	O
reported	O
a	O
series	O
(	O
A	O
)	O
of	O
1	O
,	O
25D3-resistant	O
variants	O
of	O
HL60	B-cell_line
cells	I-cell_line
which	O
proliferate	O
in	O
the	O
presence	O
of	O
1	O
,	O
25D3	O
and	O
do	O
not	O
express	O
differentiation	O
markers	O
(	O
Exp.	O
Cell	O
Res.	O
224	O
,	O
312	O
,	O
1996	O
)	O
.	O

To	O
determine	O
whether	O
different	O
cellular	B-protein
factors	I-protein
were	O
involved	O
in	O
E3	O
regulation	O
in	O
lymphocytes	B-cell_type
as	O
compared	O
with	O
HeLa	B-cell_line
cells	I-cell_line
,	O
both	O
DNA	O
binding	O
and	O
transfection	O
analysis	O
with	O
the	O
E3	B-DNA
promoter	I-DNA
in	O
both	O
cell	O
types	O
were	O
performed	O
.	O

The	O
induction	O
of	O
immediate-early	B-DNA
(	I-DNA
IE	I-DNA
)	I-DNA
response	I-DNA
genes	I-DNA
,	O
such	O
as	O
egr-1	B-DNA
,	O
c-fos	B-DNA
,	O
and	O
c-jun	B-DNA
,	O
occurs	O
rapidly	O
after	O
the	O
activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Inhibition	O
by	O
IL-10	B-protein
of	O
proinflammatory	B-protein
cytokine	I-protein
release	O
appears	O
to	O
occur	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
for	O
TNF-alpha	B-protein
and	O
both	O
transcriptionally	O
and	O
posttranscriptionally	O
for	O
IL-1beta	B-protein
.	O

Furthermore	O
,	O
we	O
discuss	O
recent	O
advances	O
that	O
have	O
led	O
to	O
a	O
better	O
understanding	O
of	O
how	O
cytokines	B-protein
elicit	O
intracellular	O
responses	O
,	O
as	O
well	O
as	O
their	O
role	O
in	O
normal	O
lymphoid	O
development	O
.	O

Using	O
in	O
vivo	O
and	O
in	O
vitro	O
binding	O
assays	O
,	O
we	O
confirm	O
that	O
Bob1	B-protein
binds	O
to	O
CIITA	B-protein
.	O

HIV-TF1	B-protein
had	O
a	O
molecular	O
weight	O
of	O
39	O
,	O
000	O
.	O

Inducible	O
nitric	O
oxide	O
:	O
an	O
autoregulatory	O
feedback	O
inhibitor	O
of	O
vascular	O
inflammation	O
.	O

Further	O
,	O
in	O
consecutive	O
samples	O
of	O
fresh	O
blood	O
obtained	O
from	O
patients	O
with	O
B-CLL	B-cell_line
cells	I-cell_line
,	O
the	O
addition	O
of	O
IL-10	B-protein
inhibited	O
B-CLL	B-cell_line
proliferation	O
,	O
enhanced	O
B-CLL	B-cell_line
differentiation	O
,	O
but	O
did	O
not	O
induce	O
apoptosis	O
.	O

Expression	O
of	O
FOG	B-protein
(	O
riend	B-protein
ATA	I-protein
)	O
,	O
which	O
binds	O
to	O
GATA-1	B-protein
and	O
acts	O
as	O
a	O
cofactor	O
for	O
GATA-binding	B-protein
proteins	I-protein
,	O
decreased	O
transactivation	O
activity	O
of	O
GATA-1	B-protein
for	O
the	O
MBP	B-DNA
promoter	I-DNA
in	O
a	O
dose-dependent	O
manner	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
PML/RARalpha	B-protein
fusion	I-protein
protein	I-protein
causes	O
transcriptional	O
repression	O
by	O
recruiting	O
the	O
nuclear	B-protein
corepressor	I-protein
(	I-protein
N-CoR	I-protein
)	I-protein
histone	I-protein
deacetylase	I-protein
complex	I-protein
to	O
the	O
DNA	O
,	O
which	O
results	O
in	O
decreased	O
histone	B-protein
acetylation	O
and	O
a	O
repressive	O
chromatin	B-DNA
organization	O
.	O

Since	O
the	O
AES	B-protein
proteins	I-protein
are	O
part	O
of	O
a	O
set	O
of	O
transcriptional	O
repressors	O
encoded	O
by	O
the	O
Enhancer	B-DNA
of	I-DNA
split	I-DNA
[	I-DNA
E	I-DNA
(	I-DNA
spl	I-DNA
)	I-DNA
]	I-DNA
genes	I-DNA
,	O
and	O
since	O
these	O
repressors	O
are	O
activated	O
to	O
suppress	O
cell	O
differentiation	O
in	O
response	O
to	O
Notch	B-protein
receptors	I-protein
signalling	O
,	O
the	O
AES	O
peptides	O
may	O
represent	O
a	O
novel	O
class	O
of	O
self-antigens	B-protein
that	O
deserve	O
further	O
consideration	O
as	O
tumor	B-protein
Ag	I-protein
in	O
epithelial	O
cancers	O
.	O

Hydrogen	O
peroxide	O
and	O
oxygen	O
radicals	O
are	O
agents	O
commonly	O
produced	O
during	O
inflammatory	O
processes	O
.	O

Two	O
regions	O
were	O
identified	O
:	O
region	B-DNA
I	I-DNA
(	O
-182	B-DNA
to	I-DNA
-162	I-DNA
bp	I-DNA
)	O
contained	O
an	O
overlapping	O
Sp1/Egr-1	B-DNA
site	I-DNA
,	O
and	O
region	B-DNA
II	I-DNA
(	O
-119	B-DNA
to	I-DNA
-88	I-DNA
)	O
contained	O
CRE	B-DNA
and	O
NF-kappaB	B-DNA
(	I-DNA
designated	I-DNA
kappaB3	I-DNA
)	I-DNA
sites	I-DNA
.	O

RESULTS	O
:	O
Dose-dependent	O
inhibition	O
was	O
demonstrated	O
for	O
all	O
glucocorticoids	O
in	O
both	O
patient	O
groups	O
,	O
with	O
the	O
steroid-resistant	O
group	O
requiring	O
approximately	O
2	O
log-fold	O
more	O
glucocorticoids	O
for	O
an	O
equivalent	O
degree	O
of	O
inhibition	O
.	O

Activated	O
viral	O
gene	O
expression	O
associated	O
with	O
phenotypic	O
conversion	O
of	O
group	B-cell_line
I	I-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
to	O
group	B-cell_line
II	I-cell_line
or	O
III	B-cell_line
restores	O
the	O
Egr-1	B-DNA
gene	I-DNA
expression	O
.	O

To	O
identify	O
mechanisms	O
responsible	O
for	O
this	O
lineage-specific	O
and	O
interferon-regulated	O
expression	O
,	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
sequence	I-DNA
of	O
the	O
gene	O
has	O
been	O
characterized	O
.	O

Demonstration	O
of	O
clonal	O
cell	O
growth	O
by	O
analysis	O
of	O
X-chromosome	B-DNA
inactivation	O
(	O
XCI	O
)	O
patterns	O
in	O
females	O
provides	O
a	O
promising	O
tool	O
for	O
diagnosis	O
.	O

Induction	O
of	O
24	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
synthesis	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
observed	O
in	O
the	O
fifth	O
cell	B-cell_line
line	I-cell_line
,	O
designated	O
Ro-VDR	B-cell_line
,	O
although	O
the	O
sensitivity	O
to	O
hormone	O
treatment	O
was	O
lower	O
than	O
in	O
the	O
control	B-cell_line
cell	I-cell_line
line	I-cell_line
from	O
a	O
normal	O
donor	O
.	O

Redox	O
status	O
of	O
cells	O
influences	O
constitutive	O
or	O
induced	O
NF-kappa	B-protein
B	I-protein
translocation	O
and	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
activity	O
in	O
human	B-cell_line
T	I-cell_line
and	I-cell_line
monocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

An	O
association	O
between	O
hSIE	B-DNA
and	O
Stat-3	B-protein
after	O
MHC-I	B-protein
ligation	O
was	O
directly	O
demonstrated	O
by	O
precipitating	O
Stat-3	B-protein
from	O
nuclear	O
extracts	O
with	O
biotinylated	O
hSIE	B-DNA
probe	I-DNA
and	O
avidin	B-protein
-coupled	O
agarose	O
.	O

To	O
further	O
analyze	O
potential	O
cross	O
points	O
between	O
positively	O
and	O
negatively	O
regulating	O
signaling	O
pathways	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
we	O
tested	O
the	O
effects	O
of	O
activators	O
of	O
the	O
adenylate	B-protein
cyclase	I-protein
or	O
PKA	B-protein
on	O
two	O
parallel	O
mitogen-activated	O
protein	O
kinase	O
signaling	O
pathways	O
mediated	O
by	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
(	O
ERK	B-protein
)	O
and	O
c-Jun	B-protein
N-terminal	I-protein
kinase	I-protein
.	O

Five	O
T-cell	B-cell_line
clones	I-cell_line
specific	O
for	O
a	O
T-cell	B-protein
epitope	I-protein
located	O
at	O
the	O
carboxyterminal	B-protein
region	I-protein
of	O
HBxAg	B-protein
were	O
established	O
and	O
found	O
to	O
belong	O
to	O
the	O
CD2/CD4-positive	B-cell_line
,	I-cell_line
CD8-negative	I-cell_line
subtype	I-cell_line
.	O

From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
CD38	B-protein
is	O
ATRA	O
inducible	O
in	O
myeloid	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
and	O
normal	B-cell_type
CD34+	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
.	O

We	O
propose	O
that	O
mutations	O
of	O
MDS1/EVI1	B-DNA
either	O
by	O
gene	O
truncation	O
resulting	O
in	O
the	O
transcription	B-protein
repressor	I-protein
EVI1	I-protein
or	O
by	O
gene	O
fusion	O
to	O
AML1	B-protein
lead	O
to	O
an	O
altered	O
cellular	O
response	O
to	O
growth	O
and	O
differentiation	B-protein
factors	I-protein
that	O
could	O
result	O
in	O
leukemic	O
transformation	O
.	O

However	O
,	O
not	O
only	O
is	O
expression	O
of	O
the	O
beta-casein	B-DNA
gene	I-DNA
regulated	O
by	O
STAT5	B-protein
but	O
it	O
is	O
also	O
affected	O
by	O
other	O
molecules	O
such	O
as	O
glucocorticoid	O
and	O
Ras	B-protein
.	O

These	O
results	O
indicate	O
a	O
variation	O
in	O
transcriptional	O
regulation	O
rather	O
than	O
mRNA	O
stability	O
between	O
the	O
alleles	B-DNA
.	O

This	O
review	O
outlines	O
general	O
features	O
of	O
signal	O
transduction	O
and	O
several	O
aspects	O
of	O
cytokine	B-protein
networks	I-protein
are	O
discussed	O
with	O
emphasis	O
on	O
:	O
transcriptional	O
regulation	O
of	O
Th1	O
and	O
Th2-specific	O
cytokine	B-DNA
genes	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
,	O
the	O
roles	O
of	O
cytokines	B-protein
and	O
their	O
receptors	O
in	O
growth	O
and	O
differentiation	O
of	O
hemopoietic	B-cell_type
cells	I-cell_type
,	O
and	O
the	O
manipulation	O
of	O
cytokine	B-protein
networks	I-protein
.	O

G-CSF	B-protein
receptors	I-protein
lack	O
intrinsic	O
tyrosine	B-protein
kinase	I-protein
activity	O
,	O
but	O
activation	O
of	O
the	O
receptor	O
results	O
in	O
the	O
rapid	O
induction	O
of	O
tyrosine	O
kinase	O
activity	O
.	O

These	O
cDNA	O
were	O
2343	O
bp	O
long	O
and	O
their	O
transcription	O
initiation	O
site	O
was	O
located	O
814	B-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
J	B-DNA
delta	I-DNA
1	I-DNA
segment	I-DNA
.	O

However	O
,	O
chronically	B-cell_type
HIV-infected	I-cell_type
cells	I-cell_type
appear	O
to	O
be	O
resistant	O
to	O
glucocorticoid-evoked	O
cell	O
death	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
human	B-DNA
LOX-1	I-DNA
gene	I-DNA
is	O
a	O
new	O
member	O
of	O
the	O
natural	B-protein
killer	I-protein
gene	I-protein
complex	I-protein
with	O
a	O
unique	O
expression	O
profile	O
.	O

TACI	B-protein
-induced	O
activation	O
of	O
NF-AT	B-protein
was	O
specifically	O
blocked	O
by	O
a	O
dominant-negative	B-protein
CAML	I-protein
mutant	I-protein
,	O
thus	O
implicating	O
CAML	B-protein
as	O
a	O
signaling	O
intermediate	O
.	O

With	O
the	O
murine	B-DNA
cDNA	I-DNA
clones	I-DNA
several	O
aspects	O
of	O
TCF-1	B-protein
were	O
analyzed	O
.	O

In	O
addition	O
,	O
BHRF1	B-protein
protected	O
these	O
cells	O
from	O
monocyte-mediated	O
killing	O
but	O
failed	O
to	O
protect	O
them	O
from	O
killing	O
mediated	O
by	O
lymphokine-activated	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O

The	O
molecular	O
mass	O
of	O
these	O
factors	O
is	O
approximately	O
28	O
kDa	O
,	O
and	O
their	O
DNA	O
binding	O
characteristics	O
are	O
indistinguishable	O
from	O
those	O
of	O
the	O
novel	O
nuclear	B-protein
factor	I-protein
MS-2	B-protein
.	O

Therefore	O
,	O
to	O
evaluate	O
the	O
mechanism	O
of	O
TPA	O
responsiveness	O
of	O
the	O
SNE	B-DNA
motifs	I-DNA
and	O
of	O
a	O
related	O
16-bp	O
SEE	B-DNA
(	O
SRF/ETS	B-DNA
element	I-DNA
)	O
motif	O
found	O
in	O
the	O
HCMV	B-DNA
and	I-DNA
chimpanzee	I-DNA
CMV	I-DNA
MIE	I-DNA
enhancers	I-DNA
,	O
we	O
have	O
examined	O
the	O
functional	O
responses	O
and	O
protein	O
binding	O
properties	O
of	O
multimerized	B-DNA
wild-type	I-DNA
and	I-DNA
mutant	I-DNA
elements	I-DNA
added	O
upstream	O
to	O
the	O
SCMV	B-DNA
MIE	I-DNA
or	O
simian	B-DNA
virus	I-DNA
40	I-DNA
minimal	I-DNA
promoter	I-DNA
regions	I-DNA
in	O
the	O
U-937	B-cell_line
,	O
K-562	B-cell_line
,	O
HL-60	B-cell_line
,	O
THP-1	B-cell_line
,	O
and	O
Jurkat	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

It	O
has	O
been	O
demonstrated	O
that	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
and	O
interleukin-10	B-protein
(	O
IL-10	B-protein
)	O
have	O
various	O
reverse	O
effects	O
on	O
macrophages	B-cell_type
;	O
however	O
,	O
the	O
molecular	O
mechanism	O
of	O
this	O
difference	O
has	O
not	O
been	O
fully	O
understood	O
.	O

This	O
higher	O
NF-kappa	B-protein
B	I-protein
activity	O
was	O
restricted	O
to	O
the	O
CD4+	B-cell_type
T-cell	I-cell_type
subset	I-cell_type
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
hydrocortisone	O
and	O
other	O
glucocorticoids	O
inhibit	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
generation	O
by	O
mononuclear	B-cell_type
(	I-cell_type
MNC	I-cell_type
)	I-cell_type
and	I-cell_type
polymorphonuclear	I-cell_type
leucocytes	I-cell_type
(	O
PMNL	B-cell_type
)	O
.	O

Antigen	O
receptor	O
signals	O
could	O
be	O
mimicked	O
by	O
suboptimal	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
with	O
phorbol	O
esters	O
in	O
combination	O
with	O
calcium	O
mobilization	O
by	O
an	O
ionophore	O
.	O

RESULTS	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
found	O
that	O
in	O
the	O
presence	O
of	O
rabbit	O
reticulocyte	O
lysate	O
,	O
human	B-protein
ER	I-protein
reduced	O
the	O
binding	O
activities	O
of	O
chicken	B-protein
immature	I-protein
erythrocyte	I-protein
nuclear	I-protein
extracted	I-protein
proteins	I-protein
to	O
GATA	B-DNA
and	I-DNA
CACCC	I-DNA
sites	I-DNA
in	O
the	O
H5	B-DNA
promoter	I-DNA
and	I-DNA
enhancer	I-DNA
.	O

IL-3	B-protein
,	O
IL-4	B-protein
,	O
and	O
IL-5	B-protein
independently	O
up-regulated	O
TGF-beta1	B-RNA
mRNA	I-RNA
and	O
product	O
expression	O
by	O
eosinophils	B-cell_type
in	O
all	O
donors	O
.	O

We	O
incubated	O
sodium	O
oleate	O
with	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
for	O
0	O
to	O
72	O
hours	O
,	O
followed	O
by	O
coincubation	O
of	O
oleate	O
with	O
human	B-protein
recombinant	I-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
,	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-1alpha	I-protein
,	O
IL-1beta	B-protein
,	O
IL-4	B-protein
,	O
Escherichia	O
coli	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
or	O
phorbol	O
12-myristate	O
13-acetate	O
for	O
a	O
further	O
6	O
to	O
24	O
hours	O
.	O

Fusion	O
of	O
the	O
upstream	B-DNA
portion	I-DNA
of	O
the	O
delta	B-DNA
promoter	I-DNA
to	O
the	O
truncated	O
beta	B-DNA
globin	I-DNA
promoter	I-DNA
yielded	O
a	O
modest	O
increase	O
in	O
promoter	O
strength	O
relative	O
to	O
the	O
truncated	B-DNA
beta	I-DNA
gene	I-DNA
promoter	I-DNA
,	O
indicating	O
the	O
presence	O
of	O
a	O
positive	B-DNA
transcriptional	I-DNA
element	I-DNA
(	O
s	O
)	O
in	O
the	O
upstream	B-DNA
delta	I-DNA
globin	I-DNA
regulatory	I-DNA
region	I-DNA
.	O

This	O
resurgence	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
protein	O
acts	O
to	O
restore	O
an	O
equilibrium	O
in	O
which	O
NF-kappa	B-protein
B	I-protein
is	O
again	O
inhibited	O
.	O

Together	O
these	O
data	O
demonstrate	O
that	O
the	O
v-abl	B-protein
protein	I-protein
specifically	O
interferes	O
with	O
light-chain	B-DNA
gene	I-DNA
rearrangement	O
by	O
suppressing	O
at	O
least	O
two	O
pathways	O
essential	O
for	O
this	O
stage	O
of	O
B-cell	B-cell_type
differentiation	O
and	O
suggest	O
that	O
tyrosine	O
phosphorylation	O
is	O
important	O
in	O
regulating	O
RAG	B-DNA
gene	I-DNA
expression	O
.	O

Therefore	O
,	O
we	O
analyzed	O
the	O
expression	O
,	O
DNA	O
binding	O
,	O
and	O
transcriptional	O
activity	O
of	O
the	O
endogenous	B-protein
RA	I-protein
and	I-protein
VitD3	I-protein
receptors	I-protein
[	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
(	O
RARs	B-protein
)	O
,	O
retinoid	B-protein
X	I-protein
receptors	I-protein
(	O
RXRs	B-protein
)	O
,	O
and	O
VitD3	B-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
]	O
in	O
the	O
U-937	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
in	O
which	O
RA	O
and	O
VitD3	O
induce	O
distinct	O
monocytic	O
differentiation	O
pathways	O
.	O

Immunosuppression	O
by	O
glucocorticoids	O
:	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
through	O
induction	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
synthesis	O
[	O
see	O
comments	O
]	O

We	O
conclude	O
that	O
the	O
transrepressive	O
effect	O
of	O
glucocorticoids	O
on	O
IL-2	B-DNA
gene	I-DNA
transcription	O
is	O
exclusively	O
mediated	O
by	O
GRalpha	B-protein
.	O

The	O
observed	O
phenomena	O
might	O
be	O
caused	O
by	O
downregulation	O
of	O
an	O
IL-2R	B-DNA
regulation	I-DNA
gene	I-DNA
,	O
and	O
might	O
play	O
a	O
key	O
role	O
in	O
the	O
expansion	O
of	O
choriocarcinoma	O
,	O
and	O
possibly	O
in	O
the	O
survival	O
of	O
the	O
fetal	O
allograft	O
.	O

Transcriptional	O
and	O
post-transcriptional	O
regulation	O
of	O
c-jun	B-DNA
expression	O
during	O
monocytic	O
differentiation	O
of	O
human	B-cell_line
myeloid	I-cell_line
leukemic	I-cell_line
cells	I-cell_line
.	O

Antibodies	B-protein
to	O
Duffy	B-protein
antigens	I-protein
are	O
responsible	O
for	O
some	O
cases	O
of	O
transfusion	O
incompatibility	O
and	O
newborn	O
hemolytic	O
disease	O
.	O

There	O
was	O
no	O
detectable	O
binding	O
of	O
in	O
vitro	O
translated	O
Jun/Fos	B-protein
heterodimer	I-protein
(	O
AP-1	B-protein
)	O
to	O
the	O
NF-AT	B-protein
sequence	O
,	O
and	O
the	O
NF-AT	B-DNA
sequence	I-DNA
was	O
unable	O
to	O
inhibit	O
the	O
binding	O
of	O
Jun/Fos	B-protein
to	O
the	O
AP-1	B-DNA
sequence	I-DNA
.	O

Furthermore	O
,	O
cyclosporin	O
A	O
,	O
but	O
not	O
rapamycin	O
,	O
blocked	O
the	O
synergistic	O
induction	O
of	O
IL-8	B-protein
expression	O
achieved	O
with	O
anti-CD3	B-protein
and	O
anti-	O
CD28	B-protein
costimulation	O
.	O

In	O
order	O
to	O
investigate	O
the	O
nature	O
of	O
the	O
A6H	B-protein
mAb	I-protein
costimulus	O
at	O
the	O
transcriptional	O
level	O
we	O
have	O
examined	O
induction	O
of	O
the	O
transcription	B-protein
factors	I-protein
OCT-1	B-protein
,	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
which	O
are	O
known	O
to	O
be	O
transcriptional	B-protein
regulators	I-protein
of	O
several	O
cytokine	B-protein
and	O
cytokine	B-protein
receptor	O
genes	O
,	O
including	O
the	O
IL-2	B-DNA
and	I-DNA
IL-2R	I-DNA
genes	I-DNA
.	O

Results	O
indicate	O
that	O
TIMP-1-positive	B-cell_line
BL	I-cell_line
lines	I-cell_line
show	O
resistance	O
to	O
cold-shock-induced	O
apoptosis	O
.	O

In	O
view	O
of	O
the	O
therapeutic	O
efficiency	O
of	O
glucocorticoids	O
in	O
AD	O
and	O
findings	O
of	O
abnormal	O
cAMP	O
and	O
cAMP-phosphodiesterase	O
activity	O
,	O
the	O
elevated	O
GR	B-protein
concentrations	O
in	O
AD	O
lend	O
support	O
to	O
the	O
hypothesis	O
of	O
a	O
compensatory	O
GR	B-protein
upregulation	O
due	O
to	O
an	O
insufficient	O
action	O
of	O
endogenous	O
cortisol	O
or	O
to	O
altered	O
cAMP-induced	O
GR	B-protein
expression	O
.	O

Induction	O
of	O
apoptosis	O
of	O
mononucleated	B-cell_type
cells	I-cell_type
is	O
a	O
physiological	O
process	O
for	O
regulating	O
the	O
intensity	O
of	O
the	O
immune	O
response	O
.	O

These	O
data	O
indicate	O
that	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
sites	I-DNA
of	O
the	O
HIV	B-DNA
promoter	I-DNA
are	O
essential	O
for	O
its	O
transactivation	O
during	O
HHV-6	O
(	O
GS	O
)	O
infection	O
.	O

Various	O
levels	O
of	O
expression	O
were	O
found	O
on	O
seborrheic	O
keratoses	O
,	O
while	O
the	O
expression	O
level	O
on	O
basal	O
cell	O
epitheliomas	O
was	O
low	O
.	O

To	O
better	O
understand	O
the	O
regulation	O
of	O
this	O
pivotal	O
gene	O
,	O
we	O
have	O
analyzed	O
the	O
human	B-DNA
genomic	I-DNA
DNA	I-DNA
sequence	I-DNA
upstream	O
of	O
the	O
B29	B-protein
ATG	B-DNA
start	I-DNA
codon	I-DNA
for	O
transcriptional	O
control	O
activity	O
.	O

Blockade	O
of	O
T-cell	O
activation	O
by	O
dithiocarbamates	O
involves	O
novel	O
mechanisms	O
of	O
inhibition	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
.	O

Specific	O
staining	O
as	O
well	O
as	O
electron	O
microscopic	O
examinations	O
revealed	O
the	O
accumulation	O
of	O
metal	O
gold	O
in	O
the	O
cells	O
,	O
supporting	O
our	O
previous	O
hypothesis	O
that	O
gold	O
ions	O
could	O
block	O
NF-kappaB	B-protein
-DNA	O
binding	O
by	O
a	O
redox	O
mechanism	O
.	O

We	O
show	O
here	O
that	O
in	O
the	O
early	O
phases	O
of	O
apoptosis	O
,	O
pRB	B-protein
is	O
posttranslationally	O
modified	O
by	O
a	O
tissue	O
transglutaminase	O
(	O
tTG	B-protein
)	O
-catalyzed	O
reaction	O
.	O

In	O
contrast	O
,	O
mild	O
oxidation	O
with	O
glucose	B-protein
oxidase	I-protein
selectively	O
inhibits	O
p75	B-protein
and	O
p85	B-protein
binding	O
while	O
not	O
blocking	O
p50	B-protein
and	O
p55	B-protein
interactions	O
.	O

Here	O
,	O
we	O
present	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
full-length	B-DNA
cDNA	I-DNA
clone	I-DNA
encoding	O
NF-X2	B-protein
.	O

Aiolos	B-protein
transcription	B-protein
factor	I-protein
controls	O
cell	O
death	O
in	O
T	B-cell_type
cells	I-cell_type
by	O
regulating	O
Bcl-2	B-protein
expression	O
and	O
its	O
cellular	O
localization	O
.	O

They	O
later	O
fuse	O
,	O
and	O
,	O
under	O
the	O
influence	O
of	O
the	O
surrounding	O
mesenchyme	O
,	O
the	O
mature	O
organ	O
develops	O
,	O
being	O
mainly	O
composed	O
of	O
ductal	O
,	O
exocrine	O
and	O
endocrine	O
compartments	O
.	O

The	O
assembly	O
of	O
this	O
tri-molecular	B-protein
complex	I-protein
permits	O
the	O
activated	O
Rho-family	B-protein
GTPases	I-protein
to	O
regulate	O
target	O
effectors	O
that	O
interact	O
through	O
nck	B-protein
.	O

Its	O
expression	O
remained	O
very	O
low	O
in	O
nuclei	O
of	O
HIV1-infected	B-cell_type
macrophages	I-cell_type
.	O

In	O
leukemia	O
,	O
the	O
highest	O
frequency	O
(	O
30	O
%	O
)	O
is	O
found	O
in	O
acute	O
myeloid	O
leukemia	O
.	O

Early	B-protein
B-cell	I-protein
factor	I-protein
(	O
EBF	B-protein
)	O
is	O
a	O
transcription	B-protein
factor	I-protein
suggested	O
as	O
essential	O
for	O
early	O
B-lymphocyte	B-cell_type
development	O
by	O
findings	O
in	O
mice	O
where	O
the	O
coding	O
gene	O
has	O
been	O
inactivated	O
by	O
homologous	O
disruption	O
.	O

We	O
recently	O
reported	O
that	O
prolonged	O
exposure	O
of	O
human	B-cell_type
aortic	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
HAEC	B-cell_line
)	O
to	O
low	O
shear	O
stress	O
flow	O
patterns	O
is	O
associated	O
with	O
a	O
sustained	O
increase	O
in	O
the	O
activated	O
form	O
of	O
the	O
transcriptional	O
regulator	O
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
.	O

Two	O
regions	O
,	O
DP1	B-DNA
(	O
-140	B-DNA
to	I-DNA
-92	I-DNA
bp	I-DNA
)	O
and	O
DP2	B-DNA
(	O
-353	B-DNA
to	I-DNA
-304	I-DNA
bp	I-DNA
)	O
of	O
the	O
promoter	O
were	O
essential	O
for	O
transcription	O
in	O
HeLa	B-cell_line
cells	I-cell_line
and	O
human	B-cell_type
peripheral	I-cell_type
monocytes	I-cell_type
.	O

The	O
Fc	B-protein
epsilon	I-protein
RI-gamma	I-protein
chains	I-protein
are	O
expressed	O
in	O
a	O
variety	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
where	O
they	O
play	O
a	O
critical	O
role	O
in	O
signal	O
transduction	O
.	O

Pregnancy-induced	O
hypertension	O
(	O
PIH	O
)	O
is	O
a	O
frequent	O
cause	O
of	O
maternal	O
and	O
neonatal	O
morbidity	O
and	O
mortality	O
.	O

These	O
receptor	O
functions	O
required	O
the	O
presence	O
of	O
the	O
box	B-protein
3	I-protein
motifs	I-protein
,	O
as	O
shown	O
by	O
the	O
analysis	O
of	O
the	O
mouse	O
IL-10R	B-protein
constructs	O
containing	O
progressively	B-protein
truncated	I-protein
cytoplasmic	I-protein
domains	I-protein
.	O

We	O
demonstrated	O
,	O
by	O
applying	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
slightly	O
impaired	O
AP-1	B-protein
DNA	O
binding	O
activity	O
in	O
NCL	B-cell_type
lymphocytes	I-cell_type
and	O
strong	O
in	O
DS	B-cell_type
ones	I-cell_type
.	O

Numerous	O
studies	O
have	O
shown	O
that	O
,	O
upon	O
HIV1	O
infection	O
,	O
human	B-cell_line
promonocytic	I-cell_line
U937	I-cell_line
cells	I-cell_line
were	O
induced	O
to	O
differentiate	O
,	O
as	O
indicated	O
,	O
for	O
example	O
,	O
by	O
increased	O
expression	O
of	O
adhesion	B-protein
molecules	I-protein
.	O

Moreover	O
,	O
M-CSF	B-protein
-induced	O
expression	O
of	O
the	O
fos-related	B-DNA
gene	I-DNA
,	O
fra-1	B-DNA
,	O
was	O
delayed	O
compared	O
to	O
that	O
for	O
both	O
c-fos	B-DNA
and	O
fos-B	B-DNA
.	O

Transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
is	O
crucial	O
in	O
activating	O
the	O
transcription	O
of	O
genes	O
encoding	O
proinflammatory	B-protein
cytokines	I-protein
.	O

Type	B-protein
I	I-protein
IFNs	I-protein
(	O
IFN-alpha/beta	B-protein
)	O
,	O
in	O
addition	O
to	O
IL-12	B-protein
,	O
have	O
been	O
shown	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
differentiation	O
of	O
human	O
,	O
but	O
not	O
mouse	O
,	O
Th	B-cell_type
cells	I-cell_type
.	O

Prostaglandin	O
E2	O
(	O
PGE2	O
)	O
,	O
a	O
pleiotropic	B-protein
immunomodulatory	I-protein
molecule	I-protein
,	O
is	O
observed	O
at	O
elevated	O
levels	O
during	O
HIV-1	O
infection	O
as	O
well	O
as	O
during	O
the	O
course	O
of	O
other	O
pathogenic	O
infections	O
.	O

In	O
this	O
report	O
,	O
we	O
present	O
data	O
demonstrating	O
that	O
HIV	O
LTR	B-DNA
activation	O
is	O
not	O
a	O
general	O
consequence	O
of	O
cellular	B-DNA
DNA	I-DNA
damage	O
,	O
but	O
rather	O
a	O
process	O
unique	O
to	O
specific	O
genotoxic	O
stimuli	O
,	O
and	O
that	O
it	O
does	O
not	O
necessarily	O
depend	O
on	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

To	O
elucidate	O
the	O
mechanisms	O
that	O
regulate	O
the	O
constitutive	O
and	O
inducible	O
expression	O
of	O
CD69	B-protein
by	O
leukocytes	B-cell_type
,	O
we	O
isolated	O
the	O
promoter	B-DNA
region	I-DNA
of	O
the	O
CD69	B-protein
gene	O
and	O
carried	O
out	O
its	O
functional	O
characterization	O
.	O

Moreover	O
,	O
STAT5	B-protein
was	O
found	O
to	O
be	O
the	O
predominant	O
STAT	B-protein
transcription	I-protein
factor	I-protein
used	O
by	O
IL-2	B-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
and	O
specifically	O
required	O
a	O
COOH-terminal	B-protein
region	I-protein
of	O
IL-2R	B-protein
beta	I-protein
(	O
Ser386-Val525	B-protein
)	O
,	O
while	O
STAT5	B-protein
recruitment	O
was	O
not	O
correlated	O
to	O
activation	O
of	O
IL-2R	B-protein
gamma	I-protein
or	O
JAK3	B-protein
.	O

METHODS	O
:	O
Eight	O
malignant	B-cell_line
lymphocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
primary	B-cell_line
cultures	I-cell_line
of	O
lymphocytic	B-cell_type
leukemia	I-cell_type
and	I-cell_type
lymphoma	I-cell_type
cells	I-cell_type
were	O
treated	O
with	O
As2O3	O
,	O
with	O
or	O
without	O
dithiothreitol	O
(	O
DTT	O
)	O
or	O
buthionine	O
sulfoximine	O
(	O
BSO	O
)	O
(	O
an	O
inhibitor	O
of	O
glutathione	O
synthesis	O
)	O
.	O

Antibodies	B-protein
are	O
produced	O
exclusively	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

We	O
show	O
that	O
stimulation	O
with	O
a	O
synthetic	O
ceramide	O
analog	O
results	O
in	O
JNK	B-protein
activation	O
as	O
well	O
as	O
apoptosis	O
,	O
suggesting	O
ceramide	O
release	O
occurs	O
proximal	O
to	O
JNK	B-protein
activation	O
in	O
Fas	B-protein
signaling	O
.	O

Based	O
on	O
nucleotide	O
sequence	O
requirements	O
and	O
immunoreactivity	O
,	O
we	O
demonstrate	O
that	O
this	O
DNA-protein	B-protein
complex	I-protein
is	O
comprised	O
of	O
the	O
AP-1	B-protein
components	O
,	O
Fos	B-protein
and	O
Jun	B-protein
.	O

Dexamethasone	O
had	O
different	O
effects	O
on	O
LPS-induced	O
TNFalpha	B-protein
and	O
IL-10	B-protein
secretion	O
;	O
whereas	O
it	O
suppressed	O
TNFalpha	B-protein
in	O
a	O
dose-dependent	O
fashion	O
,	O
its	O
effect	O
on	O
IL-10	B-protein
secretion	O
was	O
biphasic	O
,	O
producing	O
stimulation	O
at	O
lower	O
,	O
and	O
inhibition	O
at	O
higher	O
doses	O
.	O

The	O
studies	O
described	O
herein	O
demonstrate	O
that	O
the	O
activation	O
domain	O
.	O

Hirsutism	O
,	O
graded	O
by	O
the	O
modified	O
Ferriman-Gallwey	O
score	O
,	O
and	O
hormonal	O
parameters	O
were	O
evaluated	O
basally	O
and	O
at	O
4-month	O
intervals	O
during	O
treatment	O
.	O

Pancreas	O
organogenesis	O
is	O
a	O
highly	O
regulated	O
process	O
,	O
in	O
which	O
two	O
anlage	O
evaginate	O
from	O
the	O
primitive	O
gut	O
.	O

The	O
accumulation	O
of	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
in	O
the	O
thymus	O
was	O
found	O
only	O
in	O
tg	O
epsilon26	O
mice	O
,	O
not	O
in	O
other	O
human	B-cell_line
CD3epsilon	I-cell_line
transgenic	I-cell_line
mouse	I-cell_line
lines	I-cell_line
or	O
other	O
T	O
cell-deficient	O
mice	O
,	O
including	O
CD3-epsilon	O
knockout	O
mice	O
and	O
TCR-beta/TCR-delta	O
double	O
knockout	O
mice	O
.	O

We	O
have	O
generated	O
a	O
monoclonal	B-protein
antibody	I-protein
,	O
BZ1	B-protein
,	O
to	O
BZLF1	B-protein
which	O
reacts	O
in	O
immunohistology	O
,	O
immunoblotting	O
,	O
and	O
immunoprecipitation	O
and	O
which	O
recognizes	O
both	O
the	O
active	B-protein
,	I-protein
dimeric	I-protein
form	I-protein
and	O
the	O
inactive	B-protein
,	I-protein
monomeric	I-protein
form	I-protein
of	O
the	O
protein	O
.	O

The	O
results	O
demonstrate	O
that	O
alterations	O
in	O
NF	B-protein
kappaB	I-protein
family	I-protein
proteins	I-protein
,	O
specifically	O
the	O
failure	O
of	O
p65	B-protein
translocation	O
to	O
the	O
nucleus	O
,	O
occur	O
earlier	O
and	O
more	O
frequently	O
than	O
the	O
decrease	O
in	O
zeta-chain	B-protein
.	O

In	O
agreement	O
with	O
this	O
finding	O
,	O
Northern	O
experiments	O
where	O
p65	O
and	O
p105	O
mRNA	O
levels	O
were	O
determined	O
,	O
demonstrated	O
that	O
expression	O
of	O
these	O
components	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	O
factor	O
were	O
not	O
affected	O
by	O
IL-10	B-protein
or	O
IL-4	B-protein
.	O

The	O
sequence	O
of	O
one	O
of	O
these	O
elements	B-DNA
,	O
OSE2	O
,	O
is	O
identical	O
to	O
the	O
DNA-binding	B-DNA
site	I-DNA
of	O
the	O
PEBP2	B-protein
alpha/AML-1	I-protein
transcription	I-protein
factors	I-protein
,	O
the	O
mammalian	B-protein
homologues	I-protein
of	O
the	O
Drosophila	B-protein
Runt	I-protein
protein	I-protein
.	O

We	O
used	O
expression	O
cloning	O
to	O
identify	O
interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
as	O
one	O
factor	O
that	O
suppressed	O
growth	O
of	O
a	O
pre-B-cell	B-cell_line
variant	I-cell_line
line	I-cell_line
,	O
1A9-M	B-cell_line
.	O

Similarly	O
,	O
CTL	B-cell_type
raised	O
against	O
the	O
parent	O
peptide	O
did	O
not	O
recognize	O
the	O
succinimide	O
derivative	O
of	O
this	O
peptide	O
.	O

These	O
EKLF-/-	B-cell_line
ES	I-cell_line
cells	I-cell_line
were	O
capable	O
of	O
undergoing	O
in	O
vitro	O
differentiation	O
to	O
form	O
definitive	O
erythroid	O
colonies	O
that	O
were	O
similar	O
in	O
size	O
and	O
number	O
to	O
those	O
formed	O
by	O
wild-type	B-cell_type
ES	I-cell_type
cells	I-cell_type
.	O

The	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activity	O
of	O
the	O
v-abl	B-DNA
oncogene	I-DNA
has	O
been	O
demonstrated	O
to	O
subvert	O
the	O
normal	O
second	O
messenger	O
systems	O
used	O
by	O
lymphoid	B-cell_type
cells	I-cell_type
for	O
growth	O
and	O
differentiation	O
.	O

NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
members	I-protein
regulating	O
the	O
ICAM-1	B-DNA
promoter	I-DNA
in	O
monocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
.	O

The	O
addition	O
of	O
oxygen	B-protein
radical	I-protein
scavenger	I-protein
enzymes	I-protein
(	O
catalase	B-protein
,	O
superoxide	B-protein
dismutase	I-protein
)	O
and	O
antioxidant	O
(	O
probucol	O
)	O
inhibited	O
these	O
events	O
.	O

Apoptosis	O
mediated	O
by	O
HIV	B-protein
protease	I-protein
is	O
preceded	O
by	O
cleavage	O
of	O
Bcl-2	B-protein
.	O

Both	O
C5b-9	B-protein
and	O
C5b-7	B-protein
,	O
but	O
not	O
C5b6	B-protein
,	O
increased	O
Raf-1	B-protein
kinase	O
activity	O
maximum	O
3.3-fold	O
at	O
2	O
min	O
and	O
2.8-fold	O
at	O
5	O
min	O
,	O
respectively	O
.	O

Transcripts	O
for	O
osteoprotegerin	B-protein
ligand	I-protein
(	O
OPGL	B-protein
)	O
,	O
an	O
osteoclast	B-protein
differentiation	I-protein
factor	I-protein
(	O
also	O
known	O
as	O
RANKL	B-protein
and	O
TRANCE	B-protein
)	O
are	O
expressed	O
,	O
likely	O
by	O
adherent	B-cell_type
cells	I-cell_type
.	O

The	O
c-rel	B-DNA
protooncogene	I-DNA
encodes	O
a	O
subunit	O
of	O
the	O
NF-kappa	B-protein
B-like	I-protein
family	I-protein
of	I-protein
transcription	I-protein
factors	I-protein
.	O

Kappa	B-protein
B	I-protein
(	I-protein
kappa	I-protein
B	I-protein
)	I-protein
enhancer	I-protein
binding	I-protein
proteins	I-protein
isolated	O
from	O
the	O
nuclei	O
of	O
activated	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
produce	O
two	O
distinct	O
nucleoprotein	B-protein
complexes	I-protein
when	O
incubated	O
with	O
the	O
kappa	B-DNA
B	I-DNA
element	I-DNA
from	O
the	O
interleukin-2	B-DNA
receptor-alpha	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
.	O

In	O
addition	O
,	O
transcriptional	O
activity	O
of	O
IL-2	B-protein
and	O
metallothionein	B-DNA
enhancer	I-DNA
and	I-DNA
promoter	I-DNA
regions	I-DNA
and	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
,	O
NF-kappaB	B-protein
,	O
and	O
NF-AT	B-protein
were	O
analyzed	O
by	O
chloramphenicol	B-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
respectively	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
p50/p65/c-Rel	B-protein
and	O
STAT-6	B-protein
are	O
effectively	O
induced	O
by	O
CD40L	B-protein
and	O
IL-4	B-protein
,	O
respectively	O
,	O
and	O
bind	O
to	O
specific	O
DNA	B-DNA
motifs	I-DNA
within	O
the	O
ECS	B-DNA
.	O

We	O
report	O
that	O
two	O
20-epi	O
analogues	O
,	O
MC1627	O
and	O
MC1288	O
,	O
induced	O
differentiation	O
and	O
transcription	O
of	O
p21	B-DNA
(	O
Waf1	B-DNA
,	O
Cip1	B-DNA
)	O
,	O
a	O
key	O
VDR	B-DNA
target	I-DNA
gene	I-DNA
involved	O
in	O
growth	O
inhibition	O
,	O
at	O
a	O
concentration	O
100-fold	O
lower	O
than	O
that	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

This	O
observation	O
is	O
likely	O
to	O
relate	O
to	O
the	O
findings	O
that	O
TAL1	B-protein
and	O
LMO	B-protein
are	O
highly	O
synergistic	O
in	O
T-cell	O
tumorigenesis	O
in	O
double-transgenic	O
mice	O
.	O

In	O
addition	O
,	O
we	O
observed	O
an	O
altered	O
expression	O
level	O
of	O
AML1	B-protein
along	O
with	O
the	O
myeloid	O
differentiation	O
in	O
several	O
hemopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

We	O
conclude	O
that	O
the	O
MAP	B-protein
kinase	I-protein
signal	O
transduction	O
pathway	O
consisting	O
of	O
Raf-1	B-protein
,	O
MEK1	B-protein
,	O
and	O
ERK1	B-protein
and	O
ERK2	B-protein
functions	O
in	O
the	O
stimulation	O
IL-2	B-DNA
gene	I-DNA
transcription	O
in	O
activated	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Is	O
GATA-1	B-protein
necessary	O
for	O
globin	O
gene	O
switching	O
?	O
GATA-1	B-protein
may	O
be	O
modified	O
differently	O
during	O
development	O
so	O
that	O
the	O
locus	O
control	O
region	O
can	O
interact	O
with	O
different	O
globin	B-DNA
promoters	I-DNA
.	O

These	O
results	O
are	O
in	O
striking	O
contrast	O
to	O
the	O
increase	O
in	O
nuclear	O
NF	B-protein
kappa	I-protein
B	I-protein
and	O
HIV-1	O
replication	O
induced	O
by	O
phorbol	O
esters	O
in	O
promonocytic	B-cell_line
leukemia	I-cell_line
cells	I-cell_line
U937	I-cell_line
and	O
HL-60	B-cell_line
,	O
and	O
emphasize	O
the	O
importance	O
of	O
studying	O
cytokine	B-protein
regulation	O
of	O
HIV-1	O
in	O
normal	B-cell_type
monocytes	I-cell_type
.	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
novel	O
serine/threonine	B-protein
kinase	I-protein
that	O
phosphorylated	O
the	O
proto-oncogene	B-protein
product	I-protein
,	O
c-Fos	B-protein
,	O
and	O
is	O
termed	O
Fos	B-protein
kinase	I-protein
.	O

Furthermore	O
,	O
these	O
oxidative	O
stresses	O
inhibited	O
activity	O
of	O
calcineurin	O
,	O
a	O
serine/	O
threonine	B-protein
phosphatase	I-protein
that	O
regulates	O
NFAT	B-protein
activation	O
.	O

This	O
HIV-mediated	O
mechanism	O
results	O
in	O
a	O
self-perpetuating	O
loop	O
of	O
NF-kappa	B-protein
B	I-protein
production	O
.	O

We	O
found	O
that	O
they	O
reduced	O
the	O
initial	O
interleukin-1beta	B-RNA
mRNA	I-RNA
transcription	O
rate	O
through	O
prevention	O
of	O
degradation	O
of	O
inhibitor-kappaB	B-protein
alpha	I-protein
.	O

The	O
Jak	O
family	O
of	O
tyrosine	B-protein
kinases	I-protein
are	O
known	O
to	O
mediate	O
some	O
of	O
the	O
effects	O
of	O
cytokines	B-protein
or	O
hematopoietic	B-protein
growth	I-protein
factors	I-protein
by	O
recruitment	O
and	O
tyrosine	O
phosphorylation	O
of	O
a	O
variety	O
of	O
Stat	B-protein
(	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	O
proteins	O
.	O

Glucocorticoid	O
hormone	O
suppression	O
of	O
human	O
neutrophil	B-cell_type
-mediated	O
tumor	O
cell	O
cytostasis	O
.	O

Increased	O
natural	O
killer	O
cell	O
activity	O
correlates	O
with	O
low	O
or	O
negative	O
expression	O
of	O
the	O
HER-2/neu	B-DNA
oncogene	I-DNA
in	O
patients	O
with	O
breast	O
cancer	O
.	O

We	O
have	O
carried	O
out	O
a	O
detailed	O
analysis	O
of	O
the	O
cellular	O
immune	O
functions	O
of	O
breast	O
cancer	O
patients	O
in	O
comparison	O
with	O
healthy	O
controls	O
.	O

Upon	O
treatment	O
with	O
a	O
large	O
variety	O
of	O
inducers	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
beta	I-protein
are	O
proteolytically	O
degraded	O
,	O
resulting	O
in	O
NF-kappa	B-protein
B	I-protein
translocation	O
into	O
the	O
nucleus	O
.	O

To	O
investigate	O
the	O
molecular	O
basis	O
for	O
the	O
critical	O
regulatory	O
interaction	O
between	O
NF-kappa	B-protein
B	I-protein
and	O
I	B-protein
kappa	I-protein
B/MAD-3	I-protein
,	O
a	O
series	O
of	O
human	B-protein
NF-kappa	I-protein
B	I-protein
p65	I-protein
mutants	I-protein
was	O
identified	O
that	O
functionally	O
segregated	O
DNA	O
binding	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
-mediated	O
inhibition	O
,	O
and	O
I	B-protein
kappa	I-protein
B	I-protein
-induced	O
nuclear	O
exclusion	O
of	O
this	O
transcription	B-protein
factor	I-protein
.	O

These	O
data	O
suggest	O
that	O
NF-kappaB	B-protein
plays	O
a	O
key	O
role	O
in	O
low	O
shear-induced	O
VCAM-1	B-protein
expression	O
and	O
that	O
pathways	O
mediating	O
low	O
shear-	O
and	O
cytokine-induced	O
EC-Mn	O
adhesion	O
may	O
be	O
differentially	O
regulated	O
.	O

Transcriptional	B-protein
factors	I-protein
of	O
the	O
NFAT	B-protein
family	I-protein
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
expression	O
of	O
several	O
cytokine	B-DNA
genes	I-DNA
during	O
the	O
immune	O
response	O
,	O
such	O
as	O
the	O
genes	O
for	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
and	O
IL-4	B-protein
,	O
among	O
others	O
.	O

Much	O
of	O
our	O
focus	O
in	O
understanding	O
Th1/Th2	O
development	O
has	O
been	O
on	O
the	O
signals	O
delivered	O
by	O
IL-12	B-protein
and	O
IL-4	B-protein
as	O
final	O
determinants	O
of	O
terminal	O
T	O
cell	O
differentiation	O
.	O

The	O
regulatory	B-DNA
regions	I-DNA
of	O
several	O
genes	O
specifically	O
expressed	O
in	O
B	B-cell_type
cells	I-cell_type
contain	O
functional	B-DNA
binding	I-DNA
sites	I-DNA
for	O
Oct2	B-protein
.	O

Helix	B-protein
III	I-protein
is	O
less	O
rigid	O
,	O
makes	O
an	O
average	O
angle	O
of	O
about	O
90	O
degrees	O
with	O
helices	B-protein
I	I-protein
and	I-protein
II	I-protein
,	O
and	O
constitutes	O
the	O
other	O
arm	O
of	O
the	O
molecule	O
.	O

NF-kappaB	B-protein
is	O
a	O
potent	O
cellular	O
activator	O
of	O
HIV-1	O
gene	O
expression	O
.	O

We	O
show	O
that	O
IFN-alpha	B-protein
and	O
IFN-gamma	B-protein
rapidly	O
and	O
efficiently	O
enhanced	O
STAT1	B-protein
,	O
STAT2	B-protein
,	O
p48	B-protein
,	O
and	O
IRF-1	B-DNA
gene	I-DNA
expression	O
.	O

This	O
allows	O
us	O
to	O
characterize	O
these	O
two	O
granule	O
populations	O
with	O
regard	O
to	O
their	O
content	O
of	O
membrane	B-protein
proteins	I-protein
,	O
which	O
become	O
incorporated	O
into	O
the	O
plasma	O
membrane	O
during	O
exocytosis	O
.	O

In	O
summary	O
,	O
CD40	B-protein
signaling	O
preferentially	O
induces	O
SAPK	B-protein
but	O
not	O
MAPK	B-protein
.	O

Differanisole	O
A	O
in	O
combination	O
with	O
9cisRA	O
may	O
have	O
implications	O
for	O
therapy	O
of	O
acute	O
promyelocytic	O
leukemia	O
patients	O
.	O

Despite	O
progress	O
in	O
understanding	O
the	O
death	O
signals	O
transduced	O
from	O
Fas	B-protein
,	O
very	O
little	O
is	O
known	O
with	O
regard	O
to	O
the	O
mechanisms	O
by	O
which	O
Fas	B-protein
expression	O
is	O
regulated	O
.	O

The	O
molecular	O
genetic	O
basis	O
of	O
the	O
translocation	O
supports	O
its	O
integral	O
role	O
in	O
pathogenesis	O
.	O

In	O
addition	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
LAZ3/BCL6	B-protein
by	O
Northern	O
blot	O
analysis	O
on	O
multiple	O
human	O
tissues	O
.	O

The	O
SRG3	B-protein
protein	I-protein
is	O
expressed	O
about	O
three	O
times	O
higher	O
in	O
thymocytes	B-cell_type
than	O
in	O
peripheral	B-cell_type
lymphocytes	I-cell_type
.	O

It	O
is	O
concluded	O
that	O
,	O
in	O
contrast	O
to	O
a	O
previous	O
study	O
,	O
PBMC	B-cell_type
are	O
not	O
a	O
common	O
site	O
of	O
persistent	O
group	O
C	O
adenoviral	O
infection	O
.	O

We	O
postulated	O
that	O
the	O
oncogenic	O
effect	O
of	O
RBTN-2	B-protein
in	O
T	O
cells	O
is	O
likely	O
mediated	O
by	O
binding	B-protein
protein	I-protein
(	O
s	O
)	O
with	O
T	O
cell-specific	O
expression	O
.	O

Histopathological	O
analysis	O
revealed	O
lymphomas	O
of	O
T-cell	O
type	O
,	O
often	O
comprising	O
a	O
minor	O
B-cell	O
component	O
.	O

This	O
NF-kappaB	B-protein
binding	I-protein
complex	I-protein
is	O
composed	O
of	O
transcriptionally	B-protein
active	I-protein
p65	I-protein
(	I-protein
RelA	I-protein
)	I-protein
/p50	I-protein
heterodimers	I-protein
and	O
results	O
primarily	O
from	O
the	O
targeted	O
degradation	O
of	O
IkappaB-alpha	B-protein
,	O
an	O
inhibitor	O
that	O
sequesters	O
Rel/kappaB	B-protein
in	O
the	O
cytoplasm	O
.	O

Similar	O
to	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
,	O
primary	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
,	O
when	O
precultured	O
with	O
a	O
low	O
dose	O
of	O
LPS	O
,	O
also	O
become	O
tolerant	O
and	O
produce	O
little	O
TNF	B-protein
after	O
LPS	O
stimulation	O
.	O

Further	O
studies	O
will	O
have	O
to	O
prove	O
if	O
Urapidil	O
is	O
suited	O
for	O
prepartal	O
treatment	O
of	O
PIH	O
as	O
well	O
.	O

An	O
essential	O
role	O
for	O
NF-kappaB	B-protein
in	O
human	B-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cell	I-cell_type
survival	O
.	O

Elucidation	O
of	O
the	O
mechanism	O
involved	O
in	O
this	O
inhibition	O
of	O
IgE	B-protein
production	O
shows	O
that	O
epsilon	O
germline	B-DNA
transcription	O
is	O
decreased	O
by	O
RA	O
,	O
whereas	O
production	O
of	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
was	O
not	O
enhanced	O
in	O
the	O
presence	O
of	O
RA	O
.	O

These	O
observations	O
suggest	O
that	O
a	O
high	O
WT1	B-DNA
expression	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
is	O
incompatible	O
with	O
differentiation	O
.	O

They	O
do	O
not	O
directly	O
intercept	O
intracellular	O
signalling	O
molecules	O
.	O

The	O
use	O
of	O
tissue	O
obtained	O
from	O
ectopic	O
pregnancy	O
may	O
become	O
an	O
excellent	O
model	O
to	O
identify	O
the	O
mechanism	O
of	O
trophoblast	O
invasion	O
in	O
eutopic	O
pregnancies	O
.	O

Life-table	O
analysis	O
(	O
Mantel-Cox	O
)	O
was	O
used	O
to	O
assess	O
the	O
probability	O
of	O
disease-free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

The	O
1.955-kb	B-DNA
viral	I-DNA
segment	I-DNA
includes	O
a	O
dyad	O
symmetry	O
region	O
located	O
between	O
two	O
small	B-DNA
nuclear	I-DNA
RNA	I-DNA
genes	I-DNA
and	O
is	O
located	O
upstream	O
of	O
the	O
dihydrofolate	B-DNA
reductase	I-DNA
gene	I-DNA
homolog	I-DNA
.	O

Flow	O
cytometry	O
showed	O
that	O
L-selectin	B-protein
was	O
expressed	O
on	O
fresh	O
ATL	B-cell_line
cells	I-cell_line
along	O
with	O
other	O
activation	B-protein
antigens	I-protein
.	O

The	O
position	O
of	O
the	O
ZEBRA	B-protein
activation	I-protein
domain	I-protein
does	O
not	O
influence	O
its	O
biological	O
activity	O
.	O

Evidence	O
is	O
also	O
presented	O
,	O
using	O
Fe2+/Cu2+	O
ions	O
,	O
that.OH	O
generated	O
from	O
H2O2	O
through	O
Fenton	O
reactions	O
could	O
be	O
a	O
candidate	O
oxygen	O
reactive	O
species	O
to	O
directly	O
activate	O
STAT3	B-protein
.	O

Collectively	O
,	O
our	O
results	O
demonstrate	O
that	O
nuclear	O
translocation	O
and	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
rank	O
among	O
the	O
short-term	O
cellular	O
responses	O
elicited	O
following	O
CD30	B-protein
ligation	O
.	O

One	O
of	O
the	O
members	O
of	O
this	O
multigene	O
family	O
,	O
cGATA-3	B-protein
,	O
is	O
most	O
abundantly	O
expressed	O
in	O
the	O
T-lymphocyte	B-cell_type
cell	I-cell_type
lineage	I-cell_type
.	O

All	O
tumor	B-cell_line
cell	I-cell_line
lines	I-cell_line
from	O
the	O
B-cell	B-cell_type
lineage	I-cell_type
and	O
a	O
few	O
from	O
the	O
T-cell	B-cell_type
lineage	I-cell_type
express	O
Oct-2	B-protein
.	O

6.	O
Partitioning	O
of	O
SMX-NHOH	O
into	O
red	B-cell_type
blood	I-cell_type
cells	I-cell_type
was	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
lower	O
than	O
with	O
the	O
hydroxylamine	O
of	O
dapsone	O
.	O

Calcineurin	B-protein
mutants	I-protein
render	O
T	B-cell_type
lymphocytes	I-cell_type
resistant	O
to	O
cyclosporin	O
A	O
.	O

Each	O
of	O
the	O
remaining	O
four	O
patients	O
also	O
yielded	O
at	O
least	O
one	O
type-specific	B-cell_line
T-cell	I-cell_line
clone	I-cell_line
reactive	O
with	O
an	O
HSV-2	O
epitope	O
mapping	O
to	O
approximately	O
0.67	O
to	O
0.73	O
map	O
units	O
.	O

This	O
inhibition	O
correlates	O
with	O
decreased	O
MMP-9	B-protein
secretion	O
as	O
determined	O
by	O
Western	O
blotting	O
.	O

These	O
data	O
suggest	O
that	O
transcriptional	O
activation	O
of	O
human	B-DNA
embryonic	I-DNA
zeta	I-DNA
2	I-DNA
globin	I-DNA
gene	I-DNA
and	O
the	O
fetal/adult	B-DNA
alpha	I-DNA
globin	I-DNA
genes	I-DNA
is	O
mediated	O
by	O
erythroid	O
cell-specific	O
and	O
developmental	B-protein
stage-specific	I-protein
nuclear	I-protein
factor-DNA	I-protein
complexes	I-protein
which	O
form	O
at	O
the	O
enhancer	B-DNA
(	O
HS-40	B-DNA
)	O
and	O
the	O
globin	B-DNA
promoters	I-DNA
.	O

The	O
tissue	O
from	O
both	O
patients	O
generated	O
a	O
polyclonal	O
pattern	O
of	O
X	B-DNA
chromosome	I-DNA
inactivation	O
of	O
the	O
human	B-DNA
androgen	I-DNA
receptor	I-DNA
gene	I-DNA
.	O

Thus	O
the	O
VLA-5	B-protein
fibronectin	I-protein
receptor	I-protein
on	O
CD4	B-cell_line
cells	I-cell_line
can	O
play	O
a	O
complementary	O
role	O
in	O
CD3	B-protein
-	O
TCR	B-protein
-mediated	O
signal	O
transduction	O
through	O
its	O
interaction	O
with	O
fibronectin	B-protein
.	O

A	O
novel	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
(	O
RAR	B-protein
)	O
-selective	O
antagonist	O
inhibits	O
differentiation	O
and	O
apoptosis	O
of	O
HL-60	B-cell_line
cells	I-cell_line
:	O
implications	O
of	O
RARalpha	B-protein
-mediated	O
signals	O
in	O
myeloid	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O

Our	O
study	O
was	O
aimed	O
at	O
investigating	O
the	O
role	O
of	O
this	O
cell	O
population	O
in	O
progesterone-dependent	O
immunomodulation	O
.	O

T	O
cell	O
proliferation	O
and	O
production	O
of	O
IL-2	B-protein
,	O
IL-4	B-protein
,	O
and	O
IFN-gamma	B-protein
induced	O
by	O
both	O
CD3	B-protein
and	O
CD3	B-protein
/CD28	B-protein
ligation	O
and	O
the	O
nuclear	O
expression	O
of	O
the	O
c-Jun	B-protein
and	I-protein
ATF-2	I-protein
proteins	I-protein
are	O
each	O
blocked	O
by	O
the	O
p38	B-protein
MAPK	I-protein
inhibitor	O
SB203580	O
.	O

These	O
experiments	O
demonstrate	O
that	O
it	O
is	O
possible	O
to	O
modulate	O
IFN-beta	O
transcription	O
in	O
vitro	O
but	O
indicate	O
that	O
additional	O
proteins	O
may	O
be	O
required	O
to	O
fully	O
activate	O
IFN-beta	B-protein
transcription	O
.	O

Anti-TR55	B-protein
antibody	I-protein
cross-linking	O
in	O
chronically	B-cell_line
infected	I-cell_line
U1	I-cell_line
promonocytic	I-cell_line
cultures	I-cell_line
could	O
only	O
partially	O
substitute	O
for	O
TNF-alpha-induced	O
HIV-1	O
expression	O
.	O

Inv	B-DNA
(	I-DNA
16	I-DNA
)	I-DNA
(	I-DNA
p13	I-DNA
;	I-DNA
q22	I-DNA
)	I-DNA
fuses	O
the	O
gene	O
encoding	O
the	O
beta	B-protein
subunit	I-protein
of	O
Pebp2	B-protein
to	O
the	O
MYH11	B-DNA
gene	I-DNA
encoding	O
a	O
smooth	B-protein
muscle	I-protein
myosin	I-protein
heavy	I-protein
chain	I-protein
(	O
Smmhc	B-protein
)	O
.	O

Statistical	O
analysis	O
was	O
performed	O
in	O
order	O
to	O
determine	O
the	O
prognostic	O
value	O
of	O
the	O
polyamine	O
patterns	O
of	O
tumor	O
tissues	O
and	O
erythrocytes	O
in	O
comparison	O
with	O
clinical	O
and	O
histological	O
prognostic	O
factors	O
.	O

EGF	O
treatment	O
induced	O
IgM	B-protein
production	O
in	O
cells	O
transfected	O
with	O
an	O
intact	O
gp130	B-protein
cytoplasmic	I-protein
tail	I-protein
,	O
but	O
not	O
in	O
untransfected	B-cell_line
cells	I-cell_line
or	O
cells	O
transfected	O
with	O
a	O
cytoplasmic	B-protein
tail	I-protein
lacking	O
all	O
four	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
Stat	I-protein
)	I-protein
binding	I-protein
sites	I-protein
.	O

All-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
successfully	O
used	O
in	O
the	O
cyto-differentiating	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

Mutational	O
analysis	O
of	O
UAS1	B-DNA
sequences	I-DNA
combined	O
with	O
in	O
vitro	O
bandshift	O
assays	O
revealed	O
the	O
presence	O
of	O
three	O
binding	B-DNA
sites	I-DNA
for	O
cellular	B-protein
factors	I-protein
in	O
this	O
region	O
.	O

The	O
proximal	O
element	O
is	O
a	O
composite	O
site	O
that	O
binds	O
members	O
of	O
the	O
CREB/ATF	B-protein
,	O
AP-1	B-protein
,	O
and	O
octamer	B-protein
families	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

Complex	B-protein
2	I-protein
corresponds	O
to	O
binding	O
of	O
transcription	B-protein
factor	I-protein
(	O
upstream	B-protein
stimulatory	I-protein
factor	I-protein
)	O
to	O
an	O
E-box	B-DNA
motif	I-DNA
in	O
the	O
5	B-DNA
'	I-DNA
portion	I-DNA
of	O
the	O
NIP	B-DNA
region	I-DNA
.	O

Although	O
the	O
TNF-alpha	B-protein
level	O
in	O
culture	O
supernatants	O
was	O
below	O
the	O
sensitivity	O
of	O
an	O
ELISA	O
assay	O
system	O
,	O
addition	O
of	O
anti-	O
TNF-alpha	B-protein
antibody	O
in	O
culture	O
medium	O
could	O
partially	O
suppress	O
the	O
heat	O
shock	O
induced	O
HIV-1	O
production	O
.	O

Proliferation	O
of	O
T	B-cell_type
cells	I-cell_type
was	O
induced	O
by	O
immobilized	O
anti-CD3	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
an	O
additional	O
costimulatory	O
signal	O
delivered	O
by	O
anti-CD28	B-protein
mAb	I-protein
.	O

The	O
c-Jun	B-protein
delta-domain	I-protein
inhibits	O
neuroendocrine	B-DNA
promoter	I-DNA
activity	O
in	O
a	O
DNA	O
sequence-	O
and	O
pituitary-specific	O
manner	O
.	O

Since	O
it	O
is	O
known	O
that	O
PGE2	O
is	O
able	O
to	O
increase	O
cAMP	O
levels	O
,	O
we	O
investigated	O
whether	O
it	O
can	O
affect	O
gene	O
expression	O
through	O
the	O
activation	O
of	O
the	O
transcription	B-protein
factors	I-protein
which	O
bind	O
enhancer	O
elements	O
in	O
the	O
promoter	O
regions	O
of	O
cAMP-regulated	B-DNA
genes	I-DNA
.	O

Here	O
we	O
demonstrate	O
that	O
NF-AT	B-protein
is	O
formed	O
when	O
a	O
signal	O
from	O
the	O
antigen	B-protein
receptor	I-protein
induces	O
a	O
pre-existing	O
cytoplasmic	O
subunit	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
combine	O
with	O
a	O
newly	O
synthesized	O
nuclear	O
subunit	O
of	O
NF-AT	B-protein
.	O

Besides	O
p50	B-protein
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
decreased	O
the	O
levels	O
of	O
another	O
NF-kappa	B-protein
B	I-protein
protein	I-protein
,	O
namely	O
c-rel	B-protein
.	O

The	O
activity	O
of	O
DNA	B-protein
binding	I-protein
NF-kappa	I-protein
B	I-protein
dimers	I-protein
is	O
tightly	O
controlled	O
by	O
accessory	B-protein
proteins	I-protein
called	O
I	B-protein
kappa	I-protein
B	I-protein
subunits	I-protein
of	O
which	O
there	O
are	O
also	O
five	O
different	O
species	O
currently	O
known	O
in	O
vertebrates	O
.	O

PG490	O
also	O
inhibits	O
PMA-stimulated	O
activation	O
of	O
a	O
chimeric	B-protein
transcription	I-protein
factor	I-protein
in	O
which	O
the	O
C-terminal	B-protein
TA1	I-protein
transactivation	I-protein
domain	I-protein
of	O
NF-kappaB	B-protein
p65	I-protein
is	O
fused	O
to	O
the	O
DNA	B-protein
binding	I-protein
domain	I-protein
of	O
GAL4	B-protein
.	O

Purified	O
OTF1	B-protein
from	O
HeLa	B-cell_line
cells	I-cell_line
and	O
OTF1	B-protein
and	O
OTF2	B-protein
from	O
B	B-cell_type
cells	I-cell_type
bound	O
to	O
identical	O
sequences	O
within	O
the	O
heavy-chain	B-DNA
promoter	I-DNA
.	O

LPS	O
activation	O
of	O
THP-1	B-cell_line
cells	I-cell_line
resulted	O
in	O
phosphorylation	O
of	O
MAD3	B-protein
(	O
an	O
I	B-protein
kappa	I-protein
B	I-protein
-like	O
protein	O
)	O
,	O
a	O
rapid	O
increase	O
in	O
MAD3	B-RNA
mRNA	I-RNA
,	O
and	O
an	O
increase	O
in	O
MAD3	B-protein
protein	O
by	O
2	O
h	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
in	O
anorexia	O
nervosa	O
and	O
Cushing	O
's	O
disease	O
.	O

Secondarily	O
,	O
heat	O
shock	O
of	O
Hyon	B-cell_line
cells	I-cell_line
stabilized	O
the	O
c-myc	B-RNA
mRNA	I-RNA
level	O
by	O
increasing	O
its	O
half-life	O
from	O
24	O
to	O
45	O
min	O
.	O

Fibroblast	B-protein
growth	I-protein
factors	I-protein
(	O
FGFs	B-protein
)	O
are	O
heparin-binding	B-protein
proteins	I-protein
crucial	O
to	O
embryogenesis	O
,	O
angiogenesis	O
,	O
and	O
wound	O
healing	O
.	O

Oct-1	B-protein
,	O
a	O
POU	B-protein
domain	I-protein
transcription	I-protein
factor	I-protein
,	O
was	O
identified	O
as	O
a	O
repressor	O
of	O
HLA-DRA	B-DNA
promoter	O
activity	O
in	O
the	O
Rb-defective	B-cell_type
cells	I-cell_type
.	O

Role	O
of	O
IKK1	B-protein
and	O
IKK2	B-protein
in	O
lipopolysaccharide	O
signaling	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
early	O
signaling	O
events	O
in	O
proliferating	B-cell_type
and	O
terminally	B-cell_type
differentiated	I-cell_type
cells	I-cell_type
following	O
G-CSF	B-protein
stimulation	O
to	O
determine	O
whether	O
identical	O
signaling	O
cascades	O
are	O
activated	O
.	O

Both	O
proteins	O
impart	O
cAMP-regulated	O
transcriptional	O
activity	O
to	O
a	O
heterologous	B-DNA
DNA-binding	I-DNA
domain	I-DNA
,	O
showing	O
that	O
cAMP	O
directly	O
modulates	O
the	O
transcriptional	O
stimulatory	O
activity	O
of	O
CREB	B-protein
.	O

HIV-1	B-protein
Vpr	I-protein
suppresses	O
immune	O
activation	O
and	O
apoptosis	O
through	O
regulation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
[	O
see	O
comments	O
]	O

During	O
latent	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
of	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
six	B-protein
viral	I-protein
nuclear	I-protein
antigen	I-protein
(	O
EBNAs	B-protein
)	O
are	O
expressed	O
from	O
long	B-RNA
primary	I-RNA
transcripts	I-RNA
by	O
means	O
of	O
alternative	B-RNA
splicing	I-RNA
and	O
alternative	B-RNA
polyadenylylation	I-RNA
sites	I-RNA
.	O

Variant	O
receptor	O
transcripts	O
lacking	O
exon	B-DNA
5	I-DNA
or	O
exon	B-DNA
7	I-DNA
,	O
which	O
encodes	O
the	O
hormone	O
binding	O
domain	O
,	O
were	O
identified	O
in	O
the	O
majority	O
of	O
the	O
cells	O
.	O

Moreover	O
,	O
TAR	B-DNA
-independent	O
transactivation	O
of	O
HIV-1	O
transcription	O
is	O
reproduced	O
in	O
vitro	O
in	O
an	O
astrocyte	O
factor-dependent	O
manner	O
which	O
correlates	O
with	O
kappa	O
B-binding	O
activity	O
.	O

A	O
unique	O
subclone	O
of	O
a	O
bone	B-cell_line
marrow-derived	I-cell_line
stromal	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
BMS2.4	B-cell_line
,	O
produces	O
soluble	B-protein
factors	I-protein
that	O
inhibit	O
proliferation	O
of	O
several	O
types	O
of	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Interestingly	O
,	O
the	O
deduced	O
amino	O
acid	O
sequence	O
was	O
found	O
to	O
be	O
related	O
to	O
fungal	B-protein
C8-C7	I-protein
sterol	I-protein
isomerase	I-protein
,	O
encoded	O
by	O
the	O
ERG2	B-DNA
gene	I-DNA
.	O

This	O
mechanism	O
can	O
have	O
a	O
role	O
in	O
directing	O
the	O
cytolytic	O
action	O
of	O
NK	B-cell_type
cells	I-cell_type
towards	O
the	O
virus-infected	B-cell_type
and	I-cell_type
cancer	I-cell_type
cells	I-cell_type
.	O

We	O
have	O
earlier	O
found	O
that	O
in	O
Jurkat	O
cells	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
enhances	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
accumulation	O
induced	O
by	O
adenosine	O
receptor	O
stimulation	O
or	O
activation	O
of	O
Gs	B-protein
.	O

Consequently	O
,	O
the	O
present	O
study	O
was	O
addressed	O
to	O
understand	O
this	O
phenomenon	O
and	O
revealed	O
the	O
existence	O
of	O
a	O
unique	B-protein
47	I-protein
kDa	I-protein
protein	I-protein
factor	I-protein
having	O
affinity	O
for	O
this	O
SRE	B-DNA
sequence	I-DNA
in	O
lymphocytes	B-cell_type
from	O
normal	O
subjects	O
as	O
well	O
as	O
its	O
absence	O
in	O
lymphocytes	B-cell_type
from	O
untreated	O
CML	O
patients	O
.	O

Thus	O
,	O
an	O
adherent	O
population	O
of	O
cells	O
,	O
with	O
preosteoclast/	O
osteoclast	B-cell_type
phenotypic	O
properties	O
,	O
arises	O
selectively	O
under	O
simple	O
culture	O
conditions	O
from	O
normal	O
PBMC	B-cell_type
.	O

A	O
similar	O
half-life	O
was	O
determined	O
in	O
IM-9	B-cell_line
cells	I-cell_line
and	O
was	O
also	O
unaffected	O
by	O
steroid	O
treatment	O
.	O

Reactive	O
oxygen	O
species	O
and	O
antioxidants	O
in	O
inflammatory	O
diseases	O
.	O

Biochemically	O
we	O
show	O
that	O
the	O
stimulated	O
tyrosine	O
phosphorylation	O
of	O
Vav	B-protein
,	O
Shc	B-protein
,	O
and	O
ZAP-70	B-protein
itself	O
is	O
diminished	O
,	O
whereas	O
that	O
of	O
Slp-76	B-protein
is	O
increased	O
in	O
cells	O
reconstituted	O
with	O
Delta	B-protein
.	O

Our	O
results	O
indicated	O
that	O
the	O
extracellular	B-protein
domain	I-protein
of	O
the	O
type	B-protein
II	I-protein
IL-1R	I-protein
was	O
capable	O
of	O
functionally	O
interacting	O
with	O
interleukin-1	B-protein
and	O
transmitting	O
the	O
resulting	O
signal	O
to	O
a	O
heterologous	B-protein
cytoplasmic	I-protein
domain	I-protein
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
importance	O
of	O
NF-kappaB	B-protein
induction	O
in	O
the	O
up-regulation	O
of	O
the	O
B	O
cell	O
activation	O
markers	O
ICAM-1	B-protein
and	O
CD71	B-protein
by	O
LMP1	B-protein
.	O

The	O
data	O
presented	O
here	O
indicate	O
that	O
(	O
1	O
)	O
the	O
12-lipoxygenase	B-protein
activity	O
of	O
murine	O
macrophages	O
is	O
upregulated	O
in	O
vitro	O
and	O
in	O
vivo	O
by	O
IL-4	B-protein
and/or	O
IL-13	B-protein
,	O
(	O
2	O
)	O
this	O
upregulation	O
requires	O
expression	O
of	O
the	O
transcription	B-protein
factor	I-protein
STAT6	B-protein
,	O
and	O
(	O
3	O
)	O
the	O
constitutive	O
expression	O
of	O
the	O
enzyme	O
appears	O
to	O
be	O
STAT6	B-protein
independent	O
.	O

Recently	O
,	O
there	O
has	O
been	O
some	O
progress	O
in	O
the	O
understanding	O
of	O
the	O
signal	O
transduction	O
pathways	O
activated	O
by	O
these	O
cytokines	B-protein
in	O
eosinophils	B-cell_type
.	O

Expression	O
of	O
a	O
rapamycin-resistant	B-protein
mutant	I-protein
of	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
in	O
T	B-cell_type
cells	I-cell_type
could	O
restore	O
rapamycin-suppressed	O
E2F	B-protein
responses	O
.	O

Much	O
attention	O
has	O
recently	O
focused	O
on	O
the	O
observation	O
that	O
UV	O
light	O
can	O
activate	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O

Specific	O
inhibitors	O
of	O
p70	B-protein
(	I-protein
S6	I-protein
)	I-protein
-kinase	I-protein
(	O
rapamycin	O
)	O
,	O
and	O
Gi	B-protein
protein	I-protein
(	O
pertussis	B-protein
toxin	I-protein
)	O
,	O
prevented	O
induction	O
of	O
IL-10	B-protein
production	O
by	O
gp41	B-protein
in	O
monocytes	B-cell_type
,	O
while	O
inhibitors	O
of	O
the	O
phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PI	B-protein
3-kinase	I-protein
)	O
(	O
wortmannin	O
)	O
and	O
mitogen-activated	O
protein	O
kinase	O
(	O
MAPK	B-protein
)	O
pathway	O
(	O
PD	O
98059	O
)	O
did	O
not	O
.	O

Of	O
p38	B-protein
MAPk	I-protein
isoforms	I-protein
studied	O
,	O
only	O
p38alpha	B-protein
and	O
p38delta	B-protein
were	O
detected	O
in	O
neutrophils	B-cell_type
.	O

Allelic	O
variation	O
at	O
the	O
3'-end	O
of	O
the	O
vitamin	B-DNA
D	I-DNA
receptor	I-DNA
(	I-DNA
VDR	I-DNA
)	I-DNA
gene	I-DNA
has	O
been	O
associated	O
with	O
a	O
3-5-fold	O
increased	O
risk	O
of	O
developing	O
prostate	O
cancer	O
and	O
with	O
differences	O
in	O
bone	O
mineralization	O
.	O

Hormones	O
such	O
as	O
1	O
alpha	O
,	O
25-dihydroxy	O
vitamin	O
D3	O
(	O
D3	O
)	O
,	O
all-trans	O
retinoic	O
acid	O
,	O
and	O
9-cis	O
retinoic	O
acid	O
stimulate	O
differentiation	O
of	O
myeloid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
via	O
their	O
interaction	O
with	O
specific	O
hormone	B-protein
receptors	I-protein
.	O

However	O
,	O
the	O
Ets	B-protein
protein	I-protein
(	O
s	O
)	O
that	O
regulated	O
GPIX	B-DNA
promoter	I-DNA
expression	O
was	O
unknown	O
.	O

This	O
correlates	O
with	O
changes	O
of	O
nuclear	O
protein-binding	O
activities	O
to	O
two	O
motifs	O
,	O
site	B-protein
alpha	I-protein
and	I-protein
beta	I-protein
,	O
within	O
the	O
CD28	B-DNA
minimal	I-DNA
promoter	I-DNA
.	O

Protein	B-protein
kinase	I-protein
C-zeta	I-protein
mediates	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
human	B-cell_type
immunodeficiency	I-cell_type
virus-infected	I-cell_type
monocytes	I-cell_type
.	O

Human	O
immunodeficiency	O
virus-type	O
1	O
(	O
HIV-1	O
)	O
infection	O
is	O
characterized	O
by	O
a	O
chronic	O
state	O
of	O
immune	O
hyperactivation	O
in	O
patients	O
.	O

Clinical	O
outcome	O
was	O
not	O
found	O
to	O
be	O
related	O
to	O
immunophenotypic	O
differences	O
.	O

HIV-1	O
expressing	O
IkappaB-alphaS32/36A	B-protein
down-regulates	O
viral	O
expression	O
and	O
is	O
highly	O
attenuated	O
in	O
both	O
Jurkat	B-cell_line
and	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

Recent	O
studies	O
suggest	O
that	O
CD40-CD40	B-protein
ligand	I-protein
,	O
OX-OX40	B-protein
ligand	I-protein
,	O
a	O
group	O
of	O
cytokines	B-protein
and	O
intracellular	O
transcriptional	O
factors	O
may	O
all	O
contribute	O
to	O
B-lymphocyte	O
differentiation	O
control	O
.	O

Then	O
,	O
cells	O
were	O
incubated	O
with	O
medium	O
or	O
IL-10	B-protein
(	O
100	O
ng/ml	O
)	O
for	O
10	O
to	O
120	O
min	O
.	O

When	O
the	O
wild-type	B-protein
hGR	I-protein
and	O
hGR-Ile	B-protein
729	I-protein
were	O
expressed	O
in	O
CV-1	B-cell_line
cells	I-cell_line
that	O
were	O
cotransfected	O
with	O
the	O
mouse	B-DNA
mammary	I-DNA
tumor	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
fused	O
to	O
the	O
chloramphenicol	B-DNA
acetyl	I-DNA
transferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
gene	I-DNA
,	O
the	O
hGR-Ile	B-protein
729	I-protein
conferred	O
a	O
fourfold	O
decrease	O
in	O
apparent	O
potency	O
on	O
dexamethasone	O
stimulation	O
of	O
CAT	B-protein
activity	O
.	O

Tepoxalin	O
's	O
effect	O
on	O
NF	B-protein
kappa	I-protein
B	I-protein
is	O
also	O
reversed	O
by	O
the	O
addition	O
of	O
iron	O
salts	O
.	O

Chloramphenicol	B-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
assay	O
after	O
transient	O
cotransfection	O
showed	O
about	O
a	O
fivefold	O
transactivation	O
of	O
the	O
L-selectin	B-DNA
promoter	I-DNA
by	O
Tax	B-protein
.	O

Receptor/Stat	O
interaction	O
is	O
mediated	O
by	O
the	O
src	B-protein
homology	I-protein
2	I-protein
(	I-protein
SH2	I-protein
)	I-protein
domain	I-protein
of	O
the	O
corresponding	O
Stat	B-protein
protein	I-protein
.	O

The	O
70	B-protein
kDa	I-protein
heat	I-protein
shock	I-protein
protein	I-protein
(	O
Hsp70	B-protein
)	O
is	O
a	O
highly	O
conserved	O
,	O
ubiquitous	B-protein
protein	I-protein
involved	O
in	O
chaperoning	B-protein
proteins	I-protein
to	O
various	O
cellular	O
organelles	O
.	O

We	O
argue	O
that	O
in	O
vivo	O
RelA	B-protein
homodimers	I-protein
are	O
likely	O
to	O
play	O
a	O
dominant	O
role	O
in	O
TNF-alpha	B-protein
-induced	O
ICAM-1	B-protein
transcription	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

In	O
addition	O
,	O
ALY	B-protein
can	O
increase	O
DNA	O
binding	O
by	O
both	O
LEF-1	B-protein
and	O
AML	B-protein
proteins	I-protein
.	O

However	O
,	O
the	O
NF-IL6	B-DNA
gene	I-DNA
is	O
expressed	O
in	O
a	O
variety	O
of	O
nonmyeloid	O
cell	O
types	O
and	O
is	O
strongly	O
inducible	O
in	O
response	O
to	O
inflammatory	O
stimuli	O
,	O
making	O
it	O
an	O
unlikely	O
candidate	O
to	O
have	O
an	O
exclusive	O
role	O
as	O
a	O
combinatorial	O
differentiation	O
switch	O
during	O
myelopoiesis	O
in	O
human	B-cell_type
cells	I-cell_type
.	O

Recently	O
,	O
we	O
have	O
developed	O
a	O
quantitative	O
assay	O
using	O
competitive	O
reverse	B-protein
transcriptase	I-protein
polymerase	I-protein
chain	O
reaction	O
that	O
estimates	O
the	O
number	O
of	O
AML1/ETO	B-RNA
transcripts	I-RNA
in	O
t	O
(	O
8	O
;	O
21	O
)	O
acute	O
myelogenous	O
leukemia	O
(	O
AML	O
)	O
,	O
in	O
order	O
to	O
determine	O
the	O
degree	O
of	O
leukemic	O
cell	O
contamination	O
in	O
PBSC	B-cell_type
harvests	O
,	O
and	O
to	O
monitor	O
minimal	O
residual	O
disease	O
(	O
MRD	O
)	O
quantitatively	O
in	O
patients	O
with	O
t	O
(	O
8	O
;	O
21	O
)	O
AML	O
.	O

Co-transfection	O
with	O
dominant-negative	B-protein
mutant	I-protein
TNFRI	I-protein
inhibited	O
EC	B-cell_type
activation	O
by	O
NK	O
cell	O
membrane	O
extracts	O
and	O
by	O
NK	B-cell_type
cells	I-cell_type
by	O
80	O
%	O
and	O
47	O
%	O
,	O
respectively	O
.	O

These	O
experiments	O
demonstrate	O
that	O
HSV-1	O
is	O
a	O
competent	O
vector	O
for	O
expression	O
of	O
these	O
VZV	B-protein
proteins	I-protein
and	O
support	O
the	O
feasibility	O
of	O
engineering	O
a	O
combined	O
vaccine	O
for	O
these	O
closely	O
related	O
alpha-herpesviruses	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
both	O
surfactants	O
decreased	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

Interferon-gamma	B-protein
and	O
the	O
sexual	O
dimorphism	O
of	O
autoimmunity	O
.	O

It	O
is	O
suggested	O
that	O
each	O
of	O
these	O
proteins	O
recognizes	O
primarily	O
a	O
structural	O
feature	O
of	O
the	O
RNA	O
rather	O
than	O
a	O
specific	O
sequence	O
.	O

The	O
expression	O
of	O
hGATA-3	B-protein
,	O
a	O
T	B-protein
cell-specific	I-protein
factor	I-protein
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
transcription	O
of	O
TcR	B-DNA
delta	I-DNA
locus	I-DNA
,	O
was	O
analyzed	O
by	O
Northern	O
blot	O
,	O
in	O
cultured	O
NK	B-cell_line
cell	I-cell_line
population	I-cell_line
and	O
clones	O
(	O
but	O
not	O
in	O
freshly	O
derived	O
cell	O
populations	O
)	O
.	O

NF-kappa	B-protein
B	I-protein
activation	O
was	O
independent	O
of	O
the	O
transmembrane	B-protein
domain	I-protein
of	O
CD40	B-protein
,	O
suggesting	O
that	O
it	O
is	O
independent	O
of	O
p23	B-protein
,	O
a	O
molecule	O
that	O
associates	O
with	O
CD40	B-protein
in	O
a	O
region	O
other	O
than	O
the	O
cytoplasmic	B-protein
domain	I-protein
.	O

In	O
contrast	O
,	O
the	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
IARC	B-cell_line
301	I-cell_line
,	O
expresses	O
these	O
two	O
genes	O
constitutively	O
and	O
we	O
have	O
previously	O
demonstrated	O
that	O
its	O
growth	O
depends	O
on	O
the	O
autocrine	O
production	O
of	O
this	O
T	B-protein
cell	I-protein
growth	I-protein
factor	I-protein
and	O
high	B-protein
affinity	I-protein
IL-2R	I-protein
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
develop	O
U937	B-cell_line
transfectants	O
expressing	O
antisense	O
VDR	B-RNA
mRNA	I-RNA
,	O
and	O
to	O
use	O
these	O
to	O
examine	O
the	O
role	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-VDR	B-protein
interaction	O
in	O
this	O
lineage	O
.	O

Since	O
the	O
induction	O
of	O
NF-AT	B-protein
and	O
AP-1	B-protein
is	O
induced	O
by	O
the	O
same	O
stimuli	O
that	O
stimulate	O
IL-2	B-protein
production	O
,	O
these	O
results	O
indicate	O
that	O
the	O
immunosuppressant	O
action	O
of	O
CsA	O
and	O
FK506	O
is	O
exerted	O
at	O
the	O
level	O
of	O
these	O
trans-activating	B-protein
factors	I-protein
.	O

Investigating	O
cytokines	B-protein
known	O
to	O
affect	O
B	O
cell	O
differentiation	O
,	O
we	O
have	O
recently	O
shown	O
that	O
IL-6	B-protein
production	O
is	O
augmented	O
by	O
RA	O
.	O

The	O
structural	O
organization	O
of	O
the	O
393	B-protein
amino	I-protein
acid	I-protein
long	I-protein
human	I-protein
TRAMP	I-protein
is	O
most	O
homologous	O
to	O
TNF	B-protein
receptor	I-protein
1	I-protein
.	O

As	O
shown	O
by	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
respectively	O
,	O
treatment	O
with	O
CsA	O
leads	O
to	O
decreased	O
TF	B-RNA
mRNA	I-RNA
expression	O
and	O
reduced	O
activation	O
of	O
the	O
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
,	O
which	O
is	O
known	O
to	O
contribute	O
to	O
the	O
induction	O
of	O
the	O
TF	B-DNA
promotor	I-DNA
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Oligoclonal	O
expansion	O
of	O
B	B-cell_type
cells	I-cell_type
in	O
the	O
livers	O
with	O
ILFs	O
was	O
confirmed	O
by	O
an	O
analysis	O
of	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
gene	I-DNA
rearrangement	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

The	O
binding	O
of	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
(	O
a	O
DNA	B-protein
binding	I-protein
protein	I-protein
that	O
specifically	O
recognizes	O
the	O
P	B-DNA
sequence	I-DNA
)	O
to	O
the	O
P	B-DNA
sequence	I-DNA
was	O
abolished	O
when	O
oligonucleotides	O
carrying	O
base	O
substitutions	O
were	O
used	O
,	O
indicating	O
that	O
the	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
interaction	O
is	O
sequence-specific	O
and	O
that	O
binding	O
specificity	O
of	O
the	O
protein	O
paralleled	O
the	O
sequence	O
requirements	O
for	O
IL-4	B-protein
expression	O
in	O
vivo	O
.	O

NF-kappaB-mediated	B-cell_type
up-regulation	I-cell_type
of	O
Bcl-x	B-protein
and	O
Bfl-1/A1	B-protein
is	O
required	O
for	O
CD40	B-protein
survival	O
signaling	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

Human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV-1	I-protein
)	I-protein
Tat	I-protein
,	O
an	O
early	O
regulatory	B-protein
protein	I-protein
that	O
is	O
critical	O
for	O
viral	O
gene	O
expression	O
and	O
replication	O
,	O
transactivates	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
via	O
its	O
binding	O
to	O
the	O
transactivation	B-DNA
response	I-DNA
element	I-DNA
(	O
TAR	B-DNA
)	O
and	O
,	O
along	O
with	O
other	O
cellular	O
factors	O
,	O
increases	O
viral	O
transcription	O
initiation	O
and	O
elongation	O
.	O

We	O
wished	O
to	O
determine	O
if	O
this	O
developmentally	O
related	O
interaction	O
is	O
a	O
consequence	O
of	O
myeloid	O
differentiation	O
or	O
an	O
intrinsic	O
differentiating	O
stimulus	O
.	O

PPARgamma	B-protein
is	O
also	O
expressed	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
and	O
is	O
up-regulated	O
in	O
activated	O
monocytes/macrophages	B-cell_type
.	O

Interaction	O
between	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
-	O
and	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
-mediated	O
signaling	O
is	O
suggested	O
by	O
the	O
ability	O
of	O
the	O
PKC	B-protein
activating	O
phorbol	O
ester	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
to	O
inhibit	O
GR	B-protein
-dependent	O
transcription	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
.	O

[	O
Induction	O
of	O
apoptosis	O
in	O
lymphocytes	B-cell_type
by	O
glucocorticoids	O
:	O
between	O
physiology	O
and	O
pharmacology	O
]	O

This	O
atrophy	O
induction	O
does	O
not	O
involve	O
apoptotic	O
mechanisms	O
in	O
thymocytes	B-cell_type
affected	O
by	O
the	O
bcl-2	B-DNA
proto-oncogene	I-DNA
.	O

We	O
have	O
recently	O
established	O
a	O
novel	O
APL	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
UF-1	B-cell_line
)	O
with	O
features	O
of	O
RA	O
resistance	O
.	O

Interleukin-8	B-protein
(	O
IL-8	B-protein
)	O
is	O
a	O
chemokine	B-protein
that	O
belongs	O
to	O
the	O
alpha-chemokine	B-protein
or	O
CXC	B-protein
subfamily	I-protein
and	O
is	O
produced	O
by	O
a	O
wide	O
variety	O
of	O
human	O
cells	O
,	O
including	O
monocytes	B-cell_type
and	O
polymorphonuclear	B-cell_type
cells	I-cell_type
(	O
PMN	B-cell_type
)	O
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
production	O
by	O
lavage	B-cell_type
cells	I-cell_type
from	O
tuberculosis	O
patients	O
correlated	O
with	O
the	O
number	O
of	O
CD8+	O
T	B-cell_type
lymphocytes	I-cell_type
present	O
but	O
not	O
other	O
cell	O
types	O
.	O

Targeted	O
disruption	O
of	O
the	O
MyD88	B-DNA
gene	I-DNA
results	O
in	O
loss	O
of	O
IL-1-	O
and	O
IL-18-mediated	O
function	O
.	O

In	O
addition	O
,	O
RFX1	B-protein
can	O
bind	O
simultaneously	O
,	O
most	O
likely	O
as	O
a	O
heterodimer	B-protein
,	O
with	O
the	O
transcription	B-protein
factor	I-protein
MIBP1	B-protein
to	O
NRE	B-DNA
gamma	I-DNA
.	O

The	O
location	O
of	O
Sp140	B-protein
in	O
the	O
NB	O
,	O
and	O
expression	O
of	O
this	O
gene	O
in	O
cells	O
involved	O
in	O
host	O
defense	O
,	O
suggest	O
that	O
Sp140	B-protein
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O

The	O
phenomenon	O
of	O
glucocorticoid	O
resistance	O
in	O
major	O
depressive	O
disorder	O
remains	O
unexplained	O
.	O

These	O
proteins	O
interacted	O
specifically	O
with	O
the	O
symmetric	B-DNA
NF-kappa	I-DNA
B	I-DNA
site	I-DNA
from	O
the	O
interferon	B-DNA
beta	I-DNA
(	I-DNA
IFN-beta	I-DNA
)	I-DNA
promoter	I-DNA
.	O

The	O
cAMP-response	B-DNA
element	I-DNA
CRE	B-DNA
,	O
TGACGTCA	O
,	O
present	O
in	O
the	O
21	B-DNA
base-pair	I-DNA
sequence	I-DNA
,	O
appears	O
to	O
be	O
essential	O
for	O
specific	O
protein-	O
TRE	B-DNA
-DNA	O
interactions	O
because	O
mutation	O
of	O
the	O
two	O
G	O
's	O
destroys	O
this	O
complex	O
.	O

T-cell	B-cell_type
-directed	O
TAL-1	B-protein
expression	O
induces	O
T-cell	O
malignancies	O
in	O
transgenic	O
mice	O
.	O

The	O
extracellular	O
domain	O
of	O
the	O
murine	B-protein
G-CSF	I-protein
receptor	I-protein
was	O
required	O
for	O
the	O
activity	O
of	O
SB	O
247464	O
,	O
suggesting	O
that	O
the	O
compound	O
acts	O
by	O
oligomerizing	B-protein
receptor	I-protein
chains	I-protein
.	O

These	O
differences	O
in	O
gene	O
expression	O
have	O
not	O
been	O
molecularly	O
defined	O
.	O

This	O
was	O
due	O
to	O
the	O
presence	O
of	O
active	O
NF-kappa	B-protein
B	I-protein
complexes	I-protein
in	O
the	O
nucleus	O
of	O
CD45	B-protein
-T	O
cells	O
.	O

These	O
data	O
indicated	O
that	O
c-Fos	B-protein
/c-Jun	B-protein
,	O
c-Rel	B-protein
/p65	B-protein
,	O
and	O
Sp1	B-protein
regulate	O
TF	B-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

The	O
cDNA	B-DNA
that	O
we	O
isolated	O
is	O
identical	O
to	O
the	O
cDNA	B-DNA
of	O
the	O
recently	O
positionally	O
cloned	O
mouse	B-DNA
embryonic	I-DNA
ectoderm	I-DNA
development	I-DNA
gene	I-DNA
,	O
eed	O
.	O

Interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
plays	O
a	O
central	O
role	O
in	O
numerous	O
inflammatory	O
and	O
immune	O
processes	O
.	O

These	O
results	O
suggest	O
that	O
an	O
age-associated	O
decline	O
in	O
the	O
induction	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
in	O
activated	O
T	B-cell_type
cells	I-cell_type
from	O
elderly	O
individuals	O
may	O
be	O
attributable	O
to	O
altered	O
regulation	O
of	O
the	O
inhibitor	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
and	O
may	O
play	O
an	O
important	O
role	O
in	O
immune	O
dysregulation	O
accompanying	O
aging	O
.	O

ZEBRA	B-protein
activation	O
domain	O
swap	O
constructs	O
retain	O
ZEBRA	B-protein
's	O
native	O
abilities	O
to	O
activate	O
specific	O
EBV	B-DNA
promoters	I-DNA
,	O
to	O
disrupt	O
EBV	O
latency	O
,	O
and	O
to	O
stimulate	O
replication	O
at	O
the	O
EBV	B-DNA
lytic	I-DNA
origin	I-DNA
.	O

During	O
the	O
differentiation	O
process	O
of	O
cells	O
from	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	I-cell_line
we	O
observed	O
a	O
transient	O
transcriptional	O
upregulation	O
of	O
a	O
human	B-protein
carboxylesterase	I-protein
analyzed	O
by	O
means	O
of	O
Northern	O
blots	O
.	O

Upregulation	O
of	O
bcl-2	B-DNA
by	O
the	O
Epstein-Barr	B-protein
virus	I-protein
latent	I-protein
membrane	I-protein
protein	I-protein
LMP1	B-protein
:	O
a	O
B-cell-specific	O
response	O
that	O
is	O
delayed	O
relative	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
to	O
induction	O
of	O
cell	B-protein
surface	I-protein
markers	I-protein
.	O

Transcriptional	O
up-regulation	O
of	O
the	O
c-sis/platelet-derived	B-DNA
growth	I-DNA
factor-B	I-DNA
(	I-DNA
PDGF-B	I-DNA
)	I-DNA
proto-oncogene	I-DNA
by	O
the	O
Tax	B-protein
protein	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
has	O
been	O
implicated	O
as	O
one	O
possible	O
mechanism	O
of	O
cellular	O
transformation	O
by	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
.	O

Lastly	O
,	O
we	O
demonstrated	O
that	O
p38	B-protein
kinase	O
activity	O
played	O
a	O
central	O
role	O
in	O
IL-1beta	B-protein
production	O
and	O
that	O
it	O
was	O
rapidly	O
up-regulated	O
following	O
infection	O
.	O

Cellular	O
activation	O
by	O
thrombin	O
leads	O
to	O
the	O
phosphorylation	O
of	O
multiple	B-protein
proteins	I-protein
,	O
most	O
of	O
which	O
are	O
unidentified	O
.	O

Although	O
bacterial	O
lipopolysaccharides	O
(	O
LPS	O
)	O
and	O
several	O
other	O
microbial	O
agonists	O
can	O
bind	O
to	O
mCD14	B-protein
(	O
membrane	B-protein
CD14	I-protein
)	O
,	O
a	O
cell-surface	O
receptor	O
found	O
principally	O
on	O
monocytes	B-cell_type
and	O
neutrophils	B-cell_type
,	O
host-derived	O
mCD14	B-protein
ligands	O
are	O
poorly	O
defined	O
.	O

In	O
particular	O
,	O
these	O
cell	B-cell_line
lines	I-cell_line
may	O
help	O
understand	O
the	O
relative	O
contribution	O
of	O
HHV-8	O
and	O
EBV	O
to	O
PEL	O
growth	O
and	O
development	O
and	O
may	O
facilitate	O
the	O
identification	O
of	O
recurrent	O
cytogenetic	O
abnormalities	O
highlighting	O
putative	O
novel	O
cancer	O
related	O
loci	O
relevant	O
to	O
PEL	B-cell_line
.	O

The	O
mean	O
dissociation	O
constant	O
(	O
Kd	O
)	O
was	O
similar	O
in	O
both	O
sexes	O
(	O
1.35	O
+/-	O
0.70	O
x	O
10	O
(	O
-10	O
)	O
M	O
in	O
males	O
,	O
1.13	O
+/-	O
0.66	O
x	O
10	O
(	O
-10	O
)	O
M	O
in	O
females	O
)	O
,	O
but	O
the	O
concentration	O
of	O
binding	O
sites	O
(	O
Nmax	O
)	O
was	O
significantly	O
lower	O
in	O
females	O
(	O
2.32	O
+/-	O
0.92	O
fmol/10	O
(	O
7	O
)	O
PBMC	B-cell_type
vs	O
4.43	O
+/-	O
1.38	O
fmol/10	O
(	O
7	O
)	O
PBMC	B-cell_type
in	O
males	O
;	O
p	O
=	O
0.0001	O
)	O
.	O

Corticosteroids	O
are	O
the	O
preeminent	O
antiinflammatory	O
agents	O
although	O
the	O
molecular	O
mechanisms	O
that	O
impart	O
their	O
efficacy	O
have	O
not	O
been	O
defined	O
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
and	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-3	I-protein
induced	O
tyrosine	O
phosphorylation	O
of	O
92-kDa	B-protein
protein	I-protein
in	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
.	O

However	O
,	O
the	O
clinically	O
significant	O
class	O
of	O
AIDS	O
NHL	O
designated	O
immunoblastic	O
lymphoma	O
plasmacytoid	O
(	O
AIDS	O
IBLP	O
)	O
lacks	O
any	O
consistent	O
genetic	O
alterations	O
.	O

We	O
demonstrate	O
here	O
that	O
beta-catenin	B-protein
can	O
be	O
imported	O
into	O
the	O
nucleus	O
independently	O
of	O
LEF/TCF	B-protein
binding	O
,	O
and	O
it	O
may	O
also	O
be	O
exported	O
from	O
nuclei	O
.	O

The	O
peroxisome	O
proliferator-activated	O
receptor	O
(	O
PPARalpha	O
)	O
transcription	B-protein
factor	I-protein
is	O
expressed	O
in	O
HL-60	B-cell_line
cells	I-cell_line
,	O
but	O
no	O
changes	O
were	O
observed	O
in	O
its	O
expression	O
upon	O
HL-60	O
cell	O
differentiation	O
.	O

Hepatocyte	B-protein
nuclear	I-protein
factor-1	I-protein
alpha	I-protein
(	O
HNF-1	B-protein
alpha	I-protein
)	O
is	O
a	O
homeodomain-containing	B-protein
protein	I-protein
that	O
functions	O
as	O
a	O
dimer	B-protein
.	O

In	O
the	O
present	O
study	O
,	O
we	O
monitored	O
Oct-2	B-protein
expression	O
in	O
cells	O
arrested	O
for	O
the	O
activation	O
of	O
NF-kappaB	B-protein
,	O
an	O
LPS-responsive	B-protein
member	I-protein
of	O
the	O
Rel	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O

Molecular	O
,	O
biochemical	O
and	O
epidemiological	O
evidence	O
implicate	O
HTLV-I	O
as	O
an	O
etiologic	O
agent	O
of	O
adult	O
T	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

One	O
gene	O
encodes	O
a	O
protein	O
,	O
RFX5	B-protein
,	O
that	O
is	O
a	O
member	O
of	O
the	O
RFX	B-protein
family	I-protein
of	I-protein
DNA	I-protein
binding	I-protein
proteins	I-protein
.	O

Thus	O
,	O
microtubules	B-protein
participate	O
in	O
intracellular	O
25	O
(	O
OH	O
)	O
D3	O
transport	O
,	O
and	O
their	O
integrity	O
determines	O
normal	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
.	O

We	O
used	O
reverse	B-protein
transcriptase	I-protein
-polymerase	O
chain	O
reaction	O
to	O
examine	O
both	O
fetal	O
and	O
term	O
neonatal	O
cord	O
bloods	O
for	O
mRNA	O
expression	O
of	O
three	O
transcription	B-protein
factors	I-protein
implicated	O
in	O
T-cell	O
activation	O
:	O
c-jun	B-protein
,	O
c-fos	B-protein
,	O
and	O
NF	B-protein
kappa	I-protein
B	I-protein
(	O
p50	B-protein
subunit	I-protein
)	O
.	O

Cell	B-protein
surface	I-protein
markers	I-protein
in	O
the	O
YJ	B-cell_line
cells	I-cell_line
were	O
positive	O
for	O
CD33	B-protein
and	O
were	O
negative	O
for	O
CD34	B-protein
,	O
CD16	B-protein
and	O
CD23	B-protein
.	O

Different	O
types	O
of	O
acute	B-cell_type
myeloid	I-cell_type
leukemia	I-cell_type
blast	I-cell_type
cells	I-cell_type
were	O
induced	O
to	O
differentiate	O
in	O
vitro	O
with	O
all-trans-retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
vitamin	O
D3	O
(	O
VD	O
)	O
.	O

One	O
of	O
the	O
most	O
important	O
cytokines	B-protein
involved	O
in	O
immune	O
response	O
regulation	O
is	O
interleukin	O
2	O
(	O
IL-2	O
)	O
,	O
a	O
potent	O
activator	O
of	O
the	O
proliferation	O
and	O
function	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O

It	O
is	O
also	O
evident	O
that	O
the	O
TF.VIIa	B-protein
complex	I-protein
is	O
proteolytically	O
active	O
and	O
can	O
activate	O
the	O
zymogen	B-protein
plasma	I-protein
factor	I-protein
X	I-protein
to	O
the	O
serine	B-protein
protease	I-protein
Xa	I-protein
in	O
free	O
solution	O
,	O
inferring	O
that	O
extended	O
substrate	O
recognition	O
by	O
induced	O
structural	O
loci	O
of	O
the	O
TF.VIIa	B-protein
complex	I-protein
are	O
created	O
from	O
either	O
or	O
both	O
proteins	O
to	O
constitute	O
a	O
new	B-protein
recognition	I-protein
structure	I-protein
.	O

Here	O
we	O
report	O
that	O
cross-linking	O
of	O
Fc	B-protein
gamma	I-protein
RI	I-protein
or	O
Fc	B-protein
gamma	I-protein
RII	I-protein
by	O
adherent	B-protein
human	I-protein
IgG	I-protein
or	O
by	O
specific	O
anti-Fc	B-protein
gamma	I-protein
R	I-protein
mAb	I-protein
activates	O
HIV-1	O
gene	O
expression	O
in	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
BF24	B-cell_line
and	O
increased	O
HIV	B-RNA
RNA	I-RNA
expression	O
in	O
monocytes	B-cell_type
from	O
HIV	O
infected	O
patients	O
as	O
assayed	O
by	O
reverse	O
transcription-PCR	O
.	O

Surface	O
marker	O
analysis	O
showed	O
that	O
HMBA-induced	B-cell_line
cells	I-cell_line
expressed	O
reduced	O
levels	O
of	O
glycophorin	B-protein
A	I-protein
,	O
CD5	B-protein
,	O
CD7	B-protein
and	O
CD11b	B-protein
.	O

Full	O
activity	O
can	O
be	O
restored	O
by	O
the	O
combined	O
action	O
of	O
recombinant	O
PC4	B-protein
and	O
the	O
PC4	B-protein
-depleted	O
USA	O
fraction	O
,	O
thus	O
suggesting	O
a	O
joint	O
requirement	O
for	O
PC4	B-protein
and	O
another	O
,	O
USA-derived	O
component	O
(	O
s	O
)	O
for	O
optimal	O
function	O
of	O
Oct-1	B-protein
/OCA-B	B-protein
in	O
the	O
reconstituted	O
system	O
.	O

rNF-IL6	B-protein
expressed	O
in	O
bacteria	O
was	O
shown	O
to	O
specifically	O
bind	O
to	O
PRE-I	B-DNA
.	O

Here	O
we	O
show	O
that	O
HHV-6	O
upregulates	O
Zebra	B-DNA
gene	I-DNA
transcription	O
through	O
a	O
cyclic	B-DNA
AMP-responsive	I-DNA
element	I-DNA
(	O
CRE	B-DNA
)	O
located	O
within	O
the	O
Zebra	B-DNA
promoter	I-DNA
(	O
Zp	B-DNA
)	O
.	O

Treatment	O
of	O
U-937	B-cell_line
cells	I-cell_line
with	O
TPA	O
resulted	O
in	O
a	O
rapid	O
translocation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
from	O
the	O
cytosol	O
to	O
cell	O
membrane	O
fractions	O
within	O
2-8	O
min	O
.	O

Macrophages	B-cell_type
in	O
human	O
atheroma	O
contain	O
PPARgamma	B-protein
:	O
differentiation-dependent	B-protein
peroxisomal	I-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
(	O
PPARgamma	B-protein
)	O
expression	O
and	O
reduction	O
of	O
MMP-9	B-protein
activity	O
through	O
PPARgamma	B-protein
activation	O
in	O
mononuclear	O
phagocytes	O
in	O
vitro	O
.	O

Coincident	O
with	O
many	O
inflammatory	O
diseases	O
is	O
tissue	O
hypoxia	O
.	O

However	O
,	O
plasma	O
free	O
cortisol	O
concentrations	O
were	O
similar	O
in	O
the	O
three	O
groups	O
.	O

Various	O
gene	O
products	O
from	O
other	O
viruses	O
(	O
HTLV-1	O
,	O
HSV	O
,	O
EBV	O
,	O
CMV	O
,	O
HBV	O
,	O
and	O
HHV-6	O
)	O
can	O
also	O
enhance	O
HIV-1	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
-driven	O
reporter	B-DNA
gene	I-DNA
activity	O
.	O

Intracellular	O
signals	O
that	O
mediate	O
differentiation	O
of	O
pluripotent	B-cell_type
hemopoietic	I-cell_type
progenitors	I-cell_type
to	O
dendritic	B-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
are	O
largely	O
undefined	O
.	O

In	O
vitro	O
translated	O
MAD-3	B-protein
protein	I-protein
was	O
found	O
to	O
specifically	O
inhibit	O
the	O
DNA-binding	O
activity	O
of	O
the	O
p50/p65	B-protein
NF-kappa	I-protein
B	I-protein
complex	I-protein
but	O
not	O
that	O
of	O
the	O
p50/p50	B-protein
KBF1	I-protein
factor	I-protein
or	O
of	O
other	O
DNA-binding	B-protein
proteins	I-protein
.	O

Hence	O
,	O
phosphorylation	O
of	O
linker	B-protein
proteins	I-protein
not	O
only	O
bridges	O
the	O
TCR-associated	B-protein
PTK	I-protein
,	O
ZAP-70	B-protein
,	O
with	O
downstream	O
effector	O
proteins	O
,	O
but	O
also	O
provides	O
a	O
scaffold	O
to	O
integrate	O
distinct	O
signaling	B-protein
complexes	I-protein
to	O
regulate	O
T	B-cell_type
cell	I-cell_type
function	O
.	O

These	O
differences	O
in	O
expression	O
of	O
FOS	B-DNA
and	O
FOSB	B-DNA
suggest	O
different	O
roles	O
and	O
regulation	O
.	O

Moreover	O
,	O
kappa	B-DNA
1-kappa	I-DNA
3	I-DNA
can	O
each	O
be	O
deleted	O
from	O
the	O
TNF-alpha	B-DNA
promoter	I-DNA
with	O
little	O
effect	O
on	O
the	O
gene	O
's	O
inducibility	O
by	O
PMA	O
.	O

Okadaic	O
acid	O
is	O
a	O
potent	O
inducer	O
of	O
AP-1	B-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

The	O
resting	O
and	O
stimulated	O
levels	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
were	O
reduced	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
certain	O
elderly	O
individuals	O
;	O
however	O
,	O
alterations	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
did	O
not	O
correlate	O
with	O
changes	O
in	O
IL-2	B-protein
expression	O
.	O

More	O
is	O
known	O
regarding	O
signal	O
transduction	O
events	O
that	O
occur	O
after	O
ligation	O
of	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
.	O

In	O
T	B-cell_type
cells	I-cell_type
,	O
NF-kappa	B-protein
B	I-protein
is	O
activated	O
upon	O
cellular	O
treatment	O
by	O
phorbol	O
esters	O
and	O
the	O
cytokine	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
.	O

The	O
phosphorylation	O
of	O
CREB	B-protein
that	O
results	O
in	O
activation	O
is	O
mediated	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
rather	O
than	O
by	O
protein	B-protein
kinase	I-protein
A	I-protein
.	O

Specific	O
lymphocytes	B-cell_type
were	O
induced	O
by	O
in	O
vitro	O
peptide	O
sensitization	O
and	O
screened	O
by	O
thymidine	O
uptake	O
or	O
cellular	O
cytotoxic	O
assays	O
.	O

The	O
process	O
of	O
apoptosis	O
is	O
used	O
to	O
eliminate	O
unwanted	B-cell_type
cells	I-cell_type
from	O
a	O
wide	O
variety	O
of	O
organisms	O
.	O

Expression	O
of	O
interleukin	B-protein
1beta	I-protein
and	O
other	O
cytokines	B-protein
,	O
such	O
as	O
interleukin	B-protein
6	I-protein
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
,	O
has	O
been	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
,	O
NFkappaB	B-protein
.	O

Experiments	O
with	O
T	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
confirmed	O
these	O
findings	O
and	O
suggested	O
that	O
a	O
unique	B-protein
transcription	I-protein
factor	I-protein
may	O
be	O
essential	O
for	O
human	O
IL-5	B-protein
gene	O
transcription	O
.	O

This	O
makes	O
the	O
identification	O
of	O
genetic	O
targets	O
for	O
this	O
transcription	B-protein
factor	I-protein
pertinent	O
for	O
the	O
understanding	O
of	O
early	O
B-cell	O
development	O
.	O

STAT3	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
3	I-protein
)	O
is	O
a	O
latent	O
transcription	O
factor	O
that	O
is	O
activated	O
by	O
tyrosine	O
phosphorylation	O
(	O
Tyr-705	O
)	O
in	O
cells	O
stimulated	O
with	O
cytokines	B-protein
or	O
growth	B-protein
factors	I-protein
.	O

Selective	O
activation	O
of	O
STAT1alpha	B-protein
at	O
the	O
IFN-gamma	B-protein
receptor	I-protein
is	O
achieved	O
by	O
specific	O
interaction	O
between	O
a	O
cytosolic	B-protein
tyrosine	I-protein
motif	I-protein
including	O
Y440	B-protein
in	O
the	O
IFN-gamma	B-protein
receptor	I-protein
alpha-chain	I-protein
and	O
the	O
SH2	B-protein
domain	I-protein
of	O
STAT1alpha	B-protein
.	O

T	B-cell_type
cell	I-cell_type
blasts	I-cell_type
treated	O
with	O
PMA	O
are	O
now	O
responsive	O
to	O
IFN-gamma	B-protein
.	O

Furthermore	O
,	O
introduction	O
of	O
exogenous	O
GATA-1	B-protein
in	O
both	O
MEL	B-cell_line
cells	I-cell_line
and	O
Xenopus	O
embryos	O
and	O
explants	O
relieves	O
the	O
block	O
to	O
erythroid	O
differentiation	O
imposed	O
by	O
PU.1	B-protein
.	O

Exclusive	O
paternal	O
expression	O
of	O
WT1	B-protein
was	O
also	O
shown	O
in	O
non-cultured	B-cell_type
peripheral	I-cell_type
lymphocytes	I-cell_type
from	O
the	O
latter	O
two	O
individuals	O
.	O

In	O
addition	O
,	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
revealed	O
that	O
important	O
NF-kappaB	B-protein
binding	O
activity	O
composed	O
of	O
at	O
least	O
p50	B-protein
,	O
p65	B-protein
,	O
and	O
c-Rel	B-protein
NF-kappaB	B-protein
subunits	I-protein
was	O
present	O
in	O
nuclei	O
of	O
CD40-stimulated	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

In	O
clinics	O
these	O
molecules	O
are	O
also	O
used	O
for	O
their	O
potencies	O
in	O
inducing	O
apoptosis	O
of	O
malignant	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

These	O
studies	O
have	O
indicated	O
that	O
the	O
individual	O
repeats	O
are	O
not	O
identical	O
with	O
respect	O
to	O
the	O
cellular	B-protein
factors	I-protein
with	O
which	O
they	O
interact	O
.	O

Uncoupling	O
activation-dependent	O
HS1	B-protein
phosphorylation	O
from	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
transcriptional	O
activation	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
:	O
differential	O
signaling	O
through	O
CD3	B-protein
and	O
the	O
costimulatory	O
receptors	O
CD2	B-protein
and	O
CD28	B-protein
.	O

Galectin-3	O
is	O
a	O
beta-galactoside-binding	B-protein
lectin	I-protein
previously	O
designated	O
as	O
epsilon	B-protein
BP	I-protein
(	O
IgE-binding	B-protein
protein	I-protein
)	O
,	O
CBP35	B-protein
,	O
Mac-2	B-protein
,	O
L-29	B-protein
,	O
and	O
L-34	B-protein
,	O
and	O
its	O
expression	O
has	O
been	O
associated	O
with	O
various	O
physiological	O
and	O
pathological	O
processes	O
,	O
including	O
cell	O
growth	O
,	O
tumor	O
transformation	O
,	O
and	O
metastasis	O
.	O

The	O
class	B-protein
II	I-protein
transactivator	I-protein
(	O
CIITA	B-protein
)	O
is	O
essential	O
for	O
the	O
expression	O
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
class	I-protein
II	I-protein
antigens	I-protein
.	O

However	O
,	O
we	O
have	O
also	O
found	O
that	O
Vpr	B-protein
modulates	O
T-cell	O
receptor	O
(	O
TCR	B-protein
)	O
-triggered	O
apoptosis	O
in	O
a	O
manner	O
similar	O
to	O
that	O
of	O
glucocorticoids	O
.	O

Here	O
we	O
report	O
that	O
CsA	O
treatment	O
of	O
Raji	B-cell_line
B	I-cell_line
and	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
yields	O
a	O
phosphorylated	O
form	O
of	O
NFATp	B-protein
that	O
is	O
inhibited	O
in	O
DNA-binding	O
and	O
in	O
its	O
ability	O
to	O
form	O
an	O
NFAT	B-protein
complex	I-protein
with	O
Fos	B-protein
and	O
Jun	B-protein
.	O

The	O
cell	O
surface	O
receptors	O
for	O
PRL	B-protein
and	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
are	O
structurally	O
distinct	O
,	O
but	O
share	O
regulatory	O
tasks	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

The	O
current	O
study	O
examined	O
whether	O
alterations	O
in	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
binding	O
contribute	O
to	O
poor	O
response	O
to	O
glucocorticoid	O
therapy	O
in	O
asthma	O
.	O

Possible	O
relationship	O
between	O
the	O
changes	O
in	O
IL-1	B-protein
and	O
GR	B-protein
in	O
aged	O
long-distance	O
runner	O
and	O
its	O
physiological	O
significance	O
are	O
discussed	O
.	O

LysoPC	O
may	O
thus	O
attenuate	O
activation	O
of	O
coagulation	O
during	O
inflammation	O
and	O
atherosclerosis	O
.	O

Although	O
treatment	O
with	O
TNF-alpha	B-protein
induced	O
nuclear	O
localization	O
of	O
NFkappaB	B-protein
in	O
both	O
memory	B-cell_type
and	I-cell_type
naive	I-cell_type
T	I-cell_type
cell	I-cell_type
subsets	I-cell_type
,	O
irrespective	O
of	O
the	O
age	O
of	O
the	O
donor	O
,	O
the	O
levels	O
of	O
induced	O
NFkappaB	B-protein
were	O
significantly	O
lower	O
in	O
both	O
subsets	O
of	O
T	B-cell_type
cells	I-cell_type
obtained	O
from	O
the	O
elderly	O
,	O
when	O
compared	O
to	O
those	O
in	O
young	O
.	O

This	O
gene	O
is	O
yet	O
another	O
in	O
a	O
growing	O
list	O
of	O
important	O
regulatory	O
molecules	O
whose	O
expression	O
is	O
transcriptionally	O
induced	O
upon	O
cellular	O
activation	O
.	O

The	O
mechanism	O
of	O
the	O
immunosuppressive	O
effect	O
of	O
CyA	O
and	O
FK	O
506	O
can	O
be	O
monitored	O
in	O
vivo	O
in	O
humans	O
.	O

We	O
have	O
compared	O
the	O
effects	O
of	O
Epo	B-protein
and	O
the	O
chemical	O
inducers	O
,	O
delta-aminolaevulinic	O
acid	O
(	O
delta-ALA	O
)	O
and	O
haemin	O
on	O
the	O
differentiation	O
capacity	O
of	O
UT-7	B-cell_line
cells	I-cell_line
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
NFAT	B-protein
(	O
-276	B-DNA
to	I-DNA
-261	I-DNA
)	O
,	O
the	O
distal	B-DNA
octamer	I-DNA
(	O
-256	B-DNA
to	I-DNA
-248	I-DNA
)	O
and	O
the	O
proximal	B-DNA
octamer	I-DNA
(	O
-75	B-DNA
to	I-DNA
-66	I-DNA
)	O
sites	O
not	O
only	O
act	O
as	O
enhancers	O
of	O
IL-2	B-DNA
gene	I-DNA
transcription	O
in	O
the	O
presence	O
of	O
cellular	O
stimulation	O
,	O
but	O
also	O
have	O
a	O
silencing	O
effect	O
on	O
IL-2	B-DNA
gene	I-DNA
expression	O
in	O
resting	O
cells	O
.	O

The	O
human	O
protein	O
recognized	O
by	O
the	O
EC1	B-protein
antibody	I-protein
is	O
a	O
56-kDa	B-protein
protein	I-protein
(	O
p56	B-protein
)	O
of	O
moderate	O
abundance	O
located	O
predominantly	O
in	O
the	O
cytoplasm	O
by	O
indirect	O
immunofluorescence	O
.	O

We	O
show	O
that	O
at	O
least	O
one	O
inducible	B-protein
,	O
C1	B-protein
,	O
and	O
one	O
constitutive	B-protein
,	I-protein
C2	I-protein
,	I-protein
protein	I-protein
can	O
bind	O
to	O
the	O
HIV	B-DNA
enhancer	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

The	O
effect	O
of	O
constitutive	O
Tax	B-protein
expression	O
on	O
the	O
interaction	O
of	O
NF-kappa	B-protein
B	I-protein
with	O
its	O
recognition	B-DNA
sequence	I-DNA
and	O
on	O
NF-kappa	B-protein
B	I-protein
-dependent	O
gene	O
expression	O
was	O
examined	O
in	O
T	B-cell_line
lymphoid	I-cell_line
Jurkat	I-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
19D	B-cell_line
and	O
9J	B-cell_line
)	O
stably	O
transformed	O
with	O
a	O
Tax	B-DNA
expression	I-DNA
vector	I-DNA
.	O

Plasma	O
cortisol	O
and	O
aldosterone	O
levels	O
and	O
number	O
of	O
related	O
receptors	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
were	O
measured	O
in	O
49	O
healthy	O
aged	O
subjects	O
(	O
62-97	O
yr	O
)	O
and	O
in	O
21	O
adult	O
controls	O
(	O
21-50	O
yr	O
)	O
.	O

Two	O
types	O
of	O
responses	O
were	O
compared	O
after	O
a	O
single	O
MP	O
dose	O
(	O
40	O
mg	O
bolus	O
)	O
and	O
a	O
divided	O
regimen	O
(	O
20	O
mg	O
bolus	O
and	O
a	O
5	O
mg	O
bolus	O
8	O
hours	O
later	O
)	O
in	O
six	O
healthy	O
male	O
volunteers	O
.	O

In	O
conclusion	O
,	O
we	O
propose	O
that	O
Bcl-xL	B-protein
expression	O
is	O
associated	O
with	O
differentiation	O
and	O
survival	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
along	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
.	O

The	O
carboxy-terminal	B-protein
half	I-protein
of	O
the	O
HBx	B-protein
protein	I-protein
was	O
preferentially	O
recognized	O
by	O
antibodies	B-protein
from	O
patients	O
with	O
chronic	O
hepatitis	O
and	O
contained	O
a	O
short	O
immunodominant	B-protein
antigenic	I-protein
region	I-protein
with	O
at	O
least	O
two	O
major	O
nonoverlapping	B-protein
epitopes	I-protein
.	O

Therefore	O
,	O
we	O
have	O
constructed	O
a	O
single	O
cDNA	B-DNA
that	O
encodes	O
a	O
single-chain	B-protein
protein	I-protein
,	O
called	O
Flexi-12	B-protein
,	O
which	O
retains	O
all	O
of	O
the	O
biological	O
characteristics	O
of	O
recombinant	O
IL-12	B-protein
(	O
rIL-12	B-protein
)	O
.	O

Southern	O
blot	O
analysis	O
showed	O
rearrangement	O
of	O
BCL6	B-DNA
,	O
JH	B-DNA
,	O
and	O
TCR	B-DNA
beta	I-DNA
but	O
not	O
of	O
TCR	B-DNA
delta	I-DNA
.	O

Succinate	O
alone	O
had	O
no	O
effect	O
.	O

IL-2	B-protein
-mediated	O
cell	O
cycle	O
progression	O
and	O
inhibition	O
of	O
apoptosis	O
does	O
not	O
require	O
NF-kappa	B-protein
B	I-protein
or	O
activating	O
protein-1	O
activation	O
in	O
primary	O
human	O
T	O
cells	O
.	O

Transcription	B-protein
factors	I-protein
belonging	O
to	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	I-protein
NFAT	I-protein
)	I-protein
family	I-protein
regulate	O
the	O
expression	O
of	O
cytokine	B-DNA
genes	I-DNA
and	O
other	O
inducible	O
genes	O
during	O
the	O
immune	O
response	O
.	O

IL-10	B-protein
inhibited	O
IFN-gamma	B-protein
-induced	O
STAT	B-protein
activation	O
without	O
newly	B-protein
synthesized	I-protein
protein	I-protein
.	O

The	O
role	O
of	O
early	B-DNA
growth	I-DNA
response	I-DNA
gene	I-DNA
1	I-DNA
(	O
egr-1	B-DNA
)	O
in	O
regulation	O
of	O
the	O
immune	O
response	O
.	O

Moreover	O
,	O
in	O
contrast	O
to	O
healthy	O
subjects	O
,	O
there	O
was	O
no	O
correlation	O
between	O
IC50	O
and	O
GC-R	B-protein
parameters	O
in	O
CRF	O
.	O

The	O
p56	B-protein
Src	I-protein
family	I-protein
non-receptor	I-protein
tyrosine	I-protein
kinase	I-protein
has	O
been	O
shown	O
to	O
be	O
critical	O
for	O
T	O
lymphocyte	O
differentiation	O
and	O
activation	O
.	O

Contrary	O
to	O
the	O
idea	O
that	O
protein	B-protein
kinase	I-protein
C	I-protein
is	O
involved	O
in	O
TCR	B-protein
-mediated	O
activation	O
of	O
NF-kappaB	B-protein
,	O
high	O
doses	O
of	O
staurosporine	O
did	O
not	O
interfere	O
with	O
activation	O
of	O
NF-kappaB	B-protein
by	O
PHA	B-protein
,	O
while	O
the	O
same	O
dose	O
of	O
staurosporine	O
completely	O
blocked	O
activation	O
by	O
PMA	O
.	O

In	O
EBV	O
infection	O
most	O
of	O
the	O
changes	O
,	O
including	O
the	O
early	O
induction	O
of	O
cyclin	B-protein
D2	I-protein
,	O
are	O
dependent	O
on	O
expression	O
of	O
EBV	B-DNA
genes	I-DNA
,	O
but	O
an	O
alteration	O
in	O
the	O
E2F-4	B-protein
profile	O
was	O
partly	O
independent	O
of	O
viral	O
gene	O
expression	O
,	O
presumably	O
occurring	O
in	O
response	O
to	O
signal	O
transduction	O
activated	O
when	O
the	O
virus	O
binds	O
to	O
its	O
receptor	O
,	O
CD21	B-protein
.	O

Erythroid	B-protein
Kruppel-like	I-protein
factor	I-protein
(	O
EKLF	B-protein
)	O
is	O
a	O
red	B-protein
cell-specific	I-protein
transcriptional	I-protein
activator	I-protein
that	O
is	O
crucial	O
for	O
consolidating	O
the	O
switch	O
to	O
high	O
levels	O
of	O
adult	O
beta-globin	B-protein
expression	O
during	O
erythroid	O
ontogeny	O
.	O

To	O
gain	O
further	O
insight	O
into	O
the	O
suppression	O
phenomenon	O
we	O
performed	O
luciferase	O
assays	O
which	O
show	O
that	O
silencing	O
affects	O
the	O
activity	O
of	O
the	O
B-cell-specific	B-DNA
promoter	I-DNA
of	O
CIITA	B-protein
.	O

LIF	B-protein
induced	O
a	O
dose-dependent	O
increase	O
in	O
p24	B-protein
antigen	I-protein
production	O
in	O
the	O
chronically	B-cell_line
infected	I-cell_line
promonocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
U1	I-cell_line
.	O

These	O
results	O
reveal	O
that	O
HSF3	B-protein
is	O
negatively	O
regulated	O
in	O
avian	B-cell_type
cells	I-cell_type
and	O
acquires	O
DNA-binding	O
activity	O
in	O
certain	O
cells	O
upon	O
heat	O
shock	O
.	O

Itk	B-protein
,	O
a	O
T	B-protein
cell-specific	I-protein
tyrosine	I-protein
kinase	I-protein
,	O
is	O
required	O
for	O
CD2-mediated	B-DNA
interleukin-2	I-DNA
promoter	I-DNA
activation	O
in	O
the	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
Jurkat	I-cell_line
.	O

Mitogen	O
activation	O
of	O
human	B-cell_type
peripheral	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
induces	O
the	O
formation	O
of	O
new	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
nuclear	I-protein
complexes	I-protein
.	O

Conversely	O
,	O
the	O
murine	B-DNA
kappa	I-DNA
light	I-DNA
chain	I-DNA
enhancer	I-DNA
motif	I-DNA
(	O
GGGGACTTTCCG	O
)	O
does	O
not	O
efficiently	O
bind	O
the	O
nuclear	O
p50p50	B-protein
from	O
tolerant	B-cell_line
murine	I-cell_line
P388	I-cell_line
macrophages	I-cell_line
.	O

Analysis	O
of	O
phosphotyrosine-containing	B-protein
proteins	I-protein
bound	O
to	O
truncated	O
p85	B-protein
constructs	I-protein
revealed	O
cooperative	O
binding	O
of	O
the	O
two	B-protein
SH2	I-protein
domains	I-protein
but	O
no	O
apparent	O
differences	O
between	O
the	O
N-	B-protein
and	I-protein
C-	I-protein
terminal	I-protein
SH2	I-protein
domains	I-protein
.	O

IFN	B-protein
signaling	O
is	O
mediated	O
by	O
binding	O
of	O
IFNs	B-protein
to	O
their	O
receptors	O
and	O
subsequent	O
activation	O
of	O
Janus	O
tyrosine	O
kinase	O
(	O
JAK	B-protein
)	O
-	O
STAT	B-protein
signaling	O
pathway	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
PI	B-protein
3-kinase	I-protein
in	O
TCR	B-protein
-directed	O
T-cell	O
activation	O
using	O
activated	O
or	O
inhibitory	O
versions	O
of	O
PI	B-protein
3-kinase	I-protein
.	O

Mutually	O
exclusive	O
interaction	O
of	O
a	O
novel	O
matrix	B-protein
attachment	I-protein
region	I-protein
binding	I-protein
protein	I-protein
and	O
the	O
NF-muNR	B-protein
enhancer	I-protein
repressor	I-protein
.	O

RESULTS	O
:	O
After	O
nonspecific	O
stimulation	O
,	O
IL-5	B-protein
production	O
by	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
both	O
atopic	O
and	O
nonatopic	O
subjects	O
with	O
asthma	O
was	O
significantly	O
enhanced	O
compared	O
with	O
that	O
by	O
cells	O
from	O
healthy	O
controls	O
.	O

Treatment	O
of	O
chronically	B-cell_line
HIV-infected	I-cell_line
PBMC	I-cell_line
with	O
anti-CD2	B-protein
mAb	I-protein
has	O
been	O
shown	O
to	O
induce	O
the	O
expression	O
of	O
infectious	O
virus	O
from	O
these	O
cultures	O
.	O

In	O
5	O
cases	O
there	O
was	O
a	O
divergent	O
reaction	O
with	O
ER	B-protein
and	O
PR	B-protein
antibody	O
.	O

Glucocorticoid	O
receptors	O
are	O
also	O
able	O
to	O
interact	O
with	O
transcriptional	O
factors	O
such	O
as	O
AP-1	B-protein
(	O
activator	B-protein
protein-1	I-protein
)	O
of	O
NF-kappa	B-protein
B	I-protein
(	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
showed	O
that	O
recombinant	O
C/EBPbeta	B-protein
protein	O
could	O
bind	O
to	O
the	O
potential	O
C/EBP-binding	B-DNA
site	I-DNA
(	O
bp	B-DNA
-90	I-DNA
to	I-DNA
-82	I-DNA
)	O
in	O
the	O
MBP	B-protein
promoter	O
.	O

Since	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
is	O
known	O
to	O
be	O
favored	O
under	O
oxidative	O
stress	O
conditions	O
,	O
ex	O
vivo	O
experiments	O
using	O
uninfected	O
PBMCs	B-cell_type
,	O
primary	B-cell_type
monocytes	I-cell_type
or	O
a	O
latently	O
infected	O
promonocytic	B-cell_line
U1	I-cell_line
cell	I-cell_line
line	I-cell_line
show	O
that	O
HIV-1	O
replication	O
and	O
reactivation	O
,	O
monitored	O
by	O
p24	B-protein
antigen	I-protein
measurement	O
,	O
are	O
inhibited	O
by	O
PAO	O
in	O
a	O
time-	O
and	O
concentration-dependent	O
manner	O
.	O

GM3	O
also	O
caused	O
selective	O
inhibition	O
of	O
the	O
human	B-protein
T-cell	I-protein
lymphotrophic	I-protein
virus-1	I-protein
Tax	I-protein
transactivator-induced	O
luciferase	B-protein
activity	O
from	O
a	O
reporter	O
construct	O
driven	O
by	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Our	O
results	O
suggest	O
that	O
overexpression	O
of	O
v-erbA	B-protein
is	O
required	O
for	O
its	O
function	O
as	O
an	O
oncoprotein	B-protein
.	O

Inhibition	O
of	O
PI3K	B-protein
inhibits	O
phosphorylation	O
of	O
Rb	B-protein
,	O
induction	O
of	O
cyclin	B-protein
D3	I-protein
,	O
and	O
degradation	O
of	O
p27kip1	B-protein
.	O

IL-2	B-DNA
promoter	I-DNA
activation	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
stimulated	O
with	O
superantigen	O
presented	O
by	O
Raji	B-cell_line
B	I-cell_line
cells	I-cell_line
requires	O
CD28	B-protein
activation	O
.	O

In	O
the	O
presence	O
of	O
ADP-activated	B-cell_type
platelets	I-cell_type
,	O
both	O
MCP-1	B-protein
secretion	O
and	O
ICAM-1	B-protein
surface	O
expression	O
were	O
significantly	O
increased	O
compared	O
with	O
nonstimulated	B-cell_type
platelets	I-cell_type
(	O
P	O
<	O
0.02	O
)	O
.	O

We	O
have	O
analyzed	O
the	O
regulation	O
of	O
CD14	B-protein
expression	O
during	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VitD3	O
)	O
-induced	O
monocytic	O
differentiation	O
.	O

The	O
primary	O
tumors	O
in	O
Group	O
C	O
had	O
a	O
normal	O
profile	O
of	O
p16	B-protein
,	O
p15	B-protein
and	O
CDK4	B-protein
at	O
presentation	O
.	O

CD23-induced	B-protein
NF-kappaB	I-protein
is	O
a	O
heterodimer	O
composed	O
of	O
p65/p50	B-protein
subunits	I-protein
.	O

However	O
,	O
DCs	B-cell_type
lack	O
Sp1	B-protein
,	O
which	O
may	O
explain	O
the	O
failure	O
of	O
HIV-1	O
to	O
replicate	O
in	O
purified	O
DCs	B-cell_type
.	O

RESULTS	O
:	O
In	O
all	O
cells	O
tested	O
,	O
ER	B-RNA
mRNA	I-RNA
was	O
expressed	O
without	O
prior	O
in	O
vitro	O
stimulation	O
.	O

IL-2	B-protein
secretion	O
was	O
paralleled	O
by	O
increased	O
expression	O
of	O
IL-2	B-RNA
mRNA	I-RNA
,	O
resulting	O
from	O
enhanced	O
IL-2	B-RNA
mRNA	I-RNA
stability	O
.	O

Although	O
no	O
proof	O
yet	O
exists	O
of	O
a	O
role	O
for	O
these	O
lesions	O
in	O
DLCL	O
pathogenesis	O
,	O
the	O
feature	O
of	O
the	O
BCL-6	B-protein
gene	I-protein
product	I-protein
,	O
its	O
specific	O
pattern	O
of	O
expression	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
and	O
the	O
clustering	O
of	O
lesions	O
disrupting	O
its	O
regulatory	O
domain	O
strongly	O
suggest	O
that	O
deregulation	O
of	O
BCL-6	B-protein
expression	O
may	O
contribute	O
to	O
DLCL	O
development	O
.	O

Since	O
repression	O
by	O
these	O
fusions	O
was	O
not	O
observed	O
in	O
all	O
cell	O
types	O
,	O
it	O
seems	O
likely	O
that	O
EBNA3C	B-protein
either	O
depends	O
on	O
a	O
corepressor	B-protein
which	O
may	O
interact	O
with	O
amino	B-protein
acids	I-protein
346	I-protein
to	I-protein
543	I-protein
or	O
is	O
modified	O
in	O
a	O
cell-specific	O
manner	O
in	O
order	O
to	O
repress	O
.	O

This	O
signal	O
transduction	O
is	O
dependent	O
on	O
the	O
cytoplasmic	B-protein
domain	I-protein
,	O
which	O
consists	O
of	O
213	O
amino	O
acids	O
.	O

Complementary	B-DNA
DNA	I-DNA
encoding	O
the	O
human	B-protein
T-cell	I-protein
FK506-binding	I-protein
protein	I-protein
,	O
a	O
peptidylprolyl	B-protein
cis-trans	I-protein
isomerase	I-protein
distinct	O
from	O
cyclophilin	B-protein
.	O

A	O
52-year-old	O
male	O
presented	O
himself	O
with	O
tachycardia	O
crises	O
which	O
appeared	O
first	O
during	O
childhood	O
,	O
increased	O
in	O
frequency	O
without	O
goiter	O
or	O
exophthalmos	O
.	O

Alternative	O
splicing	O
of	O
the	O
GC	B-RNA
receptor	I-RNA
(	I-RNA
GCR	I-RNA
)	I-RNA
pre-mRNA	I-RNA
generates	O
a	O
second	O
GCR	B-protein
,	O
termed	O
GCRbeta	B-protein
,	O
which	O
does	O
not	O
bind	O
GC	O
but	O
antagonizes	O
the	O
transactivating	O
activity	O
of	O
the	O
classic	O
GCR	B-protein
.	O

Expression	O
of	O
the	O
alpha-chain	B-protein
of	O
IL-2Ralpha	B-protein
on	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
(	O
PBM	B-cell_type
)	O
was	O
induced	O
by	O
M.	O
tuberculosis	O
by	O
flow	O
cytometry	O
evaluation	O
.	O

Reactive	O
oxygen	O
intermediates	O
as	O
apparently	O
widely	O
used	O
messengers	O
in	O
the	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
and	O
HIV-1	O
.	O

Though	O
specifically	O
bound	O
dexamethasone	O
measured	O
by	O
whole-cell	O
assay	O
and	O
that	O
using	O
cell	O
harvester	O
correlated	O
well	O
,	O
almost	O
by	O
one	O
order	O
lower	O
values	O
obtained	O
with	O
the	O
latter	O
method	O
render	O
it	O
non-applicable	O
for	O
receptor	O
quantitation	O
.	O

Extinction	O
of	O
immunoglobulin	B-DNA
gene	I-DNA
expression	O
in	O
B	B-cell_type
cells	I-cell_type
upon	O
fusion	O
with	O
HeLa	B-cell_line
cells	I-cell_line
is	O
preceded	O
by	O
rapid	O
nuclear	O
depletion	O
of	O
essential	B-protein
transcription	I-protein
factors	I-protein
and	O
is	O
accompanied	O
by	O
widespread	O
inactivation	O
of	O
genes	O
expressed	O
in	O
a	O
B	O
cell-specific	O
manner	O
.	O

We	O
have	O
recently	O
performed	O
a	O
detailed	O
molecular	O
analysis	O
of	O
20q	B-DNA
deletions	I-DNA
in	O
peripheral	B-cell_type
blood	I-cell_type
(	I-cell_type
PB	I-cell_type
)	I-cell_type
granulocytes	I-cell_type
and	O
defined	O
a	O
commonly	B-DNA
deleted	I-DNA
region	I-DNA
of	O
16	O
to	O
21	O
centimorgan	O
(	O
cM	O
)	O
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
preferentially	O
activates	O
the	O
94-kD	B-protein
STAT5A	I-protein
and	O
an	O
80-kD	B-protein
STAT5A	I-protein
isoform	I-protein
in	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

With	O
hot	O
acetic	O
+	O
p-toluenesulfonic	O
acid	O
5	O
underwent	O
rearrangement	O
to	O
21-acetoxy-11	O
beta	O
,	O
19-epoxypregn-5-ene-4	O
,	O
20-dione	O
(	O
8	O
)	O
Pd-C	O
hydrogenation	O
of	O
3	O
,	O
21-diacetoxy-5	O
beta	O
,	O
19-cyclopregna-2	O
,	O
9	O
(	O
11	O
)	O
-diene-4	O
,	O
20-dione	O
(	O
10	O
)	O
gave	O
3	O
,	O
21-diacetoxy-5	O
beta	O
,	O
19-cyclopregn-5-ene-4	O
,	O
20-dione	O
(	O
11	O
)	O
and	O
the	O
9	O
,	O
11-dihydro	O
derivative	O
of	O
the	O
latter	O
.	O

Isolation	O
of	O
a	O
rel-related	B-DNA
human	I-DNA
cDNA	I-DNA
that	O
potentially	O
encodes	O
the	O
65-kD	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
[	O
published	O
erratum	O
appears	O
in	O
Science	O
1991	O
Oct	O
4	O
;	O
254	O
(	O
5028	O
)	O
:	O
11	O
]	O

Endotoxin	B-protein
selectively	O
induces	O
monocyte	B-protein
Mn	I-protein
superoxide	I-protein
dismutase	I-protein
(	O
SOD	B-protein
)	O
without	O
affecting	O
levels	O
of	O
Cu	O
,	O
Zn	B-protein
SOD	I-protein
,	O
catalase	B-protein
,	O
or	O
glutathione	B-protein
peroxidase	I-protein
.	O

Diminished	O
NF-kappaB	B-protein
activity	O
has	O
been	O
shown	O
to	O
occur	O
in	O
T	B-cell_type
cells	I-cell_type
with	O
aging	O
,	O
suggesting	O
that	O
impaired	O
activation	O
of	O
NF-kappaB	B-protein
might	O
occur	O
during	O
cellular	O
senescence	O
.	O

We	O
compared	O
U-937	B-cell_line
cell	I-cell_line
adhesion	O
and	O
adhesion	B-protein
molecule	I-protein
expression	O
in	O
human	B-cell_type
umbilical	I-cell_type
venous	I-cell_type
(	O
HUVECs	B-cell_type
)	O
and	O
arterial	B-cell_type
(	I-cell_type
HUAECs	I-cell_type
)	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
exposed	O
to	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
,	O
interleukin-1	B-protein
,	O
and	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

The	O
fluoroquinolone	O
antibiotic	O
,	O
ciprofloxacin	O
(	O
cipro	O
)	O
,	O
induces	O
hyperproduction	O
of	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
and	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
in	O
stimulated	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
ATRA-dependent	O
growth	O
inhibition	O
and	O
cellular	O
differentiation	O
are	O
not	O
presently	O
understood	O
.	O

Ara-C	O
activated	O
JNKs	B-protein
only	O
after	O
prolonged	O
incubation	O
(	O
90-120	O
minutes	O
)	O
.	O

To	O
further	O
define	O
the	O
role	O
of	O
these	O
genes	O
in	O
acute	O
leukemias	O
,	O
10	O
cases	O
(	O
9	O
AML	O
and	O
1	O
ALL	O
)	O
with	O
cytogenetically	O
proven	O
t	B-DNA
(	I-DNA
10	I-DNA
;	I-DNA
11	I-DNA
)	I-DNA
(	I-DNA
p12-14	I-DNA
;	I-DNA
q13-21	I-DNA
)	I-DNA
and	O
well-characterized	O
morphology	O
,	O
immunophenotype	O
,	O
and	O
clinical	O
course	O
were	O
analyzed	O
.	O

METHOD	O
:	O
Two	O
color	O
flow	O
cytometry	O
analysis	O
was	O
used	O
on	O
peripheral	O
blood	O
samples	O
of	O
young	O
and	O
postmenopausal	O
females	O
and	O
postmenopausal	O
females	O
treated	O
with	O
estrogen	O
replacement	O
therapy	O
.	O

However	O
,	O
like	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
TCF-1	B-protein
activity	O
is	O
induced	O
by	O
phorbol	O
esters	O
and	O
other	O
T-cell	O
activators	O
.	O

The	O
Legionella	O
pneumophila	O
rpoS	B-DNA
gene	I-DNA
is	O
required	O
for	O
growth	O
within	O
Acanthamoeba	O
castellanii	O
.	O

To	O
investigate	O
the	O
mechanisms	O
accounting	O
for	O
the	O
impaired	O
responses	O
to	O
gamma	B-protein
interferon	I-protein
,	O
a	O
model	O
system	O
for	O
examining	O
overall	O
changes	O
in	O
protein	O
tyrosine	O
phosphorylation	O
,	O
activation	O
of	O
Jak1	B-protein
and	O
Jak2	B-protein
and	O
phosphorylation	O
of	O
Stat1	B-protein
was	O
developed	O
in	O
phorbol	B-cell_line
12-myristate	I-cell_line
13-acetate-differentiated	I-cell_line
U-937	I-cell_line
cells	I-cell_line
.	O

Impaired	O
induction	O
of	O
c-fos/c-jun	B-DNA
genes	I-DNA
and	O
of	O
transcriptional	B-protein
regulatory	I-protein
proteins	I-protein
binding	O
distinct	O
c-fos/c-jun	B-DNA
promoter	I-DNA
elements	I-DNA
in	O
activated	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
during	O
aging	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
an	O
EF1	B-protein
-like	O
activity	O
in	O
non-erythroid	B-cell_type
cells	I-cell_type
and	O
indicates	O
that	O
this	O
factor	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
genes	B-DNA
expressed	O
in	O
such	O
cells	O
.	O

In	O
addition	O
,	O
it	O
has	O
been	O
established	O
that	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
can	O
activate	O
the	O
expression	O
of	O
wild	B-protein
type	I-protein
p53	I-protein
in	O
concert	O
with	O
the	O
nuclear	B-protein
transcription	I-protein
factor	I-protein
,	O
NF-kappa	B-protein
B	I-protein
.	O

These	O
results	O
suggest	O
that	O
a	O
decline	O
in	O
proteasome	B-protein
activity	O
results	O
in	O
a	O
failure	O
to	O
fully	O
degrade	O
IkappaBalpha	B-protein
in	O
the	O
elderly	O
.	O

Induction	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
by	O
Cryptococcus	O
neoformans	O
and	O
Candida	O
albicans	O
.	O

FK506	O
and	O
ciclosporin	O
:	O
molecular	O
probes	O
for	O
studying	O
intracellular	O
signal	O
transduction	O
.	O

Binding	O
of	O
[	O
3H	O
]	O
VD3	O
was	O
saturable	O
,	O
with	O
approximately	O
2000-3000	O
sites/cell	O
,	O
and	O
half-maximal	O
binding	O
occurring	O
at	O
0.21-0.33	O
nM	O
.	O

Interestingly	O
,	O
it	O
was	O
shown	O
that	O
NF-kappa	B-protein
B	I-protein
-mediated	O
gene	O
transcription	O
,	O
both	O
in	O
the	O
context	O
of	O
the	O
IL-6	B-DNA
promoter	I-DNA
as	O
well	O
as	O
on	O
its	O
own	O
,	O
was	O
dependent	O
on	O
both	O
serine	O
kinase	O
activity	O
and	O
interaction	O
with	O
c-Jun	B-protein
protein	I-protein
.	O

The	O
p65	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
regulates	O
I	B-protein
kappa	I-protein
B	I-protein
by	O
two	O
distinct	O
mechanisms	O
.	O

We	O
show	O
that	O
the	O
inducible	O
nuclear	O
form	O
of	O
NF-AT	B-protein
contains	O
Fos	B-protein
and	O
Jun	B-protein
proteins	O
.	O

Agents	O
which	O
elevated	O
cAMP	O
were	O
also	O
shown	O
to	O
activate	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
suggesting	O
a	O
role	O
for	O
this	O
transcription	O
factor	O
in	O
activation	O
of	O
monocyte-endothelial	O
interactions	O
.	O

Double	O
staining	O
for	O
Bcl-6/CD20	B-protein
,	O
Bcl-6/CD3	B-protein
,	O
and	O
Bcl-6/CD57	B-protein
was	O
performed	O
in	O
selected	O
cases	O
.	O

The	O
-1053/+34	B-DNA
construct	I-DNA
allowed	O
promoter	O
activity	O
only	O
in	O
cells	O
of	O
hematopoietic	B-cell_type
origin	I-cell_type
,	O
and	O
tissue	O
specificity	O
was	O
conserved	O
in	O
all	O
other	O
constructs	O
tested	O
.	O

This	O
failure	O
to	O
degrade	O
IkappaBalpha	B-protein
may	O
underlie	O
both	O
the	O
observed	O
decrease	O
in	O
NFkappaB	B-protein
induction	O
and	O
the	O
IL-2	B-protein
receptor	O
expression	O
in	O
TNF-treated	B-cell_line
T	I-cell_line
cells	I-cell_line
during	O
aging	O
.	O

Our	O
results	O
showed	O
that	O
HCMV	O
binding	O
to	O
monocytes	B-cell_type
resulted	O
in	O
the	O
production	O
and	O
release	O
of	O
IL-1beta	B-protein
protein	I-protein
.	O

The	O
difference	O
in	O
the	O
prevalence	O
of	O
ER	B-protein
overexpression	O
between	O
high	O
and	O
low	O
risk	O
groups	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0.095	O
)	O
.	O

Trapoxin	O
is	O
a	O
microbially	O
derived	O
cyclotetrapeptide	O
that	O
inhibits	O
histone	B-protein
deacetylation	O
in	O
vivo	O
and	O
causes	O
mammalian	O
cells	O
to	O
arrest	O
in	O
the	O
cell	O
cycle	O
.	O

Expression	O
of	O
NFAT-family	B-protein
proteins	I-protein
in	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Increasing	O
RA	O
concentrations	O
reduced	O
the	O
D3	O
concentration	O
required	O
for	O
monocyte	O
differentiation	O
.	O

Three	O
cases	O
were	O
predicted	O
to	O
be	O
TSC2	B-DNA
mutations	I-DNA
on	O
the	O
basis	O
of	O
linkage	O
analysis	O
or	O
because	O
a	O
hamartoma	O
from	O
the	O
patient	O
showed	O
loss	O
of	O
heterozygosity	O
for	O
16p13.3	B-DNA
markers	I-DNA
.	O

Sequence-specific	O
DNA	O
binding	O
of	O
the	O
proto-oncoprotein	B-protein
ets-1	B-protein
defines	O
a	O
transcriptional	B-DNA
activator	I-DNA
sequence	I-DNA
within	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
of	O
the	O
Moloney	O
murine	O
sarcoma	O
virus	O
.	O

The	O
functions	O
of	O
these	O
proteins	O
can	O
be	O
antagonized	O
by	O
several	O
methods	O
,	O
each	O
with	O
specific	O
limitations	O
.	O

Stimulation	O
of	O
interferon	B-DNA
beta	I-DNA
gene	I-DNA
transcription	O
in	O
vitro	O
by	O
purified	O
NF-kappa	B-protein
B	I-protein
and	O
a	O
novel	O
TH	B-protein
protein	I-protein
.	O

Differentiation	O
assays	O
using	O
water	O
soluble	O
phorbol	O
esters	O
reveal	O
that	O
differentiation	O
becomes	O
irreversible	O
soon	O
after	O
AP-1	B-protein
appears	O
.	O

We	O
conclude	O
from	O
this	O
that	O
the	O
epsilon-globin	B-DNA
gene	I-DNA
is	O
not	O
regulated	O
by	O
competition	O
with	O
other	O
genes	O
in	O
the	O
human	B-DNA
beta-globin	I-DNA
locus	I-DNA
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
nuclear	O
localization	O
signal	O
and	O
transactivation	B-protein
domain	I-protein
of	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
constitute	O
a	O
bipartite	O
system	O
that	O
is	O
critically	O
involved	O
in	O
the	O
inhibitory	O
function	O
of	O
I	B-protein
kappa	I-protein
B/MAD-3	I-protein
.	O

Here	O
,	O
we	O
report	O
a	O
model	O
of	O
CD28	B-protein
costimulation	O
using	O
PMA	O
plus	O
the	O
natural	B-protein
ligand	I-protein
CD80	I-protein
that	O
resulted	O
in	O
very	O
limited	O
stimulation	O
of	O
IL-2	B-protein
,	O
as	O
evidenced	O
by	O
both	O
cytokine	B-protein
production	O
and	O
IL-2	B-DNA
promoter	I-DNA
stimulation	O
.	O

We	O
investigated	O
the	O
function	O
of	O
conditionally	O
expressed	O
EBNA2	B-protein
in	O
the	O
context	O
of	O
the	O
IFN	B-protein
response	O
in	O
Burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Although	O
endothelial	B-RNA
leukocyte	I-RNA
adhesion	I-RNA
molecule	I-RNA
(	I-RNA
ELAM	I-RNA
)	I-RNA
mRNA	I-RNA
synthesis	O
can	O
be	O
regulated	O
by	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
ELAM	B-protein
was	O
not	O
expressed	O
and	O
ELAM	B-RNA
mRNA	I-RNA
was	O
only	O
slightly	O
elevated	O
in	O
response	O
to	O
MM-LDL	B-protein
.	O

The	O
mutant	O
,	O
containing	O
a	O
serine-to-alanine	O
substitution	O
in	O
the	O
DNA-binding	B-protein
domain	I-protein
of	O
the	O
protein	O
,	O
bound	O
to	O
several	O
known	O
ZEBRA-binding	B-DNA
sites	I-DNA
and	O
activated	O
transcription	O
from	O
reporters	O
bearing	O
known	O
ZEBRA-responsive	B-DNA
promoters	I-DNA
but	O
did	O
not	O
disrupt	O
latency	O
in	O
EBV-infected	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Role	O
of	O
AP-1	B-protein
,	O
NF-kappa	B-protein
B/Rel	I-protein
,	O
and	O
Sp1	B-protein
proteins	O
in	O
uninduced	O
and	O
lipopolysaccharide-induced	O
expression	O
.	O

Pretreatment	O
of	O
ACH-2	B-cell_line
T	I-cell_line
cells	I-cell_line
by	O
NAC	O
followed	O
by	O
stimulation	O
with	O
PMA	O
,	O
TNF-alpha	B-protein
,	O
or	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
resulted	O
in	O
strong	O
suppression	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Two	O
variants	O
of	O
the	O
IL-4R	B-DNA
alpha-chain	I-DNA
(	I-DNA
IL-4Ralpha	I-DNA
)	I-DNA
gene	I-DNA
have	O
been	O
recently	O
identified	O
in	O
association	O
with	O
different	O
atopic	O
disorders	O
.	O

Here	O
we	O
show	O
that	O
CaMKIV/Gr	B-protein
induces	O
the	O
transcription	B-protein
factor	I-protein
activation	I-protein
protein	I-protein
1	I-protein
(	O
AP-1	B-protein
)	O
alone	O
or	O
in	O
synergy	O
with	O
T	B-protein
cell	I-protein
mitogens	I-protein
and	O
with	O
the	O
p21ras	B-protein
oncoprotein	I-protein
.	O

Tax-expressing	B-cell_line
cell	I-cell_line
lines	I-cell_line
produce	O
LT	B-protein
biologic	O
activity	O
.	O

These	O
findings	O
suggest	O
that	O
PML	B-protein
is	O
required	O
for	O
early	O
hematopoiesis	O
and	O
erythroid	O
,	O
but	O
not	O
granulocytic	O
maturation	O
.	O

The	O
mapping	O
of	O
the	O
cis-acting	B-DNA
genetic	I-DNA
cis-acting	I-DNA
segment	I-DNA
(	O
oriP	B-DNA
)	O
required	O
for	O
viral	O
episomal	O
maintenance	O
is	O
reported	O
here	O
.	O

Thus	O
antioxidants	O
vary	O
widely	O
in	O
potency	O
as	O
inhibitors	O
of	O
the	O
activation	O
of	O
transcription	B-protein
factors	I-protein
and	O
of	O
the	O
transcription	O
of	O
genes	B-DNA
for	O
pro-inflammatory	B-protein
cytokines	I-protein
.	O

We	O
observed	O
that	O
in	O
a	O
monocytic	B-cell_line
(	I-cell_line
U937	I-cell_line
)	I-cell_line
and	O
a	O
bronchial	B-cell_line
epithelial	I-cell_line
(	I-cell_line
H292	I-cell_line
)	I-cell_line
cell-line	I-cell_line
dexamethasone	O
strongly	O
suppressed	O
basal	O
and	O
induced	O
ICAM-1	B-protein
expression	O
.	O

Thirteen	O
preterms	O
of	O
the	O
latter	O
group	O
received	O
prenatal	O
steroid	O
treatment	O
.	O

After	O
stimulation	O
of	O
progesterone	O
the	O
expression	O
of	O
receptors	O
was	O
augmented	O
2-3	O
times	O
.	O

DNA	O
from	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
of	O
six	O
patients	O
from	O
five	O
families	O
with	O
various	O
degrees	O
of	O
androgen	O
insensitivity	O
was	O
studied	O
.	O

Activation	O
of	O
a	O
novel	B-DNA
gene	I-DNA
in	O
3q21	B-DNA
and	O
identification	O
of	O
intergenic	O
fusion	O
transcripts	O
with	O
ecotropic	B-DNA
viral	I-DNA
insertion	I-DNA
site	I-DNA
I	I-DNA
in	O
leukemia	O
.	O

2.	O
Our	O
study	O
involved	O
a	O
group	O
of	O
60	O
male	O
and	O
female	O
subjects	O
who	O
were	O
exposed	O
to	O
MTBE	O
and	O
benzene-contaminated	O
water	O
concentrations	O
up	O
to	O
76	O
PPB	O
for	O
MTBE	O
and	O
14	O
PPB	O
for	O
benzene	O
,	O
for	O
a	O
period	O
of	O
5	O
to	O
8	O
years	O
.	O

No	O
correlations	O
were	O
observed	O
for	O
these	O
variables	O
with	O
blood	O
pressure	O
or	O
serum	B-protein
lipoproteins	I-protein
.	O

Thus	O
,	O
Smad6	B-protein
and	O
Smad7	B-protein
exhibit	O
differential	O
inhibitory	O
effects	O
in	O
bone	O
morphogenetic	O
protein-2-	O
and	O
activin	O
A-mediated	O
signaling	O
in	O
B	B-cell_type
lineage	I-cell_type
cells	I-cell_type
.	O

We	O
tested	O
the	O
effects	O
of	O
BHA	O
,	O
a	O
phenolic	O
,	O
lipid-soluble	O
,	O
chain-breaking	O
antioxidant	O
,	O
and	O
NAC	O
,	O
a	O
known	O
glutathione	O
precursor	O
with	O
some	O
direct	O
free-radical	O
scavenging	O
properties	O
as	O
well	O
,	O
on	O
the	O
regulation	O
of	O
HIV-1	O
expression	O
in	O
latently	O
infected	O
U1	B-cell_line
cells	I-cell_line
and	O
in	O
productively	O
and	O
chronically	O
infected	O
U937	B-cell_line
cells	I-cell_line
.	O

In	O
sum	O
,	O
DM	O
regulates	O
T	B-cell_type
cell	I-cell_type
membrane	O
expression	O
of	O
IL-2R	B-protein
by	O
more	O
than	O
one	O
molecular	O
mechanism	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
one	O
function	O
of	O
c-Rel	B-protein
is	O
as	O
a	O
physiologic	O
repressor	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
and	O
IL-2R	B-protein
alpha	I-protein
promoters	O
,	O
serving	O
to	O
efficiently	O
counter	O
the	O
strong	O
transcriptional	O
activating	O
effects	O
of	O
p65	B-protein
.	O

These	O
data	O
suggest	O
that	O
CD19	B-protein
-mediated	O
signal	O
transduction	O
activates	O
different	O
transcription	B-protein
factors	I-protein
at	O
juxtaposed	O
stages	O
of	O
B	O
cell	O
development	O
that	O
may	O
culminate	O
in	O
the	O
activation	O
or	O
suppression	O
of	O
distinct	O
sets	O
of	O
genes	B-DNA
.	O

These	O
results	O
indicate	O
that	O
dexamethasone	O
is	O
able	O
to	O
abrogate	O
the	O
transcriptional	O
activity	O
of	O
the	O
human	B-DNA
granzyme	I-DNA
B	I-DNA
gene	I-DNA
promoter	I-DNA
by	O
inhibiting	O
the	O
binding	O
of	O
nuclear	B-protein
factors	I-protein
at	O
the	O
AP-1	B-DNA
and	I-DNA
Ikaros	I-DNA
sites	I-DNA
.	O

TCRzeta	B-protein
and	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
were	O
detected	O
in	O
the	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
in	O
27	O
of	O
29	O
patients	O
,	O
and	O
overall	O
,	O
reduced	O
levels	O
were	O
noted	O
visually	O
in	O
12	O
of	O
29	O
(	O
41	O
%	O
)	O
and	O
13	O
of	O
29	O
(	O
45	O
%	O
)	O
individuals	O
,	O
respectively	O
.	O

Senescent	B-cell_line
human	I-cell_line
T	I-cell_line
lymphocyte	I-cell_line
cultures	I-cell_line
are	O
unable	O
to	O
undergo	O
proliferation	O
,	O
but	O
show	O
no	O
difference	O
from	O
early	B-cell_line
passage	I-cell_line
cells	I-cell_line
in	O
cytotoxic	O
function	O
or	O
surface	O
antigenic	O
profile	O
.	O

Analyses	O
with	O
cultured	B-cell_line
cells	I-cell_line
and	O
cell-free	O
systems	O
have	O
provided	O
strong	O
evidence	O
that	O
GATA-1	B-protein
is	O
involved	O
in	O
control	O
of	O
globin	B-DNA
gene	I-DNA
expression	O
during	O
erythroid	O
differentiation	O
.	O

Low	O
levels	O
of	O
nuclear	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
were	O
detected	O
in	O
resting	O
cells	O
whereas	O
a	O
superinduction	O
was	O
obtained	O
after	O
PMA	O
activation	O
.	O

In	O
addition	O
,	O
after	O
novelty	O
stress	O
the	O
HRBC	B-cell_type
group	O
,	O
but	O
not	O
the	O
LPS	B-cell_line
group	I-cell_line
,	O
showed	O
increased	O
ACTH	O
and	O
corticosterone	O
levels	O
.	O

BSAP	B-protein
failed	O
to	O
trans-activate	O
CD19	B-DNA
promoter	I-DNA
constructs	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
or	O
non-B	B-cell_type
cells	I-cell_type
,	O
suggesting	O
that	O
cis	O
elements	O
such	O
as	O
the	O
PyG	B-DNA
and	I-DNA
GC	I-DNA
boxes	I-DNA
are	O
also	O
necessary	O
for	O
high	O
level	O
CD19	B-DNA
promoter	I-DNA
expression	O
.	O

This	O
indicates	O
that	O
the	O
beneficial	O
effects	O
of	O
ketoconazole	O
in	O
Cushing	O
's	O
disease	O
are	O
due	O
to	O
adrenal	O
cortisol	O
suppression	O
and	O
not	O
to	O
interaction	O
with	O
GcR	B-protein
of	O
target	B-cell_type
cells	I-cell_type
,	O
and	O
that	O
the	O
process	O
of	O
GcR	B-protein
regulation	O
in	O
hMNL	B-cell_type
is	O
a	O
complex	O
phenomenon	O
awaiting	O
further	O
elucidation	O
.	O

The	O
IFN	B-protein
-dependent	O
increase	O
in	O
RAR	B-protein
(	I-protein
alpha	I-protein
)	I-protein
levels	O
and	O
the	O
enhancing	O
effect	O
of	O
the	O
cytokine	B-protein
on	O
retinoid-dependent	B-protein
granulocytic	I-protein
markers	I-protein
expression	O
may	O
be	O
a	O
characteristic	O
of	O
PML-RAR	B-cell_line
positive	I-cell_line
cells	I-cell_line
,	O
since	O
the	O
phenomena	O
are	O
not	O
observed	O
in	O
HL-60	B-cell_line
promyelocytes	I-cell_line
.	O

In	O
addition	O
,	O
the	O
galectin-3	B-protein
level	O
was	O
markedly	O
increased	O
in	O
human	B-cell_type
thymocytes	I-cell_type
after	O
infection	O
with	O
HTLV-I	O
as	O
compared	O
with	O
uninfected	B-cell_type
thymocytes	I-cell_type
.	O

The	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
3	O
is	O
an	O
inducible	O
DNA-binding	B-protein
protein	I-protein
that	O
is	O
essential	O
for	O
transcriptional	O
induction	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
during	O
T	O
cell	O
activation	O
.	O

The	O
former	O
pathway	O
is	O
recruited	O
by	O
all	O
ERK	B-protein
-activating	O
stimuli	O
,	O
whereas	O
the	O
latter	O
pathway	O
uses	O
an	O
undefined	O
serine	B-protein
kinase	I-protein
and	O
is	O
recruited	O
selectively	O
by	O
cytokines	B-protein
.	O

Reverse	O
transcription-PCR	O
analysis	O
showed	O
that	O
all	O
seven	O
EBV-positive	O
tumour	O
tissues	O
constitutively	O
expressed	O
EBV	B-RNA
nuclear	I-RNA
antigen	I-RNA
(	I-RNA
EBNA	I-RNA
)	I-RNA
1	I-RNA
mRNA	I-RNA
,	O
but	O
not	O
EBNA2	B-RNA
mRNA	I-RNA
.	O

GrpL	B-protein
,	O
a	O
Grb2	B-protein
-related	O
adaptor	B-protein
protein	I-protein
,	O
interacts	O
with	O
SLP-76	B-protein
to	O
regulate	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cell	I-protein
activation	O
.	O

Molecular	O
cloning	O
of	O
SLAP-130	B-protein
,	O
an	O
SLP-76-associated	B-protein
substrate	I-protein
of	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor-stimulated	I-protein
protein	I-protein
tyrosine	I-protein
kinases	I-protein
.	O

The	O
concentration	O
of	O
corticosteroid	O
producing	O
50	O
%	O
inhibition	O
(	O
IC50	O
)	O
was	O
600	O
nM	O
,	O
70	O
nM	O
,	O
and	O
0.5	O
nM	O
for	O
hydrocortisone	O
,	O
methylprednisolone	O
,	O
and	O
dexamethasone	O
,	O
respectively	O
,	O
in	O
monocytes	B-cell_type
from	O
CS	O
individuals	O
.	O

RESULTS	O
:	O
In	O
peripheral	O
blood	O
of	O
healthy	O
pregnant	O
women	O
the	O
percentage	O
of	O
gamma/delta	B-cell_type
TCR+	I-cell_type
cells	I-cell_type
was	O
significantly	O
higher	O
(	O
P	O
<	O
0.001	O
)	O
than	O
in	O
that	O
of	O
recurrent	O
aborters	O
or	O
of	O
non-pregnant	O
individuals	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
negative	B-protein
factor	I-protein
(	O
Nef	B-protein
)	O
has	O
been	O
shown	O
to	O
down-regulate	O
the	O
transcription	B-protein
factors	I-protein
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
in	O
vitro	O
.	O

One	O
enigmatic	O
aspect	O
of	O
GATA	B-protein
factor	I-protein
expression	O
is	O
that	O
several	O
GATA	B-protein
proteins	I-protein
,	O
which	O
ostensibly	O
share	O
the	O
same	O
DNA-binding	B-protein
site	I-protein
specificity	O
,	O
are	O
coexpressed	O
in	O
erythroid	O
cells	O
.	O

Except	O
for	O
a	O
4-hour	O
advancement	O
of	O
the	O
peak	O
,	O
a	O
similar	O
circadian	O
rhythm	O
of	O
hepatic	B-protein
GR	I-protein
was	O
detected	O
in	O
rats	O
reared	O
under	O
a	O
reversed	O
lighting	O
regimen	O
(	O
12D	O
:	O
12L	O
;	O
lights	O
on	O
between	O
18	O
:	O
30	O
and	O
06	O
:	O
30	O
h	O
)	O
.	O

We	O
conclude	O
that	O
the	O
effects	O
of	O
IFN-gamma	B-protein
on	O
the	O
expression	O
of	O
the	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
may	O
be	O
important	O
for	O
the	O
modulatory	O
effects	O
of	O
IFN-gamma	B-protein
on	O
the	O
cytokine	B-protein
expression	O
in	O
activated	O
human	B-cell_type
monocytes	I-cell_type
.	O

This	O
factor	O
is	O
composed	O
of	O
a	O
DNA-binding	B-protein
protein	I-protein
(	O
ISGF3	B-protein
gamma	I-protein
)	O
,	O
which	O
normally	O
is	O
present	O
in	O
the	O
cytoplasm	O
,	O
and	O
other	O
IFN-alpha-activated	B-protein
proteins	I-protein
which	O
preexist	O
as	O
latent	B-protein
cytoplasmic	I-protein
precursors	I-protein
(	O
ISGF3	B-protein
alpha	I-protein
)	O
.	O

From	O
these	O
data	O
,	O
we	O
conclude	O
that	O
the	O
induction	O
of	O
PO-B	B-protein
DNA	O
binding	O
is	O
a	O
general	O
marker	O
of	O
HL-60	O
myelomonocytic	O
differentiation	O
,	O
but	O
that	O
qualitative	O
aspects	O
of	O
the	O
induction	O
of	O
additional	O
distinct	O
transcription	B-protein
factors	I-protein
,	O
such	O
as	O
AP-1	B-protein
,	O
may	O
contribute	O
to	O
lineage-specific	O
determinants	O
of	O
cell	O
fate	O
.	O

Northern	O
blot	O
analysis	O
of	O
SR-BP	B-protein
gene	O
expression	O
revealed	O
a	O
single	O
transcript	O
of	O
2	B-RNA
kilobases	I-RNA
which	O
was	O
widely	O
expressed	O
among	O
organs	O
,	O
with	O
the	O
highest	O
abundance	O
in	O
liver	O
and	O
the	O
lowest	O
abundance	O
in	O
brain	O
.	O

Expression	O
of	O
the	O
HIV-1	B-protein
transactivator	I-protein
Tat	B-protein
recapitulated	O
this	O
phenotype	O
and	O
was	O
associated	O
with	O
increased	O
IL-2	B-protein
secretion	O
in	O
response	O
to	O
costimulation	O
with	O
CD3	B-protein
plus	O
CD28	B-protein
.	O

Stimulation	O
of	O
the	O
latently	O
HIV-infected	B-cell_line
myelomonocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
OM-10.1	O
with	O
C.	O
neoformans	O
and	O
C.	O
albicans	O
in	O
the	O
presence	O
of	O
pooled	O
human	O
serum	O
caused	O
a	O
ratio-dependent	O
increase	O
in	O
HIV	O
production	O
.	O

Studies	O
with	O
20-epi	O
analogues	O
pointed	O
out	O
the	O
importance	O
of	O
the	O
carbon-20	O
position	O
and	O
led	O
to	O
the	O
development	O
of	O
20-methyl	O
derivatives	O
of	O
VD	O
.	O

Run-on	O
analysis	O
demonstrated	O
detectable	O
levels	O
of	O
c-jun	B-DNA
transcription	O
in	O
U-937	B-cell_line
cells	I-cell_line
and	O
that	O
this	O
rate	O
is	O
increased	O
approximately	O
40-fold	O
following	O
okadaic	O
acid	O
exposure	O
.	O

Finally	O
,	O
we	O
have	O
studied	O
the	O
progression	O
of	O
one	O
case	O
of	O
CLL	O
into	O
Richter	O
's	O
syndrome	O
and	O
have	O
found	O
that	O
the	O
Richter	B-cell_line
's	I-cell_line
cells	I-cell_line
expressed	O
about	O
25-fold	O
less	O
A-myb	B-RNA
RNA	I-RNA
than	O
the	O
CLL	B-cell_line
cells	I-cell_line
from	O
the	O
same	O
patient.	O
The	O
pattern	O
of	O
c-myb	B-DNA
and	O
B-myb	B-DNA
was	O
clearly	O
distinct	O
from	O
that	O
of	O
A-myb	B-DNA
.	O

We	O
have	O
found	O
that	O
a	O
region	O
in	O
both	O
genes	O
(	O
-276	O
to	O
-250	O
for	O
IL-2-R	B-DNA
alpha	I-DNA
and	O
-203	O
to	O
-183	O
for	O
IL-2	B-DNA
)	O
,	O
which	O
corresponds	O
to	O
a	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
element	I-DNA
,	I-DNA
is	O
specifically	O
protected	O
by	O
nuclear	B-protein
proteins	I-protein
from	O
IARC	B-cell_line
301	I-cell_line
.	O

The	O
production	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
progeny	O
was	O
followed	O
in	O
the	O
U937	B-cell_line
promonocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
after	O
stimulation	O
either	O
with	O
retinoic	O
acid	O
or	O
PMA	O
,	O
and	O
in	O
purified	B-cell_type
human	I-cell_type
monocytes	I-cell_type
and	I-cell_type
macrophages	I-cell_type
.	O

In	B-protein
vitro	I-protein
translated	I-protein
hGR	I-protein
was	O
indistinguishable	O
from	O
native	B-protein
hGR	I-protein
,	O
as	O
determined	O
by	O
migration	O
on	O
sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gels	O
,	O
sedimentation	O
on	O
sucrose	O
density	O
gradients	O
,	O
and	O
reactivity	O
with	O
antipeptide	B-protein
antibodies	I-protein
generated	O
against	O
hGR	B-protein
.	O

The	O
human	B-protein
myeloid	I-protein
cell	I-protein
nuclear	I-protein
differentiation	I-protein
antigen	I-protein
(	O
MNDA	B-protein
)	O
is	O
expressed	O
constitutively	O
in	O
cells	O
of	O
the	O
myeloid	B-cell_type
lineage	I-cell_type
,	O
appearing	O
in	O
myeloblast	B-cell_type
cells	I-cell_type
in	O
some	O
cases	O
of	O
acute	O
myeloid	O
leukemia	O
and	O
consistently	O
being	O
detected	O
in	O
promyelocyte	B-cell_type
stage	I-cell_type
cells	I-cell_type
as	O
well	O
as	O
in	O
all	O
later	B-cell_type
stage	I-cell_type
cells	I-cell_type
including	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
granulocytes	B-cell_type
.	O

Here	O
we	O
show	O
that	O
alternative	O
RNA	O
splicing	O
generates	O
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
isoforms	I-protein
with	O
properties	O
different	O
from	O
those	O
of	O
p70	B-protein
.	O

It	O
was	O
found	O
that	O
lipopolysaccharide	O
induced	O
strongly	O
both	O
c-fos	B-DNA
and	O
c-jun	B-DNA
expression	O
as	O
well	O
as	O
AP1	B-protein
formation	O
.	O

Patients	O
with	O
the	O
recessively	O
inherited	O
disorder	O
ataxia	O
telangiectasia	O
(	O
A-T	O
)	O
have	O
a	O
high	O
level	O
of	O
specific	O
chromosome	B-DNA
translocations	I-DNA
which	O
can	O
be	O
easily	O
observed	O
in	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
show	O
a	O
greatly	O
increased	O
predisposition	O
to	O
leukaemia/lymphoma	O
,	O
mainly	O
of	O
T	B-cell_type
cell	I-cell_type
origin	O
.	O

Human	B-cell_line
T-cell	I-cell_line
leukemia	I-cell_line
virus	I-cell_line
type	I-cell_line
I	I-cell_line
(	I-cell_line
HTLV-I	I-cell_line
)	I-cell_line
-infected	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
constitutively	O
produce	O
high	O
levels	O
of	O
interleukin-1alpha	B-protein
(	O
IL-1alpha	B-protein
)	O
.	O

Two	O
40mer	O
oligonucleotides	O
from	O
the	O
1st	B-DNA
and	I-DNA
the	I-DNA
2nd	I-DNA
exon	I-DNA
of	O
the	O
c-myc	B-DNA
gene	I-DNA
,	O
labeled	O
with	O
35S	O
,	O
were	O
used	O
as	O
probes	O
.	O

This	O
region	O
(	O
termed	O
the	O
zinc	B-DNA
finger	I-DNA
protein	I-DNA
binding	I-DNA
region	I-DNA
(	O
ZIP	B-DNA
)	O
)	O
serves	O
as	O
binding	O
site	O
for	O
two	O
differently	O
regulated	O
zinc	B-protein
finger	I-protein
proteins	I-protein
:	O
the	O
constitutively	B-protein
expressed	I-protein
transcription	I-protein
factor	I-protein
Sp1	B-protein
and	O
the	O
inducible	B-protein
early	I-protein
growth	I-protein
response	I-protein
protein	I-protein
EGR-1	B-protein
.	O

Monocytes	O
and	O
transformed	B-cell_line
B-cells	I-cell_line
normally	O
express	O
MNP-1	B-protein
strongly	O
and	O
MNP-2	B-protein
weakly	O
,	O
while	O
T-cells	O
strongly	O
express	O
only	O
MNP-2	B-protein
.	O

Inactivation	O
of	O
IkappaBbeta	B-protein
by	O
the	O
tax	B-protein
protein	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
:	O
a	O
potential	O
mechanism	O
for	O
constitutive	O
induction	O
of	O
NF-kappaB	B-protein
.	O

CD30	B-protein
is	O
a	O
CD40-inducible	B-protein
molecule	I-protein
that	O
negatively	O
regulates	O
CD40-mediated	B-protein
immunoglobulin	I-protein
class	O
switching	O
in	O
non-antigen-selected	B-cell_line
human	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O

The	O
exon	O
:	O
intron	O
structure	O
of	O
chicken	B-protein
IL2	I-protein
corresponds	O
almost	O
exactly	O
to	O
those	O
of	O
mammalian	O
IL2s	B-protein
with	O
the	O
exceptions	O
of	O
exon	B-DNA
2	I-DNA
and	O
introns	B-DNA
2	O
and	O
3	O
which	O
are	O
shorter	O
.	O

When	O
tested	O
in	O
a	O
radioreceptor	O
assay	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
the	O
synthesized	O
compounds	O
showed	O
only	O
low	O
relative	O
binding	O
affinities	O
(	O
RBA	O
)	O
to	O
type	B-protein
1	I-protein
receptor	I-protein
,	O
the	O
highest	O
being	O
0.72	O
%	O
for	O
13	O
(	O
aldosterone	O
=	O
100	O
%	O
)	O
.	O

After	O
exposure	O
to	O
137Cs	O
gamma	O
rays	O
at	O
a	O
dose	O
rate	O
of	O
1.17	O
Gy/min	O
,	O
a	O
maximum	O
in	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
seen	O
at	O
8	O
h	O
after	O
a	O
0.5-Gy	O
exposure	O
.	O

The	O
linkage	O
between	O
T-cell	O
and	O
dendritic	O
cell	O
development	O
in	O
the	O
mouse	O
thymus	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
long-term	O
effects	O
of	O
treatment	O
with	O
low	O
doses	O
of	O
flutamide	O
on	O
clinical	O
and	O
hormonal	O
parameters	O
,	O
as	O
well	O
as	O
on	O
the	O
androgen	B-protein
receptor	I-protein
status	O
,	O
in	O
hirsute	O
women	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
in	O
systemic	O
lupus	O
erythematosus	O
.	O

Thus	O
,	O
the	O
activity	O
of	O
a	O
bHLH	B-protein
transcription	I-protein
factor	I-protein
is	O
necessary	O
for	O
T	O
lineage	O
differentiation	O
of	O
bipotential	B-cell_type
precursors	I-cell_type
,	O
in	O
the	O
absence	O
of	O
which	O
a	O
default	O
pathway	O
leading	O
to	O
NK	O
cell	O
development	O
is	O
chosen	O
.	O

PCR	B-DNA
products	I-DNA
showing	O
PTT	O
shifts	O
were	O
directly	O
sequenced	O
,	O
and	O
mutations	O
confirmed	O
by	O
restriction	O
enzyme	O
digestion	O
where	O
possible	O
.	O

However	O
,	O
IFN	B-protein
(	I-protein
alpha	I-protein
)	I-protein
does	O
not	O
have	O
any	O
effects	O
on	O
the	O
retinoid-dependent	O
regulation	O
of	O
the	O
myeloid	B-protein
surface	I-protein
markers	I-protein
CD11b	B-protein
and	O
CD33	B-protein
.	O

B	O
cell-specific	O
transcriptional	O
promoter	O
activity	O
mediated	O
by	O
the	O
octamer	B-DNA
motif	I-DNA
requires	O
the	O
Oct1	B-protein
or	O
Oct2	B-protein
protein	I-protein
and	O
additional	O
B	B-protein
cell-restricted	I-protein
cofactors	I-protein
.	O

The	O
15-lipoxygenase	B-DNA
(	I-DNA
lox	I-DNA
)	I-DNA
gene	I-DNA
is	O
expressed	O
in	O
a	O
tissue-specific	O
manner	O
,	O
predominantly	O
in	O
erythroid	B-cell_type
cells	I-cell_type
but	O
also	O
in	O
airway	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
and	O
eosinophils	B-cell_type
.	O

We	O
have	O
found	O
that	O
,	O
in	O
the	O
human	O
pro-monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
THP-1	B-cell_line
,	O
the	O
lipopolysaccharide-induced	O
expression	O
of	O
interleukin	B-protein
1beta	I-protein
is	O
dependent	O
on	O
tyrosine	B-protein
kinase	I-protein
activation	O
.	O

The	O
alpha2beta1	B-protein
integrin	I-protein
,	O
a	O
collagen	O
receptor	O
on	O
platelets	B-cell_type
and	O
megakaryocytes	B-cell_type
,	O
is	O
required	O
for	O
normal	O
platelet	O
function	O
.	O

Expression	O
of	O
surface	O
markers	O
,	O
intracytoplasmic	O
content	O
of	O
cytokines	B-protein
cell	O
cycle	O
analysis	O
after	O
BrdU	B-protein
incorporation	O
and	O
DNA	O
staining	O
with	O
propidium	O
iodide	O
were	O
studied	O
by	O
flow	O
cytometry	O
.	O

In	O
lymphocytes	B-cell_type
,	O
the	O
octamer-binding	B-protein
protein	I-protein
Oct-2A	B-protein
and	O
variants	O
thereof	O
are	O
thought	O
to	O
contribute	O
to	O
the	O
B-cell	B-DNA
specific	I-DNA
gene	I-DNA
expression	O
,	O
while	O
the	O
ubiquitous	O
protein	O
Oct-1	O
seems	O
to	O
control	O
general	O
octamer	B-DNA
site	I-DNA
-dependent	O
transcription	O
.	O

Brief	O
exposure	O
to	O
fludarabine	O
led	O
to	O
a	O
sustained	O
loss	O
of	O
STAT1	B-protein
,	O
analogous	O
to	O
the	O
prolonged	O
period	O
of	O
immunosuppression	O
induced	O
by	O
exposure	O
to	O
the	O
drug	O
in	O
vivo	O
.	O

By	O
comparison	O
,	O
an	O
isotype-matched	B-protein
antibody	I-protein
had	O
no	O
effect	O
on	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Here	O
we	O
report	O
a	O
real-time	O
study	O
of	O
factor/DNA	O
interactions	O
using	O
a	O
surface	O
plasmon	O
resonance	O
approach	O
and	O
further	O
characterization	O
of	O
recovered	B-protein
proteins	I-protein
involved	O
in	O
this	O
interaction	O
.	O

Studies	O
with	O
5	B-DNA
'	I-DNA
deletion	I-DNA
CD20	I-DNA
promoter-CAT	I-DNA
constructs	I-DNA
have	O
previously	O
revealed	O
two	O
regions	O
of	O
the	O
promoter	B-DNA
between	O
bases	O
-186	O
and	O
-280	O
and	O
between	O
bases	O
-280	O
and	O
-454	O
which	O
contained	O
positive	B-DNA
regulatory	I-DNA
elements	I-DNA
.	O

Aldosterone	B-protein
receptors	I-protein
were	O
normal	O
in	O
both	O
patients	O

The	O
key	O
role	O
of	O
erythropoietin	B-protein
(	O
Epo	B-protein
)	O
for	O
colony	O
formation	O
by	O
early	B-cell_type
erythroid	I-cell_type
progenitors	I-cell_type
(	O
burst-forming	B-cell_type
units-erythroid	I-cell_type
[	O
BFU-E	B-cell_type
]	O
)	O
has	O
been	O
confirmed	O
.	O

An	O
early	O
event	O
in	O
acute	O
and	O
chronic	O
inflammation	O
and	O
associated	O
diseases	O
such	O
as	O
atherosclerosis	O
and	O
rheumatoid	O
arthritis	O
is	O
the	O
induced	O
expression	O
of	O
specific	O
adhesion	B-protein
molecules	I-protein
on	O
the	O
surface	O
of	O
endothelial	B-cell_type
cells	I-cell_type
(	O
ECs	B-cell_type
)	O
,	O
which	O
subsequently	O
bind	O
leukocytes	B-cell_type
.	O

Nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	I-protein
NF-kappa	I-protein
B	I-protein
)	I-protein
/Rel	I-protein
proteins	I-protein
are	O
inducible	O
transcriptional	B-protein
regulators	I-protein
of	O
numerous	O
cellular	B-DNA
genes	I-DNA
.	O

Evidence	O
from	O
several	O
systems	O
indicates	O
that	O
the	O
immediate	B-DNA
early	I-DNA
gene	I-DNA
,	O
egr-1	B-DNA
may	O
be	O
of	O
particular	O
importance	O
in	O
the	O
immune	O
system	O
.	O

LPS	O
core-	B-protein
and	I-protein
O-side	I-protein
chain-specific	I-protein
mAbs	I-protein
inhibited	O
mCD14	B-protein
-mediated	O
LPS	O
uptake	O
by	O
both	O
cell	O
types	O
in	O
the	O
presence	O
of	O
serum	O
.	O

We	O
conclude	O
that	O
the	O
serum	O
response	O
of	O
the	O
human	O
TSP	B-DNA
1	I-DNA
gene	I-DNA
requires	O
the	O
coordinated	O
function	O
of	O
an	O
SRE-	B-DNA
and	I-DNA
NF-Y-binding	I-DNA
site	I-DNA
.	O

In	O
the	O
second	O
male	O
patient	O
,	O
no	O
abnormalities	O
were	O
found	O
.	O

In	O
vitro	O
,	O
thrombin-stimulated	B-cell_type
fixed	I-cell_type
platelets	I-cell_type
bound	O
to	O
neutrophils	B-cell_type
and	O
monocytes	B-cell_type
.	O

In	O
the	O
male	O
patient	O
with	O
normal	O
receptor	O
status	O
,	O
dexamethasone	O
suppressibility	O
of	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
healthy	O
controls	O
with	O
respect	O
to	O
both	O
maximal	O
suppression	O
and	O
IC50	O
.	O

Erbstatin	O
and	O
genistein	O
inhibited	O
the	O
sIg-crosslinking-induced	O
Egr-1	B-RNA
mRNA	I-RNA
expression	O
in	O
a	O
dose-dependent	O
manner	O
parallel	O
to	O
that	O
observed	O
in	O
the	O
inhibition	O
of	O
sIg-crosslinking-induced	O
protein	O
tyrosine	O
phosphorylation	O
.	O

The	O
cells	O
lines	O
described	O
here	O
should	O
be	O
useful	O
for	O
the	O
delineation	O
of	O
signaling	O
pathways	O
utilized	O
in	O
the	O
selective	O
regulation	O
of	O
gene	O
expression	O
.	O

Here	O
we	O
identify	O
intracellular	O
signaling	O
components	O
involved	O
in	O
activation	O
of	O
NF-kappaB	B-protein
following	O
TCR	B-protein
stimulation	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
MyD88	B-protein
is	O
a	O
critical	O
component	O
in	O
the	O
signaling	O
cascade	O
that	O
is	O
mediated	O
by	O
IL-1	B-protein
receptor	I-protein
as	O
well	O
as	O
IL-18	B-protein
receptor	I-protein
.	O

After	O
exercise	O
following	O
placebo	O
administration	O
we	O
observed	O
increases	O
in	O
concentrations	O
of	O
blood	O
substrates	O
,	O
plasma	B-protein
adrenocorticotropin	I-protein
(	O
ACTH	B-protein
)	O
,	O
growth	O
hormone	O
and	O
cortisol	O
and	O
in	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
without	O
changes	O
in	O
the	O
dissociation	O
constant	O
.	O

The	O
transcription	B-protein
factor	I-protein
Pax-5	I-protein
is	O
expressed	O
during	O
the	O
early	O
stages	O
of	O
B-cell	O
differentiation	O
and	O
influences	O
the	O
expression	O
of	O
several	O
B-cell-specific	B-DNA
genes	I-DNA
.	O

Smad6	B-protein
and	O
Smad7	B-protein
prevent	O
ligand-induced	O
activation	O
of	O
signal-transducing	B-protein
Smad	I-protein
proteins	I-protein
in	O
the	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
family	I-protein
.	O

In	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
-associated	O
tumors	O
in	O
nonimmunocompromised	O
patients	O
,	O
EBV	O
gene	O
expression	O
is	O
highly	O
restricted	O
.	O

Furthermore	O
,	O
the	O
BCL-6	B-protein
rearrangements	O
can	O
be	O
used	O
to	O
identify	O
and	O
monitor	O
the	O
malignant	B-cell_type
clone	I-cell_type
with	O
sensitive	O
PCR-based	O
techniques	O
.	O

Glucocorticoid	B-protein
receptor	I-protein
characteristics	O
in	O
monocytes	B-cell_type
of	O
patients	O
with	O
corticosteroid-resistant	O
bronchial	O
asthma	O
.	O

Regrettably	O
,	O
recent	O
evidence	O
suggests	O
that	O
loss-of-function	O
alone	O
is	O
not	O
always	O
sufficient	O
to	O
prevent	O
the	O
emergence	O
of	O
virulent	O
mutants	O
.	O

Role	O
of	O
HIV-1	B-protein
Nef	I-protein
expression	O
in	O
activation	O
pathways	O
in	O
CD4	B-protein
+	O
T	O
cells	O
.	O

This	O
prompted	O
a	O
study	O
of	O
follicular	O
borders	O
with	O
Bcl-6	B-protein
staining	O
in	O
reactive	O
follicular	O
hyperplasias	O
and	O
follicular	O
lymphomas	O
to	O
compare	O
with	O
AITL/GC	O
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
determine	O
the	O
in	O
vivo	O
modulation	O
of	O
GR	B-RNA
mRNA	I-RNA
expression	O
by	O
fluticasone	O
propionate	O
(	O
FP	O
)	O
in	O
subjects	O
with	O
mild	O
asthma	O
.	O

Surprisingly	O
,	O
LMP1	B-protein
does	O
not	O
require	O
RIP	B-protein
for	O
NF-kappaB	B-protein
activation	O
.	O

We	O
find	O
that	O
,	O
although	O
the	O
variant	O
octamer	B-DNA
motif	I-DNA
binds	O
Oct-1	B-protein
and	O
Oct-2	B-protein
in	O
vitro	O
with	O
5-fold	O
lower	O
affinity	O
than	O
the	O
consensus	B-DNA
octamer	I-DNA
motif	I-DNA
,	O
mutation	O
of	O
the	O
variant	O
octamer	B-DNA
motif	I-DNA
to	O
either	O
a	O
consensus	B-DNA
octamer	I-DNA
or	O
non-octamer	B-DNA
motif	I-DNA
has	O
no	O
effect	O
on	O
transcriptional	O
activation	O
from	O
the	O
germline	B-DNA
promoter	I-DNA
.	O

RFLAT-1	B-protein
:	O
a	O
new	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factor	I-protein
that	O
activates	O
RANTES	B-DNA
gene	I-DNA
expression	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

No	O
germline	O
changes	O
or	O
rearrangements	O
were	O
observed	O
in	O
any	O
of	O
the	O
genes	O
studied	O
.	O

This	O
result	O
suggests	O
that	O
expression	O
of	O
Aldh1	B-protein
protein	I-protein
is	O
negatively	O
regulated	O
by	O
Hox11	B-protein
and	O
that	O
abnormal	O
expression	O
of	O
Aldh1	B-protein
in	O
Hox11	B-protein
null	O
mice	O
may	O
cause	O
loss	O
of	O
splenic	B-cell_type
precursor	I-cell_type
cells	I-cell_type
by	O
aberrant	O
retinoic	O
acid	O
metabolism	O

Administration	O
of	O
the	O
cytokine	B-protein
interleukin-2	I-protein
(	O
IL-2	B-protein
)	O
can	O
result	O
in	O
therapeutic	O
benefits	O
for	O
individuals	O
with	O
renal	O
cell	O
carcinoma	O
and	O
melanoma	O
.	O

Interestingly	O
,	O
an	O
inducible	O
footprint	O
between	O
-183	B-DNA
and	I-DNA
-196	I-DNA
was	O
consistently	O
observed	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
CD45RA	B-cell_type
and	I-cell_type
CD45R0	I-cell_type
T	I-cell_type
helper	I-cell_type
subsets	I-cell_type
upon	O
stimulation	O
with	O
phorbol	O
12-myristate	O
13-acetate+	O
phytohemagglutinin	B-protein
(	O
PMA+	O
PHA	B-protein
)	O
that	O
was	O
highly	O
sensitive	O
to	O
treatment	O
with	O
corticosteroids	O
.	O

Time-course	O
experiments	O
showed	O
that	O
nuclear	O
levels	O
of	O
GATA-1	B-protein
and	O
p45	B-protein
NF-E2	I-protein
proteins	O
increased	O
during	O
BA	O
treatment	O
.	O

The	O
present	O
study	O
was	O
performed	O
to	O
increase	O
our	O
understanding	O
of	O
the	O
immunosuppressive	O
activity	O
of	O
heparin	O
by	O
investigation	O
of	O
potential	O
antagonism	O
of	O
the	O
production	O
and	O
function	O
of	O
monocyte	B-protein
chemotactic	I-protein
peptide-1	I-protein
(	O
MCP-1	B-protein
)	O
,	O
a	O
chemokine	B-protein
important	O
for	O
mononuclear	O
leucocyte	O
recruitment	O
across	O
vascular	O
endothelium	O
.	O

The	O
maximal	O
stimulation	O
of	O
the	O
lymphocytes	B-cell_type
,	O
as	O
measured	O
by	O
the	O
maximal	O
thymidine	O
incorporation	O
(	O
in	O
the	O
absence	O
of	O
cortisol	O
)	O
in	O
the	O
FMS	O
group	O
was	O
approximately	O
1.5	O
times	O
higher	O
(	O
p	O
<	O
.05	O
)	O
than	O
in	O
the	O
control	O
or	O
LBP	O
group	O
.	O

CD16	B-protein
(	O
Fc	B-protein
gamma	I-protein
RIIIA	I-protein
)	O
-induced	O
expression	O
of	O
cytokine	B-RNA
mRNA	I-RNA
in	O
NK	B-cell_type
cells	I-cell_type
occurs	O
via	O
a	O
CsA-sensitive	O
and	O
Ca	O
(	O
2+	O
)	O
-dependent	O
mechanism	O
.	O

A	O
chimeric	B-DNA
TCR	I-DNA
gene	I-DNA
,	O
comprising	O
an	O
anti-hapten	B-protein
single-chain	I-protein
Ab	I-protein
variable	I-protein
fragment	I-protein
fused	O
to	O
the	O
transmembrane	B-protein
and	I-protein
cytoplasmic	I-protein
regions	I-protein
of	O
the	O
human	B-protein
TCR	I-protein
zeta-chain	I-protein
,	O
was	O
used	O
to	O
determine	O
whether	O
the	O
tetracycline-regulatable	O
system	O
could	O
be	O
used	O
to	O
regulate	O
gene	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

However	O
,	O
the	O
rapamycin-resistant	B-protein
p70	I-protein
(	I-protein
s6k	I-protein
)	I-protein
could	O
not	O
rescue	O
rapamycin	O
inhibition	O
of	O
T-cell	O
cycle	O
entry	O
,	O
consistent	O
with	O
the	O
involvement	O
of	O
additional	O
,	O
rapamycin-sensitive	O
pathways	O
in	O
the	O
control	O
of	O
T-cell	O
cycle	O
progression	O
.	O

A	O
total	O
of	O
27	O
combinations	O
of	O
different	O
promoters	B-DNA
and	O
enhancers	B-DNA
were	O
tested	O
by	O
transfection	O
into	O
cultured	B-cell_line
cells	I-cell_line
.	O

PtdIns	B-protein
3-kinase	I-protein
signals	O
can	O
not	O
mimic	O
p21ras	B-protein
and	O
induce	O
the	O
Rac	B-protein
mediated	O
responses	O
of	O
AP-1	B-protein
transcriptional	O
activation	O
.	O

Human	B-cell_line
monoblastic	I-cell_line
leukemia	I-cell_line
U937	I-cell_line
cells	I-cell_line
are	O
induced	O
to	O
differentiate	O
into	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
by	O
various	O
agents	O
.	O

We	O
show	O
that	O
the	O
function	O
of	O
such	O
closely	O
related	O
proteins	O
can	O
be	O
distinguished	O
in	O
vivo	O
by	O
matching	O
point	O
mutations	O
in	O
5'HS3	B-DNA
with	O
amino	O
acid	O
changes	O
in	O
the	O
zinc	B-protein
fingers	I-protein
of	O
Sp1	B-protein
and	O
EKLF	B-protein
.	O

For	O
this	O
purpose	O
,	O
LNCaP	B-cell_line
cells	I-cell_line
were	O
incubated	O
with	O
monocyte-conditioned	O
medium	O
(	O
MCM	O
)	O
,	O
and	O
proliferation	O
as	O
well	O
as	O
expression	O
of	O
androgen	B-protein
receptor	I-protein
(	O
AR	B-protein
)	O
and	O
secretion	O
of	O
prostate-specific	B-protein
antigen	I-protein
(	O
PSA	B-protein
)	O
were	O
assessed	O
.	O

Involvement	O
of	O
a	O
second	O
lymphoid-specific	B-DNA
enhancer	I-DNA
element	I-DNA
in	O
the	O
regulation	O
of	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
gene	I-DNA
expression	O
.	O

In	O
contrast	O
to	O
that	O
reported	O
for	O
human	B-cell_type
Jurkat	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
we	O
found	O
that	O
p38	B-protein
MAPK	I-protein
,	O
but	O
not	O
Jun	B-protein
NH2-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
,	O
is	O
weakly	O
activated	O
upon	O
stimulation	O
with	O
either	O
anti-CD3	B-protein
or	O
anti-CD28	B-protein
in	O
murine	B-cell_type
thymocytes	I-cell_type
and	O
splenic	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Clonality	O
of	O
isolated	B-cell_type
eosinophils	I-cell_type
in	O
the	O
hypereosinophilic	O
syndrome	O
.	O

Two	O
unrearranged	O
TcR	B-protein
delta	I-protein
transcripts	I-protein
had	O
a	O
size	O
similar	O
to	O
that	O
of	O
the	O
functional	O
TcR	B-RNA
delta	I-RNA
mRNA	I-RNA
(	O
2.3	O
and	O
1.3	O
kb	O
)	O
found	O
in	O
TcR	B-cell_line
gamma/delta+	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

No	O
correlation	O
between	O
chromosome	B-DNA
1	I-DNA
alterations	O
and	O
nuclear	O
grade	O
,	O
age	O
,	O
size	O
,	O
lymph-node	O
involvement	O
,	O
hormonal	O
receptor	O
presence	O
,	O
proliferation	O
activity	O
or	O
p53	B-protein
protein	O
expression	O
was	O
detected	O
.	O

We	O
have	O
previously	O
reported	O
that	O
infection	O
with	O
herpes	O
simplex	O
virus	O
type	O
1	O
(	O
HSV-1	O
)	O
activates	O
expression	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
provirus	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

This	O
proteolytic	O
event	O
liberates	O
NF-kappa	B-protein
B	I-protein
,	O
permitting	O
its	O
rapid	O
translocation	O
into	O
the	O
nucleus	O
where	O
it	O
binds	O
to	O
its	O
cognate	B-DNA
enhancer	I-DNA
elements	I-DNA
.	O

In	O
situ	O
hybridizations	O
of	O
adult	O
murine	O
tissues	O
demonstrate	O
Spi-B	B-RNA
mRNA	I-RNA
in	O
the	O
medulla	O
of	O
the	O
thymus	O
,	O
the	O
white	O
pulp	O
of	O
the	O
spleen	O
,	O
and	O
the	O
germinal	O
centers	O
of	O
lymph	O
nodes	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
role	O
of	O
CD27	B-protein
/CD70	O
interaction	O
in	O
B	O
cell	O
IgE	B-protein
synthesis	O
.	O

Interestingly	O
,	O
the	O
levels	O
of	O
p56lck	B-protein
,	O
p59fyn	B-protein
,	O
and	O
tyrosine	O
kinase	O
activity	O
were	O
higher	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
derived	O
from	O
LN	O
that	O
drained	O
D5G6	O
than	O
they	O
were	O
in	O
those	O
from	O
D5	O
tumors	O
.	O

It	O
,	O
therefore	O
,	O
appears	O
that	O
this	O
dual	O
pattern	O
of	O
genetic	O
transmission	O
may	O
indicate	O
differing	O
genetic	O
defects	O
which	O
cause	O
the	O
same	O
clinical	O
picture	O
of	O
pseudohypoaldosteronism	O
.	O

The	O
internal	O
methionine	O
codons	O
of	O
human	B-DNA
T-cell	I-DNA
leukemia	I-DNA
virus	I-DNA
type	I-DNA
II	I-DNA
rex	I-DNA
gene	I-DNA
are	O
not	O
required	O
for	O
p24rex	B-protein
production	O
or	O
virus	O
replication	O
and	O
transformation	O
.	O

Thus	O
,	O
CIITA	B-protein
not	O
only	O
activates	O
the	O
expression	O
of	O
class	B-DNA
II	I-DNA
genes	I-DNA
but	O
recruits	O
another	O
B	O
cell-specific	O
coactivator	O
to	O
increase	O
transcriptional	O
activity	O
of	O
class	B-DNA
II	I-DNA
promoters	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
.	O

Thus	O
,	O
the	O
present	O
observations	O
will	O
provide	O
a	O
further	O
insight	O
into	O
the	O
pathogenesis	O
of	O
HIV-1	O
infections	O
.	O

As	O
one	O
test	O
of	O
this	O
hypothesis	O
,	O
we	O
compared	O
the	O
abilities	O
of	O
E1A	B-protein
-and	O
E7	B-protein
-expressing	O
human	B-cell_line
fibroblastic	I-cell_line
or	I-cell_line
keratinocyte-derived	I-cell_line
human	I-cell_line
cells	I-cell_line
to	O
be	O
selectively	O
killed	O
by	O
either	O
unstimulated	B-cell_type
or	O
interferon	B-cell_line
(	I-cell_line
IFN	I-cell_line
)	I-cell_line
-activated	I-cell_line
NK	I-cell_line
cells	I-cell_line
.	O

However	O
,	O
NAC	O
did	O
not	O
significantly	O
affect	O
the	O
spontaneous	O
production	O
of	O
IgE	B-protein
by	O
atopic	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

The	O
inhibitory	O
effects	O
of	O
NAC	O
were	O
not	O
due	O
to	O
nonspecific	O
toxicity	O
as	O
neither	O
the	O
viability	O
of	O
DC	B-cell_type
nor	O
their	O
mannose	O
receptor-mediated	O
endocytosis	O
were	O
modified	O
by	O
NAC	O
.	O

Furthermore	O
,	O
the	O
tyrosine	O
phosphorylation	O
of	O
STAT1	B-protein
and	O
the	O
tyrosine	B-protein
kinases	I-protein
JAK1	B-protein
and	O
JAK2	B-protein
was	O
enhanced	O
significantly	O
in	O
RGD-adherent	B-cell_type
monocytes	I-cell_type
compared	O
with	O
control	B-cell_type
cells	I-cell_type
.	O

These	O
two	O
types	O
of	O
estrogen	O
binding	O
sites	O
existed	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O

Primary	O
structure	O
analysis	O
showed	O
that	O
the	O
encoded	O
protein	O
contains	O
three	O
tandem	B-protein
zinc-finger	I-protein
sequences	I-protein
of	O
the	O
type	O
Cys2-Xaa12-His2	B-protein
.	O

All	O
the	O
tumors	O
exhibited	O
very	O
low	O
proliferative	O
activity	O
,	O
fewer	O
than	O
10	O
%	O
of	O
the	O
tumor	O
cell	O
nuclei	O
being	O
stained	O
by	O
the	O
antibody	B-protein
MIB-1	I-protein
(	O
Ki-67	B-protein
antigen	I-protein
)	O
.	O

H1-agonists	O
(	O
histamine	O
and	O
2-methylhistamine	O
)	O
caused	O
a	O
transient	O
rise	O
of	O
[	O
Ca2+	O
]	O
,	O
and	O
H1-antagonists	O
(	O
pyrilamine	O
and	O
doxepin	O
)	O
inhibited	O
the	O
histamine-induced	O
[	O
Ca2+	O
]	O
i	O
rise	O
more	O
potently	O
than	O
the	O
H2-antagonist	O
(	O
cimetidine	O
)	O
on	O
the	O
H3-antagonist	O
(	O
impromidine	O
)	O
.	O

We	O
hypothesize	O
that	O
this	O
110-kDa	B-protein
protein	I-protein
may	O
be	O
a	O
functionally	O
important	O
B	B-protein
cell-specific	I-protein
co-activator	I-protein
of	O
A-MYB	B-protein
.	O

The	O
absence	O
of	O
ultraviolet	O
absorbance	O
maxima	O
shifts	O
in	O
the	O
presence	O
of	O
sodium	O
acetate	O
confirmed	O
that	O
the	O
synthesized	O
products	O
were	O
7-O-glucuronides	O
.	O

Previous	O
reports	O
have	O
shown	O
that	O
BA-induced	O
overexpression	O
of	O
erythroid	B-DNA
genes	I-DNA
occurred	O
at	O
the	O
transcriptional	O
level	O
,	O
suggesting	O
the	O
involvement	O
of	O
erythroid	B-protein
transcription	I-protein
factors	I-protein
.	O

In	O
the	O
T3+	O
group	O
,	O
serum	O
total	O
thyroxine	O
(	O
TT4	O
)	O
,	O
free	O
T4	O
(	O
FT4	O
)	O
,	O
and	O
TSH	O
were	O
approx	O
50	O
%	O
lower	O
than	O
both	O
basal	O
and	O
T3-values	O
.	O

An	O
electrophoretic	O
mobility	O
shift	O
assay	O
employing	O
AP-1	B-protein
and	O
NF-kappaB	B-protein
consensus	O
oligonucleotides	O
was	O
used	O
to	O
demonstrate	O
that	O
AP-1	B-protein
-binding	O
activity	O
increased	O
,	O
while	O
constitutive	O
NF-kappaB	B-protein
-binding	O
activity	O
was	O
not	O
enhanced	O
,	O
following	O
2	O
h	O
of	O
CD19	B-protein
cross-linking	O
in	O
1E8	B-cell_line
cells	I-cell_line
.	O
Supershift	O
experiments	O
revealed	O
that	O
JunD	B-protein
and	O
c-Fos	B-protein
proteins	I-protein
mediated	O
anti-	O
CD19	B-protein
induced	O
AP-1	B-protein
-binding	O
activity	O
in	O
1E8	B-cell_line
cells	I-cell_line
.	O

Selective	O
DNA-binding	O
activity	O
of	O
interleukin-10-stimulated	B-protein
STAT	I-protein
molecules	I-protein
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

By	O
screening	O
a	O
T	O
cell	O
cDNA	B-DNA
library	I-DNA
,	O
we	O
identified	O
a	O
novel	B-protein
ets	I-protein
transcription	I-protein
factor	I-protein
that	O
binds	O
RBTN-2	B-protein
.	O

Thus	O
,	O
NF-AT	B-protein
induction	O
and	O
IL-2	B-protein
secretion	O
were	O
correlated	O
with	O
the	O
levels	O
of	O
inositol	O
phosphate	O
release	O
but	O
not	O
with	O
gross	O
levels	O
of	O
tyrosine	B-protein
kinase	I-protein
activity	O
induced	O
late	O
following	O
the	O
response	O
.	O

A	O
CD28	B-protein
-associated	O
signaling	O
pathway	O
leading	O
to	O
cytokine	B-DNA
gene	I-DNA
transcription	O
and	O
T	O
cell	O
proliferation	O
without	O
TCR	B-protein
engagement	O
.	O

VSMCs	B-cell_type
derived	O
from	O
human	O
coronary	O
atherosclerotic	O
plaques	O
that	O
apoptose	O
even	O
in	O
serum	O
also	O
generated	O
thrombin	B-protein
(	O
AUC	O
of	O
260	O
+/-	O
2	O
nmol	O
x	O
min/L	O
;	O
PT	O
of	O
128	O
+/-	O
4	O
nmol/L	O
)	O
.	O

Further	O
,	O
LMP1	B-protein
does	O
not	O
require	O
TRADD	B-protein
residues	O
294	O
to	O
312	O
for	O
NF-kappaB	B-protein
activation	O
,	O
while	O
TNFR1	B-protein
requires	O
TRADD	B-protein
residues	O
296	O
to	O
302	O
.	O

Control	O
of	O
IL-5	B-protein
production	O
may	O
be	O
effective	O
for	O
the	O
management	O
of	O
allergic	O
diseases	O
.	O

Using	O
protein-DNA	O
interaction	O
assays	O
we	O
show	O
that	O
the	O
H4	B-DNA
promoter	I-DNA
contains	O
two	O
ATF/	O
CREB	B-protein
recognition	O
motifs	O
which	O
interact	O
with	O
CREB	B-protein
,	O
ATF1	B-protein
,	O
and	O
ATF2	B-protein
but	O
not	O
with	O
ATF4/CREB2	B-protein
.	O

1	O
,	O
25-Dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
plays	O
a	O
major	O
role	O
in	O
the	O
stimulation	O
of	O
bone	O
growth	O
,	O
mineralization	O
,	O
and	O
intestinal	O
calcium	O
and	O
phosphate	O
absorption	O
;	O
it	O
also	O
acts	O
as	O
a	O
general	O
inhibitor	O
of	O
cellular	O
proliferation	O
.	O

Moreover	O
,	O
we	O
demonstrate	O
a	O
novel	O
role	O
for	O
GATA-3	B-protein
in	O
directly	O
repressing	O
Th1	O
development	O
distinct	O
from	O
its	O
positive	O
actions	O
on	O
Th2-specific	B-protein
cytokines	I-protein
.	O

Blocking	O
NF-kappaB	B-protein
in	O
the	O
rheumatoid	O
joint	O
thus	O
has	O
a	O
very	O
beneficial	O
profile	O
,	O
reducing	O
both	O
the	O
inflammatory	O
response	O
and	O
the	O
tissue	O
destruction	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
of	O
the	O
TCL1	B-DNA
genomic	I-DNA
locus	I-DNA
to	O
lymphocyte	O
metaphases	O
from	O
the	O
AT	O
patient	O
with	O
the	O
T-cell	O
clonal	O
expansion	O
showed	O
that	O
the	O
breakpoint	O
of	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
lies	O
within	O
the	O
TCL1	B-DNA
locus	I-DNA
and	O
is	O
accompanied	O
by	O
an	O
inverted	O
duplication	O
of	O
the	O
distal	B-DNA
part	I-DNA
of	O
chromosome	B-DNA
14	I-DNA
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
NF-kappaB	B-protein
activation	O
by	O
LMP1	B-protein
or	O
by	O
each	O
of	O
its	O
effector	B-protein
sites	I-protein
is	O
mediated	O
by	O
a	O
pathway	O
that	O
includes	O
NIK	B-protein
,	O
IKKalpha	B-protein
,	O
and	O
IKKbeta	B-protein
.	O

Site-directed	O
mutagenesis	O
of	O
these	O
cis	B-DNA
elements	I-DNA
demonstrated	O
that	O
Cp	B-DNA
activity	O
is	O
highly	O
dependent	O
on	O
the	O
presence	O
of	O
a	O
properly	O
positioned	O
CCAAT	B-DNA
box	I-DNA
,	O
with	O
the	O
dependence	O
on	O
the	O
distal	B-DNA
CCAAT	I-DNA
box	I-DNA
apparent	O
only	O
when	O
the	O
proximal	B-DNA
CCAAT	I-DNA
box	I-DNA
was	O
deleted	O
or	O
mutated	O
.	O

No	O
effect	O
was	O
seen	O
in	O
ethanol	B-cell_line
treated	I-cell_line
controls	I-cell_line
.	O

Resting	O
T-cell	O
nuclear	O
extracts	O
contained	O
KBF1/p50	B-protein
homodimer	I-protein
.	O

Vitamin	O
D3-	O
and	O
retinoic	O
acid-induced	O
monocytic	O
differentiation	O
:	O
interactions	O
between	O
the	O
endogenous	B-protein
vitamin	I-protein
D3	I-protein
receptor	I-protein
,	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
,	O
and	O
retinoid	B-protein
X	I-protein
receptors	I-protein
in	O
U-937	B-cell_line
cells	I-cell_line
.	O

LPS-stimulated	B-cell_type
monocytes	I-cell_type
showed	O
an	O
increased	O
expression	O
of	O
p105	B-RNA
mRNA	I-RNA
,	O
the	O
precursor	O
of	O
the	O
p50	B-protein
subunit	I-protein
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
while	O
no	O
effect	O
was	O
noticed	O
on	O
the	O
expression	O
of	O
p65	B-RNA
mRNA	I-RNA
.	O

Examination	O
of	O
the	O
basal	B-protein
factors	I-protein
interacting	O
with	O
the	O
21	B-DNA
bp	I-DNA
repeat	I-DNA
elements	I-DNA
through	O
electrophoretic	O
mobility	O
shift	O
(	O
EMS	O
)	O
analyses	O
has	O
demonstrated	O
the	O
formation	O
of	O
DNA-protein	B-protein
complexes	I-protein
common	O
to	O
each	O
of	O
the	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
(	O
C1-C3	B-DNA
)	O
as	O
well	O
as	O
three	O
DNA-protein	B-protein
complexes	I-protein
specific	O
to	O
the	O
promoter	B-DNA
proximal	I-DNA
(	I-DNA
pp	I-DNA
)	I-DNA
repeat	I-DNA
(	O
U1	B-DNA
(	O
U1A/U1B	B-DNA
)	O
and	O
U2	B-DNA
;	O
1-4	O
)	O
.	O

Both	O
PMA	O
and	O
the	O
combination	O
of	O
NECA	O
and	O
forskolin	O
acted	O
together	O
either	O
to	O
increase	O
(	O
c-Fos	B-protein
)	O
or	O
decrease	O
(	O
Jun	B-protein
)	O
protein	O
levels	O
as	O
well	O
as	O
increasing	O
AP-1	B-protein
binding	O
,	O
as	O
judged	O
by	O
gel-shift	O
assay	O
,	O
and	O
AP-1	B-protein
transcriptional	O
activity	O
.	O

Finally	O
,	O
we	O
conclude	O
that	O
this	O
effect	O
of	O
CIITA	B-protein
is	O
cell-type	O
specific	O
,	O
since	O
expression	O
of	O
CIITA	B-protein
is	O
not	O
required	O
for	O
normal	O
occupation	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
promoters	I-DNA
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

Despite	O
these	O
findings	O
,	O
the	O
molecular	O
mechanisms	O
by	O
which	O
Ets	B-protein
and	I-protein
NF-kappaB/NFAT	I-protein
proteins	I-protein
cooperatively	O
regulate	O
inducible	O
T-cell	O
gene	O
expression	O
remained	O
unknown	O
.	O

An	O
active	O
v-abl	B-protein
protein	I-protein
tyrosine	I-protein
kinase	I-protein
blocks	O
immunoglobulin	B-DNA
light-chain	I-DNA
gene	I-DNA
rearrangement	O
.	O

Because	O
insertion	O
mutations	O
in	O
phoP	B-DNA
are	O
polar	O
on	O
phoQ	B-DNA
,	O
we	O
constructed	O
strains	O
that	O
expressed	O
the	O
PhoQ	B-protein
protein	I-protein
in	O
the	O
absence	O
of	O
PhoP	B-protein
to	O
test	O
whether	O
resistance	O
to	O
defensin	O
requires	O
only	O
the	O
phoQ	B-protein
gene	I-protein
product	I-protein
.	O

Three	O
of	O
the	O
27	O
patients	O
with	O
squamous	O
cell	O
carcinoma	O
showed	O
slight	O
expression	O
of	O
c-fos	O
in	O
their	O
tumor	O
cells	O
before	O
and/or	O
at	O
4	O
or	O
10	O
Gy	O
of	O
radiotherapy	O
.	O

A	O
mouse	O
carrying	O
genetic	O
defect	O
in	O
the	O
choice	O
between	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

In	O
this	O
report	O
the	O
biological	O
properties	O
of	O
the	O
compounds	O
ZK161422	O
and	O
ZK157202	O
,	O
which	O
are	O
20-methyl-	O
and	O
20-methyl-23-eneanalogues	O
,	O
respectively	O
,	O
have	O
been	O
analyzed	O
in	O
comparison	O
with	O
VD	O
.	O

IL-4	B-protein
is	O
secreted	O
by	O
activated	O
Th2	B-cell_type
but	O
not	O
Th1	B-cell_type
cells	I-cell_type
and	O
plays	O
a	O
major	O
role	O
in	O
the	O
immune	O
response	O
by	O
modulating	O
the	O
differentiation	O
of	O
naive	B-cell_type
Th	I-cell_type
cells	I-cell_type
toward	O
the	O
Th2	B-cell_type
phenotype	I-cell_type
.	O

We	O
also	O
detected	O
abnormally	O
low	O
levels	O
of	O
the	O
signaling	B-protein
molecules	I-protein
T-cell	B-protein
receptor	I-protein
(	I-protein
TCR	I-protein
)	I-protein
-zeta	I-protein
,	O
ZAP-70	B-protein
and	O
p56lck	B-protein
in	O
4	O
of	O
14	O
breast	O
cancer	O
patients	O
,	O
i.e.	O
,	O
defects	O
in	O
T-cell	B-protein
signaling	I-protein
molecules	I-protein
.	O

These	O
results	O
suggest	O
a	O
microenvironment-directed	O
,	O
two-step	O
model	O
for	O
GATA-1	B-protein
expression	O
in	O
differentiating	B-cell_type
hematopoietic	I-cell_type
progenitors	I-cell_type
that	O
involves	O
(	O
i	O
)	O
cycle-dependent	O
initiation	O
and	O
(	O
ii	O
)	O
lineage-dependent	O
maintenance	O
or	O
suppression	O
.	O

We	O
have	O
investigated	O
the	O
signal	O
transduction	O
pathway	O
from	O
Fc	B-protein
receptors	I-protein
that	O
leads	O
to	O
gene	O
activation	O
and	O
production	O
of	O
cytokines	B-protein
in	O
monocytes	B-cell_type
.	O

In	O
an	O
exploration	O
of	O
the	O
potential	O
role	O
of	O
the	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
in	O
AD	O
,	O
GR	O
density	O
and	O
affinity	O
were	O
assessed	O
on	O
mononuclear	B-cell_type
leukocytes	I-cell_type
of	O
12	O
AD	O
patients	O
and	O
12	O
healthy	O
controls	O
.	O

The	O
glucocorticoid-induced	O
reduction	O
of	O
IL-12	B-protein
production	O
was	O
antagonized	O
by	O
RU	O
486	O
,	O
a	O
glucocorticoid-receptor	O
antagonist	O
,	O
suggesting	O
that	O
it	O
was	O
mediated	O
by	O
the	O
glucocorticoid	O
receptor	O
.	O

Domain	B-protein
E	I-protein
,	O
considered	O
as	O
the	O
putative	B-protein
hormone	I-protein
binding	I-protein
domain	I-protein
(	O
HBD	B-protein
)	O
of	O
the	O
human	B-protein
mineralocorticoid	I-protein
receptor	I-protein
(	O
hMR	B-protein
)	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
as	O
a	O
fusion	O
protein	O
with	O
either	O
maltose	B-protein
binding	I-protein
protein	I-protein
(	O
MBP	B-protein
)	O
or	O
glutathione	B-protein
S-transferase	I-protein
(	O
GST	B-protein
)	O
.	O

Furthermore	O
,	O
HL-60	B-cell_line
cells	I-cell_line
transduced	O
with	O
a	O
bcl-2	B-DNA
expression	I-DNA
vector	I-DNA
showed	O
the	O
same	O
differentiation	O
response	O
to	O
retinoids	O
as	O
did	O
parental	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
even	O
though	O
apoptosis	O
was	O
inhibited	O
in	O
these	O
bcl-2-transduced	B-cell_line
cells	I-cell_line
,	O
suggesting	O
that	O
differentiation	O
and	O
apoptosis	O
are	O
regulated	O
independently	O
in	O
myeloid	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O

The	O
C/EBP	B-DNA
motif	I-DNA
is	O
bound	O
by	O
Ig/EBP-1	B-protein
in	O
pre-B	O
cell	O
and	O
T	O
cell	O
extracts	O
,	O
but	O
is	O
replaced	O
by	O
nuclear	B-protein
factor-IL-6beta	I-protein
or	O
a	O
nuclear	B-protein
factor-IL-6beta-Ig/EBP-1	I-protein
heterodimer	I-protein
in	O
plasmacytoma	O
cell	O
extracts	O
.	O

NF-kappa	B-protein
B	I-protein
activation	O
,	O
minimal	O
in	O
unstimulated	B-cell_type
cells	I-cell_type
,	O
was	O
substantially	O
up-regulated	O
by	O
fibrinogen	B-protein
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
both	O
Exosurf	O
and	O
Survanta	O
suppress	O
TNF	B-RNA
mRNA	I-RNA
and	O
secretion	O
(	O
85	O
+/-	O
4	O
%	O
mean	O
percent	O
inhibition	O
+/-	O
SEM	O
by	O
Exosurf	O
;	O
71	O
+/-	O
6	O
%	O
by	O
Survanta	O
)	O
by	O
endotoxin-stimulated	B-cell_line
THP-1	I-cell_line
,	O
a	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Because	O
erythrocytes	B-cell_type
are	O
anucleated	O
,	O
these	O
results	O
are	O
discussed	O
as	O
evidence	O
for	O
biochemical	O
changes	O
by	O
TCDD	O
without	O
requiring	O
the	O
activation	O
of	O
gene	B-protein
products	I-protein
.	O

Comparative	O
studies	O
showed	O
that	O
Fli-1	B-protein
was	O
also	O
able	O
to	O
transactivate	O
the	O
GPIbalpha	B-DNA
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
the	O
GPIIb	B-DNA
promoter	I-DNA
.	O

IL-4	B-protein
enhanced	O
CD11b	B-protein
,	O
but	O
inhibited	O
CD26	B-protein
expression	O
and	O
delayed	O
CD13	B-protein
loss	O
.	O

We	O
feel	O
that	O
these	O
experiments	O
are	O
vital	O
to	O
understanding	O
the	O
function	O
of	O
GATA-1	B-protein
during	O
erythroid	O
ontogeny	O
.	O

In	O
flies	O
,	O
this	O
pathway	O
controls	O
segment	O
polarity	O
;	O
in	O
Xenopus	O
it	O
controls	O
the	O
definition	O
of	O
the	O
body	O
axis	O
.	O

Expression	O
of	O
Egr-1	B-protein
correlates	O
with	O
the	O
transformed	O
phenotype	O
and	O
the	O
type	O
of	O
viral	O
latency	O
in	O
EBV	B-cell_line
genome	I-cell_line
positive	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

This	O
increased	O
processing	O
and	O
secretion	O
correlated	O
with	O
the	O
stimulation	O
of	O
IL-1	B-RNA
beta	I-RNA
convertase	I-RNA
mRNA	I-RNA
accumulation	O
.	O

A	O
Rel-related	B-protein
,	I-protein
mitogen-inducible	I-protein
,	I-protein
kappa	I-protein
B-binding	I-protein
protein	I-protein
has	O
been	O
cloned	O
as	O
an	O
immediate-early	B-DNA
activation	I-DNA
gene	I-DNA
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

This	O
inhibition	O
is	O
not	O
accompanied	O
by	O
a	O
loss	O
in	O
viability	O
,	O
and	O
DMDTC-treated	B-cell_type
T	I-cell_type
cells	I-cell_type
retain	O
other	O
active	O
signaling	O
pathways	O
throughout	O
the	O
exposure	O
duration	O
.	O

When	O
expressed	O
in	O
COS	B-cell_line
cells	I-cell_line
,	O
however	O
,	O
NFAT1	B-protein
is	O
capable	O
of	O
transactivation	O
,	O
but	O
it	O
is	O
not	O
regulated	O
correctly	O
:	O
its	O
subcellular	O
localization	O
and	O
transcriptional	O
function	O
are	O
not	O
affected	O
by	O
stimulation	O
of	O
the	O
COS	B-cell_line
cells	I-cell_line
with	O
ionomycin	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
.	O

Although	O
its	O
precise	O
mode	O
of	O
action	O
remains	O
elusive	O
,	O
curcumin	O
has	O
been	O
shown	O
to	O
suppress	O
the	O
activity	O
of	O
the	O
AP-1	B-protein
transcription	B-protein
factor	I-protein
in	O
cells	O
stimulated	O
to	O
proliferate	O
.	O

When	O
the	O
calcium	O
ionophore	O
was	O
used	O
in	O
conjunction	O
with	O
TPA	O
,	O
a	O
PKC	B-protein
activator	O
,	O
the	O
Zp	B-DNA
induction	O
was	O
synergistically	O
enhanced	O
.	O

We	O
have	O
therefore	O
examined	O
the	O
cellular	O
metabolism	O
,	O
disposition	O
and	O
conjugation	O
of	O
SMX	O
and	O
its	O
metabolites	O
in	O
vitro	O
.	O

Several	O
studies	O
have	O
pointed	O
to	O
a	O
link	O
between	O
immune	O
and	O
endocrine	O
systems	O
,	O
including	O
a	O
regulatory	O
function	O
of	O
GH	O
on	O
monocyte	O
activation	O
.	O

Interestingly	O
,	O
in	O
CIITA-transfected	B-cell_line
cell	I-cell_line
hybrids	I-cell_line
,	O
cell	O
surface	O
expression	O
of	O
the	O
human	B-protein
HLA-DQ	I-protein
heterodimer	I-protein
was	O
not	O
observed	O
.	O

Although	O
GABP	B-protein
expression	O
is	O
not	O
restricted	O
to	O
the	O
hematopoietic	B-cell_type
lineage	I-cell_type
,	O
its	O
interaction	O
with	O
other	O
specific	B-protein
factors	I-protein
may	O
contribute	O
to	O
the	O
tissue-specific	O
expression	O
of	O
the	O
gammac	B-DNA
gene	I-DNA
.	O

Inducible	O
nitric	O
oxide	O
(	O
iNO	O
)	O
is	O
produced	O
at	O
sites	O
of	O
vascular	O
inflammation	O
by	O
resident	O
and	O
nonresident	O
vascular	B-cell_type
wall	I-cell_type
cells	I-cell_type
,	O
but	O
its	O
role	O
in	O
the	O
inflammatory	O
process	O
is	O
not	O
known	O
.	O

Comparison	O
of	O
the	O
sequences	O
of	O
all	O
elements	B-DNA
recognized	O
by	O
TCF-1	B-protein
defines	O
a	O
consensus	B-DNA
motif	I-DNA
A/T	B-DNA
A/T	I-DNA
C	I-DNA
A	I-DNA
A/G	I-DNA
A	I-DNA
G	I-DNA
.	O

Incubation	O
of	O
HIV-infected	B-cell_type
cells	I-cell_type
with	O
monoclonal	B-protein
antibody	I-protein
(	I-protein
MAb	I-protein
)	I-protein
13B8-2	I-protein
,	O
which	O
binds	O
to	O
CD4	B-protein
in	O
a	O
region	O
critical	O
for	O
dimerization	O
of	O
the	O
receptor	O
,	O
prevented	O
apoptosis	O
without	O
inhibiting	O
HIV	O
replication	O
.	O

These	O
binding	O
sites	O
have	O
similar	O
sequences	O
and	O
multiple	O
copies	O
of	O
the	O
binding	B-DNA
sites	I-DNA
confer	O
tissue-specific	O
down-regulation	O
when	O
attached	O
to	O
a	O
minimal	B-DNA
lox	I-DNA
promoter	I-DNA
fragment	I-DNA
.	O

We	O
found	O
that	O
the	O
spontaneous	O
production	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
and	O
other	O
pro-inflammatory	B-protein
cytokines	I-protein
is	O
NF-kappaB	B-protein
-dependent	O
in	O
rheumatoid	O
synovial	O
tissue	O
,	O
in	O
contrast	O
to	O
the	O
main	O
anti-inflammatory	B-protein
mediators	I-protein
,	O
like	O
IL-10	B-protein
and	I-protein
-11	I-protein
,	O
and	O
the	O
IL-1	B-protein
receptor	I-protein
antagonist	I-protein
.	O

To	O
characterize	O
regulatory	O
sequences	O
important	O
for	O
promoter	O
activity	O
,	O
we	O
performed	O
linker	O
scanning	O
analysis	O
of	O
the	O
92-bp	B-DNA
CD11b	I-DNA
promoter	I-DNA
and	O
demonstrate	O
that	O
a	O
sequence	O
at	O
bp	O
-60	O
is	O
essential	O
for	O
CD11b	B-DNA
promoter	I-DNA
activity	O
.	O

GATA-1	B-protein
DNA	O
binding	O
activity	O
is	O
down-regulated	O
in	O
late	O
S	O
phase	O
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O

These	O
involve	O
activation	O
of	O
the	O
sodium/proton-exchanger	B-protein
of	O
the	O
cell	O
membrane	O
at	O
very	O
low	O
,	O
physiological	O
concentrations	O
of	O
aldosterone	O
with	O
an	O
acute	O
onset	O
within	O
1-2	O
minutes	O
.	O

Subunit	B-protein
6	I-protein
(	O
S6	B-protein
)	O
,	O
an	O
integral	O
component	O
of	O
the	O
26S	B-protein
protease	I-protein
from	O
human	B-cell_type
erythrocytes	I-cell_type
,	O
has	O
been	O
studied	O
by	O
SDS-PAGE	O
,	O
peptide	O
mapping	O
and	O
sequence	O
analysis	O
.	O

BLPs	B-protein
were	O
found	O
to	O
induce	O
apoptosis	O
in	O
THP-1	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
through	O
human	B-protein
Toll-like	I-protein
receptor-2	I-protein
(	I-protein
hTLR2	I-protein
)	I-protein
.	O

IL-2	B-protein
-independent	O
activation	O
and	O
proliferation	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
induced	O
by	O
CD28	B-protein
.	O

Fetal	B-cell_type
thymocytes	I-cell_type
infected	O
with	O
adenovirus	O
containing	O
mut-I	B-protein
kappa	I-protein
B	I-protein
were	O
found	O
to	O
develop	O
normally	O
until	O
the	O
CD44	B-protein
-CD25+	O
,	O
CD4	B-protein
-	O
CD8	B-protein
-	O
double-negative	O
stage	O
,	O
while	O
production	O
of	O
more	O
mature	O
double-positive	O
and	O
single-positive	O
populations	O
was	O
strongly	O
decreased	O
.	O

To	O
delineate	O
the	O
effects	O
of	O
these	O
motifs	O
on	O
the	O
replicative	O
capacity	O
of	O
HIV	O
and	O
to	O
explore	O
the	O
possibility	O
of	O
extending	O
the	O
virus	O
host	O
range	O
,	O
known	O
heterologous	B-DNA
enhancer/promoters	I-DNA
were	O
inserted	O
into	O
the	O
HIV-1	B-DNA
LTR	I-DNA
in	O
place	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
and	O
Sp1	B-DNA
binding	I-DNA
sites	I-DNA
.	O

Herpesvirus	B-cell_line
saimiri	I-cell_line
immortalized	I-cell_line
gamma	I-cell_line
delta	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
activated	O
by	O
IL-12	B-protein
.	O

Thus	O
,	O
replication	O
of	O
the	O
transcriptional	B-DNA
template	I-DNA
is	O
not	O
a	O
prerequisite	O
for	O
expression	O
with	O
late	O
kinetics	O
,	O
a	O
finding	O
inconsistent	O
with	O
the	O
current	O
models	O
which	O
posit	O
a	O
cis-active	O
relationship	O
between	O
lytic	O
EBV	O
DNA	O
replication	O
and	O
late	O
gene	O
expression	O
.	O

One	O
of	O
the	O
latter	O
elements	O
,	O
the	O
IgH	B-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
,	O
is	O
of	O
particular	O
interest	O
:	O
(	O
1	O
)	O
it	O
is	O
B	O
cell-specific	O
and	O
active	O
only	O
in	O
late	O
B	O
cell	O
development	O
;	O
(	O
2	O
)	O
in	O
rodent	O
plasmacytomas	O
and	O
in	O
some	O
human	O
Burkitt	O
's	O
lymphomas	O
it	O
is	O
part	O
of	O
a	O
locus	B-DNA
control	I-DNA
region	I-DNA
(	O
LCR	B-DNA
)	O
that	O
is	O
involved	O
in	O
deregulation	O
of	O
the	O
c-myc	B-DNA
oncogene	I-DNA
as	O
a	O
result	O
of	O
translocation	O
into	O
the	O
IgH	B-DNA
locus	I-DNA
;	O
and	O
(	O
3	O
)	O
it	O
has	O
been	O
implicated	O
in	O
the	O
mechanisms	O
that	O
control	O
Ig	B-DNA
gene	I-DNA
class	I-DNA
switch	O
recombination	O
.	O

In	O
humans	O
,	O
there	O
are	O
two	O
highly	O
homologous	B-DNA
genes	I-DNA
encoding	O
SCM-1alpha	B-protein
and	O
SCM-1beta	B-protein
.	O

The	O
mechanism	O
of	O
activation	O
was	O
analyzed	O
by	O
using	O
anti-TNF-alpha	B-protein
antibody	I-protein
and	O
various	O
inhibitors	O
.	O

S9a	O
at	O
10	O
to	O
100	O
nM	O
inhibited	O
HIV	O
production	O
as	O
potently	O
as	O
3'-azido-3'-deoxythymidine	O
(	O
AZT	O
)	O
,	O
an	O
inhibitor	O
of	O
viral	B-protein
reverse	I-protein
transcriptase	I-protein
.	O

The	O
SS	O
Oct-1	B-protein
DNA-binding	O
abnormality	O
correlated	O
significantly	O
with	O
an	O
inability	O
of	O
cells	O
to	O
exit	O
the	O
Gzero/G1	O
cell	O
cycle	O
phase	O
when	O
stimulated	O
in	O
vitro	O
.	O

Signal	O
transduction	O
abnormalities	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
patients	O
with	O
advanced	O
renal	O
carcinoma	O
:	O
clinical	O
relevance	O
and	O
effects	O
of	O
cytokine	B-protein
therapy	O
.	O

Animal	O
lectins	B-protein
play	O
important	O
roles	O
in	O
a	O
variety	O
of	O
biological	O
processes	O
via	O
their	O
recognition	O
of	O
glycoconjugates	O
.	O

Co-treatment	O
of	O
RBCs	B-cell_type
with	O
TCDD	O
and	O
NaOV	O
completely	O
blocked	O
the	O
TCDD-induced	O
increase	O
in	O
parasitemia	O
.	O

Significant	O
progress	O
has	O
been	O
made	O
in	O
gaining	O
a	O
detailed	O
understanding	O
of	O
the	O
transcriptional	O
regulation	O
of	O
the	O
interleukin-4	B-DNA
gene	I-DNA
.	O

In	O
support	O
of	O
this	O
model	O
,	O
we	O
report	O
that	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
exists	O
in	O
multiple	O
allelic	O
forms	O
that	O
exhibit	O
distinct	O
transcriptional	O
activities	O
in	O
IL-4-positive	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
certain	O
NF-kappaB/Rel	B-protein
members	I-protein
,	O
predominantly	O
c-Rel	B-protein
,	O
interact	O
with	O
enhancer	O
sequences	O
for	O
STAT5	B-protein
,	O
a	O
key	O
transcription	O
factor	O
mediating	O
IL-2	B-protein
-induced	O
T-cell	O
proliferation	O
.	O

Northern	O
blot	O
analysis	O
of	O
polyadenylated	B-RNA
RNA	I-RNA
purified	O
from	O
activated	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
revealed	O
a	O
single	B-RNA
mRNA	I-RNA
transcript	I-RNA
of	O
approximately	O
2.3	O
kb	O
.	O

The	O
enhancer	B-DNA
for	O
the	O
immunoglobulin	B-DNA
mu	I-DNA
heavy	I-DNA
chain	I-DNA
gene	I-DNA
(	O
IgH	B-protein
)	O
activates	O
a	O
heterologous	B-DNA
gene	I-DNA
at	O
the	O
pre-B	O
cell	O
stage	O
of	O
B	B-cell_type
lymphocyte	I-cell_type
differentiation	O
.	O

Activation	O
of	O
expression	O
of	O
genes	B-DNA
encoding	O
transcription	B-protein
factors	I-protein
:	O
c-fos	B-DNA
and	O
c-jun	B-DNA
and	O
formation	O
of	O
AP1	B-protein
transcriptional	I-protein
complex	I-protein
in	O
human	B-cell_type
monocytes	I-cell_type
was	O
investigated	O
.	O

The	O
binding	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
to	O
its	O
receptor	O
on	O
normal	O
T	B-cell_type
cells	I-cell_type
induces	O
nuclear	O
expression	O
of	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
,	O
activation	O
of	O
the	O
IL-2	B-DNA
receptor	I-DNA
(	I-DNA
IL-2R	I-DNA
)	I-DNA
alpha	I-DNA
chain	I-DNA
gene	I-DNA
,	O
and	O
cell	O
proliferation	O
.	O

In	O
JM	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
tax	B-protein
induced	O
LT-293	B-DNA
activity	O
by	O
two-	O
to	O
four-fold	O
,	O
though	O
there	O
was	O
no	O
induction	O
of	O
M1-CAT	B-protein
.	O

Here	O
we	O
provide	O
evidence	O
showing	O
that	O
15	O
amino	O
acids	O
in	O
the	O
carboxyl-terminal	B-protein
end	I-protein
of	O
NFATx1	B-protein
are	O
required	O
for	O
its	O
maximum	O
transactivation	O
activity	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

We	O
investigated	O
whether	O
the	O
inability	O
to	O
maintain	O
EBV-positive	B-cell_line
NPC	I-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
culture	O
was	O
related	O
to	O
Qp	B-DNA
activity	O
.	O

The	O
modified	O
vectors	O
were	O
used	O
to	O
transduce	O
human	B-cell_line
hematopoietic	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
cord	B-cell_type
blood-derived	I-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
stem/progenitor	I-cell_type
cells	I-cell_type
,	O
and	O
murine	B-cell_line
bone	I-cell_line
marrow	I-cell_line
repopulating	I-cell_line
stem	I-cell_line
cells	I-cell_line
.	O

Gel-retardation	O
experiments	O
show	O
that	O
Spi-B	B-protein
can	O
bind	O
to	O
all	O
putative	B-DNA
PU.1	I-DNA
binding	I-DNA
sites	I-DNA
,	O
but	O
do	O
not	O
reveal	O
any	O
preferred	O
Spi-B	B-DNA
binding	I-DNA
site	I-DNA
.	O

Agents	O
which	O
increased	O
cAMP	O
levels	O
,	O
including	O
cholera	O
toxin	O
,	O
pertussis	O
toxin	O
,	O
dibutyryl	O
cAMP	O
,	O
and	O
isoproterenol	O
mimicked	O
the	O
actions	O
of	O
MM-LDL	B-protein
.	O

In	O
contrast	O
,	O
minimal	O
or	O
no	O
activation	O
of	O
Stat3beta	B-protein
was	O
observed	O
,	O
suggesting	O
that	O
IL-2	B-protein
and	O
IL-15	B-protein
predominantly	O
activate	O
Stat3alpha	B-protein
in	O
human	B-cell_type
CD4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Strikingly	O
,	O
Western	O
blotting	O
and	O
immunocytochemical	O
experiments	O
indicated	O
that	O
PDTC	O
promoted	O
a	O
transient	O
and	O
rapid	O
shuttling	O
of	O
NFATp	B-protein
and	O
NFATc	B-protein
,	O
leading	O
to	O
their	O
accelerated	O
export	O
from	O
the	O
nucleus	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

AIDS-related	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
-associated	O
T	O
cell	O
lymphomas	O
are	O
emerging	O
as	O
a	O
new	O
,	O
distinct	O
histopathological	O
entity	O
.	O

These	O
studies	O
suggest	O
that	O
interaction	O
of	O
CD2	B-protein
with	O
its	O
natural	O
ligand	O
,	O
LFA-3	B-protein
,	O
may	O
play	O
a	O
role	O
in	O
regulation	O
of	O
HIV	O
expression	O
.	O

Additionally	O
,	O
overexpression	O
of	O
Vav	B-protein
,	O
but	O
not	O
SLP-76	B-protein
,	O
augments	O
CD28-induced	O
IL-2	B-DNA
promoter	I-DNA
activity	O
.	O

Unexpectedly	O
,	O
stimulation	O
of	O
cloned	B-cell_line
stably	I-cell_line
transfected	I-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
leads	O
to	O
a	O
bimodal	O
pattern	O
of	O
beta-gal	O
expression	O
in	O
which	O
some	O
cells	O
express	O
no	O
beta-gal	B-protein
and	O
others	O
express	O
high	O
levels	O
.	O

Likewise	O
,	O
reporter	O
gene	O
assays	O
using	O
luciferase	O
constructs	O
driven	O
by	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
showed	O
a	O
dose-dependent	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
controlled	O
gene	O
expression	O
by	O
selenium	O
.	O

At	O
the	O
end	O
of	O
this	O
incubation	O
the	O
resting	B-cell_type
cells	I-cell_type
were	O
stimulated	O
with	O
M-CSF	B-protein
,	O
and	O
RNA	O
was	O
isolated	O
for	O
analysis	O
by	O
Northern	O
blotting	O
.	O

A	O
human	B-DNA
putative	I-DNA
lymphocyte	I-DNA
G0/G1	I-DNA
switch	I-DNA
gene	I-DNA
containing	O
a	O
CpG-rich	B-DNA
island	I-DNA
encodes	O
a	O
small	B-protein
basic	I-protein
protein	I-protein
with	O
the	O
potential	O
to	O
be	O
phosphorylated	O
.	O

Rather	O
,	O
the	O
binding	O
affinity	O
is	O
probably	O
influenced	O
by	O
the	O
expression	O
of	O
cytosolic	B-protein
factors	I-protein
that	O
affect	O
glucocorticoid	B-protein
receptor	I-protein
function	O
.	O

ICSAT	B-protein
(	O
Interferon	B-protein
Consensus	I-protein
Sequence	I-protein
binding	I-protein
protein	I-protein
for	I-protein
Activated	I-protein
T	I-protein
cells	I-protein
)	O
is	O
a	O
lymphocyte-specific	O
member	O
of	O
the	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
(	I-protein
IRF	I-protein
)	I-protein
family	I-protein
of	O
transcription	O
factors	O
,	O
originally	O
identified	O
through	O
Southwestern	O
screening	O
of	O
the	O
ATL	B-DNA
(	I-DNA
Adult	I-DNA
T-cell	I-DNA
leukemia	I-DNA
)	I-DNA
-16T	I-DNA
expression	I-DNA
library	I-DNA
.	O

Characterization	O
of	O
Grb2-binding	B-protein
proteins	I-protein
in	O
human	B-cell_type
platelets	I-cell_type
activated	O
by	O
Fc	B-protein
gamma	I-protein
RIIA	I-protein
cross-linking	O
.	O

To	O
confirm	O
the	O
physiological	O
relevance	O
of	O
these	O
findings	O
,	O
we	O
carried	O
out	O
in	O
vivo	O
footprinting	O
experiments	O
which	O
showed	O
that	O
stimulation	O
of	O
IL-2R	B-protein
alpha	I-protein
expression	O
correlated	O
with	O
occupancy	O
of	O
the	O
GASd	B-DNA
element	I-DNA
.	O

We	O
have	O
detected	O
ER	B-DNA
codon	I-DNA
10	I-DNA
polymorphism	O
in	O
these	O
samples	O
and	O
have	O
compared	O
them	O
to	O
those	O
observed	O
in	O
breast	O
cancer	O
samples	O
.	O

Cooperation	O
between	O
core	B-protein
binding	I-protein
factor	I-protein
and	O
adjacent	B-DNA
promoter	I-DNA
elements	I-DNA
contributes	O
to	O
the	O
tissue-specific	O
expression	O
of	O
interleukin-3	B-protein
.	O

NFAT	B-protein
activation	O
is	O
mediated	O
in	O
part	O
by	O
induced	O
nuclear	O
import	O
.	O

Both	O
cell	B-cell_line
lines	I-cell_line
are	O
devoid	O
of	O
genetic	O
lesions	O
of	O
c-MYC	B-protein
,	O
BCL-2	B-protein
and	O
p53	B-protein
as	O
well	O
as	O
gross	O
rearrangements	O
of	O
BCL-6	B-protein
.	O

The	O
results	O
showed	O
that	O
the	O
activation	O
of	O
U2	O
snRNA	O
transcription	O
in	O
B-cells	B-cell_type
also	O
requires	O
an	O
enhancer	O
comprising	O
both	O
the	O
Oct	B-DNA
and	O
at	O
least	O
one	O
Sp	B-DNA
1-binding	I-DNA
site	I-DNA
.	O

Promoter	B-DNA
sequence	I-DNA
,	O
exon	O
:	O
intron	O
structure	O
,	O
and	O
synteny	O
of	O
genetic	O
location	O
show	O
that	O
a	O
chicken	B-protein
cytokine	I-protein
with	O
T-cell	O
proliferative	O
activity	O
is	O
IL2	B-protein
and	O
not	O
IL15	B-protein
.	O

T-cell	O
expression	O
of	O
the	O
human	B-DNA
GATA-3	I-DNA
gene	I-DNA
is	O
regulated	O
by	O
a	O
non-lineage-specific	B-DNA
silencer	I-DNA
.	O

Characterization	O
of	O
both	O
TCR	B-protein
chains	I-protein
documented	O
a	O
great	O
diversity	O
among	O
those	O
clones	O
and	O
the	O
persistence	O
of	O
clonotypes	O
over	O
a	O
2-yr	O
period	O
.	O

Cbl-b	B-protein
,	O
a	O
homologue	O
of	O
Cbl	B-protein
,	O
is	O
widely	O
expressed	O
in	O
many	O
tissues	O
and	O
cells	O
including	O
hematopoietic	B-cell_type
cells	I-cell_type
[	O
6	O
]	O
[	O
7	O
]	O
.	O

Human	B-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
are	O
markedly	O
deficient	O
in	O
REF-1	B-protein
and	O
AP-1	B-protein
DNA	O
binding	O
activity	O
.	O

Recent	O
studies	O
have	O
suggested	O
that	O
Y319	O
also	O
positively	O
regulate	O
ZAP-70	B-protein
function	O
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
binding	O
of	O
a	O
myeloid-specific	B-protein
factor	I-protein
(	O
PU.1	B-protein
)	O
allows	O
a	O
general	O
factor	O
(	O
Sp1	B-protein
)	O
to	O
bind	O
in	O
a	O
tissue-specific	O
fashion	O
thereby	O
contributing	O
to	O
the	O
myeloid-specific	O
expression	O
of	O
CD11b	B-cell_line
.	O

All	O
three	O
types	O
of	O
H-RS	B-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
consistently	O
negative	O
for	O
BSAP	B-protein
,	O
TCF-1	B-protein
,	O
and	O
GATA-3	B-protein
.	O

Phenylarsine	O
oxide	O
inhibits	O
ex	O
vivo	O
HIV-1	O
expression	O
.	O

Characterization	O
of	O
a	O
new	O
isoform	O
of	O
the	O
NFAT	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
)	O
gene	O
family	O
member	O
NFATc	B-protein
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1996	O
Dec	O
27	O
;	O
271	O
(	O
52	O
)	O
:	O
33705	O
]	O

Messenger	B-RNA
RNA	I-RNA
(	O
mRNA	B-RNA
)	O
levels	O
for	O
the	O
granulocyte-colony	B-protein
stimulating	I-protein
factor	I-protein
(	I-protein
G-CSF	I-protein
)	I-protein
receptor	I-protein
,	O
granulocyte-macrophage	B-protein
(	I-protein
GM	I-protein
)	I-protein
-CSF	I-protein
receptor	I-protein
alpha	I-protein
subunit	I-protein
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
receptors	I-protein
I	I-protein
(	I-protein
p55	I-protein
)	I-protein
and	I-protein
II	I-protein
(	I-protein
p75	I-protein
)	I-protein
were	O
also	O
detected	O
in	O
this	O
subset	O
in	O
addition	O
to	O
c-kit	B-protein
and	O
flt-3	B-protein
,	O
receptors	O
known	O
to	O
be	O
expressed	O
on	O
progenitor	B-cell_type
cells	I-cell_type
.	O

Immune	O
responses	O
to	O
adenoviruses	O
:	O
viral	O
evasion	O
mechanisms	O
and	O
their	O
implications	O
for	O
the	O
clinic	O
.	O

Stat	B-protein
(	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	O
and	O
Jak	B-protein
(	O
Janus	B-protein
kinases	I-protein
)	O
proteins	O
are	O
central	O
components	O
in	O
the	O
signal	O
transduction	O
events	O
in	O
hematopoietic	B-cell_type
and	I-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O

Expression	O
of	O
the	O
MAP	B-protein
kinase-specific	I-protein
phosphatase	I-protein
,	O
MKP-1	B-protein
,	O
which	O
blocks	O
ERK	B-protein
activation	O
,	O
inhibited	O
IL-2	B-DNA
promoter	I-DNA
and	O
NF-AT	B-protein
-driven	O
transcription	O
stimulated	O
by	O
a	O
calcium	O
ionophore	O
and	O
PMA	O
,	O
and	O
in	O
addition	O
,	O
MKP-1	B-protein
neutralized	O
the	O
transcriptional	O
enhancement	O
caused	O
by	O
active	O
Raf-1	O
and	O
MEK1	O
expression	O
.	O

The	O
repetitive	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
(	O
priming	O
)	O
enhances	O
the	O
expression	O
of	O
many	O
cytokines	B-protein
,	O
such	O
as	O
IL-4	O
,	O
but	O
not	O
others	O
,	O
such	O
as	O
IL-2	B-protein
.	O

More	O
importantly	O
,	O
C-JUN	O
AS	O
oligonucleotides	O
showed	O
distinct	O
effects	O
on	O
two	O
markers	O
of	O
PMA-induced	O
differentiation	O
;	O
the	O
C-JUN	O
AS	O
oligonucleotides	O
inhibited	O
cell	O
adhesion	O
,	O
whereas	O
they	O
did	O
not	O
affect	O
another	O
marker	O
of	O
differentiation	O
,	O
respiratory	O
burst	O
(	O
measured	O
by	O
nitro	O
blue	O
tetrazolium	O
reduction	O
assay	O
)	O
.	O

These	O
observations	O
indicate	O
that	O
expression	O
of	O
Egr-1	B-protein
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
of	O
myeloblasts	B-cell_type
along	O
the	O
macrophage	B-cell_type
lineage	I-cell_type
.	O

Interestingly	O
,	O
treatment	O
of	O
purified	O
HIV-TF1	B-protein
by	O
phosphatase	B-protein
greatly	O
reduced	O
its	O
DNA-binding	O
activity	O
,	O
suggesting	O
that	O
phosphorylation	O
of	O
HIV-TF1	B-protein
was	O
essential	O
for	O
DNA	O
binding	O
.	O

Ro	O
09-2210	O
was	O
also	O
able	O
to	O
inhibit	O
phorbol	O
ester/ionomycin-induced	O
activation	O
of	O
AP1	B-protein
with	O
IC50	O
=	O
<	O
10	O
nM	O
.	O

The	O
visualization	O
of	O
heavy	B-DNA
and	I-DNA
light	I-DNA
chain	I-DNA
genes	I-DNA
in	O
B-lymphoid	B-cell_type
cells	I-cell_type
showed	O
that	O
the	O
three	O
Ig	B-DNA
genes	I-DNA
are	O
differentially	O
and	O
nonrandomly	O
distributed	O
in	O
different	O
nuclear	O
subvolumes	O
:	O
the	O
kappa	B-DNA
genes	I-DNA
were	O
found	O
to	O
be	O
preferentially	O
confined	O
to	O
an	O
outer	O
nuclear	O
volume	O
,	O
whereas	O
the	O
gamma	B-DNA
and	I-DNA
lambda	I-DNA
genes	I-DNA
consistently	O
occupied	O
more	O
central	O
positions	O
within	O
the	O
nucleus	O
,	O
the	O
lambda	B-DNA
genes	I-DNA
being	O
more	O
interior	O
when	O
compared	O
with	O
the	O
gamma	B-DNA
genes	I-DNA
.	O

Further	O
characterization	O
of	O
FKHRL1	B-DNA
and	O
its	O
related	O
family	O
members	O
should	O
shed	O
light	O
on	O
the	O
transcriptional	O
mechanisms	O
of	O
this	O
fork	B-DNA
head	I-DNA
gene	I-DNA
subfamily	I-DNA
and	O
their	O
role	O
in	O
T	O
helper	O
cell	O
differentiation	O
and	O
regulation	O
of	O
cell	O
growth	O
.	O

We	O
hypothesized	O
that	O
an	O
intracellular	B-protein
vitamin	I-protein
D	I-protein
binding	I-protein
protein	I-protein
(	O
IDBP	B-protein
)	O
,	O
present	O
in	O
both	O
nuclear	O
and	O
cytoplasmic	O
fractions	O
of	O
NWP	B-cell_line
cells	I-cell_line
,	O
or	O
another	O
protein	O
(	O
s	O
)	O
may	O
cause	O
or	O
contribute	O
to	O
the	O
steroid	O
hormone-resistant	O
state	O
in	O
NWP	B-cell_line
by	O
disruption	O
of	O
the	O
receptor	O
dimerization	O
process	O
and/or	O
by	O
interference	O
of	O
receptor	B-protein
complex	I-protein
binding	O
to	O
the	O
consensus	B-DNA
response	I-DNA
elements	I-DNA
present	O
in	O
the	O
enhancer	B-DNA
regions	I-DNA
of	O
steroid-responsive	B-DNA
genes	I-DNA
.	O

Exogenous	O
recombinant	B-protein
Tat	I-protein
protein	I-protein
was	O
also	O
able	O
to	O
upregulate	O
c-fos	B-DNA
promoter	I-DNA
activity	O
in	O
serum-activated	O
Jurkat	O
and	O
U937	B-cell_line
cells	I-cell_line
,	O
as	O
well	O
as	O
endogenous	O
c-fos	B-RNA
mRNA	I-RNA
expression	O
and	O
c-Fos	B-protein
protein	O
synthesis	O
in	O
both	O
serum-activated	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
primary	B-cell_type
PBMC	I-cell_type
.	O

Impairments	O
in	O
the	O
translocation	O
of	O
Rel-B	B-protein
and	O
c-Rel	B-protein
further	O
suggest	O
that	O
the	O
NFKB	B-protein
family	I-protein
members	I-protein
Rel-A	B-protein
,	O
Rel-B	B-protein
and	O
c-Rel	B-protein
are	O
not	O
required	O
for	O
the	O
transcription	O
of	O
IL-2	B-protein
in	O
the	O
peripheral	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
of	O
patients	O
with	O
breast	O
cancer	O
.	O

Type-II	B-protein
estrogen	I-protein
binding	I-protein
sites	I-protein
in	O
a	O
lymphoblastoid	B-cell_line
cell	I-cell_line
line	I-cell_line
and	O
growth-inhibitory	O
effect	O
of	O
estrogen	O
,	O
anti-estrogen	O
and	O
bioflavonoids	O
.	O

Among	O
these	O
cytokines	B-protein
,	O
the	O
expression	O
of	O
IFN-gamma	B-protein
was	O
associated	O
with	O
high	O
levels	O
of	O
serum	B-protein
AST/ALT	I-protein
.	O

C/EBP	B-protein
proteins	I-protein
activate	O
transcription	O
from	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
in	O
macrophages/	O
monocytes	B-cell_type
.	O

We	O
reported	O
here	O
that	O
the	O
E1B	B-protein
19K	I-protein
mutant	O
viruses	O
were	O
unable	O
to	O
replicate	O
efficiently	O
in	O
a	O
monocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
U937	B-cell_line
.	O

The	O
putative	O
factors	O
that	O
couple	O
the	O
signal	O
transduction	O
from	O
surface	O
receptors	O
to	O
the	O
activation	O
of	O
cytokine	B-protein
synthesis	O
in	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cells	I-cell_type
have	O
not	O
been	O
elucidated	O
.	O

For	O
comparison	O
,	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
were	O
determined	O
in	O
lymphocytes	B-cell_type
and	O
normal	O
thyroid	O
tissue	O
of	O
euthyroid	O
patients	O
.	O

This	O
effect	O
is	O
independent	O
of	O
differentiation	O
and	O
is	O
mediated	O
by	O
RAR	B-protein
alpha	I-protein
in	O
HL-60	B-cell_type
cells	I-cell_type
,	O
suggesting	O
a	O
similar	O
role	O
for	O
RAR	B-protein
alpha	I-protein
in	O
CD38	B-protein
expression	O
in	O
other	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

Basically	O
,	O
the	O
total	O
percentage	O
of	O
the	O
CD4+	B-cell_type
,	I-cell_type
CD8+	I-cell_type
and	I-cell_type
CD56+	I-cell_type
cell	I-cell_type
populations	I-cell_type
in	O
the	O
BM	O
was	O
increased	O
and	O
in	O
the	O
following	O
order	O
:	O
MRD-/LT	O
patients	O
,	O
normal	O
volunteers	O
,	O
MRD+/LT	O
patients	O
and	O
MRD+	O
or	O
-/ST	O
patients	O
.	O

Furthermore	O
,	O
while	O
ligand-activated	O
c-erbA/TR	B-protein
accelerated	O
differentiation	O
,	O
unliganded	O
c-erbA/TR	B-protein
effectively	O
blocked	O
differentiation	O
and	O
supported	O
sustained	O
progenitor	O
growth	O
in	O
culture	O
.	O

Interleukin-12	B-protein
(	O
IL-12	B-protein
)	O
,	O
a	O
heterodimeric	B-protein
cytokine	I-protein
produced	O
by	O
activated	O
monocytes	O
and	O
dendritic	O
cells	O
,	O
plays	O
a	O
crucial	O
role	O
in	O
regulating	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
-gamma	I-protein
production	O
and	O
in	O
the	O
generation	O
of	O
IFN-gamma-producing	B-cell_type
T	I-cell_type
helper	I-cell_type
1	I-cell_type
(	I-cell_type
Th1	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O

Treatment	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
anti-CD28	B-protein
monoclonal	I-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
results	O
in	O
augmentation	O
of	O
nuclear	B-protein
c-Rel	I-protein
,	O
p50	B-protein
,	O
and	O
p65	B-protein
,	O
and	O
this	O
augmentation	O
can	O
occur	O
in	O
the	O
presence	O
of	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
.	O

The	O
work	O
reviewed	O
in	O
this	O
article	O
separates	O
T	O
cell	O
development	O
into	O
four	O
phases	O
.	O

Various	O
cellular	O
stimuli	O
relieve	O
this	O
inhibition	O
by	O
mechanisms	O
largely	O
unknown	O
,	O
leading	O
to	O
NF-kappa	B-protein
B	I-protein
nuclear	O
localization	O
and	O
transactivation	O
of	O
its	O
target	O
genes	O
.	O

We	O
identified	O
an	O
86-nucleotide	O
fragment	O
that	O
is	O
90	O
%	O
identical	O
to	O
the	O
recently	O
characterized	O
murine	B-DNA
IL-2-responsive	I-DNA
element	I-DNA
(	O
mIL-2rE	B-DNA
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
Jagged1	B-protein
is	O
a	O
Rel/NF-kappaB-responsive	B-DNA
gene	I-DNA
.	O

Pretreatment	O
with	O
the	O
broad	O
serine/threonine	O
kinase	O
inhibitor	O
staurosporine	O
partly	O
blocked	O
the	O
calyculin	B-protein
A	I-protein
-induced	O
STAT3	B-protein
phosphorylation	O
,	O
whereas	O
inhibitors	O
of	O
serine/threonine	B-protein
kinases	I-protein
,	O
such	O
as	O
mitogen-activated	B-protein
protein	I-protein
kinase-1	I-protein
extracellular-regulated	I-protein
kinase-kinase	I-protein
,	O
mitogen-activated	B-protein
protein	I-protein
p38	I-protein
kinase	I-protein
,	O
and	O
phosphatidylinositol	B-protein
3-kinase	I-protein
,	O
did	O
not	O
.	O

This	O
effect	O
appears	O
to	O
be	O
mediated	O
through	O
the	O
induction	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O

We	O
consider	O
the	O
possible	O
consequences	O
of	O
the	O
reduced	O
cellular	O
content	O
of	O
TFIIH	B-protein
for	O
the	O
clinical	O
symptoms	O
in	O
XP-B	O
or	O
XP-D	O
patients	O
,	O
and	O
discuss	O
a	O
'conditional	O
phenotype	O
'	O
that	O
may	O
involve	O
an	O
impairment	O
of	O
cellular	O
function	O
only	O
under	O
certain	O
growth	O
conditions	O
.	O

However	O
,	O
their	O
specific	O
function	O
in	O
these	O
processes	O
has	O
not	O
been	O
clearly	O
defined	O
.	O

The	O
phosphorylation	O
appears	O
to	O
be	O
related	O
to	O
the	O
signaling	O
events	O
that	O
are	O
activated	O
by	O
TRAF2	B-protein
under	O
these	O
circumstances	O
,	O
since	O
two	O
nonfunctional	O
mutants	O
were	O
found	O
to	O
be	O
phosphorylated	O
significantly	O
less	O
than	O
the	O
wild-type	B-protein
protein	I-protein
.	O

Analysis	O
of	O
mRNA	B-RNA
suggested	O
that	O
Tat	O
exerts	O
its	O
effect	O
on	O
IL-2	B-protein
primarily	O
at	O
the	O
transcriptional	O
level	O
.	O

Antibodies	O
against	O
the	O
NF-kappa	B-protein
B	I-protein
and	O
Rel	O
proteins	O
and	O
UV	O
cross-linking	O
studies	O
revealed	O
the	O
presence	O
of	O
c-Rel	B-protein
and	O
p65	O
and	O
the	O
absence	O
of	O
p50	B-protein
in	O
the	O
TF	B-protein
complex	I-protein
and	O
further	O
showed	O
that	O
c-Rel/p65	B-protein
heterodimers	I-protein
selectively	O
bound	O
to	O
the	O
TF	B-DNA
kappa	I-DNA
B-like	I-DNA
site	I-DNA
.	O

We	O
find	O
that	O
recruitment	O
of	O
EKLF	B-protein
to	O
5'HS2	B-DNA
requires	O
the	O
TATA	B-DNA
box	I-DNA
,	O
but	O
recruitment	O
to	O
5'HS3	B-DNA
depends	O
on	O
the	O
CACCC	O
and	O
TATA	B-DNA
boxes	I-DNA
of	O
the	O
beta-globin	B-DNA
promoter	I-DNA
.	O

These	O
effects	O
are	O
mediated	O
by	O
the	O
intracellular	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
.	O

We	O
previously	O
reported	O
that	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
a	O
synthetic	O
glucocorticoid	O
,	O
causes	O
apoptosis	O
in	O
mature	B-cell_line
Th	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
that	O
this	O
induction	O
of	O
cell	O
death	O
is	O
prevented	O
by	O
specific	O
cytokines	B-protein
,	O
namely	O
,	O
by	O
IL-2	B-protein
in	O
Th1	B-cell_type
cells	I-cell_type
and	O
by	O
IL-4	B-protein
in	O
Th2	B-cell_type
cells	I-cell_type
.	O

Estrogens	O
affect	O
vascular	O
tone	O
indirectly	O
by	O
modulating	O
release	O
of	O
endothelium-derived	B-protein
vasoactive	I-protein
factors	I-protein
and	O
directly	O
by	O
modulating	O
intracellular	O
calcium	O
in	O
vascular	B-cell_type
smooth	I-cell_type
muscle	I-cell_type
cells	I-cell_type
.	O

Cells	O
within	O
each	O
category	O
did	O
not	O
give	O
any	O
aberrant	O
results	O
.	O

To	O
examine	O
the	O
activation	O
status	O
of	O
the	O
transcription	B-protein
factors	I-protein
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
and	O
heat	B-protein
shock	I-protein
factor-1	I-protein
(	O
HSF-1	B-protein
)	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
were	O
performed	O
.	O

These	O
results	O
suggest	O
that	O
UV-induced	O
signal	O
transduction	O
is	O
mediated	O
via	O
cell	B-protein
surface	I-protein
receptors	I-protein
that	O
normally	O
respond	O
to	O
biological	O
stimulation	O
,	O
whereas	O
H2O2	O
is	O
able	O
to	O
partially	O
bypass	O
this	O
requirement	O
.	O

The	O
carboxyl-terminal	B-protein
cytoplasmic	I-protein
domain	I-protein
of	O
CD36	B-protein
is	O
required	O
for	O
oxidized	O
low-density	O
lipoprotein	O
modulation	O
of	O
NF-kappaB	B-protein
activity	O
by	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
.	O

Transcription	O
factor	O
Egr-1	B-protein
activity	O
down-regulates	O
Fas	O
and	O
CD23	O
expression	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Electron	O
microscopy	O
revealed	O
a	O
marked	O
increase	O
in	O
granules	O
resembling	O
those	O
specific	O
for	O
eosinophils	B-cell_type
.	O

Receptor	O
mutant	O
subclones	O
of	O
CEM-C7	B-cell_line
,	O
which	O
are	O
proven	O
to	O
be	O
completely	O
unresponsive	O
to	O
micromolar	O
concentrations	O
of	O
dexamethasone	O
when	O
grown	O
in	O
serum-supplemented	O
medium	O
,	O
become	O
partially	O
sensitive	O
to	O
the	O
hormone	O
after	O
growth	O
in	O
defined	O
medium	O
.	O

Newly	O
translated	O
STAT1	B-protein
binds	O
in	O
equilibrium	O
fashion	O
to	O
STAT2	B-protein
and	O
STAT3	B-protein
,	O
but	O
we	O
show	O
that	O
STAT2	B-protein
and	O
STAT3	B-protein
exist	O
in	O
separate	O
heterocomplexes	B-protein
with	O
STAT1	B-protein
,	O
consistent	O
with	O
a	O
model	O
in	O
which	O
STAT1	B-protein
contains	O
a	O
common	O
binding	O
site	O
for	O
other	O
STAT	B-protein
proteins	I-protein
.	O

Recombinant	B-protein
murine	I-protein
and	I-protein
human	I-protein
TCF-1	I-protein
recognized	O
the	O
same	O
sequence	O
motif	O
in	O
the	O
CD3-epsilon	B-DNA
enhancer	I-DNA
as	O
judged	O
by	O
gel	O
retardation	O
and	O
methylation	O
interference	O
assays	O
.	O

Nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activity	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
patients	O
with	O
rheumatic	O
diseases	O
:	O
a	O
preliminary	O
report	O
.	O

Examination	O
of	O
CIITA	B-RNA
mRNA	I-RNA
in	O
IK	B-protein
stably	O
transfected	O
clones	O
revealed	O
a	O
marked	O
reduction	O
of	O
CIITA	B-RNA
mRNA	I-RNA
transcription	O
.	O

To	O
examine	O
the	O
possible	O
involvement	O
of	O
the	O
increased	O
activity	O
of	O
PI	B-protein
3-kinase	I-protein
in	O
YM268-stimulated	O
glucose	O
uptake	O
,	O
the	O
enzyme	O
activity	O
was	O
estimated	O
by	O
measuring	O
the	O
phosphatidylinositol-3	O
,	O
4	O
,	O
5-trisphosphate	O
(	O
PI-3	O
,	O
4	O
,	O
5-P3	O
)	O
concentration	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

The	O
endogenous	O
levels	O
of	O
the	O
signalsome	O
components	O
were	O
unaffected	O
by	O
stimulation	O
.	O

Inhibition	O
of	O
p38alpha	B-protein
MAPk	I-protein
resulted	O
in	O
a	O
transient	O
decrease	O
in	O
TNF-alpha	B-RNA
mRNA	I-RNA
accumulation	O
but	O
persistent	O
loss	O
of	O
TNF-alpha	B-protein
synthesis	O
.	O

Peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
and	O
alloreactive	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
of	O
two	O
male	O
infants	O
born	O
to	O
consanguinous	O
parents	O
and	O
presenting	O
with	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
showed	O
a	O
pronounced	O
deficiency	O
in	O
T	O
cell	O
activation	O
.	O

B-1	B-cell_type
lymphocytes	I-cell_type
are	O
self-renewing	O
,	O
CD5+	B-cell_type
B	I-cell_type
cells	I-cell_type
that	O
display	O
a	O
propensity	O
for	O
malignant	O
transformation	O
and	O
are	O
the	O
normal	O
counterpart	O
to	O
human	O
chronic	O
lymphocytic	O
leukemias	O
.	O

We	O
describe	O
18	O
patients	O
from	O
several	O
generations	O
of	O
12	O
unrelated	O
families	O
who	O
were	O
heterozygous	O
for	O
1	O
to	O
5	O
overlapping	B-DNA
IFNGR1	I-DNA
frameshift	I-DNA
small	I-DNA
deletions	I-DNA
and	O
a	O
wild-type	B-DNA
IFNGR1	I-DNA
allele	I-DNA
.	O

Regulation	O
of	O
the	O
balance	O
of	O
cytokine	B-protein
production	O
and	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	B-protein
)	O
transcription	O
factor	O
activity	O
by	O
cytokines	B-protein
and	O
inflammatory	O
synovial	O
fluids	O
.	O

Cell	O
hemoglobinization	O
was	O
accompanied	O
by	O
the	O
increased	O
expression	O
of	O
genes	B-DNA
encoding	O
gamma-globin	B-protein
and	I-protein
porphobilinogen	I-protein
deaminase	I-protein
(	O
PBGD	B-protein
)	O
,	O
an	O
enzyme	O
of	O
heme	O
synthesis	O
.	O

Glucocorticoid	B-protein
receptor	I-protein
density	O
was	O
increased	O
in	O
AIDS	O
patients	O
with	O
an	O
Addisonian	O
picture	O
(	O
group	O
1	O
;	O
16.2	O
+/-	O
9.4	O
fmol/million	O
cells	O
)	O
compared	O
to	O
values	O
in	O
12	O
AIDS	O
patients	O
without	O
an	O
Addisonian	O
picture	O
(	O
group	O
2	O
;	O
6.05	O
+/-	O
2.6	O
fmol/million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
and	O
sex-	O
and	O
age-matched	O
controls	O
(	O
3.15	O
+/-	O
2.3	O
fmol/million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O

Over	O
a	O
72-hr	O
period	O
of	O
activation	O
,	O
the	O
expression	O
of	O
the	O
50-kDa	B-protein
NF-kappa	I-protein
B	I-protein
,	O
p50	B-protein
,	O
and	O
its	O
precursor	O
,	O
p105	B-protein
,	O
was	O
increased	O
progressively	O
.	O

Clonality	O
analysis	O
of	O
granulocytes	B-cell_type
and	O
T	B-cell_type
lymphocytes	I-cell_type
in	O
healthy	O
females	O
by	O
the	O
PCR-based	O
HUMARA	B-DNA
method	O
.	O

Activation	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
in	O
a	O
cyclosporin	O
A-resistant	O
pathway	O
.	O

Sequence	O
analysis	O
of	O
DD	B-protein
products	I-protein
revealed	O
two	O
cDNAs	B-DNA
with	O
identity	O
to	O
known	B-protein
gene	I-protein
products	I-protein
:	O
the	O
catalytic	B-protein
sub-unit	I-protein
of	I-protein
DNA-protein	I-protein
kinase	I-protein
(	O
DNA-PK	B-protein
(	I-protein
CS	I-protein
)	I-protein
)	O
,	O
and	O
the	O
peroxisomal	B-protein
enzyme	I-protein
17beta-hydroxysteroid	I-protein
dehydrogenase	I-protein
type	I-protein
IV	I-protein
(	O
17beta-HSD	B-protein
IV	I-protein
)	O
.	O

The	O
tandem	O
CRE	B-DNA
and	I-DNA
POS	I-DNA
sites	I-DNA
are	O
of	O
major	O
functional	O
importance	O
as	O
judged	O
by	O
mutational	O
and	O
electrophoretic	O
mobility	O
shift	O
analyses	O
.	O

Whereas	O
overexpression	O
of	O
BCL2	B-protein
abrogates	O
the	O
apoptotic	O
response	O
,	O
Stat3	B-protein
-independent	O
signals	O
appear	O
to	O
downregulate	O
expression	O
of	O
the	O
BCL2	B-DNA
gene	I-DNA
.	O

Comparison	O
of	O
cDNA	B-DNA
and	O
genomic	O
sequences	O
reveals	O
a	O
4-exon	B-DNA
structure	I-DNA
characteristic	O
of	O
the	O
FOS	B-DNA
family	I-DNA
of	I-DNA
genes	I-DNA
.	O

The	O
results	O
indicate	O
that	O
stimulation	O
of	O
NK	B-cell_type
cells	I-cell_type
,	O
either	O
freshly	O
isolated	O
from	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBL	B-cell_type
)	O
or	O
long-term	B-cell_line
cultured	I-cell_line
NK	I-cell_line
clones	I-cell_line
,	O
with	O
specific	O
cell	O
targets	O
results	O
in	O
an	O
increased	O
binding	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
transcription	B-protein
factors	I-protein
measured	O
by	O
gel	O
retardation	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
this	O
protein	O
contains	O
features	O
characteristic	O
of	O
transcriptional	B-protein
activators	I-protein
as	O
well	O
as	O
transcriptional	B-protein
repressors	I-protein
.	O

In	O
contrast	O
,	O
the	O
binding	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
to	O
its	O
response	O
element	O
in	O
the	O
IL2	B-DNA
enhancer	I-DNA
and	O
to	O
an	O
NF-AT-like	B-DNA
response	I-DNA
element	I-DNA
present	O
in	O
the	O
IL4	B-DNA
enhancer	I-DNA
was	O
abnormal	O
.	O

Because	O
the	O
increase	O
in	O
erythroid	B-RNA
mRNA	I-RNA
steady-state	O
level	O
in	O
anthracycline-treated	B-cell_type
cells	I-cell_type
was	O
inhibited	O
by	O
cycloheximide	O
,	O
this	O
suggests	O
that	O
transcriptional	O
activation	O
in	O
ACLA-treated	B-cell_line
cells	I-cell_line
and	O
mRNA	O
stabilization	O
in	O
DOX-treated	B-cell_type
cells	I-cell_type
were	O
dependent	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O

T	O
cell-specific	O
negative	O
regulation	O
of	O
transcription	O
of	O
the	O
human	B-protein
cytokine	I-protein
IL-4	I-protein
.	O

We	O
investigated	O
the	O
regulation	O
of	O
the	O
promoter	B-DNA
(	O
BMRF1	B-DNA
)	O
for	O
this	O
early	O
gene	O
by	O
studying	O
its	O
responsiveness	O
in	O
vitro	O
to	O
two	O
immediate-early	B-protein
viral	I-protein
transactivators	I-protein
,	O
BZLF1	B-protein
(	O
Z	B-protein
)	O
and	O
BRLF1	B-protein
(	O
R	B-protein
)	O
,	O
focusing	O
on	O
the	O
differences	O
in	O
response	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
.	O

However	O
,	O
supershift	O
assays	O
using	O
the	O
available	O
mAb	B-protein
recognizing	O
the	O
T	B-protein
cell	I-protein
NFATc	I-protein
revealed	O
no	O
detectable	O
NFATc	B-protein
protein	O
in	O
nuclear	O
and	O
cytoplasmic	O
extracts	O
from	O
CD16-	O
or	O
phorbol	B-cell_line
ester-stimulated	I-cell_line
cells	I-cell_line
at	O
any	O
time	O
tested	O
,	O
up	O
to	O
4	O
h	O
.	O

Treatment	O
with	O
calcium	O
ionophore	O
A23187	O
increased	O
Zp	B-DNA
activity	O
.	O

[	O
The	O
effect	O
of	O
24	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
dioxyvit	O
)	O
on	O
Ca	O
metabolism	O
and	O
immune	O
status	O
during	O
chronic	O
kidney	O
failure	O
]	O

Four	O
regions	O
in	O
this	O
DNA	B-DNA
fragment	I-DNA
interact	O
with	O
nuclear	B-protein
proteins	I-protein
isolated	O
from	O
monocytic	B-cell_type
cells	I-cell_type
.	O

C/EBP	B-protein
alpha	I-protein
is	O
the	O
major	O
CCAAT/enhancer-binding	B-protein
protein	I-protein
(	O
C/EBP	B-protein
)	O
form	O
binding	O
to	O
this	O
site	O
in	O
nuclear	O
extracts	O
of	O
U937	B-cell_line
cells	I-cell_line
.	O

In	O
this	O
study	O
,	O
serum	O
from	O
a	O
patient	O
with	O
primary	O
biliary	O
cirrhosis	O
was	O
used	O
to	O
identify	O
a	O
cDNA	O
encoding	O
a	O
novel	O
component	O
of	O
the	O
NB	O
,	O
a	O
140-kDa	B-protein
protein	I-protein
designated	O
Sp140	B-protein
.	O

Promoter	O
deletion	O
constructs	O
demonstrated	O
the	O
potential	O
role	O
of	O
distal	B-DNA
promoter	I-DNA
sequences	I-DNA
in	O
regulating	O
collagenase-1	B-protein
transcription	O
.	O

IL-10	B-protein
cooperates	O
with	O
TNF-alpha	B-protein
to	O
activate	O
HIV-1	O
from	O
latently	B-cell_type
and	I-cell_type
acutely	I-cell_type
infected	I-cell_type
cells	I-cell_type
of	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
.	O

IkappaBalpha	B-protein
degradation	O
and	O
NF-kappaB	B-protein
nuclear	O
translocation	O
correlate	O
with	O
transcriptional	O
activation	O
of	O
the	O
inflammatory	B-protein
cytokines	I-protein
TNF-alpha	B-protein
and	O
IL-1beta	O
.	O

RelB	B-protein
protein	O
and	O
mRNA	B-RNA
were	O
detected	O
constitutively	O
in	O
lymphocytes	B-cell_type
and	O
in	O
activated	B-cell_type
monocytes	I-cell_type
,	O
differentiated	B-cell_type
DC	I-cell_type
,	O
and	O
monocyte-derived	B-cell_line
DC	I-cell_line
.	O

Using	O
a	O
combination	O
of	O
transfection	O
,	O
protein-DNA	O
binding	O
,	O
and	O
in	O
vitro	O
transcription	O
methods	O
,	O
we	O
have	O
discovered	O
the	O
novel	B-protein
T-cell-specific	I-protein
transcriptional	I-protein
activator	I-protein
TCF-1	B-protein
(	O
for	O
T-Cell	B-protein
Factor-1	I-protein
)	O
,	O
which	O
recognizes	O
a	O
T-cell-specific	B-DNA
response	I-DNA
element	I-DNA
(	O
TCE	B-DNA
)	O
located	O
within	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

Two	O
of	O
the	O
genes	O
defective	O
in	O
the	O
five	O
complementation	O
groups	O
identified	O
in	O
the	O
class	O
II-negative	O
bare	O
lymphocyte	O
syndrome	O
or	O
corresponding	O
laboratory	O
mutants	O
have	O
been	O
cloned	O
.	O

However	O
,	O
the	O
inositol	O
phosphate	O
response	O
was	O
stronger	O
for	O
64.1	B-protein
than	O
for	O
OKT3	B-protein
.	O

C-myb	O
and	O
B-myb	B-DNA
were	O
expressed	O
in	O
all	O
neoplastic	O
groups	O
,	O
except	O
in	O
CLL	B-cell_line
cells	I-cell_line
.	O

The	O
human	B-DNA
G0/G1	I-DNA
switch	I-DNA
gene	I-DNA
,	O
G0S2	B-DNA
,	O
has	O
potential	O
NFAT-binding	B-DNA
sites	I-DNA
in	O
the	O
5	B-DNA
'	I-DNA
flank	I-DNA
and	O
encodes	O
a	O
small	B-protein
basic	I-protein
potential	I-protein
phosphoprotein	I-protein
of	O
unknown	O
function	O
.	O

Like	O
LPS	O
,	O
purified	B-protein
native	I-protein
B.	I-protein
burgdorferi	I-protein
OspA	I-protein
and	O
synthetic	O
analogs	O
of	O
OspA	B-protein
,	O
OspB	B-protein
,	O
and	O
two	O
T.	B-protein
pallidum	I-protein
lipoproteins	I-protein
(	O
Tpp47	B-protein
and	O
Tpp17	B-protein
)	O
all	O
induced	O
NF-kappa	B-protein
B	I-protein
translocation	O
in	O
THP-1	B-cell_type
human	I-cell_type
monocytoid	I-cell_type
cells	I-cell_type
.	O

The	O
Wilms	B-DNA
'	I-DNA
tumor	I-DNA
suppressor	I-DNA
gene	I-DNA
(	O
WT1	B-protein
)	O
was	O
previously	O
identified	O
as	O
being	O
imprinted	O
,	O
with	O
frequent	O
maternal	O
expression	O
in	O
human	O
placentae	O
and	O
fetal	O
brains	O
.	O

p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
mediates	O
signal	O
integration	O
of	O
TCR	B-protein
/CD28	B-protein
costimulation	O
in	O
primary	B-cell_type
murine	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
suppression	O
of	O
productive	O
LAI	O
replication	O
in	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
is	O
not	O
due	O
to	O
differential	O
expression	O
of	O
viral	B-protein
coreceptors	I-protein
,	O
nor	O
is	O
it	O
due	O
to	O
inhibition	O
of	O
activation	O
of	O
the	O
important	O
HIV	O
transcription	B-protein
factors	I-protein
,	O
nuclear	B-protein
factor-kappaB	I-protein
and	O
activator	B-protein
protein-1	I-protein
.	O

The	O
picture	O
emerging	O
is	O
of	O
a	O
close	O
relationship	O
between	O
drug	O
concentrations	O
and	O
CN	O
inhibition	O
.	O

However	O
,	O
the	O
experimentally	O
derived	O
B-lymphoblastoid	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
clone	B-cell_line
13	I-cell_line
,	O
expresses	O
high	O
levels	O
of	O
HLADQ	B-protein
in	O
the	O
absence	O
of	O
HLA-DR	B-DNA
and	O
HLA-DP	B-DNA
,	O
despite	O
its	O
mapping	O
by	O
complementation	O
analysis	O
to	O
this	O
group	O
.	O

The	O
third	O
site	O
was	O
occupied	O
in	O
quiescent	O
cells	O
or	O
in	O
cells	O
stimulated	O
by	O
anti	B-protein
CD2	I-protein
or	O
anti	B-protein
CD28	I-protein
alone	O
.	O

Cross	O
competition	O
experiments	O
with	O
an	O
octamer	O
sequence	O
from	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
,	O
the	O
BAT	B-DNA
box	I-DNA
,	O
and	O
a	O
TA-rich	O
sequence	O
present	O
in	O
the	O
CD21	B-DNA
promoter	I-DNA
revealed	O
that	O
all	O
three	O
sequences	O
bound	O
the	O
same	O
nuclear	B-protein
proteins	I-protein
suggesting	O
that	O
the	O
BAT	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
were	O
Oct-1	B-protein
and	O
Oct-2	B-protein
.	O

This	O
threshold	O
likely	O
reflects	O
the	O
NF-AT	B-protein
concentration-dependent	O
assembly	O
of	O
transcription	B-protein
complexes	I-protein
at	O
the	O
promoter	B-DNA
.	O

All	O
LCLs	B-cell_line
were	O
found	O
to	O
produce	O
both	O
RVLP	O
and	O
EBV	O
particles	O
by	O
EM	O
.	O

We	O
show	O
here	O
that	O
chronic	O
HIV	O
infection	O
results	O
in	O
both	O
induction	O
of	O
a	O
nuclear	B-protein
factor	I-protein
with	O
antigenic	O
properties	O
indistinguishable	O
from	O
those	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
permanently	O
increased	O
HIV	B-DNA
enhancer	I-DNA
activity	O
.	O

In	O
the	O
culture	O
system	O
reported	O
here	O
,	O
(	O
1	O
)	O
the	O
growth	B-protein
factor	I-protein
(	O
GF	B-protein
)	O
stimulus	O
induces	O
cord	B-cell_type
blood	I-cell_type
(	I-cell_type
CB	I-cell_type
)	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
to	O
proliferate	O
and	O
differentiate/mature	O
exclusively	O
along	O
the	O
erythroid	B-cell_type
lineage	I-cell_type
;	O
(	O
2	O
)	O
this	O
erythropoietic	O
wave	O
is	O
characterized	O
by	O
less	O
than	O
4	O
%	O
apoptotic	O
cells	O
;	O
(	O
3	O
)	O
asymmetric	O
divisions	O
are	O
virtually	O
absent	O
,	O
ie	O
,	O
nonresponsive	O
hematopoietic	B-cell_type
progenitors	I-cell_type
with	O
no	O
erythropoietic	O
potential	O
are	O
forced	O
into	O
apoptosis	O
;	O
(	O
4	O
)	O
the	O
system	O
is	O
cell	O
division	O
controlled	O
(	O
cdc	O
)	O
,	O
ie	O
,	O
the	O
number	O
of	O
divisions	O
performed	O
by	O
each	O
cell	O
is	O
monitored	O
.	O

These	O
results	O
provide	O
evidence	O
that	O
promonocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
require	O
prestimulation	O
in	O
order	O
to	O
activate	O
HUVEC	B-cell_type
and	O
that	O
TNF	B-protein
alpha	I-protein
contributes	O
to	O
this	O
phenomenon	O
.	O

All	O
agents	O
tested	O
induced	O
expression	O
of	O
Hsp60	B-protein
6	O
hr	O
after	O
application	O
.	O

Footprinting	O
analysis	O
revealed	O
that	O
the	O
identical	O
sequence	O
CCGAAACTGAAAAGG	O
,	O
designated	O
E6	B-DNA
,	O
was	O
protected	O
by	O
nuclear	O
extracts	O
from	O
B	B-cell_type
cells	I-cell_type
,	O
T	B-cell_type
cells	I-cell_type
,	O
or	O
HeLa	O
cells	O
.	O

We	O
show	O
that	O
in	O
parental	O
K562	B-cell_line
cells	I-cell_line
,	O
the	O
HSF2-alpha	B-protein
isoform	I-protein
is	O
predominantly	O
expressed	O
and	O
HSF2	B-protein
can	O
be	O
activated	O
upon	O
hemin	O
treatment	O
.	O

In	O
contrast	O
,	O
when	O
HSF2-beta	B-protein
is	O
expressed	O
at	O
levels	O
exceeding	O
those	O
of	O
endogenous	B-protein
HSF2-alpha	I-protein
,	O
the	O
hemin-induced	O
DNA	O
binding	O
activity	O
and	O
transcription	O
of	O
heat	B-DNA
shock	I-DNA
genes	I-DNA
are	O
repressed	O
,	O
whereas	O
overexpression	O
of	O
HSF2-alpha	B-protein
results	O
in	O
an	O
enhanced	O
hemin	B-protein
response	O
.	O

Fewer	O
apoptotic	B-cell_type
cell	I-cell_type
bodies	I-cell_type
were	O
present	O
in	O
ectopic	O
pregnancy	O
.	O

These	O
studies	O
demonstrate	O
that	O
CMV	O
may	O
be	O
an	O
important	O
cofactor	O
in	O
the	O
development	O
of	O
rejection	O
and	O
infection	O
after	O
transplantation	O
through	O
its	O
effects	O
on	O
IL-6	B-protein
.	O

Transcription	B-protein
factors	I-protein
required	O
for	O
lymphoid	O
lineage	O
commitment	O
.	O

The	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
Rev	B-protein
protein	I-protein
is	O
essential	O
for	O
viral	O
structural	O
protein	O
expression	O
(	O
Gag	B-protein
,	O
Pol	B-protein
,	O
and	O
Env	B-protein
)	O
and	O
,	O
hence	O
,	O
for	O
viral	O
replication	O
.	O

CEM-ICR	B-cell_line
27	I-cell_line
leukemic	I-cell_line
lymphoblasts	I-cell_line
,	O
a	O
clone	O
of	O
CEM	B-cell_line
cells	I-cell_line
which	O
lack	O
functional	O
glucocorticoid	B-protein
receptors	I-protein
and	O
therefore	O
are	O
neither	O
lysed	O
by	O
dexamethasone	O
nor	O
capable	O
of	O
showing	O
glutamine	B-protein
synthetase	I-protein
induction	O
,	O
were	O
provided	O
with	O
steroid	B-protein
receptors	I-protein
by	O
DNA	O
transfections	O
of	O
various	O
receptor	O
gene	O
constructs	O
.	O

These	O
observations	O
can	O
be	O
linked	O
with	O
the	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
when	O
uninfected	O
monocytes	O
are	O
induced	O
by	O
either	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

In	O
addition	O
,	O
these	O
promoters	O
respond	O
only	O
indirectly	O
to	O
the	O
viral	B-DNA
immediate-early	I-DNA
transactivator	I-DNA
,	O
ZEBRA	B-DNA
.	O

No	O
difference	O
in	O
plasma	O
cortisol	O
level	O
was	O
found	O
between	O
asthmatics	O
and	O
healthy	O
subjects	O
.	O

Moreover	O
,	O
ANG	B-protein
II	I-protein
stimulated	O
NF-kappaB	B-protein
activation	O
in	O
human	B-cell_type
monocytes	I-cell_type
,	O
but	O
not	O
in	O
lymphocytes	B-cell_type
from	O
the	O
same	O
preparation	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
human	B-cell_line
B	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
,	I-cell_line
B104	I-cell_line
,	O
expressed	O
surface	B-protein
IgM	I-protein
(	O
sIgM	B-protein
)	O
and	O
surface	B-protein
IgD	I-protein
(	O
sIgD	B-protein
)	O
,	O
and	O
that	O
crosslinking	O
of	O
sIgM	B-protein
and	O
sIgD	B-protein
by	O
anti-IgM	B-protein
antibody	I-protein
(	I-protein
Ab	I-protein
)	I-protein
and	O
anti-IgD	B-protein
Ab	I-protein
,	O
respectively	O
,	O
induced	O
Ca2+	O
influx	O
to	O
almost	O
the	O
same	O
degree	O
,	O
whereas	O
only	O
sIgM	B-protein
-crosslinking	O
caused	O
B104	B-cell_line
cell	I-cell_line
death	O
.	O

In	O
human	B-cell_type
monocytes	I-cell_type
,	O
the	O
inhibitors	O
of	O
these	O
phosphatases	B-protein
,	O
okadaic	O
acid	O
and	O
calyculin	O
A	O
,	O
were	O
found	O
to	O
increase	O
the	O
mRNA	O
accumulation	O
and	O
cytokine	O
production	O
of	O
interleukin-1	B-protein
beta	I-protein
and	O
interleukin-1	B-protein
alpha	I-protein
.	O

These	O
contained	O
the	O
luciferase	B-DNA
gene	I-DNA
under	O
the	O
control	O
of	O
either	O
the	O
human	B-DNA
IL2	I-DNA
upstream	I-DNA
enhancer	I-DNA
region	O
(	O
segments	O
-326	O
to	O
+45	O
)	O
or	O
three	O
repeats	O
of	O
the	O
NFAT	B-DNA
element	I-DNA
contained	O
within	O
it	O
(	O
segments	O
-255	O
to	O
-285	O
)	O
.	O

[	O
Changes	O
in	O
leucocytic	B-protein
estrogen	I-protein
receptor	I-protein
levels	O
in	O
patients	O
with	O
gynecomastia	O
]	O

X	O
inactivation	O
analysis	O
in	O
a	O
female	O
with	O
hypomelanosis	O
of	O
Ito	O
associated	O
with	O
a	O
balanced	B-DNA
X	I-DNA
;	I-DNA
17	I-DNA
translocation	I-DNA
:	O
evidence	O
for	O
functional	O
disomy	O
of	O
Xp	O
.	O

A	O
reduction	O
in	O
the	O
expression	O
of	O
p65	B-protein
was	O
produced	O
by	O
treatment	O
with	O
the	O
phosphorothioate	O
antisense	O
oligodeoxynucleotide	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
the	O
attachment	O
of	O
monocytes	O
to	O
MVEC	B-cell_line
was	O
also	O
blocked	O
by	O
the	O
PTPase	B-protein
inhibitors	O
.	O

IL-2	B-protein
-induced	O
growth	O
of	O
CD8+	B-cell_type
T	I-cell_type
cell	I-cell_type
prolymphocytic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
mediated	O
by	O
NF-kappaB	B-protein
induction	O
and	O
IL-2	B-protein
receptor	I-protein
alpha	I-protein
expression	O
.	O

E1A	B-DNA
oncogene	I-DNA
induction	O
of	O
cellular	O
susceptibility	O
to	O
killing	O
by	O
cytolytic	B-cell_type
lymphocytes	I-cell_type
through	O
target	O
cell	O
sensitization	O
to	O
apoptotic	O
injury	O
.	O

These	O
findings	O
indicate	O
that	O
T	B-cell_type
cells	I-cell_type
representing	O
different	O
activation	O
and/or	O
differentiation	O
stages	O
can	O
be	O
differentially	O
responsive	O
to	O
ROI-mediated	O
signals	O
.	O

To	O
propel	O
itself	O
in	O
infected	B-cell_type
cells	I-cell_type
,	O
the	O
pathogen	O
Shigella	O
flexneri	O
subverts	O
the	O
Cdc42	B-protein
-controlled	O
machinery	O
responsible	O
for	O
actin	B-protein
assembly	O
during	O
filopodia	O
formation	O
.	O

Recognition	O
of	O
herpes	B-protein
simplex	I-protein
virus	I-protein
type	I-protein
2	I-protein
tegument	I-protein
proteins	I-protein
by	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
infiltrating	O
human	O
genital	O
herpes	O
lesions	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
the	O
B2	B-protein
factor	I-protein
is	O
expressed	O
in	O
the	O
cytosol	O
of	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
as	O
a	O
DNA-binding	B-protein
protein	I-protein
,	O
indicating	O
that	O
it	O
is	O
not	O
associated	O
with	O
an	O
inhibitor	O
(	O
IKB	O
)	O
.	O

Three	O
E2F	B-protein
DNA-binding	O
activities	O
were	O
identified	O
in	O
resting	O
(	O
G0	O
)	O
T	B-cell_type
cells	I-cell_type
with	O
mobilities	O
in	O
gel	O
shift	O
assays	O
distinct	O
from	O
those	O
of	O
previously	O
defined	O
E2F	B-protein
complexes	O
.	O

A	O
single-chain	B-protein
Fv	I-protein
(	O
sFv	B-protein
)	O
was	O
expressed	O
from	O
the	O
variable	B-protein
regions	I-protein
of	O
the	O
CD40-specific	O
mAb	B-protein
G28-5	I-protein
.	O

The	O
drug	O
exhibited	O
distinct	O
normalizing	O
effect	O
on	O
patterns	O
of	O
calcium	O
metabolism	O
:	O
increase	O
of	O
total	O
and	O
ionized	O
Ca2+	O
and	O
of	O
25-OHD	O
,	O
decrease	O
in	O
concentration	O
of	O
parath	O
hormone	O
and	O
osteocalcine	O
in	O
blood	O
serum	O
as	O
well	O
as	O
on	O
immunological	O
parameters	O
:	O
restoration	O
of	O
decreased	O
content	O
of	O
T-	B-cell_type
and	I-cell_type
0-lymphocytes	I-cell_type
.	O

Pleural	O
effusions	O
from	O
20	O
patients	O
with	O
breast	O
cancer	O
were	O
tested	O
.	O

The	O
decrease	O
using	O
weaker	O
binding	O
peptides	O
was	O
gradual	O
as	O
stimulation	O
with	O
a	O
peptide	O
with	O
intermediate	O
affinity	O
yielded	O
intermediate	O
T	B-cell_type
cell	I-cell_type
proliferation	O
and	O
the	O
poorest	O
binding	O
peptide	O
induced	O
an	O
even	O
weaker	O
T	B-cell_type
cell	I-cell_type
response	O
.	O

Neither	O
cell	O
population	O
generated	O
significant	O
amounts	O
of	O
E2	O
from	O
E1	O
.	O

Raf-1	B-protein
activity	O
promotes	O
IL-2	O
production	O
in	O
activated	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

We	O
therefore	O
speculate	O
that	O
N-Oct-3	B-protein
and	O
other	O
N-Oct	B-protein
factors	I-protein
have	O
a	O
specific	O
role	O
in	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
nervous	O
system	O
.	O

However	O
,	O
the	O
profound	O
T	O
cell	O
deficit	O
of	O
nude	O
mice	O
indicates	O
that	O
the	O
thymus	O
is	O
by	O
far	O
the	O
most	O
potent	O
site	O
for	O
inducing	O
the	O
expansion	O
per	O
se	O
,	O
even	O
if	O
other	O
sites	O
can	O
induce	O
some	O
response	O
acquisition	O
.	O

Gangliosides	O
appear	O
to	O
act	O
at	O
an	O
early	O
step	O
of	O
activation	O
in	O
that	O
TNF	B-RNA
transcripts	I-RNA
were	O
reduced	O
and	O
the	O
mobilization	O
of	O
the	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
was	O
blocked	O
.	O

This	O
analysis	O
identified	O
one	O
such	O
element	O
repeated	O
four	O
times	O
within	O
the	O
CD11b	B-DNA
promoter	I-DNA
.	O

The	O
chemiluminescent	O
(	O
CL	O
)	O
response	O
of	O
interferon-gamma-treated	B-cell_line
U937	I-cell_line
(	I-cell_line
IFN-U937	I-cell_line
)	I-cell_line
cells	I-cell_line
to	O
sensitized	O
target	O
cells	O
has	O
been	O
used	O
to	O
detect	O
red	B-protein
cell	I-protein
,	O
platelet	B-protein
and	O
granulocyte	B-protein
antibodies	I-protein
.	O

OBJECTIVE	O
:	O
We	O
investigated	O
the	O
production	O
of	O
IL-5	B-protein
,	O
a	O
potent	O
growth	O
factor	O
and	O
chemotactic	O
factor	O
for	O
eosinophils	B-cell_type
,	O
by	O
CD4+	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
in	O
patients	O
with	O
asthma	O
.	O

Preferential	O
presentation	O
of	O
herpes	B-protein
simplex	I-protein
virus	I-protein
T-cell	I-protein
antigen	I-protein
by	O
HLA	B-protein
DQA1*0501/DQB1*0201	I-protein
in	O
comparison	O
to	O
HLA	B-protein
DQA1*0201/DQB1*0201	I-protein
.	O

When	O
expressed	O
in	O
the	O
TNT	O
System	O
,	O
squirrel	O
monkey	O
and	O
human	B-protein
glucocorticoid	I-protein
receptors	I-protein
had	O
similar	O
,	O
high	O
affinity	O
binding	O
for	O
dexamethasone	O
(	O
apparent	O
Kd	O
,	O
5.9	O
+/-	O
1.2	O
and	O
4.3	O
+/-	O
0.5	O
nmol/L	O
,	O
respectively	O
;	O
n	O
=	O
3	O
)	O
,	O
whereas	O
the	O
squirrel	B-protein
monkey	I-protein
F774L	I-protein
receptor	I-protein
had	O
lower	O
affinity	O
binding	O
(	O
apparent	O
Kd	O
,	O
20.4	O
+/-	O
2.0	O
nmol/L	O
;	O
n	O
=	O
3	O
)	O
.	O

The	O
phosphorylated	O
forms	O
of	O
E2F-4	B-protein
that	O
bind	O
to	O
the	O
E2F	B-DNA
DNA	I-DNA
site	I-DNA
are	O
different	O
from	O
hyperphosphorylated	O
E2F-4	B-protein
,	O
which	O
predominates	O
in	O
primary	B-cell_type
hemopoietic	I-cell_type
cells	I-cell_type
in	O
G0	O
.	O

Lymphocytes	B-cell_type
from	O
CML	O
patients	O
lack	O
a	O
47	B-protein
kDa	I-protein
factor	I-protein
having	O
affinity	O
for	O
a	O
genomic	B-DNA
sterol	I-DNA
regulatory	I-DNA
sequence	I-DNA
.	O

The	O
two	O
human	B-protein
GATA3	I-protein
zinc	I-protein
fingers	I-protein
are	O
encoded	O
by	O
two	O
separate	O
exons	B-DNA
highly	O
conserved	O
with	O
those	O
of	O
GATA1	B-protein
,	O
but	O
no	O
other	O
structural	O
homologies	O
between	O
these	O
two	O
genes	O
can	O
be	O
found	O
.	O

Tissue	O
transglutaminase-dependent	O
posttranslational	O
modification	O
of	O
the	O
retinoblastoma	B-protein
gene	I-protein
product	I-protein
in	O
promonocytic	B-cell_line
cells	I-cell_line
undergoing	O
apoptosis	O
.	O

This	O
sequence	O
contains	O
consensus	B-DNA
elements	I-DNA
consistent	O
with	O
myeloid-specific	O
gene	O
expression	O
,	O
including	O
a	O
PU.1	B-DNA
consensus	I-DNA
site	I-DNA
near	O
the	O
major	O
transcription	B-DNA
start	I-DNA
site	I-DNA
and	O
a	O
cluster	O
of	O
c-Myb	B-DNA
sites	I-DNA
located	O
several	O
hundred	O
bases	O
upstream	O
of	O
this	O
region	O
.	O

Electromobility	O
shift	O
assay	O
revealed	O
that	O
dexamethasone	O
abolished	O
the	O
binding	O
of	O
nuclear	B-protein
transcription	I-protein
factors	I-protein
to	O
the	O
Ikaros	B-DNA
binding	I-DNA
site	I-DNA
and	O
reduced	O
AP-1	B-protein
binding	O
activity	O
.	O

Furthermore	O
,	O
similar	O
levels	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
were	O
found	O
in	O
the	O
cytosols	O
of	O
unactivated	O
T	B-cell_type
cells	I-cell_type
from	O
both	O
young	O
and	O
elderly	O
donors	O
suggesting	O
that	O
precursor	O
levels	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
remain	O
unaltered	O
during	O
aging	O
.	O

Expression	O
of	O
the	O
beta	B-DNA
2-integrin	I-DNA
genes	I-DNA
,	O
CD11a	B-DNA
and	O
CD11b	B-DNA
,	O
was	O
clearly	O
increased	O
after	O
both	O
of	O
these	O
treatments	O
.	O

The	O
closest	O
match	O
to	O
the	O
known	O
SP-1	B-DNA
consensus	I-DNA
sequence	I-DNA
within	O
the	O
respective	O
region	O
is	O
a	O
TCCCCTCCCCT	B-DNA
motif	I-DNA
.	O

BSAP	B-protein
is	O
encoded	O
by	O
the	O
Pax-5	B-DNA
gene	I-DNA
and	O
has	O
been	O
highly	O
conserved	O
between	O
human	O
and	O
mouse	O
.	O

In	O
contrast	O
,	O
neither	O
E	B-DNA
(	I-DNA
gre	I-DNA
)	I-DNA
nor	O
EA/S	B-DNA
motifs	I-DNA
contributed	O
pronouncedly	O
to	O
Akv	O
MLV	O
transcription	O
in	O
NIH	B-cell_line
3T3	I-cell_line
cells	I-cell_line
lacking	O
DNA-binding	O
ALF1	B-protein
or	O
HEB	B-protein
and	O
E2A	B-protein
proteins	I-protein
.	O

The	O
purpose	O
of	O
these	O
studies	O
was	O
to	O
identify	O
whether	O
transcription	O
factors	O
,	O
associated	O
with	O
cytokine	O
signalling	O
,	O
affected	O
promoter	O
activity	O
of	O
the	O
corticotropin	B-DNA
releasing	I-DNA
hormone	I-DNA
(	I-DNA
CRH	I-DNA
)	I-DNA
gene	I-DNA
.	O

The	O
genes	O
encoding	O
the	O
functionally	O
related	O
hepatocyte	B-protein
nuclear	I-protein
factors	I-protein
HNF-1alpha	B-protein
and	O
HNF-4alpha	B-protein
play	O
a	O
critical	O
role	O
in	O
normal	O
pancreatic	O
beta-cell	O
function	O
.	O

Contrary	O
to	O
the	O
results	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
PDTC	O
did	O
not	O
inhibit	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
-induced	O
NF	B-protein
kappaB	I-protein
activation	O
in	O
astrocytes	B-cell_type
;	O
instead	O
PDTC	O
itself	O
induces	O
NF	B-protein
kappaB	I-protein
activation	O
in	O
astrocytes	B-cell_type
,	O
and	O
this	O
may	O
be	O
related	O
to	O
scavenging	O
of	O
endogenously	O
produced	O
NO	O
by	O
the	O
PDTC	O
iron	O
complex	O
.	O

To	O
elucidate	O
the	O
contributions	O
of	O
GATA-1	B-protein
to	O
definitive	O
hematopoiesis	O
in	O
vivo	O
,	O
we	O
have	O
examined	O
adult	O
mice	O
that	O
were	O
rendered	O
genetically	O
defective	O
in	O
GATA-1	B-protein
synthesis	O
(	O
Takahashi	O
et	O
al	O
,	O
J	O
Biol	O
Chem	O
272	O
:	O
12611	O
,	O
1997	O
)	O
.	O

The	O
work	O
strongly	O
suggests	O
that	O
EBV-replicative	O
lesions	O
are	O
subject	O
to	O
direct	O
CTL	O
control	O
in	O
vivo	O
and	O
that	O
immediate	B-protein
early	I-protein
and	I-protein
early	I-protein
proteins	I-protein
are	O
frequently	O
the	O
immunodominant	O
targets	O
.	O

Cloning	O
of	O
a	O
transcriptionally	B-protein
active	I-protein
human	I-protein
TATA	I-protein
binding	I-protein
factor	I-protein
.	O

This	O
polymorphism	O
represented	O
a	O
C-to-T	O
base	O
exchange	O
which	O
induced	O
a	O
YY1	B-DNA
consensus	I-DNA
sequence	I-DNA
and	O
is	O
present	O
in	O
a	O
region	O
of	O
the	O
promoter	O
associated	O
with	O
negative	O
transcription	O
regulation	O
.	O

TNF-alpha	B-protein
release	O
peaked	O
at	O
24	O
h	O
and	O
decreased	O
thereafter	O
,	O
and	O
it	O
was	O
dose	O
dependent	O
and	O
preceded	O
by	O
an	O
increase	O
of	O
TNF-alpha	B-RNA
mRNA	I-RNA
detectable	O
after	O
3	O
h	O
of	O
stimulation	O
with	O
mAb	B-protein
L243	I-protein
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
A/R	O
elicits	O
a	O
two-phase	O
neutrophil-endothelial	O
cell	O
adhesion	O
response	O
that	O
involves	O
transcription-independent	O
and	O
transcription-dependent	O
surface	O
expression	O
of	O
different	O
endothelial	B-protein
cell	I-protein
adhesion	I-protein
molecules	I-protein
.	O

Activation	O
through	O
the	O
Ca2+/	O
calcineurin	B-protein
pathway	O
is	O
essential	O
to	O
the	O
transcription	O
of	O
many	O
cytokine	B-DNA
genes	I-DNA
.	O

A	O
pharmacodynamic	O
model	O
for	O
basophil	O
cell	O
distribution	O
to	O
and	O
from	O
an	O
extravascular	O
compartment	O
describes	O
the	O
effects	O
of	O
MP	O
after	O
both	O
regimens	O
.	O

Polyubiquitinylated	O
c-Jun	B-protein
,	O
wbFos	B-protein
,	O
and	O
wbJun	B-protein
,	O
but	O
not	O
E220K-ubiquitinylated	B-protein
c-Jun	I-protein
,	O
were	O
readily	O
degraded	O
by	O
the	O
ATP-dependent	B-protein
26	I-protein
S	I-protein
multicatalytic	I-protein
proteases	I-protein
.	O

The	O
TCR	B-protein
alpha	I-protein
beta	I-protein
or	I-protein
-gamma	I-protein
delta	I-protein
chains	I-protein
bind	O
the	O
peptide	O
ligand	O
,	O
whereas	O
the	O
associated	O
CD3	B-protein
delta	I-protein
epsilon	I-protein
gamma	I-protein
and	O
TCR	B-protein
zeta	I-protein
subunits	I-protein
couple	O
the	O
TCR	B-protein
to	O
intracellular	O
signal	O
transduction	O
components	O
.	O

The	O
son	O
of	O
the	O
unaffected	O
twin	O
sister	O
was	O
shown	O
to	O
be	O
hemizygous	O
.	O

The	O
region	O
downstream	O
of	O
-90	O
appeared	O
critical	O
for	O
basal	O
promoter	O
activity	O
.	O

From	O
a	O
consecutive	O
series	O
of	O
350	O
cases	O
of	O
adult	O
de	O
novo	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
,	O
we	O
identified	O
20	O
cases	O
(	O
6	O
%	O
)	O
with	O
a	O
unique	O
immunophenotype	O
:	O
CD33+	O
,	O
CD56+	O
,	O
CD11a+	O
,	O
CD13lo	O
,	O
CD15lo	O
,	O
CD34+/-	O
,	O
HLA-DR	B-protein
-	O
,	O
CD16	B-protein
-	O
.	O

T-lineage	O
precursor	O
populations	O
from	O
the	O
adult	O
mouse	O
thymus	O
,	O
prior	O
to	O
T-cell	O
receptor	O
gene	O
rearrangement	O
,	O
display	O
a	O
capacity	O
to	O
produce	O
DC	B-cell_type
as	O
well	O
as	O
T	B-cell_type
cells	I-cell_type
in	O
the	O
thymus	O
,	O
and	O
are	O
very	O
efficient	O
precursors	O
of	O
DC	B-cell_type
in	O
culture	O
.	O

Inhibition	O
of	O
transcription	B-protein
factors	I-protein
belonging	O
to	O
the	O
rel/NF-kappa	B-protein
B	I-protein
family	I-protein
by	O
a	O
transdominant	B-protein
negative	I-protein
mutant	I-protein
.	O

Inasmuch	O
as	O
the	O
change	O
in	O
membrane	O
potential	O
is	O
dependent	O
on	O
elevation	O
of	O
free	O
cytosolic	O
calcium	O
,	O
the	O
hyperpolarization	O
is	O
presumably	O
through	O
opening	O
of	O
Ca	O
(	O
2+	O
)	O
-stimulated	O
K+	O
channels	O
.	O

Mammalian	B-cell_type
cells	I-cell_type
express	O
two	O
distinct	O
forms	O
of	O
transcription	B-protein
factor	I-protein
CREB	I-protein
(	O
cAMP	B-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
)	O
that	O
are	O
apparently	O
the	O
products	O
of	O
alternative	O
splicing	O
of	O
the	O
CREB	B-RNA
gene	I-RNA
transcript	I-RNA
.	O

Dehydroepiandrosterone	O
(	O
DHEA	O
)	O
,	O
the	O
predominant	O
androgen	O
secreted	O
by	O
the	O
adrenal	O
cortex	O
,	O
can	O
be	O
converted	O
to	O
both	O
potent	O
androgens	O
and	O
estrogens	O
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
produced	O
both	O
by	O
lavage	B-cell_type
cells	I-cell_type
(	O
12/12	O
tuberculosis	O
patients	O
,	O
2/6	O
sarcoidosis	O
patients	O
)	O
and	O
blood	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
3/5	O
tuberculosis	O
patients	O
,	O
0/3	O
sarcoidosis	O
patients	O
)	O
from	O
patients	O
but	O
not	O
controls	O
,	O
but	O
significantly	O
greater	O
amounts	O
were	O
produced	O
by	O
lavage	O
cells	O
from	O
tuberculosis	O
patients	O
than	O
those	O
of	O
sarcoidosis	O
patients	O
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O

The	O
4-carboranyl-substituted	O
compounds	O
(	O
7	O
,	O
11	O
)	O
showed	O
antagonistic	O
activity	O
but	O
no	O
agonistic	O
activity	O
even	O
in	O
the	O
presence	O
of	O
the	O
potent	O
synergist	O
HX630	O
.	O

The	O
winged-helix	B-protein
transcription	I-protein
factor	I-protein
Trident	B-protein
is	O
expressed	O
in	O
actively	O
dividing	B-cell_type
lymphocytes	I-cell_type
.	O

ML-9	O
had	O
little	O
or	O
no	O
effect	O
on	O
the	O
morphology	O
of	O
U937	B-cell_line
cells	I-cell_line
but	O
increased	O
the	O
expression	O
of	O
monocyte-macrophage	B-protein
lineage-associated	I-protein
surface	I-protein
antigen	I-protein
,	O
CD14	B-protein
,	O
to	O
some	O
extent	O
.	O

This	O
may	O
be	O
the	O
basis	O
of	O
the	O
therapeutic	O
effect	O
on	O
the	O
disease	O
.	O

Study	O
of	O
the	O
inhibitory	O
activities	O
of	O
phosphotyrosine-containing	O
peptides	O
derived	O
from	O
the	O
intracellular	B-protein
domain	I-protein
of	I-protein
the	I-protein
IL-4	I-protein
receptor	I-protein
provided	O
evidence	O
for	O
direct	O
coupling	O
of	O
receptor	B-protein
and	O
transcription	B-protein
factor	I-protein
during	O
the	O
IL-4	B-protein
Stat	I-protein
activation	O
cycle	O
.	O

Glucocorticoids	O
are	O
among	O
the	O
most	O
potent	O
anti-inflammatory	O
and	O
immunosuppressive	O
agents	O
.	O

In	O
THP-1	O
cells	O
transfected	O
with	O
HIV	B-DNA
plasmid	I-DNA
constructs	I-DNA
,	O
both	O
organisms	O
induced	O
transcription	O
from	O
the	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
that	O
was	O
dependent	O
on	O
intact	O
NF-kappaB	B-DNA
binding	I-DNA
sequences	I-DNA
.	O

Antibodies	O
against	O
CRE-binding	B-protein
(	I-protein
CREB	I-protein
)	I-protein
protein	I-protein
but	O
not	O
against	O
c-Fos	B-protein
or	O
c-Jun	B-protein
were	O
able	O
to	O
supershift	O
the	O
DNA-protein	B-protein
complex	I-protein
,	O
identifying	O
the	O
nature	O
of	O
the	O
transcription	B-protein
factor	I-protein
which	O
binds	O
to	O
ZII	B-DNA
as	O
a	O
member	O
of	O
the	O
CREB	B-protein
family	I-protein
of	I-protein
proteins	I-protein
.	O

We	O
conclude	O
that	O
glucocorticoids	O
differentially	O
modulate	O
TNFalpha	B-protein
and	O
IL-10	B-protein
secretion	O
by	O
human	B-cell_type
monocytes	I-cell_type
in	O
a	O
LPS	O
dose-dependent	O
fashion	O
and	O
that	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
glucocorticoids	O
is	O
altered	O
by	O
TNFalpha	B-protein
or	O
IL-10	B-protein
pretreatment	O
;	O
TNFalpha	B-protein
blocks	O
their	O
effects	O
,	O
whereas	O
IL-10	B-protein
acts	O
synergistically	O
with	O
glucocorticoids	O
.	O

The	O
signaling	O
capabilities	O
of	O
the	O
IL-10R	B-protein
for	O
activating	O
specific	O
STAT	B-protein
proteins	I-protein
and	O
inducing	O
gene	O
transcription	O
were	O
defined	O
by	O
reconstitution	O
of	O
receptor	O
functions	O
in	O
transfected	B-cell_line
tissue	I-cell_line
culture	I-cell_line
cells	I-cell_line
.	O

However	O
,	O
CTLA-4	B-protein
ligation	O
did	O
not	O
appear	O
to	O
affect	O
the	O
CD28	B-protein
-mediated	O
stabilization	O
of	O
IL-2	B-RNA
mRNA	I-RNA
.	O

Tat	B-protein
,	O
a	O
potent	O
activator	O
of	O
HIV-1	O
gene	O
expression	O
,	O
serves	O
to	O
greatly	O
increase	O
the	O
rate	O
of	O
transcription	O
directed	O
by	O
the	O
viral	B-DNA
promoter	I-DNA
.	O

Nuclear	O
extracts	O
from	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
were	O
analyzed	O
by	O
electrophoretic	O
DNA	O
mobility	O
shift	O
assays	O
.	O

Here	O
,	O
we	O
have	O
analyzed	O
the	O
mechanisms	O
involved	O
in	O
CTLA-4	B-protein
-mediated	O
inhibition	O
of	O
T	O
cell	O
activation	O
of	O
naive	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
using	O
Ab	O
cross-linking	O
.	O

The	O
generation	O
of	O
genomic	O
diversity	O
during	O
the	O
course	O
of	O
infection	O
has	O
the	O
potential	O
to	O
affect	O
all	O
aspects	O
of	O
HIV-1	O
replication	O
,	O
including	O
expression	O
of	O
the	O
proviral	B-DNA
genome	I-DNA
.	O

The	O
secretion	O
levels	O
of	O
interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
and	O
von	O
Willebrand	O
factor	O
(	O
vWF	O
)	O
were	O
determined	O
,	O
to	O
serve	O
as	O
markers	O
for	O
EC	O
activation	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
revealed	O
that	O
the	O
potential	O
NF-kappaB	B-DNA
binding	I-DNA
sequence	I-DNA
which	O
is	O
located	O
around	O
120	B-DNA
bp	I-DNA
upstream	I-DNA
of	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
in	O
murine	B-DNA
and	I-DNA
human	I-DNA
p40	I-DNA
genes	I-DNA
formed	O
an	O
NF-kappaB	B-protein
complex	I-protein
with	O
nuclear	O
extract	O
from	O
Daudi	B-cell_line
cells	I-cell_line
stimulated	O
by	O
CD40	B-protein
ligation	O
.	O

The	O
protein	O
is	O
believed	O
to	O
bind	O
small	O
lipophilic	O
substances	O
such	O
as	O
bacterial	O
derived	O
formylpeptides	O
and	O
lipopolysaccharides	O
(	O
LPS	O
)	O
and	O
might	O
function	O
as	O
a	O
modulator	O
of	O
inflammation	O
.	O

This	O
Oct-1	B-protein
-binding	O
phenotype	O
remained	O
stable	O
in	O
culture	O
for	O
up	O
to	O
3	O
days	O
prior	O
to	O
activation	O
.	O

Our	O
results	O
indicated	O
that	O
the	O
epitope	B-protein
recognized	O
by	O
18C7	B-protein
was	O
directly	O
implicated	O
in	O
hormone	O
binding	O
.	O

All	O
mutants	O
were	O
tested	O
for	O
their	O
ability	O
to	O
interfere	O
with	O
wild-type	O
CIITA	B-protein
activity	O
.	O

Restriction	O
analysis	O
revealed	O
that	O
neutrophils	B-cell_type
express	O
the	O
GH-N	B-DNA
gene	I-DNA
but	O
not	O
the	O
GH-V	B-DNA
gene	I-DNA
.	O

During	O
CD30	B-protein
signal	O
transduction	O
,	O
we	O
found	O
that	O
binding	O
of	O
TRAF2	B-protein
to	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
CD30	B-protein
results	O
in	O
the	O
rapid	O
depletion	O
of	O
TRAF2	B-protein
and	O
the	O
associated	O
protein	O
TRAF1	B-protein
by	O
proteolysis	O
.	O

This	O
endogenous	B-protein
IFN	I-protein
was	O
also	O
shown	O
to	O
play	O
a	O
role	O
in	O
maintaining	O
the	O
basal	O
level	O
of	O
expression	O
of	O
the	O
major	B-DNA
histocompatibility	I-DNA
class	I-DNA
I	I-DNA
genes	I-DNA
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

The	O
majority	O
of	O
clones	O
identified	O
correspond	O
to	O
two	O
NF-ATc	B-protein
isoforms	I-protein
that	O
differ	O
only	O
in	O
their	O
amino-terminal	B-protein
sequence	I-protein
.	O

Low	O
levels	O
of	O
viral	O
transcription	O
(	O
basal	O
transcription	O
)	O
occur	O
before	O
expression	O
of	O
the	O
virally	B-protein
encoded	I-protein
Tax	I-protein
protein	I-protein
(	O
Tax	B-protein
-mediated	O
transcription	O
)	O
.	O

Association	O
of	O
JAK1	B-protein
and	O
STAT5	B-protein
was	O
found	O
to	O
occur	O
exclusively	O
between	O
unphosphorylated	B-protein
proteins	I-protein
.	O

Tandem	B-DNA
AP-1-binding	I-DNA
sites	I-DNA
within	O
the	O
human	B-DNA
beta-globin	I-DNA
dominant	I-DNA
control	I-DNA
region	I-DNA
function	O
as	O
an	O
inducible	B-DNA
enhancer	I-DNA
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
,	O
the	O
half-life	O
of	O
c-jun	B-RNA
RNA	I-RNA
in	O
TPA-treated	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
exposed	O
to	O
cycloheximide	O
and	O
actinomycin	O
D	O
was	O
greater	O
than	O
2	O
h	O
.	O

The	O
role	O
of	O
the	O
GR	B-protein
and	O
mineralocorticoid	B-protein
receptor	I-protein
(	O
MR	B-protein
)	O
in	O
the	O
CRH	O
regulation	O
in	O
the	O
FMS	O
patients	O
remains	O
to	O
be	O
solved	O
.	O

Clones	O
with	O
proliferative	O
responses	O
to	O
recombinant	B-protein
truncated	I-protein
glycoprotein	I-protein
B	I-protein
(	O
gB	B-protein
)	O
or	O
gD	B-protein
of	O
HSV-2	O
or	O
purified	O
natural	O
gC	O
of	O
HSV-2	O
comprised	O
a	O
minority	O
of	O
the	O
total	O
number	O
of	O
HSV-specific	B-cell_line
clones	I-cell_line
isolated	O
from	O
lesions	O
.	O

Further	O
Northern	O
analyses	O
indicated	O
that	O
there	O
was	O
no	O
significant	O
change	O
in	O
17beta-HSD	B-protein
IV	I-protein
or	O
DNA-PK	B-RNA
(	I-RNA
CS	I-RNA
)	I-RNA
mRNA	I-RNA
levels	O
following	O
treatment	O
with	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
although	O
expression	O
of	O
both	O
genes	O
varied	O
with	O
changes	O
in	O
cell	O
proliferation	O
.	O

A	O
small	O
but	O
significant	O
reduction	O
of	O
the	O
24-hour	O
urinary	O
cortisol	O
excretion	O
was	O
observed	O
(	O
233	O
+/-	O
109	O
and	O
157	O
+/-	O
66	O
nmol/L	O
,	O
respectively	O
;	O
P	O
<	O
.01	O
)	O
,	O
whereas	O
the	O
feedback	O
regulation	O
of	O
glucocorticoid	O
synthesis	O
by	O
means	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
as	O
assessed	O
by	O
the	O
adrenocorticotropic	O
hormone	O
test	O
remained	O
normal	O
after	O
treatment	O
with	O
FP	O
.	O

The	O
latter	O
defect	O
may	O
provide	O
an	O
explanation	O
for	O
many	O
of	O
the	O
XP	O
and	O
CS	O
symptoms	O
that	O
are	O
difficult	O
to	O
rationalize	O
based	O
solely	O
on	O
an	O
NER	O
defect	O
.	O

Also	O
,	O
in	O
a	O
promonocyte	B-cell_line
cell	I-cell_line
line	I-cell_line
chronically	O
infected	O
with	O
HIV	O
,	O
NF-kappa	B-protein
B	I-protein
expression	O
and	O
HIV	O
transcription	O
were	O
enhanced	O
on	O
stimulation	O
with	O
phorbol	O
ester	O
or	O
TNF	B-protein
alpha	I-protein
.	O

Bcd	B-RNA
mRNA	I-RNA
transcripts	I-RNA
of	O
<	O
or	O
=	O
2.6	O
kb	O
were	O
selectively	O
expressed	O
in	O
PBL	B-cell_line
and	O
testis	O
of	O
healthy	O
individuals	O
.	O

DCs	B-cell_type
express	O
high	O
levels	O
of	O
all	O
known	O
NF-kappa	B-protein
B	I-protein
and	O
Rel	B-protein
proteins	I-protein
,	O
with	O
activity	O
residing	O
primarily	O
within	O
RelB	B-protein
,	O
p50	B-protein
,	O
and	O
p65	B-protein
.	O

Northern	O
analysis	O
confirmed	O
that	O
expression	O
of	O
both	O
mRNAs	B-RNA
was	O
reduced	O
in	O
cells	O
with	O
decreased	O
numbers	O
of	O
VDR	B-protein
.	O

To	O
study	O
the	O
transcription	B-protein
factor	I-protein
requirement	O
in	O
B-cells	B-cell_type
,	O
different	O
U2	B-DNA
enhancer	I-DNA
constructions	I-DNA
were	O
transfected	O
into	O
the	O
lymphoid	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
BJA-B	B-cell_line
.	O

CTLA-4	B-protein
ligation	O
inhibited	O
CD3/	O
CD28	B-protein
-induced	O
IL-2	B-RNA
mRNA	I-RNA
accumulation	O
by	O
inhibiting	O
IL-2	B-protein
transcription	O
,	O
which	O
appears	O
to	O
be	O
mediated	O
in	O
part	O
through	O
decreasing	O
NF-AT	B-protein
accumulation	O
in	O
the	O
nuclei	O
.	O

We	O
provide	O
evidence	O
that	O
several	O
NF-kappaB	B-protein
complexes	I-protein
are	O
constitutively	O
found	O
in	O
the	O
nuclei	O
of	O
thymocytes	B-cell_type
either	O
freshly	O
isolated	O
from	O
the	O
thymus	O
or	O
maintained	O
in	O
coculture	O
with	O
autologous	O
or	O
heterologous	O
TEC	B-cell_type
.	O

The	O
negative	O
effects	O
of	O
point	O
mutations	O
in	O
the	O
LMP1	B-DNA
(	I-DNA
1-231	I-DNA
)	I-DNA
core	I-DNA
TRAF	I-DNA
binding	I-DNA
motif	I-DNA
on	O
TRAF	O
binding	O
and	O
NF-kappaB	B-protein
activation	O
genetically	O
link	O
the	O
TRAFs	B-protein
to	O
LMP1	B-protein
(	O
1-231	O
)	O
-mediated	O
NF-kappaB	B-protein
activation	O
.	O

Characterization	O
of	O
the	O
DNA-binding	B-protein
protein	I-protein
by	O
UV	O
cross-linking	O
,	O
Southwestern	O
blot	O
,	O
and	O
antibody	O
ablation/supershift	O
assays	O
revealed	O
that	O
it	O
is	O
similar	O
to	O
a	O
recently	O
reported	O
nuclear	B-protein
factor	I-protein
designated	O
SAF	B-protein
.	O

Interstitial	O
collagenase	B-protein
(	O
MMP-1	B-protein
)	O
,	O
a	O
metalloproteinase	B-protein
produced	O
by	O
resident	B-cell_type
and	I-cell_type
inflammatory	I-cell_type
cells	I-cell_type
during	O
connective	O
tissue	O
turnover	O
,	O
cleaves	O
type	B-protein
I	I-protein
collagen	I-protein
fibrils	I-protein
.	O

Conversely	O
,	O
a	O
dominant	O
negative	O
version	O
of	O
TRAF6	B-protein
failed	O
to	O
block	O
hToll	B-protein
-induced	O
activation	O
of	O
stress-activated	B-protein
protein	I-protein
kinase/c-Jun	I-protein
NH2-terminal	I-protein
kinases	I-protein
,	O
thus	O
suggesting	O
an	O
early	O
divergence	O
of	O
the	O
two	O
pathways	O
.	O

Several	O
DNA-binding	B-protein
proteins	I-protein
are	O
known	O
to	O
bind	O
this	O
sequence	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
activation	O
of	O
JAK	B-protein
/STAT	B-protein
pathway	O
upon	O
human	B-protein
interleukin-5	I-protein
(	O
hIL-5	B-protein
)	O
stimulation	O
of	O
two	O
different	O
hIL-5-responsive	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
hIL-5	B-cell_line
receptor	I-cell_line
alpha-subunit	I-cell_line
(	I-cell_line
hIL-5R	I-cell_line
alpha	I-cell_line
)	I-cell_line
cDNA-transfected	I-cell_line
TF-1	I-cell_line
(	O
TF-h5R	B-cell_line
alpha	I-cell_line
)	O
and	O
butyric-acid-treated	B-cell_line
YY-1	I-cell_line
(	O
YY-Bu	B-cell_line
)	O
,	O
and	O
peripheral	B-cell_line
eosinophils	I-cell_line
.	O

Specific	O
inhibitors	O
of	O
p38alpha	B-protein
MAPk	I-protein
blocked	O
LPS-induced	O
adhesion	O
,	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappaB	B-protein
)	O
activation	O
,	O
and	O
synthesis	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O

This	O
paper	O
presents	O
a	O
new	O
hypothesis	O
for	O
the	O
etiology	O
and	O
pathogenesis	O
of	O
celiac	O
disease	O
(	O
CD	O
)	O
.	O

Although	O
subtle	O
gene	O
movements	O
within	O
those	O
defined	O
topographical	O
regions	O
can	O
not	O
be	O
excluded	O
by	O
this	O
study	O
,	O
the	O
results	O
indicate	O
that	O
tissue	O
specificity	O
of	O
gene	O
expression	O
is	O
not	O
accompanied	O
by	O
drastic	O
changes	O
in	O
gene	O
nuclear	O
topography	O
,	O
rather	O
suggesting	O
that	O
gene	O
organization	O
within	O
the	O
nucleus	O
may	O
be	O
primarily	O
dependent	O
on	O
structural	O
constraints	O
imposed	O
on	O
the	O
respective	O
chromosomes	B-DNA
.	O

These	O
transcripts	O
can	O
encode	O
three	O
proteins	O
of	O
calculated	O
molecular	O
mass	O
32.2	B-RNA
kDa	I-RNA
,	O
27.8	B-RNA
kDa	I-RNA
,	O
and	O
14.3	B-RNA
kDa	I-RNA
.	O

Three	O
subtypes	O
of	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
(	O
RAR	B-protein
)	O
,	O
termed	O
RAR	B-protein
alpha	I-protein
,	O
RAR	B-protein
beta	I-protein
,	O
and	O
RAR	B-protein
gamma	I-protein
,	O
have	O
been	O
described	O
.	O

The	O
JAK	B-protein
(	I-protein
Janus	I-protein
kinase	I-protein
)	I-protein
family	I-protein
of	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
and	O
the	O
STATs	B-protein
(	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	O
have	O
been	O
shown	O
to	O
be	O
activated	O
in	O
response	O
to	O
a	O
number	O
of	O
cytokines	B-protein
and	O
growth	B-protein
factors	I-protein
.	O

Molecular	O
basis	O
of	O
a	O
multiple	O
lymphokine	B-protein
deficiency	O
in	O
a	O
patient	O
with	O
severe	O
combined	O
immunodeficiency	O
.	O

This	O
paper	O
reviews	O
the	O
considerable	O
data	O
available	O
relating	O
ROS	O
activity	O
and	O
antioxidant	O
defence	O
to	O
inflammatory	O
diseases	O
and	O
attempts	O
to	O
draw	O
parallels	O
with	O
periodontitis	O
,	O
in	O
an	O
effort	O
to	O
stimulate	O
more	O
periodontal	O
research	O
in	O
this	O
important	O
area	O
.	O

In	O
contrast	O
,	O
the	O
expression	O
of	O
actin	B-RNA
and	I-RNA
fibronectin	I-RNA
receptor	I-RNA
mRNA	I-RNA
was	O
more	O
sustained	O
,	O
and	O
the	O
expression	O
of	O
these	O
genes	O
remained	O
elevated	O
at	O
24	O
to	O
48	O
h	O
after	O
M-CSF	B-protein
addition	O
.	O

ROI	O
appear	O
to	O
serve	O
as	O
messengers	O
mediating	O
directly	O
or	O
indirectly	O
the	O
release	O
of	O
the	O
inhibitory	B-protein
subunit	I-protein
I	B-protein
kappa	I-protein
B	I-protein
from	O
NF-kappa	B-protein
B	I-protein
.	O

In	O
contrast	O
,	O
Staurosporine	O
alone	O
induced	O
AP-1	B-protein
translocation	O
and	O
stimulation	O
of	O
the	O
gene	O
.	O

The	O
v-src-induced	B-protein
complex	I-protein
comprised	O
the	O
p50	B-protein
and	O
p65	B-protein
components	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
as	O
determined	O
by	O
supershift	O
and	O
immunoblot	O
analysis	O
.	O

We	O
investigated	O
whether	O
BSAP	B-protein
plays	O
a	O
role	O
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
epsilon	O
germline	B-DNA
promoter	I-DNA
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Using	O
site-directed	O
mutagenesis	O
,	O
we	O
found	O
that	O
two	O
of	O
these	O
predicted	O
alpha-helices	B-protein
are	O
required	O
for	O
full	O
transcriptional	O
activation	O
by	O
CIITA	B-protein
.	O

BASH	B-protein
shows	O
a	O
substantial	O
sequence	O
similarity	O
to	O
SLP-76	B-protein
,	O
an	O
adaptor	O
protein	O
functioning	O
in	O
TCR	B-protein
-signal	O
transduction	O
.	O

Normal	O
T	B-cell_type
lymphocytes	I-cell_type
whose	O
surface	O
expression	O
of	O
CD3	B-protein
was	O
depleted	O
showed	O
impaired	O
UV-induced	O
tyrosine	O
phosphorylation	O
and	O
Ca2+	O
signals	O
.	O

Because	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
can	O
improve	O
the	O
capacity	O
of	O
macrophages	B-cell_type
to	O
kill	O
mycobacteria	O
,	O
our	O
results	O
support	O
the	O
conclusion	O
that	O
macrophage-lymphocyte	O
interactions	O
,	O
mediated	O
at	O
least	O
in	O
part	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
may	O
be	O
an	O
important	O
component	O
of	O
a	O
successful	O
antituberculous	O
immune	O
response	O
.	O

The	O
interleukin-2	B-protein
IL-2	I-protein
receptor	I-protein
beta-chain	I-protein
(	O
IL-2Rbeta	B-protein
)	O
is	O
an	O
essential	O
component	O
of	O
the	O
receptors	O
for	O
IL-2	B-protein
and	O
IL-15	B-protein
.	O

The	O
present	O
results	O
thus	O
show	O
that	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
is	O
able	O
to	O
regulate	O
E2F	B-protein
transcriptional	O
activity	O
and	O
provide	O
direct	O
evidence	O
for	O
the	O
first	O
time	O
for	O
a	O
link	O
between	O
IL-2	B-protein
receptors	O
,	O
PI	B-protein
3-kinase	I-protein
,	O
and	O
p70	B-protein
(	I-protein
s6k	I-protein
)	I-protein
that	O
regulates	O
a	O
crucial	O
G1	O
checkpoint	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Minimizing	O
energy	O
studies	O
of	O
BMT	O
structure	O
reveal	O
that	O
a	O
trans-disulfide	O
of	O
thiamine	O
(	O
holo	O
drug	O
)	O
disulfide	O
(	O
TDS	O
,	O
protodrug	O
)	O
is	O
allosterically	O
transited	O
to	O
the	O
reactive	O
twisted	O
disulfide	O
of	O
BMT	O
(	O
allo	O
drug	O
)	O
by	O
o	O
,	O
o'-bismyristoyl	O
esterification	O
of	O
TDS	O
.	O

By	O
expressing	O
mutant	O
forms	O
of	O
the	O
human	O
protein	O
in	O
this	O
cell	B-cell_line
line	I-cell_line
,	O
we	O
have	O
been	O
able	O
to	O
delineate	O
the	O
sequences	O
responsible	O
for	O
both	O
the	O
ligand-induced	O
phosphorylation	O
and	O
the	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

We	O
find	O
that	O
the	O
factor	O
that	O
binds	O
to	O
the	O
E3	B-DNA
enhancer	I-DNA
motif	I-DNA
,	O
CATGTGGC	O
,	O
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
.	O

Importantly	O
,	O
methylprednisolone-mediated	O
enhancement	O
of	O
the	O
uptake	O
of	O
apoptotic	B-cell_type
neutrophils	I-cell_type
did	O
not	O
trigger	O
the	O
release	O
of	O
the	O
chemokines	B-protein
IL-8	B-protein
and	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
.	O

Therefore	O
,	O
we	O
investigated	O
in	O
situ	O
the	O
nuclear	O
localization	O
of	O
Rel/NF-kappa	B-protein
B	I-protein
proteins	I-protein
in	O
accessory	B-cell_type
cells	I-cell_type
of	O
the	O
immune	O
system	O
by	O
immunohistochemistry	O
and	O
double	O
labeling	O
by	O
immunofluorescence	O
from	O
five	O
normal	O
human	O
tonsils	O
and	O
five	O
lymph	O
nodes	O
with	O
follicular	O
hyperplasia	O
.	O

Oxidants	O
are	O
also	O
known	O
to	O
activate	O
another	O
transcription	B-protein
factor	I-protein
,	O
activator	B-protein
protein-1	I-protein
.	O

The	O
present	O
study	O
describes	O
the	O
cloning	O
of	O
a	O
lymphoid-restricted	B-DNA
gene	I-DNA
,	O
LYSP100	B-DNA
,	O
that	O
is	O
homologous	O
to	O
another	O
protein	O
that	O
localizes	O
to	O
PML	O
NBs	O
,	O
SP100	B-protein
.	O

Although	O
the	O
activating	O
signals	O
leading	O
to	O
Egr-1	B-protein
induction	O
have	O
been	O
studied	O
extensively	O
,	O
little	O
is	O
known	O
about	O
the	O
genes	O
that	O
are	O
placed	O
further	O
downstream	O
within	O
this	O
activation	O
cascade	O
and	O
that	O
are	O
transcriptionally	O
regulated	O
by	O
Egr-1	B-protein
.	O

Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
pretreated	O
with	O
NH2Cl	O
(	O
20-70	O
microM	O
)	O
showed	O
a	O
decrease	O
in	O
the	O
expression	O
of	O
the	O
interleukin-2	B-protein
receptor	B-protein
alpha	I-protein
chain	I-protein
following	O
PMA	O
stimulation	O
.	O

Levels	O
of	O
other	O
nuclear	B-protein
factors	I-protein
involved	O
in	O
IL-2	B-protein
regulation	O
were	O
not	O
altered	O
by	O
EC	B-cell_type
,	O
although	O
NFAT-DNA	B-protein
complexes	I-protein
migrated	O
at	O
a	O
slightly	O
different	O
mobility	O
.	O

Costimulation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cell	I-cell_type
activation	O
by	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O

These	O
findings	O
implicate	O
HMG-I	B-protein
in	O
the	O
HPFH	B-cell_type
phenotype	O
;	O
we	O
speculate	O
that	O
it	O
may	O
participate	O
in	O
the	O
formation	O
of	O
multiprotein	B-protein
complexes	I-protein
that	O
regulate	O
globin	O
gene	O
expression	O
.	O

Furthermore	O
,	O
CoCl2	O
also	O
caused	O
time-dependent	O
tyrosine	O
phosphorylation	O
of	O
mitogen-activated	B-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinase	I-protein
isoform	O
ERK2	B-protein
without	O
significantly	O
affecting	O
ERK1	B-protein
,	O
indicating	O
ERK2	B-protein
is	O
the	O
preferred	O
substrate	O
for	O
upstream	B-protein
kinase	I-protein
of	O
the	O
MAPK	B-protein
pathway	O
.	O

Like	O
other	O
cytokines	O
,	O
IL-12	B-protein
mediates	O
its	O
biologic	O
activity	O
through	O
high-affinity	O
receptors	O
expressed	O
on	O
responsive	B-cell_type
cells	I-cell_type
.	O

Nonmitogenic	O
T	O
cell	O
stimulation	O
did	O
not	O
result	O
in	O
appearance	O
of	O
NF-MATp35	B-protein
.	O

Addition	O
of	O
the	O
-176	B-DNA
to	I-DNA
-96	I-DNA
sequence	I-DNA
to	O
the	O
4X	B-DNA
NF-AT-Oct	I-DNA
construct	I-DNA
did	O
not	O
impart	O
the	O
ability	O
to	O
be	O
affected	O
by	O
anergy	O
,	O
but	O
addition	O
of	O
the	O
-236	B-DNA
to	I-DNA
-96	I-DNA
sequence	I-DNA
did	O
,	O
demonstrating	O
that	O
anergy	O
is	O
an	O
active	O
inhibitory	O
process	O
and	O
that	O
more	O
than	O
the	O
presence	O
of	O
the	O
-150	B-DNA
AP-1	I-DNA
binding	I-DNA
site	I-DNA
(	O
-152	B-DNA
to	I-DNA
-147	I-DNA
)	O
is	O
required	O
to	O
mediate	O
the	O
effect	O
.	O

The	O
renin	B-protein
-angiotensin	O
system	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
atherosclerosis	O
.	O

In	O
addition	O
,	O
N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
,	O
a	O
potent	O
antioxidant	O
,	O
decreased	O
NF-kappa	B-protein
B	I-protein
activation	O
caused	O
by	O
IL-4	B-protein
,	O
anti-CD40	B-protein
mAb	I-protein
,	O
or	O
their	O
combination	O
.	O

S6	B-protein
was	O
cleaved	O
with	O
CNBr	B-protein
and	O
three	O
internal	O
peptides	O
were	O
sequenced	O
.	O

AML1	B-protein
(	I-protein
CBFalpha2	I-protein
)	I-protein
cooperates	O
with	O
B	B-protein
cell-specific	I-protein
activating	I-protein
protein	I-protein
(	I-protein
BSAP/PAX5	I-protein
)	I-protein
in	O
activation	O
of	O
the	O
B	B-DNA
cell-specific	I-DNA
BLK	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

IFN	B-protein
alpha	I-protein
levels	O
were	O
increased	O
in	O
the	O
AIDS-GR	O
group	O
(	O
17	O
+/-	O
6	O
vs	O
.	O

Furthermore	O
,	O
we	O
present	O
a	O
new	O
principle	O
for	O
searching	O
Ag	B-protein
for	O
potential	O
amphipatic	B-protein
alpha-helical	I-protein
protein	I-protein
segments	I-protein
.	O

A	O
novel	O
T-cell	B-protein
protein	I-protein
recognized	O
the	O
palindromic	B-DNA
sequence	I-DNA
within	O
site	B-DNA
B	I-DNA
and	O
also	O
bound	O
estrogen-	B-DNA
or	I-DNA
thyroid	I-DNA
hormone-response	I-DNA
elements	I-DNA
with	O
lower	O
affinity	O
.	O

The	O
rate	O
of	O
transcription	O
initiation	O
directed	O
by	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	O
)	O
of	O
HIV-1	O
increases	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
gene	O
structure	O
of	O
LOX-1	B-protein
resembles	O
that	O
of	O
the	O
natural	B-protein
killer	I-protein
cell	I-protein
receptors	I-protein
.	O

These	O
sites	O
overlap	O
the	O
P1	B-DNA
,	I-DNA
P2	I-DNA
,	I-DNA
and	I-DNA
P4	I-DNA
NFAT	I-DNA
elements	I-DNA
.	O

T	B-cell_type
lymphocytes	I-cell_type
from	O
6	O
of	O
the	O
14	O
patients	O
also	O
exhibited	O
an	O
increased	O
expression	O
of	O
the	O
dual	O
specificity	B-protein
phosphatase	I-protein
,	O
map	B-protein
kinase	I-protein
phosphatase-1	I-protein
(	O
MKP-1	B-protein
)	O
.	O

Furthermore	O
,	O
it	O
might	O
contribute	O
to	O
the	O
hypergammaglobulinemia	O
or	O
,	O
together	O
with	O
other	O
cytokines	B-protein
found	O
to	O
be	O
dysregulated	O
,	O
the	O
T-helper	O
cell	O
dysfunctions	O
observed	O
in	O
AIDS	O
patients	O
.	O

As	O
expected	O
,	O
nearly	O
all	O
control	O
mice	O
(	O
94.4	O
%	O
)	O
survived	O
irradiation	O
,	O
yet	O
this	O
irradiation	O
was	O
lethal	O
to	O
45.8	O
%	O
of	O
PML/RARalpha	B-protein
transgenic	O
mice	O
.	O

Over	O
the	O
next	O
week	O
,	O
this	O
cell	O
population	O
accumulates	O
phenotypic	O
markers	O
of	O
osteoclasts	B-cell_type
(	O
vitronectin	B-protein
receptor	I-protein
[	O
VR	B-protein
]	O
,	O
calcitonin	B-protein
receptor	I-protein
,	O
TRAP	B-protein
,	O
cathepsin	B-protein
K	I-protein
protein	I-protein
,	O
and	O
mRNA	B-RNA
)	O
with	O
increased	O
nuclearity	O
,	O
covering	O
the	O
entire	O
surface	O
by	O
15	O
days	O
.	O

Thus	O
,	O
we	O
propose	O
that	O
GATA-3	B-protein
is	O
permissive	O
,	O
but	O
not	O
sufficient	O
,	O
for	O
full	O
IL-4	B-protein
enhancement	O
and	O
may	O
act	O
through	O
GATA	B-DNA
elements	I-DNA
surrounding	O
the	O
IL-13/IL-4	B-DNA
gene	I-DNA
locus	I-DNA
.	O

We	O
previously	O
showed	O
that	O
repression	O
of	O
the	O
beta-globin	O
gene	O
appears	O
to	O
be	O
mediated	O
through	O
two	O
DNA	B-DNA
sequences	I-DNA
,	O
silencers	B-DNA
I	I-DNA
and	I-DNA
II	I-DNA
,	O
and	O
identified	O
a	O
protein	O
termed	O
BP1	B-protein
which	O
binds	O
to	O
both	O
silencer	O
sequences	O
.	O

Activation	O
of	O
T	B-cell_type
cells	I-cell_type
is	O
initiated	O
by	O
the	O
recognition	O
of	O
antigen	O
on	O
antigen	B-cell_type
presenting	I-cell_type
cells	I-cell_type
to	O
exert	O
the	O
effector	O
functions	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Tax	B-protein
-mediated	O
transformation	O
of	O
T	B-cell_type
cells	I-cell_type
likely	O
involves	O
the	O
deregulated	O
expression	O
of	O
various	O
cellular	B-DNA
genes	I-DNA
that	O
normally	O
regulate	O
lymphocyte	B-cell_type
growth	O
produced	O
by	O
altered	O
activity	O
of	O
various	O
endogenous	O
host	O
transcription	B-protein
factors	I-protein
.	O

Although	O
GM-CSF	B-protein
does	O
not	O
appear	O
to	O
be	O
essential	O
for	O
normal	O
hemopoiesis	O
,	O
overexpression	O
of	O
GM-CSF	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
some	O
diseases	O
such	O
as	O
myeloid	O
leukemia	O
and	O
chronic	O
inflammation	O
.	O

We	O
localized	O
the	O
LAM-	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
,	O
and	O
TNF-alpha	B-protein
-inducible	B-DNA
promoter	I-DNA
activity	O
to	O
a	O
-131/+15	O
(	O
positions	O
-131	O
to	O
+15	O
)	O
DNA	O
fragment	O
of	O
the	O
IL-1	B-DNA
beta	I-DNA
gene	I-DNA
by	O
deletion	O
analysis	O
and	O
chloramphenicol	B-protein
acetyltransferase	I-protein
assay	O
.	O

In	O
the	O
present	O
studies	O
,	O
rat	O
lungs	O
were	O
depleted	O
of	O
alveolar	B-cell_type
macrophages	I-cell_type
by	O
airway	O
instillation	O
of	O
liposome-encapsulated	O
dichloromethylene	O
diphosphonate	O
.	O

Because	O
oleic	O
acid	O
is	O
implicated	O
in	O
the	O
antiatherogenic	O
effects	O
attributed	O
to	O
the	O
Mediterranean	O
diet	O
,	O
we	O
investigated	O
whether	O
this	O
fatty	O
acid	O
can	O
modulate	O
endothelial	O
activation	O
,	O
ie	O
,	O
the	O
concerted	O
expression	O
of	O
gene	B-protein
products	I-protein
involved	O
in	O
leukocyte	O
recruitment	O
and	O
early	O
atherogenesis	O
.	O

Although	O
spontaneous	O
tumorigenesis	O
was	O
not	O
observed	O
,	O
IL-2	B-protein
production	O
with	O
Concanavalin	O
A	O
stimulation	O
was	O
significantly	O
increased	O
in	O
transgenic	O
mice	O
overexpressing	O
ICSAT	B-protein
.	O

In	O
monocytes	O
,	O
the	O
virus	O
was	O
bound	O
to	O
the	O
surface	O
without	O
being	O
internalized	O
.	O

In	O
comparison	O
to	O
other	O
activators	O
of	O
NF-kappa	B-protein
B	I-protein
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
,	O
we	O
did	O
not	O
detect	O
changes	O
in	O
the	O
tyrosine	O
phosphorylation	O
status	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
following	O
treatment	O
with	O
either	O
of	O
these	O
agents	O
.	O

Our	O
results	O
strongly	O
suggest	O
that	O
this	O
NF-AT	B-protein
/DNA	O
binding	O
defect	O
is	O
responsible	O
for	O
the	O
multiple	O
cytokine	B-protein
deficiency	O
and	O
the	O
SCID	O
phenotype	O
observed	O
in	O
the	O
two	O
infant	O
brothers	O
.	O

Exposure	O
to	O
VitD3	O
rapidly	O
induced	O
the	O
de	O
novo	O
expression	O
of	O
CD14	B-RNA
mRNA	I-RNA
and	O
protein	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
lipoproteins	B-protein
of	O
Treponema	O
pallidum	O
and	O
Borrelia	O
burgdorferi	O
are	O
key	O
inflammatory	O
mediators	O
during	O
syphilis	O
and	O
Lyme	O
disease	O
.	O

Immunoblot	O
analysis	O
identified	O
Fli-1	B-protein
protein	I-protein
in	O
lysates	O
derived	O
from	O
platelets	B-cell_type
.	O

In	O
addition	O
,	O
IL-2	B-protein
is	O
capable	O
of	O
increasing	O
transcript	O
levels	O
of	O
the	O
p50	B-protein
gene	O
coding	O
for	O
the	O
p50	B-protein
subunit	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	O
factor	O
,	O
whereas	O
mRNA	O
levels	O
of	O
the	O
p65	B-protein
NF-kappa	B-DNA
B	I-DNA
gene	I-DNA
remained	O
unchanged	O
.	O

In	O
the	O
mouse	O
embryo	O
,	O
mNFATc	B-RNA
transcript	I-RNA
was	O
strongly	O
expressed	O
in	O
thymus	O
,	O
lung	O
and	O
submandibular	O
gland	O
and	O
weakly	O
in	O
skeletal	O
muscle	O
and	O
heart	O
suggesting	O
that	O
mNFATc	B-protein
may	O
have	O
a	O
role	O
both	O
in	O
embryogenesis	O
and	O
in	O
mature	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
rex	B-DNA
gene	I-DNA
encodes	O
two	O
protein	O
products	O
,	O
p27rex/p21rex	B-protein
and	O
p26rex/p24rex	B-protein
in	O
HTLV-I	O
and	O
HTLV-II	O
,	O
respectively	O
.	O

The	O
age-related	O
decline	O
in	O
induction	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
could	O
not	O
be	O
attributed	O
to	O
alteration	O
in	O
the	O
composition	O
of	O
subunits	O
,	O
p50	B-protein
and	O
p65	B-protein
were	O
found	O
to	O
be	O
the	O
predominant	O
subunits	O
of	O
induced	O
NF	B-protein
kappa	I-protein
B	I-protein
in	O
T	B-cell_type
cells	I-cell_type
from	O
young	O
as	O
well	O
as	O
elderly	O
donors	O
.	O

Pretreatment	O
with	O
a	O
protein	B-protein
kinase	I-protein
C	I-protein
activator	O
,	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
caused	O
almost	O
complete	O
inhibition	O
of	O
histamine-induced	O
[	O
Ca2+	O
]	O
i	O
rise	O
,	O
but	O
did	O
not	O
do	O
so	O
by	O
activators	O
of	O
cAMP-	B-protein
and	I-protein
cGMP-dependent	I-protein
protein	I-protein
kinases	I-protein
.	O

We	O
generated	O
permanent	O
clones	O
of	O
the	O
murine	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
EL4	I-cell_line
6.1	I-cell_line
overexpressing	O
human	B-protein
(	I-protein
h	I-protein
)	I-protein
IRAK	I-protein
to	O
evaluate	O
the	O
role	O
of	O
this	O
kinase	O
in	O
IL-1	B-protein
signaling	O
.	O

The	O
relationship	O
of	O
the	O
N-Oct	B-protein
proteins	I-protein
to	O
Oct-1	B-protein
and	O
Oct-2A	B-protein
was	O
analyzed	O
by	O
proteolytic	O
clipping	O
bandshift	O
assays	O
and	O
by	O
their	O
reactivity	O
towards	O
antisera	O
raised	O
against	O
recombinant	O
Oct-1	B-protein
and	O
Oct-2A	B-protein
proteins	O
.	O

In	O
one	O
patient	O
,	O
transient	O
reduction	O
of	O
aldosterone	B-protein
receptors	I-protein
could	O
be	O
documented	O
,	O
while	O
in	O
the	O
second	O
patient	O
the	O
clinical	O
and	O
biochemical	O
parameters	O
were	O
consistent	O
with	O
transient	O
pseudohypoaldosteronism	O
.	O

Platelet	B-protein
glycoprotein	I-protein
(	O
GP	B-protein
)	O
Ib-IX-V	B-protein
is	O
a	O
multisubunit	B-protein
adhesion	I-protein
receptor	I-protein
that	O
supports	O
platelet	O
attachment	O
to	O
thrombogenic	O
surfaces	O
at	O
sites	O
of	O
vascular	O
injury	O
.	O

This	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-induced	O
G1	O
arrest	O
is	O
enhanced	O
by	O
all-trans	O
RA	O
.	O

Therefore	O
,	O
in	O
normal	B-cell_type
human	I-cell_type
monocytes	I-cell_type
M-CSF	B-protein
induces	O
immediate	B-DNA
early	I-DNA
response	I-DNA
genes	I-DNA
without	O
inducing	O
cell	O
proliferation	O
.	O

In	O
contrast	O
,	O
several	O
mutant	O
p85	B-protein
alleles	O
had	O
dramatic	O
effects	O
on	O
NFAT	B-protein
activation	O
.	O

The	O
increase	O
of	O
cortisol	O
is	O
immunosuppressive	O
and	O
reduces	O
GR	B-protein
concentration	O
both	O
in	O
nervous	O
and	O
immune	O
systems	O
.	O

Northern	O
hybridization	O
data	O
showed	O
that	O
B4-2	B-DNA
is	O
not	O
a	O
lymphoid	B-DNA
specific	I-DNA
gene	I-DNA
and	O
is	O
expressed	O
in	O
a	O
hepatoma	B-cell_line
cell	I-cell_line
line	I-cell_line
and	O
also	O
weakly	O
transcribed	O
or	O
absent	O
in	O
a	O
variety	O
of	O
other	O
cells	O
.	O

Naturally	O
processed	O
forms	O
of	O
these	O
structures	O
are	O
likely	O
to	O
occur	O
given	O
the	O
importance	O
and	O
frequency	O
of	O
deamidation	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Dysregulation	O
of	O
cytokines	B-protein
secreted	O
by	O
T	B-cell_type
cells	I-cell_type
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
.	O

Fourth	O
,	O
extensive	O
purification	O
by	O
several	O
cycles	O
of	O
TRE	B-DNA
-DNA	O
affinity	O
chromatography	O
resulted	O
in	O
the	O
32	B-protein
,	I-protein
36	I-protein
to	I-protein
42	I-protein
and	I-protein
110	I-protein
kD	I-protein
proteins	I-protein
and	O
to	O
less	O
extent	O
the	O
50	B-protein
kD	I-protein
factor	I-protein
.	O

The	O
two	B-protein
nuclear	I-protein
proteins	I-protein
NF-kappa	B-protein
B	I-protein
(	O
consisting	O
of	O
subunits	O
p50	B-protein
an	O
dp65	B-protein
)	O
and	O
the	O
DNA-binding	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
(	O
p50	B-protein
)	O
by	O
itself	O
,	O
also	O
called	O
KBF1	B-protein
,	O
are	O
constitutively	O
expressed	O
and	O
localized	O
in	O
the	O
nucleus	O
of	O
the	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
IARC	B-cell_line
301.5	I-cell_line
.	O

This	O
observation	O
supports	O
a	O
model	O
,	O
in	O
which	O
promoter	O
selectivity	O
reflects	O
the	O
selectively	O
increased	O
antiproliferative	O
effect	O
of	O
VD	O
analogues	O
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
wild-type	B-protein
ZAP-70	I-protein
induced	O
constitutive	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
.	O

These	O
transcripts	O
initiate	O
from	O
one	O
of	O
two	O
promoters	B-DNA
,	O
Cp	B-DNA
or	O
Wp	O
,	O
that	O
function	O
in	O
a	O
mutually	O
exclusive	O
fashion	O
.	O

However	O
,	O
this	O
factor	O
appeared	O
when	O
these	O
CML	O
patients	O
achieved	O
complete	O
haematological	O
remission	O
(	O
CHR	O
)	O
through	O
alpha-interferon	B-protein
therapy	O
.	O

Addition	O
of	O
untreated	O
THP-1	B-cell_line
cells	I-cell_line
had	O
little	O
effect	O
on	O
HUVEC	B-cell_type
adhesiveness	O
.	O

IL-2	B-protein
induced	O
the	O
DNA	O
binding	O
activity	O
of	O
STAT3	B-protein
and	O
STAT5	B-protein
of	O
a	O
HTLV-1-transformed	O
cell	O
line	O
and	O
then	O
stimulated	O
its	O
proliferation	O
.	O

In	O
situ	O
hybridization	O
showed	O
that	O
apart	O
from	O
lymphocytes	B-cell_type
,	O
thyroid	B-cell_type
cells	I-cell_type
themselves	O
were	O
the	O
source	O
of	O
MHC	B-protein
II	I-protein
transcripts	I-protein
.	O

Engagement	O
of	O
surface	O
immunoglobulin	O
on	O
mature	O
B	O
cells	O
leads	O
to	O
rescue	O
from	O
apoptosis	O
and	O
to	O
proliferation	O
.	O

In	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
complementary	B-DNA
DNA	I-DNA
resulted	O
in	O
the	O
synthesis	O
of	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
size	O
of	O
65	B-protein
kilodaltons	I-protein
(	O
kD	O
)	O
.	O

Thus	O
,	O
human	B-cell_type
erythroid	I-cell_type
precursors	I-cell_type
can	O
be	O
expanded	O
in	O
vitro	O
in	O
sufficient	O
numbers	O
and	O
purity	O
to	O
allow	O
its	O
usage	O
in	O
signal	O
transduction	O
studies	O
.	O

The	O
vpr	B-protein
product	I-protein
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
acts	O
in	O
trans	O
to	O
accelerate	O
virus	O
replication	O
and	O
cytopathic	O
effect	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Treatment	O
of	O
SKW	O
6.4	O
cells	O
with	O
IL	B-protein
6	I-protein
induced	O
a	O
transient	O
and	O
early	O
stimulation	O
of	O
c-fos	B-RNA
sense	I-RNA
mRNA	I-RNA
expression	O
.	O

Upregulation	O
of	O
c-Fos	B-protein
in	O
activated	B-cell_type
T	I-cell_type
lymphoid	I-cell_type
and	I-cell_type
monocytic	I-cell_type
cells	I-cell_type
by	O
human	B-protein
immunodeficiency	I-protein
virus-1	I-protein
Tat	I-protein
protein	I-protein
.	O

Before	O
exposure	O
to	O
low	O
shear	O
(	O
2	O
dyn/cm2	O
)	O
for	O
6	O
h	O
,	O
HAEC	B-cell_line
were	O
preincubated	O
with	O
or	O
without	O
the	O
antioxidants	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
or	O
N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
.	O

To	O
further	O
elucidate	O
the	O
role	O
of	O
RelB	B-protein
in	O
DC	B-cell_type
differentiation	O
,	O
mRNA	B-RNA
,	O
intracellular	O
protein	O
expression	O
,	O
and	O
DNA	O
binding	O
activity	O
of	O
RelB	B-protein
were	O
examined	O
in	O
immature	O
and	O
differentiated	O
human	B-cell_type
DC	I-cell_type
,	O
as	O
well	O
as	O
other	O
PB	B-cell_type
mononuclear	I-cell_type
cell	I-cell_type
populations	I-cell_type
.	O

SOCS-3	B-protein
is	O
tyrosine	O
phosphorylated	O
in	O
response	O
to	O
interleukin-2	B-protein
and	O
suppresses	O
STAT5	B-protein
phosphorylation	O
and	O
lymphocyte	O
proliferation	O
.	O

In	O
addition	O
,	O
inhibition	O
of	O
mRNA	B-RNA
synthesis	O
with	O
actinomycin	O
D	O
indicated	O
that	O
DOX	O
induced	O
an	O
increased	O
stability	O
of	O
PBGD	B-RNA
and	I-RNA
GATA-1	I-RNA
mRNAs	I-RNA
,	O
whereas	O
ACLA	O
did	O
not	O
affect	O
the	O
half-lives	O
of	O
these	O
mRNAs	B-RNA
.	O

The	O
discovery	O
of	O
these	O
signaling	O
pathways	O
has	O
led	O
to	O
important	O
new	O
insights	O
into	O
their	O
role	O
in	O
lymphocyte	O
maturation	O
,	O
as	O
it	O
has	O
emerged	O
that	O
mutations	O
in	O
the	O
genes	O
encoding	O
both	O
gamma	B-protein
c	I-protein
and	O
JAK3	B-protein
result	O
in	O
similar	O
forms	O
of	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
.	O

Furthermore	O
,	O
the	O
potentiated	O
aggregation	O
was	O
shown	O
to	O
result	O
from	O
an	O
increased	O
capacity	O
of	O
platelets	O
to	O
bind	O
fibrinogen	O
.	O

The	O
two	O
mutations	O
R217A	O
and	O
R294A	O
caused	O
an	O
increased	O
binding	O
efficiency	O
for	O
antagonists	O
but	O
no	O
change	O
in	O
agonist	O
binding	O
.	O

Despite	O
their	O
bipotential	O
capacity	O
,	O
these	O
progenitors	O
develop	O
predominantly	O
to	O
T	B-cell_type
cells	I-cell_type
in	O
the	O
thymus	O
.	O

Here	O
we	O
provide	O
evidence	O
that	O
this	O
transformation	O
is	O
the	O
result	O
of	O
double	O
infection	O
of	O
a	O
cell	O
with	O
two	O
virions	O
,	O
the	O
P3HR1	B-DNA
virus	I-DNA
genome	I-DNA
and	O
a	O
mini-EBV	B-DNA
plasmid	I-DNA
carrying	O
the	O
chimeric	O
EBNA2	B-DNA
gene	I-DNA
.	O

To	O
examine	O
the	O
hypothesis	O
that	O
interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
contributes	O
to	O
PMN	O
infiltration	O
and	O
lung	O
damage	O
in	O
HS	O
,	O
we	O
examined	O
the	O
lungs	O
of	O
rats	O
subjected	O
to	O
unresuscitated	O
and	O
resuscitated	O
HS	O
for	O
the	O
production	O
of	O
IL-6	B-protein
and	O
activation	O
of	O
Stat3	B-protein
.	O

In	O
the	O
tumor	O
samples	O
,	O
expression	O
of	O
LAZ3/BCL6	B-protein
was	O
observed	O
in	O
68	O
%	O
of	O
all	O
B	O
cell	O
NHL	O
and	O
none	O
of	O
the	O
non-B	O
lymphomas	O
.	O

The	O
RALDH2	B-RNA
transcripts	I-RNA
in	O
T-ALL	O
were	O
,	O
however	O
,	O
mostly	O
initiated	O
within	O
the	O
second	B-RNA
intron	I-RNA
.	O

In	O
fact	O
,	O
IFNs	B-protein
inhibit	O
growth	O
of	O
various	O
normal	B-cell_type
and	O
transformed	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O

HIV-1	B-protein
envelope	I-protein
glycoproteins	I-protein
induce	O
activation	O
of	O
activated	O
protein-1	B-protein
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Dec	O
1	O
;	O
270	O
(	O
48	O
)	O
:	O
29038	O
]	O

NF-IL6	B-RNA
mRNA	I-RNA
was	O
found	O
in	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
and	O
in	O
the	O
mouse	B-cell_line
Th2	I-cell_line
clone	I-cell_line
D10	B-cell_line
,	O
but	O
not	O
in	O
Th1	B-cell_line
clone	I-cell_line
29	I-cell_line
.	O

In	O
contrast	O
to	O
MEL	B-cell_line
cells	I-cell_line
,	O
however	O
,	O
K562	B-cell_line
cells	I-cell_line
acquired	O
a	O
macrophage-like	O
morphology	O
and	O
exhibited	O
a	O
complete	O
failure	O
to	O
generate	O
benzidine-positive	B-cell_line
cells	I-cell_line
.	O

Preparation	O
and	O
analysis	O
of	O
bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
from	O
the	O
chimeric	O
mice	O
indicated	O
that	O
the	O
bone	O
marrow	O
is	O
the	O
effective	O
site	O
for	O
specific	O
depletion	O
of	O
the	O
B-cell	B-cell_type
population	I-cell_type
.	O

Cell	O
type	O
specificity	O
and	O
activation	O
requirements	O
for	O
NFAT-1	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	O
activated	B-cell_type
T-cells	I-cell_type
)	O
transcriptional	O
activity	O
determined	O
by	O
a	O
new	O
method	O
using	O
transgenic	O
mice	O
to	O
assay	O
transcriptional	O
activity	O
of	O
an	O
individual	O
nuclear	B-protein
factor	I-protein
.	O

Further	O
definition	O
of	O
this	O
pathway	O
will	O
yield	O
new	O
insights	O
into	O
inflammation	O
initiated	O
by	O
TNFalpha	B-protein
signalling	O
.	O

TNF	B-protein
is	O
one	O
of	O
the	O
cytokines	B-protein
secreted	O
by	O
the	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Cell-to-cell	O
contact	O
activation	O
of	O
NF-kappaB	B-protein
was	O
only	O
partially	O
inhibited	O
by	O
100	O
microM	O
pyrrolidine	O
dithiocarbamate	O
and	O
was	O
not	O
correlated	O
with	O
a	O
significant	O
decrease	O
of	O
cellular	B-protein
inhibitor	I-protein
kappaB	I-protein
alpha	I-protein
.	O

The	O
clinical	O
implications	O
of	O
nuclear	O
T3R	B-protein
alterations	O
of	O
circulating	B-cell_type
lymphocytes	I-cell_type
in	O
hyperthyroidism	O
,	O
hypothyroidism	O
and	O
nonthyroidal	O
diseases	O
were	O
investigated	O
.	O

In	O
Jurkat	O
and	O
NC2.10	O
induction	O
with	O
phorbol	O
esters	O
resulted	O
in	O
the	O
appearance	O
of	O
new	O
DNA	B-protein
binding	I-protein
proteins	I-protein
of	O
85	B-protein
,	I-protein
75	I-protein
,	I-protein
and	I-protein
54	I-protein
kDa	I-protein
,	O
whereas	O
in	O
Tax	B-cell_line
expressing	I-cell_line
cells	I-cell_line
the	O
85-kDa	B-protein
protein	I-protein
and	O
a	O
92-kDa	B-protein
DNA	I-protein
binding	I-protein
protein	I-protein
were	O
constitutively	O
induced	O
.	O

We	O
demonstrate	O
that	O
,	O
in	O
primary	B-cell_type
NK	I-cell_type
cells	I-cell_type
,	O
IL-13	B-protein
,	O
but	O
not	O
IL-4	B-protein
,	O
may	O
induce	O
low	O
levels	O
of	O
IFN-gamma	B-protein
secretion	O
.	O

The	O
immunodominant	O
,	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cytotoxic	I-cell_type
T	I-cell_type
lymphocyte	I-cell_type
(	O
CTL	O
)	O
response	O
to	O
the	O
HLA-B8-restricted	O
peptide	O
,	O
RAKFKQLL	O
,	O
located	O
in	O
the	O
Epstein-Barr	B-protein
virus	I-protein
immediate-early	I-protein
antigen	I-protein
,	O
BZLF1	B-protein
,	O
is	O
characterized	O
by	O
a	O
diverse	O
T	B-protein
cell	I-protein
receptor	I-protein
(	I-protein
TCR	I-protein
)	I-protein
repertoire	I-protein
.	O

It	O
is	O
crucial	O
that	O
these	O
results	O
mirror	O
recent	O
observations	O
indicating	O
that	O
murine	O
adult	O
HPCs	B-cell_type
transduced	O
with	O
dominant	O
negative	O
ATRA	B-DNA
receptor	I-DNA
(	I-DNA
RAR	I-DNA
)	I-DNA
gene	I-DNA
are	O
immortalized	O
and	O
show	O
a	O
selective	O
blockade	O
of	O
granulocytic	O
differentiation	O
.	O

This	O
is	O
achieved	O
in	O
part	O
through	O
the	O
positive	O
activities	O
of	O
the	O
AP-1	B-DNA
and	I-DNA
Elf-1	I-DNA
sites	I-DNA
in	O
the	O
IL-3	B-DNA
promoter	I-DNA
.	O

Following	O
intracranial	O
inoculation	O
in	O
mice	O
,	O
both	O
VZV	B-protein
gE-HSV	I-protein
(	O
TK	B-protein
)	O
and	O
VZV	B-protein
IE62-HSV	I-protein
(	O
gC	B-protein
)	O
induced	O
an	O
IgG	B-protein
response	O
against	O
VZV	B-protein
gE	I-protein
or	O
VZV	B-protein
IE62	I-protein
.	O

A	O
second	O
messenger	O
cascade	O
involved	O
is	O
the	O
inositol-1	O
,	O
4	O
,	O
5-trisphosphate/calcium	O
pathway	O
which	O
responds	O
over	O
the	O
same	O
rapid	O
time	O
course	O
.	O

The	O
role	O
of	O
Rel/NF-kappa	B-protein
B	I-protein
proteins	I-protein
in	O
viral	O
oncogenesis	O
and	O
the	O
regulation	O
of	O
viral	O
transcription	O
.	O

Mouse	B-cell_type
,	I-cell_type
rat	I-cell_type
,	I-cell_type
hamster	I-cell_type
,	I-cell_type
and	I-cell_type
human	I-cell_type
cells	I-cell_type
that	O
were	O
rendered	O
cytolytic	O
susceptible	O
by	O
E1A	B-protein
were	O
also	O
sensitized	O
to	O
CL-induced	O
and	O
chemically	O
induced	O
apoptosis	O
.	O

The	O
first	O
male	O
patient	O
presented	O
with	O
mild	O
hypertension	O
.	O

Enhanced	O
turnover	O
of	O
IkappaBalpha	B-protein
and	O
the	O
accumulation	O
of	O
NF-kappaB/Rel	B-protein
proteins	I-protein
may	O
contribute	O
to	O
the	O
chronically	O
activated	O
state	O
of	O
HIV-1-infected	B-cell_line
cells	I-cell_line
.	O

Nonetheless	O
,	O
only	O
a	O
limited	O
portion	O
of	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
is	O
necessary	O
for	O
IL-7R	B-protein
signal	O
transduction	O
.	O

Characterization	O
of	O
a	O
novel	B-protein
T	I-protein
lymphocyte	I-protein
protein	I-protein
which	O
binds	O
to	O
a	O
site	O
related	O
to	O
steroid/thyroid	B-DNA
hormone	I-DNA
receptor	I-DNA
response	I-DNA
elements	I-DNA
in	O
the	O
negative	B-DNA
regulatory	I-DNA
sequence	I-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O

Activation	O
by	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
is	O
minimal	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
and	O
is	O
mediated	O
by	O
the	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
.	O

Nonimmunoglobulin	O
gene	O
hypermutation	O
in	O
germinal	B-cell_type
center	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Human	O
cytomegalovirus	O
binding	O
to	O
human	B-cell_type
monocytes	I-cell_type
induces	O
immunoregulatory	O
gene	O
expression	O
.	O

Thus	O
,	O
the	O
GATA-2	B-protein
transcription	I-protein
factor	I-protein
appears	O
to	O
play	O
a	O
role	O
in	O
regulating	O
the	O
self-renewal	O
capacity	O
of	O
early	B-cell_type
erythroid	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

The	O
helper	O
activity	O
for	O
IgE	B-protein
synthesis	O
by	O
the	O
CD27	B-protein
/CD70	O
interaction	O
did	O
not	O
contribute	O
to	O
the	O
enhancement	O
of	O
germline	B-RNA
epsilon	I-RNA
transcripts	I-RNA
.	O

IL-10	B-protein
markedly	O
reduces	O
nuclear	O
factor	O
(	B-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B/Rel	I-protein
nuclear	O
activity	O
induced	O
in	O
PBMC	B-cell_type
by	O
stimulation	O
with	O
the	O
anti-CD3	B-protein
mAb	I-protein
OKT3	B-protein
.	O

The	O
IL-10R	B-protein
,	O
together	O
with	O
reporter	O
gene	O
constructs	O
containing	O
different	O
IL-6-responsive	B-DNA
gene	I-DNA
elements	I-DNA
,	O
reconstituted	O
in	O
hepatoma	B-cell_type
cells	I-cell_type
an	O
induction	O
of	O
transcription	O
by	O
IL-10	B-protein
that	O
was	O
comparable	O
to	O
that	O
by	O
IL-6	B-protein
.	O

Ligation	O
of	O
CD3	B-protein
also	O
induces	O
the	O
tyrosine	O
phosphorylation	O
of	O
HS1	B-protein
,	O
a	O
75-kDa	B-protein
hematopoietic	I-protein
cell-specific	I-protein
intracellular	I-protein
signaling	I-protein
protein	I-protein
of	O
unknown	O
function	O
.	O

However	O
,	O
transactivation	O
of	O
the	O
CD4	B-DNA
promoter	I-DNA
by	O
ORFs	B-DNA
U86	B-DNA
and	O
U89	B-DNA
is	O
independent	O
of	O
the	O
CRE	B-DNA
element	I-DNA
,	O
suggesting	O
that	O
additional	O
HHV-6	B-DNA
ORFs	I-DNA
are	O
likely	O
to	O
contribute	O
to	O
CD4	B-DNA
gene	I-DNA
activation	O
.	O

These	O
results	O
suggest	O
that	O
1	O
)	O
lipid	O
A	O
myristoyl	O
fatty	O
acid	O
,	O
although	O
it	O
is	O
important	O
for	O
the	O
induction	O
of	O
inflammatory	B-protein
cytokine	I-protein
production	O
by	O
human	B-cell_type
monocytes	I-cell_type
,	O
is	O
not	O
necessary	O
for	O
the	O
induction	O
of	O
Mn	B-protein
SOD	I-protein
,	O
2	O
)	O
endotoxin	B-protein
-mediated	O
induction	O
of	O
Mn	B-protein
SOD	I-protein
and	O
inflammatory	O
cytokines	B-protein
are	O
regulated	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
different	O
signal	O
transduction	O
pathways	O
,	O
and	O
3	O
)	O
failure	O
of	O
the	O
mutant	B-protein
endotoxin	I-protein
to	O
induce	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
production	O
is	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
its	O
inability	O
to	O
activate	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
.	O

One	O
of	O
these	O
,	O
designated	O
Rhom-2	B-DNA
,	O
is	O
located	O
on	O
human	B-DNA
chromosome	I-DNA
11	I-DNA
at	O
band	B-DNA
11p13	I-DNA
,	O
where	O
a	O
cluster	O
of	O
T-cell	B-DNA
leukemia-specific	I-DNA
translocations	I-DNA
occur	O
;	O
all	O
translocation	O
breakpoints	O
at	O
11p13	B-DNA
are	O
upstream	O
of	O
the	O
Rhom-2	B-DNA
gene	I-DNA
.	O

The	O
multiple	O
biologic	O
activities	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
are	O
mediated	O
through	O
RAR	B-protein
and	O
retinoid	B-protein
X	I-protein
receptor	I-protein
(	I-protein
RXR	I-protein
)	I-protein
nuclear	I-protein
receptors	I-protein
that	O
interact	O
with	O
specific	O
DNA	B-DNA
target	I-DNA
sequences	I-DNA
as	O
heterodimers	B-protein
(	O
RXR-RAR	B-protein
)	O
or	O
homodimers	B-protein
(	O
RXR-RXR	B-protein
)	O
.	O

At	O
the	O
same	O
time	O
,	O
we	O
observed	O
a	O
down-regulation	O
of	O
progenitor-specific	B-protein
surface	I-protein
markers	I-protein
and	O
the	O
up-regulation	O
of	O
differentiation	B-protein
markers	I-protein
restricted	O
to	O
the	O
eosinophil	B-cell_type
and	O
myeloid	B-cell_type
lineages	I-cell_type
.	O

Specific	O
glucocorticoid	O
binding	O
at	O
different	O
levels	O
of	O
human	O
motor	O
activity	O
.	O

By	O
confocal	O
fluorescence	O
microscopy	O
,	O
we	O
observed	O
a	O
positive	O
staining	O
for	O
NF-kappa	B-protein
B	I-protein
(	O
p65	B-protein
subunit	I-protein
)	O
in	O
the	O
nuclei	O
of	O
PAEC	B-cell_line
exposed	O
for	O
1	O
hr	O
30	O
min	O
to	O
human	O
serum	O
,	O
which	O
indicated	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
this	O
setting	O
.	O

Thus	O
,	O
the	O
regulation	O
of	O
the	O
gene	O
coding	O
for	O
the	O
main	O
T	B-protein
cell	I-protein
growth	I-protein
factor	I-protein
changes	O
irreversibly	O
after	O
the	O
first	O
encounter	O
of	O
T	O
cells	O
with	O
antigen	O
.	O

BCL-6	B-protein
expression	O
during	O
B-cell	O
activation	O
.	O

Androgen	B-protein
binding	I-protein
sites	I-protein
have	O
been	O
identified	O
in	O
circulating	B-cell_type
human	I-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
of	O
healthy	O
donors	O
of	O
both	O
sexes	O
.	O

On	O
first	O
encounter	O
with	O
antigen	O
,	O
naive	B-cell_type
CD4+	I-cell_type
T	I-cell_type
helper	I-cell_type
(	I-cell_type
Th	I-cell_type
)	I-cell_type
cells	I-cell_type
differentiate	O
into	O
cytokine-producing	B-cell_line
effector	I-cell_line
cells	I-cell_line
.	O

Modulation	O
of	O
endogenous	O
IL-1	B-protein
beta	I-protein
and	O
IL-1	B-protein
receptor	I-protein
antagonist	O
results	O
in	O
opposing	O
effects	O
on	O
HIV	O
expression	O
in	O
chronically	B-cell_line
infected	I-cell_line
monocytic	I-cell_line
cells	I-cell_line
.	O

Moreover	O
,	O
the	O
effect	O
of	O
cell	O
adhesion	O
to	O
fibronectin	O
or	O
laminin	O
was	O
studied	O
to	O
investigate	O
mechanisms	O
involved	O
in	O
STAT1	B-protein
activation	O
.	O

These	O
results	O
indicate	O
that	O
a	O
decreased	O
concentration	O
of	O
VDR	B-protein
secondary	O
to	O
persistent	O
hypophosphatemia	O
is	O
one	O
of	O
the	O
causes	O
of	O
vitamin	O
D	O
resistance	O
in	O
XLH	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
have	O
investigated	O
the	O
mechanism	O
(	O
s	O
)	O
whereby	O
Tax	B-protein
transactivates	O
the	O
c-sis/PDGF-B	B-DNA
proto-oncogene	I-DNA
.	O

These	O
findings	O
suggest	O
that	O
Turner	O
mosaicism	O
of	O
the	O
45	B-cell_line
,	I-cell_line
X	I-cell_line
cell	I-cell_line
line	I-cell_line
may	O
have	O
contributed	O
to	O
this	O
atypical	O
presentation	O
in	O
an	O
XY	O
female	O
,	O
although	O
we	O
can	O
not	O
exclude	O
abnormalities	O
of	O
other	O
genes	O
related	O
to	O
sex	O
differentiation	O
.	O

The	O
AP-1	B-DNA
site	I-DNA
mediated	O
the	O
response	O
to	O
PMA	O
stimulation	O
while	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
responded	O
to	O
IL-1	B-protein
stimulation	O
.	O

Recent	O
molecular	O
evidence	O
points	O
to	O
transient	O
and/or	O
stage-specific	O
expression	O
of	O
delta-	B-protein
and	I-protein
kappa-opioid	I-protein
receptors	I-protein
by	O
thymic	B-cell_type
and	I-cell_type
peripheral	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Our	O
data	O
also	O
show	O
that	O
the	O
immunosuppressive	O
agent	O
cyclosporin	O
A	O
down-regulates	O
CD95L	B-protein
transcription	O
by	O
inhibiting	O
the	O
function	O
of	O
this	O
positive	O
regulatory	B-DNA
element	I-DNA

In	O
CsA-treated	B-cell_line
leukocytes	I-cell_line
stimulated	O
by	O
calcium	O
ionophore	O
,	O
the	O
degree	O
of	O
reduction	O
in	O
CN	B-protein
activity	O
was	O
accompanied	O
by	O
a	O
similar	O
degree	O
of	O
inhibition	O
of	O
each	O
event	O
tested	O
:	O
dephosphorylation	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cell	I-protein
proteins	I-protein
,	O
nuclear	O
DNA	O
binding	O
,	O
activation	O
of	O
a	O
transfected	B-DNA
reporter	I-DNA
gene	I-DNA
construct	I-DNA
,	O
IFN-gamma	O
and	O
IL-2	O
mRNA	O
accumulation	O
,	O
and	O
IFN-gamma	B-protein
production	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
evidence	O
indicating	O
that	O
signal	O
transduction	O
pathways	O
induced	O
by	O
PGE2	O
necessitate	O
the	O
participation	O
of	O
cyclic	O
AMP	O
,	O
protein	B-protein
kinase	I-protein
A	I-protein
,	O
and	O
Ca2+	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
Tax	B-protein
associates	O
with	O
and	O
is	O
negatively	O
regulated	O
by	O
the	O
NF-kappa	B-protein
B2	I-protein
p100	I-protein
gene	I-protein
product	I-protein
:	O
implications	O
for	O
viral	O
latency	O
.	O

This	O
variation	O
was	O
the	O
result	O
of	O
a	O
duplication	O
of	O
a	O
short	B-DNA
DNA	I-DNA
sequence	I-DNA
(	O
CTG-motif	B-DNA
)	O
.	O

A	O
novel	O
T-cell	B-protein
trans-activator	I-protein
that	O
recognizes	O
a	O
phorbol	B-DNA
ester-inducible	I-DNA
element	I-DNA
of	O
the	O
interleukin-2	B-DNA
promoter	I-DNA
.	O

B	B-cell_type
lymphocytes	I-cell_type
in	O
the	O
peripheral	O
circulation	O
are	O
maintained	O
in	O
a	O
non-proliferative	O
state	O
.	O

Transcription	B-protein
factors	I-protein
of	O
the	O
NFAT	B-protein
family	I-protein
play	O
a	O
key	O
role	O
in	O
the	O
transcription	O
of	O
cytokine	B-DNA
genes	I-DNA
and	O
other	O
genes	O
during	O
the	O
immune	O
response	O
.	O

The	O
BRLF1	B-protein
product	I-protein
Rta	I-protein
functions	O
as	O
a	O
transcriptional	O
activator	O
in	O
both	O
B	B-cell_type
lymphocytes	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
.	O

Nuclear	O
run-off	O
assays	O
and	O
half-life	O
studies	O
showed	O
that	O
accumulation	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
by	O
9-cis	O
RA	O
was	O
due	O
to	O
enhanced	O
transcription	O
.	O

Proliferation	O
and	O
immunologic	O
function	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
are	O
initiated	O
by	O
signals	O
from	O
the	O
antigen	B-protein
receptor	I-protein
that	O
are	O
inhibited	O
by	O
the	O
immunosuppressant	O
FK506	O
but	O
not	O
by	O
its	O
structural	O
analog	O
,	O
rapamycin	O
.	O

O-side	B-protein
chain-specific	I-protein
mAb	I-protein
concurrently	O
enhanced	O
complement-dependent	O
LPS	O
uptake	O
by	O
monocytes	O
through	O
complement	B-protein
receptor-1	I-protein
(	O
CR1	B-protein
)	O
and	O
uptake	O
by	O
CHO-CD14	B-cell_line
cells	I-cell_line
involving	O
another	O
heat-labile	B-protein
serum	I-protein
factor	I-protein
(	O
s	O
)	O
and	O
cell-associated	B-protein
recognition	I-protein
molecule	I-protein
(	O
s	O
)	O
.	O

Isoforms	O
Pax-5b	B-protein
and	O
Pax-5e	B-protein
have	O
spliced	O
out	O
their	O
second	O
exon	O
,	O
resulting	O
in	O
proteins	O
with	O
only	O
a	O
partial	O
DNA-binding	B-protein
domain	I-protein
.	O

Seven	O
of	O
15	O
fibroblast	B-cell_line
lines	I-cell_line
were	O
heterozygous	O
for	O
polymorphic	B-DNA
alleles	I-DNA
,	O
and	O
the	O
expression	O
patterns	O
were	O
variable	O
,	O
i.e.	O
,	O
equal	O
,	O
unequal	O
or	O
monoallelic	O
paternal	O
expression	O
in	O
three	O
,	O
two	O
and	O
two	O
cases	O
,	O
respectively	O
.	O

These	O
data	O
suggest	O
that	O
,	O
in	O
addition	O
to	O
its	O
established	O
role	O
as	O
a	O
hormone-dependent	B-protein
trans-activator	I-protein
,	O
VDR	B-protein
may	O
influence	O
gene	O
expression	O
by	O
ligand-independent	O
mechanisms	O
.	O

Since	O
the	O
activation	O
of	O
NFAT	B-protein
is	O
MAPK	B-protein
-dependent	O
these	O
findings	O
suggested	O
that	O
the	O
activation	O
of	O
MAPK	B-protein
by	O
Tpl-2	B-protein
is	O
either	O
independent	O
or	O
only	O
partially	O
dependent	O
on	O
MEK1	B-protein
and	O
MEK2	B-protein
.	O

The	O
results	O
demonstrate	O
that	O
okadaic	O
acid	O
treatment	O
is	O
associated	O
with	O
induction	O
of	O
a	O
differentiated	O
monocyte	O
phenotype	O
characterized	O
by	O
:	O
(	O
a	O
)	O
growth	O
arrest	O
;	O
(	O
b	O
)	O
increases	O
in	O
Mac-1	B-protein
cell	I-protein
surface	I-protein
antigen	I-protein
expression	O
;	O
(	O
c	O
)	O
down-regulation	O
of	O
c-myc	B-protein
transcripts	I-protein
;	O
and	O
(	O
d	O
)	O
induction	O
of	O
tumor	B-DNA
necrosis	I-DNA
factor	I-DNA
gene	I-DNA
expression	O
.	O

Calcineurin	B-protein
and	O
the	O
biological	O
effect	O
of	O
cyclosporine	O
and	O
tacrolimus	O
.	O

These	O
effects	O
of	O
aldosterone	O
were	O
blocked	O
by	O
the	O
aldosterone	O
antagonist	O
canrenone	O
(	O
140	O
nmol/l	O
)	O
.	O

The	O
immunogenetic	O
basis	O
of	O
severe	O
infections	O
caused	O
by	O
bacille	O
Calmette-Guerin	O
vaccine	O
and	O
environmental	O
mycobacteria	O
in	O
humans	O
remains	O
largely	O
unknown	O
.	O

Nuclear	O
run-on	O
assays	O
and	O
mRNA	O
stability	O
studies	O
demonstrated	O
that	O
M-CSF	B-protein
regulates	O
c-jun	B-DNA
expression	O
by	O
both	O
an	O
increase	O
in	O
transcription	O
rate	O
and	O
a	O
prolongation	O
in	O
the	O
half-life	O
of	O
c-jun	B-RNA
transcripts	I-RNA
.	O

Because	O
surfactant	B-protein
protein	I-protein
(	I-protein
SP	I-protein
)	I-protein
A	I-protein
is	O
involved	O
in	O
local	O
host	O
defense	O
in	O
the	O
lung	O
and	O
alters	O
immune	O
cell	O
function	O
by	O
modulating	O
the	O
expression	O
of	O
proinflammatory	B-protein
cytokines	I-protein
as	O
well	O
as	O
surface	B-protein
proteins	I-protein
involved	O
in	O
inflammation	O
,	O
we	O
hypothesized	O
that	O
SP-A	B-protein
exerts	O
its	O
action	O
,	O
at	O
least	O
in	O
part	O
,	O
via	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

The	O
apparent	O
dual	O
function	O
of	O
this	O
protein	O
is	O
discussed	O
.	O

In	O
other	O
experiments	O
,	O
the	O
Xq13	B-DNA
region	I-DNA
carrying	O
XIC/XIST	B-DNA
was	O
localized	O
by	O
computer	O
enhancement	O
of	O
the	O
DAPI	O
banding	O
pattern	O
.	O

Polyunsaturated	O
fatty	O
acids	O
and	O
eicosanoids	O
bind	O
and	O
activate	O
PPARgamma	B-protein
,	O
suggesting	O
that	O
these	O
lipids	O
may	O
serve	O
as	O
hormonal	O
regulators	O
of	O
a	O
variety	O
of	O
biological	O
processes	O
.	O

Tyrosine	B-protein
kinase	I-protein
inhibition	O
by	O
herbimycin	O
A	O
diminished	O
J393/CD43	B-protein
-mediated	O
apoptosis	O
,	O
whereas	O
inhibition	O
of	O
phosphotyrosine	B-protein
phosphatase	I-protein
activity	O
by	O
bis	O
(	O
maltolato	O
)	O
oxovanadium-IV	O
enhanced	O
cell	O
death	O
.	O

Activity	O
of	O
the	O
CaM	B-protein
kinases	I-protein
was	O
determined	O
using	O
a	O
synthetic	O
peptide	O
substrate	O
both	O
in	O
the	O
absence	O
and	O
presence	O
of	O
an	O
inhibitor	O
specific	O
for	O
the	O
CaM	B-protein
kinase	I-protein
family	I-protein
,	O
KN-62	O
.	O

The	O
protein	O
phosphorylation	O
patterns	O
in	O
the	O
two	O
monkeys	O
exhibited	O
quantitative	O
,	O
qualitative	O
,	O
and	O
kinetic	O
differences	O
.	O

In	O
contrast	O
,	O
virus	O
reactivation	O
was	O
not	O
observed	O
following	O
CD4	B-protein
oligomerization	O
by	O
antibodies	B-protein
that	O
bind	O
other	O
epitopes	O
in	O
D1	B-protein
,	O
including	O
the	O
D1/CDR3-loop	B-protein
.	O

Both	O
pathways	O
were	O
fully	O
blocked	O
by	O
Bcl-2	B-protein
or	O
Bcl-X	B-protein
(	I-protein
L	I-protein
)	I-protein
.	O

Paramyxovirus	O
infection	O
induced	O
a	O
5-	O
to	O
10-fold	O
increase	O
in	O
the	O
steady-state	O
level	O
of	O
TNF-alpha	B-RNA
RNA	I-RNA
in	O
U9-IIIB	B-cell_line
cells	I-cell_line
compared	O
with	O
U937	B-cell_line
cells	I-cell_line
,	O
suggesting	O
that	O
HIV-infected	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
produced	O
higher	O
levels	O
of	O
TNF-alpha	B-protein
than	O
did	O
normal	O
cells	O
after	O
a	O
secondary	O
virus	O
infection	O
.	O

Examination	O
of	O
18	O
AML	O
samples	O
by	O
EMSA	O
revealed	O
the	O
presence	O
of	O
E2F	B-protein
binding	O
and	O
no	O
gross	O
abnormalities	O
were	O
detected	O
.	O

Within	O
this	O
group	O
of	O
patients	O
,	O
NK	B-cell_type
cell	I-cell_type
activity	O
was	O
significantly	O
lower	O
(	O
45.6	O
+/-	O
16.1	O
%	O
)	O
compared	O
with	O
the	O
group	O
with	O
no	O
HER-2/neu	B-protein
overexpression	O
(	O
57.3	O
+/-	O
11.0	O
%	O
)	O
.	O

Alternative	O
splicing	O
of	O
exon	B-RNA
10	I-RNA
of	O
the	O
TSC2	B-DNA
gene	I-DNA
may	O
be	O
a	O
normal	O
variant	O
.	O

A	O
novel	O
B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
,	O
BSAP	B-protein
,	O
was	O
identified	O
as	O
a	O
mammalian	B-protein
homolog	I-protein
of	O
the	O
sea	B-protein
urchin	I-protein
protein	I-protein
TSAP	B-protein
,	O
which	O
interacts	O
with	O
the	O
promoters	B-DNA
of	O
four	O
tissue-specific	B-DNA
late	I-DNA
histone	I-DNA
H2A-2	I-DNA
and	I-DNA
H2B-2	I-DNA
genes	I-DNA
.	O

Interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
is	O
produced	O
by	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
and	O
certain	O
subsets	O
of	O
T	B-cell_type
cells	I-cell_type
,	O
but	O
the	O
basis	O
for	O
its	O
selective	O
expression	O
is	O
unknown	O
.	O

We	O
now	O
show	O
that	O
in	O
EBV-transformed	B-cell_line
B	I-cell_line
lymphocytes	I-cell_line
most	O
of	O
TRAF1	B-protein
or	O
TRAF3	B-protein
and	O
5	O
%	O
of	O
TRAF2	B-protein
are	O
associated	O
with	O
LMP1	B-protein
and	O
that	O
most	O
of	O
LMP1	B-protein
is	O
associated	O
with	O
TRAF1	B-protein
or	O
TRAF3	B-protein
.	O

Recently	O
,	O
members	O
of	O
the	O
Lef/Tcf	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
have	O
been	O
identified	O
as	O
protein	O
partners	O
of	O
beta-catenin	B-protein
,	O
explaining	O
how	O
beta-catenin	B-protein
alters	O
gene	O
expression	O
.	O

Although	O
anti-CD3	B-protein
alone	O
or	O
fibronectin	B-protein
alone	O
can	O
not	O
induce	O
IL-2	B-protein
message	O
by	O
CD4	B-cell_line
cells	I-cell_line
,	O
the	O
combination	O
of	O
anti-CD3	B-protein
plus	O
fibronectin	B-protein
induced	O
IL-2	B-protein
message	O
by	O
CD4	B-cell_line
cells	I-cell_line
.	O

The	O
composite	B-DNA
motif	I-DNA
binds	O
a	O
multi-protein	B-protein
hematopoietic-specific	I-protein
transcription	I-protein
factor	I-protein
complex	I-protein
which	O
includes	O
GATA-1	B-protein
,	O
SCL/tal-1	B-protein
,	I-protein
E2A	B-protein
,	O
Lmo2	B-protein
and	O
Ldb-1	B-protein
.	O

In	O
contrast	O
,	O
it	O
was	O
found	O
to	O
be	O
TNF-alpha	B-protein
independent	O
in	O
the	O
early	O
time	O
point	O
.	O

The	O
binding	O
activity	O
of	O
the	O
X1	B-protein
box	I-protein
DNA-binding	I-protein
protein	I-protein
RFX	B-protein
was	O
examined	O
and	O
found	O
to	O
be	O
present	O
in	O
wild-type	B-cell_line
B	I-cell_line
cells	I-cell_line
and	O
the	O
mutant	O
RJ2.2.5	B-cell_line
but	O
was	O
absent	O
in	O
SJO	B-cell_line
and	O
Jurkat	B-cell_line
.	O

Maximal	O
inhibition	O
of	O
IgE	B-protein
production	O
for	O
B	B-cell_type
cells	I-cell_type
was	O
at	O
10	O
(	O
-8	O
)	O
mol/L	O
for	O
all-trans	O
RA	O
(	O
94	O
%	O
+/-	O
1.8	O
%	O
)	O
and	O
96	O
%	O
+/-	O
3.2	O
%	O
for	O
13-cis	O
RA	O
.	O

RA	O
-triggered	O
GALdbd-	O
RARalpha	B-protein
hybrid	O
activity	O
in	O
these	O
cells	O
indicates	O
that	O
the	O
multipotent	O
EML	B-cell_type
cells	I-cell_type
harbor	O
substantial	O
nuclear	O
hormone	O
receptor	O
coactivator	B-protein
activity	O
.	O

Furthermore	O
,	O
TIMP-1	B-protein
upregulation	O
induced	O
expression	O
of	O
Bcl-XL	B-protein
but	O
not	O
Bcl-2	B-protein
as	O
well	O
as	O
decreased	O
NF-kappaB	B-protein
activity	O
as	O
compared	O
with	O
controls	O
.	O

The	O
human	B-cell_line
myelomonocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
U-937	I-cell_line
as	O
a	O
model	O
for	O
studying	O
alterations	O
in	O
steroid-induced	O
monokine	O
gene	O
expression	O
:	O
marked	O
enhancement	O
of	O
lipopolysaccharide-stimulated	B-RNA
interleukin-1	I-RNA
beta	I-RNA
messenger	I-RNA
RNA	I-RNA
levels	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
.	O

Ras-related	B-protein
GTP-binding	I-protein
proteins	I-protein
and	O
leukocyte	B-cell_type
signal	O
transduction	O
.	O

We	O
propose	O
that	O
one	O
of	O
the	O
targets	O
of	O
PGE2	O
,	O
whose	O
effect	O
distinguishes	O
Th1	B-cell_line
from	O
Th2	O
,	O
resides	O
in	O
the	O
downstream	O
PKC/Ras	B-protein
-mediated	O
pathway	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
ability	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNFalpha	B-protein
,	O
a	O
proinflammatory	B-protein
cytokine	I-protein
)	O
and	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-10	I-protein
(	O
an	O
anti-inflammatory	B-protein
cytokine	I-protein
)	O
to	O
differentially	O
regulate	O
the	O
sensitivity	O
of	O
human	B-cell_type
monocytes	I-cell_type
/macrophages	B-cell_type
to	O
glucocorticoids	O
.	O

The	O
role	O
of	O
H2O2	O
and	O
other	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
as	O
an	O
integratory	O
secondary	O
messenger	O
for	O
divergent	O
T	O
cell	O
signals	O
has	O
been	O
complicated	O
by	O
the	O
fact	O
that	O
various	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
differ	O
markedly	O
in	O
the	O
levels	O
of	O
NF-kappaB	B-protein
activation	O
induced	O
by	O
oxidant	O
stress	O
.	O

Exposure	O
of	O
monocytic	B-cell_type
cells	I-cell_type
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
activates	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
of	O
proteins	O
and	O
leads	O
to	O
the	O
rapid	O
induction	O
of	O
inflammatory	B-protein
gene	I-protein
products	I-protein
,	O
including	O
tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
.	O

Relative	O
levels	O
were	O
then	O
correlated	O
with	O
a	O
series	O
of	O
clinical	O
variables	O
including	O
response	O
to	O
therapy	O
,	O
performance	O
status	O
,	O
survival	O
,	O
disease	O
sites	O
,	O
age	O
,	O
and	O
others	O
.	O

The	O
RAR-RXR	B-protein
as	O
well	O
as	O
the	O
RXR-RXR	B-protein
pathway	O
is	O
involved	O
in	O
signaling	O
growth	O
inhibition	O
of	O
human	B-cell_line
CD34+	I-cell_line
erythroid	I-cell_line
progenitor	I-cell_line
cells	I-cell_line
.	O

Transcription	O
mediated	O
by	O
NFAT	B-protein
is	O
highly	O
inducible	O
in	O
effector	O
CD4+	B-cell_type
T	I-cell_type
helper	I-cell_type
2	I-cell_type
(	I-cell_type
Th2	I-cell_type
)	I-cell_type
cells	I-cell_type
but	O
not	O
in	O
Th1	B-cell_type
cells	I-cell_type
.	O

Nitric	O
oxide	O
subserves	O
diverse	O
physiologic	O
roles	O
in	O
the	O
nervous	O
system	O
.	O

Northern	O
analyses	O
suggested	O
that	O
the	O
reiterated	B-DNA
splicing	I-DNA
sites	I-DNA
of	O
the	O
representative	O
mutants	O
were	O
all	O
used	O
in	O
RNA	O
splicing	O
,	O
and	O
the	O
closest	O
donor	O
and	O
recipient	O
joints	O
were	O
used	O
most	O
frequently	O
.	O

The	O
levels	O
of	O
the	O
apoptosis	O
effector	O
proteins	O
Bak	B-protein
and	O
Bad	B-protein
were	O
enhanced	O
,	O
whereas	O
there	O
was	O
a	O
slight	O
down-regulation	O
of	O
the	O
apoptosis	B-protein
suppressor	I-protein
protein	I-protein
Bcl-2	B-protein
after	O
treatment	O
of	O
the	O
cells	O
with	O
PDBu	O
and	O
DMSO	O
.	O

In	O
addition	O
to	O
Zap-70	B-protein
,	O
the	O
3BP2	B-protein
SH2	I-protein
domain	I-protein
associated	O
in	O
vitro	O
with	O
LAT	B-protein
,	O
Grb2	B-protein
,	O
PLCgamma1	B-protein
,	O
and	O
Cbl	B-protein
from	O
activated	O
T	O
cell	O
lysates	O
.	O

At	O
10	O
to	O
100	O
micromol/L	O
for	O
>	O
24	O
hours	O
,	O
oleate	O
inhibited	O
the	O
expression	O
of	O
all	O
adhesion	B-protein
molecules	I-protein
tested	O
.	O

Transactivation	O
by	O
some	O
DNA	O
viruses	O
has	O
been	O
implicated	O
in	O
inducing	O
HIV-1	O
replication	O
and	O
pathogenesis	O
.	O

Preincubation	O
of	O
endothelial	B-cell_type
cells	I-cell_type
with	O
endotoxin	O
[	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
1	O
microgram/ml	O
]	O
led	O
to	O
a	O
4-fold	O
increase	O
in	O
subsequent	O
adherence	O
of	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
(	O
P	O
<	O
0.0001	O
,	O
n	O
=	O
10	O
)	O
to	O
endothelial	B-cell_type
cells	I-cell_type
,	O
an	O
increase	O
that	O
was	O
markedly	O
attenuated	O
when	O
endothelial	B-cell_type
cells	I-cell_type
were	O
treated	O
with	O
dexamethasone	O
(	O
IC50	O
<	O
1	O
nM	O
,	O
P	O
<	O
0.0001	O
,	O
n	O
=	O
6	O
or	O
7	O
)	O
during	O
preincubation	O
with	O
LPS	O
.	O

Expression	O
studies	O
as	O
well	O
as	O
the	O
use	O
of	O
transgenic	O
animals	O
have	O
demonstrated	O
that	O
the	O
A-MYB	B-protein
transcription	B-protein
factor	I-protein
plays	O
central	O
and	O
specific	O
role	O
in	O
the	O
regulation	O
of	O
mature	B-cell_type
B	I-cell_type
cell	I-cell_type
proliferation	O
and/or	O
differentiation	O
.	O

Both	O
primers	O
detected	O
a	O
single	O
copy	O
of	O
the	O
adenovirus	B-DNA
type	I-DNA
2	I-DNA
genome	I-DNA
but	O
were	O
less	O
sensitive	O
for	O
the	O
group	O
B	O
type	O
35	O
.	O

Anoxia/reoxygenation-induced	O
tolerance	O
with	O
respect	O
to	O
polymorphonuclear	O
leukocyte	O
adhesion	O
to	O
cultured	B-cell_line
endothelial	I-cell_line
cells	I-cell_line
.	O

The	O
results	O
showed	O
that	O
the	O
activity	O
of	O
plasma	O
IL-1	B-protein
in	O
aged	O
long-distance	O
runner	O
was	O
209	O
%	O
,	O
223	O
%	O
and	O
145	O
%	O
of	O
the	O
control	O
at	O
14.7-18.7	O
,	O
3.8-7.0	O
and	O
1.5-2.6	O
KD	O
fractions	O
.	O

We	O
have	O
demonstrated	O
that	O
lipoarabinomannan	B-protein
(	O
LAM	B-protein
)	O
from	O
the	O
mycobacterial	O
cell	O
wall	O
,	O
which	O
was	O
virtually	O
devoid	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
stimulated	O
mononuclear	B-cell_type
phagocytes	I-cell_type
to	O
release	O
IL-6	B-protein
in	O
a	O
dose-response	O
manner	O
.	O

We	O
now	O
show	O
that	O
the	O
core	O
contains	O
a	O
single	O
critical	O
c-Myb	B-DNA
binding	I-DNA
site	I-DNA
.	O

A	O
second	O
peak	O
was	O
observed	O
at	O
a	O
later	O
time	O
point	O
following	O
LPS	O
stimulation	O
,	O
which	O
consisted	O
of	O
both	O
IKK-alpha	O
and	O
-beta	O
activity	O
.	O

We	O
show	O
that	O
ES-derived	B-cell_type
embryoid	I-cell_type
bodies	I-cell_type
express	O
the	O
full	O
complement	O
of	O
mouse	B-DNA
embryonic	I-DNA
globin	I-DNA
genes	I-DNA
in	O
the	O
correct	O
temporal	O
order	O
and	O
that	O
on	O
further	O
differentiation	O
,	O
a	O
switch	O
occurs	O
to	O
the	O
fetal/adult	B-DNA
genes	I-DNA
.	O

Although	O
the	O
mechanism	O
of	O
LTR	B-DNA
activation	O
remains	O
obscure	O
,	O
several	O
lines	O
of	O
investigation	O
have	O
suggested	O
that	O
it	O
is	O
a	O
result	O
of	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	B-protein
factor	I-protein
(	O
s	O
)	O
following	O
signaling	O
events	O
related	O
to	O
generalized	O
DNA	O
damage	O
.	O

Expression	O
of	O
neither	O
HTLV-1	B-protein
tax	I-protein
in	O
Jurkat	B-cell_line
T-cells	I-cell_line
nor	O
EBV	O
in	O
B-cells	B-cell_type
had	O
any	O
effect	O
on	O
MNP-1	B-protein
or	O
MNP-2	B-protein
expression	O
,	O
showing	O
that	O
the	O
effect	O
is	O
specific	O
for	O
HIV-1	B-protein
tat	I-protein
.	O

However	O
,	O
it	O
has	O
been	O
recently	O
reported	O
that	O
the	O
NH2	B-protein
regulatory	B-protein
domain	I-protein
is	O
sufficient	O
to	O
mediate	O
CD4	B-protein
accessory	O
function	O
.	O

In	O
conclusion	O
,	O
this	O
case	O
report	O
emphasizes	O
1	O
)	O
the	O
possibility	O
of	O
a	O
syndrome	O
of	O
acquired	O
PHA	O
with	O
severe	O
hyperkalemia	O
after	O
resection	O
of	O
the	O
ileum	O
and	O
colon	O
responding	O
to	O
oral	O
salt	O
supplementation	O
;	O
2	O
)	O
the	O
major	O
increase	O
in	O
AVP	O
and	O
the	O
small	O
increase	O
in	O
ANH	O
;	O
3	O
)	O
the	O
strong	O
increase	O
in	O
urinary	O
THF	O
with	O
low	O
THE/THF	O
and	O
alpha	O
THF/THF	O
ratios	O
;	O
4	O
)	O
the	O
normal	O
number	O
of	O
lymphocytic	B-protein
mineralocorticoid	I-protein
receptors	I-protein
outside	O
the	O
acute	O
episode	O
.	O

With	O
the	O
antibodies	O
Ki-67	B-protein
and	O
anti-p-145	B-protein
an	O
increased	O
rate	O
of	O
nuclear	O
and	O
nucleolar	O
staining	O
resulted	O
in	O
cells	O
from	O
highly	O
malignant	O
lymphomas	O
.	O

By	O
contrast	O
,	O
the	O
amounts	O
of	O
actin	B-protein
and	O
beta-tubulin	B-protein
were	O
not	O
significantly	O
altered	O
.	O

We	O
hypothesized	O
that	O
this	O
increased	O
viral	O
transcription	O
was	O
mediated	O
,	O
in	O
part	O
,	O
through	O
the	O
phosphorylation	O
of	O
CREB	B-protein
.	O

The	O
nuclear	O
body	O
(	O
NB	O
)	O
is	O
a	O
cellular	O
organelle	O
that	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O

We	O
report	O
here	O
that	O
both	O
NF-M-dependent	B-DNA
promoter	I-DNA
constructs	I-DNA
and	O
resident	O
genes	O
could	O
be	O
activated	O
by	O
addition	O
of	O
beta-estradiol	O
to	O
the	O
NF-M-estrogen	B-cell_line
receptor	I-cell_line
expressing	I-cell_line
progenitors	I-cell_line
.	O

Dendritic	B-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
are	O
potent	O
APCs	B-cell_type
that	O
enter	O
resting	O
tissues	O
as	O
precursors	O
and	O
,	O
after	O
Ag	O
exposure	O
,	O
differentiate	O
and	O
migrate	O
to	O
draining	O
lymph	O
nodes	O
.	O

These	O
data	O
indicate	O
that	O
CVZ	O
is	O
recognizing	O
two	O
glucocorticoid	B-protein
binding	I-protein
sites	I-protein
on	O
the	O
human	O
GR	B-protein
or	O
a	O
protein	O
very	O
similar	O
to	O
it	O
.	O

Neither	O
the	O
PLC	B-protein
gamma	I-protein
1	I-protein
overexpression	O
induced	O
by	O
IFN	B-protein
nor	O
the	O
increased	O
hydrolytic	O
activity	O
of	O
the	O
enzyme	B-protein
appear	O
to	O
be	O
affected	O
by	O
pretreatment	O
of	O
the	O
cells	O
with	O
the	O
protein	O
tyrosine	B-protein
kinase	I-protein
inhibitor	O
genistein	O
,	O
which	O
is	O
known	O
to	O
prevent	O
the	O
association	O
of	O
ISGF3	B-protein
components	O
.	O

Consistent	O
with	O
theses	O
results	O
,	O
nuclear	O
extracts	O
prepared	O
from	O
quiescent	O
cells	O
formed	O
a	O
specific	O
complex	O
with	O
this	O
element	O
,	O
whereas	O
extracts	O
prepared	O
from	O
cells	O
treated	O
with	O
anti	B-protein
CD2	I-protein
+	O
anti	B-protein
CD28	I-protein
failed	O
to	O
do	O
so	O
after	O
cells	O
entered	O
a	O
proliferative	O
state	O
.	O

SR	O
31747A	O
,	O
defined	O
as	O
a	O
sigma	O
ligand	O
,	O
is	O
a	O
novel	O
immunosuppressive	O
agent	O
that	O
blocks	O
proliferation	O
of	O
human	B-cell_type
and	I-cell_type
mouse	I-cell_type
lymphocytes	I-cell_type
.	O

Virtually	O
all	O
B-cell	B-cell_line
lines	I-cell_line
,	O
with	O
the	O
exception	O
of	O
some	O
myeloma	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
are	O
positive	O
for	O
BSAP	B-protein
,	O
which	O
is	O
the	O
transcription	B-protein
factor	I-protein
for	O
promoters	B-DNA
for	O
several	O
B-cell	B-protein
markers	I-protein
,	O
including	O
VpreB1	B-protein
,	O
lambda	B-protein
5	I-protein
,	O
CD19	B-protein
,	O
and	O
CD20	B-protein
.	O

The	O
mechanisms	O
involved	O
in	O
the	O
inhibition	O
of	O
growth	O
of	O
a	O
human	B-cell_line
B	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
B104	B-cell_line
,	O
by	O
anti-MHC	B-protein
class	I-protein
II	I-protein
antibodies	I-protein
(	O
Ab	B-protein
)	O
were	O
compared	O
with	O
those	O
in	O
anti-IgM	B-protein
Ab	I-protein
-induced	O
B104	O
growth	O
inhibition	O
.	O

Taken	O
together	O
these	O
results	O
demonstrate	O
that	O
the	O
IK	B-protein
protein	I-protein
plays	O
a	O
key	O
role	O
in	O
the	O
constitutive	O
expression	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
antigens	I-protein
and	O
that	O
inhibition	O
induced	O
by	O
IK	B-protein
is	O
upstream	O
of	O
CIITA	B-DNA
in	O
this	O
regulatory	O
pathway	O
.	O

Grf40	B-protein
,	O
A	O
novel	O
Grb2	B-protein
family	I-protein
member	I-protein
,	O
is	O
involved	O
in	O
T	O
cell	O
signaling	O
through	O
interaction	O
with	O
SLP-76	B-protein
and	O
LAT	B-protein
.	O

Recently	O
,	O
many	O
investigators	O
have	O
been	O
interested	O
in	O
the	O
study	O
on	O
eosinophil	B-cell_type
biology	O
since	O
genes	O
association	O
with	O
eosinophils	B-cell_type
such	O
as	O
interleukin-5	B-protein
or	O
eosinophil	B-protein
granule	I-protein
proteins	I-protein
(	O
EPO	B-protein
,	O
ECP	B-protein
,	O
EDN	B-protein
,	O
MBP	B-protein
,	O
and	O
CLC	B-protein
)	O
,	O
were	O
isolated	O
.	O

This	O
interaction	O
is	O
believed	O
to	O
be	O
an	O
important	O
component	O
of	O
the	O
mechanism	O
of	O
transactivation	O
.	O

Mutation	O
of	O
the	O
core	O
ETS	B-DNA
binding	I-DNA
site	I-DNA
from	O
-GGAA-	B-DNA
to	I-DNA
-GGAT-	I-DNA
prevents	O
the	O
binding	O
of	O
ETS-like	B-protein
factors	I-protein
with	O
the	O
exception	O
of	O
ETS1	B-protein
.	O

We	O
have	O
therefore	O
investigated	O
the	O
changes	O
in	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
activity	O
upon	O
exposure	O
of	O
monocytes	B-cell_type
to	O
M-CSF	B-protein
.	O

A	O
novel	O
B-cell	B-protein
lineage-specific	I-protein
transcription	I-protein
factor	I-protein
present	O
at	O
early	O
but	O
not	O
late	O
stages	O
of	O
differentiation	O
.	O

A	O
cDNA	B-DNA
clone	I-DNA
,	O
B4-2	B-DNA
,	O
was	O
isolated	O
from	O
a	O
natural	B-DNA
killer	I-DNA
(	I-DNA
NK	I-DNA
)	I-DNA
minus	I-DNA
T	I-DNA
cell	I-DNA
subtractive	I-DNA
library	I-DNA
.	O

Our	O
findings	O
may	O
indicate	O
the	O
presence	O
of	O
a	O
reactivated	O
virus	O
hosted	O
in	O
these	O
cells	O
.	O

Infection	O
of	O
target	B-cell_type
cells	I-cell_type
with	O
cytopathic	O
viruses	O
inhibits	O
IFN	B-protein
induction	O
of	O
cytolytic	O
resistance	O
to	O
NK	O
cell-mediated	O
cytolysis	O
[	O
IFN	B-protein
-mediated	O
cytoprotection	O
(	O
IFN	B-protein
-MCP	O
)	O
]	O
.	O

Hypoxic	O
endothelia	O
showed	O
a	O
>	O
10-fold	O
increase	O
in	O
sensitivity	O
to	O
inhibitors	O
of	O
proteasome	B-protein
activation	O
,	O
and	O
combinations	O
of	O
hypoxia	O
and	O
LPS	O
enhanced	O
proteasome	B-protein
-dependent	O
cytoplasmic-to-nuclear	O
localization	O
of	O
the	O
nuclear	B-protein
transcription	I-protein
factor-kappa	I-protein
B	I-protein
p65	I-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
subunit	I-protein
.	O

In	O
addition	O
,	O
Fli-1	B-protein
binding	O
of	O
the	O
GPIX	B-DNA
Ets	I-DNA
site	I-DNA
was	O
identified	O
in	O
antibody	O
supershift	O
experiments	O
in	O
nuclear	O
extracts	O
derived	O
from	O
hematopoietic	B-cell_type
human	I-cell_type
erythroleukemia	I-cell_type
cells	I-cell_type
.	O

The	O
transactivator	B-protein
CIITA	B-protein
behaves	O
as	O
a	O
master	O
controller	O
of	O
constitutive	O
and	O
inducible	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
activation	O
,	O
but	O
its	O
exact	O
mechanism	O
of	O
action	O
is	O
not	O
known	O
.	O

The	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-dependent	I-protein
phosphatase	I-protein
calcineurin	B-protein
,	O
a	O
target	O
of	O
FK506	O
and	O
CsA	O
,	O
synergizes	O
with	O
PKC	B-protein
-induced	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
in	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

p45	B-protein
subunit	I-protein
of	O
NF-E2	B-protein
contains	O
a	O
basic-leucine	B-protein
zipper	I-protein
domain	I-protein
and	O
dimerizes	O
with	O
the	O
small	B-protein
Maf	I-protein
family	I-protein
protein	I-protein
to	O
form	O
functional	O
NF-E2	B-protein
complex	I-protein
.	O

Subcloning	O
of	O
the	O
variant	B-DNA
NF-kappa	I-DNA
B	I-DNA
segments	I-DNA
into	O
LTR-driven	B-DNA
CAT	I-DNA
expression	I-DNA
vectors	I-DNA
confirmed	O
a	O
correlation	O
between	O
promoter	O
activity	O
and	O
replicative/cytopathic	O
capacity	O
.	O

Differences	O
in	O
phosphorylation	O
of	O
the	O
IL-2R	B-protein
associated	I-protein
JAK/STAT	I-protein
proteins	I-protein
between	O
HTLV-I	B-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
,	I-cell_line
IL-2-independent	I-cell_line
and	I-cell_line
IL-2-dependent	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
uncultured	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
adult	O
T-cell	O
lymphoma/leukemia	O
.	O

c-jun	B-RNA
mRNA	I-RNA
levels	O
were	O
superinduced	O
in	O
cells	O
treated	O
with	O
both	O
okadaic	O
acid	O
and	O
cycloheximide	O
,	O
whereas	O
inhibition	O
of	O
protein	O
synthesis	O
had	O
little	O
,	O
if	O
any	O
,	O
effect	O
on	O
okadaic	O
acid-induced	O
c-jun	B-DNA
transcription	O
.	O

In	O
addition	O
,	O
T	O
cell	O
proliferation	O
was	O
completely	O
resistant	O
to	O
the	O
actions	O
of	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

Immunofluorescence	O
studies	O
on	O
thymic	B-cell_type
populations	I-cell_type
of	O
mice	O
carrying	O
transgenes	O
in	O
various	O
combinations	O
of	O
these	O
regulatory	B-DNA
DNA	I-DNA
elements	I-DNA
revealed	O
that	O
thymocytes	B-cell_type
control	O
the	O
CD4	B-DNA
gene	I-DNA
in	O
a	O
different	O
manner	O
than	O
mature	O
peripheral	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Granulocyte	O
DNA	O
from	O
four	O
patients	O
exhibited	O
allele	O
loss	O
on	O
20q	B-DNA
.	O

They	O
correlated	O
with	O
markers	O
of	O
tumor	O
aggressivity	O
(	O
axillary	O
node	O
involvement	O
and	O
especially	O
with	O
markers	O
of	O
high	O
mitotic	O
rate	O
as	O
Ki-67	O
staining	O
,	O
histological	O
grade	O
)	O
.	O

We	O
have	O
used	O
in	O
situ	O
hybridization	O
to	O
define	O
these	O
rearrangements	O
at	O
the	O
molecular	O
level	O
.	O

To	O
define	O
these	O
targets	O
for	O
SHP1	B-protein
we	O
have	O
compared	O
the	O
effects	O
of	O
constitutively	O
active	O
and	O
inactive	O
mutants	O
of	O
SHP1	B-protein
on	O
TCR	B-protein
signaling	O
.	O

Since	O
medical	O
treatments	O
or	O
stress	O
commonly	O
increase	O
opioid	O
levels	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
mechanisms	O
by	O
which	O
opioids	O
affect	O
T	O
lymphocyte	O
functions	O
.	O

Exposure	O
to	O
NSAIDs	O
had	O
a	O
complex	O
effect	O
on	O
HSP	O
gene	O
expression	O
and	O
while	O
sulindac	O
activated	O
the	O
stress	O
responsive	O
HSP70B	B-DNA
promoter	I-DNA
,	O
sodium	O
salicylate	O
did	O
not	O
.	O

In	O
the	O
examination	O
of	O
the	O
induction	O
of	O
autoimmunity	O
in	O
transgenic	O
mice	O
,	O
evidence	O
has	O
been	O
obtained	O
further	O
implicating	O
the	O
lymphokine	B-protein
interferon-gamma	B-protein
in	O
the	O
etiology	O
of	O
autoimmunity	O
.	O

Analysis	O
of	O
monocytes	B-cell_type
from	O
familial	O
hypercholesterolemic	O
(	O
FH	O
)	O
subjects	O
,	O
who	O
frequently	O
develop	O
xanthomatosis	O
,	O
revealed	O
a	O
significant	O
number	O
of	O
subjects	O
with	O
elevated	O
STAT1alpha	O
and	O
IP-10	O
expression	O
.	O

Selection	O
of	O
down-regulated	B-DNA
sequences	I-DNA
along	O
the	O
monocytic	O
differentiation	O
of	O
leukemic	B-cell_line
HL60	I-cell_line
cells	I-cell_line
.	O

NF-E1	B-protein
is	O
encoded	O
by	O
the	O
same	O
gene	O
as	O
the	O
YY-1	B-protein
protein	I-protein
,	O
which	O
binds	O
to	O
the	O
adeno-associated	B-DNA
virus	I-DNA
P5	I-DNA
promoter	I-DNA
.	O

In	O
contrast	O
,	O
soluble	B-protein
factors	I-protein
secreted	O
by	O
stromal	B-cell_type
cells	I-cell_type
induce	O
Tcell	O
survival	O
in	O
a	O
resting	O
G0/G1	O
state	O
.	O

Transient	O
cotransfection	O
of	O
tat	B-DNA
cDNA	I-DNA
in	O
sense	O
orientation	O
(	O
tat/S	B-DNA
)	O
,	O
together	O
with	O
a	O
plasmid	B-DNA
containing	O
the	O
c-fos	B-DNA
promoter	I-DNA
(	O
FC3	B-DNA
,	O
from-	O
711	B-DNA
to	I-DNA
+42	I-DNA
)	O
in	O
front	O
of	O
the	O
bacterial	B-DNA
chloramphenicol	I-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
gene	I-DNA
significantly	O
enhanced	O
CAT	B-protein
activity	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
activated	O
by	O
the	O
addition	O
of	O
15	O
%	O
fetal	O
calf	O
serum	O
(	O
FCS	O
)	O
or	O
5	O
micrograms/mL	O
phytohemagglutinin	B-protein
plus	O
10	O
(	O
-7	O
)	O
mol/L	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
U937	B-cell_line
cells	I-cell_line
activated	O
by	O
15	O
%	O
FCS	O
or	O
10	O
(	O
-7	O
)	O
mol/L	O
PMA	O
.	O

In	O
transient	O
transfection	O
assays	O
,	O
mutant	O
forms	O
of	O
Rev	B-protein
have	O
been	O
identified	O
that	O
inhibit	O
wild-type	O
Rev	B-protein
activity	O
and	O
therefore	O
suppress	O
viral	O
replication	O
.	O

Although	O
the	O
mean	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
were	O
40	O
%	O
lower	O
in	O
hyperthyroid	O
than	O
in	O
euthyroid	O
subjects	O
,	O
this	O
difference	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

The	O
CRO-AP/3	B-cell_line
and	O
CRO-AP/5	B-cell_line
cell	I-cell_line
lines	I-cell_line
may	O
provide	O
a	O
valuable	O
model	O
for	O
clarifying	O
the	O
pathogenesis	O
of	O
PEL	B-cell_line
.	O

Tax	B-protein
stimulated	O
transcription	O
through	O
NF-kappaB	B-protein
and	O
the	O
cyclic	B-DNA
AMP-responsive	I-DNA
element-like	I-DNA
sequence	I-DNA
in	O
the	O
HTLV-1	O
promoter	O
.	O

Glucocorticoids	O
are	O
mediating	O
their	O
effects	O
after	O
binding	O
to	O
an	O
intracellular	B-protein
receptor	I-protein
belonging	O
to	O
the	O
steroid	B-protein
receptor	I-protein
superfamily	I-protein
:	O
the	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
.	O

We	O
investigated	O
expression	O
of	O
the	O
IL-2Ralpha	B-protein
in	O
bronchoalveolar	B-cell_type
lavage	I-cell_type
(	I-cell_type
BAL	I-cell_type
)	I-cell_type
cells	I-cell_type
in	O
active	O
pulmonary	O
tuberculosis	O
,	O
and	O
evaluated	O
the	O
mechanism	O
Mycobacterium	O
tuberculosis	O
induces	O
in	O
the	O
IL-2Ralpha	B-protein
using	O
the	O
THP-1	B-cell_line
mononuclear	I-cell_line
phagocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Our	O
findings	O
show	O
that	O
suppression	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
with	O
cell-permeable	O
SN50	O
peptide	O
,	O
which	O
masks	O
the	O
nuclear	O
localization	O
sequence	O
of	O
NF-kappa	B-protein
B1	I-protein
dimers	I-protein
and	O
prevents	O
their	O
nuclear	O
localization	O
,	O
induces	O
apoptosis	O
in	O
resting	B-cell_type
normal	I-cell_type
human	I-cell_type
PBL	I-cell_type
.	O

Resorption	O
lacunae	O
can	O
be	O
observed	O
by	O
day	O
22	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
amino-terminal	B-protein
portion	I-protein
of	O
Sp140	B-protein
was	O
similar	O
to	O
Sp100	B-protein
,	O
a	O
previously	O
identified	O
NB	B-protein
protein	I-protein
.	O

Incubation	O
with	O
2	O
microM	O
MBP	B-protein
showed	O
that	O
,	O
after	O
a	O
1	O
h	O
lag	O
,	O
the	O
level	O
of	O
IL-8	B-protein
release	O
increased	O
with	O
time	O
for	O
approximately	O
10	O
h	O
.	O

Until	O
now	O
,	O
ER	B-protein
status	O
has	O
been	O
assessed	O
using	O
a	O
steroid	O
binding	O
assay	O
(	O
SBA	O
)	O
which	O
has	O
many	O
inherent	O
problems	O
.	O

Chicken	B-protein
NF-M	I-protein
transcription	I-protein
factor	I-protein
,	O
in	O
cooperation	O
with	O
either	O
c-Myb	B-protein
or	O
v-Myb	B-protein
,	O
is	O
active	O
in	O
the	O
combinatorial	O
activation	O
of	O
myeloid-cell-specific	B-DNA
genes	I-DNA
in	O
heterologous	B-cell_type
cell	I-cell_type
types	I-cell_type
,	O
such	O
as	O
embryonic	B-cell_type
fibroblasts	I-cell_type
.	O

No	O
degradation	O
of	O
p105	B-protein
and	I-protein
p100	I-protein
inhibitors	I-protein
was	O
observed	O
under	O
these	O
conditions	O
.	O

Carboxylesterases	B-protein
play	O
an	O
important	O
role	O
in	O
defense	O
and	O
clearance	O
mechanisms	O
of	O
the	O
monocyte/macrophage	O
system	O
.	O

Second	O
,	O
we	O
studied	O
the	O
modulation	O
of	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
dexamethasone	O
by	O
preincubation	O
with	O
TNFalpha	B-protein
or	O
IL-10	B-protein
and	O
measurement	O
of	O
LPS-stimulated	O
IL-6	B-protein
secretion	O
.	O

We	O
demonstrate	O
that	O
this	O
part	O
of	O
the	O
BCL6	B-protein
molecule	I-protein
contains	O
an	O
autonomous	B-protein
transrepressor	I-protein
domain	I-protein
and	O
that	O
two	O
noncontiguous	B-protein
regions	I-protein
,	O
including	O
the	O
POZ	B-protein
motif	I-protein
,	O
mediate	O
maximum	O
transrepressive	O
activity	O
.	O

Identification	O
of	O
Bcd	B-DNA
,	O
a	O
novel	O
proto-oncogene	B-DNA
expressed	O
in	O
B-cells	B-cell_type
.	O

Vitamin	B-protein
D	I-protein
receptor	I-protein
3'-untranslated	B-DNA
region	I-DNA
polymorphisms	O
:	O
lack	O
of	O
effect	O
on	O
mRNA	O
stability	O
.	O

Biochemical	O
analysis	O
of	O
the	O
region	O
-158/-90	B-DNA
revealed	O
a	O
binding	O
site	O
for	O
transcription	B-protein
factors	I-protein
of	O
the	O
polyomavirus	B-protein
enhancer-binding	I-protein
protein	I-protein
2/core-binding	I-protein
factor	I-protein
(	I-protein
PEBP2/CBF	I-protein
)	I-protein
family	I-protein
at	O
position	B-DNA
-103	I-DNA
.	O

Phorbol	O
ester	O
treatment	O
of	O
a	O
pre-B	B-cell_line
cell	I-cell_line
line	I-cell_line
up-regulated	O
CD19	B-protein
expression	O
,	O
induced	O
Egr-1	B-protein
,	O
and	O
enhanced	O
the	O
footprint	O
over	O
the	O
GC	O
box	O
.	O

In	O
this	O
report	O
we	O
describe	O
the	O
use	O
of	O
recombinant	O
retroviruses	O
to	O
characterize	O
the	O
activity	O
of	O
an	O
exogenous	B-DNA
promoter	I-DNA
in	O
primary	O
cells	O
obtained	O
from	O
patients	O
with	O
lymphoproliferative	O
disorders	O
.	O

The	O
effect	O
of	O
AuTG	O
on	O
NF-kappaB	B-protein
-dependent	O
gene	O
expression	O
was	O
confirmed	O
by	O
a	O
transient	O
CAT	B-protein
assay	O
.	O

The	O
effect	O
of	O
toremifene	O
therapy	O
on	O
serum	B-protein
immunoglobulin	I-protein
levels	O
in	O
breast	O
cancer	O
.	O

Within	O
24	O
h	O
following	O
LPS	O
stimulation	O
there	O
was	O
a	O
striking	O
increase	O
in	O
the	O
levels	O
of	O
c-Rel	B-protein
,	O
p105	B-protein
,	O
and	O
p50	B-protein
in	O
the	O
cytosol	O
.	O

However	O
,	O
cytokine-induced	O
NF-kappaB	B-protein
activation	O
and	O
VCAM-1	B-protein
expression	O
are	O
blocked	O
by	O
both	O
PDTC	O
and	O
NAC	O
.	O

In	O
monocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
TNF-alpha	B-protein
induced	O
two	O
nuclear	B-protein
complexes	I-protein
which	O
in	O
vitro	O
bound	O
to	O
the	O
ICAM-1	B-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
.	O

Multiple	O
prolactin-responsive	B-DNA
elements	I-DNA
mediate	O
G1	O
and	O
S	O
phase	O
expression	O
of	O
the	O
interferon	B-DNA
regulatory	I-DNA
factor-1	I-DNA
gene	I-DNA
.	O

The	O
NB4	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
which	O
is	O
derived	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	O
with	O
APL	O
during	O
relapse	O
,	O
can	O
be	O
used	O
as	O
a	O
model	O
system	O
to	O
study	O
the	O
growth	O
and	O
differentiation	O
of	O
APL	B-cell_line
cells	I-cell_line
.	O

A	O
lowered	O
affinity	O
to	O
dexamethasone	O
was	O
found	O
in	O
one	O
female	O
patient	O
,	O
while	O
a	O
lowered	O
number	O
of	O
receptors	O
was	O
found	O
in	O
three	O
patients	O
.	O

These	O
results	O
indicate	O
that	O
the	O
somatic	O
hypermutation	O
mechanism	O
active	O
in	O
GC	B-cell_type
B	I-cell_type
cells	I-cell_type
physiologically	O
targets	O
non-Ig	B-DNA
sequences	I-DNA
.	O

This	O
activation	O
is	O
inhibited	O
by	O
known	O
inhibitors	O
of	O
NF-kappa	B-protein
B	I-protein
or	O
by	O
simultaneous	O
treatment	O
of	O
the	O
cells	O
with	O
surfactant	O
lipids	O
.	O

Interleukin-6	B-protein
protein	O
and	O
IL-6	B-RNA
mRNA	I-RNA
were	O
measured	O
in	O
control	O
and	O
CMV	B-cell_type
immediate	I-cell_type
early	I-cell_type
transfected	I-cell_type
cells	I-cell_type
.	O

One	O
consequence	O
of	O
the	O
activation	O
of	O
PKC	B-protein
can	O
be	O
increased	O
expression	O
of	O
mitogen-activated	B-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinase	I-protein
pathways	O
.	O

Analysis	O
of	O
the	O
expression	O
of	O
human	B-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
protein	I-protein
in	O
stable	O
transfectants	O
of	O
mouse	B-cell_line
70Z/3	I-cell_line
cells	I-cell_line
shows	O
that	O
,	O
as	O
for	O
the	O
endogenous	O
murine	O
protein	O
,	O
exogenous	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
degraded	O
in	O
response	O
to	O
inducers	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
,	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
lipopolysaccharide	O
.	O

Site-directed	O
mutagenesis	O
of	O
binding	O
sites	O
for	O
the	O
repressor	B-protein
proteins	I-protein
BP1	I-protein
and	I-protein
BP2	I-protein
in	O
the	O
upstream	B-DNA
portion	I-DNA
of	O
the	O
beta	B-DNA
globin	I-DNA
gene	I-DNA
flanking	I-DNA
region	I-DNA
led	O
to	O
a	O
4-6	O
fold	O
increase	O
in	O
promoter	O
activity	O
.	O

Chronic	O
myeloproliferative	O
diseases	O
(	O
MPDs	O
)	O
are	O
not	O
associated	O
with	O
consistent	O
cytogenetic	O
or	O
molecular	O
abnormalities	O
.	O

This	O
region	O
is	O
responsive	O
to	O
transactivation	O
by	O
Tat	B-protein
.	O

Because	O
the	O
Nef	B-protein
protein	O
does	O
not	O
affect	O
the	O
surface	O
expression	O
of	O
the	O
CD3	B-protein
-TCR	O
complex	O
,	O
we	O
conclude	O
that	O
the	O
Nef	B-protein
protein	O
down-regulates	O
the	O
transcriptional	O
factors	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
in	O
T	B-cell_type
cells	I-cell_type
in	O
vitro	O
through	O
an	O
effect	O
on	O
the	O
TCR-dependent	O
signal	O
transduction	O
pathway	O
.	O

However	O
they	O
are	O
not	O
functional	O
on	O
a	O
truncated	O
TNF-alpha	B-DNA
promoter	I-DNA
,	O
indicating	O
that	O
promoter	O
context	O
and	O
cell	O
type	O
specificity	O
influence	O
the	O
PMA	O
inducible	O
function	O
of	O
these	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
sites	I-DNA
.	O

A	O
novel	O
Ets-related	B-protein
transcription	I-protein
factor	I-protein
,	O
Elf-1	B-protein
,	O
binds	O
to	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
2	I-DNA
regulatory	I-DNA
elements	I-DNA
that	O
are	O
required	O
for	O
inducible	O
trans	O
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
Stat1alpha	B-protein
and	O
Stat3	B-protein
act	O
as	O
negative	O
regulators	O
in	O
EPO	B-protein
-induced	O
erythroid	O
differentiation	O
.	O

These	O
results	O
collectively	O
reveal	O
a	O
complex	O
interaction	O
of	O
STAT5	B-protein
with	O
other	O
signaling	O
pathways	O
and	O
illustrate	O
that	O
regulation	O
of	O
gene	O
expression	O
requires	O
integration	O
of	O
opposing	O
signals	O

The	O
consequent	O
decrease	O
in	O
the	O
nuclear	O
levels	O
of	O
c-Jun	B-protein
and	O
JunD	B-protein
leads	O
to	O
diminished	O
binding	O
of	O
c-Jun/c-Fos	B-protein
and	O
JunD/c-Fos	B-protein
heterodimers	I-protein
to	O
the	O
AP-1	B-DNA
consensus	I-DNA
sequence	I-DNA
in	O
the	O
TNF	B-DNA
promoter	I-DNA
and	O
,	O
thus	O
,	O
to	O
decreased	O
transactivation	O
of	O
the	O
TNF	B-DNA
gene	I-DNA
.	O

The	O
inhibition	O
in	O
protein	O
synthesis	O
correlates	O
with	O
specific	O
regulation	O
of	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
4E-BP1	B-protein
and	O
4E-BP2	B-protein
.	O

A	O
combination	O
of	O
differential	O
splicing	O
and	O
alternative	O
use	O
of	O
promoters	B-DNA
generates	O
four	O
mRNA	B-RNA
isoforms	I-RNA
,	O
of	O
2.6	O
kb	O
and	O
1.3-1.5	O
kb	O
in	O
size	O
.	O

We	O
have	O
shown	O
that	O
the	O
Z	B-protein
gene	I-protein
product	I-protein
,	O
which	O
binds	O
to	O
AP-1	B-DNA
sites	I-DNA
as	O
a	O
homodimer	O
and	O
has	O
sequence	O
similarity	O
to	O
c-Fos	B-DNA
,	O
can	O
efficiently	O
activate	O
the	O
EBV	B-DNA
early	I-DNA
promoter	I-DNA
,	O
BMRF1	B-DNA
,	O
in	O
certain	O
cell	O
types	O
(	O
i.e.	O
,	O
HeLa	B-cell_line
cells	I-cell_line
)	O
but	O
not	O
others	O
(	O
i.e.	O
,	O
Jurkat	B-cell_line
cells	I-cell_line
)	O
.	O

These	O
studies	O
are	O
the	O
first	O
to	O
demonstrate	O
the	O
significance	O
of	O
extrarenal	B-protein
,	I-protein
nonepithelial	I-protein
mineralocorticoid	I-protein
receptors	I-protein
and	O
the	O
related	O
effector	O
mechanism	O
in	O
different	O
disorders	O
of	O
the	O
water	O
and	O
electrolyte	O
balance	O
in	O
man	O
.	O

Gel	O
retardation	O
and	O
methylation	O
interference	O
studies	O
revealed	O
that	O
bacterially	B-protein
produced	I-protein
AP-2	I-protein
bound	O
specifically	O
and	O
with	O
high	O
affinity	O
to	O
all	O
three	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
,	O
and	O
that	O
it	O
required	O
the	O
core	B-DNA
sequence	I-DNA
AGGC	O
for	O
specific	O
binding	O
.	O

Prior	O
studies	O
have	O
identified	O
several	O
transcription	B-protein
factors	I-protein
that	O
contribute	O
to	O
the	O
activity	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
in	O
stimulated	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

When	O
the	O
same	O
MTHC	B-cell_line
lines	I-cell_line
are	O
exposed	O
to	O
TNF-alpha	B-protein
in	O
combination	O
with	O
IFN-gamma	B-protein
,	O
the	O
cells	O
instead	O
become	O
DC	B-cell_type
.	O

Together	O
,	O
our	O
results	O
indicate	O
that	O
occupancy	O
of	O
the	O
viral	B-DNA
enhancer	I-DNA
by	O
NF-kappaB	B-protein
(	I-protein
p50/p65	I-protein
)	I-protein
heterodimers	I-protein
is	O
required	O
for	O
ongoing	O
transcription	O
of	O
integrated	O
HIV	O
provirus	O
in	O
monocytes	B-cell_type
,	O
even	O
in	O
cells	O
chronically	O
infected	O
and	O
permanently	O
producing	O
functional	O
HIV	B-protein
Tat	I-protein
protein	I-protein
.	O

However	O
,	O
we	O
have	O
found	O
that	O
ICSAT	B-protein
has	O
a	O
different	O
repressive	O
effect	O
from	O
that	O
of	O
IRF-2	B-protein
or	O
ICSBP	B-protein
in	O
some	O
IFN-responsive	B-DNA
reporter	I-DNA
constructs	I-DNA
.	O

Functional	O
analyses	O
of	O
DNA	B-DNA
fragments	I-DNA
containing	O
the	O
TATA	B-DNA
element	I-DNA
and	O
the	O
identification	O
of	O
a	O
DNase	B-DNA
I-hypersensitive	I-DNA
chromatin	I-DNA
site	I-DNA
(	O
HS	B-DNA
1	I-DNA
)	O
in	O
close	O
proximity	O
to	O
the	O
TATA	B-DNA
box	I-DNA
suggest	O
that	O
the	O
identified	O
TATA	B-DNA
motif	I-DNA
is	O
important	O
for	O
elk-1	B-DNA
transcription	O
in	O
vivo	O
.	O

Surprisingly	O
,	O
although	O
stimulation	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
either	O
CHO-CD80	B-protein
or	O
anti-CD28	B-protein
mAb	I-protein
resulted	O
in	O
robust	O
tyrosine	O
phosphorylation	O
of	O
CD28	B-protein
itself	O
,	O
ligation	O
with	O
CHO-CD86	B-protein
was	O
unable	O
to	O
induce	O
detectable	O
CD28	B-protein
tyrosyl	O
phosphorylation	O
over	O
a	O
range	O
of	O
stimulation	O
conditions	O
.	O

Interferon-gamma	B-protein
modulates	O
the	O
lipopolysaccharide-induced	O
expression	O
of	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
at	O
the	O
mRNA	O
and	O
protein	O
level	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

The	O
data	O
indicate	O
that	O
oncogenes	B-DNA
activate	O
the	O
cytotoxicity	O
of	O
NK	O
cell	O
granules	O
.	O

The	O
induction	O
of	O
AP1	B-protein
by	O
okadaic	O
acid	O
suggests	O
that	O
protein	B-protein
phosphatases	I-protein
1	I-protein
and	I-protein
2A	I-protein
(	O
PP1	B-protein
and	O
PP2A	B-protein
)	O
may	O
be	O
involved	O
in	O
T	O
cell	O
activation	O
as	O
important	O
negative	O
regulators	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP1	B-protein
.	O

In	O
the	O
latter	O
A-myb	B-DNA
did	O
not	O
correlate	O
with	O
phenotype	O
or	O
clinical	O
stage	O
.	O

Binding	O
of	O
YY1	B-protein
and	O
Oct1	B-protein
to	O
a	O
novel	O
element	O
that	O
downregulates	O
expression	O
of	O
IL-5	B-protein
in	O
human	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
overlapping	O
expression	O
patterns	O
and	O
similar	O
in	O
vitro	O
binding	O
and	O
trans-activation	O
activities	O
on	O
various	O
promoter	B-DNA
elements	I-DNA
of	O
NF-AT-regulated	B-DNA
genes	I-DNA
suggest	O
some	O
redundancy	O
in	O
the	O
function	O
of	O
these	O
proteins	O
.	O

Cleavage	O
of	O
transcription	B-protein
factor	I-protein
SP1	B-protein
by	O
caspases	B-protein
during	O
anti-IgM-induced	O
B-cell	B-cell_type
apoptosis	O
.	O

Isoelectric	O
focusing	O
demonstrated	O
that	O
TPO	B-protein
induced	O
fetal	O
and	O
adult	O
Hb	O
synthesis	O
,	O
whereas	O
EPO	B-protein
induced	O
embryonic	O
,	O
fetal	O
,	O
and	O
adult	O
Hb	O
synthesis	O
.	O

Here	O
we	O
report	O
that	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
Tcf-1	B-protein
also	O
becomes	O
transcriptionally	O
active	O
through	O
interaction	O
with	O
beta-catenin	B-protein
,	O
suggesting	O
that	O
the	O
Wnt	O
signal	O
transduction	O
pathway	O
is	O
operational	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
as	O
well	O
.	O

Promoter	O
function	O
of	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
was	O
evaluated	O
by	O
transfection	O
of	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
promoter/chloramphenicol	I-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
chimera	I-DNA
plasmids	I-DNA
into	O
platelet-like	O
K562	B-cell_line
cells	I-cell_line
.	O

5.	O
Neutrophil	O
apoptosis	O
and	O
inhibition	O
of	O
neutrophil	O
function	O
were	O
induced	O
at	O
lower	O
concentrations	O
of	O
SMX-NHOH	O
and	O
SMX-NO	O
than	O
those	O
inducing	O
loss	O
of	O
membrane	O
viability	O
,	O
with	O
SMX	O
having	O
no	O
effect	O
.	O

RNA	O
from	O
control	O
resting	B-cell_type
cells	I-cell_type
contained	O
low	O
to	O
undetectable	O
levels	O
of	O
c-jun	B-RNA
,	O
fibronectin	B-RNA
receptor	I-RNA
,	O
and	O
actin	B-RNA
mRNA	I-RNA
.	O

We	O
identified	O
several	O
anti-Ig	O
response	O
elements	O
within	O
Zp	B-DNA
,	O
which	O
were	O
originally	O
defined	O
as	O
12-O-tetradecanoylphorbol-13-acetate	B-DNA
(	I-DNA
TPA	I-DNA
)	I-DNA
response	I-DNA
elements	I-DNA
(	O
ZI	O
repeats	O
and	O
ZII	B-DNA
,	O
an	O
AP-1-like	B-DNA
domain	I-DNA
)	O
.	O

CLEO	O
defines	O
a	O
binding	B-DNA
site	I-DNA
for	O
protein	O
(	O
s	O
)	O
whose	O
optimum	O
binding	O
is	O
stimulated	O
by	O
PMA	O
and	O
A23187	O
.	O

The	O
constitutively	O
active	O
type	O
of	O
the	O
CN	B-protein
A	I-protein
subunit	I-protein
,	O
which	O
lacks	O
the	O
auto-inhibitory	B-protein
and	O
calmodulin-binding	B-protein
domains	I-protein
,	O
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
activate	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
.	O

In	O
the	O
cell	O
types	O
tested	O
,	O
the	O
LS	O
mutations	O
indicated	O
an	O
apparent	O
requirement	O
not	O
only	O
for	O
the	O
intact	O
NF-kappa	B-protein
B	I-protein
and	O
SP1-binding	B-DNA
sites	I-DNA
but	O
also	O
for	O
several	O
regions	O
between	O
-201	B-DNA
and	I-DNA
-130	I-DNA
not	O
previously	O
associated	O
with	O
viral	O
infectivity	O
.	O

Oct2	B-protein
transactivation	O
from	O
a	O
remote	B-DNA
enhancer	I-DNA
position	I-DNA
requires	O
a	O
B-cell-restricted	O
activity	O
.	O

Conversely	O
,	O
a	O
significant	O
negative	O
correlation	O
was	O
found	O
between	O
VDR	B-protein
and	O
serum	O
creatinine	O
values	O
when	O
A-CRF	O
and	O
M-CRF	O
were	O
considered	O
altogether	O
(	O
r	O
=	O
-0.63	O
;	O
p	O
<	O
0.01	O
)	O
.	O

CD40	B-protein
is	O
an	O
important	O
signaling	O
and	O
activation	O
Ag	O
found	O
on	O
certain	O
bone	B-cell_type
marrow-derived	I-cell_type
cells	I-cell_type
.	O

Resistance	O
to	O
glucocorticoid	O
therapy	O
has	O
been	O
observed	O
in	O
patients	O
with	O
autoimmune/inflammatory	O
diseases	O
and	O
may	O
be	O
related	O
to	O
the	O
inflammatory	O
process	O
itself	O
.	O

Positive	B-DNA
regulatory	I-DNA
element	I-DNA
I	I-DNA
(	O
PRE-I	B-DNA
)	O
is	O
a	O
strong	O
enhancer	B-DNA
element	I-DNA
essential	O
for	O
expression	O
of	O
the	O
human	B-DNA
IL-4	I-DNA
gene	I-DNA
.	O

G28-5	B-protein
sFv	I-protein
was	O
a	O
more	O
potent	O
agonist	O
than	O
G28-5	B-protein
IgG	I-protein
and	O
was	O
able	O
to	O
stimulate	O
CD40	B-protein
responses	O
by	O
B	B-cell_type
cells	I-cell_type
and	O
monocytes	O
.	O

We	O
observed	O
that	O
Abs	O
directed	O
against	O
unique	O
domains	O
of	O
STAT6	B-protein
have	O
differential	O
effects	O
on	O
complexes	O
in	O
T	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
NK	B-cell_type
cells	I-cell_type
,	O
suggesting	O
different	O
STAT6	B-protein
isoforms	I-protein
.	O

Macrophage-colony-stimulating	B-protein
factor	I-protein
(	O
M-CSF	B-protein
)	O
,	O
also	O
referred	O
to	O
as	O
CSF-1	B-protein
,	O
regulates	O
the	O
survival	O
,	O
growth	O
,	O
differentiation	O
and	O
functional	O
activity	O
of	O
monocytes	B-cell_type
by	O
binding	O
to	O
a	O
single	O
class	O
of	O
high-affinity	B-protein
cell	I-protein
surface	I-protein
receptors	I-protein
,	O
known	O
to	O
be	O
the	O
product	O
of	O
the	O
c-fms	B-DNA
protooncogene	I-DNA
.	O

Identification	O
of	O
an	O
inducible	B-protein
regulator	I-protein
of	O
c-myb	B-DNA
expression	O
during	O
T-cell	B-cell_type
activation	O
.	O

Its	O
occurrence	O
is	O
considered	O
to	O
be	O
extremely	O
rare	O
.	O

We	O
now	O
show	O
that	O
IL-2	B-protein
regulation	O
of	O
STAT3	B-protein
proteins	I-protein
in	O
T	B-cell_type
cells	I-cell_type
is	O
a	O
complex	O
response	O
involving	O
activation	O
of	O
two	O
forms	O
of	O
STAT3	B-protein
:	O
90-kDa	O
STAT3alpha	B-protein
and	O
an	O
83-kDa	B-protein
carboxyl-terminal	I-protein
truncated	I-protein
STAT3beta	I-protein
.	O

However	O
,	O
in	O
3	O
postmenopausal	O
patients	O
a	O
short	O
course	O
of	O
estrogen	O
or	O
tamoxifen	O
resulted	O
in	O
a	O
marked	O
increase	O
of	O
type	B-protein
II	I-protein
EBS	I-protein
levels	O
.	O

Production	O
of	O
HIV-1	O
from	O
latently	O
infected	O
cells	O
requires	O
host	O
cell	O
activation	O
by	O
T-cell	B-protein
mitogens	I-protein
(	O
T.Folks	O
,	O
D.M.Powell	O
,	O
M.M.Lightfoote	O
,	O
S.Benn	O
,	O
M.A.	O
Martin	O
,	O
and	O
A.S.Fauci	O
,	O
Science	O
231	O
:	O
600-602	O
,	O
1986	O
;	O
D.Zagury	O
,	O
J.	O
Bernard	O
,	O
R.Leonard	O
,	O
R.Cheynier	O
,	O
M.Feldman	O
,	O
P.S.Sarin	O
,	O
and	O
R.C.	O
Gallo	O
,	O
Science	O
231	O
:	O
850-853	O
,	O
1986	O
)	O
.	O

These	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
elements	I-DNA
are	O
recognized	O
by	O
a	O
structurally	O
related	O
family	O
of	O
interactive	O
proteins	O
that	O
includes	O
p50	B-protein
,	O
p65	B-protein
,	O
and	O
the	O
product	O
of	O
the	O
c-rel	B-DNA
protooncogene	I-DNA
(	O
c-Rel	B-protein
)	O
.	O

The	O
transmembrane	O
domains	O
are	O
well	O
conserved	O
,	O
but	O
there	O
is	O
striking	O
sequence	O
divergence	O
of	O
the	O
carboxy-terminal	B-protein
cytoplasmic	I-protein
domain	I-protein
essential	O
for	O
B-cell	B-cell_type
immortalization	O
and	O
interaction	O
with	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
signaling	O
pathway	O
.	O

LPS	O
stimulation	O
increased	O
the	O
binding	O
of	O
c-Jun-containing	B-protein
complexes	I-protein
.	O

The	O
gene	O
encoding	O
a	O
chicken	B-protein
cytokine	I-protein
with	O
T-cell	O
proliferative	O
activity	O
was	O
cloned	O
,	O
sequenced	O
,	O
and	O
mapped	O
.	O

Using	O
a	O
combination	O
of	O
bacterial	O
motility	O
assays	O
in	O
platelet	O
extracts	O
with	O
Escherichia	O
coli	O
expressing	O
the	O
Shigella	B-protein
IcsA	I-protein
protein	I-protein
and	O
in	O
vitro	O
analysis	O
of	O
reconstituted	O
systems	O
from	O
purified	B-protein
proteins	I-protein
,	O
we	O
show	O
here	O
that	O
the	O
bacterial	B-protein
protein	I-protein
IcsA	I-protein
binds	O
N-WASP	B-protein
and	O
activates	O
it	O
in	O
a	O
Cdc42	B-protein
-like	O
fashion	O
.	O

However	O
,	O
reconstitution	O
of	O
these	O
X-SCID	B-cell_type
B	I-cell_type
cells	I-cell_type
with	O
gammac	B-protein
enhanced	O
IL-4	B-protein
-mediated	O
responses	O
including	O
STAT6	B-protein
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
and	O
resulted	O
in	O
increased	O
CD23	B-protein
expression	O
.	O

Our	O
results	O
demonstrate	O
that	O
NF-IL6	B-protein
is	O
involved	O
in	O
transcriptional	O
activation	O
of	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
lineage-restricted	B-protein
transcription	I-protein
factor	I-protein
GATA-1	B-protein
is	O
required	O
for	O
differentiation	O
of	O
erythroid	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
cells	I-cell_type
.	O

As	O
in	O
HMG1B	B-protein
,	O
the	O
overall	O
structure	O
of	O
the	O
Sox-4	B-protein
HMG	B-protein
box	I-protein
is	O
L-shaped	O
and	O
is	O
maintained	O
by	O
a	O
cluster	O
of	O
conserved	O
,	O
mainly	O
aromatic	O
residues	O
.	O

Further	O
,	O
monocytes	B-cell_type
from	O
patients	O
demonstrate	O
an	O
augmented	O
susceptibility	O
to	O
a	O
productive	O
infection	O
with	O
HIV-1	O
in	O
vitro	O
.	O

We	O
now	O
report	O
the	O
identification	O
of	O
a	O
cDNA	B-DNA
clone	I-DNA
(	O
15B-7	B-DNA
)	O
,	O
from	O
a	O
Jurkat	B-DNA
expression	I-DNA
library	I-DNA
,	O
that	O
binds	O
specifically	O
to	O
the	O
DRE	B-DNA
1	I-DNA
regulatory	I-DNA
sequence	I-DNA
.	O

ChtM	O
was	O
inhibited	O
by	O
hydrocortisone	O
(	O
F	O
)	O
of	O
physiological	O
concentration	O
(	O
10	O
(	O
-9	O
)	O
-10	O
(	O
-7	O
)	O
mol/L	O
)	O
which	O
was	O
dose-dependent	O
and	O
completely	O
antagonized	O
by	O
the	O
competitive	O
antagonist	O
,	O
RU38486	O
.	O

STAT1	B-protein
alpha	I-protein
activation	O
by	O
IL-12	B-protein
correlated	O
with	O
increased	O
phosphorylation	O
of	O
serine	O
,	O
but	O
not	O
tyrosine	O
.	O

This	O
alternative	O
pathway	O
of	O
Tat	B-protein
activation	O
is	O
mediated	O
by	O
the	O
viral	B-DNA
enhancer	I-DNA
,	O
a	O
kappa	O
B	O
domain	O
capable	O
of	O
binding	O
the	O
prototypical	O
form	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	B-protein
B	I-protein
)	O
present	O
in	O
many	O
cell	O
types	O
,	O
including	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Specific	O
DNA	O
protein	B-protein
complex	I-protein
formation	O
was	O
observed	O
with	O
the	O
probes	O
from	O
the	O
beta-casein	O
and	O
IRF-1	B-DNA
gene	I-DNA
promoters	I-DNA
,	O
but	O
not	O
with	O
the	O
ISRE	O
oligonucleotide	O
probe	O
,	O
when	O
cell	O
extracts	O
from	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
and	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
were	O
investigated	O
.	O

So	O
we	O
think	O
that	O
GCR	B-protein
is	O
more	O
sensitive	O
than	O
the	O
plasma	O
cortisol	O
level	O
to	O
reflect	O
the	O
aging	O
change	O
of	O
the	O
adrenal	O
cortex	O
function	O
.	O

Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
expression	O
and	O
replication	O
are	O
under	O
tight	O
regulatory	O
control	O
.	O

We	O
show	O
here	O
that	O
c-Rel	B-protein
binds	O
to	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
as	O
homodimers	B-protein
as	O
well	O
as	O
heterodimers	B-protein
with	O
p50	B-protein
.	O

Competition	O
experiments	O
did	O
not	O
reveal	O
any	O
high-affinity	B-DNA
binding	I-DNA
site	I-DNA
for	O
BSAP	B-protein
in	O
known	O
regulatory	B-DNA
regions	I-DNA
of	O
immunoglobulin	B-DNA
and	I-DNA
class	I-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
genes	I-DNA
,	O
suggesting	O
that	O
BSAP	B-protein
is	O
a	O
regulator	O
of	O
a	O
different	O
set	O
of	O
B-lymphoid-specific	B-DNA
genes	I-DNA
.	O

The	O
nature	O
of	O
the	O
nuclear	B-protein
factor	I-protein
(	O
s	O
)	O
that	O
control	O
TNF-alpha	B-protein
gene	O
transcription	O
in	O
humans	O
remains	O
obscure	O
,	O
although	O
NF-kappaB	B-protein
has	O
been	O
suggested	O
.	O

However	O
,	O
for	O
IL-4	B-protein
this	O
was	O
accompanied	O
with	O
a	O
reduction	O
of	O
AP-1	O
and	O
NF-IL6	O
binding	O
activity	O
whereas	O
IL-10	B-protein
only	O
inhibited	O
AP-1	B-protein
binding	O
activity	O
.	O

Furthermore	O
,	O
the	O
substitution	O
of	O
this	O
GATA	B-DNA
binding	I-DNA
site	I-DNA
by	O
a	O
canonical	O
TFIID	B-DNA
binding	I-DNA
site	I-DNA
suppresses	O
the	O
promoter	O
activity	O
.	O

Analysis	O
of	O
DNA	O
binding	O
revealed	O
that	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
response	O
to	O
TNF	B-protein
was	O
significantly	O
inhibited	O
under	O
these	O
conditions	O
.	O

Elucidation	O
of	O
IL-5	B-protein
-specific	O
regulatory	O
mechanisms	O
may	O
facilitate	O
the	O
development	O
of	O
novel	O
treatments	O
for	O
allergic	O
diseases	O
associated	O
with	O
eosinophilic	O
inflammation	O
.	O

A	O
new	O
variant	O
translocation	O
in	O
acute	O
promyelocytic	O
leukaemia	O
:	O
molecular	O
characterization	O
and	O
clinical	O
correlation	O
.	O

The	O
activity	O
of	O
IL-1	B-protein
was	O
expressed	O
as	O
its	O
ability	O
to	O
stimulate	O
3H-TdR	B-protein
incorporation	O
in	O
the	O
thymocytes	B-cell_type
of	O
C57	O
mice	O
.	O

In	O
a	O
series	O
of	O
functional	O
studies	O
we	O
found	O
that	O
modulation	O
of	O
the	O
level	O
of	O
the	O
mRNAs	B-RNA
coding	O
for	O
both	O
the	O
c-myc	B-DNA
oncogene	I-DNA
and	O
the	O
growth	O
factor	O
known	O
as	O
granulocyte-monocyte	O
colony	O
stimulating	O
activity	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
correlated	O
with	O
the	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
status	O
of	O
these	O
cells	O
.	O

Furthermore	O
there	O
was	O
a	O
clear-cut	O
synergy	O
between	O
the	O
PKC	B-protein
stimulator	O
and	O
the	O
cAMP	O
elevating	O
agents	O
.	O

Mutations	O
of	O
sites	O
that	O
suppress	O
NF-AT	B-protein
binding	O
impair	O
the	O
induction	O
and	O
strong	O
NF-ATp	B-protein
-mediated	O
transactivation	O
of	O
the	O
CD25	B-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

A	O
family	O
of	O
transcriptional	B-protein
activators	I-protein
has	O
recently	O
been	O
identified	O
in	O
chickens	O
;	O
these	O
transcriptional	B-protein
activators	I-protein
recognize	O
a	O
common	O
consensus	B-DNA
motif	I-DNA
(	O
WGATAR	B-DNA
)	O
through	O
a	O
conserved	O
C4	B-protein
zinc	I-protein
finger	I-protein
DNA-binding	I-protein
domain	I-protein
.	O

5'HS3	B-DNA
contains	O
six	O
G-rich	O
motifs	O
that	O
are	O
essential	O
for	O
its	O
activity	O
.	O

This	O
effect	O
required	O
surface	O
expression	O
of	O
the	O
CD45	B-protein
PTPase	I-protein
and	O
was	O
not	O
observed	O
in	O
CD45-deficient	B-cell_line
variants	I-cell_line
of	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

This	O
effect	O
was	O
dependent	O
upon	O
the	O
duration	O
of	O
exposure	O
to	O
L.	O
donovani	O
and	O
was	O
maximal	O
and	O
complete	O
at	O
16	O
h	O
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
and	O
interleukin-7	B-protein
(	O
IL-7	B-protein
)	O
,	O
secreted	O
during	O
this	O
interaction	O
,	O
are	O
critical	O
cytokines	O
for	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
transactivation	O
through	O
NF-kappaB	B-protein
-dependent	O
activation	O
.	O

To	O
investigate	O
the	O
inhibitory	O
mechanisms	O
,	O
we	O
constructed	O
a	O
secreted-type	B-DNA
placental	I-DNA
alkaline	I-DNA
phosphatase	I-DNA
(	I-DNA
PLAP	I-DNA
)	I-DNA
reporter	I-DNA
gene	I-DNA
whose	O
transcription	O
is	O
controlled	O
by	O
a	O
1.4-kb	B-DNA
human	I-DNA
TNF-alpha	I-DNA
promoter	I-DNA
.	O

Down-regulation	O
of	O
NF-kappa	B-protein
B	I-protein
protein	I-protein
levels	O
in	O
activated	O
human	O
lymphocytes	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1996	O
Jan	O
9	O
;	O
93	O
(	O
1	O
)	O
:	O
524	O
]	O

We	O
conclude	O
that	O
apoptotic	B-cell_type
VSMCs	I-cell_type
possess	O
a	O
significant	O
thrombin	B-protein
-generating	O
capacity	O
secondary	O
to	O
phosphatidylserine	O
exposure	O
.	O

The	O
BCL-6	B-RNA
gene	I-RNA
encoding	O
a	O
nuclear-located	B-protein
Kruppel-type	I-protein
zinc	I-protein
finger	I-protein
protein	I-protein
is	O
rearranged	O
in	O
about	O
30	O
%	O
diffuse	O
large	O
B-cell	B-cell_type
lymphomas	I-cell_type
and	O
is	O
expressed	O
predominantly	O
in	O
normal	O
germinal	B-cell_type
center	I-cell_type
B	I-cell_type
cells	I-cell_type
and	O
related	O
lymphomas	O
.	O

The	O
allele	B-DNA
-specific	O
regulation	O
of	O
Pax5	B-protein
raises	O
the	O
intriguing	O
possibility	O
that	O
monoallelic	O
expression	O
may	O
also	O
be	O
the	O
mechanism	O
causing	O
the	O
haploinsufficiency	O
of	O
other	O
Pax	B-DNA
genes	I-DNA
.	O

METHODS	O
.	O

NK	O
cell	O
cytotoxicity	O
is	O
a	O
fast	O
and	O
efficient	O
mechanism	O
of	O
target	O
cell	O
lysis	O
.	O

They	O
bind	O
to	O
the	O
kappa	B-DNA
B	I-DNA
motifs	I-DNA
with	O
different	O
relative	O
affinities	O
that	O
may	O
reflect	O
their	O
different	O
contribution	O
in	O
the	O
expression	O
of	O
various	O
promoters	B-DNA
.	O

Aldosterone	O
levels	O
returned	O
to	O
normal	O
nonpregnant	O
values	O
after	O
delivery	O
.	O

Upon	O
transfection	O
into	O
Nb2	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
1.7	O
kilobases	O
(	O
kb	O
)	O
of	O
IRF-1	B-DNA
5'-flanking	I-DNA
DNA	I-DNA
linked	O
to	O
a	O
chloramphenicol	B-DNA
acetyl	I-DNA
transferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
reporter	I-DNA
gene	I-DNA
mediated	O
a	O
30-fold	O
induction	O
of	O
CAT	B-protein
enzyme	I-protein
activity	O
in	O
response	O
to	O
24	O
h	O
of	O
PRL	B-protein
stimulation	O
.	O

We	O
studied	O
49	O
cases	O
of	O
B-cell	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
using	O
immunostaining	O
of	O
cytospin	O
preparations	O
.	O

Additionally	O
,	O
IFN-gamma	B-protein
activity	O
but	O
not	O
IL-1	O
,	O
IL-2	O
,	O
or	O
IL-4	O
activity	O
was	O
present	O
in	O
culture	O
supernatants	O
72	O
h	O
after	O
R24	B-protein
stimulation	O
.	O

After	O
this	O
event	O
,	O
we	O
observed	O
a	O
rise	O
in	O
intracellular	O
Ca2+	O
concentration	O
,	O
corresponding	O
to	O
an	O
influx	O
.	O

There	O
is	O
a	O
single	O
methionine	B-DNA
codon-initiated	I-DNA
open	I-DNA
reading	I-DNA
frame	I-DNA
of	O
1	O
,	O
458	O
nt	O
in	O
frame	O
with	O
a	O
homeobox	B-DNA
and	O
a	O
CAX	B-DNA
repeat	I-DNA
,	O
and	O
the	O
open	B-DNA
reading	I-DNA
frame	I-DNA
is	O
predicted	O
to	O
encode	O
a	O
protein	O
of	O
51	O
,	O
659	O
daltons	O
.	O

The	O
activation	O
of	O
calcineurin	B-protein
and	O
the	O
nuclear	O
import	O
of	O
NF-ATc	B-protein
can	O
both	O
be	O
blocked	O
by	O
cyclosporin	O
A	O
or	O
FK506	O
in	O
complex	O
with	O
their	O
respective	O
immunophilins	B-protein
.	O

For	O
this	O
expression	O
pattern	O
the	O
first	O
280	B-DNA
bp	I-DNA
upstream	I-DNA
of	O
the	O
major	B-DNA
transcriptional	I-DNA
start	I-DNA
site	I-DNA
seems	O
to	O
be	O
sufficient	O
.	O

Comparison	O
of	O
retinoic	O
acid	O
and	O
phorbol	O
myristate	O
acetate	O
as	O
inducers	O
of	O
monocytic	O
differentiation	O
.	O

Tyloxapol	O
also	O
reduces	O
the	O
viscosity	O
of	O
CF	O
sputum	O
(	O
from	O
463	O
+/-	O
133	O
to	O
128	O
+/-	O
52	O
centipoise	O
)	O
.	O

To	O
determine	O
whether	O
CIF	B-protein
blocks	O
at	O
the	O
level	O
of	O
IL2	B-protein
transcription	O
,	O
we	O
introduced	O
reporter	O
plasmids	O
into	O
the	O
human	B-cell_line
T	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
Jurkat	I-cell_line
by	O
transient	O
transfection	O
.	O

Dose-response	O
experiments	O
suggested	O
that	O
steroid	O
doses	O
currently	O
used	O
in	O
clinical	O
medicine	O
are	O
suboptimal	O
in	O
repressing	O
NFkappaB	B-protein
-mediated	O
cytokine	B-protein
production	O
in	O
the	O
inflammatory	O
lesions	O
.	O

Nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
is	O
a	O
redox	B-protein
sensitive	I-protein
cytosolic	I-protein
transcription	I-protein
factor	I-protein
.	O

Functional	O
B-cell	O
response	O
in	O
intrahepatic	O
lymphoid	O
follicles	O
in	O
chronic	O
hepatitis	O
C	O
.	O

Stable	O
expression	O
of	O
HB24	B-DNA
,	O
a	O
diverged	B-DNA
human	I-DNA
homeobox	I-DNA
gene	I-DNA
,	O
in	O
T	O
lymphocytes	O
induces	O
genes	O
involved	O
in	O
T	O
cell	O
activation	O
and	O
growth	O
.	O

IFN-alpha/beta	B-protein
specifically	O
induced	O
tyrosine	O
phosphorylation	O
and	O
translocation	O
into	O
nucleus	O
of	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
2	I-protein
protein	I-protein
in	O
the	O
T	B-cell_line
cell	I-cell_line
clones	I-cell_line
.	O

Consistent	O
with	O
its	O
Rel/NF-kappaB	B-protein
-dependent	O
induction	O
,	O
Jagged1	B-protein
was	O
found	O
to	O
be	O
highly	O
expressed	O
in	O
splenic	B-cell_type
B	I-cell_type
cells	I-cell_type
where	O
c-Rel	B-protein
is	O
expressed	O
constitutively	O
.	O

The	O
NFAT	B-protein
-luc	O
assay	O
is	O
a	O
useful	O
technique	O
for	O
the	O
rapid	O
,	O
sensitive	O
measurement	O
of	O
CIF	B-protein
or	O
other	O
immunosuppressants	O
with	O
a	O
similar	O
mode	O
of	O
action	O
.	O

It	O
is	O
demonstrated	O
here	O
with	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
monocytes	B-cell_type
that	O
different	O
stimuli	O
,	O
including	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
and	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
cause	O
rapid	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
,	O
with	O
concomitant	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
followed	O
by	O
a	O
dramatic	O
increase	O
in	O
I	B-RNA
kappa	I-RNA
B-alpha	I-RNA
mRNA	I-RNA
and	O
protein	O
synthesis	O
.	O

We	O
conclude	O
that	O
a	O
different	O
set	O
of	O
proteins	B-protein
recognize	O
IL-2	B-DNA
and	I-DNA
IL-4	I-DNA
genes	I-DNA
.	O

A	O
55-kDa	B-protein
isoform	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
gamma-2	I-protein
,	O
lacks	O
the	O
190	B-protein
C-terminal	I-protein
amino	I-protein
acids	I-protein
of	O
p70	B-protein
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
.	O

Unlike	O
ligation	O
of	O
CD3	B-protein
,	O
stimulation	O
with	O
anti-CD28	B-protein
mAb	I-protein
or	O
CHO	B-cell_line
cells	I-cell_line
expressing	O
the	O
CD28	B-protein
ligands	I-protein
CD80	B-protein
or	O
CD86	B-protein
did	O
not	O
lead	O
to	O
tyrosine	O
phosphorylation	O
of	O
HS1	B-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

These	O
results	O
indicate	O
that	O
CD40	B-protein
-CD40L	B-protein
interactions	O
may	O
play	O
an	O
important	O
role	O
in	O
augmenting	O
antitumor	O
immunity	O
and	O
inducing	O
apoptosis	O
in	O
some	O
CD40	B-protein
-positive	O
immunogenic	O
human	O
MMs	O
.	O

AML1	B-protein
plays	O
a	O
critical	O
role	O
during	O
hematopoiesis	O
and	O
chromosomal	O
translocations	O
involving	O
AML1	B-protein
are	O
commonly	O
associated	O
with	O
different	O
forms	O
of	O
leukemia	O
,	O
including	O
pre-B	O
acute	O
lymphoblastic	O
leukemia	O
.	O

p52	B-protein
and	O
RelB	B-protein
were	O
detected	O
in	O
the	O
nuclei	O
in	O
both	O
CD1a+	B-cell_line
and	O
CD68+	B-cell_line
cells	I-cell_line
from	O
the	O
T	O
cell	O
area	O
,	O
whereas	O
p50	B-protein
was	O
found	O
only	O
in	O
CD68-	B-cell_line
and	I-cell_line
CD1a-	I-cell_line
cells	I-cell_line
.	O

In	O
the	O
four	O
families	O
with	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
there	O
was	O
always	O
one	O
parent	O
with	O
reduced	O
receptor	O
binding	O
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leucocytes	I-cell_type
and	O
elevated	O
serum	O
hormone	O
levels	O
.	O

Peculiarly	O
,	O
eccrine	O
poromas	O
and	O
undifferentiated	O
spindle-shaped	O
basal	O
cell	O
epitheliomas	O
were	O
totally	O
unstained	O
.	O

The	O
findings	O
indicate	O
that	O
MNDA	B-protein
expression	O
is	O
regulated	O
by	O
mechanisms	O
similar	O
to	O
other	O
myelomonocytic	B-DNA
cell	I-DNA
specific	I-DNA
genes	I-DNA
and	O
genes	O
up-regulated	O
by	O
interferon	B-protein
alpha	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
whether	O
activities	O
of	O
these	O
phosphatases	O
are	O
necessary	O
for	O
the	O
expression	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O

T-PLL	O
is	O
also	O
seen	O
in	O
non-A-T	O
individuals	O
where	O
expression	O
of	O
either	O
TCL1	B-protein
(	O
at	O
14q32	B-DNA
)	O
or	O
the	O
c6.1B/MTCP1	B-protein
A1	I-protein
transcript	I-protein
(	O
at-Xq28	B-DNA
)	O
has	O
been	O
demonstrated	O
in	O
just	O
a	O
few	O
instances	O
.	O

An	O
intact	O
paired	O
domain	O
was	O
shown	O
to	O
be	O
both	O
necessary	O
and	O
sufficient	O
for	O
DNA	O
binding	O
of	O
BSAP	B-protein
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assays	O
using	O
the	O
E1	B-DNA
oligonucleotide	O
as	O
probe	O
,	O
nuclear	O
extracts	O
from	O
unstimulated	O
T	O
and	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
formed	O
a	O
constitutive	B-protein
complex	I-protein
termed	O
complex	B-protein
I	I-protein
,	O
while	O
nuclear	O
extracts	O
from	O
stimulated	O
SCM-1-producer	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
formed	O
a	O
higher	B-protein
mobility	I-protein
complex	I-protein
termed	O
complex	B-protein
II	I-protein
with	O
a	O
concomitant	O
decrease	O
in	O
complex	B-protein
I	I-protein
.	O

SIT	B-protein
is	O
a	O
disulfide-linked	B-protein
homodimeric	I-protein
glycoprotein	I-protein
that	O
is	O
expressed	O
in	O
lymphocytes	B-cell_type
.	O

While	O
virus	O
derived	O
from	O
the	O
clone	O
containing	O
the	O
M47	B-protein
mutation	O
retained	O
the	O
ability	O
to	O
immortalize	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
the	O
M22	B-protein
mutant	O
lost	O
the	O
ability	O
to	O
immortalize	O
infected	B-cell_type
cells	I-cell_type
.	O

These	O
species	O
showed	O
different	O
cell	O
cycle	O
kinetics	O
.	O

We	O
also	O
find	O
that	O
NF-E2	B-protein
,	O
another	O
trans-acting	B-protein
factor	I-protein
of	O
the	O
erythrocytic	B-cell_type
lineage	I-cell_type
,	O
is	O
present	O
in	O
megakaryocytes	B-cell_line
.	O

Mononuclear	B-cell_type
phagocytes	I-cell_type
play	O
a	O
major	O
role	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

The	O
HVS	O
STP-C488	B-protein
P10	O
--	O
>	O
R	O
mutant	O
was	O
deficient	O
in	O
human	O
T-lymphocyte	O
transformation	O
to	O
interleukin-2-independent	O
growth	O
but	O
showed	O
wild-type	O
phenotype	O
for	O
marmoset	O
T-lymphocyte	O
transformation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Cell	O
activation	O
and	O
apoptosis	O
by	O
bacterial	B-protein
lipoproteins	I-protein
through	O
toll-like	B-protein
receptor-2	I-protein
.	O

In	O
UCSD-AML1	B-cell_line
,	O
we	O
have	O
also	O
identified	O
fusion	B-RNA
transcripts	I-RNA
between	O
the	O
ecotropic	B-DNA
viral	I-DNA
insertion	I-DNA
site	I-DNA
I	I-DNA
(	I-DNA
EVI1	I-DNA
)	I-DNA
gene	I-DNA
in	O
3q26	B-DNA
and	O
GR6	B-DNA
and	O
between	O
EVI1	B-DNA
and	O
Ribophorin	B-DNA
I	I-DNA
that	O
maps	O
30	O
kb	O
telomeric	O
to	O
GR6	B-DNA
in	O
3q21	B-DNA
.	O

Analysis	O
of	O
the	O
nuclear	O
extracts	O
with	O
anti-STAT	B-protein
Abs	I-protein
indicated	O
that	O
they	O
contained	O
STAT-3	B-protein
and	O
additional	O
proteins	O
crossreactive	O
with	O
the	O
STAT	B-protein
family	I-protein
.	O

Gene	O
targeting	O
studies	O
have	O
demonstrated	O
crucial	O
roles	O
for	O
the	O
transcription	B-protein
factors	I-protein
Ikaros	B-protein
and	O
Aiolos	B-protein
in	O
regulating	O
multiple	O
stages	O
of	O
B	O
and	O
T	O
cell	O
development	O
.	O

MHC	B-protein
class	I-protein
II	I-protein
molecules	O
also	O
serve	O
as	O
receptors	O
for	O
B-cell	B-cell_type
stimulation	O
by	O
microbial	B-protein
superantigens	I-protein
.	O

Activation	O
of	O
TGF-beta	B-protein
2	I-protein
transcription	O
correlates	O
with	O
the	O
loss	O
of	O
binding	O
activity	O
for	O
an	O
80	B-protein
kDA	I-protein
glial	I-protein
labile	I-protein
repressor	I-protein
protein	I-protein
,	O
GLRP	B-protein
,	O
to	O
a	O
responsive	O
region	O
within	O
the	O
TFG-beta	B-DNA
2	I-DNA
promoter	I-DNA
.	O

Although	O
a	O
13-kilobase-pair	B-DNA
(	I-DNA
kb	I-DNA
)	I-DNA
human	I-DNA
c-fes	I-DNA
transgene	I-DNA
exhibits	O
high	O
levels	O
of	O
expression	O
in	O
mice	O
,	O
the	O
sequences	O
that	O
confer	O
myeloid-cell-specific	O
expression	O
of	O
the	O
human	B-DNA
c-fes	I-DNA
gene	I-DNA
have	O
not	O
been	O
defined	O
.	O

This	O
finding	O
may	O
provide	O
a	O
tool	O
to	O
improve	O
current	O
protocols	O
of	O
immunotherapy	O
and	O
insights	O
to	O
how	O
tumor	B-cell_type
cells	I-cell_type
are	O
or	O
are	O
not	O
killed	O
by	O
LAK	B-cell_line
cells	I-cell_line
.	O

We	O
modeled	O
this	O
degree	O
of	O
CN	B-protein
inhibition	O
in	O
primary	B-cell_type
human	I-cell_type
leukocytes	I-cell_type
in	O
vitro	O
in	O
order	O
to	O
study	O
the	O
effect	O
of	O
partial	O
CN	B-protein
inhibition	O
on	O
the	O
downstream	O
signaling	O
events	O
that	O
lead	O
to	O
gene	O
activation	O
.	O

Thus	O
Oct-2	B-protein
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cellular	O
gene	O
expression	O
in	O
both	O
B	B-cell_type
cells	I-cell_type
and	O
neuronal	B-cell_type
cells	I-cell_type
as	O
well	O
as	O
in	O
the	O
control	O
of	O
viral	O
latency	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
a	O
mutated	O
form	O
of	O
the	O
human	B-DNA
CIITA	I-DNA
gene	I-DNA
,	O
coding	O
for	O
a	O
protein	O
lacking	O
the	O
amino	B-protein
terminal	I-protein
151	I-protein
amino	I-protein
acids	I-protein
,	O
acts	O
as	O
a	O
potent	O
dominant-negative	O
suppressor	O
of	O
HLA	B-protein
class	I-protein
II	I-protein
expression	O
.	O

Here	O
,	O
we	O
demonstrate	O
the	O
testosterone	O
responsiveness	O
of	O
murine	B-cell_type
splenic	I-cell_type
T	I-cell_type
cells	I-cell_type
in	O
vitro	O
as	O
well	O
as	O
the	O
presence	O
of	O
unconventional	B-protein
cell	I-protein
surface	I-protein
receptors	I-protein
for	O
testosterone	O
and	O
classical	B-protein
intracellular	I-protein
AR	I-protein
.	O

The	O
271C	O
--	O
>	O
T	O
substitution	O
represents	O
a	O
considerable	O
change	O
in	O
chemical	O
nature	O
(	O
Arg91	O
--	O
>	O
Cys	O
)	O
,	O
one	O
which	O
may	O
affect	O
the	O
antigenic	O
determinants	O
of	O
DARC	B-protein
,	O
and	O
thus	O
be	O
of	O
clinical	O
significance	O
.	O

In	O
this	O
study	O
we	O
have	O
identified	O
the	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
(	O
PPAR	B-protein
)	O
as	O
a	O
new	O
thyroid	B-protein
hormone	I-protein
receptor	I-protein
(	I-protein
THR	I-protein
)	I-protein
auxiliary	I-protein
nuclear	I-protein
protein	I-protein
,	O
heterodimerizing	O
with	O
THR	B-protein
in	O
solution	O
.	O

We	O
previously	O
detected	O
a	O
tissue-specific	B-DNA
promoter	I-DNA
preceding	O
the	O
exon	O
encoding	O
the	O
N	B-protein
terminus	I-protein
of	O
the	O
pp52	B-protein
leukocyte	I-protein
protein	I-protein
.	O

CsA	O
neither	O
inhibits	O
the	O
processing	O
of	O
the	O
NF-kappa	B-protein
B1	I-protein
precursor	I-protein
p105	B-protein
to	O
p50	B-protein
,	O
nor	O
does	O
it	O
``	O
stabilize	O
''	O
the	O
C-terminal	O
portion	O
of	O
p105	B-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
,	O
which	O
is	O
degraded	O
during	O
p105	B-protein
processing	O
to	O
mature	B-protein
p50	I-protein
.	O

These	O
studies	O
also	O
suggest	O
monocyte	O
MCP-1	B-protein
expression	O
induced	O
through	O
RA	O
may	O
modulate	O
cell	O
migration	O
.	O

Sequence	O
comparisons	O
also	O
predict	O
other	O
potential	O
transcription	O
factor	O
binding	O
sites	O
as	O
yet	O
undescribed	O
in	O
mammalian	B-DNA
IL2	I-DNA
promoters	I-DNA
.	O

The	O
immediate-early	B-DNA
gene	I-DNA
egr-1	B-DNA
encodes	O
a	O
transcription	B-protein
factor	I-protein
(	O
EGR1	B-protein
)	O
that	O
links	O
B-cell	B-protein
antigen	I-protein
receptor	I-protein
(	O
BCR	B-protein
)	O
signals	O
to	O
downstream	O
activation	O
events	O
through	O
the	O
regulation	O
of	O
previously	O
unidentified	O
target	B-DNA
genes	I-DNA
.	O

Indirect	O
immunofluorescence	O
shows	O
that	O
IL-2	B-protein
controls	O
the	O
cellular	O
distribution	O
of	O
Aiolos	B-protein
and	O
induces	O
its	O
tyrosine	O
phosphorylation	O
,	O
required	O
for	O
dissociation	O
from	O
Ras	B-protein
.	O

We	O
observed	O
that	O
HMDS	O
,	O
similar	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
increases	O
the	O
expression	O
of	O
CAT	B-DNA
reporter	I-DNA
gene	I-DNA
suggesting	O
increased	O
activity	O
of	O
NF-kappaB	B-protein
.	O

The	O
difference	O
between	O
them	O
was	O
significant	O
statistically	O
.	O

Patients	O
'	O
disease	O
activity	O
was	O
measured	O
by	O
the	O
SLE	O
Disease	O
Activity	O
Index	O
(	O
SLEDAI	O
)	O
.	O

In	O
human	B-RNA
histiocytic	I-RNA
U937	I-RNA
cells	I-RNA
mRNA	I-RNA
of	O
clone	O
pAT	O
133	O
was	O
constitutively	O
expressed	O
,	O
whereas	O
mRNA	B-RNA
of	O
pAT	B-protein
225/EGR1	I-protein
was	O
induced	O
upon	O
induction	O
of	O
terminal	O
differentiation	O
.	O

In	O
this	O
system	O
,	O
simultaneous	O
exposure	O
to	O
CD40L	B-protein
together	O
with	O
either	O
IL-4	B-protein
or	O
IFN-gamma	B-protein
does	O
not	O
lead	O
to	O
the	O
activation	O
of	O
novel	O
Rel/STAT	B-protein
complexes	I-protein
.	O

These	O
data	O
suggest	O
that	O
in	O
activated	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
CD28	B-protein
-derived	O
signals	O
can	O
stimulate	O
proliferation	O
at	O
least	O
in	O
part	O
via	O
NF-kappaB	O
and	O
AP-1	O
generation	O
,	O
and	O
that	O
this	O
response	O
uses	O
both	O
acidic	B-protein
sphingomyelinase	I-protein
and	O
phosphatidylinositol	B-protein
3-kinase	I-protein
-linked	O
pathways	O
.	O

Nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
was	O
originally	O
described	O
as	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	I-protein
athat	O
supported	O
the	O
activation	O
of	O
cytokine	B-protein
gene	O
expression	O
and	O
mediated	O
the	O
immunoregulatory	B-protein
effects	O
of	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

The	O
promoter	O
activity	O
of	O
cell	B-DNA
cycle	I-DNA
regulated	I-DNA
histone	I-DNA
H4	I-DNA
genes	I-DNA
is	O
regulated	O
by	O
at	O
least	O
four	O
principal	B-DNA
cis-acting	I-DNA
elements	I-DNA
which	O
mediate	O
G1/S	O
phase	O
control	O
and/or	O
enhancement	O
of	O
transcription	O
during	O
the	O
cell	O
cycle	O
.	O

CONCLUSIONS	O
:	O
Intestinal	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
initiate	O
an	O
inflammatory	O
response	O
with	O
resulting	O
neutrophil-mediated	O
tissue	O
damage	O
in	O
response	O
to	O
E.	O
histolytica	O
infection	O
;	O
this	O
inflammatory	O
cascade	O
can	O
be	O
blocked	O
by	O
inhibiting	O
the	O
transcription	O
of	O
genes	O
regulated	O
by	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
.	O

Epo	B-protein
caused	O
an	O
increase	O
in	O
the	O
proportion	O
of	O
cells	O
expressing	O
cell	O
surface	O
glycophorin	B-protein
A	I-protein
(	O
GPA	B-protein
)	O
and	O
up-regulated	O
beta-	B-protein
and	I-protein
gamma-globin	I-protein
by	O
several	O
fold	O
.	O

Not	O
only	O
functional	O
but	O
also	O
specific	O
binding	O
interactions	O
between	O
CIITA	B-protein
and	O
CBP	B-protein
were	O
demonstrated	O
.	O

We	O
have	O
also	O
examined	O
how	O
one	O
5'HS	B-DNA
affects	O
the	O
recruitment	O
of	O
EKLF	B-protein
to	O
another	O
5'HS	B-DNA
.	O

An	O
unexpected	O
finding	O
was	O
that	O
the	O
Ig	O
levels	O
decreased	O
during	O
the	O
follow-up	O
period	O
.	O

After	O
appropriate	O
stimulation	O
,	O
both	O
NF-AT	B-protein
and	O
AP-1	B-protein
are	O
peculiarly	O
sensitive	O
to	O
the	O
protein	O
synthesis	O
inhibitor	O
anisomycin	O
.	O

Our	O
results	O
suggest	O
that	O
substances	O
in	O
serum	O
influence	O
steroid	O
effects	O
on	O
these	O
cells	O
and	O
that	O
the	O
molecular	O
details	O
of	O
glucocorticoid	O
hormone	O
action	O
may	O
be	O
pursued	O
more	O
precisely	O
in	O
a	O
clearly	O
defined	O
culture	O
medium	O
.	O

The	O
B	B-protein
cell-associated	I-protein
surface	I-protein
molecule	I-protein
CD40	B-protein
plays	O
a	O
key	O
role	O
in	O
T	O
cell-dependent	O
B	O
cell	O
maturation	O
,	O
as	O
individuals	O
with	O
defects	O
in	O
either	O
CD40	B-protein
or	O
its	O
ligand	O
are	O
impaired	O
in	O
immunoglobulin	B-protein
isotype	O
class	O
switching	O
and	O
germinal	O
center	O
formation	O
.	O

Moreover	O
,	O
the	O
induction	O
of	O
both	O
Jak	B-protein
1	I-protein
and	I-protein
3	I-protein
,	O
and	O
STAT	B-protein
5	I-protein
activity	O
strongly	O
correlated	O
with	O
the	O
growth-promoting	O
effects	O
of	O
IL-7	B-protein
,	O
suggesting	O
that	O
this	O
signal	O
transduction	O
mechanism	O
may	O
play	O
a	O
key	O
role	O
in	O
IL-7	B-protein
-induced	O
proliferation	O
.	O

Sublethal	O
levels	O
of	O
oxidative	O
stress	O
are	O
well	O
known	O
to	O
alter	O
T	O
cell	O
functional	O
responses	O
,	O
but	O
the	O
underlying	O
mechanisms	O
are	O
unknown	O
.	O

This	O
report	O
is	O
concerned	O
with	O
the	O
prediction	O
of	O
natural	O
killer	B-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	I-cell_type
activity	O
in	O
61	O
Stage	O
I	O
and	O
II	O
breast	O
cancer	O
patients	O
,	O
between	O
the	O
ages	O
of	O
25	O
and	O
70	O
,	O
who	O
were	O
accrued	O
to	O
this	O
project	O
.	O

The	O
host	O
mechanisms	O
regulated	O
by	O
such	O
permissivity	O
factors	O
are	O
potential	O
targets	O
for	O
anti-HIV-1	O
therapy	O
.	O

We	O
propose	O
that	O
,	O
in	O
resting	B-cell_type
cells	I-cell_type
,	O
NFAT	B-protein
is	O
targeted	O
to	O
a	O
region	O
of	O
the	O
calcineurin	B-protein
catalytic	I-protein
domain	I-protein
that	O
does	O
not	O
overlap	O
the	O
calcineurin	B-protein
active	I-protein
site	I-protein
.	O

This	O
region	O
contains	O
elements	O
which	O
are	O
shared	O
with	O
the	O
transcriptional	B-DNA
enhancers	I-DNA
of	O
other	O
genes	O
including	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
1	I-protein
,	O
interferon	B-protein
beta	I-protein
,	O
and	O
interferon-inducible	B-DNA
genes	I-DNA
.	O

Induction	O
of	O
the	O
PILOT	B-protein
gene	O
is	O
detectable	O
in	O
human	O
T	B-cell_type
cells	I-cell_type
20	O
min	O
following	O
activation	O
in	O
the	O
presence	O
of	O
cycloheximide	O
and	O
is	O
fully	O
suppressed	O
by	O
CyA	O
.	O

In	O
contrast	O
,	O
anergic	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
contained	O
severely	O
reduced	O
levels	O
of	O
AP-1	B-protein
and	O
Fos/Jun-containing	B-protein
NF-AT	I-protein
complexes	I-protein
but	O
expressed	O
significant	O
amounts	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
Oct	B-protein
binding	I-protein
proteins	I-protein
after	O
SEA	B-protein
stimulation	O
.	O

Interferon-alpha	B-protein
(	O
IFN-alpha	B-protein
)	O
is	O
a	O
pleiotropic	B-protein
cytokine	I-protein
that	O
has	O
antiviral	O
,	O
antiproliferative	O
,	O
and	O
immunoregulatory	B-protein
functions	O
.	O

These	O
results	O
not	O
only	O
indicate	O
the	O
existence	O
of	O
a	O
DHEA	B-protein
receptor	I-protein
,	O
but	O
also	O
suggest	O
that	O
T	B-cell_type
cells	I-cell_type
become	O
susceptible	O
to	O
regulation	O
by	O
DHEA	O
during	O
the	O
process	O
of	O
signal-induced	O
activation	O
.	O

In	O
contrast	O
,	O
E7	B-protein
blocked	O
neither	O
IFN	B-protein
-stimulated	O
gene	O
expression	O
nor	O
IFN	B-protein
's	O
induction	O
of	O
cytolytic	O
resistance	O
,	O
thereby	O
precluding	O
the	O
selective	O
lysis	O
of	O
HPV-transformed	B-cell_line
cells	I-cell_line
by	O
IFN-activated	B-cell_line
NK	I-cell_line
cells	I-cell_line
.	O

Analysis	O
of	O
cytosolic	O
extracts	O
indicated	O
that	O
NF-kappa	B-protein
B	I-protein
levels	O
were	O
increased	O
in	O
HIV-infected	B-cell_type
cells	I-cell_type
.	O

STAT1	B-protein
,	O
which	O
is	O
activated	O
in	O
response	O
to	O
many	O
lymphocyte-activating	B-protein
cytokines	I-protein
including	O
the	O
interferons	B-protein
,	O
is	O
essential	O
for	O
cell-mediated	O
immunity	O
,	O
as	O
the	O
absence	O
of	O
this	O
protein	O
is	O
associated	O
with	O
prominent	O
defects	O
in	O
the	O
ability	O
to	O
control	O
viral	O
infections	O
.	O

We	O
investigated	O
the	O
involvement	O
of	O
STATs	B-protein
in	O
the	O
transformation	O
of	O
T-cells	B-cell_type
by	O
HTLV-1	O
.	O

The	O
action	O
of	O
adenoviral	B-protein
E1A	I-protein
oncoprotein	I-protein
on	O
host	B-DNA
immune-response	I-DNA
genes	I-DNA
has	O
been	O
attributed	O
to	O
interaction	O
with	O
p300/CBP-type	B-protein
transcriptional	I-protein
coactivators	I-protein
in	O
competition	O
with	O
endogenous	B-protein
transcription	I-protein
factors	I-protein
such	O
as	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
proteins	I-protein
.	O

Similar	O
arrays	O
of	O
functionally	O
important	O
NF-kappaB/NFAT	B-DNA
and	I-DNA
Ets	I-DNA
binding	I-DNA
sites	I-DNA
are	O
present	O
in	O
the	O
transcriptional	B-DNA
enhancers	I-DNA
of	O
human	O
immunodeficiency	O
viruses	O
types	O
1	O
and	O
2	O
(	O
HIV-1	O
and	O
HIV-2	O
)	O
,	O
suggesting	O
that	O
this	O
pattern	O
of	O
nuclear	B-DNA
protein	I-DNA
binding	I-DNA
sites	I-DNA
reflects	O
an	O
evolutionarily	O
conserved	O
mechanism	O
for	O
regulating	O
inducible	O
T-cell	O
gene	O
expression	O
that	O
has	O
been	O
co-opted	O
during	O
HIV	O
evolution	O
.	O

Acute	O
hepatic	O
injury	O
caused	O
by	O
reactive	O
oxygen	O
intermediate	O
production	O
was	O
induced	O
by	O
an	O
intraperitoneal	O
injection	O
of	O
CCl4	O
in	O
mice	O
.	O

We	O
have	O
described	O
the	O
isolation	O
of	O
chemically	O
induced	O
CEM	B-cell_line
subclones	I-cell_line
that	O
express	O
CD4	B-protein
receptors	I-protein
and	O
bind	O
soluble	O
gp120	B-protein
,	O
yet	O
show	O
a	O
markedly	O
reduced	O
susceptibility	O
to	O
infection	O
with	O
HIV-1	O
.	O

A	O
kappa	B-DNA
B-site	I-DNA
was	O
identified	O
in	O
the	O
promoter	O
of	O
the	O
intercellular	B-DNA
adhesion	I-DNA
molecule-1	I-DNA
(	I-DNA
ICAM-1	I-DNA
)	I-DNA
gene	I-DNA
,	O
which	O
is	O
involved	O
in	O
regulation	O
of	O
ICAM-1	B-protein
expression	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
and	O
glucocorticoids	O
.	O

The	O
promoter	B-DNA
and	O
5	B-DNA
'	I-DNA
flanking	I-DNA
sequences	I-DNA
controlling	O
human	O
B29	B-DNA
gene	I-DNA
expression	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
focuses	O
on	O
the	O
functional	O
analysis	O
of	O
the	O
human	B-DNA
IL-5	I-DNA
(	I-DNA
hIL-5	I-DNA
)	I-DNA
promoter	I-DNA
and	O
characterization	O
of	O
cis	O
-regulatory	O
elements	O
and	O
transcription	O
factors	O
involved	O
in	O
the	O
suppression	O
of	O
IL-5	B-protein
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
erythropoietin	B-protein
,	O
which	O
is	O
also	O
required	O
for	O
erythroid	O
cell	O
survival	O
,	O
cooperates	O
with	O
GATA-1	B-protein
to	O
stimulate	O
bcl-xL	B-protein
gene	O
expression	O
and	O
to	O
maintain	O
erythroid	O
cell	O
viability	O
during	O
terminal	O
maturation	O
.	O

Elf-1	B-protein
contains	O
a	O
DNA	B-protein
binding	I-protein
domain	I-protein
that	O
is	O
nearly	O
identical	O
to	O
that	O
of	O
E74	B-protein
,	O
the	O
ecdysone-inducible	B-protein
Drosophila	I-protein
transcription	I-protein
factor	I-protein
required	O
for	O
metamorphosis	O
(	O
hence	O
the	O
name	O
Elf-1	B-protein
,	O
for	O
E74-like	B-protein
factor	I-protein
1	I-protein
)	O
.	O

The	O
expression	O
patterns	O
suggest	O
that	O
RBTN-2	B-protein
normally	O
interacts	O
equally	O
with	O
elf-2a	B-protein
and	O
elf-2b	B-protein
.	O

Phosphatidylinositol	B-protein
3-kinase	I-protein
(	O
PI3-K	B-protein
)	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
in	O
many	O
cell	O
types	O
.	O

Permanently	O
arresting	O
this	O
ongoing	O
immune	O
response	O
with	O
either	O
pharmaceutical	O
agents	O
or	O
immunotherapy	O
is	O
a	O
major	O
challenge	O
for	O
immunology	O
.	O

The	O
function	O
of	O
a	O
putative	B-DNA
NFAT-1	I-DNA
site	I-DNA
in	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
enhancer	I-DNA
has	O
been	O
analyzed	O
.	O

Proerythroblasts	B-cell_type
and	O
megakaryocytes	B-cell_type
massively	O
accumulated	O
in	O
the	O
spleens	O
of	O
the	O
heterozygotes	O
,	O
and	O
we	O
showed	O
that	O
the	O
neomycin	B-DNA
resistance	I-DNA
gene	I-DNA
(	O
which	O
is	O
the	O
positive	O
selection	O
marker	O
in	O
ES	B-cell_type
cells	I-cell_type
)	O
was	O
expressed	O
profusely	O
in	O
the	O
abnormally	O
abundant	O
cells	O
generated	O
in	O
the	O
GATA-1.05	B-protein
mutant	O
females	O
.	O

Human	B-protein
neutrophil	I-protein
elastase	I-protein
proteolytically	O
activates	O
the	O
platelet	B-protein
integrin	I-protein
alphaIIbbeta3	B-protein
through	O
cleavage	O
of	O
the	O
carboxyl	B-protein
terminus	I-protein
of	O
the	O
alphaIIb	B-protein
subunit	I-protein
heavy	I-protein
chain	I-protein
.	O

In	O
this	O
study	O
three	O
novel	O
clones	O
were	O
constructed	O
in	O
which	O
the	O
ZEBRA	B-protein
activation	I-protein
region	I-protein
was	O
repositioned	O
to	O
the	O
carboxy	B-protein
terminus	I-protein
of	O
the	O
protein	O
.	O

1	O
,	O
25-Dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
]	O
induces	O
differentiation	O
and	O
inhibits	O
proliferation	O
of	O
myeloid	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
from	O
various	O
lines	O
and	O
patients	O
;	O
these	O
effects	O
are	O
probably	O
mediated	O
through	O
the	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptor	I-protein
.	O

These	O
results	O
confirm	O
that	O
sequences	O
in	O
the	O
upstream	B-DNA
promoter	I-DNA
region	I-DNA
of	O
the	O
adult	B-DNA
beta	I-DNA
globin	I-DNA
gene	I-DNA
contribute	O
to	O
its	O
factor-mediated	O
suppression	O
early	O
in	O
development	O
and	O
then	O
may	O
modulate	O
its	O
expression	O
at	O
a	O
later	O
stage	O
.	O

The	O
human	B-DNA
androgen	I-DNA
receptor	I-DNA
gene	I-DNA
(	O
HUMARA	B-DNA
)	O
assay	O
is	O
the	O
newest	O
of	O
such	O
methods	O
,	O
and	O
the	O
majority	O
of	O
the	O
female	O
population	O
can	O
be	O
assessed	O
by	O
this	O
relatively	O
simple	O
procedure	O
.	O

However	O
,	O
X	B-protein
failed	O
to	O
react	O
with	O
a	O
variety	O
of	O
antibodies	O
against	O
Rb	B-protein
or	O
p107	B-protein
,	O
implicating	O
the	O
involvement	O
of	O
an	O
E1A-binding	B-protein
protein	I-protein
other	O
than	O
Rb	B-protein
or	O
p107	B-protein
.	O

The	O
number	O
of	O
estrogen	B-protein
receptors	I-protein
(	O
ER	B-protein
)	O
in	O
human	B-cell_type
peripheral	I-cell_type
leucocytes	I-cell_type
in	O
12	O
women	O
with	O
menopausal	O
type	O
II	O
diabetes	O
was	O
measured	O
with	O
radio-ligand	O
binding	O
method	O
.	O

In	O
addition	O
,	O
we	O
have	O
isolated	O
a	O
third	O
NF-kappa	B-protein
B	I-protein
inhibitor	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
epsilon	I-protein
(	O
1	O
)	O
.	O

This	O
was	O
in	O
contrast	O
to	O
normal	O
peripheral	O
blood	O
B	B-cell_type
lymphocytes	I-cell_type
or	O
CD5+	B-cell_type
)	I-cell_type
B	I-cell_type
cells	I-cell_type
isolated	O
from	O
tonsils	O
,	O
in	O
which	O
this	O
phosphorylation	O
was	O
absent	O
.	O

Thus	O
,	O
compared	O
with	O
findings	O
in	O
control	O
cells	O
,	O
class	B-protein
II	I-protein
molecules	I-protein
in	O
infected	B-cell_type
cells	I-cell_type
colocalized	O
to	O
a	O
minimal	O
extent	O
with	O
a	O
lysosomal-associated	B-protein
membrane	I-protein
protein-1	I-protein
+	O
endosomal	O
compartment	O
.	O

It	O
is	O
remarkable	O
that	O
in	O
B-CLL	B-cell_type
cells	I-cell_type
the	O
nuclear	O
appearance	O
and	O
DNA	O
binding	O
of	O
specific	O
transcription	B-protein
factors	I-protein
is	O
dramatically	O
affected	O
whereas	O
other	O
members	O
of	O
the	O
same	O
factor	B-protein
family	I-protein
remained	O
unaltered	O
in	O
these	O
leukemic	O
cells	O
.	O

We	O
have	O
used	O
a	O
human	O
T-lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
model	O
of	O
cAMP	B-DNA
response	I-DNA
element	I-DNA
(	O
CRE	B-DNA
)	O
transcription	O
to	O
investigate	O
the	O
influence	O
of	O
lymphocyte	O
activation	O
on	O
transcription	O
from	O
homologous	O
regions	O
in	O
the	O
viral	B-DNA
promoter	I-DNA
.	O

The	O
results	O
show	O
that	O
Ras	B-protein
can	O
initiate	O
a	O
Rac-1	B-protein
mediated	O
pathway	O
that	O
regulates	O
the	O
transcriptional	O
function	O
of	O
AP-1	B-protein
complexes	I-protein
.	O

The	O
strategy	O
described	O
here	O
provides	O
a	O
new	O
approach	O
for	O
studying	O
protein-protein	O
interactions	O
that	O
govern	O
the	O
complex	O
regulation	O
of	O
gene	O
expression	O
.	O

We	O
conclude	O
that	O
p56	B-protein
exists	O
in	O
cytosol	O
in	O
a	O
higher	O
order	O
complex	O
containing	O
hsp70	B-protein
and	O
hsp90	B-protein
,	O
both	O
of	O
which	O
in	O
turn	O
have	O
been	O
found	O
to	O
be	O
associated	O
with	O
untransformed	B-protein
steroid	I-protein
receptors	I-protein
.	O

The	O
proteins	O
may	O
prove	O
useful	O
in	O
protecting	O
adenovirus	B-DNA
gene	I-DNA
therapy	I-DNA
vectors	I-DNA
and	O
transplanted	B-cell_line
cells	I-cell_line
from	O
the	O
immune	O
system	O
.	O

There	O
was	O
a	O
trend	O
approaching	O
statistical	O
significance	O
for	O
patients	O
with	O
c-erbB2	B-DNA
amplifications	O
to	O
have	O
positive	O
lymph	O
nodes	O
at	O
surgery	O
(	O
P	O
=	O
0.09	O
)	O
.	O

Supershifts	O
with	O
anti-STAT	O
antibodies	O
identified	O
these	O
as	O
STAT1	B-protein
and	O
STAT5	B-protein
complexes	I-protein
.	O

Experiments	O
in	O
COS-1	B-cell_line
and	O
EL-4	B-cell_line
cells	I-cell_line
confirmed	O
both	O
hypotheses	O
and	O
revealed	O
that	O
the	O
second	O
factor	O
activated	O
by	O
Tpl-2	B-protein
is	O
NF-kappaB	B-protein
.	O

A	O
2-bp	B-DNA
mutation	I-DNA
within	O
the	O
CBF	B-protein
site	O
resulted	O
in	O
a	O
2-3-fold	O
decrease	O
in	O
the	O
activities	O
of	O
both	O
a	O
69-bp	B-DNA
proximal	I-DNA
promoter	I-DNA
fragment	I-DNA
and	O
a	O
627-bp	B-DNA
full-length	I-DNA
promoter	I-DNA
fragment	I-DNA
.	O

Both	O
phosphorylation	O
of	O
PECAM-1	B-protein
and	O
transendothelial	O
migration	O
of	O
monocytes	B-cell_type
in	O
response	O
to	O
CoCl2	O
were	O
inhibited	O
by	O
protein	O
kinase	O
inhibitor	O
(	O
GF109203X	O
)	O
and	O
augmented	O
by	O
protein	O
phosphatase	O
inhibitor	O
(	O
Calyculin	O
A	O
)	O
.	O

HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
also	O
binds	O
to	O
a	O
second	O
oligonucleotide	O
containing	O
a	O
BP1	B-DNA
binding	I-DNA
site	I-DNA
located	O
in	O
a	O
negative	B-DNA
control	I-DNA
region	I-DNA
upstream	O
of	O
the	O
delta-globin	B-DNA
gene	I-DNA
,	O
suggesting	O
a	O
role	O
for	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
in	O
repression	O
of	O
adult	O
globin	O
genes	O
.	O

Transient	O
short-term	O
expression	O
of	O
the	O
Tax	B-protein
protein	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type-I	O
(	O
HTLV-I	O
)	O
leads	O
to	O
activation	O
of	O
the	O
pleiotropic	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
.	O

The	O
AD1	B-protein
and	O
AD2	B-protein
transactivation	O
domains	O
of	O
E2A	B-protein
are	O
essential	O
for	O
the	O
antiapoptotic	O
activity	O
of	O
the	O
chimeric	B-protein
oncoprotein	I-protein
E2A-HLF	B-protein
.	O

A	O
semiquantitative	O
reverse	B-protein
transcriptase	I-protein
-linked	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
was	O
used	O
for	O
analysis	O
of	O
gene	O
expression	O
in	O
the	O
treated	B-cell_type
cells	I-cell_type
.	O

These	O
affected	O
animals	O
displayed	O
marked	O
splenomegaly	O
,	O
anemia	O
,	O
and	O
thrombocytopenia	O
.	O

A	O
block	O
to	O
RNA	O
elongation	O
is	O
largely	O
responsible	O
for	O
decreased	O
c-myc	B-DNA
transcription	O
.	O

The	O
effect	O
of	O
transmembrane	O
signaling	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
ionomycin	O
,	O
and/or	O
sn-1	O
,	O
2	O
dioctanoyl	O
glycerol	O
,	O
was	O
also	O
determined	O
.	O

A	O
decrease	O
in	O
helicase	O
and	O
DNA-dependent	B-protein
ATPase	I-protein
activities	O
was	O
also	O
observed	O
with	O
the	O
mutated	O
recombinant	O
XPB	B-protein
protein	I-protein
.	O

This	O
finding	O
indicates	O
that	O
phospholipase	B-protein
A2	I-protein
and	O
5-lipoxygenase	B-protein
are	O
also	O
involved	O
.	O

The	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
is	O
a	O
causative	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
.	O

We	O
also	O
identified	O
Sp1	B-protein
,	O
Sp3	O
,	O
and	O
NGFI-A/Egr-1	B-protein
as	O
the	O
primary	B-protein
nuclear	I-protein
transcription	I-protein
factors	I-protein
binding	O
to	O
TRE1	B-DNA
which	O
mediate	O
Tax	B-protein
responsiveness	O
.	O

Indomethacin	O
blocked	O
PGE2	O
release	O
,	O
but	O
had	O
no	O
influence	O
on	O
the	O
observed	O
effects	O
of	O
C3a	B-protein
,	O
suggesting	O
that	O
the	O
effects	O
of	O
C3a	B-protein
on	O
IL-6	B-protein
production	O
are	O
independent	O
of	O
PGE2	O
formation	O
by	O
monocytes	B-cell_type
.	O

[	O
Plasma	O
cortisol	O
concentration	O
and	O
blood	O
leukocyte	O
content	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
patients	O
with	O
deficiency-cold	O
vs	O
deficiency-heat	O
syndromes	O
]	O

Finally	O
,	O
proliferation	O
induced	O
by	O
both	O
IL-2	B-protein
-and	O
IL-3	B-protein
was	O
significantly	O
inhibited	O
in	O
the	O
presence	O
of	O
SOCS-3	B-protein
.	O

Recently	O
,	O
we	O
have	O
identified	O
a	O
repression	B-protein
domain	I-protein
located	O
within	O
the	O
N	B-protein
terminus	I-protein
of	O
Oct-2a	B-protein
(	O
amino	B-protein
acids	I-protein
2-99	I-protein
)	O
.	O

The	O
active	O
vitamin	O
D3	O
metabolite	O
1	O
,	O
25-dihydroxycholecalciferol	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
acts	O
as	O
an	O
antiproliferative	O
and	O
differentiating	O
agent	O
for	O
the	O
monoblastoid	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
and	O
as	O
an	O
important	O
immunologic	O
mediator	O
implicated	O
particularly	O
in	O
the	O
function	O
of	O
cells	O
belonging	O
to	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
.	O

Interestingly	O
,	O
CTLA4Ig	O
did	O
not	O
significantly	O
inhibit	O
the	O
activation	O
of	O
either	O
NF	B-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
or	O
AP-1	B-DNA
reporters	I-DNA
.	O

The	O
Notch	B-protein
receptor	I-protein
protein	I-protein
was	O
originally	O
identified	O
in	O
Drosophila	O
and	O
is	O
known	O
to	O
mediate	O
cell	O
to	O
cell	O
communication	O
and	O
influence	O
cell	O
fate	O
decisions	O
.	O

A	O
dominant-negative	B-protein
version	I-protein
of	O
STAT5b	B-protein
,	O
but	O
not	O
of	O
STAT5a	B-protein
,	O
interfered	O
with	O
IL-4	B-protein
-induced	O
DNA	O
synthesis	O
in	O
Ba/F3	B-cell_line
cells	I-cell_line
,	O
suggesting	O
an	O
involvement	O
of	O
STAT5b	B-protein
in	O
the	O
control	O
of	O
cell	O
proliferation	O
through	O
IL-4R	B-protein
.	O

In	O
conclusion	O
,	O
the	O
presence	O
of	O
myeloid-associated	B-RNA
growth	I-RNA
factor	I-RNA
receptor	I-RNA
transcripts	I-RNA
in	O
CD34+	B-cell_line
CB	I-cell_line
subsets	I-cell_line
does	O
not	O
discriminate	O
the	O
various	O
stages	O
of	O
differentiation	O
,	O
with	O
the	O
exception	O
of	O
the	O
M-CSF	B-protein
receptor	I-protein
.	O

Furthermore	O
,	O
epithelial	O
levels	O
of	O
activated	O
Stat1	B-protein
correlated	O
with	O
levels	O
of	O
expression	O
for	O
epithelial	B-protein
ICAM-1	I-protein
,	O
IRF-1	B-protein
,	O
and	O
Stat1	B-protein
,	O
and	O
in	O
turn	O
,	O
ICAM-1	B-protein
levels	O
correlated	O
with	O
T-cell	O
accumulation	O
in	O
tissue	O
.	O

CD45	B-protein
-dependent	O
events	O
such	O
as	O
tyrosine	B-protein
phosphorylation	I-protein
of	O
Shc	B-protein
,	O
activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
,	O
transcription	B-protein
factors	I-protein
,	O
and	O
stimulation	O
of	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
promoter	I-DNA
and	O
of	O
CD69	B-protein
and	O
CD25	B-protein
surface	O
expression	O
paralleled	O
activation	O
of	O
the	O
tyrosine	B-protein
kinases	I-protein
lck	B-protein
and	O
fyn	B-protein
.	O

Six	O
PTT	O
shifts	O
were	O
identified	O
.	O

The	O
effects	O
of	O
selenium	O
were	O
specific	O
for	O
NF-kappa	B-protein
B	I-protein
,	O
since	O
the	O
activity	O
of	O
the	O
transcription	O
factor	O
AP-1	B-protein
was	O
not	O
suppressed	O
.	O

The	O
pathway	O
whereby	O
EBV	O
infects	O
T	B-cell_type
cells	I-cell_type
as	O
well	O
as	O
the	O
initial	O
EBV	O
transcriptional	O
program	O
in	O
T	B-cell_type
cells	I-cell_type
has	O
not	O
been	O
established	O
.	O

An	O
insertion	O
mutation	O
was	O
constructed	O
in	O
the	O
rpoS	B-DNA
gene	I-DNA
on	O
the	O
chromosome	O
of	O
L.	O
pneumophila	O
,	O
and	O
the	O
ability	O
of	O
this	O
mutant	O
strain	O
to	O
survive	O
various	O
stress	O
conditions	O
was	O
assayed	O
and	O
compared	O
with	O
results	O
for	O
the	O
wild-type	O
strain	O
.	O

Incubation	O
of	O
human	O
whole	O
blood	O
with	O
PGG-Glucan	O
significantly	O
enhanced	O
the	O
oxidative	O
burst	O
response	O
of	O
subsequently	B-cell_type
isolated	I-cell_type
blood	I-cell_type
leukocytes	I-cell_type
to	O
both	O
soluble	O
and	O
particulate	O
activators	O
in	O
a	O
dose-dependent	O
manner	O
,	O
and	O
increased	O
leukocyte	O
microbicidal	O
activity	O
.	O

METHODS	O
:	O
Purified	O
T	B-cell_type
cells	I-cell_type
were	O
obtained	O
from	O
adenoidal	O
tissues	O
,	O
and	O
incubated	O
with	O
RA	O
(	O
10	O
(	O
-7	O
)	O
M	O
)	O
or	O
DMSO	O
solvent/media	O
control	O
for	O
0	O
,	O
6-8	O
,	O
and	O
24	O
h	O
.	O

Sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
showed	O
significant	O
aldosterone	O
binding	O
at	O
a	O
molecular	O
weight	O
of	O
approximately	O
50000	O
Dalton	O
which	O
was	O
absent	O
with	O
1	O
microM	O
cold	O
aldosterone	O
,	O
but	O
not	O
cortisol	O
in	O
the	O
binding	O
media	O
.	O

These	O
results	O
suggest	O
that	O
the	O
expression	O
of	O
bcl-6	B-protein
protein	I-protein
may	O
be	O
associated	O
with	O
morphological	O
differentiation	O
in	O
normal	O
and	O
neoplastic	B-cell_type
epidermal	I-cell_type
cells	I-cell_type
.	O

Uncoupling	O
of	O
nonreceptor	O
tyrosine	B-protein
kinases	I-protein
from	O
PLC-gamma1	B-protein
in	O
an	O
SLP-76-deficient	O
T	O
cell	O
.	O

The	O
activity	O
of	O
the	O
NH2-terminal	B-protein
transactivation	I-protein
domain	I-protein
is	O
modulated	O
by	O
an	O
adjacent	O
regulatory	B-protein
region	I-protein
that	O
contains	O
several	O
conserved	B-DNA
sequence	I-DNA
motifs	I-DNA
represented	O
only	O
in	O
the	O
NFAT	B-protein
family	I-protein
.	O

Subsequently	O
,	O
increasing	O
expression	O
along	O
the	O
erythroid	O
pathway	O
contrasts	O
with	O
an	O
abrupt	O
downregulation	O
in	O
the	O
granulocyte-macrophage	B-cell_type
lineage	I-cell_type
.	O

In	O
addition	O
,	O
V3-BH10	B-protein
generated	O
the	O
arrest	O
of	O
Kit225	B-cell_line
cells	I-cell_line
and	O
also	O
purified	B-cell_line
CD8-positive	I-cell_line
lymphocytes	I-cell_line
in	O
G1	O
phase	O
in	O
the	O
presence	O
of	O
IL-2	B-protein
.	O

This	O
remodeling	O
of	O
promoter	O
chromatin	O
structure	O
resulted	O
in	O
3-fold	O
increases	O
in	O
beta-globin	B-DNA
gene	I-DNA
transcription	O
and	O
induction	O
,	O
and	O
inhibited	O
long-term	O
beta-globin	B-DNA
gene	I-DNA
silencing	O
.	O

Interferons	B-protein
(	O
IFNs	B-protein
)	O
inhibit	O
induction	O
by	O
IL-4	B-protein
of	O
multiple	O
genes	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

We	O
report	O
here	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-mediated	O
repression	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
is	O
cycloheximide	O
resistant	O
,	O
suggesting	O
that	O
it	O
is	O
a	O
direct	O
transcriptional	O
repressive	O
effect	O
on	O
IL-2	B-protein
expression	O
by	O
the	O
vitamin	B-protein
D3	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
only	O
one	O
of	O
the	O
apparently	O
nonfunctional	B-DNA
sequence	I-DNA
motifs	I-DNA
was	O
bound	O
with	O
factors	O
in	O
vivo	O
.	O

Yet	O
,	O
IFN-alpha	B-protein
was	O
able	O
to	O
activate	O
binding	O
of	O
STAT5	B-protein
to	O
the	O
high-affinity	O
IFP53	O
GAS	O
site	O
.	O

Moreover	O
,	O
combined	O
mutation	O
of	O
both	O
microB	B-DNA
and	O
OCTA	B-DNA
sites	I-DNA
further	O
reduced	O
enhancer	O
activity	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

The	O
other	O
,	O
CIITA	B-protein
,	O
encodes	O
a	O
large	O
protein	O
with	O
a	O
defined	O
acidic	B-protein
transcriptional	I-protein
activation	I-protein
domain	I-protein
;	O
this	O
protein	O
does	O
not	O
interact	O
with	O
DNA	O
.	O

This	O
probe	O
was	O
used	O
to	O
identify	O
a	O
rel-related	B-DNA
complementary	I-DNA
DNA	I-DNA
that	O
hybridized	O
to	O
a	O
2.6-kilobase	B-RNA
messenger	I-RNA
RNA	I-RNA
present	O
in	O
human	B-cell_type
T	I-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

The	O
vpr	B-protein
product	I-protein
is	O
the	O
first	O
regulatory	O
protein	O
of	O
HIV-1	O
to	O
be	O
found	O
in	O
the	O
virus	O
particle	O
.	O

If	O
,	O
as	O
the	O
literature	O
suggests	O
,	O
NK	O
activity	O
is	O
relevant	O
to	O
breast	O
cancer	O
control	O
,	O
and	O
since	O
ER	B-protein
-tumors	O
have	O
a	O
worse	O
prognosis	O
,	O
we	O
suggest	O
here	O
that	O
perhaps	O
such	O
tumors	O
are	O
resistant	O
to	O
control	O
by	O
NK	B-cell_type
cells	I-cell_type
because	O
they	O
lack	O
the	O
ability	O
to	O
attract	O
an	O
accumulation	O
of	O
effector	B-cell_type
cells	I-cell_type
to	O
the	O
tumor	O
site	O
,	O
or	O
because	O
blocking	O
factors	O
at	O
the	O
site	O
of	O
the	O
tumor	O
prevent	O
local	O
tumor	O
control	O
at	O
the	O
site	O
of	O
action	O
.	O

TPO	B-protein
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
TPO	B-protein
receptor	O
but	O
not	O
the	O
erythropoietin	B-protein
(	I-protein
EPO	I-protein
)	I-protein
receptor	I-protein
.	O

Our	O
studies	O
provide	O
an	O
explanation	O
for	O
a	O
previous	O
observation	O
that	O
TCRG	B-RNA
mRNA	I-RNA
levels	O
,	O
but	O
not	O
mRNA	O
levels	O
for	O
T	B-protein
cell	I-protein
receptor	I-protein
alpha	I-protein
and	I-protein
-beta	I-protein
,	O
are	O
increased	O
by	O
ionomycin	O
treatment	O
.	O

The	O
amount	O
of	O
vimentin	B-RNA
mRNA	I-RNA
was	O
also	O
increased	O
during	O
recovery	O
from	O
stress	O
,	O
indicating	O
that	O
vimentin	B-protein
expression	O
was	O
not	O
exclusively	O
regulated	O
at	O
the	O
protein	O
level	O
.	O

The	O
derived	O
103-amino-acid	B-protein
basic	I-protein
protein	I-protein
has	O
two	O
potential	O
alpha-helical	B-protein
domains	I-protein
separated	O
by	O
a	O
hydrophobic	B-protein
region	I-protein
with	O
the	O
potential	O
to	O
generate	O
turns	O
and	O
assume	O
a	O
beta-sheet	O
conformation	O
.	O

We	O
previously	O
demonstrated	O
that	O
G-CSF	B-protein
activated	O
a	O
distinct	O
Stat3-like	B-protein
protein	I-protein
in	O
immature	B-cell_type
and	I-cell_type
mature	I-cell_type
normal	I-cell_type
myeloid	I-cell_type
cells	I-cell_type
,	O
StatG	B-protein
.	O

Coproporphyrinogen	B-protein
oxidase	I-protein
(	O
CPO	B-protein
)	O
catalyzes	O
the	O
sixth	O
step	O
of	O
the	O
heme	B-protein
biosynthetic	O
pathway	O
.	O

The	O
current	O
study	O
investigates	O
the	O
hypothesis	O
that	O
CD40	B-protein
expressed	O
on	O
lung	B-cell_type
fibroblasts	I-cell_type
is	O
an	O
activation	O
structure	O
and	O
mechanism	O
for	O
interaction	O
with	O
hemopoietic	B-cell_type
cells	I-cell_type
.	O

Distinct	O
patterns	O
of	O
chromosome	B-DNA
1	I-DNA
abnormalities	O
were	O
found	O
among	O
the	O
histologic	O
types	O
of	O
breast	O
carcinoma	O
.	O

LPS	O
stimulation	O
of	O
HDMEC	B-cell_type
and	O
THP-1	B-cell_line
cells	I-cell_line
initiated	O
an	O
IL-1	B-protein
receptor	I-protein
-like	O
NF-kappaB	B-protein
signaling	O
cascade	O
.	O

The	O
isoleucine	O
for	O
valine	O
substitution	O
at	O
amino	O
acid	O
729	O
impairs	O
the	O
function	O
of	O
the	O
hGR	B-protein
and	O
is	O
the	O
likely	O
cause	O
of	O
primary	O
cortisol	O
resistance	O
in	O
this	O
subject	O
.	O

C5a	O
,	O
a	O
potent	O
peptide	O
chemoattractant	O
,	O
stimulates	O
interleukin-8	B-protein
(	O
IL-8	B-protein
)	O
secretion	O
from	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O

The	O
induction	O
of	O
AP-1	B-protein
by	O
p21ras	B-protein
also	O
requires	O
Rac-1	B-protein
function	O
.	O

The	O
common	B-protein
gamma-chain	I-protein
(	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
)	O
is	O
a	O
functional	O
component	O
of	O
the	O
IL-4R	B-protein
,	O
yet	O
cells	O
lacking	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
are	O
able	O
to	O
respond	O
to	O
IL-4	B-protein
.	O

In	O
this	O
study	O
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
model	O
in	O
which	O
isolated	O
lung	B-cell_type
cells	I-cell_type
can	O
be	O
submitted	O
to	O
a	O
prolonged	B-cell_line
cyclic	I-cell_line
pressure-stretching	I-cell_line
strain	I-cell_line
resembling	O
that	O
of	O
conventional	O
mechanical	O
ventilation	O
.	O

Thus	O
,	O
the	O
GAS	O
sequence	O
in	O
the	O
CAEV	B-DNA
LTR	I-DNA
is	O
essential	O
for	O
the	O
response	O
to	O
IFN-gamma	B-protein
and	O
a	O
STAT1-like	B-protein
factor	I-protein
binds	O
to	O
this	O
site	O
.	O

In	O
conclusion	O
,	O
elevated	O
IFN	B-protein
alpha	I-protein
levels	O
in	O
AIDS-GR	O
may	O
be	O
due	O
to	O
the	O
lack	O
of	O
inhibitory	O
effect	O
of	O
cortisol	O
on	O
IFN	B-protein
alpha	I-protein
production	O
due	O
to	O
cortisol	O
resistance	O
in	O
monocytes	B-cell_type

We	O
studied	O
the	O
effects	O
of	O
TPA	O
on	O
the	O
regulation	O
of	O
c-jun	B-DNA
gene	O
expression	O
in	O
HL-60	B-cell_line
cells	I-cell_line
during	O
monocytic	O
differentiation	O
.	O

BCL-6	B-protein
and	O
the	O
molecular	O
pathogenesis	O
of	O
B-cell	O
lymphoma	O
.	O

Demonstration	O
of	O
a	O
1	B-protein
,	I-protein
25-dihydroxyvitamin	I-protein
D3-responsive	I-protein
protein	I-protein
in	O
human	B-cell_type
lymphocytes	I-cell_type
:	O
immunologic	O
crossreactivity	O
and	O
inverse	O
regulation	O
with	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
.	O

Furthermore	O
,	O
the	O
present	O
results	O
demonstrate	O
clearly	O
that	O
mycoplasma	B-protein
products	I-protein
can	O
have	O
a	O
profound	O
impact	O
on	O
the	O
activation	O
status	O
of	O
eukaryotic	B-cell_type
cells	I-cell_type
.	O

In	O
this	O
report	O
,	O
it	O
is	O
demonstrated	O
that	O
Elf-1	B-protein
contains	O
a	O
sequence	O
motif	O
that	O
is	O
highly	O
related	O
to	O
the	O
Rb	B-protein
binding	I-protein
sites	I-protein
of	O
several	O
viral	O
oncoproteins	B-protein
and	O
binds	O
to	O
the	O
pocket	O
region	O
of	O
Rb	B-protein
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Moreover	O
,	O
the	O
gp130	B-protein
-induced	O
activity	O
of	O
this	O
reporter	B-DNA
gene	I-DNA
was	O
abrogated	O
by	O
Stat3EE	B-protein
,	O
a	O
mutant	O
Stat3	B-protein
incapable	O
of	O
binding	O
DNA	O
.	O

It	O
is	O
also	O
an	O
inhibitor	O
of	O
HIV	O
replication	O
in	O
CD8+	B-cell_type
T-cells	I-cell_type
.	O

Ectopic	O
overexpression	O
of	O
IRF-1	B-protein
results	O
in	O
the	O
activation	O
of	O
the	O
endogenous	B-DNA
gene	I-DNA
for	O
ICE	B-protein
and	O
enhances	O
the	O
sensitivity	O
of	O
cells	O
to	O
radiation-induced	O
apoptosis	O
.	O

X-rays-induced	O
secretion	O
of	O
cellular	B-protein
factor	I-protein
(	O
s	O
)	O
that	O
enhance	O
(	O
s	O
)	O
HIV-1	B-DNA
promoter	I-DNA
transcription	O
in	O
various	O
non-irradiated	B-cell_line
transfected	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Mutational	O
studies	O
of	O
the	O
-236	B-DNA
to	I-DNA
-96	I-DNA
sequence	I-DNA
indicated	O
that	O
the	O
presence	O
of	O
both	O
the	O
-130	B-DNA
AP-1-like	I-DNA
site	I-DNA
(	O
-187	B-DNA
to	I-DNA
-181	I-DNA
)	O
and	O
the	O
-150	B-DNA
proximal	I-DNA
AP-1	I-DNA
site	I-DNA
were	O
necessary	O
to	O
observe	O
anergy	O
.	O

Interleukin	B-protein
2	I-protein
and	I-protein
15	I-protein
activate	O
Stat3alpha	B-protein
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

We	O
recently	O
reported	O
that	O
human	B-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
do	O
not	O
express	O
AP-1	B-protein
DNA	O
binding	O
activity	O
(	O
Monick	O
,	O
M.	O
M.	O
,	O
Carter	O
,	O
A.	O
B.	O
,	O
Gudmundsson	O
,	O
G.	O
,	O
Geist	O
,	O
L.	O
J.	O
,	O
and	O
Hunninghake	O
,	O
G.	O
W.	O
(	O
1998	O
)	O
Am.	O
J.	O
Physiol.	O
275	O
,	O
L389-L397	O
)	O
.	O

Mosaicism	O
of	O
46	B-cell_line
,	I-cell_line
X	I-cell_line
,	I-cell_line
-Y	I-cell_line
,	I-cell_line
t	I-cell_line
(	I-cell_line
Y	I-cell_line
;	I-cell_line
15	I-cell_line
)	I-cell_line
(	I-cell_line
q12	I-cell_line
;	I-cell_line
p13	I-cell_line
)	I-cell_line
/45	I-cell_line
,	I-cell_line
X	I-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
found	O
in	O
skin	O
samples	O
from	O
the	O
patient	O
's	O
elbow	O
and	O
genital	O
regions	O
,	O
although	O
there	O
were	O
no	O
clinical	O
stigmata	O
of	O
Turner	O
syndrome	O
.	O

METHODS	O
:	O
Platelets	B-cell_type
were	O
collected	O
from	O
112	O
drug-free	O
patients	O
with	O
bipolar	O
disorder	O
(	O
52	O
euthymic	O
,	O
29	O
depressed	O
,	O
and	O
31	O
manic	O
)	O
and	O
62	O
healthy	O
subjects	O
.	O

Aside	O
from	O
an	O
N-terminal	B-DNA
acidic	I-DNA
transcriptional	I-DNA
activation	I-DNA
domain	I-DNA
,	O
little	O
is	O
known	O
about	O
how	O
this	O
factor	O
functions	O
.	O

After	O
dexamethasone	O
suppression	O
(	O
1	O
mg	O
at	O
11	O
p.m.	O
)	O
Type	B-protein
I	I-protein
receptors	I-protein
always	O
decrease	O
in	O
controls	O
while	O
the	O
response	O
of	O
Type	B-protein
II	I-protein
is	O
not	O
homogeneous	O
.	O

We	O
concluded	O
that	O
steroid	O
hormones	O
might	O
be	O
closely	O
related	O
to	O
tumor	O
cell	O
infiltration	O
of	O
some	O
malignant	B-cell_type
soft	I-cell_type
tissue	I-cell_type
tumors	I-cell_type
.	O

We	O
present	O
a	O
model	O
in	O
which	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
alters	O
DNA	O
conformation	O
to	O
allow	O
binding	O
of	O
repressor	B-protein
proteins	I-protein
,	O
and	O
in	O
which	O
the	O
relative	O
amount	O
of	O
HMG-I	O
(	O
Y	O
)	O
helps	O
to	O
determine	O
the	O
repressive	O
state	O
of	O
the	O
beta-globin	B-DNA
gene	I-DNA
.	O

The	O
gammac	B-protein
chain	I-protein
is	O
a	O
subunit	O
of	O
multiple	O
cytokine	B-protein
receptors	I-protein
(	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
,	O
IL-4	B-protein
,	O
IL-7	B-protein
,	O
IL-9	B-protein
,	O
and	O
IL-15	B-protein
)	O
,	O
the	O
expression	O
of	O
which	O
is	O
restricted	O
to	O
hematopoietic	B-cell_type
lineages	I-cell_type
.	O

Furthermore	O
,	O
Egr-1	B-protein
induction	O
was	O
required	O
for	O
endogenous	O
NF-kappa	B-DNA
B1	I-DNA
gene	O
expression	O
,	O
since	O
PMA/	O
PHA-stimulated	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
expressing	O
antisense	O
Egr-1	B-RNA
RNA	I-RNA
were	O
inhibited	O
in	O
their	O
ability	O
to	O
upregulate	O
NF-kappa	O
B1	O
transcription	O
.	O

AR	B-protein
protein	I-protein
decreased	O
by	O
70	O
%	O
and	O
PSA	B-protein
levels	O
in	O
supernatants	O
from	O
LNCaP	B-cell_line
cells	I-cell_line
were	O
reduced	O
by	O
approximately	O
80	O
%	O
following	O
treatment	O
with	O
MCM	O
.	O

The	O
I	B-protein
gamma	I-protein
3	I-protein
ECS	B-DNA
lies	O
upstream	O
of	O
the	O
major	B-DNA
I	I-DNA
gamma	I-DNA
3	I-DNA
transcription	I-DNA
initiation	I-DNA
site	I-DNA
and	O
displays	O
more	O
than	O
90	O
%	O
identity	O
with	O
the	O
corresponding	O
human	B-DNA
I	I-DNA
gamma	I-DNA
1	I-DNA
,	O
I	B-DNA
gamma	I-DNA
2	I-DNA
,	O
and	O
I	B-DNA
gamma	I-DNA
4	I-DNA
regions	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Since	O
the	O
CTL	B-cell_type
response	O
to	O
virus	O
infection	O
is	O
often	O
focused	O
on	O
one	O
or	O
a	O
few	O
immunodominant	B-protein
epitopes	I-protein
,	O
one	O
approach	O
to	O
circumvent	O
this	O
response	O
is	O
to	O
create	O
vectors	O
that	O
lack	O
these	O
immunodominant	B-protein
epitopes	I-protein
.	O

IL-12	B-protein
induces	O
IFN	B-protein
regulating	I-protein
factor-1	I-protein
(	I-protein
IRF-1	I-protein
)	I-protein
gene	O
expression	O
in	O
human	O
NK	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
.	O

Virtually	O
no	O
information	O
is	O
available	O
on	O
regulation	O
and	O
functions	O
of	O
CD38	B-protein
.	O

Although	O
evidence	O
indicates	O
that	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
exerts	O
direct	O
physiological	O
effects	O
,	O
its	O
mechanism	O
of	O
action	O
remains	O
unknown	O
.	O

How	O
important	O
are	O
the	O
anti-inflammatory	O
(	O
non	O
T	O
)	O
effects	O
of	O
CyA	O
,	O
and	O
which	O
cells	O
do	O
they	O
operate	O
in	O
?	O

In	O
agreement	O
with	O
this	O
,	O
decrease	O
in	O
the	O
insulin	B-RNA
mRNA	I-RNA
and	O
insulin	O
content	O
was	O
observed	O
in	O
the	O
glycation-induced	B-cell_type
cells	I-cell_type
.	O

Therefore	O
we	O
first	O
examined	O
the	O
participation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
germline	B-cell_line
C	I-cell_line
epsilon	I-cell_line
transcription	O
in	O
a	O
human	B-cell_line
Burkitt	I-cell_line
lymphoma	I-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
DND39	B-cell_line
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
presence	O
of	O
the	O
CD4	B-protein
cytoplasmic	I-protein
tail	I-protein
is	O
critical	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-induced	O
apoptosis	O
(	O
J.Corbeil	O
,	O
M.Tremblay	O
,	O
and	O
D.D.Richman	O
,	O
J.Exp.Med.183	O
:	O
39-48	O
,	O
1996	O
)	O
.	O

Predicted	B-protein
peptide	I-protein
sequence	I-protein
of	O
ORF2	B-DNA
contained	O
a	O
zinc	B-protein
finger	I-protein
domain	I-protein
which	O
showed	O
significant	O
homology	O
to	O
GC	B-protein
box	I-protein
binding	I-protein
proteins	I-protein
BTEB2	B-protein
and	O
SP1	B-protein
.	O

Transactivation	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
promoter	I-DNA
by	O
human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
strains	O
GS	O
and	O
Z-29	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
identification	O
of	O
transactivating	B-DNA
HHV-6	I-DNA
(	I-DNA
GS	I-DNA
)	I-DNA
gene	I-DNA
fragments	I-DNA
.	O

The	O
Id	O
family	O
of	O
helix-loop-helix	B-protein
proteins	I-protein
function	O
as	O
negative	O
regulators	O
of	O
DNA	O
binding	O
,	O
basic	O
helix-loop-helix	B-protein
proteins	I-protein
in	O
the	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

However	O
,	O
the	O
change	O
in	O
p130	B-protein
phosphorylation	O
in	O
response	O
to	O
alpha-IFN	B-protein
occurs	O
before	O
dephosphorylation	O
of	O
pRb	B-protein
is	O
complete	O
because	O
loss	O
of	O
p130	B-protein
Form	I-protein
3	I-protein
occurs	O
throughout	O
the	O
cell	O
cycle	O
prior	O
to	O
complete	O
arrest	O
in	O
G1	O
,	O
whereas	O
pRb	B-protein
is	O
dephosphorylated	O
only	O
in	O
G1	O
.	O

Taken	O
together	O
,	O
these	O
data	O
provide	O
evidence	O
for	O
differential	O
regulation	O
of	O
the	O
translational	O
machinery	O
during	O
human	O
myeloid	O
differentiation	O
,	O
specific	O
to	O
the	O
monocytic/macrophage	O
pathway	O
or	O
to	O
the	O
granulocytic	O
pathway	O
.	O

In	O
these	O
cells	O
,	O
CD36	B-protein
is	O
involved	O
in	O
phagocytosis	O
of	O
apoptotic	B-cell_type
cells	I-cell_type
,	O
and	O
foam	O
cell	O
formation	O
by	O
uptake	O
of	O
oxidized	B-protein
low	I-protein
density	I-protein
lipoprotein	I-protein
.	O

These	O
findings	O
show	O
that	O
healthy	O
virus	O
carriers	O
maintain	O
a	O
high	O
frequency	O
of	O
BZLF1-specific	B-cell_type
memory	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
potentially	O
to	O
control	O
virus	O
spread	O
from	O
lytically	B-cell_type
infected	I-cell_type
cells	I-cell_type
.	O

The	O
biologic	O
actions	O
of	O
GM-CSF	B-protein
are	O
mediated	O
by	O
binding	O
to	O
a	O
specific	O
receptor	O
consisting	O
of	O
two	O
chains	O
designated	O
as	O
alpha	B-protein
and	I-protein
beta	I-protein
subunits	I-protein
.	O

We	O
find	O
that	O
a	O
short	O
enhancer	O
element	O
containing	O
the	O
NF-kappa	B-DNA
B	I-DNA
binding	I-DNA
site	I-DNA
from	O
the	O
interleukin-2	B-DNA
receptor	I-DNA
alpha-chain	I-DNA
gene	I-DNA
(	O
IL-2R	B-protein
alpha	I-protein
)	O
is	O
preferentially	O
activated	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Proliferation	O
and	O
cytokine	B-protein
release	O
were	O
inhibited	O
in	O
RA	O
patients	O
to	O
the	O
same	O
extent	O
as	O
in	O
healthy	O
controls	O
.	O

Class	O
II	O
transactivator-independent	O
endothelial	O
cell	O
MHC	B-protein
class	I-protein
II	I-protein
gene	O
activation	O
induced	O
by	O
lymphocyte	O
adhesion	O
.	O

In	O
summary	O
,	O
we	O
derived	O
an	O
experimental	O
system	O
that	O
allows	O
us	O
to	O
dissect	O
the	O
function	O
of	O
GATA-1	B-protein
in	O
red	B-cell_type
cell	I-cell_type
development	O
at	O
a	O
genetic	O
level	O
.	O

This	O
review	O
considers	O
the	O
evidence	O
for	O
different	O
theories	O
of	O
the	O
histogenesis	O
of	O
endometriosis	O
and	O
discusses	O
possible	O
immune	O
factors	O
that	O
may	O
be	O
involved	O
in	O
the	O
pathophysiology	O
of	O
the	O
disease	O
.	O

We	O
found	O
that	O
treatment	O
with	O
dexamethasone	O
induced	O
eosinophil	B-cell_type
apoptosis	O
.	O

Overexpression	O
of	O
the	O
p50	B-protein
,	O
p65	B-protein
and	O
Rel	B-protein
proteins	I-protein
in	O
these	O
cells	O
showed	O
that	O
significant	O
activation	O
of	O
the	O
IL-2R	B-protein
alpha	I-protein
kappa	B-DNA
B	I-DNA
site	I-DNA
was	O
observed	O
only	O
with	O
Rel	B-protein
and	O
Rel	B-protein
plus	O
p65	B-protein
.	O

Here	O
,	O
we	O
studied	O
the	O
role	O
of	O
serine/threonine	B-protein
phosphatases	I-protein
in	O
STAT3	B-protein
signaling	O
in	O
human	B-cell_line
antigen-specific	I-cell_line
CD4	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
cutaneous	B-cell_line
T	I-cell_line
cell	I-cell_line
lymphoma	I-cell_line
lines	I-cell_line
,	O
expressing	O
a	O
constitutively	O
activated	O
STAT3	B-protein
.	O

Cellular	O
proliferation	O
was	O
determined	O
by	O
5-bromo-2'-deoxyuridine	O
incorporation	O
into	O
DNA	O
and	O
flow	O
cytometry	O
and	O
by	O
use	O
of	O
a	O
mitotic	O
arrest	O
assay	O
.	O

The	O
diameter	O
of	O
the	O
PCVs	O
also	O
increased	O
with	O
increasing	O
inflammatory	O
infiltrate	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

Both	O
these	O
signals	O
were	O
necessary	O
for	O
expression	O
of	O
the	O
reporter	B-DNA
gene	I-DNA
.	O

The	O
addition	O
of	O
rCTLA4Ig	O
,	O
which	O
blocks	O
CD28	B-protein
binding	O
to	O
its	O
ligand	O
,	O
to	O
the	O
cultures	O
decreased	O
IL-2	B-DNA
promoter	I-DNA
activation	O
by	O
>	O
80	O
%	O
.	O

The	O
inactive	O
precursor	O
,	O
lyso-platelet-activating	B-protein
factor	I-protein
,	O
at	O
a	O
concentration	O
as	O
high	O
as	O
10	O
(	O
-7	O
)	O
M	O
had	O
no	O
effect	O
on	O
any	O
of	O
the	O
membrane	O
phospholipids	O
.	O

These	O
results	O
demonstrate	O
that	O
IRAK	B-protein
directly	O
triggers	O
NFkappaB	B-protein
-mediated	O
gene	O
expression	O
in	O
EL4	B-cell_line
cells	I-cell_line
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
the	O
alterations	O
in	O
the	O
HPA	O
axis	O
and	O
in	O
the	O
cortisol	O
metabolism	O
observed	O
in	O
PCOS	O
are	O
not	O
related	O
to	O
GR	B-protein
deficiency	O
.	O

In	O
vivo	O
footprint	O
analysis	O
of	O
the	O
HLA-DRA	B-DNA
gene	I-DNA
promoter	I-DNA
:	O
cell-specific	O
interaction	O
at	O
the	O
octamer	B-DNA
site	I-DNA
and	O
up-regulation	O
of	O
X	O
box	O
binding	O
by	O
interferon	B-protein
gamma	I-protein
.	O

Bcl-2	B-protein
:	O
a	O
repressor	O
of	O
lymphocyte	B-cell_type
death	O
.	O

No	O
receptor	O
abnormalities	O
were	O
detected	O
in	O
the	O
MDD	O
group	O
;	O
thus	O
any	O
cellular	O
defect	O
leading	O
to	O
a	O
lack	O
of	O
responsiveness	O
to	O
GC	O
in	O
the	O
MDD	O
patients	O
,	O
if	O
present	O
,	O
probably	O
lies	O
beyond	O
the	O
initial	O
receptor	O
binding	O
.	O

A	O
recent	O
study	O
showed	O
a	O
MLL/AF10	B-DNA
fusion	I-DNA
in	O
all	O
cases	O
of	O
AML	O
with	O
t	B-DNA
(	I-DNA
10	I-DNA
;	I-DNA
11	I-DNA
)	I-DNA
and	O
various	O
breakpoints	O
on	O
chromosome	B-DNA
11	I-DNA
ranging	O
from	O
q13	B-DNA
to	O
q23	B-DNA
.	O

Estrogen	B-protein
and	O
progesterone	B-protein
receptors	I-protein
in	O
vernal	O
keratoconjunctivitis	O
.	O

Thus	O
,	O
competition	O
between	O
two	O
general	O
transcriptional	B-protein
activators	I-protein
,	O
RelA	B-protein
and	O
NF-ATp	B-protein
,	O
mediates	O
the	O
inhibitory	O
effect	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
stimulation	O
on	O
IL4	B-protein
expression	O
and	O
may	O
contribute	O
to	O
differential	O
gene	O
expression	O
in	O
TH	B-cell_line
cells	I-cell_line
.	O

This	O
effect	O
was	O
paralleled	O
by	O
a	O
reduction	O
in	O
the	O
expression	O
of	O
MSR	B-protein
protein	O
and	O
mRNA	B-RNA
.	O

Host	O
defense	O
mechanisms	O
triggered	O
by	O
microbial	B-protein
lipoproteins	I-protein
through	O
toll-like	B-protein
receptors	I-protein
.	O

Cells	O
were	O
analyzed	O
by	O
in	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
.	O

PLB-IIIB	B-cell_line
cells	I-cell_line
clearly	O
possessed	O
a	O
more	O
monocytic	O
phenotype	O
than	O
the	O
parental	B-cell_type
myeloblasts	I-cell_type
,	O
as	O
determined	O
by	O
differential	O
staining	O
,	O
increased	O
expression	O
of	O
the	O
myeloid-specific	B-protein
surface	I-protein
markers	I-protein
,	O
and	O
transcription	O
of	O
the	O
c-fms	B-DNA
proto-oncogene	I-DNA
.	O

TAR	B-DNA
independent	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
in	O
phorbol	O
ester	O
stimulated	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Hypoxic	O
induction	O
of	O
interleukin-8	B-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O

The	O
role	O
of	O
jun	B-DNA
and	I-DNA
fos	I-DNA
gene	I-DNA
family	I-DNA
members	I-DNA
in	O
12-O-tetradecanoylphorbol-13-acetate	O
induced	O
hemopoietic	O
differentiation	O
.	O

Latency	O
breaking	O
activity	O
,	O
however	O
,	O
was	O
transferred	O
from	O
activator	B-cell_line
to	O
reporter	B-cell_line
cells	I-cell_line
when	O
active	O
,	O
exogenous	O
virus	O
was	O
added	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
eosinophils	B-cell_type
infiltrating	O
into	O
different	O
pathologic	O
processes	O
elaborate	O
TGF-alpha	B-protein
and	O
TGF-beta1	B-protein
.	O

If	O
GATA-1	B-cell_line
-red	I-cell_line
cells	I-cell_line
were	O
available	O
,	O
the	O
analyses	O
would	O
involve	O
the	O
actual	O
transcription	O
of	O
or	O
chromatin	O
structure	O
surrounding	O
the	O
globin	B-DNA
genes	I-DNA
.	O

Our	O
results	O
indicate	O
that	O
CCK-8	O
exerts	O
a	O
trophic	O
effect	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
through	O
stimulation	O
of	O
CCK	B-protein
(	I-protein
B	I-protein
)	I-protein
receptors	I-protein
by	O
modulation	O
of	O
expression	O
of	O
AP-1-regulated	B-DNA
genes	I-DNA
.	O

We	O
provide	O
formal	O
proof	O
that	O
the	O
phenotypic	O
and	O
attenuating	O
characteristics	O
of	O
IkappaB-alphaS32/36A	B-protein
permit	O
its	O
stable	O
maintenance	O
in	O
a	O
live	O
,	O
replicating	O
HIV-1	O
despite	O
180	O
days	O
of	O
forced	O
ex	O
vivo	O
passaging	O
in	O
tissue	O
culture	O
.	O

The	O
dissociation	O
constant	O
was	O
not	O
affected	O
by	O
methylprednisolone	O
treatment	O
in	O
either	O
group	O
.	O

In	O
promoter	O
transactivation	O
as	O
well	O
as	O
primary	O
B	O
cell	O
transformation	O
assays	O
these	O
chimeric	O
EBNA2	B-protein
proteins	O
are	O
able	O
to	O
substitute	O
for	O
wild-type	B-protein
EBNA2	I-protein
in	O
the	O
presence	O
of	O
oestrogen	O
.	O

These	O
increases	O
occur	O
in	O
the	O
absence	O
of	O
protein	O
synthesis	O
but	O
are	O
dependent	O
on	O
inactivation	O
of	O
the	O
v-abl	B-protein
protein	I-protein
tyrosine	I-protein
kinase	I-protein
.	O

Gel	O
supershift	O
assays	O
demonstrated	O
that	O
thrombin	B-protein
induced	O
binding	O
of	O
NF-kappa	B-protein
Bp65	I-protein
(	O
Rel	B-protein
A	I-protein
)	O
to	O
downstream	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
of	O
the	O
ICAM-1	B-DNA
promoter	I-DNA
.	O

Stably	O
transfected	O
Jurkat	O
cells	O
behaved	O
similarly	O
to	O
the	O
transiently	O
transfected	O
ones	O
with	O
respect	O
to	O
inhibition	O
by	O
CIF	B-protein
and	O
cyclosporine	O
.	O

The	O
same	O
parameters	O
have	O
been	O
examined	O
in	O
a	O
group	O
of	O
soccer	O
players	O
for	O
comparison	O
with	O
the	O
sedentary	O
group	O
.	O

The	O
comparison	O
of	O
the	O
obtained	O
values	O
with	O
intraarterial	O
measurements	O
demonstrates	O
a	O
good	O
correlation	O
between	O
the	O
two	O
methods	O
.	O

Oct-2	B-protein
is	O
a	O
transcription	B-protein
factor	I-protein
that	O
binds	O
specifically	O
to	O
octamer	B-DNA
DNA	I-DNA
motifs	I-DNA
in	O
the	O
promoters	B-DNA
of	O
immunoglobulin	B-DNA
and	I-DNA
interleukin-2	I-DNA
genes	I-DNA
.	O

This	O
translocation	O
is	O
characteristic	O
of	O
a	O
small	O
subset	O
of	O
non-Hodgkin	O
lymphomas	O
exhibiting	O
plasmacytoid	O
differentiation	O
.	O

Pax-5	B-DNA
encodes	O
the	O
transcription	B-protein
factor	I-protein
BSAP	B-protein
which	O
plays	O
an	O
essential	O
role	O
in	O
early	O
B	O
cell	O
development	O
and	O
midbrain	O
patterning	O
.	O

Serum	O
Ig	O
levels	O
were	O
followed	O
up	O
to	O
two	O
years	O
after	O
or	O
during	O
the	O
therapy	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
fibroblast	O
conditioned	O
medium	O
(	O
FCM	O
)	O
is	O
able	O
to	O
inhibit	O
both	O
TNF	B-RNA
mRNA	I-RNA
accumulation	O
and	O
protein	O
release	O
in	O
peripheral	B-cell_line
blood-derived	I-cell_line
human	I-cell_line
monocytes	I-cell_line
(	O
PBM	B-cell_line
)	O
stimulated	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Here	O
we	O
demonstrate	O
that	O
Bcl-3	B-protein
can	O
aid	O
kappa	B-DNA
B	I-DNA
site	I-DNA
-dependent	O
transcription	O
in	O
vivo	O
by	O
counteracting	O
the	O
inhibitory	O
effects	O
of	O
p50/NF-kappa	B-protein
B	I-protein
homodimers	I-protein
.	O

This	O
enhancement	O
was	O
eliminated	O
if	O
a	O
conserved	B-DNA
20-bp	I-DNA
sequence	I-DNA
was	O
removed	O
from	O
the	O
intron	B-DNA
or	O
if	O
a	O
dominant-negative	B-protein
ets-binding	I-protein
factor	I-protein
was	O
co-transfected	O
with	O
the	O
reporter	B-DNA
gene	I-DNA
.	O

In	O
each	O
case	O
the	O
allele	O
loss	O
was	O
caused	O
by	O
an	O
interstitial	O
deletion	O
because	O
heterozygosity	O
at	O
distal	B-DNA
markers	I-DNA
was	O
retained	O
and	O
because	O
quantitative	O
Southern	O
blotting	O
demonstrated	O
hemizygosity	O
.	O

2	O
)	O
The	O
FI	O
of	O
the	O
chemotactic	O
migration	O
rate	O
of	O
PMN	B-cell_type
by	O
cortisol	O
also	O
showed	O
diurnal	O
changes	O
which	O
were	O
synchronous	O
with	O
that	O
of	O
GR	B-protein
.	O

Glucocorticoid	B-protein
receptors	I-protein
are	O
down-regulated	O
in	O
inflamed	O
colonic	O
mucosa	O
but	O
not	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
[	O
see	O
comments	O
]	O

IL-12	B-protein
is	O
a	O
critical	B-protein
immunoregulatory	I-protein
cytokine	I-protein
that	O
promotes	O
cell-mediated	O
immune	O
responses	O
and	O
the	O
differentiation	O
of	O
naive	O
CD4+	B-cell_type
cells	I-cell_type
to	O
Th1	B-cell_type
cells	I-cell_type
;	O
however	O
,	O
relatively	O
few	O
IL-12	B-protein
target	O
genes	O
have	O
been	O
identified	O
.	O

Phagocyte	O
recognition	O
,	O
uptake	O
,	O
and	O
nonphlogistic	O
degradation	O
of	O
neutrophils	B-cell_type
and	O
other	O
leukocytes	B-cell_type
undergoing	O
apoptosis	O
promote	O
the	O
resolution	O
of	O
inflammation	O
.	O

BSAP	B-protein
:	O
a	O
key	O
regulator	O
of	O
B-cell	B-cell_type
development	O
and	O
differentiation	O
.	O

Following	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
stimulation	O
,	O
SLP-76	B-protein
and	O
Vav	B-protein
both	O
undergo	O
tyrosine	O
phosphorylation	O
and	O
associate	O
with	O
each	O
other	O
via	O
the	O
SH2	O
domain	O
of	O
Vav	B-protein
and	O
phosphorylated	O
tyrosines	O
of	O
SLP-76	B-protein
.	O

The	O
response	O
element	O
for	O
NF-AT	B-protein
is	O
a	O
sequence	O
localized	O
between	O
-285/-254	B-DNA
in	O
the	O
IL-2	B-DNA
regulatory	I-DNA
region	I-DNA
.	O

These	O
findings	O
demonstrate	O
that	O
certain	O
cytokines	O
,	O
including	O
IFN-gamma	B-protein
and	O
IL-10	B-protein
,	O
antagonize	O
the	O
ability	O
of	O
IL-4	B-protein
and	O
IL-13	B-protein
to	O
induce	O
increased	O
expression	O
of	O
the	O
IL-1RI	O
and	O
IL-1RII	B-DNA
genes	I-DNA
in	O
monocytes	B-cell_type
.	O

Plasma	O
sialyltransferase	B-protein
levels	O
in	O
psychiatric	O
disorders	O
as	O
a	O
possible	O
indicator	O
of	O
HPA	O
axis	O
function	O
.	O

Both	O
methods	O
demonstrated	O
that	O
the	O
tal-1	B-protein
gene	O
is	O
expressed	O
in	O
megakaryocytes	O
and	O
erythroblasts	O
as	O
well	O
as	O
in	O
basophilic	B-cell_type
granulocytes	I-cell_type
.	O

We	O
investigated	O
the	O
hypothesis	O
that	O
polymorphic	O
nucleotides	O
within	O
the	O
IL-10	B-DNA
and	I-DNA
TGF-beta	I-DNA
gene	I-DNA
promoters	I-DNA
would	O
link	O
to	O
the	O
expression	O
of	O
allergies	O
and	O
asthma	O
.	O

We	O
have	O
investigated	O
the	O
constitutive	O
and	O
inducible	O
transcriptional	O
activity	O
mediated	O
by	O
five	O
kappa	B-DNA
B-related	I-DNA
sequence	I-DNA
elements	I-DNA
in	O
two	O
different	O
cell	O
types	O
.	O

Resting	B-cell_type
T	I-cell_type
cells	I-cell_type
express	O
very	O
low	O
levels	O
of	O
c-Myb	B-protein
protein	I-protein
.	O

Results	O
similar	O
to	O
those	O
observed	O
with	O
U-937	B-cell_line
cells	I-cell_line
were	O
also	O
obtained	O
with	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O

The	O
phosphorylation	O
of	O
STAT	B-protein
proteins	I-protein
on	O
serine	O
residues	O
is	O
also	O
required	O
for	O
competent	O
STAT	B-protein
transcription	O
.	O

Both	O
haemin	O
and	O
delta-ALA	O
caused	O
a	O
de	O
novo	O
increase	O
in	O
alpha-globin	B-protein
expression	O
as	O
well	O
as	O
enhancing	O
Epo	B-protein
-induced	O
beta-globin	B-protein
expression	O
,	O
leading	O
to	O
a	O
marked	O
increase	O
in	O
haemoglobin	O
production	O
.	O

Activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
transcription	B-protein
factor	I-protein
(	O
NF-AT	B-protein
)	O
is	O
a	O
key	O
event	O
underlying	O
lymphocyte	O
action	O
.	O

During	O
B	O
and	O
T	O
cell	O
differentiation	O
and	O
proliferation	O
many	O
genes	O
are	O
induced	O
or	O
repressed	O
while	O
certain	O
genes	O
are	O
constitutively	O
expressed	O
.	O

ICSAT	B-protein
is	O
structurally	O
most	O
closely	O
related	O
to	O
the	O
previously	O
cloned	O
ICSBP	B-protein
,	O
a	O
member	O
of	O
the	O
IFN	B-protein
regulatory	I-protein
factor	I-protein
(	I-protein
IRF	I-protein
)	I-protein
family	I-protein
of	O
proteins	O
that	O
binds	O
to	O
interferon	B-DNA
consensus	I-DNA
sequences	I-DNA
(	O
ICSs	B-DNA
)	O
found	O
in	O
many	O
promoters	O
of	O
the	O
IFN-regulated	B-DNA
genes	I-DNA
.	O

It	O
is	O
intriguing	O
that	O
the	O
A-myb	B-DNA
genome	I-DNA
has	O
been	O
localised	O
relatively	O
close	O
to	O
the	O
c-myc	B-DNA
gene	I-DNA
on	O
chromosome	B-DNA
8	I-DNA
,	O
suggesting	O
that	O
the	O
c-myc	O
translocation	O
in	O
BL	O
and	O
B-ALL	O
may	O
affect	O
A-myb	B-protein
transcription	O
.	O

Inhibition	O
of	O
RNA	B-protein
polymerase	I-protein
II	I-protein
transcription	O
in	O
human	B-cell_type
cells	I-cell_type
by	O
synthetic	O
DNA-binding	O
ligands	O
[	O
see	O
comments	O
]	O

Activation	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
promoters	I-DNA
requires	O
binding	O
of	O
at	O
least	O
three	O
distinct	O
multi-protein	B-protein
complexes	I-protein
(	O
RFX	B-protein
,	O
X2BP	B-protein
and	O
NF-Y	B-protein
)	O
.	O

Sequence	O
analyses	O
of	O
pCD41	B-DNA
indicate	O
that	O
there	O
are	O
two	O
potential	O
open	B-DNA
reading	I-DNA
frames	I-DNA
(	O
ORFs	B-DNA
)	O
,	O
A	B-DNA
and	O
B	B-DNA
,	O
which	O
are	O
homologous	O
to	O
the	O
ORFs	B-DNA
found	O
in	O
the	O
genomic	O
clone	O
pGD41	B-DNA
.	O

Use	O
of	O
arsenic	O
trioxide	O
(	O
As2O3	O
)	O
in	O
the	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
:	O
II	O
.	O

Treatment	O
of	O
normal	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
with	O
cysteamine	O
in	O
vitro	O
was	O
found	O
to	O
inhibit	O
proliferation	O
in	O
a	O
dose-dependent	O
manner	O
,	O
with	O
essentially	O
complete	O
inhibition	O
occurring	O
at	O
a	O
dose	O
of	O
400	O
microM	O
.	O

M.	O
tuberculosis	O
ManLAM	O
resulted	O
in	O
clear	O
induction	O
of	O
the	O
luciferase	B-DNA
gene	I-DNA
placed	O
under	O
the	O
control	O
of	O
the	O
wild-type	B-DNA
,	I-DNA
but	I-DNA
not	I-DNA
the	I-DNA
kappaB-mutated	I-DNA
,	I-DNA
HIV-1	I-DNA
LTR	I-DNA
region	I-DNA
.	O

In	O
addition	O
,	O
in	O
vitro	O
differentiation	O
of	O
monocytes	B-cell_type
to	O
a	O
macrophage-like	B-cell_type
cell	I-cell_type
resulted	O
in	O
decreased	O
amounts	O
of	O
REF-1	B-protein
.	O

CONCLUSIONS	O
:	O
(	O
1	O
)	O
GCs	O
of	O
AITL/GC	O
differed	O
from	O
those	O
of	O
other	O
reactive	O
follicular	O
hyperplasias	O
and	O
follicular	O
lymphomas	O
,	O
and	O
staining	O
for	O
Bcl-6	B-protein
was	O
useful	O
to	O
discern	O
them	O
.	O

Together	O
,	O
these	O
studies	O
demonstrate	O
that	O
HTLV-1	O
Tax	B-protein
exploits	O
a	O
distal	O
part	O
of	O
the	O
proinflammatory	B-protein
cytokine	I-protein
signaling	O
cascade	O
leading	O
to	O
induction	O
of	O
NF-kappaB	B-protein
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
the	O
major	B-protein
envelope	I-protein
glycoprotein	I-protein
of	O
HIV	O
,	O
glycoprotein	B-protein
120	I-protein
(	O
gp120	B-protein
)	O
,	O
to	O
regulate	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
)	O
expression	O
in	O
glial	B-cell_type
cells	I-cell_type
,	O
because	O
ICAM-1	B-protein
is	O
important	O
in	O
mediating	O
immune	O
responsiveness	O
in	O
the	O
CNS	O
,	O
facilitating	O
entry	O
of	O
HIV-infected	B-cell_type
cells	I-cell_type
into	O
the	O
CNS	O
,	O
and	O
promoting	O
syncytia	O
formation	O
.	O

The	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
repressed	O
erythroid	O
differentiation	O
and	O
erythroid-specific	B-DNA
gene	I-DNA
expression	O
.	O

The	O
physiological	O
significance	O
and	O
possible	O
clinical	O
relevance	O
of	O
the	O
variant	O
ER	B-protein
forms	O
remain	O
to	O
be	O
elucidated	O
.	O

In	O
an	O
effort	O
to	O
further	O
elucidate	O
the	O
biological	O
effects	O
of	O
A	O
beta	O
towards	O
microglia	B-cell_type
,	O
we	O
investigated	O
the	O
ability	O
of	O
A	O
beta	O
peptides	O
to	O
activate	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
in	O
the	O
N9	B-cell_line
murine	I-cell_line
microglial	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Taking	O
the	O
IL-2	B-DNA
gene	I-DNA
as	O
a	O
candidate	O
,	O
we	O
examined	O
the	O
effect	O
of	O
cysteamine	O
treatment	O
on	O
early	B-DNA
gene	I-DNA
expression	O
during	O
lymphocyte	O
activation	O
,	O
and	O
on	O
the	O
activity	O
of	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
NF-AT	B-protein
and	O
Oct1	B-protein
,	O
whose	O
functions	O
are	O
required	O
for	O
expression	O
of	O
the	O
IL-2	B-protein
mRNA	O
.	O

HLA	B-protein
class	I-protein
I	I-protein
-mediated	O
induction	O
of	O
cell	O
proliferation	O
involves	O
cyclin	B-DNA
E	I-DNA
-mediated	O
inactivation	O
of	O
Rb	O
function	O
and	O
induction	O
of	O
E2F	B-protein
activity	O
.	O

Thirty	O
percent	O
of	O
GC	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
but	O
not	O
naive	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
displayed	O
mutations	O
in	O
the	O
742	B-DNA
bp	I-DNA
region	I-DNA
analyzed	O
within	O
the	O
first	O
intron	O
of	O
BCL-6	B-protein
(	O
overall	O
frequency	O
:	O
5	O
x	O
10	O
(	O
-4	O
)	O
/bp	O
)	O
.	O

These	O
data	O
suggest	O
that	O
L.	O
pneumophila	O
possesses	O
a	O
growth	O
phase-dependent	O
resistance	O
to	O
stress	O
that	O
is	O
independent	O
of	O
RpoS	B-protein
control	O
and	O
that	O
RpoS	B-protein
likely	O
regulates	O
genes	O
that	O
enable	O
it	O
to	O
survive	O
in	O
the	O
environment	O
within	O
protozoa	O
.	O

Similar	O
effects	O
were	O
obtained	O
for	O
the	O
c-fos	B-DNA
gene	I-DNA
.	O

This	O
rhythmic	O
differentiation	O
disappeared	O
after	O
the	O
patients	O
had	O
been	O
given	O
the	O
antiandrogen	O
drug	O
.	O

Cross-competition	O
assays	O
among	O
the	O
P-like	B-DNA
elements	I-DNA
revealed	O
element-specific	B-protein
and	I-protein
common	I-protein
complexes	I-protein
.	O

In	O
contrast	O
,	O
the	O
class	B-cell_line
II-positive	I-cell_line
nonlymphoid	I-cell_line
glioblastoma	I-cell_line
cell	I-cell_line
line	I-cell_line
does	O
not	O
exhibit	O
interactions	O
at	O
the	O
octamer	B-DNA
site	I-DNA
despite	O
the	O
presence	O
of	O
the	O
ubiquitous	B-protein
OTF-1	I-protein
factor	I-protein
and	O
an	O
open	B-DNA
binding	I-DNA
site	I-DNA
.	O

Activation	O
of	O
individual	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
results	O
in	O
differential	O
lymphokine	B-protein
expression	O
:	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
is	O
preferentially	O
produced	O
by	O
T	B-cell_line
helper	I-cell_line
type	I-cell_line
1	I-cell_line
(	I-cell_line
TH1	I-cell_line
)	I-cell_line
cells	I-cell_line
,	O
which	O
are	O
involved	O
in	O
cell-mediated	O
immune	O
responses	O
,	O
whereas	O
IL-4	B-protein
is	O
synthesized	O
by	O
TH2	B-cell_line
cells	I-cell_line
,	O
which	O
are	O
essential	O
for	O
humoral	O
immunity	O
.	O

The	O
transcriptional	B-DNA
start	I-DNA
sites	I-DNA
were	O
identified	O
by	O
an	O
RNase	B-protein
protection	O
assay	O
.	O

The	O
high	O
prevalence	O
of	O
promoter	O
methylation	O
suggests	O
that	O
this	O
molecular	O
abnormality	O
can	O
be	O
used	O
to	O
monitor	O
disease	O
activity	O
during	O
therapy	O
.	O

Thus	O
,	O
select	O
genetic	O
aberrations	O
in	O
the	O
apoptotic	O
pathway	O
reveal	O
a	O
cell	O
autonomous	O
coregulation	O
of	O
activation	O
.	O

Estrogen	B-protein
receptor	I-protein
diminishes	O
DNA-binding	O
activities	O
of	O
chicken	B-protein
GATA-1	I-protein
and	O
CACCC-binding	B-protein
proteins	I-protein
.	O

In	O
response	O
to	O
secondary	O
pathogenic	O
infections	O
or	O
antigenic	O
challenge	O
,	O
cytokine	B-protein
gene	O
expression	O
is	O
rapidly	O
induced	O
,	O
enhanced	O
,	O
and	O
sustained	O
over	O
prolonged	O
periods	O
in	O
HIV-1-infected	B-cell_line
myeloid	I-cell_line
cells	I-cell_line
compared	O
with	O
uninfected	B-cell_type
cells	I-cell_type
.	O

In	O
light	O
of	O
the	O
evidence	O
showing	O
physical	O
and	O
functional	O
interactions	O
between	O
Oct	B-protein
factors	I-protein
and	O
OCA-B	B-protein
,	O
we	O
propose	O
a	O
mechanism	O
of	O
action	O
for	O
OCA-B	B-protein
and	O
discuss	O
the	O
implications	O
of	O
OCA-B	B-protein
for	O
the	O
transcriptional	O
regulation	O
of	O
other	O
tissue-specific	B-DNA
promoters	I-DNA
.	O

This	O
study	O
shows	O
that	O
human	O
peripheral	O
blood	O
monocytes	B-cell_type
(	O
PBMo	B-cell_type
)	O
also	O
respond	O
to	O
MDHM	O
with	O
increases	O
in	O
IL-1	B-protein
beta	I-protein
,	O
IL-6	B-protein
and	O
TNF	B-protein
alpha	I-protein
expression	O
,	O
both	O
at	O
the	O
mRNA	O
and	O
protein	O
level	O
.	O

These	O
data	O
demonstrate	O
a	O
new	O
antiapoptotic	O
role	O
for	O
Notch-1	B-protein
,	O
providing	O
evidence	O
that	O
,	O
in	O
addition	O
to	O
regulating	O
cell	O
fate	O
decisions	O
,	O
Notch-1	B-protein
can	O
play	O
a	O
critical	O
role	O
in	O
controlling	O
levels	O
of	O
cell	O
death	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

A	O
transfected	O
IFN-beta	O
promoter	O
responded	O
to	O
EBNA2	B-protein
activation	O
,	O
and	O
a	O
sequence	O
closely	O
resembling	O
a	O
RBP-Jkappa	B-DNA
binding	I-DNA
site	I-DNA
was	O
pinpointed	O
as	O
a	O
potential	O
target	O
of	O
EBNA2	B-protein
activity	O
.	O

Thus	O
,	O
IL-2	B-protein
may	O
be	O
another	O
important	O
cytokine	B-protein
modulated	O
by	O
RA	O
in	O
the	O
immune	O
response	O
.	O

The	O
Bcd	B-DNA
proto-oncogene	B-DNA
was	O
activated	O
by	O
a	O
truncation	O
in	O
the	O
5	B-DNA
'	I-DNA
UTR	I-DNA
.	O

Tax1	B-protein
,	O
a	O
transcriptional	B-protein
trans-activator	I-protein
of	O
the	O
Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
,	O
induces	O
the	O
expression	O
of	O
many	O
cellular	O
genes	O
through	O
interaction	O
with	O
at	O
least	O
three	O
distinct	O
cellular	B-protein
transcription	I-protein
factors	I-protein
;	O
CREB/ATF	B-protein
,	O
NF-kappaB	B-protein
,	O
and	O
SRF	B-protein
.	O

These	O
results	O
suggest	O
that	O
clinical	O
glucocorticoid	O
resistance	O
in	O
chronic	O
asthma	O
does	O
not	O
reflect	O
abnormal	O
glucocorticoid	O
clearance	O
but	O
may	O
be	O
due	O
at	O
least	O
partly	O
to	O
a	O
relative	O
insensitivity	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
to	O
glucocorticoids	O
.	O

Two	O
subclones	O
were	O
found	O
to	O
have	O
an	O
abnormal	O
response	O
to	O
the	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
activator	O
PMA	O
.	O

Dominant	B-protein
negative	I-protein
mutants	I-protein
of	O
NIK	B-protein
,	O
IKKalpha	B-protein
,	O
or	O
IKKbeta	B-protein
substantially	O
inhibited	O
NF-kappaB	B-protein
activation	O
by	O
LMP1	B-protein
or	O
by	O
each	O
of	O
its	O
effector	B-protein
sites	I-protein
.	O

Gel	O
retardation	O
assays	O
with	O
STAT-binding	O
oligonucleotides	O
showed	O
that	O
IL-7	B-protein
induces	O
the	O
formation	O
of	O
two	O
major	O
STAT	B-protein
complexes	I-protein
in	O
BCP-ALL	B-cell_line
cells	I-cell_line
.	O

We	O
now	O
show	O
that	O
:	O
1	O
)	O
CVZ	O
has	O
more	O
than	O
one	O
binding	O
site	O
in	O
a	O
second	O
,	O
independent	O
,	O
B-cell	B-cell_line
line	I-cell_line
,	O
IM-9	B-cell_line
;	O
2	O
)	O
the	O
antiglucocorticoid	O
RU	O
38486	O
is	O
able	O
to	O
block	O
both	O
CVZ	O
's	O
higher	O
and	O
lower	O
affinity	O
sites	O
;	O
3	O
)	O
all	O
of	O
CVZ	B-protein
's	I-protein
binding	I-protein
sites	I-protein
are	O
on	O
a	O
protein	O
immunologically	O
indistinguishable	O
from	O
the	O
human	O
GR	B-protein
;	O
and	O
4	O
)	O
freshly	O
isolated	O
clones	O
of	O
CVZ-resistant	O
cells	O
have	O
lost	O
all	O
binding	O
sites	O
for	O
CVZ	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
binding	O
to	O
cell-surface	O
heparan	O
sulphate	O
is	O
essential	O
for	O
optimal	O
activity	O
of	O
IFN-gamma	B-protein
and	O
that	O
free	O
heparin	O
competitively	O
inhibits	O
this	O
sequestration	O
process	O
.	O

The	O
second	O
objective	O
was	O
to	O
compare	O
in	O
vitro	O
responses	O
of	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
with	O
responses	O
to	O
VZV	O
peptides	O
induced	O
in	O
vivo	O
after	O
immunization	O
with	O
varicella	O
vaccine	O
.	O

We	O
find	O
that	O
the	O
dissociation	O
constant	O
of	O
rapamycin	O
to	O
the	O
FK506	B-protein
binding	I-protein
protein	I-protein
FKBP	B-protein
(	O
Kd	O
=	O
0.2	O
nM	O
)	O
is	O
close	O
to	O
the	O
dissociation	O
constant	O
of	O
FK506	O
to	O
FKBP	B-protein
(	O
Kd	O
=	O
0.4	O
nM	O
)	O
and	O
to	O
their	O
effective	O
biologic	O
inhibitory	O
concentrations	O
.	O

HIV-1	B-DNA
LTR	I-DNA
activity	O
in	O
human	B-cell_line
CD40-activated	I-cell_line
B	I-cell_line
lymphocytes	I-cell_line
is	O
dependent	O
on	O
NF-kappaB	B-protein
.	O

The	O
same	O
gene	O
segment	O
was	O
not	O
transcribed	O
in	O
IL-5-nonproducing	B-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
,	O
suggesting	O
that	O
human	O
T	O
cell	O
IL-5	B-protein
synthesis	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O

Both	O
c-Fos	B-protein
and	O
c-Jun	B-protein
protein	O
levels	O
were	O
increased	O
after	O
Con	O
A	O
and	O
PHA	O
stimulation	O
.	O

Early	O
buds	O
are	O
characterized	O
by	O
a	O
branching	O
morphogenesis	O
of	O
the	O
ductal	O
epithelium	O
from	O
which	O
endocrine	B-cell_type
and	I-cell_type
exocrine	I-cell_type
precursor	I-cell_type
cells	I-cell_type
bud	O
to	O
eventually	O
form	O
the	O
two	O
other	O
compartments	O
.	O

p94	B-protein
and	O
p95	B-protein
share	O
homology	O
with	O
Stat1	B-protein
at	O
the	O
phosphorylation	B-protein
site	I-protein
and	O
in	O
the	O
Src	B-protein
homology	I-protein
2	I-protein
(	I-protein
SH2	I-protein
)	I-protein
domain	I-protein
,	O
but	O
otherwise	O
are	O
immunologically	O
distinct	O
from	O
Stat1	B-protein
.	O

The	O
lymphoid-specific	B-protein
transcription	I-protein
factor	I-protein
Oct-2a	B-protein
is	O
implicated	O
in	O
B	O
cell-specific	O
transcriptional	O
activity	O
via	O
the	O
octamer	O
motif	O
.	O

TLR2	B-protein
and	O
TLR4	B-protein
were	O
expressed	O
on	O
the	O
cell	O
surface	O
of	O
HDMEC	B-cell_type
and	O
THP-1	B-cell_line
cells	I-cell_line
.	O

A	O
subpopulation	O
of	O
smaller	O
cells	O
did	O
not	O
express	O
the	O
differentiation	O
markers	O
after	O
cadmium	O
stimulation	O
.	O

These	O
findings	O
indicate	O
that	O
imbalanced	O
expression	O
of	O
the	O
GR	B-protein
isoforms	I-protein
may	O
be	O
a	O
mechanism	O
of	O
GC	O
resistance	O
,	O
and	O
may	O
have	O
implications	O
for	O
tumorigenesis	O
by	O
enhancing	O
cell	O
survival	O
.	O

However	O
,	O
exposure	O
of	O
U-937	B-cell_line
cells	I-cell_line
to	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
increased	O
by	O
200	O
%	O
the	O
level	O
of	O
IL-1	B-RNA
beta	I-RNA
mRNA	I-RNA
detected	O
and	O
decreased	O
by	O
three	O
orders	O
of	O
magnitude	O
the	O
concentration	O
of	O
LPS	O
required	O
to	O
achieve	O
steady	O
state	O
mRNA	O
levels	O
equivalent	O
to	O
those	O
observed	O
in	O
U-937	B-cell_line
cells	I-cell_line
not	O
preincubated	O
with	O
the	O
hormone.2+o	O

The	O
Ala-substituted	O
peptide	O
was	O
recognized	O
by	O
the	O
T	B-cell_line
cell	I-cell_line
clone	I-cell_line
at	O
neutral	O
pH	O
only	O
when	O
it	O
was	O
present	O
in	O
the	O
APC	B-cell_line
culture	I-cell_line
throughout	O
the	O
stimulation	O
process	O
.	O

However	O
,	O
we	O
could	O
not	O
prove	O
that	O
Th2	B-protein
type	I-protein
cytokines	I-protein
had	O
a	O
protective	O
effect	O
on	O
hepatocytes	B-cell_type
.	O

These	O
results	O
indicate	O
that	O
the	O
mechanism	O
by	O
which	O
YM268	O
increased	O
glucose	O
uptake	O
,	O
may	O
be	O
accounted	O
for	O
in	O
part	O
by	O
the	O
enhancement	O
of	O
GLUT1	B-protein
and	O
GLUT4	B-protein
expression	O
through	O
PPARgamma	B-protein
activation	O
.	O

Specifically	O
,	O
Stat1alpha	B-protein
may	O
activate	O
a	O
cell	B-DNA
cycle-associated	I-DNA
gene	I-DNA
(	O
s	O
)	O
,	O
leading	O
to	O
the	O
entry	O
of	O
cells	O
into	O
the	O
cell	O
cycle	O
.	O

To	O
determine	O
whether	O
specific	O
members	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
family	I-protein
contribute	O
to	O
this	O
effect	O
,	O
we	O
have	O
examined	O
the	O
abilities	O
of	O
different	O
NF-kappa	B-protein
B	I-protein
subunits	I-protein
to	O
act	O
with	O
Tat-I	B-protein
to	O
stimulate	O
transcription	O
of	O
HIV	O
in	O
Jurkat	B-cell_type
T-leukemia	I-cell_type
cells	I-cell_type
.	O

However	O
,	O
using	O
ATL-16T	O
nuclear	O
extract	O
,	O
we	O
demonstrated	O
that	O
GATA-4	B-protein
is	O
the	O
only	O
GATA-binding	B-protein
protein	I-protein
that	O
forms	O
specific	O
DNA-protein	B-protein
complex	I-protein
with	O
the	O
-70	B-DNA
GATA	I-DNA
site	I-DNA
.	O

We	O
also	O
show	O
that	O
ectopic	O
expression	O
of	O
PU.1	B-protein
in	O
Xenopus	O
embryos	O
is	O
sufficient	O
to	O
block	O
erythropoiesis	O
during	O
normal	O
development	O
.	O

We	O
also	O
observed	O
an	O
increase	O
in	O
electrophoretic	O
mobility	O
of	O
the	O
predominant	O
E2F	B-protein
components	I-protein
,	O
DP1	B-protein
and	O
E2F4	B-protein
,	O
as	O
B-lymphocytes	B-cell_type
progressed	O
from	O
G0	O
into	O
early	O
G1	O
.	O

Combinations	O
of	O
hypoxia	O
and	O
LPS	O
significantly	O
increased	O
lymphocyte	O
binding	O
,	O
and	O
such	O
increases	O
were	O
inhibited	O
by	O
addition	O
of	O
anti-ICAM-1	B-protein
antibodies	I-protein
or	O
antisense	O
oligonucleotides	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
transcripts	O
of	O
the	O
E2A	B-DNA
gene	I-DNA
can	O
be	O
detected	O
in	O
a	O
wide	O
range	O
of	O
cell	O
types	O
.	O

Nuclear	O
and	O
post-nuclear	O
extracts	O
were	O
prepared	O
from	O
two	O
B-lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
known	O
to	O
be	O
representative	O
of	O
the	O
vitamin	B-cell_line
D-resistant	I-cell_line
and	O
wild	B-cell_line
type	I-cell_line
phenotypes	I-cell_line
,	O
respectively	O
.	O

The	O
intracellular	O
localization	O
of	O
NFkappaB	B-protein
after	O
TNFalpha	B-protein
simulation	O
was	O
determined	O
by	O
confocal	O
immunocytochemistry	O
using	O
an	O
anti-p65	B-protein
antibody	I-protein
.	O

We	O
show	O
that	O
this	O
sequence	O
binds	O
the	O
transcription	B-protein
factor	I-protein
Sp1	B-protein
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Activation	O
of	O
primary	B-cell_type
human	I-cell_type
T-lymphocytes	I-cell_type
through	O
CD2	B-protein
plus	I-protein
CD28	I-protein
adhesion	I-protein
molecules	I-protein
induces	O
long-term	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

But	O
the	O
logarithmic	O
mean	O
of	O
ER	B-protein
content	O
in	O
lymphocytes	B-cell_type
,	O
expressed	O
by	O
fmol/mg	O
of	O
cytosolic	B-protein
protein	I-protein
,	O
in	O
14	O
patients	O
with	O
active	O
SLE	O
(	O
0.9356	O
+/-	O
0.31	O
)	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
13	O
patients	O
with	O
inactive	O
SLE	O
(	O
0.2979	O
+/-	O
0.23	O
,	O
P	O
less	O
than	O
0.001	O
)	O
and	O
in	O
the	O
controls	O
(	O
0.6204	O
+/-	O
0.52	O
,	O
P	O
less	O
than	O
0.001	O
)	O
.	O

Generation	O
of	O
CD1+RelB+	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
and	O
tartrate-resistant	B-cell_type
acid	I-cell_type
phosphatase-positive	I-cell_type
osteoclast-like	I-cell_type
multinucleated	I-cell_type
giant	I-cell_type
cells	I-cell_type
from	O
human	B-cell_type
monocytes	I-cell_type
.	O

Retinoic	O
acid-induced	O
expression	O
of	O
CD38	B-protein
antigen	I-protein
in	O
myeloid	B-cell_type
cells	I-cell_type
is	O
mediated	O
through	O
retinoic	B-protein
acid	I-protein
receptor-alpha	I-protein
.	O

This	O
assay	O
has	O
potential	O
as	O
a	O
screen	O
to	O
establish	O
the	O
immunogenicity	O
of	O
viral	O
antigens	O
in	O
vitro	O
using	O
T	B-cell_type
cells	I-cell_type
from	O
naive	O
donors	O
.	O

Campomelic	O
dysplasia	O
(	O
CMPD1	O
)	O
and	O
autosomal	O
XY	O
sex	O
reversal	O
(	O
SRA1	O
)	O
are	O
caused	O
by	O
mutations	O
in	O
the	O
SRY-related	B-DNA
gene	I-DNA
SOX9	B-DNA
on	O
17q	B-DNA
.	O

In	O
contrast	O
,	O
CD19	B-protein
cross-linking	O
in	O
BLIN-1	B-cell_line
cells	I-cell_line
resulted	O
in	O
the	O
induction	O
of	O
NF-kappaB	B-protein
,	O
but	O
had	O
no	O
apparent	O
effect	O
on	O
AP-1	B-protein
-binding	O
activity	O
.	O

IL-10	B-protein
also	O
activated	O
Stat5	B-protein
in	O
Ba/F3	B-cell_line
cells	I-cell_line
that	O
stably	O
expressed	O
the	O
murine	O
IL-10	B-protein
receptor	I-protein
.	O

Finally	O
,	O
a	O
110-kDa	B-protein
protein	I-protein
has	O
been	O
identified	O
in	O
the	O
nuclei	O
of	O
all	O
the	O
B	B-cell_line
,	I-cell_line
but	I-cell_line
not	I-cell_line
T	I-cell_line
,	I-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
specifically	O
binds	O
to	O
this	O
A-MYB	B-protein
N-terminal	I-protein
domain	I-protein
.	O

The	O
results	O
obtained	O
by	O
transient	O
transfection	O
of	O
fos	O
-CAT	B-DNA
constructs	I-DNA
that	O
contained	O
serial	B-DNA
5'-deletion	I-DNA
mutations	I-DNA
showed	O
that	O
the	O
region	O
between	O
-3134	O
and	O
-3059	O
appears	O
to	O
be	O
required	O
for	O
the	O
induction	O
of	O
transcription	O
by	O
LPS	O
.	O

Supershift	O
analysis	O
revealed	O
these	O
proteins	O
to	O
be	O
Egr-1	B-protein
and	O
Egr-2	B-protein
(	O
Krox-20	O
)	O
;	O
Egr-3	B-protein
was	O
not	O
detected	O
.	O

Characterization	O
of	O
the	O
human	B-DNA
elk-1	I-DNA
promoter	I-DNA
.	O

A	O
number	O
of	O
genes	O
known	O
to	O
be	O
induced	O
following	O
T	O
cell	O
activation	O
and	O
associated	O
with	O
cell	O
growth	O
were	O
increased	O
in	O
the	O
transfectants	B-cell_line
,	O
including	O
c-fos	B-DNA
,	O
c-myc	B-DNA
,	O
c-myb	B-DNA
,	O
HLA-DR	B-DNA
,	O
lck	B-DNA
,	O
NF-kappa	B-protein
B	I-protein
,	O
interleukin-2	B-DNA
and	O
interleukin-2	B-DNA
receptor	I-DNA
alpha	I-DNA
(	O
IL-2R	B-DNA
alpha	I-DNA
)	O
.	O

Since	O
the	O
protein	O
has	O
a	O
homeodomain	B-DNA
and	O
can	O
activate	O
transcription	O
,	O
it	O
probably	O
exerts	O
at	O
least	O
some	O
of	O
its	O
effects	O
in	O
vivo	O
by	O
regulation	O
of	O
target	B-DNA
genes	I-DNA
.	O

In	O
contrast	O
,	O
LPS-mediated	O
nuclear	O
binding	O
of	O
nuclear	B-protein
factor-kappaB/Rel	I-protein
to	O
a	O
TF-specific	B-DNA
kappaB	I-DNA
site	I-DNA
was	O
inhibited	O
by	O
lysoPC	O
.	O

We	O
found	O
that	O
in	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
HUVEC	B-cell_type
)	O
,	O
CoCl2	O
at	O
2	O
mM	O
concentration	O
induced	O
the	O
surface	O
expression	O
of	O
a	O
subset	O
of	O
CAMs	B-protein
(	O
VCAM-1	B-protein
)	O
and	O
activation	O
of	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
in	O
the	O
nuclear	O
extracts	O
of	O
HUVEC	B-cell_type
.	O

This	O
loss	O
of	O
STAT1	B-protein
was	O
also	O
seen	O
in	O
cells	O
from	O
patients	O
treated	O
with	O
fludarabine	O
in	O
vivo	O
.	O

The	O
remaining	O
86	O
%	O
correspond	O
to	O
unknown	O
genes	B-DNA
of	O
which	O
92	O
%	O
have	O
been	O
confirmed	O
to	O
be	O
differentially	O
expressed	O
.	O

We	O
have	O
pursued	O
our	O
investigation	O
of	O
the	O
role	O
of	O
the	O
CD4	B-protein
transduction	O
pathway	O
in	O
HIV-induced	O
apoptosis	O
.	O

Two	O
distinct	O
forms	O
of	O
active	B-protein
transcription	I-protein
factor	I-protein
CREB	I-protein
(	O
cAMP	B-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
)	O
.	O

Significantly	O
,	O
expression	O
of	O
the	O
newly	O
identified	O
Fas-regulatory	B-DNA
gene	I-DNA
,	O
TDAG51	B-DNA
,	O
was	O
found	O
to	O
be	O
dependent	O
upon	O
the	O
activity	O
of	O
PKC	B-protein
.	O

Whereas	O
TPCK	B-protein
inhibits	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
and	O
,	O
consequently	O
,	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
it	O
markedly	O
enhances	O
the	O
activity	O
of	O
JNK	B-protein
,	O
the	O
MAP	B-protein
kinase-related	I-protein
kinase	I-protein
that	O
phosphorylates	O
the	O
transactivation	B-protein
domain	I-protein
of	O
c-Jun	B-protein
.	O

Viral	O
gene	O
expression	O
may	O
be	O
reactivated	O
by	O
stimulation	O
of	O
the	O
cells	O
with	O
LPS	O
or	O
cytokines	B-protein
such	O
as	O
TNF-alpha	B-protein
in	O
vitro	O
.	O

In	O
5	O
patients	O
the	O
granulocytes	B-cell_type
appeared	O
polyclonal	O
and	O
in	O
1	O
patient	O
unilateral	O
X	O
inactivation	O
was	O
observed	O
in	O
both	O
granulocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
.	O

NAC	O
not	O
only	O
blocks	O
the	O
effect	O
of	O
TPCK	O
but	O
enhances	O
mitogenesis	O
and	O
cytokine	B-protein
production	O
(	O
>	O
2.5-fold	O
in	O
some	O
cases	O
)	O
upon	O
activation	O
of	O
unsuppressed	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

We	O
have	O
applied	O
flow	O
cytometry	O
to	O
the	O
investigation	O
of	O
interferon-gamma	B-protein
activation	O
of	O
human	B-cell_type
monocytes	I-cell_type
.	O

Body	O
weight	O
,	O
body	O
mass	O
index	O
,	O
body	O
fat	O
,	O
lean	O
body	O
mass	O
,	O
blood-glucose	O
,	O
cholesterol	O
,	O
HDL-cholesterol	B-protein
,	O
triglyceride	O
,	O
beta-lipoproteins	B-protein
,	O
insulin	O
,	O
gonadotropin	O
,	O
estradiol	O
,	O
testosterone	O
,	O
SHBG	B-protein
,	O
T3	B-protein
,	O
T4	B-protein
and	O
TSH	O
levels	O
as	O
well	O
as	O
estradiol	O
and	O
progesterone	O
receptor	O
levels	O
in	O
excised	O
tumor	O
were	O
studied	O
in	O
40	O
patients	O
with	O
breast	O
cancer	O
prior	O
to	O
conservative	O
treatment	O
.	O

In	O
contrast	O
,	O
IL-13	B-protein
levels	O
were	O
not	O
elevated	O
.	O

Thus	O
the	O
response	O
of	O
K562	B-cell_line
cells	I-cell_line
to	O
HMBA	O
may	O
provide	O
a	O
useful	O
experimental	O
system	O
for	O
studying	O
the	O
molecular	O
mechanisms	O
responsible	O
for	O
downmodulation	O
of	O
lineage-restricted	O
transcription	B-protein
factors	I-protein
during	O
hemopoietic	O
lineage	O
commitment	O
.	O

In	O
addition	O
,	O
both	O
heat	O
and	O
cadmium	O
produced	O
an	O
increase	O
in	O
the	O
amount	O
of	O
the	O
intermediate	B-protein
filament	I-protein
protein	I-protein
vimentin	B-protein
,	O
as	O
determined	O
by	O
immunoblot	O
and	O
immunofluorescence	O
assays	O
.	O

Finally	O
,	O
the	O
inhibition	O
of	O
class	B-DNA
II	I-DNA
gene	I-DNA
expression	O
by	O
the	O
glucocorticoid	O
hormone	O
could	O
be	O
attributed	O
to	O
the	O
squelching	O
of	O
CBP	B-protein
by	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

Transfection	O
of	O
an	O
expression	B-DNA
vector	I-DNA
containing	O
ORF2	B-DNA
but	O
not	O
full	B-DNA
length	I-DNA
cDNA	I-DNA
was	O
able	O
to	O
transform	O
NIH3T3	B-cell_line
cells	I-cell_line
and	O
induce	O
tumors	O
in	O
nude	O
mice	O
.	O

Exposure	O
to	O
SFs	B-cell_type
during	O
priming	O
resulted	O
in	O
an	O
81	O
%	O
inhibition	O
of	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
-gamma	I-protein
,	O
but	O
not	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
4	I-protein
,	O
production	O
by	O
effector	B-cell_type
cells	I-cell_type
generated	O
in	O
priming	O
cultures	O
.	O

The	O
decreased	O
expression	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
indicates	O
that	O
the	O
ras	B-DNA
oncogene	I-DNA
blocks	O
terminal	O
differentiation	O
to	O
plasma	B-cell_type
cells	I-cell_type
,	O
possibly	O
by	O
inhibiting	O
the	O
activity	O
of	O
lymphocyte-specific	B-protein
transcription	I-protein
factors	I-protein
.	O

In	O
this	O
study	O
,	O
the	O
effects	O
of	O
flavonoids	O
on	O
NFkappaB	B-protein
/inhibitor-kappaB	O
(	O
IkappaB	B-protein
)	O
system	O
in	O
ECV304	B-cell_line
cells	I-cell_line
activated	O
with	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNFalpha	B-protein
)	O
were	O
examined	O
.	O

Therefore	O
,	O
we	O
additionally	O
investigated	O
other	O
transcription	B-protein
factors	I-protein
of	O
possible	O
importance	O
such	O
as	O
CREB	B-protein
,	O
CTF	B-protein
,	O
OTF-1	B-protein
,	O
and	O
OTF-2	B-protein
.	O

In	O
the	O
present	O
paper	O
plasma	O
membranes	O
from	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
were	O
covalently	O
photolabeled	O
with	O
a	O
[	O
125I	O
]	O
-aldosterone	O
derivative	O
.	O

Thus	O
,	O
reduced	O
levels	O
of	O
PKC	B-protein
-induced	O
nuclear	O
NF-kB	B-protein
activity	O
in	O
two	O
T	O
cell	O
subclones	O
did	O
not	O
affect	O
their	O
normal	O
cell	O
growth	O
,	O
but	O
correlated	O
with	O
a	O
pronounced	O
reduction	O
in	O
their	O
susceptibility	O
to	O
HIV-1	O
infection	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
on	O
mononuclear	B-cell_type
leukocytes	I-cell_type
in	O
Alzheimer	O
's	O
disease	O
.	O

HS	B-DNA
I	I-DNA
directs	O
high-level	O
expression	O
of	O
reporter	O
GATA-1/lacZ	B-DNA
genes	I-DNA
to	O
primitive	B-cell_type
and	I-cell_type
definitive	I-cell_type
erythroid	I-cell_type
cells	I-cell_type
and	O
megakaryocytes	B-cell_type
in	O
transgenic	O
mice	O
.	O

A	O
truncation	B-protein
mutant	I-protein
of	O
LEF-1	B-protein
(	O
HMG-88	B-protein
)	O
,	O
which	O
contains	O
the	O
HMG	B-protein
box	I-protein
but	O
lacks	O
the	O
trans-activation	B-protein
domain	I-protein
,	O
did	O
not	O
activate	O
transcription	O
from	O
nucleosomal	B-DNA
DNA	I-DNA
,	O
indicating	O
that	O
bending	O
of	O
DNA	O
by	O
the	O
HMG	B-protein
domain	I-protein
is	O
not	O
sufficient	O
to	O
activate	O
transcription	O
in	O
vitro	O
.	O

The	O
cytokines	O
interleukin-1	O
beta	O
(	O
IL-1	B-protein
beta	I-protein
)	O
and	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	B-protein
)	O
are	O
released	O
by	O
mononuclear	B-cell_type
phagocytes	I-cell_type
in	O
vitro	O
after	O
stimulation	O
with	O
mycobacteria	O
and	O
are	O
considered	O
to	O
mediate	O
pathophysiologic	O
events	O
,	O
including	O
granuloma	O
formation	O
and	O
systemic	O
symptoms	O
.	O

Northern	O
blot	O
analysis	O
as	O
well	O
as	O
Ab	O
blocking	O
and	O
cytokine	B-protein
secretion	O
studies	O
indicated	O
that	O
the	O
induction	O
of	O
either	O
endogenous	B-protein
TNF-alpha	I-protein
or	O
IL-10	B-protein
was	O
not	O
involved	O
in	O
the	O
cooperativity	O
,	O
nor	O
was	O
an	O
up-regulation	O
of	O
TNF-alpha	B-protein
receptors	I-protein
.	O

A	O
new	O
exon	B-DNA
containing	O
a	O
highly	O
basic	O
region	O
(	O
4c	O
)	O
was	O
characterized	O
,	O
between	B-DNA
exons	I-DNA
4	I-DNA
and	I-DNA
5	I-DNA
.	O

However	O
,	O
there	O
is	O
a	O
non-significant	O
trend	O
towards	O
a	O
down-regulation	O
of	O
hTR	B-RNA
beta	I-RNA
1	I-RNA
mRNA	I-RNA
levels	O
in	O
hyperthyroid	O
patients	O
.	O

Thus	O
,	O
EBV	O
binding	O
to	O
its	O
cellular	O
receptor	O
on	O
resting	O
B	O
cells	O
triggers	O
an	O
NF-kappaB	B-protein
-dependent	O
intracellular	O
signaling	O
pathway	O
which	O
is	O
required	O
for	O
infection	O
.	O

Staphylococcal	B-protein
enterotoxins	I-protein
(	O
SE	B-protein
)	O
stimulate	O
T	B-cell_type
cells	I-cell_type
expressing	O
the	O
appropriate	O
variable	B-protein
region	I-protein
beta	I-protein
chain	I-protein
of	I-protein
(	I-protein
V	I-protein
beta	I-protein
)	I-protein
T-cell	I-protein
receptors	I-protein
and	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
several	O
autoimmune	O
diseases	O
.	O

UV	O
cross-linking	O
experiments	O
suggested	O
that	O
a	O
distinct	O
E2F	B-protein
DNA-binding	O
protein	O
is	O
uniquely	O
associated	O
with	O
the	O
S-phase	B-protein
p107	I-protein
complex	I-protein
and	O
is	O
not	O
associated	O
with	O
Rb	B-protein
.	O

Now	O
,	O
we	O
report	O
the	O
solution	O
structure	O
of	O
the	O
sequence-specific	B-protein
HMG-box	I-protein
of	O
the	O
SRY-related	B-protein
protein	I-protein
Sox-4	B-protein
.	O

These	O
results	O
demonstrate	O
that	O
Rb	B-protein
interacts	O
specifically	O
with	O
a	O
lineage-restricted	B-protein
Ets	I-protein
transcription	I-protein
factor	I-protein
.	O

NF-kappa	B-protein
B	I-protein
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
.	O

Thrombin	B-protein
plays	O
a	O
critical	O
role	O
in	O
platelet	O
activation	O
,	O
hemostasis	O
,	O
and	O
thrombosis	O
.	O

Although	O
sensitivity	O
to	O
M-CSF	B-protein
can	O
be	O
modulated	O
by	O
regulation	O
of	O
receptor	O
expression	O
and	O
function	O
,	O
M-CSF	B-protein
responsiveness	O
is	O
largely	O
determined	O
at	O
a	O
postreceptor	O
level	O
.	O

These	O
features	O
are	O
very	O
different	O
from	O
those	O
observed	O
in	O
B104	B-cell_line
cell	I-cell_line
death	O
induced	O
by	O
anti-IgM	B-protein
Ab	I-protein
.	O

In	O
the	O
present	O
study	O
we	O
have	O
examined	O
the	O
immune	O
modulating	O
effects	O
of	O
RA	O
on	O
IL-2	B-RNA
mRNA	I-RNA
,	O
another	O
important	O
cytokine	B-protein
for	O
B	O
cell	O
immunoglobulin	B-protein
production	O
,	O
the	O
expression	O
of	O
IL-2	B-protein
receptors	I-protein
on	O
T	B-cell_type
cells	I-cell_type
,	O
and	O
the	O
RA	B-protein
nuclear	I-protein
receptors	I-protein
.	O

Somatic	O
hypermutation	O
is	O
the	O
most	O
critical	O
mechanism	O
underlying	O
the	O
diversification	O
of	O
Ig	B-DNA
genes	I-DNA
.	O

B-myb	B-protein
is	O
also	O
involved	O
in	O
the	O
control	O
of	O
proliferation	O
and	O
differentiation	O
,	O
but	O
,	O
unlike	O
c-myb	B-DNA
,	O
it	O
is	O
expressed	O
in	O
many	O
cell	O
types	O
.	O

The	O
Mpl	B-protein
receptor	I-protein
is	O
a	O
member	O
of	O
the	O
hematopoietin	B-protein
receptor	I-protein
superfamily	I-protein
lacking	O
intrinsic	O
kinase	O
activity	O
.	O

In	O
agreement	O
with	O
the	O
results	O
of	O
gel	O
retardation	O
assays	O
,	O
tandem	O
copies	O
of	O
the	O
E6	B-DNA
motif	I-DNA
stimulated	O
transcription	O
in	O
ARH77	B-cell_line
and	O
Raji	B-cell_line
cells	I-cell_line
but	O
not	O
in	O
Jurkat	B-cell_line
or	O
HeLa	B-cell_line
cells	I-cell_line
.	O

Monoclonal	B-protein
anti-endothelial	I-protein
cell	I-protein
antibodies	I-protein
from	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
activate	O
endothelial	O
cells	O
from	O
large	O
vessels	O
.	O

ATF/CREB	B-protein
and	O
Sp	B-protein
family	I-protein
members	I-protein
interacted	O
with	O
the	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
to	O
form	O
DNA-protein	B-protein
complexes	I-protein
common	O
to	O
all	O
cell	O
types	O
examined	O
.	O

No	O
lytic	O
effect	O
on	O
the	O
reporter	O
cells	O
could	O
be	O
measured	O
,	O
neither	O
by	O
cocultivation	O
of	O
activator	B-cell_line
cells	I-cell_line
nor	O
by	O
coincubation	O
of	O
BZLF	B-protein
1	I-protein
-containing	O
cell	O
lysates	O
.	O

When	O
freshly	O
isolated	O
,	O
highly	O
enriched	O
(	O
>	O
98	O
%	O
)	O
T	B-cell_type
cells	I-cell_type
are	O
examined	O
for	O
IFN-gamma	B-protein
responsiveness	O
;	O
these	O
cells	O
can	O
respond	O
to	O
IFN-gamma	B-protein
and	O
express	O
beta-chain	B-protein
.	O

Normal	O
human	B-cell_type
monocytes	I-cell_type
were	O
isolated	O
,	O
carefully	O
washed	O
,	O
and	O
incubated	O
for	O
36	O
to	O
48	O
h	O
in	O
fetal	O
bovine	O
serum-containing	O
medium	O
.	O

Rel/NF-kappa	B-protein
B	I-protein
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
that	O
consists	O
of	O
multiple	B-protein
polypeptide	I-protein
subunits	I-protein
,	O
and	O
is	O
subject	O
to	O
complex	O
regulatory	O
mechanisms	O
that	O
involve	O
protein-protein	O
interactions	O
,	O
phosphorylation	O
,	O
ubiquitination	O
,	O
proteolytic	O
degradation	O
,	O
and	O
nucleocytoplasmic	O
translocation	O
.	O

We	O
recently	O
reported	O
that	O
a	O
garlic	O
compound	O
,	O
S-allyl	O
cysteine	O
(	O
SAC	O
)	O
,	O
protects	O
bovine	B-cell_type
pulmonary	I-cell_type
artery	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
from	O
oxidant	O
injury	O
induced	O
by	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
.	O

These	O
lipid	O
mediators	O
increase	O
activity	O
of	O
transcription	B-protein
factors	I-protein
and	O
expression	O
of	O
cytokine	B-DNA
genes	I-DNA
indicating	O
a	O
function	O
for	O
cytosolic	B-protein
phospholipase	I-protein
A2	I-protein
in	O
signal	O
transduction	O
and	O
inflammation	O
.	O

We	O
have	O
determined	O
that	O
the	O
developmental	O
control	O
of	O
immunoglobulin	B-DNA
kappa	I-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
(	O
kappa	B-DNA
E3	I-DNA
'	I-DNA
)	O
activity	O
is	O
the	O
result	O
of	O
the	O
combined	O
influence	O
of	O
positive-	B-DNA
and	I-DNA
negative-acting	I-DNA
elements	I-DNA
.	O

All	O
mAECA	B-protein
possessed	O
high	O
activity	O
against	O
macrovascular	B-cell_line
EC	I-cell_line
,	O
but	O
none	O
had	O
significant	O
antimicrovascular	O
EC	O
activity	O
.	O

The	O
data	O
strongly	O
suggest	O
an	O
endocrine	O
,	O
autocrine	O
and/or	O
paracrine	O
role	O
for	O
calcitriol	O
in	O
immune	O
regulation	O
.	O

The	O
control	O
of	O
lytic	O
replication	O
of	O
Epstein-Barr	O
virus	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
(	O
Review	O
)	O
.	O

Some	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
were	O
stimulated	O
with	O
estradiol	O
,	O
PMA	O
,	O
and	O
ionomycin	O
.	O

However	O
,	O
the	O
response	O
to	O
HIV-1	B-protein
Tat	I-protein
by	O
a	O
LTR	B-DNA
in	O
which	O
the	O
interleukin	B-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
-2	I-DNA
homology	I-DNA
NFAT-1	I-DNA
region	I-DNA
was	O
mutated	O
resulted	O
in	O
almost	O
complete	O
elimination	O
of	O
suppression	O
by	O
CD8+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

These	O
data	O
are	O
well	O
in	O
line	O
with	O
the	O
long-standing	O
notion	O
that	O
interindividual	O
differences	O
in	O
platelet	B-protein
monoamine	I-protein
oxidase	I-protein
may	O
represent	O
differences	O
in	O
expression	O
of	O
the	O
enzyme	O
rather	O
than	O
genotypic	O
variation	O
.	O

This	O
pathway	O
involves	O
the	O
Rac1	B-protein
and	O
Cdc42	B-protein
GTPases	B-protein
,	O
two	O
enzymes	O
which	O
are	O
not	O
required	O
for	O
NF-kappaB	B-protein
activation	O
by	O
IL-1beta	B-protein
in	O
epithelial	B-cell_type
cells	I-cell_type
.	O

The	O
specificity	O
of	O
DNA	O
binding	O
by	O
cell-free	B-protein
synthesized	I-protein
hGR	I-protein
was	O
analyzed	O
further	O
by	O
examining	O
the	O
abilities	O
of	O
various	B-DNA
DNAs	I-DNA
to	O
compete	O
for	O
binding	O
to	O
a	O
naturally	O
occurring	O
GRE	B-DNA
found	O
in	O
the	O
mouse	B-DNA
mammary	I-DNA
tumor	I-DNA
virus-long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O

When	O
we	O
analyzed	O
the	O
nature	O
of	O
STAT	B-protein
proteins	I-protein
capable	O
of	O
binding	O
to	O
IL-2Ralpha	B-protein
,	O
pim-1	B-DNA
,	I-DNA
and	I-DNA
IRF-1	I-DNA
GAS	I-DNA
elements	I-DNA
after	O
cytokine	B-protein
stimulation	O
,	O
we	O
observed	O
IFN-alpha	B-protein
-induced	O
binding	O
of	O
STAT1	B-protein
,	O
STAT3	B-protein
,	O
and	O
STAT4	B-protein
,	O
but	O
not	O
STAT5	B-protein
to	O
all	O
of	O
these	O
elements	O
.	O

While	O
Jurkat	B-cell_line
cells	I-cell_line
both	O
secrete	O
and	O
respond	O
to	O
IFN-gamma	B-protein
in	O
an	O
autocrine	O
loop	O
,	O
it	O
seems	O
likely	O
that	O
the	O
responding	O
cells	O
may	O
differ	O
from	O
those	O
synthesizing	O
this	O
cytokine	B-protein
in	O
the	O
mononuclear	B-cell_line
cell	I-cell_line
cultures	I-cell_line
in	O
the	O
light	O
of	O
the	O
recent	O
report	O
that	O
Th1	B-cell_line
cells	I-cell_line
lack	O
the	O
IFN-gamma	B-protein
receptor	O
chain	O
necessary	O
for	O
activation	O
of	O
STAT1	B-protein
(	O
Pernis	O
,	O
A.	O
,	O
Gupta	O
,	O
S.	O
,	O
Gollob	O
,	O
K.J.	O
,	O
Garfein	O
,	O
E.	O
,	O
Coffman	O
,	O
R.L.	O
,	O
Schindler	O
,	O
C.	O
,	O
and	O
Rothman	O
,	O
P.	O
,	O
Science	O
1995.	O
269	O
:	O
245	O
)	O
.	O

Reversible	O
differentiation	O
of	O
human	B-cell_line
monoblastic	I-cell_line
leukemia	I-cell_line
U937	I-cell_line
cells	I-cell_line
by	O
ML-9	O
,	O
an	O
inhibitor	O
of	O
myosin	B-protein
light	I-protein
chain	I-protein
kinase	I-protein
.	O

Expression	O
of	O
DNA	O
in	O
reticulocyte	O
lysates	O
or	O
in	O
Escherichia	O
coli	O
yielded	O
a	O
protein	O
that	O
was	O
competent	O
for	O
both	O
DNA	O
binding	O
and	O
transcription	O
activation	O
.	O

T	B-cell_type
lymphocytes	I-cell_type
appeared	O
to	O
be	O
an	O
important	O
source	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
production	O
,	O
since	O
purified	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
all	O
patients	O
with	O
tuberculosis	O
produced	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
production	O
by	O
these	O
cells	O
correlated	O
closely	O
with	O
that	O
produced	O
by	O
unseparated	O
lavage	B-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
to	O
E1A-negative	B-cell_line
,	I-cell_line
parental	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
IFN	B-protein
-MCP	O
was	O
blocked	O
in	O
Ad5	O
E1A-transfected	B-cell_line
epithelial	I-cell_line
and	O
fibroblastic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Mycoplasma	O
fermentans-derived	O
high-molecular-weight	O
material	O
(	O
MDHM	O
)	O
was	O
originally	O
described	O
to	O
induce	O
differentiation	O
of	O
murine	B-cell_type
thymocytes	I-cell_type
to	O
cytolytic	B-cell_type
effector	I-cell_type
T-cells	I-cell_type
by	O
stimulating	O
IL-6	B-protein
release	O
from	O
adherent	B-cell_type
cells	I-cell_type
.	O

However	O
,	O
the	O
cells	O
obtained	O
from	O
IL-2	B-protein
-treated	O
patients	O
did	O
not	O
have	O
low-level	O
constitutive	O
expression	O
of	O
STAT	B-protein
binding	I-protein
factors	I-protein
as	O
did	O
LAK	B-protein
cells	I-protein
.	O

The	O
conserved	O
TRAF3	B-DNA
binding	I-DNA
sites	I-DNA
in	O
LMP1	B-protein
and	O
the	O
CD30	B-protein
Hodgkin	I-protein
's	I-protein
disease	I-protein
marker	I-protein
provides	O
further	O
evidence	O
that	O
a	O
TRAF3	B-protein
-mediated	O
signal	O
transduction	O
pathway	O
may	O
be	O
important	O
in	O
malignant	O
transformation	O
.	O

The	O
expression	O
of	O
an	O
active	O
PKB	B-protein
is	O
sufficient	O
to	O
induce	O
E2F	B-protein
activity	O
.	O

Those	O
cytokines	B-protein
may	O
modulate	O
the	O
differentiation	O
of	O
monocytes	B-cell_type
by	O
CSFs	B-protein
.	O

In	O
situ	O
immunolabelling	O
revealed	O
that	O
upregulation	O
of	O
protein	O
expression	O
by	O
IFN-alpha	B-protein
is	O
a	O
consequence	O
of	O
a	O
marked	O
increase	O
in	O
both	O
the	O
number	O
and	O
the	O
intensity	O
of	O
the	O
staining	O
of	O
so-called	O
PML	B-protein
nuclear	I-protein
bodies	I-protein
.	O

The	O
initiation	O
of	O
this	O
growth	O
transforming	O
infection	O
depends	O
on	O
a	O
viral	B-DNA
promoter	I-DNA
in	O
BamHI	O
W	O
(	O
Wp	O
)	O
whose	O
regulation	O
is	O
poorly	O
understood	O
.	O

Oct-2	B-RNA
mRNA	I-RNA
induction	O
during	O
antigen-driven	O
T-cell	B-cell_type
activation	O
was	O
blocked	O
by	O
cyclosporin	O
A	O
,	O
as	O
well	O
as	O
by	O
protein	O
synthesis	O
inhibitors	O
.	O

Surrogate	O
thyroglobulin	B-protein
receptors	I-protein
and	O
T	O
cell	O
proliferation	O
in	O
Hashimoto	O
's	O
thyroiditis	O
.	O

In	O
two	O
patients	O
,	O
VDR	B-protein
was	O
increased	O
after	O
daily	O
phosphate	O
supplementation	O
was	O
started	O
.	O

We	O
have	O
investigated	O
the	O
role	O
that	O
C/EBP	B-protein
proteins	I-protein
play	O
in	O
induction	O
and	O
replication	O
of	O
HIV-1	O
.	O

Site-directed	O
mutagenesis	O
demonstrated	O
that	O
these	O
TRAF	B-protein
binding	I-protein
sites	I-protein
exhibited	O
selective	O
binding	O
for	O
different	O
TRAF	B-protein
proteins	I-protein
.	O

In	O
this	O
study	O
we	O
examined	O
the	O
influence	O
of	O
local	O
estrogen	O
metabolism	O
on	O
the	O
differentiation	O
of	O
HL60	B-cell_line
cells	I-cell_line
and	O
normal	O
primitive	O
myeloid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

Deactivation	O
of	O
mononuclear	B-cell_type
phagocytes	I-cell_type
is	O
critical	O
to	O
limit	O
the	O
inflammatory	O
response	O
but	O
can	O
be	O
detrimental	O
in	O
the	O
face	O
of	O
progressive	O
infection	O
.	O

CONCLUSION	O
:	O
We	O
suggest	O
that	O
Oct1	B-protein
,	O
YY1	B-protein
,	O
and	O
octamer-like	B-protein
factors	I-protein
binding	O
to	O
the	O
-90/-79	B-DNA
sequence	I-DNA
within	O
the	O
proximal	B-DNA
IL-5	I-DNA
promoter	I-DNA
are	O
involved	O
in	O
suppression	O
of	O
IL-5	B-protein
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
DBF	B-DNA
site	I-DNA
is	O
an	O
interferon-responsive	B-DNA
factor	I-DNA
(	I-DNA
IRF	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
and	O
that	O
the	O
AP3-L	B-DNA
motif	I-DNA
binds	O
the	O
T-cell-specific	B-protein
factor	I-protein
NF-AT	B-protein
.	O

Glucocorticoid	B-protein
receptors	I-protein
,	O
fibromyalgia	O
and	O
low	O
back	O
pain	O
.	O

The	O
study	O
of	O
NF-kappaB	B-protein
showed	O
that	O
oxLDLs	B-protein
led	O
to	O
a	O
decrease	O
of	O
activation-induced	B-protein
p65/p50	I-protein
NF-kappaB	B-protein
heterodimer	O
binding	O
to	O
DNA	O
,	O
whereas	O
the	O
presence	O
of	O
the	O
constitutive	O
nuclear	O
form	O
of	O
p50	B-protein
dimer	I-protein
was	O
unchanged	O
.	O

Tyrosine	O
phosphorylation	O
of	O
IFN-gammaR	B-protein
,	O
Jak1	B-protein
,	O
Jak2	B-protein
,	O
and	O
Stat1alpha	B-protein
was	O
examined	O
by	O
immunoblotting	O
.	O

Synergistic	O
transactivation	O
of	O
the	O
LPS	B-DNA
response	I-DNA
element	I-DNA
in	O
Drosophila	B-cell_line
Schneider	I-cell_line
cells	I-cell_line
by	O
coexpression	O
of	O
c-Fos	B-protein
,	O
c-Jun	B-protein
,	O
c-Rel	B-protein
,	O
and	O
p65	B-protein
or	O
c-Jun	B-protein
and	O
p65	B-protein
required	O
the	O
transactivation	B-protein
domains	I-protein
of	O
c-Jun	B-protein
and	O
p65	B-protein
.	O

However	O
,	O
inhibition	O
of	O
HIV-1	O
replication	O
appears	O
not	O
to	O
be	O
directly	O
correlated	O
with	O
GSH	O
levels	O
.	O

H2O2-induced	O
nuclear	O
translocation	O
of	O
STAT3	B-protein
to	O
form	O
sequence-specific	B-protein
DNA-bound	I-protein
complexes	I-protein
was	O
evidenced	O
by	O
immunoblotting	O
of	O
nuclear	O
fractions	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
and	O
vanadate	O
was	O
found	O
to	O
strongly	O
synergize	O
with	O
H2O2	O
.	O

A	O
distinctive	O
pattern	O
of	O
differentially	O
expressed	O
cDNAs	B-DNA
is	O
evident	O
where	O
macrophage-specific	B-DNA
cDNAs	I-DNA
are	O
homologous	O
to	O
genes	O
encoding	O
cytoskeletal	B-protein
and	I-protein
cell-surface	I-protein
proteins	I-protein
,	O
whereas	O
the	O
DC	B-cell_type
-specific	O
cDNAs	B-DNA
are	O
homologous	O
to	O
signaling	B-DNA
,	I-DNA
chemokine	I-DNA
,	I-DNA
and	I-DNA
IFN-gamma-inducible	I-DNA
genes	I-DNA
.	O

CD	O
patients	O
are	O
victimized	O
by	O
this	O
self-distructed	O
immune	O
response	O
because	O
of	O
inheritance	O
of	O
certain	O
combinations	O
of	O
HLA-DQ	O
and	O
DR	O
haplotypes	O
.	O

It	O
has	O
been	O
proposed	O
that	O
the	O
cross-priming	O
of	O
CTL	O
responses	O
in	O
vivo	O
involves	O
the	O
transfer	O
to	O
host	O
APCs	B-cell_type
of	O
heat	B-protein
shock	I-protein
protein	I-protein
glycoprotein	I-protein
96	I-protein
-chaperoned	O
antigenic	O
peptides	O
released	O
from	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
of	O
dying	B-cell_type
or	I-cell_type
infected	I-cell_type
cells	I-cell_type
.	O

Similar	O
glucocorticoid-mediated	O
potentiation	O
was	O
observed	O
with	O
5-day	O
M	O
phi	O
uptake	O
of	O
alternative	O
apoptotic	O
``	O
targets	O
''	O
(	O
eosinophils	B-cell_type
and	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
)	O
and	O
in	O
uptake	O
of	O
apoptotic	B-cell_type
neutrophils	I-cell_type
by	O
alternative	O
phagocytes	B-cell_type
(	O
human	B-cell_type
glomerular	I-cell_type
mesangial	I-cell_type
cells	I-cell_type
and	O
murine	B-cell_line
M	I-cell_line
phi	I-cell_line
elicited	O
into	O
the	O
peritoneum	O
or	O
derived	O
from	O
bone	O
marrow	O
)	O
.	O

HLA	O
binding	O
characteristics	O
and	O
generation	O
of	O
cytotoxic	B-cell_type
lymphocytes	I-cell_type
against	O
peptides	O
derived	O
from	O
oncogenic	B-protein
proteins	I-protein
.	O

Heterokaryons	B-cell_line
formed	O
by	O
the	O
fusion	O
of	O
anergic	B-cell_type
murine	I-cell_type
T	I-cell_type
cells	I-cell_type
to	O
normal	B-cell_type
murine	I-cell_type
T	I-cell_type
cells	I-cell_type
also	O
failed	O
to	O
accumulate	O
intracellular	B-protein
IL-2	I-protein
protein	I-protein
in	O
response	O
to	O
stimulation	O
either	O
with	O
the	O
combination	O
of	O
CD3	B-protein
and	O
CD28	B-protein
mAbs	I-protein
or	O
with	O
ionomycin	O
plus	O
a	O
protein	B-protein
kinase	I-protein
C	I-protein
-activating	O
phorbol	O
ester	O
.	O

Consistent	O
with	O
the	O
role	O
of	O
NF-kappaB	B-protein
in	O
mediating	O
dopamine	O
responsiveness	O
,	O
the	O
proteasome	O
inhibitor	O
MG132	O
abolished	O
dopamine-induced	O
transcriptional	O
activation	O
.	O

A	O
highly	O
conserved	O
19-bp	O
element	O
located	O
immediately	O
5	O
'	O
of	O
the	O
human	B-DNA
GM-CSF	I-DNA
TATA	I-DNA
box	I-DNA
(	O
bp	B-DNA
-34	I-DNA
to	I-DNA
-52	I-DNA
)	O
,	O
herein	O
called	O
purine	B-DNA
box	I-DNA
1	I-DNA
(	O
PB1	B-DNA
)	O
,	O
has	O
been	O
shown	O
to	O
bind	O
a	O
T-cell	B-protein
nuclear	I-protein
protein	I-protein
complex	I-protein
and	O
to	O
be	O
required	O
for	O
transcriptional	O
induction	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
following	O
T-cell	O
activation	O
.	O

We	O
compared	O
glucocorticoid	O
receptor	O
binding	O
characteristics	O
and	O
glucocorticoid	O
responsiveness	O
of	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
(	O
HML	B-cell_type
)	O
from	O
hypertensive	O
patients	O
and	O
matched	O
normotensive	O
volunteers	O
.	O

Stimulation	O
of	O
PPARgamma	B-protein
with	O
troglitazone	O
or	O
15-deoxy-delta12	O
,	O
14-prostaglandin	O
J2	O
in	O
human	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
inhibited	O
MMP-9	B-protein
gelatinolytic	O
activity	O
in	O
a	O
concentration-dependent	O
fashion	O
as	O
revealed	O
by	O
zymography	O
.	O

These	O
markers	O
will	O
be	O
useful	O
to	O
study	O
the	O
role	O
of	O
genetic	O
variation	O
in	O
these	O
genes	O
in	O
the	O
pathogenesis	O
of	O
type	O
2	O
diabetes	O
.	O

We	O
demonstrate	O
here	O
the	O
interaction	O
of	O
RANK	B-protein
with	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
factors	I-protein
(	I-protein
TRAFs	I-protein
)	I-protein
1	I-protein
,	I-protein
2	I-protein
,	I-protein
3	I-protein
,	I-protein
5	I-protein
,	I-protein
and	I-protein
6	I-protein
both	O
in	O
vitro	O
and	O
in	O
cells	O
.	O

Induction	O
of	O
phosphatidylinositol	O
turnover	O
and	O
EGR-1	B-RNA
mRNA	I-RNA
expression	O
by	O
crosslinking	O
of	O
surface	O
IgM	B-protein
and	O
IgD	B-protein
in	O
the	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
B104	I-cell_line
.	O

Molecular	O
mechanisms	O
of	O
neutrophil-endothelial	O
cell	O
adhesion	O
induced	O
by	O
redox	O
imbalance	O
.	O

Peptidoglycan	O
(	O
PGN	O
)	O
,	O
the	O
major	O
cell	O
wall	O
component	O
of	O
Gram-positive	O
bacteria	O
,	O
induces	O
secretion	O
of	O
cytokines	B-protein
in	O
macrophages	B-cell_type
through	O
CD14	B-protein
,	O
the	O
pattern	O
recognition	O
receptor	O
that	O
binds	O
lipopolysaccharide	O
and	O
other	O
microbial	O
products	O
.	O

Except	O
for	O
the	O
conserved	O
zinc-finger	B-protein
domains	I-protein
,	O
the	O
amino	B-protein
acid	I-protein
sequences	I-protein
of	O
the	O
three	O
proteins	O
are	O
distinct	O
.	O

Furthermore	O
,	O
the	O
dose	O
of	O
OKT3	B-protein
required	O
to	O
achieve	O
half-maximal	O
activation	O
was	O
the	O
same	O
using	O
PMA	O
or	O
different	O
concentrations	O
of	O
alpha	B-protein
4	I-protein
beta	I-protein
1	I-protein
ligands	O
.	O

Thus	O
,	O
RFX5	B-protein
can	O
activate	O
transcription	O
only	O
in	O
cooperation	O
with	O
CIITA	B-protein
.	O

TCDD	O
mediates	O
atrophy	O
induction	O
through	O
its	O
specific	O
receptor	O
(	O
the	O
AhR	B-protein
)	O
and	O
not	O
through	O
effects	O
on	O
the	O
estrogen	O
receptor	O
.	O

Human	B-cell_type
T	I-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
demonstrate	O
an	O
early	O
and	O
transient	O
hyperpolarization	O
after	O
ligand	O
binding	O
.	O

Accordingly	O
,	O
increased	O
AP-1	B-protein
DNA-binding	O
activity	O
and	O
AP-1	B-protein
-dependent	O
transcriptional	O
activity	O
were	O
detected	O
exclusively	O
in	O
IL-2-stimulated	B-cell_line
cells	I-cell_line
.	O

During	O
fetal	O
development	O
,	O
it	O
is	O
required	O
at	O
the	O
earliest	O
stage	O
of	O
T	O
cell	O
and	O
B	O
cell	O
specification	O
.	O

Co-infection	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
HIV-1	O
and	O
HHV-6	O
can	O
lead	O
to	O
both	O
activation	O
of	O
the	O
HIV-1	B-DNA
promoter	I-DNA
and	O
acceleration	O
of	O
the	O
cytopathic	O
effects	O
.	O

We	O
now	O
report	O
that	O
dimers	O
consisting	O
of	O
p50	B-protein
NFkappaB1	I-protein
,	O
p65	B-protein
RelA	I-protein
,	O
and/or	O
c-Rel	B-protein
are	O
present	O
in	O
neutrophils	B-cell_type
and	O
that	O
the	O
greater	O
part	O
of	O
these	O
protein	B-protein
complexes	I-protein
is	O
physically	O
associated	O
with	O
cytoplasmic	B-protein
IkappaB-alpha	I-protein
in	O
resting	O
cells	O
.	O

Analysis	O
of	O
the	O
predicted	O
amino	O
acid	O
sequence	O
suggests	O
that	O
overall	O
protein	B-protein
structure	I-protein
is	O
conserved	O
,	O
but	O
the	O
receptor	O
binding	O
sites	O
are	O
not	O
.	O

We	O
infer	O
that	O
the	O
murine	B-protein
and	I-protein
human	I-protein
GATA-3	I-protein
proteins	I-protein
play	O
a	O
central	O
and	O
highly	O
conserved	O
role	O
in	O
vertebrate	O
T-cell-specific	O
transcriptional	O
regulation	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
provide	O
further	O
evidence	O
for	O
a	O
dysregulation	O
of	O
the	O
HPA	O
axis	O
in	O
PTSD	O
.	O

The	O
in	O
vitro	O
immunization	O
of	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
four	O
patients	O
in	O
remission	O
(	O
S.R.	O
,	O
F.R.	O
,	O
M.M.	O
,	O
P.	O
G.	O
)	O
with	O
BCR1/25	O
,	O
a	O
25-mer	O
pml/	O
RAR-alpha	B-protein
,	O
did	O
not	O
elicit	O
either	O
a	O
polyclonal	O
or	O
a	O
clonal	O
immune	O
response	O
specific	O
to	O
the	O
peptide	O
.	O

The	O
T	O
cell	O
tyrosine	O
kinase	B-protein
ZAP-70	I-protein
was	O
found	O
to	O
be	O
highly	O
responsive	O
to	O
UV	O
and	O
H2O2	O
treatment	O
.	O

YY1	B-protein
,	O
a	O
widely	O
distributed	O
human	B-protein
transcription	I-protein
factor	I-protein
,	O
is	O
known	O
to	O
inhibit	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
transcription	O
and	O
virus	O
production	O
.	O

P-LPS-induced	O
expression	O
of	O
the	O
monocyte	B-DNA
chemoattractant	I-DNA
protein	I-DNA
1	I-DNA
(	I-DNA
MCP-1	I-DNA
)	I-DNA
gene	I-DNA
in	O
the	O
cells	O
was	O
inhibited	O
markedly	O
by	O
treatment	O
with	O
anti-human	O
CD14	B-protein
antibody	O
and	O
was	O
completely	O
inhibited	O
by	O
herbimycin	O
A	O
,	O
a	O
potent	O
inhibitor	O
of	O
tyrosine	B-protein
kinase	I-protein
.	O

Oxidative	O
stress	O
triggers	O
STAT3	B-protein
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

A	O
TBP	O
mutant	O
defective	O
in	O
interaction	O
with	O
TBP-associated	B-protein
factor	I-protein
TAFII250	B-protein
also	O
failed	O
to	O
mediate	O
transactivation	O
through	O
the	O
CIITA	B-protein
activation	I-protein
domain	I-protein
.	O

Both	O
complexes	O
were	O
critically	O
dependent	O
on	O
the	O
NF-AT	B-DNA
core	I-DNA
sequence	I-DNA
TTTCC	O
in	O
the	O
E1	B-DNA
element	I-DNA
and	O
were	O
partially	O
supershifted	O
by	O
anti-NF-ATp	B-protein
.	O

Blocking	O
mAbs	B-protein
against	O
CD18	B-protein
and	O
CD11b	B-protein
abrogated	O
fibrinogen	B-protein
-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Two	O
sets	O
of	O
nested	B-DNA
primers	I-DNA
were	O
designed	O
to	O
conserved	O
sequences	O
in	O
the	O
adenovirus	B-DNA
E1A	I-DNA
and	I-DNA
hexon	I-DNA
genes	I-DNA
.	O

Viral	B-protein
trans-activators	I-protein
such	O
as	O
Tax	B-protein
(	O
human	O
T	O
cell	O
leukemia	O
virus-1	O
,	O
HTLV-1	O
)	O
and	O
E2	B-protein
(	O
bovine	O
papilloma	O
virus	O
,	O
BPV	O
)	O
proteins	O
are	O
other	O
agents	O
which	O
activate	O
lymphokine	B-DNA
gene	I-DNA
expression	O
by	O
bypassing	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
mediated	O
signaling	O
.	O

When	O
NK	B-cell_type
cells	I-cell_type
were	O
costimulated	O
with	O
IL-13	B-protein
and	O
IL-2	B-protein
,	O
IL-13	B-protein
generally	O
resulted	O
in	O
two	O
types	O
of	O
reactivity	O
:	O
IL-13	B-protein
synergized	O
with	O
IL-2	B-protein
to	O
stimulate	O
IFN-gamma	B-protein
production	O
or	O
it	O
modestly	O
inhibited	O
IL-2	B-protein
-mediated	O
IFN-gamma	B-protein
production	O
.	O

Each	O
volunteer	O
performed	O
these	O
exercise	O
twice	O
,	O
following	O
either	O
an	O
intravenous	O
injection	O
of	O
phosphocreatine	O
(	O
PCr	O
)	O
or	O
a	O
placebo	O
of	O
an	O
isotonic	O
NaCl	O
solution	O
.	O

Cobalt	O
chloride-induced	O
signaling	O
in	O
endothelium	O
leading	O
to	O
the	O
augmented	O
adherence	O
of	O
sickle	B-cell_type
red	I-cell_type
blood	I-cell_type
cells	I-cell_type
and	O
transendothelial	O
migration	O
of	O
monocyte-like	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
is	O
blocked	O
by	O
PAF-receptor	O
antagonist	O
.	O

Although	O
the	O
CD8+	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
response	O
to	O
latently	B-cell_type
infected	I-cell_type
cells	I-cell_type
is	O
well	O
characterized	O
,	O
very	O
little	O
is	O
known	O
about	O
T	O
cell	O
controls	O
over	O
lytic	O
infection	O
;	O
this	O
imbalance	O
in	O
our	O
understanding	O
belies	O
the	O
importance	O
of	O
virus-replicative	O
lesions	O
in	O
several	O
aspects	O
of	O
EBV	O
disease	O
pathogenesis	O
.	O

We	O
also	O
tested	O
for	O
the	O
ability	O
of	O
defensins	B-protein
NP-1	B-protein
,	O
NP-5	B-protein
,	O
and	O
HNP-1	B-protein
to	O
activate	O
pag	B-DNA
expression	O
and	O
found	O
that	O
these	O
peptides	O
have	O
no	O
effect	O
.	O

One	O
consequence	O
of	O
MEF2C	B-protein
activation	O
is	O
increased	O
c-jun	B-DNA
gene	I-DNA
transcription	O
.	O

These	O
sequences	O
were	O
chosen	O
for	O
study	O
because	O
mass-spectrometric	O
analysis	O
(	O
MS	O
)	O
of	O
a	O
CTL	B-cell_type
active	O
HPLC	O
peptide	O
fraction	O
eluted	O
from	O
immunoaffinity	B-protein
precipitated	I-protein
HLA-A2	I-protein
molecule	I-protein
,	O
revealed	O
:	O
(	O
a	O
)	O
the	O
presence	O
of	O
an	O
ion	O
with	O
a	O
mass-to-charge	O
ratio	O
(	O
m/z	O
)	O
of	O
793	O
which	O
was	O
more	O
abundant	O
than	O
other	O
ions	O
of	O
similar	O
masses	O
;	O
(	O
b	O
)	O
the	O
tentatively	O
reconstituted	O
sequence	O
of	O
the	O
ion	O
793	O
matched	O
the	O
sequence	O
of	O
peptide	O
G76	O
.	O

In	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
a	O
human	O
T-cell	B-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
induces	O
NF	B-protein
kappaB	I-protein
activation	O
that	O
is	O
inhibited	O
by	O
PDTC	O
.	O

A	O
PMA	B-DNA
responsive	I-DNA
element	I-DNA
was	O
localized	O
to	O
a	O
region	O
between	O
-95	B-DNA
and	I-DNA
-36	I-DNA
bp	I-DNA
relative	O
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
.	O

These	O
results	O
indicate	O
that	O
PGG-Glucan	O
enhances	O
neutrophil	O
anti-microbial	O
functions	O
and	O
that	O
interaction	O
between	O
this	O
beta-glucan	O
and	O
human	B-cell_type
neutrophils	I-cell_type
is	O
mediated	O
by	O
the	O
glycosphingolipid	O
lactosylceramide	O
present	O
at	O
the	O
cell	O
surface	O
.	O

These	O
results	O
are	O
consistent	O
with	O
a	O
model	O
for	O
cell-type	O
specific	O
regulation	O
in	O
which	O
binding	O
of	O
the	O
NF-muNR	B-protein
repressor	I-protein
to	O
the	O
IgH	B-DNA
enhancer	I-DNA
prevents	O
nuclear	O
matrix	O
attachment	O
in	O
inappropriate	O
cells	O
by	O
interfering	O
with	O
MAR-BP1	B-protein
/enhancer	B-DNA
interaction	O
.	O

Furthermore	O
,	O
the	O
significance	O
of	O
the	O
present	O
study	O
is	O
that	O
the	O
T	B-cell_type
cells	I-cell_type
,	O
not	O
the	O
antigen-presenting	B-cell_type
cells	I-cell_type
,	O
are	O
likely	O
to	O
be	O
the	O
limiting	O
element	O
in	O
the	O
T	O
cell	O
proliferative	O
response	O
to	O
TG	B-protein
and	O
other	O
thyroid	B-protein
autoantigens	I-protein
.	O

The	O
most	O
likely	O
interpretation	O
of	O
our	O
results	O
is	O
that	O
both	O
the	O
ubiquitous	O
transcription	B-protein
factor	I-protein
,	O
OTF-1	B-protein
,	O
and	O
the	O
B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
,	O
OTF-2	B-protein
,	O
can	O
activate	O
U2	B-RNA
snRNA	I-RNA
transcription	O
.	O

Ionizing	O
radiation	O
triggers	O
a	O
signal	O
in	O
human	B-cell_type
B-lymphocyte	I-cell_type
precursors	I-cell_type
that	O
is	O
intimately	O
linked	O
to	O
an	O
active	O
protein-tyrosine	B-protein
kinase	I-protein
regulatory	O
pathway	O
.	O

Here	O
,	O
Stuart	O
Schreiber	O
and	O
Gerald	O
Crabtree	O
review	O
recent	O
findings	O
that	O
indicate	O
CsA	O
and	O
FK506	O
operate	O
as	O
prodrugs	O
:	O
they	O
bind	O
endogenous	B-protein
intracellular	I-protein
receptors	I-protein
,	O
the	O
immunophilins	B-protein
,	O
and	O
the	O
resulting	O
complex	O
targets	O
the	O
protein	B-protein
phosphatase	I-protein
,	I-protein
calcineurin	B-protein
,	O
to	O
exert	O
the	O
immunosuppressive	O
effect	O
.	O

Two	O
peptides	O
,	O
P2	O
and	O
P8	O
,	O
induced	O
naive	O
T	O
cell	O
proliferation	O
less	O
effectively	O
and	O
were	O
also	O
less	O
immunogenic	O
for	O
T	B-cell_type
cells	I-cell_type
from	O
vaccinated	O
or	O
naturally	O
immune	O
donors	O
.	O

Our	O
study	O
suggests	O
that	O
the	O
interaction	O
of	O
Tax	B-protein
with	O
the	O
transcription	B-protein
factor	I-protein
TFIIA	B-protein
may	O
play	O
a	O
role	O
in	O
Tax	B-protein
-mediated	O
transcriptional	O
activation	O
.	O

The	O
characterization	O
of	O
these	O
proteins	O
in	O
human	B-cell_type
primary	I-cell_type
haemopoietic	I-cell_type
cells	I-cell_type
and	O
acute	B-cell_type
myeloid	I-cell_type
leukaemia	I-cell_type
(	I-cell_type
AML	I-cell_type
)	I-cell_type
blasts	I-cell_type
may	O
thus	O
give	O
an	O
insight	O
to	O
the	O
molecular	O
mechanisms	O
governing	O
proliferation	O
and	O
leukaemogenesis	O
in	O
these	O
cells	O
.	O

No	O
mutation	O
was	O
identified	O
in	O
either	O
of	O
the	O
genes	O
in	O
the	O
gynecomastias	O
.	O

The	O
modulation	O
of	O
glucocorticoid	B-protein
receptor	I-protein
content	O
by	O
3-O-methyl-D-glucose	O
transport	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocyte	I-cell_type
in	O
obesity	O
.	O

C-fos	B-DNA
has	O
been	O
reported	O
to	O
be	O
one	O
of	O
the	O
immediate	B-DNA
early	I-DNA
genes	I-DNA
in	O
signal	O
transduction	O
systems	O
after	O
many	O
kinds	O
of	O
stresses	O
,	O
including	O
ionizing	O
radiation	O
.	O

Corticosteroid	B-protein
receptors	I-protein
and	O
lymphocyte	B-cell_type
subsets	I-cell_type
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
in	O
aging	O
.	O

Eosinophils	B-cell_type
express	O
mRNA	B-RNA
for	O
GATA-1	B-protein
,	O
GATA-2	B-protein
,	O
and	O
GATA-3	B-protein
.	O

Whereas	O
c-Fos/c-Jun	B-protein
heterodimers	I-protein
do	O
not	O
exist	O
in	O
B	B-cell_line
cells	I-cell_line
,	O
they	O
form	O
and	O
bind	O
to	O
the	O
X2-box	B-DNA
in	O
class	B-cell_line
II	I-cell_line
nonexpressing	I-cell_line
cells	I-cell_line
.	O

Treatment	O
of	O
human	B-cell_type
erythrocytes	I-cell_type
with	O
10	O
microM	O
sodium	O
orthovanadate	O
(	O
NaOV	O
)	O
,	O
an	O
inhibitor	O
of	O
plasma	B-protein
membrane	I-protein
Ca-ATPase	I-protein
and	O
phosphotyrosine	B-protein
phosphatase	I-protein
,	O
decreased	O
parasitemia	O
by	O
30	O
%	O
.	O

In	O
contrast	O
,	O
CsA	O
inhibited	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
the	O
NF-AT	B-DNA
,	O
but	O
not	O
the	O
AP-1	B-DNA
and	O
NF-kB	B-DNA
plasmids	I-DNA
.	O

Severe	O
5-fluorouracil	O
toxicity	O
secondary	O
to	O
dihydropyrimidine	B-protein
dehydrogenase	I-protein
deficiency	O
.	O

The	O
cascade	O
of	O
events	O
within	O
the	O
first	O
few	O
minutes	O
of	O
T	B-cell_type
cell	I-cell_type
stimulation	O
has	O
been	O
well	O
characterized	O
.	O

Moreover	O
,	O
RA	O
induced	O
apoptosis	O
of	O
CD34+	B-cell_type
cells	I-cell_type
and	O
CD34+CD71+	B-cell_type
cells	I-cell_type
stimulated	O
with	O
erythropoietin	B-protein
.	O

Rhabdomyosarcomas	O
do	O
not	O
contain	O
mutations	O
in	O
the	O
DNA	O
binding	O
domains	O
of	O
myogenic	O
transcription	B-protein
factors	I-protein
.	O

However	O
,	O
the	O
mechanisms	O
involved	O
in	O
the	O
activation	O
of	O
AP-1	B-protein
by	O
antioxidants	O
are	O
largely	O
unknown	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
Egr-1	B-RNA
mRNA	I-RNA
activating	O
signals	O
through	O
sIgM	B-protein
and	O
sIgD	B-protein
are	O
protein	O
tyrosine	O
kinase-	O
and	O
PKC-dependent	O
,	O
but	O
protein	B-protein
kinase	I-protein
A	I-protein
-independent	O
.	O

Biologic	O
effects	O
of	O
IL-13	B-protein
on	O
primary	B-cell_type
human	I-cell_type
NK	I-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
have	O
not	O
been	O
well	O
defined	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
the	O
non-steroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
activate	O
heat	B-protein
shock	I-protein
transcription	I-protein
factor	I-protein
(	O
HSF1	B-protein
)	O
from	O
a	O
latent	B-protein
cytoplasmic	I-protein
form	I-protein
to	O
a	O
nuclear	B-protein
,	I-protein
DNA	I-protein
binding	I-protein
state	I-protein
.	O

Of	O
the	O
23	O
cases	O
,	O
19	O
were	O
classified	O
as	O
NK-cell	O
and	O
4	O
as	O
T-cell	O
tumours	O
.	O

alpha	B-protein
4	I-protein
beta	I-protein
1	I-protein
ligation	O
alone	O
had	O
no	O
effect	O
on	O
transcription	B-protein
factor	I-protein
binding	O
.	O

Recently	O
,	O
several	O
groups	O
have	O
described	O
marked	O
alterations	O
in	O
signal	O
transduction	O
elements	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
cancer	O
patients	O
or	O
in	O
mice	O
bearing	O
tumor	O
for	O
a	O
few	O
weeks	O
(	O
>	O
26	O
days	O
)	O
.	O

Epstein-Barr	O
virus	O
binding	O
to	O
CD21	B-protein
activates	O
the	O
initial	O
viral	B-DNA
promoter	I-DNA
via	O
NF-kappaB	B-protein
induction	O
.	O

These	O
data	O
show	O
that	O
neither	O
NF-kappa	B-protein
B	I-protein
nor	O
AP-1	B-protein
activation	O
is	O
required	O
for	O
IL-2	B-protein
-mediated	O
survival	O
or	O
cell	O
cycle	O
progression	O
in	O
activated	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
preliminary	O
studies	O
,	O
we	O
have	O
analyzed	O
the	O
hematopoietic	B-protein
growth	I-protein
factor	I-protein
(	O
HGF	B-protein
)	O
requirement	O
of	O
hematopoietic	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
(	O
HPCs	B-cell_type
)	O
purified	O
from	O
embryonic-fetal	O
liver	O
(	O
FL	O
)	O
and	O
grown	O
in	O
fetal	O
calf	O
serum-supplemented	O
(	O
FCS+	O
)	O
clonogenic	O
culture	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
pyruvate	B-DNA
kinase	I-DNA
erythroid-specific	I-DNA
promoter	I-DNA
.	O

The	O
bursa	O
of	O
Fabricius	O
is	O
a	O
gut-associated	O
lymphoid	O
organ	O
that	O
is	O
essential	O
for	O
the	O
generation	O
of	O
a	O
diversified	O
B	B-cell_type
cell	I-cell_type
repertoire	I-cell_type
in	O
the	O
chicken	O
.	O

Several	O
new	O
functions	O
of	O
Ras	B-protein
,	O
such	O
as	O
downregulation	O
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
molecules	I-protein
,	O
upregulation	O
of	O
certain	O
cytokines	B-protein
,	O
growth	B-protein
factors	I-protein
and	O
degradative	B-protein
enzymes	I-protein
have	O
been	O
uncovered	O
in	O
the	O
last	O
decade	O
.	O

Glucocorticoid-induced	O
apoptosis	O
and	O
regulation	O
of	O
NF-kappaB	B-protein
activity	O
in	O
human	B-cell_type
leukemic	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

We	O
show	O
that	O
the	O
constitutive	O
expression	O
of	O
the	O
T24	B-DNA
Ha-ras	I-DNA
oncogene	I-DNA
in	O
EBV-immortalized	B-cell_line
B	I-cell_line
lymphoblasts	I-cell_line
was	O
associated	O
with	O
the	O
induction	O
of	O
the	O
interleukin	B-protein
2	I-protein
receptor	I-protein
alpha	I-protein
subunit	I-protein
,	O
with	O
an	O
impaired	O
immunoglobulin	B-DNA
gene	I-DNA
expression	O
,	O
altered	O
adhesion	O
properties	O
and	O
increased	O
survival	O
in	O
serum-free	O
medium	O
.	O

These	O
experiments	O
show	O
that	O
FGF-1	B-protein
stimulation	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
provides	O
a	O
second	O
signal	O
that	O
augments	O
TCR-mediated	O
IL-2	B-protein
production	O
.	O

To	O
test	O
whether	O
disordered	O
memory	B-cell_type
T	I-cell_type
cell	I-cell_type
differentiation	O
contributes	O
to	O
the	O
typical	O
Th1-dominated	O
chronic	O
inflammation	O
in	O
RA	O
we	O
investigated	O
differentiation	O
of	O
resting	B-cell_type
CD4+	I-cell_type
memory	I-cell_type
T	I-cell_type
cells	I-cell_type
in	O
patients	O
with	O
early	O
(	O
6	O
wk	O
to	O
12	O
mo	O
)	O
untreated	O
RA	O
and	O
in	O
age-	O
and	O
sex-matched	O
healthy	O
controls	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
the	O
results	O
of	O
competition	O
experiments	O
analyzing	O
the	O
normal	O
components	O
of	O
NF-AT	B-protein
showed	O
that	O
the	O
age-related	O
reductions	O
in	O
stimulus-dependent	O
NF-AT	B-protein
complexes	I-protein
corresponded	O
to	O
the	O
slow	O
migrating	O
complexes	O
that	O
were	O
composed	O
of	O
c-Fos/c-Jun	B-protein
AP-1	B-protein
.	O

CD80	B-protein
and	O
CD86	B-protein
are	O
not	O
equivalent	O
in	O
their	O
ability	O
to	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
CD28	B-protein
.	O

The	O
assessment	O
of	O
synovial	O
lymphocyte	O
reactivity	O
to	O
adenovirus	O
antigen	O
stimulation	O
was	O
undertaken	O
in	O
patients	O
with	O
persistent	O
or	O
recurrent	O
inflammatory	O
arthritis	O
.	O

For	O
purposes	O
of	O
comparison	O
,	O
microglia	B-cell_type
were	O
also	O
stimulated	O
with	O
bacterial	O
LPS	O
,	O
a	O
known	O
NF-kappa	B-protein
B	I-protein
inducer	O
.	O

The	O
processing	O
of	O
p105	B-protein
occurs	O
constitutively	O
in	O
vivo	O
but	O
can	O
be	O
markedly	O
enhanced	O
by	O
various	O
cellular	O
activation	O
agents	O
,	O
although	O
the	O
underlying	O
regulatory	O
mechanism	O
is	O
not	O
yet	O
clear	O
.	O

The	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
interacts	O
with	O
an	O
EBNA2	B-DNA
responsive	I-DNA
cis-element	I-DNA
of	O
the	O
terminal	B-DNA
protein	I-DNA
1	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

The	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
transforming	I-protein
protein	I-protein
LMP1	I-protein
appears	O
to	O
be	O
a	O
constitutively	B-protein
activated	I-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
(	O
TNFR	B-protein
)	O
on	O
the	O
basis	O
of	O
an	O
intrinsic	O
ability	O
to	O
aggregate	O
in	O
the	O
plasma	O
membrane	O
and	O
an	O
association	O
of	O
its	O
cytoplasmic	B-protein
carboxyl	I-protein
terminus	I-protein
(	O
CT	B-protein
)	O
with	O
TNFR-associated	B-protein
factors	I-protein
(	O
TRAFs	B-protein
)	O
.	O

The	O
pocket	B-protein
protein-E2F	I-protein
complexes	I-protein
are	O
convergence	O
points	O
for	O
cell	O
cycle	O
signaling	O
.	O

In	O
this	O
report	O
we	O
present	O
the	O
characterisation	O
of	O
NF-kappaB	B-protein
subunits	I-protein
engaged	O
in	O
complexes	O
binding	O
to	O
the	O
HIV-1	B-DNA
NF-kappaB	I-DNA
site	I-DNA
in	O
human	B-cell_line
8e51	I-cell_line
T-cells	I-cell_line
,	O
that	O
harbour	O
a	O
defective	O
HIV-1	O
.	O

Coexpression	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
and	O
Sp1	B-protein
transcription	B-protein
factors	I-protein
in	O
human	O
immunodeficiency	O
virus	O
1-induced	O
,	O
dendritic	O
cell-T-cell	O
syncytia	O
.	O

The	O
algorithm	O
was	O
constructed	O
with	O
the	O
aim	O
of	O
identifying	O
segments	O
in	O
Ag	B-protein
which	O
are	O
resistant	O
to	O
proteolytic	O
degradation	O
by	O
the	O
enzymes	O
cathepsin	B-protein
B	I-protein
,	I-protein
L	I-protein
,	I-protein
and	I-protein
D	I-protein
.	O

The	O
greater	O
selectivity	O
of	O
PF	O
,	O
compared	O
with	O
FK506	O
,	O
at	O
both	O
the	O
molecular	O
and	O
cellular	O
levels	O
may	O
prove	O
advantageous	O
in	O
manipulating	O
T	O
cell	O
responses	O
in	O
vivo	O
.	O

We	O
demonstrate	O
in	O
this	O
report	O
that	O
overexpression	O
of	O
an	O
activated	O
form	O
of	O
Rho	B-protein
enhances	O
AP-1	B-protein
activity	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
in	O
the	O
presence	O
of	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
but	O
activated	O
Rho	B-protein
(	O
V14Rho	B-protein
)	O
has	O
little	O
or	O
no	O
effect	O
on	O
NFAT	B-protein
,	O
Oct-1	B-protein
,	O
and	O
NF-kappaB	B-DNA
enhancer	I-DNA
element	I-DNA
activities	O
under	O
similar	O
conditions	O
.	O

Estrogen	B-protein
receptors	I-protein
are	O
found	O
on	O
vascular	B-cell_type
endothelial	I-cell_type
and	I-cell_type
smooth	I-cell_type
muscle	I-cell_type
cells	I-cell_type
;	O
their	O
expression	O
is	O
influenced	O
by	O
exposure	O
to	O
the	O
hormone	O
.	O

Molecular	O
cloning	O
and	O
functional	O
characterization	O
of	O
murine	B-protein
cDNA	I-protein
encoding	I-protein
transcription	I-protein
factor	I-protein
NFATc	B-protein
.	O

In	O
vivo	O
function	O
of	O
an	O
interleukin	B-protein
2	I-protein
receptor	I-protein
beta	I-protein
chain	I-protein
(	B-protein
IL-2Rbeta	I-protein
)	I-protein
/IL-4Ralpha	I-protein
cytokine	I-protein
receptor	I-protein
chimera	I-protein
potentiates	O
allergic	O
airway	O
disease	O
.	O

TRAF2	B-protein
is	O
a	O
signal	B-protein
transducing	I-protein
adaptor	I-protein
molecule	I-protein
which	O
binds	O
to	O
the	O
CD40	B-protein
cytoplasmic	I-protein
domain	I-protein
.	O

The	O
interaction	O
of	O
LMP1	B-protein
and	O
JAK3	B-protein
leads	O
to	O
the	O
enhanced	O
tyrosine	O
auto/transphosphorylation	O
of	O
JAK3	B-protein
within	O
minutes	O
after	O
crosslinking	O
of	O
a	O
conditional	O
NGF-R	B-protein
:	I-protein
LMP1	I-protein
chimera	I-protein
and	O
is	O
a	O
prerequisite	O
for	O
the	O
activation	O
of	O
STAT	B-protein
transcription	I-protein
factors	I-protein
.	O

Prevalence	O
of	O
aneuploidy	O
,	O
overexpressed	O
ER	B-protein
,	O
and	O
overexpressed	O
EGFR	B-protein
in	O
random	O
breast	O
aspirates	O
of	O
women	O
at	O
high	O
and	O
low	O
risk	O
for	O
breast	O
cancer	O
.	O

NF-kappa	B-protein
B	I-protein
activation	O
correlated	O
with	O
the	O
ability	O
of	O
CD40	B-protein
to	O
induce	O
Ab	O
secretion	O
and	O
the	O
up-regulation	O
of	O
ICAM-1	B-protein
and	O
LFA-1	B-protein
.	O

Dexamethasone	O
inhibits	O
binding	O
to	O
the	O
Ikaros	B-protein
and	O
AP-1	B-DNA
regulatory	I-DNA
elements	I-DNA
of	O
the	O
granzyme	B-DNA
B	I-DNA
promoter	I-DNA
.	O

In	O
situ	O
RT-PCR	O
detection	O
of	O
Epstein-Barr	B-RNA
virus	I-RNA
immediate-early	I-RNA
transcripts	I-RNA
in	O
CD4+	B-cell_type
and	I-cell_type
CD8+	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
the	O
expression	O
of	O
CD14	B-protein
in	O
human	B-cell_type
gingival	I-cell_type
fibroblasts	I-cell_type
and	O
to	O
show	O
that	O
the	O
signal-transducing	O
pathway	O
of	O
P-LPS	O
in	O
the	O
cells	O
is	O
mediated	O
by	O
CD14	B-protein
.	O

CONCLUSIONS	O
:	O
Levels	O
of	O
Rap1	B-protein
and	O
the	O
catalytic	B-protein
subunit	I-protein
of	O
cAMP-dependent	B-protein
protein	I-protein
kinase	I-protein
are	O
altered	O
in	O
the	O
platelets	B-cell_type
of	O
bipolar	O
patients	O
.	O

Ad2	O
infection	O
induced	O
transient	O
increase	O
in	O
the	O
mRNA	B-RNA
levels	O
for	O
TNF-alpha	B-protein
and	O
IL-1	B-protein
beta	I-protein
in	O
both	O
monocytes	B-cell_type
and	O
in	O
macrophages	B-cell_type
,	O
although	O
the	O
kinetics	O
of	O
the	O
transcription	O
was	O
slightly	O
different	O
.	O

mRNA	B-RNA
levels	O
for	O
IL-13R	B-protein
alpha1	I-protein
,	O
but	O
not	O
IL-4R	B-protein
alpha	I-protein
,	O
were	O
markedly	O
decreased	O
in	O
in	B-cell_line
vitro	I-cell_line
monocyte-derived	I-cell_line
macrophages	I-cell_line
(	O
MDMac	B-cell_line
)	O
,	O
and	O
with	O
increasing	O
time	O
of	O
monocytes	B-cell_type
in	O
culture	O
correlated	O
with	O
the	O
loss	O
of	O
IL-13	B-protein
regulation	O
of	O
lipopolysaccharide-induced	O
TNF-alpha	B-protein
production	O
.	O

Furthermore	O
,	O
ADT	O
treated	O
Wurzburg	B-cell_line
cells	I-cell_line
had	O
significantly	O
higher	O
glutathione	O
levels	O
as	O
compared	O
with	O
untreated	B-cell_type
cells	I-cell_type
.	O

Upon	O
cell	O
activation	O
,	O
displacement	O
of	O
the	O
autoinhibitory	B-protein
domain	I-protein
by	O
calmodulin	B-protein
binding	O
allows	O
NFAT	B-protein
to	O
bind	O
additionally	O
to	O
the	O
calcineurin	B-protein
active	I-protein
site	I-protein
,	O
thus	O
positioning	O
NFAT	B-protein
for	O
immediate	O
dephosphorylation	O
at	O
functional	O
phosphoserine	O
residues	O
.	O

Lymphoid	B-protein
enhancer-binding	I-protein
factor	I-protein
1	I-protein
(	O
LEF-1	B-protein
)	O
is	O
a	O
regulatory	B-protein
high	I-protein
mobility	I-protein
group	I-protein
(	I-protein
HMG	I-protein
)	I-protein
protein	I-protein
that	O
activates	O
the	O
T	B-DNA
cell	I-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
TCR	I-DNA
alpha	I-DNA
)	I-DNA
enhancer	I-DNA
in	O
a	O
context-restricted	O
manner	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

We	O
show	O
that	O
the	O
human	B-DNA
GATA3	I-DNA
gene	I-DNA
contains	O
six	O
exons	B-DNA
distributed	O
over	O
17	O
kb	O
of	O
DNA	O
.	O

These	O
foci	O
,	O
which	O
were	O
preferentially	O
found	O
adjacent	O
to	O
nucleoli	O
or	O
at	O
the	O
nuclear	O
periphery	O
,	O
did	O
not	O
represent	O
sites	O
of	O
active	O
transcription	O
or	O
binding	O
of	O
GATA-1	B-protein
to	O
consensus	B-DNA
sites	I-DNA
in	O
the	O
beta-globin	B-DNA
loci	I-DNA
.	O

In	O
the	O
absence	O
of	O
IL-3	B-protein
,	O
enforced	O
expression	O
of	O
the	O
human	B-DNA
NFIL3/E4BP4	I-DNA
cDNA	I-DNA
promoted	O
the	O
survival	O
but	O
not	O
the	O
growth	O
of	O
IL-3-dependent	B-cell_type
pro-B	I-cell_type
cells	I-cell_type
.	O

All	O
of	O
this	O
evidence	O
indicates	O
that	O
the	O
transcription	B-protein
factor	I-protein
BSAP	B-protein
may	O
not	O
only	O
play	O
an	O
important	O
role	O
in	O
B-cell	O
differentiation	O
but	O
also	O
in	O
neural	O
development	O
and	O
spermatogenesis	O
.	O

Results	O
from	O
this	O
study	O
indicate	O
that	O
soluble	O
,	O
heparin-like	O
GAGs	O
can	O
block	O
IFN-gamma	B-protein
-dependent	O
up-regulation	O
of	O
MCP-1	B-protein
production	O
by	O
cultured	B-cell_line
endothelial	I-cell_line
cells	I-cell_line
,	O
and	O
can	O
also	O
antagonize	O
the	O
leucocyte-activating	O
and	O
migration-promoting	O
properties	O
of	O
pre-existing	O
MCP-1	B-protein
.	O

Similar	O
kinetics	O
of	O
c-jun	B-DNA
induction	O
by	O
TPA	O
were	O
observed	O
in	O
human	B-cell_line
U-937	I-cell_line
and	O
THP-1	B-cell_line
monocytic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O

Thus	O
,	O
GATA-3	B-protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
balance	O
between	O
Th1	B-cell_type
and	O
Th2	B-cell_type
subsets	I-cell_type
in	O
immune	O
responses	O
.	O

Dominant	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocyte	I-cell_type
response	O
to	O
the	O
immediate-early	B-protein
trans-activator	I-protein
protein	I-protein
,	O
BZLF1	B-protein
,	O
in	O
persistent	O
type	O
A	O
or	O
B	O
Epstein-Barr	O
virus	O
infection	O
.	O

We	O
have	O
analyzed	O
several	O
molecular	O
aspects	O
of	O
IBR/F	B-protein
and	O
shown	O
that	O
the	O
factor	O
associates	O
as	O
stable	O
homodimers	B-protein
and	O
that	O
the	O
dimer	B-protein
is	O
the	O
relevant	B-protein
DNA-binding	I-protein
species	I-protein
.	O

Deletion	O
studies	O
revealed	O
that	O
the	O
CD95L	B-DNA
proximal	I-DNA
promoter	I-DNA
sequence	I-DNA
from	O
-220	B-DNA
to	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
is	O
essential	O
for	O
T	O
cell	O
stimulation-induced	O
expression	O
of	O
CD95L	B-protein
.	O

Impaired	O
binding	O
of	O
a	O
DQ2	B-protein
and	O
DQ8	B-protein
-binding	O
HSV	O
VP16	O
peptide	O
to	O
a	O
DQA1*0501/DQB1*0302	B-protein
trans	I-protein
class	I-protein
II	I-protein
heterodimer	I-protein
.	O

To	O
determine	O
if	O
platelet	O
thromboxane	B-protein
receptors	I-protein
are	O
under	O
transcriptional	O
control	O
,	O
we	O
isolated	O
and	O
characterized	O
human	B-DNA
genomic	I-DNA
DNA	I-DNA
clones	I-DNA
containing	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
thromboxane	B-DNA
receptor	I-DNA
gene	I-DNA
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
suggest	O
that	O
estrogen	O
modulates	O
the	O
monocyte	B-cell_type
numbers	O
and	O
its	O
effects	O
may	O
be	O
mediated	O
through	O
the	O
ER	B-protein
in	O
the	O
monocytes	B-cell_type
.	O

Differential	O
regulation	O
of	O
coproporphyrinogen	B-DNA
oxidase	I-DNA
gene	I-DNA
between	O
erythroid	B-cell_type
and	I-cell_type
nonerythroid	I-cell_type
cells	I-cell_type
.	O

The	O
presence	O
of	O
a	O
flagellum	O
was	O
not	O
required	O
for	O
binding	O
of	O
P.	O
aeruginosa	O
to	O
macrophages	B-cell_type
but	O
was	O
critical	O
for	O
the	O
subsequent	O
internalization	O
of	O
the	O
bacterium	O
,	O
suggesting	O
that	O
this	O
factor	O
or	O
a	O
surface	O
ligand	O
associated	O
with	O
its	O
assembly	O
was	O
responsible	O
for	O
stimulation	O
of	O
nonopsonic	O
phagocytosis	O
.	O

We	O
report	O
the	O
structure	O
and	O
regulation	O
of	O
a	O
gene	O
represented	O
by	O
clone	B-DNA
pAT	I-DNA
133	I-DNA
,	O
which	O
is	O
induced	O
upon	O
transition	O
from	O
a	O
resting	O
state	O
(	O
G0	O
)	O
through	O
the	O
early	O
phase	O
of	O
the	O
cell	O
cycle	O
(	O
G1	O
)	O
.	O

A	O
putative	O
function	O
of	O
BHRF1	B-protein
in	O
EBV-infected	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
may	O
be	O
to	O
protect	O
virus-infected	O
cells	O
from	O
TNF-	O
and/or	O
anti-Fas-	O
induced	O
cell	O
death	O
in	O
order	O
to	O
maximize	O
virus	O
production	O
.	O

First	O
,	O
anti-CD45	B-protein
antibodies	I-protein
did	O
not	O
affect	O
basal	O
but	O
decreased	O
activated	O
levels	O
of	O
expression	O
from	O
the	O
HIV-1	B-DNA
LTR	I-DNA
.	O

Here	O
we	O
show	O
that	O
the	O
response	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
may	O
be	O
governed	O
by	O
two	O
independent	O
sequences	O
located	O
5	O
'	O
to	O
the	O
site	O
of	O
transcription	O
initiation	O
sequences	O
that	O
bind	O
either	O
NFAT-1	B-protein
or	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O

Differential	O
regulation	O
of	O
IL-6	B-DNA
gene	I-DNA
transcription	O
and	O
expression	O
by	O
IL-4	B-protein
and	O
IL-10	B-protein
in	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

As	O
early	O
as	O
2	O
h	O
after	O
addition	O
of	O
the	O
inhibitor	O
to	O
the	O
culture	O
medium	O
,	O
there	O
was	O
an	O
inhibition	O
of	O
both	O
constitutive	O
activation	O
of	O
NF-kappaB	B-protein
and	O
HIV-1	O
genome	O
expression	O
.	O

A	O
single	O
point	O
assay	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	O
human	O
lymphocytes	B-cell_type
based	O
on	O
the	O
measurement	O
of	O
specific	O
dexamethasone	O
binding	O
has	O
been	O
developed	O
and	O
compared	O
with	O
a	O
common	O
multi-point	O
Scatchard	O
analysis	O
.	O

This	O
inhibition	O
was	O
not	O
mediated	O
through	O
Nef	B-protein
phosphorylation	O
on	O
Thr-15	O
or	O
GTP-binding	O
activity	O
because	O
mutations	O
in	O
critical	O
sites	O
did	O
not	O
alter	O
this	O
inhibition	O
.	O

Two	O
homologues	O
of	O
the	O
rhombotin	B-DNA
gene	I-DNA
have	O
now	O
been	O
isolated	O
.	O

We	O
are	O
currently	O
engaged	O
in	O
defining	O
where	O
the	O
two	O
signals	O
integrate	O
along	O
the	O
AP-1	B-protein
/	O
NF-kappa	B-protein
B	I-protein
pathway	O
.	O

These	O
findings	O
have	O
suggested	O
that	O
JAK3	B-protein
represents	O
a	O
pharmacological	O
target	O
to	O
control	O
certain	O
lymphoid-derived	O
diseases	O
.	O

Studies	O
have	O
demonstrated	O
abnormalities	O
of	O
the	O
CD3/T-cell	B-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
and	O
pathways	O
of	O
signal	O
transduction	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
animals	O
and	O
patients	O
with	O
advanced	O
malignancy	O
.	O

The	O
role	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
signaling	O
in	O
activated	O
DRA	B-DNA
transcription	O
.	O

We	O
have	O
investigated	O
the	O
molecular	O
and	O
biochemical	O
basis	O
for	O
activation	O
of	O
interleukin	B-protein
3	I-protein
(	O
IL3	B-protein
)	O
gene	O
expression	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
following	O
CD3	O
and	O
CD2	O
receptor	O
stimulation	O
or	O
activation	O
by	O
phytohemagglutinin	B-protein
plus	O
phorbol	O
12-myristate	O
13-acetate	O
.	O

NF	B-protein
kappaB	I-protein
activation	O
in	O
glia	B-cell_type
from	O
mice	O
lacking	O
nNOS	B-protein
responds	O
more	O
rapidly	O
to	O
PDTC	O
compared	O
with	O
astrocytes	B-cell_type
from	O
wild-type	O
mice	O
.	O

The	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factor	I-protein
GATA-1	B-protein
is	O
a	O
major	O
regulator	O
of	O
gene	O
expression	O
in	O
erythroid	B-cell_type
,	I-cell_type
megakaryocyte	I-cell_type
,	I-cell_type
and	I-cell_type
mast	I-cell_type
cell	I-cell_type
lineages	I-cell_type
.	O

In	O
vertebrates	O
,	O
five	O
distinct	O
DNA	B-protein
binding	I-protein
subunits	I-protein
are	O
currently	O
known	O
which	O
might	O
extensively	O
heterodimerize	O
,	O
thereby	O
forming	O
complexes	O
with	O
distinct	O
transcriptional	O
activity	O
,	O
DNA	O
sequence	O
specificity	O
,	O
and	O
cell	O
type-	O
and	O
cell	O
stage-specific	O
distribution	O
.	O

In	O
both	O
diseases	O
a	O
strong	O
correlation	O
(	O
r	O
=	O
0.79	O
,	O
P	O
<	O
0.001	O
)	O
was	O
observed	O
between	O
the	O
percentage	O
of	O
cells	O
in	O
the	O
synovial	O
lining	O
that	O
were	O
positive	O
for	O
nuclear	B-protein
C/EBP	I-protein
beta	I-protein
and	O
lining	O
cell	O
depth	O
.	O

Second	O
messenger	O
up-regulation	O
of	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
transcription	O
is	O
absent	O
in	O
androgen	B-cell_line
insensitive	I-cell_line
human	I-cell_line
prostatic	I-cell_line
carcinoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
PC-3	B-cell_line
and	O
DU-145	B-cell_line
.	O

More	O
frequent	O
use	O
of	O
the	O
classical	O
Oct2a	B-protein
and	O
Oct2b	B-protein
isoforms	O
was	O
observed	O
in	O
the	O
lipopolysaccharide-stimulated	B-cell_line
B	I-cell_line
cells	I-cell_line
,	O
while	O
a	O
preference	O
for	O
the	O
Oct2ab	B-protein
and	O
Oct2ba	B-protein
isoforms	O
was	O
observed	O
in	O
lipopolysaccharide	B-cell_line
plus	I-cell_line
phorbol-di-butyrate-treated	I-cell_line
cells	I-cell_line
.	O

The	O
activation	O
of	O
HIV	O
production	O
by	O
G.	O
vaginalis	O
suggests	O
that	O
genital	O
tract	O
infection	O
with	O
G.	O
vaginalis	O
increases	O
the	O
risk	O
of	O
HIV	O
transmission	O
by	O
increasing	O
HIV	O
expression	O
in	O
the	O
genital	O
tract	O
.	O

We	O
conclude	O
from	O
these	O
results	O
that	O
the	O
functional	O
activity	O
of	O
members	O
of	O
the	O
rel	B-protein
family	I-protein
is	O
regulated	O
by	O
their	O
interaction	O
with	O
DNA	O
and	O
that	O
Rel	B-protein
can	O
be	O
a	O
potent	O
transcriptional	O
activator	O
on	O
specific	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
.	O

The	O
c-jun	B-RNA
mRNA	I-RNA
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
human	B-cell_type
peripheral-blood	I-cell_type
monocytes	I-cell_type
at	O
relatively	O
high	O
levels	O
,	O
was	O
also	O
slightly	O
augmented	O
by	O
LTB4	O
,	O
although	O
to	O
a	O
much	O
lower	O
extent	O
than	O
c-fos	B-DNA
.	O

The	O
importance	O
of	O
these	O
sites	O
was	O
confirmed	O
by	O
in	O
vivo	O
studies	O
in	O
gene-targeted	O
mice	O
deficient	O
of	O
either	O
Oct-2	B-protein
,	O
Bob1	B-protein
,	O
or	O
both	O
NF-kappaB	B-protein
subunits	O
p50	O
and	O
p52	O
.	O

Our	O
data	O
demonstrate	O
that	O
those	O
cell	B-cell_line
lines	I-cell_line
lacking	O
capability	O
to	O
form	O
metastatic	O
tumors	O
in	O
vivo	O
are	O
susceptible	O
to	O
TNF	B-protein
induced	O
apoptosis	O
in	O
vitro	O
.	O

The	O
ability	O
to	O
regulate	O
AR	B-DNA
gene	I-DNA
transcription	O
via	O
the	O
second	O
messenger	O
pathway	O
is	O
lost	O
in	O
the	O
PC-3	B-cell_line
and	I-cell_line
DU-145	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

These	O
results	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
an	O
AP-1-related	B-protein
protein	I-protein
is	O
regulated	O
by	O
the	O
cAMP-dependent	O
second-messenger	O
pathway	O
and	O
suggest	O
that	O
JunD	B-protein
and	O
other	O
AP-1-related	B-protein
proteins	I-protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
by	O
cAMP-dependent	O
intracellular	O
signaling	O
pathways	O
.	O

Effector	O
pathways	O
for	O
this	O
guanine	B-protein
nucleotide	I-protein
binding	I-protein
protein	I-protein
in	O
T	B-cell_type
cells	I-cell_type
are	O
mediated	O
by	O
the	O
serine/threonine	B-protein
kinase	I-protein
Raf-1	B-protein
and	O
the	O
Ras-related	B-protein
GTPase	I-protein
Rac-1	B-protein
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
hypoxia	O
constitutes	O
a	O
stimulus	O
for	O
leukocyte	O
chemotaxis	O
and	O
tissue	O
leukostasis	O
.	O

ACH-2	B-cell_line
,	O
derived	O
from	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
CEM	B-cell_line
)	O
,	O
is	O
chronically	O
infected	O
with	O
HIV-1	O
,	O
with	O
low	O
levels	O
of	O
constitutive	O
virus	O
expression	O
.	O

Copyright	O
1998	O
Elsevier	O
Science	O
Ireland	O
Ltd	O
.	O

These	O
RelB+	B-cell_type
APC	I-cell_type
were	O
potent	O
stimulators	O
of	O
the	O
MLR	B-protein
.	O

However	O
,	O
nuclear	O
targets	O
for	O
PI3K	B-protein
are	O
not	O
known	O
.	O

Our	O
results	O
provide	O
evidence	O
that	O
the	O
lysis	O
mechanism	O
in	O
the	O
ICR27	B-cell_line
lymphoblasts	I-cell_line
is	O
restored	O
when	O
functional	O
receptor	O
number	O
is	O
restored	O
.	O

In	O
this	O
study	O
we	O
present	O
a	O
deletion	O
analysis	O
of	O
the	O
N-terminal	B-protein
region	I-protein
of	O
Oct-2a	B-protein
to	O
determine	O
the	O
minimal	B-protein
repression	I-protein
domain	I-protein
.	O

Receptors	O
for	O
the	O
Fc	B-protein
portion	I-protein
of	O
immunoglobulin	B-protein
molecules	I-protein
(	O
FcR	B-protein
)	O
present	O
on	O
leukocyte	O
cell	O
membranes	O
mediate	O
a	O
large	O
number	O
of	O
cellular	O
responses	O
that	O
are	O
very	O
important	O
in	O
host	O
defense	O
,	O
including	O
phagocytosis	O
,	O
cell	O
cytotoxicity	O
,	O
production	O
and	O
secretion	O
of	O
inflammatory	B-protein
mediators	I-protein
,	O
and	O
modulation	O
of	O
the	O
immune	O
response	O
.	O

This	O
study	O
examined	O
the	O
effects	O
of	O
leukemia	B-protein
inhibitory	I-protein
factor	I-protein
(	O
LIF	B-protein
)	O
on	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
replication	O
in	O
mononuclear	B-cell_type
phagocytes	I-cell_type
(	O
MNP	B-cell_type
)	O
.	O

The	O
results	O
suggested	O
that	O
GcR	B-protein
in	O
hMNL	B-cell_type
are	O
down-regulated	O
by	O
synthetic	O
steroids	O
given	O
in	O
vivo	O
,	O
but	O
they	O
showed	O
very	O
mild	O
down-regulation	O
in	O
hypercortisolemic	O
patients	O
suffering	O
from	O
Cushing	O
's	O
disease	O
.	O

A	O
Tat-responsive	B-DNA
element	I-DNA
is	O
found	O
upstream	O
within	O
the	O
viral	B-DNA
promoter	I-DNA
that	O
in	O
glial-derived	B-cell_line
cell	I-cell_line
lines	I-cell_line
allows	O
transactivation	O
in	O
the	O
absence	O
of	O
TAR	B-RNA
.	O

Finally	O
,	O
although	O
it	O
has	O
been	O
reported	O
that	O
EBNA3C	B-protein
can	O
upregulate	O
CD21	B-protein
in	O
some	O
B	B-cell_type
cells	I-cell_type
,	O
we	O
were	O
unable	O
to	O
demonstrate	O
any	O
effect	O
of	O
EBNA3C	B-protein
on	O
reporter	B-DNA
plasmids	I-DNA
which	O
contain	O
the	O
CD21	B-DNA
promoter	I-DNA
.	O

We	O
also	O
observed	O
that	O
ketoconazole	O
was	O
a	O
weak	O
competitor	O
of	O
GcR	B-protein
in	O
intact	B-cell_type
cells	I-cell_type
,	O
although	O
it	O
significantly	O
inhibited	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
in	O
cytosolic	O
preparations	O
from	O
rat	O
tissues	O
.	O

MR	B-protein
were	O
reduced	O
before	O
delivery	O
(	O
96	O
+/-	O
27	O
receptors/cell	O
)	O
,	O
and	O
SPD	O
increased	O
(	O
64	O
+/-	O
8	O
mV	O
)	O
,	O
with	O
both	O
parameters	O
normalizing	O
after	O
delivery	O
(	O
MR	B-protein
,	O
242	O
+/-	O
79	O
;	O
SPD	O
,	O
14.0	O
+/-	O
4	O
mV	O
)	O
.	O

When	O
18C7	B-protein
was	O
incubated	O
with	O
liganded	B-protein
MR	I-protein
,	O
it	O
was	O
able	O
to	O
partly	O
displace	O
(	O
20	O
%	O
)	O
the	O
hormone	O
from	O
its	O
binding	O
site	O
.	O

We	O
demonstrate	O
the	O
nuclear	O
localization	O
of	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
in	O
PBL	B-cell_type
by	O
different	O
techniques	O
:	O
Western	O
blot	O
,	O
indirect	O
immunofluorescence	O
and	O
electron	O
microscopy	O
.	O

In	O
a	O
different	O
study	O
,	O
GATA-3	B-protein
was	O
shown	O
to	O
be	O
sufficient	O
for	O
the	O
expression	O
of	O
IL-4	B-protein
and	O
other	O
Th2	B-DNA
cytokine	I-DNA
genes	I-DNA
.	O

It	O
was	O
proposed	O
that	O
the	O
mechanism	O
of	O
antiviral	O
action	O
of	O
S9a	O
was	O
on	O
the	O
host	O
cell	O
,	O
by	O
blocking	O
TNF-alpha	B-protein
transcription	O
via	O
a	O
Tat	B-protein
-induced	O
tar-independent	O
loop	O
,	O
which	O
decreases	O
downstream	O
NF-kappaB	B-protein
activation	O
of	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
.	O

The	O
SH3	B-protein
domains	I-protein
of	O
Grb2	B-protein
form	O
a	O
stable	O
complex	O
with	O
SOS1	B-protein
and	O
two	O
proteins	O
of	O
75	B-protein
kD	I-protein
and	O
120	B-protein
kD	I-protein
,	O
which	O
undergo	O
tyrosine	O
phosphorylation	O
in	O
Fc	B-cell_line
gamma	I-cell_line
RIIA	I-cell_line
stimulated	I-cell_line
cells	I-cell_line
.	O

This	O
provides	O
substantial	O
evidence	O
for	O
an	O
allosteric	O
effect	O
on	O
the	O
catalytic	O
cleft	O
of	O
VIIa	B-protein
that	O
is	O
imparted	O
by	O
binding	O
to	O
TF	B-protein
,	O
its	O
cognate	O
catalytic	O
cofactor	B-protein
.	O

An	O
in	O
vitro	O
effect	O
of	O
aldosterone	O
on	O
intracellular	O
sodium	O
,	O
potassium	O
and	O
calcium	O
concentrations	O
and	O
cell	O
volume	O
was	O
shown	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O

Interleukin-10	B-protein
inhibits	O
expression	O
of	O
both	O
interferon	B-DNA
alpha-	I-DNA
and	I-DNA
interferon	I-DNA
gamma-	I-DNA
induced	I-DNA
genes	I-DNA
by	O
suppressing	O
tyrosine	O
phosphorylation	O
of	O
STAT1	B-protein
.	O

This	O
approach	O
uses	O
monoclonal	B-protein
antibodies	I-protein
that	O
distinguish	O
between	O
the	O
native	O
and	O
phosphorylated	O
forms	O
of	O
STAT-1	B-protein
.	O

Using	O
a	O
fragment	O
of	O
K	B-protein
protein	I-protein
as	O
bait	O
in	O
the	O
yeast	O
two-hybrid	O
screen	O
,	O
we	O
isolated	O
a	O
cDNA	B-DNA
that	O
encodes	O
a	O
protein	O
whose	O
primary	O
structure	O
has	O
extensive	O
similarity	O
to	O
the	O
Drosophila	B-protein
melanogaster	I-protein
extra	I-protein
sex	I-protein
combs	I-protein
(	I-protein
esc	I-protein
)	I-protein
gene	I-protein
product	I-protein
,	O
Esc	B-protein
,	O
a	O
putative	O
silencer	O
of	O
homeotic	B-DNA
genes	I-DNA
.	O

Changes	O
of	O
any	O
cysteine	O
residue	O
of	O
the	O
hRAR	B-protein
alpha-LBD	I-protein
had	O
no	O
significant	O
influence	O
on	O
the	O
binding	O
of	O
all-trans	O
RA	O
or	O
9-cis	O
RA	O
.	O

The	O
CD28RE	B-DNA
sequence	O
reveals	O
similarity	O
to	O
the	O
consensus	B-DNA
kappaB	I-DNA
binding	I-DNA
motif	I-DNA
.	O

The	O
triptolide-induced	O
apoptosis	O
is	O
accompanied	O
by	O
increase	O
of	O
DEVD-cleavable	O
caspases	B-protein
activity	O
and	O
degradation	O
of	O
caspase	B-protein
substrate	I-protein
poly	I-protein
(	I-protein
ADP-ribose	I-protein
)	I-protein
polymerase	I-protein
(	O
PARP	B-protein
)	O
.	O

Cellular	O
immune	O
and	O
cytokine	O
pathways	O
resulting	O
in	O
tissue	B-protein
factor	I-protein
expression	O
and	O
relevance	O
to	O
septic	O
shock	O
.	O

This	O
cis-acting	B-DNA
sequence	I-DNA
contains	O
the	O
core	B-DNA
binding	I-DNA
motif	I-DNA
,	O
(	O
A/T	O
)	O
GATA	O
(	O
A/G	O
)	O
,	O
for	O
GATA-binding	B-protein
family	I-protein
proteins	I-protein
and	O
thus	O
suggests	O
the	O
involvement	O
of	O
these	O
family	O
members	O
.	O

By	O
using	O
deletion	O
mutants	O
of	O
the	O
c-fos	B-DNA
promoter	I-DNA
,	O
we	O
found	O
that	O
the	O
minimal	B-DNA
DNA	I-DNA
sequence	I-DNA
required	O
for	O
Tat	B-protein
activity	O
was	O
located	O
between	O
nucleotides	B-DNA
-404/-220	I-DNA
and	O
that	O
the	O
serum	B-DNA
responsive	I-DNA
element	I-DNA
(	O
SRE	B-DNA
,	O
-317/-288	B-DNA
)	O
,	O
present	O
within	O
this	O
region	O
,	O
was	O
still	O
responsive	O
to	O
Tat	B-protein
.	O

The	O
restricted	O
pattern	O
of	O
SCL	B-protein
protein	I-protein
synthesis	O
is	O
consistent	O
with	O
the	O
restricted	O
expression	O
of	O
SCL	B-RNA
mRNA	I-RNA
documented	O
previously	O
.	O

We	O
found	O
frequent	O
hypermutation	O
in	O
follicular	O
lymphoma	O
(	O
25	O
of	O
59	O
=	O
42	O
%	O
)	O
(	O
germinal	O
center	O
cell	O
origin	O
)	O
and	O
mucosa-associated	O
lymphoid	O
tissue	O
(	O
MALT	O
)	O
lymphoma	O
(	O
19	O
of	O
45	O
=	O
42	O
%	O
)	O
(	O
postgerminal	O
center	O
)	O
,	O
but	O
only	O
occasionally	O
in	O
mantle	O
cell	O
lymphoma	O
(	O
1	O
of	O
21	O
=	O
4.8	O
%	O
)	O
(	O
pregerminal	O
center	O
)	O
.	O

The	O
nature	O
of	O
the	O
nuclear	O
factors	O
involved	O
in	O
regulation	O
of	O
these	O
cytokine	B-DNA
genes	I-DNA
is	O
still	O
unknown	O
.	O

More	O
extensive	O
deletion	O
of	O
sequences	O
upstream	O
of	O
Cp	B-DNA
,	O
including	O
the	O
EBNA2-dependent	B-DNA
enhancer	I-DNA
,	O
resulted	O
in	O
nearly	O
complete	O
loss	O
of	O
Cp	B-DNA
activity	O
.	O

We	O
conclude	O
that	O
potentiation	O
of	O
nonphlogistic	O
clearance	O
of	O
apoptotic	B-cell_type
leukocytes	I-cell_type
by	O
phagocytes	B-cell_type
is	O
a	O
hitherto	O
unrecognized	O
property	O
of	O
glucocorticoids	O
that	O
has	O
potential	O
implications	O
for	O
therapies	O
aimed	O
at	O
promoting	O
the	O
resolution	O
of	O
inflammatory	O
diseases	O
.	O

This	O
study	O
assessed	O
the	O
effects	O
of	O
anti-inflammatory	O
glucocorticoids	O
on	O
this	O
leukocyte	O
clearance	O
mechanism	O
.	O

Site-directed	O
mutagenesis	O
demonstrated	O
that	O
this	O
HS-40	B-DNA
enhancer-	O
zeta	B-DNA
2	I-DNA
globin	I-DNA
promoter	I-DNA
interaction	O
is	O
mediated	O
by	O
the	O
two	O
GATA-1	O
factor	O
binding	O
motifs	O
located	O
at	O
-230	O
and	O
-104	O
,	O
respectively	O
.	O

Deletion	O
mapping	O
and	O
hybrid	B-DNA
promoter	I-DNA
constructs	I-DNA
demonstrate	O
that	O
the	O
newly	O
identified	O
Tat-responsive	B-DNA
element	I-DNA
corresponds	O
to	O
a	O
sequence	O
within	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
previously	O
identified	O
as	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
,	O
or	O
NF-kappa	B-DNA
B	I-DNA
domain	I-DNA
.	O

[	O
Corticoids	O
and	O
allergy	O
]	O

The	O
transcription	O
and	O
transformation	O
activity	O
of	O
c-Jun	B-protein
is	O
governed	O
by	O
a	O
27-amino	B-protein
acid	I-protein
regulatory	I-protein
motif	I-protein
,	O
labeled	O
the	O
delta-domain	B-protein
,	O
which	O
is	O
deleted	O
in	O
v-Jun	B-protein
.	O

The	O
transcription	B-protein
factor	I-protein
Spi-1/PU.1	B-protein
as	O
well	O
as	O
the	O
closely	O
related	O
factor	O
Spi-B	B-protein
bound	O
to	O
the	O
PU-box	B-DNA
in	O
B-cells	O
.	O

The	O
E2A-HLF	B-protein
(	I-protein
hepatic	I-protein
leukemia	I-protein
factor	I-protein
)	I-protein
oncoprotein	I-protein
,	O
generated	O
in	O
pro-B	B-cell_type
lymphocytes	I-cell_type
by	O
fusion	O
of	O
the	O
trans-activation	B-protein
domain	I-protein
of	O
E2A	B-protein
to	O
the	O
basic	B-protein
region/leucine	I-protein
zipper	I-protein
(	I-protein
bZIP	I-protein
)	I-protein
domain	I-protein
of	O
HLF	B-protein
,	O
functions	O
as	O
an	O
anti-apoptotic	B-protein
transcription	I-protein
factor	I-protein
in	O
leukemic	O
cell	O
transformation	O
.	O

The	O
regulation	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
following	O
the	O
triggering	O
of	O
HLA-DR	B-protein
antigens	I-protein
by	O
mAb	B-protein
L243	I-protein
has	O
been	O
studied	O
at	O
various	O
times	O
in	O
Raji	B-cell_line
cells	I-cell_line
.	O

In	O
allergic	O
bronchial	O
asthma	O
,	O
inflammation	O
seems	O
to	O
be	O
orchestrated	O
predominantly	O
by	O
a	O
subset	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
with	O
a	O
phenotype	O
similar	O
to	O
the	O
Th2	B-cell_type
subset	I-cell_type
able	O
to	O
produce	O
IL-4	B-protein
and	O
IL-5	B-protein
.	O

Clonality	O
analysis	O
utilizing	O
X-chromosome	B-DNA
inactivation	O
has	O
been	O
used	O
in	O
the	O
study	O
of	O
various	O
diseases	O
,	O
including	O
hematological	O
malignancies	O
.	O

However	O
,	O
the	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocyte	I-cell_type
(	O
CTL	B-cell_type
)	O
response	O
to	O
Ad	O
could	O
limit	O
the	O
effectiveness	O
of	O
such	O
approaches	O
.	O

Corticosteroid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
:	O
a	O
possible	O
marker	O
of	O
brain	O
involution	O
?	O

In	O
myeloid	B-cell_type
cells	I-cell_type
,	O
CD38	B-protein
is	O
expressed	O
during	O
early	O
stages	O
of	O
differentiation	O
.	O

This	O
review	O
analyzes	O
various	O
molecular	O
alterations	O
responsible	O
for	O
the	O
deficient	O
response	O
to	O
corticosteroid	O
treatment	O
observed	O
in	O
steroid-resistant	O
bronchial	O
asthmatic	O
subjects	O
.	O

Moreover	O
,	O
its	O
rapid	O
activation	O
suggests	O
it	O
may	O
have	O
a	O
wider	O
role	O
within	O
signal	O
transduction	O
cascades	O
in	O
lymphocytes	B-cell_type
.	O

In	O
a	O
study	O
of	O
cellular	B-protein
proteins	I-protein
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
murine	O
retroviruses	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
we	O
have	O
discovered	O
that	O
a	O
member	O
of	O
the	O
ets	B-DNA
gene	I-DNA
family	I-DNA
encodes	O
a	O
sequence-specific	B-protein
DNA-binding	I-protein
protein	I-protein
.	O

A	O
region	O
upstream	O
to	O
the	O
first	O
exon	O
,	O
and	O
highly	O
conserved	O
between	O
mouse	O
and	O
man	O
,	O
acts	O
as	O
an	O
erythroid	O
specific	O
enhancer	O
in	O
transient	O
assays	O
,	O
if	O
linked	O
to	O
the	O
GATA-1	B-protein
or	O
to	O
the	O
SV40	O
promoter	O
.	O

It	O
is	O
our	O
contention	O
that	O
CD	O
is	O
triggered	O
by	O
the	O
binding	O
of	O
one	O
or	O
more	O
gliadin	O
peptides	O
to	O
CD-associated	B-protein
HLA	I-protein
class	I-protein
II	I-protein
molecules	I-protein
.	O

TF	B-protein
is	O
the	O
primary	O
cellular	O
initiator	O
of	O
the	O
coagulation	B-protein
protease	I-protein
cascades	O
.	O

Similarly	O
,	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
deficient	O
in	O
CD3	O
or	O
CD45	O
expression	O
also	O
gave	O
impaired	O
UV	O
responses	O
.	O

Among	O
24	O
ALL	O
,	O
6	O
were	O
of	O
the	O
null	O
and	O
11	O
of	O
the	O
common	O
type	O
and	O
all	O
these	O
were	O
negative	O
for	O
A-myb	B-protein
expression	O
;	O
on	O
the	O
other	O
hand	O
,	O
all	O
7	O
B-ALL	O
cases	O
(	O
slg+	O
)	O
,	O
as	O
well	O
as	O
one	O
fresh	O
BL	O
case	O
with	O
bone	O
marrow	O
infiltration	O
,	O
expressed	O
A-myb	B-DNA
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
Tax	B-protein
is	O
thought	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
immortalization	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
DNA-binding	B-protein
protein	I-protein
GATA-1	B-protein
is	O
required	O
for	O
normal	O
erythroid	O
development	O
and	O
regulates	O
erythroid-expressed	B-DNA
genes	I-DNA
in	O
maturing	B-cell_type
erythroblasts	I-cell_type
.	O

In	O
contrast	O
to	O
wild-type	B-cell_line
B	I-cell_line
cells	I-cell_line
,	O
neither	O
of	O
the	O
class	B-cell_line
II	I-cell_line
mutant	I-cell_line
cell	I-cell_line
lines	I-cell_line
could	O
use	O
the	O
X	B-DNA
box	I-DNA
region	I-DNA
to	O
direct	O
the	O
expression	O
of	O
a	O
transiently	O
transfected	O
reporter	B-DNA
gene	I-DNA
,	O
indicating	O
that	O
the	O
X	O
box-dependent	O
transcriptional	O
pathway	O
is	O
defective	O
in	O
these	O
cells	O
.	O

NF-kappaB	B-protein
regulates	O
Fas/APO-1/CD95-	O
and	O
TCR-	O
mediated	O
apoptosis	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

BZLF	B-protein
1	I-protein
,	O
transiently	O
expressed	O
in	O
R7-57	B-cell_line
reporter	I-cell_line
cells	I-cell_line
,	O
was	O
the	O
only	O
EBV	B-protein
trans-activator	I-protein
found	O
,	O
sufficient	O
in	O
inducing	O
the	O
viral	O
lytic	O
cycle	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Purified	B-protein
SR-BP	I-protein
retained	O
its	O
binding	O
properties	O
and	O
migrated	O
on	O
SDS-polyacrylamide	O
gel	O
as	O
a	O
Mr	B-protein
28	I-protein
,	I-protein
000	I-protein
protein	I-protein
.	O

In	O
contrast	O
,	O
AP-1	B-protein
from	O
PHA-activated	B-cell_type
cells	I-cell_type
contains	O
c-Jun	B-protein
and	O
low	O
levels	O
of	O
c-Fos	B-protein
.	O

BACKGROUND	O
.	O

Activated	O
ras	B-protein
expression	O
also	O
replaced	O
the	O
requirement	O
for	O
PKC	B-protein
stimulation	O
in	O
activation	O
of	O
the	O
T-cell	B-protein
transcription	I-protein
factor	I-protein
NF-AT	B-protein
.	O

A	O
mammalian	B-protein
histone	I-protein
deacetylase	I-protein
related	O
to	O
the	O
yeast	B-protein
transcriptional	I-protein
regulator	I-protein
Rpd3p	B-protein
[	O
see	O
comments	O
]	O

Nevertheless	O
,	O
a	O
multimer	O
of	O
the	O
microB	B-DNA
motif	I-DNA
alone	O
showed	O
no	O
enhancer	O
activity	O
.	O

Binding	O
of	O
plasma	B-protein
Factor	I-protein
VII/VIIa	I-protein
to	O
the	O
tissue	B-protein
factor	I-protein
(	I-protein
TF	I-protein
)	I-protein
receptor	I-protein
initiates	O
the	O
coagulation	B-protein
protease	I-protein
cascades	O
.	O

Certain	O
classes	O
of	O
AIDS	O
NHL	O
are	O
associated	O
with	O
alterations	O
in	O
oncogenes	B-DNA
or	O
tumor-suppressor	B-DNA
genes	I-DNA
or	O
infections	O
by	O
oncogenic	O
herpesviruses	O
.	O

Hirsutism	O
markedly	O
improved	O
in	O
all	O
women	O
during	O
the	O
treatment	O
(	O
Ferriman-Gallwey	O
score	O
after	O
1	O
year	O
:	O
4.1	O
+/-	O
0.5	O
versus	O
14.1	O
+/-	O
0.9	O
)	O
.	O

In	O
contrast	O
to	O
anti-CD3/IL-2-activated	B-cell_line
LN	I-cell_line
cells	I-cell_line
,	O
adoptive	O
transfer	O
of	O
freshly	O
isolated	O
tumor-draining	B-cell_type
LN	I-cell_type
T	I-cell_type
cells	I-cell_type
has	O
no	O
therapeutic	O
activity	O
.	O

Although	O
CTCF	B-protein
has	O
been	O
characterized	O
in	O
some	O
detail	O
,	O
there	O
is	O
very	O
little	O
information	O
about	O
the	O
regulation	O
of	O
CTCF	B-protein
activity	O
.	O

By	O
contrast	O
,	O
the	O
expression	O
of	O
other	O
adherence-associated	B-DNA
early	I-DNA
genes	I-DNA
,	O
such	O
as	O
IL-8	B-protein
and	O
IL-1	B-protein
beta	I-protein
,	O
was	O
not	O
up-regulated	O
in	O
PBMC	B-cell_type
of	O
tuberculous	O
patients	O
.	O

One	O
contains	O
hsp90	B-protein
bound	O
to	O
hsp70	B-protein
and	O
p60	B-protein
and	O
this	O
complex	O
forms	O
spontaneously	O
in	O
the	O
absence	O
of	O
ATP	O
.	O

NGAL	B-protein
levels	O
varied	O
in	O
these	O
tumors	O
from	O
undetectable	O
to	O
exceeding	O
those	O
in	O
normal	O
breast	O
parenchyma	O
.	O

Dose-response	O
studies	O
showed	O
that	O
10	O
(	O
-7	O
)	O
to	O
10	O
(	O
-6	O
)	O
mol/L	O
9-cis	O
RA	O
(	O
12	O
hours	O
)	O
resulted	O
in	O
peak	O
levels	O
of	O
C/EBP	B-RNA
epsilon	I-RNA
mRNA	I-RNA
;	O
but	O
even	O
10	O
(	O
-10	O
)	O
mol/L	O
9-cis	O
RA	O
increased	O
levels	O
of	O
these	O
transcripts	O
.	O

The	O
transfected	B-cell_line
cell	I-cell_line
lines	I-cell_line
expressed	O
elevated	O
levels	O
of	O
spi-1	B-RNA
mRNA	I-RNA
and	O
protein	O
and	O
high	O
Spi-1	B-protein
-DNA	O
binding	O
activity	O
.	O

Tyrosine	B-protein
kinase	I-protein
and	O
cAMP-dependent	B-protein
protein	I-protein
kinase	I-protein
activities	O
in	O
CD40-activated	B-cell_line
human	I-cell_line
B	I-cell_line
lymphocytes	I-cell_line
.	O

Both	O
forskolin	O
and	O
dibutyryl	O
cAMP	O
,	O
which	O
elevate	O
intracellular	O
cAMP	O
by	O
independent	O
mechanisms	O
,	O
inhibited	O
TNFalpha	B-protein
and	O
tissue	B-protein
factor	I-protein
expression	O
at	O
the	O
level	O
of	O
transcription	O
.	O

We	O
have	O
developed	O
a	O
monoclonal	B-protein
antibody	I-protein
,	O
Yae	B-protein
,	O
which	O
is	O
specific	O
for	O
Pan/E2A	B-protein
proteins	I-protein
,	O
and	O
have	O
used	O
the	O
Yae	B-protein
antibody	I-protein
to	O
examine	O
a	O
variety	O
of	O
endocrine	B-cell_type
and	I-cell_type
nonendocrine	I-cell_type
cell	I-cell_type
lineages	I-cell_type
for	O
differences	O
in	O
Pan/	O
E2A	B-protein
protein	I-protein
expression	O
,	O
subcellular	O
localization	O
,	O
and	O
heteromeric	O
complex	O
formation	O
.	O

Activation	O
of	O
c-Jun	B-protein
N-terminal	I-protein
kinase	I-protein
in	O
bacterial	B-cell_type
lipopolysaccharide-stimulated	I-cell_type
macrophages	I-cell_type
.	O

However	O
,	O
some	O
peculiar	O
differences	O
were	O
observed	O
between	O
the	O
TEC	B-cell_line
,	O
either	O
IFN-gamma	B-protein
-induced	O
or	O
not	O
,	O
and	O
the	O
constitutive	O
B	B-cell_line
cells	I-cell_line
.	O

Nondividing	O
macrophages	B-cell_type
from	O
normal	O
individuals	O
also	O
expressed	O
1	B-RNA
,	I-RNA
25	I-RNA
(	I-RNA
OH	I-RNA
)	I-RNA
2D3	I-RNA
receptor	I-RNA
RNA	I-RNA
.	O

Although	O
phenotypically	O
normal	O
,	O
the	O
proliferative	O
response	O
of	O
the	O
childrens	O
'	O
T	B-cell_type
cells	I-cell_type
was	O
strongly	O
reduced	O
but	O
could	O
be	O
improved	O
by	O
the	O
addition	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
.	O

There	O
was	O
no	O
competition	O
between	O
TPO	B-protein
and	O
EPO	B-protein
for	O
binding	O
to	O
EPO	B-protein
receptor	I-protein
.	O

We	O
demonstrate	O
here	O
that	O
STAT	B-protein
protein	I-protein
heterocomplexes	I-protein
exist	O
prior	O
to	O
cytokine	B-protein
treatment	O
.	O

Ab-associated	O
changes	O
in	O
the	O
uptake	O
and	O
cellular	O
distribution	O
of	O
FITC-LPS	O
were	O
assessed	O
by	O
flow	O
cytometry	O
and	O
laser	O
scanning	O
confocal	O
microscopy	O
in	O
human	B-cell_line
CD14-transfected	I-cell_line
Chinese	I-cell_line
hamster	I-cell_line
ovary	I-cell_line
fibroblasts	I-cell_line
(	O
CHO-CD14	B-cell_line
cells	I-cell_line
)	O
and	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
T	O
cell	O
tropic	O
strain	O
of	O
HIV	O
,	O
LAI	O
,	O
does	O
not	O
replicate	O
in	O
naive	B-cell_type
CD4	I-cell_type
T	I-cell_type
cells	I-cell_type
stimulated	O
by	O
cross-linking	O
CD3	B-protein
and	O
CD28	B-protein
.	O

The	O
KBF1	B-protein
factor	I-protein
,	O
which	O
binds	O
to	O
the	O
enhancer	B-DNA
A	I-DNA
located	O
in	O
the	O
promoter	B-DNA
of	O
the	O
mouse	B-DNA
MHC	I-DNA
class	I-DNA
I	I-DNA
gene	I-DNA
H-2Kb	B-DNA
,	O
is	O
indistinguishable	O
from	O
the	O
p50	B-protein
DNA	I-protein
binding	I-protein
subunit	I-protein
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
,	O
which	O
regulates	O
a	O
series	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

SLP-76	B-protein
and	O
Vav	B-protein
,	O
two	O
hematopoietic	B-protein
cell	I-protein
specific	I-protein
molecules	I-protein
,	O
are	O
critical	O
for	O
T	O
cell	O
development	O
and	O
activation	O
.	O

The	O
first	B-DNA
intron	I-DNA
acted	O
as	O
a	O
strong	O
transcriptional	O
activator	O
in	O
a	O
position-dependent	O
manner	O
and	O
with	O
no	O
cell-type	O
specificity	O
.	O

We	O
have	O
identified	O
a	O
DNA	B-DNA
segment	I-DNA
that	O
confers	O
responsiveness	O
to	O
antigen	O
stimulation	O
signals	O
on	O
the	O
human	B-DNA
interleukin	I-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
4	I-DNA
gene	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

It	O
was	O
concluded	O
that	O
even	O
when	O
LMP1	B-protein
is	O
unable	O
to	O
activate	O
NF-kappaB	B-protein
,	O
it	O
is	O
still	O
capable	O
of	O
inducing	O
certain	O
characteristics	O
of	O
activated	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
strongly	O
suggesting	O
that	O
LMP1	B-protein
can	O
also	O
activate	O
cells	O
independently	O
of	O
NF-kappaB	B-protein
.	O

Ara-C	O
activated	O
SMase	B-protein
with	O
10	O
minutes	O
in	O
both	O
Jurkat	O
and	O
EL4	B-cell_line
cells	I-cell_line
,	O
while	O
phorbol	O
ester	O
(	O
PMA	O
)	O
had	O
no	O
effect	O
.	O

Expression	O
of	O
the	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV	I-protein
)	I-protein
protease	I-protein
in	O
cultured	B-cell_line
cells	I-cell_line
leads	O
to	O
apoptosis	O
,	O
preceded	O
by	O
cleavage	O
of	O
bcl-2	B-protein
,	O
a	O
key	O
negative	O
regulator	O
of	O
cell	O
death	O
.	O

OCA-B	B-protein
is	O
a	O
B-cell-specific	B-protein
coregulator	I-protein
of	O
the	O
broadly	O
expressed	O
POU	B-protein
domain	I-protein
transcription	I-protein
factor	I-protein
Oct-1	B-protein
.	O

We	O
conclude	O
that	O
NF-kappaB	B-protein
is	O
a	O
context-dependent	O
apoptosis	O
regulator	O
.	O

63	O
%	O
nucleotide	O
identity	O
with	O
a	O
more	O
conserved	O
core	O
of	O
169	B-DNA
base	I-DNA
pairs	I-DNA
(	O
86	O
%	O
identity	O
)	O
.	O

These	O
diurnal	O
variations	O
in	O
GR	B-protein
might	O
serve	O
to	O
coordinate	O
the	O
reactivity	O
of	O
the	O
target	B-cell_type
cells	I-cell_type
to	O
cortisol	O
because	O
the	O
diurnal	O
rhythms	O
of	O
a	O
GR	B-protein
-mediated	O
response	O
,	O
the	O
fractional	O
inhibition	O
of	O
chemotactic	O
migration	O
rate	O
of	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
by	O
cortisol	O
,	O
were	O
found	O
to	O
be	O
synchronous	O
with	O
those	O
of	O
GR	B-protein
.	O

Treatment	O
of	O
the	O
cells	O
with	O
ionomycin	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
molecular	O
weight	O
of	O
NFATp	B-protein
and	O
a	O
loss	O
of	O
32P	O
,	O
consistent	O
with	O
NFATp	B-protein
dephosphorylation	O
.	O

In	O
contrast	O
,	O
TNFRp55-deficient	O
mice	O
are	O
severely	O
impaired	O
to	O
clear	O
L.	O
monocytogenes	O
and	O
readily	O
succumb	O
to	O
infection	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
HOCl	O
should	O
be	O
considered	O
as	O
an	O
oxidative	O
species	O
capable	O
of	O
inducing	O
NF-kappaB	B-protein
in	O
a	O
T-lymphocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
through	O
a	O
transduction	O
mechanism	O
involving	O
ROS	O
,	O
and	O
having	O
a	O
long-distance	O
effect	O
through	O
subsequent	O
TNF-alpha	B-protein
release	O
.	O

TCR	B-protein
signaling	O
was	O
triggered	O
by	O
treating	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
PHA	B-protein
or	O
anti-CD3	B-protein
Abs	I-protein
,	O
and	O
NF-kappaB	B-protein
activation	O
was	O
monitored	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
and/or	O
by	O
kappaB	B-protein
-dependent	O
reporter	O
assays	O
.	O

Taken	O
together	O
,	O
our	O
results	O
will	O
help	O
to	O
understand	O
the	O
complex	O
interactions	O
occurring	O
between	O
HHV-6	O
and	O
the	O
CD4	B-DNA
promoter	I-DNA
and	O
provide	O
additional	O
information	O
regarding	O
the	O
class	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
the	O
control	O
of	O
CD4	B-DNA
gene	I-DNA
expression	O
.	O

We	O
found	O
that	O
AES	O
peptides	O
G75	O
(	O
128-135	B-protein
)	O
and	O
G76	O
(	O
128-135	B-protein
)	O
(	O
L128G	O
)	O
reconstituted	O
CTL	O
recognition	O
at	O
concentrations	O
ranging	O
between	O
200-500	O
nM	O
.	O

This	O
study	O
suggests	O
a	O
therapeutic	O
approach	O
against	O
AIDS	O
by	O
application	O
of	O
two	O
drugs	O
,	O
one	O
against	O
a	O
cellular	O
and	O
the	O
other	O
a	O
viral	O
target	O
,	O
which	O
may	O
provide	O
an	O
approach	O
to	O
the	O
problem	O
of	O
frequent	O
emergence	O
of	O
resistant	O
variants	O
to	O
combinations	O
of	O
drugs	O
that	O
target	O
only	O
HIV	B-DNA
genes	I-DNA
.	O

This	O
provides	O
the	O
hormone	O
with	O
an	O
interesting	O
therapeutic	O
potential	O
.	O

The	O
'octamer	B-DNA
'	I-DNA
sequence	I-DNA
,	O
ATGCAAAT	O
or	O
its	O
complement	O
ATTTGCAT	O
,	O
is	O
a	O
key	O
element	O
for	O
the	O
transcriptional	O
regulation	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
in	O
B-lymphocytes	B-cell_type
as	O
well	O
as	O
a	O
number	O
of	O
housekeeping	B-DNA
genes	I-DNA
in	O
all	O
cell	O
types	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
in	O
mononuclear	B-cell_type
cells	I-cell_type
of	O
patients	O
with	O
sepsis	O
.	O

Proliferation	O
to	O
tetanus	O
toxoid	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
groups	O
.	O

This	O
element	O
includes	O
binding	O
sites	O
for	O
NF-E2	B-protein
,	O
AP-1	B-protein
,	O
GATA-1	B-protein
and	O
Sp-1	B-protein
.	O

It	O
,	O
thus	O
,	O
appears	O
as	O
an	O
integral	B-protein
membrane	I-protein
protein	I-protein
.	O

Spi-1/PU.1	B-protein
is	O
a	O
hematopoietic	B-protein
transcription	I-protein
factor	I-protein
of	O
the	O
Ets	B-protein
family	I-protein
.	O

Allergen-specific	O
T	B-cell_type
cells	I-cell_type
in	O
atopic	O
patients	O
are	O
polarized	O
IL-4-producing	B-cell_line
Th2	I-cell_line
cells	I-cell_line
,	O
promoting	O
IgE	B-protein
synthesis	O
by	O
B	B-cell_type
cells	I-cell_type
.	O

In	O
addition	O
,	O
NAC	O
blocks	O
the	O
suppression	O
of	O
T	O
cell	O
mitogenesis	O
and	O
cytokine	B-protein
production	O
by	O
protease	O
inhibitors	O
such	O
as	O
N-tosylphenylalanine	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
.	O

In	O
addition	O
,	O
transcripts	O
were	O
detected	O
in	O
RNA	O
prepared	O
from	O
tonsil	B-cell_type
B	I-cell_type
cells	I-cell_type
and	O
in	O
situ	O
hybridization	O
studies	O
localized	O
them	O
in	O
the	O
germinal	O
center	O
region	O
of	O
adult	O
tonsil	O
.	O

The	O
expression	O
of	O
the	O
p50	B-protein
and	I-protein
p65	I-protein
NF-kappa	I-protein
B	I-protein
subunits	I-protein
was	O
also	O
shown	O
to	O
be	O
regulated	O
differentially	O
after	O
exposures	O
to	O
1.0	O
and	O
2.0	O
Gy	O
.	O

BHA	O
was	O
found	O
to	O
suppress	O
not	O
only	O
PMA-	O
or	O
TNF-induced	O
,	O
but	O
also	O
constitutive	O
,	O
HIV-enhancer	O
activity	O
concomitant	O
to	O
an	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
both	O
lymphoblastoid	B-cell_line
T	I-cell_line
(	O
J.Jhan	B-cell_line
)	O
and	O
monocytic	B-cell_line
(	I-cell_line
U937	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

These	O
data	O
add	O
further	O
evidence	O
to	O
previous	O
observations	O
from	O
the	O
authors	O
'	O
laboratory	O
that	O
certain	O
tumor	O
characteristics	O
may	O
be	O
associated	O
with	O
reactions	O
of	O
the	O
host	O
with	O
breast	O
cancer	O
.	O

Mutation	O
of	O
the	O
CBF1/RBP-Jkappa	B-protein
binding	I-protein
site	I-protein
in	O
EBNA3C	B-protein
abrogated	O
repression	O
,	O
strongly	O
suggesting	O
that	O
CBF1/RBP-Jkappa	B-protein
is	O
necessary	O
for	O
targeting	O
the	O
viral	O
protein	O
to	O
Cp	B-DNA
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
triptolide	O
is	O
the	O
major	O
active	O
component	O
in	O
the	O
extract	O
that	O
inhibits	O
antigen	O
or	O
mitogen	B-protein
-induced	O
T	O
cell	O
proliferation	O
.	O

Partial	O
cortisol	O
receptor	O
resistance	O
might	O
be	O
less	O
rare	O
than	O
previously	O
thought	O
.	O

Moreover	O
,	O
each	O
proximal	B-DNA
P	I-DNA
element	I-DNA
is	O
essential	O
for	O
optimal	O
IL-4	B-DNA
promoter	I-DNA
activity	O
.	O

Signal	O
transduction	O
by	O
DR3	B-protein
,	O
a	O
death	B-protein
domain-containing	I-protein
receptor	I-protein
related	O
to	O
TNFR-1	B-protein
and	O
CD95	B-protein
.	O

Moreover	O
,	O
mRNA	B-RNA
for	O
IL-2	B-protein
and	O
IFN-gamma	B-protein
could	O
not	O
be	O
detected	O
.	O

Molecular	O
mechanisms	O
of	O
steroid	O
action	O
:	O
a	O
novel	O
type	O
of	O
cross-talk	O
between	O
glucocorticoids	O
and	O
NF-kappa	B-protein
B	I-protein
transcription	B-protein
factors	I-protein
.	O

Consistent	O
with	O
this	O
phenotype	O
,	O
the	O
myeloid	B-protein
transcription	I-protein
factor	I-protein
PU.1	I-protein
,	O
but	O
not	O
the	O
erythroid	B-protein
transcription	I-protein
factor	I-protein
GATA-1	I-protein
,	O
is	O
expressed	O
in	O
47.10	B-cell_line
cells	I-cell_line
.	O

These	O
results	O
provide	O
new	O
insights	O
into	O
how	O
gp120	B-protein
can	O
influence	O
the	O
involvement	O
of	O
glial	B-cell_type
cells	I-cell_type
in	O
the	O
pathogenesis	O
of	O
AIDS	O
dementia	O
complex	O
.	O

Previous	O
studies	O
have	O
shown	O
constitutive	O
activation	O
of	O
IL-4	B-protein
and	O
IL-7	B-protein
signaling	O
pathways	O
,	O
as	O
measured	O
by	O
activation	O
of	O
Janus	B-protein
protein	I-protein
kinase	I-protein
(	I-protein
JAK	I-protein
)	I-protein
1	I-protein
,	O
JAK3	B-protein
,	O
STAT5	B-protein
,	O
and	O
STAT6	B-protein
,	O
in	O
pre-B	B-cell_type
cells	I-cell_type
transformed	O
by	O
v-Abl	B-protein
.	O

Inhibition	O
of	O
anti-CD3	B-protein
monoclonal	I-protein
antibody	I-protein
-induced	O
T-cell	O
proliferation	O
by	O
dexamethasone	O
,	O
isoproterenol	O
,	O
or	O
prostaglandin	O
E2	O
either	O
alone	O
or	O
in	O
combination	O
.	O

Cross-linking	O
of	O
FcR	B-protein
,	O
on	O
the	O
THP-1	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
by	O
immune	B-protein
complexes	I-protein
resulted	O
in	O
both	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
and	O
interleukin	B-protein
1	I-protein
production	O
.	O

The	O
translocated	B-DNA
PAX-5	I-DNA
gene	I-DNA
is	O
deregulated	O
by	O
the	O
insertion	O
of	O
IgH	B-DNA
regulatory	I-DNA
elements	I-DNA
into	O
its	O
5	B-DNA
'	I-DNA
region	I-DNA
,	O
which	O
may	O
contribute	O
to	O
tumorigenesis	O
by	O
interfering	O
with	O
the	O
shut-down	O
of	O
PAX-5	B-protein
transcription	O
and	O
thus	O
with	O
the	O
completion	O
of	O
plasma	B-cell_type
cell	I-cell_type
differentiation	O

Pb	O
did	O
not	O
activate	O
NF-kappa	B-protein
B	I-protein
in	O
4	O
different	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
suggesting	O
that	O
lymphoid	O
cell	O
lines	O
may	O
not	O
be	O
reliable	O
surrogates	O
for	O
the	O
study	O
of	O
transcriptional	O
activation	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Adaptor	O
function	O
for	O
the	O
Syk	B-protein
kinases-interacting	I-protein
protein	I-protein
3BP2	B-protein
in	O
IL-2	B-protein
gene	O
activation	O
.	O

Their	O
mean	O
Kd	O
(	O
affinity	O
)	O
was	O
also	O
significantly	O
lower	O
than	O
that	O
found	O
in	O
the	O
healthy	O
controls	O
(	O
obese	O
Kd	O
:	O
2.92	O
+/-	O
0.84	O
nmol/l	O
,	O
control	O
Kd	O
:	O
4.55	O
+/-	O
0.67	O
nM	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Acetylsalicylic	O
acid	O
and	O
sodium	O
salicylate	O
inhibit	O
LPS-induced	O
NF-kappa	B-protein
B/c-Rel	I-protein
nuclear	O
translocation	O
,	O
and	O
synthesis	O
of	O
tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alfa	I-protein
(	O
TNF-alpha	B-protein
)	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Based	O
on	O
the	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
model	O
for	O
AIDS	O
,	O
loss-of-function	O
(	O
e.g.	O
deletion	O
of	O
accessory	O
genes	O
such	O
as	O
nef	B-DNA
)	O
has	O
been	O
forwarded	O
as	O
a	O
primary	O
approach	O
for	O
creating	O
enfeebled	O
,	O
but	O
replication-competent	O
,	O
HIV-1/SIV	O
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
C.	O
pneumoniae-mediated	O
activation	O
of	O
endothelial	B-cell_type
cells	I-cell_type
and	O
demonstrated	O
an	O
enhanced	O
expression	O
of	O
endothelial	B-protein
adhesion	I-protein
molecules	I-protein
followed	O
by	O
subsequent	O
rolling	O
,	O
adhesion	O
,	O
and	O
transmigration	O
of	O
leukocytes	B-cell_type
(	O
monocytes	B-cell_type
,	O
granulocytes	B-cell_type
)	O
.	O

In	O
this	O
study	O
we	O
analyzed	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
(	I-protein
TcR	I-protein
)	I-protein
delta	I-protein
transcripts	I-protein
expressed	O
by	O
CD3-CD16+	B-cell_line
cells	I-cell_line
and	O
we	O
investigated	O
whether	O
these	O
cells	O
expressed	O
the	O
hGATA-3	B-protein
T	I-protein
cell	I-protein
transcription	I-protein
factor	I-protein
and	O
the	O
recombination-activating	B-DNA
gene	I-DNA
(	I-DNA
RAG	I-DNA
)	I-DNA
-1	I-DNA
.	O

Marked	O
differences	O
were	O
found	O
in	O
response	O
to	O
priming	O
.	O

Interferon	B-protein
regulatory	I-protein
factor	I-protein
2	I-protein
(	O
IRF-2	B-protein
)	O
is	O
a	O
transcriptional	B-protein
regulatory	I-protein
protein	I-protein
that	O
terminates	O
interferon	B-protein
beta	I-protein
expression	O
initiated	O
by	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
1	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
functional	O
role	O
of	O
cysteine	O
and	O
arginine	O
residues	O
in	O
the	O
ligand-binding	B-protein
domain	I-protein
of	O
hRAR	B-protein
alpha	I-protein
(	O
hRAR	B-protein
alpha-LBD	I-protein
,	O
amino	B-protein
acids	I-protein
154	I-protein
to	I-protein
462	I-protein
)	O
.	O

In	O
addition	O
,	O
BLPs	B-protein
stimulated	O
nuclear	B-protein
factor-kappaB	I-protein
,	O
a	O
transcriptional	B-protein
activator	I-protein
of	O
multiple	B-DNA
host	I-DNA
defense	I-DNA
genes	I-DNA
,	O
and	O
activated	O
the	O
respiratory	O
burst	O
through	O
hTLR2	B-protein
.	O

Regulation	O
of	O
GR	O
binding	O
by	O
FKBP51	B-protein
represents	O
a	O
previously	O
unrecognized	O
mechanism	O
for	O
regulating	O
glucocorticoid	O
sensitivity	O
.	O

Signals	O
leading	O
to	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
are	O
stronger	O
in	O
neonatal	B-cell_type
than	I-cell_type
adult	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

However	O
,	O
p38	B-protein
MAPK	I-protein
is	O
activated	O
strongly	O
and	O
synergistically	O
by	O
either	O
CD3/CD28	B-protein
coligation	O
or	O
PMA/Ca2+	O
ionophore	O
stimulation	O
,	O
which	O
mimics	O
TCR	B-protein
-	O
CD3/CD28	B-protein
-mediated	O
signaling	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
NF-kappa	B-protein
B	I-protein
plays	O
an	O
important	O
role	O
in	O
long-term	O
activation	O
of	O
human	B-cell_type
primary	I-cell_type
T-lymphocytes	I-cell_type
via	O
CD2	B-protein
+	O
CD28	B-protein
.	O

NF-kappa	B-protein
B	I-protein
is	O
a	O
DNA-binding	B-protein
regulatory	I-protein
factor	I-protein
able	O
to	O
control	O
transcription	O
of	O
a	O
number	O
of	O
genes	O
,	O
including	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
genes	I-DNA
.	O

We	O
found	O
that	O
activation	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
by	O
a	O
combination	O
of	O
phytohemagglutinin	B-protein
and	O
phorbol	O
12-myristate	O
13-acetate	O
led	O
to	O
a	O
dramatic	O
inhibition	O
of	O
thrombin	B-RNA
receptor	I-RNA
mRNA	I-RNA
expression	O
and	O
to	O
a	O
concomitant	O
loss	O
of	O
the	O
thrombin	B-protein
response	O
.	O

Transgenic	O
mice	O
with	O
human	B-DNA
CD3epsilon	I-DNA
gene	I-DNA
have	O
been	O
shown	O
to	O
exhibit	O
early	O
arrest	O
of	O
T	O
cell	O
development	O
in	O
the	O
thymus	O
.	O

The	O
functional	O
synergy	O
between	O
IL-12	B-protein
and	O
IL-2	B-protein
involves	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
and	O
is	O
associated	O
with	O
the	O
augmentation	O
of	O
STAT	O
serine	O
phosphorylation	O
.	O

Two-color	O
immunohistochemistry	O
demonstrated	O
that	O
both	O
macrophages	B-cell_type
and	O
fibroblast-like	B-cell_type
synoviocytes	I-cell_type
were	O
positive	O
for	O
nuclear	O
C/EBP	B-protein
beta	I-protein
.	O

We	O
propose	O
that	O
ets-1	B-protein
functions	O
as	O
a	O
transcriptional	O
activator	O
of	O
mammalian	O
type-C	O
retroviruses	O
and	O
speculate	O
that	O
ets-related	B-DNA
genes	I-DNA
constitute	O
a	O
new	O
group	O
of	O
eukaryotic	B-protein
DNA-binding	I-protein
proteins	I-protein
.	O

Such	O
proteasome	B-protein
activation	O
correlated	O
with	O
hypoxia-evoked	O
decreases	O
in	O
both	O
extracellular	O
and	O
intracellular	O
pH	O
.	O

We	O
show	O
that	O
nNOS	B-protein
is	O
the	O
predominant	O
isoform	O
constitutively	O
expressed	O
in	O
glia	B-cell_type
.	O

Preincubation	O
of	O
cells	O
with	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
augmented	O
IL-1	B-RNA
beta	I-RNA
mRNA	I-RNA
levels	O
only	O
in	O
U-937	B-cell_line
and	O
HL-60	B-cell_line
cells	O
.	O

No	O
significant	O
association	O
between	O
NGAL	B-protein
expression	O
and	O
disease-free	O
or	O
overall	O
survival	O
was	O
observed	O
.	O

There	O
appears	O
to	O
be	O
no	O
relationship	O
between	O
the	O
number	O
of	O
AML1/ETO	B-RNA
transcripts	I-RNA
found	O
in	O
the	O
infused	O
PBSC	B-cell_type
harvests	O
and	O
the	O
incidence	O
of	O
leukemic	O
relapse	O
following	O
autologous	O
PBSCT	O
in	O
our	O
study	O
.	O

We	O
have	O
also	O
shown	O
that	O
tyrosine	O
phosphorylation	O
of	O
the	O
STAT	B-protein
4	I-protein
transcription	I-protein
factor	I-protein
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
unique	O
to	O
the	O
IL-12	B-protein
signaling	O
pathway	O
,	O
occurs	O
with	O
Flexi-12	B-protein
at	O
levels	O
similar	O
to	O
those	O
seen	O
with	O
rIL-12	B-protein
.	O

We	O
show	O
by	O
antibody	O
supershift	O
experiments	O
and	O
UV	O
cross-linking	O
followed	O
by	O
denaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
that	O
both	O
CREB	O
and	O
ATF	O
family	O
members	O
bind	O
to	O
this	O
region	O
in	O
vitro	O
.	O

Overexpression	O
of	O
a	O
V14Rho	B-DNA
construct	I-DNA
incapable	O
of	O
membrane	O
localization	O
(	O
CAAX	B-DNA
deleted	I-DNA
)	O
abolishes	O
PMA-induced	O
AP-1	B-protein
transcriptional	O
activation	O
.	O

c-Myb	B-protein
protein	I-protein
was	O
strongly	O
evident	O
in	O
T	B-cell_type
lymphoblasts	I-cell_type
in	O
which	O
the	O
enhancer	B-DNA
was	O
active	O
and	O
was	O
localized	O
within	O
discrete	O
nuclear	O
structures	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
quantitative	O
DNase	B-protein
footprinting	O
of	O
the	O
TNF-alpha	B-DNA
promoter	I-DNA
using	O
increasing	O
amounts	O
of	O
recombinant	O
NFATp	B-protein
demonstrated	O
that	O
the	O
-76	B-DNA
site	I-DNA
binds	O
to	O
NFATp	B-protein
with	O
a	O
higher	O
affinity	O
than	O
the	O
kappa	B-DNA
3	I-DNA
site	I-DNA
.	O

Latent	B-RNA
membrane	I-RNA
protein	I-RNA
(	I-RNA
LMP	I-RNA
)	I-RNA
2A	I-RNA
mRNA	I-RNA
was	O
detected	O
in	O
three	O
of	O
seven	O
cases	O
;	O
however	O
,	O
neither	B-RNA
LMP1	I-RNA
nor	I-RNA
LMP2B	I-RNA
mRNA	I-RNA
was	O
detected	O
in	O
any	O
of	O
the	O
tumours	O
tested	O
.	O

All	O
Rights	O
Reserved	O
.	O

Human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
quasispecies	I-DNA
differ	O
in	O
basal	O
transcription	O
and	O
nuclear	B-protein
factor	I-protein
recruitment	O
in	O
human	B-cell_type
glial	I-cell_type
cells	I-cell_type
and	I-cell_type
lymphocytes	I-cell_type
.	O

Recent	O
development	O
of	O
primary	B-cell_line
cultures	I-cell_line
of	O
human	B-cell_line
megakaryocytes	I-cell_line
and	O
the	O
molecular	O
cloning	O
of	O
genes	O
that	O
are	O
specific	O
to	O
this	O
lineage	O
offer	O
the	O
possibility	O
of	O
getting	O
some	O
insights	O
into	O
the	O
genetic	O
mechanisms	O
that	O
control	O
megakaryocytopoiesis	O
.	O

However	O
,	O
under	O
conditions	O
of	O
inflammatory	O
response	O
after	O
infection	O
,	O
TNF	B-protein
might	O
also	O
be	O
present	O
in	O
the	O
intermediate	B-cell_type
thymocyte	I-cell_type
compartment	I-cell_type
,	O
leading	O
to	O
efficient	O
HIV	O
replication	O
in	O
these	O
cells	O
.	O

A	O
high-affinity	O
calcineurin	B-protein
-binding	O
peptide	O
was	O
selected	O
from	O
combinatorial	O
peptide	O
libraries	O
based	O
on	O
the	O
calcineurin	B-protein
docking	I-protein
motif	I-protein
of	O
NFAT	B-protein
.	O

The	O
ability	O
of	O
E2A-HLF	B-protein
to	O
prolong	O
the	O
survival	O
of	O
interleukin-3	B-cell_line
(	I-cell_line
IL-3	I-cell_line
)	I-cell_line
-dependent	I-cell_line
murine	I-cell_line
pro-B	I-cell_line
cells	I-cell_line
after	O
IL-3	B-protein
withdrawal	O
suggests	O
that	O
it	O
disrupts	O
signaling	O
pathways	O
normally	O
responsible	O
for	O
cell	O
suicide	O
,	O
allowing	O
the	O
cells	O
to	O
accumulate	O
as	O
transformed	B-cell_type
lymphoblasts	I-cell_type
.	O

In	O
mice	O
exposed	O
to	O
hypoxia	O
(	O
PO2	O
approximately	O
30-40	O
Torr	O
)	O
,	O
there	O
was	O
increased	O
pulmonary	O
leukostasis	O
,	O
as	O
evidenced	O
by	O
increased	O
myeloperoxidase	B-protein
activity	O
in	O
tissue	O
homogenates	O
.	O

The	O
human	B-DNA
interferon	I-DNA
beta	I-DNA
(	I-DNA
IFN-beta	I-DNA
)	I-DNA
regulatory	I-DNA
element	I-DNA
consists	O
of	O
multiple	O
enhanson	B-DNA
domains	I-DNA
which	O
are	O
targets	O
for	O
transcription	B-protein
factors	I-protein
involved	O
in	O
inducible	O
expression	O
of	O
the	O
promoter	B-DNA
.	O

Epstein-Barr	O
virus-transformed	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
n	O
=	O
7	O
)	O
and	O
B	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
(	O
n	O
=	O
2	O
)	O
established	O
from	O
patients	O
with	O
SLE	O
and	O
a	O
healthy	O
individual	O
were	O
used	O
as	O
a	O
B	O
cell	O
source	O
.	O

In	O
situ	O
hybridization	O
to	O
viral	B-DNA
DNA	I-DNA
and	O
immunocytochemistry	O
for	O
Ad5	O
E1A	B-protein
protein	I-protein
localized	O
the	O
virus	O
to	O
airway	O
and	O
alveolar	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
.	O

CD40-	O
or	O
pervanadate-mediated	O
I	O
kappa	O
B	O
tyrosine	O
phosphorylation	O
was	O
not	O
detected	O
.	O

We	O
show	O
that	O
the	O
transcription	B-protein
factor	I-protein
NFATc	B-protein
was	O
sufficient	O
as	O
a	O
cellular	O
factor	O
to	O
induce	O
a	O
highly	O
permissive	O
state	O
for	O
HIV-1	O
replication	O
in	O
primary	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

By	O
Northern	O
blot	O
analysis	O
,	O
DM	O
caused	O
a	O
comparable	O
decrease	O
in	O
IL-2R	B-protein
alpha	I-protein
and	O
in	O
IL-2R	B-protein
beta	I-protein
mRNA	O
levels	O
to	O
membrane	O
receptor	O
expression	O
in	O
mitogen-stimulated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Although	O
IL-4	B-protein
activated	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
6	I-protein
in	O
addition	O
to	O
NF-kappaB	B-protein
,	O
NAC	O
treatment	O
or	O
the	O
transfection	O
of	O
decoy	O
oligodeoxynucleotides	O
for	O
NF-kappaB	B-protein
or	O
STAT6	B-protein
only	O
partly	O
blocked	O
IL-4	B-protein
-induced	O
germline	B-DNA
Cepsilon	O
transcription	O
.	O

IkappaB	B-protein
further	O
reduces	O
the	O
translocation	O
of	O
NF-kappaB	B-protein
into	O
the	O
nucleus	O
thus	O
preventing	O
the	O
expression	O
of	O
proinflammatory	B-DNA
genes	I-DNA
.	O

We	O
describe	O
the	O
embryonic	O
expression	O
of	O
musculin	B-protein
,	O
a	O
new	O
murine	O
member	O
of	O
the	O
bHLH	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

Transcriptional	O
activation	O
of	O
human	B-DNA
zeta	I-DNA
2	I-DNA
globin	I-DNA
promoter	I-DNA
by	O
the	O
alpha	B-DNA
globin	I-DNA
regulatory	I-DNA
element	I-DNA
(	O
HS-40	B-DNA
)	O
:	O
functional	O
role	O
of	O
specific	O
nuclear	B-protein
factor-DNA	I-protein
complexes	I-protein
.	O

The	O
chromatin	O
structure	O
of	O
the	O
human	B-DNA
beta-globin	I-DNA
gene	I-DNA
locus	I-DNA
assumes	O
a	O
transcriptionally-active	O
conformation	O
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O

This	O
presents	O
several	O
problems	O
in	O
vectors	O
,	O
particularly	O
those	O
in	O
which	O
additional	O
genes	O
,	O
either	O
a	O
co-stimulatory	B-DNA
gene	I-DNA
or	O
a	O
selectable	O
marker	O
,	O
are	O
inserted	O
.	O

These	O
data	O
may	O
expand	O
the	O
understanding	O
of	O
the	O
anti-thrombotic	O
and	O
anti-inflammatory	O
effects	O
of	O
these	O
drugs	O
when	O
activation	O
of	O
monocytes	B-cell_type
occurs	O
.	O

Our	O
objective	O
was	O
to	O
identify	O
the	O
mechanisms	O
underlying	O
such	O
phenomena	O
.	O

Confirmation	O
of	O
the	O
unique	O
significance	O
of	O
zinc	O
for	O
immune	O
function	O
provides	O
a	O
better	O
understanding	O
of	O
the	O
mechanisms	O
of	O
specific	O
zinc-mediated	O
immune	O
modulation	O
.	O

Ro	O
09-2210	O
exhibits	O
potent	O
anti-proliferative	O
effects	O
on	O
activated	O
T	B-cell_type
cells	I-cell_type
by	O
selectively	O
blocking	O
MKK	B-protein
activity	O
.	O

Cytokines	B-protein
have	O
been	O
identified	O
by	O
immunohistochemistry	O
in	O
granulomas	O
in	O
animal	O
models	O
of	O
bacillus	O
Calmette-Guerin	O
(	O
BCG	O
)	O
infection	O
and	O
are	O
released	O
by	O
mononuclear	B-cell_type
phagocytes	I-cell_type
upon	O
stimulation	O
by	O
mycobacterial	O
proteins	O
.	O

Twelve	O
amino	O
acid	O
peptides	O
encompassing	O
either	O
of	O
these	O
two	O
tyrosine	O
residues	O
in	O
phosphorylated	B-protein
form	I-protein
coprecipitated	O
Stat3	B-protein
but	O
not	O
Stat1	B-protein
and	O
blocked	O
IL-10	B-protein
-induced	O
Stat3	B-protein
phosphorylation	O
in	O
a	O
cell-free	O
system	O
.	O

CONCLUSIONS	O
:	O
NF-kappaB	B-protein
is	O
the	O
main	O
transcription	O
factor	O
involved	O
in	O
the	O
signal	O
transduction	O
pathway	O
of	O
CD23	B-protein
in	O
monocytes	B-cell_type
.	O

When	O
introduced	O
in	O
front	O
of	O
a	O
luciferase	B-DNA
reporter	I-DNA
gene	I-DNA
,	O
this	O
promoter	O
is	O
able	O
to	O
direct	O
a	O
high	O
luciferase	B-protein
activity	O
in	O
a	O
human	B-cell_line
B-LCL	I-cell_line
.	O

In	O
this	O
study	O
,	O
each	O
of	O
the	O
four	O
different	O
isoforms	O
of	O
WT1	B-DNA
was	O
constitutively	O
overexpressed	O
in	O
the	O
leukemic	B-cell_line
cell	I-cell_line
line	I-cell_line
K562	I-cell_line
.	O

Up-regulation	O
of	O
high-affinity	O
dehydroepiandrosterone	O
binding	O
activity	O
by	O
dehydroepiandrosterone	O
in	O
activated	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Relative	O
affinities	O
of	O
transcriptional	B-DNA
regulatory	I-DNA
elements	I-DNA
for	O
their	O
respective	O
factor	O
have	O
been	O
essentially	O
studied	O
by	O
bandshift	O
analysis	O
.	O

No	O
age-related	O
differences	O
were	O
found	O
in	O
the	O
expression	O
of	O
either	O
of	O
these	O
two	O
proto-oncogenes	B-DNA
by	O
anti-CD2	O
activated	O
T	O
cells	O
.	O

The	O
cell	B-cell_line
lines	I-cell_line
exhibit	O
a	O
low	O
level	O
of	O
constitutive	O
TNF	B-RNA
mRNA	I-RNA
expression	O
.	O

Total	O
RNA	O
isolated	O
from	O
the	O
index	O
subject	O
's	O
mononuclear	B-cell_type
leukocytes	I-cell_type
was	O
used	O
to	O
produce	O
first	O
strand	O
hGR	B-DNA
cDNAs	I-DNA
,	O
and	O
the	O
entire	O
hGR	B-DNA
cDNA	I-DNA
was	O
amplified	O
in	O
segments	O
and	O
sequenced	O
.	O

Recent	O
studies	O
have	O
implicated	O
the	O
family	O
of	O
AP1	B-protein
factors	I-protein
as	O
components	O
of	O
the	O
murine	B-protein
NF-AT	I-protein
complex	I-protein
.	O

The	O
function	O
of	O
oriP	B-DNA
depends	O
on	O
a	O
trans-acting	B-protein
factor	I-protein
(	O
s	O
)	O
encoded	O
by	O
the	O
viral	B-DNA
genome	I-DNA
.	O

This	O
inhibitory	O
effect	O
was	O
limited	O
to	O
the	O
first	O
2	O
h	O
after	O
mitogenic	O
activation	O
,	O
localizing	O
the	O
time-frame	O
of	O
action	O
of	O
cysteamine	O
to	O
within	O
the	O
commitment	O
period	O
.	O

The	O
XPB	B-protein
mutation	O
causes	O
a	O
severe	O
NER	O
defect	O
.	O

TAR	B-DNA
-independent	O
transactivation	O
by	O
Tat	B-protein
in	O
cells	O
derived	O
from	O
the	O
CNS	O
:	O
a	O
novel	O
mechanism	O
of	O
HIV-1	O
gene	O
regulation	O
.	O

Challenges	O
in	O
developing	O
new	O
therapeutic	O
strategies	O
include	O
not	O
only	O
identifying	O
novel	O
agents	O
,	O
but	O
also	O
improving	O
the	O
definitions	O
of	O
clinical	O
endpoints	O
and	O
defining	O
efficacy	O
at	O
the	O
biologic	O
level	O
.	O

To	O
extend	O
these	O
initial	O
observations	O
,	O
we	O
have	O
examined	O
the	O
effect	O
of	O
antioxidant	O
treatment	O
on	O
the	O
activity	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinases	I-protein
erk1	B-protein
and	O
erk2	B-protein
,	O
as	O
members	O
of	O
a	O
signal	O
transduction	O
pathway	O
known	O
to	O
directly	O
regulate	O
transcription	O
factor	O
function	O
.	O

A	O
cell-type-independent	B-DNA
lipopolysaccharide	I-DNA
(	I-DNA
LPS	I-DNA
)	I-DNA
-responsive	I-DNA
enhancer	I-DNA
element	I-DNA
located	O
between	O
-3757	B-DNA
and	I-DNA
-2729	I-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
(	O
cap	B-DNA
site	I-DNA
)	O
consisted	O
of	O
at	O
least	O
six	O
discrete	O
subregions	O
which	O
were	O
essential	O
to	O
the	O
maximal	O
induction	O
by	O
LPS	O
in	O
transfected	B-cell_line
monocytes	I-cell_line
.	O

We	O
therefore	O
propose	O
that	O
such	O
cross-talking	O
among	O
distinct	O
adhesion	O
molecules	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
inflammation	O
,	O
including	O
RA	O
synovitis	O
.	O

In	O
this	O
study	O
,	O
we	O
created	O
transgenic	O
mice	O
overexpressing	O
ICSAT	B-protein
in	O
lymphocytes	B-cell_type
.	O

By	O
using	O
a	O
SOX9	B-DNA
coding	I-DNA
sequence	I-DNA
polymorphism	I-DNA
,	O
expression	O
of	O
both	O
SOX9	B-DNA
alleles	O
has	O
been	O
demonstrated	O
by	O
the	O
reverse	B-protein
transcriptase	I-protein
polymerase	O
chain	O
reaction	O
in	O
lymphoblastoid	B-cell_type
cells	I-cell_type
from	O
one	O
of	O
the	O
translocation	O
cases	O
.	O

Absorptive	O
hypercalciuria	O
(	O
a	O
stone-forming	O
condition	O
)	O
is	O
characterized	O
by	O
gut	O
hyperabsorption	O
of	O
calcium	O
,	O
hypercalciuria	O
,	O
and	O
reduced	O
bone	O
density	O
.	O

We	O
demonstrated	O
that	O
the	O
Mycobacterium	O
tuberculosis	O
cell	O
wall	O
component	O
lipoarabinomannan	O
(	O
LAM	O
)	O
is	O
a	O
very	O
potent	O
inducer	O
of	O
IL-1	B-DNA
beta	I-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
investigated	O
the	O
mechanism	O
of	O
this	O
effect	O
.	O

One	O
of	O
the	O
putative	O
targets	O
of	O
calcineurin	B-protein
is	O
the	O
pre-existing	O
,	O
cytosolic	B-protein
component	I-protein
of	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFATp	B-protein
;	O
also	O
referred	O
to	O
as	O
NFAT1	B-protein
)	O
,	O
which	O
is	O
one	O
of	O
several	O
transcription	B-protein
factors	I-protein
required	O
for	O
the	O
expression	O
of	O
interleukin	B-protein
2	I-protein
.	O

This	O
study	O
concerns	O
9	O
iv	O
drug	O
abusers	O
with	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
who	O
developed	O
hypercortisolism	O
without	O
the	O
clinical	O
signs	O
or	O
metabolic	O
consequences	O
of	O
hypercortisolism	O
.	O

In	O
contrast	O
to	O
its	O
transient	O
pattern	O
of	O
nuclear	O
induction	O
during	O
an	O
immune	O
response	O
,	O
NF-kappaB	B-protein
is	O
constitutively	O
activated	O
in	O
cells	O
expressing	O
the	O
Tax	B-protein
transforming	I-protein
protein	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-1	O
)	O
.	O

The	O
balance	O
between	O
type	O
1	O
and	O
2	O
T	O
helper	O
cell	O
cytokine	O
production	O
plays	O
an	O
important	O
role	O
in	O
several	O
animal	O
models	O
of	O
autoimmunity	O
,	O
and	O
skewed	O
patterns	O
of	O
cytokine	B-protein
expression	O
have	O
been	O
described	O
in	O
human	O
inflammatory	O
diseases	O
.	O

Kd	O
values	O
(	O
mean+/-SE	O
)	O
for	O
cortisol	O
in	O
HML	B-cell_type
of	O
hypertensive	O
patients	O
were	O
higher	O
than	O
in	O
control	O
subjects	O
(	O
24.6+/-2.4	O
versus	O
17.5+/-1.7	O
nmol/L	O
,	O
P	O
<	O
.04	O
)	O
.	O

Interfollicular	O
cells	O
are	O
negative	O
for	O
Bcl-6	B-protein
protein	I-protein
,	O
except	O
for	O
rare	O
CD3+/CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
findings	O
also	O
suggest	O
that	O
a	O
later	O
feedback	O
``	O
talking	O
''	O
may	O
exist	O
between	O
eosinophils	B-cell_type
and	O
Th2	B-cell_line
lymphocytes	I-cell_line
.	O

Analysis	O
of	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
complex	I-protein
has	O
revealed	O
that	O
both	O
proteins	O
can	O
interact	O
with	O
related	O
DNA	O
sequences	O
through	O
either	O
homo-	O
or	O
heterodimer	O
formation	O
.	O

Recent	O
reports	O
demonstrated	O
that	O
ionizing	O
radiation	O
in	O
the	O
dose	O
range	O
of	O
2-50	O
Gy	O
results	O
in	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
human	B-cell_line
KG-1	I-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
and	O
human	B-cell_type
B-lymphocyte	I-cell_type
precursor	I-cell_type
cells	I-cell_type
;	O
the	O
precise	O
mechanism	O
involved	O
and	O
the	O
significance	O
are	O
not	O
yet	O
known	O
.	O

Thus	O
,	O
each	O
factor	O
may	O
function	O
as	O
a	O
novel	B-protein
negative	I-protein
regulator	I-protein
of	O
transcription	O
.	O

Finally	O
,	O
we	O
have	O
correlated	O
the	O
response	O
of	O
the	O
cells	O
to	O
G-CSF	B-protein
or	O
TGF-beta1	B-protein
with	O
the	O
ability	O
of	O
the	O
normal	O
and	O
fusion	B-protein
proteins	I-protein
to	O
activate	O
or	O
repress	O
promoters	O
which	O
they	O
can	O
directly	O
regulate	O
by	O
binding	O
to	O
the	O
promoter	B-DNA
site	I-DNA
.	O

Each	O
of	O
these	O
domains	O
possessed	O
strong	O
homology	O
to	O
motifs	O
previously	O
found	O
to	O
bind	O
the	O
cellular	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
.	O

Long	O
term	O
culture	O
of	O
TPA-differentiated	B-cell_type
U-937	I-cell_type
cells	I-cell_type
in	O
the	O
absence	O
of	O
phorbol	O
ester	O
for	O
32-36	O
days	O
resulted	O
in	O
a	O
process	O
of	O
retrodifferentiation	O
.	O

These	O
results	O
indicate	O
that	O
,	O
although	O
purified	O
peptide/glycoprotein	B-protein
96	I-protein
complexes	I-protein
are	O
potent	O
immunogens	O
,	O
the	O
mechanism	O
of	O
CTL	O
cross-priming	O
in	O
vivo	O
does	O
not	O
depend	O
upon	O
antigenic	O
peptides	O
in	O
the	O
ER	O
of	O
immunizing	B-cell_type
cells	I-cell_type
.	O

In	O
vivo	O
footprinting	O
by	O
ligation-mediated	O
PCR	O
was	O
performed	O
to	O
correlate	O
in	O
vivo	O
protein	O
binding	O
with	O
functional	O
activity	O
.	O

Displacement	O
of	O
an	O
E-box-binding	B-protein
repressor	I-protein
by	O
basic	B-protein
helix-loop-helix	I-protein
proteins	I-protein
:	O
implications	O
for	O
B-cell	O
specificity	O
of	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
enhancer	I-DNA
.	O

IL-13	B-protein
activation	O
of	O
STAT6	B-protein
was	O
reduced	O
in	O
MDMac	B-cell_line
which	O
was	O
associated	O
with	O
diminished	O
IL-13	B-protein
-induced	O
expression	O
of	O
CD23	B-protein
and	O
MHC	B-protein
class	I-protein
II	I-protein
.	O

We	O
examined	O
signaling	O
molecules	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
obtained	O
from	O
women	O
with	O
breast	O
cancer	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
NF-ATp	B-protein
,	O
one	O
of	O
the	O
most	O
prominent	O
members	O
of	O
family	O
of	O
NF-AT	B-protein
transcription	I-protein
factors	I-protein
in	O
peripheral	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
in	O
T	O
cell	O
activation	O
and	O
differentiation	O
we	O
created	O
NF-ATp	B-protein
-deficient	O
mice	O
by	O
gene	O
targeting	O
.	O

METHODS	O
:	O
We	O
compared	O
hydrocortisone	O
,	O
beclomethasone	O
dipropionate	O
,	O
triamcinolone	O
acetonide	O
,	O
flunisolide	O
,	O
and	O
budesonide	O
with	O
regard	O
to	O
their	O
capacity	O
to	O
inhibit	O
phytohemagglutinin	B-protein
-induced	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cell	I-cell_type
proliferation	O
from	O
six	O
patients	O
with	O
steroid-sensitive	O
asthma	O
and	O
seven	O
patients	O
with	O
steroid-resistant	O
asthma	O
.	O

Visualization	O
of	O
the	O
endogenous	B-protein
NF-kappa	I-protein
B	I-protein
p50	I-protein
subunit	I-protein
in	O
the	O
nucleus	O
of	O
follicular	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
in	O
germinal	O
centers	O
.	O

The	O
majority	O
of	O
these	O
TCC	B-cell_line
exhibited	O
a	O
strongly	O
polarized	O
Th2	O
cytokine	B-protein
profile	O
,	O
and	O
the	O
production	O
of	O
IFN-gamma	B-protein
could	O
not	O
be	O
induced	O
by	O
exogenous	O
IL-12	B-protein
.	O

In	O
addition	O
,	O
the	O
present	O
results	O
indicate	O
that	O
SCL	B-protein
protein	I-protein
size	O
was	O
determined	O
by	O
regulation	O
of	O
translation	O
in	O
a	O
cell-specific	O
manner	O
.	O

We	O
have	O
previously	O
shown	O
that	O
tyloxapol	O
is	O
a	O
potent	O
antioxidant	O
for	O
hydroxyl	O
radicals	O
(	O
OH	O
)	O
.	O

In	O
contrast	O
to	O
the	O
negative	O
autoregulation	O
of	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
expression	O
seen	O
in	O
most	O
cells	O
and	O
tissues	O
,	O
GR	B-protein
expression	O
is	O
positively	O
autoregulated	O
in	O
human	B-cell_type
leukemic	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
in	O
other	O
cells	O
sensitive	O
to	O
glucocorticoid-induced	O
cell	O
death	O
.	O

Substantial	O
decreases	O
of	O
IL-2	B-protein
production	O
were	O
observed	O
for	O
cell	O
cultures	O
from	O
7	O
of	O
12	O
elderly	O
individuals	O
in	O
response	O
to	O
the	O
different	O
stimuli	O
,	O
whereas	O
the	O
levels	O
of	O
IL-2	B-protein
produced	O
by	O
stimulated	O
T	B-cell_type
cells	I-cell_type
from	O
other	O
elderly	O
individuals	O
were	O
equivalent	O
to	O
those	O
observed	O
for	O
stimulated	O
T	O
cells	O
of	O
young	O
subjects	O
.	O

This	O
leads	O
to	O
significantly	O
lower	O
transcription	O
enhancement	O
by	O
sites	O
derived	O
from	O
the	O
interleukin	B-protein
2	I-protein
receptor	I-protein
or	O
T-cell	B-DNA
receptor	I-DNA
genes	I-DNA
in	O
S194	B-cell_line
cells	I-cell_line
.	O

Cellular	O
pathways	O
for	O
induction	O
of	O
programmed	O
cell	O
death	O
(	O
PCD	O
)	O
have	O
been	O
identified	O
,	O
but	O
little	O
is	O
known	O
about	O
specific	O
extracellular	O
matrix	O
processes	O
that	O
may	O
affect	O
apoptosis	O
along	O
those	O
pathways	O
.	O

The	O
SRG3	B-protein
protein	I-protein
contains	O
an	O
acidic	B-protein
NH2	I-protein
terminus	I-protein
,	O
a	O
myb-like	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
,	O
a	O
leucine-zipper	B-protein
motif	I-protein
,	O
and	O
a	O
proline-	B-protein
and	I-protein
glutamine-rich	I-protein
region	I-protein
at	O
its	O
COOH	B-protein
terminus	I-protein
.	O

It	O
is	O
generally	O
assumed	O
that	O
most	O
mammalian	B-DNA
genes	I-DNA
are	O
transcribed	O
from	O
both	O
alleles	B-DNA
.	O

We	O
have	O
shown	O
previously	O
that	O
trifluoromethylketone	O
inhibitors	O
of	O
cytosolic	B-protein
phospholipase	I-protein
A2	I-protein
suppressed	O
interleukin-1beta	O
protein	O
and	O
steady-state	O
mRNA	O
levels	O
in	O
human	O
lipopolysaccharide-stimulated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
.	O

Moreover	O
,	O
the	O
steroid	B-protein
receptor	I-protein
agonist	O
cortisol	O
(	O
10	O
microM	O
)	O
,	O
but	O
not	O
its	O
inactive	O
metabolite	O
tetrahydrocortisol	O
(	O
10	O
microM	O
)	O
,	O
diminished	O
LPS-induced	O
endothelial	O
cell	O
adhesiveness	O
.	O

These	O
data	O
suggest	O
the	O
potential	O
utility	O
of	O
agents	O
that	O
disrupt	O
calcineurin	B-protein
-mediated	O
signal	O
transduction	O
pathways	O
by	O
blocking	O
formation	O
of	O
the	O
catalytically	B-protein
active	I-protein
dimer	I-protein
of	O
calcineurin	B-protein
A	I-protein
and	I-protein
B	I-protein
subunits	I-protein
.	O

Differential	O
monocyte	O
adhesion	O
and	O
adhesion	B-protein
molecule	I-protein
expression	O
in	O
venous	O
and	O
arterial	O
endothelial	O
cells	O
.	O

However	O
,	O
the	O
EKLF-/-	B-cell_line
colonies	I-cell_line
were	O
poorly	O
hemoglobinized	O
and	O
enucleated	B-cell_type
erythrocytes	I-cell_type
in	O
these	O
colonies	O
contained	O
numerous	O
Heinz	O
bodies	O
.	O

Mechanisms	O
for	O
transduction	O
of	O
IL-6	B-protein
-induced	O
signals	O
were	O
then	O
evaluated	O
in	O
IL-6-stimulated	B-cell_line
1A9-M	I-cell_line
cells	I-cell_line
.	O

We	O
report	O
two	O
patients	O
with	O
transient	O
pseudohypoaldosteronism	O
due	O
to	O
obstructive	O
renal	O
disease	O
.	O

Mutation	O
of	O
Ikaros	B-protein
or	O
AP-1	B-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
context	O
of	O
the	O
granzyme	B-DNA
B	I-DNA
promoter	I-DNA
demonstrated	O
that	O
both	O
sites	O
participate	O
in	O
dexamethasone-mediated	O
inhibition	O
of	O
the	O
granzyme	B-DNA
B	I-DNA
promoter	I-DNA
activity	O
.	O

The	O
shift	O
in	O
pRB	B-protein
molecular	O
weight	O
was	O
reproduced	O
by	O
adding	O
exogenous	O
purified	O
tTG	O
to	O
extracts	O
obtained	O
from	O
viable	O
U937	B-cell_line
cells	I-cell_line
and	O
was	O
prevented	O
by	O
dansylcadaverine	O
,	O
a	O
potent	O
enzyme	O
inhibitor	O
.	O

Endogenous	O
and	O
therapeutic	O
steroid	O
hormones	O
affect	O
the	O
immune	O
system	O
,	O
and	O
inflammatory	O
diseases	O
are	O
associated	O
with	O
activation	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
,	O
providing	O
evidence	O
of	O
an	O
immune-endocrine	O
interplay	O
.	O

Specifically	O
,	O
9-cis-RA	O
potently	O
inhibited	O
the	O
growth	O
of	O
BFU-E	O
response	O
to	O
erythropoietin	B-protein
(	O
Epo	B-protein
)	O
(	O
100	O
%	O
)	O
,	O
stem	B-protein
cell	I-protein
factor	I-protein
(	O
SCF	B-protein
)	O
+	O
Epo	B-protein
(	O
92	O
%	O
)	O
,	O
IL-3	B-protein
+	O
Epo	B-protein
(	O
97	O
%	O
)	O
,	O
IL-4	B-protein
+	O
Epo	B-protein
(	O
88	O
%	O
)	O
,	O
and	O
IL-9	B-protein
+	O
Epo	B-protein
(	O
100	O
%	O
)	O
.	O

However	O
,	O
the	O
expression	O
of	O
the	O
CD14	B-protein
Ag	I-protein
,	O
a	O
receptor	B-protein
molecule	I-protein
for	O
LPS-LPS	B-protein
binding	I-protein
protein	I-protein
complexes	I-protein
,	O
was	O
unaffected	O
by	O
gangliosides	O
.	O

We	O
have	O
investigated	O
the	O
role	O
of	O
ascorbate	O
,	O
AFR	O
and	O
dehydroascorbate	O
(	O
DHA	O
)	O
in	O
the	O
activation	O
of	O
the	O
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
in	O
Jurkat	B-cell_line
T-cells	I-cell_line
stimulated	O
by	O
tumour	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O

GC	B-protein
receptor	I-protein
was	O
blocked	O
with	O
mifepristone	O
.	O

Computer-assisted	O
analysis	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
indicates	O
that	O
FKBP	B-protein
exhibits	O
no	O
internal	O
homology	O
and	O
does	O
not	O
have	O
significant	O
sequence	O
similarity	O
to	O
any	O
other	O
amino	O
acid	O
sequences	O
of	O
known	O
proteins	O
,	O
including	O
cyclophilin	B-protein
.	O

In	O
macrophages	B-cell_type
,	O
a	O
slight	O
enhancement	O
of	O
TNF-alpha	B-protein
production	O
was	O
seen	O
,	O
whereas	O
IL-1	B-protein
beta	I-protein
was	O
not	O
detected	O
.	O

In	O
a	O
3	O
day	O
intervention	O
study	O
in	O
which	O
600	O
mg	O
of	O
the	O
antioxidant	O
thioctic	O
acid	O
(	O
alpha-lipoic	O
acid	O
)	O
per	O
day	O
were	O
given	O
to	O
nine	O
patients	O
with	O
diabetic	O
nephropathy	O
oxidative	O
stress	O
in	O
plasma	O
samples	O
was	O
decreased	O
by	O
48	O
%	O
and	O
NF-kappaB	B-protein
binding	O
activity	O
in	O
ex	O
vivo	O
isolated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
by	O
38	O
%	O
.	O

In	O
contrast	O
,	O
levels	O
of	O
the	O
transcriptional	B-protein
factor	I-protein
AP-1	I-protein
,	O
which	O
is	O
not	O
known	O
to	O
be	O
important	O
in	O
B	B-cell_type
cell	I-cell_type
Ig	B-protein
production	O
,	O
were	O
reduced	O
by	O
TGF-beta	B-protein
.	O

Increases	O
in	O
interferon-gamma	B-protein
production	O
and	O
natural	O
killer	O
cell	O
activity	O
in	O
response	O
to	O
IL-18	B-protein
are	O
abrogated	O
.	O

Recent	O
analysis	O
of	O
gene-targeted	O
mice	O
has	O
allowed	O
a	O
direct	O
assessment	O
of	O
the	O
functional	O
roles	O
of	O
several	B-protein
E-protein	I-protein
family	I-protein
members	I-protein
in	O
hematopoiesis	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
CyA	O
,	O
aspirin	O
,	O
and	O
indomethacin	O
on	O
T	O
cell	O
proliferation	O
using	O
a	O
proliferation	O
assay	O
.	O

Using	O
this	O
RAR-selective	O
antagonist	O
,	O
and	O
RXR	B-protein
and	O
RAR	B-protein
agonist	O
,	O
we	O
demonstrate	O
the	O
RAR	B-protein
-mediated	O
signaling	O
pathway	O
is	O
important	O
for	O
differentiation	O
and	O
apoptosis	O
of	O
myeloid	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
.	O

Nuclei	O
from	O
GATA-1	B-cell_line
-mutant	I-cell_line
embryonic	I-cell_line
stem	I-cell_line
cells	I-cell_line
can	O
still	O
be	O
reprogrammed	O
to	O
express	O
their	O
globin	B-DNA
genes	I-DNA
in	O
erythroid	B-cell_type
heterokaryons	I-cell_type
,	O
indicating	O
that	O
de	O
novo	O
induction	O
of	O
GATA-1	B-protein
is	O
not	O
required	O
for	O
globin	B-DNA
gene	I-DNA
activation	O
following	O
cell	O
fusion	O
.	O

We	O
raise	O
the	O
hypothesis	O
that	O
delta	B-protein
Spi-B	I-protein
might	O
affect	O
Spi-B	B-protein
function	O
by	O
recruiting	O
factors	O
involved	O
in	O
Spi-B	B-protein
activity	O
.	O

We	O
now	O
find	O
that	O
cytokine-driven	O
(	O
granulocyte-macrophage	O
CSF	O
and	O
TNF-alpha	O
)	O
CD34+	O
HPC	B-cell_line
--	O
>	O
DC	O
differentiation	O
is	O
preferentially	O
blocked	O
by	O
inhibitors	O
of	O
PKC	B-protein
activation	O
.	O

The	O
results	O
clearly	O
demonstrate	O
that	O
anoxia/reoxygenation	O
(	O
A/R	O
)	O
leads	O
to	O
a	O
biphasic	O
increase	O
in	O
neutrophil	O
adhesion	O
to	O
HUVECs	B-cell_line
,	O
with	O
peak	O
responses	O
occurring	O
at	O
30	O
minutes	O
(	O
phase	O
1	O
)	O
and	O
240	O
minutes	O
(	O
phase	O
2	O
)	O
after	O
reoxygenation	O
.	O

Using	O
deletion	B-DNA
mutants	I-DNA
,	O
the	O
downstream	O
parathyroid	B-DNA
hormone-related	I-DNA
protein	I-DNA
(	I-DNA
PTHrP	I-DNA
)	I-DNA
promoter	I-DNA
is	O
shown	O
to	O
be	O
responsive	O
to	O
both	O
HTLV-I	B-protein
and	I-protein
HTLV-II	I-protein
Tax	I-protein
as	O
well	O
as	O
the	O
AP1/c-jun	B-DNA
proto-oncogene	I-DNA
.	O

We	O
demonstrate	O
that	O
the	O
HIV-1	B-DNA
LTR	I-DNA
responds	O
better	O
than	O
the	O
HIV-2	B-DNA
LTR	I-DNA
to	O
T	O
cell	O
activation	O
signals	O
.	O

LR1	B-protein
also	O
binds	O
Ig	B-protein
heavy	I-protein
chain	I-protein
switch	O
region	O
sequences	O
and	O
may	O
function	O
in	O
class	O
switch	O
recombination	O
.	O

We	O
show	O
here	O
by	O
mobility-shift	O
assay	O
that	O
E2F-containing	B-protein
DNA-binding	I-protein
complexes	I-protein
were	O
detected	O
in	O
HTLV-I-infected	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
and	O
leukemic	B-cell_type
cells	I-cell_type
obtained	O
from	O
ATL	O
patients	O
but	O
not	O
in	O
an	O
uninfected	B-cell_line
T-cell	I-cell_line
line	I-cell_line
,	O
Jurkat	B-cell_line
,	O
and	O
normal	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
,	O
when	O
RBTN-2	B-protein
is	O
inappropriately	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
RBTN-2	B-protein
would	O
interact	O
predominantly	O
with	O
elf-2b	B-protein
;	O
this	O
interaction	O
may	O
lead	O
to	O
T	O
cell	O
proliferation	O
.	O

Due	O
to	O
a	O
switch	O
from	O
the	O
use	O
of	O
a	O
3	B-DNA
'	I-DNA
polyA	I-DNA
site	I-DNA
to	O
a	O
more	O
proximal	B-DNA
polyA	I-DNA
site	I-DNA
,	O
NF-ATc	B-protein
expression	O
switches	O
from	O
the	O
synthesis	O
of	O
the	O
two	O
longer	O
isoforms	O
in	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
that	O
of	O
short	O
isoform	B-protein
A	I-protein
in	O
T	B-cell_type
effector	I-cell_type
cells	I-cell_type
.	O

This	O
is	O
accompanied	O
by	O
opposite	O
glucocorticoid	B-protein
receptor	I-protein
changes	O
,	O
respectively	O
opposing	O
and	O
favoring	O
glucocorticoid	O
actions	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
4-h	O
NK	O
cytolysis	O
assays	O
were	O
performed	O
on	O
IFN-gamma-treated	B-cell_line
human	I-cell_line
cells	I-cell_line
infected	O
with	O
an	O
Ad5	O
E1A	B-DNA
deletion	O
mutant	O
,	O
dl343	O
,	O
or	O
transfected	O
with	O
the	O
Ad5	B-DNA
E1A	I-DNA
gene	I-DNA
.	O

Despite	O
this	O
drastic	O
effect	O
in	O
vivo	O
,	O
the	O
in	O
vitro	O
immortalization	O
of	O
erythropoietin-dependent	B-cell_type
erythroid	I-cell_type
progenitors	I-cell_type
unexpectedly	O
occurred	O
at	O
low	O
frequency	O
,	O
and	O
all	O
four	O
cell	B-cell_line
lines	I-cell_line
established	O
expressed	O
both	O
erythrocytic	B-protein
(	I-protein
globins	I-protein
)	I-protein
and	I-protein
megakaryocytic	I-protein
markers	I-protein
(	O
glycoprotein	B-protein
IIb	I-protein
,	O
platelet	B-protein
factor	I-protein
4	I-protein
)	O
as	O
well	O
as	O
Spi-1	B-protein
and	O
Fli-1	B-protein
transcripts	I-protein
at	O
permissive	O
temperature	O
.	O

The	O
finding	O
that	O
HL-60/vinc/R	B-cell_line
cells	I-cell_line
respond	O
to	O
TPA	O
with	O
induction	O
of	O
a	O
monocytic	O
phenotype	O
,	O
but	O
not	O
c-jun	B-DNA
expression	O
,	O
suggests	O
that	O
c-jun	B-DNA
induction	O
is	O
not	O
obligatory	O
for	O
monocytic	O
differentiation	O
.	O

Northern	O
blot	O
analysis	O
revealed	O
in	O
these	O
cells	O
,	O
an	O
increase	O
in	O
the	O
transcription	O
of	O
these	O
two	O
proto-oncogenes	B-DNA
,	O
and	O
this	O
increase	O
was	O
amplified	O
after	O
treatment	O
with	O
phorbol	O
myristate	O
acetate	O
.	O

MBP	B-protein
also	O
induced	O
transient	O
increases	O
in	O
mRNA	B-RNA
for	O
macrophage	B-protein
inflammatory	I-protein
protein	I-protein
(	I-protein
MIP	I-protein
)	I-protein
-1alpha	I-protein
and	O
MIP-1beta	B-protein
,	O
but	O
did	O
not	O
stimulate	O
the	O
release	O
of	O
either	O
chemokine	B-protein
.	O

cDNA	B-DNA
clones	I-DNA
for	O
the	O
human	B-protein
erythroid	I-protein
ALAS	I-protein
isozyme	I-protein
were	O
isolated	O
from	O
a	O
fetal	O
liver	O
library	O
.	O

Coordination	O
of	O
the	O
immune	O
response	O
to	O
injury	O
or	O
disease	O
in	O
the	O
brain	O
is	O
postulated	O
to	O
involve	O
bi-directional	O
discourse	O
between	O
the	O
immune	O
system	O
and	O
the	O
central	O
nervous	O
system	O
.	O

The	O
development	O
of	O
improved	O
glucocorticoid-based	O
drugs	O
will	O
require	O
the	O
separation	O
of	O
beneficial	O
from	O
deleterious	O
effects	O
.	O

We	O
previously	O
suggested	O
that	O
the	O
measurement	O
of	O
corticosteroid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
is	O
an	O
index	O
of	O
an	O
analogous	O
pattern	O
in	O
brain	O
.	O

Gene	O
inactivation	O
studies	O
on	O
the	O
PU.1	B-DNA
,	I-DNA
Ikaros	I-DNA
and	I-DNA
GATA-3	I-DNA
genes	I-DNA
have	O
revealed	O
that	O
their	O
encoded	O
factors	O
are	O
essential	O
for	O
the	O
earliest	O
commitment	O
step	O
into	O
the	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
lymphoid	I-cell_type
lineages	I-cell_type
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
IL-10-activated	B-protein
STAT1	I-protein
has	O
a	O
specificity	O
in	O
binding	O
to	O
the	O
GAS-motif	B-DNA
sequences	I-DNA
,	O
whereas	O
IFN-gamma-activated	B-protein
STAT1	I-protein
and	O
STAT5	B-protein
have	O
a	O
broader	O
spectrum	O
in	O
binding	O
to	O
the	O
GAS-motif	B-DNA
sequences	I-DNA
.	O

A	O
direct	O
temporal	O
correlation	O
exists	O
between	O
HIV	O
infection	O
and	O
the	O
appearance	O
of	O
NF-kappaB	B-protein
DNA-binding	O
activity	O
in	O
myelomonoblastic	B-cell_line
PLB-985	I-cell_line
cells	I-cell_line
.	O

Little	O
effect	O
was	O
observed	O
with	O
50-kDa	B-protein
forms	I-protein
of	O
p105	B-protein
NF-kappa	B-protein
B	I-protein
or	O
rel	B-protein
,	O
in	O
combination	O
with	O
p65	B-protein
or	O
full-length	B-protein
c-rel	I-protein
,	O
which	O
do	O
not	O
stimulate	O
the	O
HIV	B-DNA
enhancer	I-DNA
in	O
these	O
cells	O
.	O

High	O
retinoidal	O
activity	O
(	O
agonist	O
or	O
antagonist	O
for	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
(	O
RAR	B-protein
)	O
requires	O
a	O
carboxylic	O
acid	O
moiety	O
and	O
an	O
appropriate	O
hydrophobic	O
group	O
located	O
at	O
a	O
suitable	O
position	O
on	O
the	O
molecule	O
.	O

Effects	O
of	O
aldosterone	O
on	O
intralymphocytic	O
sodium	O
and	O
potassium	O
in	O
patients	O
with	O
essential	O
hypertension	O
.	O

The	O
human	B-DNA
T-cell	I-DNA
leukemia	I-DNA
virus	I-DNA
type	I-DNA
I	I-DNA
(	I-DNA
HTLV-I	I-DNA
)	I-DNA
promoter	I-DNA
contains	O
three	O
copies	O
of	O
imperfect	O
repeats	O
of	O
a	O
21-base	O
pair	O
sequence	O
designated	O
here	O
as	O
TRE	B-DNA
(	O
Tax-response	B-DNA
element	I-DNA
)	O
that	O
is	O
responsive	O
to	O
the	O
virally	B-protein
encoded	I-protein
transactivator	I-protein
protein	I-protein
Tax	B-protein
.	O

Recently	O
,	O
the	O
transcription	B-protein
factor	I-protein
GATA-3	B-protein
was	O
shown	O
to	O
be	O
selectively	O
expressed	O
in	O
Th2	O
but	O
not	O
Th1	B-cell_type
cells	I-cell_type
and	O
to	O
augment	O
Th2-specific	B-protein
cytokines	I-protein
.	O

The	O
main	O
aims	O
of	O
this	O
work	O
were	O
to	O
examine	O
in	O
women	O
:	O
the	O
relationship	O
between	O
the	O
freely	O
exchangeable	O
Ca2+	O
(	O
FECa2+	O
)	O
in	O
the	O
dense	O
tubules	O
and	O
the	O
activity	O
of	O
the	O
sarco	B-protein
(	I-protein
endo	I-protein
)	I-protein
plasmic	I-protein
reticulum	I-protein
(	I-protein
SER	I-protein
)	I-protein
Ca2+-ATPase	I-protein
(	I-protein
SERCA	I-protein
)	I-protein
in	O
platelets	B-cell_type
,	O
and	O
the	O
relationship	O
of	O
these	O
parameters	O
with	O
blood	O
pressure	O
and	O
serum	B-protein
lipoproteins	I-protein
.	O

The	O
heterogeneous	B-protein
nuclear	I-protein
ribonucleoprotein	I-protein
K	I-protein
protein	I-protein
represents	O
a	O
novel	O
class	O
of	O
proteins	O
that	O
may	O
act	O
as	O
docking	O
platforms	O
that	O
orchestrate	O
cross-talk	O
among	O
molecules	O
involved	O
in	O
signal	O
transduction	O
and	O
gene	O
expression	O
.	O

Another	O
important	O
region	O
is	O
downstream	O
of	O
the	O
BOX1	B-protein
motif	I-protein
and	O
contains	O
a	O
STAT3	B-DNA
binding	I-DNA
motif	I-DNA
YLPQ	B-DNA
.	O

Both	O
ATF/CRE	B-DNA
motifs	I-DNA
overlap	O
binding	B-DNA
sequences	I-DNA
for	O
the	O
multifunctional	B-protein
YY1	I-protein
transcription	I-protein
factor	I-protein
,	O
which	O
has	O
previously	O
been	O
shown	O
to	O
be	O
nuclear	O
matrix	O
associated	O
.	O

A	O
second	O
translocation	O
adjacent	O
to	O
rhombotin	B-DNA
was	O
found	O
and	O
at	O
the	O
same	O
position	O
as	O
in	O
the	O
previous	O
example	O
.	O

However	O
,	O
TNF	B-protein
signaling	O
is	O
largely	O
abolished	O
,	O
as	O
judged	O
by	O
the	O
failure	O
of	O
TNF	B-protein
to	O
induce	O
NF-kappa	B-protein
B	I-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
from	O
TNFRp55	B-protein
-deficient	O
mice	O
.	O

The	O
presence	O
of	O
aberrant	O
ER	B-protein
forms	O
in	O
Oestrogen-dependent	O
tumours	O
has	O
been	O
discussed	O
in	O
correlation	O
with	O
tumour	O
progression	O
.	O

In	O
addition	O
,	O
seeking	O
social	O
support	O
as	O
a	O
coping	O
strategy	O
,	O
as	O
well	O
as	O
the	O
perceived	O
quality	O
of	O
support	O
,	O
also	O
entered	O
the	O
model	O
to	O
account	O
for	O
a	O
significant	O
amount	O
of	O
NK	O
activity	O
variance	O
(	O
multivariate	O
F	O
=	O
5.25	O
,	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Contrary	O
to	O
the	O
interaction	O
with	O
PKC	B-protein
,	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
synergize	O
with	O
TNF-alpha	B-protein
not	O
at	O
the	O
level	O
of	O
IkB	B-protein
alpha	I-protein
phosphorylation	O
,	O
but	O
at	O
the	O
level	O
of	O
its	O
degradation	O
.	O

When	O
transcriptionally	O
active	O
,	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
promoter	B-DNA
contains	O
a	O
nucleosome-free	O
region	O
encompassing	O
both	O
the	O
promoter/enhancer	B-DNA
region	I-DNA
and	O
a	O
large	O
region	O
(	O
255	B-DNA
nucleotides	I-DNA
[	O
nt	O
]	O
)	O
downstream	O
of	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
.	O

We	O
therefore	O
reexamined	O
this	O
issue	O
by	O
using	O
two	O
different	O
experimental	O
approaches	O
that	O
allowed	O
LMP1	B-protein
-induced	O
effects	O
to	O
be	O
monitored	O
immediately	O
following	O
expression	O
of	O
the	O
viral	O
protein	O
and	O
in	O
the	O
absence	O
of	O
selective	O
pressures	O
;	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	B-protein
factor	I-protein
and	O
upregulation	O
of	O
the	O
cell	B-protein
adhesion	I-protein
molecule	I-protein
ICAM-1	B-protein
were	O
used	O
as	O
early	O
indices	O
of	O
LMP1	B-protein
function	O
.	O

Three	O
RFLPs	B-DNA
(	O
TaqI	B-DNA
,	O
ApaI	B-DNA
,	O
BsmI	B-DNA
)	O
define	O
two	O
common	O
haplotypes	O
:	O
BAt	O
and	O
baT	O
.	O

We	O
describe	O
a	O
patient	O
with	O
APL	O
in	O
whom	O
the	O
leukaemic	O
clone	O
was	O
characterized	O
by	O
a	O
true	O
variant	O
of	O
the	O
classical	B-DNA
t	I-DNA
(	I-DNA
15	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
.	O

NF-kappaB	B-protein
only	O
partially	O
mediates	O
Epstein-Barr	B-protein
virus	I-protein
latent	I-protein
membrane	I-protein
protein	I-protein
1	I-protein
activation	O
of	O
B	O
cells	O
.	O

These	O
studies	O
suggest	O
that	O
antagonism	O
by	O
dexamethasone	O
of	O
endotoxin	B-protein
-induced	O
inflammation	O
is	O
a	O
specific	O
instance	O
of	O
the	O
general	O
biological	O
principle	O
that	O
the	O
glucocorticoid	B-protein
receptor	I-protein
is	O
a	O
hormone-dependent	O
regulator	O
of	O
transcription	O
.	O

Gel-shift	O
analysis	O
reveals	O
the	O
constitutive	O
presence	O
of	O
nuclear	O
factors	O
in	O
resting	B-cell_type
PBL	I-cell_type
that	O
bind	O
to	O
the	O
proximal	B-DNA
AP-1	I-DNA
site	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
that	O
contain	O
immunoreactive	O
c-Jun	B-protein
but	O
not	O
c-Fos	B-protein
protein	O
.	O

We	O
have	O
developed	O
a	O
three-layer	O
Percoll	O
density	O
gradient	O
that	O
allows	O
separation	O
of	O
the	O
different	O
granules	O
and	O
vesicles	O
from	O
human	B-cell_type
neutrophils	I-cell_type
;	O
in	O
particular	O
,	O
it	O
allows	O
separation	O
of	O
specific	O
and	O
gelatinase	O
granules	O
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
and	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
are	O
produced	O
by	O
stimulation	O
with	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
leukemia	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
.	O

This	O
stimulation	O
can	O
also	O
be	O
abolished	O
by	O
inhibitors	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
but	O
it	O
is	O
unaffected	O
by	O
calcium	O
channel	O
blocker	O
or	O
cyclosporine	O
A	O
.	O

Pseudohypoaldosteronism	O
in	O
eight	O
families	O
:	O
different	O
forms	O
of	O
inheritance	O
are	O
evidence	O
for	O
various	O
genetic	O
defects	O
.	O

In	O
this	O
report	O
we	O
begin	O
to	O
uncover	O
the	O
influence	O
of	O
platelet-activating	B-protein
factor	I-protein
on	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

Analysis	O
of	O
interactions	O
between	O
huGATA-3	B-protein
transcription	O
factor	O
and	O
three	O
GATA	B-DNA
regulatory	I-DNA
elements	I-DNA
of	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
by	O
surface	O
plasmon	O
resonance	O
.	O

(	O
iii	O
)	O
LMP1	B-protein
expression	O
in	O
Daudi	B-cell_line
and	O
P3HR-1-infected	B-cell_line
cells	I-cell_line
was	O
controlled	O
at	O
the	O
mRNA	B-RNA
level	O
,	O
and	O
EBNA-2	B-protein
expression	O
in	O
Daudi	B-cell_line
cells	I-cell_line
increased	O
LMP1	B-RNA
mRNA	I-RNA
.	O

Some	O
enhancing	O
regions	O
contained	O
consensus	O
,	O
GATA	B-DNA
sites	I-DNA
that	O
bound	O
Th2-specific	B-protein
complexes	I-protein
.	O

Immunoelectron	O
microscopy	O
revealed	O
LANDs	O
to	O
be	O
globular	O
,	O
electron-dense	O
structures	O
morphologically	O
distinct	O
from	O
the	O
annular	O
structures	O
characteristic	O
of	O
PML	O
NBs	O
.	O

NF-IL6	B-protein
is	O
an	O
important	O
transcriptional	O
regulator	O
of	O
genes	O
induced	O
in	O
activated	B-cell_type
monocytes/macrophages	I-cell_type
,	O
and	O
NF-IL6	B-protein
is	O
the	O
only	O
CCAAT/enhancer-binding	B-protein
protein	I-protein
(	I-protein
C/EBP	I-protein
)	I-protein
family	I-protein
member	O
whose	O
steady-state	O
mRNA	O
levels	O
increase	O
upon	O
activation	O
of	O
monocytes	B-cell_type
(	O
1	O
)	O
.	O

Accordingly	O
,	O
Western	O
blots	O
with	O
antibodies	B-protein
specific	O
for	O
the	O
DNA-binding	O
domain	O
,	O
that	O
is	O
common	O
to	O
all	O
forms	O
,	O
identify	O
multiple	O
proteins	O
.	O

We	O
conclude	O
that	O
downregulation	O
of	O
WT1	B-DNA
during	O
induced	O
differentiation	O
of	O
K562	B-cell_line
cells	I-cell_line
is	O
not	O
a	O
prerequisite	O
for	O
erythroid	O
or	O
megakaryocytic	O
differentiation	O
of	O
these	O
cells	O
.	O

Using	O
FACS	O
,	O
Northern	O
blotting	O
,	O
and	O
nuclear	O
run-on	O
analyses	O
,	O
we	O
demonstrate	O
that	O
the	O
up-regulation	O
of	O
CD14	B-protein
expression	O
during	O
monocytic	O
cell	O
maturation	O
is	O
regulated	O
mainly	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
,	O
and	O
that	O
new	O
protein	O
synthesis	O
is	O
required	O
for	O
CD14	B-protein
induction	O
.	O

Here	O
,	O
we	O
intend	O
to	O
demonstrate	O
the	O
requirement	O
of	O
GATA-1	B-protein
and	O
NF-E2	B-protein
transcription	B-protein
factors	I-protein
in	O
the	O
BA-induced	O
erythroid	O
differentiation	O
of	O
human	B-cell_line
leukemic	I-cell_line
K562	I-cell_line
cells	I-cell_line
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
IgH-luciferase	B-DNA
construct	I-DNA
was	O
induced	O
upon	O
ligation	O
of	O
the	O
full-length	B-protein
chimeric	I-protein
receptor	I-protein
but	O
not	O
by	O
truncated	B-protein
gp130	I-protein
receptors	I-protein
.	O

In	O
contrast	O
,	O
FK506	O
or	O
EGTA	O
(	O
Ca2+	O
chelator	O
)	O
similarly	O
affected	O
the	O
formation	O
of	O
kappa	B-protein
B-like	I-protein
site	I-protein
binding	I-protein
complexes	I-protein
,	O
which	O
were	O
not	O
recognized	O
by	O
any	O
antibodies	B-protein
against	O
the	O
human	B-protein
Rel	I-protein
family	I-protein
proteins	I-protein
(	O
c-Rel	B-protein
,	O
p65	B-protein
,	O
p50	B-protein
,	O
and	O
p49	B-protein
)	O
.	O

Thus	O
,	O
IL-10	B-protein
inhibits	O
IFN-gamma	B-protein
-induced	O
ICAM-1	B-protein
expression	O
in	O
monocytes	B-cell_type
primarily	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

NF-	O
CLE0	B-DNA
gamma	O
binding	O
is	O
induced	O
by	O
PMA/A23187	O
and	O
is	O
inhibited	O
by	O
treatment	O
with	O
CsA	O
.	O

The	O
gene	O
encoding	O
the	O
retinoic	B-protein
acid-synthesizing	I-protein
enzyme	I-protein
aldehyde	B-protein
dehydrogenase	I-protein
1	I-protein
(	O
Aldh1	B-protein
)	O
,	O
initially	O
called	O
Hdg-1	B-protein
,	O
was	O
found	O
to	O
be	O
ectopically	O
activated	O
by	O
HOX11	B-protein
in	O
this	O
system	O
.	O

We	O
thus	O
propose	O
that	O
during	O
an	O
in	O
vivo	O
chronic	O
response	O
,	O
a	O
narrow	O
range	O
of	O
avidity	O
of	O
the	O
TCR-CD8	B-protein
complex	I-protein
conditions	O
long-term	O
clonotype	O
persistence	O
,	O
and	O
that	O
the	O
level	O
of	O
CD8	B-protein
contribution	O
is	O
adjusted	O
to	O
keep	O
clonotypes	O
with	O
variable	O
TCR	B-protein
affinities	O
within	O
this	O
avidity	O
window	O
.	O

To	O
examine	O
whether	O
an	O
active	O
negative	O
regulatory	O
process	O
occurs	O
,	O
we	O
created	O
a	O
reporter	B-DNA
construct	I-DNA
containing	O
as	O
an	O
enhancer	B-DNA
four	O
copies	O
of	O
the	O
NF-AT	B-DNA
site	I-DNA
and	O
one	O
copy	O
of	O
the	O
octamer	B-DNA
site	I-DNA
(	O
4X	B-DNA
NF-AT-Oct	I-DNA
)	O
.	O

The	O
molecular	O
cloning	O
of	O
the	O
NFAT	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
has	O
facilitated	O
rapid	O
progress	O
in	O
the	O
understanding	O
of	O
the	O
signalling	O
mechanisms	O
that	O
control	O
the	O
activity	O
of	O
NFAT	B-protein
.	O

In	O
monocytic	B-cell_type
cells	I-cell_type
,	O
IL-1beta	B-protein
treatment	O
led	O
to	O
a	O
production	O
of	O
ROIs	O
which	O
is	O
independent	O
of	O
the	O
5-LOX	B-protein
enzyme	I-protein
but	O
requires	O
the	O
NADPH	O
oxidase	O
activity	O
.	O

Double-stimulation	O
was	O
used	O
to	O
demonstrate	O
that	O
,	O
in	O
a	O
T	B-cell_line
lymphocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
CEM	B-cell_line
)	O
,	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
rapidly	O
induced	O
NF-kappa	B-protein
B	I-protein
through	O
a	O
signaling	O
pathway	O
which	O
did	O
not	O
involve	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
and	O
was	O
different	O
from	O
the	O
activation	O
triggered	O
by	O
either	O
H2O2	O
or	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O

Phosphorylation	O
of	O
Jak2	B-protein
in	O
tax	B-cell_line
transformed	I-cell_line
cells	I-cell_line
resulted	O
from	O
high	O
expression	O
of	O
IL-6	O
.	O

A	O
polymorphism	O
that	O
affects	O
OCT-1	B-protein
binding	O
to	O
the	O
TNF	B-DNA
promoter	I-DNA
region	I-DNA
is	O
associated	O
with	O
severe	O
malaria	O
[	O
see	O
comments	O
]	O

The	O
HIV-2	B-DNA
LTR	I-DNA
was	O
found	O
to	O
contain	O
two	O
enhancers	B-DNA
.	O

The	O
number	O
of	O
mineralocorticoid	B-protein
receptors	I-protein
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
was	O
in	O
the	O
lower	O
normal	O
range	O
for	O
age	O
,	O
while	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
was	O
reduced	O
.	O

Currently	O
,	O
adenovirus	O
(	O
Ad	O
)	O
is	O
being	O
considered	O
as	O
a	O
vector	O
for	O
the	O
treatment	O
of	O
cystic	O
fibrosis	O
as	O
well	O
as	O
other	O
diseases	O
.	O

Finally	O
,	O
in	O
JAK-1-deficient	B-cell_line
HeLa	I-cell_line
cells	I-cell_line
,	O
STAT6	B-protein
activation	O
by	O
IL-4	B-protein
is	O
completely	O
abolished	O
.	O

Therefore	O
,	O
the	O
mechanisms	O
leading	O
to	O
disruption	O
of	O
EBV	O
latency	O
appear	O
to	O
be	O
cell-type	O
specific	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
determine	O
whether	O
CD14	B-protein
is	O
expressed	O
in	O
gingival	B-cell_type
fibroblasts	I-cell_type
and	O
to	O
define	O
the	O
P-LPS-mediated	O
signal-transducing	B-protein
mechanism	O
in	O
the	O
cells	O
.	O

The	O
transactivator	O
HTLV-I	B-protein
Tax	I-protein
activates	O
the	O
promoter	B-DNA
of	O
the	O
gene	O
coding	O
for	O
the	O
interleukin	B-protein
2	I-protein
alpha-chain	I-protein
receptor	I-protein
(	O
IL-2R	B-protein
alpha	I-protein
)	O
via	O
a	O
kappa	B-DNA
B	I-DNA
site	I-DNA
that	O
can	O
bind	O
several	O
protein	O
species	O
of	O
the	O
rel	B-protein
family	I-protein
.	O

However	O
,	O
the	O
intracellular	O
mechanisms	O
for	O
these	O
effects	O
of	O
ethanol	O
are	O
yet	O
to	O
be	O
understood	O
.	O

Coexpression	O
of	O
the	O
interleukin-13	B-DNA
and	I-DNA
interleukin-4	I-DNA
genes	I-DNA
correlates	O
with	O
their	O
physical	O
linkage	O
in	O
the	O
cytokine	B-DNA
gene	I-DNA
cluster	I-DNA
on	O
human	B-DNA
chromosome	I-DNA
5q23-31	I-DNA
.	O

On	O
the	O
other	O
hand	O
,	O
PNU156804	O
efficiently	O
inhibits	O
the	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
transcription	O
factors	O
.	O

Further	O
,	O
the	O
method	O
described	O
can	O
be	O
used	O
to	O
monitor	O
disease	O
progression	O
.	O

Finally	O
,	O
the	O
AP-1	B-DNA
(	I-DNA
-186	I-DNA
to	I-DNA
-176	I-DNA
)	I-DNA
and	I-DNA
the	I-DNA
kappa	I-DNA
B	I-DNA
sites	I-DNA
(	O
-206	B-DNA
to	I-DNA
-195	I-DNA
)	O
respond	O
to	O
different	O
cellular	O
activation	O
in	O
EL4	B-cell_line
cells	I-cell_line
.	O

Here	O
we	O
report	O
the	O
expression	O
of	O
a	O
fork	B-protein
head	I-protein
domain	I-protein
protein	I-protein
in	O
human	B-cell_type
T	I-cell_type
helper	I-cell_type
cells	I-cell_type
.	O

The	O
gC2-	B-cell_line
and	I-cell_line
gD2-specific	I-cell_line
CD4+	I-cell_line
clones	I-cell_line
had	O
cytotoxic	O
activity	O
.	O

This	O
expression	O
pattern	O
can	O
not	O
be	O
accounted	O
for	O
by	O
cell-cycle	O
position	O
or	O
heritable	O
variation	O
.	O

IL-6	O
levels	O
in	O
all	O
IBD	O
groups	O
with	O
and	O
without	O
steroids	O
were	O
significantly	O
different	O
from	O
those	O
in	O
control	O
subjects	O
.	O

Although	O
BCL-6	B-protein
(	O
-	O
)	O
/syn-1	O
(	O
+	O
)	O
RS	B-cell_line
cells	I-cell_line
of	O
HIV-HD	O
express	O
CD40	B-protein
,	O
they	O
are	O
not	O
surrounded	O
by	O
CD40	B-cell_type
ligand-positive	I-cell_type
(	I-cell_type
CD40L+	I-cell_type
)	I-cell_type
reactive	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
which	O
,	O
in	O
HD	O
of	O
the	O
general	O
population	O
,	O
are	O
thought	O
to	O
regulate	O
the	O
disease	O
phenotype	O
through	O
CD40	B-protein
/CD40L	B-protein
interactions	O
.	O

The	O
Epstein-Barr	O
virus	O
latent	B-protein
membrane	I-protein
protein-1	I-protein
(	O
LMP-1	B-protein
)	O
is	O
an	O
integral	B-protein
membrane	I-protein
protein	I-protein
which	O
transforms	O
fibroblasts	B-cell_type
and	O
is	O
essential	O
for	O
EBV-mediated	O
B-cell	O
immortalization	O
.	O

The	O
action	O
of	O
glucocorticosteroids	O
is	O
mediated	O
through	O
glucocorticoid	B-protein
receptors	I-protein
present	O
in	O
the	O
cellular	O
cytoplasm	O
.	O

The	O
number	O
of	O
GCR	B-protein
may	O
be	O
improved	O
by	O
inhalation	O
of	O
oxygen	O
.	O

Hormone-induced	O
Tax	B-protein
activation	O
induces	O
a	O
long-lasting	O
activation	O
of	O
NF-kappaB	B-protein
,	O
which	O
is	O
a	O
major	O
target	O
of	O
reactive	O
oxygen	O
intermediates	O
.	O

Expression	O
of	O
a	O
highly	O
specific	O
protein	O
inhibitor	O
for	O
cyclic	B-protein
AMP-dependent	I-protein
protein	I-protein
kinases	I-protein
in	O
interleukin-1	B-cell_line
(	I-cell_line
IL-1	I-cell_line
)	I-cell_line
-responsive	I-cell_line
cells	I-cell_line
blocked	O
IL-1-induced	B-DNA
gene	I-DNA
transcription	O
that	O
was	O
driven	O
by	O
the	O
kappa	B-DNA
immunoglobulin	I-DNA
enhancer	I-DNA
or	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
.	O

Cupric	O
ion	O
blocks	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
through	O
inhibiting	O
the	O
signal-induced	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

Interaction	O
of	O
fibronectin	B-protein
with	O
VLA-5	B-protein
receptor	I-protein
on	O
CD4	B-cell_line
cells	I-cell_line
induces	O
the	O
AP-1	B-protein
transcription	I-protein
factor	I-protein
.	O

To	O
assess	O
the	O
phosphorylation	O
of	O
serine	O
residues	O
of	O
STAT1	B-protein
and	O
STAT3	B-protein
in	O
CLL	B-cell_line
cells	I-cell_line
,	O
we	O
raised	O
antibodies	O
that	O
specifically	O
recognize	O
the	O
form	O
of	O
STAT1	B-protein
phosphorylated	O
on	O
ser-727	O
and	O
the	O
form	O
of	O
STAT3	B-protein
phosphorylated	O
on	O
ser-727	O
.	O

Differential	O
inhibition	O
of	O
Smad6	B-protein
and	O
Smad7	B-protein
on	O
bone	O
morphogenetic	O
protein-	O
and	O
activin-mediated	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Characterization	O
of	O
a	O
CD43/leukosialin	B-protein
-mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	B-cell_type
T-lymphoblastoid	I-cell_type
cells	I-cell_type
.	O

We	O
further	O
show	O
that	O
subdominant	O
latent	O
cycle	O
reactivities	O
to	O
epitopes	O
in	O
the	O
latent	B-protein
membrane	I-protein
protein	I-protein
LMP2	I-protein
,	O
though	O
rarely	O
undetectable	O
in	O
LCL	B-cell_line
-stimulated	O
populations	O
,	O
can	O
be	O
reactivated	O
by	O
DC	O
stimulation	O
and	O
selectively	O
expanded	O
as	O
polyclonal	O
CTL	B-cell_line
lines	I-cell_line
;	O
the	O
adoptive	O
transfer	O
of	O
such	O
preparations	O
may	O
be	O
of	O
value	O
in	O
targeting	O
certain	O
EBV-positive	O
malignancies	O
.	O

Our	O
results	O
demonstrate	O
that	O
short-term	O
incubation	O
of	O
these	O
cells	O
with	O
oxLDL	B-protein
activated	I-protein
p50/p65	I-protein
containing	O
NF-kappa	B-protein
B	I-protein
dimers	I-protein
and	O
induced	O
the	O
expression	O
of	O
the	O
target	B-DNA
gene	I-DNA
IL-8	I-DNA
.	O

In	O
addition	O
,	O
H-7	O
(	O
10	O
microM	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
serine/threonine	B-protein
kinases	I-protein
,	O
significantly	O
blocked	O
IL-10	B-protein
mediated	O
c-fos	B-DNA
expression	O
(	O
p	O
<	O
0.05	O
)	O
.	O

To	O
study	O
whether	O
this	O
represents	O
glucocorticoid	O
(	O
GC	O
)	O
resistance	O
,	O
[	O
3H	O
]	O
-DEX-binding	O
assays	O
were	O
used	O
to	O
measure	O
,	O
in	O
vitro	O
,	O
the	O
GC	B-protein
receptor	I-protein
affinity	O
(	O
1/Kd	O
)	O
and	O
number	O
(	O
Bmax	O
)	O
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
of	O
11	O
MDD	O
patients	O
and	O
15	O
control	O
subjects	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
molecular	O
mechanism	O
by	O
which	O
agents	O
that	O
elevate	O
intracellular	O
cAMP	O
inhibit	O
the	O
expression	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNFalpha	B-protein
)	O
,	O
tissue	B-protein
factor	I-protein
,	O
endothelial	B-protein
leukocyte	I-protein
adhesion	I-protein
molecule-1	I-protein
,	O
and	O
vascular	B-DNA
cell	I-DNA
adhesion	I-DNA
molecule-1	I-DNA
genes	I-DNA
.	O

Deletion	O
of	O
the	O
PLZF	B-protein
POZ	I-protein
domain	I-protein
partially	O
abrogated	O
the	O
inhibitory	O
effect	O
of	O
PLZF-RAR	B-protein
alpha	I-protein
on	O
RA-induced	O
differentiation	O
and	O
on	O
RA-mediated	O
type	B-protein
II	I-protein
TGase	I-protein
up-regulation	O
,	O
suggesting	O
that	O
POZ-mediated	O
protein	O
interactions	O
might	O
be	O
responsible	O
for	O
the	O
inhibitory	O
transcriptional	O
activities	O
of	O
PLZF-RAR	B-protein
alpha	I-protein
.	O

Here	O
we	O
demonstrate	O
that	O
both	O
Smad6	B-protein
and	O
Smad7	B-protein
are	O
human	B-protein
bone	I-protein
morphogenetic	I-protein
protein-2	I-protein
(	O
hBMP-2	B-protein
)	O
-inducible	O
antagonists	O
of	O
hBMP-2	B-protein
-induced	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
mouse	B-cell_line
B	I-cell_line
cell	I-cell_line
hybridoma	I-cell_line
HS-72	B-cell_line
cells	I-cell_line
.	O

Increased	O
interleukin	B-protein
2	I-protein
transcription	O
in	O
murine	B-cell_type
lymphocytes	I-cell_type
by	O
ciprofloxacin	O
.	O

We	O
used	O
oligonucleotide	O
probes	O
from	O
the	O
beta-casein	B-DNA
and	I-DNA
IRF-1	I-DNA
gene	I-DNA
promoters	I-DNA
and	O
the	O
ISRE	O
probe	O
to	O
detect	O
STAT	B-protein
proteins	I-protein
in	O
nuclear	O
extracts	O
from	O
acute	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
in	O
bandshift	O
assays	O
.	O

Only	O
a	O
few	O
cells	O
showed	O
viral	B-protein
capsid	I-protein
antigen	I-protein
(	O
VCA	B-protein
)	O
.	O

Present	O
data	O
suggest	O
that	O
H2O2	O
and	O
vanadate	O
are	O
likely	O
to	O
inhibit	O
the	O
activity	O
of	O
intracellular	B-protein
tyrosine	I-protein
phosphatase	I-protein
(	O
s	O
)	O
,	O
leading	O
to	O
enhanced	O
STAT3	B-protein
tyrosine	O
phosphorylation	O
and	O
hence	O
its	O
translocation	O
to	O
the	O
nucleus	O
.	O

Four	O
patients	O
(	O
22	O
%	O
)	O
had	O
a	O
family	O
history	O
of	O
breast/ovarian	O
cancer	O
in	O
at	O
least	O
one	O
first-	O
or	O
second-degree	O
relative	O
;	O
however	O
,	O
no	O
BRCA2	B-DNA
mutation	O
was	O
identified	O
among	O
them	O
.	O

Changes	O
in	O
c-fos	B-DNA
expression	O
induced	O
by	O
radiation	O
therapy	O
in	O
tumor	O
tissues	O
have	O
not	O
yet	O
been	O
reported	O
.	O

Hox11	B-DNA
is	O
a	O
homeobox	B-DNA
gene	I-DNA
essential	O
for	O
spleen	O
formation	O
in	O
mice	O
,	O
since	O
atrophy	O
of	O
the	O
anlage	O
of	O
a	O
developing	O
spleen	O
occurs	O
in	O
early	O
embryonic	O
development	O
in	O
Hox11	O
null	O
mice	O
.	O

Mildly	O
oxLDLs	B-protein
(	O
50	O
and	O
100	O
microgram/ml	O
)	O
decreased	O
the	O
number	O
of	O
lymphoblasts	B-cell_type
and	O
the	O
level	O
of	O
IL-2	O
concentration	O
in	O
the	O
culture	O
supernatants	O
after	O
activation	O
of	O
lymphocytes	B-cell_type
by	O
phytohaemagglutinin	B-protein
and	O
PMA+ionomycin	O
.	O

Mutual	O
association	O
of	O
signal	B-protein
transducing	I-protein
proteins	I-protein
within	O
the	O
receptor	O
complex	O
was	O
then	O
studied	O
in	O
dependence	O
of	O
ligand	O
stimulation	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
growth	B-protein
factor	I-protein
does	O
induce	O
the	O
activation	O
of	O
STAT3	B-protein
and	O
STAT5	B-protein
in	O
these	O
cells	O
,	O
as	O
has	O
been	O
previously	O
demonstrated	O
.	O

The	O
binding	O
affinity	O
was	O
not	O
different	O
between	O
patients	O
and	O
controls	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
a	O
unique	O
involvement	O
of	O
the	O
RXR-RXR	B-protein
pathway	O
in	O
mediating	O
growth	O
inhibition	O
of	O
erythroid	B-cell_type
but	O
not	O
myeloid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

Cutting	O
edge	O
:	O
dominant	O
effect	O
of	O
Ile50Val	B-protein
variant	I-protein
of	O
the	O
human	B-protein
IL-4	I-protein
receptor	I-protein
alpha-chain	I-protein
in	O
IgE	B-protein
synthesis	O
.	O

The	O
process	O
of	O
activation	O
involves	O
calcium	O
mobilization	O
,	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
,	O
and	O
phosphorylation	O
of	O
tyrosine	B-protein
kinases	I-protein
.	O

These	O
results	O
suggest	O
that	O
two	O
distinct	O
IL-4	B-protein
signaling	O
pathways	O
exist	O
.	O

Mitochondrial	O
transmembrane	O
potential	O
(	O
delta	O
psi	O
(	O
m	O
)	O
)	O
was	O
measured	O
by	O
means	O
of	O
rhodamine	O
123	O
staining	O
and	O
flow	O
cytometry	O
.	O

We	O
identified	O
several	O
genes	O
up-regulated	O
by	O
IL-12	B-protein
,	O
namely	O
,	O
MIP-1alpha	B-protein
,	O
MIP-1beta	B-protein
,	O
IL-1RA	B-protein
,	O
and	O
IFN	B-protein
regulatory	I-protein
factor-1	I-protein
(	I-protein
IRF-1	I-protein
)	I-protein
.	O

In	O
this	O
study	O
we	O
have	O
produced	O
an	O
antisera	O
specific	O
for	O
STAT3alpha	B-protein
proteins	I-protein
phosphorylated	O
on	O
serine	O
727	O
and	O
used	O
this	O
to	O
monitor	O
the	O
phosphorylation	O
of	O
this	O
residue	O
during	O
T	O
lymphocyte	O
activation	O
.	O

4	O
.	O

In	O
HIV-1	O
,	O
the	O
sequences	O
that	O
respond	O
to	O
these	O
signaling	O
events	O
are	O
found	O
in	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
and	O
comprise	O
the	O
transcriptional	B-DNA
enhancer	I-DNA
,	O
which	O
contains	O
two	O
conserved	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
.	O

Binding	O
sites	O
for	O
testosterone	O
on	O
the	O
surface	O
of	O
both	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
and	I-cell_type
CD8	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
subsets	I-cell_type
of	O
T	B-cell_type
cells	I-cell_type
are	O
directly	O
revealed	O
with	O
the	O
impeded	O
ligand	O
testosterone-BSA-FITC	O
by	O
confocal	O
laser	O
scanning	O
microscopy	O
(	O
CLSM	O
)	O
and	O
flow	O
cytometry	O
,	O
respectively	O
.	O

Whereas	O
the	O
NF-kappaB	B-protein
binding	O
activity	O
in	O
Tax-expressing	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
consisted	O
mostly	O
of	O
p50/c-Rel	B-protein
,	O
fresh	O
ATL	O
samples	O
contained	O
p50/p50	B-protein
and	I-protein
p50/p65	I-protein
heterodimers	I-protein
.	O

These	O
findings	O
are	O
consistent	O
with	O
a	O
model	O
for	O
Rex	B-protein
-mediated	O
trans-activation	O
in	O
which	O
Rex-viral	B-protein
mRNA	I-protein
complexes	I-protein
are	O
targeted	O
for	O
nuclear	O
export	O
by	O
the	O
direct	O
action	O
of	O
the	O
activation	B-protein
domain	I-protein
.	O

Novel	O
therapies	O
for	O
inflammatory	O
bowel	O
disease	O
.	O

The	O
amount	O
of	O
c-myb	B-RNA
mRNA	I-RNA
in	O
K562	B-cell_line
cells	I-cell_line
was	O
reduced	O
during	O
the	O
differentiation	O
induced	O
by	O
Epo	B-protein
.	O

The	O
antigenic	O
specificity	O
of	O
an	O
HLA	B-cell_line
DQ2-restricted	I-cell_line
,	I-cell_line
HSV-2	I-cell_line
type-specific	I-cell_line
T-cell	I-cell_line
clone	I-cell_line
was	O
mapped	O
to	O
amino	B-protein
acids	I-protein
425	I-protein
to	I-protein
444	I-protein
of	O
VP16	B-protein
of	O
HSV-2	O
by	O
sequential	O
use	O
of	O
an	O
intertypic	O
recombinant	O
virus	O
containing	O
VP16	B-protein
of	O
HSV-2	O
in	O
an	O
HSV-1	O
background	O
,	O
recombinant	B-protein
VP16	I-protein
fusion	I-protein
proteins	I-protein
,	O
and	O
synthetic	O
peptides	O
.	O

Activation	O
of	O
distinct	O
transcription	B-protein
factors	I-protein
in	O
neutrophils	B-cell_type
by	O
bacterial	O
LPS	O
,	O
interferon-gamma	B-protein
,	O
and	O
GM-CSF	B-protein
and	O
the	O
necessity	O
to	O
overcome	O
the	O
action	O
of	O
endogenous	B-protein
proteases	I-protein
.	O

Two	O
new	O
isoforms	O
were	O
found	O
that	O
generate	O
novel	O
amino-	B-protein
or	I-protein
carboxy-terminal	I-protein
sequences	I-protein
.	O

This	O
report	O
describes	O
studies	O
indicating	O
that	O
the	O
most	O
proximal	O
of	O
these	O
two	O
regulatory	B-DNA
elements	I-DNA
is	O
an	O
important	O
determinant	O
of	O
its	O
restricted	O
expression	O
.	O

It	O
is	O
concluded	O
that	O
(	O
i	O
)	O
patients	O
with	O
CLL	O
rarely	O
express	O
ER	B-protein
and	O
(	O
ii	O
)	O
immunocytochemical	O
staining	O
of	O
cytospin	O
preparations	O
is	O
a	O
valid	O
technique	O
for	O
the	O
measurement	O
of	O
ER	B-protein
.	O

Stimulation	O
of	O
human	B-cell_type
tonsillar	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
with	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
and	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
rapidly	O
induced	O
the	O
activation	O
of	O
distinct	O
nuclear	B-protein
factors	I-protein
with	O
different	O
mobilities	O
,	O
both	O
of	O
which	O
bind	O
the	O
IL-4	B-DNA
response	I-DNA
element	I-DNA
(	O
IL-4RE	B-DNA
)	O
of	O
CD23b	B-DNA
promoter	I-DNA
as	O
examined	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
unexpected	O
expression	O
of	O
megakaryocytic	B-DNA
genes	I-DNA
is	O
a	O
specific	O
property	O
of	O
immortalized	B-cell_line
cells	I-cell_line
that	O
can	O
not	O
be	O
explained	O
only	O
by	O
enhanced	O
expression	O
of	O
Spi-1	B-DNA
and/or	I-DNA
Fli-1	I-DNA
genes	I-DNA
.	O

In	O
contrast	O
,	O
T	O
cell	O
activation	O
induces	O
a	O
parallel	O
decline	O
in	O
both	O
site	O
alpha-	O
and	O
beta-binding	O
activities	O
.	O

Our	O
data	O
show	O
that	O
IFNs	B-protein
and	O
IL-1	B-protein
upregulate	O
PML	O
transcript	O
and	O
protein	O
expression	O
in	O
a	O
time	O
and	O
dose-dependent	O
manner	O
.	O

Thus	O
,	O
exposure	O
to	O
IL-6	B-protein
may	O
inhibit	O
expression	O
of	O
the	O
class	B-protein
A	I-protein
MSR	I-protein
in	O
differentiated	O
macrophages	B-cell_type
at	O
transcriptional	O
levels	O
.	O

We	O
demonstrate	O
that	O
expression	O
of	O
Tax	B-protein
can	O
induce	O
the	O
E2F-containing	B-protein
DNA-binding	I-protein
complexes	I-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Thus	O
,	O
autoreactive	B-cell_type
T-cells	I-cell_type
identify	O
a	O
novel	B-protein
antigen	I-protein
,	O
p38	B-protein
jun-B	I-protein
,	O
in	O
IDDM	O
and	O
appear	O
to	O
indicate	O
subjects	O
at	O
risk	O
for	O
the	O
development	O
of	O
clinical	O
disease	O
.	O

We	O
propose	O
that	O
the	O
requirement	O
for	O
precise	O
spacing	O
of	O
the	O
muA	B-DNA
and	I-DNA
muB	I-DNA
elements	I-DNA
is	O
due	O
in	O
part	O
to	O
a	O
directed	O
DNA	O
bend	O
induced	O
by	O
PU.1	B-protein
.	O

We	O
found	O
that	O
the	O
adenylate	B-protein
cyclase	I-protein
activator	O
,	O
forskolin	O
,	O
inhibits	O
anti-CD3	B-protein
-induced	O
shift	O
in	O
Lck	B-protein
electrophoretic	O
mobility	O
,	O
suggesting	O
an	O
intervention	O
at	O
the	O
TCR	B-protein
-coupled	O
phosphoinositide	O
turnover	O
that	O
precedes	O
the	O
activation	O
of	O
PKC	B-protein
.	O

The	O
amplified	O
product	O
showed	O
an	O
identical	B-DNA
nucleotide	I-DNA
sequence	I-DNA
to	O
the	O
DNA-binding	B-protein
domain	I-protein
of	O
the	O
human	B-protein
intestinal	I-protein
receptor	I-protein
.	O

Hox11	B-protein
null	O
mouse	O
embryos	O
have	O
elevated	O
Aldh1	B-RNA
mRNA	I-RNA
in	O
spleen	O
primordia	O
prior	O
to	O
atrophy	O
,	O
while	O
Aldh1	B-protein
seems	O
to	O
be	O
repressed	O
by	O
Hox11	B-protein
during	O
organogenesis	O
of	O
the	O
spleens	O
of	O
wild-type	O
mice	O
.	O

The	O
effect	O
of	O
Rho	B-protein
on	O
AP-1	B-protein
is	O
independent	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
pathway	O
,	O
as	O
a	O
dominant-negative	B-protein
MEK	I-protein
and	O
a	O
MEK	B-protein
inhibitor	O
(	O
PD98059	O
)	O
did	O
not	O
affect	O
Rho	B-protein
-induced	O
AP-1	B-protein
activity	O
.	O

The	O
same	O
is	O
true	O
for	O
nuclear	O
extracts	O
taken	O
from	O
the	O
murine	B-cell_line
P388D1	I-cell_line
macrophage	I-cell_line
cell	I-cell_line
line	I-cell_line
when	O
tested	O
with	O
the	O
-516	B-DNA
motif	I-DNA
of	O
the	O
murine	B-DNA
TNF	I-DNA
promoter	I-DNA
(	O
GGGGGCTTTCCC	O
)	O
.	O

The	O
flow	O
of	O
information	O
from	O
calcium-mobilizing	B-protein
receptors	I-protein
to	O
nuclear	B-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells	I-DNA
(	I-DNA
NFAT	I-DNA
)	I-DNA
-dependent	I-DNA
genes	I-DNA
is	O
critically	O
dependent	O
on	O
interaction	O
between	O
the	O
phosphatase	B-protein
calcineurin	B-protein
and	O
the	O
transcription	B-protein
factor	I-protein
NFAT	B-protein
.	O

The	O
number	O
and	O
apparent	O
dissociation	O
constant	O
of	O
glucocorticoid	B-protein
receptor	I-protein
were	O
measured	O
using	O
a	O
whole-cell	O
binding	O
assay	O
.	O

Proteins	O
of	O
the	O
ATF/	O
CREB	B-protein
class	O
of	O
transcription	B-protein
factors	I-protein
stimulate	O
gene	O
expression	O
of	O
several	O
cell	B-DNA
growth-related	I-DNA
genes	I-DNA
through	O
protein	B-DNA
kinase	I-DNA
A-related	I-DNA
cAMP	I-DNA
response	I-DNA
elements	I-DNA
.	O

These	O
findings	O
suggested	O
that	O
the	O
increase	O
in	O
c-jun	B-RNA
RNA	I-RNA
observed	O
during	O
TPA-induced	O
monocytic	O
differentiation	O
is	O
mediated	O
by	O
both	O
transcriptional	O
and	O
post-transcriptional	O
mechanisms	O
.	O

We	O
have	O
investigated	O
whether	O
a	O
palmitate	B-protein
conjugate	I-protein
of	O
a	O
human	B-protein
monoclonal	I-protein
antibody	I-protein
specific	O
for	O
thyroglobulin	B-protein
(	O
TG	B-protein
)	O
could	O
function	O
as	O
a	O
surrogate	B-protein
TG	I-protein
receptor	I-protein
on	O
blood	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
separated	O
into	O
fractions	O
enriched	O
for	O
T	B-cell_type
cells	I-cell_type
or	O
depleted	O
of	O
T	B-cell_type
cells	I-cell_type
(	O
non-T	B-cell_type
cells	I-cell_type
)	O
.	O

IFN-gamma	B-protein
triggers	O
a	O
well-defined	O
signal	O
transduction	O
pathway	O
,	O
which	O
although	O
not	O
directly	O
stimulated	O
by	O
monocyte	O
adherence	O
to	O
fibronectin	B-protein
or	O
arginine-glycine-aspartate	B-protein
(	I-protein
RGD	I-protein
)	I-protein
-coated	I-protein
substrata	I-protein
,	O
was	O
enhanced	O
significantly	O
in	O
these	O
matrix-adherent	B-cell_type
cells	I-cell_type
.	O

Further	O
,	O
we	O
have	O
found	O
that	O
these	O
factors	O
cooperate	O
in	O
the	O
repression	O
of	O
LTR	B-DNA
expression	O
and	O
viral	O
replication	O
.	O

The	O
two	O
AP-1	B-DNA
sites	I-DNA
bound	O
c-Fos/c-Jun	B-protein
heterodimers	I-protein
in	O
both	O
unstimulated	B-cell_type
and	I-cell_type
LPS-stimulated	I-cell_type
cells	I-cell_type
.	O

Signaling	O
through	O
HLA	B-protein
class	I-protein
I	I-protein
molecules	I-protein
induced	O
cyclin	B-DNA
E	I-DNA
-associated	O
kinase	O
activity	O
within	O
4	O
h	O
in	O
quiescent	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
,	O
and	O
appeared	O
to	O
mediate	O
the	O
inactivation	O
of	O
Rb	B-protein
.	O

In	O
promoter	B-DNA
regions	I-DNA
,	O
the	O
actively	B-DNA
transcribed	I-DNA
genes	I-DNA
demonstrated	O
extensive	O
and	O
consistent	O
footprints	O
over	O
the	O
canonical	O
elements	O
,	O
such	O
as	O
CACCC	B-DNA
and	I-DNA
CCAAT	I-DNA
motifs	I-DNA
.	O

The	O
expression	O
of	O
the	O
nuclear	B-protein
factors	I-protein
Evi-1	B-protein
and	O
c-myb	B-protein
,	O
known	O
to	O
inhibit	O
erythroid	O
differentiation	O
,	O
did	O
not	O
decrease	O
.	O

The	O
Epstein-Barr	B-protein
virus	I-protein
oncogene	I-protein
product	I-protein
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
engages	O
the	O
tumor	O
necrosis	O
factor	O
receptor-associated	O
death	O
domain	O
protein	O
to	O
mediate	O
B	O
lymphocyte	O
growth	O
transformation	O
and	O
activate	O
NF-kappaB	O
.	O

Furthermore	O
,	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
induced	O
24-hydroxylase	B-protein
mRNA	O
expression	O
and	O
metabolic	O
activity	O
in	O
both	O
U937	B-cell_line
cells	I-cell_line
and	O
lectin-activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
yet	O
failed	O
to	O
induce	O
24-hydroxylase	B-RNA
mRNA	I-RNA
or	O
its	O
metabolic	O
activity	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Thromboxane	O
receptor	B-DNA
promoter	I-DNA
activity	O
,	O
as	O
assessed	O
by	O
CAT	B-protein
expression	O
,	O
was	O
relatively	O
weak	O
but	O
was	O
significantly	O
enhanced	O
by	O
phorbol	O
ester	O
treatment	O
.	O

It	O
has	O
been	O
shown	O
that	O
eosinophil	O
stimulation	O
by	O
these	O
cytokines	B-protein
is	O
associated	O
with	O
increases	O
in	O
tyrosine	O
phosphorylation	O
of	O
several	O
cellular	O
substrates	O
.	O

Northern	O
analysis	O
revealed	O
expression	O
of	O
a	O
minor	O
1.1	B-RNA
kb	I-RNA
Id-3L	I-RNA
transcript	I-RNA
together	O
with	O
the	O
predominant	O
0.95	B-RNA
kb	I-RNA
Id-3	I-RNA
transcript	I-RNA
in	O
the	O
majority	O
of	O
adult	O
human	O
tissues	O
analysed	O
.	O

Immunocytochemical	O
analysis	O
indicates	O
that	O
recombinant	O
NFAT1	B-protein
localizes	O
in	O
the	O
cytoplasm	O
of	O
transiently	B-cell_type
transfected	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
translocates	O
into	O
the	O
nucleus	O
in	O
a	O
CsA-sensitive	O
manner	O
following	O
ionomycin	O
stimulation	O
.	O

The	O
core	O
of	O
the	O
promoter	B-DNA
(	O
positions	B-DNA
-42	I-DNA
to	I-DNA
+11	I-DNA
)	O
is	O
recognized	O
by	O
the	O
lymphoid	B-protein
cell-specific	I-protein
transcription	I-protein
factors	I-protein
Ets-1	B-protein
,	O
LEF1	B-protein
,	O
and	O
AML1	B-protein
as	O
well	O
as	O
by	O
CREB/ATF-1	B-protein
,	O
as	O
is	O
demonstrated	O
in	O
gel	O
shift	O
and	O
footprinting	O
experiments	O
.	O

The	O
cell	O
death	O
was	O
independent	O
of	O
wild-type	B-protein
p53	I-protein
and	O
was	O
not	O
inhibited	O
by	O
an	O
anti-apoptotic	B-protein
protein	I-protein
EIB19K	I-protein
.	O

In	O
this	O
study	O
the	O
effect	O
of	O
anti-estrogen	O
(	O
toremifene	O
)	O
therapy	O
on	O
serum	B-protein
immunoglobulin	I-protein
(	O
IgA	B-protein
,	O
IgM	B-protein
,	O
IgG	B-protein
)	O
levels	O
in	O
breast	O
cancer	O
patients	O
was	O
investigated	O
.	O

In	O
contrast	O
,	O
the	O
binding	O
activities	O
of	O
two	O
ubiquitous	O
transcription	B-protein
factors	I-protein
,	O
Oct1	B-protein
and	O
Sp1	B-protein
,	O
remain	O
high	O
in	O
G2/M	O
.	O

Molecular	O
cloning	O
of	O
FKHRL1P2	B-protein
,	O
a	O
member	O
of	O
the	O
developmentally	O
regulated	O
fork	B-protein
head	I-protein
domain	I-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O

In	O
gel-shift	O
assays	O
,	O
the	O
-1280	B-DNA
element	I-DNA
and	O
the	O
c-fos	B-DNA
SRE	I-DNA
cross	I-DNA
-competed	O
,	O
whereas	O
their	O
functional	O
and	O
binding	B-DNA
mutants	I-DNA
did	O
not	O
.	O

Furthermore	O
,	O
the	O
SH2-deleted	B-protein
Grf40	I-protein
mutant	I-protein
led	O
to	O
a	O
marked	O
inhibition	O
of	O
these	O
regulatory	O
activities	O
,	O
the	O
effect	O
of	O
which	O
is	O
apparently	O
stronger	O
than	O
that	O
of	O
the	O
SH2-deleted	B-protein
Grb2	I-protein
mutant	I-protein
.	O

Bacterial	O
vaginosis	O
(	O
BV	O
)	O
is	O
associated	O
with	O
an	O
increased	O
rate	O
of	O
sexual	O
transmission	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
type	O
1	O
,	O
and	O
Gardnerella	O
vaginalis	O
is	O
frequently	O
isolated	O
from	O
the	O
genital	O
tracts	O
of	O
women	O
with	O
BV	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
Entamoeba	O
histolytica	O
infection	O
of	O
the	O
intestine	O
can	O
induce	O
severe	O
gut	O
inflammation	O
.	O

By	O
ablating	O
the	O
expression	O
of	O
the	O
endogenous	O
GATA-1	B-DNA
gene	I-DNA
,	O
we	O
are	O
in	O
a	O
position	O
to	O
introduce	O
a	O
variety	O
of	O
constructs	O
that	O
harbor	O
subtle	O
modifications	O
in	O
flanking	O
or	O
protein-coding	B-DNA
sequences	I-DNA
.	O

In	O
search	O
of	O
a	O
molecular	O
mechanism	O
for	O
the	O
transcriptional	O
induction	O
of	O
ISGs	B-DNA
,	O
we	O
observed	O
an	O
EBNA2	B-protein
-dependent	O
synthesis	O
of	O
IFN-beta	O
mRNA	O
at	O
low	O
levels	O
and	O
the	O
secretion	O
of	O
low	O
amounts	O
of	O
IFN	O
.	O

Here	O
,	O
we	O
analyzed	O
large	O
genomic	B-DNA
IL-4	I-DNA
regions	I-DNA
for	O
enhancer	O
activity	O
and	O
interaction	O
with	O
transcription	B-protein
factors	I-protein
.	O

mBob1	B-protein
interacts	O
with	O
the	O
octamer	B-protein
transcription	I-protein
factors	I-protein
Oct-1	B-protein
and	O
Oct-2	B-protein
and	O
stimulates	O
transcription	O
mediated	O
by	O
these	O
factors	O
.	O

Such	O
differentiation	O
block	O
by	O
AML1a	B-protein
was	O
canceled	O
by	O
the	O
concomitant	O
overexpression	O
of	O
AML1b	B-protein
.	O

Intracellular	O
ILs	B-protein
were	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

To	O
further	O
evaluate	O
the	O
role	O
of	O
X	B-protein
box	I-protein
DNA-binding	I-protein
proteins	I-protein
in	O
class	B-DNA
II	I-DNA
gene	I-DNA
expression	O
,	O
the	O
role	O
of	O
the	O
X	B-DNA
box	I-DNA
region	I-DNA
was	O
examined	O
in	O
both	O
class	B-cell_line
II-positive	I-cell_line
and	O
-negative	B-cell_line
lymphoid	I-cell_line
cells	I-cell_line
.	O

Human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tat	I-protein
upregulates	O
interleukin-2	B-protein
secretion	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

This	O
is	O
correlated	O
with	O
an	O
increased	O
expression	O
of	O
activation	B-protein
markers	I-protein
CD44	B-protein
and	O
CD69	B-protein
and	O
decreased	O
expression	O
of	O
CD62	B-protein
.	O

Reciprocally	O
,	O
inhibition	O
of	O
NF-kappaB	B-protein
activation	O
by	O
a	O
soluble	O
peptide	O
inhibitor	O
or	O
a	O
dominant	O
form	O
of	O
the	O
NF-kappaB	B-protein
inhibitor	O
,	O
IkappaB	B-protein
,	O
makes	O
the	O
cells	O
more	O
susceptible	O
to	O
Fas-mediated	O
apoptosis	O
.	O

ADT	O
(	O
0.1	O
mM	O
)	O
also	O
inhibited	O
H2O2	O
induced	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
in	O
the	O
peroxide	B-cell_line
sensitive	I-cell_line
human	I-cell_line
Wurzburg	I-cell_line
T-cells	I-cell_line
.	O

The	O
YJ	B-cell_line
cell	I-cell_line
line	I-cell_line
should	O
be	O
useful	O
for	O
elucidating	O
the	O
molecular	O
mechanisms	O
governing	O
lineage	O
switching	O
from	O
the	O
eosinophil	B-cell_type
to	O
monocytic	B-cell_type
or	I-cell_type
neutrophil	I-cell_type
lineages	I-cell_type
.	O

A	O
functional	O
role	O
of	O
the	O
GrpL-SLP-76	B-protein
complex	I-protein
is	O
suggested	O
by	O
the	O
ability	O
of	O
GrpL	B-protein
to	O
act	O
alone	O
or	O
in	O
concert	O
with	O
SLP-76	B-protein
to	O
augment	O
NF-AT	B-protein
activation	O
in	O
Jurkat	B-cell_line
T	B-cell_type
cells	I-cell_type
.	O

The	O
binding	O
of	O
oxidized	O
low-density	O
lipoprotein	O
(	O
Ox	O
LDL	O
)	O
by	O
monocyte	B-cell_type
-macrophages	B-cell_type
causes	O
pleiotropic	O
effects	O
,	O
including	O
changes	O
in	O
gene	O
expression	O
,	O
and	O
is	O
thought	O
to	O
represent	O
an	O
early	O
event	O
in	O
atherogenesis	O
.	O

Internal	O
ribosome	O
binding	O
likely	O
requires	O
the	O
interaction	O
of	O
trans-acting	B-protein
factors	I-protein
that	O
recognize	O
both	O
the	O
mRNA	B-RNA
and	O
the	O
ribosomal	B-protein
complex	I-protein
.	O

A	O
truncated	O
version	O
of	O
430-444	O
,	O
i.e.	O
,	O
VP16	O
433-442	O
,	O
binds	O
with	O
an	O
affinity	O
10-fold	O
lower	O
compared	O
to	O
430-444	O
at	O
acidic	O
pH	O
,	O
and	O
binding	O
at	O
neutral	O
pH	O
was	O
barely	O
detectable	O
.	O

CD28	B-protein
costimulation	O
augments	O
IL-2	B-protein
secretion	O
of	O
activated	O
lamina	O
propria	O
T	O
cells	O
by	O
increasing	O
mRNA	O
stability	O
without	O
enhancing	O
IL-2	B-protein
gene	O
transactivation	O
.	O

Int-2	B-DNA
was	O
amplified	O
in	O
13.1	O
%	O
and	O
c-myc	B-DNA
was	O
amplified	O
in	O
10.3	O
%	O
.	O

Peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
9/19	O
SS	O
patients	O
were	O
found	O
to	O
be	O
defective	O
in	O
their	O
ability	O
to	O
bind	O
an	O
october	B-protein
sequence	I-protein
(	O
Oct-1	B-protein
)	O
.	O

We	O
demonstrate	O
that	O
SLAP-130	B-protein
is	O
hematopoietic	O
cell-specific	O
and	O
associates	O
with	O
the	O
SH2	B-protein
domain	I-protein
of	O
SLP-76	B-protein
.	O

This	O
structural	O
and	O
functional	O
complementarity	O
for	O
residue	O
57	O
and	O
a	O
specific	O
peptide	O
residue	O
identifies	O
this	O
interaction	O
as	O
a	O
key	O
controlling	O
determinant	O
of	O
restricted	O
recognition	O
in	O
HLA-DQ-specific	O
immune	O
response	O
.	O

It	O
is	O
,	O
therefore	O
,	O
suggested	O
that	O
clarification	O
of	O
the	O
mechanisms	O
of	O
differential	O
gene	O
expression	O
in	O
Th1/Th2	B-cell_line
should	O
lead	O
to	O
rational	O
strategies	O
for	O
manipulating	O
pathological	O
immune	O
responses	O
.	O

It	O
can	O
only	O
be	O
activated	O
in	O
a	O
tissue-specific	O
manner	O
by	O
elements	O
that	O
lie	O
downstream	O
of	O
the	O
initiation	B-DNA
site	I-DNA
.	O

The	O
interaction	O
of	O
purified	O
octamer	B-protein
transcription	I-protein
factors	I-protein
1	O
and	O
2	O
(	O
OTF1	B-protein
and	O
OTF2	B-protein
)	O
with	O
the	O
MOPC	B-DNA
141	I-DNA
promoter	I-DNA
was	O
studied	O
by	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
DNase	B-protein
I	I-protein
footprinting	O
.	O

Detection	O
of	O
intracellular	B-protein
phosphorylated	I-protein
STAT-1	I-protein
by	O
flow	O
cytometry	O
.	O

The	O
polymorphism	O
at	O
residue	O
57	O
of	O
the	O
DQB1	O
polypeptide	O
is	O
of	O
particular	O
interest	O
since	O
it	O
may	O
play	O
a	O
major	O
structural	O
role	O
in	O
the	O
formation	O
of	O
a	O
salt	B-protein
bridge	I-protein
structure	I-protein
at	O
one	O
end	O
of	O
the	O
peptide-binding	B-protein
cleft	I-protein
of	O
the	O
DQ	O
molecules	O
.	O

We	O
propose	O
a	O
model	O
for	O
the	O
regulation	O
of	O
Bcl-2	B-protein
expression	O
via	O
Aiolos	B-protein
.	O

The	O
active	O
nuclear	O
form	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
complex	I-protein
is	O
composed	O
of	O
two	O
DNA	B-protein
binding	I-protein
subunits	I-protein
,	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
and	O
NF-kappa	B-protein
B	I-protein
p50	I-protein
,	O
both	O
of	O
which	O
share	O
extensive	O
N-terminal	O
sequence	O
homology	O
with	O
the	O
v-rel	B-protein
oncogene	I-protein
product	I-protein
.	O

IL-10	B-protein
preincubation	O
resulted	O
in	O
the	O
inhibition	O
of	O
gene	O
expression	O
for	O
several	O
IFN-induced	B-DNA
genes	I-DNA
,	O
such	O
as	O
IP-10	B-protein
,	O
ISG54	B-protein
,	O
and	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
.	O

In	O
the	O
peripheral	O
blood	B-cell_type
lymphocytes	I-cell_type
an	O
even	O
more	O
striking	O
downregulation	O
of	O
the	O
GR	O
by	O
its	O
cognate	O
ligand	O
was	O
documented	O
(	O
30.3	O
+/-	O
26.5	O
and	O
8.8	O
+/-	O
5	O
amol	O
GR	B-RNA
mRNA	I-RNA
/microg	O
RNA	O
,	O
respectively	O
;	O
P	O
<	O
.001	O
)	O
,	O
possibly	O
reflecting	O
differences	O
in	O
glucocorticoid	O
sensitivity	O
between	O
tissues	O
.	O

Thus	O
,	O
IL-10	B-protein
and	O
IL-4	B-protein
similarly	O
affect	O
IL-6	B-protein
expression	O
.	O

LPS	O
treatment	O
of	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
,	O
murine	B-cell_type
bone	I-cell_type
marrow-derived	I-cell_type
macrophages	I-cell_type
,	O
and	O
the	O
human	B-cell_line
monocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	I-cell_line
resulted	O
in	O
rapid	O
activation	O
of	O
the	O
p46	B-protein
and	I-protein
p54	I-protein
isoforms	I-protein
of	O
JNK	B-protein
.	O

BSAP	B-protein
is	O
exclusively	O
restricted	O
to	O
the	O
B-cell	O
lineage	O
of	O
lymphoid	O
differentiation	O
.	O

GCR	B-protein
on	O
MNL	B-cell_type
and	O
PML	B-cell_type
in	O
6	O
Yang	O
deficient	O
patients	O
were	O
3473	O
+/-	O
413	O
and	O
4433	O
+/-	O
651	O
sites/cell	O
respectively	O
,	O
statistically	O
significant	O
from	O
the	O
normal	O
control	O
group	O
(	O
4462	O
+/-	O
962	O
and	O
5622	O
+/-	O
782	O
sites/cell	O
respectively	O
,	O
P	O
less	O
than	O
0.05	O
)	O
.	O

The	O
effect	O
of	O
the	O
pRB	B-protein
posttranslational	O
modification	O
during	O
apoptosis	O
was	O
investigated	O
by	O
determining	O
the	O
E2F-1	B-protein
levels	O
and	O
by	O
isolating	O
and	O
characterizing	O
pRB-null	B-cell_line
clones	I-cell_line
from	O
U937	B-cell_line
cells	I-cell_line
.	O

In	O
this	O
review	O
we	O
evaluate	O
the	O
possible	O
in	O
vivo	O
role	O
of	O
different	O
transcription	O
factors	O
and	O
transcriptional	O
mechanisms	O
in	O
T	O
cell	O
differentiation	O
and	O
the	O
immune	O
response	O
.	O

Expression	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
requires	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
through	O
stimulation	O
of	O
the	O
TCR	B-protein
and	O
costimulation	O
through	O
accessory	B-protein
receptors	I-protein
.	O

In	O
addition	O
,	O
LTB4	O
mediated	O
transactivation	O
of	O
a	O
heterologous	B-DNA
promoter	I-DNA
construct	I-DNA
containing	O
the	O
NF-chi	B-DNA
B	I-DNA
or	O
the	O
NF-IL6	B-DNA
enhancer	I-DNA
,	O
but	O
not	O
the	O
AP-1	B-DNA
enhancer	I-DNA
.	O

Analysis	O
of	O
the	O
biochemical	O
and	O
cell	O
biological	O
properties	O
of	O
these	O
HSFs	B-protein
reveals	O
that	O
HSF3	B-protein
has	O
properties	O
in	O
common	O
with	O
both	O
HSF1	B-protein
and	O
HSF2	B-protein
and	O
yet	O
has	O
features	O
which	O
are	O
distinct	O
from	O
both	O
.	O

The	O
type	B-protein
I	I-protein
interleukin-1	I-protein
receptor	I-protein
(	O
IL-1R	B-protein
)	O
is	O
capable	O
of	O
transducing	O
a	O
signal	O
resulting	O
in	O
promoter	O
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

TNF	B-protein
is	O
the	O
major	O
inducer	O
of	O
NF-kappaB	B-protein
and	O
particularly	O
of	O
the	O
p50-p65	B-protein
complex	I-protein
,	O
whereas	O
IL-7	B-protein
acts	O
as	O
a	O
cofactor	O
by	O
sustaining	O
the	O
expression	O
of	O
the	O
p75	B-protein
TNF	I-protein
receptor	I-protein
.	O

Numerous	O
genes	O
required	O
during	O
the	O
immune	O
or	O
inflammation	O
response	O
as	O
well	O
as	O
the	O
adhesion	O
process	O
are	O
regulated	O
by	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
.	O

Perhaps	O
deoxycorticosterone	O
or	O
a	O
hitherto	O
unknown	O
mineralocorticoid	O
is	O
responsible	O
for	O
the	O
hypertension	O
and	O
altered	O
MR	B-protein
-status	O
.	O

Blood	B-cell_type
monocytes	I-cell_type
from	O
patients	O
with	O
active	O
tuberculosis	O
are	O
activated	O
in	O
vivo	O
,	O
as	O
evidenced	O
by	O
an	O
increase	O
in	O
the	O
stimulated	O
release	O
of	O
proinflammatory	B-protein
cytokines	I-protein
,	O
such	O
as	O
TNF-alpha	B-protein
,	O
and	O
the	O
spontaneous	O
expression	O
of	O
IL-2R	B-protein
.	O

We	O
failed	O
to	O
find	O
any	O
correlation	O
between	O
age	O
and	O
X-	B-DNA
chromosome	I-DNA
inactivation	O
pattern	O
(	O
r	O
=	O
0.17	O
)	O
,	O
even	O
subdividing	O
the	O
subjects	O
in	O
different	O
age	O
groups	O
according	O
to	O
the	O
criteria	O
used	O
by	O
other	O
researchers	O
,	O
and	O
therefore	O
reaffirm	O
that	O
,	O
when	O
tested	O
for	O
with	O
well-standardized	O
and	O
accurate	O
criteria	O
,	O
extremely	O
unbalanced	O
inactivation	O
of	O
the	O
X	B-DNA
chromosome	I-DNA
is	O
a	O
truly	O
uncommon	O
phenomenon	O
in	O
normal	O
women	O
.	O

Furthermore	O
,	O
Elf-1	B-protein
interacts	O
specifically	O
with	O
the	O
E74	B-DNA
target	I-DNA
sequence	I-DNA
and	O
can	O
stimulate	O
transcription	O
driven	O
by	O
the	O
E74	B-DNA
site	I-DNA
independent	O
of	O
mitogenic	O
signaling	O
.	O

Whereas	O
the	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
3	I-protein
(	O
Stat3	B-protein
)	O
was	O
phosphorylated	O
and	O
activated	O
,	O
there	O
was	O
no	O
effect	O
on	O
either	O
Stat1	B-protein
or	O
Stat5	B-protein
.	O

A	O
negative	O
regulatory	O
region	O
containing	O
a	O
glucocorticosteroid	B-DNA
response	I-DNA
element	I-DNA
(	O
nGRE	B-DNA
)	O
in	O
the	O
human	B-DNA
interleukin-1beta	I-DNA
gene	I-DNA
.	O

Interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
promoter	I-DNA
-reporter	B-DNA
gene	I-DNA
behavior	O
closely	O
parallels	O
the	O
endogenous	B-DNA
gene	I-DNA
in	O
response	O
to	O
T	B-protein
cell	I-protein
receptor	I-protein
and	O
costimulatory	O
signals	O
.	O

Furthermore	O
,	O
replacement	O
of	O
the	O
gamma	B-protein
(	I-protein
c	I-protein
)	I-protein
cytoplasmic	B-protein
domain	I-protein
by	O
a	O
severely	B-protein
truncated	I-protein
erythropoeitin	I-protein
receptor	I-protein
does	O
not	O
affect	O
measured	O
IL-7R	B-protein
signaling	O
events	O
.	O

The	O
effect	O
of	O
this	O
synergism	O
was	O
perceptible	O
at	O
the	O
level	O
of	O
induction	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
,	O
a	O
process	O
critical	O
for	O
T	O
cell	O
growth	O
.	O

High	O
level	O
gene	O
expression	O
of	O
these	O
TAR	B-DNA
mutant	I-DNA
constructs	I-DNA
in	O
phorbol	B-cell_line
ester-treated	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
was	O
eliminated	O
by	O
second	O
site	O
mutations	O
in	O
the	O
enhancer	B-DNA
region	I-DNA
or	O
by	O
disruption	O
of	O
the	O
tat	B-DNA
gene	I-DNA
.	O

Moreover	O
,	O
a	O
strong	O
induction	O
of	O
the	O
enzyme	O
was	O
observed	O
in	O
red	B-cell_type
cells	I-cell_type
during	O
experimental	O
anemia	O
in	O
mice	O
.	O

Proteins	O
exist	O
in	O
leukocytes	B-cell_type
able	O
to	O
modify	O
GTP-binding	B-protein
protein	I-protein
function	O
in	O
this	O
manner	O
,	O
and	O
their	O
activity	O
may	O
be	O
regulated	O
by	O
signals	O
generated	O
on	O
phagocyte	O
stimulation	O
.	O

These	O
results	O
are	O
the	O
first	O
to	O
suggest	O
that	O
surfactant	O
's	O
suppressive	O
effects	O
on	O
inflammatory	B-protein
cytokine	I-protein
production	O
may	O
involve	O
transcriptional	O
regulation	O
through	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Evidence	O
that	O
calcineurin	O
is	O
rate-limiting	O
for	O
primary	O
human	O
lymphocyte	O
activation	O
.	O

Angiotensin	B-protein
II	I-protein
activates	O
the	O
proinflammatory	B-protein
transcription	I-protein
factor	I-protein
nuclear	B-protein
factor-kappaB	I-protein
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Viruses	O
containing	O
the	O
human	B-DNA
cytomegalovirus	I-DNA
immediate-early	I-DNA
enhancer	I-DNA
exhibited	O
infectious	O
kinetics	O
similar	O
to	O
that	O
of	O
wild-type	O
HIV	O
in	O
activated	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
and	O
AA2	B-cell_line
cells	I-cell_line
but	O
replicated	O
less	O
efficiently	O
in	O
H9	B-cell_line
and	I-cell_line
CEM	I-cell_line
cells	I-cell_line
.	O

We	O
found	O
very	O
little	O
detectable	O
activation	O
of	O
AP-1	B-protein
,	O
as	O
assessed	O
in	O
a	O
gel	O
shift	O
assay	O
,	O
in	O
alveolar	B-cell_type
macrophages	I-cell_type
,	O
whereas	O
monocytes	B-cell_type
showed	O
a	O
substantial	O
activation	O
of	O
AP-1	B-protein
by	O
PMA	O
.	O

We	O
found	O
,	O
however	O
,	O
that	O
PI	B-protein
3-kinase	I-protein
profoundly	O
influenced	O
the	O
transactivation	O
capacity	O
of	O
'	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
'	O
(	O
NF-AT	B-protein
)	O
elicited	O
by	O
the	O
TCR	B-protein
:	O
expression	O
of	O
an	O
activated	O
form	O
of	O
PI	B-protein
3-kinase	I-protein
inhibited	O
TCR	B-protein
-mediated	O
NF-AT	B-protein
responses	O
,	O
whereas	O
expression	O
of	O
a	O
dominant	O
negative	O
mutant	O
of	O
PI	B-protein
3-kinase	I-protein
potently	O
enhanced	O
TCR	B-protein
-controlled	O
NF-AT	B-protein
induction	O
.	O

Although	O
GLRP	B-protein
shares	O
some	O
characteristics	O
with	O
the	O
inducible	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
,	O
it	O
appears	O
to	O
be	O
distinct	O
from	O
known	O
AP-1	B-protein
family	I-protein
members	I-protein
.	O

In	O
most	O
cell	O
lines	O
,	O
proteins	O
of	O
molecular	O
weight	O
49	O
and	O
44	O
kDa	O
were	O
found	O
,	O
however	O
two	O
myeloid	O
cell	O
lines	O
expressed	O
only	O
lower	O
molecular	B-protein
weight	I-protein
species	I-protein
of	I-protein
24	I-protein
and	I-protein
22	I-protein
kDa	I-protein
.	O

The	O
JAK	B-protein
kinases	I-protein
and	O
the	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
factors	I-protein
have	O
been	O
found	O
to	O
be	O
essential	O
components	O
.	O

In	O
conclusion	O
,	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
in	O
ex	O
vivo	O
isolated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
of	O
patients	O
with	O
diabetes	O
mellitus	O
correlates	O
with	O
the	O
degree	O
of	O
diabetic	O
nephropathy	O
.	O

TR	B-protein
alpha	I-protein
1	I-protein
and	O
TR	B-protein
beta	I-protein
2	I-protein
each	O
formed	O
a	O
single	O
major	O
TR	B-protein
:	I-protein
TREp	I-protein
complex	I-protein
which	O
comigrated	O
with	O
the	O
least	O
retarded	O
complex	O
formed	O
by	O
GH3	O
NE	O
,	O
while	O
TR	B-protein
beta	I-protein
1	I-protein
formed	O
multiple	O
complexes	O
suggesting	O
that	O
it	O
can	O
bind	O
to	O
TREp	B-DNA
as	O
an	O
oligomer	B-protein
.	O

Our	O
results	O
suggest	O
that	O
the	O
JNK	B-protein
pathway	O
may	O
regulate	O
NF-kappa	B-protein
B	I-protein
-mediated	O
gene	O
transcription	O
through	O
its	O
phosphorylation	O
and	O
activation	O
of	O
c-Jun	B-protein
.	O

By	O
contrast	O
,	O
T	B-cell_type
cells	I-cell_type
from	O
elderly	O
subjects	O
with	O
normal	O
levels	O
of	O
IL-2	B-protein
production	O
exhibited	O
normal	O
activation	O
of	O
AP-1	B-protein
and	O
NF-AT	B-protein
.	O

The	O
resistant	O
patients	O
showed	O
no	O
significant	O
improvements	O
in	O
airflow	O
limitation	O
.	O

We	O
conclude	O
that	O
sodium	O
phenylacetate	O
treatment	O
of	O
K562	B-cell_line
cells	I-cell_line
increases	O
gamma-globin	B-RNA
mRNA	I-RNA
and	O
induces	O
cell	O
maturation	O
as	O
judged	O
by	O
morphology	O
without	O
affecting	O
the	O
expression	O
of	O
the	O
erythroid	B-protein
transcription	I-protein
factors	I-protein
,	O
some	O
of	O
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
beta-like	B-DNA
globin	I-DNA
genes	I-DNA
.	O

Nuclear	O
run-on	O
transcription	O
assays	O
showed	O
that	O
IL-10	B-protein
inhibited	O
the	O
rate	O
of	O
IFN-gamma	B-protein
-induced	O
transcription	O
of	O
the	O
ICAM-1	B-DNA
gene	I-DNA
,	O
and	O
mRNA	O
stability	O
studies	O
showed	O
that	O
IL-10	B-protein
did	O
not	O
alter	O
the	O
half-life	O
of	O
IFN-gamma-induced	B-RNA
ICAM-1	I-RNA
message	I-RNA
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-activated	I-protein
factor	I-protein
6	I-protein
(	O
TRAF6	B-protein
)	O
and	O
the	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
-inducing	I-protein
kinase	I-protein
(	O
NIK	B-protein
)	O
are	O
both	O
involved	O
in	O
subsequent	O
steps	O
of	O
NF-kappaB	B-protein
activation	O
.	O

Structurally	O
,	O
the	O
LCR	B-DNA
is	O
defined	O
by	O
the	O
presence	O
of	O
four	O
domains	O
of	O
erythroid-specific	O
chromatin	O
structure	O
.	O

The	O
S.	O
cerevisiae	O
and	O
Sch.	O
pombe	O
systems	O
support	O
effects	O
of	O
acidic	B-protein
activator	I-protein
proteins	I-protein
,	O
provided	O
a	O
further	O
protein	O
fraction	O
from	O
S.	O
cerevisiae	O
is	O
supplied	O
.	O

The	O
KBF1/p50	B-protein
factor	I-protein
binds	O
as	O
a	O
homodimer	B-protein
but	O
can	O
also	O
form	O
heterodimers	B-protein
with	O
the	O
products	O
of	O
other	O
members	O
of	O
the	O
same	O
family	O
,	O
like	O
the	O
c-rel	B-DNA
and	I-DNA
v-rel	I-DNA
(	I-DNA
proto	I-DNA
)	I-DNA
oncogenes	I-DNA
.	O

In	O
parallel	O
,	O
CD2	B-protein
+	O
CD28	B-protein
activation	O
triggered	O
a	O
significant	O
intracellular	O
thiol	O
decrease	O
,	O
suggesting	O
that	O
oxygen	O
radicals	O
are	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
adhesion	B-protein
molecules	I-protein
.	O

A	O
mutant	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
was	O
isolated	O
that	O
lacked	O
expression	O
of	O
SLP-76	B-protein
(	O
SH2	B-protein
domain-containing	I-protein
leukocyte	I-protein
protein	I-protein
of	O
76	O
kilodaltons	O
)	O
,	O
a	O
hematopoietically	B-protein
expressed	I-protein
adaptor	I-protein
protein	I-protein
and	O
PTK	B-protein
substrate	I-protein
.	O

Most	O
interestingly	O
,	O
expression	O
of	O
CD95	B-protein
(	O
Fas/Apo-1	B-protein
)	O
and	O
of	O
CD23	B-protein
was	O
down-regulated	O
in	O
all	O
K46	B-cell_line
transfectants	I-cell_line
.	O

Whereas	O
the	O
CRE	B-DNA
site	I-DNA
was	O
essential	O
in	O
mediating	O
the	O
negative	O
activity	O
of	O
the	O
upstream	B-DNA
regulatory	I-DNA
region	I-DNA
in	O
Jurkat	B-cell_line
but	O
not	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
mutation	O
of	O
the	O
Sp1/AP-2	B-DNA
site	I-DNA
decreased	O
promoter	O
activity	O
in	O
both	O
cell	O
lines	O
.	O

Elastatinal	O
had	O
some	O
of	O
the	O
same	O
effects	O
as	O
GDSP	O
but	O
was	O
less	O
potent	O
and	O
effective	O
.	O

Continuous	O
treatment	O
of	O
monocytes	B-cell_type
with	O
IL-1beta	B-protein
,	O
but	O
not	O
with	O
TNF-alpha	B-protein
,	O
could	O
almost	O
completely	O
prevent	O
GC-induced	O
cell	O
death	O
.	O

This	O
phenomenon	O
can	O
be	O
mimicked	O
by	O
administering	O
MP	O
in	O
divided	O
doses	O
.	O

Also	O
,	O
gel	O
mobility	O
shift	O
analyses	O
using	O
specific	O
antiserum	O
revealed	O
decrease	O
in	O
the	O
DNA-binding	O
activity	O
of	O
an	O
insulin	B-protein
gene	I-protein
transcription	I-protein
factor	I-protein
,	O
PDX-1/IPF1/STF-1	B-protein
.	O

NF-AT	B-protein
DNA	O
binding	O
can	O
be	O
reconstituted	O
in	O
vitro	O
using	O
semi-purified	B-protein
AP1	I-protein
proteins	I-protein
mixed	O
with	O
cytosol	O
from	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Erythroid	O
differentiation	O
involves	O
the	O
activation	O
of	O
a	O
number	O
of	O
erythroid-specific	O
genes	O
,	O
most	O
of	O
which	O
,	O
including	O
the	O
globin	B-DNA
genes	I-DNA
and	O
the	O
erythropoietin	B-DNA
receptor	I-DNA
(	I-DNA
Epo-R	I-DNA
)	I-DNA
gene	I-DNA
,	O
are	O
,	O
at	O
least	O
in	O
part	O
,	O
regulated	O
by	O
the	O
transcription	B-protein
factor	I-protein
GATA-1	B-protein
.	O

We	O
previously	O
reported	O
that	O
monocyte	O
adhesion	O
to	O
tumor	B-cell_line
necrosis	I-cell_line
factor-alpha	I-cell_line
(	I-cell_line
TNF-alpha	I-cell_line
)	I-cell_line
-treated	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
increased	O
expression	O
of	O
tissue	O
factor	O
and	O
CD36	B-protein
on	O
monocytes	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
these	O
transcription	B-protein
factors	I-protein
become	O
activated	O
under	O
stimulatory	O
conditions	O
which	O
are	O
known	O
to	O
induce	O
gene	O
transcription	O
in	O
neutrophils	B-cell_type
.	O

Subsequent	O
cross-linking	O
of	O
CD15	O
increased	O
CAT	B-protein
activity	O
.	O

Overproduction	O
of	O
NFKB2	B-protein
(	O
lyt-10	B-protein
)	O
and	O
c-Rel	B-protein
:	O
a	O
mechanism	O
for	O
HTLV-I	B-protein
Tax	I-protein
-mediated	O
trans-activation	O
via	O
the	O
NF-kappa	B-protein
B	I-protein
signalling	O
pathway	O
.	O

These	O
results	O
indicate	O
that	O
the	O
functional	O
activity	O
of	O
ligands	O
built	O
from	O
the	O
binding	B-protein
site	I-protein
of	O
G28-5	B-protein
is	O
highly	O
dependent	O
upon	O
the	O
size	O
and	O
physical	O
properties	O
of	O
the	O
molecule	O
both	O
in	O
solution	O
and	O
on	O
the	O
cell	O
surfaces	O
.	O

Stat3	B-protein
recruitment	O
by	O
two	O
distinct	O
ligand-induced	B-protein
,	I-protein
tyrosine-phosphorylated	I-protein
docking	I-protein
sites	I-protein
in	O
the	O
interleukin-10	B-protein
receptor	I-protein
intracellular	I-protein
domain	I-protein
.	O

Exposing	O
human	B-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
HUVECs	B-cell_line
)	O
to	O
anoxia/reoxygenation	O
(	O
A/R	O
)	O
results	O
in	O
an	O
increase	O
in	O
polymorphonuclear	O
leukocyte	O
(	O
PMN	B-cell_type
)	O
adhesion	O
to	O
HUVECs	B-cell_line
.	O

Role	O
of	O
transcriptional	O
regulation	O
by	O
DNA	B-DNA
sequence	I-DNA
motifs	I-DNA
and	O
mRNA	O
stabilization	O
.	O

The	O
two	O
proteins	O
differ	O
in	O
their	O
surface	O
charge	O
,	O
since	O
they	O
are	O
separable	O
by	O
anion-exchange	O
chromatography	O
.	O

The	O
entry	O
of	O
microorganisms	O
into	O
the	O
body	O
induces	O
inflammatory	O
processes	O
.	O

In	O
contrast	O
,	O
no	O
effect	O
on	O
the	O
levels	O
of	O
the	O
octamer	B-protein
binding	I-protein
proteins	I-protein
,	O
Oct-1	B-protein
or	O
Oct-2	B-protein
,	O
were	O
found	O
.	O

CNI-1493	O
blocked	O
neither	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
increases	O
in	O
the	O
expression	O
of	O
TNF	B-RNA
mRNA	I-RNA
nor	O
the	O
translocation	O
of	O
nuclear	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
to	O
the	O
nucleus	O
in	O
macrophages	B-cell_type
activated	O
by	O
15	O
min	O
of	O
LPS	O
stimulation	O
,	O
indicating	O
that	O
CNI-1493	O
does	O
not	O
interfere	O
with	O
early	O
NF-kappa	B-protein
B	I-protein
-mediated	O
transcriptional	O
regulation	O
of	O
TNF	B-protein
.	O

Co-ligation	O
of	O
the	O
A6H	B-protein
antigen	O
and	O
the	O
CD3	B-protein
complex	I-protein
induced	O
expression	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
whereas	O
no	O
increase	O
in	O
NF-kappa	B-protein
B	I-protein
and	O
octamer-binding	B-protein
(	I-protein
Oct	I-protein
)	I-protein
proteins	I-protein
was	O
seen	O
compared	O
to	O
T	B-cell_type
cells	I-cell_type
stimulated	O
with	O
anti-CD3	B-protein
alone	O
.	O

Reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
analyses	O
revealed	O
that	O
adult	O
and	O
embryonic	B-DNA
globin	I-DNA
genes	I-DNA
were	O
appropriately	O
regulated	O
,	O
with	O
the	O
exception	O
of	O
beta	B-protein
h1-globin	I-protein
,	O
which	O
continued	O
to	O
be	O
expressed	O
at	O
a	O
very	O
low	O
level	O
.	O

According	O
to	O
current	O
models	O
the	O
inhibitory	O
capacity	O
of	O
I	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
(	I-protein
alpha	I-protein
)	I-protein
would	O
be	O
mediated	O
through	O
the	O
retention	O
of	O
Rel/NF-kappaB	B-protein
proteins	I-protein
in	O
the	O
cytosol	B-cell_type
.	O

To	O
define	O
novel	B-protein
proteins	I-protein
involved	O
in	O
the	O
early	O
transcriptional	O
response	O
during	O
the	O
activation	O
of	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
we	O
used	O
a	O
high-resolution	O
,	O
two-dimensional	O
gel	O
electrophoresis	O
system	O
to	O
identify	O
nuclear	B-protein
,	I-protein
deoxyribonucleic	I-protein
acid	I-protein
(	I-protein
DNA	I-protein
)	I-protein
binding	I-protein
proteins	I-protein
exhibiting	O
rapid	O
changes	O
in	O
phosphorylation	O
following	O
cell	O
stimulation	O
.	O

The	O
growth	O
inhibition	O
of	O
U937	B-cell_line
cells	I-cell_line
by	O
ML-9	O
was	O
also	O
reversible	O
.	O

One	O
of	O
the	O
viral	O
proteins	O
involved	O
in	O
this	O
process	O
might	O
be	O
the	O
Tat	B-protein
protein	I-protein
.	O

Finally	O
,	O
TFIIA	B-protein
facilitates	O
Tax	B-protein
transactivation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

A	O
novel	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
receptor	I-protein
family	I-protein
,	O
designated	O
TRAMP	B-protein
,	O
has	O
been	O
identified	O
.	O

In	O
contrast	O
,	O
no	O
upregulation	O
of	O
the	O
lipoxygenase	B-protein
activity	O
was	O
observed	O
when	O
the	O
macrophages	B-cell_type
were	O
prepared	O
from	O
homozygous	O
STAT6	B-protein
-deficient	O
mice	O
.	O

Here	O
we	O
demonstrate	O
the	O
binding	O
of	O
NFATp	B-protein
from	O
lysates	O
of	O
T	B-cell_type
cells	I-cell_type
to	O
immobilized	O
calcineurin	B-protein
.	O

In	O
summary	O
,	O
platelet-activating	B-protein
factor	I-protein
is	O
shown	O
here	O
to	O
have	O
a	O
direct	O
and	O
profound	O
effect	O
on	O
a	O
pure	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

LPS	O
binding	O
to	O
plasma	O
membrane	O
receptors	O
and	O
internalization	O
of	O
LPS	O
into	O
monocytes	B-cell_type
were	O
not	O
affected	O
by	O
lysoPC	O
.	O

Treatment	O
of	O
human	B-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cell	I-cell_line
(	I-cell_line
HUVEC	I-cell_line
)	I-cell_line
monolayers	I-cell_line
for	O
6	O
hours	O
with	O
0.2	O
mmol/L	O
diamide	O
and	O
1	O
mmol/L	O
buthionine	O
sulfoximine	O
(	O
BSO	O
)	O
decreased	O
GSH	O
levels	O
and	O
increased	O
the	O
ratio	O
of	O
GSSG	O
to	O
GSH	O
without	O
cell	O
toxicity	O
.	O

However	O
,	O
disruption	O
of	O
a	O
membrane-proximal	B-protein
proline-rich	I-protein
sequence	I-protein
motif	I-protein
(	O
'	O
box1	B-protein
'	O
)	O
in	O
either	O
subunit	O
of	O
the	O
bipartite	B-protein
IL-4R	I-protein
abolished	O
not	O
only	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
Janus	B-protein
kinases	I-protein
JAK1	B-protein
and	O
JAK3	B-protein
,	O
but	O
also	O
IL-4	B-protein
-triggered	O
activation	O
of	O
STAT5	B-protein
and	O
concomitant	O
cell	O
proliferation	O
.	O

Detection	O
of	O
various	O
other	O
intracellular	B-protein
signaling	I-protein
proteins	I-protein
is	O
also	O
described	O
.	O

The	O
data	O
indicate	O
that	O
decrease	O
of	O
ER	B-protein
levels	O
in	O
cell	O
may	O
involve	O
in	O
the	O
pathogenesis	O
of	O
climacteric	O
syndrome	O
.	O

I	B-protein
kappa	I-protein
B/MAD-3	I-protein
masks	O
the	O
nuclear	O
localization	O
signal	O
of	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
and	O
requires	O
the	O
transactivation	B-protein
domain	I-protein
to	O
inhibit	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
DNA	O
binding	O
.	O

CONCLUSIONS	O
:	O
MZF-1	B-RNA
and	I-RNA
MZF-2	I-RNA
mRNAs	I-RNA
seem	O
to	O
be	O
produced	O
by	O
the	O
alternative	O
use	O
of	O
two	O
different	O
transcription	B-DNA
initiation	I-DNA
sites	I-DNA
.	O

The	O
cDNA	B-DNA
hybridized	O
to	O
multiple	O
transcripts	O
in	O
pre-B	B-cell_line
and	I-cell_line
B-cell	I-cell_line
lines	I-cell_line
,	O
but	O
transcripts	O
were	O
not	O
detected	O
at	O
significant	O
levels	O
in	O
plasmacytoma	B-cell_line
,	O
T-cell	B-cell_line
,	O
and	O
nonlymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Expression	O
of	O
BHRF1	B-protein
in	O
MCF-Fas	B-cell_line
cells	I-cell_line
conferred	O
nearly	O
complete	O
resistance	O
against	O
both	O
anti-Fas	B-protein
antibody	I-protein
and	O
TNF-mediated	O
apoptosis	O
.	O

The	O
effects	O
of	O
phorbol	O
ester	O
on	O
MNDA	B-RNA
mRNA	I-RNA
appeared	O
to	O
be	O
associated	O
with	O
induced	O
differentiation	O
since	O
inhibiting	O
cell	O
proliferation	O
did	O
not	O
alter	O
the	O
level	O
of	O
MNDA	B-RNA
mRNA	I-RNA
and	O
cell	O
cycle	O
variation	O
in	O
MNDA	B-RNA
mRNA	I-RNA
levels	O
were	O
not	O
observed	O
.	O

Upon	O
TPA	O
treatment	O
,	O
the	O
activity	O
of	O
ERK1	B-protein
and	O
ERK2	B-protein
rapidly	O
increased	O
,	O
with	O
maximal	O
induction	O
between	O
1	O
and	O
3	O
h	O
,	O
while	O
ERK2	B-protein
protein	O
levels	O
remained	O
constant	O
.	O

Our	O
data	O
support	O
the	O
hypothesis	O
that	O
p13MTCP1	B-protein
and	O
p14TCL1	B-protein
form	O
a	O
new	O
protein	B-protein
family	I-protein
that	O
plays	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	O
of	O
T-PLL	O
and	O
related	O
conditions	O
.	O

Optimal	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
requires	O
at	O
least	O
two	O
signals	O
.	O

We	O
determined	O
whether	O
Hsp70	B-protein
induction	O
by	O
TS	O
was	O
mediated	O
by	O
the	O
activation	O
of	O
the	O
HS	B-protein
transcription	I-protein
factor	I-protein
,	O
HSF	B-protein
.	O

Resolution	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
in	O
gel	O
shift	O
analysis	O
shows	O
that	O
the	O
binding	B-protein
protein	I-protein
,	O
mobilized	O
in	O
naive	B-cell_line
Mono	I-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
,	O
consists	O
mainly	O
of	O
p50-p65	B-protein
heterodimers	I-protein
,	O
while	O
in	O
tolerant	B-cell_line
cells	I-cell_line
,	O
the	O
p50	B-protein
homodimer	I-protein
is	O
predominant	O
.	O

Deletion	O
mutants	O
containing	O
1.3	B-DNA
,	I-DNA
0.6	I-DNA
,	I-DNA
and	I-DNA
0.2	I-DNA
kb	I-DNA
5'-flanking	I-DNA
DNA	I-DNA
were	O
incrementally	O
less	O
transcriptionally	O
active	O
,	O
although	O
0.2	O
kb	O
still	O
mediated	O
a	O
12-fold	O
induction	O
by	O
PRL	B-protein
.	O

Using	O
the	O
[	O
3H	O
]	O
thymidine	O
proliferation	O
assay	O
,	O
we	O
determined	O
reactivity	O
to	O
purified	B-protein
recombinant	I-protein
SSB	I-protein
(	O
rSSB	B-protein
)	O
in	O
20	O
patients	O
with	O
SS	O
and	O
19	O
controls	O
.	O

Mapping	O
of	O
B-cell	B-protein
epitopes	I-protein
of	O
the	O
human	B-protein
hepatitis	I-protein
B	I-protein
virus	I-protein
X	I-protein
protein	I-protein
.	O

These	O
data	O
demonstrate	O
that	O
VitD3	O
induces	O
CD14	B-protein
indirectly	O
through	O
some	O
intermediary	B-protein
factor	I-protein
,	O
and	O
suggest	O
a	O
critical	O
role	O
for	O
Sp1	B-protein
in	O
this	O
process	O
.	O

We	O
found	O
that	O
these	O
parameters	O
were	O
indistinguishable	O
for	O
one	O
of	O
the	O
PRL-	B-protein
and	I-protein
IL-2-induced	I-protein
factors	I-protein
.	O

The	O
class	B-protein
II	I-protein
trans-activator	I-protein
CIITA	I-protein
interacts	O
with	O
the	O
TBP-associated	B-protein
factor	I-protein
TAFII32	I-protein
.	O

The	O
clinical	O
significance	O
of	O
these	O
findings	O
remains	O
unclear	O
.	O

The	O
involvement	O
of	O
the	O
CCK	B-protein
(	I-protein
B	I-protein
)	I-protein
receptor	I-protein
in	O
such	O
a	O
stimulation	O
was	O
demonstrated	O
by	O
the	O
inhibiting	O
effect	O
of	O
the	O
selective	O
CCK	B-protein
(	I-protein
B	I-protein
)	I-protein
receptor	I-protein
antagonist	O
PD-135	O
,	O
158	O
.	O

Pervanadate	O
synergized	O
with	O
signals	O
delivered	O
by	O
T-cell	B-cell_type
antigen	B-protein
receptor	I-protein
engagement	O
or	O
by	O
a	O
phorbol	O
ester	O
to	O
induce	O
interleukin	O
2	O
production	O
.	O

Molecular	O
and	O
biochemical	O
approaches	O
demonstrated	O
that	O
LMP1	B-protein
usurps	O
cellular	O
signaling	O
pathways	O
resulting	O
in	O
the	O
induction	O
of	O
NF-kappaB	B-protein
and	O
AP-1	B-protein
via	O
two	O
C-terminal	B-protein
activating	I-protein
regions	I-protein
.	O

For	O
example	O
,	O
in	O
experiments	O
involving	O
proviral	O
clones	O
with	O
LTRs	B-DNA
containing	O
one	O
or	O
two	O
NF-kappa	B-DNA
B	I-DNA
elements	I-DNA
(	O
and	O
no	O
Sp1	B-DNA
binding	I-DNA
sites	I-DNA
)	O
,	O
a	O
hierarchy	O
of	O
cellular	O
permissivity	O
to	O
virus	O
replication	O
(	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
=	O
MT4	B-cell_line
greater	O
than	O
H9	B-cell_line
greater	O
than	O
CEM	B-cell_line
greater	O
than	O
Jurkat	B-cell_line
)	O
was	O
observed	O
.	O

EL-4	B-cell_type
cells	I-cell_type
were	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
enhancer	B-DNA
region	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
reporter	I-DNA
gene	I-DNA
.	O

The	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
promoter	I-DNA
consists	O
of	O
several	O
independent	O
T	B-DNA
cell	I-DNA
receptor	I-DNA
(	I-DNA
TcR	I-DNA
)	I-DNA
responsive	I-DNA
elements	I-DNA
.	O

The	O
rapid	O
expansion	O
of	O
the	O
number	O
of	O
women	O
now	O
suitable	O
for	O
X	O
inactivation	O
analysis	O
has	O
however	O
given	O
rise	O
to	O
new	O
controversies	O
,	O
one	O
of	O
the	O
more	O
troublesome	O
being	O
the	O
possibility	O
of	O
a	O
modification	O
of	O
the	O
pattern	O
of	O
X-	B-DNA
chromosome	I-DNA
inactivation	O
pattern	O
in	O
blood	B-cell_type
cells	I-cell_type
of	O
elderly	O
women	O
.	O

Finally	O
,	O
we	O
show	O
that	O
two	O
other	O
I	B-protein
kappaB	I-protein
molecules	I-protein
,	O
I	B-protein
kappaB	I-protein
beta	I-protein
and	O
the	O
recently	O
identified	O
I	B-protein
kappaB	I-protein
epsilon	I-protein
,	O
are	O
not	O
degraded	O
in	O
the	O
1.3E2	B-cell_line
cell	O
line	O
following	O
stimulation	O
.	O

Our	O
result	O
is	O
different	O
from	O
the	O
reported	O
properties	O
of	O
human	B-protein
CCR-4	I-protein
.	O

Other	O
I	B-protein
kappa	I-protein
B	I-protein
proteins	I-protein
are	O
rather	O
involved	O
in	O
terminating	O
NF-kappa	B-protein
B	I-protein
's	O
activity	O
in	O
the	O
nucleus	O
.	O

Effects	O
of	O
CD45	B-protein
on	O
NF-kappa	B-protein
B	I-protein
.	O

However	O
,	O
the	O
cellular	O
signaling	O
pathway	O
(	O
s	O
)	O
caused	O
by	O
hypoxia	O
is	O
poorly	O
understood	O
.	O

Furthermore	O
,	O
a	O
truncated	O
form	O
of	O
NFAT1	B-protein
acts	O
as	O
a	O
dominant-negative	O
,	O
reducing	O
IL-4	B-DNA
promoter	I-DNA
activity	O
in	O
primed	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
confirming	O
the	O
importance	O
of	O
endogenous	B-protein
NFAT	I-protein
to	O
increased	O
IL-4	B-protein
gene	O
expression	O
by	O
effector	O
T	O
cells	O
.	O

CONCLUSION	O
.	O

Contrary	O
to	O
previous	O
assumptions	O
,	O
we	O
observed	O
that	O
p65	B-protein
homodimers	O
can	O
interact	O
with	O
a	O
subset	O
of	O
DNA	O
sequences	O
not	O
recognized	O
by	O
p50	B-protein
homodimers	I-protein
.	O

Genomic	O
organization	O
,	O
sequence	O
,	O
and	O
transcriptional	O
regulation	O
of	O
the	O
human	B-DNA
eotaxin	I-DNA
gene	I-DNA
.	O

Here	O
,	O
we	O
characterize	O
the	O
putative	B-protein
human	I-protein
homolog	I-protein
of	O
NRL	B-protein
,	O
neutrophil	B-protein
gelatinase-associated	I-protein
lipocalin	I-protein
(	O
NGAL	B-protein
)	O
.	O

These	O
results	O
indicate	O
that	O
IL-10	B-protein
,	O
in	O
addition	O
to	O
down-regulating	O
the	O
cellular	O
immune	O
response	O
to	O
HIV-1	O
,	O
may	O
also	O
play	O
a	O
role	O
in	O
TNF-alpha	B-protein
-mediated	O
activation	O
of	O
HIV-1	O
replication	O
in	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
.	O

Convergence	O
of	O
costimulatory	O
signals	O
and	O
differences	O
from	O
transformed	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Two	O
Jurkat	B-cell_line
cell	I-cell_line
clones	I-cell_line
have	O
been	O
stably	O
transfected	O
with	O
a	O
reporter	B-DNA
vector	I-DNA
for	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
.	O

Compared	O
to	O
normal	B-cell_type
lymphocytes	I-cell_type
,	O
MOLT-4	B-cell_line
and	I-cell_line
CEM	I-cell_line
cells	I-cell_line
exhibited	O
an	O
altered	O
cell	O
cycle	O
regulation	O
of	O
thymidine	B-protein
kinase	I-protein
,	O
a	O
much	O
higher	O
intracellular	O
activity	O
of	O
this	O
enzyme	B-protein
,	O
and	O
higher	O
thymidine	B-RNA
kinase	I-RNA
mRNA	I-RNA
expression	O
.	O

Cotransfection	O
of	O
a	O
CD44	B-DNA
promoter-chloramphenicol	I-DNA
acetyltransferase	I-DNA
reporter	I-DNA
construct	I-DNA
with	O
an	O
egr-1	B-DNA
expression	I-DNA
vector	I-DNA
resulted	O
in	O
a	O
6.5-	O
to	O
8.5-fold	O
induction	O
of	O
transcriptional	O
activity	O
relative	O
to	O
an	O
empty	B-DNA
expression	I-DNA
vector	I-DNA
.	O

Finally	O
,	O
GATA-1	B-protein
protein	O
level	O
was	O
shown	O
to	O
be	O
increased	O
in	O
ACLA-treated	B-cell_line
but	I-cell_line
not	I-cell_line
in	I-cell_line
DOX-treated	I-cell_line
cells	I-cell_line
.	O

In	O
humans	O
infected	O
with	O
the	O
HIV-1	O
virus	O
there	O
may	O
be	O
a	O
disproportionate	O
severity	O
of	O
signs	O
and	O
symptoms	O
of	O
illness	O
compared	O
to	O
the	O
fraction	O
of	O
CD4+	B-cell_line
infected	I-cell_line
T-lymphoid	I-cell_line
cells	I-cell_line
.	O

We	O
have	O
found	O
that	O
the	O
recruitment	O
of	O
EKLF	B-protein
to	O
5'HS3	B-DNA
depends	O
on	O
the	O
presence	O
of	O
5'HS2	B-DNA
in	O
cis	O
,	O
but	O
the	O
recruitment	O
to	O
5'HS2	B-DNA
does	O
not	O
depend	O
on	O
5'HS3	B-DNA
.	O

125I-IL-13	B-protein
did	O
not	O
bind	O
to	O
colon	B-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
but	O
unlabeled	O
IL-13	B-protein
competed	O
for	O
the	O
binding	O
of	O
125I-IL-4	B-protein
.	O

It	O
is	O
supposed	O
that	O
some	O
effects	O
may	O
be	O
due	O
to	O
membrane	O
alterations	O
.	O

The	O
effects	O
of	O
Ara-C	O
on	O
JNK	B-protein
activity	O
may	O
be	O
mediated	O
through	O
secondary	O
response	O
pathways	O
.	O

Mice	O
deficient	O
for	O
the	O
55	B-protein
kd	I-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
are	O
resistant	O
to	O
endotoxic	O
shock	O
,	O
yet	O
succumb	O
to	O
L.	O
monocytogenes	O
infection	O
.	O

The	O
high	O
concentration	O
of	O
foreign	B-protein
antigen	I-protein
in	O
the	O
lumen	B-cell_type
of	O
the	O
gastrointestinal	O
tract	O
is	O
separated	O
from	O
the	O
underlying	O
lymphocytes	B-cell_type
by	O
a	O
single	O
cell	O
layer	O
of	O
polarized	O
epithelium	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
applied	O
these	O
two	O
markers	O
to	O
the	O
study	O
of	O
HD	O
histogenesis	O
.	O

Pretreatment	O
with	O
TNFalpha	B-protein
diminished	O
,	O
and	O
with	O
IL-10	B-protein
improved	O
,	O
the	O
ability	O
of	O
dexamethasone	O
to	O
suppress	O
IL-6	B-protein
secretion	O
in	O
whole-blood	B-cell_type
cell	I-cell_type
cultures	I-cell_type
(	O
P	O
<	O
0.01	O
for	O
both	O
)	O
and	O
to	O
enhance	O
IL-1	B-protein
receptor	O
antagonist	O
secretion	O
by	O
U937	O
cells	O
(	O
P	O
<	O
0.05	O
for	O
both	O
)	O
.	O

Helix-loop-helix	B-protein
(	I-protein
HLH	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
are	O
involved	O
in	O
cellular	O
growth	O
and	O
differentiation	O
.	O

Differentiation	O
of	O
U-937	B-cell_line
promonocytic	I-cell_line
cells	I-cell_line
by	O
etoposide	O
and	O
ICRF-193	O
,	O
two	O
antitumour	O
DNA	B-protein
topoisomerase	I-protein
II	I-protein
inhibitors	O
with	O
different	O
mechanisms	O
of	O
action	O
.	O

However	O
,	O
presentation	O
of	O
endogenously	O
synthesized	O
IE1	B-protein
can	O
be	O
restored	O
when	O
U373	B-cell_line
MG	I-cell_line
cells	I-cell_line
are	O
transfected	O
with	O
CIITA	B-DNA
prior	O
to	O
infection	O
with	O
HCMV	O
.	O

Both	O
PKC-	O
dependent	O
and	O
-independent	O
activation	O
of	O
ERK	B-protein
were	O
sensitive	O
to	O
inhibition	O
by	O
forskolin	O
or	O
a	O
cell-permeable	O
cAMP	O
analogue	O
,	O
dbcAMP	O
.	O

(	O
vii	O
)	O
Two	O
deletions	O
within	O
the	O
EBNA-2	B-protein
gene	O
which	O
rendered	O
EBV	O
transformation	O
incompetent	O
did	O
not	O
transactivate	O
LMP1	B-protein
,	O
whereas	O
a	O
transformation-competent	B-DNA
EBNA-2	I-DNA
deletion	I-DNA
mutant	I-DNA
did	O
transactivate	O
LMP1	B-protein
.	O

In	O
contrast	O
,	O
OTF-1	B-protein
-enriched	O
protein	O
fractions	O
did	O
not	O
affect	O
DRA	B-DNA
gene	I-DNA
transcription	O
although	O
it	O
functionally	O
enhanced	O
the	O
transcription	O
of	O
another	O
gene	O
.	O

Signal	O
transduction	O
through	O
interferon-gamma	B-protein
receptor	I-protein
on	O
human	B-cell_type
eosinophils	I-cell_type
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
determined	O
that	O
the	O
pattern	O
of	O
band	O
migration	O
differed	O
between	O
the	O
two	O
cell	O
types	O
.	O

The	O
induction	O
of	O
tyrosine	O
phosphorylation	O
of	O
p80c-rel	B-protein
was	O
unique	O
to	O
G-CSF	B-protein
in	O
that	O
granulocyte-macrophage	B-protein
colony	I-protein
stimulating	I-protein
factor	I-protein
which	O
also	O
stimulates	O
neutrophils	B-cell_type
and	O
induces	O
tyrosine	O
phosphorylation	O
does	O
not	O
result	O
in	O
tyrosine	O
phosphorylation	O
of	O
p80c-rel	B-protein
.	O

Some	O
of	O
the	O
most	O
potent	O
antiinflammatory	O
and	O
immunosuppressive	O
agents	O
are	O
synthetic	O
glucocorticoids	O
.	O

RANTES	B-protein
is	O
expressed	O
late	O
(	O
3-5	O
days	O
)	O
after	O
activation	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

The	O
mechanism	O
of	O
reduced	O
GR	B-protein
levels	O
in	O
relation	O
to	O
age	O
and	O
sport	O
activity	O
could	O
involve	O
a	O
loss	O
or	O
an	O
involution	O
of	O
receptor	O
synthesis	O
.	O

However	O
,	O
other	O
X1	O
box-specific	O
activities	O
were	O
detected	O
in	O
all	O
these	O
cell	B-cell_line
lines	I-cell_line
.	O

Proinflammatory	B-cell_type
neutrophil	I-cell_type
stimuli	O
also	O
promoted	O
the	O
accumulation	O
of	O
IkappaB-alpha	B-RNA
mRNA	I-RNA
transcripts	I-RNA
,	O
resulting	O
in	O
the	O
reexpression	O
of	O
the	O
IkappaB-alpha	B-protein
protein	I-protein
.	O

Western-blot	O
analysis	O
of	O
the	O
sedimentation	O
peak	O
showed	O
the	O
concomitant	O
presence	O
of	O
MBP-HBD	B-protein
by	O
a	O
monoclonal	B-protein
anti-MBP	I-protein
antibody	I-protein
,	O
and	O
hsp90	B-protein
by	O
a	O
monoclonal	B-protein
anti-hsp	I-protein
antibody	I-protein
.	O

A	O
survey	O
of	O
genes	B-DNA
potentially	O
regulated	O
by	O
this	O
family	O
of	O
factors	B-protein
primarily	O
revealed	O
genes	B-DNA
involved	O
in	O
growth-related	O
metabolism	O
.	O

Recent	O
reports	O
have	O
demonstrated	O
that	O
differential	O
expression	O
of	O
cell	O
surface	O
molecules	O
,	O
such	O
as	O
adhesion	B-protein
molecule	I-protein
and	O
chemokine	B-protein
receptor	I-protein
,	O
is	O
involved	O
in	O
their	O
recruitment	O
into	O
target	O
tissues	O
.	O

Induction	O
of	O
the	O
enhancer	B-DNA
may	O
have	O
a	O
role	O
in	O
the	O
increase	O
in	O
globin	B-DNA
gene	I-DNA
transcription	O
that	O
characterizes	O
erythroid	O
maturation	O
.	O

It	O
is	O
concluded	O
that	O
,	O
in	O
contrast	O
to	O
a	O
previous	O
study	O
,	O
PBMC	B-cell_type
are	O
not	O
a	O
common	O
site	O
of	O
persistent	O
group	O
C	O
adenoviral	O
infection	O
.	O

With	O
the	O
aim	O
of	O
identifying	O
genetic	O
targets	O
for	O
these	O
transcription	O
factors	O
,	O
we	O
stably	O
transfected	B-DNA
cDNAs	I-DNA
encoding	O
EBF	B-protein
or	O
a	O
covalent	O
homodimer	O
of	O
E47	B-protein
,	O
individually	O
or	O
together	O
,	O
into	O
immature	B-cell_line
hematopoietic	I-cell_line
Ba/F3	I-cell_line
cells	I-cell_line
,	O
which	O
lack	O
both	O
factors	O
.	O

It	O
was	O
found	O
that	O
treatment	O
with	O
IFN-gamma	B-protein
induces	O
changes	O
in	O
the	O
occupancy	O
of	O
the	O
DRA	B-DNA
gene	I-DNA
regulatory	I-DNA
sequences	I-DNA
by	O
nuclear	B-protein
factors	I-protein
.	O

Unexpectedly	O
,	O
expression	O
of	O
the	O
same	O
EBNA2	B-protein
-oestrogen	O
receptor	O
fusion	O
protein	O
in	O
established	B-cell_line
human	I-cell_line
B	I-cell_line
cell	I-cell_line
lymphoma	I-cell_line
lines	I-cell_line
resulted	O
in	O
growth	O
retardation	O
or	O
growth	O
arrest	O
upon	O
the	O
addition	O
of	O
oestrogen	O
.	O

In	O
addition	O
,	O
assay	O
of	O
PBMC	B-cell_type
by	O
the	O
adenovirus-specific	O
PCR	O
may	O
help	O
detect	O
early	O
invasive	O
disease	O
and	O
warrants	O
further	O
evaluation	O
.	O

Viral	O
gene	O
expression	O
was	O
assayed	O
by	O
the	O
level	O
of	O
p24	B-protein
gag	I-protein
protein	I-protein
released	O
from	O
cultures	O
transfected	O
with	O
the	O
proviral	O
constructs	O
.	O

As	O
shown	O
by	O
mobility-shift	O
,	O
methylation	O
interference	O
,	O
and	O
mutational	O
analyses	O
,	O
the	O
mammalian	B-protein
protein	I-protein
BSAP	B-protein
recognizes	O
all	O
four	O
sea	B-DNA
urchin	I-DNA
binding	I-DNA
sites	I-DNA
in	O
a	O
manner	O
indistinguishable	O
from	O
TSAP	B-protein
;	O
however	O
,	O
the	O
two	O
proteins	O
differ	O
in	O
molecular	O
weight	O
.	O

In	O
all	O
3	O
cases	O
,	O
a	O
characteristic	O
immunophenotype	O
was	O
identified	O
(	O
CD4+	B-protein
,	O
CD13	B-protein
-	O
,	O
CD33+	O
,	O
CD65s+	O
)	O
.	O

These	O
results	O
support	O
the	O
feasibility	O
and	O
usefulness	O
of	O
this	O
systematic	O
approach	O
to	O
studying	O
variation	O
in	O
gene	O
expression	O
patterns	O
in	O
human	O
cancers	O
as	O
a	O
means	O
to	O
dissect	O
and	O
classify	O
solid	O
tumors	O
.	O

The	O
murine	B-protein
and	I-protein
human	I-protein
factors	I-protein
are	O
abundantly	O
expressed	O
in	O
a	O
variety	O
of	O
human	B-cell_line
and	I-cell_line
murine	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
and	O
can	O
activate	O
transcription	O
through	O
a	O
tissue-specific	B-DNA
GATA-binding	I-DNA
site	I-DNA
identified	O
within	O
the	O
human	B-DNA
T-cell	I-DNA
receptor	I-DNA
delta	I-DNA
gene	I-DNA
enhancer	I-DNA
.	O

Four	O
P-like	B-DNA
elements	I-DNA
are	O
required	O
for	O
optimal	O
transcription	O
of	O
the	O
mouse	B-DNA
IL-4	I-DNA
gene	I-DNA
:	O
involvement	O
of	O
a	O
distinct	O
set	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
and	O
activator	B-protein
protein-1	I-protein
family	I-protein
proteins	I-protein
.	O

Hence	O
,	O
the	O
diploid	O
state	O
of	O
the	O
genome	O
offers	O
the	O
advantage	O
that	O
a	O
loss-of-function	O
mutation	O
in	O
one	O
allele	B-DNA
can	O
be	O
compensated	O
for	O
by	O
the	O
remaining	O
wild-type	B-DNA
allele	I-DNA
of	O
the	O
same	O
gene	O
.	O

In	O
addition	O
,	O
the	O
macrophage	O
transcription	B-protein
factor	I-protein
PU.1	O
binds	O
the	O
CD11b	B-DNA
promoter	I-DNA
in	O
vitro	O
and	O
in	O
vivo	O
close	O
to	O
the	O
Sp1	B-DNA
site	I-DNA
.	O

We	O
also	O
examined	O
the	O
involvement	O
of	O
other	O
signal	O
transduction	O
pathways	O
.	O

However	O
,	O
activation	O
of	O
the	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
leading	O
to	O
enhanced	O
HIV-1	O
replication	O
can	O
be	O
induced	O
by	O
antigens	B-protein
,	O
mitogens	O
,	O
and	O
cytokines	B-protein
(	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
[	O
TNF-alpha	B-protein
]	O
,	O
interleukin	B-protein
1	I-protein
,	O
and	O
interleukin-2	B-protein
)	O
.	O

Human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
can	O
activate	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
promoter	I-DNA
and	O
accelerate	O
cytopathic	O
effects	O
in	O
HIV-infected	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
addition	O
to	O
biophysical	O
properties	O
,	O
pulmonary	O
surfactant	O
has	O
immunomodulatory	O
activity	O
.	O

We	O
conclude	O
that	O
transcription	O
activation	O
by	O
LEF-1	B-protein
in	O
vitro	O
is	O
a	O
chromatin	B-DNA
-dependent	O
process	O
that	O
requires	O
a	O
functional	O
trans-activation	B-protein
domain	I-protein
in	O
addition	O
to	O
the	O
HMG	B-protein
domain	I-protein
.	O

ZEBRA	B-protein
,	O
a	O
transcriptional	O
activator	O
,	O
initiates	O
the	O
EBV	O
lytic	O
cascade	O
by	O
activating	O
viral	O
gene	O
expression	O
.	O

Immunohistochemical	O
study	O
of	O
steroid	O
hormones	O
and	O
an	O
estrogen	O
binding	O
assay	O
in	O
malignant	B-cell_type
soft	I-cell_type
tissue	I-cell_type
tumors	I-cell_type
.	O

A	O
motif	O
presenting	O
a	O
strong	O
similarity	O
to	O
an	O
initiator	O
was	O
detected	O
,	O
as	O
well	O
as	O
putative	B-DNA
binding	I-DNA
sites	I-DNA
for	O
Sp1	B-protein
,	O
GATA-2	B-protein
,	O
LyF-1	B-protein
,	O
ets-1	B-protein
,	O
AP1	B-protein
,	O
and	O
MZF1	B-protein
transcription	B-protein
factors	I-protein
,	O
and	O
two	O
GAS	B-DNA
motifs	I-DNA
.	O

Importantly	O
,	O
additional	O
testing	O
of	O
a	O
corresponding	O
set	O
of	O
peptides	O
covering	O
the	O
complete	O
sequence	O
of	O
pp65	B-protein
on	O
10	O
of	O
these	O
donors	O
identified	O
individuals	O
whose	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
recognized	O
IE-1	B-protein
but	O
not	O
pp65	B-protein
and	O
vice	O
versa	O
,	O
clearly	O
illustrating	O
that	O
either	O
protein	O
may	O
be	O
a	O
major	O
target	O
.	O

These	O
bacterially-produced	B-DNA
MR	I-DNA
constructs	I-DNA
had	O
no	O
steroid	O
binding	O
activity	O
per	O
se	O
.	O

Cotransfection	O
of	O
Sp3	B-protein
along	O
with	O
CD11c	B-DNA
promoter-luciferase	I-DNA
constructs	I-DNA
into	O
Sp-deficient	B-cell_line
Drosophila	I-cell_line
Schneider	I-cell_line
2	I-cell_line
cells	I-cell_line
showed	O
that	O
Sp3	B-protein
could	O
activate	O
the	O
CD11c	B-DNA
promoter	I-DNA
.	O

The	O
hormone	O
delayed	O
terminal	O
differentiation	O
into	O
erythrocytes	B-cell_type
,	O
which	O
was	O
assayed	O
by	O
morphology	O
,	O
hemoglobin	B-protein
accumulation	O
,	O
and	O
the	O
expression	O
of	O
genes	O
characteristic	O
for	O
immature	B-cell_type
cells	I-cell_type
.	O

The	O
effect	O
of	O
18C7	B-protein
on	O
the	O
binding	O
was	O
similar	O
with	O
both	O
hormones	O
.	O

Previously	O
we	O
and	O
others	O
showed	O
by	O
targeted	O
gene	O
disruption	O
that	O
the	O
zinc	B-DNA
finger	I-DNA
gene	I-DNA
,	O
erythroid	B-protein
Kruppel-like	I-protein
factor	I-protein
(	O
EKLF	B-protein
)	O
,	O
is	O
required	O
for	O
expression	O
of	O
the	O
beta-globin	B-DNA
gene	I-DNA
in	O
mice	O
,	O
presumably	O
through	O
interaction	O
with	O
a	O
high-affinity	B-DNA
binding	I-DNA
site	I-DNA
in	O
the	O
proximal	B-DNA
promoter	I-DNA
.	O

Overall	O
the	O
mechanism	O
of	O
transactivation	O
by	O
the	O
human	B-protein
B-cell-specific	I-protein
CIITA	I-protein
is	O
very	O
similar	O
to	O
that	O
mediated	O
by	O
the	O
herpes	B-protein
virus	I-protein
transactivator	I-protein
VP16	B-protein
in	O
the	O
ways	O
that	O
have	O
been	O
tested	O
.	O

IL-2	B-protein
and	O
IL-7	B-protein
induce	O
heterodimerization	O
of	O
STAT5	B-protein
isoforms	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphoblasts	I-cell_type
.	O

Single	O
strand	O
conformation	O
polymorphism	O
analysis	O
of	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
mutations	O
in	O
patients	O
with	O
androgen	O
insensitivity	O
syndromes	O
:	O
application	O
for	O
diagnosis	O
,	O
genetic	O
counseling	O
,	O
and	O
therapy	O
.	O

The	O
suppressive	O
activity	O
was	O
lost	O
in	O
molecules	O
,	O
lacking	O
the	O
sugar	O
moiety	O
or	O
the	O
lipid	O
moiety	O
.	O

In	O
consistence	O
,	O
the	O
c-Myc	B-protein
and	O
E1A	B-protein
overexpressing	O
fibroblasts	B-cell_type
were	O
more	O
sensitive	O
to	O
the	O
cytolytic	O
effects	O
of	O
isolated	O
NK	O
cell-derived	O
granules	O
than	O
parental	B-cell_type
cells	I-cell_type
.	O

Fine	O
mapping	O
by	O
in	O
vivo	O
footprinting	O
demonstrated	O
five	O
transcription	O
factor	O
binding	O
sites	O
that	O
are	O
occupied	O
in	O
both	O
resting	O
and	O
activated	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
;	O
these	O
are	O
tandem	B-DNA
CRE	I-DNA
motifs	I-DNA
,	O
a	O
Sp1	B-DNA
site	I-DNA
,	O
an	O
overlapping	O
Egr-1/Sp1	B-DNA
site	I-DNA
,	O
and	O
a	O
novel	O
palindromic	B-DNA
octamer	I-DNA
sequence	I-DNA
(	O
POS	B-DNA
)	O
.	O

A	O
variety	O
of	O
factors	O
are	O
known	O
to	O
play	O
a	O
role	O
in	O
terminal	O
neutrophil	B-cell_type
maturation	O
,	O
including	O
the	O
vitamin	O
A	O
derivative	O
,	O
retinoic	O
acid	O
.	O

We	O
will	O
discuss	O
recent	O
experimental	O
evidences	O
suggesting	O
that	O
LPS	O
might	O
share	O
a	O
pathway	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
with	O
other	O
inducers	O
of	O
the	O
factor	O
.	O

Molecular	O
mechanisms	O
underlying	O
selective	O
expression	O
of	O
cytokines	B-protein
by	O
T	B-cell_type
cells	I-cell_type
remain	O
poorly	O
understood	O
.	O

Two	O
sets	O
of	O
nested	O
primers	O
were	O
designed	O
to	O
conserved	O
sequences	O
in	O
the	O
adenovirus	B-DNA
E1A	I-DNA
and	I-DNA
hexon	I-DNA
genes	I-DNA
.	O

A	O
primary	O
site	O
of	O
infection	O
by	O
human	O
adenoviruses	O
is	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

Abnormalities	O
of	O
retinoblastoma	B-protein
protein	I-protein
(	O
pRB	B-protein
)	O
and	O
mutations	O
of	O
RB	O
gene	O
have	O
been	O
reported	O
in	O
up	O
to	O
70	O
%	O
of	O
MM	O
patients	O
and	O
80	O
%	O
of	O
MM-derived	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Bipotential	B-cell_type
T/natural	I-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
are	O
present	O
in	O
the	O
human	O
thymus	O
.	O

Moreover	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
CMV	O
induced	O
the	O
formation	O
of	O
NF-kappaB	B-protein
and	O
AP-1	B-protein
complexes	I-protein
.	O

These	O
complexes	O
are	O
coordinately	O
expressed	O
except	O
during	O
replicative	O
senescence	O
,	O
which	O
is	O
characterized	O
by	O
the	O
down-modulation	O
of	O
site	B-protein
beta	I-protein
-but	O
not	O
site	B-protein
alpha	I-protein
-binding	O
activities	O
.	O

Synergistic	O
suppression	O
of	O
T-cell	O
proliferation	O
was	O
observed	O
when	O
various	O
concentrations	O
of	O
DEX	O
and	O
PGE2	O
,	O
but	O
not	O
DEX	O
and	O
ISO	O
,	O
were	O
added	O
to	O
cultures	O
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
adenovirus	O
2	O
(	O
Ad2	O
)	O
infection	O
on	O
human	B-cell_type
monocytes	I-cell_type
and	O
monocyte-derived	B-cell_type
macrophages	I-cell_type
with	O
regard	O
to	O
expression	O
of	O
TNF-alpha	B-protein
and	O
IL-1	B-protein
beta	I-protein
.	O

Six	O
tandem	O
repeats	O
of	O
the	O
P	B-DNA
element	I-DNA
linked	O
to	O
the	O
SV40	B-DNA
promoter	I-DNA
responded	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
while	O
that	O
of	O
other	O
elements	O
did	O
not.	O
It	O
would	O
thus	O
appear	O
that	O
components	O
of	O
each	O
P-like	B-protein
element-binding	I-protein
complexes	I-protein
are	O
not	O
identical	O
and	O
may	O
coordinately	O
contribute	O
to	O
transcriptional	O
activity	O
.	O

Immunophenotype	O
of	O
intraductal	O
carcinoma	O
.	O

A	O
transcript	O
of	O
the	O
ALAS	B-DNA
IRE	I-DNA
,	O
mutated	O
in	O
the	O
conserved	O
loop	O
of	O
the	O
IRE	B-DNA
,	O
did	O
not	O
readily	O
form	O
this	O
protein	B-protein
-	I-protein
RNA	I-protein
complex	I-protein
.	O

We	O
further	O
demonstrated	O
that	O
aspirin	O
,	O
but	O
not	O
dexamethasone	O
,	O
suppressed	O
IFN-gamma	B-protein
-induced	O
STAT	B-protein
activation	O
.	O

Induction	O
of	O
Bcl-x	B-protein
(	I-protein
L	I-protein
)	I-protein
expression	O
by	O
human	B-protein
T-cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax	I-protein
through	O
NF-kappaB	B-protein
in	O
apoptosis-resistant	B-cell_line
T-cell	I-cell_line
transfectants	I-cell_line
with	O
Tax	B-protein
.	O

Irrespective	O
of	O
the	O
human	O
cell	O
partner	O
used	O
for	O
fusion	O
,	O
a	O
certain	O
number	O
of	O
hybrids	B-cell_line
lost	O
CD5	B-protein
surface	O
expression	O
over	O
a	O
period	O
of	O
time	O
in	O
culture	O
.	O

Patients	O
with	O
steroid-resistant	O
asthma	O
have	O
been	O
shown	O
to	O
have	O
a	O
reduced	O
GCR	B-protein
binding	O
affinity	O
.	O

An	O
isotype-specific	O
activator	O
of	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
that	O
is	O
independent	O
of	O
class	B-protein
II	I-protein
transactivator	I-protein
.	O

Alpha	B-protein
4	I-protein
beta	I-protein
1	I-protein
(	I-protein
CD49d/CD29	I-protein
)	I-protein
integrin	I-protein
costimulation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
enhances	O
transcription	B-protein
factor	I-protein
and	O
cytokine	O
induction	O
in	O
the	O
absence	O
of	O
altered	O
sensitivity	O
to	O
anti-CD3	B-protein
stimulation	O
.	O

Both	O
compounds	O
show	O
about	O
2-fold	O
lower	O
affinity	O
to	O
the	O
VD	O
receptor	O
(	O
VDR	O
)	O
than	O
VD	O
.	O

The	O
production	O
of	O
the	O
granulocyte-macrophage	B-protein
colony	I-protein
stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
is	O
completely	O
dependent	O
on	O
the	O
two	O
signals	O
.	O

This	O
was	O
associated	O
with	O
the	O
down-regulation	O
of	O
IL-12p40	B-RNA
mRNA	I-RNA
expression	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
3-carboranyl-substituted	O
compounds	O
(	O
8	O
,	O
12	O
)	O
showed	O
potential	O
agonistic	O
activity	O
,	O
but	O
no	O
antagonistic	O
activity	O
.	O

GDSP	O
also	O
completely	O
inhibited	O
superoxide	O
formation	O
in	O
the	O
human	B-cell_type
neutrophils	I-cell_type
stimulated	O
by	O
N-formyl-methionine-leucine-phenyl-alanine	O
(	O
fMLP	O
)	O
or	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

Several	O
cis-acting	B-DNA
regulatory	I-DNA
sites	I-DNA
are	O
required	O
for	O
induction	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
after	O
stimulation	O
.	O

Nonetheless	O
transcription	O
of	O
both	O
the	O
endogenous	O
and	O
the	O
transfected	O
gene	O
was	O
inducible	O
by	O
PMA	O
treatment	O
.	O

These	O
results	O
suggest	O
that	O
homodimerization	O
of	O
the	O
IL-4Ralpha	B-protein
chain	I-protein
is	O
sufficient	O
to	O
transduce	O
Jak1	B-protein
-dependent	O
intracellular	O
signals	O
that	O
lead	O
to	O
IgE	B-protein
isotype	I-protein
switching	O
.	O

The	O
generality	O
of	O
this	O
finding	O
was	O
confirmed	O
by	O
the	O
induction	O
of	O
Bcl-xL	B-protein
in	O
human	B-cell_line
myeloid	I-cell_line
U-937	I-cell_line
cells	I-cell_line
,	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
monocytes	I-cell_type
exposed	O
to	O
phorbol	O
ester	O
,	O
and	O
mouse	B-cell_line
thioglycollate-activated	I-cell_line
and	I-cell_line
resident	I-cell_line
peritoneal	I-cell_line
macrophages	I-cell_line
.	O

In	O
vitro	O
suppression	O
of	O
programmed	O
cell	O
death	O
of	O
B	B-cell_type
cells	I-cell_type
by	O
tissue	O
inhibitor	O
of	O
metalloproteinases-1	B-protein
.	O

Thus	O
,	O
signaling	O
in	O
NK3.3	B-cell_line
cells	I-cell_line
is	O
not	O
always	O
identical	O
with	O
that	O
in	O
primary	B-cell_type
NK	I-cell_type
cells	I-cell_type
.	O

NF-AT	B-protein
activation	O
induced	O
by	O
a	O
CAML	B-protein
-interacting	O
member	O
of	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
superfamily	I-protein
.	O

A	O
newly	O
identified	O
motif	O
called	O
the	O
B29	B-DNA
conserved	I-DNA
sequence	I-DNA
(	O
BCS	B-DNA
)	O
,	O
found	O
upstream	O
of	O
both	O
human	B-DNA
and	I-DNA
murine	I-DNA
B29	I-DNA
promoters	I-DNA
,	O
appears	O
to	O
stimulate	O
B29	B-protein
transcription	O
through	O
a	O
novel	O
mechanism	O
.	O

These	O
phosphotyrosines	O
serve	O
as	O
docking	B-protein
sites	I-protein
for	O
latent	O
,	O
cytoplasmic	B-protein
transcription	I-protein
factors	I-protein
known	O
as	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
Stat	I-protein
)	I-protein
proteins	I-protein
.	O

Inhibition	O
of	O
iNO	B-protein
synthase	I-protein
(	O
iNOS	B-protein
)	O
activity	O
with	O
N	O
omega-monomethyl-L-arginine	O
in	O
endothelial-RAW264.7	B-cell_line
cocultures	I-cell_line
,	O
stimulated	O
with	O
murine-specific	B-protein
IFN-gamma	I-protein
and	O
LPS	O
,	O
decreased	O
iNO	O
production	O
by	O
86	O
%	O
,	O
augmented	O
VCAM-1	B-protein
and	O
iNOS	B-protein
expression	O
in	O
endothelial	O
and	O
RAW264.7	B-cell_line
cells	I-cell_line
,	O
respectively	O
,	O
and	O
increased	O
monocyte	O
adhesion	O
to	O
the	O
endothelial	O
cell	O
surface	O
.	O

Egr-1	B-protein
expression	O
correlates	O
with	O
the	O
cellular	O
phenotype	O
and	O
the	O
specific	O
pattern	O
of	O
viral	O
latency	O
established	O
within	O
the	O
individual	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Our	O
findings	O
demonstrate	O
that	O
truncated	B-RNA
TSG101	I-RNA
and	I-RNA
FHIT	I-RNA
transcripts	I-RNA
are	O
commonly	O
detected	O
in	O
both	O
normal	O
and	O
malignant	O
tissues	O
and	O
that	O
a	O
significant	O
fraction	O
of	O
these	O
are	O
likely	O
to	O
be	O
the	O
result	O
of	O
aberrant	O
splicing	O
.	O

The	O
importance	O
of	O
many	O
of	O
these	O
genes	O
relates	O
to	O
the	O
role	O
their	O
transcription	B-protein
factor	I-protein
products	I-protein
play	O
in	O
dictating	O
patterns	O
of	O
expression	O
of	O
downstream	O
,	O
function-related	B-DNA
genes	I-DNA
.	O

We	O
provide	O
evidence	O
that	O
in	O
monocytes	O
as	O
well	O
as	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
both	O
IL-4	B-protein
and	O
IL-13	B-protein
activate	O
the	O
same	O
recently	O
identified	O
transcription	B-protein
factor	I-protein
NF-IL4	B-protein
which	O
binds	O
to	O
the	O
specific	B-DNA
responsive	I-DNA
element	I-DNA
IL-4RE	I-DNA
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
relationship	O
between	O
ras	O
transformation	O
and	O
differentiation	O
of	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

A	O
mutant	O
of	O
KBF1/p50	B-protein
(	O
delta	B-protein
SP	I-protein
)	O
,	O
unable	O
to	O
bind	O
to	O
DNA	O
but	O
able	O
to	O
form	O
homo-	O
or	O
heterodimers	B-protein
,	O
has	O
been	O
constructed	O
.	O

Hypothetically	O
,	O
on/off	O
switches	O
of	O
lineage-restricted	B-protein
transactivators	I-protein
may	O
underlie	O
the	O
binary	O
fate	O
decisions	O
of	O
hematopoietic	B-cell_type
progenitors	I-cell_type
.	O

Increased	O
Stat1	O
and	O
Stat3	O
mRNA	O
and	O
protein	O
levels	O
were	O
detected	O
,	O
respectively	O
4	O
and	O
24	O
h	O
after	O
activation	O
.	O

The	O
ATRA-induced	O
expression	O
of	O
IRF-1	B-protein
,	O
an	O
activator	O
of	O
transcription	O
and	O
repressor	O
of	O
transformation	O
,	O
may	O
be	O
one	O
of	O
the	O
molecular	O
mechanisms	O
of	O
ATRA-induced	O
growth	O
inhibition	O
,	O
and	O
the	O
basis	O
for	O
the	O
synergistic	O
actions	O
of	O
ATRA	O
and	O
IFNs	B-protein
in	O
myeloid	B-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O

We	O
also	O
show	O
that	O
platelet-activating	B-protein
factor	I-protein
from	O
10	O
(	O
-12	O
)	O
to	O
10	O
(	O
-6	O
)	O
M	O
induced	O
rapid	O
and	O
significant	O
elevation	O
in	O
intracellular	O
calcium	O
levels	O
,	O
whereas	O
lyso-	O
platelet-activating	B-protein
factor	I-protein
was	O
again	O
ineffective	O
.	O

A	O
transcriptional	B-DNA
regulatory	I-DNA
element	I-DNA
is	O
associated	O
with	O
a	O
nuclease-hypersensitive	B-DNA
site	I-DNA
in	O
the	O
pol	B-DNA
gene	I-DNA
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

They	O
may	O
also	O
prove	O
useful	O
in	O
the	O
identification	O
of	O
new	O
,	O
ubiquitous	B-protein
cellular	I-protein
transcription	I-protein
factors	I-protein
.	O

Type-II	B-protein
estrogen-binding	I-protein
sites	I-protein
(	O
type-II	B-protein
EBS	I-protein
)	O
have	O
been	O
demonstrated	O
in	O
the	O
human	B-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
line	I-cell_line
IM-9	B-cell_line
using	O
a	O
whole-cell	O
assay	O
with	O
(	O
6	O
,	O
7-3H	O
)	O
estradiol	O
(	O
3H-E2	O
)	O
as	O
tracer	O
.	O

This	O
study	O
determined	O
if	O
the	O
Ad5-induced	O
inhibition	O
of	O
IFN	B-protein
-MCP	O
was	O
independent	O
of	O
adenovirus	O
(	O
Ad	O
)	O
infection	O
and	O
secondary	O
only	O
to	O
the	O
expression	O
of	O
the	O
Ad	B-DNA
early	I-DNA
region	I-DNA
1A	I-DNA
gene	I-DNA
(	O
E1A	B-DNA
)	O
.	O

PMA	O
treatment	O
caused	O
a	O
concentration-	O
and	O
time-dependent	O
increase	O
in	O
both	O
c-Fos	O
and	O
Jun	O
immunoreactivity	O
in	O
contrast	O
to	O
cAMP	O
elevation	O
that	O
had	O
only	O
a	O
slight	O
effect	O
.	O

Evidence	O
for	O
a	O
polyclonal	O
etiology	O
of	O
palmar	O
fibromatosis	O
.	O

Prolonged	O
suppression	O
of	O
trans-gene	O
expression	O
for	O
up	O
to	O
7	O
days	O
was	O
observed	O
after	O
doxycycline	O
was	O
removed	O
from	O
the	O
cultures	O
,	O
but	O
eventual	O
recovery	O
of	O
surface	O
expression	O
was	O
complete	O
,	O
and	O
the	O
absolute	O
time	O
to	O
recovery	O
was	O
directly	O
proportional	O
to	O
the	O
initial	O
concentration	O
of	O
the	O
drug	O
.	O

LMP1	B-protein
is	O
a	O
potent	O
effector	O
of	O
B-lymphocyte	O
activation	O
and	O
can	O
act	O
synergistically	O
with	O
EBNA-2	B-protein
to	O
induce	O
cellular	O
CD23	O
gene	O
expression	O
.	O

Tax	B-protein
alone	O
was	O
also	O
inactive	O
.	O

Indeed	O
,	O
this	O
viral	B-protein
protein	I-protein
,	O
which	O
is	O
essential	O
for	O
productive	O
infection	O
,	O
has	O
also	O
been	O
shown	O
to	O
display	O
growth-stimulating	O
properties	O
and	O
immunomodulatory	O
activities	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
tumor-derived	O
gangliosides	O
may	O
blunt	O
antitumor	O
immune	O
responses	O
in	O
patients	O
with	O
RCCs	O
.	O

In	O
patients	O
suffering	O
from	O
Cushing	O
's	O
syndrome	O
,	O
the	O
circadian	O
rhythm	O
of	O
plasma	O
cortisol	O
either	O
disappeared	O
or	O
was	O
inverted	O
while	O
that	O
of	O
GR	B-protein
did	O
not	O
significantly	O
deviate	O
from	O
the	O
normal	O
subjects	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
and	O
analyses	O
of	O
a	O
yeast	O
artificial	O
chromosome	O
contig	O
revealed	O
that	O
the	O
human	B-DNA
LOX-1	I-DNA
gene	I-DNA
is	O
located	O
in	O
the	O
natural	B-protein
killer	I-protein
gene	I-protein
complex	I-protein
on	O
chromosome	B-DNA
12p12-p13	I-DNA
,	O
where	O
the	O
genes	O
of	O
the	O
natural	B-protein
killer	I-protein
cell	I-protein
receptors	I-protein
cluster	O
.	O

Two	O
explanations	O
for	O
hyporesponsiveness	O
of	O
the	O
human	B-DNA
iNOS	I-DNA
promoter	I-DNA
to	O
LPS	O
+/-	O
IFN-gamma	B-protein
were	O
found	O
:	O
(	O
1	O
)	O
multiple	O
inactivating	O
nucleotide	O
substitutions	O
in	O
the	O
human	O
counterpart	O
of	O
the	O
enhancer	B-DNA
element	I-DNA
that	O
has	O
been	O
shown	O
to	O
regulate	O
LPS/	O
IFN-gamma	B-protein
induced	O
expression	O
of	O
the	O
mouse	B-DNA
iNOS	I-DNA
gene	I-DNA
;	O
and	O
(	O
2	O
)	O
and	O
absence	O
of	O
one	O
or	O
more	O
nuclear	B-protein
factors	I-protein
in	O
human	B-cell_type
macrophages	I-cell_type
(	O
e.g.	O
,	O
an	O
LPS-inducible	B-protein
nuclear	I-protein
factor-kappa	I-protein
B/Rel	I-protein
complex	I-protein
)	O
,	O
that	O
is	O
(	O
are	O
)	O
required	O
for	O
maximal	O
expression	O
of	O
the	O
gene	O
.	O

Three	O
mouse	O
strains	O
(	O
C57BL/10SnJ	O
[	O
H-2b	O
]	O
,	O
C3HeB/FeJ	O
[	O
H-2k	O
]	O
,	O
and	O
BALB/cByJ	O
[	O
H-2d	O
]	O
)	O
were	O
immunized	O
with	O
wild-type	O
Ad	O
or	O
Ad	O
vectors	O
lacking	O
the	O
immunodominant	B-protein
antigen	I-protein
(	O
s	O
)	O
,	O
and	O
the	O
CTL	B-cell_type
responses	O
were	O
measured	O
.	O

This	O
antibody	O
recognized	O
both	O
the	O
denatured	O
and	O
native	B-protein
MR	I-protein
forms	I-protein
,	O
as	O
well	O
as	O
the	O
hetero-oligomeric	B-protein
MR	I-protein
form	I-protein
and	O
the	O
transformed	B-protein
MR	I-protein
state	I-protein
.	O

Similar	O
findings	O
were	O
obtained	O
with	O
bryostatin	O
1	O
(	O
10	O
nM	O
)	O
,	O
another	O
activator	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O

The	O
other	O
two	O
contained	O
mutations	O
in	O
regions	O
that	O
do	O
not	O
have	O
homology	O
to	O
described	O
proteins	O
.	O

As	O
assessed	O
with	O
mutagenized	B-DNA
promoters	I-DNA
,	O
the	O
most	O
important	O
IL-2	B-DNA
cis-regulatory	I-DNA
elements	I-DNA
in	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
are	O
the	O
proximal	B-DNA
AP-1	I-DNA
site	I-DNA
and	O
the	O
NF-	B-DNA
kappaB	I-DNA
site	I-DNA
.	O

Furthermore	O
,	O
deletion	O
and	O
mutation	O
analyses	O
of	O
the	O
VCAM-1	B-DNA
promoter	I-DNA
performed	O
with	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
constructs	I-DNA
revealed	O
that	O
Tax	B-protein
was	O
trans	O
activating	O
the	O
VCAM-1	B-DNA
promoter	I-DNA
via	O
two	O
NF-kappaB	B-DNA
sites	I-DNA
present	O
at	O
bp	O
-72	O
and	O
-57	O
in	O
the	O
VCAM-1	B-DNA
gene	I-DNA
promoter	I-DNA
,	O
with	O
both	O
of	O
them	O
being	O
required	O
for	O
the	O
Tax	B-protein
-induced	O
expression	O
of	O
this	O
adhesion	B-protein
molecule	I-protein
.	O

The	O
Wilms	B-DNA
'	I-DNA
tumor	I-DNA
gene	I-DNA
(	O
WT1	B-DNA
)	O
encodes	O
a	O
transcription	B-protein
factor	I-protein
of	O
the	O
zinc	B-protein
finger	I-protein
type	I-protein
.	O

In	O
competition	O
and	O
antibody	O
supershift	O
assays	O
in	O
EMSA	O
,	O
complexes	O
formed	O
with	O
P	B-DNA
or	O
P2	B-DNA
proved	O
to	O
contain	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	I-protein
NFAT	I-protein
)	I-protein
family	I-protein
proteins	I-protein
as	O
major	O
components	O
.	O

Human	O
umbilical	O
vein	O
ECs	B-cell_type
were	O
pretreated	O
with	O
alpha-tcp	O
before	O
stimulation	O
with	O
known	O
agonists	O
of	O
monocyte	O
adhesion	O
:	O
IL-1	B-protein
(	O
10	O
ng/ml	O
)	O
,	O
LPS	O
(	O
10	O
ng/ml	O
)	O
,	O
thrombin	B-protein
(	O
30	O
U/ml	O
)	O
,	O
or	O
PMA	O
(	O
10	O
nM	O
)	O
.	O

5-Aminolevulinate	B-protein
synthase	I-protein
(	O
ALAS	B-protein
)	O
catalyzes	O
the	O
first	O
step	O
of	O
the	O
heme	B-protein
biosynthetic	O
pathway	O
.	O

With	O
the	O
use	O
of	O
specific	B-protein
antibodies	I-protein
we	O
have	O
determined	O
the	O
composition	O
of	O
each	O
complex	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Here	O
,	O
we	O
present	O
clinical	O
,	O
cytogenetic	O
,	O
and	O
molecular	O
data	O
from	O
a	O
new	O
CMPD1/SRA1	O
patient	O
with	O
t	B-DNA
(	I-DNA
6	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
(	I-DNA
q14	I-DNA
;	I-DNA
q24	I-DNA
)	I-DNA
.	O

Immunohistochemical	O
staining	O
demonstrated	O
RelB	B-protein
within	O
the	O
differentiated	B-cell_type
lymph	I-cell_type
node	I-cell_type
interdigitating	I-cell_type
DC	I-cell_type
and	O
follicular	B-cell_type
DC	I-cell_type
,	O
but	O
not	O
undifferentiated	B-cell_type
DC	I-cell_type
in	O
normal	O
skin	O
.	O

It	O
is	O
clear	O
that	O
sufficient	O
numbers	O
of	O
functional	O
glucocorticoid	B-protein
receptors	I-protein
are	O
required	O
to	O
mediate	O
lysis	O
,	O
but	O
whether	O
they	O
do	O
so	O
through	O
the	O
classical	O
model	O
of	O
steroid	O
hormone	O
activation	O
and	O
modulation	O
of	O
gene	O
expression	O
has	O
not	O
been	O
established	O
.	O

IFN-gamma-primed	B-cell_line
lung	I-cell_line
fibroblasts	I-cell_line
costimulate	O
T	O
lymphocyte	O
proliferation	O
utilizing	O
CD40	B-protein
,	O
but	O
not	O
the	O
well-studied	O
costimulatory	B-protein
molecules	I-protein
B7-1	B-protein
and	O
B7-2	B-protein
.	O

The	O
HIV-mediated	O
NF-kappa	B-protein
B	I-protein
activation	O
is	O
selectively	O
reduced	O
by	O
AO	O
to	O
PKC-zeta	B-protein
.	O

LPS	O
stimulation	O
did	O
not	O
give	O
rise	O
to	O
a	O
persistent	O
nuclear	O
accumulation	O
of	O
RelB	B-protein
and	O
c-Rel	B-protein
,	O
whereas	O
nuclear	O
c-Rel	B-protein
,	O
but	O
not	O
RelB	B-protein
,	O
accumulated	O
after	O
B	O
cell	O
receptor	O
stimulation	O
.	O

However	O
,	O
AML1/ETO	B-protein
can	O
also	O
synergize	O
with	O
the	O
transcription	B-protein
factor	I-protein
AML1	B-protein
to	O
enhance	O
the	O
activity	O
of	O
the	O
M-CSF	B-DNA
receptor	I-DNA
promoter	I-DNA
.	O

The	O
homologous	O
peptide	O
430-444	O
,	O
442A	O
has	O
an	O
Asp	O
to	O
Ala	O
substitution	O
at	O
position	O
442	O
and	O
binds	O
to	O
DQ0302	O
with	O
a	O
Kd	O
similar	O
to	O
433-442	O
.	O

Further	O
analysis	O
of	O
the	O
MBP	B-DNA
promoter	I-DNA
region	I-DNA
identified	O
a	O
C/EBP	B-DNA
(	I-DNA
CCAAT/enhancer-binding	I-DNA
protein	I-DNA
)	I-DNA
consensus	I-DNA
binding	I-DNA
site	I-DNA
6	O
bp	O
upstream	O
of	O
the	O
functional	O
GATA-binding	B-DNA
site	I-DNA
in	O
the	O
MBP	B-DNA
gene	I-DNA
.	O

The	O
promoter	O
activity	O
from	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
was	O
greatly	O
augmented	O
by	O
co-transfecting	O
the	O
Trx-expressing	B-DNA
plasmid	I-DNA
,	O
whose	O
effect	O
was	O
dependent	O
on	O
the	O
NF	B-protein
kappa	I-protein
B	I-protein
-binding	O
sites	O
.	O

Signal	O
transduction	O
pathways	O
triggered	O
by	O
the	O
FcepsilonRIIb	B-protein
receptor	I-protein
(	O
CD23	B-protein
)	O
in	O
human	B-cell_type
monocytes	I-cell_type
lead	O
to	O
nuclear	B-protein
factor-kappaB	I-protein
activation	O
.	O

In	O
vitro	O
binding	O
of	O
aldosterone	O
to	O
mineralocorticoid	B-protein
receptors	I-protein
on	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
(	O
HML	B-cell_type
)	O
and	O
its	O
effects	O
on	O
the	O
intracellular	O
sodium	O
and	O
potassium	O
concentrations	O
of	O
HML	B-cell_type
have	O
already	O
been	O
described	O
.	O

These	O
results	O
suggest	O
that	O
the	O
NF-kappaB	B-DNA
binding	I-DNA
site	I-DNA
located	O
around	O
120	O
bp	O
upstream	O
of	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
in	O
murine	B-DNA
and	I-DNA
human	I-DNA
p40	I-DNA
promoter	I-DNA
regions	I-DNA
could	O
be	O
important	O
for	O
the	O
p40	B-protein
induction	O
by	O
CD40	B-protein
ligation	O
via	O
activation	O
of	O
NF-kappaB	B-protein
.	O

B-cell-specific	O
transcription	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
is	O
mediated	O
by	O
the	O
interaction	O
of	O
a	O
POU	B-DNA
domain	I-DNA
containing	O
transcription	B-protein
factor	I-protein
Oct-1	B-protein
or	O
Oct-2	B-protein
,	O
with	O
the	O
B-cell-specific	B-protein
coactivator	I-protein
OCA-B	B-protein
(	O
Bob-1	B-protein
,	O
OBF-1	B-protein
)	O
and	O
a	O
prototype	B-DNA
octamer	I-DNA
element	I-DNA
.	O

CTL	O
recognition	O
of	O
an	O
altered	O
peptide	O
associated	O
with	O
asparagine	O
bond	O
rearrangement	O
.	O

NF-kappaB	B-protein
activation	O
is	O
required	O
for	O
C5a-induced	B-DNA
interleukin-8	I-DNA
gene	I-DNA
expression	O
in	O
mononuclear	B-cell_type
cells	I-cell_type
.	O

Gel	O
electrophoresis	O
mobility	O
shift	O
assays	O
and	O
DNaseI	B-protein
footprinting	O
assays	O
demonstrate	O
that	O
these	O
negative	O
regulatory	O
sequences	O
are	O
recognized	O
differently	O
by	O
proteins	O
present	O
in	O
nuclear	O
extracts	O
obtained	O
from	O
HeLa	B-cell_line
and	O
K562	B-cell_line
cells	I-cell_line
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
showed	O
that	O
Tax	B-protein
increased	O
the	O
DNA	O
binding	O
activity	O
of	O
both	O
Sp1	B-protein
and	O
NGFI-A/Egr-1	B-protein
using	O
a	O
TRE1	B-DNA
probe	I-DNA
.	O

When	O
co-transfected	O
with	O
a	O
construct	O
capable	O
of	O
overexpressing	O
the	O
tyrosine	B-protein
kinase	I-protein
p59fyn	B-protein
,	O
the	O
reporter	B-DNA
gene	I-DNA
was	O
activated	O
by	O
PMA	B-protein
alone	O
.	O

Constitutive	O
and	O
inducible	O
protein/DNA	O
interactions	O
of	O
the	O
IFN-gamma	B-DNA
promoter	I-DNA
in	O
vivo	O
were	O
detected	O
in	O
all	O
T	B-cell_type
cells	I-cell_type
tested	O
.	O

Our	O
results	O
showed	O
that	O
BSAP	B-protein
plays	O
a	O
role	O
in	O
both	O
IL-4	B-protein
-dependent	O
induction	O
and	O
CD40	B-protein
-mediated	O
upregulation	O
of	O
human	O
epsilon	O
germline	B-DNA
transcription	O
.	O

IL4	B-protein
and	I-protein
IL13	I-protein
receptors	I-protein
share	O
the	O
gamma	B-protein
c	I-protein
chain	I-protein
and	O
activate	O
STAT6	B-protein
,	I-protein
STAT3	I-protein
and	I-protein
STAT5	I-protein
proteins	I-protein
in	O
normal	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Because	O
these	O
induced	O
gene	O
products	O
have	O
NF-kappaB	B-DNA
sites	I-DNA
in	O
their	O
promoter	B-DNA
regions	I-DNA
,	O
we	O
next	O
examined	O
whether	O
there	O
was	O
an	O
up-regulation	O
of	O
nuclear	O
NF-kappaB	B-protein
levels	O
.	O

The	O
dephosphorylation	O
of	O
NFATp	B-protein
was	O
accompanied	O
by	O
localization	O
of	O
the	O
protein	O
to	O
the	O
nuclear	O
fraction	O
.	O

The	O
results	O
define	O
the	O
rhombotin	B-DNA
gene	O
family	O
as	O
a	O
class	O
of	O
T-cell	B-DNA
oncogenes	I-DNA
with	O
duplicated	O
cysteine-rich	B-DNA
LIM	I-DNA
domains	I-DNA
.	O

We	O
propose	O
that	O
malignant	O
cell	O
cytokine	B-protein
production	O
may	O
help	O
explain	O
this	O
observation	O
.	O

Cis-acting	B-DNA
elements	I-DNA
with	O
NFkappaB	B-DNA
,	I-DNA
AP1	I-DNA
and	I-DNA
ETS-like	I-DNA
binding	I-DNA
motifs	I-DNA
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
,	O
and	O
are	O
important	O
or	O
essential	O
for	O
transcriptional	O
activity	O
following	O
T	O
cell	O
activation	O
.	O

The	O
NGAL	B-protein
gene	O
is	O
highly	O
homologous	O
to	O
the	O
mouse	B-DNA
gene	I-DNA
24p3	I-DNA
.	O

At	O
the	O
end	O
of	O
both	O
treatment	O
periods	O
symptoms	O
were	O
scored	O
after	O
allergen	O
provocation	O
(	O
100	O
,	O
1000	O
,	O
10000	O
BU/mL	O
)	O
and	O
during	O
the	O
9.5	O
hours	O
after	O
this	O
challenge	O
.	O

This	O
inhibition	O
is	O
mediated	O
by	O
induction	O
of	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
inhibitory	O
protein	O
,	O
which	O
traps	O
activated	O
NF-kappa	B-protein
B	I-protein
in	O
inactive	B-protein
cytoplasmic	I-protein
complexes	I-protein
.	O

Soluble	O
interleukin-2	B-protein
receptor-alpha	I-protein
(	O
IL-2Ralpha	B-protein
)	O
has	O
been	O
reported	O
to	O
be	O
increased	O
in	O
the	O
sera	O
of	O
patients	O
with	O
advanced	O
tuberculosis	O
,	O
and	O
levels	O
decline	O
after	O
therapy	O
in	O
accordance	O
with	O
improvement	O
of	O
radiologic	O
findings	O
.	O

The	O
effects	O
of	O
GDSP	O
were	O
also	O
measured	O
on	O
superoxide	O
formation	O
by	O
activated	B-cell_type
human	I-cell_type
neutrophils	I-cell_type
.	O

NF-kappa	B-protein
B	I-protein
,	O
a	O
50	B-protein
kDa/65	I-protein
kDa	I-protein
(	I-protein
p50/p65	I-protein
)	I-protein
heterodimer	I-protein
,	O
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
involved	O
in	O
the	O
positive	O
regulation	O
of	O
various	O
immune	B-DNA
genes	I-DNA
.	O

Analysis	O
of	O
cytokine	B-protein
signaling	O
in	O
patients	O
with	O
extrinsic	O
asthma	O
and	O
hyperimmunoglobulin	O
E	O
.	O

Rapid	O
and	O
strong	O
induction	O
of	O
promoter	O
activity	O
was	O
lost	O
in	O
constructs	O
with	O
a	O
mutant	B-DNA
AP-1	I-DNA
element	I-DNA
;	O
however	O
,	O
at	O
16-96	O
h	O
post-PMA	O
,	O
the	O
mutant	B-DNA
collagenase-1	I-DNA
promoter	I-DNA
displayed	O
AP-1	B-protein
independent	O
PMA-mediated	O
transactivation	O
.	O

Some	O
of	O
these	O
complexes	O
were	O
demonstrated	O
to	O
contain	O
NF-IL6	B-protein
by	O
using	O
anti-C/EBP	B-protein
beta	I-protein
Abs	I-protein
.	O

We	O
have	O
shown	O
earlier	O
that	O
NF-M	B-protein
,	O
the	O
chicken	B-protein
homolog	I-protein
of	O
C/EBP	B-protein
beta	I-protein
,	O
is	O
specifically	O
expressed	O
in	O
myelomonocytic	B-cell_type
and	I-cell_type
eosinophilic	I-cell_type
cells	I-cell_type
of	O
the	O
hematopoietic	O
system	O
.	O

To	O
determine	O
whether	O
BCL-6	B-protein
mutations	O
represent	O
a	O
tumor-associated	O
phenomenon	O
or	O
reflect	O
a	O
physiologic	O
mechanism	O
,	O
we	O
screened	O
single	O
human	B-cell_type
tonsillar	I-cell_type
GC	I-cell_type
B	I-cell_type
cells	I-cell_type
for	O
mutations	O
occurring	O
in	O
the	O
BCL-6	B-DNA
5'-noncoding	I-DNA
region	I-DNA
and	O
in	O
the	O
Ig	B-DNA
variable	I-DNA
heavy	I-DNA
chain	I-DNA
sequences	I-DNA
.	O

This	O
shows	O
that	O
gelatinase	B-protein
granules	O
are	O
functionally	O
important	O
relative	O
to	O
specific	O
granules	O
in	O
mediating	O
early	O
inflammatory	O
responses	O
.	O

To	O
determine	O
the	O
contribution	O
of	O
BRCA1	B-DNA
and	O
BRCA2	B-DNA
mutations	O
to	O
the	O
pathogenesis	O
of	O
male	O
breast	O
cancer	O
in	O
Hungary	O
,	O
the	O
country	O
with	O
the	O
highest	O
male	O
breast	O
cancer	O
mortality	O
rates	O
in	O
continental	O
Europe	O
,	O
a	O
series	O
of	O
18	O
male	O
breast	O
cancer	O
patients	O
and	O
three	O
patients	O
with	O
gynecomastia	O
was	O
analyzed	O
for	O
germ-line	O
mutations	O
in	O
both	O
BRCA1	B-DNA
and	O
BRCA2	B-DNA
.	O

Such	O
observations	O
indicate	O
that	O
IL-4	B-protein
Stat	I-protein
has	O
the	O
same	O
functional	B-protein
domain	I-protein
for	O
both	O
receptor	O
coupling	O
and	O
dimerization	O
.	O

Thus	O
,	O
LPS	O
activation	O
of	O
human	O
monocytic	B-cell_type
cells	I-cell_type
results	O
in	O
nuclear	O
expression	O
of	O
c-Rel/p50	B-protein
and	O
p50/p65	B-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
and	O
induces	O
phosphorylation	O
of	O
MAD3	B-protein
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
transcription	B-protein
factor	I-protein
GATA-3	I-protein
is	O
expressed	O
in	O
Th2	B-cell_line
but	I-cell_line
not	I-cell_line
Th1	I-cell_line
cells	I-cell_line
and	O
is	O
crucial	O
for	O
activation	O
of	O
the	O
IL-5	B-DNA
promoter	I-DNA
by	O
different	O
stimuli	O
.	O

A	O
serum-independent	B-cell_line
HL60	I-cell_line
cell	I-cell_line
line	I-cell_line
was	O
induced	O
towards	O
the	O
neutrophil	O
lineage	O
by	O
treatment	O
with	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
for	O
24	O
h	O
.	O

Deletional	O
analysis	O
and	O
site-directed	O
mutagenesis	O
of	O
the	O
EA-D	B-DNA
promoter	I-DNA
demonstrated	O
that	O
in	O
epithelial	B-cell_type
cells	I-cell_type
the	O
potential	O
AP-1	B-DNA
binding	I-DNA
site	I-DNA
plays	O
an	O
essential	O
role	O
in	O
Z	B-protein
responsiveness	O
,	O
although	O
sequences	O
further	O
upstream	O
are	O
also	O
important	O
.	O

Immunoblot	O
analysis	O
showed	O
that	O
the	O
p50	O
subunit	O
was	O
constitutively	O
expressed	O
in	O
monocytes	B-cell_type
and	O
MDMs	B-cell_type
.	O

NGAL	B-protein
was	O
expressed	O
in	O
bone	O
marrow	O
and	O
in	O
tissues	O
that	O
are	O
prone	O
to	O
exposure	O
to	O
microorganisms	O
.	O

However	O
,	O
the	O
intensity	O
of	O
the	O
complex	O
formed	O
appeared	O
to	O
increase	O
when	O
nuclear	O
extracts	O
from	O
PMA-treated	B-cell_line
cells	I-cell_line
were	O
used	O
.	O

The	O
hematopoietic	B-protein
transcription	I-protein
factor	I-protein
PU.1	B-protein
is	O
downregulated	O
in	O
human	B-cell_line
multiple	I-cell_line
myeloma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Associations	O
between	O
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
and	O
autoantibodies	B-protein
to	O
the	O
ribonucleoproteins	B-protein
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
and	O
La	B-protein
(	I-protein
SSB	I-protein
)	I-protein
have	O
been	O
reported	O
in	O
these	O
patients	O
.	O

Glucocorticoid	B-protein
receptors	I-protein
on	O
mononuclear	B-cell_type
leukocytes	I-cell_type
in	O
polycystic	O
ovary	O
syndrome	O
.	O

Together	O
,	O
these	O
results	O
show	O
that	O
NF-kappa	B-protein
B	I-protein
controls	O
the	O
expression	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
by	O
means	O
of	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

The	O
cloning	O
of	O
the	O
complementary	B-DNA
DNA	I-DNA
for	O
the	O
50K	B-protein
subunit	I-protein
helped	O
to	O
identify	O
an	O
exclusively	O
cytoplasmic	B-protein
105K	I-protein
precursor	I-protein
(	O
p105	B-protein
)	O
(	O
V.B.	O
,	O
P.K.	O
and	O
A.I.	O
,	O
manuscript	O
submitted	O
)	O
.	O

Closer	O
examination	O
using	O
non-transformed	B-cell_line
murine	I-cell_line
Th1	I-cell_line
and	I-cell_line
Th2	I-cell_line
clones	I-cell_line
suggested	O
that	O
a	O
balance	O
between	O
the	O
activities	O
of	O
the	O
two	O
signaling	O
pathways	O
contributes	O
to	O
cytokine	B-DNA
gene	I-DNA
expression	O
.	O

GR	B-protein
was	O
determined	O
by	O
whole	O
cell	O
assay	O
with	O
3H-Dex	O
.	O

In	O
contrast	O
,	O
a	O
mutant	O
of	O
Tax	B-protein
that	O
selectively	O
fails	O
to	O
activate	O
nuclear	O
NF-kappa	B-protein
B	I-protein
expression	O
does	O
not	O
associate	O
with	O
p100	B-protein
.	O

We	O
have	O
recently	O
cloned	O
the	O
CD14	B-DNA
5	I-DNA
'	I-DNA
upstream	I-DNA
sequence	I-DNA
and	O
demonstrated	O
its	O
tissue-specific	B-DNA
promoter	I-DNA
activity	O
.	O

A	O
study	O
on	O
the	O
circadian	O
rhythm	O
of	O
glucocorticoid	B-protein
receptor	I-protein
.	O

In	O
uterine	O
pregnancy	O
,	O
the	O
ratio	O
of	O
BCL-2	B-protein
to	O
CD3	O
was	O
0.44	O
and	O
0.39	O
for	O
CD56	O
.	O

Regulation	O
of	O
PAK	O
activation	O
and	O
the	O
T	O
cell	O
cytoskeleton	O
by	O
the	O
linker	B-protein
protein	I-protein
SLP-76	B-protein
.	O

Rapid	O
tyrosine	O
phosphorylation	O
of	O
key	O
cellular	O
proteins	O
is	O
a	O
crucial	O
event	O
in	O
the	O
transduction	O
of	O
activation	O
signals	O
to	O
T-lymphocytes	B-cell_type
.	O

Direct	O
interaction	O
of	O
hematopoietic	B-protein
transcription	I-protein
factors	I-protein
PU.1	I-protein
and	I-protein
GATA-1	I-protein
:	O
functional	O
antagonism	O
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O

The	O
human	O
homologue	O
of	O
Drosophila	B-protein
Toll	I-protein
(	O
hToll	B-protein
)	O
is	O
a	O
recently	O
cloned	O
receptor	O
of	O
the	O
interleukin	B-protein
1	I-protein
receptor	I-protein
(	I-protein
IL-1R	I-protein
)	I-protein
superfamily	I-protein
,	O
and	O
has	O
been	O
implicated	O
in	O
the	O
activation	O
of	O
adaptive	O
immunity	O
.	O

The	O
cyclin-dependent	B-DNA
kinase	I-DNA
inhibitor	I-DNA
p27Kip1	B-DNA
plays	O
an	O
important	O
role	O
in	O
regulating	O
cell-cycle	O
progression	O
.	O

The	O
unique	O
characteristics	O
of	O
this	O
new	O
pathway	O
for	O
steroid	O
action	O
include	O
its	O
rapid	O
time	O
course	O
,	O
10	O
,	O
000-fold	O
selectivity	O
for	O
aldosterone	O
over	O
cortisol	O
and	O
the	O
ineffectiveness	O
of	O
spironolactones	O
,	O
classical	O
mineralocorticoid	O
antagonists	O
,	O
as	O
antagonists	O
of	O
the	O
response	O
.	O

We	O
identified	O
the	O
NF-kappaB	B-DNA
site	I-DNA
in	O
the	O
FasL	B-DNA
promoter	I-DNA
that	O
contributes	O
to	O
such	O
regulation	O
.	O

Cytokine	B-protein
rescue	O
from	O
glucocorticoid	O
induced	O
apoptosis	O
in	O
T	B-cell_type
cells	I-cell_type
is	O
mediated	O
through	O
inhibition	O
of	O
IkappaBalpha	B-protein
.	O

Phospholipid	O
analyses	O
indicated	O
a	O
selective	O
increase	O
in	O
the	O
lysoPC	O
content	O
of	O
the	O
monocytes	B-cell_type
after	O
preincubation	O
with	O
the	O
lysophospholipid	O
.	O

Activation	O
of	O
mature	O
B	B-cell_type
cells	I-cell_type
via	O
Ag	B-protein
receptor	I-protein
cross-linking	O
induces	O
transient	O
expression	O
of	O
the	O
transcription	B-protein
factor	I-protein
Egr-1	B-protein
.	O

In	O
conclusion	O
,	O
HIV-1	O
and	O
HIV-2	O
are	O
differentially	O
regulated	O
by	O
T	O
cell	O
activation	O
signals	O
,	O
and	O
this	O
difference	O
may	O
account	O
for	O
the	O
longer	O
period	O
of	O
viral	O
latency	O
observed	O
with	O
HIV-2	O
than	O
with	O
HIV-1	O
infection	O
.	O

In	O
our	O
study	O
,	O
we	O
determined	O
the	O
induction	O
of	O
apoptosis	O
by	O
GC	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

There	O
is	O
now	O
also	O
increasing	O
evidence	O
that	O
some	O
family	O
members	O
may	O
act	O
as	O
oncogenes	B-DNA
or	O
tumour	B-DNA
suppressor	I-DNA
genes	I-DNA
.	O

We	O
investigated	O
the	O
upstream	B-DNA
regulatory	I-DNA
elements	I-DNA
of	O
the	O
human	B-DNA
IL-4	I-DNA
promoter	I-DNA
.	O

This	O
occurs	O
with	O
fast	O
kinetics	O
after	O
stimulation	O
,	O
via	O
a	O
CsA-sensitive	O
and	O
Ca	O
(	O
2+	O
)	O
-dependent	O
mechanism	O
that	O
does	O
not	O
require	O
de	O
novo	O
protein	O
synthesis	O
.	O

The	O
signals	O
controlling	O
the	O
expression	O
of	O
the	O
receptor	B-protein
protein	I-protein
for	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
in	O
normal	O
human	B-cell_type
lymphocytes	I-cell_type
and	O
the	O
relationship	O
of	O
this	O
protein	O
to	O
the	O
classical	B-protein
vitamin	I-protein
D	I-protein
receptor	I-protein
were	O
examined	O
.	O

Thus	O
,	O
C/EBPepsilon	B-protein
is	O
regulated	O
in	O
a	O
complex	O
fashion	O
and	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
genes	O
involved	O
in	O
myeloid	O
differentiation	O
.	O

PATIENTS	O
:	O
Sixteen	O
anorexic	O
patients	O
,	O
aged	O
16-27	O
years	O
,	O
with	O
a	O
mean	O
+/-	O
SEM	O
body	O
mass	O
index	O
of	O
14.2	O
+/-	O
2.0	O
(	O
ranging	O
from	O
11.1	O
to	O
17.4	O
)	O
,	O
and	O
15	O
normal	O
women	O
were	O
studied	O
.	O

In	O
conclusion	O
,	O
lysoPC	O
markedly	O
decreases	O
LPS-mediated	O
TF	O
expression	O
of	O
human	B-cell_type
monocytes	I-cell_type
,	O
the	O
effect	O
probably	O
being	O
mediated	O
by	O
both	O
transcriptional	O
and	O
posttranscriptional	O
mechanisms	O
.	O

Binding	O
data	O
were	O
derived	O
from	O
Scatchard	O
analysis	O
.	O

META	B-DNA
(	I-DNA
D+	I-DNA
)	I-DNA
directed	O
transcription	O
of	O
a	O
linked	O
luciferase	B-DNA
gene	I-DNA
,	O
and	O
gel	O
shift	O
analysis	O
revealed	O
binding	O
of	O
inducible	O
,	O
CsA-sensitive	B-protein
T	I-protein
cell	I-protein
factors	I-protein
,	O
in	O
parallel	O
with	O
transfection	O
results	O
.	O

As2O3-induced	O
apoptosis	O
was	O
preceded	O
by	O
delta	O
psi	O
(	O
m	O
)	O
collapse	O
.	O

Cytomegalovirus	B-protein
IE	I-protein
gene	I-protein
products	I-protein
significantly	O
enhanced	O
LPS	O
stimulation	O
of	O
IL-6	B-DNA
promoter	I-DNA
activity	O
in	O
both	O
IL-6	B-protein
CAT	O
and	O
IL-6	O
luciferase	O
assays	O
.	O

One	O
of	O
these	O
NFAT-like	B-DNA
elements	I-DNA
encompassed	O
overlapping	O
Oct-	B-DNA
and	I-DNA
NFATp/c-binding	I-DNA
sites	I-DNA
,	O
which	O
functioned	O
in	O
a	O
highly	O
synergistic	O
manner	O
.	O

The	O
IL-3	B-protein
enhancer	O
spanned	O
an	O
inducible	O
cyclosporin	B-DNA
A-sensitive	I-DNA
DNase	I-DNA
I-hypersensitive	I-DNA
site	I-DNA
found	O
only	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
,	O
induction	O
of	O
differentiation	O
but	O
not	O
of	O
proliferation	O
was	O
followed	O
by	O
a	O
25-	O
to	O
30-fold	O
increase	O
in	O
the	O
nuclear	O
level	O
of	O
the	O
tumor	B-protein
suppressor	I-protein
proteins	I-protein
p53	I-protein
(	O
wild	O
type	O
)	O
,	O
pRb	B-protein
,	O
and	O
p130/Rb2	B-protein
and	O
of	O
the	O
p53-dependent	B-protein
cyclin	I-protein
kinase	I-protein
inhibitor	I-protein
p21/Cip1	B-protein
.	O

For	O
a	O
better	O
understanding	O
of	O
the	O
Ig	B-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
components	I-DNA
,	O
we	O
have	O
cloned	O
and	O
analyzed	O
individual	O
sequence	B-DNA
elements	I-DNA
.	O

Interactions	O
between	O
the	O
class	B-protein
II	I-protein
transactivator	I-protein
and	O
CREB	B-protein
binding	I-protein
protein	I-protein
increase	O
transcription	O
of	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
.	O

Gel	O
retardation	O
assays	O
with	O
THP-1	B-cell_line
cell	I-cell_line
extracts	O
identified	O
gamma-IFN	B-protein
inducible	O
DNA	O
binding	O
activity	O
to	O
three	O
potential	O
STATI	B-DNA
DNA	I-DNA
binding	I-DNA
elements	I-DNA
in	O
the	O
human	B-DNA
IP-10	I-DNA
promoter	I-DNA
region	I-DNA
from	O
nucleotides	B-DNA
-	I-DNA
245	I-DNA
to	I-DNA
-	I-DNA
188	I-DNA
.	O

Molecular	O
analysis	O
using	O
Southern	O
blot	O
hybridisation	O
,	O
PCR	O
,	O
and	O
direct	O
DNA	O
sequencing	O
showed	O
that	O
neither	O
the	O
patient	O
nor	O
her	O
brother	O
had	O
a	O
detectable	O
deletion	O
or	O
other	O
abnormalities	O
of	O
Y	O
chromosome	O
sequences	O
,	O
including	O
the	O
SRY	B-DNA
(	I-DNA
sex	I-DNA
determining	I-DNA
region	I-DNA
of	I-DNA
the	I-DNA
Y	I-DNA
chromosome	I-DNA
)	I-DNA
gene	I-DNA
sequence	I-DNA
.	O

These	O
effects	O
were	O
blocked	O
by	O
mAbs	B-protein
against	O
endothelial	B-protein
and/or	I-protein
leukocyte	I-protein
adhesion	I-protein
molecules	I-protein
(	O
beta1	B-protein
and	I-protein
beta2	I-protein
integrins	I-protein
)	O
.	O

Although	O
hypoxia	O
alone	O
did	O
not	O
induce	O
ICAM-1	B-protein
,	O
the	O
combination	O
of	O
LPS	O
and	O
hypoxia	O
enhanced	O
(	O
3	O
+/-	O
0.4-fold	O
over	O
normoxia	O
)	O
ICAM-1	B-protein
expression	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replicates	O
more	O
efficiently	O
in	O
vitro	O
in	O
differentiated	B-cell_type
macrophages	I-cell_type
than	O
in	O
freshly	B-cell_type
isolated	I-cell_type
monocytes	I-cell_type
.	O

Twenty-seven	O
patients	O
with	O
tumors	O
of	O
the	O
oral	O
cavity	O
,	O
oropharynx	O
,	O
and	O
maxillary	O
sinus	O
were	O
examined	O
,	O
all	O
of	O
which	O
were	O
confirmed	O
as	O
squamous	O
cell	O
carcinomas	O
.	O

No	O
modification	O
of	O
c-myc	B-DNA
expression	O
could	O
be	O
detected	O
on	O
treatment	O
with	O
histamine	O
or	O
its	O
analogues	O
.	O

Currently	O
available	O
data	O
indicate	O
that	O
erythroid	O
and	O
megakaryocytic	O
differentiation	O
pathways	O
are	O
closely	O
related	O
to	O
each	O
other	O
,	O
and	O
there	O
may	O
exist	O
progenitor	B-cell_type
cells	I-cell_type
common	O
to	O
those	O
two	O
lineages	O
may	O
exist	O
.	O

We	O
describe	O
here	O
a	O
heterodimeric	B-protein
binding	I-protein
complex	I-protein
of	O
NF-kappaB	B-protein
subunits	I-protein
(	O
c-Rel	B-protein
and	O
p65	B-protein
)	O
which	O
is	O
identical	O
to	O
the	O
one	O
obtained	O
using	O
the	O
HIV-LTR-kappaB	B-DNA
site	I-DNA
as	O
recognition	O
sequence	O
and	O
different	O
from	O
the	O
one	O
(	O
c-Rel	B-protein
and	O
p50	B-protein
)	O
observed	O
with	O
nuclear	O
extracts	O
from	O
Mo	B-cell_line
T-lymphoid	I-cell_line
HTLV-II	I-cell_line
infected	I-cell_line
cells	I-cell_line
.	O

Monocyte	O
adhesion	O
and	O
spreading	O
on	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
is	O
dependent	O
on	O
Rho	B-protein
-regulated	O
receptor	O
clustering	O
.	O

These	O
results	O
suggest	O
a	O
critical	O
role	O
of	O
c-jun	B-DNA
in	O
both	O
cell	O
proliferation	O
and	O
PMA-induced	O
cell	O
adhesion	O
but	O
not	O
in	O
PMA-induced	O
respiratory	O
burst	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
show	O
that	O
the	O
nucleoprotein	B-protein
complex	I-protein
formed	O
on	O
the	O
upstream	B-DNA
site	I-DNA
(	O
NF	B-protein
kappa	I-protein
B1	I-protein
)	O
contains	O
the	O
classical	B-protein
p50/p65	I-protein
heterodimer	I-protein
.	O

In	O
conclusion	O
,	O
AIDS	O
patients	O
with	O
hypercortisolism	O
and	O
clinical	O
features	O
of	O
peripheral	O
resistance	O
to	O
glucocorticoids	O
are	O
characterized	O
by	O
abnormal	B-protein
glucocorticoid	I-protein
receptors	I-protein
on	O
lymphocytes	B-cell_type
.	O

Although	O
activated	O
in	O
T	O
cell	O
leukemias	O
,	O
expression	O
of	O
SCL	B-protein
and	O
LYL-1	B-protein
is	O
low	O
or	O
undetectable	O
in	O
normal	B-cell_type
T	I-cell_type
cell	I-cell_type
populations	I-cell_type
.	O

Compared	O
with	O
the	O
interaction	O
of	O
VDR	B-protein
with	O
RXR	B-protein
or	O
GRIP-1	B-protein
,	O
the	O
differentiation	O
dose-response	O
most	O
closely	O
correlated	O
to	O
the	O
ligand-dependent	O
recruitment	O
of	O
the	O
DRIP	B-protein
coactivator	I-protein
complex	I-protein
to	O
VDR	B-protein
and	O
to	O
the	O
ability	O
of	O
the	O
receptor	O
to	O
activate	O
transcription	O
in	O
a	O
cell-free	O
system	O
.	O

From	O
sequence	O
analysis	O
,	O
two	O
of	O
these	O
appear	O
to	O
be	O
novel	O
transcription	B-protein
factor	I-protein
binding	B-DNA
sites	I-DNA
,	O
whereas	O
the	O
third	O
was	O
identified	O
as	O
a	O
cyclic	B-DNA
AMP	I-DNA
response	I-DNA
element	I-DNA
(	O
CRE	B-DNA
)	O
.	O

Our	O
previous	O
data	O
have	O
indicated	O
that	O
formylated	O
indolocarbazoles	O
which	O
are	O
formed	O
by	O
UV	O
irradiation	O
of	O
tryptophan	O
solutions	O
are	O
very	O
potent	O
Ah-receptor	O
agonists	O
.	O

Using	O
a	O
human	B-DNA
TSH	I-DNA
receptor	I-DNA
(	I-DNA
TSH-R	I-DNA
)	I-DNA
cDNA	I-DNA
probe	I-DNA
,	O
we	O
investigated	O
TSH-R	B-protein
transcript	O
levels	O
in	O
13	O
human	O
thyroid	O
fragments	O
by	O
Northern	O
blot	O
analysis	O
;	O
7	O
Graves	O
'	O
disease	O
,	O
2	O
Hashimoto	O
's	O
disease	O
,	O
3	O
endemic	O
goiter	O
,	O
and	O
1	O
healthy	O
thyroid	O
gland	O
were	O
studied	O
.	O

We	O
have	O
previously	O
shown	O
that	O
NF-AT1	B-protein
is	O
constitutively	O
active	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
stably	O
transfected	O
with	O
the	O
Tax	B-DNA
cDNA	I-DNA
,	O
although	O
the	O
underlying	O
molecular	O
mechanism	O
and	O
physiological	O
relevance	O
of	O
this	O
finding	O
remain	O
unclear	O
.	O

Finally	O
,	O
no	O
transcription	O
of	O
the	O
RAG-1	B-DNA
gene	I-DNA
could	O
be	O
detected	O
in	O
all	O
NK	B-cell_line
cell	I-cell_line
lines	I-cell_line
or	O
clones	O
analyzed	O
.	O

Environmental	O
estrogens	O
or	O
estrogen	O
disrupters	O
have	O
recently	O
received	O
a	O
great	O
deal	O
of	O
attention	O
because	O
of	O
their	O
potential	O
health	O
impact	O
on	O
reproductive	O
tissues	O
.	O

Interleukin	B-protein
2	I-protein
induced	O
proliferation	O
but	O
not	O
NF-kappa	B-protein
B	I-protein
translocation	O
or	O
LTR	B-DNA
transactivation	O
.	O

The	O
patients	O
carrying	O
B27	B-protein
antigen	I-protein
had	O
lymphocytic	O
receptor	O
concentrations	O
under	O
the	O
levels	O
of	O
such	O
in	O
patients	O
free	O
of	O
the	O
antigen	O
carriage	O
.	O

Addition	O
of	O
ubiquitin	B-protein
protein	I-protein
ligase	I-protein
E3	I-protein
substantially	O
enhanced	O
the	O
E214K	B-protein
-mediated	O
ubiquitinylation	O
of	O
c-Jun	B-protein
and	O
c-Fos	B-protein
.	O

Activation	O
of	O
the	O
signal	O
transducer	O
and	O
transcription	O
(	O
STAT	B-protein
)	O
signaling	O
pathway	O
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O

To	O
further	O
understand	O
its	O
mechanism	O
of	O
action	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
HU	O
on	O
regulation	O
of	O
c-jun	B-DNA
expression	O
prior	O
to	O
the	O
onset	O
of	O
erythroid	O
differentiation	O
of	O
K562	B-cell_line
cells	I-cell_line
.	O

High	O
affinity	O
aldosterone	O
binding	O
to	O
plasma	O
membrane	O
rich	O
fractions	O
from	O
mononuclear	B-cell_type
leukocytes	I-cell_type
:	O
is	O
there	O
a	O
membrane	B-protein
receptor	I-protein
for	O
mineralocorticoids	O
?	O

FasL-dependent	B-DNA
reporter	I-DNA
constructs	I-DNA
in	O
MRL-lpr/lpr	B-cell_line
and	I-cell_line
C3H-gld/gld	I-cell_line
CD4	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
CD8	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
T	I-cell_line
cells	I-cell_line
were	O
constitutively	O
active	O
,	O
and	O
this	O
activity	O
was	O
largely	O
prevented	O
by	O
mutation	O
of	O
the	O
critical	O
Egr	B-DNA
family	I-DNA
binding	I-DNA
element	I-DNA
.	O

Pretreatment	O
with	O
dexamethasone	O
tapered	O
NFkappaB	B-protein
translocation	O
into	O
the	O
nucleus	O
.	O

These	O
activated	B-protein
kinases	I-protein
then	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
multiple	B-protein
intracellular	I-protein
proteins	I-protein
,	O
eventually	O
leading	O
to	O
T-cell	O
activation	O
.	O

Proteins	O
in	O
the	O
second	O
group	O
carry	O
a	O
single	B-protein
HMG	I-protein
box	I-protein
with	O
affinity	O
for	O
the	O
minor	O
groove	O
of	O
the	O
heptamer	B-DNA
motif	I-DNA
AACAAAG	O
or	O
variations	O
thereof	O
.	O

The	O
presence	O
of	O
an	O
AP-1	B-protein
protein	O
in	O
the	O
NF-AT	B-protein
protein	O
complex	O
may	O
regulate	O
NF-AT	B-protein
-binding	O
activity	O
through	O
protein-protein	O
interaction	O
.	O

Regulation	O
of	O
replicative	O
functions	O
in	O
the	O
Epstein-Barr	B-DNA
virus	I-DNA
(	I-DNA
EBV	I-DNA
)	I-DNA
genome	I-DNA
is	O
mediated	O
through	O
activation	O
of	O
a	O
virally	B-protein
encoded	I-protein
transcription	I-protein
factor	I-protein
,	O
Z	B-protein
(	O
BZLF1	B-protein
)	O
.	O

By	O
using	O
an	O
infectious	O
molecular	O
clone	O
of	O
HTLV-II	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
the	O
internal	O
ATGs	O
of	O
the	O
rex	B-DNA
gene	I-DNA
on	O
Rex	B-protein
protein	O
production	O
and	O
function	O
.	O

Most	O
of	O
these	O
cells	O
have	O
rearranged	O
their	O
heavy-chain	B-DNA
locus	I-DNA
but	O
not	O
their	O
light	B-DNA
chain	I-DNA
genes	I-DNA
,	O
suggesting	O
that	O
an	O
active	O
v-abl	B-protein
protein	I-protein
interferes	O
with	O
this	O
differentiation	O
step	O
.	O

However	O
,	O
apoptosis	O
was	O
much	O
higher	O
in	O
FTOC	O
infected	O
with	O
adenovirus	O
containing	O
mut-I	B-protein
kappa	I-protein
B	I-protein
than	O
in	O
FTOC	O
infected	O
with	O
a	O
control	O
virus	O
.	O

Taken	O
together	O
,	O
these	O
results	O
support	O
our	O
conclusion	O
that	O
transcriptional	O
transactivation	O
is	O
a	O
necessary	O
signaling	O
component	O
of	O
S49	O
cell	O
apoptosis	O
,	O
although	O
an	O
additional	O
role	O
for	O
GR	B-protein
-mediated	O
transrepression	O
can	O
not	O
be	O
excluded	O
.	O

In	O
unstimulated	B-cell_type
cells	I-cell_type
which	O
do	O
not	O
secrete	O
IL-2	B-protein
,	O
only	O
Sp1	B-protein
binds	O
to	O
this	O
region	O
,	O
while	O
in	O
stimulated	B-cell_line
IL-2	I-cell_line
secreting	I-cell_line
cells	I-cell_line
the	O
inducible	B-protein
EGR-1	I-protein
protein	I-protein
recognizes	O
this	O
element	O
.	O

[	O
Age-related	O
changes	O
in	O
glucocorticoid	B-protein
and	I-protein
mineralocorticoid	I-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
of	O
healthy	O
persons	O
and	O
patients	O
with	O
hypertension	O
]	O

This	O
resulted	O
in	O
only	O
a	O
partial	O
inhibition	O
of	O
TNF	B-protein
-or	O
PMA-	O
induced	O
HIV	O
replication	O
in	O
U1	B-cell_line
cells	I-cell_line
,	O
and	O
no	O
detectable	O
effect	O
on	O
HIV	O
replication	O
in	O
chronically	B-cell_line
infected	I-cell_line
U937	I-cell_line
cells	I-cell_line
.	O

The	O
GCR	B-protein
binding	O
affinity	O
for	O
budesonide	O
was	O
significantly	O
higher	O
in	O
both	O
groups	O
(	O
i.e.	O
,	O
lower	O
dissociation	O
constant	O
)	O
than	O
that	O
obtained	O
for	O
dexamethasone	O
.	O

Transcriptional	O
activation	O
of	O
the	O
human	B-DNA
TF	I-DNA
gene	I-DNA
in	O
monocytic	B-cell_type
cells	I-cell_type
exposed	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
mediated	O
by	O
binding	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
to	O
a	O
kappa	B-DNA
B	I-DNA
site	I-DNA
in	O
the	O
TF	B-DNA
promoter	I-DNA
.	O

In	O
the	O
first	O
patients	O
studied	O
,	O
we	O
found	O
no	O
significant	O
modification	O
in	O
the	O
expression	O
of	O
the	O
97	B-protein
kDa	I-protein
Ca	I-protein
(	I-protein
2+	I-protein
)	I-protein
-ATPase	I-protein
by	O
Western	O
blotting	O
using	O
the	O
PL/IM	B-protein
430	I-protein
monoclonal	I-protein
antibody	I-protein
which	O
specifically	O
recognized	O
this	O
isoform	O
.	O

In	O
order	O
to	O
understand	O
the	O
role	O
of	O
NF-kappaB	B-protein
in	O
EBV	O
transformation	O
we	O
have	O
established	O
stably	O
transfected	O
IkappaBalpha	B-protein
into	O
lymphoblastoid	B-cell_type
cells	I-cell_type
.	O

In	O
germinal	O
centers	O
GC	O
,	O
p50	B-protein
,	O
p52	B-protein
,	O
and	O
RelB	B-protein
were	O
found	O
in	O
the	O
nuclei	O
of	O
FDC	B-cell_type
only	O
and	O
were	O
not	O
detected	O
in	O
the	O
nuclei	O
of	O
CD68+	B-cell_line
cells	I-cell_line
.	O

Rapid	O
nongenomic	O
in	O
vitro	O
effects	O
of	O
aldosterone	O
on	O
intracellular	O
electrolytes	O
,	O
cell	O
volume	O
,	O
and	O
Na	B-protein
(	I-protein
+	I-protein
)	I-protein
-H+	I-protein
antiport	I-protein
have	O
been	O
found	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
(	O
HML	B-cell_type
)	O
.	O

The	O
control	O
of	O
cell	O
survival	O
and	O
cell	O
death	O
is	O
of	O
central	O
importance	O
in	O
tissues	O
with	O
high	O
cell	O
turnover	O
such	O
as	O
the	O
lymphoid	O
system	O
.	O

Of	O
these	O
,	O
11	O
were	O
found	O
to	O
possess	O
DNA-binding	O
properties	O
.	O

Another	O
limitation	O
is	O
that	O
antioxidant	O
concentrations	O
high	O
enough	O
to	O
block	O
NK-kappa	B-protein
B	I-protein
activation	O
were	O
shown	O
to	O
have	O
a	O
suppressive	O
effect	O
on	O
immune	O
functions	O
in	O
vitro	O
,	O
because	O
NAC	O
and	O
BHA	O
blocked	O
IL-2-induced	B-cell_type
PBMC	I-cell_type
proliferation	O
.	O

Activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
in	O
lipopolysaccharide-stimulated	B-cell_line
U937	I-cell_line
cells	I-cell_line
.	O

Comparative	O
analysis	O
of	O
NFAT	B-protein
(	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
)	O
complex	O
in	O
human	B-cell_type
T	I-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

In	O
this	O
study	O
,	O
a	O
CD40	B-protein
-dependent	O
B	O
cell	O
culture	O
system	O
was	O
used	O
to	O
examine	O
the	O
role	O
of	O
different	O
signal	B-DNA
transduction	I-DNA
elements	I-DNA
.	O

We	O
report	O
here	O
that	O
monocytes/macrophages	B-cell_type
in	O
human	O
atherosclerotic	O
lesions	O
(	O
n	O
=	O
12	O
)	O
express	O
immunostainable	B-protein
PPARgamma	I-protein
.	O

The	O
present	O
paper	O
reviews	O
the	O
data	O
supporting	O
a	O
new	O
,	O
two-step	O
model	O
for	O
non-genomic	O
and	O
genomic	O
aldosterone	O
effects	O
.	O

Cotransfection	O
of	O
the	O
C/EBP-epsilon	B-protein
sense	O
and	O
antisense	O
expression	O
constructs	O
together	O
with	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
vectors	I-DNA
containing	O
myeloid-cell-specific	B-DNA
c-mim	I-DNA
and	I-DNA
human	I-DNA
myeloperoxidase	I-DNA
promoters	I-DNA
suggested	O
a	O
role	O
for	O
C/EBP-epsilon	B-protein
transcription	B-protein
factor	I-protein
in	O
the	O
regulation	O
of	O
a	O
subset	O
of	O
myeloid-cell-specific	B-DNA
genes	I-DNA
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
specific	O
interaction	O
with	O
PU.1	B-protein
on	O
a	O
myeloid	B-DNA
PU.1	I-DNA
binding	I-DNA
site	I-DNA
.	O

The	O
present	O
study	O
demonstrates	O
that	O
triggering	O
of	O
complement	B-protein
receptors	I-protein
CR1	B-protein
(	O
CD35	B-protein
)	O
and	O
CR3	B-protein
(	O
CD11b/CD18	B-protein
)	O
enhances	O
viral	O
replication	O
in	O
HIV-infected	B-cell_line
human	I-cell_line
monocytic	I-cell_line
cells	I-cell_line
.	O

It	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
both	O
B	B-cell_type
cells	I-cell_type
and	O
non-B	B-cell_type
cells	I-cell_type
,	O
where	O
it	O
can	O
mediate	O
transcriptional	O
activation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

However	O
,	O
major	O
side	O
effects	O
severely	O
limit	O
their	O
therapeutic	O
use	O
.	O

Furthermore	O
,	O
we	O
propose	O
that	O
these	O
putative	O
CD	O
peptides	O
bind	O
to	O
oligosaccharide	O
residues	O
on	O
HLA	B-protein
class	I-protein
II	I-protein
molecules	I-protein
distal	O
to	O
the	O
peptide-binding	B-protein
groove	I-protein
invoking	O
recognition	O
and	O
binding	O
by	O
specialized	O
subsets	O
of	O
gamma	B-cell_type
delta	I-cell_type
T	I-cell_type
cell	I-cell_type
receptor-bearing	I-cell_type
lymphocytes	I-cell_type
.	O

We	O
investigated	O
the	O
involvement	O
of	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
factors	I-protein
in	O
this	O
phenomenon	O
and	O
reported	O
the	O
specific	O
,	O
time-dependent	O
,	O
activation	O
of	O
STAT1	B-protein
protein	O
starting	O
at	O
day	O
0/1	O
of	O
cultivation	O
and	O
maximally	O
expressed	O
at	O
day	O
5	O
.	O

The	O
onset	O
of	O
apoptosis	O
in	O
both	O
cell	O
types	O
can	O
be	O
delayed	O
by	O
hemopoietins	B-protein
and	O
inflammatory	B-protein
mediators	I-protein
.	O

Stable	O
transfection	O
of	O
U937	B-cell_line
cells	I-cell_line
with	O
sense	O
or	O
antisense	B-DNA
RXR-alpha	I-DNA
cDNA	I-DNA
suggests	O
a	O
role	O
for	O
RXR-alpha	B-protein
in	O
the	O
control	O
of	O
monoblastic	O
differentiation	O
induced	O
by	O
retinoic	O
acid	O
and	O
vitamin	O
D	O
.	O

SRG3	B-DNA
encodes	O
1	O
,	O
100	O
amino	O
acids	O
and	O
has	O
33-47	O
%	O
identity	O
with	O
SWI3	B-protein
protein	I-protein
over	O
three	O
regions	O
.	O

These	O
initial	O
changes	O
are	O
followed	O
by	O
the	O
eventual	O
loss	O
of	O
TCR	B-protein
zeta	I-protein
chain	I-protein
and	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
and	O
a	O
marked	O
decrease	O
in	O
cytotoxic	O
function	O
.	O

The	O
AML1	B-DNA
and	I-DNA
CBF	I-DNA
beta	I-DNA
genes	I-DNA
that	O
encode	O
CBF	B-protein
each	O
have	O
the	O
ability	O
to	O
influence	O
cell	O
growth	O
and	O
differentiation	O
and	O
have	O
been	O
implicated	O
as	O
proto-oncogenes	B-DNA
in	O
acute	O
myeloid	O
leukemia	O
.	O

Cloning	O
of	O
a	O
mitogen-inducible	B-DNA
gene	I-DNA
encoding	O
a	O
kappa	B-protein
B	I-protein
DNA-binding	I-protein
protein	I-protein
with	O
homology	O
to	O
the	O
rel	B-DNA
oncogene	I-DNA
and	O
to	O
cell-cycle	B-DNA
motifs	I-DNA
.	O

Jak1	B-protein
expression	O
is	O
required	O
for	O
mediating	O
interleukin-4-induced	O
tyrosine	O
phosphorylation	O
of	O
insulin	O
receptor	O
substrate	O
and	O
Stat6	B-protein
signaling	B-protein
molecules	I-protein
.	O

In	O
addition	O
,	O
mutation	O
of	O
the	O
Y-box	B-DNA
element	I-DNA
alone	O
abrogated	O
Tax1	B-protein
-mediated	O
activation	O
.	O

We	O
investigated	O
the	O
mechanisms	O
by	O
which	O
proinflammatory	B-protein
mediator	I-protein
,	O
thrombin	B-protein
,	O
released	O
during	O
intravascular	O
coagulation	O
and	O
tissue	O
injury	O
,	O
induces	O
ICAM-1	B-protein
(	O
CD54	B-protein
)	O
expression	O
in	O
endothelial	B-cell_type
cells	I-cell_type
.	O

After	O
3	O
h	O
incubation	O
the	O
specific	O
binding	O
power	O
with	O
[	O
3H	O
]	O
Dex	O
was	O
decreased	O
by	O
23.3	O
+/-	O
10.0	O
,	O
32.2	O
+/-	O
13.2	O
and	O
54.3	O
+/-	O
9.2	O
%	O
(	O
P	O
greater	O
than	O
0.05	O
,	O
P	O
greater	O
than	O
0.05	O
and	O
P	O
less	O
than	O
0.01	O
as	O
compared	O
with	O
the	O
control	O
value	O
of	O
100	O
in	O
the	O
absence	O
of	O
insulin	B-protein
)	O
respectively	O
in	O
the	O
presence	O
of	O
20	O
mU/L	O
(	O
physiological	O
testing	O
concentration	O
)	O
,	O
200	O
mU/L	O
(	O
physiological	O
upper	O
limit	O
)	O
and	O
2	O
,	O
000	O
mU/L	O
(	O
pharmacological	O
concentration	O
)	O
insulin	B-protein
in	O
the	O
incubation	O
medium	O
.	O

The	O
I	O
alpha1	O
promoter	O
activates	O
transcription	O
of	O
the	O
human	B-DNA
germ-line	I-DNA
C	I-DNA
alpha1	I-DNA
gene	I-DNA
for	O
IgA1	B-protein
and	O
mediates	O
the	O
transforming	B-protein
growth	I-protein
factor	I-protein
(	I-protein
TGF	I-protein
)	I-protein
-beta1	I-protein
responsiveness	O
of	O
this	O
locus	O
.	O

At	O
present	O
,	O
the	O
role	O
of	O
the	O
IKKs	O
in	O
LPS	O
signaling	O
has	O
not	O
been	O
investigated	O
.	O

PI	B-protein
3-kinase	I-protein
is	O
also	O
regulated	O
by	O
the	O
haematopoietic	O
cytokines	O
that	O
determine	O
T-cell	O
differentiation	O
and	O
lymphocyte	B-cell_type
proliferation	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
transgenic	O
mice	O
carrying	O
the	O
human	B-DNA
IRF-1	I-DNA
gene	I-DNA
linked	O
to	O
the	O
human	B-DNA
immunoglobulin	I-DNA
heavy-chain	I-DNA
enhancer	I-DNA
.	O

The	O
results	O
demonstrate	O
that	O
multidrug-resistant	B-cell_line
HL-60	I-cell_line
cells	I-cell_line
,	O
designated	O
HL-60/vinc	O
,	O
fail	O
to	O
respond	O
to	O
TPA	O
with	O
an	O
increase	O
in	O
c-jun	B-RNA
transcripts	I-RNA
or	O
other	O
phenotypic	O
characteristics	O
of	O
monocytic	O
differentiation	O
.	O

Furthermore	O
,	O
OFT-1	O
appeared	O
to	O
have	O
approximately	O
the	O
same	O
transactivation	O
ability	O
as	O
OTF-2	B-protein
when	O
normalized	O
for	O
binding	O
activity	O
.	O

In	O
the	O
present	O
study	O
we	O
demonstrate	O
that	O
mitogen	B-protein
activation	O
of	O
human	B-cell_type
peripheral	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
induces	O
nuclear	O
factors	O
that	O
form	O
complexes	O
with	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
.	O

Ras	B-DNA
oncogene	I-DNA
transformation	O
of	O
human	B-cell_type
B	I-cell_type
lymphoblasts	I-cell_type
is	O
associated	O
with	O
lymphocyte	O
activation	O
and	O
with	O
a	O
block	O
of	O
differentiation	O
.	O

Similar	O
to	O
the	O
E2	O
response	O
,	O
the	O
slope	O
factors	O
for	O
alpha-zearalenol	O
,	O
zearalenone	O
,	O
and	O
genistein	O
were	O
close	O
to	O
3.0	O
,	O
suggesting	O
positive	O
cooperativity	O
in	O
the	O
estrogenic	O
response	O
.	O

Interestingly	O
,	O
Id2	B-RNA
,	O
but	O
not	O
Id3	B-RNA
,	O
mRNA	O
was	O
strongly	O
expressed	O
in	O
4/5	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
infected	O
with	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
(	O
ATL-1k	B-cell_line
,	O
MT-2	B-cell_line
,	O
S-LB1	B-cell_line
)	O
and	O
type	O
II	O
(	O
Mo	B-cell_line
)	O
.	O

These	O
data	O
suggest	O
that	O
although	O
MC903	O
and	O
KH1060	O
may	O
bind	O
the	O
VDRnuc	B-protein
,	O
that	O
the	O
differentiative	O
activities	O
of	O
these	O
agents	O
requires	O
nongenomic	O
signaling	O
pathways	O
.	O

Transfection	O
of	O
c-jun	B-DNA
promoter	I-DNA
constructs	I-DNA
confirmed	O
the	O
marked	O
difference	O
between	O
PMA	O
and	O
okadaic	O
acid	O
in	O
inducing	O
c-jun	B-DNA
transcription	O
.	O

Similarly	O
,	O
there	O
was	O
no	O
detectable	O
basal	O
phosphorylation	O
of	O
Jak3	B-protein
and	O
STAT5	B-protein
in	O
the	O
leukemic	B-cell_type
cells	I-cell_type
from	O
ATLL	O
patients	O
(	O
0/8	O
and	O
0/3	O
,	O
respectively	O
)	O
.	O

However	O
,	O
the	O
components	O
of	O
the	O
NF-kappaB	B-protein
complexes	I-protein
were	O
different	O
in	O
monocytes	B-cell_type
and	O
B	O
cells	O
,	O
because	O
p50	B-protein
is	O
part	O
of	O
the	O
NF-kappaB	B-protein
complex	I-protein
induced	O
by	O
CD40	B-protein
triggering	O
in	O
both	O
monocytes	B-cell_type
and	O
B	B-cell_type
cells	I-cell_type
,	O
whereas	O
p65	B-protein
was	O
only	O
induced	O
in	O
B	B-cell_type
cells	I-cell_type
.	O
In	O
contrast	O
,	O
although	O
the	O
Janus	B-protein
kinase	I-protein
3	I-protein
tyrosine	I-protein
kinase	I-protein
was	O
associated	O
with	O
CD40	B-protein
molecules	O
in	O
both	O
monocytes	B-cell_type
and	O
resting	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
Janus	B-protein
kinase	I-protein
3	I-protein
phosphorylation	O
induction	O
was	O
observed	O
only	O
in	O
CD40-activated	B-cell_line
monocytes	I-cell_line
,	O
with	O
subsequent	O
induction	O
of	O
STAT5a	B-protein
DNA	O
binding	O
activity	O
in	O
the	O
nucleus	O
.	O

Previous	O
transfection	O
studies	O
of	O
HIV	B-DNA
LTR	I-DNA
constructs	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
gene	I-DNA
indicated	O
that	O
multiple	O
regulatory	B-DNA
regions	I-DNA
including	O
the	O
enhancer	B-DNA
,	O
SP1	B-DNA
,	O
TATA	B-DNA
and	O
TAR	B-DNA
regions	I-DNA
were	O
important	O
for	O
HIV	O
gene	O
expression	O
.	O

Efficient	O
gene	O
activation	O
requires	O
the	O
heterodimerization	O
of	O
VDR	B-protein
with	O
Retinoid	B-protein
X	I-protein
Receptors	I-protein
(	O
RXR	B-protein
)	O
.	O

TPO	B-protein
is	O
a	O
hormone	O
constitutively	O
produced	O
mainly	O
by	O
the	O
liver	O
and	O
kidney	O
.	O

The	O
suppressor	O
function	O
was	O
determined	O
using	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
into	O
phytohemagglutinin-activated	B-cell_line
peripheral	I-cell_line
blood	I-cell_line
lymphocytes	I-cell_line
.	O

Systemic	O
hGR	B-protein
levels	O
in	O
untreated	O
IBD	O
patients	O
did	O
not	O
differ	O
significantly	O
from	O
those	O
in	O
control	O
subjects	O
.	O

Moreover	O
,	O
following	O
IL-2	B-protein
stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
,	O
SOCS-3	B-protein
was	O
able	O
to	O
interact	O
with	O
the	O
IL-2	B-protein
receptor	I-protein
complex	I-protein
,	O
and	O
in	O
particular	O
tyrosine	B-protein
phosphorylated	I-protein
Jak1	I-protein
and	O
IL-2Rbeta	B-protein
.	O

We	O
previously	O
showed	O
that	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
and	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
M-CSF	B-protein
)	O
stimulate	O
the	O
differentiation	O
of	O
human	B-cell_type
monocytes	I-cell_type
into	O
two	O
phenotypically	O
distinct	O
types	O
of	O
macrophages	B-cell_type
.	O

The	O
transcription	B-protein
factor	I-protein
,	O
Nuclear	B-protein
Factor	I-protein
of	I-protein
Activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
is	O
a	O
major	O
target	O
for	O
p21ras	B-protein
and	O
calcium	O
signalling	O
pathways	O
in	O
the	O
IL-2	B-DNA
gene	I-DNA
and	O
is	O
induced	O
by	O
p21ras	B-protein
signals	O
acting	O
in	O
synergy	O
with	O
calcium	O
/calcineurin	B-protein
signals	O
.	O

Assembly	O
of	O
terminal	B-protein
complement	I-protein
complexes	I-protein
(	O
TCC	B-protein
)	O
C5b-7	B-protein
,	O
C5b-8	B-protein
,	O
and	O
C5b-9	B-protein
on	O
target	O
cells	O
during	O
acute	O
and	O
chronic	O
inflammation	O
induces	O
hydrolysis	O
of	O
plasma	O
membrane	O
phospholipids	O
and	O
heterotrimeric	O
G	B-protein
protein	I-protein
activation	O
.	O

Lipopolysaccharide	O
induction	O
of	O
the	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha	I-DNA
promoter	I-DNA
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

Replication	O
of	O
human	O
immunodeficiency	O
virus-1	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
is	O
dependent	O
on	O
the	O
autocrine	O
secretion	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
through	O
the	O
control	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activation	O
.	O

However	O
,	O
this	O
mutated	B-DNA
NF	I-DNA
kappa	I-DNA
B	I-DNA
promoter	I-DNA
was	O
not	O
transactivated	O
during	O
HHV-6	O
(	O
GS	O
)	O
infection	O
or	O
after	O
cotransfection	O
with	O
pZVB70	B-DNA
or	O
pZVB10	B-DNA
.	O

In	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
transcription	O
from	O
the	O
NFAT	B-DNA
site	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
is	O
activated	O
strongly	O
by	O
NFATx1	B-protein
but	O
only	O
weakly	O
by	O
NFATx2	B-protein
.	O

The	O
prevalent	O
complex	O
is	O
the	O
heterodimer	B-protein
p50-p65	I-protein
.	O

The	O
spatial	O
distribution	O
of	O
human	B-DNA
immunoglobulin	I-DNA
genes	I-DNA
within	O
the	O
nucleus	O
:	O
evidence	O
for	O
gene	O
topography	O
independent	O
of	O
cell	O
type	O
and	O
transcriptional	O
activity	O
.	O

The	O
developmental	O
stage-specificity	O
of	O
PYBF	B-protein
and	O
the	O
location	O
of	O
its	O
binding	O
site	O
between	O
the	O
fetal	B-DNA
and	I-DNA
adult	I-DNA
beta-globin	I-DNA
(	I-DNA
HBB	I-DNA
)	I-DNA
-like	I-DNA
genes	I-DNA
suggest	O
that	O
PBYF	B-protein
and	O
its	O
binding	O
site	O
may	O
function	O
in	O
fetal-to-adult	O
globin	B-DNA
gene	I-DNA
switching	O
.	O

Increased	O
expression	O
of	O
wild-type	O
NFAT1	B-protein
substantially	O
increases	O
IL-4	B-DNA
promoter	I-DNA
activity	O
in	O
unprimed	O
CD4	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
suggesting	O
NFAT1	B-protein
may	O
be	O
limiting	O
for	O
IL-4	B-protein
gene	O
expression	O
in	O
this	O
cell	O
type	O
.	O

As	O
determined	O
by	O
transient	O
expression	O
and	O
RNA	O
analyses	O
,	O
the	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
also	O
increased	O
rates	O
of	O
transcription	O
from	O
the	O
wild-type	O
DRA	B-DNA
promoter	I-DNA
but	O
not	O
from	O
a	O
DRA	B-DNA
promoter	I-DNA
bearing	O
clustered	O
point	O
mutations	O
in	O
the	O
X2	B-DNA
box	I-DNA
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
analyze	O
the	O
roles	O
of	O
the	O
two	O
GR	B-protein
isoforms	I-protein
on	O
glucocorticoid-mediated	O
transrepression	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O

In	O
T	B-cell_type
cells	I-cell_type
,	O
IL-13	B-protein
inhibits	O
anti-CD3	O
mAb/IL-2-	O
or	O
PHA-mediated	O
IFN-gamma	O
production	O
and	O
enhances	O
cytolytic	O
potential	O
.	O

Costimulation	O
requirement	O
for	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
transcription	O
factor	O
activation	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

We	O
and	O
others	O
have	O
shown	O
that	O
SAA	B-protein
gene	O
is	O
induced	O
in	O
monocyte/macrophage	B-cell_type
cells	I-cell_type
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Thus	O
it	O
appears	O
that	O
there	O
may	O
often	O
be	O
malfunction	O
of	O
the	O
normal	O
glucocorticoid	O
response	O
in	O
HIV-infected	B-cell_type
cells	I-cell_type
probably	O
due	O
to	O
altered	O
interactions	O
between	O
the	O
glucocorticoid	B-protein
receptor	I-protein
and	O
its	O
hormone	O
.	O

To	O
study	O
the	O
influence	O
of	O
NFkappaB	B-protein
activity	O
on	O
apoptosis	O
mediated	O
by	O
TRAIL	B-protein
,	O
CD95	O
,	O
TNFalpha	B-protein
,	O
or	O
doxorubicin	O
,	O
NFkappaB	B-protein
activation	O
was	O
inhibited	O
using	O
the	O
proteasome	B-protein
inhibitor	O
N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal	O
or	O
transient	O
overexpression	O
of	O
mutant	B-protein
IkappaBalpha	I-protein
.	O

Granulosa	O
cell	O
tumor	O
of	O
the	O
ovary	O
.	O

In	O
many	O
pathological	O
situations	O
,	O
the	O
balance	O
between	O
Th1	O
and	O
Th2	O
immune	O
responses	O
determines	O
the	O
outcome	O
of	O
diverse	O
immunologically	O
mediated	O
clinical	O
syndromes	O
including	O
infectious	O
,	O
autoimmune	O
,	O
and	O
allergic	O
diseases	O
.	O

This	O
indirect	O
response	O
is	O
mediated	O
by	O
other	O
viral	O
or	O
virally	O
induced	O
activities	O
downstream	O
of	O
ZEBRA	B-DNA
in	O
the	O
lytic	O
cascade	O
.	O

We	O
have	O
investigated	O
mechanisms	O
and	O
consequences	O
of	O
STAT5	B-protein
activation	O
through	O
the	O
human	B-protein
IL-4	I-protein
receptor	I-protein
(	O
IL-4R	B-protein
)	O
.	O

